PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BANEULOS, S; ARRONDO, JLR; GONI, FM; PIFAT, G				BANEULOS, S; ARRONDO, JLR; GONI, FM; PIFAT, G			SURFACE-CORE RELATIONSHIPS IN HUMAN LOW-DENSITY-LIPOPROTEIN AS STUDIED BY INFRARED-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-B; SECONDARY STRUCTURE; PROTEINS; OXIDATION; SEQUENCE; RECEPTOR; DOMAINS; B-100	The secondary structure of human apolipoprotein B at 37 degrees C is estimated to be 24% alpha-helix, 23% beta-sheet, 6% beta-turns, 24% unordered structure, and 24% ''beta-strands,'' characterized by a band around 1618 cm(-1), and consistent with extended string-like chains in contact with the lipid moiety not forming beta-sheets. When cooled to a temperature below the cholesteryl ester transition at 30 degrees C, the ordering of the low density lipoprotein core results in reversible changes in the protein conformation, decreasing the apparent amount of alpha-helix, beta-strand, and unordered structure below 30 degrees C and increasing beta-sheet and beta-turns. Lowering the ionic strength affects the core-associated transitions, shifting their temperature from 30 to 20 degrees C, and modifying protein conformation below the transition, An additional thermal event is ob served at 75 degrees C, leading to irreversible protein denaturation, In the broad temperature range between the 30 and 75 degrees C transitions, apolipoprotein B is stable toward both temperature and ionic strength changes, After thermal denaturation, the protein retains a certain degree of ordered structure.	UNIV BASQUE COUNTRY, DEPT BIOQUIM, E-48080 BILBAO, SPAIN; RUDJER BOSKOVIC INST, ZAGREB 41001, CROATIA	University of Basque Country; Rudjer Boskovic Institute			Goni, Felix M/M-5425-2015; Banuelos, Sonia/N-9128-2019	Goni, Felix M/0000-0001-6270-9216; Banuelos, Sonia/0000-0002-1399-381X				ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; ARRONDO JLR, 1987, J BIOL CHEM, V262, P9037; ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHATTERTON JE, 1991, J BIOL CHEM, V266, P5955; DEARBORN DG, 1969, P NATL ACAD SCI USA, V62, P179, DOI 10.1073/pnas.62.1.179; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; EFIMOV AV, 1993, PROG BIOPHYS MOL BIO, V60, P201, DOI 10.1016/0079-6107(93)90015-C; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1989, BIOCHIM BIOPHYS ACTA, V1006, P147, DOI 10.1016/0005-2760(89)90338-X; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HERAK JN, 1988, CHEM PHYS LIPIDS, V59, P135; HERZYK E, 1987, BIOCHIM BIOPHYS ACTA, V922, P145, DOI 10.1016/0005-2760(87)90148-2; JACKSON M, 1991, BIOCHEMISTRY-US, V30, P9681, DOI 10.1021/bi00104a016; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; MUGA A, 1993, ARCH BIOCHEM BIOPHYS, V300, P451, DOI 10.1006/abbi.1993.1061; NAUMANN D, 1993, BIOCHEMISTRY-US, V32, P3162, DOI 10.1021/bi00063a031; PIERCE JA, 1990, ANAL CHEM, V62, P477, DOI 10.1021/ac00204a011; PIFAT G, 1981, INT J BIOL MACROMOL, V3, P282, DOI 10.1016/0141-8130(81)90043-X; RUDEL LL, 1986, J LIPID RES, V27, P465; SCANU A, 1969, P NATL ACAD SCI USA, V62, P171, DOI 10.1073/pnas.62.1.171; SCHNITZER E, 1994, CHEM PHYS LIPIDS, V70, P63, DOI 10.1016/0009-3084(94)90048-5; SESHADRI S, 1994, BIOCHEMISTRY-US, V33, P1351, DOI 10.1021/bi00172a010; STEELE JCH, 1979, J BIOL CHEM, V254, P1633; Susi H., 1969, STRUCTURE STABILITY, P575; TALL AR, 1978, J CLIN INVEST, V62, P1354, DOI 10.1172/JCI109256; WALSH MT, 1986, J LIPID RES, V27, P316; WALSH MT, 1990, J LIPID RES, V31, P1051; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG PW, 1987, BIOCHEMISTRY-US, V26, P2706, DOI 10.1021/bi00384a009	33	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9192	9196						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721835				2022-12-27	WOS:A1995QU08900023
J	FREEMANTLE, SJ; TAYLOR, SM; KRYSTAL, G; MORAN, RG				FREEMANTLE, SJ; TAYLOR, SM; KRYSTAL, G; MORAN, RG			UPSTREAM ORGANIZATION OF AND MULTIPLE TRANSCRIPTS FROM THE HUMAN FOLYLPOLY-GAMMA-GLUTAMATE SYNTHETASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; FOLATE-DEPENDENT ENZYMES; TRANSFER-RNA-SYNTHETASES; CHINESE-HAMSTER CELLS; ONE-CARBON METABOLISM; MAMMALIAN-CELLS; RAT-LIVER; METHOTREXATE POLYGLUTAMATES; MESSENGER-RNAS; OVARY CELLS	Folylpoly-gamma-glutamate synthetase (FPGS) is essential for the survival of proliferating mammalian cells and central to the action of all ''classical'' folate antimetabolites. We report the isolation of cDNAs corresponding to the 5' ends of FPGS mRNA from both human and hamster cells which include a start codon upstream of and in-frame with the AUG in the previously reported FPGS open reading frame. The predicted hamster and human amino-terminal extension peptides have features consistent with a mitochondrial targeting sequence. Ribo-nuclease protection and 5'-rapid amplification of cDNA ends assays indicated multiple transcriptional start sites consistent with the sequence of the promoter region of this gene, which was highly GC-rich and did not contain TATA or CCAAT elements. These start sites would generate two classes of transcripts, one including the upstream AUG and one in which only the downstream AUG would be available for translation initiation. Transfection of the full length human cDNA into cells lacking FPGS restored their ability to grow in the absence of glycine, a product of mitochondrial folate metabolism, as well as of thymidine and purines. Therefore, we propose that the mitochondrial and cytosolic forms of FPGS are derived from the same gene, arising from the use of the two different translation initiation codons, and that the translation products differ by the presence of a 42-residue amino-terminal mitochondrial leader peptide.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University					NCI NIH HHS [CA 27605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARREDO J, 1992, MOL PHARMACOL, V42, P687; BARREDO JC, 1994, BLOOD, V84, P564; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CHANG ZF, 1993, CANCER RES, V53, P3253; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JONES C, 1980, CYTOGENET CELL GENET, V28, P181, DOI 10.1159/000131529; KIKUCHI G, 1973, MOL CELL BIOCHEM, V1, P169, DOI 10.1007/BF01659328; KIM YK, 1991, J BIOL CHEM, V267, P2723; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; ODA T, 1990, J BIOL CHEM, V265, P7513; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; RUMBERGER BG, 1990, CANCER RES, V50, P4639; Sambrook J, 1989, MOL CLONING LABORATO; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SUZUKI T, 1992, EUR J BIOCHEM, V207, P767, DOI 10.1111/j.1432-1033.1992.tb17107.x; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; TAYLOR S M, 1986, P937; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WHITEHEAD VM, 1990, BLOOD, V76, P44; WITTWER AJ, 1981, J BIOL CHEM, V256, P4109; WU M, 1987, J BIOL CHEM, V262, P12275	41	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9579	9584		10.1074/jbc.270.16.9579	http://dx.doi.org/10.1074/jbc.270.16.9579			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721888	hybrid			2022-12-27	WOS:A1995QU08900077
J	HIGAZI, AAR; BARGHOUTI, II; ABUMUCH, R				HIGAZI, AAR; BARGHOUTI, II; ABUMUCH, R			IDENTIFICATION OF AN INHIBITOR OF TISSUE-TYPE PLASMINOGEN ACTIVATOR-MEDIATED FIBRINOLYSIS IN HUMAN NEUTROPHILS - A ROLE FOR DEFENSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING SYSTEM; SKIN REACTIONS; HYPERSENSITIVITY; UROKINASE; KINETICS; BINDING; LIPOPROTEIN(A); STREPTOKINASE; DEPOSITION; LEUKOCYTES	An inhibitor of tissue-type plasminogen activator (tPA)-mediated and plasminogen-dependent fibrinolysis was isolated from human neutrophils. On a G-50 gel filtration column, the antifibrinolytic activity present in neutrophil homogenates comigrated with proteins of <13 kDa, The inhibitory fraction had only a slight effect on urokinase with plasminogen- or plasmin-mediated fibrinolysis and no effect on urokinase- or plasmin-mediated cleavage of H-D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251). The neutrophil-derived fraction inhibited tPA with plasminogen activity on S-2251 but not on H-D-isoleucyl-L-prolyl-L-arginine-p-nitroanilide (S-2288). The inhibition of tPA-mediated and plasminogen-dependent fibrinolysis or S-2251 cleavage showed a competitive pattern and could be relieved by increasing the concentration of plasminogen. The same fraction also inhibited binding of plasminogen to fibrin. Consecutive purification steps revealed that the molecular mass of the inhibitor was 1-5 kDa, Polylysine-Sepharose affinity chromatography indicated that the inhibitor is a protein of 4 kDa, migrating as one band on SDS-polyacrylamide gel electrophoresis. Amino acid sequence analysis of this band showed the presence of two sequences, differing by one amino acid, which are identical to defensin I and II. Comparison of the sequences of plasminogen and defensin showed homology of defensin to the plasminogen kringles known to contain the lysine binding sites. The close structural similarity between defensin and plasminogen kringles and the ability of defensin to compete with plasminogen on binding to fibrin explain the ability of defensin to inhibit tPA-mediated, plasminogen-dependent fibrinolysis, These results suggest that the antifibrinolytic activity of defensin may have a biological function in preventing the spread of infection.	HADASSAH UNIV HOSP,DEPT CLIN BIOCHEM,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								BATEMAN A, 1991, J BIOL CHEM, V266, P7524; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CHURCH WR, 1991, HYBRIDOMA, V10, P659, DOI 10.1089/hyb.1991.10.659; COLVIN RB, 1979, J CLIN INVEST, V63, P1302, DOI 10.1172/JCI109425; COLVIN RB, 1975, J IMMUNOL, V114, P377; COLVIN RB, 1973, J EXP MED, V138, P686, DOI 10.1084/jem.138.3.686; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EDWARDS RL, 1978, SCIENCE, V200, P541, DOI 10.1126/science.644314; EDWARDS RL, 1992, SEMIN HEMATOL, V29, P202; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HIGAZI AA, 1992, BIOCHEM J, V282, P863, DOI 10.1042/bj2820863; HIGAZI AA, 1994, BIOCHEM J, V300, P251, DOI 10.1042/bj3000251; HOWARD GC, 1993, LAB INVEST, V69, P373; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS M, 1983, EUR J BIOCHEM, V135, P379, DOI 10.1111/j.1432-1033.1983.tb07665.x; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MATZNER Y, 1984, J LAB CLIN MED, V103, P227; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; Menkin V, 1938, PHYSIOL REV, V18, P366, DOI 10.1152/physrev.1938.18.3.366; MOVAT HZ, 1960, BRIT J EXP PATHOL, V41, P97; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; PERDUE JF, 1981, J BIOL CHEM, V256, P2767; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; SHAVIT R, 1983, SCIENCE, V220, P728; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; TAKADA A, 1987, THROMB RES, V45, P371, DOI 10.1016/0049-3848(87)90226-X; TAKADA A, 1983, THROMB RES, V30, P309, DOI 10.1016/0049-3848(83)90085-3; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; VERSTRAETE M, 1985, DRUGS, V29, P236, DOI 10.2165/00003495-198529030-00003; VERSTRAETE M, 1986, BLOOD, V67, P1529; VICTOR J., 1994, HEMOSTASIS THROMBOSI, P1023; WALLEN P, 1978, PROGR CHEM FIBRINOLY, V3, P167	40	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9472	9477		10.1074/jbc.270.16.9472	http://dx.doi.org/10.1074/jbc.270.16.9472			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721874	hybrid			2022-12-27	WOS:A1995QU08900063
J	KLEIN, HG; DUVERGER, N; ALBERS, JJ; MARCOVINA, S; BREWER, HB; SANTAMARINAFOJO, S				KLEIN, HG; DUVERGER, N; ALBERS, JJ; MARCOVINA, S; BREWER, HB; SANTAMARINAFOJO, S			IN-VITRO EXPRESSION OF STRUCTURAL DEFECTS IN THE LECITHIN-CHOLESTEROL ACYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISH EYE DISEASE; SITE-DIRECTED MUTAGENESIS; DIFFERENT ALLELIC MUTATIONS; HIGH-DENSITY-LIPOPROTEIN; AMINO-ACID EXCHANGE; LCAT DEFICIENCY; SECONDARY STRUCTURE; FAMILIAL LECITHIN; MOLECULAR DEFECT; ESTERIFICATION RATE	Classic LCAT deficiency (CLD) and fish eye disease (FED) are two clinically distinct syndromes, associated with defects in the lecithin-cholesterol acyltransferase (LCAT) gene resulting in total (CLD) or partial (FED) enzyme deficiency. In order to investigate the underlying molecular mechanisms that lead to different phenotypic expression in CLD and FED, LCAT mutants associated with either CLD (LCAT(147), LCAT(156), and LCAT(228)) or FED (LCAT(10), LCAT(123), LCAT(158), LCAT(293), LCAT(300), and LCAT(347)) were expressed in vitro in human embryonic kidney 293 cells and characterized with respect to LCAT expression and enzyme activity, Evaluation of mutant LCAT gene transcription by Northern blot analysis demonstrated LCAT mRNA of normal size and concentration. Although all constructs gave rise to similar intracellular LCAT mass, the amount of enzyme present in the media for LCAT(147), LCAT(156),and LCAT(300) was reduced to less than 10% of normal, suggesting that these mutations disrupted LCAT secretion. Western blot analysis of cell culture media containing wild type or mutant LCAT demonstrated the presence of a single normal-sized band of 67 kDa. The ability of the different enzymes to esterify free cholesterol in high density lipoprotein-like proteoliposomes (alpha-LCAT-specific activity) was reduced to less than 5% of normal for CLD mutants LCAT(147) and LCAT(228) and FED mutants LCAT(10) LCAT(123), LCAT(293), and LCAT(347), whereas that of LCAT(156), LCAT(158), and LCAT(300) ranged from 45 to 110% LCAT of control. Although most FED mutant LCAT enzymes retained the ability to esterify free cholesterol present in alpha- and beta-lipoproteins of heat-inactivated plasma, esterification was undetectable in all CLD mutants (LCAT(147), LCAT(156), and LCAT(228)). In contrast, all mutant enzymes retained the ability to hydrolyze the water soluble, short-chained fatty acid substrate p-nitrophenol-butyrate, In summary, our studies establish the functional significance of nine LCAT gene defects associated with either FED or CLD. Characterization of the expressed LCAT mutants identified multiple, overlapping functional abnormalities that include defects in secretion and/or disruption of enzymic activity. All nine LCAT mutants retained the ability to hydrolyze the water-soluble PNPB substrate, indicating intact hydrolytic function, Based on these studies we propose that mutations in LCAT residues 147, 156, 228 (CLD) and 10, 123, 158, 293, 300, and 347 (FED) do not disrupt the functional domain mediating LCAT phospholipase activity, but alter structural domains involved in lipid binding or transesterification.	NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,NW LIPID RES CTR,DEPT MED,SEATTLE,WA 98103	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NHLBI NIH HHS [HL 3-00H6] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1981, J LIPID RES, V22, P1206; ALBERS JJ, 1981, J CLIN INVEST, V67, P141, DOI 10.1172/JCI110006; Assmann G, 1991, CURR OPIN LIPIDOL, V2, P110; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BUJO H, 1991, BIOCHEM BIOPH RES CO, V181, P933, DOI 10.1016/0006-291X(91)92026-G; CARLSON LA, 1982, EUR J CLIN INVEST, V12, P41, DOI 10.1111/j.1365-2362.1982.tb00938.x; CHEN CH, 1982, J LIPID RES, V23, P680; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLET X, 1991, BIOCHEMISTRY-US, V30, P3228, DOI 10.1021/bi00227a010; DOBIASOVA M, 1986, PHYSIOL BOHEMOSLOV, V35, P319; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; FRANCONE OL, 1993, BIOCHIM BIOPHYS ACTA, V1166, P301, DOI 10.1016/0005-2760(93)90110-U; FUNKE H, 1991, P NATL ACAD SCI USA, V88, P4855, DOI 10.1073/pnas.88.11.4855; FUNKE H, 1993, J CLIN INVEST, V91, P677, DOI 10.1172/JCI116248; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GOTODA T, 1991, LANCET, V338, P778, DOI 10.1016/0140-6736(91)90665-C; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMQUIST L, 1987, ACTA MED SCAND, V222, P23; JAUHIAINEN M, 1988, J BIOL CHEM, V263, P6525; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; JAUHIAINEN M, 1989, J BIOL CHEM, V264, P1963; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; KARMIN O, 1993, J LIPID RES, V34, P81; KLEIN HG, 1992, J CLIN INVEST, V89, P499, DOI 10.1172/JCI115612; KLEIN HG, 1993, J LIPID RES, V34, P49; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; MAEDA E, 1991, BIOCHEM BIOPH RES CO, V178, P460, DOI 10.1016/0006-291X(91)90129-U; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; ROGNE S, 1987, BIOCHEM BIOPH RES CO, V148, P161, DOI 10.1016/0006-291X(87)91090-4; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SEGREST JP, 1992, J LIPID RES, V33, P141; SKRETTING G, 1992, BIOCHEM BIOPH RES CO, V182, P583, DOI 10.1016/0006-291X(92)91772-I; SKRETTING G, 1992, FEBS LETT, V309, P307, DOI 10.1016/0014-5793(92)80795-I; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; TARAMELLI R, 1990, HUM GENET, V85, P195; YANG CY, 1987, J BIOL CHEM, V262, P3086	44	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9443	9447		10.1074/jbc.270.16.9443	http://dx.doi.org/10.1074/jbc.270.16.9443			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721870	hybrid			2022-12-27	WOS:A1995QU08900059
J	NISHIKAWA, N; OISHI, M; KIYAMA, R				NISHIKAWA, N; OISHI, M; KIYAMA, R			CONSTRUCTION OF A HUMAN GENOMIC LIBRARY OF CLONES CONTAINING POLY(DG-DA)CENTER-DOT-POLY(DT-DC) TRACTS BY MG2+-DEPENDENT TRIPLEX AFFINITY CAPTURE - DNA POLYMORPHISM ASSOCIATED WITH THE TRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER CHROMATID EXCHANGE; SITE-SPECIFIC CLEAVAGE; GENETIC-LINKAGE MAP; HANDED Z-DNA; HELIX FORMATION; H-DNA; SEQUENCES; PURIFICATION; ELEMENT; INVITRO	Microsatellite DNA is a useful tool for detecting DNA polymorphisms among species or individuals, especially those among closely related individuals, We constructed a library of clones that contained poly(dG-dA). poly(dT-dC) tracts from human genomic DNA by Mg2+-dependent tripler DNA formation, Examination of tripler DNA formation in the presence of various metal ions Mg2+, Mn2+, or Zn2+ revealed that the procedure worked best in the presence of Mg2+, Affinity enrichment was performed with AluI-digested chromosomal DNA mixed with biotinylated (dG-dA)(17) in the presence of Mg2+, A library constructed after three cycles of affinity enrich ment showed that over 80% of the clones contained at least one poly(dG-dA) poly(dT-dC) tract, Most of them contained a perfect (dG-dA)(n) repeat 30-84 base pairs in length, while some contained variants such as (dC-dT)(10)-(dC)-(dC-dT)(9). Using the clones from the library as a probe, we detected DNA polymorphisms associated with the repeat length of the tracts in the Japanese population, We also detected a microsatellite instability among the tracts in a cancer tissue sample.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BLAHO JA, 1986, P NATL ACAD SCI USA, V37, P107; BLAHO JA, 1989, PROG NUCLEIC ACID RE, V37, P107; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DUALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOX KR, 1992, NUCLEIC ACIDS RES, V20, P1235, DOI 10.1093/nar/20.6.1235; GUT SH, 1987, NUCLEIC ACIDS RES, V15, P9691, DOI 10.1093/nar/15.23.9691; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; ITO T, 1992, P NATL ACAD SCI USA, V89, P495, DOI 10.1073/pnas.89.2.495; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KIYAMA R, 1994, J MOL BIOL, V237, P193, DOI 10.1006/jmbi.1994.1221; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LEBLANCSTRACESKI JM, 1994, GENOMICS, V19, P341, DOI 10.1006/geno.1994.1067; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LYAMICHEV VI, 1991, NUCLEIC ACIDS RES, V19, P1633, DOI 10.1093/nar/19.7.1633; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P585, DOI 10.1093/nar/21.3.585; MALKOV VA, 1992, NUCLEIC ACIDS RES, V20, P4889, DOI 10.1093/nar/20.18.4889; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NOGUCHI CT, 1991, BLOOD, V78, P2548; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; USDIN K, 1989, J BIOL CHEM, V264, P15681; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WEINREB A, 1988, P NATL ACAD SCI USA, V85, P529, DOI 10.1073/pnas.85.2.529; WEISSENBACH J, 1993, CURR OPIN GENET DEV, V3, P414, DOI 10.1016/0959-437X(93)90114-5; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WROGEMANN K, 1993, EXS, V67, P141; YOKOTA H, 1994, ANAL BIOCHEM, V219, P131, DOI 10.1006/abio.1994.1241	45	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9258	9264		10.1074/jbc.270.16.9258	http://dx.doi.org/10.1074/jbc.270.16.9258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721845	hybrid			2022-12-27	WOS:A1995QU08900033
J	WONGKAJORNSILP, A; ROSENBERRY, TL				WONGKAJORNSILP, A; ROSENBERRY, TL			UPTAKE OF EXOGENOUS SN-1-ACYL-2-LYSO-PHOSPHATIDYLINOSITOL INTO HELA S3 CELLS - REACYLATION ON THE CELL-SURFACE AND METABOLISM TO GLUCOSAMINYL(ACYL)PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; GLYCOINOSITOL PHOSPHOLIPID ANCHOR; BACILLUS-THURINGIENSIS; MAMMALIAN-CELLS; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS; MEMBRANES; KINETICS; MUTANTS	A HeLa S3 subline is unusual in accumulating relatively large amounts of glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), a derivative of phosphatidylinositol (PI) in which both GlcN and a fatty acid are linked to inositol hydroxyl groups (D, Sevlever, D, Humphrey, and T, L, Rosenberry, submitted for publication), This lipid is a proposed intermediate on the biosynthetic pathway for glycosyl-PI (GPI) anchors of membrane proteins, In this study we demonstrate for the first time that exogenous inositol phospholipids can enter this biosynthetic pathway and be metabolized to GlcN(acyl)PI. When HeLa S3 cells were incubated for 24 h with exogenous PI or sn-1-acyl-2-lyso-phosphatidylinositol (lyse-PI) labeled with H-3 in the inositol group, 25-30% of the label was recovered in cell-associated lipids and most of the remaining 70-75% in hydrophilic metabolites in the medium, The predominant labeled lipid was PI, with smaller amounts of lyso-PI, phosphatidylinositol 4-phosphate (PIP), and GlcN(acyl)PI. Both exogenous lipid precursors gave the same distribution of labeled lipids, and a similar distribution was observed for endogenous inositol phospholipids metabolically labeled with [H-3]inositol. Addition of excess inositol had no effect on the conversion of [H-3]lyso-PI to [H-3]GlcN(acyl)PI, indicating that the conversion did not result from breakdown to [H-3]inositol followed by resynthesis, The cellular orientation of incorporated PI and lyse-PI was determined by incubating cells at 4 degrees C with PI-specific phospholipase C (PI-PLC), This enzyme cleaves only PI and lyse-PI on the outer leaflet of the cell membrane, After 24-h incubation with either precursor, only about 15% of cell-associated [H-3]PI or [H-3]lyso-PI was on the outer leaflet, However, more than 60% of the [H-3]PI was on the outer leaflet after 1-h incubation with either precursor, suggesting that substantial sn-2 acylation of exogenous [H-3]lyso-PI occurred in the outer leaflet, This suggestion was confirmed by examining labeled lipids in cells after uptake of [H-3]lyso-PI at 4 degrees C, No transmembrane translocation of lyso-PI, PI phosphorylation, or PI glycosylation occurred at this temperature, but some sn-2 acylation was apparent and more than 90% of the [H-3]PI formed was on the outer leaflet, These data indicate that sn-2 acylation can occur in the outer leaflet of the cell membrane, perhaps by transacylation from other cell surface phospholipids.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; MAHIDOL UNIV, SIRIRAJ HOSP, FAC MED, DEPT PHARMACOL, BANGKOK 10700, THAILAND	Case Western Reserve University; Mahidol University			Wongkajornsilp, Adisak/AAH-7668-2019	Wongkajornsilp, Adisak/0000-0002-3965-0997	NIDDK NIH HHS [DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BESTERMAN JM, 1992, BIOCHEMISTRY-US, V31, P2046, DOI 10.1021/bi00122a022; BUTIKOFER P, 1990, J BIOL CHEM, V265, P16035; CATT KJ, 1989, ANNU REV MED, V40, P487; DARNELL JC, 1991, BIOCHIM BIOPHYS ACTA, V1084, P279, DOI 10.1016/0005-2760(91)90070-X; DEEG MA, 1992, J BIOL CHEM, V267, P18573; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; GANONG BR, 1991, AM J MED SCI, V302, P304, DOI 10.1097/00000441-199111000-00009; GARDAM MA, 1989, BIOCHEMISTRY-US, V28, P884, DOI 10.1021/bi00428a072; HENDRICKSON HS, 1992, BIOCHEMISTRY-US, V31, P12169, DOI 10.1021/bi00163a028; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; HIDAKA M, 1993, BIOCHEM BIOPH RES CO, V191, P571, DOI 10.1006/bbrc.1993.1256; HIGGINS JA, 1989, BIOCHEM J, V259, P913, DOI 10.1042/bj2590913; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOHENGASSER CJM, 1986, J BIOL CHEM, V261, P6255; LOW MG, 1977, BIOCHEM J, V162, P235, DOI 10.1042/bj1620235; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROSS TS, 1986, J BIOL CHEM, V261, P1119; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; SINGH N, 1994, MOL CELL BIOL, V14, P21, DOI 10.1128/MCB.14.1.21; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TING AE, 1990, J BIOL CHEM, V265, P5337; UEDA E, 1993, J BIOL CHEM, V268, P9998; VOLWERK JJ, 1992, J CELL PHYSIOL, V151, P613, DOI 10.1002/jcp.1041510322; WALTER EI, 1990, J IMMUNOL, V144, P1030; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707	30	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9147	9153		10.1074/jbc.270.16.9147	http://dx.doi.org/10.1074/jbc.270.16.9147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721829	hybrid			2022-12-27	WOS:A1995QU08900017
J	DUPORT, C; BAYSSE, C; MICHELBRIAND, Y				DUPORT, C; BAYSSE, C; MICHELBRIAND, Y			MOLECULAR CHARACTERIZATION OF PYOCIN S3, A NOVEL S-TYPE PYOCIN FROM PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; CYSTIC-FIBROSIS; DNASE; DETERMINANT; SEQUENCE; CLONING; GENES; AP41	The genetic determinant for the soluble pyocin S3 was isolated from a genomic library constructed in the plasmid pGV1122, of Pseudomonas aeruginosa strain P12 isolated from a cystic fibrosis patient. The nucleotide sequence of a 3270-base pair DNA fragment was determined, and the two structural genes, pyoS3A and pyoS3I, and the 3'- and 5'-flanking regions were localized. Transcription (Northern blot) analysis showed that the two genes were co-transcribed. The genes pyoS3A and pyoS3I code for polypeptides of 767 and 154 amino acids, respectively, with calculated molecular weights of 81,385 and 17,047. Pyocin S3 was produced in Escherichia coli from a plasmid and purified as a complex of two components (S3A and S3I) corresponding to the pyoS3A and pyoS3I gene products, respectively. The S3A component, like pyocin S3, had a killing effect involving DNase activity and was inhibited by the S3I protein. Comparisons of the predicted amino acid sequence of the two components of pyocin S3 to those of pyocins S1, S2, and AP41 indicate that pyocin S3 is a new type of S-type pyocin.			DUPORT, C (corresponding author), FAC MED BESANCON, BACTERIOL LAB, F-25030 BESANCON, FRANCE.			Baysse, Christine/0000-0003-1318-2192				BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CARLOMAGNO MS, 1985, J BACTERIOL, V163, P362, DOI 10.1128/JB.163.1.362-368.1985; DERETIC V, 1989, BIO-TECHNOL, V7, P1250; FEGAN M, 1991, J CLIN MICROBIOL, V29, P2151, DOI 10.1128/JCM.29.10.2151-2157.1991; FYFE JAM, 1984, J CLIN MICROBIOL, V20, P47, DOI 10.1128/JCM.20.1.47-50.1984; Godard C, 1993, Eur J Med, V2, P117; Govan J. R. W., 1978, METHOD MICROBIOL, V10, P61, DOI 10.1016/S0580-9517(08)70660-3; GOVAN JRW, 1974, J GEN MICROBIOL, V80, P1; GOVAN JRW, 1986, SCAND J INFECT DIS, P31; HAMON Y, 1956, ANN I PASTEUR PARIS, V91, P82; HAMON Y, 1961, ANN I PASTEUR, V88, P193; HIGERD TB, 1967, J BACTERIOL, V93, P1976, DOI 10.1128/JB.93.6.1976-1986.1967; HOLLOWAY BW, 1960, J PATHOL BACTERIOL, V80, P448, DOI 10.1002/path.1700800237; ITO S, 1970, J GEN APPL MICROBIOL, V16, P205, DOI 10.2323/jgam.16.3_205; JACOB F, 1954, ANN I PASTEUR PARIS, V86, P149; KAGEYAMA M, 1964, J BIOCHEM-TOKYO, V55, P49, DOI 10.1093/oxfordjournals.jbchem.a127839; KIEFFER BL, 1991, GENE, P115; KURODA K, 1979, J BIOCHEM, V85, P7, DOI 10.1093/oxfordjournals.jbchem.a132332; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEEMANS J, 1982, GENE, V19, P361, DOI 10.1016/0378-1119(82)90027-0; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MATSUI H, 1993, J BACTERIOL, V175, P1257, DOI 10.1128/JB.175.5.1257-1263.1993; OHKAWA I, 1980, J BIOCHEM-TOKYO, V87, P323, DOI 10.1093/oxfordjournals.jbchem.a132740; PATERSON AC, 1965, J GEN MICROBIOL, V39, P295, DOI 10.1099/00221287-39-3-295; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Sambrook J, 1989, MOL CLONING LABORATO; SANO Y, 1984, J BACTERIOL, V158, P562, DOI 10.1128/JB.158.2.562-570.1984; SANO Y, 1981, J BACTERIOL, V146, P733, DOI 10.1128/JB.146.2.733-739.1981; SANO Y, 1993, J BACTERIOL, V175, P2907, DOI 10.1128/JB.175.10.2907-2916.1993; SANO Y, 1993, MOL GEN GENET, V237, P161, DOI 10.1007/BF00282797; SANO Y, 1993, J BACTERIOL, V175, P6179, DOI 10.1128/JB.175.19.6179-6185.1993; SANO Y, 1993, J BACTERIOL, V175, P912, DOI 10.1128/JB.175.3.912-915.1993; SANO Y, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P352; SAVIOZ A, 1993, MOL GEN GENET, V238, P74, DOI 10.1007/BF00279533; SCHATT E, 1989, J BACTERIOL, V171, P6218, DOI 10.1128/jb.171.11.6218-6226.1989; SEO YH, 1990, BIOCHEM BIOPH RES CO, V172, P455, DOI 10.1016/0006-291X(90)90694-I; SMITH AW, 1992, J BACTERIOL, V174, P4847, DOI 10.1128/JB.174.14.4847-4849.1992; TREDGETT MW, 1990, J MED MICROBIOL, V32, P169, DOI 10.1099/00222615-32-3-169; VLIEGENTHART JS, 1991, ANTIMICROB AGENTS CH, V35, P892, DOI 10.1128/AAC.35.5.892; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANISCHPERRON C, 1985, GENE, V33, P13	42	53	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8920	8927		10.1074/jbc.270.15.8920	http://dx.doi.org/10.1074/jbc.270.15.8920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721800	hybrid			2022-12-27	WOS:A1995QT44800079
J	KIM, JH; LEE, KN; YI, GS; YU, MH				KIM, JH; LEE, KN; YI, GS; YU, MH			A THERMOSTABLE MUTATION LOCATED AT THE HYDROPHOBIC CORE OF ALPHA(1)-ANTITRYPSIN SUPPRESSES THE FOLDING DEFECT OF THE Z-TYPE VARIANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILE REACTIVE CENTER; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; BETA-SHEET; SITE LOOP; SERPINS; ALPHA-1-ANTITRYPSIN; INTACT; TRANSITION; STABILITY	A thermostable mutation, F51L, at the hydrophobic core of human alpha(1)-antitrypsin (alpha(1)AT) increased the conformational stability of the molecule by decreasing the unfolding rate significantly without altering the refolding rate, The mutation specifically influenced the transition between the native state and a compact intermediate, which retained similar to 70% of the far-UV CD signal, but which had most of the fluorescence signal already de quenched. The mutant alpha(1)AT protein was more resistant than the wild-type protein to the insertion of the tetradecapeptide mimicking the sequence of the reactive center loop, indicating that the mutation increases the closing of the central beta-sheet, the A-sheet, in the native state. The F51L mutation enhanced the folding efficiency of the Z-type (E342K) genetic variation, which causes aggregation of the molecule in the liver. It has been shown previously that the aggregation of the Z protein occurs via loop sheet polymerization, in which the reactive center loop of one molecule is inserted into the opening of the A-sheet of another molecule. Our results strongly suggest that the hydrophobic core of alpha(1)AT regulates the opening-closing of the A-sheet and that certain genetic variations that cause opening of the A-sheet can be corrected by inserting an additional stable mutation into the hydrophobic core.	KOREA ADV INST SCI & TECHNOL,GENET ENGN RES INST,PROT ENGN GRP,TAEJON 305333,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)			Yi, Gwan-Su/A-7896-2011	Yi, Gwan-Su/0000-0003-0012-6546				BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; CROWTHER D C, 1992, Current Opinion in Biotechnology, V3, P399, DOI 10.1016/0958-1669(92)90169-J; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; FLETTERICK RJ, 1994, NAT STRUCT BIOL, V1, P201, DOI 10.1038/nsb0494-201; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWON KS, 1994, J BIOL CHEM, V269, P9627; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15338; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PERKINS SJ, 1992, J MOL BIOL, V228, P1235, DOI 10.1016/0022-2836(92)90329-I; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	29	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8597	8601		10.1074/jbc.270.15.8597	http://dx.doi.org/10.1074/jbc.270.15.8597			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721761	hybrid			2022-12-27	WOS:A1995QT44800037
J	KOEPP, AE; HEZARI, M; ZAJICEK, J; VOGEL, BS; LAFEVER, RE; LEWIS, NG; CROTEAU, R				KOEPP, AE; HEZARI, M; ZAJICEK, J; VOGEL, BS; LAFEVER, RE; LEWIS, NG; CROTEAU, R			CYCLIZATION OF GERANYLGERANYL DIPHOSPHATE TO TAXA-4(5),11(12)-DIENE IS THE COMMITTED STEP OF TAXOL BIOSYNTHESIS IN PACIFIC YEW	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE QUANTUM NMR; TAXUS-BREVIFOLIA; BARK; CHEMISTRY; AGENTS; H-1	The biosynthesis of taxol (paclitaxel) and related tax aids in Pacific yew (Taxus brevifolia) is thought to involve the cyclization of geranylgeranyl diphosphate to a taxadiene followed by extensive oxygenation of this diterpene olefin intermediate, A cell-free preparation from sapling yew stems catalyzed the conversion of [1-H-3]geranylgeranyl diphosphate to a cyclic diterpene oIefin that, when incubated with stem sections, was converted in good radiochemical yield to several highly functionalized taxanes, including 10-deacetyl baccatin III and taxol itself. Addition of the labeled olefin to a yew bark extract, followed by radiochemically guided fractionation, provided sufficient product to establish the structure as taxa-4(5),11(12)-diene by two-dimensional NMR spectroscopic methods, Therefore, the first dedicated step in taxol biosynthesis is the conversion of the universal diterpenoid precursor geranylgeranyl diphosphate to taxa-4(5),11(12)-diene, rather than to the 4(20),11(12)-diene isomer previously suggested an the basis of the abundance of taxoids with double bonds in these positions. The very common occurrence of taxane derivatives bearing the 4(20)-ene-5-oxy functional grouping, and the lack of oxygenated derivatives bearing a 4(5)-double bond, suggest that hydroxylation at C-5 of taxadiene with allylic rearrangement of the double bond is an early step in the conversion of this olefin intermediate to taxol.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, UNIV NMR SPECT CTR, PULLMAN, WA 99164 USA	Washington State University; Washington State University				Lewis, Norman/0000-0001-5742-032X	NATIONAL CANCER INSTITUTE [R37CA055254, R01CA055254] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1981, J MAGN RESON, V42, P501, DOI 10.1016/0022-2364(81)90272-9; BEGLEY MJ, 1990, TETRAHEDRON, V46, P4907, DOI 10.1016/S0040-4020(01)85602-7; BORMAN S, 1994, CHEM ENG NEWS, V72, P32, DOI 10.1021/cen-v072n008.p032; CRAGG GM, 1993, J NAT PROD, V56, P1657, DOI 10.1021/np50100a001; CRAGG GM, 1991, CANCER CELL-MON REV, V3, P233; DEMARCANO DP, 1969, J CHEM SOC CHEM COMM, P1282, DOI 10.1039/c29690001282; ELLIS D, 1993, 1993 P INT YEW RES C; FETTNETO AG, 1992, BIO-TECHNOL, V10, P1572, DOI 10.1038/nbt1292-1572; FLEMING PE, 1994, J AM CHEM SOC, V116, P4137, DOI 10.1021/ja00088a083; FLEMING PE, 1993, J AM CHEM SOC, V115, P805, DOI 10.1021/ja00055a072; FLOSS HG, 1995, TAXOL SCI APPLICATIO; GEORG GI, 1994, EXPERT OPIN THER PAT, V4, P109; GIBSON DM, 1993, PLANT CELL REP, V12, P479, DOI 10.1007/BF00236091; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUENARD D, 1993, ACCOUNTS CHEM RES, V26, P160, DOI 10.1021/ar00028a005; GUERITTEVOEGELEIN F, 1987, J NAT PROD, V50, P9, DOI 10.1021/np50049a002; HARRISON JW, 1966, J CHEM SOC C, P1933, DOI 10.1039/j39660001933; HOLMES FA, 1995, ACS SYM SER, V583, P31; KELSEY RG, 1992, J NAT PROD, V55, P912, DOI 10.1021/np50085a010; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; KINGSTON DGI, 1993, PROG CHEM ORG NAT PR, V61, P1; KINGSTON DGI, 1995, TAXANE ANTICANCER AG, P203; LAFEVER RE, 1994, ARCH BIOCHEM BIOPHYS, V313, P139, DOI 10.1006/abbi.1994.1370; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; NETO AGF, 1992, PLANTA MED, V58, P464, DOI 10.1055/s-2006-961515; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; SATTERWHITE DM, 1988, J CHROMATOGR, V452, P61, DOI 10.1016/S0021-9673(01)81437-0; STIERLE A, 1993, SCIENCE, V260, P214, DOI 10.1126/science.8097061; STROBEL GA, 1992, PLANT SCI, V84, P65, DOI 10.1016/0168-9452(92)90209-5; STROBEL GA, 1993, PLANT SCI, V92, P1, DOI 10.1016/0168-9452(93)90060-D; VANCE NC, 1994, PHYTOCHEMISTRY, V36, P1241, DOI 10.1016/S0031-9422(00)89644-2; VIDENSEK N, 1990, J NAT PROD, V53, P1609, DOI 10.1021/np50072a039; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; West C. A., 1981, BIOSYNTHESIS ISOPREN, V1, P375; WHEELER NC, 1992, J NAT PROD, V55, P432, DOI 10.1021/np50082a005; WHEELER NC, 1993, J FOREST, V91, P15; WITHERUP KM, 1990, J NAT PROD, V53, P1249, DOI 10.1021/np50071a017; ZAMIR LO, 1992, TETRAHEDRON LETT, V33, P5235, DOI 10.1016/S0040-4039(00)79141-6; [No title captured]; [No title captured]	42	167	188	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8686	8690		10.1074/jbc.270.15.8686	http://dx.doi.org/10.1074/jbc.270.15.8686			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721772	hybrid			2022-12-27	WOS:A1995QT44800050
J	MENG, QH; BERGERON, J; SPARKS, DL; MARCEL, YL				MENG, QH; BERGERON, J; SPARKS, DL; MARCEL, YL			ROLE OF APOLIPOPROTEIN-A-I IN CHOLESTEROL TRANSFER BETWEEN LIPOPROTEINS - EVIDENCE FOR INVOLVEMENT OF SPECIFIC APOA-I DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; CELL-DERIVED CHOLESTEROL; UNESTERIFIED CHOLESTEROL; PLASMA-LIPOPROTEINS; PHOSPHATIDYLCHOLINE; ACYLTRANSFERASE; MECHANISM; LECITHIN; EXCHANGE; COMPLEXES	A series of monoclonal antibodies against epitopes spanning different domains of apoA-I have been tested for their effects on unesterified cholesterol transfer be tween low density lipoprotein (LDL) and well-defined homogenous lipoproteins reconstituted with phosphatidylcholine, cholesterol, and apoA-I (LpA-I). Antibodies 2G11 (reacting between residues 25 and 110), A05 (residues 25-82), A03 (residues 135-140), A44 and r5G9 (residues 149-186), and 4A12 (residues 173-205) significantly inhibit cholesterol transfer from LDL to Lp2A-I while they enhance transfer in the opposite direction, thus causing an increased net transfer to LDL. Most of these monoclonal antibodies (mAbs) also enhance phospholipid transfer to LDL but in a lesser and variable proportion relative to cholesterol. Their epitopes are mainly contained within domains that are predicted to be amphipathic alpha-helices. In contrast, mAbs 4H1 (residues 2-8), 3G10 (residues 96-121), and 5F6 (residues 116-141) have little or no effect on either cholesterol or phospholipid transfer, and the epitopes for these three mAbs have been shown in earlier studies to be structurally and functionally related, Their immunoreactivity responds similarly to variation in lipoprotein cholesterol content, and the antibodies binding to these sites compete with one another and have similar effects on the cholesterol esterification reaction. Thus, the current results are compatible with the hypothesis that they form an integrated domain with a common function in cholesterol metabolism, possibly as part of a hinge domain. Most mAbs were found to increase significantly the a-helicity of apoA-I in the Lp2A-I immunecomplexes, suggesting that they may increase the stability of the lipid-bound apoA-I, However, not unexpectedly, there is no correlation between the effects of mAbs on alpha-helicity and their effects on cholesterol or phospholipid transfer since each mAb has a discrete effect on these transfers. These studies demonstrate the specificity of LpA-I particles in cholesterol transport and document the existence of apoA-I domains with different functions in cholesterol transport.	UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT PATHOL & LAB MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa								AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BAKA CL, 1994, J BIOL CHEM, V269, P10288; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BITTMAN R, 1984, BIOCHIM BIOPHYS ACTA, V772, P117, DOI 10.1016/0005-2736(84)90034-8; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEN GC, 1986, METHOD ENZYMOL, V128, P519; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; HANDA T, 1992, BIOCHEMISTRY-US, V31, P1415, DOI 10.1021/bi00120a018; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1985, BIOCHEMISTRY-US, V24, P3508, DOI 10.1021/bi00335a018; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCHOOMUN J, 1994, BBA-LIPID LIPID MET, V1212, P319, DOI 10.1016/0005-2760(94)90206-2; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1982, BIOCHEMISTRY-US, V21, P2964, DOI 10.1021/bi00541a025; MARCEL YL, 1987, J LIPID RES, V28, P768; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P7110, DOI 10.1021/bi00346a014; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MENG QH, 1993, J BIOL CHEM, V268, P16966; MENG QH, 1994, IN PRESS J BIOL CHEM; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; MILNE R, 1987, MOL IMMUNOL, V24, P127, DOI 10.1016/0161-5890(87)90084-8; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PETIT E, 1987, BIOCHIM BIOPHYS ACTA, V919, P287, DOI 10.1016/0005-2760(87)90268-2; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STECK TL, 1988, J BIOL CHEM, V263, P13023; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; TALL AR, 1978, BIOCHIM BIOPHYS ACTA, V513, P185, DOI 10.1016/0005-2736(78)90172-4; WILLIAMS PT, 1991, J LIPID RES, V31, P1131	40	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8588	8596		10.1074/jbc.270.15.8588	http://dx.doi.org/10.1074/jbc.270.15.8588			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721760	hybrid			2022-12-27	WOS:A1995QT44800036
J	HANNER, M; MOEBIUS, FF; WEBER, F; GRABNER, M; STRIESSNIG, J; GLOSSMANN, H				HANNER, M; MOEBIUS, FF; WEBER, F; GRABNER, M; STRIESSNIG, J; GLOSSMANN, H			PHENYLALKYLAMINE CA2+ ANTAGONIST BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE; ENDOPLASMIC-RETICULUM; EXPRESSION CLONING; CEREBRAL-ISCHEMIA; SIGMA-RECEPTORS; IDENTIFICATION; SITES; POLYPEPTIDE; COTRANSPORT; OPIPRAMOL	We recently characterized (Moebius, F. F., Burrows, G. G., Striessnig, J., and Glossmann H. (1993) Mol. Pharmacol . 43, 139-144) and purified (Moebius, F. B., Banner, M., Knaus, H. G., Weber, F., Striessnig, J., and Glossmann, H. (1994) J. Biol. Chem. 269, 29314-29320) a binding protein for the phenylalkylamine Ca2+ antagonist emopamil. The emopamil-binding protein (EBP) acts as a high affinity acceptor for several antiischemic drugs and thus represents a potential common molecular target for an tiischemic drug action. Degenerate oligonucleotides were synthesized according to the N-terminal amino acid sequence of purified EBP and used to amplify a guinea pig cDNA with reverse transcriptase-polymerase chain reaction and to clone full-length cDNAs from guinea pig and human liver cDNA libraries. The cDNAs coded for 229 (guinea pig) and 230 (human) amino acid 27-kDa polypeptides without significant sequence homology with any known protein. However, EBP shared structural features with pro- and eukaryotic drug transport proteins. The amino acid identity between human and guinea pig EBP was 73%. Hydrophobicity plots predicted four transmembrane segments. The C terminus contained a lysine-rich consensus sequence for the retrieval of type I integral membrane proteins to the endoplasmic reticulum. The heterologous expression of human and guinea pig EBP in Saccharomyces cerevisiae demonstrated that the expression of EBP alone is sufficient to form high affinity drug- and cation-binding do mains identical to the [H-3] emopamil-binding site of guinea pig liver. Northern and Western blot analysis revealed high abundance of EBP in guinea pig epithelial tissues as liver, bowel, adrenal gland, testis, ovary, and uterus and low densities in brain, cerebellum, skeletal muscle, and heart. EBP is suggested to be the first structurally characterized member of a family of high affinity microsomal drug acceptor proteins carrying so called s-binding sites.	UNIV INNSBRUCK, INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck			Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266				BLOCK F, 1993, ACTA NEUROL SCAND, V88, P35; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CHATELAIN P, 1987, EUR J PHARMACOL, V144, P83, DOI 10.1016/0014-2999(87)90012-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOWDHURY JR, 1985, P NATL ACAD SCI USA, V82, P2990, DOI 10.1073/pnas.82.9.2990; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; DELEAN A, 1978, AM J PHYSIOL, V4, pE97; ELGER B, 1994, EUR J PHARMACOL, V254, P65, DOI 10.1016/0014-2999(94)90371-9; FERRIS CD, 1991, MOL PHARMACOL, V39, P199; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; GRIEP MA, 1992, J BIOL CHEM, V267, P3052; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JACKSON MR, 1993, EMBO J, V12, P317; KAISER P, 1994, FEBS LETT, V350, P1, DOI 10.1016/0014-5793(94)00656-3; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MATSUMOTO M, 1993, STROKE, V24, P1228, DOI 10.1161/01.STR.24.8.1228; MOEBIUS FF, 1994, J BIOL CHEM, V269, P29314; MOEBIUS FF, 1993, MOL PHARMACOL, V44, P966; MOEBIUS FF, 1993, MOL PHARMACOL, V43, P139; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; RAO TS, 1990, NEUROPHARMACOLOGY, V29, P1199, DOI 10.1016/0028-3908(90)90045-S; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TAUTZ D, 1992, IN SITU HYBRIDIZATIO, P61; WALKER JM, 1990, PHARMACOL REV, V42, P355; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454; ZECH C, 1991, EUR J PHARM-MOLEC PH, V208, P119, DOI 10.1016/0922-4106(91)90062-M; ZIVIN JA, 1989, BRAIN RES, V482, P189, DOI 10.1016/0006-8993(89)90560-X	39	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7551	7557		10.1074/jbc.270.13.7551	http://dx.doi.org/10.1074/jbc.270.13.7551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706302	hybrid			2022-12-27	WOS:A1995QQ43100077
J	IGARASHI, K; ITOH, K; MOTOHASHI, H; HAYASHI, N; MATUZAKI, Y; NAKAUCHI, H; NISHIZAWA, M; YAMAMOTO, M				IGARASHI, K; ITOH, K; MOTOHASHI, H; HAYASHI, N; MATUZAKI, Y; NAKAUCHI, H; NISHIZAWA, M; YAMAMOTO, M			ACTIVITY AND EXPRESSION OF MURINE SMALL MAF FAMILY PROTEIN MAFK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; LOCUS ACTIVATION REGION; DOMINANT CONTROL REGION; LEUCINE ZIPPER PROTEIN; BETA-GLOBIN GENE; DNA-BINDING; C-JUN; MONOCLONAL-ANTIBODY; MESSENGER-RNA; V-MAF	Transcription factor NF-EB is believed to be crucial for the regulation of erythroid-specific gene transcription, The three small Maf family proteins (MafF, MafG, and MafK), which are closely related to c-Maf proto oncoprotein, constitute half of NF-ES activity by virtue of forming heterodimers with the large, tissue-restricted subunit of NF-E2 (p45), We isolated cDNA clones encoding the murine small Maf family protein MafK and characterized the structure, activity, and expression profile of MafK mRNA. Functional analyses demonstrate that MafK binds to consensus NF-ES sites in the absence of p45 in vitro and represses transcription of NF-ES site dependent reporter genes in transient transfection assays, while p45 introduced into cells alone does not effectively bind to DNA and does not affect transcription, In the presence of p45, MafK confers site-specific DNA binding activity to p45, and p45 in turn mediates transcriptional activation with its amino-terminal proline-rich domain, mRNA for MafK is expressed in fractions enriched for hematopoietic stem cells as well as erythroid cells, suggesting that MafK plays an important regulatory role in hematopoiesis.	UNIV TSUKUBA, INST BASIC MED SCI, DEPT IMMUNOL, TSUKUBA, IBARAKI 305, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC ONCOL, SAKYO KU, KYOTO 606, JAPAN	University of Tsukuba; Kyoto University	IGARASHI, K (corresponding author), TOHOKU UNIV, SCH MED, DEPT BIOCHEM, AOBA KU, 2-1 SEIRYOMACHI, SENDAI, MIYAGI 98077, JAPAN.		Yamamoto, Masayuki/A-4873-2010; Itoh, Ken/B-9506-2013; Motohashi, Hozumi/AAZ-2628-2020	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; Igarashi, Kazuhiko/0000-0002-2470-2475				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; ELFORD PR, 1992, CYTOKINE, V4, P232, DOI 10.1016/1043-4666(92)90061-U; ENGEL JD, 1994, NATURE, V367, P516; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FUJITA H, 1991, J BIOL CHEM, V266, P17494; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARLOW E, 1988, ANTIBODIES LABORATOR; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618; JUTILA MA, 1988, EUR J IMMUNOL, V18, P1819, DOI 10.1002/eji.1830181125; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, IN PRESS MOL CELL BI, V15; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PAGANO M, 1992, ONCOGENE, V7, P1681; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; RIFKIND RA, 1969, J CELL BIOL, V40, P343, DOI 10.1083/jcb.40.2.343; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	56	106	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7615	7624		10.1074/jbc.270.13.7615	http://dx.doi.org/10.1074/jbc.270.13.7615			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706310	hybrid			2022-12-27	WOS:A1995QQ43100087
J	MONNING, U; SANDBRINK, R; WEIDEMANN, A; BANATI, RB; MASTERS, CL; BEYREUTHER, K				MONNING, U; SANDBRINK, R; WEIDEMANN, A; BANATI, RB; MASTERS, CL; BEYREUTHER, K			EXTRACELLULAR-MATRIX INFLUENCES THE BIOGENESIS OF AMYLOID PRECURSOR PROTEIN IN MICROGLIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; MESSENGER-RNA; NEXIN-II; NERVOUS-SYSTEM; EXPRESSION; DOMAIN; BRAIN; LOCALIZATION; DERIVATIVES	During axotomy studies, we discovered that the beta A4-amyloid precursor protein (APP) participates in immune responses of the central nervous system. Since microglia constitute the main immune effector cell population of this response, we used the murine microglial cell line BV-2 to analyze immune response-related APP expression. We show that interaction of microglia with the extracellular environment, particularly components of the extracellular matrix, affects APP secretion as well as intracellular APP biogenesis and catabolism. Fibronectin enhanced APP secretion and decreased the level of cellular mature transmembrane APP, whereas laminin and collagen caused a decrease in secretion and an accumulation of cellular mature APP and APP fragments. Our results demonstrate that APP plays a fundamental role in the regulation of microglial mobility, i.e. migration, initial target recognition, and binding. The decrease in APP secretion and the concomitant increase in cellular mature APP were accompanied by an accumulation of C-terminal APP fragments. Enrichment of APP and APP fragments is assumedly based on inhibition of catabolic processes that is caused by a disorganization of the actin microfilament network. These observations provide evidence that microglia, which are closely associated with certain amyloid deposits in the brain of Alzheimer patients, can play a key role in initial events of amyloidogenesis by initiating accumulation of APP and also of amyloidogenic APP fragments in response to physiological changes upon brain injury.	UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY; MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,D-82452 PLANEGG,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Ruprecht Karls University Heidelberg; Max Planck Society; University of Melbourne								BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BREEN KC, 1992, MOL CHEM NEUROPATHOL, V16, P109, DOI 10.1007/BF03159964; BUSH AI, 1990, J BIOL CHEM, V265, P15977; CHAMAK B, 1991, NEUROSCIENCE, V45, P513, DOI 10.1016/0306-4522(91)90267-R; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Del Rio P., 1932, CYTOLOGY CELLULAR PA, P481; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GEHRMANN J, 1992, LAB INVEST, V67, P100; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Graeber MB, 1990, BRAIN PATHOL, V1, P2, DOI 10.1111/j.1750-3639.1990.tb00630.x; GUILIAN D, 1988, J NEUROSCI, V8, P4707; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; HILBICH C, 1991, EUR J BIOCHEM, V201, P61, DOI 10.1111/j.1432-1033.1991.tb16256.x; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; KONIG G, 1992, J BIOL CHEM, V267, P10804; LEFCORT F, 1992, DEVELOPMENT, V116, P767; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MONNING U, 1994, FEBS LETT, V342, P267, DOI 10.1016/0014-5793(94)80514-8; MONNING U, 1982, J BIOL CHEM, V267, P23950; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MULTHAUP G, 1992, J PROTEIN CHEM, V11, P298; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; REFOLO LM, 1991, J NEUROSCI, V11, P3888; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIGEMATSU K, 1992, BRAIN RES, V593, P117, DOI 10.1016/0006-8993(92)91272-G; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887	65	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7104	7110		10.1074/jbc.270.13.7104	http://dx.doi.org/10.1074/jbc.270.13.7104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706247	hybrid			2022-12-27	WOS:A1995QQ43100017
J	LI, XM; ROCK, F; CHONG, P; COCKLE, S; KEATING, A; ZILTENER, H; KLEIN, M				LI, XM; ROCK, F; CHONG, P; COCKLE, S; KEATING, A; ZILTENER, H; KLEIN, M			STRUCTURE-FUNCTION ANALYSIS OF THE C-TERMINAL SEGMENT OF HUMAN INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX DIPOLE MODEL; BIOLOGICAL-ACTIVITY; GROWTH-FACTOR; AMINO-ACIDS; HUMAN IL-6; RECEPTOR; PROTEINS; CYTOKINES; INVOLVEMENT; SPECIFICITY	It has been hypothesized that interleukin-6 (IL-6) and granulocyte-colony-stimulating factor (G-CSF) may fold as four-alpha-helix bundle proteins. To probe the functional role of the putative fourth helical segment of IL-6 (D-helix), a chimeric IL-6/G-CSF analog containing the predicted D-helix of G-CSF as well as a panel of IL-6 D-helix point mutants were analyzed for their respective secondary structure, antigenicity, and receptor binding and biological activities. The putative D-helix of IL-6 could not be replaced by its G-CSF counterpart in spite of their high degree of similarity and thus is indispensable for the antigenic and functional integrity of the IL-6 receptor binding site. Conversely, the grafting of the G-CSF D-helix did not confer any G-CSF activity to IL-6. A synthetic helical peptide containing the IL-6 D-helix was inactive, even when mixed with or linked to a peptide from the A-helix known to be involved in the active site. However, the conserved residues F173, R179, and R182 found in the D-helices of both IL-6 and G-CSF critically contribute to the architecture of the IL-6 active site. Indeed, mutation of F173 or R179 markedly affected IL-6 receptor binding and biological activities, but not the conformation of a major neutralization epitope. Furthermore, substitution of R182 resulted in a significant unfolding of the D-helix accompanied by a drastic loss in IL-6 antigenicity and functional activities. Nevertheless, residues other than F173, R179, and R182 also contribute to IL-6 specificity.	TORONTO HOSP, ONCOL RES LAB, TORONTO, ON, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER V6T 1W5, BC, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of British Columbia; University of British Columbia; University of Toronto; University of Toronto	LI, XM (corresponding author), CONNAUGHT CTR BIOTECHNOL RES, N YORK M2R 3T4, ON, CANADA.		Chong, Pele/E-3855-2010					BAKER PE, 1978, J IMMUNOL, V121, P2168; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; BRAKENHOFF JPJ, 1991, THESIS U AMSTERDAM; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLOGSTON CL, 1989, ARCH BIOCHEM BIOPHYS, V272, P144, DOI 10.1016/0003-9861(89)90205-1; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; GASCAN H, 1989, LYMPHOKINE RES, V8, P79; HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010; HJERTEN S, 1983, BIOCHIM BIOPHYS ACTA, V736, P130, DOI 10.1016/0005-2736(83)90178-5; HORII Y, 1989, J IMMUNOL, V143, P3949; JOURDAN M, 1990, ARTHRITIS RHEUM-US, V33, P398, DOI 10.1002/art.1780330313; Keating A, 1990, Methods Mol Biol, V5, P339, DOI 10.1385/0-89603-150-0:339; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOUSSEKERDILES MC, 1992, BLOOD, V79, P3179; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LEEBEEK FWG, 1992, FEBS LETT, V306, P262, DOI 10.1016/0014-5793(92)81013-C; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; PROVECHER SW, 1991, BIOCHEMISTRY-US, V20, P33; ROCK F, 1992, PROTEIN ENG, V5, P583, DOI 10.1093/protein/5.6.583; SAMBROOK L, 1989, MOL CLONING LABORATO; SHAKED Z, 1985, Patent No. 156354; SHINMEI M, 1989, SEMIN ARTHRITIS RHEU, V18, P27, DOI 10.1016/0049-0172(89)90081-4; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SNOUWAERT JN, 1991, J BIOL CHEM, V266, P23097; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010	42	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22377	22384						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693665				2022-12-27	WOS:A1993MD34800031
J	VALENTA, R; FERREIRA, F; GROTE, M; SWOBODA, I; VRTALA, S; DUCHENE, M; DEVILLER, P; MEAGHER, RB; MCKINNEY, E; HEBERLEBORS, E; KRAFT, D; SCHEINER, O				VALENTA, R; FERREIRA, F; GROTE, M; SWOBODA, I; VRTALA, S; DUCHENE, M; DEVILLER, P; MEAGHER, RB; MCKINNEY, E; HEBERLEBORS, E; KRAFT, D; SCHEINER, O			IDENTIFICATION OF PROFILIN AS AN ACTIN-BINDING PROTEIN IN HIGHER-PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR WEIGHT; SACCHAROMYCES-CEREVISIAE; PLATELET EXTRACTS; F-ACTIN; PROFILACTIN; SEQUENCE; PURIFICATION; ALLERGENS; CELLS; CDNA	Profilin is a low molecular weight protein involved in the organization of the mammalian and protozoan cytoskeleton as well as in signal transduction. In this study, profilin is identified as an actin-binding protein in higher plants which is present in monocot and dicot angiosperms. Birch pollen profilin and actin can be co-purified as a complex, and purified recombinant birch profilin can be used as an affinity matrix to obtain birch pollen actin. The binding of I-125-labeled recombinant birch pollen profilin to plant and animal actins can be blocked by profilin-specific antibodies that react with different epitopes of birch profilin. One of the blocking antibodies was raised against the 25 COOH-terminal amino acids indicating the importance of this region in the profilactin complex formation.	UNIV VIENNA,INST MICROBIOL & GENET,A-1090 VIENNA,AUSTRIA; UNIV MUNSTER,INST MED PHYS,W-4400 MUNSTER,GERMANY; UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; FAC MED ALEXIS CARREL,F-69372 LYON,FRANCE	University of Vienna; University of Munster; University System of Georgia; University of Georgia	VALENTA, R (corresponding author), UNIV VIENNA,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA.		Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Duchêne, Michael/G-6659-2019	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Duchêne, Michael/0000-0003-1232-3600; Valenta, Rudolf/0000-0001-5944-3365; Swoboda, Ines/0000-0002-9164-1721; Vrtala, Susanne/0000-0003-4250-8243				AMPE C, 1988, FEBS LETT, V228, P17, DOI 10.1016/0014-5793(88)80575-1; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; CONDEELIS JS, 1974, EXP CELL RES, V88, P435, DOI 10.1016/0014-4827(74)90269-9; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; EDAMATSU M, 1991, BIOCHEM BIOPH RES CO, V175, P543, DOI 10.1016/0006-291X(91)91599-8; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; Heslop-Harrison J., 1989, Sexual Plant Reproduction, V2, P199, DOI 10.1007/BF00195579; HESLOPHARRISON J, 1986, J CELL SCI, V86, P1; ISENBERG G, 1980, NATURE, V288, P455, DOI 10.1038/288455a0; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; MARKEY F, 1981, CELL, V23, P145, DOI 10.1016/0092-8674(81)90279-8; MCLEAN BG, 1990, CELL MOTIL CYTOSKEL, V17, P276; OECHSNER U, 1987, NUCLEIC ACIDS RES, V15, P9078, DOI 10.1093/nar/15.21.9078; REICHSTEIN E, 1979, J BIOL CHEM, V254, P6174; ROTHKEGEL M, 1993, EUR J CELL BIOL S, V37, P42; Staiger CJ, 1991, CURR OPIN CELL BIOL, V3, P33, DOI 10.1016/0955-0674(91)90163-S; SWOBODA I, 1992, MOL BIOL IMMUNOLOGY, P169; TAKAGI T, 1990, EUR J BIOCHEM, V192, P777, DOI 10.1111/j.1432-1033.1990.tb19289.x; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; TANG XJ, 1989, CELL MOTIL CYTOSKEL, V12, P216, DOI 10.1002/cm.970120404; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WIDADA JS, 1989, NUCLEIC ACIDS RES, V17, P2855, DOI 10.1093/nar/17.7.2855	38	107	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22777	22781						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693678				2022-12-27	WOS:A1993MD34800086
J	MAHENDROO, MS; MENDELSON, CR; SIMPSON, ER				MAHENDROO, MS; MENDELSON, CR; SIMPSON, ER			TISSUE-SPECIFIC AND HORMONALLY CONTROLLED ALTERNATIVE PROMOTERS REGULATE AROMATASE CYTOCHROME-P450 GENE-EXPRESSION IN HUMAN ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN BIOSYNTHESIS; STROMAL CELLS; DROSOPHILA-MELANOGASTER; PLASMA ANDROSTENEDIONE; SEXUAL-DIFFERENTIATION; PLACENTAL AROMATASE; GLUCOSE TRANSPORTER; RIBONUCLEIC-ACID; BREAST-TISSUE; MESSENGER-RNA	Estrogen biosynthesis is catalyzed by a microsomal enzyme, aromatase cytochrome P450 (P450arom; the product of the CYP19 gene). The human CYP19 gene comprises nine coding exons, II-X. Additionally, tissue-specific expression is determined by the use of tissue-specific promoters, which give rise to P450arom transcripts with unique 5'-noncoding sequences. In placenta, P450arom transcripts contain one of two 5'-untranslated exons, I.1 or I.2, while ovarian transcripts instead contain sequence consistent with the use of a promoter, PII, which is proximal to the start of translation. To characterize transcripts present in adipose tissue and adipose stromal cells (ASC) in culture, cDNA libraries were constructed by the RACE (rapid amplification of cDNA ends) procedure. Four P450arom transcripts with unique 5' termini were identified, leading to the characterization of two unique 5'-untranslated exons of the CYP19 gene, I.3 and I.4. Whereas I.3-specific sequence is expressed in adipose tissue as well as in ACS maintained under all culture conditions, I.4-specific sequence is apparently present only in breast adipose tissue, and ACS stimulated with glucocorticoids. On the other hand, PII-specific sequence is present only in cells stimulated with cAMP analogues and is absent from cells stimulated with glucocorticoids. We conclude that CYP19 gene expression in human adipose tissue likely utilizes two novel promoters and, furthermore, that alternative promoter usage in cultured ASC is a function of the hormonal environment in which the cells are maintained.	UNIV TEXAS,SW MED CTR,CECIL H & IDA GREEN CTR REPROD BIOL SCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET GYNECOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mendelson, Carole Ruth/0000-0003-1696-9791	NIA NIH HHS [AG08174] Funding Source: Medline; NICHD NIH HHS [5-T32-HD07190] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008174, R37AG008174] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412; AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CASPI E, 1984, J AM CHEM SOC, V106, P7282, DOI 10.1021/ja00335a090; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLINE TW, 1984, GENETICS, V107, P231; COLE PA, 1988, J AM CHEM SOC, V110, P1284, DOI 10.1021/ja00212a043; EDMAN CD, 1978, AM J OBSTET GYNECOL, V130, P456, DOI 10.1016/0002-9378(78)90288-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, PERKINELMER CETUS AM, P11; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOTO J, 1977, SCIENCE, V195, P80, DOI 10.1126/science.831259; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; HEMSELL DL, 1974, J CLIN ENDOCR METAB, V38, P476, DOI 10.1210/jcem-38-3-476; HICKEY GJ, 1990, MOL ENDOCRINOL, V4, P3, DOI 10.1210/mend-4-1-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KELLIS JT, 1987, J BIOL CHEM, V262, P4413; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MAHENDROO MS, 1992, 74TH ANN END SOC M, P378; Maniatis T., 1982, MOL CLONING; MATSUMINE H, 1991, J BIOL CHEM, V266, P19900; MCALLISTER JM, 1993, IN PRESS ENDOCRINOLO; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MENDELSON CR, 1985, ARCH BIOCHEM BIOPHYS, V243, P480, DOI 10.1016/0003-9861(85)90525-9; MENDELSON CR, 1986, ENDOCRINOLOGY, V118, P968, DOI 10.1210/endo-118-3-968; MILLER WR, 1991, J STEROID BIOCHEM, V39, P783, DOI 10.1016/0960-0760(91)90026-2; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NAKAJIN S, 1986, BIOCHEM BIOPH RES CO, V134, P704, DOI 10.1016/S0006-291X(86)80477-6; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; ONEILL JS, 1988, BRIT MED J, V296, P741, DOI 10.1136/bmj.296.6624.741; OSAWA Y, 1987, Steroids, V50, P11, DOI 10.1016/0039-128X(83)90058-2; PRICE T, 1992, J CLIN ENDOCR METAB, V74, P1247, DOI 10.1210/jc.74.6.1247; RYAN KJ, 1959, J BIOL CHEM, V234, P268; SIMPSON ER, 1981, P NATL ACAD SCI-BIOL, V78, P5690, DOI 10.1073/pnas.78.9.5690; SIMPSON ER, 1989, ENDOCR REV, V10, P136, DOI 10.1210/edrv-10-2-136; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; TODA K, 1992, EUR J BIOCHEM, V205, P303, DOI 10.1111/j.1432-1033.1992.tb16781.x; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	46	283	289	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19463	19470						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690033				2022-12-27	WOS:A1993LW81900050
J	SORIMACHI, H; ISHIURA, S; SUZUKI, K				SORIMACHI, H; ISHIURA, S; SUZUKI, K			A NOVEL TISSUE-SPECIFIC CALPAIN SPECIES EXPRESSED PREDOMINANTLY IN THE STOMACH COMPRISES 2 ALTERNATIVE SPLICING PRODUCTS WITH AND WITHOUT CA2+-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; ACTIVATED NEUTRAL PROTEASE; HAND STRUCTURE-DOMAIN; MOLECULAR-CLONING; MESSENGER-RNA; CDNA CLONES; SEQUENCE-ANALYSIS; BINDING PROTEIN; SMALL SUBUNIT; KINASE-C	Our previous studies have demonstrated that, in addition to the conventional mu- and m-calpains ubiquitously expressed in tissues, a muscle-specific calpain comprising a novel member of the large subunit family (p94 or nCL-1, which stands for novel Calpain Large subunit) exists in muscle cells. To clarify the physiological function of nCL-1, we screened cDNA libraries of various rat tissues for other tissue-specific calpains and, as a result, discovered a novel member of the calpain large subunit family. RNA blot analysis showed that the mRNA is expressed predominantly in the stomach. Isolated cDNA clones could be structurally divided into two groups, whose 5'-halves of about 1.1 kilobase pairs were identical, but whose 3'-halves bore no similarity at all. This suggests generation by an alternative splicing mechanism, which was proved by genomic DNA cloning. Open reading frames were found encoding 703 and 381 amino acid residues with calculated molecular masses of 79,554 and 42,591 for nCL-2 and -2', respectively. The deduced amino acid sequence of nCL-2 is very similar to those of other calpain large subunits and can be aligned without significant insertions or deletions, suggesting that nCL-2 should possess cysteine protease activity and calcium binding ability. nCL-2' is identical to the N-terminal half of nCL-2 and, thus, contains only the cysteine protease domain but not the calcium binding domain. Possible roles of the calpain family are discussed based on these findings.			SORIMACHI, H (corresponding author), UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN.		Sorimachi, Hiroyuki/C-6448-2009	Sorimachi, Hiroyuki/0000-0001-9509-6727				ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; EMORI Y, 1986, FEBS LETT, V194, P249, DOI 10.1016/0014-5793(86)80094-1; EMORI Y, 1986, J BIOL CHEM, V261, P9465; EMORI Y, 1986, J BIOL CHEM, V261, P9472; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; MURACHI T, 1989, BIOCHEM INT, V18, P263; OHNO S, 1990, CYTOGENET CELL GENET, V53, P225, DOI 10.1159/000132937; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; Sambrook J, 1989, MOL CLONING LABORATO; SORIMACHI H, 1990, BIOL CHEM H-S, V371, P171; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1990, EUR J BIOCHEM, V193, P775, DOI 10.1111/j.1432-1033.1990.tb19399.x; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1160, P55, DOI 10.1016/0167-4838(92)90037-E; SUZUKI K, 1991, BIOMED BIOCHIM ACTA, V50, P483; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V8, P167; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	28	151	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19476	19482						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690035				2022-12-27	WOS:A1993LW81900052
J	PADMAKUMAR, R; BANERJEE, R				PADMAKUMAR, R; BANERJEE, R			EVIDENCE FROM ELECTRON-PARAMAGNETIC-RESONANCE SPECTROSCOPY OF THE PARTICIPATION OF RADICAL INTERMEDIATES IN THE REACTION CATALYZED BY METHYLMALONYL-COENZYME-A MUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHIONINE SYNTHASE; COA MUTASE; ESCHERICHIA-COLI; CLOSTRIDIUM-THERMOACETICUM; ADENOSYLCOBALAMIN; REARRANGEMENT; ENZYME; MODEL; COB(II)ALAMIN; MECHANISM	Recombinant methylmalonyl-coenzyme A (CoA) mutase from Propionibacterium shermanii has been purified 20-fold to near homogeneity in a highly active form, Neither the apoenzyme (the form in which the enzyme is isolated) nor the holoenzyme (reconstituted with the cofactor, adenosylcobalamin) has an electron paramagnetic resonance (EPR) spectrum associated with it, However, the addition of either the substrate, methyl malonyl CoA, or the product, succinyl-CoA results in the appearance of a transient EPR signal, The signal has hyperfine features that indicate coupling of the unpaired electron to the cobalt nucleus, In the presence of [CD3]methylmalonyl-CoA, an EPR signal is also seen and is similar to that obtained in the presence of protiated substrate, Power saturation studies reveal the presence of two components, a slow relaxing species (with an apparent g value of 2.11) and a fast relaxing species (with an apparent g value of 2.14) that can be partially resolved at low temperature and high power, The EPR-active intermediate is observed under catalytic conditions and is approximately midway in its resonance position between a free radical and cob(II)alamin, It is postulated to represent an exchange coupled cob(II)alamin free radical pair, The signal bears close resemblance to those observed with partially dehydrated polycrystalline adenosylcobalamin following laser photolysis (Ghanekar, V, D., Lin, R. J., Coffman, R, E., and Blakley, R, L, (1981) Biochem. Biophys, Res, Commun, 101, 215-221) and with the adenosylcobalamin-dependent ribonucleotide reductase under freeze-quench conditions (Orme-Johnson, W, H., Beinert, H., and Blakley, R, L, (1974) J. Biol, Chem, 249, 2338-2343), When cob(II)alamin is generated under noncatalytic conditions (i.e. in the presence of propionyl-CoA or by electrochemical reduction of enzyme-bound hydroxocob(III)alamin), a different EPR signal is observed with g perpendicular to = 2.26 and g parallel to = 2.00, typical of base on cob(II)alamin.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAGAM A, 1986, ELECTRON PARAMAGNETI, P491; ALLEN SHG, 1964, J BACTERIOL, V87, P171, DOI 10.1128/JB.87.1.171-187.1964; AN G, 1980, GENE, V12, P33, DOI 10.1016/0378-1119(80)90013-X; BABIOR B, 1969, BIOCHEM BIOPH RES CO, V34, P441, DOI 10.1016/0006-291X(69)90401-X; BABIOR BM, 1974, J BIOL CHEM, V249, P4537; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BEUTTNER GR, 1977, BIOCHIM BIOPHYS ACTA, V480, P495; CHANEKAR VD, 1981, BIOCHEM BIOPH RES CO, V101, P215; CHOI GY, 1990, P NATL ACAD SCI USA, V87, P3174, DOI 10.1073/pnas.87.8.3174; COCKLE SA, 1972, J AM CHEM SOC, V94, P275, DOI 10.1021/ja00756a050; COFFMAN RE, 1976, BIOCHIM BIOPHYS ACTA, V444, P307, DOI 10.1016/0304-4165(76)90247-6; DOWD P, 1992, J AM CHEM SOC, V114, P7949, DOI 10.1021/ja00046a073; FINKE RG, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P244; FINLAY TH, 1973, J BIOL CHEM, V248, P1285; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HARDER SR, 1989, ANAL BIOCHEM, V181, P283, DOI 10.1016/0003-2697(89)90244-3; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HARKINS TT, 1994, SCIENCE, V263, P958, DOI 10.1126/science.8310292; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; HULL WE, 1988, EUR J BIOCHEM, V173, P191, DOI 10.1111/j.1432-1033.1988.tb13984.x; KEEP NH, 1993, BIOCHEM J, V295, P387, DOI 10.1042/bj2950387; KELLERMEYER RW, 1964, J BIOL CHEM, V239, P2562; LEUTBECHER U, 1992, FEBS LETT, V307, P144, DOI 10.1016/0014-5793(92)80754-5; MATSUI SM, 1983, NEW ENGL J MED, V308, P857, DOI 10.1056/NEJM198304143081501; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; MICHEL C, 1992, EUR J BIOCHEM, V205, P767, DOI 10.1111/j.1432-1033.1992.tb16841.x; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; PADMAKUMAR R, 1993, ANAL BIOCHEM, V214, P318, DOI 10.1006/abio.1993.1494; PILBROW JR, 1982, B12, P431; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SCHEPLER KL, 1975, BIOCHIM BIOPHYS ACTA, V397, P510, DOI 10.1016/0005-2744(75)90141-2; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; TAOKA S, 1994, J BIOL CHEM, V269, P31630; WOLLOWITZ S, 1984, J AM CHEM SOC, V106, P8319, DOI 10.1021/ja00338a066; ZHAO Y, 1994, EUR J BIOCHEM, V225, P891, DOI 10.1111/j.1432-1033.1994.0891b.x; ZHAO Y, 1992, ANGEW CHEM INT EDIT, V31, P215, DOI 10.1002/anie.199202151	38	69	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9295	9300		10.1074/jbc.270.16.9295	http://dx.doi.org/10.1074/jbc.270.16.9295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721850	hybrid			2022-12-27	WOS:A1995QU08900038
J	SOUID, AK; PENEFSKY, HS				SOUID, AK; PENEFSKY, HS			ENERGETICS OF ATP DISSOCIATION FROM THE MITOCHONDRIAL ATPASE DURING OXIDATIVE-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SITE COOPERATIVITY; BEEF-HEART; ADENOSINE-TRIPHOSPHATASE; SUBMITOCHONDRIAL PARTICLES; PARACOCCUS-DENITRIFICANS; RESPIRATORY-CHAIN; MECHANISM; HYDROLYSIS; KINETICS; F0F1-ATPASE	The dissociation constant (K-dATP) for ATP bound in the high affinity catalytic site of membrane-bound beef heart mitochondrial ATPase (F-1) was calculated from the ratio of the rate constants for the reverse dissociation step (k(-1)) and the forward binding step (k(+1)). k(-1) for ATP bound to submitochondrial particles or to submitochondrial particles washed with KCl so as to activate ATPase activity was accelerated by about five orders of magnitude during respiratory chain-linked oxidations of NADH, In the presence of NADH and 0.1 mM ADP, k(-1) increased more than six orders of magnitude, These energy-dependent dissociations of ATP were sensitive to the uncoupler carbonyl cyanide p-trifluoromethyloxyphenylhydrazone. Only small changes in k(+1) were observed in the presence of NADH or NADH and ADP. K-dATP at 23 degrees C in the absence of NADH and ADP was 10(-12) M, in the presence of NADH, 3 mu M, and in the presence of NADH and 0.1 mM ADP, 60 mu M. Thus, the dissociation of ATP during the transition from non-energized to energized states was, under these conditions, accompanied by observed free energy changes of 8 and 9.7 kcal/mol, respectively.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PEDIAT, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021737] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; BELTRAN C, 1986, EUR J BIOCHEM, V160, P163, DOI 10.1111/j.1432-1033.1986.tb09953.x; BEYER RE, 1967, METHOD ENZYMOL, V10, P186; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CROSS RL, 1982, J BIOL CHEM, V257, P2101; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FERGUSON SJ, 1976, BIOCHEM J, V159, P347, DOI 10.1042/bj1590347; FERGUSON SJ, 1977, BIOCHEM J, V168, P299, DOI 10.1042/bj1680299; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HARRIS DA, 1977, BIOCHIM BIOPHYS ACTA, V459, P560, DOI 10.1016/0005-2728(77)90054-8; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HELDT HW, 1972, EUR J BIOCHEM, V30, P434, DOI 10.1111/j.1432-1033.1972.tb02115.x; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; MAGNUSSON RP, 1976, J BIOL CHEM, V251, P7417; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1986, J BIOL CHEM, V261, P14031; MATSUNOYAGI A, 1988, BIOCHEMISTRY-US, V27, P335, DOI 10.1021/bi00401a050; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; MATSUNOYAGI A, 1985, P NATL ACAD SCI USA, V82, P7550, DOI 10.1073/pnas.82.22.7550; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; PENEFSKY H, 1991, ADV ENZYMOL REL AREA, V64, P173; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3728; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3735; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10518, DOI 10.1021/bi00498a014; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; Senior A E, 1979, Methods Enzymol, V55, P391; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WEBER J, 1994, J BIOL CHEM, V269, P20462	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9074	9082		10.1074/jbc.270.16.9074	http://dx.doi.org/10.1074/jbc.270.16.9074			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721821	hybrid			2022-12-27	WOS:A1995QU08900009
J	BROWN, NF; WEIS, BC; HUSTI, JE; FOSTER, DW; MCGARRY, JD				BROWN, NF; WEIS, BC; HUSTI, JE; FOSTER, DW; MCGARRY, JD			MITOCHONDRIAL CARNITINE PALMITOYLTRANSFERASE-I ISOFORM SWITCHING IN THE DEVELOPING RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; MALONYL-COA; ENZYME-SYSTEM; METABOLISM; CLONING; KETOGENESIS; EXPRESSION	The expression pattern of mitochondrial carnitine palmitoyltransferase (CPT) enzymes was examined in the developing rat heart. Whereas the specific activity of CPT II increased similar to 3 fold during the first month of life, the profile for CPT I, which is composed of both liver (L) and muscle (M) isoforms, was more complex. Exposure of mitochondria to [H-3]etomoxir (a covalent ligand for CPT I), followed by fluorographic analysis of the membrane proteins, established that while in the adult heart L-CPT I represents a very minor constituent, its contribution is much greater in the newborn animal. Use of the related inhibitor, 2-[6-(2,4-dinitrophenoxy)hexyl]oxirane-2-carboxylic acid (specific for L-CPT I), allowed the activities of the two CPT I variants to be quantified separately. The results showed that in the neonatal heart, L-CPT I contributes similar to 25% to total CPT I activity (in V-max terms), the value falling during growth of the pups (with concomitant increasing expression of the Id isoform) to its adult level of 2-3%. Because the myocardial carnitine content is very low at birth and rises dramatically over the next several weeks, it can be estimated that L-CPT I (K-m for carnitine of only 30 mu M compared with a value of 500 CCM for M-CPT I) is responsible for some 60% of total cardiac fatty acid oxidation in the newborn rat; the value falls to similar to 4% in adult animals. Should these findings have a parallel in humans, they could have important implications for understanding the pathophysiological consequences of inherited L CPT I deficiency syndromes.	UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, GIFFORD LABS DIABET RES, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018573, P01DK042582, R01DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18573, DK42582] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BERGMAN AJIW, 1994, PEDIATR RES, V36, P582, DOI 10.1203/00006450-199411000-00007; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; DECLERCQ PE, 1987, J BIOL CHEM, V262, P812; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; DUAN C, 1992, J APPL PHYSIOL, V72, P901, DOI 10.1152/jappl.1992.72.3.901; ESSER V, 1993, J BIOL CHEM, V268, P5817; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; GLICK MR, 1974, ANAL BIOCHEM, V61, P32, DOI 10.1016/0003-2697(74)90329-7; JONES CT, 1985, PHYSIOL REV, V65, P357, DOI 10.1152/physrev.1985.65.2.357; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P137; MCGARRY JD, 1985, METHOD ENZYMAT AN, P474; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; MURTHY MSR, 1994, J BIOL CHEM, V269, P18283; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; ROBLESVALDES C, 1976, J BIOL CHEM, V251, P6007; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SAUDUBRAY JM, 1992, PROG CLIN BIOL RES, V375, P271; THUMELIN S, 1994, BIOCHEM J, V300, P583, DOI 10.1042/bj3000583; WARSHAW JB, 1972, DEV BIOL, V28, P537, DOI 10.1016/0012-1606(72)90001-2; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WITTELS B, 1965, J CLIN INVEST, V44, P1639, DOI 10.1172/JCI105270; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714	34	136	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8952	8957		10.1074/jbc.270.15.8952	http://dx.doi.org/10.1074/jbc.270.15.8952			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721804	hybrid			2022-12-27	WOS:A1995QT44800083
J	CASEY, JR; DING, Y; KOPITO, RR				CASEY, JR; DING, Y; KOPITO, RR			THE ROLE OF CYSTEINE RESIDUES IN THE ERYTHROCYTE PLASMA-MEMBRANE ANION-EXCHANGE PROTEIN, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SITE-DIRECTED MUTAGENESIS; ANKYRIN-BINDING SITE; BAND-3 PROTEIN; TRANSPORT PROTEIN; BACTERIORHODOPSIN MUTANTS; TRANSMEMBRANE PROTEINS; RECEPTOR; CDNA; ASSOCIATION	AE1 (Band 3), a congruent to 110-kDa integral plasma membrane protein, facilitates the electroneutral movement of Cl- and HCO3- across the erythrocyte membrane and serves as the primary attachment site for the erythrocyte spectrin-actin cytoskeleton. In this investigation, we have characterized the role of native cysteines in the function of AE1, We have constructed a mutant version of human AE1 (AE1C(-)) in which all five cysteines of AE1 were replaced with serines. Wild-type and AE1C(-) cDNAs were expressed by transient transfection of human embryonic kidney cells. Two of the mutated cysteines in AE1C(-) are in a region involved in ankyrin binding, and ankyrin binding has previously been shown to be sensitive to the oxidation state of these cysteines. However, the K-D values for ankyrin binding by AE1 and AE1C(-) were indistinguishable, suggesting that AE1 cysteines are not essential components of the ankyrin-binding site. Using size exclusion chromatography, both AE1 and AE1C(-) were found to associate as a mixture of dimers and high molecular mass complexes. The rate of anion exchange by AE1C(-), as measured in a reconstituted microsome sulfate transport assay, was indistinguishable from that by AE1 and was inhibited by 4,4'-diisothiocyanodihydrostilbene- 2,2'-disulfonate. We conclude that the cysteines of AE1 are not required for the anion exchange or cytoskeletal binding roles of the protein.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University				Casey, Joseph/0000-0002-9890-5056				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BEPPU M, 1990, J BIOL CHEM, V265, P3226; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; Creighton TE, 1983, PROTEINS STRUCTURES; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DING Y, 1994, J BIOL CHEM, V269, P32201; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBNER S, 1992, BIOCHEM J, V285, P17; IWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12273, DOI 10.1021/bi00097a001; KANG DC, 1994, BBA-BIOMEMBRANES, V1194, P341, DOI 10.1016/0005-2736(94)90317-4; KAY MMB, 1984, P NATL ACAD SCI-BIOL, V81, P5753, DOI 10.1073/pnas.81.18.5753; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOPITO RR, 1985, J CELL BIOCHEM, V29, P1, DOI 10.1002/jcb.240290102; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11443; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; NAKASHIMA H, 1980, J BIOCHEM-TOKYO, V88, P933, DOI 10.1093/oxfordjournals.jbchem.a133081; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OKUBO K, 1991, J BIOL CHEM, V266, P16420; REITHMEIER RAF, 1979, J BIOL CHEM, V254, P6151; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; REITHMEIER RAF, 1992, J BIOL CHEM, V2, P181; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; THOMAS HA, 1989, AM J PHYSIOL, V26, pC537; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI A, 1988, BIOCHEMISTRY-US, V27, P7447, DOI 10.1021/bi00419a041; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	59	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8521	8527		10.1074/jbc.270.15.8521	http://dx.doi.org/10.1074/jbc.270.15.8521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721750	hybrid			2022-12-27	WOS:A1995QT44800026
J	KANOFSKY, JR; SIMA, PD				KANOFSKY, JR; SIMA, PD			SINGLET OXYGEN GENERATION FROM THE REACTION OF OZONE WITH PLANT-LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; BIOMOLECULES; DEPOSITION; CELLS	Aqueous extracts of the intercellular fluid from Sedum album L. leaves generated singlet oxygen chemiluminescence at 1270 nm when exposed to a nitrogen gas stream containing ozone at 21 +/- 2 ppm. The concentration of ascorbic acid in the intercellular fluid extracts was 310 +/- 40 mu M. The intensity of the singlet oxygen chemiluminescence from the intercellular fluid extracts was comparable with the chemiluminescence from a control solution containing 300 mu M ascorbic acid. The intensity of the singlet oxygen emission from intercellular fluid treated with ascorbate oxidase was 0.19 +/- 0.07 of the intensity of the singlet oxygen chemiluminescence from untreated samples of intercellular fluid extract. The simplest explanation for the effect of ascorbate oxidase is that ascorbic acid is the major ozone target generating singlet oxygen. Much weaker singlet oxygen chemiluminescence was detected at 1270 nm when intact S. album L. plant tips were exposed to a nitrogen gas stream containing ozone at 22 +/- 5 ppm. Various explanations for the relatively low intensity of the singlet oxygen chemiluminescence from intact S. album L. plant tips are discussed.	US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,RES SERV,HINES,IL 60141; LOYOLA UNIV,STRITCH SCH MED,DEPT MED,MAYWOOD,IL 60153; LOYOLA UNIV,STRITCH SCH MED,DEPT MOLEC & CELLULAR BIOCHEM,MAYWOOD,IL 60153	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Loyola University Chicago	KANOFSKY, JR (corresponding author), US DEPT VET AFFAIRS,VET AFFAIRS EDWARD HINES JR HOSP,MED SERV,BOX 278,HINES,IL 60141, USA.							BADER H, 1981, WATER RES, V15, P449, DOI 10.1016/0043-1354(81)90054-3; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; CASTILLO FJ, 1988, ENVIRON EXP BOT, V28, P231, DOI 10.1016/0098-8472(88)90033-0; CHAMEIDES WL, 1989, ENVIRON SCI TECHNOL, V23, P595, DOI 10.1021/es00063a013; GIAMALVA D, 1985, BIOCHEM BIOPH RES CO, V133, P773, DOI 10.1016/0006-291X(85)90971-4; KANGASJARVI J, 1994, PLANT CELL ENVIRON, V17, P783, DOI 10.1111/j.1365-3040.1994.tb00173.x; KANOFSKY JR, 1993, PHOTOCHEM PHOTOBIOL, V58, P335, DOI 10.1111/j.1751-1097.1993.tb09570.x; KANOFSKY JR, 1991, J BIOL CHEM, V266, P9039; KANOFSKY JR, 1989, CHEM-BIOL INTERACT, V70, P1, DOI 10.1016/0009-2797(89)90059-8; KANOFSKY JR, 1994, ARCH BIOCHEM BIOPHYS, V312, P244, DOI 10.1006/abbi.1994.1306; KANOFSKY JR, 1983, J BIOL CHEM, V258, P5991; KANOFSKY JR, 1995, ARCH BIOCHEM BIOPHYS, V316, P52, DOI 10.1006/abbi.1995.1009; KANOFSKY JR, 1988, J BIOL CHEM, V263, P14171; KERSTIENS G, 1989, NEW PHYTOL, V112, P13, DOI 10.1111/j.1469-8137.1989.tb00303.x; KRASNOVSKII AA, 1988, MOL MEKHANIZMY BIOL, P23; LAISK A, 1989, PLANT PHYSIOL, V90, P1163, DOI 10.1104/pp.90.3.1163; LEE EH, 1984, ENVIRON EXP BOT, V24, P331, DOI 10.1016/0098-8472(84)90030-3; LUWE MWF, 1993, PLANT PHYSIOL, V101, P969, DOI 10.1104/pp.101.3.969; MATHESON IBC, 1975, PHOTOCHEM PHOTOBIOL, V21, P165, DOI 10.1111/j.1751-1097.1975.tb06647.x; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; ROUGEE M, 1986, CR ACAD SCI II, V302, P1223; SALTZMAN BE, 1959, ANAL CHEM, V31, P1914, DOI 10.1021/ac60155a078; WAYNE RP, 1985, SINGLET MOL OXYGEN, P00081	23	62	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7850	7852		10.1074/jbc.270.14.7850	http://dx.doi.org/10.1074/jbc.270.14.7850			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713876	hybrid			2022-12-27	WOS:A1995QR52600012
J	MORELLA, KK; LAI, CF; KUMAKI, S; KUMAKI, N; WANG, YP; BLUMAN, EM; WITTHUHN, BA; IHLE, JN; GIRI, J; GEARING, DP; COSMAN, D; ZIEGLER, SF; TWEARDY, DJ; CAMPOS, SP; BAUMANN, H				MORELLA, KK; LAI, CF; KUMAKI, S; KUMAKI, N; WANG, YP; BLUMAN, EM; WITTHUHN, BA; IHLE, JN; GIRI, J; GEARING, DP; COSMAN, D; ZIEGLER, SF; TWEARDY, DJ; CAMPOS, SP; BAUMANN, H			THE ACTION OF INTERLEUKIN-2 RECEPTOR SUBUNITS DEFINES A NEW-TYPE OF SIGNALING MECHANISM FOR HEMATOPOIETIN RECEPTORS IN HEPATIC CELLS AND FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RAT ALPHA-1-ACID GLYCOPROTEIN; GROWTH-HORMONE-RECEPTOR; PLASMA-PROTEIN GENES; CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; NATURAL-KILLER-CELLS; ERYTHROPOIETIN RECEPTOR; GAMMA-CHAIN; CYTOKINE RECEPTORS	The gene regulatory functions of the human IL-2 receptor (IL-2R) were reconstituted in transiently transfected hepatoma cells. The combination of IL-2R beta and -gamma mediated a strong stimulation via the cytokine response element of the alpha(1)-acid glycoprotein gene and the hematopoietin receptor response element, but none via the IL-6 response element of the sis-inducible element. IL-2R alpha enhanced 10-fold the sensitivity of the IL-2R beta .gamma complex to respond to IL-2 or IL-15, but did not modify the specificity or the magnitude of maximal gene regulation. A homodimerizing chimeric receptor G-CSFR-IL-2R beta could mimic the IL-2R action. The IL-2R-mediated gene regulation was similar to that seen with receptors for IL-4 and IL-7, but differed from that for IL-6 type cytokines, thrombopoietin, erythropoietin, and growth hormone. The activation of STAT proteins by the IL-2R was assessed in transfected L-cells and COS-1 cells. Although IL-2R subunits were highly expressed in these cells, no STAT protein activation was detectable. Transient overexpression of JAK3 was unable to change the signaling specificity of the hematopoietin receptors in rat hepatoma, L-, and COS cells, but established a prominent activation of the IL-6 response elements by the IL-2R and IL-4R in HepG2 cells. The data support the model that the IL-2R and related hematopoietin receptors produce at least two separate signals which control gene expression.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA; CHILDRENS HOSP BUFFALO, DIV ENDOCRINOL, BUFFALO, NY 14222 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; SYSTEMIX INC, PALO ALTO, CA 94304 USA; DARWIN MOLEC CORP, BOTHELL, WA 98021 USA; PITTSBURGH CANC INST, PITTSBURGH, PA 15213 USA	Roswell Park Cancer Institute; St Jude Children's Research Hospital; Novartis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute			Bluman, Eric M./K-5849-2019; Tweardy, David/L-3929-2019; witthuhn, bruce/GSE-3193-2022	Bluman, Eric M./0000-0002-3848-1677; 	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BANCROFT GJ, 1993, CURR OPIN IMMUNOL, V5, P503, DOI 10.1016/0952-7915(93)90030-V; BAUMANN H, 1993, J IMMUNOL, V151, P1456; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAUMANN H, 1993, J IMMUNOL, V151, P4248; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPOS SP, 1994, CYTOKINE, V6, P485, DOI 10.1016/1043-4666(94)90075-2; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MATOS ME, 1993, J EXP MED, V178, P1079, DOI 10.1084/jem.178.3.1079; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; PRUITT SC, 1988, GENE, V66, P121, DOI 10.1016/0378-1119(88)90230-2; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEINMAN RA, 1994, BLOOD, V83, P119; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TORRIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; ULTSCH M, 1993, J MOL BIOL, V231, P1133, DOI 10.1006/jmbi.1993.1359; VIGON I, 1993, ONCOGENE, V8, P2607; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	88	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8298	8310		10.1074/jbc.270.14.8298	http://dx.doi.org/10.1074/jbc.270.14.8298			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713938	hybrid			2022-12-27	WOS:A1995QR52600077
J	MURIAUX, D; GIRARD, PM; BONNETMATHONIERE, B; PAOLETTI, J				MURIAUX, D; GIRARD, PM; BONNETMATHONIERE, B; PAOLETTI, J			DIMERIZATION OF HIV-1(LAI) RNA AT LOW IONIC-STRENGTH - AN AUTOCOMPLEMENTARY SEQUENCE IN THE 5' LEADER REGION IS EVIDENCED BY AN ANTISENSE OLIGONUCLEOTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; MOLONEY MURINE LEUKEMIA; REVERSE TRANSCRIPTION; NUCLEOCAPSID PROTEIN; DIMER FORMATION; RETROVIRAL RNA; CIS ELEMENTS; GENOMIC RNA; INVITRO; RECOMBINATION	Genomic human immunodeficiency virus type 1 (HIV-1) RNA consists of two identical RNA molecules joined noncovalently near their 5' ends in a region called the dimer linkage structure (DLS). Previous work has shown that the putative DLS is localized in a 113-nucleotide domain encompassing the 5' end of the gag gene. This region contains conserved purine tracks that are thought to mediate dimerization through purine quartets. However, recently, an HIV-1(Mal) RNA dimerization model was proposed as the HIV-1(Mal) RNA dimerization initiation site, involving another region upstream from the splice donor site and possibly confined within a stem-loop. In the present study, we have investigated the dimerization of HIV-1(Lai) RNA, using in vitro dimerization assays under conditions of low ionic strength, predictive RNA secondary structures determined by computer folding, and antisense DNA oligonucleotides in order to discriminate between these two models. Our results suggest that purine quartets are not involved in the dimer structure of HIV-1(Lai) RNA and have led to the identification of a region upstream from the splice donor site. This region, comprising an autocomplementary sequence in a possible stem-loop structure, is responsible for the formation of dimeric HIV-1(Lai) RNA.	INST GUSTAVE ROUSSY,PHARMACOL & PHYSICOCHIM MACROMOLEC LAB,CNRS,URA 147,UNITE BIOCHIM ENZYMOL,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; BERKHOUT B, 1993, FASEB J, V7, P181, DOI 10.1096/fasebj.7.1.8422965; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; COFFIN JM, 1984, RNA TUMOR VIRUSES, V1, P261; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1992, J VIROL, V66, P7245, DOI 10.1128/JVI.66.12.7245-7252.1992; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HASELTINE WA, 1977, P NATL ACAD SCI USA, V74, P989, DOI 10.1073/pnas.74.3.989; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; KATOH I, 1993, J VIROL, V67, P1830, DOI 10.1128/JVI.67.4.1830-1839.1993; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Maniatis T., 1982, MOL CLONING; MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145; MARQUET R, 1991, NUCLEIC ACIDS RES, V18, P2349; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; MYERS G, 1992, HUMAN RETROVIRUSES A; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; ROY C, 1990, NUCLEIC ACIDS RES, V18, P7287, DOI 10.1093/nar/18.24.7287; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; TURNER DH, 1987, COLD SPRING HARB SYM, V52, P123, DOI 10.1101/SQB.1987.052.01.017; WEISS S, 1992, GENE, V121, P203, DOI 10.1016/0378-1119(92)90123-7; WEISS S, 1993, NUCLEIC ACIDS RES, V21, P4879, DOI 10.1093/nar/21.21.4879; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	35	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8209	8216		10.1074/jbc.270.14.8209	http://dx.doi.org/10.1074/jbc.270.14.8209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713927	hybrid			2022-12-27	WOS:A1995QR52600066
J	ZHANG, P; FRUGULHETTI, I; JIANG, YQ; HOLT, GL; CONDIT, RC; LEE, MYWT				ZHANG, P; FRUGULHETTI, I; JIANG, YQ; HOLT, GL; CONDIT, RC; LEE, MYWT			EXPRESSION OF THE CATALYTIC SUBUNIT OF HUMAN DNA-POLYMERASE-DELTA IN MAMMALIAN-CELLS USING A VACCINIA VIRUS VECTOR SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' EXONUCLEASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE; REPLICATION; PURIFICATION; PROTEIN	The catalytic polypeptide of human DNA polymerase delta was overexpressed in BSC-40 cells (African green monkey kidney cell line) using the vaccinia virus/pTM1 system. The recombinant human DNA polymerase delta was purified to homogeneity in two steps using an immunoaffinity column and a single-stranded DNA-cellulose column. Levels of expression were about 1% of soluble cytosolic protein. The recombinant catalytic subunit was fully active and exhibited enzymatic properties similar to that of the native two-subunit enzyme including the possession of an associated 3' to 5' exonuclease activity. Recombinant pol delta was stimulated by proliferating cell nuclear antigen (PCNA); however, the degree of stimulation was lower than that of the native human enzyme. Analysis of a double mutant of the catalytic subunit, H142R/F144S, showed that it had a greatly reduced sensitivity to PCNA, suggesting that the PCNA binding site of pol delta may be located in this region of the N terminus.	UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV FLORIDA,DEPT MICROBIOL & IMMUNOL,GAINESVILLE,FL 32610	University of Miami; State University System of Florida; University of Florida			Paixão, Izabel/S-7490-2019; Paixão, Izabel/AAM-1668-2020		NIGMS NIH HHS [GM31973] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1993, J BIOL CHEM, V268, P982; BROWN WC, 1993, J BIOL CHEM, V268, P32176; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; DOTTO GP, 1981, VIROLOGY, V114, P463, DOI 10.1016/0042-6822(81)90226-9; DOTTO GP, 1984, J MOL BIOL, V172, P507, DOI 10.1016/S0022-2836(84)80020-0; DOTTO GP, 1983, VIROLOGY, V30, P252; FEHER Z, 1994, BBA-GENE STRUCT EXPR, V1218, P35, DOI 10.1016/0167-4781(94)90098-1; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HRUBY DE, 1979, J VIROL, V29, P705, DOI 10.1128/JVI.29.2.705-715.1979; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LU CD, 1992, BIOCHEMISTRY-US, V31, P12403, DOI 10.1021/bi00164a015; MILLER LK, 1988, AN REV MICROBIOL, V42, P8177; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAKANO R, 1991, GENE, V105, P173, DOI 10.1016/0378-1119(91)90148-5; PIGNEDE G, 1991, J MOL BIOL, V222, P209, DOI 10.1016/0022-2836(91)90207-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988	32	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7993	7998		10.1074/jbc.270.14.7993	http://dx.doi.org/10.1074/jbc.270.14.7993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713899	hybrid			2022-12-27	WOS:A1995QR52600035
J	CALVERT, CM; SANDERS, D				CALVERT, CM; SANDERS, D			INOSITOL TRISPHOSPHATE-DEPENDENT AND TRISPHOSPHATE-INDEPENDENT CA2+ MOBILIZATION PATHWAYS AT THE VACUOLAR MEMBRANE OF CANDIDA-ALBICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CALCIUM RELEASE; NEUROSPORA-CRASSA; PLASMA-MEMBRANE; CA-2+ RELEASE; ION CHANNELS; YEAST-CELLS; H+-ATPASE; OAT ROOTS; RED BEET	Vacuolar membrane vesicles were isolated from Candida albicans protoplasts, and marker enzyme assays were employed to identify the membranes as vacuolar in origin, The mechanisms of Ca2+ uptake and Ca2+ release at the vacuolar membrane were investigated, Ca2+ accumulation by vacuolar membrane vesicles can be generated via H+/Ca2+ antiport. The inside-acid pH is in turn generated by a vacuolar-type HC-ATPase, as demonstrated by the sensitivity of Ca2+ uptake to ionophores and the vacuolar H+-ATPase inhibitor bafilomycin A(1). Vacuolar membrane vesicles exhibit two Ca2+ release pathways: one induced by inositol 1,4,5-trisphosphate (InsP(3)) and the other by inside-positive voltage. These two pathways are distinct with respect to the amount of Ca2+ released, the nature of response to successive stimuli, and their respective pharmacological profiles, The InsP(3)-gated pathway exhibits a K-0.5 for InsP(3) of 2.4 mu M but is not activated by inositol 4,5-bisphosphate or inositol 1,3,4,5-tetrakisphosphate at concentrations up to 50 mu M. Ca2+ release by InsP(3) is blocked partially by low molecular weight heparin, Ca2+ released by the voltage-sensitive pathway occurs at membrane potentials estimated to be over a physiological range from 0 to 80 mV. The voltage-sensitive Ca2+ release pathway can be blocked by lanthanide ions and organic channel blockers such as ruthenium red and verapamil. Furthermore, the voltage-sensitive Ca2+ release pathway exhibits Ca2+-induced Ca2+ release. These findings are discussed in relation to the mechanism of Ca2+-mediated cellular signaling in C. albicans and other fungi.	UNIV YORK, DEPT BIOL, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of York - UK								ALLEN GJ, 1994, PLANT CELL, V6, P685, DOI 10.1105/tpc.6.5.685; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BELDE PJM, 1993, FEBS LETT, V323, P113, DOI 10.1016/0014-5793(93)81460-H; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERTL A, 1990, P NATL ACAD SCI USA, V87, P7824, DOI 10.1073/pnas.87.20.7824; BERTL A, 1992, J EXP BIOL, V172, P271; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; BIDEN TJ, 1984, BIOCHEM J, V223, P467, DOI 10.1042/bj2230467; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BROSNAN JM, 1990, NATURE, V344, P593, DOI 10.1038/344593b0; BROSNAN JM, 1990, FEBS LETT, V260, P70, DOI 10.1016/0014-5793(90)80068-T; BROSNAN JM, 1993, PLANT CELL, V5, P931, DOI 10.1105/tpc.5.8.931; BUSH DR, 1986, PLANT PHYSIOL, V80, P549, DOI 10.1104/pp.80.2.549; CHATTAWAY FW, 1981, J GEN MICROBIOL, V123, P233; CHUEH SH, 1986, J BIOL CHEM, V261, P1388; CORNELIUS G, 1989, BIOCHEM BIOPH RES CO, V162, P852, DOI 10.1016/0006-291X(89)92388-7; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DATTA A, 1992, CURR SCI INDIA, V62, P400; GADD GM, 1992, J GEN MICROBIOL, V138, P1561, DOI 10.1099/00221287-138-8-1561; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GREEN JR, 1988, ISOLATION MEMBRANES, P135; HALACHMI D, 1989, FEBS LETT, V256, P55, DOI 10.1016/0014-5793(89)81717-X; HEDRICH R, 1987, NATURE, V329, P833, DOI 10.1038/329833a0; HODGES TK, 1974, METHOD ENZYMOL, V32, P397; IIDA H, 1990, J BIOL CHEM, V265, P21216; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; JEAN T, 1986, J BIOL CHEM, V261, P6414; JENNINGS IR, 1988, PLANT PHYSIOL, V79, P1257; JOHANNES E, 1992, PLANT J, V2, P97, DOI 10.1111/j.1365-313X.1992.00097.x; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO H, 1989, J BIOL CHEM, V264, P3116; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LASKER BA, 1992, EXP MYCOL, V16, P155, DOI 10.1016/0147-5975(92)90022-J; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; LEIGH RA, 1980, PLANTA, V150, P222, DOI 10.1007/BF00390830; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILLER AJ, 1990, P NATL ACAD SCI USA, V87, P9348, DOI 10.1073/pnas.87.23.9348; MIYAKAWA T, 1989, J BACTERIOL, V171, P1417, DOI 10.1128/jb.171.3.1417-1422.1989; MUTHUKUMAR G, 1984, J BACTERIOL, V159, P390, DOI 10.1128/JB.159.1.390-392.1984; MUTHUKUMAR G, 1987, FEMS MICROBIOL LETT, V41, P253; Odds FC., 1988, CANDIDA CANDIDOSIS; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; OKOROKOV LA, 1985, FEBS LETT, V192, P303, DOI 10.1016/0014-5793(85)80130-7; PARANJAPE V, 1990, J GEN MICROBIOL, V136, P2149, DOI 10.1099/00221287-136-11-2149; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; RANJEVA R, 1988, FEBS LETT, V230, P137, DOI 10.1016/0014-5793(88)80657-4; REDDY ASN, 1987, J BIOCHEM-TOKYO, V101, P569, DOI 10.1093/jb/101.3.569; ROBSON GD, 1991, MYCOL RES, V95, P1082, DOI 10.1016/S0953-7562(09)80551-0; Rottenberg H, 1979, Methods Enzymol, V55, P547; ROY BG, 1987, FEMS MICROBIOL LETT, V41, P327; SABIE FT, 1989, MYCOPATHOLOGIA, V108, P47, DOI 10.1007/BF00436783; SCHEKMAN R, 1982, MOL BIOL YEAST SACCH, P651; SCHMID J, 1988, J GEN MICROBIOL, V134, P2622; SCHULTZ C, 1990, BIOCHEM BIOPH RES CO, V166, P1319, DOI 10.1016/0006-291X(90)91010-P; SCHUMAKER KS, 1987, J BIOL CHEM, V262, P3944; SCHUMAKER KS, 1986, J BIOL CHEM, V261, P2172; SHEPHERD MG, 1985, ANNU REV MICROBIOL, V39, P579, DOI 10.1146/annurev.mi.39.100185.003051; SOLL DR, 1986, BIOESSAYS, V5, P5, DOI 10.1002/bies.950050103; STEIN WD, 1990, CHANNELS CARRIERS PU, P221; STEWART E, 1988, J GEN MICROBIOL, V134, P1079; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; UCHIDA E, 1988, METHOD ENZYMOL, V157, P544; WADA JM, 1994, PLANT CELL, V6, P669; Widell S., 1990, The plant plasma membrane., P16; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; ZHOU XL, 1991, SCIENCE, V253, P1415, DOI 10.1126/science.1716786	68	44	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7272	7280		10.1074/jbc.270.13.7272	http://dx.doi.org/10.1074/jbc.270.13.7272			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706267	hybrid			2022-12-27	WOS:A1995QQ43100040
J	GENTRYWEEKS, CR; SPOKES, J; THOMPSON, J				GENTRYWEEKS, CR; SPOKES, J; THOMPSON, J			BETA-CYSTATHIONASE FROM BORDETELLA-AVIUM - ROLE(S) OF LYSINE-214 AND CYSTEINE RESIDUES IN ACTIVITY AND CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; PYRIDOXAL-PHOSPHATE; BINDING-SITE; TRYPTOPHAN SYNTHASE; ESCHERICHIA-COLI; SULFANE SULFUR; SUBSTITUTION; POLYMERASE; SUBUNIT; GENES	beta-Cystathionase (EC 4.4.1.8) from Bordetella avium is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that catalyzes the hydrolysis of L-cystine to yield pyruvic acid, NH3, and thiocysteine. The latter compound is highly toxic toward MC3T3-E1 osteogenic cells, rat os teosarcoma cells, and other cell lines maintained in tissue culture (Gentry-Weeks, C. R., Keith, J. M., and Thompson, J. (1993) J. Biol. Chem. 268, 7298-7314). Site directed mutagenesis has established that lysine 214 of the sequence TKYVGGHSD, is primarily responsible for internal aldimine binding of PLP in the holoenzyme. Translation of the DNA sequence of the beta-cystathionase gene (metC) from B. avium, reveals 4 cysteine residues/enzyme subunit (M(r) = 42,600), and spectrophotometric analysis with 4,4' dithiodipyridine showed that there were no disulfide linkages in the native protein. beta-Cystathionase is inhibited by sulfhydryl-reactive agents, including N-ethyhmaleimide (NEM). To elucidate the mechanism of NEM inhibition, each of the 4 cysteine residues at positions 88, 117, 279, and 309 was individually replaced by alanine or glycine. The mutant proteins C88A, C117G, C279G, and C309A were purified to homogeneity, and each was assayed for enzyme activity, PLP-binding, NEM sensitivity, and susceptibility to chymotrypsin digestion. The activities of mutant proteins C88A and C279G were comparable with that of the native enzyme, and since both forms were inhibited by NEM, neither cysteine 88 nor 279 are prerequisite for enzyme activity. By elimination, cysteine residues 117 and 309 must be the targets for alkylation, and resultant inactivation of beta-cystathionase, by the -SH reactive agent. Substitution of cysteine 117 and 309 with glycine and alanine, respectively, yielded the inactive proteins C117G and C309A. PLP was not detectable in these proteins, and their absorption spectra lacked the peak (at 420 nm) that is characteristic of internal PLP-Schiff base formation. Edman degradation revealed that C117G (M(r) similar to 36,000) also lacked the first 63 amino acids comprising the N terminus of the native protein. The beta-cystathionase mutants C117G and C309A showed enhanced susceptibility to chymotrypsin digestion. Cysteine residues 117 and 309 may reside in conformationally sensitive environments, and in the native enzyme these amino acids most probably serve a structural function. Toxicity assays performed with the various mutant proteins obtained by site-directed mutagenesis established that only catalytically active forms of beta-cystathionase were cytotoxic for tissue culture cells.			GENTRYWEEKS, CR (corresponding author), NIDR,MICROBIAL ECOL LAB,BLDG 30,RM 532,30 CONVENT DR,MSC 4350,BETHESDA,MD 20892, USA.		Gentry-Weeks, Claudia/J-2248-2017	Gentry-Weeks, Claudia/0000-0002-9214-3193				ABDOLRASULNIA R, 1980, BIOORG CHEM, V9, P253, DOI 10.1016/0045-2068(80)90026-7; [Anonymous], INTRO PROTEIN STRUCT; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BEWLEY TA, 1969, INT J PROT RES, V1, P117; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BURNELL JN, 1977, BIOCHIM BIOPHYS ACTA, V481, P246, DOI 10.1016/0005-2744(77)90157-7; CAVALLINI D., 1960, ENZYMOLOGIA, V22, P161; COHEN GN, 1987, ESCHERICHIA COLI SAL, P429; Davis L., 1972, ENZYMES, V7, P33; DELAVIERKLUTCHK.C, 1965, J BIOL CHEM, V240, P2537; DELAVIERKLUTCHK.C, 1965, BIOCHIM BIOPHYS ACTA, V99, P375; FLAVIN M, 1962, J BIOL CHEM, V237, P768; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GENTRYWEEKS CR, 1993, J BIOL CHEM, V268, P7298; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KASTURI S, 1992, J BIOL CHEM, V267, P23427; LU ZC, 1993, J BIOL CHEM, V268, P8727; MARTEL A, 1987, BIOCHEM BIOPH RES CO, V147, P565, DOI 10.1016/0006-291X(87)90968-5; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1989, J BIOL CHEM, V264, P6280; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; PARK YM, 1989, MOL GEN GENET, V216, P164, DOI 10.1007/BF00332246; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; SNELL EE, 1970, ENZYMES, P335; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TOOHEY JI, 1989, BIOCHEM J, V264, P625, DOI 10.1042/bj2640625; WOOD JL, 1987, METHOD ENZYMOL, V143, P25; WOOD JL, 1982, ADV EXP MED BIOL, V148, P327	31	12	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7695	7702		10.1074/jbc.270.13.7695	http://dx.doi.org/10.1074/jbc.270.13.7695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706318	hybrid			2022-12-27	WOS:A1995QQ43100096
J	STEINHILBER, D; BRUNGS, M; WERZ, O; WIESENBERG, I; DANIELSSON, C; KAHLEN, JP; NAYERI, S; SCHRADER, M; CARLBERG, C				STEINHILBER, D; BRUNGS, M; WERZ, O; WIESENBERG, I; DANIELSSON, C; KAHLEN, JP; NAYERI, S; SCHRADER, M; CARLBERG, C			THE NUCLEAR RECEPTOR FOR MELATONIN REPRESSES 5-LIPOXYGENASE GENE-EXPRESSION IN HUMAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							9-CIS RETINOIC ACID; CELLS; SUPERFAMILY; PROMOTER; CULTURE	The two subtypes of retinoid Z receptor (RZR alpha and beta) and the three splicing variants of retinoid orphan receptor (ROR alpha 1, alpha 2, and alpha 3) form a subfamily within the superfamily of nuclear hormone receptors, Very recently we found that the pineal gland hormone melatonin is a natural ligand of RZR alpha and RZR beta. Ligand-induced transcriptional control is therefore proposed to mediate physiological functions of melatonin in the brain where RZR beta is expressed, but also in peripheral tissues, where RZR alpha was found. However, no natural RZR responding genes have been identified yet. Here, we report that a response element in the promoter of 5-lipoxygenase binds specifically RZR alpha and ROR alpha 1, but not ROR alpha 2 and alpha 3. 5-Lipoxygenase is a key enzyme in the biosynthesis of leukotrienes, which are known to be allergic and inflammatory mediators. We could show that the activity of the whole 5-lipoxygenase promoter as well as of the RZR response element fused to the heterologous thymidine kinase promoter could be repressed by melatonin. The hormone down-regulated the expression of 5-lipoxygenase about 5-fold in B lymphocytes, which express RZR alpha, In contrast, 5-lipoxygenase mRNA levels were not affected in differentiated monocytic and granulocytic cell lines, which do not express RZR alpha. This indicates that 5-lipoxygenase is the first natural RZR alpha responding gene. Furthermore, our results open up a new perspective in understanding the involvement of melatonin in inflammatory and immunological reactions.	UNIV GENEVA,HOP CANTONAL,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; UNIV TUBINGEN,INST PHARMAZEUT,D-72076 TUBINGEN,GERMANY; CIBA GEIGY AG,PHARM FORSCH,CH-4002 BASEL,SWITZERLAND	University of Geneva; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Novartis			Steinhilber, Dieter/J-3221-2012; Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BROCK TG, 1994, J BIOL CHEM, V269, P22059; BRUNGS M, 1994, P NATL ACAD SCI USA, V92, P107; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; COS S, 1991, J PINEAL RES, V10, P36, DOI 10.1111/j.1600-079X.1991.tb00007.x; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; KRAUSE DN, 1991, ANNU REV PHARMACOL, V31, P549; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; STEINHILBER D, 1993, P NATL ACAD SCI USA, V90, P5984, DOI 10.1073/pnas.90.13.5984; Steinhilber D, 1994, Pharm Acta Helv, V69, P3, DOI 10.1016/0031-6865(94)90024-8; STEINHILBER D, 1993, BIOCHIM BIOPHYS ACTA, V1178, P1, DOI 10.1016/0167-4889(93)90104-W; WALDHAUSER F, 1993, EXPERIENTIA, V49, P671, DOI 10.1007/BF01923949; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; YING SW, 1993, EUR J PHARM-MOLEC PH, V246, P89, DOI 10.1016/0922-4106(93)90084-M; ZIEGLERHEITBROC.HW, 1988, INT J CANCER, V41, P456	36	239	245	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7037	7040		10.1074/jbc.270.13.7037	http://dx.doi.org/10.1074/jbc.270.13.7037			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706239	hybrid			2022-12-27	WOS:A1995QQ43100007
J	STEINERT, PM; MAREKOV, LN; PARRY, DAD				STEINERT, PM; MAREKOV, LN; PARRY, DAD			DIVERSITY OF INTERMEDIATE FILAMENT STRUCTURE - EVIDENCE THAT THE ALIGNMENT OF COILED-COIL MOLECULES IN VIMENTIN IS DIFFERENT FROM THAT IN KERATIN INTERMEDIATE FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFILAMENT-L PROTEIN; INVITRO; CELLS; ARCHITECTURE; HETERODIMER; EXPRESSION; COMPLEXES; REGISTER; SUBUNITS	Although vimentin intermediate filaments (IF) are morphologically similar to all other IF types, cells have evolved different ways of manipulating vimentin and keratin IF. The structural basis for such differences is unknown. We have explored this by use of cross-linking experiments on vimentin oligomers, polymers, and intact IF to determine the axial length of vimentin molecules and the degrees to which neighboring molecules are aligned in IF. Our data reveal that the homodimer vimentin molecule (43.9 nm) is clearly shorter than a keratin heterodimer molecule (46.2 nm). Vimentin assemblies contain three modes of antiparallel molecular alignments: A11 and A22 in two-molecule or larger oligomeric assemblies, in which the two molecules are staggered so as to bring their 1B and 2B rod domain segments, respectively, into register; and A12 in higher order molecular assemblies in which the two neighboring molecules are largely overlapped. Since the repeat axial length of the vimentin assemblies (42.6 nm) is less than the molecular length, this means there is an overlap (designated as alignment A(CN)) of about 1 nm (5-10 residues) between the end of the 2B and beginning of the IA rod domain segments of similarly directed molecules in the IF. Interestingly, these four modes of nearest neighbor molecular alignments also occur in keratin IF. However, the degree of stagger of alignments in the A11 and A22 modes is different (staggers of -19.5 for vimentin versus -16.6 nm for keratin, and 23.3 and 28.6 nm, respectively). Two-dimensional surface lattice maps of the two IF types are very similar, except for differences in molecule alignments and different axial repeats of 21.4 nm in vimentin and 22.6 nm in keratin IF. Although vimentin-keratin hybrid molecules can be induced to form in vitro, they do not assemble into higher order structures. The data suggest that vimentin and keratin are incapable of assembly into IF in vitro or in vivo simply because their molecules are of different axial lengths and because the exact axial alignments of neighboring molecules are different.	MASSEY UNIV,DEPT PHYS & BIOPHYS,PALMERSTON NORTH,NEW ZEALAND	Massey University	STEINERT, PM (corresponding author), NIAMSD,SKIN BIOL BRANCH,BLDG 6,RM 425,BETHESDA,MD 20892, USA.							BRAGG PD, 1980, EUR J BIOCHEM, V106, P493; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; DESSEV G, 1988, DEV BIOL, V130, P543, DOI 10.1016/0012-1606(88)90349-1; Fraser R.D.B., 1990, CELLULAR MOL BIOL IN, P205; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; FRASER RDB, 1985, BIOSCIENCE REP, V5, P573, DOI 10.1007/BF01117070; GEISLER N, 1993, FEBS LETT, V323, P63, DOI 10.1016/0014-5793(93)81449-A; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GOLDMAN RD, 1990, CELLULAR MOL BIOL IN; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HENDERSON D, 1982, J MOL BIOL, V155, P173, DOI 10.1016/0022-2836(82)90444-2; HERRLING J, 1991, INT J BIOL MACROMOL, V13, P115, DOI 10.1016/0141-8130(91)90059-4; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HISANAGA S, 1990, J MOL BIOL, V211, P857, DOI 10.1016/0022-2836(90)90079-2; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MILAM L, 1982, J CELL BIOL, V94, P592, DOI 10.1083/jcb.94.3.592; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; POTSCHKA M, 1990, EUR J CEL LBIOL, V190, P505; QUAX W, 1983, CELL, V35, P215, DOI 10.1016/0092-8674(83)90224-6; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; SKALLI O, 1992, Trends in Cell Biology, V2, P308, DOI 10.1016/0962-8924(92)90121-3; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1993, J BIOL CHEM, V268, P2878; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; STEINERT PM, 1993, IN PRESS BIOCHEMISTR; STEINERT PM, 1982, COLD SPRING HARB SYM, V46, P465; STEVEN AC, 1990, CELLULAR MOL BIOL IN, P533; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; ZACKROFF RV, 1979, P NATL ACAD SCI USA, V76, P6226, DOI 10.1073/pnas.76.12.6226	45	143	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24916	24925						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693709				2022-12-27	WOS:A1993MG67300061
J	CUTLER, RL; LIU, L; DAMEN, JE; KRYSTAL, G				CUTLER, RL; LIU, L; DAMEN, JE; KRYSTAL, G			MULTIPLE CYTOKINES INDUCE THE TYROSINE PHOSPHORYLATION OF SHC AND ITS ASSOCIATION WITH GRB2 IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; INTERLEUKIN-3; RECEPTOR; KINASE; RAS; CLONING; PRODUCT; DOMAIN	The identification and characterization of proteins that become tyrosine-phosphorylated in response to growth factor stimulation is critical to furthering our understanding of the signal transduction pathways involved in regulating cell proliferation and differentiation. In this report we demonstrate that interleukin-3, erythropoietin, and steel factor all induce the tyrosine phosphorylation of the SH2 containing protein, p52shc. These studies were carried out with various human and murine cell lines to document that this is a common event in hemopoietic cells. We also show that upon tyrosine phosphorylation, p52shc becomes associated with the adaptor protein, Grb2. The formation of this complex may directly link tyrosine phosphorylation events to Ras activation in hemopoietic progenitors and may be a critical step in stimulating these cells to transit through G1 into S phase.	BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER V5Z 1L3,BC,CANADA	British Columbia Cancer Agency				Krystal, Gerald/0000-0002-1961-6281				ALAI M, 1992, J BIOL CHEM, V267, P18021; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KRYSTAL G, 1991, HEMATOL PATHOL, V5, P141; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MURTHY SC, 1989, BLOOD, V73, P1180; OKUDA K, 1992, BLOOD, V79, P2880; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMIESON S, 1993, J BIOL CHEM, V268, P7310; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SORENSEN PHB, 1989, BLOOD, V73, P406; TORTI M, 1992, J BIOL CHEM, V267, P8293	34	234	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21463	21465						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691810				2022-12-27	WOS:A1993MC80900003
J	XU, M; AKABAS, MH				XU, M; AKABAS, MH			AMINO-ACIDS LINING THE CHANNEL OF THE GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR IDENTIFIED BY CYSTEINE SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GATED ION CHANNELS; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-BIOLOGY; BRAIN; PERMEATION; SUBUNITS	The binding of gamma-aminobutyric acid (GABA) to gamma-aminobutyric acid type A (GABA(A)) receptors triggers the opening of an anion-selective channel. To identify amino acid residues that line the channel, we combined cysteine mutagenesis and covalent chemical modification. We mutated, one at a time, four consecutive residues (268-271) in the M2 membrane-spanning segment of the rat GABA(A) receptor alpha1 subunit to cysteine and expressed the mutant alpha1 subunits, together with either the beta1 subunit or the beta1 and gamma2 subunits, in Xenopus oocytes. We probed the susceptibility of the cysteine substitution mutants to covalent modification by charged, sulfhydryl reagents added extracellularly. We assumed that among the residues in membrane-spanning segments, only those lining the channel would be susceptible to modification by polar reagents and that such modification would irreversibly alter conduction. We infer that the residues Thr-268 and Ile-271 are exposed in the channel in both the open and closed states but that Leu-269 and Ser-270 are not exposed. The susceptibility of Thr-268 and Ile-271 in the closed state implies that the gate must be closer to the cytoplasmic end of the channel than Thr-268.	COLUMBIA UNIV COLL PHYS & SURG,CTR MOLEC RECOGNIT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University				Akabas, Myles/0000-0001-8781-7846	NINDS NIH HHS [NS07065] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ERICKSSON AE, 1992, SCIENCE, V255, P178; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Kenyon G L, 1977, Methods Enzymol, V47, P407; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NISHIMURA C, 1982, NEUROCHEM INT, V4, P413, DOI 10.1016/0197-0186(82)90084-5; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	24	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21505	21508						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691812				2022-12-27	WOS:A1993MC80900014
J	SARTOR, O; ROBBINS, KC				SARTOR, O; ROBBINS, KC			SUBSTRATE-SPECIFICITY FOR NORMAL BUT NOT MUTATIONALLY ACTIVATED VARIANTS OF SRC FAMILY KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; SH3 DOMAINS; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; STABLE ASSOCIATION; CATALYTIC DOMAINS; PP60SRC SUBSTRATE; CELLULAR PROTEINS; CELLS; GENE	Although structural features and expression patterns of the src family of tyrosine kinases have been extensively analyzed, there are no direct comparative studies of the putative protein substrates that are tyrosine-phosphorylated by the normal cellular versions of these enzymes. In this report, we have expressed normal and enzymatically activated versions of the fyn, fgr, and src translational products by transfection of appropriate cDNAs into mouse fibroblasts. Because the same parental cell line was used for all transfections, each enzyme was expressed in a similar milieu of potential in vivo substrates. After verification of appropriate expression from each transfected cDNA and assessment of relative transforming potency, a series of putative protein substrates was specifically assayed for expression and tyrosine phosphorylation. Our data indicate that the normal src family kinases display some degree of substrate specificity but that specificity is diminished when these enzymes are constitutively activated. In the course of these studies, tyrosine-phosphorylated proteins were noted to coimmunoprecipitate with some of these putative in vivo substrates. Some of these coimmunoprecipitating proteins have been reported previously, whereas others, such as the presence of p59fyn in anti-p80/85 immunoprecipitates, are heretofore undescribed.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	SARTOR, O (corresponding author), NCI,CLIN PHARMACOL BRANCH,RM 12N226,BLDG 10,BETHESDA,MD 20892, USA.							CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1989, ONCOGENE RES, V1, P185; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SARTOR O, 1992, J BIOL CHEM, V267, P3460; SARTOR O, 1992, J BIOL CHEM, V267, P21044; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SUDOL M, 1993, IN PRESS MOL BASIS H; VEILLETTE A, 1992, ONCOGENE, V7, P971; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	34	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21014	21020						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691803				2022-12-27	WOS:A1993MA28800059
J	TILLY, BC; VANDENBERGHE, N; TERTOOLEN, LGJ; EDIXHOVEN, MJ; DEJONGE, HR				TILLY, BC; VANDENBERGHE, N; TERTOOLEN, LGJ; EDIXHOVEN, MJ; DEJONGE, HR			PROTEIN-TYROSINE PHOSPHORYLATION IS INVOLVED IN OSMOREGULATION OF IONIC CONDUCTANCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN EPITHELIAL-CELLS; RESISTANCE P-GLYCOPROTEIN; VOLUME REGULATION; CHANNELS; INTEGRINS; PATHWAYS; ADHESION; LINE	Using the human Intestine 407 cell line as a model, we investigated a possible role for tyrosine kinase(s) in regulating the ion efflux pathways induced by hyposmotic stimulation (regulatory volume decrease, RVD). Pretreatment of I-125-- and Rb-86+-loaded cells with the phosphotyrosine phosphatase inhibitor sodium orthovanadate (200 muM) potentiated isotope efflux triggered by mild hypotonicity (10-20%) but did not further increase the efflux in response to more vigorous osmotic stimulation (30% hypotonicity). The tyrosine kinase inhibitors herbimycin A and genistein largely reduced the osmoshock-induced efflux in both control and vanadate-pretreated cells, while not affecting calcium-activated Rb-86+ efflux. Potentiation of the RVD response by vanadate was confirmed by direct measurements of hypotonicity-induced changes in cell volume. Hypotonic shock alone triggered a rapid and transient increase in tyrosine phosphorylation of several proteins as well as phosphorylation of mitogen-activated protein kinase. Furthermore, the potentiating effects of vanadate on hypotonicity-induced ion efflux and mitogen-activated protein (MAP) kinase phosphorylation were mimicked by epidermal growth factor. Neither vanadate nor epidermal growth factor provoked a RVD-like ionic response under isotonic conditions. These results indicate that tyrosine phosphorylation is an essential step in the RVD response and suggest a novel role of growth factors in the cellular defense against osmotic stress.	UNIV HOSP LEIDEN,DEPT ENDOCRINOL,2300 RC LEIDEN,NETHERLANDS; NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	TILLY, BC (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,DEPT BIOCHEM,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAUSSINGER D, 1990, HEPATOLOGY, V11, P243, DOI 10.1002/hep.1840110214; HAZAMA A, 1988, J PHYSIOL-LONDON, V402, P687, DOI 10.1113/jphysiol.1988.sp017229; HENLE G, 1957, J IMMUNOL, V79, P54; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JILL E, 1987, AM J PHYSIOL, V252, pF1; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KUBO M, 1992, J PHYSIOL-LONDON, V456, P351, DOI 10.1113/jphysiol.1992.sp019340; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; OKADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P201, DOI 10.1016/0005-2736(92)90348-P; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SWARUP G, 1982, J BIOL CHEM, V257, P7298; UEHARA Y, 1989, CANCER RES, V49, P780; VAANDRAGER AB, 1991, AM J PHYSIOL, V261, pG958, DOI 10.1152/ajpgi.1991.261.6.G958; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	23	197	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					19919	19922						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690749				2022-12-27	WOS:A1993LY01900002
J	SANO, M; HAYAKAWA, K; KATO, I				SANO, M; HAYAKAWA, K; KATO, I			PURIFICATION AND CHARACTERIZATION OF AN ENZYME RELEASING LACTO-N-BIOSE FROM OLIGOSACCHARIDES WITH TYPE-1 CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID RESIDUES; ALPHA-L-FUCOSIDASE; LINKED OLIGOSACCHARIDES; SUGAR CHAINS; ANTIGEN; GLYCOSPHINGOLIPIDS; ADHESION; LIGAND; FETUIN; ALMOND	An enzyme specific for oligosaccharides with type 1 chain was purified 7,000-fold from the culture broth of Streptomyces sp. 142. The enzyme, lacto-N-biosidase, was induced and secreted into culture medium when the strain was cultured in the presence of porcine stomach mucin. The enzyme was purified by anion-exchange chromatography on Q Sepharose, cation-exchange chromatography on S Sepharose, fast protein liquid chromatography on a Mono S column, and gel filtration chromatography on TSK gel HW55S. To remove contaminating alpha-1,3/4-fucosidase and beta-N-acetylglucosaminidase, final purification was done by fast protein liquid chromatography on a Mono S column and affinity chromatography on N-acetylglucosamine agarose. The purified enzyme gave only one major protein band with an apparent M(r) of 60,000 on sodium dodesyl sulfate-polyacrylamide gel electrophoresis. The enzyme had maximum activity at pH 5.5 and was stable at the pH range of 4.0-10.0. Substrate specificity studies with oligosaccharides labeled with 2-aminopyridine showed that the enzyme specifically hydrolyzed lacto-N-tetraose and the N-acetyllactosamine type of triantennary sugar chain with the type 1 chain, but did not hydrolyze type 2 chain oligosaccharides or the type 1 chain oligosaccharides with fucose or sialic acid including lacto-N-fucopentaose I and II and alpha-2,3-sialyl lacto-N-tetraose. The enzyme released lacto-N-biose from asialofetuin, and almost all oligosaccharides in asialofetuin were found to have only type 2 chains. Sequential digestion of extended type 1 chain oligosaccharides with alpha-1,3/4-fucosidase and lacto-N-biosidase was possible.			SANO, M (corresponding author), TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,3-4-1 SETA,OTSU,SHIGA 52021,JAPAN.							BERG EL, 1991, J BIOL CHEM, V266, P14869; EGGENS I, 1989, J BIOL CHEM, V264, P9476; GOELZ SE, 1992, TRENDS GLYCOSCI GLYC, V4, P14; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HOYER LL, 1991, J BIOCHEM-TOKYO, V110, P462, DOI 10.1093/oxfordjournals.jbchem.a123603; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OGATAARAKAWA M, 1977, ARCH BIOCHEM BIOPHYS, V181, P353, DOI 10.1016/0003-9861(77)90514-8; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; SANO M, 1992, P NATL ACAD SCI USA, V89, P8512, DOI 10.1073/pnas.89.18.8512; SANO M, 1992, J BIOL CHEM, V267, P1522; SCUDDER P, 1990, J BIOL CHEM, V265, P16472; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STROUD MR, 1992, EUR J BIOCHEM, V203, P577, DOI 10.1111/j.1432-1033.1992.tb16586.x; STROUD MR, 1991, J BIOL CHEM, V266, P8439; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TAKASAKI S, 1986, BIOCHEMISTRY-US, V25, P5709, DOI 10.1021/bi00367a054; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372	20	17	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18560	18566						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689556				2022-12-27	WOS:A1993LV65900031
J	DESOUZA, S; LOCHNER, J; MACHIDA, CM; MATRISIAN, LM; CIMENT, G				DESOUZA, S; LOCHNER, J; MACHIDA, CM; MATRISIAN, LM; CIMENT, G			A NOVEL NERVE GROWTH FACTOR-RESPONSIVE ELEMENT IN THE STROMELYSIN-1 (TRANSIN) GENE THAT IS NECESSARY AND SUFFICIENT FOR GENE-EXPRESSION IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; ONCOGENE-INDUCED TRANSIN; PHOSPHOLIPASE-C-GAMMA; DNA-BINDING PROTEINS; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; PROTEASE TRANSIN; RAT FIBROBLASTS	Stromelysin-1 (ST-1) is an extracellular matrix metalloproteinase whose expression is transcriptionally regulated by nerve growth factor (NGF) in the PC12 rat pheochromocytoma cell line. In this paper, we define sequences in the proximal ST-1 promoter that contain a novel NGF-responsive element(s). We show that this cis-acting promoter element can bind nuclear proteins from both untreated and NGF-treated PC12 cells in a specific and saturable manner and is sufficient to confer NGF-inducibility to a heterologous promoter. At least a portion of this NGF-responsive element lies within a 12-base pair region between positions -241 and -229 of the ST-1 promoter and bears no sequence homology to other known transcriptional elements. In contrast to what has been reported for fibroblasts, an AP1 site centered around position -68 does not seem to be involved in the growth factor regulation of ST-1 in PC12 cells. These results suggest that the NGF regulation of ST-1 gene expression involves different promoter elements, and possibly different transcription factors, from that described for ST-1 induction by other growth factors.	LEWIS & CLARK COLL,DEPT CHEM,PORTLAND,OR 97219; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Vanderbilt University	DESOUZA, S (corresponding author), OREGON HLTH SCI UNIV,SCH MED,DEPT CELL BIOL & ANAT L215,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS27886] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027886] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN JM, 1987, MOL BRAIN RES, V3, P39, DOI 10.1016/0169-328X(87)90042-8; ALOE L, 1979, P NATL ACAD SCI USA, V76, P1246, DOI 10.1073/pnas.76.3.1246; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COCHET C, 1991, J BIOL CHEM, V266, P637; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DAY ML, 1990, J BIOL CHEM, V265, P15253; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LENORMAND P, 1992, MOL CELL BIOL, V12, P2793, DOI 10.1128/MCB.12.6.2793; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MACHIDA CM, 1988, MOL CELL BIOL, V8, P2479, DOI 10.1128/MCB.8.6.2479; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINTHWORBY CA, 1995, J BIOL CHEM, V269, P15460; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NG NFL, 1993, J BIOL CHEM, V268, P25329; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NORDSTROM LA, 1995, IN PRESS MOL CELL NE; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SALTON SRJ, 1991, J NEUROCHEM, V57, P991, DOI 10.1111/j.1471-4159.1991.tb08248.x; Sambrook J, 1989, MOL CLONING LABORATO; SANZ L, 1994, J BIOL CHEM, V269, P10044; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMPSON MA, 1992, MOL CELL BIOL, V12, P2501, DOI 10.1128/MCB.12.6.2501; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU BY, 1989, J BIOL CHEM, V264, P9000	72	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9106	9114		10.1074/jbc.270.16.9106	http://dx.doi.org/10.1074/jbc.270.16.9106			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721824	hybrid			2022-12-27	WOS:A1995QU08900012
J	JEFFERSON, AB; MAJERUS, PW				JEFFERSON, AB; MAJERUS, PW			PROPERTIES OF TYPE-II INOSITOL POLYPHOSPHATE 5-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANE; HUMAN-ERYTHROCYTES; CARBOXYL METHYLATION; PHOSPHOLIPASE-C; HUMAN-PLATELETS; BOVINE BRAIN; RAT-BRAIN; POLYPHOSPHOINOSITIDES	We have isolated additional cDNA clones encoding type II inositol polyphosphate 5-phosphatase (5-phosphatase II) resulting in a combined cDNA of 3076 nucleotides encoding a protein of 942 amino acids. The 5-phosphatase II hydrolyzed both Ins(1,4,5)P-3 to Ins(1,4)P-2 and the phospholipid PtdIns(4,B)P-2 to PtdIns(4)P both in vitro and in vivo. There are two motifs highly conserved between types I and II 5-phosphatase and several other proteins presumed to be inositol phosphatases suggesting a possible role in catalysis. The type II Fi-phosphatase also contains homology to several GTPase activating proteins although no such activity for 5-phosphatase II was found. The predicted protein ends with the sequence CNPL, suggesting that it is iso prenylated as a mechanism for membrane attachment. We found evidence for isoprenylation by demonstrating incorporation of [H-3]mevalonate into native but not C939S mutant B-phosphatase II expressed in Sig insect cells. Furthermore, we showed that membrane localization and the activity of 5-phosphatase II toward its lipid substrate PtdIns(4,5)P-2 is reduced by eliminating 5-phosphatase II isoprenylation in the mutant C939S relative to the native enzyme.			JEFFERSON, AB (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, P50HL014147, R37HL016634, T32HL007088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16634, HL 14147, HL 07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BALDWIN GS, 1993, TRENDS BIOCHEM SCI, V18, P378, DOI 10.1016/0968-0004(93)90093-3; BECK KA, 1991, J BIOL CHEM, V266, P4442; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; COOPER PH, 1975, BIOCHEM J, V150, P537, DOI 10.1042/bj1500537; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DESMEDT F, 1994, FEBS LETT, V347, P639; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLDSCHMIDTCLER.PJ, 1990, SCIENCE, V247, P1575; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, J BIOL CHEM, V266, P20840; HODGKIN M, 1994, BIOCHEM J, V297, P637, DOI 10.1042/bj2970637; HUANG FL, 1991, J BIOL CHEM, V266, P8727; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEE CZ, 1994, VIROLOGY, V199, P169, DOI 10.1006/viro.1994.1109; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MEMON AR, 1989, BIOCHEM BIOPH RES CO, V162, P1295, DOI 10.1016/0006-291X(89)90814-0; MISSIAEN L, 1989, BIOCHEM J, V261, P1055, DOI 10.1042/bj2611055; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MULLER E, 1986, BIOCHEM J, V235, P775; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; PALMER FBS, 1990, BIOCHEM CELL BIOL, V68, P800; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; ROACH PD, 1981, BIOCHIM BIOPHYS ACTA, V661, P323, DOI 10.1016/0005-2744(81)90021-8; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; VERJANS B, 1990, CELL SIGNAL, V2, P595, DOI 10.1016/0898-6568(90)90082-L	59	113	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9370	9377		10.1074/jbc.270.16.9370	http://dx.doi.org/10.1074/jbc.270.16.9370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721860	hybrid			2022-12-27	WOS:A1995QU08900049
J	PHILIPS, N; BASHEY, RI; JIMENEZ, SA				PHILIPS, N; BASHEY, RI; JIMENEZ, SA			INCREASED ALPHA-1(I) PROCOLLAGEN GENE-EXPRESSION IN TIGHT-SKIN (TSK) MICE MYOCARDIAL FIBROBLASTS IS DUE TO A REDUCED INTERACTION OF A NEGATIVE REGULATORY SEQUENCE WITH AP-1 TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; BIOCHEMICAL-CHARACTERIZATION; CARDIAC FIBROBLASTS; CONNECTIVE-TISSUE; MESSENGER-RNAS; 1ST INTRON; FOS JUN; MOUSE; PROMOTER; BINDING	The TSK mouse, a model of fibrosis, displays exaggerated connective tissue accumulation in skin and visceral organs including the heart, To study the mechanisms of myocardial fibrosis in TSK mice, we established several strains of TSK mice myocardial fibroblasts in culture and examined the regulation of collagen gene expression in these cells, These strains displayed increased collagen gene expression in comparison with myocardial fibroblasts established from normal mice. On an average, the TSK myocardial fibroblast cultures showed a 4-fold increase in collagen synthesis and 4.4- and 3.6-fold increases, respectively, in alpha 1(I) and alpha 1(III) collagen mRNA steady state levels, The increased alpha 1(I) and alpha 1(III) collagen mRNA levels were mainly due to increased transcription rates (3.4- and 3.8-fold higher, respectively) of the respective genes, Furthermore, we showed that the up-regulation of alpha 1(I) procollagen gene transcription in TSK mice myocardial fibroblasts was due to the lack of the strong inhibitory influence of a regulatory sequence contained in the promoter region encompassing nucleotides -675 to -804, Nuclear extracts from TSK mice myocardial fibroblasts showed lower DNA binding activity to oligonucleotides spanning the mapped regulatory sequence as well as to a consensus AP-1 sequence, but not to a consensus SP-l sequence, and supershift experiments with an AP-1 antibody confirmed the interaction of these oligonucleotides with AP-1 protein. These observations indicate that a strong negative regulatory sequence contained within -0.675 to -0.804 kilobase of the alpha 1(I) procollagen promoter binds AP-1 transcription factor and mediates inhibition of gene transcription in normal murine myocardial fibroblasts, The TSK mice myocardial fibroblasts lack this inhibitory control, due to lower available amounts and/or decreased binding activity to this inhibitory sequence, and hence display increased alpha 1(I) procollagen gene expression.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV RHEUMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University				Jimenez, Sergio/0000-0001-5213-1203	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM032564] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 32564] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASHEY RI, 1983, CONNECT TISSUE RES, V12, P17, DOI 10.3109/03008208309005608; BASHEY RI, 1993, CARDIOVASC RES, V27, P1061, DOI 10.1093/cvr/27.6.1061; BASHEY RI, 1992, J MOL CELL CARDIOL, V24, P691, DOI 10.1016/0022-2828(92)93383-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN D, 1990, CARDIOVASC RES, V24, P578, DOI 10.1093/cvr/24.7.578; DAVIS LG, 1986, BASIC METHODS MOL BI, P147; DIEGELMANN RF, 1972, DEV BIOL, V28, P443, DOI 10.1016/0012-1606(72)90028-0; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRENCH BT, 1985, GENE, V39, P311, DOI 10.1016/0378-1119(85)90329-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MC, 1976, AM J PATHOL, V82, P493; HARBERS K, 1984, P NATL ACAD SCI-BIOL, V81, P1504, DOI 10.1073/pnas.81.5.1504; JIMENEZ SA, 1986, J BIOL CHEM, V261, P657; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JIMENEZ SA, 1984, ARTHRITIS RHEUM-US, V27, P180, DOI 10.1002/art.1780270209; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIAN JB, 1991, J CELL BIOCHEM, V45, P9, DOI 10.1002/jcb.240450106; LIAU G, 1985, J BIOL CHEM, V260, P3773; MARTY FL, 1985, NCUELCI ACIDS RES, V13, P1431; OSBORN TG, 1987, J MOL CELL CARDIOL, V19, P581, DOI 10.1016/S0022-2828(87)80363-2; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SIMKEVICH CP, 1992, BIOCHEM J, V286, P179, DOI 10.1042/bj2860179; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; YAO JL, 1992, CIRC RES, V71, P831, DOI 10.1161/01.RES.71.4.831; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X; [No title captured]	36	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9313	9321		10.1074/jbc.270.16.9313	http://dx.doi.org/10.1074/jbc.270.16.9313			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721853	hybrid			2022-12-27	WOS:A1995QU08900041
J	STREUSAND, VJ; BJORK, I; GETTINS, PGW; PETITOU, M; OLSON, ST				STREUSAND, VJ; BJORK, I; GETTINS, PGW; PETITOU, M; OLSON, ST			MECHANISM OF ACCELERATION OF ANTITHROMBIN-PROTEINASE REACTIONS BY LOW-AFFINITY HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTEASE INACTIVATION; MOLECULAR WEIGHT HEPARIN; ANTI-THROMBIN-III; FACTOR-XA; CONFORMATIONAL CHANGE; CIRCULAR-DICHROISM; TRANSIENT KINETICS; BINDING-SITE; SPECTROSCOPY; INHIBITION	The role of the sequence-specific pentasaccharide region of high affinity heparin (HAH) in heparin acceleration of antithrombin-proteinase reactions was elucidated by determining the accelerating mechanism of low affinity heparin (LAH) lacking this sequence, LAH was shown to be free of HAH (<0.001%) from the lack of exchange of added fluorescein-labeled HAH into LAH after separating the polysaccharides by antithrombin-agarose chromatography, Fluorescence titrations showed that LAH bound to antithrombin with a 1000-fold weaker affinity (K-D 19 +/- 6 mu M) and 5-6-fold smaller fluorescence enhancement (8 +/- 3%) than HAH. LAH accelerated the antithrombin-thrombin reaction with a bell shaped dependence on heparin concentration resembling that of HAH, but with the bell-shaped curve shifted to similar to 100-fold higher polysaccharide concentrations and with a similar to 100-fold reduced maximal accelerating effect, Rapid kinetic studies indicated these differences arose from a reverse order of assembly of an intermediate heparin-thrombin-antithrombin ternary complex and diminished ability of LAH to bridge antithrombin and thrombin in this complex, as compared to HAH, By contrast, LAH and HAH both accelerated the antithrombin factor Xa reaction with a simple saturable dependence on heparin or inhibitor concentrations which paralleled the formation of an antithrombin-heparin binary complex, The maximal accelerations of the two heparins in this case correlated with the inhibitor fluorescence enhancements induced by the polysaccharides, consistent with the accelerations arising from conformational activation of antithrombin. H-1 NMR difference spectroscopy of antithrombin complexes with LAH and HAH and competitive binding studies were consistent with LAH accelerating activity being mediated by binding to the same site on the inhibitor as HAH, These results demonstrate that LAH accelerates antithrombin-proteinase reactions by bridging and conformational activation mechanisms similar to those of HAH, with the reduced magnitude of LAH accelerations resulting both from a decreased antithrombin affinity and the inability to induce a full activating conformational change in the inhibitor.	UNIV ILLINOIS,CTR MOLEC BIOL ORAL DIS,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612; HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202; SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,UPPSALA,SWEDEN; SANOFI RECH,GENTILLY,FRANCE	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Henry Ford Health System; Henry Ford Hospital; Swedish University of Agricultural Sciences; Sanofi-Aventis; Sanofi France					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049234, R37HL049234, R37HL039888, R01HL039888, R29HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39888, HL-49234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1978, EUR J BIOCHEM, V90, P7, DOI 10.1111/j.1432-1033.1978.tb12568.x; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; FAN BQ, 1994, FEBS LETT, V354, P84, DOI 10.1016/0014-5793(94)01083-8; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GETTINS P, 1992, J BIOL CHEM, V267, P21946; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GRAY E, 1994, THROMB HAEMOSTASIS, V71, P203; Griffin J H, 1976, Methods Enzymol, V45, P56; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; JACQUES LB, 1977, METHOD BIOCHEM ANAL, V24, P203; JORDAN R, 1979, J BIOL CHEM, V254, P2902; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; NAGASAWA K, 1978, BIOCHIM BIOPHYS ACTA, V544, P430, DOI 10.1016/0304-4165(78)90110-1; NESHEIM ME, 1983, J BIOL CHEM, V253, P14708; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1980, THROMB RES, V17, P595, DOI 10.1016/0049-3848(80)90100-0; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; Olson Steven T., 1994, Perspectives in Drug Discovery and Design, V1, P479, DOI 10.1007/BF02171861; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TOLLEFSEN DM, 1989, HEPARIN CHEM BIOL PR, P257; UCHIYAMA H, 1981, J BIOCHEM-TOKYO, V89, P185, DOI 10.1093/oxfordjournals.jbchem.a133180	44	75	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9043	9051		10.1074/jbc.270.16.9043	http://dx.doi.org/10.1074/jbc.270.16.9043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721817	hybrid			2022-12-27	WOS:A1995QU08900005
J	TREMEAU, O; LEMAIRE, C; DREVET, P; PINKASFELD, S; DUCANCEL, F; BOULAIN, JC; MENEZ, A				TREMEAU, O; LEMAIRE, C; DREVET, P; PINKASFELD, S; DUCANCEL, F; BOULAIN, JC; MENEZ, A			GENETIC-ENGINEERING OF SNAKE TOXINS - THE FUNCTIONAL SITE OF ERABUTOXIN-A, AS DELINEATED BY SITE-DIRECTED MUTAGENESIS, INCLUDES VARIANT RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIAL PROTEIN REFINEMENT; NAJA-NIGRICOLLIS VENOM; ACETYLCHOLINE-RECEPTOR; ALPHA-BUNGAROTOXIN; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; 0.140-NM RESOLUTION; CURAREMIMETIC TOXIN; SEQUENCE-ANALYSIS; ELECTRON-DENSITY	Using site-directed mutagenesis, we previously identified some residues that probably belong to the site by which Erabutoxin a (Ea), a sea snake toxin, recognizes the nicotinic acetylcholine receptor (AcChoR) (Pillet, L., Tremeau, O., Ducancel, F. Drevet, P., Zinn-Justin, S., Pinkasfeld, S., Boulain, J.-C., and Menez, A. (1993) J. Biol. Chem. 268, 909-916). We have now studied the effect of mutating 26 new positions on the affinity of Ea for AcChoR. The mutations are F4A, N5V, H6A, Q7L, S9G, Q10A, P11N, Q12A, T13V, T14A, K15A, T16A, Delta S18, E21A, Y25F, Q28A, S30A, T35A, I36R, P44V, T45A, V46A, K47A, P48Q, I50Q, and S53A. Binding affinity decreases upon mutation at Gln-7, Gln-10 and to a lesser extent at His-6, Ser-9 and Tyr-25 whereas it increases upon mutation at Ile-36. Other mutations have no effect on Ea affinity. In addition, new mutations of the previously explored Ser-8, Asp-81, Arg-33, and Glu-38 better explain the functional role of these residues in Ea. The previous and present mutational analysis suggest that the ''functional'' site of Ea covers a homogeneous surface of at least 680 A(2), encompassing the three toxin loops, and includes both conserved and variant residues. The variable residues might contribute to the selectivity of Ea for some AcChoRs, including those from fish, the prey of sea snakes.	CEA, DSV, DEPT INGN ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								AGARD DA, 1982, ACTA CRYSTALLOGR A, V38, P186, DOI 10.1107/S0567739482000436; ARNOUX B, 1994, FEBS LETT, V342, P12, DOI 10.1016/0014-5793(94)80574-1; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BOURNE PE, 1985, EUR J BIOCHEM, V153, P521, DOI 10.1111/j.1432-1033.1985.tb09333.x; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; BURDEN SJ, 1975, P NATL ACAD SCI USA, V72, P3245, DOI 10.1073/pnas.72.8.3245; Chang C.C., 1979, SNAKE VENOMS, P309; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; Dufton M.J., 1991, P259; Endo T., 1991, P165; FAURE G, 1983, BIOCHEMISTRY-US, V22, P2068, DOI 10.1021/bi00278a006; FULACHIER MH, 1994, FEBS LETT, V338, P331, DOI 10.1016/0014-5793(94)80294-7; HARVEY AL, 1984, BRIT J PHARMACOL, V82, P709, DOI 10.1111/j.1476-5381.1984.tb10810.x; Heatwole H., 1987, SEA SNAKES; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; HORI H, 1976, BIOCHEM J, V153, P217, DOI 10.1042/bj1530217; INAGAKI F, 1978, EUR J BIOCHEM, V89, P433, DOI 10.1111/j.1432-1033.1978.tb12546.x; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; ISHIKAWA Y, 1985, BRAIN RES, V346, P82, DOI 10.1016/0006-8993(85)91097-2; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; LAPLANTE SR, 1990, INT J PEPT PROT RES, V36, P227; Lee C.Y., 1976, P193; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; LOW BW, 1979, HDB EXPT PHARMACOLOG, V52, P213; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; MENEZ A, 1982, TOXICON, V20, P95, DOI 10.1016/0041-0101(82)90172-6; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; MENEZ A, 1984, J PHYSIOLOGY PARIS, V79, P196; MORI N, 1991, J PHARM PHARMACOL, V43, P785, DOI 10.1111/j.2042-7158.1991.tb03482.x; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; PILLET L, 1993, J BIOL CHEM, V268, P909; PRASAD L, 1993, J BIOL CHEM, V268, P10705; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; RUAN KH, 1990, P NATL ACAD SCI USA, V87, P6156, DOI 10.1073/pnas.87.16.6156; RYDEN L, 1973, INT J PEPT PROT RES, V5, P261; SAITOH T, 1980, FEBS LETT, V116, P30, DOI 10.1016/0014-5793(80)80522-9; SALUDJIAN P, 1992, ACTA CRYSTALLOGR B, V48, P520, DOI 10.1107/S010876819200096X; SATO S, 1970, J BIOCHEM, V68, P867, DOI 10.1093/oxfordjournals.jbchem.a129425; SATO S, 1971, BIOCHEM J, V122, P453, DOI 10.1042/bj1220453; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011; ZINNJUSTIN S, 1994, PROTEIN ENG, V7, P917, DOI 10.1093/protein/7.7.917	59	133	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9362	9369		10.1074/jbc.270.16.9362	http://dx.doi.org/10.1074/jbc.270.16.9362			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721859	hybrid			2022-12-27	WOS:A1995QU08900048
J	FONSECA, MI; BUTTON, DC; BROWN, RD				FONSECA, MI; BUTTON, DC; BROWN, RD			AGONIST REGULATION OF ALPHA(1B)-ADRENERGIC RECEPTOR SUBCELLULAR-DISTRIBUTION AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SMOOTH-MUSCLE CELLS; DDT1 MF-2 CELLS; ALPHA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; INTRACELLULAR CA-2+; DESENSITIZATION; SUBTYPES; CDNA; EXPRESSION	We have monitored agonist-induced alpha(1B)-adrenergic receptor (alpha(1B)AR) redistribution by immunocytochemical procedures in concert with functional measurements of agonist-elicited [H-3]inositol phosphate (InsP) production in human embryonal kidney 293 cells stably expressing alpha(1B)AR cDNA (HEK293/alpha(1B)). Anti-peptide antibodies directed against the carboxyl-terminal decapeptide of the alpha(1B)AR were prepared and shown to react specifically with alpha(1B)AR on immunoblots and in situ in HEK293/alpha(1B) transfectants. Treatment of HEK293/alpha(1B) cells with norepinephrine (10 mu M) results in a rapid (5-15 min) and striking internalization of cell surface receptor as visualized by confocal immunofluorescence microscopy. Receptor redistribution is sustained in the presence of agonist, rapidly reversed upon agonist removal, and prevented by the alpha(1) antagonist prazosin. Receptor internalizes to endosomes, as shown by colocalization with transferrin receptor, an endosomal marker. Activation of protein kinase C (PKC) with phorbol 12-myristate 13-acetate (50 nM) causes receptor endocytosis similar to agonist; agonist-induced internalization is blocked by the PKC inhibitor staurosporine (0.5 mu M). In parallel experiments, agonist-induced [H-3]InsP production is abolished by phorbol 12-myristate 13-acetate but potentiated by staurosporine. Inhibition of receptor internalization with hypertonic sucrose attenuates agonist-induced [H-3]InsP formation; this effect is reversed by concomitant inhibition of PKC with staurosporine. These results suggest that PKC-dependent phosphorylation occurring as a consequence of alpha(1)AR stimulation induces receptor desensitization and internalization. Internalized receptor is reactivated and continuously recycled to the cell surface during agonist exposure.	UNIV ILLINOIS,DEPT PHARMACOL MC 868,CHICAGO,IL 60612; NIMH,CELL BIOL LAB,BETHESDA,MD 20892	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)					NIGMS NIH HHS [GM 41470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER SK, 1984, MOL PHARMACOL, V26, P405; BAHOUTH SW, 1991, TRENDS PHARMACOL SCI, V12, P338, DOI 10.1016/0165-6147(91)90593-H; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BAZAN E, 1993, EUR J PHARM-MOLEC PH, V245, P173, DOI 10.1016/0922-4106(93)90125-S; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RD, 1986, MOL PHARMACOL, V29, P531; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COWLEN MS, 1987, J PHARMACOL EXP THER, V243, P527; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DROOGMANS G, 1977, J GEN PHYSIOL, V70, P129, DOI 10.1085/jgp.70.2.129; FONSECA MI, 1991, BRIAN RES, V563, P63; FRATELLI M, 1987, FEBS LETT, V212, P149, DOI 10.1016/0014-5793(87)81575-2; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAN C, 1987, MOL PHARMACOL, V32, P505; HAN C, 1987, NATURE, V329, P333, DOI 10.1038/329333a0; HANFT G, 1989, BRIT J PHARMACOL, V97, P691, DOI 10.1111/j.1476-5381.1989.tb12005.x; HARDEN TK, 1980, SCIENCE, V210, P44; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HUGHES RJ, 1986, MOL PHARMACOL, V29, P521; HUTSON NJ, 1976, J BIOL CHEM, V251, P5200; KAN WH, 1979, BIOCHEM BIOPH RES CO, V91, P303, DOI 10.1016/0006-291X(79)90618-1; KURZ JB, 1991, MOL PHARMACOL, V41, P375; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; LURIE KG, 1985, J PHARMACOL EXP THER, V234, P147; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MINNEMAN KP, 1987, ALPHA1 ADRENERGIC RE, P269; MORROW AL, 1986, MOL PHARMACOL, V29, P321; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; REECE JF, 1990, CALCIUM CHANNEL MODULATORS IN HEART AND SMOOTH MUSCLE, P125; RUFFOLO RR, 1991, PHARMACOL REV, V43, P275; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SHAO YP, 1993, MOL PHARMACOL, V44, P247; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; TERMAN BI, 1988, BIOCHEM J, V253, P363, DOI 10.1042/bj2530363; TOEWS ML, 1987, MOL PHARMACOL, V31, P58; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WICKBERG JES, 1983, LIFE SCI, V33, P1409; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YU SS, 1993, J BIOL CHEM, V268, P337; Zhu S.-J., 1993, Society for Neuroscience Abstracts, V19, P500	50	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8902	8909		10.1074/jbc.270.15.8902	http://dx.doi.org/10.1074/jbc.270.15.8902			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721798	hybrid			2022-12-27	WOS:A1995QT44800077
J	IWAMOTO, T; WAKABAYASHI, S; SHIGEKAWA, M				IWAMOTO, T; WAKABAYASHI, S; SHIGEKAWA, M			GROWTH FACTOR-INDUCED PHOSPHORYLATION AND ACTIVATION OF AORTIC SMOOTH-MUSCLE NA+/CA2+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SARCOLEMMAL NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; MEMBRANE CA-2+ PUMP; DEPENDENT PHOSPHORYLATION; FUNCTIONAL EXPRESSION; PRIMARY CULTURE; SQUID AXONS; CELLS; CLONING	Although the Na+/Ca2+ exchanger is one of the major Ca2+ extrusion systems in excitable tissues, little is known about its regulation via protein phosphorylation. We now present evidence that the Na+/Ca2+ exchanger is phosphorylated in quiescent and growth factor-stimulated cultured aortic smooth muscle cells. The Na+/Ca2+ exchanger was isolated from P-32-labeled cells by immunoprecipitation with a specific polyclonal antibody. Phosphorylation of the exchanger was increased by up to 1.7-fold in response to platelet-derived growth factor-EE (PDGF-BB), alpha-thrombin, or phorbol 12-myristate 13-acetate (PMA). However, angiotensin II did not enhance the phosphorylation significantly. The extent of phosphorylation appeared to correlate with the growth factor-induced increase in cell 1,2-diacylglycerol. At least four phosphopeptides (P1 to P4) were detected by tryptic phosphopeptide map analysis of the phosphorylated exchanger, suggesting that phosphorylation occurred at multiple sites. PDGF-BB and PMA increased phosphorylation of the same phosphopeptides (in particular P1). Phosphorylated amino acids were exclusively serine residues in both quiescent and stimulated cells. We found that growth factors enhanced Na+/Ca2+ exchange activity and that there was a good correlation between the growth factor-induced stimulations tions of phosphorylation and exchange activity. PDGF-BB-induced induced activation of the exchanger was abolished by prior long treatment of cells with PMA. These results suggest that the Na+/Ca2+ exchanger is activated by protein kinase C-dependent phosphorylation in response to growth factors in vascular smooth muscle cells.	NATL CARDIOVASC CTR, RES INST, DEPT MOLEC PHYSIOL, SUITA, OSAKA 565, JAPAN	National Cerebral & Cardiovascular Center - Japan								BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; CARONI P, 1983, EUR J BIOCHEM, V132, P451, DOI 10.1111/j.1432-1033.1983.tb07383.x; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; CHOYI MA, 1991, AM J PHYSIOL, V261, pC685; CIRILLO M, 1993, CIRC RES, V72, P847, DOI 10.1161/01.RES.72.4.847; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DILIBERTO PA, 1990, J CELL BIOCHEM, V44, P39, DOI 10.1002/jcb.240440104; DIPOLO R, 1987, BIOCHIM BIOPHYS ACTA, V897, P347, DOI 10.1016/0005-2736(87)90432-9; DIPOLO R, 1984, J GEN PHYSIOL, V84, P895, DOI 10.1085/jgp.84.6.895; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FUKUDA T, 1990, J BIOCHEM-TOKYO, V108, P629, DOI 10.1093/oxfordjournals.jbchem.a123254; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; FURUKAWA KI, 1991, J BIOL CHEM, V266, P12337; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HUANG CL, 1987, J BIOL CHEM, V262, P14134; IWAMOTO T, 1994, CAN J PHARM PHYSL S1, V72, P527; IWATA Y, 1993, FEBS LETT, V329, P227, DOI 10.1016/0014-5793(93)80227-L; IWATA Y, 1994, FEBS LETT, V355, P65, DOI 10.1016/0014-5793(94)01174-5; KHOYI MA, 1993, AM J PHYSIOL, V265, pC1325; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OGURUSU T, 1990, J BIOCHEM-TOKYO, V108, P222, DOI 10.1093/oxfordjournals.jbchem.a123184; PANET R, 1991, J CELL BIOL, V114, P337, DOI 10.1083/jcb.114.2.337; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Philipson K D, 1993, Int Rev Cytol, V137C, P199; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; SMITH JB, 1990, AM J PHYSIOL, V259, pC302, DOI 10.1152/ajpcell.1990.259.2.C302; SMITH JB, 1989, AM J PHYSIOL, V256, pC147, DOI 10.1152/ajpcell.1989.256.1.C147; VIGNE P, 1988, J BIOL CHEM, V263, P8078; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583	45	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8996	9001		10.1074/jbc.270.15.8996	http://dx.doi.org/10.1074/jbc.270.15.8996			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721810	hybrid			2022-12-27	WOS:A1995QT44800090
J	ZHANG, QY; ROMBEL, I; REDDY, GN; GANG, JB; SHEN, CKJ				ZHANG, QY; ROMBEL, I; REDDY, GN; GANG, JB; SHEN, CKJ			FUNCTIONAL ROLES OF IN-VIVO FOOTPRINTED DNA MOTIFS WITHIN AN ALPHA-GLOBIN ENHANCER - ERYTHROID LINEAGE AND DEVELOPMENTAL STAGE SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; REGULATORY ELEMENT UPSTREAM; LOCUS-CONTROL REGION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GENE-EXPRESSION; MOLECULAR-GENETICS; INDUCIBLE ENHANCER; HUMAN-HEMOGLOBIN; FAR UPSTREAM	Transcriptional regulation of the human alpha-like globin genes, embryonic zeta 2 and adult alpha, during erythroid development is mediated by a distal enhancer, HS 40. Previous protein-DNA binding studies have shown that HS-40 consists of multiple nuclear factor binding motifs that are occupied in vivo in an erythroid lineage- and developmental stage-specific manner. We have systematically analyzed the functional roles of these factor binding motifs of HS-40 by site-directed mutagenesis and transient expression assay in erythroid cell cultures. Three of these HS-40 enhancer motifs, 5'NF-E2/ AP1, GT II, and GATA-1(c), positively regulate the zeta 2-globin promoter activity in embryonic/fetal erythroid K562 cells and the adult alpha-globin promoter activity in adult erythroid MEL cells. On the other hand, the 3'NF-E2/AP1 motif is able to exert both positive and negative regulatory effects on the zeta 2-globin promoter activity in K562 cells, and this dual function appears to be modulated through differential binding of the ubiquitous AP1 factors and the erythroid-enriched NF-E2 factor. Mutation in the GATA-1(d) motif, which exhibits an adult erythroid-specific genomic footprint, decreases the HS-40 enhancer function in dimethyl sulfoxide-induced MEL cells but not in K562 cells. These studies have defined the regulatory roles of the different HS-40 moths. The remarkable correlation between genomic footprinting data and the mutagenesis results also suggests that the erythroid lineage- and developmental stage-specific regulation of human alpha-like globin promoters is indeed modulated by stable binding of specific nuclear factors in vivo.	UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-29800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALBITAR M, 1989, BLOOD, V74, P629; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11371; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V12, P2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHUI DHK, 1989, BLOOD, V74, P1409; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; DEISSEROTH A, 1979, P NATL ACAD SCI USA, V76, P2185, DOI 10.1073/pnas.76.5.2185; ELLIS J, 1993, EMBO J, V12, P129; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOURDON G, 1994, NUCLEIC ACIDS RES, V22, P4139, DOI 10.1093/nar/22.20.4139; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER JL, 1993, BLOOD, V82, P1900; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; REN SC, 1993, BLOOD, V81, P1058; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHARPE JA, 1992, EMBO J, V11, P4565, DOI 10.1002/j.1460-2075.1992.tb05558.x; SHARPE JA, 1993, P NATL ACAD SCI USA, V90, P11262, DOI 10.1073/pnas.90.23.11262; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STAMATOYANNOPOU.G, 1991, SCIENCE, V252, P383; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VYAS P, 1992, BLOOD, V80, P1832; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	59	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8501	8505		10.1074/jbc.270.15.8501	http://dx.doi.org/10.1074/jbc.270.15.8501			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721747	hybrid			2022-12-27	WOS:A1995QT44800023
J	LIU, HZ; XIONG, SH; SHI, YW; SAMUEL, SJ; LACHAAL, M; JUNG, CY				LIU, HZ; XIONG, SH; SHI, YW; SAMUEL, SJ; LACHAAL, M; JUNG, CY			ATP-SENSITIVE BINDING OF A 70-KDA CYTOSOLIC PROTEIN TO THE GLUCOSE-TRANSPORTER IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR SEQUESTRATION; ADIPOSE-CELLS; INSULIN; GLUT4; PHOSPHORYLATION; IDENTIFICATION; TRANSLOCATION; ISOFORMS; MEMBRANE; TERMINUS	We have identified a 70-kDa cytosolic protein (GTBP70) in rat adipocytes that binds to glutathione S-transferase fusion proteins corresponding to the cytoplasmic domains of the facilitative glucose transporter isoforms Glut1, Glut2, and Glut4. GTBP70 did not bind to irrelevant fusion proteins, indicating that the binding is specific to the glucose transporter. GTBP70 binding to the glucose transporter showed little isoform specificity but was significantly subdomain-specific; it bound to the C-terminal domain and the central loop, but not to the N-terminal domain of Glut4. The GTBP70 binding to Glut4 was not affected by the presence of 2 mM EDTA, 2.4 mM Ca2+, or 150 mm K+. The binding was inhibited by ATP in a dose-dependent manner, with 50% inhibition at 10 mM ATP. This inhibition was specific to ATP, as ADP and AMP-PCP (adenosine 5'-(beta,gamma-methylenetriphosphate)) were without effect. GTBP70 did not react with antibodies against phosphotyrosine, phosphothreonine, or phosphoserine, suggesting that it is not a phosphoprotein. The binding of GTBP70 to Glut4 was not affected by the pretreatment of adipocytes with insulin. When these experiments were repeated using rat hepatocyte cytosols, no ATP-sensitive 70-kDa protein binding to the glucose transporter fusion proteins was evident, suggesting that either GTBP70 expression or its function is cell-specific. These findings strongly suggest the possibility that GTBP70 may play a key role in glucose transporter regulation in insulin target cells such as adipocytes.	VET ADM MED CTR,BIOPHYS LAB,BUFFALO,NY 14215; SUNY BUFFALO,DEPT BIOPHYS SCI,BUFFALO,NY 14215	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13376] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, J BIOL CHEM, V267, P19636; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BELL GI, 1993, J BIOL CHEM, V268, P1916; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1993, J CELL BIOL, V122, P127; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; KONO T, 1981, J BIOL CHEM, V256, P6400; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LIN JL, 1992, BIOCHEM BIOPH RES CO, V184, P865, DOI 10.1016/0006-291X(92)90670-G; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MORGAN A, 1993, BIOCHEM SOC T, V21, P401, DOI 10.1042/bst0210401; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; RAMPAL AL, 1995, J BIOL CHEM, V270, P3938, DOI 10.1074/jbc.270.8.3938; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	29	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7869	7875		10.1074/jbc.270.14.7869	http://dx.doi.org/10.1074/jbc.270.14.7869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713880	hybrid			2022-12-27	WOS:A1995QR52600016
J	OKAMOTO, K; NISHINO, T				OKAMOTO, K; NISHINO, T			MECHANISM OF INHIBITION OF XANTHINE-OXIDASE WITH A NEW TIGHT-BINDING INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DEHYDROGENASE; PURIFICATION; SPECTROSCOPY; MOLYBDENUM; FORMS; EXAFS; INACTIVATION; ALLOPURINOL; RADICALS	The mechanism of inhibition of milk xanthine oxidase and xanthine dehydrogenase by the tight binding inhibitor, sodium-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo[1,5-alpha]-1,3,5-triazine-4-olate monohydrate (BOF-4272), was studied after separation of the two isomers. The steady state kinetics showed that the inhibition by these compounds was a mixed type. One of the isomers had a K-i value of 1.2 x 10(-9) M and a K-i' value of 9 x 10(-9) M, while the other isomer had a K-i value of 3 x 10(-7) M and a K-i' value of 9 x 10(-6) M. Spectral changes were not observed by mixing either the oxidized or reduced form of the enzyme with BOF-4272 on various substrates showed that BOF-4272 bound to the xanthine binding site of the enzyme. K-d values of the enzyme and one of the isomers, which has a higher affinity for the enzyme, were also found to be 2 x 10(-9) M for the desulfo-form using fluorometric titration, and the binding has stoichiometry of 1:1. The inhibitor could not bind to the enzyme when the enzyme was previously treated with oxipurinol.	NIPPON MED COLL, DEPT BIOCHEM & MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN	Nippon Medical School								Ball EG, 1939, J BIOL CHEM, V128, P51; BORDAS J, 1980, BIOCHEM J, V191, P499, DOI 10.1042/bj1910499; Bray R. C., 1975, ENZYMES, P300; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; Eger BT, 1994, FLAVINS AND FLAVOPROTEINS 1993, P727; ELION GB, 1963, BIOCHEM PHARMACOL, V12, P85, DOI 10.1016/0006-2952(63)90012-1; GEORGE GN, 1988, BIOCHEMISTRY-US, V27, P3603, DOI 10.1021/bi00410a011; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; HILLE R, 1981, PHARMACOL THERAPEUT, V14, P249, DOI 10.1016/0163-7258(81)90063-2; HUNT J, 1992, J BIOL CHEM, V267, P21479; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MOORHOUSE PC, 1987, FEBS LETT, V213, P23, DOI 10.1016/0014-5793(87)81458-8; NAKAMURA M, 1992, J BIOCHEM-TOKYO, V92, P1279; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; NISHINO T, 1986, J BIOL CHEM, V261, P1242; OLSON JS, 1974, J BIOL CHEM, V249, P4350; PARKS DA, 1983, AM J PHYSIOL, V245, pG285, DOI 10.1152/ajpgi.1983.245.2.G285; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SAITO T, 1989, J BIOL CHEM, V264, P10015; SATO S, 1991, ADV EXP MED BIOL, V309, P135; SHLAFER M, 1982, CIRCULATION, V66, P85; SPECTOR T, 1968, BIOCHEM BIOPH RES CO, V32, P1039, DOI 10.1016/0006-291X(68)90134-4; SPECTOR T, 1970, J BIOL CHEM, V245, P5079; STIRPE F, 1969, J BIOL CHEM, V244, P3855; SUZUKI H, 1994, J CLIN INVEST, V93, P155, DOI 10.1172/JCI116939; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4	34	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7816	7821		10.1074/jbc.270.14.7816	http://dx.doi.org/10.1074/jbc.270.14.7816			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713871	hybrid			2022-12-27	WOS:A1995QR52600007
J	PIAN, MS; DOBBS, LG				PIAN, MS; DOBBS, LG			EVIDENCE FOR G-BETA-GAMMA-MEDIATED CROSS-TALK IN PRIMARY CULTURES OF LUNG ALVEOLAR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL CYCLASE; SURFACTANT SECRETION; II CELLS; RAT LUNG; CLONING; EXPRESSION; INHIBITION; PHOSPHATIDYLCHOLINE; SEQUENCE; STIMULATION	In the presence of activated G(s alpha) the beta gamma complex of heterotrimeric G proteins (beta gamma) stimulates adenylyl cyclase (AC) in membranes prepared from cells expressing recombinant AC II or AC IV, Conditional stimulation of AC by beta gamma has been hypothesized to integrate cross-talk between G(s)- and non-G(s)-coupled regulation of cellular cAMP (Tang, W. J., and Gilman, A. G. (1991) Science 254, 1500-1503). Although observations in cells expressing recombinant receptors, G(alpha)s, and AC support this hypothesis (Federman, A. D., Conklin, B. R., Schrader, K. A., Reed, R. R,, and Bourne, H. R. (1992) Nature 356, 159-161), this mechanism has not been investigated in differentiated cells. Expression of AC II has been reported only in lung, olfactory, and brain tissue. We found that rat lung alveolar type II cells express AC II and IV. Therefore, we hypothesized that beta gamma conditionally stimulates AC in type II cells. Consistent with this hypothesis, we found that the alpha(2)-adrenergic agonist UK14304 did not affect basal cAMP in type II cells but potentiated terbutaline stimulated cAMP accumulation. Treatment of cells with pertussis toxin partially inhibited terbutaline stimulated cAMP accumulation and completely inhibited the effects of UK14304. In type II cell membranes, purified beta gamma tripled the terbutaline-stimulated increase in AC activity. In contrast, beta gamma inhibited AC activity in the absence of terbutaline. The addition of purified G(o alpha) blocked beta gamma induced effects. In summary, type II cells expressing endogenous AC II and TV regulate cAMP accumulation and AC activity in a manner consistent with conditional stimulation by beta gamma. These observations support the overall hypothesis that conditional stimulation of AC by beta gamma integrates cross-talk between signal transduction systems in differentiated cells,	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	PIAN, MS (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-02157, HL-24075] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024075, K08HL002157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BROWN LAS, 1981, J BIOL CHEM, V256, P66; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHANDER A, 1990, AM J PHYSIOL, V258, pL241, DOI 10.1152/ajplung.1990.258.6.L241; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CORBET A, 1983, AM REV RESPIR DIS, V128, P695; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; FANESTIL DD, 1965, J GERONTOL, V20, P462; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILFILLAN AM, 1987, J PHARMACOL EXP THER, V241, P907; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GOBRAN LI, 1990, AM J PHYSIOL, V258, pL45, DOI 10.1152/ajplung.1990.258.2.L45; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MESCHER EJ, 1983, EXP LUNG RES, V5, P173, DOI 10.3109/01902148309061512; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PIAN MS, 1994, AM J PHYSIOL, V266, pL375, DOI 10.1152/ajplung.1994.266.4.L375; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RICE WR, 1984, BIOCHIM BIOPHYS ACTA, V805, P261, DOI 10.1016/0167-4889(84)90081-8; RYBIN VO, 1991, AM J PHYSIOL, V260, pL539, DOI 10.1152/ajplung.1991.260.6.L539; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TSILIBARY EC, 1983, J HISTOCHEM CYTOCHEM, V31, P1289, DOI 10.1177/31.11.6684669; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7427	7430		10.1074/jbc.270.13.7427	http://dx.doi.org/10.1074/jbc.270.13.7427			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706288	hybrid			2022-12-27	WOS:A1995QQ43100062
J	KOIDE, M; KAWAHARA, Y; NAKAYAMA, I; TSUDA, T; YOKOYAMA, M				KOIDE, M; KAWAHARA, Y; NAKAYAMA, I; TSUDA, T; YOKOYAMA, M			CYCLIC AMP-ELEVATING AGENTS INDUCE AN INDUCIBLE TYPE OF NITRIC-OXIDE SYNTHASE IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS - SYNERGISM WITH THE INDUCTION ELICITED BY INFLAMMATORY CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOUSE MACROPHAGES; INTERFERON-GAMMA; INTERLEUKIN-1; NITRATE; LIPOPOLYSACCHARIDE; BIOSYNTHESIS; EXPRESSION; PROTEINS; CLONING	In cultured vascular smooth muscle cells, interferon gamma (IFN-gamma) induced the accumulation of nitrite, a stable metabolite of nitric oxide, in a dose- and time-dependent manner. In parallel with this reaction, this cytokine increased the mRNA and protein levels of an inducible macrophage-type of nitric oxide synthase (iNOS). Forskolin, a direct activator of adenylate cyclase, or dibutyryl cAMP alone caused small increases in nitrite accumulation and iNOS mRNA and protein levels and synergistically enhanced the IFN-gamma-stimulated reactions. 8-Bromo-cGMP neither increased by itself nor synergized with IFN-gamma to increase the same reactions. Prostaglandin E1 and beraprost, a stable analogue of prostaglandin I2, which by themselves showed only marginal effects on these reactions, also synergized with IFN-gamma to stimulate the reactions. Interleukin 1beta or tumor necrosis factor alpha stimulated the same reactions which were similarly enhanced by forskolin. These results indicate that an elevation of intracellular cAMP, particularly in combination with inflammatory cytokines, positively regulates nitric oxide production at the level of iNOS mRNA expression in vascular smooth muscle cells.	KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN	Kobe University								AKIBA T, 1986, BRIT J PHARMACOL, V89, P703, DOI 10.1111/j.1476-5381.1986.tb11174.x; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; JOLY GA, 1992, CIRC RES, V71, P331, DOI 10.1161/01.RES.71.2.331; JONASSON L, 1988, LAB INVEST, V58, P310; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY P, 1991, LAB INVEST, V64, P5; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARNER SJC, 1989, J IMMUNOL, V142, P100; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	31	191	194	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24959	24966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693710				2022-12-27	WOS:A1993MG67300066
J	AHMED, A; PETER, GJ; TAYLOR, PM; HARPER, AA; RENNIE, MJ				AHMED, A; PETER, GJ; TAYLOR, PM; HARPER, AA; RENNIE, MJ			SODIUM-INDEPENDENT CURRENTS OF OPPOSITE POLARITY EVOKED BY NEUTRAL AND CATIONIC AMINO-ACIDS IN NEUTRAL AND BASIC-AMINO-ACID TRANSPORTER CRNA-INJECTED OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; RAT-KIDNEY; EXPRESSION CLONING; CYSTINE; SYSTEM; CDNA	To elucidate the electrical events associated with the movement of amino acids by the neutral and basic amino acid transporter (NBAT)-encoded protein (Yan, N., Mosckovitz, R., Gerber, L. D., Mathew, S., Murty, V. V. V. S., Tate, S. S., and Udenfriend, S. (1994) Proc. Natl. Acad. Sci. USA 91, 7548-7552), we have investigated the membrane potential and current changes associated with the increased transport of amino acids across the cell membrane of NBAT cRNA injected Xenopus laevis oocytes. Superfusion of 0.05 mM L-phenylalanine, in current-clamped NBAT-injected oocytes, caused a hyperpolarization (8.5 +/- 0.9 mV), but superfusion of L-arginine caused a depolarization (18.3 +/- 1.3 mV). In voltage-clamped (-60 mV) oocytes, superfusion of L-phenylalanine evoked a sodium- and chloride-independent, saturable (K-m = 0.34 +/- 0.02 mM, I-max = 31.3 +/- 0.5 nA), outward current. This outward current was reduced in the presence of high external [K] and was barium-sensitive. Outward currents were also evoked by L-leucine, L-glutamine, L-alanine, D-phenylalanine, and L-beta-phenylalanine. Superfusion of L-arginine evoked a saturable (K-m = 0.09 +/- 0.02 mM, I-max = -29.2 +/- 1.8 nA) inward current; L-lysine and D-arginine also evoked inward currents. L-Glutamate and beta-alanine failed to evoke any currents. Effluxes of L-[H-3]phenylalanine and L-[H-3]arginine were trans-stimulated in the presence of either amino acid. Flux-current comparisons indicated amino acid:charge movement stoichiometry of 1:1 for both neutral and cationic amino acids. These findings indicate that the amino acid transport activity(ies) expressed in NBAT cRNA-injected oocytes is electrogenic by a mechanism including the outward movement of a net positive charge (potassium ion or cationic amino acid) in exchange for uptake of a neutral amino acid.			AHMED, A (corresponding author), UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 4HN,SCOTLAND.		Taylor, Peter M/A-4667-2010; Harper, Alexander/A-4688-2010	Ahmed, Aamir/0000-0001-7405-5336				BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TAYLOR MA, 1987, DEV BIOL, V124, P287, DOI 10.1016/0012-1606(87)90480-5; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; VEYHL M, 1993, J BIOL CHEM, V268, P25041; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YAN N, 1994, P NATL ACAD SCI USA, V91, P7548, DOI 10.1073/pnas.91.16.7548	15	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8482	8486		10.1074/jbc.270.15.8482	http://dx.doi.org/10.1074/jbc.270.15.8482			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721744	hybrid			2022-12-27	WOS:A1995QT44800020
J	VANDENHAZEL, HB; KIELLANDBRANDT, MC; WINTHER, JR				VANDENHAZEL, HB; KIELLANDBRANDT, MC; WINTHER, JR			RANDOM SUBSTITUTION OF LARGE PARTS OF THE PROPEPTIDE OF YEAST PROTEINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH-REPAIR; SACCHAROMYCES-CEREVISIAE; VACUOLAR HYDROLASES; CARBOXYPEPTIDASE-Y; ESCHERICHIA-COLI; HOST STRAINS; PEP4 GENE; SYSTEM; AUTOACTIVATION; MATURATION	The yeast aspartic protease, proteinase A, has a 54 amino-acid propeptide, which is removed during activation of the zymogen in the vacuole. Apart from being involved inhibition/activation, the propeptide has been shown to be essential for formation of a stable active enzyme (van den Hazel, H. B., Kielland-Brandt, M. C., and Winther, J. R. (1993) J. Biol. Chem. 268, 18002-18007). We have investigated the sequence requirements for function of the propeptide. The N-terminal half and the C-terminal half of the propeptide were replaced by random sequences at the genetic level, and collections of the mutants were subjected to a colony screen for ones exhibiting activity. A high frequency (around 1%) of active constructs was found, which indicates a very high tolerance for mutations in the propeptide. Thirty-nine functional mutant forms containing random sequence at either the N- or C-terminal half of the propeptide were characterized. Comparison of the propeptides of the active constructs suggests that a particular lysine residue is important for efficient biosynthesis of proteinase A.	CARLSBERG LAB, DEPT YEAST GENET, DK-2500 COPENHAGEN, DENMARK				Kielland-Brandt, Morten C./D-2563-2015; Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154; Kielland-Brandt, Morten/0000-0002-1272-3877				AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FOLTMANN B, 1988, BIOL CHEM H-S, V369, P311; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P867, DOI 10.1111/j.1432-1033.1992.tb17118.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; LEWIS MK, 1990, NUCLEIC ACIDS RES, V18, P3439, DOI 10.1093/nar/18.12.3439; OLESEN K, 1993, PROTEIN ENG, V6, P409, DOI 10.1093/protein/6.4.409; RAMOS C, 1994, J BIOL CHEM, V269, P7006; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIELECKI AR, 1991, J MOL BIOL, V219, P671, DOI 10.1016/0022-2836(91)90664-R; SIKORSKI RS, 1989, GENETICS, V122, P19; SORENSEN SO, 1994, EUR J BIOCHEM, V220, P19, DOI 10.1111/j.1432-1033.1994.tb18594.x; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; WINTHER JR, 1994, J BIOL CHEM, V269, P22007; WINTHER JR, 1989, THESIS U COPENHAGEN; WINTHER JR, 1991, EUR J BIOCHEM, V197, P61; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	37	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8602	8609		10.1074/jbc.270.15.8602	http://dx.doi.org/10.1074/jbc.270.15.8602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721762	hybrid			2022-12-27	WOS:A1995QT44800038
J	WATANABE, T; WAGA, I; HONDA, Z; KUROKAWA, K; SHIMIZU, T				WATANABE, T; WAGA, I; HONDA, Z; KUROKAWA, K; SHIMIZU, T			PROSTAGLANDIN-F2-ALPHA STIMULATES FORMATION OF P21(RAS)-GTP COMPLEX AND MITOGEN-ACTIVATED PROTEIN-KINASE IN NIH-3T3 CELLS VIA G(Q)-PROTEIN-COUPLED PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MAP KINASE; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; GENE-EXPRESSION; BETA-GAMMA; 3T3 CELLS; PHOSPHORYLATION; FIBROBLASTS; RECEPTOR	Prostaglandin (PG) F-2 alpha activated mitogen-activated protein (MAP) kinase and MAP kinase kinase in NIH-3T3 cells by a mechanism that was completely inhibited by protein kinase inhibitors, staurosporine (20 nM) or H-7 (20 mu M), but was insensitive to pretreatment with islet-activating protein (100 ng/ml; 24 h) or 12-O-tetradecanoylphorbol 13-acetate (2.5 mu M; 24 h). PGF(2 alpha) stimulation also led to a significant increase in Ras . GTP complex. Transfection of a cDNA encoding a constitutively active mutant of G(q) alpha-subunit (Q209L) mimicked PGF(2 alpha)-induced MAP kinase activation, increase in Ras GTP complex, and DNA synthesis in these cells, suggesting that activation of G(q) mediates the PGF(2 alpha)-activation of Ras-MAP kinase pathway and mitogenesis in NIH-3T3 cells. These data provide a new insight into regulatory mechanisms of Pas-MAP kinase pathway through heterotrimeric G-protein-mediated pathways.	UNIV TOKYO, FAC MED, DEPT BIOCHEM, TOKYO 113, JAPAN	University of Tokyo	WATANABE, T (corresponding author), UNIV TOKYO, FAC MED, DEPT INTERNAL MED, DIV 1, TOKYO 113, JAPAN.							ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CARAUBON S, 1993, BIOCHEM J, V293, P381; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JIMENEZDEASUA L, 1975, P NATL ACAD SCI USA, V72, P2724; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KANAMORI M, 1981, J PHARMACOL EXP THER, V217, P494; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKAO A, 1993, J CELL PHYSIOL, V155, P257, DOI 10.1002/jcp.1041550206; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SETH A, 1991, J BIOL CHEM, V266, P23521; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WATANABE T, 1991, BIOCHIM BIOPHYS ACTA, V1074, P398, DOI 10.1016/0304-4165(91)90091-T; WATANABE T, 1994, J BIOL CHEM, V269, P17619; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	50	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8984	8990		10.1074/jbc.270.15.8984	http://dx.doi.org/10.1074/jbc.270.15.8984			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721808	hybrid			2022-12-27	WOS:A1995QT44800088
J	COLAMONICI, OR; PLATANIAS, LC; DOMANSKI, P; HANDA, R; GILMOUR, KC; DIAZ, MO; REICH, N; PITHAROWE, P				COLAMONICI, OR; PLATANIAS, LC; DOMANSKI, P; HANDA, R; GILMOUR, KC; DIAZ, MO; REICH, N; PITHAROWE, P			TRANSMEMBRANE SIGNALING BY THE ALPHA-SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR IS ESSENTIAL FOR ACTIVATION OF THE JAK KINASES AND THE TRANSCRIPTIONAL FACTOR ISGF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; HUMAN CHROMOSOME-21; IFN-ALPHA; PROTEIN; BETA; GENE; DOMAINS; BINDING; CELLS	The Type I interferon (IFN) receptor has a multisubunit structure. The component of the receptor that has been most thoroughly studied is the alpha subunit. Expression of the alpha subunit in mouse L-929 cells confers antiviral response to human IFN alpha 8, but not to human IFN alpha 2 or IFN beta. This antiviral effect is observed without a significant increase in IFN binding. It has not been determined why mouse cells expressing the human alpha subunit show different response to the antiviral activity of distinct human Type I IFNs. In this report, we demonstrate that the response to human Type I IFNs in mouse cells expressing the alpha subunit is dependent on cross-binding to the mouse receptor. This is supported by the finding that human IFN alpha 8, but not human IFN alpha 2, cross-binds to the mouse receptor even in the absence of expression of the human alpha subunit. We also demonstrate that only mouse cells expressing the human alpha subunit are able to tyrosine-phosphorylate p135(tyk2) and JAK-1 and to form the ISGF3 complex in response to human IFN alpha 8. These results demonstrate that the alpha subunit is essential for IFN alpha signaling through the JAK kinases and ISGF3.	LOYOLA UNIV,DIV HEMATOL ONCOL,CHICAGO,IL; EDWARD HINES JR VET ADM MED CTR,MAYWOOD,IL 60153; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Johns Hopkins University; Johns Hopkins Medicine	COLAMONICI, OR (corresponding author), UNIV TENNESSEE,DEPT PATHOL,899 MADISON AVE,MEMPHIS,TN 38163, USA.				NATIONAL CANCER INSTITUTE [R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER; NCI NIH HHS [CA55079, R29CA507703] Funding Source: Medline; NIAID NIH HHS [AI19737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOVICH C, 1994, CYTOKINE, V6, P414, DOI 10.1016/1043-4666(94)90066-3; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BENOIT P, 1993, J IMMUNOL, V150, P707; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; EPSTEIN CJ, 1982, BIOCHEM BIOPH RES CO, V107, P1060, DOI 10.1016/0006-291X(82)90629-5; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LEVY DE, 1989, GENE DEV, V3, P1203; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MEISTER A, 1986, J GEN VIROL, V67, P1633, DOI 10.1099/0022-1317-67-8-1633; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; PLATANIAS LC, 1993, J IMMUNOL, V150, P3226; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; REVEL M, 1976, NATURE, V260, P139, DOI 10.1038/260139a0; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOH JM, 1994, J BIOL CHEM, V269, P18102; TAN YH, 1976, NATURE, V260, P141, DOI 10.1038/260141a0; TAN YH, 1974, SCIENCE, V186, P61, DOI 10.1126/science.186.4158.61; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z	38	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8188	8193		10.1074/jbc.270.14.8188	http://dx.doi.org/10.1074/jbc.270.14.8188			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713924	hybrid			2022-12-27	WOS:A1995QR52600063
J	GILON, P; BIRD, GSJ; BIAN, XP; YAKEL, JL; PUTNEY, JW				GILON, P; BIRD, GSJ; BIAN, XP; YAKEL, JL; PUTNEY, JW			THE CA2+-MOBILIZING ACTIONS OF A JURKAT CELL EXTRACT ON MAMMALIAN-CELLS XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL TRISPHOSPHATE; INFLUX; THAPSIGARGIN; STORES; CA2+; OSCILLATIONS; INHIBITION; MESSENGER; PROTEIN	Randriamampita and Tsien (Randriamampita, C., and Tsien, R. Y, (1993) Nature 364, 809-814) suggested that an acid-extracted fraction from a Jurkat cell line contains a messenger responsible for the coupling of calcium entry to the depletion of intracellular stores, i.e. capacitative calcium entry, We found that the extract, prepared as described by Randriamampita and Tsien, caused Ca2+ entry in 1321N1 astrocytoma cells which was not blocked by the D-myo-1,4,5-trisphosphate-receptor antagonist, heparin. In contrast to astrocytoma cells, when applied to mouse lacrimal acinar cells and rat hepatocytes the Jurkat extract always caused the release of intracellular Ca2+, followed by Ca2+ entry across the plasma membrane, This activity of the extract on lacrimal cells was blocked by either intracellular injection of heparin or extracellular atropine, Similarly prepared lacrimal cell extracts gave Ca2+ responses when applied to astrocytoma cells or lacrimal cells which were similar to Obese for Jurkat-derived extract, However, extracts from hepatocytes had no effect, In most Xenopus oocytes, the Jurkat extract had no effect, while in a few oocytes, the extract gave a [Ca2+](i) response similar to that seen in lacrimal cells, that is, release of Ca2+ followed by Ca2+ entry. We conclude that the actions of the Jurkat cell extract are not consistent with its containing the long sought messenger for capacitative calcium entry, It is Likely that this fraction contains a number of factors that mediate Ca2+ response in different cell types, possibly through receptor-mediated mechanisms.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,CALCIUM REGULAT SECT,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; Yakel, Jerrel/0000-0001-5463-674X				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1995, NATURE, V373, P481, DOI 10.1038/373481b0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WHITE MM, 1990, MOL PHARMACOL, V37, P720	19	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8050	8055		10.1074/jbc.270.14.8050	http://dx.doi.org/10.1074/jbc.270.14.8050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713906	hybrid			2022-12-27	WOS:A1995QR52600043
J	WEI, L; HUBBARD, SR; HENDRICKSON, WA; ELLIS, L				WEI, L; HUBBARD, SR; HENDRICKSON, WA; ELLIS, L			EXPRESSION, CHARACTERIZATION, AND CRYSTALLIZATION OF THE CATALYTIC CORE OF THE HUMAN INSULIN-RECEPTOR PROTEIN-TYROSINE KINASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGED AMINO-ACIDS; BETA-SUBUNIT; CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; AUTOPHOSPHORYLATION SITES; CRYSTAL-STRUCTURE; INTACT-CELLS; PHOSPHORYLATION; REPLACEMENT; RESIDUES	The deduced primary sequence of the cytoplasmic protein-tyrosine kinase domain of the insulin receptor contains a conserved kinase homology region (receptor residues 1002-1257) flanked by a juxtamembrane region and a C-terminal tail. A soluble 48-kDa derivative (residues 959-1355) containing these regions but lacking the first six residues of the juxtamembrane region had earlier been synthesized in Sf9 cells using a baculovirus expression system. The catalytic core of the kinase domain was studied first by proteolytic analysis of the 48-kDa kinase and then by expressing a series of truncated kinase domains in transiently transfected COS cells. Based on these studies, two core kinases of 34 (residues 985-1283) and 35 (residues 978-1283) kDa, respectively, were overexpressed in Sf9 cells. Biochemical characterization of the 35-kDa kinase revealed that the core kinase conserved the major functional properties of the native receptor kinase domain. Activity of the 35-kDa kinase toward a synthetic peptide increased more than 200-fold upon autophosphorylation, which occurred exclusively at Tyr-1158, Tyr-1162, and Tyr-1163; the largest increase was observed between bis- and trisphosphorylation of the kinase. The activated 35- and 48-kDa kinases were similar with respect to specific activity and ATP ang Mg2+ requirements for peptide phosphorylation. Moreover, autophosphorylation appeared to initiate predominantly at Tyr-1162, immediately followed by phosphorylation at Tyr-1158 and then at Tyr-1163. The rate of autophosphorylation was dependent on enzyme concentration, consistent with a trans-phosphorylation mechanism. Finally, the 35-kDa kinase was crystallized, making possible elucidation of its three-dimensional structure by x-ray crystallography.	TEXAS A&M UNIV,INST BIOSCI & TECHNOL,WM KECK CTR GENOME INFORMAT,HOUSTON,TX 77030; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Texas A&M University System; Columbia University; Columbia University; Howard Hughes Medical Institute								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COBB MH, 1989, J BIOL CHEM, V264, P18701; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; GRUPPUSO PA, 1992, BIOCHEM BIOPH RES CO, V189, P1457, DOI 10.1016/0006-291X(92)90238-G; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LEVINE BA, 1991, J BIOL CHEM, V266, P13405; LEVINE BA, 1991, J BIOL CHEM, V266, P12369; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; NEMENOFF RA, 1984, J BIOL CHEM, V259, P5058; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; Summers MD, 1987, TEXAS AGR EXPT STATI; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAVARE JM, 1992, BIOCHEM BIOPH RES CO, V188, P86, DOI 10.1016/0006-291X(92)92353-Y; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WEI L, 1994, CURR OPIN STRUC BIOL, V4, P450, DOI 10.1016/S0959-440X(94)90115-5; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	42	115	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8122	8130		10.1074/jbc.270.14.8122	http://dx.doi.org/10.1074/jbc.270.14.8122			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713916	hybrid			2022-12-27	WOS:A1995QR52600054
J	TSAIMORRIS, CH; GENG, Y; BUCZKO, E; DUFAU, ML				TSAIMORRIS, CH; GENG, Y; BUCZKO, E; DUFAU, ML			CHARACTERIZATION OF DIVERSE FUNCTIONAL ELEMENTS IN THE UPSTREAM SP1 DOMAIN OF THE RAT LUTEINIZING-HORMONE RECEPTOR GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; DNA; BOX; RECOGNITION; ACTIVATION; SEQUENCE; PROTEINS; CLONING; BINDS; SITES	Transcription of the luteinizing hormone receptor gene is dependent on Sp1-induced promoter activation from two Sp1 binding domains (Sp1(2) and Sp1(4)) within the 173-base pair promoter. Of the two Sp1 binding domains, the canonical GC box (GGGCGG) was determined by mutation to be the binding element for only the Sp1(2) domain. The Sp1 binding element within the Sp1(4) domain was identified by mutation and immunological/competition studies as the 5'-GGG GTG GGG that conforms to a Zif-268 like three zinc finger binding domain, rather than the canonical 3' Sp1(4) GC box (GGGCGG). The guanines in the third trinucleotide (GGG GTG GGG) were not required for Sp1 binding, although they increased binding affinity, Non-Sp1 protein(s) bind the 3' Sp1(4), GC box, and by themselves exhibit transcriptional activity, Tissue specific differences were localized to this non-Sp1 binding domain, which functionally substituted for the downstream activating M1 regulatory domain in non expressing but not in expressing cells, Mutations of both non-Sp1 and M1 domains were required for inhibition of promoter activity in constructs that retained the Sp1 binding elements in non expressing cells, indicating that together these domains may play a role in regulation of luteinizing hormone receptor gene expression.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,MOLEC ENDOCRINOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Tsai Morris, Chon Hwa/0000-0002-8113-0979				ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERG JM, 1992, P NATL ACAD SCI USA, V51, P1109; BLAKE MC, 1990, MOL CELL BIOL, V10, P6635; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REBOIS RV, 1982, J CELL BIOL, V94, P70, DOI 10.1083/jcb.94.1.70; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SHIN SI, 1967, ENDOCRINOLOGY, V81, P440, DOI 10.1210/endo-81-3-440; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TSAIMORRIS CH, 1994, J BIOL CHEM, V269, P15868; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; WORRAD DM, 1994, DEVELOPMENT, V120, P2347; YASUMURA Y, 1966, CANCER RES, V26, P529	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7487	7494		10.1074/jbc.270.13.7487	http://dx.doi.org/10.1074/jbc.270.13.7487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706295	hybrid			2022-12-27	WOS:A1995QQ43100070
J	DU, XP; GU, MY; WEISEL, JW; NAGASWAMI, C; BENNETT, JS; BOWDITCH, R; GINSBERG, MH				DU, XP; GU, MY; WEISEL, JW; NAGASWAMI, C; BENNETT, JS; BOWDITCH, R; GINSBERG, MH			LONG-RANGE PROPAGATION OF CONFORMATIONAL-CHANGES IN INTEGRIN-ALPHA(IIB)BETA(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IIB; PLATELET GPIIB-IIIA; ELECTRON-MICROSCOPY; SYNTHETIC PEPTIDES; FIBRINOGEN BINDING; CYTOPLASMIC DOMAIN; INSULIN-RECEPTOR; RECOGNITION SITE; DISULFIDE BONDS; LIGAND-BINDING	Integrin adhesion receptors participate in two-way transfer of information across the plasma membrane. For example, cytoplasmic events, such as activation of protein kinase C, cause an increase in the fibrinogen (Fg) binding affinity of the extracellular domain of integrin alpha(IIb)beta3 (''inside-out signaling''). Conversely, ligand binding to alpha(IIb)beta3 results in the generation of intracellular signals. We used anti-LIBS2, an anti-beta3 monoclonal antibody, to understand potential mechanisms of this bidirectional signaling. Anti-LIBS2 bound to alpha(IIb)beta3 with low affinity (K(d) = 7.4 muM), and mimicked inside-out signaling by promoting Fg binding. The affinity of anti-LIBS2 binding was increased 20-fold (K(d) = 326 nm) by addition of an Fg-mimetic synthetic peptide, RGDS. Thus, anti-LIBS2 and ligands (Fg and Fg-mimetic peptides) bind cooperatively to integrin alpha(IIb)beta3, indicating a functional linkage between the ligand-binding site and the antibody-binding site. The anti-LIBS2-binding site was mapped by its binding to proteolytic and recombinant fragments of the beta3 subunit. The epitope was located within an 89-residue region immediately adjacent to the transmembrane domain and 400 residues carboxyl-terminal to the known ligand-binding site(s). Electron microscope images of rotary shadowed ternary complexes of Fg, anti-LIBS2, and alpha(IIb)beta3 revealed that the ligand-binding site and anti-LIBS2 epitope are separated by about 16 nm. This indicates that propagated long distance conformational changes can occur in alpha(IIb)beta3. Such changes are likely to be involved in the bidirectional signaling function of this integral membrane protein.	UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	DU, XP (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-28235, HL-30954] Funding Source: Medline; NIAMS NIH HHS [AR-27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028235, R01HL030954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAJT ML, 1992, J BIOL CHEM, V267, P3789; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DONNER DB, 1983, J BIOL CHEM, V258, P9413; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU X, 1991, CELL, V65, P49; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; GINSBERG MH, 1980, BLOOD, V55, P661; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; METZGER H, 1983, CONTEMP TOP MOLEC IM, V9, P115; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NIEWIAROWSKI S, 1989, BIOCHIM BIOPHYS ACTA, V983, P91, DOI 10.1016/0005-2736(89)90384-2; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PILCH PF, 1980, SCIENCE, V210, P1152, DOI 10.1126/science.7003712; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PONCZ M, 1987, J BIOL CHEM, V262, P8476; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	54	185	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23087	23092						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693683				2022-12-27	WOS:A1993MF51500022
J	GRONBORG, M; WULFF, BS; RASMUSSEN, JS; KJELDSEN, T; GAMMELTOFT, S				GRONBORG, M; WULFF, BS; RASMUSSEN, JS; KJELDSEN, T; GAMMELTOFT, S			STRUCTURE-FUNCTION RELATIONSHIP OF THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; DOMAIN AUTOPHOSPHORYLATION; CELLS; PROTEIN; PHOSPHORYLATION; SPECIFICITY; MITOGENESIS; REPLACEMENT; BINDING; TRANSMISSION	Insulin-like growth factor I (IGF-1) and insulin receptors are structurally similar with ligand-stimulated tyrosine kinase activity in their cytoplasmic domains. The function of the insulin receptor tyrosine kinase in signal transduction has been studied extensively in contrast to the IGF-I receptor tyrosine kinase. In the present study we have analyzed the regulatory function of the IGF-I receptor tyrosine kinase and carboxyl-terminal domains in mitogenic signaling by overexpression of mutant IGF-I receptors in mouse NIH-3T3 fibroblasts. A mutant IGF-I receptor, in which 3 tyrosines (Tyr1131, Tyr1135, and Tyr1136) analogous to the three major autophosphorylation sites in the insulin receptor kinase were replaced by phenylalanines, was devoid of kinase activity in vivo and in vitro and inactive with respect to IGF-I internalization and stimulation of thymidine incorporation. Another mutant IGF-I receptor, which lacks the 49 carboxyl-terminal amino acids (residues 1289-1337) of the beta-subunit, was fully active. Our data suggest that the structure-function relationship of the IGF-I receptor tyrosine kinase activation and signal transduction is similar to that of the insulin receptor.	BISPEBJERG HOSP,DEPT CLIN CHEM,BISPEBJERG BAKKE 23,DK-2400 COPENHAGEN,DENMARK; NOVO NORDISK IND,DK-2880 BAGSVAERD,DENMARK	University of Copenhagen; Bispebjerg Hospital; Novo Nordisk				Kjeldsen, Thomas/0000-0003-0094-9286				ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDO A, 1992, J BIOL CHEM, V267, P12788; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DREJER K, 1991, DIABETES, V40, P1488, DOI 10.2337/diabetes.40.11.1488; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GAMMELTOFT S, 1989, PEPTIDE HORMONES PRO, P176; GAMMELTOFT S, 1990, PEPTIDE HORMONE ACTI, V7, P1; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P812; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NIELSEN FC, 1991, J NEUROCHEM, V56, P12, DOI 10.1111/j.1471-4159.1991.tb02556.x; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V264, P12820; THORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VERLAND S, 1989, MOL CELL ENDOCRINOL, V67, P207, DOI 10.1016/0303-7207(89)90211-6; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; ZHANG B, 1991, J BIOL CHEM, V266, P990	38	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23435	23440						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693688				2022-12-27	WOS:A1993MF51500074
J	PAN, JL; MCEVER, RP				PAN, JL; MCEVER, RP			CHARACTERIZATION OF THE PROMOTER FOR THE HUMAN P-SELECTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NF-KAPPA-B; TISSUE-SPECIFIC EXPRESSION; GRANULE MEMBRANE-PROTEIN; DNA-BINDING PROTEIN; PLATELET FACTOR-IV; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; FUNCTIONAL-ANALYSIS; ENDOTHELIAL-CELLS	P-selectin, an adhesion receptor for leukocytes, is synthesized selectively by megakaryocytes and endothelial cells. We have cloned the 5'-flanking region of the human P-selectin gene and conducted a preliminary analysis of its features. As determined by primer extension, RNase protection, and anchored polymerase chain reaction cloning, there were multiple transcriptional initiation sites from -95 to -25 nucleotides relative to the start of protein-coding sequence. Transfection of bovine aortic endothelial cells with serially truncated segments of the 5'-flanking region linked to luciferase indicated that the sequence from -249 to -13 was sufficient to promote high level gene expression. Deletions to -197, -147, and -128 gradually reduced expression to basal levels, and further deletion to -100 abolished expression. The sequence from -309 to -13 supported only basal luciferase expression in COS-7, 293, or HeLa cells. Putative regulatory elements in the short 5'-flanking sequence included a CACCC sequence, two inverted repeats similar to binding sites for the ETS and NF-kappaB/rel families, a GATA motif, and a sequence related to the GT-IIC element of the SV40 enhancer. The GATA element was functional, as it bound recombinant GATA-2, and mutations in the core sequence impaired both nuclear protein binding and gene expression. These data suggest that the P-selectin gene is regulated by a combination of cis elements and their cognate transcription factors.	UNIV OKLAHOMA HLTH SCI CTR,HLTH SCI CTR,WK WARREN MED RES INST,DEPT MED,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA HLTH SCI CTR,HLTH SCI CTR,WK WARREN MED RES INST,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation								ASSOULINE Z, 1988, BIOCHEM BIOPH RES CO, V153, P1159, DOI 10.1016/S0006-291X(88)81349-4; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COX LH, 1991, BLOOD, V77, P286; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EISMAN R, 1990, BLOOD, V76, P336; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1993, STRUCTURE, FUNCTION, AND REGULATION OF MOLECULES INVOLVED IN LEUKOCYTE ADHESION, P135; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NOMURA N, 1991, J BIOL CHEM, V266, P8590; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SANDERS WE, 1992, BLOOD, V80, P795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UZAN G, 1991, J BIOL CHEM, V266, P8932; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WELLER A, 1992, J BIOL CHEM, V267, P15176; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; WITTE DP, 1986, CANCER-AM CANCER SOC, V58, P238, DOI 10.1002/1097-0142(19860715)58:2<238::AID-CNCR2820580207>3.0.CO;2-#; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	61	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22600	22608						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693674				2022-12-27	WOS:A1993MD34800063
J	WARSHAWSKY, I; BU, GJ; SCHWARTZ, AL				WARSHAWSKY, I; BU, GJ; SCHWARTZ, AL			IDENTIFICATION OF DOMAINS ON THE 39-KDA PROTEIN THAT INHIBIT THE BINDING OF LIGANDS TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; HIGH-AFFINITY; COMPLEXES; CLONING; TYPE-1; LIVER; GP330	The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP/alpha2MR) binds and internalizes several plasma proteins including tissue-type plasminogen activator (t-PA) and alpha2-macroglobulin-protease complexes (alpha2M*). A 39-kDa protein that copurifies with LRP/alpha2MR inhibits the binding and uptake of ligands by LRP/alpha2MR, including t-PA and alpha2M*. To define domains on the 39-kDa protein which are essential for inhibition of t-PA and alpha2M* binding to LRP/alpha2MR, we have generated bacterial expression constructs encoding discrete regions of the 39-kDa protein as fusion proteins with glutathione S-transferase. Inhibition of t-PA and alpha2M* binding to LRP/alpha2MR on rat hepatoma MH1C1 cells are shown to require amino acid residues 18-24 and 100-107 on the 39-kDa protein. Inhibition of t-PA but not alpha2M* binding to LRP/alpha2MR is also mediated by residues 200-225 and 311-319. The same 39-kDa protein constructs that inhibit alpha2M* and t-PA binding to MH1C1 cells are able to bind directly to purified LRP/alpha2MR immobilized on nitrocellulose. Thus, our studies demonstrate several specific regions on the 39-kDa protein which are required for the inhibition of t-PA and alpha2M* binding to LRP/alpha2MR.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	WARSHAWSKY, I (corresponding author), WASHINGTON UNIV,CHILDRENS HOSP,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63130, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646, T32HL007275] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07275, HL17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; Landon, 1977, Methods Enzymol, V47, P145; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	27	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22046	22054						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691821				2022-12-27	WOS:A1993MC80900091
J	SHI, YB; BROWN, DD				SHI, YB; BROWN, DD			THE EARLIEST CHANGES IN GENE-EXPRESSION IN TADPOLE INTESTINE INDUCED BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR BETA GENES; XENOPUS-LAEVIS; AMPHIBIAN METAMORPHOSIS; LARVAL	Genes induced by thyroid hormone (TH) to change their expression in the Xenopus laevis gastrointestinal (GI) tract have been isolated using a subtractive hybridization method. An exhaustive search for down-regulated genes identified a single gene. Thirty-two different cDNA fragments derived from the up-regulated mRNA of tadpole intestine 18 h after addition of TH were cloned. They map to no more than 22 distinct genes. The isolation of multiple cDNA fragments derived from a single mRNA indicates that the complexity of up-regulated genes is limited. Both ubiquitous and intestine-specific up-regulated genes were found in this screen. The majority of these genes respond directly to TH induction as judged by the resistance of up-regulation to inhibitors of protein synthesis. The biological significance of these genes is supported by their dramatic regulation in the GI tract during spontaneous metamorphosis.	CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science	SHI, YB (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.			Shi, Yun-Bo/0000-0002-6330-0639				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN PP, 1978, HORMONAL PROTEINS PE, P273; DAUCA M, 1978, BIOL CELLULAIRE, V31, P277; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Foulkes, 1991, HORMONAL CONTROL REG, P257; Fox H., 1981, P327; Galton VA, 1983, MOL BASIS THYROID HO, P445; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; ISHIZUYAOKA A, 1987, ANAT ANZEIGER, V164, P81; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; Janes RG, 1934, J EXP ZOOL, V67, P73, DOI 10.1002/jez.1400670103; KANAMORI A, 1993, P NATL ACAD SCI USA, V90, P6013, DOI 10.1073/pnas.90.13.6013; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KORDYLEWSKI L, 1983, Z MIKROSK ANAT FORSC, V97, P719; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; Maniatis T., 1982, MOL CLONING; MARSHALL JA, 1978, J ANAT, V126, P133; MCAVOY JW, 1977, J EXP ZOOL, V202, P129, DOI 10.1002/jez.1402020115; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V259, P144, DOI 10.1016/0003-9861(87)90479-6; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Nunez EA, 1989, CURR OPIN CELL BIOL, V1, P177, DOI 10.1016/0955-0674(89)90083-5; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHI YB, 1992, J BIOL CHEM, V267, P733; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WANG Z, 1993, J BIOL CHEM, V268, P16270; WEBER R, 1967, BIOCHEMISTRY ANIMAL, V2, P227; White B.A., 1981, P363; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97	37	165	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20312	20317						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690754				2022-12-27	WOS:A1993LY01900060
J	SIMARD, J; COUET, J; DUROCHER, F; LABRIE, Y; SANCHEZ, R; BRETON, N; TURGEON, C; LABRIE, F				SIMARD, J; COUET, J; DUROCHER, F; LABRIE, Y; SANCHEZ, R; BRETON, N; TURGEON, C; LABRIE, F			STRUCTURE AND TISSUE-SPECIFIC EXPRESSION OF A NOVEL MEMBER OF THE RAT 3-BETA-HYDROXYSTEROID DEHYDROGENASE/DELTA(5)-DELTA(4) ISOMERASE (3-BETA-HSD) FAMILY - THE EXCLUSIVE 3-BETA-HSD GENE EXPRESSED IN THE SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE DELTA-5-DELTA-4 ISOMERASE; DEHYDROGENASE/DELTA-5-DELTA-4 ISOMERASE; IMMUNOHISTOCHEMICAL LOCALIZATION; PERIPHERAL-TISSUES; HUMAN PLACENTA; LIVER; CELLS; DELTA-5->4-ISOMERASE; SEQUENCE; MEMBRANE	Structures of cDNA clones encoding three members of the rat 3beta-hydroxysteroid dehydrogenase/DELTA5-DELTA4 isomerase (3beta-HSD) family were characterized. To search for potential new types of 3beta-HSD, rat types I and II 3beta-HSD cDNAs were used as probes to screen a rat genomic DNA library. Among the clones isolated, one encodes a novel predicted rat 3beta-HSD isoenzyme, chronologically designated type IV. The corresponding full-length cDNA was thereafter isolated by selective polymerase chain reaction amplification from rat ovary and day- 15 placenta cDNA libraries. The rat type IV 3beta-HSD cDNA encodes a predicted 372-amino acid protein of 41,854 daltons, which shares 90.9, 87.9, and 78.8% sequence identity with rat types 1, II, and III proteins, respectively. Ribonuclease protection assay reveals that type IV 3beta-HSD is the sole 3beta-HSD mRNA species detectable in the skin and represents the predominant species in the placenta while being also detectable in the ovary and, to a lower degree, in the adrenal gland. Transient expression of type IV cDNA in SW- 13 cells indicates 3beta-HSD activity similar to that of rat type I 3beta-HSD. The presence of multiple 3beta-HSD genes should permit differential and tissue-specific regulation of this rate-limiting enzymatic activity essential in the biosynthesis of all classes of steroid hormones in both classical steroidogenic and intracrine peripheral tissues.	UNIV LAVAL, QUEBEC CITY G1V 4G2, QUEBEC, CANADA	Laval University	SIMARD, J (corresponding author), CHUL, RES CTR, MRC, MOLEC ENDOCRINOL GRP, 2705 LAURIER BLVD, QUEBEC CITY G1V 4G2, PQ, CANADA.			Durocher, Francine/0000-0001-8012-4641; Simard, Jacques/0000-0001-6906-3390; Couet, Jacques/0000-0001-5409-8689				ABALAIN JH, 1989, J STEROID BIOCHEM, V34, P467, DOI 10.1016/0022-4731(89)90129-5; ARCHIBALD A, 1973, THESIS U NEWCASTLE U; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAIN PA, 1991, P NATL ACAD SCI USA, V88, P8870, DOI 10.1073/pnas.88.20.8870; BARTSCH W, 1990, ANN NY ACAD SCI, V595, P53, DOI 10.1111/j.1749-6632.1990.tb34282.x; BONNEY RC, 1985, J STEROID BIOCHEM, V23, P347, DOI 10.1016/0022-4731(85)90415-7; CLARKE TR, 1992, 74TH ANN M END SOC S, P426; COUET J, 1992, ENDOCRINOLOGY, V131, P3034, DOI 10.1210/en.131.6.3034; COUET J, 1992, 74TH ANN M END SOC S, P426; COUET J, 1992, 9TH P INT C END NIC, P508; Dalla Valle L, 1992, J STEROID BIOCHEM, V43, P1095, DOI 10.1016/0960-0760(92)90337-I; DELAUNOIT Y, 1992, J BIOL CHEM, V267, P4513; DRUCKER WD, 1972, J CLIN ENDOCR METAB, V35, P48, DOI 10.1210/jcem-35-1-48; DUMONT M, 1992, J INVEST DERMATOL, V99, P415, DOI 10.1111/1523-1747.ep12616131; DUPONT E, 1992, J CLIN ENDOCR METAB, V74, P994, DOI 10.1210/jc.74.5.994; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAY JB, 1978, J ENDOCRINOL, V79, P29, DOI 10.1677/joe.0.0790029; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LABRIE F, 1992, J STEROID BIOCHEM, V43, P805, DOI 10.1016/0960-0760(92)90308-6; LABRIE F, 1992, COLLOQ INSE, V222, P89; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; LACHANCE Y, 1991, DNA CELL BIOL, V10, P701, DOI 10.1089/dna.1991.10.701; LACHANCE Y, 1990, J BIOL CHEM, V265, P20469; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LORENCE MC, 1990, MOL ENDOCRINOL, V4, P1850, DOI 10.1210/mend-4-12-1850; LORENCE MC, 1991, MOL CELL ENDOCRINOL, V80, P21, DOI 10.1016/0303-7207(91)90139-J; LORENCE MC, 1990, ENDOCRINOLOGY, V126, P2493, DOI 10.1210/endo-126-5-2493; LUUTHE V, 1990, ANN NY ACAD SCI, V595, P386, DOI 10.1111/j.1749-6632.1990.tb34312.x; MARTEL C, 1992, J STEROID BIOCHEM, V41, P597, DOI 10.1016/0960-0760(92)90390-5; MILEWICH L, 1991, J CLIN ENDOCR METAB, V73, P1134, DOI 10.1210/jcem-73-5-1134; MILEWICH LA, 1977, J STEROID BIOCHEM, V8, P813; NAVILLE D, 1991, MOL ENDOCRINOL, V5, P1090, DOI 10.1210/mend-5-8-1090; PELLETIER G, 1992, J STEROID BIOCHEM, V43, P451, DOI 10.1016/0960-0760(92)90084-V; POCHI PE, 1969, J INVEST DERMATOL, V52, P32, DOI 10.1038/jid.1969.4; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; RHEAUME E, 1992, NAT GENET, V1, P239, DOI 10.1038/ng0792-239; RILEY SC, 1992, J CLIN ENDOCR METAB, V75, P956, DOI 10.1210/jc.75.3.956; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAYA ME, 1992, J CUTAN PATHOL, V19, P309, DOI 10.1111/j.1600-0560.1992.tb01367.x; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHARP F, 1978, HISTOCHEM J, V10, P517, DOI 10.1007/BF01003134; SIMARD J, 1991, J BIOL CHEM, V266, P14842; SIMARD J, 1991, MOL CELL ENDOCRINOL, V75, P101, DOI 10.1016/0303-7207(91)90224-G; SIMARD J, 1993, MOL ENDOCRINOL, V7, P716, DOI 10.1210/me.7.5.716; SIMARD J, 1991, SERONO SYMP, P274; SIMPSON NB, 1983, J INVEST DERMATOL, V81, P139, DOI 10.1111/1523-1747.ep12543363; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; ZHAO HF, 1991, J BIOL CHEM, V266, P583; ZHAO HF, 1990, ENDOCRINOLOGY, V127, P3237, DOI 10.1210/endo-127-6-3237; ZHAO HF, 1989, FEBS LETT, V259, P153, DOI 10.1016/0014-5793(89)81516-9	59	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19659	19668						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690038				2022-12-27	WOS:A1993LW81900079
J	GURNETT, CA; KAHL, SD; ANDERSON, RD; CAMPBELL, KP				GURNETT, CA; KAHL, SD; ANDERSON, RD; CAMPBELL, KP			ABSENCE OF THE SKELETAL-MUSCLE SARCOLEMMA CHLORIDE CHANNEL CLC-1 IN MYOTONIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							1,4-DIHYDROPYRIDINE RECEPTOR; RYANODINE RECEPTOR; RELEASE CHANNEL; CONDUCTANCE; PROTEINS; VOLTAGE; IDENTIFICATION; EXPRESSION; POTASSIUM; MEMBRANES	The voltage dependent chloride channel CIC-1 stabilizes resting membrane potential in skeletal muscle. Mutations in the CIC-1 gene are responsible for both human autosomal recessive generalized myotonia and autosomal dominant myotonia congenita. To understand the tissue distribution and subcellular localization of CIC-1 and to evaluate its role in an animal model of myotonia, antibodies were raised against the carboxyl terminus of this protein. Expression of the 130-kDa CIC-1 protein is unique to skeletal muscle, consistent with its mRNA tissue distribution. Immunolocalization shows prominent CIC-1 antigen in the sarcolemma of both type I and II muscle fibers. Sarcolemma localization is confirmed by Western analysis of skeletal muscle subcellular fractions. The ADR myotonic mouse (phenotype ADR, genotype adr/adr), in which defective CIC-1 mRNA has been identified, is shown here to be absent in CIC-1 protein expression, whereas other skeletal muscle sarcolemma protein expression appears normal, Immunohistochemistry of skeletal muscle from ADR and other mouse models of human muscle disease demonstrate that the absence of CIC-1 chloride channel is a defect specific to ADR mice.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa				Gurnett, Christina/0000-0001-9129-315X; Kahl, Steven/0000-0001-7085-9556; Campbell, Kevin/0000-0003-2066-5889				ADRIAN RH, 1976, J PHYSIOL-LONDON, V258, P125, DOI 10.1113/jphysiol.1976.sp011410; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DULHUNTY AF, 1979, J MEMBRANE BIOL, V45, P293, DOI 10.1007/BF01869290; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GRONEMEIER M, 1994, J BIOL CHEM, V269, P5963; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HEINY JA, 1990, PFLUG ARCH EUR J PHY, V416, P288, DOI 10.1007/BF00392065; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; PUSCH M, 1994, PHYSIOL REV, V74, P813, DOI 10.1152/physrev.1994.74.4.813; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; SHARP AH, 1987, J BIOL CHEM, V262, P12309; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; WEBERSCHURHOLZ S, 1993, J BIOL CHEM, V268, P547; WISCHMEYER E, 1993, NEUROMUSCULAR DISORD, V3, P267, DOI 10.1016/0960-8966(93)90019-G	32	57	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9035	9038		10.1074/jbc.270.16.9035	http://dx.doi.org/10.1074/jbc.270.16.9035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721815				2022-12-27	WOS:A1995QU08900003
J	DIALLINAS, G; GORFINKIEL, L; ARST, HN; CECCHETTO, G; SCAZZOCCHIO, C				DIALLINAS, G; GORFINKIEL, L; ARST, HN; CECCHETTO, G; SCAZZOCCHIO, C			GENETIC AND MOLECULAR CHARACTERIZATION OF A GENE ENCODING A WIDE SPECIFICITY PURINE PERMEASE OF ASPERGILLUS-NIDULANS REVEALS A NOVEL FAMILY OF TRANSPORTERS CONSERVED IN PROKARYOTES AND EUKARYOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR CONSTITUTIVE MUTATION; NITROGEN METABOLITE REPRESSION; ACID-XANTHINE PERMEASE; PUTATIVE ZINC FINGER; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; SEQUENCE; PROTEIN	In Aspergillus nidulans, loss of-function mutations in the uapA and azgA genes, encoding the major uric acid-xanthine and hypoxanthine-adenine-guanine permeases, respectively, result in impaired utilization of these purines as sole nitrogen sources. The residual growth of the mutant strains is due to the activity of a broad specificity purine permease. We have identified uapC, the gene coding for this third permease through the isolation of both gain-of-function and loss-of-function mutations. Uptake studies with wild-type and mutant strains confirmed the genetic analysis and showed that the UapC protein contributes 30% and 8-10% to uric acid and hypoxanthine transport rates, respectively. The uapC gene was cloned, its expression studied, its sequence and transcript map established, and the sequence of its putative product analyzed. uapC message accumulation is: (i) weakly induced by 2-thiouric acid; (ii) repressed by ammonium; (iii) dependent on functional uaY and areA regulatory gene products (mediating uric acid induction and nitrogen metabolite repression, respectively); (iv) increased by uapC gain-of-function mutations which specifically, but partially, suppress a leucine to valine mutation in the zinc finger of the protein coded by the areA gene. The putative uapC gene product is a highly hydrophobic protein of 580 amino acids (M(r) = 61,251) including 12-14 putative transmembrane segments. The UapC protein is highly similar (58% identity) to the UapA permease and significantly similar (23-34% identity) to a number of bacterial transporters. Comparisons of the sequences and hydropathy profiles of members of this novel family of transporters yield insights into their structure, functionally important residues, and possible evolutionary relationships.	ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND; UNIV REPUBL MONTEVIDEO,FAC CIENCIAS,SECC BIOQUIM,MONTEVIDEO,URUGUAY	Imperial College London; Universidad de la Republica, Uruguay	DIALLINAS, G (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,UA 1354,BATIMENT 409,F-91405 ORSAY,FRANCE.		Diallinas, George/AAE-8457-2019	Diallinas, George/0000-0002-3426-726X				ALDERSON T, 1967, MUTAT RES, V4, P567, DOI 10.1016/0027-5107(67)90043-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARST HN, 1975, NATURE, V254, P31, DOI 10.1038/254031a0; ARST HN, 1973, MOL GEN GENET, V126, P111, DOI 10.1007/BF00330988; BRYNESTAD S, 1994, MICROBIOL-UK, V140, P97, DOI 10.1099/13500872-140-1-97; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; DARLINGTON AJ, 1967, J BACTERIOL, V93, P937, DOI 10.1128/JB.93.3.937-940.1967; DIALLINAS G, 1989, GENETICS, V122, P341; DIALLINAS G, 1989, THESIS U PARIS 11 FR; EISENBERG D, 1982, ANN REV BIOCH, V53, P595; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FU YH, 1990, P NATL ACAD SCI USA, V87, P5331, DOI 10.1073/pnas.87.14.5331; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; GHIM SY, 1994, J BACTERIOL, V176, P3698, DOI 10.1128/JB.176.12.3698-3707.1994; GORFINKIEL L, 1993, J BIOL CHEM, V268, P23376; GORTON DJ, 1983, THESIS U ESSEX UK; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GRENSON M, 1992, MOL ASPECTS TRANSPOR, V21, P219; GRIFFITH DA, 1993, J BIOL CHEM, V268, P20085; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HYNES MJ, 1970, MOL GEN GENET, V108, P97, DOI 10.1007/BF02430516; IRNIGER S, 1994, P NATL ACAD SCI USA, V91, P257, DOI 10.1073/pnas.91.1.257; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; LLOYD AT, 1991, MOL GEN GENET, V230, P288, DOI 10.1007/BF00290679; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCCULLY KS, 1965, GENET RES, V6, P352, DOI 10.1017/S0016672300004249; OESTREICHER N, 1993, J BIOL CHEM, V268, P23382; PAJOR AM, 1993, J BIOL CHEM, V267, P3557; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PROUDFOOT NJ, 1979, NATURE, V279, P376, DOI 10.1038/279376a0; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SAIER MH, 1994, BIOESSAYS, V16, P23, DOI 10.1002/bies.950160104; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAZZOCC.C, 1968, BIOCHIM BIOPHYS ACTA, V166, P557, DOI 10.1016/0005-2787(68)90243-8; SCAZZOCCHIO C, 1982, GENETICS, V100, P185; SCAZZOCCHIO C, 1973, MOL GEN GENET, V125, P147, DOI 10.1007/BF00268868; SCAZZOCCHIO C, 1978, NATURE, V274, P177, DOI 10.1038/274177a0; SCAZZOCCHIO C, 1994, IN PRESS ASPERGILLUS, P221; Scazzocchio C., 1977, GENETICS PHYSL ASPER, P255; SEALYLEWIS HM, 1978, MOL GEN GENET, V164, P303, DOI 10.1007/BF00333161; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SOPHIANOPOULOU V, 1989, MOL MICROBIOL, V3, P705, DOI 10.1111/j.1365-2958.1989.tb00219.x; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; SUAREZ T, 1991, MOL GEN GENET, V230, P359, DOI 10.1007/BF00280292; SUAREZ T, 1991, MOL GEN GENET, V230, P369, DOI 10.1007/BF00280293; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TURNER RJ, 1994, J BACTERIOL, V176, P3708, DOI 10.1128/JB.176.12.3708-3722.1994; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202	62	85	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8610	8622						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721763				2022-12-27	WOS:A1995QT44800039
J	HARRINGTON, L; HULL, C; CRITTENDEN, J; GREIDER, C				HARRINGTON, L; HULL, C; CRITTENDEN, J; GREIDER, C			GEL SHIFT AND UV CROSS-LINKING ANALYSIS OF TETRAHYMENA TELOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSFERASE-ACTIVITY; REVERSE-TRANSCRIPTASE; PRIMER SPECIFICITY; RNA-POLYMERASE; RIBONUCLEOPROTEIN; IDENTIFICATION; ELONGATION; MECHANISM; CLEAVAGE; SEQUENCE	Telomerase is an unusual ribonucleoprotein that synthesizes new telomeres onto chromosome ends. The enzyme has been most extensively characterized in ciliates, where the RNA component has been cloned from several species, and its elongation properties have been characterized in detail. To understand the substrate specificity and protein composition of telomerase, we have used gel shift and UV cross-linking to characterize the enzyme from the ciliate Tetrahymena thermophila. In a mobility shift assay, a complex was identified that contained telomerase RNA,co-purified with telomerase activity, and was sensitive to nuclease treatment. The mobility shift complexes specifically formed using several different single-stranded, telomeric sequences but not non-telomeric primers. These results suggest that the specificity of telomerase for G-rich primer sequences occurs at least in part at the level of primer binding. UV cross-linking analysis identified a 100-kDa cross-linked protein that may be a telomerase component.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,GENET PROGRAM,STONY BROOK,NY 11794	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Crittenden, Jill/0000-0002-1981-1917				AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; AVILION AA, 1992, DEV GENET, V13, P80, DOI 10.1002/dvg.1020130113; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT, V88; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HARRINGTON LA, 1993, CHARACTERIZATION PUR; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MORIN GB, 1909, NATURE, V353, P454; NG L, 1993, J BIOL CHEM, V268, P13571; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Sambrook J, 1989, MOL CLONING LABORATO; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	37	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8893	8901		10.1074/jbc.270.15.8893	http://dx.doi.org/10.1074/jbc.270.15.8893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721797	hybrid			2022-12-27	WOS:A1995QT44800076
J	VANHOLDE, K; ZLATANOVA, J				VANHOLDE, K; ZLATANOVA, J			CHROMATIN HIGHER-ORDER STRUCTURE - CHASING A MIRAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							X-RAY-SCATTERING; ELECTRON-MICROSCOPY; 3-DIMENSIONAL RECONSTRUCTION; FIBERS; MODEL; SUPERSTRUCTURE; NUCLEOSOME; DNA; ORGANIZATION; OLIGOMERS				VANHOLDE, K (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331, USA.		Zlatanova, Jordanka/B-3273-2009					BALDWIN JP, 1978, J APPL CRYSTALLOGR, V11, P484, DOI 10.1107/S0021889878013667; BARTOLOME S, 1994, J CELL SCI, V107, P2983; BORDAS J, 1986, EUR BIOPHYS J BIOPHY, V13, P175, DOI 10.1007/BF00542561; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CAMPBELL AM, 1978, NUCLEIC ACIDS RES, V5, P1571, DOI 10.1093/nar/5.5.1571; CARPENTER BG, 1976, NUCLEIC ACIDS RES, V3, P89; FINCH JT, 1975, P NATL ACAD SCI USA, V72, P3320, DOI 10.1073/pnas.72.9.3320; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; GERCHMAN SE, 1987, P NATL ACAD SCI USA, V84, P7802, DOI 10.1073/pnas.84.22.7802; GIANNASCA PJ, 1993, J CELL SCI, V105, P551; GRIFFITH JD, 1975, SCIENCE, V187, P1202, DOI 10.1126/science.187.4182.1202; GRUZDEV A D, 1981, Biophysics (English Translation of Biofizika), V26, P249; HOROWITZ RA, 1994, J CELL BIOL, V125, P1, DOI 10.1083/jcb.125.1.1; KOCH MHJ, 1989, PROTEIN NUCLEIC ACID, P163; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; MARION C, 1981, EUR J BIOCHEM, V120, P169, DOI 10.1111/j.1432-1033.1981.tb05685.x; MARION C, 1984, J BIOMOL STRUCT DYN, V2, P303, DOI 10.1080/07391102.1984.10507569; MCDOWALL AW, 1986, EMBO J, V5, P1395, DOI 10.1002/j.1460-2075.1986.tb04373.x; MCGHEE JD, 1980, CELL, V22, P87, DOI 10.1016/0092-8674(80)90157-9; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; OLINS A L, 1973, Journal of Cell Biology, V59, P252; OLINS AL, 1974, SCIENCE, V183, P330, DOI 10.1126/science.183.4122.330; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PEREZGRAU L, 1984, NUCLEIC ACIDS RES, V12, P2987, DOI 10.1093/nar/12.6.2987; RATTNER JB, 1979, J CELL BIOL, V81, P453, DOI 10.1083/jcb.81.2.453; SEN D, 1986, BIOCHEMISTRY-US, V25, P3441, DOI 10.1021/bi00359a052; STAYNOV DZ, 1981, INT J BIOL MACROMOL, V5, P310; SUBIRANA JA, 1983, J BIOMOL STRUCT DYN, V1, P705, DOI 10.1080/07391102.1983.10507476; SUBIRANA JA, 1992, FEBS LETT, V302, P105, DOI 10.1016/0014-5793(92)80416-E; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TRIFONOV EN, 1990, THEORETICAL BIOCH MO, P377; TSANEV R, 1992, REPLICATION TRANSCRI, P1; VANHOLDE KE, 1988, CHROMATIN, P289; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK C L F, 1973, Journal of Cell Biology, V59, P368; WOODCOCK CL, 1991, J CELL SCI, V99, P107; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; WOODCOCK CL, 1994, J CELL BIOL, V125, P11, DOI 10.1083/jcb.125.1.11; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; YANG GL, 1994, NAT STRUCT BIOL, V1, P761, DOI 10.1038/nsb1194-761; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	46	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8373	8376		10.1074/jbc.270.15.8373	http://dx.doi.org/10.1074/jbc.270.15.8373			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721727	hybrid			2022-12-27	WOS:A1995QT44800001
J	BAZAR, L; MEIGHEN, D; HARRIS, V; DUNCAN, R; LEVENS, D; AVIGAN, M				BAZAR, L; MEIGHEN, D; HARRIS, V; DUNCAN, R; LEVENS, D; AVIGAN, M			TARGETED MELTING AND BINDING OF A DNA REGULATORY ELEMENT BY A TRANSACTIVATOR OF C-MYC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERCOILED PM2 DNA; SINGLE-STRANDED-DNA; MUNG BEAN NUCLEASE; IONIC ENVIRONMENT; TRANSCRIPTION; PROTEIN; CELLS; GENE; SEQUENCES; PROMOTER	A far upstream element (FUSE) of c-myc stimulates promoter activity when bound by a newly identified trans-acting protein, which is expressed in cycling cells. Since FUSE binding protein (FBP) binds only the noncoding strand (NCS) of its regulatory element in a sequence-specific manner, and not double-stranded (ds) DNA, formation of the protein . DNA complex in vivo first requires unwinding of the DNA helix. In this report, we show evidence that FBP forces strand separation of short stretches of linear dsDNA. Because FUSE is contained within a region of helical instability that is partially unwound in negatively supercoiled DNA, it is a target for more extensive duplex strand separation by FBP, which first exposes and then selectively binds its NCS cognate sequence. In contrast, other single-stranded DNA binding proteins (SSBs) do not demonstrate this FUSE targeting activity. The novel linkage of regional dsDNA melting with cis-element binding by a transcriptional activator has broad implications in the regulation of eukaryotic gene expression.	GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT MED, WASHINGTON, DC 20007 USA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Duncan, Robert/I-8168-2015; Levens, David/C-9216-2009	Duncan, Robert/0000-0001-8409-2501; Levens, David/0000-0002-7616-922X	NATIONAL CANCER INSTITUTE [R29CA054818] Funding Source: NIH RePORTER; NCI NIH HHS [CA54818] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DROGE P, 1991, NUCLEIC ACIDS RES, V19, P2941, DOI 10.1093/nar/19.11.2941; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HORWITZ MSZ, 1988, SCIENCE, V241, P703, DOI 10.1126/science.2456617; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KOWALSKI D, 1984, NUCLEIC ACIDS RES, V12, P7071, DOI 10.1093/nar/12.18.7071; KOWALSKI D, 1982, J BIOL CHEM, V257, P7820; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Maxam A M, 1980, Methods Enzymol, V65, P499; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; NEGISHI Y, 1994, ONCOGENE, V9, P1133; PANAYOTATOS N, 1987, J BIOL CHEM, V262, P11364; RIOU JF, 1993, FEBS LETT, V334, P369, DOI 10.1016/0014-5793(93)80714-6; SHEFLIN LG, 1984, NUCLEIC ACIDS RES, V12, P7087, DOI 10.1093/nar/12.18.7087; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUNITHA I, 1994, BBA-MOL CELL RES, V1221, P348, DOI 10.1016/0167-4889(94)90260-7; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UMEK RM, 1987, NUCLEIC ACIDS RES, V15, P4467; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121	33	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8241	8248		10.1074/jbc.270.14.8241	http://dx.doi.org/10.1074/jbc.270.14.8241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713931	hybrid			2022-12-27	WOS:A1995QR52600070
J	LUNDSTROMLJUNG, J; HOLMGREN, A				LUNDSTROMLJUNG, J; HOLMGREN, A			GLUTAREDOXIN ACCELERATES GLUTATHIONE-DEPENDENT FOLDING OF REDUCED RIBONUCLEASE-A TOGETHER WITH PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM PROTEIN; ESCHERICHIA-COLI GLUTAREDOXIN; BOND FORMATION INVIVO; THIOREDOXIN REDUCTASE; ACTIVE-SITE; ALKALINE-PHOSPHATASE; PHOSPHOLIPASE-C; MIXED DISULFIDE; REGENERATION; CATALYSIS	Glutaredoxin (Grx) contains a redox-active disulfide and catalyzed thiol-disulfide interchange reactions with specificity for GSH. The dithiol form of Grx reduces mixed disulfides involving GSH or protein disulfides. During oxidative refolding of 8 mu M reduced and denatured ribonuclease RNase-(SH)(8) in a redox buffer of 1 mM GSH and 0.2 mM GSSG to yield native RNase-(S-2)(4), a large number of GSH-mixed disulfide species are formed. A lag phase that precedes formation of folded active RNase at a steady-state rate was shortened or eliminated by the presence of a catalytic concentration (0.5 mu M) of Escherichia coli Grx together with protein disulfide-isomerase (PDI), its procaryotic equivalent E. coli DsbA, or the PDI analogue the E. coli thioredoxin mutant protein P34H. A mutant Grx in which one of the active site cysteine residues (Cys-11 and Cys-14) had been replaced by serine, C14S Grx, had similar effect compared with its wild-type counterpart. This demonstrated that Grx acted by a monothiol mechanism involving only Cys-11 and that RNase-S-SG-mixed disulfides were the substrates. Grx displayed synergistic activity together with PDI only in GSH/GSSG redox buffers with sufficiently low redox potential (E'(0) of -208 or -181 mV) to allow reduction of the active site of Grx. In refolding systems that do not depend on glutathione, like cystamine/cysteamine or in the presence of selenite (SeO32-), no synergistic activity of Grx was observed with PDI. We conclude that Grx acts by reducing mixed disulfides between GSH and RNase that are rate-limiting in enzyme-catalyzed refolding.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MED NOBEL INST BIOCHEM,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet								AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; BARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; BUSHWELLER JH, 1993, EUR J BIOCHEM, V327, P327; CHAUDHURI MM, 1992, BIOCHEM J, V281, P645, DOI 10.1042/bj2810645; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FULLEKRUG I, 1994, J CELL SCI, V107, P2719; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KONISHI Y, 1982, BIOCHEMISTRY-US, V21, P4741, DOI 10.1021/bi00262a034; KONISHI Y, 1981, BIOCHEMISTRY-US, V20, P3945, DOI 10.1021/bi00517a001; KONISHI Y, 1982, BIOCHEMISTRY-US, V21, P4734, DOI 10.1021/bi00262a033; KONISHI Y, 1982, P NATL ACAD SCI USA, V79, P5734, DOI 10.1073/pnas.79.18.5734; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2690, DOI 10.1021/bi00061a029; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2680, DOI 10.1021/bi00061a028; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2697; RUPP K, 1994, J BIOL CHEM, V269, P2501; SCHERAGA HA, 1987, P NATL ACAD SCI USA, V84, P5740, DOI 10.1073/pnas.84.16.5740; SCOTT EM, 1963, J BIOL CHEM, V238, P3928; SHAFFER SW, 1975, J BIOL CHEM, V250, P8483; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; SODANO P, 1991, J MOL BIOL, V221, P1311; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETLAUFER DB, 1987, PROTEIN ENG, V1, P141, DOI 10.1093/protein/1.2.141; XIA TH, 1992, PROTEIN SCI, V1, P310	59	50	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7822	7828		10.1074/jbc.270.14.7822	http://dx.doi.org/10.1074/jbc.270.14.7822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713872	hybrid			2022-12-27	WOS:A1995QR52600008
J	PEYRET, P; PEREZ, P; ALRIC, M				PEYRET, P; PEREZ, P; ALRIC, M			STRUCTURE, GENOMIC ORGANIZATION, AND EXPRESSION OF THE ARABIDOPSIS-THALIANA ACONITASE GENE - PLANT ACONITASE SHOW SIGNIFICANT HOMOLOGY WITH MAMMALIAN IRON-RESPONSIVE ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; PIG-HEART ACONITASE; MESSENGER-RNA; CYTOSOLIC ACONITASE; REGULATORY FACTOR; AGROBACTERIUM-TUMEFACIENS; MITOCHONDRIAL ACONITASE; FERRITIN; CLUSTER; PURIFICATION	We report the purification of the unstable aconitase enzyme from melon needs and the NH2-terminal amino acid sequence determination. Antibodies raised against this protein enabled the first isolation and characterization of cDNA encoding aconitase in plants. A full-length cDNA clone of 3210 base pairs was isolated from a library of cDNA clones derived from immature pods of Arabidopsis thaliana. The amino acid sequence deduced from the open reading frame includes the sequence obtained by direct sequencing of the NH2 terminus of the purified enzyme. Genomic clones of the aconitase gene were isolated, and comparison of the cDNA ang genomic sequences reveals that the coding sequence is divided among 20 exons. There are five putative sites for transcription initiation. The aconitase gene is constitutively expressed, but at a low level, during most developmental stages, with a dramatic increase during seed and pollen maturation and during germination. Surprisingly, plant aconitases have reasonably high homology to binding proteins for iron-responsive elements from mammalian species, opening the possibility that a similar type of translational regulation occurs in plants.	LAB BIOCEM GRP LIMAGRAIN, F-63170 CLERMONT FERRAND, FRANCE					PEYRET, Pierre/0000-0003-3114-0586				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BROUQUISSE R, 1987, PLANT PHYSIOL, V84, P1402, DOI 10.1104/pp.84.4.1402; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHATTON B, 1988, J BIOL CHEM, V263, P52; COURTOISVERNIQUET F, 1993, BIOCHEM J, V294, P103, DOI 10.1042/bj2940103; DALE PJ, 1989, PLANT SCI, V63, P237, DOI 10.1016/0168-9452(89)90249-5; DEBELLIS L, 1993, PHYSIOL PLANTARUM, V88, P485, DOI 10.1111/j.1399-3054.1993.tb01363.x; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EANES RZ, 1971, BIOCHIM BIOPHYS ACTA, V227, P204, DOI 10.1016/0005-2744(71)90181-1; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; GLUSKER JP, 1971, ENZYMES, V5, P413; Goodall GJ, 1991, OXFORD SURVEYS PLANT, V7, P255; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HIRZMANN J, 1993, NUCLEIC ACIDS RES, V21, P3597, DOI 10.1093/nar/21.15.3597; HOLSTERS M, 1978, MOL GEN GENET, V163, P181, DOI 10.1007/BF00267408; JEFFERSON RA, 1987, EMBO J, V6, P3901; JORDANOV J, 1992, J BIOL CHEM, V267, P16775; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY C, 1972, BIOCHEM BIOPH RES CO, V47, P740; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONECKI DS, 1992, BIOCHEMISTRY-US, V31, P8363, DOI 10.1021/bi00150a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LOBREAUX S, 1991, BIOCHEM J, V274, P601, DOI 10.1042/bj2740601; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; POVEY S, 1976, ANN HUM GENET, V39, P413, DOI 10.1111/j.1469-1809.1976.tb00145.x; QUATTROCCHIO F, 1990, PLANT MOL BIOL, V15, P81, DOI 10.1007/BF00017726; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; RUZICKA FJ, 1978, J BIOL CHEM, V253, P2514; Sambrook J, 1989, MOL CLONING LABORATO; SELIGMAN PA, 1987, MOL BASIS BLOOD DISE, P219; SLAUGHTER CA, 1978, CYTOGENET CELL GENET, V22, P223, DOI 10.1159/000130941; SPENCE MJ, 1991, PLANT MOL BIOL, V17, P499, DOI 10.1007/BF00040644; TELSER J, 1986, J BIOL CHEM, V261, P4840; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANTUNEN AJ, 1990, PLANT CELL, V2, P393, DOI 10.1105/tpc.2.5.393; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; WU M, 1987, J BIOL CHEM, V262, P12275; YU Y, 1992, J BIOL CHEM, V267, P19005; ZHENG L, 1992, J BIOL CHEM, V267, P7895	65	53	61	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8131	8137		10.1074/jbc.270.14.8131	http://dx.doi.org/10.1074/jbc.270.14.8131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713917	hybrid			2022-12-27	WOS:A1995QR52600055
J	SONG, LX; FRICKER, LD				SONG, LX; FRICKER, LD			CALCIUM-DEPENDENT AND PH-DEPENDENT AGGREGATION OF CARBOXYPEPTIDASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SECRETOGRANIN-I; CHROMAFFIN GRANULES; SECRETORY PROTEINS; ENKEPHALIN CONVERTASE; ENDOPROTEASE FAMILY; CHROMOGRANIN-A; IDENTIFICATION; KEX2; GLYCOPROTEINS; PURIFICATION	Carboxypeptides E (CPE) is involved with the biosynthesis of numerous peptide hormones and neurotransmitters. Several forms of CPE have been previously detected in neuroendocrine cells, including a form which is soluble at pH 5.5 (S-CPE), a form which can be extracted from membranes with 1 M NaCl at pH 5.5 (M1-CPE), and a form which requires both 1% Triton X-100 and 1 M NaCl for extraction from membranes at pH 5.5 (M2-CPE). Like other peptide processing enzymes, CPE is known to be sorted into peptide-containing secretory vesicles of the regulated pathway. One mechanism that has been proposed to be important for sorting of regulated pathway proteins is Ca2+ and pH-induced aggregation. CPE purified from bovine pituitary membranes aggregates at pH 5.5 when the concentration of CPE is 0.3 mu g/mu l or higher, but not when the concentration is 0.01 mu g/mu l. Aggregation of CPE is pH-dependent, with very little aggregation occurring at pH 6 or above. At pH 5.0-5.5, the M2 form of CPE shows a greater tendency to aggregate than the other two forms. At pH 6, Ca2+ concentrations from 1-30 mM increase the aggregation of M1- and M2-CPE, but not S-CPE. The aggregation of M2-CPE does not explain the apparent membrane binding of this protein since the aggregate is solubilized by 1% Triton X-100 at pH 5.5 or by pH 6.0, whereas M2-CPE is not extracted from membranes under these conditions. Taken together, these results are consistent with a model in which the decreasing pH and increasing Ca2+ levels in the trans Golgi network induce the aggregation of CPE, which contributes to the sorting of this protein into regulated pathway secretory vesicles.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER; NIDA NIH HHS [K02 DA-00194, R01 DA-04494] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AGUILARDIOSDADO M, 1994, DIABETES, V43, P418, DOI 10.2337/diabetes.43.3.418; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHRISTIE DL, 1990, BIOCHEM J, V270, P57, DOI 10.1042/bj2700057; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1994, IN PRESS NEUROPROTOC, V5; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GORR SU, 1992, J BIOL CHEM, V267, P21595; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LASLOP A, 1986, NEUROSCI LETT, V72, P300, DOI 10.1016/0304-3940(86)90530-6; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MITRA A, 1994, J BIOL CHEM, V269, P19876; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NALAMACHU SR, 1994, J BIOL CHEM, V269, P11192; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PALMER DJ, 1992, J BIOL CHEM, V267, P19806; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; ROOS N, 1988, SCANNING MICROSCOPY, V2, P33; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1641; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; SUPATTAPONE S, 1984, J NEUROCHEM, V42, P1017, DOI 10.1111/j.1471-4159.1984.tb12705.x; YOO SH, 1990, J BIOL CHEM, V265, P14414; [No title captured]	41	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7963	7967		10.1074/jbc.270.14.7963	http://dx.doi.org/10.1074/jbc.270.14.7963			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713894	hybrid			2022-12-27	WOS:A1995QR52600030
J	JENSTER, G; VANDERKORPUT, HAGM; TRAPMAN, J; BRINKMANN, AO				JENSTER, G; VANDERKORPUT, HAGM; TRAPMAN, J; BRINKMANN, AO			IDENTIFICATION OF 2 TRANSCRIPTION ACTIVATION UNITS IN THE N-TERMINAL DOMAIN OF THE HUMAN ANDROGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; CHICKEN PROGESTERONE-RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; BULBAR MUSCULAR-ATROPHY; DNA-BINDING; RESPONSE ELEMENT; THYROID-HORMONE; NONRECEPTOR FACTORS; FUNCTIONAL DOMAINS; ESTROGEN-RECEPTOR	To locate in detail the regions in the human androgen receptor (AR) involved in transcription activation, a series of N-terminal deletions was introduced in the wild type AR and in a constitutively active AR. The different constructs were tested for their capacity to activate transcription. Almost the entire N-terminal domain (residues 1-485) was necessary for full wild type AR activity when cotransfected with the (GRE)(2)tkCAT reporter in HeLa cells. In contrast, a smaller part of the N-terminal domain (amino acids 360-528) was sufficient for the constitutively active AR to induce transcription of the same (GRE)(2)tkCAT reporter in HeLa cells. This demonstrates the capacity of the AR to use different regions in the N-terminal domain as transcription activation units (TAUs). To obtain additional information of AR N-terminal TAUs, the GAL4 DNA binding domain was linked to either the entire or parts of the AR N-terminal domain and cotransfected with the (UAS)(2)tkCAT reporter in HeLa cells. The results confirmed that the first 485 amino acid residues accommodate a transcription activation function. When the chimeric AR-GAL4 constructs were tested on a different reporter ((UAS)(5)E1bCAT), a small shift in position of the TAU, responsible for full transcription activation, was observed. The data presented show that the size and location of the active TAU in the human AR is variable, being dependent on the promoter context and the presence or absence of the ligand binding domain.	ERASMUS UNIV ROTTERDAM, DEPT ENDOCRINOL & REPROD, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam								ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANIAHMAD C, 1991, J MOL BIOL, V222, P155, DOI 10.1016/0022-2836(91)90202-H; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DE LUCA LM, 1991, FASEB J, V5, P2924; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER PW, 1989, MOL CELL ENDOCRINOL, V61, P257, DOI 10.1016/0303-7207(89)90137-8; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ING NH, 1992, J BIOL CHEM, V267, P17617; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MCPHAUL MJ, 1991, J CLIN INVEST, V87, P1413, DOI 10.1172/JCI115147; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANLAAR JH, 1989, MOL CELL ENDOCRINOL, V67, P29, DOI 10.1016/0303-7207(89)90227-X; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	56	306	322	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7341	7346		10.1074/jbc.270.13.7341	http://dx.doi.org/10.1074/jbc.270.13.7341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706276	hybrid, Green Submitted			2022-12-27	WOS:A1995QQ43100049
J	LARSEN, LK; KRISTIANSEN, K				LARSEN, LK; KRISTIANSEN, K			TRANSCRIPTION IN-VITRO OF TETRAHYMENA CLASS-II AND CLASS-III GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-FREE TRANSCRIPTION; INVITRO TRANSCRIPTION; ACCURATE TRANSCRIPTION; PROMOTER ELEMENTS; SEQUENCE ELEMENTS; NUCLEAR-PROTEIN; REDUCTASE GENE; THERMOPHILA; BINDING	A method for preparation of transcriptionally active nuclear extracts from the ciliated protozoan Tetrahymena thermophila is described. Cells were lysed in the presence of gum arabic, and nuclei were further purified in the presence of Ficoll 400. Highly concentrated nuclear extracts were prepared by ultracentrifugation of nuclei in a buffer containing potassium glutamate and spermidine. These extracts supported accurate transcription initiation of T. thermophila class II and III genes. Using the histone HS-II gene as a template, we demonstrated that physiologically induced changes in transcriptional activity in vivo were reflected in the transcriptional activity of the nuclear extract in vitro. By electrophoretic mobility shift assays, five conserved sequence elements in the upstream region of the histone H3-II gene were shown specifically to bind proteins in extracts from exponentially growing as well as from starved cells, and by UV cross-linking we further characterized the specific binding of two proteins to an oligonucleotide containing a conserved CCAAT box motif. Transcription competition experiments showed that addition of this oligonucleotide decreased transcription significantly. Competition with oligonucleotides corresponding to the two proximal conserved sequence elements almost completely abolished transcription of the H3-II gene suggesting that binding of transacting factors to these elements is crucial for initiation of transcription.	ODENSE UNIV, DEPT MOLEC BIOL, DK-5230 ODENSE, DENMARK	University of Southern Denmark			Kristiansen, Karsten/J-5148-2014	Kristiansen, Karsten/0000-0002-6024-0917				BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BRUNK CF, 1990, NUCLEIC ACIDS RES, V18, P323, DOI 10.1093/nar/18.2.323; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG S, 1991, GENE, V100, P173, DOI 10.1016/0378-1119(91)90363-G; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DEMCZUK S, 1991, NUCLEIC ACIDS RES, V19, P677, DOI 10.1093/nar/19.3.677; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EICHLER W, 1989, BIOL CHEM H-S, V370, P451, DOI 10.1515/bchm3.1989.370.1.451; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HANSEN TS, 1991, GENE, V105, P143, DOI 10.1016/0378-1119(91)90144-Z; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KUMAZAKI T, 1982, NUCLEIC ACIDS RES, V10, P4409, DOI 10.1093/nar/10.14.4409; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; LUEHRSEN KR, 1980, CURR MICROBIOL, V4, P123, DOI 10.1007/BF02602905; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUURA T, 1986, GENE, V49, P225; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; NIELSEN H, 1986, EMBO J, V86, P2711; NIELSEN JN, 1993, NUCLEIC ACIDS RES, V21, P3631, DOI 10.1093/nar/21.16.3631; NILSSON B, 1983, NUCLEIC ACIDS RES, V11, P8019, DOI 10.1093/nar/11.22.8019; NORGAARD P, 1992, EUR J BIOCHEM, V210, P621; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PEDERSON DS, 1984, NUCLEIC ACIDS RES, V12, P3003, DOI 10.1093/nar/12.6.3003; PEDERSON DS, 1986, MOL CELL BIOL, V6, P3014, DOI 10.1128/MCB.6.8.3014; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; ROSENDAHL G, 1991, GENE, V98, P161, DOI 10.1016/0378-1119(91)90169-C; SAKUNJO S, 1980, CELL, V19, P13; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; SUTIPHONG J, 1984, BIOCHEMISTRY-US, V23, P6319, DOI 10.1021/bi00321a005; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P180, DOI 10.1093/nar/22.2.180; TURKEWITZ AP, 1991, EMBO J, V10, P1979, DOI 10.1002/j.1460-2075.1991.tb07727.x; TYLER BM, 1985, P NATL ACAD SCI USA, V82, P5450, DOI 10.1073/pnas.82.16.5450; TYLER BM, 1987, J MOL BIOL, V196, P801, DOI 10.1016/0022-2836(87)90406-2; VACCARO M, 1990, P NATL ACAD SCI USA, V87, P3047, DOI 10.1073/pnas.87.8.3047; VANWIJNEN AJ, 1987, NUCLEIC ACIDS RES, V15, P1679, DOI 10.1093/nar/15.4.1679; VERDIER JM, 1990, NUCLEIC ACIDS RES, V18, P7033, DOI 10.1093/nar/18.23.7033; Warburg O, 1942, BIOCHEM Z, V310, P384; WARNER JR, 1993, TRANSLATIONAL APPARATUS, P109; YAO MC, 1991, P NATL ACAD SCI USA, V88, P9493, DOI 10.1073/pnas.88.21.9493; YOGANATHAN T, 1992, BIOCHEM J, V285, P721, DOI 10.1042/bj2850721; ZAHRADKA P, 1988, EUR J BIOCHEM, V171, P37, DOI 10.1111/j.1432-1033.1988.tb13755.x; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	61	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7601	7608		10.1074/jbc.270.13.7601	http://dx.doi.org/10.1074/jbc.270.13.7601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706308	hybrid			2022-12-27	WOS:A1995QQ43100085
J	GUIMOND, S; MACCARANA, M; OLWIN, BB; LINDAHL, U; RAPRAEGER, AC				GUIMOND, S; MACCARANA, M; OLWIN, BB; LINDAHL, U; RAPRAEGER, AC			ACTIVATING AND INHIBITORY HEPARIN SEQUENCES FOR FGF-2 (BASIC FGF) - DISTINCT REQUIREMENTS FOR FGF-1, FGF-2, AND FGF-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MYOGENIC DIFFERENTIATION; ENDOTHELIAL-CELLS; FACTOR RECEPTOR-1; BINDING SEQUENCE; SULFATE; IDENTIFICATION; PROTEINS; RELEASE; SURFACE	Chlorate-treated Swiss 3T3 fibroblasts, with impaired synthesis of heparan sulfate proteoglycan, were used as target cells in assessing the ability of exogenous heparin-derived saccharides to promote the mitogenic activity of basic fibroblast growth factor 2 (FGF-2). Full-size native heparin (carrying iduronosyl 2-O-sulfate and glucosaminyl 6-O-sulfate groups), as well as a dodecasaccharide fraction isolated after limited deaminative cleavage of heparin, were efficient promoters, whereas the corresponding decasaccharides, or smaller oligosaccharides, were inactive. Neither selectively 2-O-desulfated nor preferentially 6-O-desulfated heparin were active. However, the latter derivative competed with native heparin for binding to FGF-2 and thus blocked the ability of native heparin to promote the mitogenic activity of FGF-2. The 6-O-desulfated heparin also prevented the ability of FGF-2 to suppress myogenic differentiation in MM14 mouse myoblasts. The binding region for FGF-2 has been identified as a pentasaccharide sequence containing a single essential O-sulfate group, at C2 of iduronic acid (1). It is proposed that the dodecasaccharide sequence required to promote receptor signaling by FGF-2 encompasses this pentasaccharide region, which binds the growth factor, and a site interacting with the receptor that contains essential 2-O- and 6-O-sulfate groups. Similar studies involving the related growth factors, FGF-1 and FGF-4, revealed differential effects of saccharides. The mitogenic effect induced by FGF-1 thus was not blocked by either the 2-O- or the 6-O-desulfated heparins. However, both of these derivatives, at high concentrations, promote mitogenic activity of FGF-4. It is concluded that specific saccharide sequences within heparan sulfate glycosaminoglycan chains favor the signaling by distinct members of the FGF family.	UNIV WISCONSIN, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Uppsala University			maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921	NICHD NIH HHS [HD21881] Funding Source: Medline; NIGMS NIH HHS [GM48850] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD021881, R01HD021881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048850] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Hauschka SD, 1979, MUSCLE REGENERATION, P311; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U., 1989, HEPARIN, P159; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PEJLER G, 1988, J BIOL CHEM, V263, P5197; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	512	519	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					23906	23914						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693696				2022-12-27	WOS:A1993MF29400033
J	SKALSKI, V; CHANG, CN; DUTSCHMAN, G; CHENG, YC				SKALSKI, V; CHANG, CN; DUTSCHMAN, G; CHENG, YC			THE BIOCHEMICAL BASIS FOR THE DIFFERENTIAL ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVITY OF 2 CIS ENANTIOMERS OF 2',3'-DIDEOXY-3'-THIACYTIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-ALPHA; REVERSE-TRANSCRIPTASE; REPLICATION; 3'-AZIDO-3'-DEOXYTHYMIDINE; INHIBITION; INVITRO; 2'-DEOXY-3'-THIACYTIDINE; 2',3'-DIDEOXYCYTIDINE; 5'-TRIPHOSPHATE; TRIPHOSPHATE	Two cis stereoisomers of 2',3'-dideoxy-3'-thiacytidine (SddC) were investigated for their activity against human immunodeficiency virus type 1 (HIV-1) in human acute lymphoblastic leukemia H-9 cells. (-)-SddC is six times more potent against HIV-1 and at Least 1.7-fold less cytotoxic than (+)-SddC. Metabolism studies showed that the intracellular accumulation of the active triphosphate form of (-)-SddC is more than 2-fold greater than that of (+)-SddCTP in H-9 cells. In contrast, (+)SddCTP is approximately 1.5 times more potent than (-)-SddCTP as an inhibitor of HIV-1 reverse transcriptase using a RRNA template (K(i) = 0.22 and 0.0.34 muM, respectively) and gapped DNA (K(i) = 0.53 and 1.02 muM, respectively). The enantiomers are comparable as substrates for incorporation into DNA by the RNA-dependent HIV-1 reverse transcriptase; however, neither analog is incorporated as readily as dCTP. The above observations do not explain the difference in the anti-HIV potency between the enantiomers. A novel 3'-5' exonuclease was partially purified from the cytosol of H-9 cells and assayed for the removal of (+)- and (-)-SddCMP-terminated DNA. Removal of (+)-SddCMP was approximately two to three times faster from 3'-terminals of single-stranded and double-stranded DNA, whereas on DNA/RNA substrates, the exonucleolytic cleavage of (+)-SddCMP proceeded approximately six times faster than that of (-)-SddCMP. This result correlates with the observed difference in the anti-HIV effect between the two compounds and suggests that this novel enzyme may be an important determinant of their antiviral activities.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University					NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER; NCI NIH HHS [CA44358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEACH JW, 1992, J ORG CHEM, V57, P2217, DOI 10.1021/jo00034a006; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CAMMACK N, 1992, BIOCHEM PHARMACOL, V43, P2059, DOI 10.1016/0006-2952(92)90162-C; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CHENG YC, 1991, ANN NY ACAD SCI, V616, P217; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HAO Z, 1988, MOL PHARMACOL, V34, P431; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HUANG P, 1992, J BIOL CHEM, V267, P2817; MELLORS JW, 1993, MOL PHARMACOL, V43, P11; PARKER WB, 1991, J BIOL CHEM, V266, P1754; SEGEL IH, 1990, ENZYME KINETICS BEHA, P104; SHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672; STARNES MC, 1987, VIRUS GENES, V23, P241; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76	24	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23234	23238						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693686				2022-12-27	WOS:A1993MF51500047
J	LUKACS, GL; CHANG, XB; BEAR, C; KARTNER, N; MOHAMED, A; RIORDAN, JR; GRINSTEIN, S				LUKACS, GL; CHANG, XB; BEAR, C; KARTNER, N; MOHAMED, A; RIORDAN, JR; GRINSTEIN, S			THE DELTA-F508 MUTATION DECREASES THE STABILITY OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN THE PLASMA-MEMBRANE - DETERMINATION OF FUNCTIONAL HALF-LIVES ON TRANSFECTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; BREFELDIN-A; CHLORIDE CONDUCTANCE; CL CHANNEL; GENE; CFTR; IDENTIFICATION; LOCALIZATION; TRANSPORT; EXPRESSION	Deletion of the phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator (CFTR) is the most prevalent mutation in cystic fibrosis (CF). This mutation (DELTAF508CFTR) leads to a reduced cAMP-sensitive Cl- conductance in epithelial cells. While the mutant protein can function as a Cl- channel, it seems to be misprocessed and unable to accumulate at normal levels in the plasma membrane. Under conditions where the biosynthetic block of DELTAF508CFTR is not complete, the residence time of DELTAF508CFTR in the plasma membrane is a critical determinant of the cAMP-sensitive Cl- conductance. To assess the stability of the mutant and wild-type CFTR, we compared their functional half-lives at the plasma membrane of transfected Chinese hamster ovary cells. The plasma membrane Cl- conductance was assessed by patch-clamp recordings and/or by fluorimetric determinations of the membrane potential. Accumulation of DELTAF508CFTR in the plasma membrane was promoted by growing the transfected cells at reduced temperature (24-28-degrees-C), and was verified by immunoblotting and by detecting the appearance of a plasmalemmal cAMP-activated Cl- conductance. Subsequently increasing the temperature to 37-degrees-C inhibited further delivery of newly synthesized DELTAF508CFTR to the surface membrane. By studying the time dependence of the disappearance of the Cl- conductance, the functional half-life of the mutant protein at the plasma membrane was determined to be <4 h, which is considerably shorter than the half-life of wild-type CFTR (>24 h). The latter was estimated by terminating protein synthesis or secretion with cycloheximide or brefeldin A, respectively. Inhibition of protein synthesis did not alter the rate of disappearance of DELTAF508CFTR at 37-degrees-C, validating the difference in turnover between mutant and wild-type CFTR. These results indicate that the structural abnormality of DELTAF508CFTR affects not only the delivery of the protein to the plasma membrane, but also its stability therein. Moreover, they suggest that overcoming the processing block at the endoplasmic reticulum may not suffice to restore normal Cl- conductance in CF.			LUKACS, GL (corresponding author), HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.			Lukacs, Gergely/0000-0003-0900-0675				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CANHUI L, 1993, NAT GENET, V3, P311; CHENG SH, 1990, CELL, V65, P1; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MATUSLEIBOVITCH N, 1992, BIOCHEM J, V285, P753, DOI 10.1042/bj2850753; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SORSCHER EJ, 1991, P NATL ACAD SCI USA, V88, P7759, DOI 10.1073/pnas.88.17.7759; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K	37	325	332	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21592	21598						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691813				2022-12-27	WOS:A1993MC80900027
J	LEFEVRE, F; BOULAY, V				LEFEVRE, F; BOULAY, V			A NOVEL AND ATYPICAL TYPE ONE INTERFERON GENE EXPRESSED BY TROPHOBLAST DURING EARLY-PREGNANCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATE VIRUS INDUCIBILITY; TRANSCRIPTION FACTOR AP-2; ALPHA-INTERFERON; STRUCTURAL-ANALYSIS; ANTIVIRAL ACTIVITY; PIG CONCEPTUSES; CLASS-II; SEQUENCE; PROTEIN; CLONING	Low stringency screening of day 14-15 pig-conceptus CDNA library using an interferon (IFN)-omega probe has led to the isolation of a novel type one (type I) IFN gene physiologically expressed by trophoblast during the period of implantation in the uterus. It encodes a 170-amino acid preprotein with two potential N-glycosylation sites and a predicted N-terminal signal peptide of 21 residues. This protein was shorter and richer in Cys residues than other type I IFNs and distantly related to all of them including IFN-tau, the trophoblast IFNs of ruminants, with amino acid identities ranging between 27 and 42%. Moreover, its antiviral activity was resistant to neutralization by antisera directed against several IFN-alpha, -beta, -omega, and -tau family members. The pig genome contained only two intronless, nonallelic loci homologous to the cDNA, one of them corresponding to the cDNA. This gene had a single transcription initiation site. Its upstream putative regulatory regions had no similarity with those of other type I IFN genes and did not display the typical clustering of short sequence motifs thought to be involved in virus inducibility but, instead, a modular structure of 30-40-base pair direct repeats. These data highlight the very atypical characteristics of this gene and its product and suggest that it represents the first member of a yet unknown family of type I IFNs present in other mammalian species according to sequence divergence analysis.			LEFEVRE, F (corresponding author), INRA,CTR RECH JOUY EN JOSAS,UNITE VIROL & IMMUNOL MOLEC,DOMAINE VILVERT,F-78352 JOUY EN JOSAS,FRANCE.							ADOLF GR, 1987, J GEN VIROL, V68, P1669, DOI 10.1099/0022-1317-68-6-1669; ADOLF GR, 1990, VIROLOGY, V175, P410, DOI 10.1016/0042-6822(90)90425-Q; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHARD T, 1986, BRIT J OBSTET GYNAEC, V93, P1145, DOI 10.1111/j.1471-0528.1986.tb08635.x; CHARLIER M, 1989, GENE, V77, P341, DOI 10.1016/0378-1119(89)90082-6; CHARLIER M, 1991, MOL CELL ENDOCRINOL, V76, P161, DOI 10.1016/0303-7207(91)90270-3; CHARPIGNY G, 1988, FEBS LETT, V228, P12, DOI 10.1016/0014-5793(88)80574-X; CROSS JC, 1991, P NATL ACAD SCI USA, V88, P3817, DOI 10.1073/pnas.88.9.3817; CROSS JC, 1989, BIOL REPROD, V40, P1109, DOI 10.1095/biolreprod40.5.1109; CROSS JC, 1992, J INTERFERON RES S1, V12, P78; Demaeyer E., 1988, INTERFERONS OTHER RE; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dron M., 1992, INTERFERON PRINCIPLE, P33; DUCGOIRAN P, 1985, P NATL ACAD SCI USA, V82, P5010, DOI 10.1073/pnas.82.15.5010; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Felsenstein J., 1991, PHYLIP PHYLOGENETIC; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FOWLER AK, 1980, NATURE, V886, P266; FRENGEN E, 1991, GENOMICS, V10, P949, DOI 10.1016/0888-7543(91)90184-G; GOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749; HANSEN TR, 1991, J BIOL CHEM, V266, P3060; HARNEY JP, 1989, BIOL REPROD, V41, P277, DOI 10.1095/biolreprod41.2.277; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; IMAKAWA K, 1989, MOL ENDOCRINOL, V3, P127, DOI 10.1210/mend-3-1-127; LABONNARDIERE C, 1991, J REPROD FERTIL, V91, P469, DOI 10.1530/jrf.0.0910469; LABONNARDIERE C, 1986, ANN INST PASTEUR VIR, V137E, P171, DOI 10.1016/S0769-2617(86)80202-7; LANGER JA, 1985, PHARMACOL THERAPEUT, V27, P371, DOI 10.1016/0163-7258(85)90076-2; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEFEVRE F, 1990, EUR J IMMUNOL, V20, P2485, DOI 10.1002/eji.1830201119; LEFEVRE F, 1992, J INTERFERON RES S1, V12, P186; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MAHMOUDI M, 1989, BIOTECHNIQUES, V7, P331; MARTAL J, 1979, J REPROD FERTIL, V56, P63, DOI 10.1530/jrf.0.0560063; MEGE D, 1991, J INTERFERON RES, V11, P341, DOI 10.1089/jir.1991.11.341; MIRANDO MA, 1990, J REPROD FERTIL, V88, P197, DOI 10.1530/jrf.0.0880197; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Miyata T, 1985, Interferon, V6, P1; MOREHEAD H, 1984, BIOCHEMISTRY-US, V23, P2500, DOI 10.1021/bi00306a028; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERLER F, 1980, CELL, V20, P555, DOI 10.1016/0092-8674(80)90641-8; PERRY JS, 1962, J REPROD FERTIL, V4, P175, DOI 10.1530/jrf.0.0040175; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; ROMEO G, 1992, INTERFERON PRINCIPLE, P271; ROMEROHERRERA AE, 1973, NATURE, V246, P389, DOI 10.1038/246389a0; RUBINSTEIN M, 1981, ARCH BIOCHEM BIOPHYS, V210, P307, DOI 10.1016/0003-9861(81)90194-6; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SEN GC, 1992, J BIOL CHEM, V267, P5017; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; SINGER DS, 1987, NUCLEIC ACIDS RES, V15, P2780, DOI 10.1093/nar/15.6.2780; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; VAIMAN D, 1990, FEBS LETT, V265, P12, DOI 10.1016/0014-5793(90)80871-F; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WHYTE A, 1986, ARCH ANAT MICROSC MO, V75, P91; WIENER AM, 1986, ANNU REV BIOCHEM, V55, P631; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; YOUSSOUFIAN H, 1993, MOL CELL BIOL, V13, P98, DOI 10.1128/MCB.13.1.98; ZOUARI K, 1991, J INTERFERON RES S1, V11, P135; ZOUARI K, 1991, J INTERFERON RES S1, V11, P134	66	75	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19760	19768						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690039				2022-12-27	WOS:A1993LW81900091
J	WALKER, F; DEBLAQUIERE, J; BURGESS, AW				WALKER, F; DEBLAQUIERE, J; BURGESS, AW			TRANSLOCATION OF PP60(C-SRC) FROM THE PLASMA-MEMBRANE TO THE CYTOSOL AFTER STIMULATION BY PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-KINASE-C; MORPHOLOGICAL TRANSFORMATION; PHASE-SEPARATION; TYROSINE KINASE; FACTOR RECEPTOR; TRITON X-114; SRC PROTEIN; PHOSPHORYLATION; ASSOCIATION	The src family of protein-tyrosine kinases has long been implicated in signal transduction by growth factor receptors. In particular, pp60c-src, the product of the protooncogene c-src, has been shown to associate with the activated platelet-derived growth factor (PDGF) receptor. We demonstrate that, following stimulation of quiescent cells with PDGF, pp60c-src, is translocated from the plasma membrane to the cytosol. This phenomenon was better defined utilizing an isolated plasma membrane system. The release of pp60c-src from the membrane in response to PDGF is accompanied by a 4-fold activation of its kinase activity and by phosphorylation at the amino terminus on serine/threonine residues as well as tyrosine residues. This amino-terminal phosphorylation appears to be responsible for a change in hydrophobicity of the pp60c-src, molecule and hence for its release from the membrane. The kinase responsible for the serine/threonine phosphorylation and the concomitant release of pp60c-src has been identified as the cAMP-dependent protein kinase. Thus, PDGF stimulation activates at least two membrane-associated kinases (pp60c-src and cAMP-dependent protein kinase) very early in its signal transduction pathway.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital								ALCARAZ G, 1984, J BIOL CHEM, V259, P4922; BAGRODIA S, 1991, NATURE, V349, P1722; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURGESS AW, 1983, EMBO J, V2, P2065, DOI 10.1002/j.1460-2075.1983.tb01701.x; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER JA, 1989, PEPTIDES PROTEIN PHO; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; FEDER D, 1989, J BIOL CHEM, V264, P8205; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TAMURA T, 1984, FEBS LETT, V177, P151, DOI 10.1016/0014-5793(84)81001-7; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; WALKER F, 1991, J BIOL CHEM, V266, P2746; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	31	75	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19552	19558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690037				2022-12-27	WOS:A1993LW81900063
J	GUO, HL; PRICE, DH				GUO, HL; PRICE, DH			MECHANISM OF DMS-II-MEDIATED PAUSE SUPPRESSION BY DROSOPHILA RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTOR; FACTOR-S-II; ASCITES TUMOR-CELLS; FACTOR-SII; STIMULATORY FACTORS; INITIATION-FACTOR; MESSENGER-RNA; GENE; PURIFICATION; COMPLEX	Transcription elongation factor S-II mediates nascent transcript cleavage by RNA Polymerase II (Reines, D. (1992) J. Biol. Chem. 267, 3795-3800). We have examined the mechanism of action of the Drosophila S-II analog, DmS-II, in a defined transcription system. Our results show that DmS-II is necessary and sufficient to activate nascent transcript cleavage by RNA polymerase II during transcription of a dC-tailed template. The pattern of transcripts resulting from prolonged action by DmS-II indicates that there are kinetic barriers to transcript shortening. During the cleavage reaction, the polymerase remains in register with the template strand and generates mainly nucleotide dimers. The ability of DmS-II to mediate transcript shortening resides in the carboxyl-terminal half of the protein. Our results support a model for pause suppression in which DmS-II binds to the paused polymerase, causes one cleavage event and is then released from the complex. Elongation by the polymerase then allows a second encounter with the pause site and a second chance of passing the site. Complete pause suppression may require multiple transcript shortening events for some polymerase molecules.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; FLORES O, 1989, J BIOL CHEM, V264, P8913; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAUSKOPF A, 1991, MOL CELL BIOL, V11, P3515, DOI 10.1128/MCB.11.7.3515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1984, CELL, V38, P423, DOI 10.1016/0092-8674(84)90497-5; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1979, EXP CELL RES, V124, P63, DOI 10.1016/0014-4827(79)90257-X; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	47	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18762	18770						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689559				2022-12-27	WOS:A1993LV65900062
J	MACH, V; TAKIYA, S; OHNO, K; HANDA, H; IMAI, T; SUZUKI, Y				MACH, V; TAKIYA, S; OHNO, K; HANDA, H; IMAI, T; SUZUKI, Y			SILK GLAND FACTOR-I INVOLVED IN THE REGULATION OF BOMBYX SERICIN-1 GENE CONTAINS FORK HEAD MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-DOMAIN; NUCLEAR FACTOR-III; TRANSCRIPTIONAL ACTIVATION; DROSOPHILA; PROTEIN; FAMILY; SITES; PROMOTER	Silk gland factor-1 (SGF-1) regulates transcription of the Bombyx sericin-l gene via interaction with the SA site. In this study, two related SGF-1 polypeptides of apparent molecular masses of 40 and 41 kDa were purified. Specific interaction of these proteins with the SA site was demonstrated by electrophoretic mobility shift and dimethyl sulfate methylation interference assays. The SGF-1 40-kDa protein was partially sequenced and characterized as a new member of the fork head/HNF-3 family. Several full-length cDNAs encoding the SGF-1 40-kDa and possibly also the 41-kDa proteins were cloned and sequenced. SGF-1 mRNA is expressed consistently with the presumed role of the SGF-1 protein product in regulating the sericin-l gene. The SGF-1 protein contains putative transactivation domains, We conclude that the 40- and 41-kDa SGF-1 proteins affect transcription of the sericin-1 gene via binding to the SA site.	NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Tokyo Institute of Technology			Takiya, Shigeharu/A-6439-2012	Ohno, Kaoru/0000-0001-7648-3940; Imai, Takeshi/0000-0002-9503-7353				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FUKUTA M, 1993, J BIOL CHEM, V268, P19471; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; KIGUCHI K, 1981, J INSECT PHYSIOL, V27, P805, DOI 10.1016/0022-1910(81)90072-X; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEMAIGRE FP, 1993, J BIOL CHEM, V268, P19896; MATSUNO K, 1990, NUCLEIC ACIDS RES, V18, P1853, DOI 10.1093/nar/18.7.1853; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; OBARA T, 1988, DEV BIOL, V127, P384, DOI 10.1016/0012-1606(88)90325-9; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J, 1989, MOL CLONING LABORATO; SUZUKI Y, 1994, INT J DEV BIOL, V38, P231; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5	24	78	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9340	9346		10.1074/jbc.270.16.9340	http://dx.doi.org/10.1074/jbc.270.16.9340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721856				2022-12-27	WOS:A1995QU08900045
J	MIKHAILENKO, I; KOUNNAS, MZ; STRICKLAND, DK				MIKHAILENKO, I; KOUNNAS, MZ; STRICKLAND, DK			LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR MEDIATES THE CELLULAR INTERNALIZATION AND DEGRADATION OF THROMBOSPONDIN - A PROCESS FACILITATED BY CELL-SURFACE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING COMPETITIVE INHIBITOR; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; PLATELET THROMBOSPONDIN; EXTRACELLULAR-MATRIX; HIGH-AFFINITY; ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E; MESSENGER-RNA; GROWTH-FACTOR	Thrombospondin (TSP) is a cell and matrix glycoprotein that interacts with a variety of molecules. Newly synthesized thrombospondin is either incorporated into the extracellular matrix, or binds to the cell surface where it is rapidly internalized and degraded (McKeown-Longo, P. J., Hanning, R., and Mosher, D. F. (1984) J. Cell Biol. 98, 22-28). In the current investigation we identify the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP) as a receptor responsible for mediating the internalization of TSP leading to its degradation. LRP is a large cell surface receptor consisting of a 515-kDa heavy chain and an 85-kDa light chain proteolytically derived from a 600-kDa precursor. A specific and high affinity interaction between purified LRP and TSP was demonstrated by homologous ligand competition experiments, where a K-D of 3-20 nM was measured using different preparations of TSP. The binding of TSP to purified LRP was completely inhibited by the 39-kDa receptor associated protein, a known antagonist of ligand binding by LRP. Cultured fibroblasts rapidly internalize and degrade I-125-labeled TSP via a receptor-mediated process. This process is inhibited by receptor-associated protein and by antibodies against LRP, indicating that LRP is mediating the cellular internalization of TSP. Our studies also confirm that the efficient catabolism of TSP requires the participation of cell surface proteoglycans, since digestion of cells with heparitinase markedly reduces the extent of LRP-mediated TSP degradation. The ability of LRP to directly bind and mediate the cellular internalization and degradation of TSP indicates that this receptor may play an important role in the catabolism of TSP in vivo.	AMER RED CROSS,HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855	American Red Cross					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CONESE M, 1994, J BIOL CHEM, V269, P17886; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DIXIT VM, 1984, J BIOL CHEM, V259, P100; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHAV J, 1982, CELL, V31, P253, DOI 10.1016/0092-8674(82)90425-1; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1985, J CELL BIOL, V103, P1635; LAWLER J, 1986, J BIOL CHEM, V258, P12098; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MARGOSSIAN SS, 1994, J BIOL CHEM, V256, P7495; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MEDH JD, 1994, J BIOL CHEM, V270, P536; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	61	126	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9543	9549		10.1074/jbc.270.16.9543	http://dx.doi.org/10.1074/jbc.270.16.9543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721883	hybrid			2022-12-27	WOS:A1995QU08900072
J	PRENDERGAST, JA; PTAK, C; ARNASON, TG; ELLISON, MJ				PRENDERGAST, JA; PTAK, C; ARNASON, TG; ELLISON, MJ			INCREASED UBIQUITIN EXPRESSION SUPPRESSES THE CELL-CYCLE DEFECT ASSOCIATED WITH THE YEAST UBIQUITIN-CONJUGATING ENZYME, CDC34 (UBC3) - EVIDENCE FOR A NONCOVALENT INTERACTION BETWEEN CDC34 AND UBIQUITIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; DEPENDENT PROTEOLYSIS; MULTIUBIQUITIN CHAIN; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE-PRODUCTS; PROTEIN; DEGRADATION; RAD6; E2	The yeast ubiquitin (Uh) conjugating enzyme CDC34 plays a crucial role in the progression of the cell cycle from the G(1) to S phase, In an effort to identify proteins that interact with CDC34 we undertook a genetic screen to isolate genes whose increased expression suppressed the cell cycle defect associated with the cdc34-2 temperature-sensitive allele, From this screen, the poly-Ub gene UBI4 was identified as a moderately strong suppressor, The fact that the overexpression of a gene encoding a single Ub protein could also suppress the cdc34-2 allele indicated that suppression was related to the increased abundance of Ub, Ub overexpression was found to suppress two other structurally unrelated cdc34 mutations, in addition to the cdc34-2 allele, In all three cases, suppression depended on the expression of Ub with an intact carboxyl terminus, Only the cdc34-2 allele, however, could be suppressed by Ub with an amino acid substitution at lysine 48 which is known to be involved in multi-Ub chain assembly, Genetic results showing allele specific suppression of cdc34 mutations by various Ub derivatives suggested a specific noncovalent interaction between Ub and CDC34, Consistent with this prediction, we have shown by chemical crosslinking the existence of a specific noncovalent Ub binding site on CDC34, Together, these genetic and biochemical experiments indicate that Ub suppression of these cdc34 mutations results from the combined contributions of Ub-CDC34 thiol ester formation and a noncovalent interaction between Ub and CDC34 and therefore suggest that the correct positioning of Uh on a surface of the ubiquitin conjugating enzyme is a requirement of enzyme function.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BAMEZAI S, 1989, BIOCHEM BIOPH RES CO, V162, P89, DOI 10.1016/0006-291X(89)91966-9; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P4618, DOI 10.1128/MCB.13.8.4618; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOLLINGSWORTH NM, 1993, GENETICS, V133, P785; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PTAK C, 1994, J BIOL CHEM, V269, P26539; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHERMAN F, 1981, METHODS YEAST GENETI, P163; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235	47	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9347	9352		10.1074/jbc.270.16.9347	http://dx.doi.org/10.1074/jbc.270.16.9347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721857	hybrid			2022-12-27	WOS:A1995QU08900046
J	PYTOWSKI, B; JUDGE, TW; MCGRAW, TE				PYTOWSKI, B; JUDGE, TW; MCGRAW, TE			AN INTERNALIZATION MOTIF IS CREATED IN THE CYTOPLASMIC DOMAIN OF THE TRANSFERRIN RECEPTOR BY SUBSTITUTION OF A TYROSINE AT THE FIRST POSITION OF A PREDICTED TIGHT TURN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; SIGNAL; ENDOCYTOSIS; SEQUENCE; CONFORMATION; MUTAGENESIS; PROTEINS; PATHWAY; CDNA; LDL	Receptors are internalized from the plasma membrane at similar to 10 times the rate of bulk membrane. The pre dominant model for the motif that promotes rapid internalization proposes a requirement for a tyrosine located in the first position of a tight turn. In this report we show that an internalization motif can be created de novo by substituting a tyrosine for the first or last residues of a tetrapeptide GDNS (residues 31-34) that is predicted to form a tight turn within the cytoplasmic domain of the human transferrin receptor. These substitutions restore wild-type levels of internalization to transferrin receptors that are poorly internalized due to missense mutations in the native internalization motif. The introduction of a tyrosine at the first or last position of the GDNS tetrapeptide in a transferrin receptor containing an unmodified wild-type internalization motif significantly increases the internalization rate above that of the wild-type receptor. Our results indicate that a functional novel internalization motif can be created by placing specific aromatic amino acids within the overall structure of an existing beta-turn in a cytoplasmic domain of a receptor.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University								BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; ROTH MG, 1993, ADV CELL MOL BIOL M, V1, P19; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILEY HS, 1982, J BIOL CHEM, V257, P4222	24	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9067	9073		10.1074/jbc.270.16.9067	http://dx.doi.org/10.1074/jbc.270.16.9067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721820	hybrid			2022-12-27	WOS:A1995QU08900008
J	SANDS, BE; OGATA, H; LYNCHDEVANEY, K; DEBEAUMONT, M; EZZELL, RM; PODOLSKY, DK				SANDS, BE; OGATA, H; LYNCHDEVANEY, K; DEBEAUMONT, M; EZZELL, RM; PODOLSKY, DK			MOLECULAR-CLONING OF THE RAT INTESTINAL TREFOIL FACTOR GENE - CHARACTERIZATION OF AN INTESTINAL GOBLET CELL-ASSOCIATED PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SPASMOLYTIC POLYPEPTIDE PSP; SUCRASE-ISOMALTASE GENE; PROTEIN-KINASE-C; REPORTER GENE; TRANSCRIPTIONAL ELEMENTS; RESPONSIVE ELEMENT; SEQUENCE-ANALYSIS; MESSENGER-RNA; P-DOMAIN	Intestinal trefoil factor (ITF) is a small peptide bearing the unique motif of intrachain disulfide bonds characteristic of the trefoil family, Previous work had localized expression of ITF primarily within goblet cells in the small and large bowel, making it a candidate gene for the study of the molecular basis of intestinal and goblet cell-specific gene expression, In order to study the regulation of ITF expression, we have cloned the rat ITF gene and sequenced 1.7 kilobases of the 5'-flanking region, RNase protection analysis demonstrated a single transcriptional start site, Various lengths of the 5'-flanking region were linked to the reporter gene luciferase and transfected into the colon cancer cell lines LS174T and Caco-2, representing, respectively, cells with and without goblet cell-like phenotype, Expression in the goblet cell-like LS174T colon cancer cell line was nearly 10-fold greater than expression in Caco-2 cells which exhibit columnar enterocyte-like phenotype, The pattern of goblet cell-associated selective transcription required only 153 base pairs of the rat ITF 5'-flanking sequence, Transfection of a construct of human growth hormone under the control of the rat ITF promoter in the N2 subclone of HT-29 cells demonstrated expression of the reporter gene only in those cells exhibiting a goblet cell phenotype as assessed by expression of immuno-reactive mucin, These initial studies of the 5' flanking region of the ITF gene demonstrate the presence of cis-regulatory elements capable of directing goblet cell specific expression.	MASSACHUSETTS GEN HOSP,CTR STUDY INFLAMMATORY BOWEL DIS,GASTROINTESTINAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SURG RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Sands, Bruce/R-7887-2019; Ogata, H/B-3964-2014	Sands, Bruce/0000-0001-5762-5042; 	NIDDK NIH HHS [DK46906, DK43351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK046906] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABYATSKY MW, 1994, GASTROENTEROLOGY, V106, pA43; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BOLL W, 1991, AM J HUM GENET, V48, P889; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHINERY R, 1992, BIOCHEM J, V285, P5, DOI 10.1042/bj2850005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P66; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JEFFREY GP, 1994, GASTROENTEROLOGY, V106, P336, DOI 10.1016/0016-5085(94)90590-8; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; JORGENSEN KH, 1982, REGUL PEPTIDES, V3, P207, DOI 10.1016/0167-0115(82)90126-4; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEFEBVRE O, 1993, J CELL BIOL, V122, P191, DOI 10.1083/jcb.122.1.191; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MILLAN JL, 1987, NUCLEIC ACIDS RES, V15, P10599, DOI 10.1093/nar/15.24.10599; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; OGATA S, 1993, CANCER RES, V52, P5971; OHMORI H, 1994, J BIOL CHEM, V269, P17833; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; PODOLSKY DK, 1986, J CLIN INVEST, V77, P1251, DOI 10.1172/JCI112428; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; ROBINE S, 1993, J BIOL CHEM, V268, P11426; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TAUPIN DR, 1994, GASTROENTEROLOGY, V106, pA195; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1993, J BIOL CHEM, V268, P13956; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402; WU GD, 1992, J BIOL CHEM, V267, P7863	51	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9353	9361		10.1074/jbc.270.16.9353	http://dx.doi.org/10.1074/jbc.270.16.9353			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721858	hybrid			2022-12-27	WOS:A1995QU08900047
J	ARYSTARKHOVA, E; GIBBONS, DL; SWEADNER, KJ				ARYSTARKHOVA, E; GIBBONS, DL; SWEADNER, KJ			TOPOLOGY OF THE NA,K-ATPASE - EVIDENCE FOR EXTERNALIZATION OF A LABILE TRANSMEMBRANE STRUCTURE DURING HEATING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ALPHA-SUBUNIT; CYTOPLASMIC SURFACE; CATALYTIC SUBUNIT; EXTRACELLULAR DOMAIN; CATION OCCLUSION; PROTEIN-KINASE; OUTER MEDULLA; NA+/K+-ATPASE; NA/K-ATPASE	The topological organization of the Na,K-ATPase alpha subunit is controversial. Detection of extracellular proteolytic cleavage sites would help define the topology, and so attempts were made to find conditions and proteases that would permit digestion of Na,K-ATPase in sealed right-side-out vesicles from renal medulla, The beta subunit is predominantly extracellular and could mask the surface of the alpha subunit, Most of the tested proteases cleaved beta, and some digested it extensively, However, without further disruption of structure, there was still no digestion of the alpha subunit. Reduction (at 50 degrees C) of disulfide bonds that might stabilize the beta subunit fragments, or heating alone at 55 degrees C, permitted tryptic digestion of alpha at a site close to the C terminus, while simultaneously increasing digestion of beta. A 90-kDa N-terminal fragment of alpha was recovered, but the C-terminal fragment was further digested. Heating and reduction resulted in the extracellular exposure of a protein kinase A phosphorylation site, Ser-938, and the C terminus, both of which have been proposed to be located on the intracellular surface. At the same time, access to a distant protein kinase C phosphorylation site was not increased. The data suggest that the harsh treatment simultaneously resulted in alteration of the beta subunit and the extrusion of a segment of alpha that normally spans the membrane, without causing complete denaturation or opening the sealed vesicles. Preincubation with Rb+ was protective, consistent with prior evidence that it stabilizes the protein segments in the C-terminal third of alpha. We conclude that this portion of the alpha subunit contains a transmembrane structure with unique lability to heating.	MASSACHUSETTS GEN HOSP, MEMBRANE BIOL LAB, BOSTON, MA 02129 USA	Harvard University; Massachusetts General Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36271] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; CHIN GJ, 1985, BIOCHEMISTRY-US, V24, P5943, DOI 10.1021/bi00342a038; DZHANDZHUGAZYAN KN, 1985, BIOCHIM BIOPHYS ACTA, V817, P165, DOI 10.1016/0005-2736(85)90079-3; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EMERICK MC, 1993, J BIOL CHEM, V268, P23455; FARLEY RA, 1986, BIOCHIM BIOPHYS ACTA, V873, P136, DOI 10.1016/0167-4838(86)90199-8; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISCHER TH, 1983, BIOCHEM J, V211, P771, DOI 10.1042/bj2110771; FISONE G, 1994, J BIOL CHEM, V269, P9368; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; GEERING K, 1993, AM J PHYSIOL, V265, pC1169, DOI 10.1152/ajpcell.1993.265.4.C1169; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOLDSHLEGER R, 1994, SODIUM PUMP, P309; GOLDSHLEGER R, 1994, BIOPHYS J, V66, pA235; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HOMAREDA H, 1993, BIOCHEM CELL BIOL, V71, P410, DOI 10.1139/o93-060; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; KYTE J, 1987, BIOCHEMISTRY-US, V26, P8350, DOI 10.1021/bi00399a049; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, KIDNEY INT, V45, pS32; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; MODYANOV N, 1991, SOC GEN PHY, V46, P99; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MODYANOV NN, 1992, ANN NY ACAD SCI, V671, P134; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; ROBINSON JD, 1980, BIOCHIM BIOPHYS ACTA, V598, P543, DOI 10.1016/0005-2736(80)90034-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT DR, 1992, BIOCHIM BIOPHYS ACTA, V1112, P246, DOI 10.1016/0005-2736(92)90398-6; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; THIBAULT D, 1993, BIOCHEMISTRY-US, V32, P2813, DOI 10.1021/bi00062a012; YOON KL, 1994, J BIOL CHEM, V269, P28249	67	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8785	8796		10.1074/jbc.270.15.8785	http://dx.doi.org/10.1074/jbc.270.15.8785			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721785	hybrid			2022-12-27	WOS:A1995QT44800063
J	GUZDER, SN; BAILLY, V; SUNG, P; PRAKASH, L; PRAKASH, S				GUZDER, SN; BAILLY, V; SUNG, P; PRAKASH, L; PRAKASH, S			YEAST DNA-REPAIR PROTEIN RAD23 PROMOTES COMPLEX-FORMATION BETWEEN TRANSCRIPTION FACTOR TFIIH AND DNA-DAMAGE RECOGNITION FACTOR RAD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; GENE; ENCODES; ENDONUCLEASE; HELICASE; EXCISION; ATPASE; CTD	Saccharomyces cerevisiae, the multisubunit RNA polymerase II general transcription factor TFIIH is indispensable for transcription initiation and some of its subunits are known to be required for nucleotide excision repair (NER) of DNA damaged by ultraviolet light. RAD3, a subunit of TFIIH, binds UV-damaged DNA in an ATP-dependent manner. It has, however, remained unclear how TFIIH is assembled with the other damage recognition component RAD14. Here, we demonstrate a higher order complex consisting of TFIIH, RAD14, and another NER protein RAD23, and complex formation between TFIIH and RAD14 is facilitated by the RAD23 protein.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NCI NIH HHS [CA41261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SAYER MH, 1992, J BIOL CHEM, V267, P23376; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555	23	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8385	8388		10.1074/jbc.270.15.8385	http://dx.doi.org/10.1074/jbc.270.15.8385			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721729	hybrid			2022-12-27	WOS:A1995QT44800004
J	LIU, JN; GUREWICH, V				LIU, JN; GUREWICH, V			INACTIVATION OF THE INTRINSIC ACTIVITY OF PROUROKINASE BY DIISOPROPYL FLUOROPHOSPHATE IS REVERSIBLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-CHAIN UROKINASE; PLASMINOGEN ACTIVATION; GLU-PLASMINOGEN; PROUROKINASE; PROENZYME; FIBRIN; FORM	Single chain urokinase-type plasminogen activator or pro-urokinase (pro-UK) has been reported to have a significant intrinsic amidolytic and plasminogen activator activity, estimated to be about 0.2-0.6% that of two-chain urokinase (UK). However, it has also been suggested that this reported activity is related entirely to trace UK contaminants generated during the analytic procedures. In an attempt to resolve this controversy, it was decided to measure the incorporation of diisopropyl fluorophosphate (DFP) by pro-UK and UK. Surprisingly, it was found that although >98% of the apparent intrinsic activity of pro-UK was inhibited by 5 mM DFP, >97% of this activity was recoverable after exhaustive dialysis of the preparation. This finding could not be explained by UK generation, which was excluded. Instead, the findings indicated that DFP inhibition of pro-UK, in contrast to UK and other serine proteases, was largely reversible. The reaction rate of the reversible inhibition was significantly slower than that of irreversible inhibition by DFP. When the hydrolysis of DFP (2 mM) during incubation (37 degrees C) with or without pro-UK (20 mu M) was compared, a >5-fold acceleration of DFP hydrolysis in the presence of pro-UK was found, whereas little loss of DFP occurred in the presence of UK (20 mu M), consistent with 1:1 stoichiometry. This suggested that pro-UK acted as a slow DFPase in the reaction, a finding consistent with a reversible DFP-enzyme reaction. It was concluded that pro-UK has a distinct and measurable intrinsic catalytic activity, which is qualitatively unique and thereby distinguishable from that of UK as well as other serine proteases.	HARVARD UNIV,DEACONESS HOSP,SCH MED,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215	Harvard University; Harvard Medical School								COLLEN D, 1986, J BIOL CHEM, V261, P1259; ELLIS V, 1987, J BIOL CHEM, V262, P14998; HUSAIN SS, 1983, ARCH BIOCHEM BIOPHYS, V220, P31, DOI 10.1016/0003-9861(83)90383-1; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; LIU JN, 1992, J BIOL CHEM, V267, P15289; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; PANNELL R, 1986, BLOOD, V67, P1215; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; STRYER L, 1988, BIOCHEMISTRY-US, P223; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; WUN TC, 1982, J BIOL CHEM, V257, P7262	15	14	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8408	8410		10.1074/jbc.270.15.8408	http://dx.doi.org/10.1074/jbc.270.15.8408			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721734	hybrid			2022-12-27	WOS:A1995QT44800010
J	NOVOKHATNY, V; MEDVED, L; LIJNEN, HR; INGHAM, K				NOVOKHATNY, V; MEDVED, L; LIJNEN, HR; INGHAM, K			TISSUE-TYPE PLASMINOGEN-ACTIVATOR (TPA) INTERACTS WITH UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) VIA TPAS LYSINE BINDING-SITE - AN EXPLANATION OF THE POOR FIBRIN AFFINITY OF RECOMBINANT TPA/UPA CHIMERIC MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; AMINO-ACIDS 1; T-PA; SCU-PA; SYNERGISTIC COMBINATIONS; THROMBOLYTIC PROPERTIES; PROTHROMBIN FRAGMENT-2; DOMAIN-STRUCTURE; FUSION PROTEIN; SPECIFICITY	Differential scanning calorimetry was used to study the domain structure and intramolecular interactions of tPA/uPA chimeras. A high temperature transition centered near 90 degrees C was observed upon melting of the tPA/uPA chimera (amino acids 1-274 of tPA and 138-411 of uPA) and its variant lacking the finger and epidermal growth factor-like modules (residues 1-3 and 87-274 of tPA and 138-411 of uPA). Since neither of the two parent plasminogen activators display such a stable structure, one may suggest that a new stabilizing intramolecular interaction occurs in the chimeras, We found that occupation of the lysine binding site of tPA by a lysine or arginine side chain from the urokinase moiety is responsible for the high temperature transition as well as for the failure of the chimeras to exhibit the expected fibrin binding properties, All uPA species, single- and two-chain high molecular weight uPA (pro-Uk and HMW-Uk) and two-chain low molecular weight uPA (LMW-Uk), interact intermolecularly with tPA and its kringle-containing derivatives. This intermolecular interaction was strongly inhibited by epsilon-aminocaproic acid indicating that the lysine binding site of tPA is involved. The binding of uPA with the fluorescein-labeled A-chain of tPA, registered by changes in fluorescence anisotropy, was estimated to have a K-d range of 1-7 mu M. The interaction of tPA with uPA determined by solid-phase assays appeared to be tighter, with a K-d range of 50-300 nM. Two synthetic peptides, with and without carboxyl-terminal lysine, corresponding to urokinase residues 144-158 and 144-157, were similar to 100-fold more potent than epsilon-aminocaproic acid with respect to inhibition of the tPA-uPA interaction, indicating that the tPA binding site on urokinase is located within this sequence, close to the activation site Lys(158)-Ile(159). The discovered intermolecular interaction may be related to the reported synergistic effect of simultaneous administration of these two plasminogen activators.	AMER RED CROSS, JEROME H HOLLAND LAB, ROCKVILLE, MD 20855 USA; CATHOLIC UNIV LEUVEN, CTR MOLEC & VASC BIOL, B-3000 LOUVAIN, BELGIUM	American Red Cross; KU Leuven			Lijnen, Roger/AAA-4085-2020	Medved, Leonid/0000-0002-3665-9849				APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BOCK PE, 1992, J BIOL CHEM, V267, P14974; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; COLLEN D, 1986, PROG HEMOST THROMB, V8, P1; COLLEN D, 1986, AM HEART J, V112, P1083, DOI 10.1016/0002-8703(86)90323-6; COLLEN D, 1986, THROMB HAEMOSTASIS, V56, P35; COLLEN D, 1987, THROMB HAEMOSTASIS, V58, P943; COLLEN D, 1987, AM J CARDIOL, V60, P431, DOI 10.1016/0002-9149(87)90280-3; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P3326, DOI 10.1021/bi00128a004; DEVRIES C, 1988, BIOCHEMISTRY-US, V27, P2565, DOI 10.1021/bi00407a044; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GHEYSEN D, 1987, J BIOL CHEM, V262, P11779; GUREWICH V, 1986, THROMB RES, V44, P217, DOI 10.1016/0049-3848(86)90137-4; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; ICHINOSE A, 1986, J CLIN INVEST, V78, P163, DOI 10.1172/JCI112546; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LEE SG, 1988, J BIOL CHEM, V263, P2917; LI X, 1994, J MOL BIOL, V235, P1548, DOI 10.1006/jmbi.1994.1106; LIJNEN HR, 1988, J BIOL CHEM, V263, P19083; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LIJNEN HR, 1987, SEMIN THROMB HEMOST, V13, P152, DOI 10.1055/s-2007-1003486; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; MUNK GAW, 1990, FIBRINOLYSIS, V4, P1; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NELLES L, 1990, THROMB HAEMOSTASIS, V64, P53; NELLES L, 1987, J BIOL CHEM, V262, P10855; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; NOVOKHATNY VV, 1989, THROMB RES, V53, P243, DOI 10.1016/0049-3848(89)90099-6; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; PIERARD L, 1987, J BIOL CHEM, V262, P11771; Privalov P L, 1986, Methods Enzymol, V131, P4; RADEK JT, 1988, ARCH BIOCHEM BIOPHYS, V267, P776, DOI 10.1016/0003-9861(88)90087-2; ROBBINS KC, 1987, SEMIN THROMB HEMOST, V13, P131, DOI 10.1055/s-2007-1003483; SONG A, 1992, SCI CHINA SER B, V35, P966; SPRIGGS DJ, 1989, BLOOD, V73, P1207; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; STUMP DC, 1986, J BIOL CHEM, V261, P7120; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670	45	14	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8680	8685		10.1074/jbc.270.15.8680	http://dx.doi.org/10.1074/jbc.270.15.8680			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721771	hybrid			2022-12-27	WOS:A1995QT44800049
J	RAMIREZ, MT; POST, GR; SULAKHE, PV; BROWN, JH				RAMIREZ, MT; POST, GR; SULAKHE, PV; BROWN, JH			M(1) MUSCARINIC RECEPTORS HETEROLOGOUSLY EXPRESSED IN CARDIAC MYOCYTES MEDIATE RAS-DEPENDENT CHANGES IN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; PROTEIN-KINASE-C; ATRIAL-NATRIURETIC-FACTOR; ALPHA-ADRENERGIC STIMULATION; MYOCARDIAL-CELLS; ACETYLCHOLINE-RECEPTORS; ADENYLYL CYCLASE; HEART MYOCYTES; HYPERTROPHY; SUBTYPES	Stimulation of alpha(1)-adrenergic receptors in neonatal ventricular cardiomyocytes induces hypertrophic changes including activation of the atrial natriuretic factor (ANF) gene. This receptor couples to G(q) to activate phospholipase C (PLC) and protein kinase C, which have been implicated as mediators of the hypertrophic response. To directly determine whether receptor coupling to G(q)/PLC is sufficient to induce ANF expression, we expressed wild-type and chimeric muscarinic cholinergic receptors (mAChRs) with altered G-protein coupling properties in cardiac myocytes and examined their ability to activate an ANF promoter/luciferase reporter gene. The cholinergic agonist carbachol failed to induce transcriptional activation of the ANF reporter gene through endogenous G(i)-linked M(2)mAChRs or in cells transfected with M(2)mAChRs. In contrast, in cells transfected with M(1)mAChRs, which effectively couple to G(q)/PLC, carbachol increased ANF reporter gene expression 10-fold and also increased ANF protein, as deter mined by immunofluorescence. Carbachol-mediated ANF gene expression was inhibited by the mAChR antagonist pirenzepine with a K-i value characteristic of an M(1)mAChR. Studies using chimeric M(1)- and M(2)mAChRs demonstrated that the N-terminal 21 amino acids of the third intracellular loop of the M(1)mAChR were required for receptor coupling to ANF gene expression. This region, previously shown to specify receptor coupling to G(q)/PLC, also conferred partial activity to a chimeric M(2) receptor. We further demonstrated that M(1)mAChR coupling to ANF gene expression was Ras-dependent since co-expression of dominant-interfering Ala-15 Ras inhibited M(1)mAChR-induced ANF expression by 60%. In contrast, ANF expression induced by the chimeric M(2) receptor was not blocked by dominant interfering Ras. We suggest that receptor coupling to G(q)/PLC is sufficient to induce ANF expression and that a Ras-dependent pathway contributes additional signals required for maximal M(1)mAChR-mediated ANF gene expression.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, BIOMED SCI GRAD PROGRAM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, P01HL046345, T32HL007444, R37HL028143] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07444, HL46345, HL28143] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BONNER TI, 1992, TRENDS PHARMACOL SCI, V13, P48, DOI 10.1016/0165-6147(92)90021-W; BRAUN AP, 1990, EUR J PHARM-MOLEC PH, V189, P201, DOI 10.1016/0922-4106(90)90024-R; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; DORJE F, 1991, MOL PHARMACOL, V40, P459; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; HAMMER R, 1980, NATURE, V283, P90, DOI 10.1038/283090a0; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEE HR, 1988, J BIOL CHEM, V263, P7352; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RAMIREZ MT, 1994, FASEB J, V8, pA385; RAMIREZ MT, 1995, MOLMECHANISMS MUSCAR; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU DQ, 1992, J BIOL CHEM, V267, P25798; YANG CM, 1993, AM J PHYSIOL, V265, pC666, DOI 10.1152/ajpcell.1993.265.3.C666	44	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8446	8451		10.1074/jbc.270.15.8446	http://dx.doi.org/10.1074/jbc.270.15.8446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721739	hybrid			2022-12-27	WOS:A1995QT44800015
J	WOLFF, EC; LEE, YB; CHUNG, SI; FOLK, JE; PARK, MH				WOLFF, EC; LEE, YB; CHUNG, SI; FOLK, JE; PARK, MH			DEOXYHYPUSINE SYNTHASE FROM RAT TESTIS - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4D; POSTTRANSLATIONAL FORMATION; SACCHAROMYCES-CEREVISIAE; HYPUSINE FORMATION; PROTEIN; SPERMIDINE; POLYAMINES; CELLS; IDENTIFICATION; PROLIFERATION	Deoxyhypusine synthase is the first enzyme involved in the post translational formation of hypusine, a unique amino acid that occurs at one position in a single cellular protein, eukaryotic translation initiation factor 5A (eIF-5A). This NAD-dependent enzyme catalyzes the formation of deoxyhypusine by transfer of the butylamine portion of spermidine to the epsilon-amino group of a specific lysine residue in the eIF-5A precursor. Its purification from rat testis was accomplished by ammonium sulfate fractionation and successive ion-exchange chromatographic steps, followed by chromatofocusing on a hydrophilic resin (Mono P). A pI of 4.7 was determined by isoelectric focusing, Amino acid sequences of five tryptic peptides of the pure enzyme did not correspond to any sequences in the protein data banks. The enzyme migrates as a single band ton SDS-polyacrylamide gel electrophoresis with an apparent monomer molecular mass of similar to 42,000 Da. Matrix-assisted laser desorption mass spectrometry gave a monomer mass of 40,800 Da. There is evidence, however, that the active enzyme exists as a tetramer of this subunit. Rabbit polyclonal antibodies to the 42-kDa protein precipitated deoxyhypusine synthase activity. The enzyme shows a strict specificity for NAD. Purified deoxyhypusine synthase catalyzes the overall synthesis of deoxyhypusine and, in the absence of the eIF-5A precursor, catalyzes the cleavage of spermidine.			WOLFF, EC (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,ENZYME CHEM SECT,BLDG 30,RM 211,30 CONVENT DR,MSC 4330,BETHESDA,MD 20892, USA.							ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BENINATI S, 1988, BIOCHIM BIOPHYS ACTA, V952, P325, DOI 10.1016/0167-4838(88)90134-3; BERGSTROM J, 1982, PROTIDES BIOL FLUIDS, P641; Bollag DM, 1991, PROTEIN METHODS, P95; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DOU QP, 1990, BIOCHIM BIOPHYS ACTA, V1036, P128, DOI 10.1016/0304-4165(90)90024-Q; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YS, UNPUB; KANG HA, 1994, J BIOL CHEM, V269, P3934; KANG K, UNPUB; KIM HT, 1990, J BIOL CHEM, V265, P3636; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; SACKETT DL, 1989, ANAL BIOCHEM, V180, P319, DOI 10.1016/0003-2697(89)90439-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; SMITH PK, 1985, ANAL BIOCHEM, V150, P75; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TAO Y, 1994, FASEB J, V8, pA1359; TORRELIO BM, 1984, EXP CELL RES, V154, P454, DOI 10.1016/0014-4827(84)90169-1; WEBER K, 1971, J BIOL CHEM, V246, P4504; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; YANG YC, 1990, BIOCHIM BIOPHYS ACTA, V1033, P133; 1982, CHROMATOFOCUSING POL	37	55	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8660	8666		10.1074/jbc.270.15.8660	http://dx.doi.org/10.1074/jbc.270.15.8660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721768	hybrid			2022-12-27	WOS:A1995QT44800046
J	HATTORI, M; HORIUCHI, R; HOSAKA, K; HAYASHI, H; KOJIMA, I				HATTORI, M; HORIUCHI, R; HOSAKA, K; HAYASHI, H; KOJIMA, I			SIALYLLACTOSE-MEDIATED CELL-INTERACTION DURING GRANULOSA-CELL DIFFERENTIATION - IDENTIFICATION OF ITS BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; EMBRYONAL CARCINOMA-CELLS; PHOSPHATIDYLCHOLINE BILAYERS; CARBOHYDRATE-RECOGNITION; GANGLIOSIDE GM3; MELANOMA-CELLS; NERVOUS-SYSTEM; SIALYL-LEX; RECEPTOR; GLYCOLIPIDS	The present study was designed to prove the carbohydrate-binding proteins interacting with cell surface sialyllactosylceramide (G(M3), NeuAc alpha 2-->3Gal beta-4Glc beta--> 1'Cer), which is highly expressed during differentiation of rat ovarian granulosa cells. As a specific ligand for the sialyllactose (SL)-binding proteins on granulosa cells, we used a radioiodinated multivalent SL-linked albumin (Alb-(SL)(17)). The specific association of the ligand to the putative proteins on the intact cells was competitively inhibited by G(M3) more effectively than other gangliosides, sialyllactotetraosylceramide, sialylneolactotetraosylceramide, and several glycoproteins with N-linked oligosaccharides. However, the proteins had no specificity for the side chain (N-acetyl or N-glycolyl forms) of sialic acid in G(M3). Scatchard analysis of Alb(SL)(17) binding showed high (K-b = 6.4 x 10(-10) M) and low (K-d = 3.1 x 10(-8) M) affinity population of binding sites. By direct binding of I-125-Alb-(SL)(17) to SL-binding proteins on Western blots, the putative proteins with molecular masses of 35, 18, and 14 kDa were detected. The interaction of the multivalent derivative with these binding proteins was differently modulated by Ca2+ and Mn2+. The SL-binding proteins occurred in immature granulosa cells and progressively decreased during differentiation, whereas their endogenous ligand G(M3) increased. These results indicate that relatively low molecular weight SL-binding proteins exist on the surface of immature granulosa cells and that they may serve as receptor sites for newly synthesized G(M3) during differentiation.	GUNMA UNIV, INST MOLEC & CELLULAR REGULAT, DEPT CELL BIOL, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, INST MOLEC & CELLULAR REGULAT, DEPT MOLEC MED, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT BIOCHEM, MAEBASHI, GUMMA 371, JAPAN	Gunma University; Gunma University; Gunma University								AHMED H, 1989, J BIOL CHEM, V264, P18673; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARONDES SH, 1981, ANNU REV BIOCHEM, V50, P207, DOI 10.1146/annurev.bi.50.070181.001231; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FRAZIER W, 1979, ANNU REV BIOCHEM, V48, P491, DOI 10.1146/annurev.bi.48.070179.002423; GABIUS HJ, 1986, ANTICANCER RES, V6, P573; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HATTORI M, 1994, BBA-MOL CELL RES, V1221, P47, DOI 10.1016/0167-4889(94)90214-3; HATTORI M, 1992, MOL CELL ENDOCRINOL, V88, P47, DOI 10.1016/0303-7207(92)90008-T; HATTORI M, 1991, MOL CELL ENDOCRINOL, V81, P69, DOI 10.1016/0303-7207(91)90205-7; HATTORI M, 1988, MOL CELL ENDOCRINOL, V57, P17; HATTORI MA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P101, DOI 10.1016/0167-4889(92)90106-L; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; Ito M, 1994, Seikagaku, V66, P99; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; NAKAISHI H, 1988, BIOCHEM BIOPH RES CO, V150, P766, DOI 10.1016/0006-291X(88)90457-3; NEEDHAM LK, 1993, J CELL BIOL, V121, P397, DOI 10.1083/jcb.121.2.397; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; ROCK P, 1991, BIOCHEMISTRY-US, V30, P19, DOI 10.1021/bi00215a003; ROSEN SD, 1989, J IMMUNOL, V142, P1895; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHARON N, 1984, BIOL CELL, V51, P239, DOI 10.1111/j.1768-322X.1984.tb00304.x; SHUR BD, 1982, J BIOL CHEM, V257, P6871; TIEMEYER M, 1990, J BIOL CHEM, V265, P11990; TIEMEYER M, 1989, J BIOL CHEM, V264, P1671; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YAMADA KM, 1981, J CELL PHYSIOL, V109, P343, DOI 10.1002/jcp.1041090218; YAMADA KM, 1983, EXP CELL RES, V143, P295, DOI 10.1016/0014-4827(83)90054-X; YOHE HC, 1983, J NEUROSCI RES, V9, P401, DOI 10.1002/jnr.490090406	43	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7858	7863		10.1074/jbc.270.14.7858	http://dx.doi.org/10.1074/jbc.270.14.7858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713878	hybrid			2022-12-27	WOS:A1995QR52600014
J	KOBAYASHI, H; GOTOH, J; HIRASHIMA, Y; FUJIE, M; SUGINO, D; TERAO, T				KOBAYASHI, H; GOTOH, J; HIRASHIMA, Y; FUJIE, M; SUGINO, D; TERAO, T			INHIBITORY EFFECT OF A CONJUGATE BETWEEN HUMAN UROKINASE AND URINARY TRYPSIN-INHIBITOR ON TUMOR-CELL INVASION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL FRAGMENT; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANES; RECEPTOR; METASTASIS; PURIFICATION; DEGRADATION; BINDING; PROTEIN	Proteolytic enzymes such as urokinase-type plasminogen activator (uPA), plasmin, and collagenase mediate proteolysis by a variety of tumor cells. uPA secreted by tumor cells can be bound to a cell surface receptor via a growth factor-like domain within the amino-terminal fragment (ATF) of the uPA molecule with high affinity. Urinary trypsin inhibitor (UTI) efficiently inhibits the soluble and the tumor cell-surface receptor-bound plasmin and subsequently reduces tumor cell invasion and the formation of metastasis. The anti-invasive effect is dependent on the anti-plasmin activity of the UTI molecule, domain II in particular. We synthesized a conjugate between ATF of human uPA and a native UTI molecule or domain II of UTI (HI-8). The effect of the conjugates (ATF . UTI or ATF . HI-8) on tumor cell invasion in vitro was investigated. ATF . UTI and ATF . HI-8 bound to U937 cells in a rapid, saturable, dose-dependent, and reversible manner. A large part of receptor-bound ATF . UTI and ATF . HI-8 remains on the cell surface for at least 5 h at 37 degrees C. Inhibition of tumor cell surface receptor-bound plasmin by ATF . UTI and ATF . HI-8 was markedly enhanced when compared with tumor cells treated either with ATF, UTI, or HI-8. Results of a cell invasion assay showed that ATF . UTI and ATF . HI-8 is very effective at targeting HI-8 specifically to uPA receptor-expressing tumor cells, whereas tumor cells devoid of uPA receptor may be less affected by the conjugates. Our results indicate that cell surface uPA and plasmin activity is essential to the invasive process and that the conjugates exhibit plasmin inhibition to the close environment of the cell surface and subsequently inhibit the tumor cell invasion through Matrigel in an in vitro invasion assay.	HAMAMATSU UNIV SCH MED, CTR EQUIPMENT, HAMAMATSU, SHIZUOKA 43131, JAPAN; NISSIN FOOD PROD CO LTD, NISSIN CENT RES INST, KUSATSU, SHIGA 525, JAPAN	Hamamatsu University School of Medicine	KOBAYASHI, H (corresponding author), HAMAMATSU UNIV SCH MED, DEPT OBSTET & GYNECOL, HANDACHO 3600, HAMAMATSU, SHIZUOKA 43131, JAPAN.							CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; HEARING VJ, 1988, CANCER RES, V48, P1270; HELMAN CM, 1985, J BIOL CHEM, V260, P11581; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; KOBAYASHI H, 1993, BRIT J CANCER, V67, P537, DOI 10.1038/bjc.1993.99; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; LIOTTA LA, 1983, LAB INVEST, V49, P636; MAEDA M, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P256; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OLSON D, 1992, J BIOL CHEM, V267, P9129; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSTROWSKI LE, 1986, CANCER RES, V46, P4121; PLOUG M, 1991, J BIOL CHEM, V266, P1926; REICH R, 1988, CANCER RES, V48, P3307; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; WACHTER E, 1981, H-S Z PHYSIOL CHEM, V362, P1351, DOI 10.1515/bchm2.1981.362.2.1351; WUN TC, 1989, J BIOL CHEM, V264, P7862	28	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8361	8366		10.1074/jbc.270.14.8361	http://dx.doi.org/10.1074/jbc.270.14.8361			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713945	hybrid			2022-12-27	WOS:A1995QR52600084
J	ZHANG, SJ; ZENG, XR; ZHANG, P; TOOMEY, NL; CHUANG, RY; CHANG, LS; LEE, MYWT				ZHANG, SJ; ZENG, XR; ZHANG, P; TOOMEY, NL; CHUANG, RY; CHANG, LS; LEE, MYWT			A CONSERVED REGION IN THE AMINO-TERMINUS OF DNA-POLYMERASE-DELTA IS INVOLVED IN PROLIFERATING CELL NUCLEAR ANTIGEN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' EXONUCLEASE ACTIVITY; REPLICATION INVITRO; CATALYTIC SUBUNIT; AUXILIARY PROTEIN; CALF THYMUS; KINASES; CYCLIN; ORIGIN; MOTIF; SITE	Synthetic peptides to selected sequences in human DNA polymerase delta (pol delta) were used to identify the region involved in the interaction of pol delta to proliferating cell nuclear antigen. Peptides corresponding to sequences in five regions in the amino terminus of human pol delta and three in the carboxyl terminus, which are conserved with the yeast homologs of pol delta, were tested. These studies showed that the peptide corresponding to the N2 region (residues 129-149) selectively and specifically inhibited the PCNA stimulation of pol delta. This inhibition was relieved by titration with excess PCNA. The identification of the N-2 region as being involved in PCNA binding was supported by studies that demonstrated that the N2 peptide could bind PCNA. Deletion mutants of pol delta expressed in Sf9 cells provided evidence that the binding region for PCNA was located in the first 182 residues of the amino terminus. These studies provide reasonable evidence that residues within the region 129-149 of pol delta are involved in the binding site for PCNA.	UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; CHILDRENS HOSP,DEPT PEDIAT,COLUMBUS,OH 43205	University of Miami; University System of Ohio; Ohio State University; Nationwide Childrens Hospital			Chang, Long-sheng/E-2871-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BROTT DA, 1993, J CELL BIOCHEM, V52, P362, DOI 10.1002/jcb.240520312; BROWN WC, 1993, J BIOL CHEM, V268, P21706; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; DONG Q, 1993, MOL CELL BIOL, V13, P8090; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; HAO H, 1992, CHROMOSOMA, V102, P121; HRUBY VJ, 1992, SYNTHETIC PEPTIDES U, P259; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027	35	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7988	7992		10.1074/jbc.270.14.7988	http://dx.doi.org/10.1074/jbc.270.14.7988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713898	hybrid			2022-12-27	WOS:A1995QR52600034
J	BAI, G; KUSIAK, JW				BAI, G; KUSIAK, JW			FUNCTIONAL-ANALYSIS OF THE PROXIMAL 5'-FLANKING REGION OF THE N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT GENE, NMDAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MESSENGER-RNA; BINDING PROTEIN; NERVOUS-SYSTEM; GABA-A; PROMOTER; RAT; EXPRESSION; CELLS; CLONING	The NMDAR1 receptor subunit is a common subunit of N-methyl-D-aspartate receptors. We have previously characterized 3 kilobases (kb) of 5'-flanking sequence of the NMDAR1 gene and now report on the ability of this region to direct transcription of a reporter gene and on its interaction with nuclear proteins, The sequence 356 base pairs (bp) 5' of the first nucleotide of codon 1 was sufficient to express a luciferase reporter gene in rat PC12 pheochromocytoma cells, Additional sequences upstream of nucleotide -356 influenced the activity approximately 2-fold. A labeled 112-bp fragment (position -356 to -245) formed six complexes (C1A and -B, C2A and -B, and C3A and -B), grouped as three double bands, with nuclear extracts from PC12 cells, Competition with Sp1 oligonucleotides abolished formation of C2A and -B and C3A and -B complexes. Sp1 antibody recognized the C3A complex in supershift experiments, Prior immunoprecipitation of nuclear extracts with Spl antibody abolished formation of C2A and -B and C3A and -B complexes. Purified Sp1 protein alone did not form a C3A complex but potentiated its formation when PC12 nuclear extract was added, A CC-rich sequence in this fragment was protected from DNase I digestion by nuclear extract, These results suggest that a 356-bp sequence comprises the NMDAR1 basal promoter, and that NMDAR1 gene expression may be regulated by Sp1-like nuclear factors.			BAI, G (corresponding author), NIA, GERONTOL RES CTR, MOLEC NEUROBIOL UNIT, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA.							ABMAYR SM, 1990, CURRENT PROTOCOLS MO; Awobuluyi M., 1994, Society for Neuroscience Abstracts, V20, P237; BAI G, 1993, MOL CELL BIOL, V13, P993, DOI 10.1128/MCB.13.2.993; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BRANN DW, 1993, NEUROENDOCRINOLOGY, V58, P666, DOI 10.1159/000126607; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROSE N, 1993, J BIOL CHEM, V268, P22663; Casado M., 1994, Society for Neuroscience Abstracts, V20, P495; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DAY ML, 1990, J BIOL CHEM, V265, P15253; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FRANKLIN SO, 1993, MOL BRAIN RES, V19, P93, DOI 10.1016/0169-328X(93)90153-G; GANDELMAN KY, 1991, J NEUROCHEM, V56, P1024, DOI 10.1111/j.1471-4159.1991.tb02024.x; GASS P, 1993, J CEREBR BLOOD F MET, V13, P337, DOI 10.1038/jcbfm.1993.42; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; IKEDA K, 1993, EUR J BIOCHEM, V218, P195, DOI 10.1111/j.1432-1033.1993.tb18365.x; ISHIDA N, 1994, NEUROSCI LETT, V166, P211, DOI 10.1016/0304-3940(94)90488-X; ISHII T, 1993, J BIOL CHEM, V268, P2836; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LESCH KP, 1992, EUR J PHARM-MOLEC PH, V227, P109, DOI 10.1016/0922-4106(92)90151-K; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONAGHAN DT, 1985, BRAIN RES, V340, P378, DOI 10.1016/0006-8993(85)90936-9; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PRATT GD, 1993, NEUROSCIENCE, V57, P307, DOI 10.1016/0306-4522(93)90064-M; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; Sambrook J, 1989, MOL CLONING LABORATO; Schatten L. J., 1994, Society for Neuroscience Abstracts, V20, P495; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SUBRAMANIAM S, 1991, J PHARMACOL EXP THER, V256, P811; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; WENK GL, 1991, NEUROBIOL AGING, V12, P93, DOI 10.1016/0197-4580(91)90047-N; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	55	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7737	7744		10.1074/jbc.270.13.7737	http://dx.doi.org/10.1074/jbc.270.13.7737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706322	hybrid			2022-12-27	WOS:A1995QQ43100102
J	BUGGY, JJ; LIVINGSTON, JN; RABIN, DU; YOOWARREN, H				BUGGY, JJ; LIVINGSTON, JN; RABIN, DU; YOOWARREN, H			GLUCAGON-CENTER-DOT-GLUCAGON-LIKE PEPTIDE-I RECEPTOR CHIMERAS REVEAL DOMAINS THAT DETERMINE SPECIFICITY OF GLUCAGON BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; IDENTIFICATION; EXPRESSION; CLONING	The binding of glucagon to its hepatic receptor triggers a G-protein-mediated signal that ultimately leads to an increase in hepatic glucose production (gluconeogenesis) and glycogen breakdown (glycogenolysis). In order to elucidate the structural domain(s) of the human glucagon receptor (hGR) involved in the selective binding of glucagon, a series of chimeras was constructed in which various domains of the hGR were replaced by homologous regions from the receptor for the glucoin-cretin hormone, glucagon-like peptide I (GLP-IR), hGR and GLP-IR are quite similar (47% amino acid identity) yet have readily distinguishable ligand binding characteristics; glucagon binds to the recombinant hGR expressed in COS-7 cells with a K-d that is 1000-fold lower than the K-d for glucagon binding to GLP-IR, In the present study, chimeric receptors were transiently expressed in COS-7 cells and analyzed for glucagon binding, Expression of each receptor chimera was confirmed by immunofluorescence staining using a hGR-specific monoclonal antibody, This report identifies several noncontiguous domains of the hGR that are important for high affinity glucagon binding, Mast notable are the membrane-proximal half of the amino-terminal extension, the first extracellular loop, and the third, fourth, and sixth transmembrane domains.	MILES INC,INST METAB DISORDERS,SIGNAL TRANSDUCT GRP,W HAVEN,CT 06516									CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; DILLON JS, 1993, ENDOCRINOLOGY, V133, P1907, DOI 10.1210/en.133.4.1907; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUPRE J, 1991, ENDOCRINE PANCREAS, P253; EBERT R, 1987, Diabetes Metabolism Reviews, V3, P1; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; IYENGAR R, 1984, J BIOL CHEM, V259, P5222; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; LOK S, 1994, GENE, V140, P203, DOI 10.1016/0378-1119(94)90545-2; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; Sambrook J, 1989, MOL CLONING LABORATO; SMITH RJ, 1989, ENDOCRINOLOGY, P1333; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THORENS B, 1992, IABETES, V42, P1678; UNGER RH, 1992, WILLIAMS TXB ENDOCRI, P1255; UNGER RH, 1990, DIABETES MELLITUS TH; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454	22	65	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7474	7478		10.1074/jbc.270.13.7474	http://dx.doi.org/10.1074/jbc.270.13.7474			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706293	hybrid			2022-12-27	WOS:A1995QQ43100068
J	CHAIKOF, EL; CABAN, R; YAN, CN; RAO, GN; RUNGE, MS				CHAIKOF, EL; CABAN, R; YAN, CN; RAO, GN; RUNGE, MS			GROWTH-RELATED RESPONSES IN ARTERIAL SMOOTH-MUSCLE CELLS ARE ARRESTED BY THROMBIN RECEPTOR ANTISENSE SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; BALLOON ANGIOPLASTY; ANTITHROMBIN-III; PHOSPHOLIPASE-C; G-PROTEIN; DESENSITIZATION; RESTENOSIS; EXPRESSION; ACTIVATION; INDUCTION	The capacity of antisense sequences to the thrombin receptor to selectively inhibit thrombin receptor expression and limit mitogenic responses in vascular wall cells was investigated in vitro, Eight phosphorothioate oligodeoxynucleotides based on the sequences of the rat thrombin receptor (including sense, antisense, scrambled, and missense controls) were synthesized, characterized, and purified by high performance liquid chromatography, The antisense oligodeoxynucleotide (ODN 4) inhibitory effect was sequence-specific and both time-and concentration-dependent. A reduction in serum or alpha-thrombin-induced smooth muscle cell (SMC) proliferation was noted as early as 3 days at 30 mu M (82%; 6.17 +/- 1.01 versus 34.08 +/- 3.89 x 10(4) cells/well; p < 0.05) and at a dose as low as 15 mu M after 4 days in culture (19%; p < 0.05), Nonspecific effects were enhanced after prolonged exposure of SMC to the antisense oligodeoxynucleotide (greater than or equal to 6 days), A reduction of inositol phosphate generation greater than 50% (p < 0.05) was detected after exposure of SMC to antisense but not to sense or scrambled nucleotide sequences, This was observed after stimulation with both thrombin and SFFLRN (thrombin receptor peptide agonist), Northern blot analysis and enzyme-linked immunosorbent assays revealed 50 and 22% decreases, respectively, in thrombin receptor mRNA and protein (cell surface) levels in antisense oligonucleotide-treated (72 h) SMC as compared to untreated cells, suggesting that thrombin receptor down-regulation occurred at the pretranslational level, Thus, thrombin receptor-specific antisense sequences inhibit growth-related effects both of serum and thrombin on smooth muscle cells, potentially providing a new strategy for selective inhibition of receptor-mediated arterial injury responses.	EMORY UNIV,SCH MED,DEPT SURG,DIV VASC,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,ATLANTA,GA 30322; UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV CARDIOL,GALVESTON,TX 77555	Emory University; Emory University; University of Texas System; University of Texas Medical Branch Galveston					NHLBI NIH HHS [HL-48667, HL-02414] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002414, P01HL048667] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1992, AM J RESP CELL MOL, V6, P123, DOI 10.1165/ajrcmb/6.2.123; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1988, J BIOL CHEM, V263, P5348; CARNEY DH, 1992, J CLIN INVEST, V89, P1469, DOI 10.1172/JCI115737; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DAVIDSON A, 1991, FEBS LETT, V284, P252, DOI 10.1016/0014-5793(91)80697-2; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DETWILER TC, 1992, SEMIN THROMB HEMOST, V18, P600; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; GIBBONS GH, 1993, CLIN RES, V41, P143; GIMPLE LW, 1992, CIRCULATION, V86, P1536, DOI 10.1161/01.CIR.86.5.1536; GOROG PG, 1993, THROMB HAEMOSTASIS, V69, P804; GRAHAM DJ, 1990, J VASC SURG, V11, P307, DOI 10.1067/mva.1990.17098; HATTON MWC, 1989, AM J PATHOL, V135, P499; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; JOSEPHSILVERSTE.J, 1987, SEMIN THROMB HEMOST, V13, P504; KNOLLER S, 1991, EUR J BIOCHEM, V195, P801, DOI 10.1111/j.1432-1033.1991.tb15769.x; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LIBBY P, 1989, TRANSPLANT P, V21, P3677; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; MELZIG M, 1986, BIOMED BIOCHIM ACTA, V45, P1199; MINTER AJ, 1992, THROMB HAEMOSTASIS, V67, P718; MORONI MC, 1992, J BIOL CHEM, V267, P2714; OKAZAKI H, 1992, CIRC RES, V71, P1285, DOI 10.1161/01.RES.71.6.1285; PARIS S, 1987, J BIOL CHEM, V262, P1970; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHWARTZ SM, 1993, J CARDIOVASC PHARM S, V1, pS31; SOFF GA, 1991, BLOOD, V77, P515; TRAVO P, 1980, BLOOD VESSELS, V17, P110; WEISS RH, 1991, BIOCHEM BIOPH RES CO, V181, P617, DOI 10.1016/0006-291X(91)91235-5; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WEST AP, 1991, MOL CELL ENDOCRINOL, V79, pR9, DOI 10.1016/0303-7207(91)90111-5; WILCOX JN, 1991, CIRCULATION, V84, P432, DOI 10.1161/01.CIR.84.1.432; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975; ZWAGINGA JJ, 1990, ARTERIOSCLEROSIS, V10, P437, DOI 10.1161/01.ATV.10.3.437	39	34	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7431	7436		10.1074/jbc.270.13.7431	http://dx.doi.org/10.1074/jbc.270.13.7431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706289	hybrid			2022-12-27	WOS:A1995QQ43100063
J	NAKAMURA, J; LOU, L				NAKAMURA, J; LOU, L			BIOCHEMICAL-CHARACTERIZATION OF HUMAN GMP SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IMMUNOSUPPRESSIVE ACTIVITY; IDENTIFICATION; PURIFICATION; BIOSYNTHESIS; COREPRESSORS; REPRESSOR	GMP synthetase (EC 6.3.5.2) plays a key role in the de novo synthesis of guanine nucleotides. It is a potential target for immunosuppressive therapy, Recently, the human enzyme was purified to homogeneity (Hirst, M., Haliday, E., Nakamura, J., and Leu, L. (1994) J. Biol. Chem. 269, 23830-23837). We now report the characterization of this enzyme in terms of its biochemical and kinetic properties, We found that there are distinct features of the human enzyme that has not been reported for GMP synthetase from other sources, There are two variant forms of human GMP synthetase, Their catalytic properties are very similar, although their isoelectric points are different, They most likely represent posttranslational modification variants, Magnesium ion is required for enzyme activity, and the requirement is beyond levels needed for ATP chelation, Magnesium appears to be an essential activator and there may be more than one binding site, Interaction of GMP synthetase with xanthosine 5'-monophosphate (XMP), a substrate, exhibits sigmoidal kinetics with a Hill coefficient of 1.48 +/- 0.07. This positive cooperativity is not due to ligand-induced oligomerization, since GMP synthetase remains a monomer in the presence of XMP and other substrates. Decoyinine, a selective inhibitor of GMP synthetase, inhibits the human enzyme reversibly with uncompetitive inhibition kinetics toward glutamine and XMP and noncompetitive kinetics toward ATP.	SYNTEX INC, DISCOVERY RES, INST BIOCHEM & CELL BIOL, PALO ALTO, CA 94304 USA	Syntex Corporation								BERMAN KM, 1970, J BIOL CHEM, V245, P5309; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; Dixon M., 1979, ENZYMES, P381; EUGUI EM, 1993, ANN NY ACAD SCI, V685, P309, DOI 10.1111/j.1749-6632.1993.tb35881.x; FUKUYAMA TT, 1966, J BIOL CHEM, V241, P4745; HIRAI K, 1987, J BIOCHEM, V102, P893, DOI 10.1093/oxfordjournals.jbchem.a122130; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; HIRST M, 1994, J BIOL CHEM, V269, P23830; JAFFEE BD, 1993, TRANSPLANT P, V25, P19; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; MENG LM, 1990, MOL MICROBIOL, V4, P2187, DOI 10.1111/j.1365-2958.1990.tb00580.x; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; Morrison J F, 1979, Methods Enzymol, V63, P257; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; NYK N, 1969, BIOCHEMISTRY-US, V8, P2787; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; PATEL N, 1975, J BIOL CHEM, V250, P2609; ROBERTSON JG, 1993, BIOCHEMISTRY-US, V32, P3769, DOI 10.1021/bi00065a032; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SATAMOTO N, 1972, J BIOL CHEM, V247, P5880; Segel I. H., 1975, ENZYME KINETICS, P360; SLECHTA L, 1960, BIOCHEM BIOPH RES CO, V3, P596, DOI 10.1016/0006-291X(60)90068-1; Spector T, 1978, Methods Enzymol, V51, P219; UKADA S, 1963, J BIOL CHEM, V238, P2797; VONDERSAAL W, 1985, BIOCHEMISTRY-US, V24, P5343, DOI 10.1021/bi00341a011; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; ZALKIN H, 1985, J BIOL CHEM, V260, P3350; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4; ZALKIN H, 1977, J BIOL CHEM, V252, P5431	31	36	36	4	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7347	7353		10.1074/jbc.270.13.7347	http://dx.doi.org/10.1074/jbc.270.13.7347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706277	hybrid			2022-12-27	WOS:A1995QQ43100050
J	STUTTS, MJ; GABRIEL, SE; OLSEN, JC; GATZY, JT; OCONNELL, TL; PRICE, EM; BOUCHER, RC				STUTTS, MJ; GABRIEL, SE; OLSEN, JC; GATZY, JT; OCONNELL, TL; PRICE, EM; BOUCHER, RC			FUNCTIONAL CONSEQUENCES OF HETEROLOGOUS EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CHLORIDE CHANNEL; GROWTH-FACTOR; CL CHANNEL; GENE; PHOSPHORYLATION; CFTR	We studied the consequences of cystic fibrosis transmembrane conductance regulator (CFTR) expression in NIH-3T3 fibroblasts as a model for the effects of virally transduced CFTR expression in non-epithelial cells. Fibroblasts were infected with a retrovirus vector that contained the human CFTR and neo(r) cDNAs. We selected and expanded G418-resistant clones that encompassed a range of CFTR expression. CFTR-mediated Cl- conductance function was measured as whole cell current, and CFTR protein was quantitated by immunoblot analysis. Overall, there was a good relationship between CFTR protein levels and CFTR-mediated Cl- conductance. Some clones had consistently high basal levels of CFTR-mediated Cl- conductance. This variation in function was partially explained by CFTR protein levels and was not due to clonal variation in cAMP metabolism. High levels of CFTR expression were associated with depolarization of fibroblast membrane potential. The CFTR-expressing clones with the largest basally active CFTR Cl- conductances and the most depolarized membrane potentials also exhibited slower growth rates. These results suggest that potential side effects of gene replacement therapy for cystic fibrosis include functional consequences of CFTR expression in non-epithelial cells.	UNIV N CAROLINA,LINEBERGER CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	STUTTS, MJ (corresponding author), UNIV N CAROLINA,CTR CYST FIBROSIS RES,CB 7020,CHAPEL HILL,NC 27599, USA.							BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; ESTACION M, 1991, J PHYSIOL-LONDON, V436, P579, DOI 10.1113/jphysiol.1991.sp018568; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; MAGNI M, 1991, J BIOL CHEM, V266, P6329; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1992, BIOPHYS J, V62, P1, DOI 10.1016/S0006-3495(92)81759-9	18	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20653	20658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690761				2022-12-27	WOS:A1993LY01900104
J	COLOGNATOPYKE, H; OREAR, JJ; YAMADA, Y; CARBONETTO, S; CHENG, YS; YURCHENCO, PD				COLOGNATOPYKE, H; OREAR, JJ; YAMADA, Y; CARBONETTO, S; CHENG, YS; YURCHENCO, PD			MAPPING OF NETWORK-FORMING, HEPARIN-BINDING, AND ALPHA-1-BETA-1 INTEGRIN-RECOGNITION SITES WITHIN THE ALPHA-CHAIN SHORT ARM OF LAMININ-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; MEDIATE CELL ATTACHMENT; NEURITE OUTGROWTH; GLOBULAR DOMAIN; CALCIUM-BINDING; LONG-ARM; MULTIDOMAIN PROTEIN; COLLAGEN RECEPTOR; NIDOGEN COMPLEX; B1 CHAIN	Cell-interactive and architecture-forming functions are associated with the short arms of basement membrane laminin-1. To map and characterize these functions, we expressed recombinant mouse laminin-1 alpha-chain extending from the N terminus through one third of domain IIIb. This dumbbell-shaped glycoprotein (r alpha 1(VI-IVb)'), secreted by mammalian cells, was found to possess three activities. 1) Laminin polymerization was quantitatively inhibited by recombinant protein, supporting an alpha-chain role for a three-short arm interaction model of laminin self-assembly. 2) r alpha 1(VI IVb)' bound to heparin, and the activity was localized to a subfragment corresponding to domain VI by I-125-heparin blotting. 3) PC12 rat pheochromocytoma cells adhered to, and rapidly extended branching neurites on, r alpha 1(VI-IVb)', with adhesion inhibited by alpha 1 and beta 1 integrin chain-specific antibodies. The ability of anti-laminin antibody to block PC12 cell adhesion to laminin was selectively prevented by absorption with r alpha 1(VI-IVb)' or alpha-chain domain VI fragment. This active integrin-recognition site could furthermore be distinguished from a second cryptic alpha 1 beta 1-binding site exposed by heat treatment of fragment P1', a short arm fragment lacking globules. Thus, a polymer-forming, a heparin-binding, and the active alpha 1 beta 1 integrin-recognition site are all clustered at the end of the alpha-chain short arm, the latter two resident solely in domain VI.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MICROBIOL & MOLEC GENET,PISCATAWAY,NJ 08854; NIDR,BETHESDA,MD 20892; MCGILL UNIV,CTR RES NEUROSCI,MONTREAL,PQ H3A 2B2,CANADA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); McGill University				Yurchenco, Peter/0000-0003-0387-2317	NIDDK NIH HHS [R01-DK36425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLYMAN RI, 1994, J CELL SCI, V107, P1007; COLOGNATOPYKE H, 1994, MOL BIOL CELL, V5, pA304; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DUBAND JL, 1992, DEVELOPMENT, V116, P585; DUBAND JL, 1988, DEVELOPMENT, V101, P461; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; GOODMAN SL, 1987, J CELL BIOL, V105, P589, DOI 10.1083/jcb.105.1.589; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PERRIS R, 1989, DEV BIOL, V136, P222, DOI 10.1016/0012-1606(89)90144-9; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; RAO CN, 1990, BIOCHEMISTRY-US, V29, P6768, DOI 10.1021/bi00481a004; REH TA, 1987, NATURE, V330, P68, DOI 10.1038/330068a0; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TAWIL N, 1993, J CELL BIOL, V120, P261, DOI 10.1083/jcb.120.1.261; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TOMASELLI KJ, 1993, J NEUROSCI, V13, P4880; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER DC, 1987, DEV BIOL, V121, P510, DOI 10.1016/0012-1606(87)90187-4; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Yurchenco P.D., 1993, MOL CELLULAR ASPECTS, P19; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	54	107	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9398	9406		10.1074/jbc.270.16.9398	http://dx.doi.org/10.1074/jbc.270.16.9398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721864	hybrid			2022-12-27	WOS:A1995QU08900053
J	COOL, DR; FENGER, M; SNELL, CR; LOH, YP				COOL, DR; FENGER, M; SNELL, CR; LOH, YP			IDENTIFICATION OF THE SORTING SIGNAL MOTIF WITHIN PROOPIOMELANOCORTIN FOR THE REGULATED SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; B SECRETOGRANIN-I; DISULFIDE BOND; PROTEIN; CELLS; PROOPIOMELANOCORTIN; PITUITARY; GRANULES; PEPTIDES; AGGREGATION	The NH2-terminal region of pro-opiomelanocortin (POMC) is highly conserved across species, having two disulfide bridges that cause the formation of an amphipathic hairpin loop structure between the 2nd and 3rd cysteine residues (Cys(8) to Cys(20)). The role that the NH2-terminal region of pro-opiomelanocortin plays in acting as a molecular sorting signal for the regulated secretory pathway was investigated by using site-directed mutagenesis either to disrupt one or more of the disulfide bridges or to delete the amphipathic loop entirely. When POMC was expressed in Neuro-2a cells, ACTH immunoreactive material was localized in punctate secretory granules in the cell body and along the neurites, with heavy labeling at the tips. ACTH was secreted from these POMC-transfected cells in a regulated manner. Disruption of both disulfide bridges or the second disulfide bridge or removal of the amphipathic hairpin loop resulted in constitutive secretion of the mutant POMC from the cells and a lack of punctate secretory granule immunostaining within the cells. We have modeled the NH2-terminal POMC Cys(8) to Cys(20) domain and have identified it as an amphipathic loop containing four highly conserved hydrophobic and acidic amino acid residues (Asp(10)-Leu(11)-Glu(14)-Leu(18)). Thus the sorting signal for POMC to the regulated secretory pathway appears to be encoded by a specific conformational motif comprised of a 13-amino acid amphipathic loop structure stabilized by a disulfide bridge, located at the NH2 terminus of the molecule.	SANDOZ INST MED RES, LONDON WC1E 6BN, ENGLAND	Novartis; Sandoz	COOL, DR (corresponding author), NICHHD, DEV NEUROBIOL LAB, CELLULAR NEUROBIOL SECT, BLDG 49, RM 5A38, BETHESDA, MD 20892 USA.							ARVAN P, 1991, J BIOL CHEM, V266, P14171; BAKER BI, 1974, CELL TISSUE RES, V151, P481; BENNETT HPJ, 1986, INT J PEPT PROT RES, V27, P306; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHEVRIER D, 1991, MOL CELL ENDOCRINOL, V79, P109, DOI 10.1016/0303-7207(91)90101-W; CHEVRIER D, 1993, MOL CELL ENDOCRINOL, V94, P213, DOI 10.1016/0303-7207(93)90170-O; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; DAY NC, 1993, NEUROPEPTIDES, V24, P253, DOI 10.1016/0143-4179(93)90013-Z; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; ELKABES S, 1989, DEV BRAIN RES, V46, P85, DOI 10.1016/0165-3806(89)90145-4; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; KAWAUCHI H, 1983, ARCH BIOCHEM BIOPHYS, V227, P343, DOI 10.1016/0003-9861(83)90462-9; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KITAHARA N, 1988, COMP BIOCHEM PHYS B, V91, P365, DOI 10.1016/0305-0491(88)90155-1; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 1988, MOL MECHANISMS SECRE, P525; Maniatis T., 1982, MOL CLONING; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MILGRAM SL, 1994, J CELL SCI, V107, P737; NOEL G, 1989, J NEUROCHEM, V52, P1050, DOI 10.1111/j.1471-4159.1989.tb01846.x; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; ORCI L, 1987, CELL, V51, P1089; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; ROY P, 1991, MOL CELL ENDOCRINOL, V82, P237, DOI 10.1016/0303-7207(91)90037-S; SALBERT G, 1992, MOL ENDOCRINOL, V6, P1605, DOI 10.1210/me.6.10.1605; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SCOTT AP, 1974, J ENDOCRINOL, V63, pP24; SEVARINO KA, 1991, J BIOL CHEM, V266, P18507; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245	38	137	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8723	8729		10.1074/jbc.270.15.8723	http://dx.doi.org/10.1074/jbc.270.15.8723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721777	hybrid			2022-12-27	WOS:A1995QT44800055
J	MELCHER, T; MAAS, S; HIGUCHI, M; KELLER, W; SEEBURG, PH				MELCHER, T; MAAS, S; HIGUCHI, M; KELLER, W; SEEBURG, PH			EDITING OF ALPHA-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID RECEPTOR GLUR-B PRE-MESSENGER-RNA IN-VITRO REVEALS SITE-SELECTIVE ADENOSINE TO INOSINE CONVERSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; RNA; CHANNELS	In neurons of the mammalian brain primary transcripts of genes encoding subunits of glutamate receptor channels can undergo RNA editing, leading to altered properties of the transmitter-activated channel. Editing of these transcripts is a nuclear process that targets specific adenosines and requires a double-stranded RNA structure configured from complementary exonic and intronic sequences. We show here that the two independent editing sites in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR-B pre-mRNA are edited with positional accuracy by nuclear extract from HeLa cells. Nucleotide analysis by thin layer chromatography of the edited RNA sequences revealed selective adenosine to inosine conversion, mast likely reflecting the participation of double-stranded RNA adenosine deaminase. Our results predict the presence of inosine-containing codons in other mammalian mRNAs.	UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,D-69120 HEIDELBERG,GERMANY; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg; University of Basel								BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; BASS BL, 1993, RNA WORLD, P383; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHAN L, 1992, J BIOL CHEM, V267, P25621; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RUSHIZKY GW, 1963, J BIOL CHEM, V238, P371; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SHUB DA, 1994, RNA PROCESSING PRACT, V2, P211; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Wahle E., 1994, RNA PROCESSING PRACT, VII, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8566	8570		10.1074/jbc.270.15.8566	http://dx.doi.org/10.1074/jbc.270.15.8566			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721757	hybrid			2022-12-27	WOS:A1995QT44800033
J	SCHONHERR, E; HAUSSER, H; BEAVAN, L; KRESSE, H				SCHONHERR, E; HAUSSER, H; BEAVAN, L; KRESSE, H			DECORIN-TYPE-I COLLAGEN INTERACTION - PRESENCE OF SEPARATE CORE PROTEIN-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; SKIN PROTEODERMATAN SULFATE; FIBRILLAR COLLAGEN; TENDON COLLAGEN; LOCALIZATION; FIBROBLASTS; TISSUES; FIBRONECTIN; ENDOCYTOSIS; EXPRESSION	Interactions between the core protein of the small dermatan sulfate proteoglycan decorin and type I collagen have been considered to influence the kinetics of collagen fibrillogenesis and the diameter of and the distance between the fibrils. A variety of recombinant core protein fragments were expressed in Escherichia coli, extracted from inclusion bodies, and renatured in the presence of bovine serum albumin, which was essential for obtaining functional activity. A recombinant protein lacking the first 14 amino acids of the mature core protein (P15-329) interacted with reconstituted type I collagen fibrils and inhibited collagen fibrillogenesis almost as efficiently as intact decorin purified from fibroblast secretions under non-denaturing conditions, Peptides comprising amino acids 15-183 (P15-183) and 185-329 (P185-329) were able to compete for the binding of wild-type decorin, with P15-183 being more active than P185-329, Several other peptides were much less effective, Binding studies using radioactively labeled peptides P15-183 and P185-329 gave direct evidence for the independent binding of both peptides, Peptides 15-183 and 15-125 had the capability of inhibiting collagen fibrillogenesis, whereas peptide 185-329 was inactive, These data suggest (i) that there are at least two separate binding domains for the interaction between decorin core protein and type I collagen and (ii) that binding is not necessarily correlated with an alteration of collagen fibrillogenesis.			SCHONHERR, E (corresponding author), UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, WALDEYERSTR 15, D-48149 MUNSTER, GERMANY.							BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DAY AA, 1986, NUCLEIC ACIDS RES, V14, P9861, DOI 10.1093/nar/14.24.9861; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GLOSSL J, 1983, BIOCHEM J, V215, P295; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; POGANY G, 1992, BIOCHEM BIOPH RES CO, V189, P165, DOI 10.1016/0006-291X(92)91539-3; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; ROSENBERG L, 1993, DERMATAN SULPHATE PR, P225; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SCOTT PG, 1990, CONNECT TISSUE RES, V24, P225, DOI 10.3109/03008209009152151; Spiro R. C., 1994, Molecular Biology of the Cell, V5, p303A; ULDBJERG N, 1988, BIOCHEM J, V251, P643, DOI 10.1042/bj2510643; VANKUPPEVELT THMSM, 1987, HISTOCHEM J, V19, P520, DOI 10.1007/BF01675423; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WITSCHPREHM P, 1992, ARTHRITIS RHEUM-US, V35, P1042, DOI 10.1002/art.1780350909; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	37	180	181	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8877	8883		10.1074/jbc.270.15.8877	http://dx.doi.org/10.1074/jbc.270.15.8877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721795	hybrid			2022-12-27	WOS:A1995QT44800074
J	GUIRAMAND, J; MONTMAYEUR, JP; CERALINE, J; BHATIA, M; BORRELLI, E				GUIRAMAND, J; MONTMAYEUR, JP; CERALINE, J; BHATIA, M; BORRELLI, E			ALTERNATIVE SPLICING OF THE DOPAMINE D2 RECEPTOR DIRECTS SPECIFICITY OF COUPLING TO G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PHOSPHATIDYLINOSITOL HYDROLYSIS; BOUND CONFORMATION; MASTOPARAN-X; RAT-BRAIN; AGONISTS; REGIONS; SELECTIVITY; MUTAGENESIS; EXPRESSION	Two isoforms of the dopamine D2 receptor have been characterized, D2L (long) and D2S (short), generated by alternative splicing from the same gene, They differ by an in-frame insert of 29 amino acids specific to D2L within the putative third intracytoplasmic loop of the receptor, We have previously demonstrated (Montmayeur, J.-P., Guiramand, J., and Borelli, E. (1993) Mol. Endocrinol. 7, 161-170) that D2S and D2L, although presenting very similar pharmacological profiles, couple differently to the alpha-subunit of guanine nucleotide-binding regulatory proteins (G-prateins). In particular, D2L, but not D2S, requires the presence of the alpha-subunit of the inhibitory G protein (G alpha i2) to elicit greater inhibition of adenylyl cyclase activity, The insert present in D2L must therefore confer the specificity of interaction with G alpha i2. Thus, we introduced substitution mutations within the D2L insert, These mutant receptors were expressed in JEG3 cells, a G alpha i2-deficient cell line, scoring for those presenting an increased inhibition of adenylyl cyclase by dopamine, Our analysis identified two mutants, S259/262A and D249V, with these properties, These results dearly show that the insert present in D2L plays a critical role in the selectivity for the G-proteins interacting with the receptor.	UNIV LOUIS PASTEUR STRASBOURG 1,IGBMC,CNRS,INSERM,U184,F-67404 ILLKIRCH GRAFFENS,FRANCE; COMMUNAUTE URBAINE STRASBOURG,STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Guiramand, Janique/E-1376-2013; Montmayeur, Jean-Pierre R/A-5723-2009; Borrelli, Emiliana/M-8994-2018	Montmayeur, Jean-Pierre/0000-0002-0942-1114; CERALINE, Jocelyn/0000-0001-6476-8797				CHIO CL, 1990, NATURE, V343, P266, DOI 10.1038/343266a0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CREESE I, 1979, EUR J PHARMACOL, V56, P411, DOI 10.1016/0014-2999(79)90274-7; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DELEAN A, 1982, MOL PHARMACOL, V22, P290; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGA T, 1994, J NEUROCHEM, V63, P400; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LIU YF, 1994, J BIOL CHEM, V269, P13880; MILLER JC, 1990, BIOCHEM BIOPH RES CO, V166, P109, DOI 10.1016/0006-291X(90)91917-H; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MONTMAYEUR JP, 1991, FEBS LETT, V2, P239; ODOWD BF, 1990, FEBS LETT, V262, P8, DOI 10.1016/0014-5793(90)80140-E; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; RAO DD, 1990, FEBS LETT, V263, P18, DOI 10.1016/0014-5793(90)80695-F; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SEEMAN P, 1985, MOL PHARMACOL, V28, P391; SELBIE LA, 1989, DNA-J MOLEC CELL BIO, V8, P683, DOI 10.1089/dna.1.1989.8.683; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; TITELER M, 1979, EUR J PHARMACOL, V56, P291, DOI 10.1016/0014-2999(79)90187-0; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219	35	146	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7354	7358		10.1074/jbc.270.13.7354	http://dx.doi.org/10.1074/jbc.270.13.7354			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706278	hybrid, Green Submitted			2022-12-27	WOS:A1995QQ43100051
J	MADISON, EL; COOMBS, GS; COREY, DR				MADISON, EL; COOMBS, GS; COREY, DR			SUBSTRATE-SPECIFICITY OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR - CHARACTERIZATION OF THE FIBRIN INDEPENDENT SPECIFICITY OF T-PA FOR PLASMINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR PRECURSOR; STRUCTURAL DOMAINS; ESCHERICHIA-COLI; B-CHAIN; SEQUENCE; PROTEIN; FIBRONECTIN; PROTHROMBIN; INVOLVEMENT; THROMBIN	Tissue-type plasminogen activator (t-PA) is a remarkably specific protease: the only known substrate of this enzyme in vivo is a single peptide bond (Arg(560)-Va1(561)) within the proenzyme plasminogen. Part of the substrate specificity of t-PA is due to a ternary interaction between fibrin, BPA, and plasminogen which reduces the K-m of t-PA for plasminogen by a factor of 440. However, even in the absence of fibrin, t-PA continues to hydrolyze plasminogen more rapidly than does trypsin, a homologous serine protease. We have measured the extent of the specificity of t-PA for plasminogen by assaying t-PA and trypsin toward substrates modeled after the peptide sequence in plasminogen surrounding Ar-960-Val(561). Surprisingly, t-PA hydrolyzes these substrates with kappa(cat)/K-m values which are 28,000-210,000-fold lower than those obtained using trypsin. Both the high activity toward plasminogen and the low activity toward peptides are also exhibited by the isolated protease domain. This suggests that the protease domain, in spite of its high homology to the nonspecific enzyme trypsin, is inherently specific for recognition of one or more structural features displayed by native plasminogen.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT PHARMACOL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MADISON, EL (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA.			Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [R01 HL52475] Funding Source: Medline; NIGMS NIH HHS [5P32GMO8287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; COLLEN D, 1991, BLOOD, V78, P3114; DODD I, 1986, THROMB HAEMOSTASIS, V55, P94; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FOSTER D, 1984, P NATL ACAD SCI-BIOL, V81, P4766, DOI 10.1073/pnas.81.15.4766; GANU VS, 1982, PEPTIDE PROTEIN RES, V20, P421; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; HOLLAND SK, 1987, EMBO J, V6, P1875, DOI 10.1002/j.1460-2075.1987.tb02446.x; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; LIGHT A, 1980, ANAL BIOCHEM, V106, P199, DOI 10.1016/0003-2697(80)90138-4; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MARSH HC, 1982, BIOCHEMISTRY-US, V21, P6167, DOI 10.1021/bi00267a022; MARSH HC, 1983, BIOCHEMISTRY-US, V22, P4170, DOI 10.1021/bi00287a002; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NARAYANA SVL, 1994, J MOL BIOL, V235, P695, DOI 10.1006/jmbi.1994.1021; NELLES L, 1987, J BIOL CHEM, V262, P10855; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; OLSSON G, 1982, FEBS LETT, V145, P317, DOI 10.1016/0014-5793(82)80191-9; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; RIJKEN DC, 1986, J BIOL CHEM, V261, P3098; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; Taylor J. R., 1982, INTRO ERROR ANAL STU; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WALLEN P, 1982, BIOCHIM BIOPHYS ACTA, V719, P318, DOI 10.1016/0304-4165(82)90105-2; WIMAN B, 1977, EUR J BIOCHEM, V76, P129, DOI 10.1111/j.1432-1033.1977.tb11578.x; WOHL RC, 1980, J BIOL CHEM, V255, P2005	43	70	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7558	7562		10.1074/jbc.270.13.7558	http://dx.doi.org/10.1074/jbc.270.13.7558			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706303	hybrid			2022-12-27	WOS:A1995QQ43100078
J	WOTTON, D; LAKE, RA; FARR, CJ; OWEN, MJ				WOTTON, D; LAKE, RA; FARR, CJ; OWEN, MJ			THE HIGH-MOBILITY GROUP TRANSCRIPTION FACTOR, SOX4, TRANSACTIVATES THE HUMAN CD2 ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC ENHANCER; RECEPTOR ALPHA-GENE; DNA-BINDING SPECIFICITIES; TRANSGENIC MICE; HMG BOX; GATA FAMILY; BETA-GENE; PROTEIN; EXPRESSION; IDENTIFICATION	A strong T cell-specific enhancer is located 3' to the human CD2 gene, Six sequences within this enhancer are bound by proteins present in T cell nuclear extracts, These sequences share homology with sequences bound by several transcription factors involved in T cell- and lymphoid-specific transcription, The results presented here demonstrate that the human T cell-specific transcription factor, SOX4, is able to bind to one of these regions; further, SOX4 transactivates transcription of a reporter gene via three tandem copies of this sequence, The binding of SOX4 to this site is not via a canonical HMG protein binding sequence, identifying a novel class of binding site for this protein, A second sequence within the CD2 enhancer closely resembles the IL-2 NF-AT site, We show that it is bound by the ets-related factor, Elf1. However, unlike the IL-2 NF-AT sequence, the CD2 NF-AT like sequence is unable to confer transcriptional inducibility on a reporter gene, Consistent with this result, we show that the observed increase in expression of CD2 protein on the cell surface following T cell activation is a post-transcriptional event.	ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND	Imperial College London; University of Cambridge	WOTTON, D (corresponding author), IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Farr, Christine/0000-0002-5357-5962; Wotton, David/0000-0002-4652-5350				CANTRELL DA, 1988, IMMUNOLOGY, V65, P393; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HO IC, 1990, J EXP MED, V172, P1443, DOI 10.1084/jem.172.5.1443; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMOUN M, 1981, J EXP MED, V153, P207, DOI 10.1084/jem.153.1.207; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LAMB JR, 1982, J IMMUNOL, V128, P233; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P3157; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OOSTERWEGEL MA, 1991, INT IMMUNOL, V3, P1189, DOI 10.1093/intimm/3.11.1189; PROSSER HM, 1991, EUR J IMMUNOL, V21, P161, DOI 10.1002/eji.1830210124; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	47	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7515	7522		10.1074/jbc.270.13.7515	http://dx.doi.org/10.1074/jbc.270.13.7515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706298	hybrid			2022-12-27	WOS:A1995QQ43100073
J	CAI, H; BLOOM, LB; ERITJA, R; GOODMAN, MF				CAI, H; BLOOM, LB; ERITJA, R; GOODMAN, MF			KINETICS OF DEOXYRIBONUCLEOTIDE INSERTION AND EXTENSION AT ABASIC TEMPLATE LESIONS IN DIFFERENT SEQUENCE CONTEXTS USING HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC-APYRIMIDINIC SITES; DNA POLYMERASE-ALPHA; ESCHERICHIA-COLI; REPAIR ENZYMES; BASE PAIR; MUTAGENESIS; OPPOSITE; FIDELITY; SPECIFICITY; MECHANISM	Deoxyribonucleotide insertion efficiencies were measured opposite site-directed abasic template lesions using human immunodeficiency virus 1 reverse transcriptase (HIV-1RT), and the efficiencies to continue primer synthesis beyond the lesion, by addition of the ''next correct'' deoxynucleotide, were measured as a function of sequence context. Insertion of purines was favored over pyrimidines, A > G > T is similar to C. Primer extension past the lesion occurred by two distinct mechanisms, either by direct or by misalignment extension. An ''A-rule'' appeared to hold for the case of direct extension, where the abasic template moiety is intrahelical, aligned opposite the primer 3'-terminus. In misalignment extension, the primer terminus is realigned from a site directly opposite the lesion to a new position opposite a neighboring template base 5' to the lesion. Direct extension efficiencies were measured in 16 different configurations, by varying 4 bases at the primer 3'-termini and 4 at the 5'-side (downstream) of the lesion. The predominant order of direct extension was A > G > T is similar to C, similar to that observed for insertion. Reduced primer extension rates were not caused by a reduction in HIV-1 RT-DNA binding. Primers terminating in C showed inefficient direct extension, but were readily extended via misaligned configurations. The ratios of direct-to-misalignment extension efficiencies were 27:1, 2.5:1, and 1:25 for A, G, and C opposite the lesion, respectively. For the case of primers terminating in T, misalignment extension was not observed. A striking result was that while primers were extended past an abasic lesion by HIV-1 RT in both direct and misalignment modes, avian myeloblastosis virus RT failed to catalyze significant extension by either mode.	CTR RES & DEV, DEPT MOLEC GENET, E-08034 BARCELONA, SPAIN		CAI, H (corresponding author), UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA.		Bloom, Linda B/F-3684-2014; Eritja, Ramon/B-5613-2008	Eritja, Ramon/0000-0001-5383-9334	NIA NIH HHS [AG11398] Funding Source: Medline; NIGMS NIH HHS [GM21422, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422, R01GM042554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRIDGES BA, 1985, P NATL ACAD SCI USA, V82, P4193, DOI 10.1073/pnas.82.12.4193; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; ERITJA R, 1987, NUCLEOS NUCLEOT, V6, P803, DOI 10.1080/15257778708073426; GENTIL A, 1990, BIOCHEM BIOPH RES CO, V173, P704, DOI 10.1016/S0006-291X(05)80092-0; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; KLINEDINST DK, 1992, MOL CARCINOGEN, V6, P32, DOI 10.1002/mc.2940060107; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LAWLEY PD, 1963, BIOCHEM J, V89, P127, DOI 10.1042/bj0890127; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; NG L, 1989, J BIOL CHEM, V264, P13018; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888	36	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23567	23572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693691				2022-12-27	WOS:A1993MF51500093
J	SOWERS, KR; THAI, TT; GUNSALUS, RP				SOWERS, KR; THAI, TT; GUNSALUS, RP			TRANSCRIPTIONAL REGULATION OF THE CARBON-MONOXIDE DEHYDROGENASE GENE (CDHA) IN METHANOSARCINA-THERMOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL COENZYME-M; RNA-POLYMERASE-BINDING; METHANOCOCCUS-VANNIELII; ENZYME COMPLEX; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOTHRIX-SOEHNGENII; NUCLEOTIDE-SEQUENCE; PLASMID DNA; M REDUCTASE; ACETYL-COA	The mechanisms of gene regulation in the phylogenetic domain Archaea are not yet understood. To examine the expression of a gene encoding a highly regulated catabolic enzyme from the methanogenic archaea, a Methanosarcina thermophila lambdagt11 chromosomal library was probed with antiserum prepared against the 89-kDa subunit of carbon monoxide dehydrogenase, an enzyme which is required for growth and methanogenesis from acetate. A 2.3-kilobase DNA fragment was isolated that encoded 300 bases of the 5'-end of cdhA, the gene which encodes the 89-kDa subunit, and 2 kilobases upstream of cdhA that included an upstream open reading frame (ORF1). Primer extension analyses determined that cdhA and ORF1 each had a single transcriptional initiation site located 370 and 9 nucleotides, respectively, 5' of the putative translation initiation codons for cdhA and ORF1. Each promoter element had sequence similarity to a consensus archaeal promoter sequence. Three discrete mRNA cdhA transcripts of 9.5, 5.6, and 4.8 kilobases and one mRNA ORF1 transcript of <2 kilobases were identified. All four transcripts were optimally expressed in cells grown with acetate, while growth with the more energetically favorable substrates methanol and trimethylamine caused a significant reduction in levels of the cdhA and ORF1 mRNA's. The half-lives of the 5' ends of the three cdhA transcripts and entire ORF1 mRNA transcript were approximately 2 min upon addition of methanol to cells growing exponentially in medium that contained acetate. Results of this study demonstrate that transcription of both cdhA and ORF1 is highly regulated in response to substrate by this methanogenic archaeon.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALLMANSBERGER R, 1988, NUCLEIC ACIDS RES, V16, P7419, DOI 10.1093/nar/16.15.7419; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOKRANZ M, 1988, J BACTERIOL, V170, P568, DOI 10.1128/jb.170.2.568-577.1988; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; BROWN JW, 1988, NUCLEIC ACIDS RES, V16, P135, DOI 10.1093/nar/16.1.135; BROWN JW, 1989, FEMS MICROBIOL LETT, V60, P131, DOI 10.1111/j.1574-6968.1989.tb03432.x; CLEMENTS AP, 1992, J BACTERIOL, V174, P5244, DOI 10.1128/JB.174.16.5244-5250.1992; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; FAN CL, 1991, BIOCHEMISTRY-US, V30, P431, DOI 10.1021/bi00216a018; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER R, 1988, FEBS LETT, V228, P249, DOI 10.1016/0014-5793(88)80009-7; GRAHAME DA, 1987, J BIOL CHEM, V262, P3706; HANNAHAN D, 1983, J MOL BIOL, V166, P557; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JETTEN MSM, 1989, EUR J BIOCHEM, V181, P437, DOI 10.1111/j.1432-1033.1989.tb14744.x; KRZYCKI JA, 1985, J BACTERIOL, V163, P1000, DOI 10.1128/JB.163.3.1000-1006.1985; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDIE LL, 1989, J BIOL CHEM, V264, P18392; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MURAKAWA GJ, 1991, J BACTERIOL, V173, P28, DOI 10.1128/jb.173.1.28-36.1991; NAUMANN E, 1984, ARCH MICROBIOL, V138, P79, DOI 10.1007/BF00425412; NELSON MJK, 1984, J BACTERIOL, V160, P526, DOI 10.1128/JB.160.2.526-532.1984; OSHIMA T, 1986, THERMOPHILES GENERAL, P137; PATEL PS, 1988, J BACTERIOL, V170, P3390, DOI 10.1128/jb.170.8.3390-3395.1988; REEVE JN, 1992, ANNU REV MICROBIOL, V46, P165; Sambrook J, 1989, MOL CLONING LABORATO; SMITH MR, 1978, APPL ENVIRON MICROB, V36, P870, DOI 10.1128/AEM.36.6.870-879.1978; SOWERS KR, 1988, J BACTERIOL, V170, P998, DOI 10.1128/jb.170.2.998-1002.1988; TERLESKY KC, 1988, J BIOL CHEM, V263, P4080; TERLESKY KC, 1987, J BIOL CHEM, V262, P15392; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; THOMM M, 1988, J BACTERIOL, V170, P1958, DOI 10.1128/jb.170.4.1958-1961.1988; WEIL CF, 1988, J BACTERIOL, V170, P4718, DOI 10.1128/jb.170.10.4718-4726.1988; WHITE WB, 1992, J BACTERIOL, V174, P4997, DOI 10.1128/JB.174.15.4997-5004.1992; WICH G, 1986, NUCLEIC ACIDS RES, V14, P2459, DOI 10.1093/nar/14.6.2459; WIDDEL F, 1989, ARCH MICROBIOL, V152, P322, DOI 10.1007/BF00425168; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZINDER SH, 1985, J BACTERIOL, V163, P317, DOI 10.1128/JB.163.1.317-323.1985	47	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23172	23178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693685				2022-12-27	WOS:A1993MF51500036
J	TIMERMAN, AP; OGUNBUMNI, E; FREUND, E; WIEDERRECHT, G; MARKS, AR; FLEISCHER, S				TIMERMAN, AP; OGUNBUMNI, E; FREUND, E; WIEDERRECHT, G; MARKS, AR; FLEISCHER, S			THE CALCIUM-RELEASE CHANNEL OF SARCOPLASMIC-RETICULUM IS MODULATED BY FK-506-BINDING PROTEIN - DISSOCIATION AND RECONSTITUTION OF FKBP-12 TO THE CALCIUM-RELEASE CHANNEL OF SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-BINDING-PROTEIN; JUNCTIONAL TERMINAL CISTERNAE; RYANODINE RECEPTOR; CYCLOSPORINE-A; CA-2+ RELEASE; CYCLOPHILIN; FK-506; FK506; PURIFICATION; RAPAMYCIN	The ryanodine receptor/calcium release channel (CRC) of rabbit skeletal muscle terminal cisternae (TC) of sarcoplasmic reticulum (SR) has been found to be tightly associated with FK-506 binding protein (FKBP-12), the cytosolic receptor (immunophilin) for the immunosuppressant drug FK-506 (Jayaraman, T., Brillantes, A. M., Timerman, A. P., Fleischer, S., Erdjument-Bromage, H., Tempst, P., and Marks, A. (1992) J. Biol. Chem. 267, 9474-9477). In this study, a procedure is described to dissociate FKBP from TC and reconstitute human recombinant FKBP-12 back to the ryanodine receptor so that the role of the immunophilin on CRC activity can be assessed. Titration of TC vesicles with FK-506 dissociates FKBP from the ryanodine receptor. Sedimentation of FK-506-treated vesicles effectively separates the TC from the soluble FKBP-FK506 complex which remains in the supernatant. The FKBP-deficient TC vesicles have altered functional characteristics: 1) the ATP-stimulated calcium uptake rate of TC vesicles is reduced 2-fold; and 2) the threshold concentration of caffeine required to induce calcium release from TC vesicles is decreased. These changes appear to reflect modification of the calcium release channel since: 1) severalfold higher concentrations of FK-506 do not alter the calcium uptake rate of either longitudinal tubules of SR, or TC vesicles in the presence of ruthenium red; 2) human recombinant FKBP reassociates with FKBP-deficient TC but not with control TC or longitudinal tubules of SR; and 3) the reduced Ca2+ uptake rate in FKBP-deficient TC is restored to control values in the FKBP-reconstituted TC. These studies demonstrate that FKBP-12 modulates the CRC of rabbit skeletal muscle sarcoplasmic reticulum.	VANDERBILT UNIV,DEPT MOLEC BIOL,NASHVILLE,TN 37235; MERCK RES LABS,RAHWAY,NJ 07065; MERCK RES LABS,RAHWAY,NJ 07065; MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL & MOLEC MED,NEW YORK,NY 10021	Vanderbilt University; Merck & Company; Merck & Company; Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHU A, 1987, ARCH BIOCHEM BIOPHYS, V248, P13; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1983, J MUSCLE RES CELL M, V4, P233, DOI 10.1007/BF00712033; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; PALADE P, 1987, J BIOL CHEM, V262, P6135; SAITO A, 1989, Biophysical Journal, V55, p206A; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1991, TRANSPLANT P, V23, P1; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH KA, 1988, INTERLEUKIN, V2, P1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	332	337	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					22992	22999						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693682				2022-12-27	WOS:A1993MF51500009
J	SIDOLI, A; TAMBORINI, E; GIUNTINI, I; LEVI, S; VOLONTE, G; PAINI, C; DELALLA, C; SICCARDI, AG; BARALLE, FE; GALLIANI, S; AROSIO, P				SIDOLI, A; TAMBORINI, E; GIUNTINI, I; LEVI, S; VOLONTE, G; PAINI, C; DELALLA, C; SICCARDI, AG; BARALLE, FE; GALLIANI, S; AROSIO, P			CLONING, EXPRESSION, AND IMMUNOLOGICAL CHARACTERIZATION OF RECOMBINANT LOLIUM-PERENNE ALLERGEN LOL P-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRASS POLLEN ALLERGEN; AMINO-ACID-SEQUENCE; DUST MITE ALLERGEN; FERRITIN-H-CHAIN; ESCHERICHIA-COLI; MAJOR ALLERGEN; CDNA CLONING; SKIN-TEST; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS	The molecular cloning of the cDNA encoding for an isoallergenic form of Lol p II, a major rye grass (Lolium perenne) pollen allergen, was performed by polymerase chain reaction amplification on mRNA extracted from pollen. The amino acid sequence derived from the cDNA was truncated by 4 and 5 residues at the NH2- and COOH-terminal ends, respectively, and differed only in one position from that previously reported. This cDNA was expressed in Escherichia coli by fusion to the carboxyl terminus of the human ferritin H-chain. The molecule was produced in high yields as a soluble protein and was easily purified. The protein retains the multimeric quaternary structure of ferritin, and it exposes on the surface the allergenic moiety, which can be recognized in Western blotting and in enzyme-linked immunosorbent assay experiments by specific IgE from allergic patients. The recombinant allergen was used to analyze the sera of 26 patients allergic to L. perenne compared with control sera. The results were in good agreement with the values obtained with the radioallergosorbent test assay. In addition, histamine release experiments in whole blood from an allergic patient and skin prick tests showed that the recombinant allergen retains some of the biological properties of the natural compound. These findings indicate that the availability of homogeneous recombinant allergens may be useful for the development of more specific diagnostic and therapeutic procedures. Moreover, this expression system may be of more general interest for producing large amounts of soluble protein domains in E. coli.	BYK GULDEN ITALIA SPA,I-20100 MILAN,ITALY; INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; PRIMM SRL,I-20134 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO SCI & TECNOL BIOMED,I-20122 MILAN,ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan	SIDOLI, A (corresponding author), IST SCI H SAN RAFFAELE,DIPARTIMENTO RIC BIOL & TECNOL,VIA OLGETTINA 58,I-20132 MILAN,ITALY.		arosio, paolo/E-6817-2010; Tamborini, Elena/C-3307-2017; levi, sonia/A-3161-2015	Tamborini, Elena/0000-0002-3819-8687; levi, sonia/0000-0002-5092-0847; Baralle, Francisco/0000-0002-4645-2809; arosio, paolo/0000-0002-5343-8992				ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; ANSARI AA, 1989, J BIOL CHEM, V264, P11181; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BALDO BA, 1988, ALLERGY, V43, P81; BASKAR S, 1992, J IMMUNOL, V148, P2378; BREITENEDER H, 1988, INT ARCH ALLER A IMM, V87, P19, DOI 10.1159/000234643; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1965, EUR POLYM J, V1, P63; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1987, GENE, V51, P269, DOI 10.1016/0378-1119(87)90315-5; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; LUZZAGO A, 1989, EMBO J, V8, P569, DOI 10.1002/j.1460-2075.1989.tb03411.x; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; MOSER M, 1992, J IMMUNOL, V149, P454; NELSON HS, 1983, ANN ALLERGY, V51, P411; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; RAFNAR T, 1992, J BIOL CHEM, V267, P2119; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANTAMBROGIO P, 1992, J BIOL CHEM, V2672, P14077; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHEN HD, 1991, CLIN EXP ALLERGY, V21, P675, DOI 10.1111/j.1365-2222.1991.tb03195.x; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH DJ, 1989, INT ARCH ALLER A IMM, V90, P78, DOI 10.1159/000235004; 1989, ALLERGY CPH, V44, P369	40	32	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21819	21825						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691817				2022-12-27	WOS:A1993MC80900060
J	HAAS, AL; BABOSHINA, O; WILLIAMS, B; SCHWARTZ, LM				HAAS, AL; BABOSHINA, O; WILLIAMS, B; SCHWARTZ, LM			COORDINATED INDUCTION OF THE UBIQUITIN CONJUGATION PATHWAY ACCOMPANIES THE DEVELOPMENTALLY PROGRAMMED DEATH OF INSECT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; DEPENDENT PROTEOLYSIS; DEGRADATION SIGNAL; ALZHEIMERS-DISEASE; PROTEIN; APOPTOSIS; ATP; LOCALIZATION; SYSTEM; GENE	The developmentally programmed cell death of abdominal intersegmental muscles in the tobacco hawkmoth Manduca sexta is coincident with a 10-fold induction of the polyubiquitin gene as a hormonally regulated event (Schwartz, L. M., Myer, A., Kosz, L., Engelstein, M., and Maier, C. (1990) Neuron 5, 411-419), Solid phase immunochemical assays measuring intersegmental muscle pools of free and conjugated ubiquitin reveal that the induction of polyubiquitin mRNA is accompanied by a proportional increase in total ubiquitin polypeptide, Ubiquitin conjugate pools increase 10-fold at eclosion, during which loss of muscle protein mass is maximum, A smaller but measurable increase in ubiquitin conjugates is observed earlier in pupal development coincident with a modest enhanced degradation of myofibrillar proteins, Accumulation of ubiquitin conjugates is accompanied by induction in the pathway for polypeptide ligation, including the activating enzyme (E1), several carrier protein (E2) isoforms, and ubiquitin:protein isopeptide ligase (E3), Both accumulation of ubiquitin polypeptide and the enzymes of the conjugation pathway are subject to regulation by declining titers of the insect molting hormone 20-hydroxyecdysone, which signals onset of programmed cell death in the intersegmental muscles, Thus, programmed cell death within the intersegmental muscles is accomplished in part by stimulation of the ubiquitin-mediated degradative pathway through a coordinated induction of ubiquitin and the enzymes responsible for its conjugation to yield proteolytic intermediates, This suggests enzymes required for ubiquitin conjugation may represent additional genes recruited for developmentally programmed death.	UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst	HAAS, AL (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.		Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040458, R01GM034009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K04AG000492] Funding Source: NIH RePORTER; NIA NIH HHS [AG00492] Funding Source: Medline; NIGMS NIH HHS [GM34009, GM40458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; D'MELLO SR, 1993, NEUROREPORT, V4, P355, DOI 10.1097/00001756-199304000-00003; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; FAHRBACH SE, 1994, J COMP NEUROL, V343, P464, DOI 10.1002/cne.903430309; FINLAYSON LH, 1956, Q J MICROSC SCI, V97, P215; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GREGORI L, 1987, J BIOL CHEM, V262, P2562; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, CURRENT COMMUNICATIO, P178; HAAS AL, 1988, UBIQUITIN, P173; HAYASHI T, 1992, J NEUROSCI RES, V31, P561, DOI 10.1002/jnr.490310321; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KATO H, 1993, BRAIN RES, V619, P339, DOI 10.1016/0006-8993(93)91631-2; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; LAUZON RJ, 1993, CELL TISSUE RES, V272, P115, DOI 10.1007/BF00323577; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; PICKART CM, 1991, DEV GROWTH DIFFER, V33, P587; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RILEY DA, 1988, J HISTOCHEM CYTOCHEM, V36, P621, DOI 10.1177/36.6.2835410; Schueler P A, 1988, J Chem Neuroanat, V1, P165; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SCHWARTZ LM, 1993, DEV BIOL, V158, P448, DOI 10.1006/dbio.1993.1202; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SCHWARTZ LM, 1983, DEV BIOL, V99, P103, DOI 10.1016/0012-1606(83)90257-9; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; SCHWARTZ LM, 1982, J NEUROBIOL, V23, P1312; SUN DH, 1995, J NEUROBIOL, V26, P119, DOI 10.1002/neu.480260110; TABATON M, 1991, P NATL ACAD SCI USA, V88, P2098, DOI 10.1073/pnas.88.6.2098; WIGHTMAN G, 1992, NEUROSCI LETT, V139, P269, DOI 10.1016/0304-3940(92)90569-S; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; WOLFF T, 1991, DEVELOPMENT, V113, P825; YEE WM, 1993, EXP BRAIN RES, V94, P193	56	119	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9407	9412		10.1074/jbc.270.16.9407	http://dx.doi.org/10.1074/jbc.270.16.9407			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721865	hybrid			2022-12-27	WOS:A1995QU08900054
J	MICHELOTTI, EF; TOMONAGA, T; KRUTZSCH, H; LEVENS, D				MICHELOTTI, EF; TOMONAGA, T; KRUTZSCH, H; LEVENS, D			CELLULAR NUCLEIC-ACID BINDING-PROTEIN REGULATES THE CT ELEMENT OF THE HUMAN C-MYC PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; CHROMATIN STRUCTURE; GROWTH-FACTOR; K-PROTEIN; GENE; EXPRESSION; TRANSCRIPTION; RIBONUCLEOPROTEIN; REGION; CELLS	The CT element of the c-myc gene is required for promoter P1 usage and can drive expression of a heterologous promoter, Both double strand (Sp1) and single strand (hnRNP K) CT-binding proteins have been implicated as mediators of CT action, Although significant levels of CT activity persisted following Sp1 immunodepletion, EGTA totally abolished transactivation, thus implicating another metal requiring factor in CT element activity, As hnRNP K binds to one strand of the CT element, but has no metal requirement, the opposite (purine-rich strand) was examined as a target for a met al-dependent protein, A zinc-requiring purine strand binding activity was identified as cellular nucleic acid binding protein (CNBP), a protein previously implicated in the regulation of sterol responsive genes. Two forms of CNBP differed in their relative binding to the CT- or sterol-response elements, CNBP was shown to be a bona fide regulator of the CT element by cotransfection of a CNBP expression vector that stimulated expression of a CT-driven but not an AP1-dependent reporter. These data suggest that hnRNP K and CNBP bind to opposite strands and co-regulate the CT element.	NCI,DEPT PATHOL,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X				COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COONEY M, 1989, SCIENCE, V241, P456; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	29	212	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9494	9499		10.1074/jbc.270.16.9494	http://dx.doi.org/10.1074/jbc.270.16.9494			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721877	hybrid			2022-12-27	WOS:A1995QU08900066
J	OLIVARES, L; ARAGON, C; GIMENEZ, C; ZAFRA, F				OLIVARES, L; ARAGON, C; GIMENEZ, C; ZAFRA, F			THE ROLE OF N-GLYCOSYLATION IN THE TARGETING AND ACTIVITY OF THE GLYT1 GLYCINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE DOPAMINE TRANSPORTER; NA+ GLUCOSE COTRANSPORTER; CENTRAL-NERVOUS-SYSTEM; BRUSH-BORDER MEMBRANE; HIGH AFFINITY UPTAKE; RAT-BRAIN; SPINAL-CORD; FUNCTIONAL-CHARACTERIZATION; LINKED OLIGOSACCHARIDES; SEROTONIN TRANSPORTER	To elucidate the role of N-glycosylation in the function of the high affinity glycine transporter GLYT1, we have investigated the effect of the glycosylation inhibitor tunicamycin as well as the effect of the disruption of the putative glycosylation sites by site-directed mutagenesis, SDS-polyacrylamide gel electrophoresis of proteins from GLYT1-transfected COS cells reveals a major band of 80-100 kDa and a minor one of 57 kDa, Treatment with tunicamycin produces a 40% inhibition in transport activity and a decrease in the intensity of the 80-100-kDa band, whereas the 57-kDa band decreases in size to yield a 47-kDa protein corresponding to the unglycosylated form of the transporter, Simultaneous mutation of Asn-169, Asn-172, Asn-182, and Asn-188 to Gln also produces the 47-kDa form of the protein, indicating that there are no additional sites for N-glycosylation, Progressive mutation of the potential glycosylation sites produces a progressive decrease in transport activity and in size of the protein, indicating that the four putative glycosylation sites are actually glycosylated. N-Glycosylation of the GLYT1 is not indispensable for the transport activity itself, as demonstrated by enzymatic deglycosylation of the transporter, Analysis of surface proteins by biotinylation and by immunofluorescence demonstrates that a significant portion of the unglycosylated GLYT1 mutant remains in the intracellular compartment, This suggests that the carbohydrate moiety of glycine transporter GLYT1 is necessary for the proper trafficking of the protein to the plasma membrane.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Aragon, Carmen/K-9783-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008	Aragon, Carmen/0000-0001-8287-9386; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109				ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BALCAR VJ, 1973, J NEUROCHEM, V20, P529, DOI 10.1111/j.1471-4159.1973.tb12152.x; BENNETT JP, 1973, J NEUROCHEM, V21, P1533, DOI 10.1111/j.1471-4159.1973.tb06037.x; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADO M, 1993, J BIOL CHEM, V268, P27313; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; FEDELE E, 1992, BRAIN RES, V572, P154, DOI 10.1016/0006-8993(92)90464-K; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAYES G, 1994, J BIOL CHEM, V269, P24143; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HENN FA, 1971, P NATL ACAD SCI USA, V68, P2686, DOI 10.1073/pnas.68.11.2686; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRAYAMA BA, 1992, BIOCHIM BIOPHYS ACTA, V1103, P37, DOI 10.1016/0005-2736(92)90054-P; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JOHNSTON GA, 1971, J NEUROCHEM, V18, P1951, DOI 10.1111/j.1471-4159.1971.tb09601.x; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KEINAN S, 1992, BIOCHEMISTRY-US, V31, P1974; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KIM KM, 1994, MOL PHARMACOL, V45, P608; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; LEW R, 1992, BRAIN RES, V584, P266, DOI 10.1016/0006-8993(92)90905-O; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LOGAN WJ, 1972, BRAIN RES, V42, P413, DOI 10.1016/0006-8993(72)90540-9; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; OTT RJ, 1992, J BIOL CHEM, V267, P133; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PATEL A, 1993, J NEUROCHEM, V61, P496; PETERSON GL, 1977, ANAL BIOCHEM, V83, P246; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1986, J BIOL CHEM, V261, P5437; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SERSHEN H, 1979, J NEUROCHEM, V32, P719, DOI 10.1111/j.1471-4159.1979.tb04554.x; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TATE CG, 1994, J BIOL CHEM, V269, P26303; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P8230; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683; ZAFRA F, 1986, BRAIN RES, V397, P108, DOI 10.1016/0006-8993(86)91374-0; ZAFRA F, 1995, IN PRESS J NEUROSCI	61	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9437	9442		10.1074/jbc.270.16.9437	http://dx.doi.org/10.1074/jbc.270.16.9437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721869	hybrid			2022-12-27	WOS:A1995QU08900058
J	REDDY, LG; JONES, LR; CALA, SE; OBRIAN, JJ; TATULIAN, SA; STOKES, DL				REDDY, LG; JONES, LR; CALA, SE; OBRIAN, JJ; TATULIAN, SA; STOKES, DL			FUNCTIONAL RECONSTITUTION OF RECOMBINANT PHOSPHOLAMBAN WITH RABBIT SKELETAL CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; 3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN KINASE; PUMP ATPASE; MONOCLONAL-ANTIBODY; CALCIUM-TRANSPORT; CA-2+ PUMP; PHOSPHORYLATION; CA2+; SLOW; PURIFICATION	Phospholamban (PLB) is a small, transmembrane protein that resides in the cardiac sarcoplasmic reticulum (SR) and regulates the activity of Ca2+-ATPase in response to P-adrenergic stimulation. We have used the baculovirus expression system in Sf21 cells to express milligram quantities of wild-type PLB. After purification by antibody affinity chromatography, the function of this recombinant PLB was tested by reconstitution with Ca2+-ATPase purified from skeletal SR. The results obtained with recombinant PLB were indistinguishable from those obtained with purified, canine cardiac PLB. In particular, PLB reduced the apparent calcium affinity of Ca2+-ATPase but had no effect on V-max. At pCa 6.8, PLB inhibited both calcium uptake and ATPase activity of Ca2+-ATPase by 50%. This inhibition was fully reversed by addition of a monoclonal antibody to PLB, which mimics the physiological effects of PLB phosphorylation. Maximal PLB regulatory effects occurred at a molar stoichiometry of similar to 3:1, PLB/Ca2+-ATPase. We also investigated peptides corresponding to the two main domains of PLB. The membrane-spanning domain, PLB(26-52), appeared to uncouple ATPase hydrolysis from calcium transport, even though the permeability of the reconstituted vesicles was not altered. The cytoplasmic peptide, PLB(1-31), had little effect, even at a 300:1 molar excess over Ca2+-ATPase.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT MED,INDIANAPOLIS,IN 46202; UNIV VIRGINIA,HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; DUPONT MERCK PHARMACEUT CO,WILMINGTON,DE 19806	Indiana University System; Indiana University-Purdue University Indianapolis; University of Virginia; DuPont					NHLBI NIH HHS [HL49428, HL06308, HL48807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, P01HL048807, R37HL049428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; CALA SE, 1993, BIOPHYS J, V64, pA375; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; JAKAB G, 1988, BIOCHEMISTRY-US, V27, P3799, DOI 10.1021/bi00410a042; JONES LR, 1993, J BIOL CHEM, V268, P11486; JONES LR, 1985, J BIOL CHEM, V260, P7721; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIMURA Y, 1991, J MOL CELL CARDIOL, V23, P1223, DOI 10.1016/0022-2828(91)90080-6; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; KRANIAS EG, 1985, J BIOL CHEM, V260, P1006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVIN D, 1990, J VIROL, V64, P37; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; LEVY D, 1990, BIOCHEMISTRY-US, V29, P9480, DOI 10.1021/bi00492a022; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; MANNS A, 1991, BIOTECHNIQUES, V10, P154; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; SZYMANSKA G, 1990, MEMBRANE BIOCHEM, V9, P1; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1974, J BIOL CHEM, V249, P6174; TATULIAN SA, 1995, IN PRESS BIOCHEMISTR; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VORHERR T, 1993, PROTEIN SCI, V2, P339; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VOSS J, 1994, BIOPHYS J, V67, P1900; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	48	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9390	9397		10.1074/jbc.270.16.9390	http://dx.doi.org/10.1074/jbc.270.16.9390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721863	hybrid			2022-12-27	WOS:A1995QU08900052
J	CHOUDHARY, SK; WYKES, SM; KRAMER, JA; MOHAMED, AN; KOPPITCH, F; NELSON, JE; KRAWETZ, SA				CHOUDHARY, SK; WYKES, SM; KRAMER, JA; MOHAMED, AN; KOPPITCH, F; NELSON, JE; KRAWETZ, SA			A HAPLOID EXPRESSED GENE-CLUSTER EXISTS AS A SINGLE CHROMATIN DOMAIN IN HUMAN SPERM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; BASIC NUCLEAR-PROTEIN; I-SENSITIVE DOMAIN; TRANSGENIC MICE; SEQUENCE; LOCUS; TRANSCRIPTION; PROTAMINE-1; EVOLUTION; REGION	Mammalian spermiogenesis is marked by the initial disruption of the nuclear-histone-DNA complex by the transition proteins for ultimate replacement with protamines. The genes for three of these low molecular weight basic nuclear proteins exist as a single linear array of PRM1, PRM2, and TNP2 on human chromosome 16p13.2. To begin to address the mechanism governing their transcriptional potentiation, a region of similar to 40 kilobases of the human genome encompassing these genes was introduced into the germ line of mice. Fluorescence in situ hybridization and Southern analysis showed that this segment of the human genome integrated into independent chromosomal sites while maintaining its fidelity. Transcript analysis demonstrated that the expression of the endogenous mouse protamine Prm1 and Prm2 genes as well as the mouse transition protein Tnp2 gene were expressed along with their human transgene counterparts. The pattern of expression of these transgenic human genes within this multigenic cluster faithfully represented that observed in vivo. In addition, all members of this transgenic gene cluster were expressed in proportions similar to those in human testis. Copy number-dependent and position-independent expression of the transgenic construct demonstrated that the corresponding biological locus was contained within this segment of the human genome. Furthermore, DNase I sensitivity established that in sperm the human PRM1-->PRM2-->TNP2 genic domain was contained as an similar to 28.5-kilobase contiguous segment bounded by an array of nuclear matrix associated topoisomerase II consensus sites. This is the first description of a multigenic male gamete-specific domain as a fundamental gene regulatory unit. A model of haploid-specific gene determination is presented.	WAYNE STATE UNIV, SCH MED, DEPT OBSTET & GYNECOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, CTR MOLEC MED & GENET, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, CTR HUMAN GROWTH & DEV, DETROIT, MI 48201 USA; HARPER GRACE HOSP, DEPT PATHOL, DETROIT, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University			krawetz, stephen/GQQ-3308-2022		NICHD NIH HHS [1RO1HD285040A1, N01-HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028504, N01HD002911] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARONE JG, 1994, J ANDROL, V15, P139; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BEISEL J, 1991, ACT CYTOGENETICS LAB, P183; BOULIKAS T, 1993, J CELL BIOCHEM, V53, P1, DOI 10.1002/jcb.240530102; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIXON GH, 1986, CHROMOSOMAL PROTEINS, P287; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P113; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GOUDINE M, 1983, P NATL ACAD SCI USA, V80, P7551; GRIMES SR, 1975, BIOCHEM BIOPH RES CO, V67, P182, DOI 10.1016/0006-291X(75)90300-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGANB, 1986, MANIPULATING MOUSE E, P174; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618; KRAWETZ SA, 1988, J MOL EVOL, V27, P291, DOI 10.1007/BF02101190; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LIN CC, 1975, CAN J GENET CYTOL, V17, P81, DOI 10.1139/g75-009; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; Meistrich M., 1989, HISTONES OTHER BASIC, P165; NELSON JE, 1993, J BIOL CHEM, V268, P2932; NELSON JE, 1994, J BIOL CHEM, V269, P31067; NELSON JE, 1995, DNA SEQUENCE, V5, P163, DOI 10.3109/10425179509029356; OLIVA R, 1990, J MOL EVOL, V30, P333, DOI 10.1007/BF02101888; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; PESCHON JJ, 1989, ANN NY ACAD SCI, V564, P186, DOI 10.1111/j.1749-6632.1989.tb25897.x; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; QUERALT R, 1993, GENE, V133, P197, DOI 10.1016/0378-1119(93)90638-J; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; SCHULTER G, 1989, BIOCHEM BIOPH RES CO, V197, P110; SELLOS D, 1990, EUR J BIOCHEM, V190, P21, DOI 10.1111/j.1432-1033.1990.tb15540.x; SIPPEL AE, 1993, COLD SPRING HARB SYM, V58, P37, DOI 10.1101/SQB.1993.058.01.007; SMITH RD, 1984, BIOCHEMISTRY-US, V23, P2970, DOI 10.1021/bi00308a019; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; SVINARICH DM, 1992, J BIOL CHEM, V267, P14382; TOMILIN NV, 1990, FEBS LETT, V263, P69, DOI 10.1016/0014-5793(90)80707-P; UNNI E, 1992, J BIOL CHEM, V267, P25359; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	51	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8755	8762		10.1074/jbc.270.15.8755	http://dx.doi.org/10.1074/jbc.270.15.8755			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721781	hybrid			2022-12-27	WOS:A1995QT44800059
J	MEZGUELDI, M; MENDRE, C; CALAS, B; KASSAB, R; FATTOUM, A				MEZGUELDI, M; MENDRE, C; CALAS, B; KASSAB, R; FATTOUM, A			CHARACTERIZATION OF THE REGULATORY DOMAIN OF GIZZARD CALPONIN - INTERACTIONS OF THE 145-163-REGION WITH F-ACTIN, CALCIUM-BINDING PROTEINS, AND TROPOMYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; CALMODULIN-BINDING; FUNCTIONAL DOMAINS; TROPONIN-T; KINASE-C; CALDESMON; INHIBITION; PURIFICATION; PHOSPHATASE; SEQUENCE	Earlier, we proposed that the interaction of gizzard calponin with F-actin, promoting the inhibition of the actomyosin ATPase activity, involves the NH2-terminal portion of the calponin segment Ala(145)-Tyr(182) (Mezgueldi, M., Fattoum, A., Derancourt, J., and Kassab, R. (1992) J. Biol. Chem. 267, 15943-15951), In this work, we have directly probed this region for actin binding sites using five peptide analogs covering different stretches of the sequence Thr(133)-Ile(163). Co-sedimentation with F-actin, actomyosin ATPase measurements, and zero-length cross-linking reactions demonstrated that the 19-residue sequence Ala(145)-Ile(163) is essential for actin interaction and ATPase inhibition, Furthermore, each peptide was tested for binding to the Ca2+-dependent proteins, caltropin and calmodulin, in both an actomyosin ATPase assay and an affinity chromatographic assay, The results revealed the Ii-residue segment Gln(153)-Ile(163), representing the COOH-terminal moiety of the F-actin binding sequence, as a crucial region for the high affinity binding of these regulatory proteins with concomitant removal of the ATPase inhibition, The 153-163 stretch contained also interactive sites for tropomyosin as assessed by affinity chromatography and spectrofluorometry. Collectively, the data support our initial results and highlight the ability of the multifunctional 145-163 region to serve as a potent regulatory domain of the smooth muscle calponin.	UNIV MONTPELLIER 1,CNRS,CTR RECH BIOCHIM MACROMOLEC,INSERM,U249,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; CHILDS TJ, 1992, BIOCHIM BIOPHYS ACTA, V1121, P41, DOI 10.1016/0167-4838(92)90334-A; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; FUJII T, 1994, J BIOCHEM-TOKYO, V116, P121, DOI 10.1093/oxfordjournals.jbchem.a124484; FUJII T, 1991, CHEM PHARM BULL, V39, P2622; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; ICHIKAWA K, 1993, BIOCHEM BIOPH RES CO, V193, P827, DOI 10.1006/bbrc.1993.1700; ITOH T, 1994, EUR J PHYSL, V427, P301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1984, BIOCHEMISTRY-US, V23, P1591, DOI 10.1021/bi00303a001; Li Bing, 1994, Molecular Biology of the Cell, V5, p399A; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; NAGUMO H, 1994, BIOCHEM BIOPH RES CO, V203, P1502, DOI 10.1006/bbrc.1994.2355; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NAKAMURA F, 1993, J BIOL CHEM, V268, P6194; NORTH AJ, 1994, J CELL SCI, V107, P437; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; Roberts G. D., 1994, Molecular Biology of the Cell, V5, p400A; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; TAKAHASHI K, 1990, J MUSCLE RES CELL M, V11, P435; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAKAHASHI K, 1991, J BIOL CHEM, V226, P13284; VALEMBOIS C, 1992, TETRAHEDRON LETT, V33, P4005, DOI 10.1016/0040-4039(92)88085-J; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WILLS FL, 1994, BIOCHEMISTRY-US, V33, P5562, DOI 10.1021/bi00184a027; WILLS FL, 1994, BIOPHYS J, V66, pA198; WINDER SJ, 1993, BIOCHEM J, V296, P827, DOI 10.1042/bj2960827; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1992, BIOCHEM J, V286, P197, DOI 10.1042/bj2860197; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046; WINDER SJ, 1992, BIOCHEM J, V288, P733, DOI 10.1042/bj2880733	41	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8867	8876		10.1074/jbc.270.15.8867	http://dx.doi.org/10.1074/jbc.270.15.8867			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721794	hybrid			2022-12-27	WOS:A1995QT44800073
J	YANG, XD; FYODOROV, D; DENERIS, ES				YANG, XD; FYODOROV, D; DENERIS, ES			TRANSCRIPTIONAL ANALYSIS OF ACETYLCHOLINE-RECEPTOR ALPHA-3 GENE PROMOTER MOTIFS THAT BIND SP1 AND AP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SODIUM-CHANNEL GENE; FUNCTIONAL DIVERSITY; REGULATORY ELEMENTS; SILENCER ELEMENT; SCG10 GENE; RAT; EXPRESSION; SUBUNIT; FAMILY	In this study, we performed an analysis of the neuronal nicotinic acetylcholine receptor alpha 3 subunit gene promoter region, -238/+47, to identify cis and trans elements that are important for basal activity in PC12 cells. Sequence analyses of the alpha 3 promoter and foot-print assays revealed an Sp1 binding site between -79 and -57 (termed the alpha 3 GA motif) and an AP2 binding site between -30 and -7. Using mobility shift analysis, we found that PC12 cell extracts contain proteins that specifically bind to the alpha 3 GA motif and are immunologically related to Sp1. Mutation of the alpha 3 GA motif, which prevented binding of Sp1, resulted in a 75% decrease in promoter activity. Mutation of the AP2 site resulted in only a minor loss of promoter activity, which is consistent with the lack of AP2 binding activity in PC12 extracts. In Drosophila Schneider line 2 (S2) cell cotransfection assays, Sp1 activated the alpha 3 promoter in a GA motif dependent manner. Furthermore, multimerization of the GA motif upstream of the beta-globin TATA box conferred Sp1 responsiveness. Our results indicate that Sp1 can activate transcription through direct interaction with the alpha 3 GA motif and that this motif plays a major role in alpha 3 promoter basal activity in PC12 cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029123] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS29123] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOULTER J, 1990, J BIOL CHEM, V265, P4472; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENSON JW, 1994, J BIOL CHEM, V269, P1046; HU MJ, 1994, J NEUROCHEM, V62, P392; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON MR, 1992, J BIOL CHEM, V267, P12202; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KIRKNESS EF, 1993, J BIOL CHEM, V268, P4420; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; RAIMONDI E, 1992, GENOMICS, V12, P849, DOI 10.1016/0888-7543(92)90324-L; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROGERS SW, 1992, J NEUROSCI, V12, P4611; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; YANG XD, 1994, J BIOL CHEM, V269, P10252; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	46	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8514	8520		10.1074/jbc.270.15.8514	http://dx.doi.org/10.1074/jbc.270.15.8514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721749	hybrid			2022-12-27	WOS:A1995QT44800025
J	BRAND, T; SCHNEIDER, MD				BRAND, T; SCHNEIDER, MD			INACTIVE TYPE-II AND TYPE-I RECEPTORS FOR TGF-BETA ARE DOMINANT INHIBITORS OF TGF-BETA-DEPENDENT TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SERINE THREONINE KINASE; SIGNAL TRANSDUCTION; ACTIVIN RECEPTOR; XENOPUS EMBRYOS; TRANSFORMING GROWTH-FACTOR-BETA-1; CARDIAC MYOCYTES; TRANSGENIC MICE; EXPRESSION; GENE	Although transforming growth factor-beta (TGF beta) is implicated in differentiation and disease, proof of in vivo function requires specific inhibitors of the TGF beta cascade. TGF beta binds a family of type I and type II receptors (T beta RI, T beta RII), containing a cytoplasmic serine/threonine kinase domain. We previously reported that kinase-deficient T beta RII (Delta kT beta RII) blocks TGF-beta-dependent transcription in cardiac myocytes. It is controversial whether both receptors are needed in all cells for gene regulation by TGF beta or whether they mediate distinct subsets of TGF-beta-dependent events. To resolve this uncertainty, TGF-beta-dependent transcription was investigated in cardiac myocytes versus mink lung epithelial cells. 1) Delta kT beta RII inhibits induction of a TGF beta-responsive reporter gene, in both cell backgrounds. 2) Charged-to-alanine mutations of key residues of the T beta RII kinase, including consensus ATP binding and amino acid recognition motifs, are competent for binding but not transcriptional activation. Each inactive receptor inhibits TGF beta-dependent transcription in both cell types. 3) Kinase-deficient T beta RI (Delta kT beta RI) likewise impairs TGF beta-dependent transcription, less completely than Delta kT beta RII; kinase-deficient activin type I receptor has no effect. 4) TGF-beta-binding proteins in cardiac cells and Mv1Lu cells are comparable by affinity labeling and immunoprecipitation; however, Mv1Lu cells express up to 3-fold higher levels of T beta RII and T beta RI. Thus, the model inferred from TGF beta-resistant cell lines (that T beta RII and T beta RI are necessary in tandem for the TGF beta-signaling complex to regulate transcription) is valid for cardiac myocytes, the cell type most prominently affected in TGF beta-deficient animals.	BAYLOR COLL MED, DEPT MED, MOLEC CARDIOL UNIT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PHYSIOL & MOLEC BIOPHYS, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Brand, Thomas/AAR-7545-2020	Brand, Thomas/0000-0001-7090-5356	NHLBI NIH HHS [P01 HL49953, R01 HL47567, T32 HL07706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953, R01HL047567, T32HL007706] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BARNETT JV, 1994, DEV DYNAM, V199, P12, DOI 10.1002/aja.1001990103; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAWLER S, 1994, DEVELOPMENT, V120, P165; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATZUAKI K, 1993, J BIOL CHEM, V268, P12719; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NISHIMATSU S, 1992, FEBS LETT, V312, P169, DOI 10.1016/0014-5793(92)80928-A; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; ROLBAND GC, 1993, BIOCHEMISTRY-US, V32, P13545, DOI 10.1021/bi00212a021; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SLAGER HG, 1993, DEV GENET, V14, P212, DOI 10.1002/dvg.1020140308; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU JM, 1994, P NATL ACAD SCI USA, V91, P7957, DOI 10.1073/pnas.91.17.7957	69	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8274	8284		10.1074/jbc.270.14.8274	http://dx.doi.org/10.1074/jbc.270.14.8274			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713935	hybrid			2022-12-27	WOS:A1995QR52600074
J	BLANCHOIN, L; FIEVEZ, S; TRAVERS, F; CARLIER, MF; PANTALONI, D				BLANCHOIN, L; FIEVEZ, S; TRAVERS, F; CARLIER, MF; PANTALONI, D			KINETICS OF THE INTERACTION OF MYOSIN SUBFRAGMENT-L WITH G-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; F-ACTIN; DEOXYRIBONUCLEASE-I; DNASE-I; TROPONIN-TROPOMYOSIN; ACTOMYOSIN ATPASE; BINDING-SITES; COMPLEX; POLYMERIZATION; CONTRACTION	The kinetics of interaction of monomeric pyrenyl-labeled G-actin with myosin subfragment-1 (S-1 (A(1)) and S-1(A(2)) isomers) has been examined in the stopped-flow at low ionic strength, The data confirm the previously reported existence of binary GS and ternary G(2)S complexes, The increase in pyrenyl-actin fluorescence which monitors the G-actin-S1 interactions is linked to the isomerization of these complexes following rapid equilibrium binding steps, The rates of isomerization are similar to 200 s(-1) for GS and similar to 50 s(-1) for G(2)S at 4 degrees C and in the absence of ATP, DNaseI and S-1 bind G-actin essentially in a mutually exclusive fashion, Both GS and G(2)S are dissociated by MgATP and MgADP, The kinetics and mechanism of ATP-induced dissociation of G(2)S are quantitatively close to the ATP-induced dissociation of F-actin-S-1, which indicates the G(2)S is a good model for the F-actin-S-1 interface, GS and G(2)S display different kinetic behaviors in response to nucleotides, GS being less efficiently dissociated than G(2)S by MgATP, This result suggests that different mechanical properties of the crossbridge might correlate with different orientations of the myosin head and different actin/myosin binding ratios.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ANDREEV OA, 1993, BIOCHEMISTRY-US, V32, P12046, DOI 10.1021/bi00096a015; ARATA T, 1991, J BIOCHEM-TOKYO, V109, P335; BARDEN JA, 1990, BIOCHEMISTRY-US, V29, P1348, DOI 10.1021/bi00457a034; BETTACHE N, 1990, BIOCHEMISTRY-US, V29, P9085, DOI 10.1021/bi00490a028; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; CHEN T, 1992, BIOCHEMISTRY-US, V31, P2941, DOI 10.1021/bi00126a014; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; COMBEAU C, 1992, BIOCHEMISTRY-US, V31, P300, DOI 10.1021/bi00116a041; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FIEVEZ S, 1993, FEBS LETT, V316, P186, DOI 10.1016/0014-5793(93)81212-I; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HOWARD J, 1994, NATURE, V368, P98, DOI 10.1038/368098a0; JIANG MY, 1994, BIOESSAYS, V16, P531, DOI 10.1002/bies.950160803; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LABBE JP, 1990, BIOCHEM J, V271, P407, DOI 10.1042/bj2710407; LHEUREUX K, 1993, BIOCHEMISTRY-US, V32, P10005, DOI 10.1021/bi00089a016; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; MANNHERZ HG, 1975, FEBS LETT, V60, P34, DOI 10.1016/0014-5793(75)80412-1; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MEJEAN C, 1987, BIOCHEM J, V244, P571, DOI 10.1042/bj2440571; MIKI M, 1987, EUR J BIOCHEM, V165, P125, DOI 10.1111/j.1432-1033.1987.tb11202.x; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN S, 1980, BIOCHEMISTRY-US, V19, P5358; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; PINDER JC, 1982, BIOCHEMISTRY-US, V21, P4886, DOI 10.1021/bi00263a009; PRICE PA, 1969, J BIOL CHEM, V244, P917; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TESI C, 1990, BIOCHEMISTRY-US, V29, P1846, DOI 10.1021/bi00459a026; VALENTINRANC C, 1992, J BIOL CHEM, V267, P21543; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	48	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7125	7133		10.1074/jbc.270.13.7125	http://dx.doi.org/10.1074/jbc.270.13.7125			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706249	hybrid			2022-12-27	WOS:A1995QQ43100020
J	FIERER, DS; CHALLBERG, MD				FIERER, DS; CHALLBERG, MD			THE STOICHIOMETRY OF BINDING OF THE HERPES-SIMPLEX VIRUS TYPE-1 ORIGIN-BINDING PROTEIN, UL9, TO ORI(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA REPLICATION; ESCHERICHIA-COLI; GEL RETARDATION; LAC PROMOTER; DOMAIN; ORIS; SEQUENCE; HELICASE; GENE; PURIFICATION	A number of studies have demonstrated that the herpes simplex virus type 1 (HSV-1) UL9 protein, which is a homodimer in solution, binds to two high affinity binding sites in each origin of replication. Interaction between the proteins bound at the two sites leads to the formation of a complex nucleoprotein structure. The simplest models for this binding interaction predict two possible binding stoichiometries: 1) one UL9 dimer is bound at each site; or 2) one UL9 monomer is bound at each site so that one UL9 dimer occupies both sites, Two recent papers have addressed this issue by using indirect methods to measure the binding stoichiometry, Martin et al. (Martin, D. W., Munoz, R. M., Oliver, D., Subler, M. A., and Deb, S. (1994) Virology 198, 71-80) reported that a monomer of UL9 binds to a single high affinity site, and Stabell and Olive (Stabell, E. C., and Olive, P. D. (1993) Nucleic Acids Res. 21, 5203-5211) concluded that a dimer of UL9 binds to a single high affinity site. We have directly measured the stoichiometry of binding of the carboxyl terminal DNA binding domain of UL9 (t-UL9) to the origin of replication using a double-label gel shift assay. Using a short synthetic double-stranded oligonucleotide containing a single UL9 binding site, one protein-DNA complex was detected in the gel shift assay, and the molar ratio of UL9 DNA binding domains to DNA binding sites in this complex was determined to be 2.0 +/- 0.1 (n = 13). Using the minimal origin sequence excised from plasmid DNA, two protein-DNA complexes were detected, The binding stoichiometry of the faster migrating complex was 1.8 +/- 0.1 (n = 15), and the stoichiometry of the more slowly migrating band was 3.7 +/- 0.4 (n = 15), The simplest explanation for these data is that UL9 binds to the origin of replication as a homodimer with one dimer bound at both high affinity sites.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Fierer, Daniel/0000-0002-3427-8022				ALLEN FS, 1972, BIOPOLYMERS, V11, P853, DOI 10.1002/bip.1972.360110410; ARBUCKLE MI, 1993, J GEN VIROL, V74, P1349, DOI 10.1099/0022-1317-74-7-1349; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DABROWSKI CE, 1994, MOL CELL BIOL, V14, P2545, DOI 10.1128/MCB.14.4.2545; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENSTEIN D, 1990, J MOL BIOL, V211, P91, DOI 10.1016/0022-2836(90)90013-C; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HERNANDEZ TR, 1991, J VIROL, V65, P1649, DOI 10.1128/JVI.65.3.1649-1652.1991; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; KORNBERG A, 1992, DNA REPLICATION, P615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MALIK AK, 1992, VIROLOGY, V190, P702, DOI 10.1016/0042-6822(92)90908-8; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MARTINEZ R, 1993, PROTEIN EXPRES PURIF, V4, P32, DOI 10.1006/prep.1993.1005; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P46; PERRY HC, 1993, VIROLOGY, V193, P73, DOI 10.1006/viro.1993.1104; SCHNEIDER GJ, 1990, J BIOL CHEM, V265, P10198; STABELL EC, 1993, NUCLEIC ACIDS RES, V21, P5203, DOI 10.1093/nar/21.22.5203; TIAN GL, 1992, J MOL BIOL, V226, P387, DOI 10.1016/0022-2836(92)90954-I; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379	40	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7330	7334		10.1074/jbc.270.13.7330	http://dx.doi.org/10.1074/jbc.270.13.7330			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706274	hybrid			2022-12-27	WOS:A1995QQ43100047
J	HAN, JH; LEE, JD; TOBIAS, PS; ULEVITCH, RJ				HAN, JH; LEE, JD; TOBIAS, PS; ULEVITCH, RJ			ENDOTOXIN INDUCES RAPID PROTEIN-TYROSINE PHOSPHORYLATION IN 70Z/3 CELLS EXPRESSING CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; SIGNAL TRANSDUCTION; LIPOPOLYSACCHARIDE LPS; MACROPHAGES; RECEPTOR; ACTIVATION; COMPLEXES; ELEMENT; SERUM	CD14, a glycosylphosphatidylinositol-anchored glycoprotein of leukocytes, binds endotoxin (lipopolysaccharide (LPS)) with high affinity. After the murine pre-B cell line 70Z/3 is transfected with DNA encoding human CD14 (hCD14), the resultant stably transfected cell line, 70Z/3-hCD14, responds to 1000-fold lower LPS concentrations than the parental CD14-negative line. We have used 70Z/3-hCD14 cells, RAW264.7 cells, and elicited murine peritoneal exudate macrophages (PEM) to study LPS-induced protein tyrosine phosphorylation. LPS induces the rapid tyrosine phosphorylation of a 38-kDa protein (p38) in 70Z/3-hCD14 cells, PEM, and RAW264.7 cells and of two isoforms of mitogen-activated protein kinases (MAPK) in only RAW264.7 cells and PEM. p38 can be distinguished from the MAPK isoforms based on differences in mobilities on SDS-polyacrylamide gel electrophoresis and the lack of reactivity of p38 with anti-MAPK antibody even after dephosphorylation with potato acid phosphatase. Synthetic lipid A induces p38 phosphorylation in 70Z/3-hCD14 cells, whereas phorbol 12-myristate 13-acetate and interferon-gamma fail to induce tyrosine phosphorylation of p38. Pretreatment of 70Z/3-hCD14 cells with anti-hCD14 monoclonal antibody or the tyrosine kinase inhibitor herbimycin A inhibits LPS-induced tyrosine phosphorylation of p38. These results suggest that increased protein tyrosine phosphorylation occurs rapidly after LPS binds to CD14 and is likely to be an important event in mediating LPS-induced cell activation.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute			Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, R37GM028485, P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM28485, GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; EMERY DW, 1989, MOL CELL BIOL, V9, P5231, DOI 10.1128/MCB.9.11.5231; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MARTIN TR, 1992, J CLIN INVEST, V90, P2209, DOI 10.1172/JCI116106; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; MOLLITOR JAS, 1990, P NATL ACAD SCI USA, V87, P10028; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; ROBIAS PS, 1993, J IMMUNOL, V150, P3011; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIRCA GD, 1989, J BIOL CHEM, V264, P21951; VOGEL SN, 1990, IMMUNOPHYSIOLOGY ROL, P238; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	29	288	311	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25009	25014						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693711				2022-12-27	WOS:A1993MG67300073
J	DURAN, E; KOMUNIECKI, RW; KOMUNIECKI, PR; WHEELOCK, MJ; KLINGBEIL, MM; MA, YC; JOHNSON, KR				DURAN, E; KOMUNIECKI, RW; KOMUNIECKI, PR; WHEELOCK, MJ; KLINGBEIL, MM; MA, YC; JOHNSON, KR			CHARACTERIZATION OF CDNA CLONES FOR THE 2-METHYL BRANCHED-CHAIN ENOYL-COA REDUCTASE - AN ENZYME INVOLVED IN BRANCHED-CHAIN FATTY-ACID SYNTHESIS IN ANAEROBIC MITOCHONDRIA OF THE PARASITIC NEMATODE ASCARIS-SUUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; COENZYME-A DEHYDROGENASE; ELECTRON-TRANSFER FLAVOPROTEIN; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ISOVALERYL-COENZYME; MESSENGER-RNA; UBIQUINONE OXIDOREDUCTASE; PYRUVATE-DEHYDROGENASE; RESPIRATORY-CHAIN	The 2-methyl branched-chain enoyl-CoA reductase plays a pivotal role in the reversal of beta-oxidation operating in anaerobic mitochondria of the parasitic nematode Ascaris suum. An affinity-purified polyclonal anti-serum against the reductase was used to screen a cDNA library constructed in lambdagt11 with poly(A)+ RNA from adult A. suum muscle. A 1.2-kilobase partial cDNA clone was isolated, subcloned, and sequenced in both directions. Additional sequence at the 5' end of the mRNA was determined by the RACE (rapid amplification of cDNA ends) procedure. Nucleotide sequence analysis of the cDNAs revealed the 22-nucleotide trans-spliced leader sequence characteristic of many nematode mRNAs, an open reading frame of 1236 nucleotides and a 3'-untranslated sequence of 109 nucleotides including a short poly(A) tail 14 nucleotides from a polyadenylation signal (AATAAA). The open reading frame encoded a 396-amino acid sequence (M(r) 43,046) including a 16-amino acid leader peptide. Two-dimensional gel electrophoresis of the purified reductase yielded multiple spots with two distinct but overlapping amino-terminal amino acid sequences. Both sequences overlapped with the sequence predicted from the mRNA, and one of the sequences was identical to the predicted sequence. Comparison of the ascarid sequence with that of mammalian acyl-CoA dehydrogenases revealed a high degree of sequence identity, suggesting that these enzymes may have evolved from a common ancestral gene even though the ascarid enzyme functions as a reductase, not as a dehydrogenase. Immunoblotting of A. suum larval stages and adult tissues with antisera that cross-reacted with each of the spots separated on two-dimensional gels suggested that the reductase was only found in adult muscle. Northern blotting using the partial cDNA revealed a hybridization band of about 1.5 kilobases and also suggested that the enzyme was tissue-specific and developmentally regulated in agreement with the results of the immunoblotting.	UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606	University System of Ohio; University of Toledo				Klingbeil, Michele/0000-0002-7236-8424	NIAID NIH HHS [AI-18427] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018427] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BARRETT J, 1973, COMP BIOCHEM PHYSIOL, V44, P331, DOI 10.1016/0300-9629(73)90486-6; Barrett J., 1976, P117; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3913, DOI 10.1021/bi00336a016; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUVRES FW, 1969, J PARASITOL, V55, P689, DOI 10.2307/3277198; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fourney R.M., 1988, FOCUS, V10, P5; FRERMAN FE, 1987, BIOCHIM BIOPHYS ACTA, V893, P161, DOI 10.1016/0005-2728(87)90035-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1983, J BIOL CHEM, V258, P9477; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; INDO Y, 1991, GENOMICS, V11, P609, DOI 10.1016/0888-7543(91)90068-P; JOHNSON KR, 1990, ANAL BIOCHEM, V190, P170, DOI 10.1016/0003-2697(90)90176-A; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; KITA K, 1992, PARASITOL TODAY, V8, P155, DOI 10.1016/0169-4758(92)90009-Q; KOHLER P, 1985, MOL BIOCHEM PARASIT, V17, P1, DOI 10.1016/0166-6851(85)90124-0; KOMUNIECKI PR, 1987, MOL BIOCHEM PARASIT, V22, P241, DOI 10.1016/0166-6851(87)90055-7; KOMUNIECKI R, 1985, J BIOL CHEM, V260, P4770; KOMUNIECKI R, 1981, J PARASITOL, V67, P841, DOI 10.2307/3280708; KOMUNIECKI R, 1989, BIOCHIM BIOPHYS ACTA, V975, P127, DOI 10.1016/S0005-2728(89)80210-5; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Maniatis T., 1982, MOL CLONING; MATSUBARA Y, 1990, J CLIN INVEST, V85, P1058, DOI 10.1172/JCI114536; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; NAITO E, 1989, J CLIN INVEST, V83, P1605, DOI 10.1172/JCI114058; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; OKAMURAIKEDA K, 1985, J BIOL CHEM, V260, P1338; OYA H, 1963, J CELL COMPAR PHYSL, V62, P287, DOI 10.1002/jcp.1030620308; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; RUFF V, 1988, MOL BIOCHEM PARASIT, V29, P1, DOI 10.1016/0166-6851(88)90113-2; RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAZ HJ, 1962, J BIOL CHEM, V237, P2053; SAZ HJ, 1960, J BIOL CHEM, V235, P914; SAZ HJ, 1981, ANNU REV PHYSIOL, V43, P323, DOI 10.1146/annurev.ph.43.030181.001543; SOUTHERN EM, 1975, J MOL BIOL, V98, P506; VANOVERDETTLING L, 1989, MOL BIOCHEM PARASIT, V36, P29, DOI 10.1016/0166-6851(89)90197-7; WARD CW, 1970, DEV BIOL, V22, P366, DOI 10.1016/0012-1606(70)90159-4; WHEELOCK MJ, 1991, MOL BIOCHEM PARASIT, V45, P9, DOI 10.1016/0166-6851(91)90022-X; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZIAI MR, 1988, ANAL BIOCHEM, V171, P192, DOI 10.1016/0003-2697(88)90141-8	59	9	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22391	22396						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693666				2022-12-27	WOS:A1993MD34800033
J	WADHWA, R; KAUL, SC; SUGIMOTO, Y; MITSUI, Y				WADHWA, R; KAUL, SC; SUGIMOTO, Y; MITSUI, Y			INDUCTION OF CELLULAR SENESCENCE BY TRANSFECTION OF CYTOSOLIC MORTALIN CDNA IN NIH-3T3-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR SUPPRESSOR GENES; INDEFINITE DIVISION; MOUSE FIBROBLASTS; GROWTH ARREST; HUMAN-CELLS; PROTEIN; ACTIN; IMMORTALITY; MECHANISMS; CANCER	We have recently identified a novel member of hsp70 family (mortalin) as a mortality marker (Wadhwa, R., Kaul, S. C., Ikawa, Y., and Sugimoto, Y. (1993) J. Biol. Chem. 268, 6615-6621). It has distinct intracellular distribution in mortal and immortal fibroblasts. Here, we report that the cytosolic (mot-1) and the perinuclear (mot-2) forms of mortalin cDNA cloned from mortal and immortal cells, respectively, differ by only two bases in the open reading frame, resulting in two amino acid changes. The induced expression of the cytosolic form by transfection of mot-1 cDNA (isolate from CD1-ICR mouse embryonic fibroblasts) to NIH 3T3 cells induced cellular senescence. However, the perinuclear form expressed by mot-2 cDNA (isolate from NIH 3T3 cells) did not yield an equivalent effect. The data suggest the senescence-inductive function of cytosolic mortalin and implicitly point to a genetic event involved in immortalization.	SHIRAKAWA INST ANIM GENET,JAPAN LIVESTOCK TECHNOL ASSOC,NISHI SHIRAKAWA,FUKUSHIMA 961,JAPAN		WADHWA, R (corresponding author), NATL INST BIOSCI & HUMAN TECHNOL,AGCY IND SCI & TECHNOL,TSUKUBA,IBARAKI 305,JAPAN.		Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYFLICK L, 1991, MUTAT RES, V256, P69, DOI 10.1016/0921-8734(91)90002-S; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAUL SC, 1993, BIOCHEM BIOPH RES CO, V193, P348, DOI 10.1006/bbrc.1993.1630; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NING Y, 1991, MUTAT RES, V256, P303, DOI 10.1016/0921-8734(91)90021-3; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; PECHAN PM, 1991, FEBS LETT, V280, P1, DOI 10.1016/0014-5793(91)80190-E; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TROFATTE RJA, 1993, CELL, V72, P791; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; WADHWA R, 1991, BIOCHEM BIOPH RES CO, V178, P269, DOI 10.1016/0006-291X(91)91809-Q; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	30	88	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22239	22242						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693662				2022-12-27	WOS:A1993MD34800007
J	NOWLIN, DM; GORCSAN, F; MOSCINSKI, M; CHIANG, SL; LOBL, TJ; CARDARELLI, PM				NOWLIN, DM; GORCSAN, F; MOSCINSKI, M; CHIANG, SL; LOBL, TJ; CARDARELLI, PM			A NOVEL CYCLIC PENTAPEPTIDE INHIBITS ALPHA-4-BETA-1 AND ALPHA-5-BETA-1 INTEGRIN-MEDIATED CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BETA-SUBUNIT; FIBRONECTIN RECEPTOR; LYMPHOCYTE ADHESION; EXTRACELLULAR-MATRIX; BINDING-SPECIFICITY; ATTACHMENT ACTIVITY; EPITHELIAL-CELLS; VLA-4 INTEGRIN; RGD PEPTIDE	Lymphocytes and monocytes initiate and modulate inflammatory and immune responses for host defense. This process is dependent upon extravasation of leukocytes from the circulation to sites of antigenic challenge and is controlled, in part, by various integrins, including alpha4beta1 and alpha5beta1. A small cyclic pentapeptide that inhibits, in vitro, both alpha4beta1 and alpha5beta1 activity is described. This peptide, Arg-Cys-Asp-Thioproline-Cys (RC*D[ThioP]C*), is cyclized by a disulfide bond through the cysteine residues (the asterisks denote cyclizing residues). RC*D(ThioP)C* inhibits alpha5beta1-mediated leukocyte adhesion to the 120-kDa Arg-Gly-Asp (RGD)-containing binding site of fibronectin. Two different adhesion activities of alpha4beta1 are also inhibited: alpha4beta1-mediated cell adhesion to the alternatively spliced CS-1 site of fibronectin and the alpha4beta1-dependent binding of leukocytes to cytokine-activated endothelial cells. Both alpha4beta1 and alpha5beta1 can be purified by affinity chromatography using the immobilized pentapeptide. The peptide does not inhibit adhesion to other extracellular matrix proteins including laminin and vitronectin. The specificity of the RC*D(ThioP)C* peptide for alpha4beta1 and alpha5beta1 suggests potential therapeutic utility for inhibiting inflammatory disease.	TANABE RES LABS,SAN DIEGO,CA 92121									AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CARDARELLI PM, 1986, P NATL ACAD SCI USA, V83, P2647, DOI 10.1073/pnas.83.8.2647; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GARCIAPARDO A, 1990, IMMUNOLOGY, V69, P121; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HARLAN JM, 1985, BLOOD, V65, P513; HAVERSTICK DM, 1985, BLOOD, V66, P946; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; KAMBER V, 1971, HELV CHIM ACTA, V94, P927; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MOYLE M, 1991, J BIOL CHEM, V266, P19650; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PULIDO R, 1991, J BIOL CHEM, V266, P10241; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAMANEN J, 1991, J MED CHEM, V34, P3114, DOI 10.1021/jm00114a022; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stewart JM, 1984, SOLID PHASE PEPTIDE; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SZEKANECZ Z, 1992, J CELL SCI, V101, P885; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	62	80	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20352	20359						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690755				2022-12-27	WOS:A1993LY01900065
J	ATTIEH, JM; HANSON, AD; SAINI, HS				ATTIEH, JM; HANSON, AD; SAINI, HS			PURIFICATION AND CHARACTERIZATION OF A NOVEL METHYLTRANSFERASE RESPONSIBLE FOR BIOSYNTHESIS OF HALOMETHANES AND METHANETHIOL IN BRASSICA-OLERACEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL S-METHYLTRANSFERASE; PHELLINUS-POMACEUS; METHYLATED SULFUR; BIOGENIC SULFUR; SULFIDE; CHLOROMETHANE; SEAWATER; CHLORIDE; VOLATILE; DONOR	A novel S-adenosyl-L-methionine:halide/bisulfide methyltransferase (EC 2.1.1.-) was purified approximately 1000-fold to apparent homogeneity from leaves of Brassica oleracea, The enzyme catalyzed the S adenosyl-L-methionine-dependent methylation of the halides iodide, bromide, and chloride to monohalomethanes and of bisulfide to methanethiol. The dual function of the enzyme was demonstrated through co-purification of the halide- and bisulfide-methylating activities in the same ratio and by studies of competition between the alternative substrates iodide and bisulfide, The purification procedure included gel filtration, anion exchange chromatography, and affinity chromatography on adenosine-agarose. Elution of the protein from a chromate-focusing column indicated a pI value of 4.8. The pH optimum of halide methylation (5.5-7.0) was different from that of bisulfide methylation (7.0-8.0). The molecular mass values for the native and denatured protein were 29.5 and 28 kDa, respectively, suggesting that the active enzyme is a monomer, The enzyme had the highest specificity constant for iodide and the next highest for bisulfide, Substrate interaction kinetics and product inhibition patterns were consistent with an Ordered Bi Bi mechanism.	UNIV MONTREAL, INST RECH BIOL VEGETALE, MONTREAL, PQ H1X 2B2, CANADA	Universite de Montreal								ANEJA VP, 1989, ACS SYM SER, V393, P2; Bell E. A., 1980, Encyclopedia of Plant Physiology. New Series. Volume 8. Secondary plant products [Bell, A.E.; Charlwood, B.V. (Editors)]., P403; BORCHARDT RT, 1978, BIOCHIM BIOPHYS ACTA, V522, P340, DOI 10.1016/0005-2744(78)90068-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasseur G. P., 1991, TRACE GAS EMISSION P, P1; Crampton MR., 1974, CHEM THIOL GROUP, P379; DECAROLIS E, 1989, BIOCHEM CELL BIOL, V67, P763, DOI 10.1139/o89-115; DESILVA JJR, 1991, BIOL CHEM ELEMENTS, P453; DIXON M, 1979, ENZYMES, P332; Dixon M., 1979, ENZYMES, P47; DROTAR A, 1987, APPL ENVIRON MICROB, V53, P2111, DOI 10.1128/AEM.53.9.2111-2118.1987; DROTAR A, 1985, PLANT CELL PHYSIOL, V26, P847; DROTAR A, 1987, APPL ENVIRON MICROB, V53, P1626, DOI 10.1128/AEM.53.7.1626-1631.1987; DUMAS B, 1988, PLANTA, V176, P36, DOI 10.1007/BF00392477; Fiske CH, 1925, J BIOL CHEM, V66, P375; GSCHWEND PM, 1985, SCIENCE, V227, P1033, DOI 10.1126/science.227.4690.1033; HARPER DB, 1990, APPL ENVIRON MICROB, V56, P3450, DOI 10.1128/AEM.56.11.3450-3457.1990; HARPER DB, 1993, MET IONS BIOL SYST, V29, P345; HARPER DB, 1986, J GEN MICROBIOL, V132, P1231; HARPER DB, 1989, APPL ENVIRON MICROB, V55, P1981, DOI 10.1128/AEM.55.8.1981-1989.1989; HEANEY RK, 1983, Z PFLANZENZUCHT, V91, P219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVELOCK JE, 1972, NATURE, V237, P452, DOI 10.1038/237452a0; LOVELOCK JE, 1975, NATURE, V256, P193, DOI 10.1038/256193a0; MANLEY SL, 1987, LIMNOL OCEANOGR, V32, P709, DOI 10.4319/lo.1987.32.3.0709; MCCARTY S, 1993, FEMS MICROBIOL LETT, V112, P93, DOI 10.1111/j.1574-6968.1993.tb06429.x; MORRISON JF, 1971, J BIOL CHEM, V246, P3977; Neidleman S L, 1983, Biochem Soc Symp, V48, P39; NRIAGU JO, 1987, SCIENCE, V237, P1189, DOI 10.1126/science.237.4819.1189; OHIGASHI K., 1951, MED JOUR OSAKA UNIV, V2, P111; PRATHER MJ, 1990, NATURE, V344, P729, DOI 10.1038/344729a0; Rennenberg H., 1991, TRACE GAS EMISSIONS, P217, DOI [10.1016/B978-0-12-639010-0.50015-7, DOI 10.1016/B978-0-12-639010-0.50015-7]; SAINI HS, 1995, IN PRESS PLANT CELL; TAKASUGI M, 1988, B CHEM SOC JPN, V61, P285, DOI 10.1246/bcsj.61.285; WEISIGER RA, 1979, ARCH BIOCHEM BIOPHYS, V196, P631, DOI 10.1016/0003-9861(79)90317-5; WEISIGER RA, 1980, BIOCHEM PHARMACOL, V29, P2885, DOI 10.1016/0006-2952(80)90029-5; WEISIGER RA, 1980, ENZYMATIC BASIS DETO, V2, P131; WHITE RH, 1982, ARCH MICROBIOL, V132, P100, DOI 10.1007/BF00690827; WUOSMAA AM, 1990, SCIENCE, V249, P160, DOI 10.1126/science.2371563; ZAFIRIOU OC, 1975, J MAR RES, V33, P75	40	102	104	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9250	9257		10.1074/jbc.270.16.9250	http://dx.doi.org/10.1074/jbc.270.16.9250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721844	hybrid			2022-12-27	WOS:A1995QU08900032
J	ZHENG, Y; OLSON, MF; HALL, A; CERIONE, RA; TOKSOZ, D				ZHENG, Y; OLSON, MF; HALL, A; CERIONE, RA; TOKSOZ, D			DIRECT INVOLVEMENT OF THE SMALL GTP-BINDING PROTEIN-RHO IN LBC ONCOGENE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; YEAST SACCHAROMYCES-CEREVISIAE; TYROSINE KINASE; CELL POLARITY; GENE-PRODUCT; RAS; GROWTH; CDC42; VAV	The lbc oncogene is tumorigenic in nude mice, transforms NIH 3T3 fibroblasts, and encodes a Dbl homology domain found in several transforming gene products including the dbl oncogene product. While both lbc- and dbl-transformed NM 3T3 foci exhibited a comparable gross appearance, Ibc-transformed cell morphology was clearly distinct from that of dbl-transformed cells. Given these differences, we investigated the biochemical activity and target specificity of the Lbc oncoprotein both in vivo and in vitro. Here we show that Lbc associates specifically with the GTP-binding protein Rho in vivo, but not with the Ras, Rac, or Cdc42Hs GTP binding proteins, and that recombinant, affinity-purified Lbc specifically catalyzes the guanine-nucleotide exchange activity of Rho in vitro. Consistent with an in vivo role for Lbc in Rho regulation, we further demonstrate that micro-injected onco-lbc potently induces actin stress fiber formation in quiescent Swiss 3T3 fibroblasts indistinguishable from that induced by Rho. Finally, Ibc-induced NIH 3T3 focus formation is inhibited by co transfection with a rho dominant-negative mutant. These results strongly indicate that the lbc oncogene encodes a specific guanine nucleotide exchange factor for Rho and causes cellular transformation through activation of the Rho signaling pathway.	UCL, MRC,MOLEC CELL BIOL LABS,CRC, ONCOGENE & SIGNAL TRANSDUCT GRP, LONDON WC1E, ENGLAND; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT HEMATOL ONCOL, BOSTON, MA 02115 USA	University of London; University College London; Harvard University; Boston Children's Hospital; Harvard Medical School	ZHENG, Y (corresponding author), CORNELL UNIV, DEPT PHARMACOL, SCHURMAN HALL, ITHACA, NY 14853 USA.		Zheng, Yi/J-7235-2015; Olson, Michael F/A-3240-2011; Olson, Michael/ABA-4240-2021	Zheng, Yi/0000-0001-7089-6074; Olson, Michael/0000-0003-3428-3507	NCI NIH HHS [R29CA62029] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA062029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1994, J BIOL CHEM, V269, P16992; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1062; SELF AJ, 1993, ONCOGENE, V8, P655; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STACEY DW, 1991, ONCOGENE, V6, P2297; TOKSOZ D, 1994, ONCOGENE, V9, P621; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	31	148	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9031	9034		10.1074/jbc.270.16.9031	http://dx.doi.org/10.1074/jbc.270.16.9031			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721814	hybrid			2022-12-27	WOS:A1995QU08900002
J	KONOLA, JT; NASTRI, HG; LOGAN, KM; KNIGHT, KL				KONOLA, JT; NASTRI, HG; LOGAN, KM; KNIGHT, KL			MUTATIONS AT PRO(67) IN THE RECA PROTEIN P-LOOP MOTIF DIFFERENTIALLY MODIFY COPROTEASE FUNCTION AND SEPARATE COPROTEASE FROM RECOMBINATION ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATES; CONFORMATIONAL-CHANGES; ATP-BINDING; DNA; LEXA; MUTAGENESIS; CLEAVAGE; REPAIR; PHAGE	The functional significance of residues in the RecA protein P-loop motif was assessed by analyzing 100 unique mutants with single amino acid substitutions in this region. Comparison of the effects on the LexA coprotease and recombination activities shows that Pro(67) is unique among these residues because only at this position did we find substitutions that caused differential effects on these functions. One mutant, Pro(67) --> Trp, displays high constitutive coprotease activity and a moderate inhibitory effect on recombination functions. Glu and Asp substitutions result in low level constitutive coprotease activity but dramatically reduce recombination activity. The purified Pro(67) --> Trp protein shows a completely relaxed specificity for NTP cofactors in LexA cleavage assays and can use shorter length oligonucleotides as cofactors for cleavage of lambda cI repressor than can wild type RecA. Interestingly, both the mutant protein and wild type RecA can use very short oligonucleotides, e.g. (dA)(6) and (dT)(6), as cofactors for LexA cleavage. We have also found two mutations at position 67, which are completely defective for LexA coprotease activity in vivo but still maintain recombinational DNA repair (Pro(67) --> Lys) and homologous recombination (Pro(67) --> Lys and Pro(67) --> Arg) activities. These findings show that the recombination activities of RecA are mutationally separable from the coprotease function and that Pro(67) is located in a functionally important position in the RecA structure.			KONOLA, JT (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44772] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; HIGASHITANI N, 1992, J BACTERIOL, V174, P1612, DOI 10.1128/jb.174.5.1612-1618.1992; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P468; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MCENTEE K, 1981, P NATL ACAD SCI-BIOL, V78, P6061, DOI 10.1073/pnas.78.10.6061; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NASTRI HG, 1994, J BIOL CHEM, V269, P26311; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; PETERSON KR, 1988, J BACTERIOL, V170, P1; ROBERTS JW, 1978, COL SPRING HARBOR S, V43, P909; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; STOLE E, 1994, J BIOL CHEM, V269, P7919; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1988, J BACTERIOL, V170, P4816, DOI 10.1128/jb.170.10.4816-4822.1988; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	38	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8411	8419		10.1074/jbc.270.15.8411	http://dx.doi.org/10.1074/jbc.270.15.8411			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721735	hybrid			2022-12-27	WOS:A1995QT44800011
J	PAN, ZX; KRAVCHENKO, VV; YE, RD				PAN, ZX; KRAVCHENKO, VV; YE, RD			PLATELET-ACTIVATING-FACTOR STIMULATES TRANSCRIPTION OF THE HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR IN MONOCYTES - CORRELATION WITH AN INCREASED KAPPA-B BINDING-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE CELLS; FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; MESSENGER-RNA; EXPRESSION; CLONING; GENE; PAF; ACETYLHYDROLASE; INDUCTION	Human peripheral blood monocytes responded to stimulation of platelet-activating factor (PAF) with up-regulation of the transcript fro heparin-binding epidermal growth factor-like growth factor (HB-EGF), a potent mitogen for vascular smooth muscle cells. This function of PAF was observed at nanomolar concentrations of the ligand, starting at 30 min after stimulation. The PAF-induced up-regulation of HB-EGF mRNA was accompanied by an increase in kappa B binding activity. These functions of PAF appeared to be mediated through the cell surface PAF receptors, as two PAF receptors antagonists, WEB 2086 and L-659,989, blocked both the up-regulation of HB-EGF mRNA and kappa B binding activity induced by PAF. The antagonists, however, had no effect on phorbol ester-induced up-regulation of HB-EGF and mRNA and kappa B binding activity. Pretreatment of monocytes with pertussis toxin inhibited these functions of PAF, whereas cholera toxin had no inhibitory effect. Pyrrolidine dithiocarbamate, an inhibitor effect. Pyrrolidine dithiocarbamate, an inhibitor for NF-kappa B activation, markedly reduced PAF-stimulated kappa B binding activity as well as up-regulation of HB-EGF mRNA. These results suggest a potential role of PAF in HB-EGF expression and provide evidence that this stimulation may occur through increased kappa B binding activity.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NIGMS NIH HHS [GM46572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BLANK ML, 1981, J BIOL CHEM, V256, P175; BOURGAIN RH, 1985, PROSTAGLANDINS, V30, P185, DOI 10.1016/0090-6980(85)90184-4; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1991, SCIENCE, V251, P986; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; HWANG SB, 1991, LIPIDS, V26, P1148, DOI 10.1007/BF02536520; Koltai M, 1992, Agents Actions Suppl, V37, P333; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NAKANO T, 1993, J BIOL CHEM, V268, P22941; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STEINBERG D, 1987, CIRCULATION, V76, P508, DOI 10.1161/01.CIR.76.3.508; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; TRIPATHI YB, 1992, BIOCHEM J, V286, P527, DOI 10.1042/bj2860527; WEYRICH AS, 1995, IN PRESS J CLIN INVE; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, P149	37	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7787	7790		10.1074/jbc.270.14.7787	http://dx.doi.org/10.1074/jbc.270.14.7787			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713868	hybrid			2022-12-27	WOS:A1995QR52600002
J	ROSENBERG, HF				ROSENBERG, HF			RECOMBINANT HUMAN EOSINOPHIL CATIONIC PROTEIN - RIBONUCLEASE-ACTIVITY IS NOT ESSENTIAL FOR CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHISTOSOMA-MANSONI; GRANULE PROTEINS; HYPEREOSINOPHILIC SYNDROME; ENDOMYOCARDIAL DISEASE; COMPARATIVE TOXICITY; TRYPANOSOMA-CRUZI; MOLECULAR-CLONING; ESCHERICHIA-COLI; CATHEPSIN-G; NEUROTOXIN	Eosinophil cationic protein (ECP) is a toxin secreted by activated human eosinophils that has anti-parasitic, antibacterial, and neurotoxic activities; ECP also has ribonuclease activity and structural homology to other mammalian ribonucleases. To determine the relationship between the ribonuclease activity and cytotoxicity of ECP, a method for producing recombinant ECP (rECP) in a prokaryotic expression system was devised. Periplasmic isolates from induced bacterial transfectants contained enzymatically active rECP; micromolar concentrations of rECP were shown to be toxic for Staphylococcus aureus (strain 502A). In contrast; recombinant eosinophil-derived neurotoxin, with 67% amino acid sequence identity to ECP, had little to no toxicity for S. aureus; these findings are analogous to those obtained with purified, granule-derived ECP and eosinophil-derived neurotoxin. Two single base pair mutations were introduced into the coding sequence of rECP (Lys(38) to Arg and His(128) to Asp) to convert ribonuclease active-site residues into non-functional counterparts. These mutations eliminated the ribonuclease activity of rECP but had no discernible effect on the antibacterial activity of this protein, demonstrating that ribonuclease activity and cytotoxicity are, in this case, independent functions of ECP.			ROSENBERG, HF (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N104,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ACKERMAN SJ, 1985, AM J TROP MED HYG, V34, P735, DOI 10.4269/ajtmh.1985.34.735; ANFINSEN CB, 1954, J BIOL CHEM, V207, P201; ARDELT W, 1991, J BIOL CHEM, V266, P245; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2; BANGALORE N, 1990, J BIOL CHEM, V265, P13584; BARKER RL, 1989, J IMMUNOL, V143, P952; BLACKBURN P, 1982, ENZYMES, P317; Blobel G, 1979, Symp Soc Exp Biol, V33, P9; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GRAY GL, 1985, GENE, V39, P247, DOI 10.1016/0378-1119(85)90319-1; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; HAMANN KJ, 1987, J PARASITOL, V73, P523, DOI 10.2307/3282130; LEHRER RI, 1989, J IMMUNOL, V142, P4428; MAKINO S, 1993, EOSINOPHILS BIOL CLI; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; MOLINA HA, 1989, IMMUNOLOGY, V66, P289; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NEWTON DL, 1994, J NEUROSCI, V14, P538; PARRILLO JE, 1979, AM J MED, V67, P572, DOI 10.1016/0002-9343(79)90227-4; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; Sambrook J, 1989, MOL CLONING LABORATO; SCHEIN CH, 1992, BIOCHEM J, V283, P137, DOI 10.1042/bj2830137; SHAFER WM, 1991, J BIOL CHEM, V266, P112; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; Spry C J, 1983, Contrib Microbiol Immunol, V7, P212; Spry CJ, 1988, EOSINOPHILS COMPREHE; SPRY CJF, 1986, POSTGRAD MED J, V62, P609, DOI 10.1136/pgmj.62.728.609; TAI PC, 1987, LANCET, V1, P643; VENGE P, 1978, BRIT J HAEMATOL, V38, P475, DOI 10.1111/j.1365-2141.1978.tb01072.x; YAZDANBAKHSH M, 1987, J IMMUNOL, V138, P3443; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	39	173	184	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7876	7881		10.1074/jbc.270.14.7876	http://dx.doi.org/10.1074/jbc.270.14.7876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713881	hybrid			2022-12-27	WOS:A1995QR52600017
J	CRAESCU, CT; BOUHSS, A; MISPELTER, J; DIESIS, E; POPESCU, A; CHIRIAC, M; BARZU, O				CRAESCU, CT; BOUHSS, A; MISPELTER, J; DIESIS, E; POPESCU, A; CHIRIAC, M; BARZU, O			CALMODULIN-BINDING OF A PEPTIDE DERIVED FROM THE REGULATORY DOMAIN OF BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SITE-DIRECTED MUTAGENESIS; LIGHT-CHAIN KINASE; NMR-SPECTROSCOPY; H-1-NMR SPECTRA; CHEMICAL-SHIFT; MULTIDIMENSIONAL NMR; CENTRAL HELIX; COMPLEX; ASSIGNMENT	This paper reports the solution conformation and calmodulin binding of a 43-residue peptide from the calmodulin-binding domain of Bordetella pertussis adenylate cyclase. The peptide (P-225-267) was synthesized and N-15-labeled at specific amino acids. It binds calmodulin with an equilibrium dissociation constant of 25 nM. Assignment of the NMR spectrum of the free peptide and analysis of the NOE connectivities and secondary shifts of C alpha protons allowed us to identify a 10-amino acid fragment (Arg(237) to Arg(246)) which is in rapid equilibrium between alpha-helical and irregular structures. Titration experiments showed that at substoichiometric molar ratios the two molecules are in intermediate exchange between free and bound conformations. Using N-15-edited methods we assigned a large part of resonances of the labeled residues in the bound peptide. Analysis of the chemical shift differences between free and bound states shows that the fragment Leu(240)-Ala(257) is the most affected by the interaction. The proton spectra of the calmodulin, in the free and complexed states were extensively assigned using homonuclear experiments. Medium- and long-range NOE patterns are consistent with a largely conserved secondary and tertiary structure. The main changes in chemical shift of calmodulin resonances are grouped in six structural regions both in NH2- and COOH-terminal domains. Intermolecular NOE connectivities indicate that the NH2-terminal of the bound peptide fragment is engulfed in the COOH-terminal domain of calmodulin. The interaction geometry appears to be similar to those previously described for myosin light chain kinase or calmodulin kinase II fragments.	INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,URA 1129,F-75724 PARIS,FRANCE; INST PASTEUR,SERV CHIM BIOMOLEC,URA 1309,LILLE,FRANCE; UNIV BUCHAREST,DEPT BIOPHYS,BUCHAREST,ROMANIA; INST ISOTOPE & MOLEC TECHNOL,R-3400 CLUJ NAPOCA,ROMANIA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Bucharest; National Institute for Research & Development of Isotopic & Molecular Technologies Cluj-Napoca	CRAESCU, CT (corresponding author), INST CURIE,BIOL SECT,INSERM,U350,BATIMENT 112,F-91405 ORSAY,FRANCE.							AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BRUIX M, 1990, BIOCHEM BIOPH RES CO, V167, P1009, DOI 10.1016/0006-291X(90)90623-U; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; CHAZIN WJ, 1987, BIOPOLYMERS, V26, P973, DOI 10.1002/bip.360260615; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KEMMINK J, 1993, J MOL BIOL, V230, P312, DOI 10.1006/jmbi.1993.1144; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LE HB, 1994, J BIOMOL NMR, V4, P341; LEVY GC, 1979, NITROGEN 15 NUCLEAR; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MUNIER H, 1993, J BIOL CHEM, V268, P1695; MUNIER H, 1991, EUR J BIOCHEM, V196, P469, DOI 10.1111/j.1432-1033.1991.tb15838.x; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; OLDENBURG DJ, 1992, BIOCHEMISTRY-US, V31, P8884, DOI 10.1021/bi00152a027; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PASTORE A, 1990, J MAGN RESON, V90, P165, DOI 10.1016/0022-2364(90)90375-J; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PRECHEUR B, 1991, EUR J BIOCHEM, V196, P67; PRESECAN E, 1987, ENZYME MICROB TECH, V9, P663, DOI 10.1016/0141-0229(87)90124-4; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; SZILAGYI L, 1989, J MAGN RESON, V83, P441, DOI 10.1016/0022-2364(89)90341-7; VEITCH NC, 1988, FEBS LETT, V238, P49, DOI 10.1016/0014-5793(88)80223-0; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOLFF J, 1973, J BIOL CHEM, V248, P350; Wolff J, 1980, P NATL ACAD SCI USA, V77, P3840; Wuthrich K., 1986, NMR PROTEINS NUCL AC	46	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7088	7096		10.1074/jbc.270.13.7088	http://dx.doi.org/10.1074/jbc.270.13.7088			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706246	hybrid			2022-12-27	WOS:A1995QQ43100015
J	FRANSEN, M; BREES, C; BAUMGART, E; VANHOOREN, JCT; BAES, M; MANNAERTS, GP; VANVELDHOVEN, PP				FRANSEN, M; BREES, C; BAUMGART, E; VANHOOREN, JCT; BAES, M; MANNAERTS, GP; VANVELDHOVEN, PP			IDENTIFICATION AND CHARACTERIZATION OF THE PUTATIVE HUMAN PEROXISOMAL C-TERMINAL TARGETING SIGNAL IMPORT RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE-REPEAT PROTEIN; AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; 3-KETOACYL-COA THIOLASE; ZELLWEGER SYNDROME; ESCHERICHIA-COLI; YEAST; TRANSFORMATION; MEMBRANE; CELLS	To identify proteins interacting with the C-terminal peroxisomal targeting signal (PTS1), we screened a human liver cDNA library by means of a Saccharomyces cerevisiae genetic system, known as the two-hybrid system. We isolated a cDNA encoding a protein that specifically bound the PTS1 topogenic signal in the intact yeast cell but also in vitro after bacterial expression and purification. Sequence analysis of the full-length cDNA revealed the presence of an open reading frame encoding a 70-kDa polypeptide that belongs to the tetratricopeptide repeat family and that is homologous to the PAS8 and PAS10 gene products, which are required for the formation of normal peroxisomes in yeast. Subcellular fractionation of human liver and immunofluorescence studies on HepG(2) cells demonstrated that this PTS1-binding protein is present exclusively in peroxisomes and that the PTS1-binding domain is located to the cytosolic side of the peroxisomal membrane. Ah available evidence indicates that the PTS1-binding protein is part of the peroxisomal protein import machinery and most probably is the long sought after human PTS1 import receptor.	CATHOLIC UNIV LEUVEN,AFDELING FARMAKOL,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,AFDELING KLIN CHEM,B-3000 LOUVAIN,BELGIUM; UNIV HEIDELBERG,INST ANAT & CELL BIOL,D-69120 HEIDELBERG,GERMANY	KU Leuven; KU Leuven; Ruprecht Karls University Heidelberg			Fransen, Marc/ADL-0723-2022; Baumgart-Vogt, Eveline/I-5945-2013; , Van Veldhoven Paul/U-6359-2019; Fransen, Marc/C-6262-2008	Baumgart-Vogt, Eveline/0000-0002-8265-3763; , Van Veldhoven Paul/0000-0002-4478-2564; Fransen, Marc/0000-0001-9284-1197; Baes, Myriam/0000-0002-2525-2269				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; ELGERSMA Y, 1993, GENETICS, V135, P731; ERDMANN R, 1992, CELL BIOCHEM FUNCT, V10, P167, DOI 10.1002/cbf.290100306; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANSEN M, 1994, BBA-GEN SUBJECTS, V1201, P157, DOI 10.1016/0304-4165(94)90036-1; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRADER M, 1994, EUR J CELL BIOL, V64, P281; SHIMOZAWA N, 1993, AM J HUM GENET, V52, P843; SHIMOZAWA N, 1991, SCIENCE, V255, P1132; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VANVELDHOVEN PP, 1994, EUR J BIOCHEM, V222, P795; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531	35	161	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7731	7736		10.1074/jbc.270.13.7731	http://dx.doi.org/10.1074/jbc.270.13.7731			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706321	hybrid			2022-12-27	WOS:A1995QQ43100101
J	MALKOWSKI, MG; WU, JY; LAZAR, JB; JOHNSON, PH; EDWARDS, BFP				MALKOWSKI, MG; WU, JY; LAZAR, JB; JOHNSON, PH; EDWARDS, BFP			THE CRYSTAL-STRUCTURE OF RECOMBINANT HUMAN NEUTROPHIL-ACTIVATING PEPTIDE-2 (M6L) AT 1.9-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-STIMULATORY ACTIVITY; CONNECTIVE-TISSUE ACTIVATION; HUMAN INTERLEUKIN-8 RECEPTOR; PROTEIN SECONDARY STRUCTURE; BOVINE PLATELET FACTOR-4; AMINO-ACID SEQUENCE; BETA-THROMBOGLOBULIN; GLOBULAR-PROTEINS; BASIC-PROTEIN; CTAP-III	Neutrophil-activating peptide-2 (NAP-2) is a 70-residue carboxyl-terminal fragment of platelet basic protein, which is found in the alpha-granules of human platelets. NAP-2, which belongs to the CXC family of chemokines that includes interleukin-8 and platelet factor 4, binds to the interleukin-8 type II receptor and induces a rise in cytosolic calcium, chemotaxis of neutrophils, and exocytosis. Crystals of recombinant NAP-2 in which the single methionine gt position 6 was replaced by leucine to facilitate expression belong to space group Pi (unit cell parameters a = 40.8, b = 43.8, and c = 44.7 Angstrom and alpha = 98.4 degrees, beta = 120.3 degrees, and gamma = 92.8 degrees), with 4 molecules of NAP-2 (M(r) = 7600) in the asymmetric unit. The molecular replacement solution calculated with bovine platelet factor 4 as the starting model was refined using rigid body refinement, manual fitting in solvent-leveled electron density maps, simulated annealing, and restrained least squares to an R-factor of 0.188 for 2 sigma data between 7.0- and 1.9-Angstrom resolution. The final refined crystal structure includes 265 solvent molecules. The overall tertiary structure, which is similar to that of platelet factor 4 and interleukin-8, includes an extended amino terminal loop, three strands of antiparallel beta-sheet arranged in a Greek key fold, and one alpha-helix at the carboxyl terminus. The Glu-Leu-Arg sequence that is critical for receptor binding is fully defined by electron density and exhibits multiple conformations.	WAYNE STATE UNIV,DEPT BIOCHEM,DETROIT,MI 48201; STANFORD RES INST INT,CELL & MOLEC BIOL LAB,MENLO PK,CA 94025	Wayne State University; SRI International; Stanford University			Malkowski, Michael G/G-4939-2011	Malkowski, Michael G/0000-0003-1025-0014; Malkowski, Michael/0000-0002-1203-7463	NHLBI NIH HHS [T32 HL07602] Funding Source: Medline; NIGMS NIH HHS [GM33192] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BEBAWY ST, 1986, J LEUKOCYTE BIOL, V39, P423, DOI 10.1002/jlb.39.4.423; BEGG GS, 1978, BIOCHEMISTRY-US, V17, P1739, DOI 10.1021/bi00602a024; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOCK PE, 1980, BIOCHEM J, V191, P769, DOI 10.1042/bj1910769; BRANDT E, 1993, MOL IMMUNOL, V30, P979, DOI 10.1016/0161-5890(93)90123-S; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; CASTOR CW, 1990, J LAB CLIN MED, V116, P516; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHAMBERS JL, 1992, 50TH AM CRYST ASS AN, V20, P87; CIAGLOWSKI RE, 1986, ARCH BIOCHEM BIOPHYS, V250, P249, DOI 10.1016/0003-9861(86)90723-X; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLORE GM, 1990, BIOCHEMISTRY-US, V9, P1689; CLUBB RT, 1994, FEBS LETT, V38, P93; COHEN AB, 1992, AM J PHYSIOL, V63, pL249; DEUEL TF, 1981, P NATL ACAD SCI USA, V8, P4584; DEUEL TF, 1977, P NATL ACAD SCI USA, V4, P2256; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; FUREY W, 1982, J APPL CRYSTALLOGR, V15, P160, DOI 10.1107/S0021889882011716; HARDIN RI, 1976, J BIOL CHEM, V251, P4273; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HERMODSON M, 1977, J BIOL CHEM, V252, P6276; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; HOOGEWERF A, 1993, MOL BIOL CELL S, V4, P286; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KUNGL AJ, 1994, FEBS LETT, V347, P300, DOI 10.1016/0014-5793(94)00573-7; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LAWLER JW, 1981, THROMB RES, V21, P121, DOI 10.1016/0049-3848(84)90039-2; LENORD EJ, 1991, J LEUKOCYTE BIOL, V49, P258; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, J BIOL CHEM, V268, P7125; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARK KS, 1990, BLOOD, V75, P1290; PETERSEN F, 1994, J IMMUNOL, V149, P2467; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; PONCZ M, 1987, BLOOD, V69, P219; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHNITZEL W, 1994, J LEUKOCYTE BIOL, V55, P763, DOI 10.1002/jlb.55.6.763; SHERRY B, 1991, CURR OPIN IMMUNOL, V3, P56, DOI 10.1016/0952-7915(91)90077-E; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; STUCKEY JA, 1992, DISSERT ABSTR, V53, P1034; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; WALEH NS, 1992, GENE, V117, P7, DOI 10.1016/0378-1119(92)90483-6; WALZ A, 1989, BIOCHEM BIOPH RES CO, V159, P969, DOI 10.1016/0006-291X(89)92203-1; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; YANG YQ, 1994, J BIOL CHEM, V269, P20110; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	77	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7077	7087		10.1074/jbc.270.13.7077	http://dx.doi.org/10.1074/jbc.270.13.7077			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706245	hybrid, Green Published			2022-12-27	WOS:A1995QQ43100014
J	TOTH, CR; HOSTUTLER, RF; BALDWIN, AS; BENDER, TP				TOTH, CR; HOSTUTLER, RF; BALDWIN, AS; BENDER, TP			MEMBERS OF THE NUCLEAR FACTOR KAPPA-B FAMILY TRANSACTIVATE THE MURINE C-MYB GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; MESSENGER-RNA; TRANSCRIPTION FACTOR; DIFFERENTIAL EXPRESSION; LYMPHOID TUMORS; T-CELLS; REGULATED EXPRESSION; REL PROTOONCOGENE; ONCOGENE PRODUCT; PROTO-ONCOGENE	Expression of the c-myb proto-oncogene is primarily detected in normal tissue and tumor cell lines of immature hematopoietic origin, and the down-regulation of c-myb expression is associated with hematopoietic mat uration, Cell lines that represent mature, differentiated hematopoietic cell types contain 10-100 fold less c-myb mRNA than immature hematopoietic cell types, Differences in steady state c-myb mRNA levels appear to be primarily maintained by a conditional block to transcription elongation that occurs in the first intron of the gene, The block to transcription elongation has been mapped, using nuclear run-on analysis, to a region of DNA sequence that is highly conserved between mouse and man, Two sets of DNA-protein interactions, flanking the site of the block to transcription elongation, were detected that exhibited DNA-binding activities that strongly correlated with low steady-state c-myb mRNA levels. Several criteria demonstrated that members of the nuclear factor kappa B (NF-kappa B) family of transcription factors were involved in the DNA-protein interactions identified in these two sets, Surprisingly, cotransfection experiments demonstrated that coexpression of members of the NF-kappa B family, specifically p50 with p65 and p65 with c-Rel, transactivated a c-myb/chloramphenicol acetyltransferase reporter construct that contained 5'-flanking sequences, exon I, intron I, and exon II of the c-myb gene, Transactivation by these heterodimer combinations was dependent on regions of the c-myb first intron containing the NF-kappa B-binding sites, These findings suggest that NF-kappa B family members may be involved in either modifying the efficiency of transcription attenuation or acting as an enhancer-like activity to increase transcription initiation, Thus, the regulation of c-myb transcription may be quite complex, and members of the NF-kappa B family likely play an important role in this regulation.	UNIV VIRGINIA,DEPT MICROBIOL & IMMUNOL,CHARLOTTESVILLE,VA 22903; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of Virginia; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA52515, CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052515] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ARIMA N, 1992, J IMMUNOL, V149, P83; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1987, J IMMUNOL, V139, P3822; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOISE LH, 1992, CELL GROWTH DIFFER, V3, P53; BOISE LH, 1992, ONCOGENE, V7, P1817; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CASTELLANO M, 1992, INT J CLIN LAB RES, V22, P159, DOI 10.1007/BF02591416; CATRON KM, 1990, CURR TOP MICROBIOL, V166, P197; CATRON KM, 1992, J IMMUNOL, V148, P934; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRIFFIN CA, 1985, CANCER RES, V45, P272; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; JACOBS SM, 1994, ONCOGENE, V9, P227; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLUG CA, 1994, GENE DEV, V8, P658; KU DH, 1993, J BIOL CHEM, V268, P2255; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIPP MA, 1987, J IMMUNOL, V139, P2143; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; SIMEK S, 1988, ONCOGENE RES, V2, P103; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; ZOBEL A, 1991, ONCOGENE, V6, P1397	77	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7661	7671		10.1074/jbc.270.13.7661	http://dx.doi.org/10.1074/jbc.270.13.7661			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706314	Green Published, hybrid			2022-12-27	WOS:A1995QQ43100092
J	BITTORF, SV; WILLIAMS, EC; MOSHER, DF				BITTORF, SV; WILLIAMS, EC; MOSHER, DF			ALTERATION OF VITRONECTIN - CHARACTERIZATION OF CHANGES INDUCED BY TREATMENT WITH UREA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; THROMBIN-ANTITHROMBIN-III; SERUM SPREADING FACTOR; TERMINAL COMPLEMENT COMPLEX; HEPARIN-BINDING PROPERTIES; MEMBRANE ATTACK COMPLEX; IMMUNOHISTOCHEMICAL DEMONSTRATION; GEL-ELECTROPHORESIS; BETA-ENDORPHIN; MESSENGER-RNA	Vitronectin circulates in blood as a 70-kDa monomer that interacts with complexes generated in the terminal steps of the coagulation and complement cascades. Vitronectin complexed to thrombin-antithrombin or C5b-9 is conformationally altered as evidenced by enhanced reactivity with monoclonal antibody 8E6 and binding to heparin; these same alterations also occur when vitronectin is treated with urea (Tomasini, B. R., and Mosher, D. F. (1988) Blood 72,903-912; Hogasenk, K., Molnes, T. E., and Harboe, M. (1992) J. BioL Chem. 267, 23076-23082). We have modified the purifications of native and urea-treated vitronectin to better control conformational state and characterized the alterations induced by urea. After treatment with N-ethylmaleimide to prevent formation of disulfide-linked multimers, purification in 8 M urea, and dialysis against physiological saline, vitronectin was largely oligomeric (approximately 800 kDa) as assessed by gel filtration and polyacrylamide gel electrophoresis in the absence of sodium dodecyl sulfate. Oligomeric urea-treated vitronectin reacted more strongly with the 8E6 antibody, bound biotinylated heparin more strongly, and neutralized the anticoagulant activity of heparin better than monomeric altered vitronectin or native vitronectin. After incubation with urea at 25-degrees-C, native vitronectin, treated during purification with dithionitrobenzoic acid to force free sulfhydryls to intramolecular disulfides, exhibited increased reactivity with antibody 8E6, increased binding to heparin, and oligomerization. In addition, incubation in urea caused rearrangement of disulfides as assessed by loss of the light chain of two-chain vitronectin. The transition for these effects occurred between 2 and 4 M urea. Thus, an irreversible conformational alteration occurs upon treatment of vitronectin with urea, resulting in oligomers that bind avidly to heparin.	UNIV WISCONSIN,DEPT MED,4285A MED SCI CTR,1300 UNIV AVE,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL29586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H; BARNES DW, 1985, J BIOL CHEM, V260, P9117; CANN JR, 1976, BIOCHEMISTRY-US, V15, P4614, DOI 10.1021/bi00666a011; CONLAN MG, 1988, BLOOD, V72, P185; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAHLBACK K, 1987, HISTOCHEMISTRY, V87, P511, DOI 10.1007/BF00492465; DAHLBACK K, 1989, J INVEST DERMATOL, V92, P727, DOI 10.1111/1523-1747.ep12721619; DAMUS PS, 1975, METHOD ENZYMOL, V45, P653; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEROMEUF C, 1993, THROMB HAEMOSTASIS, V69, P436; FALK RJ, 1987, AM J PATHOL, V127, P182; GUTTIER C, 1989, VIRCHOWS ARCH A, V414, P309; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1138; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HILDEBRAND A, 1989, BIOCHEM BIOPH RES CO, V159, P799, DOI 10.1016/0006-291X(89)90065-X; HINTNER H, 1990, BRIT J DERMATOL, V123, P39, DOI 10.1111/j.1365-2133.1990.tb01822.x; HINTNER H, 1991, J INVEST DERMATOL, V96, P747, DOI 10.1111/1523-1747.ep12470980; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; ILL CR, 1985, J BIOL CHEM, V260, P5610; INAZUKA S, 1992, HEPATOLOGY, V15, P629; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1987, J BIOL CHEM, V262, P16343; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P79; MORROW JS, 1983, METHOD ENZYMOL, V96, P298; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PEISSNER KT, 1991, ANN REV CELL BIOL, V7, P275; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PREISSNER KP, 1989, EUR J IMMUNOL, V19, P69, DOI 10.1002/eji.1830190112; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; PREISSNER KT, 1988, THROMB HAEMOSTASIS, V60, P309; REILLY JT, 1988, J CLIN PATHOL, V41, P1269, DOI 10.1136/jcp.41.12.1269; SATO R, 1990, J BIOL CHEM, V266, P11227; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SHAFFER MC, 1984, J LAB CLIN MED, V103, P783; SOLEM M, 1991, MOL CELL BIOCHEM, V100, P141; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; SUN X, 1992, SEMIN THROMB HEMOST, V18, P243, DOI 10.1055/s-2007-1002430; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; WILLIAMS EC, 1992, J LAB CLIN MED, V120, P159; YAHTOHGO T, 1988, CELL STRUCT FUNCT, V13, P281	58	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24838	24846						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693706				2022-12-27	WOS:A1993MG67300050
J	NAKAO, T; KON, K; ANDO, S; MIYATAKE, T; YUKI, N; LI, YT; FURUYA, S; HIRABAYASHI, Y				NAKAO, T; KON, K; ANDO, S; MIYATAKE, T; YUKI, N; LI, YT; FURUYA, S; HIRABAYASHI, Y			NOVEL LACTO-GANGLIO TYPE GANGLIOSIDES WITH G(M2)-EPITOPE IN BOVINE BRAIN WHICH REACT WITH IGM FROM A PATIENT OF THE AMYOTROPHIC LATERAL SCLEROSIS-LIKE DISORDER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING GLYCOSPHINGOLIPIDS; HANGANUTZIU-DEICHER ANTIGENS; GUILLAIN-BARRE-SYNDROME; MONOCLONAL-ANTIBODY; CHROMATOGRAPHY; NEUROPATHY; DISEASE; SERIES; CELLS; GM1	A motor neuron disorder resembling that of amyotrophic lateral sclerosis was found in a patient who had received the intramuscular administration of a mixture of bovine brain gangliosides (Yuki, N., Sato, S., Miyatake, T., Sugiyama, K., Katagiri, T., and Sasaki, H. (1991) Lancet 337, 1109-1110). A very high titer of anti-G(M2) IgM was detected in the patient's serum and the patient quickly recovered after plasmapheresis. The clinical course of the patient appeared to be different from amyotrophic lateral sclerosis and the anti-G(M2) IgM was thought to be the culprit. The IgM reacted with G(M2), G(M1b)-GalNAc, SPG(alpha2-3)-GalNAc, and G(D1a)-GalNAc, but not with G(A2) or G(D2), meaning that the epitope recognized by the IgM was the G(M2)-like terminal structure, GalNAcbeta1-4(Neu-Acalpha2-3)Galbeta1-. In this study, we found two novel G(M2)-epitope containing gangliosides, X1 and X2, in bovine brain gangliosides by TLC immunostaining using the patient's IgM. They were characterized as unique lacto-ganglio type gangliosides containing the following branching structures. Their unusual structures may be immunogenic to humans to induce anti-G(M2) antibody.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT MEMBRANE BIOCHEM, ITABASHI KU, TOKYO 173, JAPAN; TULANE UNIV, SCH MED, DEPT BIOCHEM, NEW ORLEANS, LA 70112 USA; TOKYO MED & DENT UNIV, SCH MED, DEPT NEUROL, BUNKYO KU, TOKYO 113, JAPAN; INST PHYS & CHEM RES, GLYCOCELL BIOL LAB, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN	Tulane University; Tokyo Medical & Dental University (TMDU); RIKEN	NAKAO, T (corresponding author), TAISHO PHARMACEUT CO LTD, RES CTR, DEPT APPL BIOL, 1-350 YOSHINO CYO, OMIYA, SAITAMA 330, JAPAN.		Yuki, Nobuhiro/H-3187-2012	Furuya, Shigeki/0000-0001-9020-3597; Hirabayashi, Yoshio/0000-0002-5774-7354	NINDS NIH HHS [NS09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BHATTI T, 1970, BIOCHIM BIOPHYS ACTA, V222, P339, DOI 10.1016/0304-4165(70)90122-4; BRADLEY WG, 1990, MUSCLE NERVE, V13, P833, DOI 10.1002/mus.880130910; DEGASPERI R, 1987, J BIOL CHEM, V262, P17149; DOHI T, 1991, J BIOL CHEM, V266, P24038; FREDDO L, 1986, NEUROLOGY, V36, P454, DOI 10.1212/WNL.36.4.454; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIGASHI H, 1984, J BIOCHEM, V95, P785, DOI 10.1093/oxfordjournals.jbchem.a134670; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HIRABAYASHI Y, 1991, J BIOL CHEM, V266, P10268; ILYAS AA, 1988, J BIOL CHEM, V263, P4369; ITOH T, 1981, J BIOL CHEM, V256, P165; KANNAGI R, 1984, J BIOL CHEM, V259, P8444; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; NAKAO T, 1991, BIOCHIM BIOPHYS ACTA, V1086, P305, DOI 10.1016/0005-2760(91)90174-G; NOBILEORAZIO E, 1992, J NEUROL SCI, V109, P200, DOI 10.1016/0022-510X(92)90169-L; PESTRONK A, 1988, ANN NEUROL, V24, P73, DOI 10.1002/ana.410240113; QUARLES RH, 1989, METHOD ENZYMOL, V179, P291; SCHONHOFER PS, 1991, LANCET, V338, P757; SCHONHOFER PS, 1992, NEW ENGL J MED, V326, P493; SHIGETA K, 1987, J BIOL CHEM, V262, P1358; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKI T, 1986, J BIOL CHEM, V261, P3075; YUKI N, 1992, MUSCLE NERVE, V15, P1371; YUKI N, 1991, LANCET, V337, P1109, DOI 10.1016/0140-6736(91)91767-O; YUKI N, 1991, LANCET, V338, P314	31	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21028	21034						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691804				2022-12-27	WOS:A1993MA28800061
J	HOLT, EH; VASAVADA, RC; BANDER, NH; BROADUS, AE; PHILBRICK, WM				HOLT, EH; VASAVADA, RC; BANDER, NH; BROADUS, AE; PHILBRICK, WM			REGION-SPECIFIC METHYLATION OF THE PARATHYROID HORMONE-RELATED PEPTIDE GENE DETERMINES ITS EXPRESSION IN HUMAN RENAL-CARCINOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG BINDING-PROTEIN; DNA METHYLATION; HUMORAL HYPERCALCEMIA; TRANSCRIPTIONAL REGULATION; CHROMATIN STRUCTURE; DENOVO METHYLATION; MESSENGER-RNAS; IDENTIFICATION; MALIGNANCY; PROMOTER	Tumor production of a parathyroid hormone-related peptide (PTHrP) is a common cause of the syndrome of humoral hypercalcemia of malignancy, which is frequently associated with renal cell carcinomas. Why certain renal cell carcinomas produce PTHrP while others do not is unknown. Using a system of 12 human renal carcinoma cell lines which either do (n = 6) or do not (n = 6) produce PTHrP, we found that the expression of the PTHrP gene in these cell lines is controlled at the transcriptional level. Transfection studies failed to demonstrate variation in PTHrP promoter activity in these cell lines sufficient to account for the differential PTHrP expression, implicating a cis-acting mechanism. Transcription of the PTHrP gene in these cell lines was found to correlate with the methylation state of specific CpG dinucleotides located within the promoter region but outside a CpG island. The functional importance of this mechanism of control was confirmed by the ability of the demethylating agent, 5-azacytidine, to induce PTHrP mRNA expression in previously nonexpressing cell lines.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; MEM SLOAN KETTERING CANC CTR,DEPT SURG,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021	Yale University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital	HOLT, EH (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,DIV ENDOCRINE,FITKIN 1,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BONNEROT C, 1990, J IMMUNOL, V144, P323; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DRAHOVSKY D, 1971, J MOL BIOL, V61, P343, DOI 10.1016/0022-2836(71)90384-6; EDWARDS YH, 1990, PHILOS T R SOC B, V326, P207, DOI 10.1098/rstb.1990.0005; GOUNARI F, 1987, GENE DEV, V1, P899, DOI 10.1101/gad.1.9.899; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; IKEDA K, 1988, J CLIN INVEST, V81, P2010, DOI 10.1172/JCI113551; IKEDA K, 1989, J BIOL CHEM, V264, P15743; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JONES PA, 1990, PHILOS T R SOC B, V326, P277, DOI 10.1098/rstb.1990.0011; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; Sambrook J, 1989, MOL CLONING LABORATO; SNELLER MC, 1987, J IMMUNOL, V138, P3505; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAYLOR SM, 1982, J MOL BIOL, V162, P679, DOI 10.1016/0022-2836(82)90395-3; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P4605, DOI 10.1073/pnas.85.13.4605; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; TURKER MS, 1989, J BIOL CHEM, V264, P11632; VASAVADA RC, 1993, MOL ENDOCRINOL, V7, P273, DOI 10.1210/me.7.2.273; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; WEIR EC, 1988, J CLIN INVEST, V81, P818, DOI 10.1172/JCI113389; YASUDA T, 1989, J BIOL CHEM, V264, P7720; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20639	20645						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690760				2022-12-27	WOS:A1993LY01900102
J	SHUMAN, S; TURNER, J				SHUMAN, S; TURNER, J			SITE-SPECIFIC INTERACTION OF VACCINIA VIRUS TOPOISOMERASE-I WITH BASE AND SUGAR MOIETIES IN DUPLEX DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLEAVAGE; BINDING	Vaccinia DNA topoisomerase specifically binds and forms a covalent adduct at DNA sites containing a conserved sequence element 5'(C/T)CCTT down in the scissile strand. The molecular interactions that contribute to recognition of the CCCTT motif in a synthetic DNA substrate have been examined using modification interference, modification protection, and analog substitution techniques. We report that topoisomerase makes contact with guanine nucleotide bases of the pentamer motif complementary strand (3'GGGAA) within the major groove of the DNA helix and that alteration of the binding surface by chemical modification is deleterious to the interaction. Additional contacts are made with guanine residues located outside the pentamer element. The enzyme is unable to form a covalent adduct with synthetic RNA substrates. Analysis of the cleavage of DNA duplexes containing 2'OMe sugars suggests that the inability of the vaccinia topoisomerase to cleave either an RNA duplex or an RNA:DNA hybrid can be accounted for by the interfering effects of a 2' sugar substituent at two or more sites within the pentamer. Interaction with the sugar at the +2T nucleotide appears to be the most critical, as judged by the effects of single sugar substitutions.			SHUMAN, S (corresponding author), SLOAN KETTERING INST CANC RES,MOLEC BIOL PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; DIGATE RJ, 1992, J BIOL CHEM, V267, P20532; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E	9	47	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18943	18950						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689562				2022-12-27	WOS:A1993LV65900085
J	HALDEMAN, MT; FINLEY, D; PICKART, CM				HALDEMAN, MT; FINLEY, D; PICKART, CM			DYNAMICS OF UBIQUITIN CONJUGATION DURING ERYTHROID-DIFFERENTIATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; DEPENDENT PROTEOLYTIC PATHWAY; PROTEIN LIGASE SYSTEM; REPAIR GENE RAD6; N-END RULE; CARRIER PROTEINS; RETICULOCYTE MATURATION; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; E6 ONCOPROTEIN	To gain insight into the role of ubiquitin-mediated proteolysis in erythroid differentiation, levels of ubiquitin conjugating enzymes (E2s) and ubiquitin conjugates were analyzed during in vitro differentiation of murine erythroleukemic (MEL) cells, After 4 days of culture in the presence of the inducer dimethyl sulfoxide, MEL cells expressed high levels of the erythroid-specific proteins, globin, and band 3. During the same interval, cellular contents (mol/cell) of E2-14K, E2-25K, and E2-35K decreased up to similar to 5-fold; as suggested by results obtained with E2-25K, this reflected a lower level of mRNA in differentiating cells. Concentrations of these E2s changed more modestly during in vitro differentiation, since cellular volume also decreased. Comparison of levels of the three E2s in undifferentiated MEL cells and reticulocytes suggests that their concentrations remain fairly constant during in vivo differentiation of proerythroblasts into reticulocytes. Thus, these components of the ubiquitin-mediated proteolytic pathway are likely to function constitutively during this interval. Two dimensional Western blots showed a broad spectrum of ubiquitin conjugates, including free multiubiquitin chains, in undifferentiated MEL cells. As seen for several E2s, the concentration of ubiquitin conjugates (including free chains) decreased modestly during in vitro differentiation. E2-20K and E2-230K, which are abundant in reticulocytes, were low or absent in undifferentiated and differentiated MEL cells, In erythroid cells these two E2s are reticulocyte-specific; apparently MEL cells do not differentiate far enough to allow induction of their expression.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043769] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43769] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1990, BIOCHEM BIOPH RES CO, V171, P705, DOI 10.1016/0006-291X(90)91203-5; BOCHES FS, 1982, SCIENCE, V215, P978, DOI 10.1126/science.7156977; BOND U, 1988, J BIOL CHEM, V263, P2384; BULL BS, 1990, HEMATOLOGY, P297; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICOLA D, 1991, FEBS LETT, V280, P137, DOI 10.1016/0014-5793(91)80222-O; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; GUO GG, 1994, J BIOL CHEM, V269, P12399; GUPTAROY B, 1992, J BIOL CHEM, V267, P15326; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1991, ADV EXP MED BIOL, V307, P191; HAAS AL, 1987, J BIOL CHEM, V262, P345; HADARI T, 1992, J BIOL CHEM, V267, P719; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSHKO A, 1982, J BIOL CHEM, V257, P13694; HERSHKO A, 1982, P NATL ACAD SCI USA, V77, P1783; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; KLEMPERER NS, 1989, BIOCHEMISTRY-US, V28, P6035, DOI 10.1021/bi00440a047; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENK SE, 1992, J CELL BIOL, V118, P301, DOI 10.1083/jcb.118.2.301; MA CP, 1994, J BIOL CHEM, V269, P3539; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MAGNANI M, 1986, J BIOL CHEM, V261, P8327; MAGNANI M, 1991, J BIOL CHEM, V266, P21018; MAGNANI M, 1994, BBA-PROTEIN STRUCT M, V1206, P180, DOI 10.1016/0167-4838(94)90206-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; PARKER D, 1985, J BIOL CHEM, V260, P604; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; PICKART CM, 1991, DEV GROWTH DIFFER, V33, P587; PICKART CM, 1988, J BIOL CHEM, V263, P12028; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; RAPOPORT SM, 1986, RETICULOCYTE; RAVIV O, 1987, BIOCHEM BIOPH RES CO, V145, P658, DOI 10.1016/0006-291X(87)91015-1; RAWNSLEY HM, 1981, CLIN BIOCH HEMATOLOG; REISS Y, 1990, J BIOL CHEM, V265, P3685; SAWYER ST, 1987, METHOD ENZYMOL, V147, P340; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; SHIMBARA N, 1993, FEBS LETT, V322, P235, DOI 10.1016/0014-5793(93)81577-M; SPEISER S, 1982, J BIOL CHEM, V257, P4122; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STECK TL, 1971, BIOCHEMISTRY-US, V10, P2617, DOI 10.1021/bi00789a031; TSUKAHARA T, 1990, EXP CELL RES, V188, P111, DOI 10.1016/0014-4827(90)90284-H; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; VOLLOCH V, 1982, J CELL BIOL, V93, P390, DOI 10.1083/jcb.93.2.390; WFES I, 1995, IN PRESS P NATL ACAD; WING SS, 1992, J BIOL CHEM, V267, P6495	79	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9507	9516		10.1074/jbc.270.16.9507	http://dx.doi.org/10.1074/jbc.270.16.9507			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721879	Green Submitted, hybrid			2022-12-27	WOS:A1995QU08900068
J	SEELIG, GF; PROSISE, WW; HAWKINS, JC; SENIOR, MM				SEELIG, GF; PROSISE, WW; HAWKINS, JC; SENIOR, MM			DEVELOPMENT OF A RECEPTOR PEPTIDE ANTAGONIST TO HUMAN GAMMA-INTERFERON AND CHARACTERIZATION OF ITS LIGAND-BOUND CONFORMATION USING TRANSFERRED NUCLEAR OVERHAUSER EFFECT SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; EXTRACELLULAR DOMAIN; IFN-GAMMA; PROTEIN; ANTIBODY; COMPLEX; BINDING; ANTIGEN; IDENTIFICATION; RECOGNITION	Polyclonal anti-idiotypic antibody raised to a synthetic discontinuous peptide derived from the human gamma-interferon (huIFN-gamma) sequence recognizes soluble human gamma-interferon receptor (Seelig, G. F., Prosise, W. W., and Taremi, S, S, (1994) J. Biol, Chem, 269, 358-363), We sought to use this reagent to identify a ligand-binding domain within IFN-gamma-receptor. To do this, the neutralizing anti-idiotypic antibody was used to probe overlapping linear peptide octamers of the extracellular do main of the huIFN-gamma receptor, A 22-amino acid residue receptor segment 120-141 identified by the antibody was synthesized, CD and NMR analysis indicates that peptide 120-141 has no apparent secondary structure in water or in water containing 50% trifluoroethanol, The synthetic receptor peptide inhibited huIFN-gamma induced expression of HLA/DR antigen on Cole 205 cells with an approximate IC50 of 35 mu M. Immobilized peptide specifically bound recombinant huIFN-gamma but did not bind human granulocyte-macrophage colony-stimulating factor on a microtiter plate in a direct binding enzyme-linked immunosorbent assay. The binding results are supported by two-dimensional transferred nuclear Overhauser effect (TRNOE) NMR data obtained on the peptide in the presence of recombinant huIFN-gamma. Characterization of the conformation of the bound peptide by TRNOE suggests that this peptide assumes a distinct conformation. Intramolecular interactions within the bound peptide were detected at two non-contiguous regions and at a third region comprising a p-turn formed by the sequence DIRK. We believe that this represents the structure of the receptor within the ligand-binding domain.	SCHERING PLOUGH CORP,RES INST,DEPT PHYS ANALYT CHEM RES & DEV,KENILWORTH,NJ 07033	Merck & Company; Schering Plough Corporation	SEELIG, GF (corresponding author), SCHERING PLOUGH CORP,RES INST,DEPT STRUCT CHEM,KENILWORTH,NJ 07033, USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWELLER JH, 1991, BIOCHEMISTRY-US, V30, P8144, DOI 10.1021/bi00247a008; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GEORGIADES JA, 1984, INTERFERONS THEIR AP, V71, P305; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GIBBS VC, 1992, MOL CELL BIOL, V11, P5860; GIBSON UEM, 1989, J IMMUNOL METHODS, V125, P105, DOI 10.1016/0022-1759(89)90083-5; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GRAY PW, 1983, P S BIOL BASIS NEW D, P35; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNN CA, 1992, J BIOL CHEM, V267, P17920; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAGABHUSAN TL, 1989, Patent No. 4751078; NAGABHUSHAN TL, 1985, INTERFERON ALPHA 2 P, P1; NEUHAUS D, 1989, NUCLEAR OVERHAUSER E, P175; NOGGLE JH, 1971, NUCLEAR OVERHAUSER E, P4; OTTING G, 1993, CURR OPIN STRUC BIOL, V3, P760, DOI 10.1016/0959-440X(93)90061-O; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RIZO J, 1992, ANNU REV BIOCHEM, V61, P387, DOI 10.1146/annurev.bi.61.070192.002131; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SEELIG GF, 1992, J CELL BIOCHEM, V16, P101; SEELIG GF, 1994, J BIOL CHEM, V269, P858; SEELIG GF, 1989, J INTERFERON RES, V4, P184; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; STUBER D, 1993, BIOCHEMISTRY-US, V32, P2432; SUKES B, 1991, J MAGN RESON, V93, P77; SZENTE BE, 1994, BIOCHEM BIOPH RES CO, V208, P1645; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TROTTA P, 1987, Patent No. 883064214; TROTTA PP, 1986, INTERFERONS CELL GRO, P497; VANVOLKENBURG MA, 1993, J IMMUNOL, V151, P6206; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P162	59	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9241	9249		10.1074/jbc.270.16.9241	http://dx.doi.org/10.1074/jbc.270.16.9241			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721843	hybrid			2022-12-27	WOS:A1995QU08900031
J	IIDAKLEIN, A; GUO, J; XIE, LY; JUPPNER, H; POTTS, JT; KRONENBERG, HM; BRINGHURST, FR; ABOUSAMRA, AB; SEGRE, GV				IIDAKLEIN, A; GUO, J; XIE, LY; JUPPNER, H; POTTS, JT; KRONENBERG, HM; BRINGHURST, FR; ABOUSAMRA, AB; SEGRE, GV			TRUNCATION OF THE CARBOXYL-TERMINAL REGION OF THE RAT PARATHYROID-HORMONE (PTH)/PTH-RELATED PEPTIDE RECEPTOR ENHANCES PTH STIMULATION OF ADENYLYL-CYCLASE BUT NOT PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; VASOACTIVE-INTESTINAL-PEPTIDE; OSTEOBLAST-LIKE CELLS; EXPRESSION CLONING; INOSITOL TRISPHOSPHATE; MOLECULAR-CLONING; SARCOMA CELLS; CALCIUM; CAMP; POLYPEPTIDE	The functional role of the rat parathyroid hormone(PTH)/PTH-related peptide (PTHrP) receptor's carboxyl-terminal region was characterized by comparing the binding and signaling properties of receptors that have 78 and 111 amino acid deletions (R513 and R480, respectively), with those of the 591-amino acid wild-type (WT) receptor. R480 and R513 have 4- and 1.5-fold lower apparent K-d values for rat PTH-(1-34) (rPTH), compared with the WT receptor (WT, 1.81 +/- 0.19 nM; R513, 1.24 +/- 0.12 nM; R480, 0.48 +/- 0.05 nM, mean +/- S.E.). PTH (100 nM) stimulated cAMP accumulation and polyphosphoinositide hydrolysis both correlated positively with receptor expression. However, whereas PTH-stimulated polyphosphoinositide hydrolysis was indistinguishable among WT and either truncated mutant at comparable levels of expressed receptors, maximal PTH-stimulated cAMP accumulation was 4-6- and 2-3-fold higher in cells expressing R480 and R513, respectively. Furthermore, pretreatment of COS-7 cells with 100 ng/ml of pertussis toxin (PTX) enhanced PTH-stimulated cAMP accumulation in cells expressing the WT receptor, but failed to do so in cells expressing either R480 or R513. Thus, sequences in the PTH/PTHrP receptor's carboxyl-terminal tail lower the affinity of the WT receptor for agonist; directly interact with, or indirectly facilitate the interaction of the receptor with a PTX-sensitive G protein that inhibits adenylyl cyclase; and decrease the efficacy with which the receptor interacts with G(s).	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Abou-Samra, Abdul/ABE-8723-2020	Abou-Samra, Abdul/0000-0001-8735-1142	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK008751] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47034, DK11794, 1-F32-DK08751] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo-124-3-1107; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2594; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRINGHURST FR, 1992, ENDOCRINOLOGY, V132, P2090; Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CIVETELLI R, 1988, AM J PHYSIOL, V253, pE660; EDELMAN A, 1986, AM J PHYSIOL, V251, pC483, DOI 10.1152/ajpcell.1986.251.4.C483; FEYEN JHM, 1984, PROSTAGLANDINS, V28, P269; GUO J, 1993, J BONE MINER RES, V8, pS176; IIDAKLEIN A, 1989, J BONE MINER RES, V4, P767; IIDAKLEIN A, 1991, ENDOCRINOLOGY, V129, P1016, DOI 10.1210/endo-129-2-1016; IIDAKLEIN A, 1989, J BONE MINER RES  S1, V4, P879; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KRONENBERG HM, 1993, HDB EXPT PHARM, V107, P507; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PINES M, 1986, BONE MINER, V1, P15; REAGAN JD, 1994, J BIOL CHEM, V269, P9; REID IR, 1987, AM J PHYSIOL, V225, pE9; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SEGRE JV, 1992, J ENDOCRINOL INVEST, V15, P11; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WANK SA, 1993, P NATIONAL ACADEMY S, V90, P6345; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711	42	84	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8458	8465		10.1074/jbc.270.15.8458	http://dx.doi.org/10.1074/jbc.270.15.8458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721741	hybrid			2022-12-27	WOS:A1995QT44800017
J	CERVANTESLAUREAN, D; LOFLIN, PT; MINTER, DE; JACOBSON, EL; JACOBSON, MK				CERVANTESLAUREAN, D; LOFLIN, PT; MINTER, DE; JACOBSON, EL; JACOBSON, MK			PROTEIN MODIFICATION BY ADP-RIBOSE VIA ACID-LABILE LINKAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; ISLET-ACTIVATING PROTEIN; ADENYLATE-CYCLASE; MEMBRANE-PROTEIN; RIBOSYLATION; RIBOSYLTRANSFERASE; INVIVO; SUBSTRATE; RESIDUE; CELLS	As substrate for protein-mono-ADP-ribosyltransferases, NAD has been shown to be the donor of ADP-ribose to many different nucleophiles found in proteins. This post-translational modification of proteins has been implicated in the regulation of membrane associated processes including signal transduction, muscle cell differentiation, and protein trafficking and secretion. Described here is the preparation and chemical characterization of low molecular weight conjugates that were used as models for an acetal linkage between ADP-ribose and the hydroxyl group of a protein acceptor such as serine, threonine, tyrosine, hydroxyproline, or hydroxylysine residues. Model conjugates of ADP-ribose containing an acetal linkage were prepared, their structures were established by NMR, and the chemical stability of the linkage to ADP-ribose was studied and compared to the other known ADP-ribosyl-amino acid linkages. The rapid release of intact ADP-ribose from the acetal model conjugates in 44% formic acid distinguished them chemically from all the other known ADP-ribosyl-amino acid modifications. Rat liver proteins were shown to be modified by ADP-ribose in vivo by acid-labile linkages, providing evidence for a new class of endogenous ADP-ribose modification of animal cell proteins. The amount of modification was approximately 16 pmol of ADP-ribose per mg of total protein, and proteins modified by acid-labile linkages were detected in all subcellular fractions examined, suggesting that the scope of this modification in vivo is broad.	UNIV KENTUCKY,DEPT CLIN SCI,LEXINGTON,KY 40536; UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536; TEXAS CHRISTIAN UNIV,DEPT CHEM,FT WORTH,TX 76129; UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,FT WORTH,TX 76107	University of Kentucky; University of Kentucky; Texas Christian University; University of North Texas System; University of North Texas Health Science Center	CERVANTESLAUREAN, D (corresponding author), UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536, USA.				NCI NIH HHS [CA43894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAON MA, 1985, BICOH J, V229, P269; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P12; ANDERSON B, 1964, NATURE, V239, P2716; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BRADFORD M, 1976, ANAL BIOCHEM, V72, P633; Burzio L.O., 1982, P103; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; Collier RJ, 1982, ADP RIBOSYLATION REA, P575; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; FERRO AM, 1978, P NATL ACAD SCI USA, V75, P809, DOI 10.1073/pnas.75.2.809; HUANG HY, 1993, BIOCHEM BIOPH RES CO, V197, P570, DOI 10.1006/bbrc.1993.2517; JACOBSON MK, 1984, METHOD ENZYMOL, V106, P483; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; JACOBSON MK, 1990, ADP RIBOSYLATING TOX, P479; KATADA T, 1982, J BIOL CHEM, V257, P7210; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KUROSAWA M, 1994, J PHARMACOL TOXICOL, V31, P135, DOI 10.1016/1056-8719(94)90075-2; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; MCDONALD LJ, 1993, J BIOL CHEM, V268, P17878; MIWA M, 1977, NUCLEIC ACIDS RES, V4, P3997, DOI 10.1093/nar/4.11.3997; MOSS J, 1978, P NATL ACAD SCI USA, V75, P3621, DOI 10.1073/pnas.75.8.3621; MOSS J, 1977, J BIOL CHEM, V52, P2455; OBARA S, 1991, EUR J BIOCHEM, V200, P75, DOI 10.1111/j.1432-1033.1991.tb21050.x; OPPENHEIMER NJ, 1978, J BIOL CHEM, V253, P4907; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SUZUKI H, 1986, J BIOL CHEM, V261, P6048; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILLIAMSON KC, 1990, ADP RIBOSYLATING TOX, P479; YOST DA, 1982, J BIOL CHEM, V257, P767; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273	36	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7929	7936		10.1074/jbc.270.14.7929	http://dx.doi.org/10.1074/jbc.270.14.7929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713889	Green Submitted, hybrid			2022-12-27	WOS:A1995QR52600025
J	LANDINI, P; VOLKERT, MR				LANDINI, P; VOLKERT, MR			TRANSCRIPTIONAL ACTIVATION OF THE ESCHERICHIA-COLI ADAPTIVE RESPONSE GENE AIDB IS MEDIATED BY BINDING OF METHYLATED ADA PROTEIN - EVIDENCE FOR A NEW CONSENSUS SEQUENCE FOR ADA-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYLATING-AGENTS; ALKA GENE; EXPRESSION; DNA; INDUCTION; IDENTIFICATION; REGULATOR; ELEMENTS; PROMOTER; REPAIR	The Escherichia coli aidB gene is part of the adaptive response to DNA methylation damage. Genes belonging to the adaptive response are positively regulated by the ada gene; the Ada protein acts as a transcriptional activator when methylated in one of its cysteine residues at position 69. Through DNaseI protection assays, we show that methylated Ada ((me)Ada) is able to bind a DNA sequence between 40 and 60 base pairs upstream of the aidB transcriptional startpoint. Binding of (me)Ada is necessary to activate transcription of the adaptive response genes; accordingly, in vitro transcription of aidB is dependent on the presence of (me)Ada. Unmethylated Ada protein shows no protection against DNaseI digestion in the aidB promoter region nor does it promote aidB in vitro transcription. The aidB Ada-binding site shows only weak homology to the proposed consensus sequences for Ada-binding sites in E. coli (AAANNAA and AAAGCGCA) but shares a higher degree of similarity with the Ada-binding regions from other bacterial species, such as Salmonella typhimurium and Bacillus subtilis. Based on the comparison of five different Ada-dependent promoter regions, we suggest that a possible recognition sequence for (me)Ada might be AATnnnnnnG-CAA. Higher concentrations of Ada are required for the binding of aidB than for the ada promoter, suggesting lower affinity of the protein for the aidB Ada-binding site. Common features in the Ada-binding regions of ada and aidB are a high A/T content, the presence of an inverted repeat structure, and their position relative to the transcriptional start site. We propose that these elements, in addition to the proposed recognition sequence, are important for binding of the Ada protein.	UNIV MASSACHUSETTS,SCH MED,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester			Landini, Paolo/B-7859-2017	Landini, Paolo/0000-0003-0999-426X; Volkert, Michael/0000-0002-0045-0912	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037052] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37052] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; BERTRANDBURGGRAF E, 1990, EMBO J, V9, P2265, DOI 10.1002/j.1460-2075.1990.tb07397.x; HAKURA A, 1991, J BACTERIOL, V173, P3663, DOI 10.1128/JB.173.12.3663-3672.1991; JEGGO P, 1979, J BACTERIOL, V139, P783, DOI 10.1128/JB.139.3.783-791.1979; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; LANDINI P, 1994, J BACTERIOL, V176, P6583, DOI 10.1128/JB.176.21.6583-6589.1994; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; MOROHOSHI F, 1990, NUCLEIC ACIDS RES, V18, P5473, DOI 10.1093/nar/18.18.5473; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; NAKABEPPU Y, 1986, P NATL ACAD SCI USA, V83, P6297, DOI 10.1073/pnas.83.17.6297; NAKAMURA T, 1988, J MOL BIOL, V202, P483, DOI 10.1016/0022-2836(88)90280-X; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; SAGET BM, 1994, P NATL ACAD SCI USA, V91, P9730, DOI 10.1073/pnas.91.21.9730; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SAKUMI K, 1993, J BACTERIOL, V175, P2455, DOI 10.1128/JB.175.8.2455-2457.1993; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; SMIRNOVA GV, 1994, MUTAT RES, V314, P51, DOI 10.1016/0921-8777(94)90060-4; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; VOLKERT MR, 1989, J BACTERIOL, V171, P1196, DOI 10.1128/jb.171.2.1196-1198.1989; VOLKERT MR, 1986, GENETICS, V112, P11; VOLKERT MR, 1989, MUTAT RES, V217, P109, DOI 10.1016/0921-8777(89)90062-1	24	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8285	8289		10.1074/jbc.270.14.8285	http://dx.doi.org/10.1074/jbc.270.14.8285			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713936	hybrid			2022-12-27	WOS:A1995QR52600075
J	SLACK, BE; BREU, J; PETRYNIAK, MA; SRIVASTAVA, K; WURTMAN, RJ				SLACK, BE; BREU, J; PETRYNIAK, MA; SRIVASTAVA, K; WURTMAN, RJ			TYROSINE PHOSPHORYLATION-DEPENDENT STIMULATION OF AMYLOID PRECURSOR PROTEIN SECRETION BY THE M3 MUSCARINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SWISS 3T3 CELLS; KINASE-C; BETA-PROTEIN; ALZHEIMERS-DISEASE; PHOSPHOLIPASE-C; PHORBOL ESTER; ADENYLYL CYCLASE; RAT ADIPOCYTES; CLEAVAGE SITE	Stimulation of m1 and m3 muscarinic acetylcholine receptors, which are coupled to phosphoinositide hydrolysis and protein kinase C activation, has been shown to increase the release of soluble amyloid precursor protein derivatives (APPs). The effect is mimicked by phorbol esters, which directly activate protein kinase C. Using human embryonic kidney cells expressing individual muscarinic receptor subtypes, we found that stimulation of APPs release by the muscarinic agonist carbachol was only partially reduced by a specific inhibitor of protein kinase C (the bisindolylmaleimide GF 109203X), while the response to phorbol 12-myristate 13-acetate (PMA) was abolished. The increase in APPs release elicited by carbachol and PMA was accompanied by elevated tyrosine phosphorylation of several proteins and reduced by tyrosine kinase inhibitors; GF 109203X significantly reduced the stimulation of tyrosine phosphorylation by carbachol and PMA. Inhibition of protein tyrosine phosphatases by vanadyl hydroperoxide markedly increased cellular tyrosine phosphorylation and enhanced APPs release as effectively as PMA and carbachol. Direct phosphorylation of amyloid precursor protein on tyrosine residues following treatment with carbachol, PMA, or vanadyl hydroperoxide was not observed. The results implicate both tyrosine phosphorylation and protein kinase C dependent mechanisms in the regulation of APPs release by G protein-coupled receptors, and suggest that carbachol and PMA increase APPs release from human embryonic kidney cells expressing m3 muscarinic receptors via partially divergent pathways that converge at a tyrosine phosphorylation-dependent step.			SLACK, BE (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139, USA.		Slack, Barbara/AAU-9917-2021	Slack, Barbara/0000-0002-7619-410X				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; ATKINSON TP, 1993, J IMMUNOL, V151, P1448; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EMMERLING MR, 1993, BIOCHEM BIOPH RES CO, V197, P292, DOI 10.1006/bbrc.1993.2474; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HU BR, 1993, J NEUROCHEM, V61, P1789, DOI 10.1111/j.1471-4159.1993.tb09817.x; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUNG AY, 1993, J BIOL CHEM, V268, P22959; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROCH JM, 1992, J BIOL CHEM, V267, P2214; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHAPIRO IP, 1991, J NEUROCHEM, V56, P1154, DOI 10.1111/j.1471-4159.1991.tb11405.x; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VENER AV, 1993, FEBS LETT, V328, P6, DOI 10.1016/0014-5793(93)80953-R; WANG R, 1991, J BIOL CHEM, V266, P16960; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	75	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8337	8344		10.1074/jbc.270.14.8337	http://dx.doi.org/10.1074/jbc.270.14.8337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713942	hybrid			2022-12-27	WOS:A1995QR52600081
J	MAZZEI, GJ; EDGERTON, MD; LOSBERGER, C; LECOANETHENCHOZ, S; GRABER, P; DURANDY, A; GAUCHAT, JF; BERNARD, A; ALLET, B; BONNEFOY, JY				MAZZEI, GJ; EDGERTON, MD; LOSBERGER, C; LECOANETHENCHOZ, S; GRABER, P; DURANDY, A; GAUCHAT, JF; BERNARD, A; ALLET, B; BONNEFOY, JY			RECOMBINANT SOLUBLE TRIMERIC CD40 LIGAND IS BIOLOGICALLY-ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							B-CELLS; IGE SYNTHESIS; EXPRESSION; INDUCTION; ANTIBODY; CLONING; SUBSET; GP39; FORM	CD40 ligand (CD40L) is expressed on the surface of activated CD4(+) T cells, basophils, and mast cells. Binding of C40L to its receptor, CD40, on the surface of B cells stimulates B cell proliferation, adhesion and differentiation. A preparation of soluble, recombinant CD40L (Tyr-45 to Leu-261), containing the full-length 29-kDa protein and two smaller fragments of 18 and 14 kDa, has been shown to induce differentiation of B cells derived either from normal donors or from patients with X-linked hyper-IgM syndrome (Durandy, A., Schiff, C., Bonnefoy, J.-Y., Forveille, M., Rousset, F., Mazzei, G., Milili, M., and Fischer, A. (1993) fur. J. Immunol. 23, 2294-2299). We have now purified each of these fragments to homogeneity and show that only the 18-kDa fragment (identified as Glu 108 to Leu-261) is biologically active. When expressed in recombinant form, the 18-kDa protein exhibited full activity in B cell proliferation and differentiation assays, was able to rescue of B cells from apoptosis, and bound soluble CD40. Sucrose gradient sedimentation shows that the 18-kDa protein sediments as an apparent homotrimer, a result consistent with the proposed trimeric structure of CD40L. This demonstrates that a soluble CD40L can stimulate CD40 in a manner indistinguishable from the membrane-bound form of the protein.	HOP NECKER ENFANTS MALAD,INSERM,U132,F-75743 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	MAZZEI, GJ (corresponding author), GLAXO INST MOLEC BIOL SA,14 CHEMIN AULX,CH-1228 PLAN LES OUATE,SWITZERLAND.		Durandy, Anne/H-7475-2017	Durandy, Anne/0000-0001-7706-8466				ALLET B, 1988, GENE, V65, P259, DOI 10.1016/0378-1119(88)90462-3; Armitage R J, 1993, Semin Immunol, V5, P401; ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; DURANDY A, 1993, EUR J IMMUNOL, V23, P2294, DOI 10.1002/eji.1830230936; FOY TM, 1993, J EXP MED, V178, P1567, DOI 10.1084/jem.178.5.1567; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HOLLENBAUGH D, 1994, IMMUNOL REV, V138, P23, DOI 10.1111/j.1600-065X.1994.tb00845.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SPRIGGS MK, 1993, J CLIN IMMUNOL, V13, P373, DOI 10.1007/BF00920012; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466	24	146	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7025	7028		10.1074/jbc.270.13.7025	http://dx.doi.org/10.1074/jbc.270.13.7025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706236	hybrid			2022-12-27	WOS:A1995QQ43100004
J	MCNEIL, L; CHINKERS, M; FORTE, M				MCNEIL, L; CHINKERS, M; FORTE, M			IDENTIFICATION, CHARACTERIZATION, AND DEVELOPMENTAL REGULATION OF A RECEPTOR GUANYLYL CYCLASE EXPRESSED DURING EARLY STAGES OF DROSOPHILA DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL CYCLASE; FAMILY; KINASE; HYBRIDIZATION; SEQUENCE; PROTEINS; EMBRYOS; CDNA	Membrane forms of guanylyl cyclase are single-transmembrane proteins that are activated by the binding of specific peptide ligands to their extracellular domains. In this report, we describe the identification and characterization of a Drosophila cDNA clone encoding a protein, DrGC-1, with high sequence identity to members of this family of receptor proteins, The protein contains a single, hydrophobic domain predicted to represent a transmembrane segment separating an extracellular domain with significant sequence identity (30%) to sea urchin egg peptide receptors from intracellular domains containing a protein kinase-like domain followed by a region with high sequence identity (65%) to cyclase catalytic domains found in receptor guanylyl cyclases from both vertebrates and invertebrates. In contrast to other members of this family, DrGC-1 is predicted to contain a carboxyl-terminal extension of 430 residues that has no homology to any described protein. Northern analysis indicates that DrGC-1 transcripts are present at variable levels in all stages of development. In situ hybridization demonstrates that high levels of uniformly distributed transcript are present in 0-2-h embryos. Later in embryogenesis (14-18 h), elevated levels of hybridization appear to be preferentially associated with muscle fibers.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHARMACOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								BREDT D, 1994, ANN REV BIOCH, V43, P175; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; GIGLIOTTI S, 1993, DEV BIOL, V159, P450, DOI 10.1006/dbio.1993.1255; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; ITOH N, 1985, DROS INF SERVICE, V61, P89; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Maniatis T., 1982, MOL CLONING; MORAN MF, 1988, ONCOGENE, V3, P665; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STJOHNSTON D, 1992, CELL, V68, P201; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; YOSHIKAWA S, 1993, J NEUROCHEM, V60, P1570, DOI 10.1111/j.1471-4159.1993.tb03324.x	25	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7189	7196		10.1074/jbc.270.13.7189	http://dx.doi.org/10.1074/jbc.270.13.7189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706258	hybrid			2022-12-27	WOS:A1995QQ43100029
J	FLETCHER, MC; SAMELSON, LE; JUNE, CH				FLETCHER, MC; SAMELSON, LE; JUNE, CH			COMPLEX EFFECTS OF PHENYLARSINE OXIDE IN T-CELLS - INDUCTION OF TYROSINE PHOSPHORYLATION AND CALCIUM MOBILIZATION INDEPENDENT OF CD45 EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYL-INOSITOL PATHWAY; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; HIGH-AFFINITY; TUBULE CELLS; ACTIVATION; KINASE; STIMULATION; PHOSPHOTYROSINE	The effects of phenylarsine oxide, a phosphotyrosine phosphatase inhibitor, on early signal transduction events in human T cells were studied. Simultaneous stimulation of T cells with anti-CD3 monoclonal antibody and phenylarsine oxide prevented increased tyrosine phosphorylation of phospholipase Cgamma1. In contrast, treatment of resting T cells with phenylarsine oxide alone resulted in increased tyrosine phosphorylation of a number of other intracellular substrates. Further, phenylarsine oxide was able to cause an immediate disruption of signal transduction in T cells after anti-CD3 stimulation, as measured by a return of intracellular calcium concentration and inositol 1,4,5-trisphosphate production to base-line levels. Surprisingly, in view of the inhibitory effects of phenylarsine oxide on T cell receptor signal transduction, treatment of T cells with phenylarsine oxide alone caused a dose-dependent increase in intracellular-free calcium concentration that was not accompanied with detectable increases in inositol 1,4,5-trisphosphate production. The phenylarsine oxide-induced increase in free calcium had distinct kinetics from antigen receptor-activated calcium mobilization and was derived from both intracellular sources and increased plasma membrane calcium permeability. This effect was independent of the CD45 transmembrane tyrosine phosphatase. Phenylarsine oxide thus has complex effects on signal transduction in T cells that suggests multiple intracellular targets, and these should be considered in the interpretation of experiments using this agent to study cellular kinase and phosphatase interactions. Finally, the effects of phenylarsine oxide on cellular calcium homeostasis may provide a mechanism of action for the therapeutic and/or toxic effects of arsenicals used for various forms of chemotherapy.	USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20889; NIH,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ABRAHAM RT, 1992, TRENDS BIOCHEM SCI, V17, P434, DOI 10.1016/0968-0004(92)90015-2; ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FELL HB, 1946, BRIT J EXP PATHOL, V27, P310; FELL HB, 1946, BRIT J EXP PATHOL, V27, P305; FREED BM, 1991, TOXICOL APPL PHARM, V107, P173, DOI 10.1016/0041-008X(91)90341-B; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GOLDMAN SJ, 1992, J BIOL CHEM, V267, P6197; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; LIAO K, 1991, J BIOL CHEM, V266, P6544; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEEK JL, 1986, P NATL ACAD SCI USA, V83, P4162, DOI 10.1073/pnas.83.12.4162; NICOTERA P, 1989, FASEB J, V3, P59, DOI 10.1096/fasebj.3.1.2910738; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PHELPS PC, 1989, LAB INVEST, V60, P630; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SMITH MW, 1992, AM J PHYSIOL, V262, pF647, DOI 10.1152/ajprenal.1992.262.4.F647; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	46	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23697	23703						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693695				2022-12-27	WOS:A1993MF51500110
J	DIMARCO, E; MATHOR, M; BONDANZA, S; CUTULI, N; MARCHISIO, PC; CANCEDDA, R; DELUCA, M				DIMARCO, E; MATHOR, M; BONDANZA, S; CUTULI, N; MARCHISIO, PC; CANCEDDA, R; DELUCA, M			NERVE GROWTH-FACTOR BINDS TO NORMAL HUMAN KERATINOCYTES THROUGH HIGH AND LOW-AFFINITY RECEPTORS AND STIMULATES THEIR GROWTH BY A NOVEL AUTOCRINE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN KERATINOCYTES; HUMAN MELANOCYTE GROWTH; FACTOR NGF RECEPTOR; TRK PROTOONCOGENE; TYROSINE PHOSPHORYLATION; NEUROTROPHIN RECEPTORS; MONOCLONAL-ANTIBODIES; INTEGRIN RECEPTORS; KINASE-ACTIVITY; MESSENGER-RNA	Normal human keratinocytes synthesize and secrete biologically active nerve growth factor (NGF) in a growth regulated fashion (Di Marco, E., Marchisio, P. C., Bondanza, S., Franzi, A. T., Cancedda, R., and De Luca, M. (1991) J. Biol. Chem. 266, 21718-21722). Here we show that the same human keratinocytes bind NGF via low and high affinity receptors. In parallel with the course of NGF synthesis, the expression of low affinity NGF receptor (p75NGFr) decreases when a confluent, differentiated, and fully stratified epithelium is obtained. In skin sections, p75NGFr is present in basal keratinocytes and absent from suprabasal, terminally differentiated cells. The trkA protooncogene product (p140trkA), a component of the NGF receptor, is not expressed by keratinocytes. Instead, keratinocytes express a new member of the trk family (that we termed trkE), which generates 3.9-kilobase transcripts. Keratinocyte-derived NGF plays a key role in the autocrine epidermal cell proliferation. This has been proven by (i) direct effect of NGF on [H-3]thymidine incorporation, (ii) inhibition of autocrine keratinocyte growth by monoclonal antibodies (alphaD11) inhibiting human NGF biological activity, and (iii) inhibition of autocrine keratinocyte proliferation by a trk-specific inhibitor, the natural alkaloid K252a. These data provide evidence that NGF, in addition to its effect as a survival and differentiation factor, is a potent regulator of cell proliferation, at least in human epithelial cells.	IST NAZL RIC CANC, DIFFERENZIAMENTO CELLULARE LAB, VIALE BENEDETTO XV 10, I-16132 GENOA, ITALY; UNIV TURIN, DIPARTIMENTO SCI BIOMED & ONCOL, I-10124 TURIN, ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Turin			De Luca, Michele/N-5883-2014; Mathor, Monica B/C-3975-2012	De Luca, Michele/0000-0002-0850-8445; Mathor, Monica B/0000-0002-7294-9106				BARKER PA, 1992, MOL CELL BIOCHEM, V110, P1, DOI 10.1007/BF02385000; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERG MM, 1992, J BIOL CHEM, V267, P13; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; CATTANEO A, 1988, J NEUROCHEM, V50, P1003, DOI 10.1111/j.1471-4159.1988.tb10565.x; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DELUCA M, 1988, EUR J CELL BIOL, V46, P176; DELUCA M, 1988, J CELL BIOL, V107, P1919, DOI 10.1083/jcb.107.5.1919; DELUCA M, 1990, TRANSPLANTATION, V50, P454, DOI 10.1097/00007890-199009000-00019; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DELUCA M, 1992, BURNS, V18, pS5, DOI 10.1016/0305-4179(92)90103-2; DELUCA M, 1993, KERATINOCYTE HDB; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; EISINGER M, 1988, P NATL ACAD SCI USA, V85, P1937, DOI 10.1073/pnas.85.6.1937; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; EVELETH DD, 1992, J CELL BIOL, V117, P291, DOI 10.1083/jcb.117.2.291; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FANTINI F, 1992, J INVEST DERMATOL, V99, P734, DOI 10.1111/1523-1747.ep12614465; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GORDON PR, 1989, J INVEST DERMATOL, V92, P565, DOI 10.1111/1523-1747.ep12709595; Green H, 1980, Harvey Lect, V74, P101; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HAEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993, DOI 10.1073/pnas.86.15.5993; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KORSCHING S, 1985, EMBO J, V4, P1389, DOI 10.1002/j.1460-2075.1985.tb03791.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MCPHERSON GA, 1985, KINETIC EBDA LIGAND, P14; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PARVINEN M, 1992, J CELL BIOL, V117, P629, DOI 10.1083/jcb.117.3.629; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROMAGNOLI G, 1990, NEW ENGL J MED, V323, P527, DOI 10.1056/NEJM199008233230806; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SHIPLEY GD, 1989, J CELL PHYSIOL, V138, P511, DOI 10.1002/jcp.1041380310; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WHEELER EF, 1992, J NEUROSCI, V12, P930; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	74	151	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22838	22846						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693679				2022-12-27	WOS:A1993MD34800096
J	DOI, R; CHOWDHURY, P; RAYFORD, PL				DOI, R; CHOWDHURY, P; RAYFORD, PL			AGONIST-REGULATED ALTERATION OF THE AFFINITY OF PANCREATIC MUSCARINIC CHOLINERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SECRETION; CHOLECYSTOKININ RECEPTOR; AMYLASE SECRETION; DOWN-REGULATION; ACINAR-CELLS; CHICK HEART; PHOSPHORYLATION; DESENSITIZATION; HYDROLYSIS; BINDING	Heterologous desensitization is a term that indicates that exposure of a cell to an agonist attenuates the response of that cell to other agonists. We examined heterologous desensitization of muscarinic cholinergic receptors of pancreatic acini and characterized mechanisms that might be responsible for desensitization. Muscarinic cholinergic receptor binding was measured by using N-[H-3]methscopolamine bromide ([H-3]NMS). N-Methscopolamine bromide (NMS), a receptor antagonist, bound to a single class of receptors with an affinity of 0.22 +/- 0.04 nM and a capacity of 61.5 +/- 5.1 fmol/mg of protein. These parameters of NMS binding sites were not altered by an addition of cholecystokinin (CCK) octapeptide, CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, thapsigargin, or 12-O-tetradecanoylphorbol-13-acetate (TPA). Analysis of competitive inhibition curve of [H-3] NMS binding by carbachol showed apparently two classes of carbachol binding sites with high affinity (38.6%) and low affinity (61.4%). Simultaneous incubation of carbachol with CCK or TPA increased the relative affinity of [H-3]NMS binding, and the competitive inhibition curves showed a single class of carbachol binding site. L-364,718 blocked the effect of CCK, and staurosporine blocked the effects of TPA and partially blocked the effect of CCK. CCK-JMV-180, vasoactive intestinal peptide, 8-bromo-cAMP, 4-bromo-A23187, and thapsigargin had no effects on the competitive binding. Second, the carbachol-induced sequestration of the receptors was examined. Incubation of acini with carbachol resulted in a decrease of [H-3] NMS binding sites, and the addition of CCK or TPA caused an inhibition of the carbachol-induced disappearance of [H-3]NMS binding sites. Finally, studies that examined the biological response of the acinar cells showed that biphasic amylase release in response to carbachol was completely suppressed by 10 nM CCK for entire range of carbachol. Taken together, these results suggest that the effect of CCK on carbachol-induced sequestration is important for the alteration of the apparent affinity of carbachol binding sites and the biological response of acinar cells to carbachol. Further, the results suggest that another factor that induces uncoupling of receptor from effector might be involved in agonist-regulated desensitization. The results, that CCK-JMV-180 or other agonists that activate the adenylate cyclase pathway did not exert these effects of CCK, suggest that protein kinase C may be one of the key factors involved in heterologous desensitization by CCK on the carbachol binding sites and the suppression of carbachol-induced amylase release.	UNIV ARKANSAS MED SCI HOSP,DEPT PHYSIOL & BIOPHYS,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences				Doi, Ryuichiro/0000-0002-7298-2301	NIDDK NIH HHS [DK30415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMOUMENE S, 1980, AM J PHYSIOL, V239, pG272, DOI 10.1152/ajpgi.1980.239.4.G272; ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; BAUMGOLD J, 1989, NEUROPHARMACOLOGY, V28, P1253, DOI 10.1016/0028-3908(89)90219-0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BRUZZONE R, 1990, GASTROENTEROLOGY, V99, P1157, DOI 10.1016/0016-5085(90)90640-M; DEHAYE JP, 1984, J BIOL CHEM, V259, P294; DOI RH, 1993, J PHARMACOL EXP THER, V264, P873; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; HONDA T, 1987, AM J PHYSIOL, V252, pG77, DOI 10.1152/ajpgi.1987.252.1.G77; HOOTMAN SR, 1991, AM J PHYSIOL, V261, pG128, DOI 10.1152/ajpgi.1991.261.1.G128; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LIGNON MF, 1987, J BIOL CHEM, V262, P7226; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MERRITT JE, 1985, BIOCHEM J, V230, P151, DOI 10.1042/bj2300151; MINNEMAN KP, 1979, MOL PHARMACOL, V16, P34; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PANDOL SJ, 1986, J BIOL CHEM, V261, P4438; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; STREB H, 1985, J BIOL CHEM, V260, P7309; THOMPSON AK, 1991, J BIOL CHEM, V266, P5004; VINAYEK R, 1990, AM J PHYSIOL, V258, pG107, DOI 10.1152/ajpgi.1990.258.1.G107; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22436	22443						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693670				2022-12-27	WOS:A1993MD34800040
J	MOUSTAKAS, A; LIN, HY; HENIS, YI; PLAMONDON, J; OCONNORMCCOURT, MD; LODISH, HF				MOUSTAKAS, A; LIN, HY; HENIS, YI; PLAMONDON, J; OCONNORMCCOURT, MD; LODISH, HF			THE TRANSFORMING GROWTH-FACTOR BETA-RECEPTORS TYPE-I, TYPE-II, AND TYPE-III FORM HETEROOLIGOMERIC COMPLEXES IN THE PRESENCE OF LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INHIBITORY RESPONSES; EXPRESSION CLONING; CELLULAR RECEPTOR; CRYSTAL-STRUCTURE; CONCOMITANT LOSS; RECENT PROGRESS; RAT-1 CELLS; BINDING; GROWTH-FACTOR-BETA-2; RESPONSIVENESS	Transforming growth factors beta (TGF-betas) are disulfide-linked dimers. In Rat-1 cells both radioiodinated TGF-beta1 and -beta2 bind to and can be chemically cross-linked to type I and II receptors (which are thought to mediate effects of cell growth suppression and gene activation), to type III proteoglycan receptors, and to a novel approximately 50-kDa protein. After detergent solubilization of cells that were cross-linked with radioiodinated TGF-beta, antibodies specific for the type II receptor precipitated labeled receptor types I and III as well as type II. In these cells, the type III receptor is the predominant TGF-beta-binding protein, and antibodies specific for it precipitate mainly this cross-linked receptor. Thus, in the presence of TGF-beta ligand, receptor types II and III and types II and I form heteromeric complexes. The majority of the type III receptor does not associate with receptor types I and II, probably reflecting the relative amounts of the three receptors on the surface of Rat-1 cells. Since TGF-beta1 but not TGF-beta2 binds to the exoplasmic domain of the type II receptor in the absence of the type III receptor, and since both TGF-beta1 and -beta2 bind with high affinity to the type III receptor, we suggest that TGF-beta2, and possibly TGF-beta1, bind initially to the type III receptor. The TGF-beta2-type III receptor complex would then interact with a type II receptor, thus modulating the affinity of the type II receptor for TGF-beta2.	WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; NATL RES COUNCEL CANADA, BIOTECHNOL RES INST, CELL SURFACE RECOGNIT GRP, MONTREAL H4P 2R2, PQ, CANADA; TEL AVIV UNIV, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); National Research Council Canada; Tel Aviv University				Henis, Yoav/0000-0002-1408-3877	NHLBI NIH HHS [HL41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHINKERS M, 1987, J CELL PHYSIOL, V130, P1, DOI 10.1002/jcp.1041300102; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANGER BO, 1986, BIOCHEMISTRY-US, V25, P3083, DOI 10.1021/bi00359a003; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1069; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MITCHELL EJ, 1992, J CELL PHYSIOL, V150, P334, DOI 10.1002/jcp.1041500217; MITCHELL EJ, 1991, BIOCHEMISTRY-US, V30, P4350, DOI 10.1021/bi00231a034; MITCHELL EJ, 1992, MOL BIOL CELL, V3, P1295, DOI 10.1091/mbc.3.11.1295; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SIEPL C, 1991, J IMMUNOL, V146, P3063; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	40	184	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22215	22218						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693660				2022-12-27	WOS:A1993MD34800001
J	LIU, C; ROTH, KE; SHEPARD, BAL; SHAFFER, JB; DIAS, JA				LIU, C; ROTH, KE; SHEPARD, BAL; SHAFFER, JB; DIAS, JA			SITE-DIRECTED ALANINE MUTAGENESIS OF PHE(33), ARG(35), AND ARG(42)-SER(43)-LYS(44) IN THE HUMAN GONADOTROPIN ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; FOLLICLE-STIMULATING-HORMONE; BETA-SUBUNIT; RECEPTOR-BINDING; GLYCOPROTEIN HORMONES; SEQUENCE-ANALYSIS; IDENTIFICATION; LUTROPIN; FOLLITROPIN; THYROTROPIN	Residues Phe33 and Arg35, individually, and a composite mutation of residues Arg42, Ser43, and Lys44 were changed to alanine in the human glycoprotein hormone common alpha-subunit using site-directed mutagenesis. These specific residues are highly conserved across species and have by chemical modification and synthetic peptide approaches been implicated in the binding of human chorionic gonadotropin (hCG) to leutinizing hormone (LH) receptor. In the present study we tested the hypothesis that specific alpha-subunit amino acid residues which stabilize the hormone receptor interaction for hCG have the same function in human follicle-stimulating hormone (hFSH). Wild type or mutant alpha-subunit cDNAs were coexpressed with wild type hFSH or hCGbeta cDNA in sialylation defective Chinese hamster ovary cells. Recombinant hormones were tested in a radioligand receptor competition assay, using rat testis membranes as a source of FSH and LH receptors. Mutant hFSH heterodimers F33A-FSH, R35A-FSH, Arg42-Ser43-Lys44/Ala42-Ala43-Ala44-FSH all displaced I-125-hFSH in a similar fashion, indicating that these residues are not important for binding of hFSH to the rat FSH receptor. On the other hand, F33A-CG evidenced a 5-fold decrease in binding, while R35A-CG had over a 100-fold decrease in binding to the rat LH receptor when compared to the wild type recombinant hCG. These data demonstrate that a receptor-binding site on the common alpha-subunit which is very important for hCG binding to LH receptor is not important for the binding of hFSH to FSH receptor. Our interpretation of these findings is that there are fundamental structural differences in the receptor interface contacts of the common alpha-subunit, which stabilize receptor binding among members of the glycoprotein hormone family.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, EMPIRE STATE PLAZA, POB 509, ALBANY, NY 12201 USA; SUNY ALBANY, SCH PUBL HLTH, DEPT BIOMED SCI, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Dias, James A/0000-0002-9792-5469	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018407] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18407] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BIDART JM, 1988, J BIOL CHEM, V263, P10364; BIELINSKA M, 1990, Journal of Cell Biology, V111, p330A; BIELINSKA M, 1992, MOL ENDOCRINOL, V6, P267; BOORSTEIN WR, 1982, NATURE, V300, P419, DOI 10.1038/300419a0; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; DIAS JA, 1992, TRENDS ENDOCRIN MET, V3, P24, DOI 10.1016/1043-2760(92)90088-I; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; FIDDES JC, 1979, NATURE, V281, P351, DOI 10.1038/281351a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAYASHIZAKI Y, 1985, FEBS LETT, V188, P394, DOI 10.1016/0014-5793(85)80409-9; JAMESON JL, 1988, MOL CELL BIOL, V8, P5100, DOI 10.1128/MCB.8.12.5100; KARDANA A, 1991, ENDOCRINOLOGY, V129, P1541, DOI 10.1210/endo-129-3-1541; KRYSTEK SR, 1992, PEPTIDE RES, V5, P165; KRYSTEK SR, 1991, BIOCHEMISTRY-US, V30, P1858, DOI 10.1021/bi00221a019; LEINUNG MC, 1991, P NATL ACAD SCI USA, V88, P9707, DOI 10.1073/pnas.88.21.9707; NISHIMURA R, 1986, Journal of Biological Chemistry, V261, P10475; PENTECOST BT, 1990, MOL ENDOCRINOL, V4, P1000, DOI 10.1210/mend-4-7-1000; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; REED DK, 1991, J BIOL CHEM, V266, P14251; ROTH KE, 1993, ENDOCRINOLOGY, V132, P2571, DOI 10.1210/en.132.6.2571; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TALMADGE K, 1992, DNA CELL BIOL, V2, P281; VANDIJK S, 1993, ENDOCRINOLOGY, V132, P534, DOI 10.1210/en.132.2.534; Ward DM, 1989, MICROHETEROGENEITY G, P2; WEINER RS, 1992, MOL CELL ENDOCRINOL, V85, P41, DOI 10.1016/0303-7207(92)90123-N; WEINER RS, 1990, ENDOCRINOLOGY, V127, P573, DOI 10.1210/endo-127-2-573; WEINER RS, 1991, ENDOCRINOLOGY, V128, P1485, DOI 10.1210/endo-128-3-1485; WEINER RS, 1992, ENDOCRINOLOGY, V131, P1026, DOI 10.1210/en.131.3.1026; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; YANAGISHITA M, 1978, ANAL BIOCHEM, V88, P1, DOI 10.1016/0003-2697(78)90393-7; YOO J, 1991, J BIOL CHEM, V266, P17741	36	31	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21613	21617						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691814				2022-12-27	WOS:A1993MC80900030
J	STEFANOVA, I; CORCORAN, ML; HORAK, EM; WAHL, LM; BOLEN, JB; HORAK, ID				STEFANOVA, I; CORCORAN, ML; HORAK, EM; WAHL, LM; BOLEN, JB; HORAK, ID			LIPOPOLYSACCHARIDE INDUCES ACTIVATION OF CD14-ASSOCIATED PROTEIN-TYROSINE KINASE P53/56LYN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATED HUMAN MONOCYTES; MONOCLONAL-ANTIBODIES; SRC FAMILY; CD14; MOLECULES	Bacterial lipopolysaccharide (LPS) induces a pleiotropic activation of the immune system which might subsequently result in septic shock. One of the cell surface receptors for LPS is the glycophosphatidylinositol-anchored protein CD14. Binding of LPS to CD14 induces production of lymphokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), IL-6, and IL-8, and CD14 is subsequently released from the cell surface. However, the mechanism of signaling via CD14 is still not known. We report here that protein tyrosine kinase (PTK) p56lyn is coupled to the LPS receptor CD14 in human monocytes. LPS rapidly activates CD14-associated p56lyn simultaneously with PTKs p58hck and p59c-fgr. Inhibition of PTKs by herbimycin A completely blocks LPS-induced down-modulation of CD14 and production of TNF-alpha and IL-1. These data suggest a critical role of PTKs in the LPS/CD14-mediated signal transduction pathway in human monocytes.	NIH, INST DENT RES, IMMUNOL LAB, BETHESDA, MD 20892 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	National Institutes of Health (NIH) - USA; Bristol-Myers Squibb	STEFANOVA, I (corresponding author), NCI, DIV CANC BIOL DIAG & CTR, METAB BRANCH, BLDG 10-4N115, BETHESDA, MD 20892 USA.							BAZIL V, 1991, J IMMUNOL, V147, P1567; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; COUTURIER C, 1992, EUR J IMMUNOL, V22, P1461, DOI 10.1002/eji.1830220619; DENTENER MA, 1993, J IMMUNOL, V150, P2885; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUENER RP, 1990, J IMMUNOL, V145, P1390; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; SCHUTT C, 1988, IMMUNOL LETT, V19, P321, DOI 10.1016/0165-2478(88)90162-9; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL LM, 1991, CURRENT PROTOCOLS IM; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1991, SCIENCE, V252, P1321, DOI 10.1126/science.252.5010.1321-a; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	19	299	300	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					20725	20728						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691802				2022-12-27	WOS:A1993MA28800012
J	COHLBERG, JA; HAJARIAN, H; TRAN, T; ALIPOURJEDDI, P; NOVEEN, A				COHLBERG, JA; HAJARIAN, H; TRAN, T; ALIPOURJEDDI, P; NOVEEN, A			NEUROFILAMENT PROTEIN HETEROTETRAMERS AS ASSEMBLY INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE TROPOMYOSIN; FILAMENT PROTEINS; MOLECULAR ARCHITECTURE; BOVINE NEUROFILAMENTS; SIZED FILAMENTS; INVITRO; PHOSPHORYLATION; DYNAMICS; SUBUNITS; VIMENTIN	Evidence is presented for the existence of a soluble heterotetramer containing the low and middle molecular weight neurofilament (NF) proteins, NF-L and NF-M, and one containing the low and high molecular weight proteins, NF-L and NF-H, and for their role in filament assembly. When a mixture of either pair of proteins was renatured in 2 M urea, 20 mM Tris, pH 7.2, a new band representing a complex was observed in native gel electrophoresis. No new band was observed with a mixture of NF-M and NF-H. Two-dimensional gel electrophoresis showed that treatment of the complexes with SDS caused them to dissociate into their constituent polypeptide chains. Native neurofilaments dissociated in 2 M urea into a mixture of LM and LH complexes. Titration of NF-L with NF-M indicated that complex formation was complete at an approximately equimolar ratio of the two proteins. The LM complex had a sedimentation coefficient, s(20,w), of 4.4 S, consistent with a tetrameric structure. Dialysis of a solution of the LM complex against 50 mM. 4-morpholineethanesuIfonic acid, 0.17 M NaCl, pH 6.25, led to the formation of 10-nm filaments in good yield. These results suggest that NF protein heterooligomers are intermediates in NF assembly and disassembly.			COHLBERG, JA (corresponding author), CALIF STATE UNIV LONG BEACH,DEPT CHEM & BIOCHEM,1250 BELLFLOWER BLVD,LONG BEACH,CA 90840, USA.							ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BALIN BJ, 1991, BRAIN RES, V556, P196, DOI 10.1016/0006-8993(91)90307-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HR, 1985, P NATL ACAD SCI USA, V82, P2354; CARDEN MJ, 1983, BIOCHEM J, V215, P227, DOI 10.1042/bj2150227; CARDEN MJ, 1986, BIOCHEM J, V234, P587, DOI 10.1042/bj2340587; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COHLBERG JA, 1987, J BIOL CHEM, V262, P17009; COHLBERG JA, 1992, MOL BIOL CELL, V3, pA365; EAGLES PAM, 1990, CELLULAR MOL BIOL IN, P37; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1981, FEBS LETT, V125, P253, DOI 10.1016/0014-5793(81)80732-6; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GEISLER N, 1980, EUR J BIOCHEM, V111, P425, DOI 10.1111/j.1432-1033.1980.tb04957.x; GOTOW T, 1992, EUR J CELL BIOL, V58, P331; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; GUILLERMO R, 1990, THESIS CALIFORNIA ST; HAJARIAN H, 1987, Journal of Cell Biology, V105, p209A; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1990, J MOL BIOL, V211, P857, DOI 10.1016/0022-2836(90)90079-2; HISANAGA S, 1994, MOL BIOL CELL, V5, P161, DOI 10.1091/mbc.5.2.161; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LIFSICS MR, 1984, BIOCHEMISTRY-US, V23, P2866, DOI 10.1021/bi00308a004; MULLIGAN L, 1991, J STRUCT BIOL, V106, P145, DOI 10.1016/1047-8477(91)90084-A; NELSON WJ, 1982, J CELL SCI, V57, P25; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; SACHER MG, 1994, J BIOL CHEM, V269, P18480; SCHERAGA HA, 1953, J AM CHEM SOC, V75, P179, DOI 10.1021/ja01097a047; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; SHECKET G, 1980, J NEUROCHEM, V35, P1335, DOI 10.1111/j.1471-4159.1980.tb09007.x; SHULMAN S, 1953, ARCH BIOCHEM BIOPHYS, V44, P230, DOI 10.1016/0003-9861(53)90028-9; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1988, ANN REV BIOCH, V59, P593; STEINERT PM, 1982, COLD SPRING HARB SYM, V46, P465; TANFORD C, 1967, J AM CHEM SOC, V89, P729, DOI 10.1021/ja00980a001; TRONCOSO JC, 1989, CYTOSKELETAL EXTRACE, P33; ZACKROFF RV, 1982, P NATL ACAD SCI-BIOL, V79, P754, DOI 10.1073/pnas.79.3.754	55	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9334	9339		10.1074/jbc.270.16.9334	http://dx.doi.org/10.1074/jbc.270.16.9334			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721855	hybrid			2022-12-27	WOS:A1995QU08900044
J	ANCIAN, P; LAMBEAU, G; MATTEI, MG; LAZDUNSKI, M				ANCIAN, P; LAMBEAU, G; MATTEI, MG; LAZDUNSKI, M			THE HUMAN 180-KDA RECEPTOR FOR SECRETORY PHOSPHOLIPASES A(2) - MOLECULAR-CLONING, IDENTIFICATION OF A SECRETED SOLUBLE FORM, EXPRESSION, AND LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; PANCREATIC-TYPE PHOSPHOLIPASE-A2; AFFINITY BINDING-PROTEIN; MANNOSE RECEPTOR; TOXIC PHOSPHOLIPASES-A2; SKELETAL-MUSCLE; MESSENGER-RNA; SNAKE-VENOM; CELLS; SITE	Secretory phospholipases A(2) (sPLA(2)) are structurally related enzymes found in mammals as well as in insect and snake venoms. They have been associated with several physiological, pathological, and toxic processes. Some of these effects are apparently linked to the existence of specific receptors for both venom and mammalian sPLA(2)s. We report here the molecular cloning and expression of one of these sPLA(2) receptors from human kidney. Two transcripts were detected. One encodes for a transmembrane form of the sPLA(2) receptor and the other one is an alternatively processed transcript, caused by polyadenylation occurring at a site within an intron in the C terminus part of the transcriptional unit. This transcript encodes for a shortened secreted soluble sPLA(2) receptor lacking the coding region for the transmembrane segment, Quantitative polymerase chain reaction experiments indicate a 1.6:1 ratio between the levels of transcripts encoding for the membrane bound and soluble forms of the receptor, respectively. Soluble and membrane bound human sPLA(2) receptors both bind sPLA(2) with high affinities. However, the binding properties of the human receptors are different from those obtained with the rabbit membrane-bound sPLA(2) receptor. The 180 kDa human sPLA(2) receptor gene has been mapped in the q23-q24 bands of chromosome 2.	CNRS,UPR 411,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE; FAC MED MARSEILLE,INSERM,U406,UNITE GENET MED & DEV,F-13385 MARSEILLE 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				ARITA H, 1991, J BIOL CHEM, V266, P19139; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS AD, 1994, J BIOL CHEM, V269, P12057; DENNIS EA, 1983, ENZYMES, P307; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FILMOREHEBERT M, 1979, J MOL BIOL, V135, P897; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P493; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAI CJ, 1978, CELL, V14, P971, DOI 10.1016/0092-8674(78)90351-3; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; LAMBEAU G, 1989, J BIOL CHEM, V64, P11503; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TOJO H, 1988, J BIOL CHEM, V263, P5724; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VADAS P, 1986, LAB INVEST, V55, P391; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WIESNER RJ, 1992, BIOCHEM BIOPH RES CO, V183, P553, DOI 10.1016/0006-291X(92)90517-O; YING Z, 1993, EUR J BIOCHEM, V215, P91, DOI 10.1111/j.1432-1033.1993.tb18010.x	53	175	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8963	8970		10.1074/jbc.270.15.8963	http://dx.doi.org/10.1074/jbc.270.15.8963			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721806	hybrid			2022-12-27	WOS:A1995QT44800085
J	HUR, MW; EDENBERG, HJ				HUR, MW; EDENBERG, HJ			CELL-SPECIFIC FUNCTION OF CIS-ACTING ELEMENTS IN THE REGULATION OF HUMAN ALCOHOL-DEHYDROGENASE-5 GENE-EXPRESSION AND EFFECT OF THE 5'-NONTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMALDEHYDE DEHYDROGENASE; POLYMERASE-II TRANSCRIPTION; BOX-BINDING-PROTEINS; ENZYMATIC-PROPERTIES; TISSUE DISTRIBUTION; MAMMALIAN-CELLS; CPG ISLANDS; CHI-ADH; CLONING; LIVER	The human alcohol dehydrogenase 5 gene (ADH5) differs from all other human alcohol dehydrogenase genes in its ubiquitous expression, although there are tissue-specific differences in the level of expression, To under stand the expression of ADH5, we characterized the structure and function of its 5' region by DNase I footprinting and transient transfection assays. The region from base pair (bp) -34 to +61, flanking the major transcription start site, had strong promoter activity in three different cell lines: HeLa, H4IIE-C3, and CV-1, and could explain the ubiquitous expression, Two Sp1 sites within that region are footprinted by nuclear extracts from all tissues and cells tested. There are sites further upstream that show cell- and tissue-specific differences in both their patterns of occupancy and their effects on promoter activity. The region between bp -34 and -64 strongly increases promoter activity in H4IIE-C3 cells, weakly activates in CV-1 cells, but has no effect in HeLa cells. The region between bp -127 and -163 is a positive element in both HeLa cells and CV-1 cells, but is a negative regulatory element in H4IIE-C3 cells. These differences in part explain the levels of expression of ADH5 in various tissues. Two regions (bp -64 to -127 and bp -163 to -365) contain negative regulatory elements that reduce promoter activity in all three cells. The 5'-nontranslated region of ADH5 contains two upstream ATGs. Insertion of 12 bp within the putative coding region of these upstream ATGs led to a 1.6-2.3-fold increase in activity. This suggests that the 5'-nontranslated region has regulatory significance.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MOLEC & MED GENET,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Edenberg, Howard/0000-0003-0344-9690	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006460, R01AA006460] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06460] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADINOLFI A, 1984, ANN HUM GENET, V48, P1, DOI 10.1111/j.1469-1809.1984.tb00828.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROWN CJ, 1992, GENE, V121, P313, DOI 10.1016/0378-1119(92)90136-D; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DULEY JA, 1985, ALCOHOL CLIN EXP RES, V9, P263, DOI 10.1111/j.1530-0277.1985.tb05747.x; EDENBERG HJ, 1992, PHARMACOGENETICS, V2, P185, DOI 10.1097/00008571-199210000-00001; EDENBERG HJ, 1991, GENETIC BASIS ALCOHO, P165; EDENBERG HJ, 1991, ADV EXP MED BIOL, V284, P233; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIRI PR, 1989, BRAIN RES, V481, P131; GIRI PR, 1989, BIOCHEM BIOPH RES CO, V164, P453, DOI 10.1016/0006-291X(89)91741-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1983, VIROLOGY, V52, P456; GUTHEIL WG, 1992, BIOCHEMISTRY-US, V31, P475, DOI 10.1021/bi00117a025; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOLMES RS, 1986, ALCOHOL ALCOHOLISM, V21, P41; HOLMES RS, 1986, ALCOHOL CLIN EXP RES, V10, P623, DOI 10.1111/j.1530-0277.1986.tb05157.x; Hur M W, 1992, DNA Seq, V3, P167, DOI 10.3109/10425179209034012; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAISER R, 1988, BIOCHEMISTRY-US, V27, P1132, DOI 10.1021/bi00404a009; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; Maniatis T., 1982, MOL CLONING; PARES X, 1981, BIOCHEM BIOPH RES CO, V98, P122, DOI 10.1016/0006-291X(81)91878-7; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEELEY TL, 1984, COMP BIOCHEM PHYS B, V78, P131, DOI 10.1016/0305-0491(84)90156-1; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHARMA CP, 1989, BIOCHEM BIOPH RES CO, V164, P631, DOI 10.1016/0006-291X(89)91507-6; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WAGNER FW, 1984, BIOCHEMISTRY-US, V23, P2193, DOI 10.1021/bi00305a014; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	43	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					9002	9009		10.1074/jbc.270.15.9002	http://dx.doi.org/10.1074/jbc.270.15.9002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721811	hybrid			2022-12-27	WOS:A1995QT44800091
J	PAN, ZQ; DURST, F; WERCKREICHHART, D; GARDNER, HW; CAMARA, B; CORNISH, K; BACKHAUS, RA				PAN, ZQ; DURST, F; WERCKREICHHART, D; GARDNER, HW; CAMARA, B; CORNISH, K; BACKHAUS, RA			THE MAJOR PROTEIN OF GUAYULE RUBBER PARTICLES IS A CYTOCHROME-P450 - CHARACTERIZATION BASED ON CDNA CLONING AND SPECTROSCOPIC ANALYSIS OF THE SOLUBILIZED ENZYME AND ITS REACTION-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLENE OXIDE SYNTHASE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; PARTHENIUM-ARGENTATUM GRAY; HYDROPEROXIDE ISOMERASE; PLANT-TISSUES; ACID; METABOLISM; MECHANISM; PURIFICATION; EXPRESSION	Guayule plants accumulate large quantities of rubber within parenchyma cells of their stembark tissues. This rubber is packed within discrete organelles called rubber particles composed primarily of a lipophilic, cis-polyisoprene core, small amounts of lipids, and several proteins, the most abundant of which is the M(r) 53,000 rubber particle protein (RPP). We have cloned and sequenced a full-length cDNA for RPP and show that it has 65% amino acid identity and 85% similarity to a cytochrome P450 known as allene oxide synthase (AOS), recently identified from flaxseed. RPP contains the same unusual heme-binding region and possesses a similar defective I-helix region as AOS, suggesting an equivalent biochemical function. Spectral analysis of solubilized RPP verifies it as a P450, and enzymatic assays reveal that it also metabolizes 13(S)hydroperoxy-(SZ,11E)-octadecadienoic acid into the expected ketol fatty acids at rates comparable with flaxseed AOS, RPP is unusual in that it lacks the amino-terminal membrane anchor and the established organelle targeting sequences found on other conventional P450s. Together, these factors place RPP in the CYP74 family of P450s and establish it as the first P450 localized in rubber particles and the first eukaryotic P450 to be identified outside endoplasmic reticulum, mitochondria, or plastids.	ARIZONA STATE UNIV,DEPT BOT,TEMPE,AZ 85287; UNIV STRASBOURG 1,INST BOT,DEPT ENZYMOL CELLULAIRE & MOLEC,INST BIOL MOLEC PLANTES,CNRS,F-67083 STRASBOURG,FRANCE; USDA ARS,PEORIA,IL 61064; CNRS,INST BIOL MOLEC PLANTES,F-67084 STRASBOURG,FRANCE; USDA ARS,WESTERN REG RES CTR,ALBANY,CA 94710	Arizona State University; Arizona State University-Tempe; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; United States Department of Agriculture (USDA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; United States Department of Agriculture (USDA)			WERCK-REICHHART, Danièle/U-3713-2019; Cornish, Katrina/A-9773-2013	WERCK-REICHHART, Danièle/0000-0003-2869-4262; Cornish, Katrina/0000-0002-3327-2454				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON JM, 1989, 2ND MESSENGERS PLANT, P181; Archer B.L., 1973, PHYTOCHEMISTRY, VII, P310; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; BACKHAUS RA, 1991, PHYTOCHEMISTRY, V30, P2493, DOI 10.1016/0031-9422(91)85088-H; BACKHAUS RA, 1985, ISRAEL J BOT, V34, P283; BACKHAUS RA, 1983, BOT GAZ, V144, P391, DOI 10.1086/337388; BENEDICT CR, 1990, PLANT PHYSIOL, V92, P816, DOI 10.1104/pp.92.3.816; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CORNISH K, 1994, PHYTOCHEMISTRY, V35, P1425, DOI 10.1016/S0031-9422(00)86868-5; CORNISH K, 1990, PHYTOCHEMISTRY, V29, P3809, DOI 10.1016/0031-9422(90)85337-F; Cornish K., 1993, Journal of Natural Rubber Research, V8, P275; DURST F, 1992, BIOCHEM SOC T, V20, P353, DOI 10.1042/bst0200353; DURST F, 1993, HDB EXPT PHARM, V105, P293; FARMER EE, 1992, PLANT PHYSIOL, V98, P995, DOI 10.1104/pp.98.3.995; GARDNER HW, 1987, PHYTOCHEMISTRY, V26, P621, DOI 10.1016/S0031-9422(00)84753-6; GARDNER HW, 1970, J LIPID RES, V11, P311; GOMEZ JB, 1975, P INT RUBBER C KUALA, V2, P143; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HASMA H, 1986, Journal of Natural Rubber Research, V1, P30; Hasma H., 1991, Journal of Natural Rubber Research, V6, P105; HO CC, 1975, P INT RUBB C KUAL LU, V2, P441; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KALB VF, 1988, P NATL ACAD SCI USA, V85, P7221, DOI 10.1073/pnas.85.19.7221; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LAU SMC, 1993, BIOCHEMISTRY-US, V32, P1945, DOI 10.1021/bi00059a010; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMURA T, 1964, J BIOL CHEM, V239, P2379; OMURA T, 1964, J BIOL CHEM, V239, P2370; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Siler D. J., 1994, Industrial Crops and Products, V2, P307, DOI 10.1016/0926-6690(94)90122-8; SILER DJ, 1993, PHYTOCHEMISTRY, V32, P1097, DOI 10.1016/S0031-9422(00)95072-6; SILER DJ, 1994, PHYTOCHEMISTRY, V36, P623, DOI 10.1016/S0031-9422(00)89786-1; SILER DJ, 1992, P INT LAT C SENS LAT, V34, P46; SONG WC, 1993, J BIOL CHEM, V268, P6293; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; TEUTSCH HG, 1993, P NATL ACAD SCI USA, V90, P4102, DOI 10.1073/pnas.90.9.4102; VICK BA, 1987, PLANT PHYSIOL, V85, P1073, DOI 10.1104/pp.85.4.1073; Vick Brady A., 1993, P167; VIOQUE E, 1962, ARCH BIOCHEM BIOPHYS, V99, P522, DOI 10.1016/0003-9861(62)90301-6; ZIMMERMAN DC, 1978, LIPIDS, V13, P313, DOI 10.1007/BF02533720; ZIMMERMAN DC, 1970, PLANT PHYSIOL, V46, P445, DOI 10.1104/pp.46.3.445; ZIMMERMAN DC, 1966, BIOCHEM BIOPH RES CO, V23, P398, DOI 10.1016/0006-291X(66)90740-6; [No title captured]	52	121	137	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8487	8494		10.1074/jbc.270.15.8487	http://dx.doi.org/10.1074/jbc.270.15.8487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721745	hybrid			2022-12-27	WOS:A1995QT44800021
J	CHOI, SY; SIVARAM, P; WALKER, DE; CURTISS, LK; GRETCH, DG; STURLEY, SL; ATTIE, AD; DECKELBAUM, RJ; GOLDBERG, IJ				CHOI, SY; SIVARAM, P; WALKER, DE; CURTISS, LK; GRETCH, DG; STURLEY, SL; ATTIE, AD; DECKELBAUM, RJ; GOLDBERG, IJ			LIPOPROTEIN-LIPASE ASSOCIATION WITH LIPOPROTEINS INVOLVES PROTEIN-PROTEIN INTERACTION WITH APOLIPOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HEPARIN-BINDING-SITES; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; IDENTIFICATION; RECEPTOR; TISSUE; MACROPHAGES; DEGRADATION; LOCALIZE	Lipoprotein lipase (LPL) hydrolyzes chylomicron and very low density lipoprotein (VLDL) triglycerides and potentiates the cellular uptake of lipoproteins. These LPL-lipoprotein associations could involve only protein-lipid interaction, or they could be modulated by apolipoproteins (ape), ApoB is the major protein component of chylomicrons, VLDL, and low density lipoprotein (LDL), ApoB100, a large glycoprotein with a molecular mass of 550 kDa, is composed of several functional domains, A carboxyl terminal region of the protein is the ligand for the LDL receptor, There are several hydrophobic domains that are believed to be important in lipid binding, The relatively hydrophilic amino-terminal region of apoB, however, has no known function, Using solid phase assays we quantified LPL lipoprotein complex formation, On a molar basis, severalfold greater amounts of LPL bound to LDL and VLDL than to high density lipoprotein at all the concentrations of LPL tested (0.9-55 nM). To assess the roles of LDL protein versus lipid, we performed competition and ligand blotting experiments, LDL and an amino-terminal fragment of apoB competed better for I-125-LPL binding to LDL than did lipid emulsion particles, Delipidation of LDL-coated plates did not alter LPL binding, On ligand blots, LPL bound to amino-terminal fragments of apoB generated by thrombin digestion but not to apoA1, apoE, or carboxyl-terminal fragments of apoB, Further evidence for LPL interaction with the amino-terminal region of apoB was obtained using anti-apoB monoclonal antibodies, Antibodies directed against the amino-terminal regions of apoB blocked LPL interaction with LDL, whereas those against the carboxyl-terminal region of apoB did not inhibit LPL interaction with LDL, Thus, we conclude that a specific interaction between LPL and the amino-terminal region of apoB may facilitate LPL association with circulating lipoproteins.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	Columbia University; Columbia University; Scripps Research Institute; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL 45095, HL 21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R37HL045095, R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHAN L, 1992, J BIOL CHEM, V267, P25621; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1985, CIRCULATION, V72, P93; DELOOF H, 1987, J LIPID RES, V28, P1455; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; EKMAN R, 1975, CLIN CHIM ACTA, V63, P29, DOI 10.1016/0009-8981(75)90374-5; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; FIELDING CJ, 1980, BIOCHIM BIOPHYS ACTA, V620, P440, DOI 10.1016/0005-2760(80)90135-6; GALEANO NF, 1994, J BIOL CHEM, V269, P511; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIETANEN E, 1977, J LIPID RES, V18, P480; HUI DY, 1986, J BIOL CHEM, V255, P1804; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHOO JC, 1981, J BIOL CHEM, V256, P7105; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRUL ES, 1988, J LIPID RES, V29, P937; KUNITAKE ST, 1990, J BIOL CHEM, V265, P20739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILNE R, 1989, J BIOL CHEM, V264, P19754; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PATTON JG, 1982, J IMMUNOL METHODS, V55, P193, DOI 10.1016/0022-1759(82)90031-X; PEASE RJ, 1990, J BIOL CHEM, V265, P553; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMADA K, 1982, BIOCHIM BIOPHYS ACTA, V710, P117, DOI 10.1016/0005-2760(82)90140-0; SHIRAI K, 1981, BIOCHIM BIOPHYS ACTA, V665, P504; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SIVARAM P, 1993, ANAL BIOCHEM, V214, P511, DOI 10.1006/abio.1993.1531; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VILELLA E, 1993, J LIPID RES, V34, P1555; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; YANG CY, 1989, J BIOL CHEM, V264, P16822	53	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8081	8086		10.1074/jbc.270.14.8081	http://dx.doi.org/10.1074/jbc.270.14.8081			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713910	hybrid			2022-12-27	WOS:A1995QR52600048
J	HANNAN, RD; LUYKEN, J; ROTHBLUM, LI				HANNAN, RD; LUYKEN, J; ROTHBLUM, LI			REGULATION OF RDNA TRANSCRIPTION FACTORS DURING CARDIOMYOCYTE HYPERTROPHY INDUCED BY ADRENERGIC AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA SYNTHESIS; PROTEIN-KINASE-C; RAT MYOCARDIAL-CELLS; CARDIAC-HYPERTROPHY; ALPHA-1-ADRENERGIC RECEPTOR; HEART-CELLS; FACTOR UBF; STIMULATION; GROWTH; DNA	Ribosomal DNA transcription is important to the regulation of cardiomyocyte ribosome content and, as a consequence, the rate of protein synthesis and accumulation during cardiac hypertrophy. We studied the regulation of ribosomal RNA synthesis and the levels of RNA polymerase I and the ribosomal DNA transcription factor, UBF, during norepinephrine-induced hypertrophy of contraction-arrested neonatal cardiomyocytes in culture. Nuclear run-on assays and Western blots demonstrated that, concomitant with hypertrophy, norepinephrine (1 mu M) increased the rate of ribosomal DNA transcription, without causing an increase in the amount of RNA polymerase I. However, the elevated rate of rRNA synthesis was accompanied by an increased cellular content of UBF protein as determined by Western analysis. Northern blots demonstrated norepinephrine-induced increases in UBF mRNA in neonatal cardiomyocytes indicating that the response was regulated, at least in part, at the pretranslational stage. Both alpha- and beta-adrenergic agents increased the level of UBF mRNA. The beta-adrenergic response was mimicked by forskolin (1 mu M) and the cyclic AMP analog dibutyryl cAMP (10 mu M). However, activation of protein kinase C by phorbol 12-myristate 13-acetate (0.1 mu M) did not increase expression of UBF. These results implicate UBF as a possible regulatory factor of the accelerated rDNA transcription observed during norepinephrine-mediated cardiomyocyte hypertrophy.	GEISINGER MED CLIN,SIGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822	Geisinger Medical Center				Hannan, Ross/0000-0002-2166-4493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046991] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47638] Funding Source: Medline; NIGMS NIH HHS [GM46991] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLO SN, 1991, J BIOL CHEM, V266, P22003; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LALLI E, 1994, J BIOL CHEM, V269, P17359; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MCDERMOTT PJ, 1991, J BIOL CHEM, V266, P4409; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MCDERMOTT PJ, 1989, CIRC RES, V64, P540; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; Morgan HECB, 1992, HEART CARDIOVASCULAR, P1505; MOSS T, 1995, IN PRESS P NUCLEIC A; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Sambrook J, 1989, MOL CLONING LABORATO; SIEHL D, 1985, AM J PHYSIOL, V248, pC309, DOI 10.1152/ajpcell.1985.248.3.C309; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; SIMPSON PC, 1990, MOL BIOL CARDIOVASCU; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WOODCOCK EA, 1987, CIRC RES, V61, P625, DOI 10.1161/01.RES.61.5.625; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417	39	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8290	8297		10.1074/jbc.270.14.8290	http://dx.doi.org/10.1074/jbc.270.14.8290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713937	hybrid			2022-12-27	WOS:A1995QR52600076
J	HSIEH, JC; ZINNEN, S; MODRICH, P				HSIEH, JC; ZINNEN, S; MODRICH, P			KINETIC MECHANISM OF THE DNA-DEPENDENT DNA-POLYMERASE-ACTIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; I KLENOW; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; H ACTIVITY; RNASE-H; HIV-1; EXPRESSION; FIDELITY; BINDING	The kinetic pathway of DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase (HIV RT) as determined by pre-steady-state methods using a defined primer/template is as follows, [GRAPHICS] where E is RT, D(n,n+1) is primer/template, dNTP is deoxyribonucleoside triphosphate, and PP(i) is pyrophosphate. The rate-determining step for enzyme turnover in single nucleotide addition is the dissociation of enzyme from DNA (k6 = 0.11 s-1). The observation of an E'.DNA.dNTP intermediate by pulse-chase analysis and the absence of a phosphorothioate elemental effect identified the rate-limiting step for nucleotide addition as a conformational change of the E.DNA.dNTP complex (k3 = 83 s-1) prior to the chemical step. Biphasic kinetics of single-turnover pyrophosphorolysis suggested that this conformational change (k-3 = 0.3 s-1) is also rate-limiting for the reverse reaction. The equilibrium constant for the chemical step (K4) is 3.8, in slight favor of the forward reaction. The large equilibrium constant (K3 = 280) for the conformational change effectively renders nucleotide addition kinetically irreversible. The dissociation constant for primer/template is 26 nM, and the association rate of enzyme and DNA (k1) is 2.3 x 10(6) M-1 s-1. Equilibrium dissociation constants for dTTP and PP(i) are 18 muM and 7.2 mM, respectively. Mg2+ enhances productive interaction of RT with DNA as judged by a 50% increase in burst amplitude in the single nucleotide addition reaction and by an 8-fold decrease in K(D) for the RT.DNA complex as determined by gel mobility shift assay. Secondary interactions of the RT.DNA complex with free DNA were observed in the absence of Mg2+.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University				Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; Benkovic S. J, 1973, ENZYMES, P201; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MULLER B, 1989, J BIOL CHEM, V264, P13975; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RESTLE T, 1990, J BIOL CHEM, V265, P8986; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2, P75; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	34	177	184	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24607	24613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693703				2022-12-27	WOS:A1993MG67300018
J	BLAIN, SW; GOFF, SP				BLAIN, SW; GOFF, SP			NUCLEASE ACTIVITIES OF MOLONEY MURINE LEUKEMIA-VIRUS REVERSE-TRANSCRIPTASE - MUTANTS WITH ALTERED SUBSTRATE SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DNA-POLYMERASE; AVIAN MYELOBLASTOSIS VIRUS; SITE-DIRECTED MUTAGENESIS; RIBONUCLEASE-H DOMAIN; RNA TUMOR-VIRUSES; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACID; RETROVIRUSES; REPLICATION	RNases H are traditionally thought to degrade RNA only in RNA-DNA hybrid form. We found that the wild-type Moloney murine leukemia virus (M-MuLV) reverse transcriptase (RT) was capable of degrading RNA in RNA-RNA duplexes as well as in RNA-DNA hybrids, as assayed by in situ gel techniques. Escherichia coli RNase H does not degrade the RNA-RNA duplex in this assay, while E. coli RNase III, a double-strand-specific ribonuclease, does. The apparent specific activity of M-MuLV RT on RNA-RNA duplexes is similar to that on RNA-DNA hybrids. Neither the DNA polymerase domain nor the RNase H domain of RT expressed individually exhibited this RNA-RNA activity. We have generated a series of mutations in the RNase H domain of M-MuLV RT, expressed the mutant enzymes in E. coli, and assayed these mutants for various activities. All RTs were as active as the wild type in the oligo(dT):poly(rA) DNA polymerase assay, and many retained both nuclease activities. Two enzymes with mutations at the carboxyl terminus of the RNase H domain retained RNA-DNA activity, but not RNA-RNA activity. Another mutant enzyme showed the opposite phenotype, retaining RNA-RNA, but not RNA-DNA, nuclease activity. Thus, we were able to genetically separate the two activities. These results may be helpful in defining enzyme-substrate interactions.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [CA 30488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030488, R37CA030488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTIMORE D, 1972, J BIOL CHEM, V247, P7282; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BENARTZI H, 1992, NUCLEIC ACIDS RES, V20, P5115, DOI 10.1093/nar/20.19.5115; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P937; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CROUCH R J, 1990, New Biologist, V2, P771; CROUCH RJ, 1970, J BIOL CHEM, V249, P1314; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; GERARD GF, 1986, DNA-J MOLEC CELL BIO, V5, P271, DOI 10.1089/dna.1986.5.271; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HARLOW E, 1988, ANTIBODIES LABORATOR, P70; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HOSTOMSKY Z, 1992, NUCLEIC ACIDS RES, V20, P5819, DOI 10.1093/nar/20.21.5819; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6354; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA S, 1984, P NATL ACAD SCI-BIOL, V81, P3447, DOI 10.1073/pnas.81.11.3447; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1991, DNA REPLICATION, P29; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; KUNKEL TA, 1987, METHOD ENZYMOL, V155, P166; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; MCCLURE MA, 1993, REVERSE TRANSCRIPTAS, P425; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MOELLING K, 1976, J VIROL, V18, P418, DOI 10.1128/JVI.18.2.418-425.1976; MOELLING K, 1971, NATURE, V234, P240; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; Sambrook J, 1989, MOL CLONING LABORATO; SKALKA A, 1993, REVERSE TRANSCRIPTAS; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1992, J VIROL, V66, P615, DOI 10.1128/JVI.66.2.615-622.1992; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; VERMA IM, 1975, J VIROL, V15, P843, DOI 10.1128/JVI.15.4.843-854.1975; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	54	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23585	23592						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693692				2022-12-27	WOS:A1993MF51500096
J	YAKUBOV, L; KHALED, Z; ZHANG, LM; TRUNEH, A; VLASSOV, V; STEIN, CA				YAKUBOV, L; KHALED, Z; ZHANG, LM; TRUNEH, A; VLASSOV, V; STEIN, CA			OLIGODEOXYNUCLEOTIDES INTERACT WITH RECOMBINANT CD4 AT MULTIPLE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTI-HIV AGENT; BINDING-SITE; DEXTRAN SULFATE; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; SYNCYTIUM FORMATION; AURINTRICARBOXYLIC ACID; PENTOSAN POLYSULFATE; HIV-GP120 BINDING; ATOMIC-STRUCTURE	Phosphodiester oligodeoxynucleotides bearing the 5'-alkylating moiety 4-(N-2-chloroethyl-N-methyl)aminobenzylamine specifically modify recombinant soluble CD4 (rsCD4) in solution. This reaction is saturable with respect to the alkylating oligonucleotide reagent. The existence of at least two binding sites, with different affinities, on the rsCD4 molecule, were demonstrated. The values of apparent K(d) for the sites are approximately 0.1 and 1 muM. The existence of two sites was confirmed by electrophoretic analysis of the modified protein, in which two distinct gel bands were seen. The modification is inhibited hy excess non-alkylating oligonucleotide, as well as by phosphorothioate oligonucleotides. Quantitative estimates of the competition constants (K(c)), for the binding of these competitors of the binding of the alkylating oligonucleotide reagent with rsCD4, have been made. By use of this method, several anionic dyes as well as potential anti-HIV therapeutic agents were also demonstrated to interact with rsCD4. Phosphorothioate oligonucleotides also inhibit binding of rsCD4 with the monoclonal antibody L71.1.1 This monoclonal antibody recognizes the CDR3-like loop (D1 domain) of the rsCD4 molecule. Thus, oligonucleotide binding sites exist on two remote regions (i.e. both the CDR2- and CDR3-like loops) of the D1 domain of CD4.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; SMITHKLINE BEECHAM PHARMACEUT, MOLEC GENET, KING OF PRUSSIA, PA 19406 USA; NOVOSIBIRSK BIOORGAN CHEM INST, NOVOSIBIRSK 630090, RUSSIA	Columbia University; GlaxoSmithKline; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS			Truneh, Alem/ABB-7891-2020; Vlassov, Valentin/F-4720-2013	Vlassov, Valentin/0000-0003-2845-2992				ANAND R, 1990, AIDS RES HUM RETROV, V6, P679, DOI 10.1089/aid.1990.6.679; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BALZARINI J, 1986, INT J CANCER, V37, P451, DOI 10.1002/ijc.2910370318; Bayever E, 1992, Antisense Res Dev, V2, P109; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CARDIN AD, 1991, J BIOL CHEM, V266, P13355; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOE HR, 1992, J ACQ IMMUN DEF SYND, V5, P204; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; CUSHMAN M, 1991, J MED CHEM, V34, P329, DOI 10.1021/jm00105a052; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; GAO WY, 1992, MOL PHARMACOL, V41, P223; KALYANARAMAN VS, 1990, J IMMUNOL, V145, P4072; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KNORRE DG, 1985, ADV ENZYME REGUL, V24, P277, DOI 10.1016/0065-2571(85)90082-2; KOZLOWSKI MR, 1992, ANTIVIR CHEM CHEMOTH, V3, P49, DOI 10.1177/095632029200300107; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LEDERMAN S, 1992, AIDS RES HUM RETROV, V8, P1599, DOI 10.1089/aid.1992.8.1599; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LIFSON JD, 1991, AIDS RES HUM RETROV, V7, P521, DOI 10.1089/aid.1991.7.521; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; NAKASHIMA H, 1987, JPN J CANCER RES, V78, P1164; NARA PL, 1989, P NATL ACAD SCI USA, V86, P7139, DOI 10.1073/pnas.86.18.7139; PARISH CR, 1990, J IMMUNOL, V145, P1188; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RAUSCH DM, 1990, ANN NY ACAD SCI, V616, P125; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; SCHOLS D, 1989, P NATL ACAD SCI USA, V86, P3322, DOI 10.1073/pnas.86.9.3322; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEC WJ, 1991, NUCLEIC ACIDS RES, V19, P5883, DOI 10.1093/nar/19.21.5883; Stein C A, 1993, Antisense Res Dev, V3, P19; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; STEIN CA, 1989, AIDS RES HUM RETROV, V5, P639, DOI 10.1089/aid.1989.5.639; STEIN CA, 1991, J ACQ IMMUN DEF SYND, V4, P686; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; THIELE B, 1989, EUR J IMMUNOL, V19, P1161, DOI 10.1002/eji.1830190630; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEAVER JL, 1990, AIDS RES HUM RETROV, V6, P1125, DOI 10.1089/aid.1990.6.1125; WEAVER JL, 1992, ANTIVIR CHEM CHEMOTH, V3, P147, DOI 10.1177/095632029200300303; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454	54	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18818	18823						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689560				2022-12-27	WOS:A1993LV65900068
J	CONDRESCU, M; GARDNER, JP; CHERNAYA, G; ACETO, JF; KROUPIS, C; REEVES, JP				CONDRESCU, M; GARDNER, JP; CHERNAYA, G; ACETO, JF; KROUPIS, C; REEVES, JP			ATP-DEPENDENT REGULATION OF SODIUM-CALCIUM EXCHANGE IN CHINESE-HAMSTER OVARY CELLS TRANSFECTED WITH THE BOVINE CARDIAC SODIUM-CALCIUM EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT-AXONS; NA+-CA2+ EXCHANGE; SARCOLEMMAL VESICLES; DYNAMIC PROPERTIES; STEADY-STATE; HEART-CELLS; EXPRESSION; PH; STIMULATION; MODULATION	Chinese hamster ovary cells expressing the bovine cardiac Na/Ca exchanger were treated with ouabain to increase [Na+](i) and stimulate Ca2+ influx by Na/Ca exchange, Depletion of cellular ATP inhibited Ca-45 uptake by 40% or more and reduced the half-maximal Na+ concentration for inhibition of Ca-45 uptake from 90 to 55 mM. ATP depletion also reduced the rate of rise in [Ca2+](i) when [Na+](o) was reduced and inhibited the decline in [Ca2+](i) when high [Na+](o) was restored, The effects of ATP depletion were either absent or reduced in cells expressing a mutant exchanger missing most of the cytosolic hydrophilic domain, We were unable to detect a phosphorylated form of the exchanger in immunoprecipitates from P-32-labeled cells. ATP depletion caused a breakdown in the actin cytoskeleton of the cells, Treatment of the cells with cytochalasin D mimicked the effects of ATP depletion on the [Na+] inhibition profile for Ca-45 uptake, Thus, ATP depletion inhibits both the Ca2+ influx and Ca2+ efflux modes of Na/Ca exchange, and may alter the competitive interactions of extracellular Na+ and Ca2+ with the transporter. The latter effect appears to be related to changes in the actin cytoskeleton.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PHYSIOL,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,HYPERTENS RES CTR,NEWARK,NJ 07103; HOFFMANN LA ROCHE INC,ROCHE RES CTR,ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Roche Holding			Kroupis, Christos/K-2725-2013	Kroupis, Christos/0000-0002-5876-2599	NHLBI NIH HHS [HL49932] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049932] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BERSHADSKY AD, 1980, EXP CELL RES, V127, P421, DOI 10.1016/0014-4827(80)90446-2; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CONDRESCU M, 1994, BIOPHYS J, V66, pA332; CONDRESCU M, 1993, BIOPHYS J, V46, pA399; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DIPOLO R, 1987, J GEN PHYSIOL, V90, P505, DOI 10.1085/jgp.90.4.505; DIPOLO R, 1991, ANN NY ACAD SCI, V639, P100, DOI 10.1111/j.1749-6632.1991.tb17294.x; DIPOLO R, 1974, J GEN PHYSIOL, V64, P503, DOI 10.1085/jgp.64.4.503; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DIPOLO R, 1993, J PHYSIOL-LONDON, V462, P71, DOI 10.1113/jphysiol.1993.sp019544; HAWORTH RA, 1987, CIRC RES, V60, P586, DOI 10.1161/01.RES.60.4.586; HAWORTH RA, 1992, CIRC RES, V71, P210, DOI 10.1161/01.RES.71.1.210; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI ZP, 1993, J BIOL CHEM, V268, P11489; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MATSUOKA S, 1992, IN PRESS J GEN PHYSL; MILLS JW, 1994, FASEB J, V8, P1161, DOI 10.1096/fasebj.8.14.7958622; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PHILIPSON KD, 1982, CIRC RES, V50, P287, DOI 10.1161/01.RES.50.2.287; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; REEVES JP, 1994, BIOPHYS J, V66, pA148; REEVES JP, 1983, J BIOL CHEM, V258, P3178; SANGER JW, 1983, EUR J CELL BIOL, V31, P197; SMITH JB, 1990, AM J PHYSIOL, V252, pC302; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012	34	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9137	9146		10.1074/jbc.270.16.9137	http://dx.doi.org/10.1074/jbc.270.16.9137			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721828	hybrid			2022-12-27	WOS:A1995QU08900016
J	PATTERSON, SD; GROSSMAN, JS; DANDREA, P; LATTER, GI				PATTERSON, SD; GROSSMAN, JS; DANDREA, P; LATTER, GI			REDUCED NUMATRIN B23 NUCLEOPHOSMIN LABELING IN APOPTOTIC JURKAT T-LYMPHOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX PROTEIN; PROGRAMMED CELL-DEATH; DIMENSIONAL GEL-ELECTROPHORESIS; INDUCED DNA FRAGMENTATION; AMINO-ACID-SEQUENCE; HELA-CELLS; NUCLEOLAR PROTEIN-B23; VENTRAL PROSTATE; LYMPHOCYTES-T; ACTINOMYCIN-D	Jurkat T-lymphoblasts were induced to undergo apoptosis by treatment with either EGTA (5 mM/24 h) or a high concentration of lovastatin (100 mu M/48 h) to identify proteins that exhibited coordinate regulation between the two treatments and thus provide candidate proteins in the common apoptotic induction pathway. A pure population of apoptotic cells, as determined by morphology, ''DNA laddering,'' and flow cytometry, was obtained by Percoll density gradient centrifugation, Cells of increased buoyant density were clearly apoptotic by all criteria. Following this gradient centrifugation, the cells were labeled with [S-35]methionine/cysteine, and lysates were separated by two-dimensional polyacrylamide gel electrophoresis. Surprisingly, the two-dimensional polyacrylamide gel electrophoresis patterns generated from the apoptotic cells did not differ dramatically from that of control cells, Thus, apoptotic Jurkat cells are able to synthesize new proteins and do not exhibit extensive proteolysis. Subsequent quantitative analysis revealed that only five proteins exhibited decreases in turnover that were common to the two treatments, No increases in protein turnover were able to be confirmed across the replicate experiments, One of the proteins that showed decreased labeling by both apoptotic inductions was an abundant nuclear protein with a pI of 5.1 and M(r) 40,000, This protein was identified as numatrin/B23/nucleophosmin (NPM) based on internal amino acid sequence, and this identity was confirmed by immunoblotting and mass spectrometry, NPM is implicated in a range of diverse cellular functions, but its role in apoptosis is unclear.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory			Patterson, Scott/A-7404-2009		NCI NIH HHS [P30-CA45508] Funding Source: Medline; NCRR NIH HHS [P41-RR02188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADACHI Y, 1993, J BIOL CHEM, V268, P13930; AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BANSAL N, 1989, LEUKEMIA RES, V13, P875, DOI 10.1016/0145-2126(89)90040-4; BAXTER GD, 1992, J IMMUNOL, V148, P1949; BAZAR LS, 1992, EXP HEMATOL, V20, P80; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BOR AMS, 1992, INT J CANCER, V52, P658, DOI 10.1002/ijc.2910520427; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRAND SR, 1994, J IMMUNOL, V152, P4120; BRUNO S, 1992, LEUKEMIA, V6, P1113; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHANG JH, 1990, J BIOL CHEM, V265, P18227; COHEN JJ, 1993, HOSP PRACT, V28, P35, DOI 10.1080/21548331.1993.11442887; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COTTER TG, 1990, ANTICANCER RES, V10, P1153; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FALCIERI E, 1994, HISTOCHEMISTRY, V102, P221; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; FINCH RA, 1992, ONCOLOGY, V49, P223; FINCH RA, 1993, J BIOL CHEM, V268, P5823; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GARRELS JI, 1989, J BIOL CHEM, V264, P5269; GAZITT Y, 1994, CANCER RES, V54, P950; GOLDSTONE SD, 1993, BIOCHEM BIOPH RES CO, V196, P619, DOI 10.1006/bbrc.1993.2294; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GORCZYCA W, 1993, INT J ONCOL, V3, P627; HAMBLIN AS, 1987, LYMPHOCYTES PRACTICA, P209; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JONES CE, 1981, BIOCHIM BIOPHYS ACTA, V667, P209, DOI 10.1016/0005-2795(81)90081-7; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LEE C, 1987, J UROLOGY, V138, P903, DOI 10.1016/S0022-5347(17)43413-6; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEITINGER N, 1993, J CELL BIOCHEM, V52, P153, DOI 10.1002/jcb.240520207; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MONARDO PJ, 1994, COMPUT APPL BIOSCI, V10, P137; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PATTERSON SD, 1994, ANAL BIOCHEM, V221, P1, DOI 10.1006/abio.1994.1371; PATTERSON SD, 1993, BIOTECHNIQUES, V15, P1076; PATTERSON SD, 1994, CELL BIOL LABORATORY, V3, P249; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; ROBAYE B, 1994, ELECTROPHORESIS, V15, P503, DOI 10.1002/elps.1150150168; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SENSIBAR JA, 1990, J UROLOGY, V143, P161, DOI 10.1016/S0022-5347(17)39902-0; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VILLA P, 1994, J NEUROCHEM, V62, P1468; VORIS BP, 1981, J BIOL CHEM, V256, P1319; WADEWITZ AG, 1988, FEBS LETT, V241, P19, DOI 10.1016/0014-5793(88)81022-6; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1982, AM J PATHOL, V109, P78; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; YAMADA T, 1980, INT J RADIAT BIOL, V37, P695, DOI 10.1080/713857566; YUNG BYM, 1990, INT J CANCER, V46, P272, DOI 10.1002/ijc.2910460222	82	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9429	9436		10.1074/jbc.270.16.9429	http://dx.doi.org/10.1074/jbc.270.16.9429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721868	hybrid			2022-12-27	WOS:A1995QU08900057
J	IMAMOTO, N; TACHIBANA, T; MATSUBAE, M; YONEDA, Y				IMAMOTO, N; TACHIBANA, T; MATSUBAE, M; YONEDA, Y			A KARYOPHILIC PROTEIN FORMS A STABLE COMPLEX WITH CYTOPLASMIC COMPONENTS PRIOR TO NUCLEAR-PORE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 STEPS; IMPORT; TRANSPORT; TRANSLOCATION; INVITRO; INHIBITION; ANTIBODIES; ENVELOPE; SIGNALS; CELLS	Targeting of karyophilic proteins to nuclear pores is known to require several cytoplasmic factors, including the nuclear location signal-binding protein. Using a digitonin-permeabilized cell-free transport assay, we have obtained a cytoplasmic fraction containing factors that specifically bind to karyophilic protein and support the nuclear binding step of the transport. Components in this fraction form a stable complex with the karyophile through interaction with nuclear location signal. Since this complex shows nuclear pore binding activity prior to nuclear entry in the absence of other cytosolic factors, we call it nuclear pore-targeting complex. It consists of karyophilic protein and four proteins of 54, 56, 66, and 90 kDa. In our reconstitution experiments, a complex with 54 and 90 kDa proteins is capable of targeting karyophiles to the nuclear pores.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN	Osaka University			Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	18	143	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8559	8565		10.1074/jbc.270.15.8559	http://dx.doi.org/10.1074/jbc.270.15.8559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721756	hybrid			2022-12-27	WOS:A1995QT44800032
J	MENON, RK; STEPHAN, DA; SINGH, M; MORRIS, SM; ZOU, LL				MENON, RK; STEPHAN, DA; SINGH, M; MORRIS, SM; ZOU, LL			CLONING OF THE PROMOTER-REGULATORY REGION OF THE MURINE GROWTH-HORMONE RECEPTOR GENE - IDENTIFICATION OF A DEVELOPMENTALLY-REGULATED ENHANCER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; RAT HEPATOCYTES; ONTOGENY; LIVER; EXPRESSION; MEMBRANES; VECTORS; INSULIN; FETAL; DNA	The growth hormone (GH) receptor is essential for the actions of GH on postnatal growth and metabolism. To identify DNA sequences involved in the regulation of transcription of the murine GH receptor gene, a 17-kilobase genomic clone containing the 5'-flanking region, exon 1, and part of intron 1 of the murine GH receptor gene was isolated. Utilizing primer extension and ribonuclease protection assays, two major transcription start sites were identified in RNA from liver of male, female, and pregnant mice. Transient transfection stud ies using a reporter gene demonstrated promoter activity in a variety of eukaryotic cells. Deletional analysis and DNA protein binding assays led to the identification of a 30-base pair enhancer element located about 3.4 kilobases upstream of the transcription start sites. Computer analysis of the nucleotide sequence of the enhancer element did not reveal any potential DNA binding motifs for known transcription factors, and this DNA element failed to exhibit binding activity for some common transcription factors. Analysis of both functional activity and DNA-protein binding activity of this enhancer element in adult and fetal hepatocytes suggests that this DNA element may play a role in the developmental expression of the GH receptor gene.	UNIV PITTSBURGH, CHILDRENS HOSP PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	MENON, RK (corresponding author), UNIV PITTSBURGH, CHILDRENS HOSP PITTSBURGH,SCH MED,DEPT PEDIAT, DIV ENDOCRINOL, 3705 5TH AVE, PITTSBURGH, PA 15213 USA.		Morris, Sidney M/I-3440-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000986, P30HD028836] Funding Source: NIH RePORTER; NICHD NIH HHS [K08-HD00986, HD28836] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; BADINGA L, 1987, MOL CELL ENDOCRINOL, V52, P85, DOI 10.1016/0303-7207(87)90100-6; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BREIER BH, 1988, J ENDOCRINOL, V119, P43, DOI 10.1677/joe.0.1190043; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DESANTE DC, 1984, BIOCHEM J, V223, P39, DOI 10.1042/bj2230039; FREEMARK M, 1986, AM J PHYSIOL, V251, pE328, DOI 10.1152/ajpendo.1986.251.3.E328; GINOT F, 1989, EUR J BIOCHEM, V180, P289, DOI 10.1111/j.1432-1033.1989.tb14646.x; GLUCKMAN PD, 1986, OXFORD REV REPROD B, V8, P1; GLUCKMAN PD, 1981, ENDOCR REV, V2, P363, DOI 10.1210/edrv-2-4-363; GLUCKMAN PD, 1983, ENDOCRINOLOGY, V112, P1607, DOI 10.1210/endo-112-5-1607; GLUCKMAN PD, 1990, ENDOCR REV, V366, P73; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; STEPHAN DA, 1993, J DEV PHYSL OXF; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WALKER JL, 1992, PEDIATR RES, V31, P335, DOI 10.1203/00006450-199204000-00006; WATERS MJ, 1990, ACTA PAEDIATR SCAND, P60	31	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8851	8859		10.1074/jbc.270.15.8851	http://dx.doi.org/10.1074/jbc.270.15.8851			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721793	hybrid			2022-12-27	WOS:A1995QT44800071
J	TOESCU, EC; PETERSEN, OH				TOESCU, EC; PETERSEN, OH			REGION-SPECIFIC ACTIVITY OF THE PLASMA-MEMBRANE CA2+ PUMP AND DELAYED ACTIVATION OF CA2+ ENTRY CHARACTERIZE THE POLARIZED, AGONIST-EVOKED CA2+ SIGNALS IN EXOCRINE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; CYTOSOLIC CA-2+ GRADIENTS; INTRACELLULAR CA2+; INOSITOL 1,4,5-TRISPHOSPHATE; OSCILLATIONS; RECEPTOR; CHANNELS; STORES; RELEASE; INFLUX	The initial release of Ca2+ from the intracellular Ca2+ stores is followed by a second phase during which the agonist-dependent Ca2+ response becomes sensitive to the extracellular Ca2+, indicating the involvement of the plasma membrane (PM) Ca2+ transport systems. The time course of activation of these transport systems, which consist of both Ca2+ extrusion and Ca2+ entry pathways, is not well established. To investigate the participation of these processes during the agonist-evoked Ca2+ response, isolated pancreatic acinar cells were exposed to maximal concentrations of an inositol 1,4,5-trisphosphate-mobilizing agonist (acetylcholine, 10 mu M) in different experimental conditions. Following the increase of [Ca2+](i), there was an almost immediate activation of the PM Ca2+ extrusion system, and maximal activity was reached within less than 2 s. The rate of Ca2+ extrusion was dependent on the level of [Ca2+](i), with a steep activation at values just above the resting [Ca2+](i) and reached a plateau value at 700 nM Ca2+. In contrast, the PM Ca2+ entry pathway was activated with a much slower time course. There was also a delay of 3-4 s between the maximal effective depletion of the intracellular Ca2+ stores and the activation of this entry pathway. By use of digital imaging data, the PM Ca2+ transport systems were also analyzed independently in two regions of the cells, the lumenal and the basal poles. With respect to the activation of the Ca2+ entry path ways, no significant difference existed between these two regions. In contrast, the PM Ca2+ pump displayed a different pattern of activity in these regions. In the basal pole, the pump activity was more sensitive to changes of [Ca2+](i) and had a higher maximal activity. Also, in the lumenal pole, the pump became saturated at values of [Ca2+](i) around 700 nM, whereas at the basal pole [Ca2+](i) had a biphasic effect on the pump activity, and higher [Ca2+](i) inhibited the pump. It is argued that these differences in sensitivity to the levels of [Ca2+](i) and the different relationship between [Ca2+](i) and the rate of extrusion at the two functional poles of the pancreatic acinar cells indicate that the plasma membrane Ca(2+)ATPase might play an important role in the polarization of the Ca2+ response.	UNIV LIVERPOOL, PHYSIOL LAB, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool			Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380				ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; KASAI H, 1993, NEUROSCI RES, V16, P1, DOI 10.1016/0168-0102(93)90002-8; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASS GEN, 1994, BIOCHEM J, V302, P5, DOI 10.1042/bj3020005; KESSLER F, 1990, J BIOL CHEM, V265, P16012; KHAN AA, 1992, SCIENCE, V249, P1166; KOCH BD, 1994, BIOCHEM J, V302, P187, DOI 10.1042/bj3020187; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAWRIE AM, 1993, CELL CALCIUM, V14, P698, DOI 10.1016/0143-4160(93)90096-O; LEE KM, 1993, J BIOL CHEM, V268, P9945; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THELER JM, 1992, J BIOL CHEM, V267, P18110; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1994, BIOCHEM J, V304, P313, DOI 10.1042/bj3040313; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TOESCU EC, 1993, J BIOL CHEM, V268, P18654; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; XU X, 1994, J BIOL CHEM, V269, P12645	47	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8528	8535		10.1074/jbc.270.15.8528	http://dx.doi.org/10.1074/jbc.270.15.8528			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721751	hybrid			2022-12-27	WOS:A1995QT44800027
J	YAMADA, S; MURAKAMI, T; TSUDA, H; YOSHIDA, K; SUGAHARA, K				YAMADA, S; MURAKAMI, T; TSUDA, H; YOSHIDA, K; SUGAHARA, K			ISOLATION OF THE PORCINE HEPARIN TETRASACCHARIDES WITH GLUCURONATE 2-O-SULFATE - HEPARINASE CLEAVES GLUCURONATE 2-O-SULFATE-CONTAINING DISACCHARIDES IN HIGHLY SULFATED BLOCKS IN HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; IDURONATE 2-SULFATE RESIDUES; HUMAN-ENDOTHELIAL CELLS; PROTEIN-LINKAGE REGION; III-BINDING SITE; FLAVOBACTERIUM-HEPARINUM; SUBSTRATE-SPECIFICITY; INTESTINAL HEPARIN; HIGH-AFFINITY; 2 SERIES	Eleven tetrasaccharides were isolated from the repeating disaccharide region of porcine intestinal heparin after strong digestion with Flavobacterium heparinase. Their structures were determined by composition analysis, enzymatic analysis, and H-1 NMR spectroscopy. Nine of them have the common tetrasaccharide backbone, Delta HexA alpha 1-4GlcN alpha 1-4IdoA alpha 1-4GlcN, where Delta HexA and IdoA represent 4,5-unsaturated hexuronic acid and L-iduronic acid, respectively, and their structural variations are based upon the positions of sulfate groups, The nine compounds include one hexasulfated, three pentasulfated and five tetrasulfated compounds, and four of them have not been isolated previously as discrete structures. The other two of the 11 tetrasaccharides have the following hitherto unreported structures with novel glucuronate 2-O-sulfate at the internal position: Delta HexA(2-sulfate)alpha 1-4GlcN(N, 6-disulfate)alpha 1-4GlcA(2-sulfate)beta 1-4GlcN(N-sulfate) and Delta HexA(2-sulphate)alpha 1-4GlcN(N,6-disulfate) alpha 1-4GlcA(2-sulfate)beta 1-4GlcN(N,6-disulfate). Thus, 2-O-sulfated glucuronate in the highly sulfated tetrasaccharide structures typical of heparin has been demonstrated. The former and the latter tetrasaccharides account for 0.31 and 0.32% (w/w) of the starting heparin, respectively. Their yield, however, is an underestimation, since these tetrasaccharide structures in longer sequences will be degraded by heparinase. Although the latter tetrasaccharide described above was unexpectedly cleaved by heparinase into two disaccharide units, the former was not degraded by the enzyme most likely due to the lack of the 6-O-sulfate group on the GlcN residue at the reducing terminus. The results indicate its capability of catalyzing both anti and syn elimination, a property shared by heparitinases I and II and chondroitinase ABC. Both tetrasaccharides were degraded into disaccharides by heparitinase II. Therefore, it is necessary to reevaluate the disaccharide composition of heparin/heparan sulfate or oligosaccharide structures, which were previously determined after heparinase or heparitinase II digestion. It is no longer possible to conclude that the 2-O-sulfated unsaturated uronic acid residues obtained from heparin/heparan sulfate by lyase digestions are always derived from iduronate 2-O-sulfate residues in the original polymer. It is quite possible that the novel glucuronate 2-O-sulfate structure in the highly sulfated region of heparin is involved in some of the biological activities of heparin.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO,TOKYO 207,JAPAN	Kobe Pharmaceutical University; Seikagaku Corporation								BAME KJ, 1991, J BIOL CHEM, V266, P10287; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CIFONELLI JA, 1962, BIOCHEM BIOPH RES CO, V7, P41, DOI 10.1016/0006-291X(62)90141-9; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FOLKMAN J, 1989, HEPARIN, P317; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HISCOCK DRR, 1994, J BIOL CHEM, V269, P4539; HORNE A, 1992, CARBOHYD RES, V225, P43, DOI 10.1016/0008-6215(92)80038-3; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KOVENSKY J, 1993, CARBOHYD RES, V245, P361, DOI 10.1016/0008-6215(93)80085-S; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LINDAHL U, 1965, J BIOL CHEM, V240, P2821; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MERCHANT ZM, 1985, BIOCHEM J, V229, P369, DOI 10.1042/bj2290369; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; Roden L., 1989, HEPARIN CHEM BIOL PR, P1; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WALKER A, 1994, J BIOL CHEM, V269, P931; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YAMAUCHI F, 1968, BIOCHEM BIOPH RES CO, V33, P721, DOI 10.1016/0006-291X(68)90218-0; YOSHIDA K, 1989, 10TH P INT S GLYC JE, P330	59	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8696	8705						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721774				2022-12-27	WOS:A1995QT44800052
J	CROSS, AR; HEYWORTH, PG; RAE, J; CURNUTTE, JT				CROSS, AR; HEYWORTH, PG; RAE, J; CURNUTTE, JT			A VARIANT X-LINKED CHRONIC GRANULOMATOUS-DISEASE PATIENT (X91(+)) WITH PARTIALLY FUNCTIONAL CYTOCHROME-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PHAGOCYTE NADPH OXIDASE; HUMAN-NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; MICROBICIDAL OXIDASE; ACTIVATION; SUPEROXIDE; COMPONENT; SUBUNITS; PROTEIN	Genetic analysis of a patient with the variant cytochrome b(-245)-positive form of chronic granulomatous disease revealed a missense mutation resulting in a Arg(54) --> Ser substitution in the gp91(phox) subunit of cytochrome b(-245). As a consequence, although no O-2(-) is made, NADPH oxidase-associated FAD accepts electrons from NADPH in the cell-free activation system and becomes reduced. The reduced flavin exhibits normal levels of iodonitrotetrazolium violet diaphorase activity, and the patient's neutrophils exhibit high levels of intracellular oxidant production and show a low level of NBT staining in the NBT slide test. Thus, this mutation appears to render the heme center of NADPH oxidase present but nonfunctional, while leaving the flavin center fully functional.			CROSS, AR (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, CAL-1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BAEHNER RL, 1976, BLOOD, V48, P309; BASS DA, 1983, J IMMUNOL, V130, P1910; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRIGGS RT, 1975, J CELL BIOL, V67, P566, DOI 10.1083/jcb.67.3.566; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1982, BIOCHEM J, V208, P759, DOI 10.1042/bj2080759; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1989, J CLIN INVEST, V83, P1236, DOI 10.1172/JCI114006; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HOPKINS PJ, 1992, AM J HUM GENET, V51; HURST JK, 1991, J BIOL CHEM, V266, P1627; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; OCHS HD, 1973, J PEDIATR-US, V83, P77, DOI 10.1016/S0022-3476(73)80316-6; OKAMURA N, 1988, BLOOD, V72, P811; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SPARKMAN TB, 1985, BIOCHIM BIOPHYS ACTA, V846, P8, DOI 10.1016/0167-4889(85)90103-X; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8	34	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8194	8200		10.1074/jbc.270.14.8194	http://dx.doi.org/10.1074/jbc.270.14.8194			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713925	hybrid			2022-12-27	WOS:A1995QR52600064
J	ISOGAI, Y; IIZUKA, T; SHIRO, Y				ISOGAI, Y; IIZUKA, T; SHIRO, Y			THE MECHANISM OF ELECTRON DONATION TO MOLECULAR-OXYGEN BY PHAGOCYTIC CYTOCHROME B(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE PRODUCTION; MICROBICIDAL OXIDASE; NEUTROPHILS; AUTOXIDATION; MYOGLOBIN; CHAIN; COMPONENT; REDUCTION; KINETICS	Phagocytic cytochrome b(558) is a unique heme-containing enzyme, which catalyzes one electron reduction of molecular oxygen to produce a superoxide anion with a six-coordinated heme iron. To clarify the mechanism of the superoxide production, we have analyzed oxidation-reduction kinetics of cytochrome b(558) purified from porcine neutrophils by stopped-flow and rapid-scanning spectroscopy. Reduced cytochrome b(558) was rapidly reoxidized by O-2 showing spectral changes with clear isosbestic points, which were also observed during the reduction of ferric cytochrome b(558) with Na2S2O4 under anaerobic conditions. The single turnover rate for the reaction with O-2 linearly depended on the O-2 concentration but was not affected by addition of CO. The rate of the reaction decreased with an increase of pH giving a pK(a) of 9.7. Under complete anaerobic conditions, ferrous cytochrome b(558) was oxidized by ferricyanide at a rate faster than by O-2. The thermodynamic analysis shows that the enthalpic energy barriers for the reactions of cytochrome b(558) are significantly lower when compared to the autoxidation of native and modified myoglobins through the formation of the iron-O-2 complex. These findings are most consistent with the electron transfer from the heme to O-2 by an outer-sphere mechanism.			ISOGAI, Y (corresponding author), INST PHYS & CHEM RES,BIOPHYS CHEM LAB,HIROSAWA 2-1,WAKO,SAITAMA 35101,JAPAN.			Isogai, Yasuhiro/0000-0001-6905-4208				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BUTLER J, 1982, J BIOL CHEM, V257, P747; Castro C. E., 1978, PORPHYRINS, V5, P1; CHU MML, 1978, BIOCHEMISTRY-US, V17, P481, DOI 10.1021/bi00596a017; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DICKERSON LD, 1993, J AM CHEM SOC, V115, P3623, DOI 10.1021/ja00062a028; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; FULTON GP, 1976, J AM CHEM SOC, V98, P2119, DOI 10.1021/ja00424a017; GLASSTONE S, 1941, THEORY RATE PROCESSE; HURST JK, 1991, J BIOL CHEM, V266, P1627; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISOGAI Y, 1993, J BIOL CHEM, V268, P4025; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KAMIYA N, 1991, J AM CHEM SOC, V118, P1826; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MIKI T, 1992, J BIOL CHEM, V267, P19673; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; POU S, 1992, J BIOL CHEM, V267, P24173; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHIRO Y, 1993, J BIOL CHEM, V268, P19983; SUGAWARA Y, 1980, EUR J BIOCHEM, V110, P241, DOI 10.1111/j.1432-1033.1980.tb04861.x; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966	32	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7853	7857		10.1074/jbc.270.14.7853	http://dx.doi.org/10.1074/jbc.270.14.7853			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713877	hybrid			2022-12-27	WOS:A1995QR52600013
J	MYERS, RL; RAY, SK; ELDRIDGE, R; CHOTANI, MA; CHIU, IM				MYERS, RL; RAY, SK; ELDRIDGE, R; CHOTANI, MA; CHIU, IM			FUNCTIONAL-CHARACTERIZATION OF THE BRAIN-SPECIFIC FGF-1 PROMOTER, FGF-1.B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; FACTOR MESSENGER-RNA; FACTOR-I; TRANSCRIPTION INITIATION; REGULATORY ELEMENTS; FACTOR FAMILY; INT-2 GENE; EXPRESSION; CLONING	Expression of alternatively spliced human FGF-1 (or aFGF) transcripts is regulated in a tissue-specific manner via multiple promoters. To identify the cis-regulatory elements in the brain-specific FGF-1.B promoter, we constructed a series of promoter deletions fused to the luciferase reporter gene and transfected into an FGF-1.B positive glioblastoma cell line, U1240MG, and a 1.B negative cell line, U1242MG. Results of transient transfections indicate three elements that are involved in the positive regulation of FGF-1.B expression. The core promoter is located in a 40-base pair region (between -92 and -49), and two regulatory regions (RR-1 and RR-2) are located within the 540-base pair region 5' to the major transcription start site (defined as +1). Electrophoretic mobility shift assays and footprinting analysis have identified sequence-specific binding sites in RR-1 and RR-2. Mutants of RR-2 abolished binding to nuclear proteins and showed diminished luciferase reporter activity. The effects seen are specific for the U1240MG cell line, supporting a role for RR-2 in the tissue-specific regulation of FGF-1.B. Southwestern analysis using an oligonucleotide probe derived from RR-2 (nucleotides -489 to -467) further identified a 37-kDa protein that is present in nuclear extracts from U1240MG and brain but not from U1242MG.	OHIO STATE UNIV, DAVIS MED RES CTR, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University			Chotani, Maqsood/E-2891-2011; Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [R01 CA45611, K04 CA01369, T32 CA09338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611, T32CA009338, K04CA001369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIU IM, 1990, FID RES FDN, V3, P57; CHIU IM, 1990, ONCOGENE, V5, P755; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; MAURO VP, 1985, NUCLEIC ACIDS RES, V13, P239, DOI 10.1093/nar/13.1.239; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MYERS RL, 1993, ONCOGENE, V8, P341; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	37	39	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8257	8266		10.1074/jbc.270.14.8257	http://dx.doi.org/10.1074/jbc.270.14.8257			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713933	hybrid			2022-12-27	WOS:A1995QR52600072
J	NISHIMURA, K; TAKETANI, S; INOKUCHI, H				NISHIMURA, K; TAKETANI, S; INOKUCHI, H			CLONING OF A HUMAN CDNA FOR PROTOPORHYRINOGEN OXIDASE BY COMPLEMENTATION IN-VIVO OF A HEMG MUTANT OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; FULL-LENGTH CDNA; MOLECULAR-CLONING; PROTOPORPHYRINOGEN OXIDASE; NUCLEOTIDE-SEQUENCE; STRUCTURAL RELATIONSHIP; BIOSYNTHETIC-PATHWAY; FERROCHELATASE; PURIFICATION; GENE	Protoporphyrinogen oxidase (PPO; EC 1.3.3.4) is the enzyme that catalyzes in the penultimate step in the heme biosynthetic pathway. Hemes are essential components of redox enzymes, such as cytochromes. Thus, a hemG mutant strain of Escherichia coli deficient in PPO is defective in aerobic respiration and grows poorly even in rich medium. By complementation with a human placental cDNA Library, we were able to isolate a clone that enhanced the poor growth of such a hemG mutant strain. The clone encoded the gene for human PPO. Sequence analysis revealed that PPO consists of 477 amino acids with a calculated molecular mass of 50.8 kilodaltons. The deduced protein exhibited a high degree of homology over its entire length to the amino acid sequence of PPO encoded by the hemY gene of Bacillus subtilis. The NH2-terminal amino acid sequence of the deduced PPO contains a conserved amino acid sequence that forms the dinucleotide-binding site in many flavin-containing proteins. Northern blot analysis revealed the synthesis of a 1.8-kilobase pair mRNA for PPO. A homogenate of the monkey kidney COS-1 cells that had been transfected with the cDNA had much higher PPO activity than an extract of control cells, and this activity was inhibited by acifluorfen, a specific inhibitor of PPO. Furthermore, the cDNA was expressed in vitro as 51-kilodalton protein, and after incubation with isolated mitochondria the protein was found to be located in the mitochondria, having just the same size as before, an indication that PPO is a mitochondrial enzyme and has no apparent transport-specific leader sequence.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 60601,JAPAN; KANSAI MED UNIV,DEPT HYG,MORIGUCHI,OSAKA 570,JAPAN	Kyoto University; Kansai Medical University								ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ARAKAWA H, 1987, EMBO J, V6, P1361, DOI 10.1002/j.1460-2075.1987.tb02376.x; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BISHOP DF, 1990, NUCLEIC ACIDS RES, V18, P7187, DOI 10.1093/nar/18.23.7187; BRANDSCH R, 1987, EUR J BIOCHEM, V167, P315, DOI 10.1111/j.1432-1033.1987.tb13338.x; CHIU JT, 1989, J AM CHEM SOC, V111, P7046, DOI 10.1021/ja00200a023; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY TA, 1994, J BIOL CHEM, V269, P813; DAYBACH JC, 1985, EUR J BIOCHEM, V149, P431; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; FRUSTACI JM, 1993, J BACTERIOL, V175, P2154, DOI 10.1128/JB.175.7.2154-2156.1993; GARI E, 1992, FEMS MICROBIOL LETT, V93, P103, DOI 10.1016/0378-1097(92)90497-C; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; Hendrix R. W, 1983, LAMBDA, VII; HSU J, 1971, PHOTOCHEM PHOTOBIOL, V13, P67, DOI 10.1111/j.1751-1097.1971.tb06092.x; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; ITO A, 1988, BIOCHEM BIOPH RES CO, V157, P970, DOI 10.1016/S0006-291X(88)80969-0; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS NJ, 1982, ENZYME, V28, P206, DOI 10.1159/000459103; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOHNO H, 1993, J BIOL CHEM, V268, P21359; LABBE P, 1990, BIOSYNTHESIS HEME CH, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; MARTASEK P, 1994, P NATL ACAD SCI USA, V91, P3024, DOI 10.1073/pnas.91.8.3024; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MIYAMOTO K, 1994, J BIOCHEM-TOKYO, V115, P545, DOI 10.1093/oxfordjournals.jbchem.a124373; MORI M, 1985, EUR J BIOCHEM, V149, P181, DOI 10.1111/j.1432-1033.1985.tb08909.x; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; NISHIMURA K, 1993, GENE, V133, P109; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; O'NEILL G P, 1990, Biofactors, V2, P227; POULSON R, 1976, J BIOL CHEM, V251, P3730; PROULX KL, 1992, PROTEIN SCI, V1, P801, DOI 10.1002/pro.5560010612; RAICH N, 1992, NUCLEIC ACIDS RES, V14, P5955; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROMEO PH, 1986, J BIOL CHEM, V261, P9825; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASARMAN A, 1993, CAN J MICROBIOL, V39, P1155, DOI 10.1139/m93-174; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIEPKER LJ, 1987, BIOCHIM BIOPHYS ACTA, V913, P349, DOI 10.1016/0167-4838(87)90146-4; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; TSAI SF, 1988, P NATL ACAD SCI USA, V85, P7049, DOI 10.1073/pnas.85.19.7049; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	55	97	107	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8076	8080		10.1074/jbc.270.14.8076	http://dx.doi.org/10.1074/jbc.270.14.8076			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713909	hybrid			2022-12-27	WOS:A1995QR52600047
J	BOGGS, KP; ROCK, CO; JACKOWSKI, S				BOGGS, KP; ROCK, CO; JACKOWSKI, S			LYSOPHOSPHATIDYLCHOLINE AND 1-O-OCTADECYL-2-O-METHYL-RAC-GLYCERO-3-PHOSPHOCHOLINE INHIBIT THE CDP-CHOLINE PATHWAY OF PHOSPHATIDYLCHOLINE SYNTHESIS AT THE CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE STEP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; PHOSPHOLIPID ANALOG HEXADECYLPHOSPHOCHOLINE; ALKYL-LYSOPHOSPHOLIPIDS; RAT HEPATOCYTES; HL-60 CELLS; HELA-CELLS; ENDOPLASMIC-RETICULUM; SELECTIVE DESTRUCTION; FEEDBACK-REGULATION; NEOPLASTIC-CELLS	The regulation of the CDP choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase (CT) step by lysophosphatidylcholine (LPC) and the nonhydrolyzable LPC analog, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3), was investigated in a colony stimulating factor 1-dependent murine macrophage cell line. LPC inhibited phosphatidylcholine synthesis in vivo and led to the accumulation of choline and phosphocholine coupled to the disappearance of CDP choline pointing to CT as the intracellular target. LPC neither inhibited cell growth nor decreased the cellular content of CT or altered the distribution of CT between soluble and particulate subcellular fractions. The inhibition of phosphatidylcholine synthesis was specific for LPC since lysophospholipids lacking the choline headgroup were not inhibitors. ET-18-OCH3 was a more potent inhibitor of phosphatidylcholine synthesis than LPC and caused the translocation of CT from the soluble compartment to the particulate compartment. Both LPC and ET-18-OCH3 were inhibitors of CT activity in vitro and kinetic analysis showed competitive inhibition with respect to the lipid activator. These data point to LPC as a negative regulator of de novo phosphatidylcholine synthesis that acts at the CT step and establish the mechanism for the inhibition of phosphatidylcholine biosynthesis by antineoplastic phospholipids.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREESEN R, 1978, CANCER RES, V38, P3894; ANDREESEN R, 1979, BLOOD, V54, P519; BERDEL WE, 1991, BRIT J CANCER, V64, P208, DOI 10.1038/bjc.1991.277; BERDEL WE, 1980, EUR J CANCER, V16, P1119; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; GEILEN CC, 1994, BBA-LIPID LIPID MET, V1211, P14, DOI 10.1016/0005-2760(94)90133-3; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; HERRMANN DBJ, 1985, J NATL CANCER I, V75, P423; HJELMSTAD RH, 1992, METHOD ENZYMOL, V209, P272; HOFFMAN DR, 1986, CANCER RES, V46, P5803; HOFFMAN DR, 1992, BIOCHIM BIOPHYS ACTA, V1127, P74, DOI 10.1016/0005-2760(92)90203-8; JACKOWSKI S, 1986, J BIOL CHEM, V261, P4978; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1992, J BIOL CHEM, V267, P1752; JAMIL H, 1990, BIOCHEM J, V270, P749, DOI 10.1042/bj2700749; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; MODOLELL M, 1979, CANCER RES, V39, P4681; MORAND JN, 1989, J BIOL CHEM, V264, P13785; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Munder P. G., 1977, IMMUNOLOGY, V7, P411; NOSEDA A, 1987, LIPIDS, V22, P878, DOI 10.1007/BF02535548; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, CAN J BIOCHEM CELL B, V61, P1147, DOI 10.1139/o83-147; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; RUNGE MH, 1980, J NATL CANCER I, V64, P1301, DOI 10.1093/jnci/64.6.1301; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TRONCHERE H, 1991, BIOCHEM BIOPH RES CO, V176, P157, DOI 10.1016/0006-291X(91)90903-K; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VALLARI DS, 1988, BIOCHEM BIOPH RES CO, V156, P1, DOI 10.1016/S0006-291X(88)80797-6; VALLARI DS, 1989, BIOCHIM BIOPHYS ACTA, V1006, P250, DOI 10.1016/0005-2760(89)90204-X; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; VOGLER WR, 1991, LIPIDS, V26, P1418, DOI 10.1007/BF02536579; VOGLER WR, 1985, EXP HEMATOL, V13, P629; VOGLER WR, 1994, LEUKEMIA LYMPHOMA, V13, P53, DOI 10.3109/10428199409051652; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WESTPHAL O, 1987, LIPIDS, V22, P787, DOI 10.1007/BF02535532; WIEDER T, 1993, BIOCHEM J, V291, P561, DOI 10.1042/bj2910561; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YAO ZM, 1990, J BIOL CHEM, V265, P4326	59	148	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7757	7764		10.1074/jbc.270.13.7757	http://dx.doi.org/10.1074/jbc.270.13.7757			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706325	hybrid			2022-12-27	WOS:A1995QQ43100105
J	MERELLO, S; PARODI, AJ; COUSO, R				MERELLO, S; PARODI, AJ; COUSO, R			CHARACTERIZATION AND PARTIAL-PURIFICATION OF A NOVEL ENZYMATIC-ACTIVITY - UDP-GLCNAC-SER-PROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE FROM THE CELLULAR SLIME-MOLD DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-A GLYCOPROTEIN; LINKED OLIGOSACCHARIDES; STRUCTURAL-ANALYSIS; LYSOSOMAL-ENZYMES; PHOSPHORYLATION; IDENTIFICATION; MEMBRANES; RESIDUES	An enzymatic activity that transfers N-acetylglucosamine-1-phosphate residues from UDP-GlcNAc to serine units in proteins (UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase) was detected in membranes of the cellular slime mold Dictyostelium discoideum. The enzyme was partially purified by affinity chromatography in concanavalin A-Sepharose and ion exchange chromatography in a Mono Q column. The enzyme showed an absolute requirement for bivalent cations, Mn2+ being more effective than Mg2+. It had a broad optimum pH value (6.5-9.0). The K-m for UDP-GlcNAc was 18 mu M. In cell free assays it used apomucin and native or 8 M urea-denatured thyroglobulin but neither bovine serum albumin nor native or denatured uteroferrin as exogenous accepters. Analysis of proteins isolated from cells grown in the presence of [P-32]phosphate and from the culture medium showed that the majority of proteins bearing the structure GlcNAc-1-P-Ser were secreted. In equilibrium density centrifugations of microsomes, the enzyme appeared in membranes having lighter densities than the enzyme that phosphorylates high mannose-type oligosaccharides. This showed that the activity that phosphorylates serine residues in proteins (UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase) is different from that phosphorylating protein-linked high mannose-type oligosaccharides (UDP-GlcNAc:glycoprotein N-acetylglucosamine-1-phosphotransferase).	FDN CAMPOMAR,INST INVEST BIOQUIM,RA-1405 BUENOS AIRES,DF,ARGENTINA	Leloir Institute								ASHWORTH JM, 1972, BIOCHEM J, V126, P601, DOI 10.1042/bj1260601; Cardelli JA, 1993, ENDOSOMES LYSOSOMES, P341; COUSO R, 1986, J BIOL CHEM, V261, P6326; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GABEL CA, 1984, J BIOL CHEM, V259, P3762; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; GUSTAFSON GL, 1979, BIOCHEM BIOPH RES CO, V86, P667, DOI 10.1016/0006-291X(79)91765-0; GUSTAFSON GL, 1980, BIOCHEM BIOPH RES CO, V94, P1439, DOI 10.1016/0006-291X(80)90580-X; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; SCHMIDT JA, 1982, DEV BIOL, V91, P296, DOI 10.1016/0012-1606(82)90036-7; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; WILLIAMS JG, 1985, EMBO J, V4, P999, DOI 10.1002/j.1460-2075.1985.tb03730.x; YOSHIDA M, 1984, EMBO J, V3, P2663, DOI 10.1002/j.1460-2075.1984.tb02191.x	22	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7281	7287		10.1074/jbc.270.13.7281	http://dx.doi.org/10.1074/jbc.270.13.7281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706268	hybrid			2022-12-27	WOS:A1995QQ43100041
J	MILARSKI, KL; ZHU, GC; PEARL, CG; MCNAMARA, DJ; DOBRUSIN, EM; MACLEAN, D; THIEMESEFLER, A; ZHANG, ZY; SAWYER, T; DECKER, SJ; DIXON, JE; SALTIEL, AR				MILARSKI, KL; ZHU, GC; PEARL, CG; MCNAMARA, DJ; DOBRUSIN, EM; MACLEAN, D; THIEMESEFLER, A; ZHANG, ZY; SAWYER, T; DECKER, SJ; DIXON, JE; SALTIEL, AR			SEQUENCE SPECIFICITY IN RECOGNITION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BY PROTEIN-TYROSINE PHOSPHATASE-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; PHOSPHOLIPASE-C; SH2 DOMAINS; TRANSFORMING ACTIVITY; CYTOPLASMIC PROTEIN; KINASE-ACTIVITY; HOMOLOGY; CLONING; CDNA; EXPRESSION	Protein tyrosine phosphatases all contain a conserved cysteine that forms an intermediate thiophosphate ester bond during tyrosine phosphate hydrolysis. A bacterial glutathione S-transferase fusion protein containing rat brain phosphatase PTP1b was constructed in which this conserved cysteine was mutated to serine. The resulting catalytically inactive enzyme was labeled in vivo to high specific activity with S-35, and the binding of this labeled fusion protein to the immunoprecipitated epidermal growth factor (EGF) receptor was evaluated. The binding was ligand-dependent, and saturation analysis revealed a nonlinear Scatchard plot, with a K(d) for high affinity binding of approximately 100 nM. A number of glutathione S-transferase fusion proteins containing src homology 2 (SH2) domains attenuated phosphatase binding in a concentration-dependent manner. Phospholipase C (PLC)gamma and the GTPase-activating protein of ras were the most potent inhibitors. Tyrosine-phosphorylated EGF receptor peptide fragments were evaluated for specific inhibition of PTP1b and PLCgamma SH2 binding to the activated receptor. One such peptide, modeled on EGF receptor tyrosine 992, blocked the binding of both fusion proteins. Another phosphopeptide, modeled on tyrosine 1148, inhibited the binding of PTP1b but not the PLCgamma fusion protein. This site specificity was confirmed by analysis of equilibrium binding of the fusion proteins to EGF receptors mutated in each of these phosphorylation sites. The results revealed clear sequence specificity in the binding of proteins involved in the regulation of intracellular signaling by receptor tyrosine kinases.	PARKE DAVIS & CO,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,2800 PLYMOUTH RD,ANN ARBOR,MI 48105; PARKE DAVIS & CO,DIV PHARMACEUT RES,DEPT CHEM,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Pfizer; Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCNAMARA DJ, 1993, IN PRESS INT J PEPT; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559; ZHU GC, 1993, J BIOL CHEM, V268, P1775	44	95	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23634	23639						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693694				2022-12-27	WOS:A1993MF51500102
J	COOK, SP; BABCOCK, DF				COOK, SP; BABCOCK, DF			SELECTIVE MODULATION BY CGMP OF THE K+ CHANNEL ACTIVATED BY SPERACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERMATOZOA; EGG PEPTIDE SPERACT; DEPENDENT PROTEIN-KINASE; POTASSIUM CHANNELS; GUANYLATE-CYCLASE; CYCLIC-GMP; HEMICENTROTUS-PULCHERRIMUS; PLASMA-MEMBRANE; RECEPTOR; CALCIUM	The egg peptide speract stimulates sperm guanylyl cyclase and presumably enhances fertilization, but the roles of cGMP in sperm responses are yet undetermined. Here we show that speract-induced accumulation of cGMP or cAMP is selectively enhanced by the phosphodiesterase inhibitors, 3-isobutyl-1-methylxanthine (IBMX) or papaverine, respectively. These inhibitors provided the unusual opportunity to examine the consequences of manipulating cGMP- and cAMP-dependent responses. The following observations suggest that cGMP mediates activation of K channels, the earliest known ionic event in speract signal transduction: 1) both cGMP content and K+ permeability are maximal within 15 s of speract stimulation and both decline after intracellular pH (pH(i)) increases in response to hyperpolarization; 2) IBMX prolongs elevation of cGMP and sustains K+ permeability after pH(i) increases; 3) both cGMP accumulation and K+ permeability also are enhanced when the pH(i) increase is prevented by an elevated concentration of external K+ (K(o)); 4) elevating pH(i) with NH4Cl bypasses the blockade imposed by high K(o) and decreases K+ permeability. Because IBMX antagonizes this action of NH4Cl, these results further suggest that elevation of pH(i) initiates an inactivation of guanylyl cyclase that leads to K channel closure. However, K+ permeability is restored upon subsequent elevation of intracellular [Ca2+] (Ca(i)), indicating either that sperm K channels possess an alternate regulatory mode, or that a distinct Ca2+-activated K permeability also participates in speract signal transduction. Regardless of the mechanism that mediates Ca(i) action, sperm K channels are identified as downstream targets of cGMP and are implicated in a feedback loop that both terminates guanylyl cyclase activity and leads to their own inactivation.	UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Babcock, Donner/0000-0002-4461-4544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022973] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22973] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD I, 1992, P NATL ACAD SCI USA, V89, P10262, DOI 10.1073/pnas.89.21.10262; BABCOCK DF, 1992, P NATL ACAD SCI USA, V89, P6001, DOI 10.1073/pnas.89.13.6001; BENTLEY JK, 1986, BIOL REPROD, V35, P1249, DOI 10.1095/biolreprod35.5.1249; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COOK SP, 1993, J BIOL CHEM, V268; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; DANGOTT LJ, 1984, J BIOL CHEM, V259, P3712; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOMINO SE, 1988, J BIOL CHEM, V263, P690; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GARBERS DL, 1982, J BIOL CHEM, V257, P2734; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; GARBERS DL, 1992, CELL, V71, P1; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P2235; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P163; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P151; LEE HC, 1988, DEV BIOL, V126, P91, DOI 10.1016/0012-1606(88)90242-4; LEE HC, 1986, J BIOL CHEM, V261, P6026; LEE HC, 1984, J BIOL CHEM, V259, P5315; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LIEVANO A, 1986, DEV BIOL, V112, P253; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; OGRADY SM, 1991, J MEMBRANE BIOL, V124, P159, DOI 10.1007/BF01870460; POTTER LR, 1992, J BIOL CHEM, V267, P14531; REINHART PH, 1991, J NEUROSCI, V11, P1627; SCHACKMANN RW, 1986, J BIOL CHEM, V261, P8719; SCHACKMANN RW, 1989, CELL BIOL FERTILIZAT, P3; SHIMOMURA H, 1986, J BIOL CHEM, V261, P5778; SUZUKI N, 1992, COMP BIOCHEM PHYS B, V102, P679, DOI 10.1016/0305-0491(92)90064-X; SUZUKI N, 1981, BIOCHEM BIOPH RES CO, V99, P1238, DOI 10.1016/0006-291X(81)90752-X; SUZUKI N, 1984, J BIOL CHEM, V259, P4874; TARE M, 1990, NATURE, V346, P69, DOI 10.1038/346069a0; TOOWICHARANONT P, 1988, J BIOL CHEM, V263, P6877; WELLS JN, 1976, BIOL REPROD, V15, P46, DOI 10.1095/biolreprod15.1.46; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YOSHINO K, 1992, EUR J BIOCHEM, V206, P887, DOI 10.1111/j.1432-1033.1992.tb16997.x; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	43	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22402	22407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693667				2022-12-27	WOS:A1993MD34800035
J	LECHLEIDER, RJ; SUGIMOTO, S; BENNETT, AM; KASHISHIAN, AS; COOPER, JA; SHOELSON, SE; WALSH, CT; NEEL, BG				LECHLEIDER, RJ; SUGIMOTO, S; BENNETT, AM; KASHISHIAN, AS; COOPER, JA; SHOELSON, SE; WALSH, CT; NEEL, BG			ACTIVATION OF THE SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SH-PTP2 BY ITS BINDING-SITE, PHOSPHOTYROSINE-1009, ON THE HUMAN PLATELET-DERIVED GROWTH-FACTOR RECEPTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE-PHOSPHATASE; PDGF RECEPTOR; SH3 DOMAINS; PHOSPHORYLATION; IDENTIFICATION; CORKSCREW; SUBUNIT; SIGNAL	Much progress has been made in elucidating early events in signal transduction by growth factor receptors with intrinsic tyrosine kinase activity. Upon ligand addition, these receptors dimerize and activate, becoming phosphorylated at a number of tyrosyl residues. These phosphorylation sites serve as docking points for proteins containing src homology-2 (SH2) domains. However, little is known about how phosphotyrosine phosphatases (PTPs), participate in these events. Recently, we and others molecularly cloned a ubiquitously expressed SH2 domain-containing PTP, SH-PTP2 (Syp, PTP1D, PTP2C), and found that it interacts directly with several activated growth factor receptors via its SH2 domains. Using a peptide competition assay, we now demonstrate that the major binding site for SH-PTP2 on the platelet-derived growth factor receptor is phosphotyrosine 1009. Immunoprecipitation studies indicate that SH-PTP2 is the previously unidentified ''64-kDa'' protein known to bind at this site. Addition of a phosphotyrosyl peptide comprising the region around Tyr-1009 stimulates SH-PTP2 activity 5-10-fold, whereas other phosphotyrosyl peptides from the platelet-derived growth factor receptor have no stimulatory effect. Our data suggest that binding of SH-PTP2 to the activated receptor in vivo should result in stimulation of SH-PTP2 activity.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DIV PULM MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, BOSTON, MA 02115 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Fred Hutchinson Cancer Center				Bennett, Anton/0000-0001-5187-7599	NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152, R01CA054786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER; NCI NIH HHS [CA54786, CA49152] Funding Source: Medline; NIGMS NIH HHS [GM20011] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1993, IN PRESS P NATL ACAD; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, J BIOL CHEM, V267, P9678; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TONKS NK, 1988, J BIOL CHEM, V263, P6731; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	292	296	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21478	21481						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691811				2022-12-27	WOS:A1993MC80900007
J	FANG, YI; ADACHI, M; KOBAYASHI, J; OHIZUMI, Y				FANG, YI; ADACHI, M; KOBAYASHI, J; OHIZUMI, Y			HIGH-AFFINITY BINDING OF 9-[H-3]METHYL-7-BROMOEUDISTOMIN-D TO THE CAFFEINE-BINDING SITE OF SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE CHANNEL; JUNCTIONAL TERMINAL CISTERNAE; RYANODINE RECEPTOR; CA-2+ RELEASE; CA2+ RELEASE; 9-METHYL-7-BROMOEUDISTOMIN-D; PURIFICATION; ACTIVATION; EXPRESSION; MECHANISMS	H-3-Labeled 9-methyl-7-bromoeudistomin D ([H-3]MBED), the most powerful inducer of Ca2+ release from sarcoplasmic reticulum (SR), was successfully prepared with a high specific activity of 10.2 Ci/mmol. [H-3]MBED bound to terminal cisternae (TC) of skeletal muscle SR in a replacable and saturable manner, indicating the existence of its specific binding site. Caffeine inhibited the [H-3]MBED binding to the TC-SR membranes from skeletal muscle with an IC50 value of 0.8 mm, in close agreement with a concentration that causes Ca2+ release from SR. Scatchard analysis gave values of K(D) = 40 nM and B(max) = 10 pmol/mg protein. The K(D) value was increased by caffeine, while that of B(max) was not changed, indicating a competitive mode of inhibition. Adenosine 5'-(beta,gamma-methylene)triphosphate enhanced [H-3]MBED binding, but ryanodine and Ca2+ did not affect it. [H-3]MBED binding to TC-SR membranes was inhibited by procaine, a representative blocker of Ca2+-induced Ca2+ release channels, whereas that was not changed by Mg2+, suggesting that procaine but not Mg2+ may exert its inhibitory effect on Ca2+-induced Ca2+ release by affecting the caffeine-binding sites. These results suggest that MBED shares the same binding site as that of caffeine in TC-SR. The [H-3]MBED is the first radiolabelled ligand for caffeine-binding sites in Ca2+ release channels and thus may provide an essential biochemical tool for elucidating this site.	TOHOKU UNIV,INST PHARMACEUT,DEPT PHARMACEUT MOLEC BIOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Tohoku University; Hokkaido University			Kobayashi, Jun'ichi/A-4253-2012					ANTONIU B, 1985, BIOCHIM BIOPHYS ACTA, V816, P9, DOI 10.1016/0005-2736(85)90387-6; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DANKO S, 1985, BIOCHIM BIOPHYS ACTA, V816, P18, DOI 10.1016/0005-2736(85)90388-8; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; ENDO M, 1981, REGULATION MUSCLE CO, P181; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FRANK GB, 1982, CAN J PHYSIOL PHARM, V60, P427, DOI 10.1139/y82-063; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KIM DH, 1983, J BIOL CHEM, V258, P9662; KOBAYASHI J, 1989, EXPERIENTIA, V45, P782, DOI 10.1007/BF01974589; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NAKAMURA Y, 1986, J BIOL CHEM, V261, P4139; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SEINO A, 1991, J PHARMACOL EXP THER, V256, P861; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; ZARKA A, 1992, BIOCHIM BIOPHYS ACTA, V1108, P13, DOI 10.1016/0005-2736(92)90109-Y	29	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18622	18625						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689557				2022-12-27	WOS:A1993LV65900041
J	GOODWIN, GW; ARTEAGA, JR; TAEGTMEYER, H				GOODWIN, GW; ARTEAGA, JR; TAEGTMEYER, H			GLYCOGEN TURNOVER IN THE ISOLATED WORKING RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER; DEGRADATION; HEPATOCYTES; METABOLISM; LACTATE	The isolated working rat heart was adapted for simultaneous determination of glycogen synthesis and degradation using a dual isotope technique. After prelabeling of glycogen with [U-C-14]glucose, glycogenolysis was determined continuously from the washout of (CO2)-C-14 plus [C-14]lactate. Glycogen synthesis was determined during the same period from incorporation of [5-H-3]glucose, In the absence of added hormones, hearts were predominantly glycogenolytic (1.5 mu mol/min/g, dry weight), and there was simultaneous synthesis (11% of the rate of glycogenolysis). The percentage of glucose taken up by the heart that could traverse the glycogen pool as a consequence of glycogen turnover was minor (5%). Insulin (10 milliunits/ml) predictably stimulated glycogen synthesis (3.6 fold) and nearly abolished glycogenolysis. Addition of glucagon (1 mu g/ml) increased contractile performance and initially stimulated glycogenolysis (3.8 fold) until glycogen was largely depleted, Net tritium incorporation was unaffected by glucagon, Both hormones stimulated glycolytic flux from exogenous glucose ((H2O)-H-3 from [5-H-3]glucose) as well as total glycolytic flux ((H2O)-H-3 plus glycogenolysis). The initial stimulation in total glycolytic flux with glucagon was largely from glycogen, explaining the lag in stimulation from exogenous glucose. The relationship between the specific radioactivity and amount of glycogen remaining after different degrees of glycogenolysis suggests that the preference of glycogenolysis for newly synthesized glycogen is only partial,	UNIV TEXAS, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, HOUSTON, TX 77030 USA	University of Texas System					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043133] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-43133] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT EJ, 1994, METABOLISM, V43, P285, DOI 10.1016/0026-0495(94)90094-9; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRAINARD JR, 1989, BIOCHEMISTRY-US, V28, P9766, DOI 10.1021/bi00451a033; CHALLISS RAJ, 1987, EUR J BIOCHEM, V163, P205, DOI 10.1111/j.1432-1033.1987.tb10756.x; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; DEPRE C, 1993, ACTA CARDIOL, V48, P147; DEVOS P, 1979, EUR J BIOCHEM, V99, P161, DOI 10.1111/j.1432-1033.1979.tb13242.x; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GOODWIN GW, 1994, AM J PHYSIOL, V267, pH462, DOI 10.1152/ajpheart.1994.267.2.H462; HUE L, 1974, BIOCHEM BIOPH RES CO, V58, P532, DOI 10.1016/S0006-291X(74)80453-5; KATZ J, 1967, BIOCHEMISTRY-US, V6, P1, DOI 10.1021/bi00853a001; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; LAUGHLIN MR, 1988, J BIOL CHEM, V263, P2285; MAGNUSSON I, 1994, AM J PHYSIOL, V266, pE796, DOI 10.1152/ajpendo.1994.266.5.E796; POSTLE AD, 1980, BIOCHEM J, V192, P65, DOI 10.1042/bj1920065; SHULMAN GI, 1988, J BIOL CHEM, V263, P5027; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; WAJNGOT A, 1991, METABOLISM, V40, P877, DOI 10.1016/0026-0495(91)90019-S; WALAAS O, 1950, J BIOL CHEM, V187, P769	20	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9234	9240		10.1074/jbc.270.16.9234	http://dx.doi.org/10.1074/jbc.270.16.9234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721842	hybrid			2022-12-27	WOS:A1995QU08900030
J	HENDY, GN; BENNETT, HPJ; GIBBS, BF; LAZURE, C; DAY, R; SEIDAH, NG				HENDY, GN; BENNETT, HPJ; GIBBS, BF; LAZURE, C; DAY, R; SEIDAH, NG			PROPARATHYROID HORMONE IS PREFERENTIALLY CLEAVED TO PARATHYROID-HORMONE BY THE PROHORMONE CONVERTASE FURIN - A MASS-SPECTROMETRIC STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEX2-LIKE PROCESSING ENDOPROTEASE; HUMAN PREPROPARATHYROID HORMONE; CONSTITUTIVE SECRETORY PATHWAY; PHASE LIQUID-CHROMATOGRAPHY; SUBTILISIN-LIKE PROTEASE; RAT PITUITARY; PROPROTEIN CONVERTASE; NUCLEOTIDE-SEQUENCE; SERINE PROTEASES; MESSENGER-RNA	Parathyroid hormone (PTH), an 84-amino acid pep tide, is the major regulator of blood calcium homeostasis. Its mRNA, in addition to encoding the mature peptide, also encodes a ''pre'' sequence of 25 amino acids and a basic ''pro'' hexapeptide, To assess which of the subtilisin like prohormone convertases can process proPTH to PTH we coinfected cells with a vaccinia virus construct expressing human preproPTH and vaccinia virus constructs expressing furin, PC1 or PC2. BSC-40 cells, having a constitutive secretory pathway, and GH4C1 cells, having a regulated secretory pathway, were used. PTH biosynthetic products in cell extracts and media were purified by high performance liquid chromatography, identified by radioimmunoassay, and unambiguously defined as either proPTH or PTH by ion spray mass spectrometry, In both cell types, furin was the most effective in processing proPTH to PTH. In all cases only PTH was released into the medium. In addition, partially purified furin and PC1 were tested for their ability to appropriately cleave a tridecapeptide spanning the prohormone cleavage site found in proPTH. Here too furin was much more effective at cleaving at the correct site. Northern blot analysis and in situ hybridization showed that furin and preproPTH mRNA are co expressed in the parathyroid, whereas PC1, PC2, and PC5 are not and PACE4 is expressed only at very low levels. Taken together these studies strongly suggest that furin is the enzyme responsible for the physiological processing of proPTH to PTH.	MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ,CANADA; BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,NEUROPEPTIDES STRUCT & METAB LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,JA DESEVE LAB BIOCHEM NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA	McGill University; McGill University; National Research Council Canada; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	HENDY, GN (corresponding author), ROYAL VICTORIA HOSP,CALCIUM RES LAB,RM H4 67,687 PINE AVE W,MONTREAL,PQ H3A 1A1,CANADA.		Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BENNETT HPJ, 1981, BIOCHEM J, V197, P391, DOI 10.1042/bj1970391; CASTILLO MJ, 1979, ANAL BIOCHEM, V99, P53, DOI 10.1016/0003-2697(79)90043-5; COHN DV, 1972, P NATL ACAD SCI USA, V69, P1521, DOI 10.1073/pnas.69.6.1521; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DRESS BM, 1994, ENDOCRINOLOGY, V134, P2057; HABENER JF, 1979, J CELL BIOL, V80, P715, DOI 10.1083/jcb.80.3.715; HABENER JF, 1976, J CLIN ENDOCR METAB, V42, P520, DOI 10.1210/jcem-42-3-520; HABENER JF, 1975, ENDOCRINOLOGY, V97, P431, DOI 10.1210/endo-97-2-431; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HEINRICH G, 1984, J BIOL CHEM, V259, P3320; HELLERMAN JG, 1984, P NATL ACAD SCI-BIOL, V81, P5340, DOI 10.1073/pnas.81.17.5340; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; JAMES S, 1994, ANAL BIOCHEM, V217, P84, DOI 10.1006/abio.1994.1086; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1991, ANAL BIOCHEM, V194, P399, DOI 10.1016/0003-2697(91)90248-R; KEMPER B, 1974, P NATL ACAD SCI USA, V71, P3731, DOI 10.1073/pnas.71.9.3731; KEMPER B, 1972, P NATL ACAD SCI USA, V69, P643, DOI 10.1073/pnas.69.3.643; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MACGREGOR RR, 1986, J BIOL CHEM, V261, P1929; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V48, P11; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PAQUET L, 1994, J BIOL CHEM, V269, P19279; RABBANI SA, 1988, J BIOL CHEM, V263, P1307; RABBANI SA, 1990, BIOCHEMISTRY-US, V29, P10080, DOI 10.1021/bi00495a010; Sambrook J, 1989, MOL CLONING LABORATO; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER DF, 1992, J BIOL CHEM, V267, P23435; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WIREN KM, 1988, J BIOL CHEM, V263, P19771	49	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9517	9525		10.1074/jbc.270.16.9517	http://dx.doi.org/10.1074/jbc.270.16.9517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721880	hybrid			2022-12-27	WOS:A1995QU08900069
J	TURNER, H; REIF, K; RIVERA, J; CANTRELL, DA				TURNER, H; REIF, K; RIVERA, J; CANTRELL, DA			REGULATION OF THE ADAPTER MOLECULE GRB2 BY THE FC-EPSILON-R1 IN THE MAST-CELL LINE RBL2H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BASOPHILIC LEUKEMIA-CELLS; ANTIGEN RECEPTOR; HIGH-AFFINITY; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; SH3 DOMAINS; ZETA-CHAIN; T-CELLS; RAS	Antigenic cross-linking of the high affinity IgE receptor (Fc epsilon R1) on mast cells results in protein tyrosine kinase activation. The object of the present study was to explore the regulation of the SH2 and SH3 domain containing adapter molecule Grb2 by Fc epsilon R1-stimulated PTK signal transduction pathways. Affinity purification of in vivo Grb2 complexes together with in vitro experiments with Grb2 glutathione S-transferase fusion proteins were used to analyze Grb2 complexes in the mast cell line RBL2H3. The data show that in RBL2H3 cells several different proteins are complexed to the SH3 domains of Grb2. These include the p21ras guanine nucleotide exchange factor Sos, two basally tyrosine-phosphorylated 110- and 120-kDa molecules, and a 75-kDa protein that is a substrate for Fc epsilon R1-activated PTKs. By analogy with Sos, p75, p110 and p120 are candidates for Grb2 effector proteins which suggests that Grb2 may be a pleiotropic adapter. Two Grb2 SH2-binding proteins were also characterized in RBL2H3 cells; the adapter She and a 33-kDa molecule. She is constitutively tyro sine phosphorylated in unstimulated cells and Fc epsilon R1 ligation induces no changes in its phosphorylation or binding to Grb2. In contrast, p33 is a substrate for Fc epsilon R1-activated PTKs and binds to Grb2 SH2 domains in Fc epsilon R1 activated but not quiescent cells. The beta subunit of the Fc epsilon R1 is a 33-kDa tyrosine phosphoprotein, but the p33 Grb2-binding protein described in the present report is not the Fc epsilon R1 beta chain and its identity is unknown. The present report thus demonstrates that there are multiple Grb2 containing protein complexes in mast cells of which a subset are Fc epsilon R1-regulated. Two other of the Grb2-binding proteins described herein are tyrosine phosphorylated in response to Fc epsilon R1 ligation: the 75-kDa protein which binds to Grb2 SH3 domains and the 33-kDa protein that associates with the Grb2 SH2 domain. We propose that protein complex formation by Grb2 is an important consequence of Fc epsilon R1 cross-linking and that this may be a signal transduction pathway which acts synergistically with calcium/PKC signals to bring about optimal mast cell end function.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,LONDON WC2A 3PX,ENGLAND; NIASD,BETHESDA,MD 20892	Cancer Research UK			Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389				BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCOLNIK EY, 1993, EMBO J, V12, P1929; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMIT L, 1994, J BIOL CHEM, V269, P20209; SU J, 1994, J BIOL CHEM, V269, P18731; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	48	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9500	9506		10.1074/jbc.270.16.9500	http://dx.doi.org/10.1074/jbc.270.16.9500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721878	hybrid			2022-12-27	WOS:A1995QU08900067
J	WANG, P; WU, P; SIEGEL, MI; EGAN, RW; BILLAH, MM				WANG, P; WU, P; SIEGEL, MI; EGAN, RW; BILLAH, MM			INTERLEUKIN (IL)-10 INHIBITS NUCLEAR FACTOR KAPPA-B (NF-KAPPA-B) ACTIVATION IN HUMAN MONOCYTES - IL-10 AND IL-4 SUPPRESS CYTOKINE SYNTHESIS BY DIFFERENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; ALPHA PROMOTER REGION; TRANSCRIPTION FACTOR; GENE; BINDING; MACROPHAGE; EXPRESSION; LIPOPOLYSACCHARIDE; SUBUNIT	Our previous studies in human monocytes have demonstrated that interleukin (IL)-10 inhibits lipopolysaccharide (LPS)-stimulated production of inflammatory cytokines, lL-1 beta, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha by blocking gene transcription. Using electrophoretic mobility shift assays (EMSA), we now show that, in monocytes stimulated with LPS or TNF alpha, IL-10 inhibits nuclear localization of nuclear factor kappa B (NF kappa B), a transcription factor involved in the expression of inflammatory cytokine genes. Several other transcription factors including NF-IL-6, AP-1, AP-2, GR, CREB, Oct-1, and Sp-1 are not affected by IL-10, This selective inhibition by IL-10 of NF kappa B activation occurs rapidly and in a dose-dependent manner and correlates well with IL-10's cytokine synthesis inhibitory activity in terms of both kinetics and dose responsiveness. Furthermore, compounds such as tosylphenylalanyl chloromethyl ketone and pyrrolidinedithiocarbamate that are known to selectively inhibit NF kappa B activation block cytokine gene transcription in LPS-stimulated monocytes. Taken together, these results suggest that inhibition of NF kappa B activation may be an important mechanism for IL-10 supression of cytokine gene transcription in human monocytes. IL-4, another cytokine that inhibits cytokine mRNA accumulation in monocytes, shows little inhibitory effect on LPS-induced NF kappa B activation. Further examination reveals that, unlike IL-10, IL-4 enhances mRNA degradation and does not suppress cytokine gene transcription. These data indicate that IL-10 and IL-4 inhibit cytokine production by different mechanisms.			WANG, P (corresponding author), SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033, USA.							BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; DOKTER WHA, 1993, BLOOD, V81, P337; DROOGMANS L, 1991, DNA SEQUENCE, V3, P115; DROUET C, 1991, J IMMUNOL, V147, P1694; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P344; GAUTAM S, 1992, J IMMUNOL, V148, P1725; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; MALEFYT RD, 1991, J EXP MED, V174, P1209; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NATSUKA S, 1992, BLOOD, V79, P460; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SERKKOLA E, 1993, EUR J BIOCHEM, V213, P243, DOI 10.1111/j.1432-1033.1993.tb17754.x; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; TAKASHIBA S, 1993, GENE, V131, P307, DOI 10.1016/0378-1119(93)90314-S; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WANG P, 1994, J IMMUNOL, V153, P811; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZHENG S, 1993, J BIOL CHEM, V268, P17233; ZHOU YL, 1994, J LEUKOCYTE BIOL, V56, P507, DOI 10.1002/jlb.56.4.507; ZIEGLERHEITBROC.HW, 1993, J IMMUNOL, V151, P6986	40	603	632	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9558	9563		10.1074/jbc.270.16.9558	http://dx.doi.org/10.1074/jbc.270.16.9558			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721885	hybrid			2022-12-27	WOS:A1995QU08900074
J	ZHIDKOVA, NI; JUSTICE, SK; MAYNE, R				ZHIDKOVA, NI; JUSTICE, SK; MAYNE, R			ALTERNATIVE MESSENGER-RNA PROCESSING OCCURS IN THE VARIABLE REGION OF THE PRO-ALPHA-1(XI) AND PRO-ALPHA-2(XI) COLLAGEN CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; XI COLLAGEN; V COLLAGEN; NH2-TERMINAL DOMAIN; MESSENGER-RNAS; DIFFERENTIAL EXPRESSION; MOLECULAR-CLONING; HUMAN CARTILAGE; II PROCOLLAGEN	An analysis was performed of differential splicing of primary transcripts in the noncollagenous variable region located in the amino terminus of the pro-alpha 1(XI) and pro-alpha 2(XI) collagen chains. The results for the pro-alpha 2(XI) chain showed that human cartilage or fibroblasts in culture contain transcripts in which a single highly acidic exon encoding for 21 amino acids is present or absent. For the chicken pro-alpha 1(XI) chain a more complex pattern of alternative splicing was detected with six possible variants. Of special interest was the alternative use of two exons (called IIA and IIB) in which DA encodes for 39 amino acids and is highly acidic (estimated pI = 3.2), whereas IIB encodes for 49 amino acids and is highly basic (estimated pI = 10.6). A similar alternative use of exon IIA or exon IIB was also observed for human chondrocytes. Northern blotting with probes specific for IIA or IIB showed that both exons are present in transcripts from cartilage but exon IIB is preferentially utilized in transcripts from tendon. Present results suggest that both the pro-alpha 1(XI) and pro-alpha 2(XI) chains of type XI collagen undergo limited processing in vivo and that the noncollagenous variable region is initially retained on the surface of the fibrils. Differential splicing in the variable region may potentially influence the interaction of collagen fibrils with other molecules of the extracellular matrix and more specifically with sulfated glycosaminoglycan chains or with hyaluronan. Such interactions may play a key role in establishing both the organization of the collagen fibrils within the extracellular matrix and in limiting the diameter of collagen fibrils.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL EYE INSTITUTE [R01EY009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030481, R01AR030481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008228] Funding Source: NIH RePORTER; NEI NIH HHS [EY09908] Funding Source: Medline; NIAMS NIH HHS [AR30481] Funding Source: Medline; NIDCR NIH HHS [DE08228] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Adolphe, 1992, BIOL REGULATION CHON, P33; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; BROWN KE, 1991, J BIOL CHEM, V266, P23268; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DHARMAVARAM RM, 1993, MATRIX, V13, P125, DOI 10.1016/S0934-8832(11)80071-5; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FESSLER LI, 1985, J BIOL CHEM, V260, P3286; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; Keene D. R., 1993, Molecular Biology of the Cell, V4, p289A; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KNOTH K, 1988, NUCLEIC ACIDS RES, V16, P10932, DOI 10.1093/nar/16.22.10932; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; NAH HD, 1992, J BIOL CHEM, V267, P22581; NAH HD, 1991, J BIOL CHEM, V266, P23446; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Parry DA, 1984, ULTRASTRUCTURE CONNE, P34; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; ROBBINS JR, 1994, EUR J CELL BIOL, V64, P264; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SEEGMILL.R, 1972, J ULTRA MOL STRUCT R, V38, P288, DOI 10.1016/S0022-5320(72)90006-8; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; THOM JR, 1991, J BIOL CHEM, V266, P7262; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; Vandenberg P., 1994, Matrix Biology, V14, P415, DOI 10.1016/0945-053X(94)90161-9; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; Yoshioka H., 1994, Matrix Biology, V14, P365, DOI 10.1016/0945-053X(94)90062-0; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	54	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9486	9493		10.1074/jbc.270.16.9486	http://dx.doi.org/10.1074/jbc.270.16.9486			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721876	hybrid			2022-12-27	WOS:A1995QU08900065
J	AKAZAWA, C; ISHIBASHI, M; SHIMIZU, C; NAKANISHI, S; KAGEYAMA, R				AKAZAWA, C; ISHIBASHI, M; SHIMIZU, C; NAKANISHI, S; KAGEYAMA, R			A MAMMALIAN HELIX-LOOP-HELIX FACTOR STRUCTURALLY RELATED TO THE PRODUCT OF DROSOPHILA PRONEURAL GENE ATONAL IS A POSITIVE TRANSCRIPTIONAL REGULATOR EXPRESSED IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACHAETE-SCUTE HOMOLOG-1; DNA-BINDING; MOLECULAR CHARACTERIZATION; NEURAL-TUBE; NEGATIVE REGULATOR; CELL PATTERN; N-MYC; ENHANCER; PROTEINS; HAIRY	We report the molecular characterization of a mouse basic helix-loop-helix factor, designated MATH-1, structurally related to the product of the Drosophila proneural gene atonal. MATH-1 mRNA is first detected in the cranial ganglions and the dorsal part of the central nervous system on embryonic day 9.5 (E9.5). From E10.5 onward, prominent expression of MATH-1 continues in the dorsal part of the central nervous system but becomes restricted to the external granular layer of the cerebellum by E18 and is undetectable in the adult nervous system. MATH-1 activates E box dependent transcription in collaboration with E47, but the activity is completely antagonized by the negative regulator of neurogenesis HES-1. These results suggest that MATH-1 may be a target of HES-1 and play a role in the differentiation of subsets of neural cells by activating E box-dependent transcription.	KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAT,KYOTO 606,JAPAN	Kyoto University; Kyoto University								AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CAMPOSORTEGA JA, 1909, ANN REV NEUROSCI, V14, P399; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELLIS HM, 1990, CELL, V62, P27; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; GARRELL J, 1990, CELL, V62, P39; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAMILTON WJ, 1962, HUMAN EMBRYOLOGY PRE, P315; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Jacobson M., 1991, DEV NEUROBIOLOGY; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGAMI T, 1994, BIOCHEM BIOPH RES CO, V203, P594, DOI 10.1006/bbrc.1994.2224; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	50	309	331	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8730	8738		10.1074/jbc.270.15.8730	http://dx.doi.org/10.1074/jbc.270.15.8730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721778	hybrid			2022-12-27	WOS:A1995QT44800056
J	MARTIN, L; CRIMAUDO, C; GERACE, L				MARTIN, L; CRIMAUDO, C; GERACE, L			CDNA CLONING AND CHARACTERIZATION OF LAMINA-ASSOCIATED POLYPEPTIDE 1C (LAP1C), AN INTEGRAL PROTEIN OF THE INNER NUCLEAR-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-RECEPTOR; ENVELOPE; BINDING; CHROMOSOMES; CELLS	Lamina-associated polypeptides 1A-1C (LAPs1A-1C) are related integral membrane proteins of the inner nuclear membrane that bind to both A- and B-type lamins and have a putative role in the membrane attachment and assembly of the nuclear lamina. In this study, we have cloned a cDNA encoding LAP1C. The DNA sequence predicts a 506-amino acid protein of largely hydrophilic character with a single membrane-spanning region between residues 311-333. Mapping of the epitope recognized by the anti-LAP1 monoclonal antibody RL13 indicates that the hydrophilic domain containing residues 1-310 is exposed to the nucleoplasm and thus that LAP1C is a type II integral membrane protein. A second class of LAP1 cDNAs was isolated that contains two protein coding nucleotide insertions in the LAP1C sequence. These probably encode parts of LAPs1A and/or -1B, suggesting that LAP1 isotypes arise from alternative splicing. Immunoblot analysis of mouse P19 teratocarcinoma cells and the P19MES-differentiated derivative of the latter suggest that LAP1 isotypes are differentially expressed during development, similar to members of the nuclear lamin family. Since the different LAP1 isotypes appear to bind lamins with different affinities, these changes in expression could be important for developmentally regulated alterations in nuclear structure.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								BAILER SM, 1990, J CELL BIOL, V110, P1489; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HENNEKES H, 1994, J CELL SCI, V107, P1019; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIZARDI PM, 1983, METHOD ENZYMOL, V96, P24; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PADAN R, 1990, J BIOL CHEM, V265, P7808; Sambrook J, 1989, MOL CLONING LABORATO; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YE Q, 1994, J BIOL CHEM, V269, P11306; YUAN J, 1991, J BIOL CHEM, V266, P9211	32	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8822	8828		10.1074/jbc.270.15.8822	http://dx.doi.org/10.1074/jbc.270.15.8822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721789	hybrid			2022-12-27	WOS:A1995QT44800067
J	ROBERTS, SC; WILSON, ME; DONELSON, JE				ROBERTS, SC; WILSON, ME; DONELSON, JE			DEVELOPMENTALLY-REGULATED EXPRESSION OF A NOVEL 59-KDA PRODUCT OF THE MAJOR SURFACE PROTEASE (MSP OR GP63) GENE FAMILY OF LEISHMANIA-CHAGASI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; DONOVANI-CHAGASI; CUTANEOUS LEISHMANIASIS; EFFECTIVE IMMUNIZATION; GLYCOPROTEIN GP63; PROTEINASE GP63; MEMBRANE ANCHOR; PROMASTIGOTES; MACROPHAGES; ATTACHMENT	All species of Leishmania express a major surface protease (Msp or gp63) that facilitates the interactions of the parasite with its environment at several steps in its life cycle. The msp gene family in Leishmania chagasi contains three classes of genes whose mRNAs are differentially expressed during parasite growth, Logarithmic phase (low infectivity) promastigotes express only 63-kDa versions of Msp, whereas stationary phase (high infectivity) promastigotes express both 63- and 59-kDa Msps. The different migrations of the 59- and 63-kDa proteins on acrylamide gels are not due to differences in N-linked glycosylation or the membrane anchor. Plasmid transfections of Leishmania demonstrate that mspS2 of the stationary gene class encodes a 59 kDa protein. Expression of the 59-kDa protein in stationary phase promastigotes ceases after about 12 weeks of in vitro cultivation when the parasites become attenuated. Attenuated parasites can be stimulated to re express the 59-kDa Msp by passage through mice followed by several in vitro passages of recovered promastigotes. Amastigotes express yet another subset of Msp proteins. Thus, the 59-kDa product of mspS2 is expressed only in stationary phase promastigotes and only after recent exposure to environmental changes encountered in the mammalian host cell.	UNIV IOWA, VET ADM MED CTR, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, VET ADM MED CTR, DEPT MICROBIOL & INTERNAL MED, IOWA CITY, IA 52242 USA; HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030126, R01AI032135, R21AI032135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30126, AI32135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beverley S M, 1993, Methods Mol Biol, V21, P333; BORDIER C, 1986, P NATL ACAD SCI USA, V83, P5988, DOI 10.1073/pnas.83.16.5988; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BUTTON LL, 1991, MOL BIOCHEM PARASIT, V44, P213, DOI 10.1016/0166-6851(91)90007-S; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CHANG CS, 1986, MOL BIOCHEM PARASIT, V18, P197, DOI 10.1016/0166-6851(86)90038-1; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; ETGES R, 1986, EMBO J, V5, P597, DOI 10.1002/j.1460-2075.1986.tb04252.x; FROMMEL TO, 1990, MOL BIOCHEM PARASIT, V38, P25, DOI 10.1016/0166-6851(90)90201-V; FUNK VA, 1994, MOL BIOCHEM PARASIT, V63, P23, DOI 10.1016/0166-6851(94)90005-1; HARLOW E, 1988, ANTIBODIES LABORATOR; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1989, IMMUNOL TODAY, V10, P328, DOI 10.1016/0167-5699(89)90188-6; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHNEIDER P, 1992, EXP PARASITOL, V75, P196, DOI 10.1016/0014-4894(92)90179-E; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; STEINKRAUS HB, 1993, MOL BIOCHEM PARASIT, V62, P173, DOI 10.1016/0166-6851(93)90107-9; TURCO SJ, 1988, PARASITOL TODAY, V4, P255, DOI 10.1016/0169-4758(88)90144-5; WEBB JR, 1991, MOL BIOCHEM PARASIT, V48, P173, DOI 10.1016/0166-6851(91)90113-K; WILSON ME, 1990, J IMMUNOL, V144, P4825; WILSON ME, 1986, J IMMUNOL, V136, P4681; WILSON ME, 1988, J IMMUNOL, V141, P265; WILSON ME, 1989, J IMMUNOL, V143, P678; WILSON ME, 1988, INFECT IMMUN, V56, P363, DOI 10.1128/IAI.56.2.363-369.1988; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	40	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8884	8892		10.1074/jbc.270.15.8884	http://dx.doi.org/10.1074/jbc.270.15.8884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721796	hybrid			2022-12-27	WOS:A1995QT44800075
J	KROOG, GS; SAINZ, E; WORLAND, PJ; AKESON, MA; BENYA, RV; JENSEN, RT; BATTEY, JF				KROOG, GS; SAINZ, E; WORLAND, PJ; AKESON, MA; BENYA, RV; JENSEN, RT; BATTEY, JF			THE GASTRIN-RELEASING PEPTIDE RECEPTOR IS RAPIDLY PHOSPHORYLATED BY A KINASE OTHER THAN PROTEIN-KINASE-C AFTER EXPOSURE TO AGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SWISS 3T3 CELLS; MUSCARINIC CHOLINERGIC RECEPTORS; LIGHT-DEPENDENT PHOSPHORYLATION; PHOTORECEPTOR MEMBRANES; INDUCED DESENSITIZATION; ADENYLATE-CYCLASE; BOMBESIN RECEPTOR; HOMOLOGOUS DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR	Several guanine nucleotide-binding protein-coupled receptors are known to be rapidly phosphorylated after agonist exposure. In this study we show that the gastrin-releasing peptide receptor (GRP-R) is rapidly phosphorylated in response to agonist exposure. When [P-32]orthophosphate-labeled cells were exposed to bombesin, the receptor was maximally phosphorylated on serine and threonine residues within 1 min. Although addition of 12-O-tetradecanoylphorbol 13-acetate also resulted in phosphorylation of the GRP-R, elimination of protein kinase C activity using the inhibitor 7-hydroxystaurosporine did not prevent bombesin-induced GRP-R phosphorylation. We conclude that a kinase other than protein kinase C is principally responsible for the rapid, agonist-induced phosphorylation of the GRP-R.	NIDDK,DIGEST DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	KROOG, GS (corresponding author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BLDG 37,RM 5D02,BETHESDA,MD 20892, USA.							BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BROWN KD, 1988, BIOCHEM J, V252, P227, DOI 10.1042/bj2520227; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; DAVIS LG, 1994, BASIC METHODS MOL BI, P624; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; FRANK RN, 1973, J BIOL CHEM, V248, P596; FRANKEL A, 1993, EXP CELL RES, V209, P398, DOI 10.1006/excr.1993.1327; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1983, PHARMACOL REV, V35, P5; HARGRAVE P A, 1980, Neurochemistry International, V1, P231, DOI 10.1016/0197-0186(80)90063-7; HARLOW E, 1988, ANTIBODIES LAB MANUA, P474; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KRIS RM, 1987, J BIOL CHEM, V262, P11215; KUHN H, 1973, BIOCHEMISTRY-US, V12, P2495; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MOODY TW, 1978, P NATL ACAD SCI USA, V75, P5372, DOI 10.1073/pnas.75.11.5372; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; SWOPE SL, 1990, MOL PHARMACOL, V37, P758; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WALSH JH, 1993, J CELL PHYSIOL, V156, P333, DOI 10.1002/jcp.1041560216; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	53	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8217	8224		10.1074/jbc.270.14.8217	http://dx.doi.org/10.1074/jbc.270.14.8217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713928	hybrid			2022-12-27	WOS:A1995QR52600067
J	LI, WQ; YU, JC; SHIN, DY; PIERCE, JH				LI, WQ; YU, JC; SHIN, DY; PIERCE, JH			CHARACTERIZATION OF A PROTEIN-KINASE C-DELTA (PKC-DELTA) ATP BINDING MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; DIFFERENTIATION; ALPHA; ACTIVATION; COMPLEX; CELLS; NPKC; CDNA	To investigate the function of protein kinase C (PKC)-delta, we mutated its ATP binding site by converting the invariant lysine in the catalytic domain (amino acid 376) to an arginine, Expression vectors containing wild type and mutant PKC-delta cDNAs were generated either with or without an influenza virus hemagglutinin epitope tag. After expression in 32D cells by transfection, the PRC-delta ATP binding mutant (PKC-delta K376R) was not able to phosphorylate itself or the PKC-delta pseudosubstrate region derived substrate, indicating that PKC-delta R376R was an inactive enzyme, PKC activity was inhibited by 67% in 32D cells coexpressing both PKC-delta wild type (PKC-delta WT) and PKC-delta R376R when compared to 32D cells expressing only PKC-delta WT, Mixture of PKC-delta WT and PKC-delta K376R kinase sources in vitro also reduced the enzymatic activity of PKC-delta WT. These results suggest that PKC-delta K376R competes with PRC-delta WT and inhibits PKC-delta WT phosphorylation of its in vitro substrate. While PKC-delta WT overexpressed in 32D cells demonstrated 12-O-tetradecanoylphorbol-13-acetate (TPA)-dependent translocation from the cytosolic to the membrane fraction, PKC-delta K376R was exclusively localized in the membrane fraction even prior to TPA stimulation. Unlike PKC-delta WT which was phosphorylated on tyrosine residue(s) only after TPA treatment, PKC-delta K376R was constitutively phosphorylated on tyrosine residue(s). Although exposure of PKC-delta WT transfectants to TPA induced 32D monocytic differentiation, the 32D/PKC-delta K376R transfectants were resistant to TPA-induced differentiation. Thus, expression of active PRC-delta is required to mediate 32D monocytic differentiation in response to TPA stimulation.	NCI, MOLEC & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BELL RM, 1991, J BIOL CHEM, V266, P4661; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ORR JW, 1994, J BIOL CHEM, V269, P27715; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VALTIERI M, 1987, J IMMUNOL, V138, P3829; ZHANG J, 1994, J BIOL CHEM, V269, P19578	22	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8311	8318		10.1074/jbc.270.14.8311	http://dx.doi.org/10.1074/jbc.270.14.8311			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713939	hybrid			2022-12-27	WOS:A1995QR52600078
J	MIDURA, RJ; CALABRO, A; YANAGISHITA, M; HASCALL, VC				MIDURA, RJ; CALABRO, A; YANAGISHITA, M; HASCALL, VC			NONREDUCING END STRUCTURES OF CHONDROITIN SULFATE CHAINS ON AGGRECAN ISOLATED FROM SWARM RAT CHONDROSARCOMA CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE; CARTILAGE PROTEOGLYCAN; EMBRYONIC CHICKEN; CORNEAL EXPLANTS; URONIC-ACID; BIOSYNTHESIS; OLIGOSACCHARIDES; CHROMATOGRAPHY	Chondrocyte cultures derived from the Swarm rat chondrosarcoma were metabolically labeled with [S-35]sulfate or [6-H-3]GlcN. Radiolabeled aggrecan was purified from the cell layer and exhaustively digested with chondroitin ABC lyase. Digestion products were resolved into disaccharide and monosaccharide residues using Toyopearl HW40S chromatography. The separated saccharide pools were reduced with NaBH4 and applied onto a CarboPAC PA1 column to resolve all of the internal disaccharide alditols (unsaturated) from the nonreducing end disaccharide (saturated) and monosaccharide alditols. Mercuric acetate treatment was used prior to carbohydrate analysis to identify unambiguously the saturated from the unsaturated disaccharides. The chondroitin sulfate (CS) chains from these aggrecan preparations contained: (a) an internal disaccharide composition of unsulfated (3-4 per chain), 4-sulfated (similar to 32 per chain), 6-sulfated (similar to 1 per 14 chains), and 4,6-sulfated disaccharides (similar to 1 per 6 chains) and (b) a nonreducing terminal composition of 4-sulfated GalNAc (similar to 4 out of every 7 chains), 4,6-disulfated GalNAc (similar to 2 out of every 7 chains), and GlcUA adjacent to a 4-sulfated GalNAc residue (similar to 1 out of every 7 chains). Thus, the vast majority of these CS chains terminated with a sulfated GalNAc residue. The presence of 4,6-disulfated GalNAc at nonreducing termini is 60-fold more abundant than 4,6-disulfated GalNAc in interior disaccharides. This observation is consistent with the suggestion that disulfation of terminal GalNAc residues is involved in chain termination.	UNIV IOWA,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242; NIDR,PROTEOGLYCAN CHEM SECT,BETHESDA,MD 20892	University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	MIDURA, RJ (corresponding author), CLEVELAND CLIN FDN,DEPT BIOMED ENGN,WB3,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CALABRO A, 1994, J BIOL CHEM, V269, P22764; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CATERSON B, 1990, J CELL SCI, V97, P411; CATERSON B, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P415; DELFERT DM, 1985, J BIOL CHEM, V260, P4446; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; HARDINGHAM TE, 1994, CARBOHYD RES, V255, P241, DOI 10.1016/S0008-6215(00)90982-0; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HEINEGARD D, 1973, CHEM SCRIPTA, V4, P199; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; JENKINS RB, 1981, J BIOL CHEM, V256, P8279; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; LOHMANDER LS, 1986, ANAL BIOCHEM, V154, P75, DOI 10.1016/0003-2697(86)90498-7; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MARK MP, 1989, DEV BIOL, V133, P475, DOI 10.1016/0012-1606(89)90051-1; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; MIDURA RJ, 1994, GLYCOBIOLOGY, V4, P333, DOI 10.1093/glycob/4.3.333; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; RODEN L, 1972, METHODS ENZYMOLOGY B, V28, P638; SAITO H, 1968, J BIOL CHEM, V243, P1536; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SILBERT JE, 1978, J BIOL CHEM, V253, P6888; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; SJOBERG I, 1973, BIOCHEM BIOPH RES CO, V54, P1125, DOI 10.1016/0006-291X(73)90809-7; SLATER RR, 1994, T ORTHOPAED RES SOC, V17, P277; SORRELL JM, 1990, J HISTOCHEM CYTOCHEM, V38, P393, DOI 10.1177/38.3.1689338; TELSER A, 1966, ARCH BIOCHEM BIOPHYS, V116, P458, DOI 10.1016/0003-9861(66)90053-1; TSUJI M, 1980, BIOCHIM BIOPHYS ACTA, V612, P373, DOI 10.1016/0005-2744(80)90120-5; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	37	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8009	8015		10.1074/jbc.270.14.8009	http://dx.doi.org/10.1074/jbc.270.14.8009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713901	hybrid			2022-12-27	WOS:A1995QR52600037
J	CHEN, TC; LAW, B; KONDRATYUK, T; ROSSIE, S				CHEN, TC; LAW, B; KONDRATYUK, T; ROSSIE, S			IDENTIFICATION OF SOLUBLE-PROTEIN PHOSPHATASES THAT DEPHOSPHORYLATE VOLTAGE-SENSITIVE SODIUM-CHANNELS IN RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-DEPENDENT PHOSPHORYLATION; RABBIT SKELETAL-MUSCLE; KINASE-C; CATALYTIC SUBUNIT; ALPHA-SUBUNIT; CALCINEURIN-A; SELECTIVE PHOSPHORYLATION; FUNCTIONAL MODULATION; REGULATORY SUBUNIT; BOVINE BRAIN	Rat brain sodium channels are phosphorylated at multiple serine residues by cAMP-dependent protein kinase, We have identified soluble rat brain phosphatases that dephosphorylate purified sodium channels, Five separable forms of sodium channel phosphatase activity were observed, Three forms (two, approximately 234 kDa and one, 192 kDa) are identical or related to phosphatase 2A, since they were 85-100% inhibited by 10 nM okadaic acid and contained a 36-kDa polypeptide recognized by a monoclonal antibody directed against the catalytic subunit of phosphatase 2A, Immunoblots performed using antibodies specific for isoforms of the B subunit of phosphatase 2A indicate that the two major peaks of phosphatase 2A-like activity, A1 and B1, are enriched in either B' or B alpha. The remaining two activities (approximately 100 kDa each) probably represent calcineurin, Each was relatively insensitive to okadaic acid, was active only in the presence of CaCl2 and calmodulin, and contained a 19-kDa polypeptide recognized by a monoclonal antibody raised against the B subunit of calcineurin, Treatment of synaptosomes with okadaic acid to inhibit phosphatase 2A or cyclosporin A to inhibit calcineurin increased apparent phosphorylation of sodium channels at cAMP-dependent phosphorylation sites, as assayed by back phosphorylation, These results indicate that phosphatase 2A and calcineurin dephosphorylate sodium channels in brain, and thus may counteract the effect of cAMP-dependent phosphorylation on sodium channel activity.	UNIV ARIZONA, COLL PHARM, DEPT PHARMACOL & TOXICOL, TUCSON, AZ 85721 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	University of Arizona; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031221, R01NS031221] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31221] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOTH RFG, 1978, BIOCHEM J, V176, P365, DOI 10.1042/bj1760365; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1979, J BIOL CHEM, V254, P1379; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; DOBROWSKY RT, 1993, ADV LIPID RES, V25, P91; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FORN J, 1978, P NATL ACAD SCI USA, V75, P5195, DOI 10.1073/pnas.75.10.5195; FURMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686; GERSHON E, 1992, J NEUROSCI, V12, P3743; GRAY EG, 1962, J ANAT, V96, P79; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; Maizel JV, 1971, METHOD VIROL, V5, P179; MATSUI H, 1991, BIOCHEM INT, V24, P1119; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NAKAYAMA H, 1992, BIOCHIM BIOPHYS ACTA, V1175, P67, DOI 10.1016/0167-4889(92)90010-9; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SILVA EFD, 1989, BIOCHIM BIOPHYS ACTA, V1009, P293, DOI 10.1016/0167-4781(89)90118-8; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; YOKOYAMA N, 1991, J BIOL CHEM, V266, P14822; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	55	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7750	7756		10.1074/jbc.270.13.7750	http://dx.doi.org/10.1074/jbc.270.13.7750			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706324	hybrid			2022-12-27	WOS:A1995QQ43100104
J	GIBBONS, DL; HOROWITZ, PM				GIBBONS, DL; HOROWITZ, PM			EXPOSURE OF HYDROPHOBIC SURFACES ON THE CHAPERONIN GROEL OLIGOMER BY PROTONATION OR MODIFICATION OF HIS-401	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; BOVINE LIVER RHODANESE; ESCHERICHIA-COLI; MITOCHONDRIAL RHODANESE; CENTRAL CAVITY; PROTEIN; POLYPEPTIDE; BINDING; SECB; ATP	Hydrophobic exposure on the chaperonin GroEL is increased 6-10-fold after the protein is treated with the His-reactive reagent diethyl pyrocarbonate (DEP), or the solution pH is lowered to 5.5. The induced hydrophobic surfaces have the same 1,1'-bis(4-anilino)naphthalene-5,5'-disulfonic acid (bis-ANS) binding characteristics as unperturbed GroEL: a K-d congruent to 3.5 mu M, a maximum intensity at similar to 500 nm, and an average fluorescence lifetime of similar to 8.0 ns. The pK(alpha) for the pH-induced transition is 6.6, most likely attributable to the only histidine in GroEL, His-401, located in the intermediate domain. The modification of one histidine residue per monomer upon DEP treatment is supported by the correlation between the change in the absorbance at 242 nm for the N-carbethoxyhistidyl derivative and the increase in bis-ANS fluorescence. GroEL at pH 5.5 is tetradecameric and can capture urea-denatured rhodanese and release it as active enzyme. The GroEL rhodanese complex is more stable to dissociation by 2.25 M urea than the complex formed at pH 7.8. We propose that His-401 is in a conformationally sensitive region such that protonation or modification can lead to increased expo sure of hydrophobic surfaces capable of binding folding intermediates.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; Brent R. P., 1973, ALGORITHMS MINIMIZAT; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; DOMINICI P, 1985, J BIOL CHEM, V260, P583; ELLIS RJ, 1990, BIOCH SOC S, V55, P145; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; KUMAGAI H, 1975, J BIOL CHEM, V250, P1661; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAZODIER P, 1991, J BACTERIOL, V173, P7382, DOI 10.1128/jb.173.22.7382-7386.1991; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; Miles E W, 1977, Methods Enzymol, V47, P431; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; OKAZAKI A, 1994, STRUCT BIOL, V1, P439; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; ROSENBERG HF, 1993, J BIOL CHEM, V268, P4499; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	54	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7335	7340		10.1074/jbc.270.13.7335	http://dx.doi.org/10.1074/jbc.270.13.7335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706275	hybrid			2022-12-27	WOS:A1995QQ43100048
J	OCONNELL, MA; CLEERE, R; LONG, A; ONEILL, LAJ; KELLEHER, D				OCONNELL, MA; CLEERE, R; LONG, A; ONEILL, LAJ; KELLEHER, D			CELLULAR PROLIFERATION AND ACTIVATION OF NF-KAPPA-B ARE INDUCED BY AUTOCRINE PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA IN THE HUMAN T-LYMPHOMA LINE HUT-78	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; FACTOR EXPRESSION; FACTOR CACHECTIN; GENE-EXPRESSION; CELLS; PROTEIN; REL; HOMOLOGY	Tumor necrosis factor (TNF) is a pleiotropic cytokine which has both cytotoxic and proliferative effects. HuT 78, a T-cell line derived from a Sezary lymphoma, is resistant to the cytotoxic effects of TNF, suggesting that TNF may be a growth factor for this cell line. The aim of this study was to determine whether autocrine TNF production could function as a growth factor for HuT 78. Resting HuT 78 and K-4 cells, a protein kinase C-beta-deficient clone of HuT 78, both produced significant amounts of TNF compared with Jurkat cells. Thymidine incorporation by HuT 78 and K-4 cells was inhibited by 90.5 and 73.2%, respectively, with addition of a neutralizing monoclonal antibody to TNF alpha, suggesting that TNF is an autocrine growth factor for these cells. HuT 78 and K-4 cells also expressed high levels of constitutively active NF kappa B, unlike Jurkat cells, which expressed high levels only upon activation with TNF or phorbol 12-myristate 13-acetate, p50 was the major component in the NF kappa B complexes in HuT 78 and K-4 cells. Anti-TNF alpha antibody dramatically decreased levels of NF kappa B in both HuT 78 and K-4 cells. As the TNF gene has an NF kappa B binding motif, an autocrine loop involving TNF induction of NF kappa B is therefore likely in these cells, These findings in a neoplastic T cell line suggest that therapy directed against TNF could be effective in a subset of T-cell lymphomas.	UNIV IRELAND TRINITY COLL,DEPT CLIN MED,DUBLIN 8,IRELAND; UNIV IRELAND TRINITY COLL,DEPT BIOCHEM,DUBLIN 8,IRELAND	Trinity College Dublin; Trinity College Dublin				O'Connell, Maria/0000-0002-0267-0951				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1990, J CLIN INVEST, V85, P248, DOI 10.1172/JCI114419; BROWNELL E, 1989, ONCOGENE, V4, P935; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; DIGEL W, 1989, BLOOD, V73, P1242; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; GEHR G, 1992, J IMMUNOL, V149, P911; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GRILLI M, 1992, INT REV CYTOL, V48, P1; HAHN T, 1985, P NATL ACAD SCI USA, V82, P3814, DOI 10.1073/pnas.82.11.3814; HAMAMOTO Y, 1990, CANCER RES, V50, P5287; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAY H, 1989, J CLIN LAB IMMUNOL, V29, P151; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; HEMAR A, 1991, J IMMUNOL, V146, P2409; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IKEBE T, 1988, J IMMUNOL, V140, P827; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO, P539; KELLEHER D, 1992, FEBS LETT, V301, P310, DOI 10.1016/0014-5793(92)80264-H; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KRONKE M, 1988, CANCER RES, V48, P5417; MARMENOUT A, 1985, EUR J BIOCHEM, V152, P515, DOI 10.1111/j.1432-1033.1985.tb09226.x; MEAGER A, 1989, J IMMUNOL METHODS, V116, P1, DOI 10.1016/0022-1759(89)90306-2; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; PROBERT L, 1993, J IMMUNOL, V151, P1894; RANGES GE, 1988, J EXP MED, V167, P1472, DOI 10.1084/jem.167.4.1472; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBIN BY, 1986, J EXP MED, V164, P1350, DOI 10.1084/jem.164.4.1350; Sambrook J, 1989, MOL CLONING LABORATO; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SPRIGGS D, 1987, P NATL ACAD SCI USA, V84, P6563, DOI 10.1073/pnas.84.18.6563; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUNG SSJ, 1988, J EXP MED, V168, P1539, DOI 10.1084/jem.168.5.1539; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; THAKUR S, 1994, ONCOGENE, V9, P2335; TRACEY K, 1989, LANCET, V20, P1122; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WARE CF, 1992, J IMMUNOL, V149, P3881; ZHANG JD, 1994, ONCOGENE, V9, P1931	59	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7399	7404		10.1074/jbc.270.13.7399	http://dx.doi.org/10.1074/jbc.270.13.7399			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706285	Green Submitted, hybrid			2022-12-27	WOS:A1995QQ43100058
J	POWELL, LD; JAIN, RK; MATTA, KL; SABESAN, S; VARKI, A				POWELL, LD; JAIN, RK; MATTA, KL; SABESAN, S; VARKI, A			CHARACTERIZATION OF SIALYLOLIGOSACCHARIDE BINDING BY RECOMBINANT SOLUBLE AND NATIVE CELL-ASSOCIATED CD22 - EVIDENCE FOR A MINIMAL STRUCTURAL RECOGNITION MOTIF AND THE POTENTIAL IMPORTANCE OF MULTISITE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; N-LINKED OLIGOSACCHARIDES; ADHESION MOLECULE; ANTIGEN CD22; ALPHA-2->6 SIALYLTRANSFERASE; LIGAND INTERACTIONS; SIALIC ACIDS; T-CELLS; LECTIN; EXPRESSION	CD22, a B cell-specific receptor of the immunoglobulin superfamily, has been demonstrated to bind to oligosaccharides containing alpha 2-6-linked sialic acid (Sia) residues. Previously, we demonstrated that the minimal structure recognized by this lectin is the trisaccharide Sia alpha 2-6Gal beta 1-4GlcNAc, as found on N-linked, O-linked, or glycolipid structures (Powell, L., and Varki, A. (1994) J. Biol. Chem. 269, 10628-10636). Here we utilize a soluble immunoglobulin fusion construct (CD22Rg) to determine directly by equilibrium dialysis the stoichiometry (2:1) and dissociation constant (32 mu M) for Neu5Ac alpha-6Gal beta 1-4Glc binding. Inhibition assays performed with over 30 different natural and synthetic sialylated and/or sulfated compounds are utilized to define in greater detail specific structural features involved in oligosaccharide-protein binding. Specifically, the critical features required for binding include the exocyclic hydroxylated side chain of the Sia residue and the alpha 2-6 linkage position to the underlying Gal unit. Surprisingly, alterations of the 2-, 3-, and 4-positions of the latter residue have limited effect on the binding. The nature of the residue to which the Gal is attached may affect binding. Bi(alpha 2-6) sialylated biantennary oligosaccharides are capable of simultaneously interacting with both lectin sites present on the dimeric CD22Rg fusion construct, giving a marked improvement in binding over monosialylated compounds. Furthermore, data are presented indicating that full-length native CD22, expressed on the surface of Chinese hamster ovary cells, is structurally and functionally a multimeric protein, demonstrating a higher apparent affinity for multiply sialylated compounds over monosialylated compounds. These observations provide a mechanism for strong CD22-dependent cell adhesion despite the relatively low K-d for protein-sugar binding.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,DEPT MED,LA JOLLA,CA 92093; ROSWELL PK CANC INST,BUFFALO,NY 14263; DUPONT CO INC,CENT SCI & ENGN,WILMINGTON,DE 19880	University of California System; University of California San Diego; Roswell Park Cancer Institute; DuPont	POWELL, LD (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR CANC 0063,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093, USA.				NCI NIH HHS [CA01649] Funding Source: Medline; NIAID NIH HHS [AI29326] Funding Source: Medline; NIGMS NIH HHS [GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032373, R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BAENZIGER JU, 1980, J BIOL CHEM, V255, P4607; BERZOFSKY JA, 1989, FUNDAMENTAL IMMUNOLO, P315; BLINKOVSKY AM, 1993, TETRAHEDRON-ASYMMETR, V4, P1221, DOI 10.1016/S0957-4166(00)80231-1; BOUE DR, 1988, BLOOD, V71, P1480; BOUE DR, 1988, J IMMUNOL, V140, P192; CHANDRASEKARAN EV, 1995, IN PRESS BIOCHEMISTR; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DEBEIRE P, 1985, EUR J BIOCHEM, V151, P607, DOI 10.1111/j.1432-1033.1985.tb09147.x; DORKEN B, 1986, J IMMUNOL, V136, P4470; ENGEL P, 1993, J IMMUNOL, V150, P4719; GUPTA D, 1993, EUR J BIOCHEM, V216, P789, DOI 10.1111/j.1432-1033.1993.tb18199.x; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HILLE A, 1989, J BIOL CHEM, V264, P13460; JAIN RK, 1995, IN PRESS CARBOHYDRAT; JAIN RK, 1994, 17TH INT CARB S OTT; KELM S, 1994, GLYCOCONJ J, V11, P120; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LEE EU, 1989, J BIOL CHEM, V264, P13848; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEE YC, 1983, J BIOL CHEM, V258, P199; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MOPPER K, 1973, ANAL BIOCHEM, V56, P440, DOI 10.1016/0003-2697(73)90210-8; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, J IMMUNOL, V138, P98; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; SABESAN S, 1994, J AM CHEM SOC, V116, P1616, DOI 10.1021/ja00084a003; SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SHUKLA AK, 1982, H-S Z PHYSIOL CHEM, V363, P255, DOI 10.1515/bchm2.1982.363.1.255; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; TORRES RM, 1992, J IMMUNOL, V149, P2641; VIG R, 1994, IN PRESS CARBOHYDRAT; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	49	120	123	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7523	7532		10.1074/jbc.270.13.7523	http://dx.doi.org/10.1074/jbc.270.13.7523			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706299	hybrid			2022-12-27	WOS:A1995QQ43100074
J	RANGANATHAN, G; ONG, JM; YUKHT, A; SAGHIZADEH, M; SIMSOLO, RB; PAUER, A; KERN, PA				RANGANATHAN, G; ONG, JM; YUKHT, A; SAGHIZADEH, M; SIMSOLO, RB; PAUER, A; KERN, PA			TISSUE-SPECIFIC EXPRESSION OF HUMAN LIPOPROTEIN-LIPASE - EFFECT OF THE 3'-UNTRANSLATED REGION ON TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; MESSENGER-RNA LEVELS; 3' UNTRANSLATED REGION; TUMOR NECROSIS FACTOR; RAT ADIPOCYTES; ORNITHINE DECARBOXYLASE; GENE-EXPRESSION; SEQUENCE; SECRETION; INSULIN	Lipoprotein lipase (LPL) is a central enzyme in lipoprotein metabolism and is expressed predominantly in adipose tissue and muscle, In these tissues, the regulation of LPL is complex and often opposite in response to the same physiologic stimulus, In addition, much regulation of LPL occurs post-transcriptionally. The hu man LPL cDNA is characterized by a long 3'-untranslated region, which has two polyadenylation signals, In this report, human adipose tissue expressed two LPL mRNA species (3.2 and 3.6 kb) due to an apparent random choice of sites for mRNA polyadenylation, whereas human skeletal and heart muscle expressed predominantly the longer 3.6-kb mRNA form. To determine whether there was any functional significance to this tissue-specific mRNA expression, poly(A)-enriched RNA from adipose tissue and muscle were translated in vitro, and the poly(A)-enriched RNA from muscle was more efficiently translated into LPL protein, The increased translatability of the 3.6-kb form was also demonstrated by cloning the full-length 3.2- and 3.6-kb LPL cDNA forms, followed by in vitro translation of in vitro prepared transcripts, To confirm that this increased efficiency of translation occurred in vivo, Chinese hamster ovary cells were transfected with the 3.2- and 3.6-kb LPL cDNAs, Cells transfected with the 3.6-kb construct demonstrated increased LPL activity and synthesis, despite no increase in levels of LPL mRNA. Thus, human muscle expresses the 3.6-kb form of LPL due to a non-random choice of polyadenylation signals, and this form is more efficiently translated than the 3.2-kb form.	CEDARS SINAI MED CTR,DEPT MED,DIV ENDOCRINOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center					NIDDK NIH HHS [DK 39176] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039176, R37DK039176, R29DK039176] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELFRAGE P, 1969, J LIPID RES, V10, P341; BRAULT D, 1992, GENE, V121, P237, DOI 10.1016/0378-1119(92)90127-B; CHNG JL, 1990, SCIENCE, V245, P1003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cryer A., 1987, LIPOPROTEIN LIPASE, P277; DAVIS RC, 1990, J BIOL CHEM, V265, P17960; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ENERBACK S, 1988, GENE, V64, P97, DOI 10.1016/0378-1119(88)90484-2; FARESE RV, 1991, METABOLISM, V40, P214, DOI 10.1016/0026-0495(91)90178-Y; FEINBERG AP, 1988, ANAL BIOCHEM, V132, P6; FRIED SK, 1989, J LIPID RES, V30, P1917; FRIED SK, 1993, J CLIN INVEST, V92, P2191, DOI 10.1172/JCI116821; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GRENS A, 1990, J BIOL CHEM, V265, P11810; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KERN PA, 1990, NEW ENGL J MED, V322, P1053, DOI 10.1056/NEJM199004123221506; KERN PA, 1988, J CLIN INVEST, V81, P398, DOI 10.1172/JCI113332; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KRUYS V, 1987, P NATL ACAD SCI USA, V89, P6030; LADU MJ, 1991, INT J BIOCHEM, V23, P405, DOI 10.1016/0020-711X(91)90167-L; MITCHELL JRD, 1992, AM J PHYSIOL, V263, pE500, DOI 10.1152/ajpendo.1992.263.3.E500; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1989, J BIOL CHEM, V264, P3177; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; ONG JM, 1994, J LIPID RES, V35, P1542; PREVIATO L, 1991, J BIOL CHEM, V266, P18958; ROJAS C, 1990, BIOCHEM J, V271, P11, DOI 10.1042/bj2710011; SAFFARI B, 1992, J LIPID RES, V33, P241; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SIMSOLO RB, 1992, J LIPID RES, V33, P89; SIMSOLO RB, 1993, J CLIN INVEST, V92, P2124, DOI 10.1172/JCI116813; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; ZECHNER R, 1991, GENOMICS, V11, P62, DOI 10.1016/0888-7543(91)90102-K	44	45	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7149	7155		10.1074/jbc.270.13.7149	http://dx.doi.org/10.1074/jbc.270.13.7149			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706252				2022-12-27	WOS:A1995QQ43100023
J	ROUSELL, J; HADDAD, EB; MAK, JCW; BARNES, PJ				ROUSELL, J; HADDAD, EB; MAK, JCW; BARNES, PJ			TRANSCRIPTIONAL DOWN-REGULATION OF M2 MUSCARINIC RECEPTOR GENE-EXPRESSION IN HUMAN EMBRYONIC LUNG (HEL-299) CELLS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; ACETYLCHOLINE-RECEPTOR; DIFFERENTIAL REGULATION; BINDING-PROPERTIES; ADENYLYL CYCLASE; AGONIST EXPOSURE; PHORBOL ESTERS; PHOSPHORYLATION; ACTIVATION; M1	m2 muscarinic receptor gene expression was investigated following stimulation of protein kinase C (PKC) with the phorbol ester 4 beta-phorbol dibutyrate (PDBu) in HEL 299 cells. PDBu (100 nM) caused a time dependent decrease in the steady-state levels of m2 receptor mRNA and in specific [H-3]N-methyl scopolamine binding. Preincubation with the PKC inhibitor GF-109203X inhibited the reduction in M(2) receptor and mRNA levels induced by PDBu, confirming the involvement of PKC, Chronic PDBu treatment also caused desensitization of the receptor as forskolin-stimulated cAMP accumulation, inhibited by carbachol in control cells, was lost upon treatment with PDBu for 24 h. Co-incubation with PDBu and the protein synthesis inhibitor cycloheximide, inhibited PDBu-mediated reduction of m2 receptor mRNA, indicating new protein synthesis is required for down-regulation. Half-life studies using the transcriptional inhibitor actinomycin D suggested that the stability of the m2 receptor mRNA was not altered by PDBu treatment (t(1/2) = 2 h) Nuclear run on assays showed a 50% reduction in the rate of m2 receptor gene transcription after treatment with PDBu for 12 h. In conclusion we have provided evidence for heterologous regulation of m2 receptor gene expression through changes in gene transcription resulting in uncoupling of M(2) receptors. Furthermore, the synthesis of an unidentified factor is required for the down-regulation process.	NATL HEART & LUNG INST,DEPT THORAC MED,LONDON SW3 6LY,ENGLAND	Imperial College London				Mak, Judith/0000-0002-8234-1313; Barnes, Peter/0000-0002-5122-4018				ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; FUKAMAUCHI F, 1994, FEBS LETT, V348, P263, DOI 10.1016/0014-5793(94)00611-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABECKER BA, 1993, BIOCHEMISTRY-US, V32, P4986, DOI 10.1021/bi00070a003; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA T, 1993, LIFE SCI, V52, P421, DOI 10.1016/0024-3205(93)90297-G; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JONES SVP, 1988, MOL PHARMACOL, V34, P421; KOMAN A, 1990, BIOCHEM J, V270, P409, DOI 10.1042/bj2700409; KOMAN A, 1993, NEUROSCI LETT, V149, P79, DOI 10.1016/0304-3940(93)90352-L; KOPP R, 1990, BIOCHEM J, V269, P73, DOI 10.1042/bj2690073; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAI WS, 1990, BIOCHEM J, V267, P23, DOI 10.1042/bj2670023; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKINNEY M, 1984, MOL PHARMACOL, V26, P156; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; ROZENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; STEEL MC, 1993, MOL PHARMACOL, V43, P694; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WANG SZ, 1990, FEBS LETT, V276, P185, DOI 10.1016/0014-5793(90)80538-T; ZHANG LB, 1993, BRIT J PHARMACOL, V108, P613, DOI 10.1111/j.1476-5381.1993.tb12850.x	40	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7213	7218		10.1074/jbc.270.13.7213	http://dx.doi.org/10.1074/jbc.270.13.7213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706260	hybrid			2022-12-27	WOS:A1995QQ43100032
J	HATTORI, M; AMETANI, A; KATAKURA, Y; SHIMIZU, M; KAMINOGAWA, S				HATTORI, M; AMETANI, A; KATAKURA, Y; SHIMIZU, M; KAMINOGAWA, S			UNFOLDING REFOLDING STUDIES ON BOVINE BETA-LACTOGLOBULIN WITH MONOCLONAL-ANTIBODIES AS PROBES - DOES A RENATURED PROTEIN COMPLETELY REFOLD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE FOLDING PATHWAY; RETINOL-BINDING PROTEIN; STRUCTURAL CHARACTERIZATION; ALPHA-LACTALBUMIN; RIBONUCLEASE-A; NMR; INTERMEDIATE; LYSOZYME; BPTI; DENATURATION	We investigated whether any local moieties within a protein molecule could completely refold from the denatured state to regain the native conformation. Bovine beta-lactoglobulin (beta-LG) was denatured in the presence of guanidine hydrochloride (GdnHCl) as the denaturant. Renaturation of the denatured beta-LG was attempted by dialyzing to remove GdnHCl. The renatured molecules regained the same retinol binding activity as that of native beta-LG, and physicochemical studies also indicated that refolding of the denatured beta-LG had been almost completely successful. Local structural differences between the native and renatured beta-LG molecules were evaluated by using our panel of four anti-beta-LG monoclonal antibodies (anti-beta-LG mAbs). The structures of the epitope regions in native beta-LG recognized by two of these mAbs were the same as those in renatured beta-LG. However, it is notable that the binding properties of the other two mAbs to native beta-LG indicated a wide structural difference in the epitope regions between the native and renatured beta-LG. These regions unable to completely refold were the same as those that unfolded preferentially to the alpha-helix region, shown in the previous report (Kaminogawa, S., Shimizu, M., Ametani, A., Hattori, M., Ando, O., Hachimura, S., Nakamura, Y., Totsuka, M., and Yamauchi, K. (1989) Biochim. Biophys. Acta 998, 50-56). Complete refolding was never attained by several renaturation conditions such as quicker or slower removal of the denaturant, nor by additional oxidation treatment after reducing the disulfide bonds. These results suggest that some specific moiety(ies) in a protein molecule cannot return to the native conformation from a denatured state, even if the other moieties refold completely, and that such a conformational difference between renatured and native forms has no affect on the biological function of ligand binding.	UNIV TOKYO,DEPT AGR CHEM,TOKYO 113,JAPAN	University of Tokyo								AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; ALEXANDER SS, 1971, BIOCHEMISTRY-US, V10, P2738, DOI 10.1021/bi00790a013; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ASCHAFFENBURG R, 1957, BIOCHEM J, V65, P273, DOI 10.1042/bj0650273; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BROWN EM, 1983, LIPIDS, V18, P111, DOI 10.1007/BF02536104; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; DARBY NJ, 1990, NATURE, V344, P715, DOI 10.1038/344715b0; FARRELL HM, 1987, J DAIRY SCI, V70, P252, DOI 10.3168/jds.S0022-0302(87)80004-8; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; FUTTERMAN S, 1972, J BIOL CHEM, V247, P5168; GAREL JR, 1973, P NATL ACAD SCI USA, V70, P3347, DOI 10.1073/pnas.70.12.3347; HEMLEY R, 1979, BIOPHYS J, V28, P447, DOI 10.1016/S0006-3495(79)85192-9; HILLQUISTDAMON AJ, 1982, BIOPOLYMERS, V21, P895; HOGG PJ, 1987, MOL IMMUNOL, V24, P797, DOI 10.1016/0161-5890(87)90064-2; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; KAMINOGAWA S, 1987, AGR BIOL CHEM TOKYO, V51, P797, DOI 10.1080/00021369.1987.10868089; KAMINOGAWA S, 1989, BIOCHIM BIOPHYS ACTA, V998, P50, DOI 10.1016/0167-4838(89)90117-9; KAMINOGAWA S, 1985, J BIOCHEM-TOKYO, V98, P1027, DOI 10.1093/oxfordjournals.jbchem.a135348; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; McKenzie HA., 1971, MILK PROTEINS, P257, DOI [10.1016/B978-0-12-485202-0.50013-0, DOI 10.1016/B978-0-12-485202-0.50013-0]; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PARVAIZ S, 1985, SCIENCE, V228, P335; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SAWER WH, 1971, BIOCHIM BIOPHYS ACTA, V243, P19; SMITH LM, 1983, J AM OIL CHEM SOC, V60, P960, DOI 10.1007/BF02660208; TOWNEND R, 1967, J BIOL CHEM, V242, P4538; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JS, 1992, SCIENCE, V256, P112, DOI 10.1126/science.256.5053.112; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	39	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22414	22419						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693669				2022-12-27	WOS:A1993MD34800037
J	CHOWRIRA, BM; BERZALHERRANZ, A; KELLER, CF; BURKE, JM				CHOWRIRA, BM; BERZALHERRANZ, A; KELLER, CF; BURKE, JM			4 RIBOSE 2'-HYDROXYL GROUPS ESSENTIAL FOR CATALYTIC FUNCTION OF THE HAIRPIN RIBOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE BINDING; RNA CLEAVAGE; TETRAHYMENA; SEQUENCE; DNA; COMPLEMENTARY; RESOLUTION; REQUIREMENT; LIGATION; DOMAIN	The hairpin ribozyme catalyzes site-specific cleavage of an RNA substrate using a magnesium-dependent transphosphorylation mechanism. Here, we describe experiments designed to test the importance of ribose 2/-hydroxyl groups for ribozyme function. Ribozymes for this work were synthesized in two segments using solid-phase RNA phosphoramidite chemistry. 2'-Deoxyribonucleotides were systematically introduced at each of the 50 positions within the ribozyme, and the catalytic activity of the resulting mixed RNA-DNA polymers was measured. Deletion of the 2'-hydroxyl group at each of four sites (A10, G11, A24, and C25) was found to result in severe inhibition of cleavage activity (k(cat/K(M) decreased by 100- to 1000-fold), although K(M) measurements and mobility-shift assays showed that substrate binding was not affected. Identical results were obtained upon substitution of these ribonucleotides with 2'-O-methyl derivatives. Inhibition by 2'-modified sugars at G11 or A24 was rescued by increased Mg2+ concentrations, suggesting that these 2'-hydroxyls may function in magnesium binding. Our results demonstrate that the 2'-hydroxyl groups at A10, G11, A24, and C25 provide essential functions for catalysis, possibly forming important tertiary contacts or magnesium coordination sites that are necessary for active site architecture.	UNIV VERMONT, DEPT MICROBIOL & MOLEC GENET, MARKEY CTR MOLEC GENET, STAFFORD HALL, BURLINGTON, VT 05405 USA	University of Vermont			Berzal-Herranz, Alfredo/K-8614-2014; , John/AAB-5945-2021	Berzal-Herranz, Alfredo/0000-0003-3722-7973; 				BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2435, DOI 10.1021/bi00432a014; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CHOWRIRA BM, 1992, NUCLEIC ACIDS RES, V20, P2835, DOI 10.1093/nar/20.11.2835; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; EGLI M, 1992, P NATL ACAD SCI USA, V89, P534, DOI 10.1073/pnas.89.2.534; EGLI M, 1993, BIOCHEMISTRY-US, V32, P3221, DOI 10.1021/bi00064a004; England T E, 1980, Methods Enzymol, V65, P65; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; KLEINEIDAM RG, 1993, NUCLEIC ACIDS RES, V21, P1097, DOI 10.1093/nar/21.5.1097; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; WALKER GT, 1988, NUCLEIC ACIDS RES, V16, P3091, DOI 10.1093/nar/16.7.3091; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; ZMUDZKA B, 1969, BIOCHEM BIOPH RES CO, V37, P895, DOI 10.1016/0006-291X(69)90215-0	39	71	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19458	19462						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690032				2022-12-27	WOS:A1993LW81900049
J	GROVES, JD; TANNER, MJA				GROVES, JD; TANNER, MJA			COEXPRESSED COMPLEMENTARY FRAGMENTS OF THE HUMAN RED-CELL ANION-EXCHANGER (BAND-3, AE1) GENERATE STILBENE DISULFONATE-SENSITIVE ANION TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; ERYTHROCYTE-MEMBRANE; ESCHERICHIA-COLI; XENOPUS-OOCYTES; OLIGOMERIZATION; RECONSTITUTION; OVALOCYTOSIS; COEXPRESSION; RECEPTORS; CLEAVAGE	We have constructed cDNA clones encoding various portions of the human red cell anion transporter (band 3), a well characterized integral membrane protein with up to 14 transmembrane segments, The biosynthesis, stability, cell surface expression, and functionality of these band 3 fragments were investigated by expression from the cRNAs into microsomal membranes using the reticulocyte cell-free translation system and in Xenopus oocytes, Co expression of the pairs of recombinants encoding the first 8 and last 6 transmembrane spans (8+6) or the first 12 and last 2 spans (12+2) of band 3 generated stilbene disulfonate-sensitive anion transport in oocytes. When the pairs of fragments 8+6 or 12+2 were co-expressed with glycophorin A (GPA), translocation to the plasma membrane of the fragment corresponding to the first 12 or the first 8 transmembrane spans was greater than in the absence of GPA Only the fragment encoding the first 12 transmembrane spans showed GPA-dependent translocation when expressed in the absence of its complementary fragment, A truncated form of band 3 encoding all 14 transmembrane spans but lacking the carboxyl-terminal 30 amino acids of the cytoplasmic tail did not induce anion transport activity in oocytes and was not translocated to the plasma membrane but appeared to be degraded in oocytes. Our results suggest that there is no single signal for the insertion of the different transmembrane spans of band 3 into membranes and that the integrity of the loops between transmembrane spans 8-9 or 12-13 is not essential for anion transport function. Our data also suggest that a region of transmembrane spans 9-12 of band 3 is involved in the process by which GPA facilitates the translocation of band 3 to the surface.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol								BIBI E, 1992, P NATL ACAD SCI USA, V89, P1524, DOI 10.1073/pnas.89.5.1524; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; BRUCE LJ, 1994, BLOOD, V84, P916; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1994, MOL MEMBR BIOL, V11, P31, DOI 10.3109/09687689409161027; GROVES JD, 1992, J BIOL CHEM, V267, P22163; GROVES JD, 1993, FEBS LETT, V330, P186, DOI 10.1016/0014-5793(93)80270-5; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOSTER W, 1990, MOL GEN GENET, V223, P379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemmon MA., 1992, CURR OPIN STRUC BIOL, V2, P511; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOO TW, 1994, J BIOL CHEM, V269, P7750; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; OKUBO K, 1994, J BIOL CHEM, V269, P1918; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; POPOT JL, 1993, CURR OPIN STRUC BIOL, V3, P532, DOI 10.1016/0959-440X(93)90079-Z; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOFIELD AE, 1992, J MOL BIOL, V223, P949, DOI 10.1016/0022-2836(92)90254-H; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1989, METHOD ENZYMOL, V173, P423; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WOOD PG, 1992, PROGR CELL RES, V2, P325; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990	39	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9097	9105		10.1074/jbc.270.16.9097	http://dx.doi.org/10.1074/jbc.270.16.9097			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721823	hybrid			2022-12-27	WOS:A1995QU08900011
J	MIZUGUCHI, G; KANEIISHII, C; TAKAHASHI, T; YASUKAWA, T; NAGASE, T; HORIKOSHI, M; YAMAMOTO, T; ISHII, S				MIZUGUCHI, G; KANEIISHII, C; TAKAHASHI, T; YASUKAWA, T; NAGASE, T; HORIKOSHI, M; YAMAMOTO, T; ISHII, S			C-MYB REPRESSION OF C-ERBB-2 TRANSCRIPTION BY DIRECT BINDING TO THE C-ERBB-2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE PRODUCT; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; NEU ONCOGENE; B-MYB; LEUCINE-ZIPPER; V-MYB; EXPRESSION; GENE; CELLS	The c-myb proto oncogene product (c-Myb) is a transcriptional activator that can bind to the specific DNA sequences. Although c-Myb also represses an artificial promoter containing the Myb binding sites, natural target genes transcriptionally repressed by c-Myb have not been identified. We have found that the human c-erbB-a promoter activity is repressed by c-Myb or B-Myb in a chloramphenicol acetyltransferase co-transfection assay. Domain analyses of c-Myb suggested that Myb re presses the c-erbB-a promoter activity by competing with positive regulators of the c-erbB-2 promoter. In in vitro transcription assays, Myb proteins containing only the DNA binding domain could repress c-erbB-2 promoter activity. Two Myb binding sites in the c-erbB-2 promoter were critical for transcriptional repression by c-Myb. One of the two Myb binding sites overlaps the TATA box, and DNase I footprint analyses indicated that c-Myb can compete with TFIID. These results suggest that Myb-induced trans-repression of the c-erbB-2 promoter partly involves competition between Myb and TFIID.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tsukuba; University of Tokyo	MIZUGUCHI, G (corresponding author), RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENET MOLEC LAB,TSUKUBA,IBARAKI 305,JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GUERIN M, 1990, ONCOGENE, V5, P131; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HU YL, 1991, ONCOGENE, V6, P1549; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KU DH, 1993, J BIOL CHEM, V268, P2255; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUSHGER B, 1990, GENE DEV, V4, P2235; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MIZUGUCHI G, 1994, FEBS LETT, V348, P80, DOI 10.1016/0014-5793(94)00578-8; MORI S, 1989, LAB INVEST, V61, P93; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NESS SA, 1989, CELL, V59, P115; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, IN PRESS ONCOGENE; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; ZOBEL A, 1991, ONCOGENE, V6, P1397	45	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9384	9389		10.1074/jbc.270.16.9384	http://dx.doi.org/10.1074/jbc.270.16.9384			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721862	hybrid			2022-12-27	WOS:A1995QU08900051
J	PINZ, KG; SHIBUTANI, S; BOGENHAGEN, DF				PINZ, KG; SHIBUTANI, S; BOGENHAGEN, DF			ACTION OF MITOCHONDRIAL-DNA POLYMERASE-GAMMA AT SITES OF BASE LOSS OR OXIDATIVE DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; 3'->5' EXONUCLEASE; CATALYTIC SUBUNIT; XENOPUS-LAEVIS; CELLS; NUCLEAR; REPAIR; IDENTIFICATION; PURIFICATION; FIDELITY	Mitochondrial DNA is subject to oxidative damage generating 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxo-dG) residues and to spontaneous or induced base loss generating abasic sites, Synthetic oligonucleotides containing these lesions were prepared and used as templates to determine their effects on the action of Xenopus Laevis DNA polymerase gamma, An analogue of an abasic site in DNA, tetrahydrofuran, was found to inhibit elongation by DNA polymerase gamma, When the DNA polymerase was able to complete translesional synthesis, a dA residue was incorporated opposite the abasic site, In contrast, elongation by DNA polymerase gamma was not inhibited by an 8-oxo-dG residue in the template strand. The polymerase inserted dA opposite 8-oxo-dG in approximately 27% of the extended products, The effects of these lesions on the 3' --> 5' exonuclease proofreading activity of DNA polymerase gamma were also investigated, The 3' --> 5' exonuclease activity excised any of the four normal bases positioned opposite either a tetrahydrofuran residue or 8-oxo-dG, suggesting that proofreading may not play a major role in avoiding misincorporation at abasic sites or 8-oxo-dG residues in the template, Thus, both of these lesions have the prospect of causing high rates of mutation during mtDNA replication.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Shibutani, Shinya/0000-0003-4190-9512	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01-ES04068] Funding Source: Medline; NIGMS NIH HHS [R01-GM29681] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BODEPUDI V, 1991, NUCLEOS NUCLEOT NUCL, V10, P755, DOI 10.1080/07328319108046660; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GRAY H, 1992, J BIOL CHEM, V267, P5835; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V176, P87, DOI 10.1016/0006-291X(91)90893-C; HEGLER J, 1993, CARCINOGENESIS, V14, P2309, DOI 10.1093/carcin/14.11.2309; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; OLSON MW, 1992, J BIOL CHEM, V267, P23136; RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1993, CHEM RES TOXICOL, V6, P625, DOI 10.1021/tx00035a006; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855	35	109	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9202	9206		10.1074/jbc.270.16.9202	http://dx.doi.org/10.1074/jbc.270.16.9202			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721837	hybrid			2022-12-27	WOS:A1995QU08900025
J	SALIMATH, PV; SPIRO, RC; FREEZE, HH				SALIMATH, PV; SPIRO, RC; FREEZE, HH			IDENTIFICATION OF A NOVEL GLYCOSAMINOGLYCAN CORE-LIKE MOLECULE .2. ALPHA-GALNAC-CAPPED XYLOSIDES CAN BE MADE BY MANY CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; BETA-D-XYLOSIDES; CHONDROITIN SULFATE BIOSYNTHESIS; EMBRYONIC-CHICKEN CARTILAGE; BREFELDIN-A; LINKED OLIGOSACCHARIDES; HEPARAN-SULFATE; SHARK CARTILAGE; HUMAN-MELANOMA; PROTEOGLYCANS	The accompanying article (Manzi, A., Salimath, P, V,, Spiro, R, C,, Keifer, P, A., and Freeze, H, H, (1995) J, Biol, Chem, 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU), The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-GalNAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains, In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides, The [6-H-3]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc, Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. This novel oligosaccharide ac counts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 mu M Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%, In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact, This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis, Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; TELIOS PHARMACEUT INC, SAN DIEGO, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA049243] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49094, R01 CA49243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen H. J., 1992, GLYCOCONJUGATES COMP; CARRINO DA, 1994, MATRIX BIOL, V14, P121, DOI 10.1016/0945-053X(94)90002-7; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; DO SI, 1992, J BIOCHEM BIOPH METH, V24, P153, DOI 10.1016/0165-022X(94)90068-X; ESKO JD, 1993, CURRENT PROTOCOLS MO; ETCHISON JR, 1995, J BIOL CHEM, V270, P756, DOI 10.1074/jbc.270.2.756; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAYES BK, 1993, J BIOL CHEM, V268, P16155; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; KIRBY SL, 1991, J CELL PHYSIOL, V148, P116, DOI 10.1002/jcp.1041480114; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; ROTH J, 1991, J ELECTRON MICR TECH, V17, P121, DOI 10.1002/jemt.1060170202; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	32	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9164	9168		10.1074/jbc.270.16.9164	http://dx.doi.org/10.1074/jbc.270.16.9164			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721831	hybrid			2022-12-27	WOS:A1995QU08900019
J	ADNANE, J; SHAO, ZH; ROBBINS, PD				ADNANE, J; SHAO, ZH; ROBBINS, PD			THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT REPRESSES TRANSCRIPTION WHEN DIRECTLY BOUND TO THE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DIRECT BINDING; CDC2 KINASE; RB PROTEIN; T-ANTIGEN; C-MYC; E2F; PHOSPHORYLATION; EXPRESSION; ACTIVATION	Rb represses E2F-mediated transcription in part by blocking the trans-activation domain of E2F. In addition, Rb can convert an E2F binding site from a positive to a negative element. To examine the effect of a Rb-DNA bound complex on transcription, full-length Rb was fused to the DNA binding domain of GAL4. Here, we report that GAL4-Rb can repress transcription mediated by either Sp1, AP-1, or p53, dependent upon the presence of both the GAL4 DNA binding domain and GAL4 binding sites. Moreover, GAL4-Rb inhibited the activity of the herpes simplex virus tk promoter from GAL4 binding sites located at a distance from the promoter. In contrast, GAL4-Rb was unable to repress basal transcription. Cotransfection of specific cyclins and cyclin dependent kinases or SV40 T-antigen abolished the repressive activity of GAL4-Rb. The domains of Rb involved in mediating the repression of transcription were mapped to regions that are overlapping, but not identical, to those required for the interaction with E2F. We propose that Rb can function as a general repressor of transcription when bound to the promoter region.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NCI NIH HHS [CA55227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MADDEN SL, 1993, ONCOGENE, V8, P1713; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO Z, 1995, IN PRESS P NATL ACAD; SRINIVASAN A, 1989, J VIROL, P5459; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YU DH, 1992, J BIOL CHEM, V267, P10203	49	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8837	8843		10.1074/jbc.270.15.8837	http://dx.doi.org/10.1074/jbc.270.15.8837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721791	hybrid			2022-12-27	WOS:A1995QT44800069
J	CATERINA, MJ; DEVREOTES, PN; BORLEIS, J; HERELD, D				CATERINA, MJ; DEVREOTES, PN; BORLEIS, J; HERELD, D			AGONIST-INDUCED LOSS OF LIGAND-BINDING IS CORRELATED WITH PHOSPHORYLATION OF CAR1, A G-PROTEIN-COUPLED CHEMOATTRACTANT RECEPTOR FROM DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE CAMP RECEPTORS; CYCLIC-AMP; CONCENTRATION-DEPENDENCE; KINASE ACTIVATION; DOWN-REGULATION; DISCOIDEUM; DESENSITIZATION; INTERNALIZATION; AGGREGATION; INHIBITORS	The parallel agonist-induced phosphorylation, alteration in electrophoretic mobility, and loss of ligand binding of a guanine nucleotide-binding regulatory protein (G protein)-coupled chemoattractant receptor from Dictyostelium (cAR1) depend upon a cluster of five C-terminal domain serine residues (Caterina, M. J., Hereld, D., and Devreotes, P. N. (1995) J. Biol. Chem. 270, 4418-4423). Analysis of mutants lacking combinations of these serines revealed that either Ser(303) or Ser(304) is required; mutants lacking both serines are defective in all of these responses. Interestingly, several mutants, in eluding those substituted at only Ser(299), Ser(302), or Ser(303) or at non-serine positions within the third cytoplasmic loop, displayed an unstable mobility shift; the alteration was rapidly reversed upon cAMP removal. These mutants also exhibited subnormal extents of loss of ligand binding, which is assessed after removal of the ligand. For the wild-type receptor, we found that the stability of phosphorylation depends upon the concentration and duration of agonist pretreatment. This suggests that, following phosphorylation of Ser(303) or Ser(304), cAR1 undergoes a further transition (EC(50) approximate to 140 nM, t(1/2) approximate to 4 min) to a relatively phosphatase resistant state. We used this insight to show that, under all conditions tested, the extent of loss of binding is correlated with the fraction of cAR1 in the altered mobility form. We discuss possible relationships between cAR1 phosphorylation and loss of ligand binding.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34933, GM07309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BRENNER M, 1984, DEV BIOL, V101, P136, DOI 10.1016/0012-1606(84)90124-6; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CATERINA MJ, 1995, J BIOL CHEM, V270, P4418, DOI 10.1074/jbc.270.9.4418; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES P, 1989, TRENDS GENET, V5, P242, DOI 10.1016/0168-9525(89)90095-4; DEVREOTES PN, 1985, J BIOL CHEM, V260, P6378; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HENDERSON EJ, 1975, J BIOL CHEM, V250, P4730; HERELD D, 1994, J BIOL CHEM, V269, P7036; JULIANI MH, 1981, J BIOL CHEM, V256, P613; KLEIN C, 1977, CELL, V10, P329, DOI 10.1016/0092-8674(77)90227-6; KLEIN P, 1985, J BIOL CHEM, V260, P1757; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MORO O, 1993, J BIOL CHEM, V268, P22273; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; TSUGA H, 1994, J BIOL CHEM, V269, P3252; VANHAASTERT PJM, 1987, J BIOL CHEM, V262, P7700; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VANHAASTERT PJM, 1992, MOL BIOL CELL, V3, P603, DOI 10.1091/mbc.3.6.603; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WANG M, 1988, DEV BIOL, V128, P72, DOI 10.1016/0012-1606(88)90268-0; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; YU SS, 1993, J BIOL CHEM, V268, P337	32	39	40	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8667	8672		10.1074/jbc.270.15.8667	http://dx.doi.org/10.1074/jbc.270.15.8667			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721769	hybrid			2022-12-27	WOS:A1995QT44800047
J	HYDER, SM; NAWAZ, Z; CHIAPPETTA, C; YOKOYAMA, K; STANCEL, GM				HYDER, SM; NAWAZ, Z; CHIAPPETTA, C; YOKOYAMA, K; STANCEL, GM			THE PROTOONCOGENE C-JUN CONTAINS AN UNUSUAL ESTROGEN-INDUCIBLE ENHANCER WITHIN THE CODING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; RAT UTERINE CELLS; RESPONSE ELEMENT; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; 3'-FLANKING REGION; NUCLEAR RECEPTORS; FOS PROTOONCOGENE; UTERUS; DNA	Estrogens have previously been shown to induce c-jun mRNA levels in target cells during hormone induced proliferation, and this appears to be a primary hormonal response involving transcriptional activation. In this report we have now identified an estrogen dependent enhancer within the coding sequence of c-jun. This element has the sequence GCAGAnnnTGACC which is identical to the consensus estrogen response element GGTCAnnnTGACC in the second half site, but varies considerably in the first half site. Synthetic oligodeoxynucleotides containing this jun sequence bind the estrogen receptor in cell-free studies using a competitive band shift assay with the consensus element. The jun element also confers hormone inducibility to re porter plasmids in yeast and mammalian based transcriptional systems. Structure-function studies illustrate that the TGACC half-site and its immediate flanking dinucleotides, but not the GCAGA half-site, are required for estrogen receptor binding. In contrast, both the GCAGA and TGACC half-sites are obligatory for hormone inducible transcriptional activation. These results suggest a model in which the estrogen receptor functions as a heterodimer to regulate transcription of the c-jun protooncogene. Coupled with reports of estrogen response elements in c-fos and estrogenic induction of c-fos and c-jun in vivo, these findings also support a role for AP-1 components as early response genes in estrogen-induced proliferation.	UNIV TEXAS,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,HOUSTON,TX 77225; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; RIKEN,TSUKUBA LIFE SCI CTR,IBARAKI,OSAKA 305,JAPAN	University of Texas System; Baylor College of Medicine; RIKEN	HYDER, SM (corresponding author), UNIV TEXAS,SCH MED,DEPT PHARMACOL,POB 20708,HOUSTON,TX 77225, USA.				NICHD NIH HHS [HD-08615] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANOLIK JH, 1993, J STEROID BIOCHEM, V46, P713, DOI 10.1016/0960-0760(93)90312-K; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BIGSBY RM, 1994, ENDOCRINOLOGY, V134, P1820, DOI 10.1210/en.134.4.1820; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; CHIAPPETTA C, 1992, J STEROID BIOCHEM, V41, P113, DOI 10.1016/0960-0760(92)90037-J; CICATIELLO L, 1992, J STEROID BIOCHEM, V41, P523, DOI 10.1016/0960-0760(92)90377-U; CLARET FX, 1994, J BIOL CHEM, V269, P14047; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; ELLISTON JF, 1990, J BIOL CHEM, V265, P11517; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORSKI J, 1993, BIOL REPROD, V48, P8, DOI 10.1095/biolreprod48.1.8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAWA NS, 1994, ENDOCRINOLOGY, V135, P1, DOI 10.1210/en.135.1.1; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hyder Salman M., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P55; HYDER SM, 1994, BIOTECHNIQUES, V17, P478; HYDER SM, 1991, GENE, V105, P281, DOI 10.1016/0378-1119(91)90164-7; HYDER SM, 1992, J BIOL CHEM, V267, P18047; HYDER SM, 1989, J STEROID BIOCHEM, V33, P965, DOI 10.1016/0022-4731(89)90247-1; HYDER SM, 1994, J STEROID BIOCHEM, V48, P69, DOI 10.1016/0960-0760(94)90252-6; INOUE S, 1991, NUCLEIC ACIDS RES, V19, P4091, DOI 10.1093/nar/19.15.4091; ITAO M, 1983, J BACTERIOL, V153, P163; KANEKO KJ, 1993, MOL ENDOCRINOL, V7, P879, DOI 10.1210/me.7.7.879; KIRKLAND JL, 1979, BIOL REPROD, V21, P269, DOI 10.1095/biolreprod21.2.269; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KITABAYASHI I, 1990, NUCLEIC ACIDS RES, V18, P3400, DOI 10.1093/nar/18.11.3400; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KOJI T, 1993, ENDOCRINOLOGY, V132, P382, DOI 10.1210/en.132.1.382; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LANNIGAN DA, 1993, MOL CELL ENDOCRINOL, V94, P47, DOI 10.1016/0303-7207(93)90050-T; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; LUCKOW B, 1984, NUCLEIC ACIDS RES, V15, P5490; MAK P, 1989, J BIOL CHEM, V264, P21613; Maniatis T., 1982, MOL CLONING; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MOENLE CM, 1994, GENETICS, V115, P255; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NAWAZ Z, 1993, MOL CARCINOGEN, V7, P76, DOI 10.1002/mc.2940070204; NEPHEW KP, 1994, ENDOCRINOLOGY, V134, P1827, DOI 10.1210/en.134.4.1827; PERSICO E, 1990, BIOCHEM BIOPH RES CO, V171, P287, DOI 10.1016/0006-291X(90)91390-E; PHAM TA, 1991, J BIOL CHEM, V266, P18179; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SIRBASKU DA, 1976, ENDOCRINOLOGY, V98, P1260, DOI 10.1210/endo-98-5-1260; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBB DK, 1990, BIOCHEM BIOPH RES CO, V168, P721, DOI 10.1016/0006-291X(90)92381-9; WEBB DK, 1993, ENDOCRINOLOGY, V133, P20, DOI 10.1210/en.133.1.20; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	57	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8506	8513		10.1074/jbc.270.15.8506	http://dx.doi.org/10.1074/jbc.270.15.8506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721748	hybrid			2022-12-27	WOS:A1995QT44800024
J	AUSSEL, C; BREITTMAYER, JP; PELASSY, C; BERNARD, A				AUSSEL, C; BREITTMAYER, JP; PELASSY, C; BERNARD, A			CALMODULIN, A JUNCTION BETWEEN 2 INDEPENDENT IMMUNOSUPPRESSIVE PATHWAYS IN JURKAT T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; PHOSPHATIDYLSERINE SYNTHESIS; TYROSINE PHOSPHORYLATION; PHOSPHOLIPID-METABOLISM; INTERLEUKIN-2 SYNTHESIS; ANTIGEN RECEPTOR; PROTEIN PHOSPHATASES; INTRACELLULAR CA-2+; AMPHIPHILIC CATIONS; PLASMA-MEMBRANE	Calmodulin (CaM) antagonists chlorpromazine, trifluoperazine, and N-(6-aminohexyl)-5-chloro-1-naphthalene-sulfonamide HCl inhibit Jurkat T cell activation, as monitored by measuring interleukin-2 synthesis in cells treated by a combination of CD3 monoclonal antibody and phorbol myristate acetate. T cell activation with CD3 monoclonal antibody is accompanied by a decreased synthesis of phosphatidylserine due to the release of Ca2+ from the endoplasmic reticulum, CaM antagonists reverse the phosphatidylserine (PtdSer) inhibition induced by CD3. This increase of PtdSer synthesis was observed in the absence of any modification of CD3 induced Ca2+ movements, Both in intact cells and in an acellular system, the increase of PtdSer synthesis induced by CaM antagonists was abolished in the presence of EGTA, indicating that the base exchange enzyme system responsible for PtdSer synthesis is regulated by CaM provided that Ca2+ is present, By contrast, cyclosporin A that inhibits T cell activation through the interaction of cyclophilin cyclosporin A complexes with the calmodulin-activated phosphatase, calcineurin, had no effect on PtdSer synthesis, Calmodulin thus appears as a junction leading to at least two independent pathways of regulation of T cell activation, one involving the calcineurin phosphatase and the other the base exchange enzyme system responsible for PtdSer synthesis.			AUSSEL, C (corresponding author), HOP ARCHET,INSERM,U343,BP 79,F-06202 NICE 03,FRANCE.							AUSSEL C, 1992, FEBS LETT, V304, P281, DOI 10.1016/0014-5793(92)80638-W; AUSSEL C, 1993, J LIPID MEDIATOR, V7, P99; AUSSEL C, 1991, J LIPID MEDIATOR, V3, P267; AUSSEL C, 1990, IMMUNOPHARMACOLOGY, V20, P97, DOI 10.1016/0162-3109(90)90012-4; AUSSEL C, 1994, CELL IMMUNOL, V155, P436, DOI 10.1006/cimm.1994.1136; AUSSEL C, 1992, CELL IMMUNOL, V139, P333, DOI 10.1016/0008-8749(92)90075-Z; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREITTMAYER JP, 1993, CELL IMMUNOL, V149, P248, DOI 10.1006/cimm.1993.1152; BUCHANAN AG, 1980, J NEUROCHEM, V34, P814; CZARNY M, 1992, BIOCHEM BIOPH RES CO, V186, P1582, DOI 10.1016/S0006-291X(05)81588-8; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; FERRUA B, 1987, J IMMUNOL METHODS, V97, P215, DOI 10.1016/0022-1759(87)90462-5; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GELFAND EW, 1989, ADV REGULATION CELL, V1, P119; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IMBODEN JB, 1985, J IMMUNOL, V134, P663; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KANFER JN, 1993, J NEUROCHEM, V60, P1228, DOI 10.1111/j.1471-4159.1993.tb03281.x; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARY D, 1987, J IMMUNOL, V139, P1179; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NIWA Y, 1986, ARCH BIOCHEM BIOPHYS, V250, P345, DOI 10.1016/0003-9861(86)90736-8; PELASSY C, 1991, J LIPID MEDIATOR, V4, P199; PELASSY C, 1992, BIOCHEM J, V288, P785, DOI 10.1042/bj2880785; PELASSY C, 1992, BIOCHEM J, V282, P443, DOI 10.1042/bj2820443; PELASSY C, 1989, CELL SIGNAL, V1, P99, DOI 10.1016/0898-6568(89)90024-7; RASMUSSEN C, 1994, EMBO J, V13, P2545, DOI 10.1002/j.1460-2075.1994.tb06544.x; SINGH IN, 1992, J LIPID MEDIATOR, V5, P301; SINGH IN, 1992, FEBS LETT, V2, P166; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	37	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8032	8036		10.1074/jbc.270.14.8032	http://dx.doi.org/10.1074/jbc.270.14.8032			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713904	hybrid			2022-12-27	WOS:A1995QR52600040
J	FREEDMAN, SJ; FURIE, BC; FURIE, B; BALEJA, JD				FREEDMAN, SJ; FURIE, BC; FURIE, B; BALEJA, JD			STRUCTURE OF THE METAL-FREE GAMMA-CARBOXYGLUTAMIC ACID-RICH MEMBRANE-BINDING REGION OF FACTOR-IX BY 2-DIMENSIONAL NMR-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO ANTICOAGULANT ACTIVITY; COAGULATION FACTOR-IX; ACTIVATED PROTEIN-C; PROTHROMBIN FRAGMENT-1; BLOOD-COAGULATION; GLA DOMAIN; SITE; SEQUENCE; RESIDUES; VARIANT	The gamma-carboxyglutamic acid-rich domain of blood coagulation Factor IX is required for the binding of the protein to phospholipid membranes. To investigate the three-dimensional structure of this domain, a synthetic peptide corresponding to residues 1-47 of Factor IX was studied by H-1 NMR spectroscopy. In the absence of metal ions, the proton chemical shift dispersion in the one-dimensional NMR spectrum indicated that the peptide contains regular structural elements. Upon the addition of Ca(II) or Mg(II), large chemical shift changes were observed in the amide proton and methyl proton regions of the spectrum, consistent with the conformational transitions that metal ions are known to induce in native Factor IX. The apopeptide was studied by two-dimensional NMR spectroscopy at 500 MHz to determine its solution structure. Protons were assigned using total correlation spectroscopy, nuclear Overhauser effect spectroscopy, and double quantum-filtered correlation spectroscopy experiments. Intensities of cross-peaks in the nuclear Overhauser effect spectrum were used to generate a set of interproton distance restraints. The structure of the apopeptide was then calculated using distance geometry methods. There are three structural elements in the apopeptide that are linked by a flexible polypeptide backbone. These elements include a short amino-terminal tetrapeptide loop (amino acids 6-9), the disulfide-containing hexapeptide loop (amino acids 18-23), and a carboxyl-terminal alpha helix (amino acids 37-46). Amide hydrogen exchange kinetics indicate that the majority of the peptide is solvent accessible, except in the carboxyl-terminal element. The structured regions in the apopeptide are insufficient to support phospholipid binding, indicating the importance of additional structural features in the Ca(II)-stabilized conformer.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; SACKLER SCH BIOMED SCI,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111	Tufts University; Tufts University; Tufts Medical Center					NHLBI NIH HHS [HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; FREEDMAN SJ, 1994, BLOOD, V84, P531; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HARLOS K, 1987, FEBS LETT, V224, P97, DOI 10.1016/0014-5793(87)80429-5; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JACOBS M, 1994, J BIOL CHEM, V269, P25494; JONES ME, 1985, BIOCHEMISTRY-US, V24, P8064, DOI 10.1021/bi00348a034; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; MORITA T, 1984, J BIOL CHEM, V259, P5698; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; SPERLING R, 1978, J BIOL CHEM, V253, P3898; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAPATA GA, 1987, FASEB J, V46, P2230; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1994, J BIOL CHEM, V269, P3590; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	29	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7980	7987		10.1074/jbc.270.14.7980	http://dx.doi.org/10.1074/jbc.270.14.7980			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713897	hybrid			2022-12-27	WOS:A1995QR52600033
J	HOLMES, EH; XU, ZH; SHERWOOD, AL; MACHER, BA				HOLMES, EH; XU, ZH; SHERWOOD, AL; MACHER, BA			STRUCTURE-FUNCTION ANALYSIS OF HUMAN ALPHA-1-]3FUCOSYLTRANSFERASES - A GDP-FUCOSE-PROTECTED, N-ETHYLMALEIMIDE-SENSITIVE SITE IN FUCT-III AND FUCT-V CORRESPONDS TO SER(178) IN FUCT-IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; SUBSTRATE SPECIFICITIES; CARBOHYDRATE ANTIGENS; DETERMINES EXPRESSION; NEGATIVE INDIVIDUALS; LACTOSE SYNTHETASE; MOLECULAR-CLONING; HUMAN-MILK; LEWIS-X; TRANSFERASE	Human alpha 1-->3fucosyltransferases constitute a family of closely related membrane-bound enzymes distinguished by differences in acceptor specificities and inherent protein biochemical properties. One such biochemical property is sensitivity to enzyme inactivation by sulfhydral-group modifying reagents such as N-ethylmaleimide. The basis for this property has been studied using a fusion protein of FucT-III anf FucT-V composed of protein A coupled to the catalytic domain of the enzyme. The results indicate that modification of FucT-V by 5,5'-dithiobis(2-nitrobenzoic acid) resulted in efficient enzyme inactivation that could be reversed by excess thiol reagent suggesting that the free sulfhydral group on the enzyme was required for activity. Recombinant forms of both FucT-III and FucT-V were irreversibly inactivated by N-ethylmaleimide and could be effectively protected from inactivation by GDP-fucose and GDP but not by UDP-galactose, fucose, or N-acetyllactosamine. Analysis of the distribution of Cys residues in aligned sequences of cloned human alpha 1-->3fucosyltransferases indicated one site, Cys(143) of FucT-III and Cys(156) of FucT-V, corresponded to the highly conservative replacement of Ser(178) in FucT-IV, an enzyme insensitive to N-ethylmaleimide. A site-directed mutagenesis experiment was performed to replace Ser(178) of FucT-IV with a Cys residue. The mutant FucT-IV enzyme was active; however, the K-m for GDP-fucose was increased about 3-fold compared to the native enzyme to 28 +/- 3 mu M. This enzyme was N-ethylmaleimide sensitive and could be partially protected by GDP-fucose but not N-acetyllactosamine. These results support the importance of Ser(178) of FucT-IV in donor substrate binding and strongly suggest analogous Cys residues are the GDP-fucose protectable, N-ethylmaleimide-sensitive sites present in FucT-III and -V.	SAN FRANCISCO STATE UNIV, DEPT CHEM & BIOCHEM, SAN FRANCISCO, CA 94132 USA	California State University System; San Francisco State University	HOLMES, EH (corresponding author), PACIFIC NW RES FDN, 720 BROADWAY, SEATTLE, WA 98122 USA.				NCI NIH HHS [CA41521, CA32826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041521, R01CA032826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALHADEFF JA, 1989, CRIT REV ONCOL HEMAT, V9, P37, DOI 10.1016/S1040-8428(89)80014-9; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BALL SP, 1991, ANN HUM GENET, V55, P225, DOI 10.1111/j.1469-1809.1991.tb00417.x; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DEVRIES T, 1995, IN PRESS J BIOL CHEM; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; GINSBURG V, 1966, METHOD ENZYMOL, V8, P293; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HEDA GD, 1992, NUCLEIC ACIDS RES, V20, P5241, DOI 10.1093/nar/20.19.5241; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; HOLMES EH, 1985, J BIOL CHEM, V260, P7619; KITCHEN BJ, 1974, BIOCHEM J, V141, P173, DOI 10.1042/bj1410173; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MAGEE SC, 1974, J BIOL CHEM, V249, P6992; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; OKEEFFE ET, 1980, BIOCHEMISTRY-US, V19, P4954, DOI 10.1021/bi00563a003; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P14730; STROUP GB, 1990, CANCER RES, V50, P6787; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257	43	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8145	8151		10.1074/jbc.270.14.8145	http://dx.doi.org/10.1074/jbc.270.14.8145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713918	hybrid			2022-12-27	WOS:A1995QR52600057
J	SYMES, AJ; RAJAN, P; CORPUS, L; FINK, JS				SYMES, AJ; RAJAN, P; CORPUS, L; FINK, JS			C/EBP-RELATED SITES IN ADDITION TO A STAT SITE ARE NECESSARY FOR CILIARY NEUROTROPHIC FACTOR-LEUKEMIA FACTOR-DEPENDENT TRANSCRIPTIONAL ACTIVATION BY THE VASOACTIVE-INTESTINAL-PEPTIDE CYTOKINE RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; ACUTE-PHASE RESPONSE; NEUROBLASTOMA CELL-LINE; INHIBITORY FACTOR; TYROSINE PHOSPHORYLATION; NUCLEAR FACTOR; ONCOSTATIN-M; SIGNAL-TRANSDUCTION; LEUCINE ZIPPER; CNTF RECEPTOR	The neuropoietic cytokines ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) regulate VIP gene expression through a cytokine response element (CyRE) which interacts with members of the STAT transcription factor family. The CyRE STAT site is, however, insufficient to mediate full transcriptional activation by CNTF/LIF, suggesting that other sequences and nuclear proteins are also important. As C/EBP proteins participate in the transcriptional effects of the related cytokine, interleukin-6, we investigated the role of possible C/EBP-binding sites in the response of the VIP CyRE to CNTF/LIF. Using DNase I footprinting, transactivation studies, DNA mobility shift assays, and mutational analysis, three sites within the VIP CyRE were identified as C/EBP-related binding sites and shown to be important to CNTF/LIF-mediated transcriptional activation. The CyRE C/EBP-related sites interact with nuclear proteins from the human neuroblastoma cell Line, NBFL, including a novel, protein synthesis-dependent, nuclear protein complex, induced by CNTF treatment, These nuclear proteins are not, however, recognized by antisera to known C/EBP proteins, Therefore, other nuclear proteins regulated by independent pathways act in concert with the JAK-STAT pathway to mediate CNTF/LIF regulation of VIP gene expression through the CyRE.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,MOLEC NEUROBIOL LAB,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital			Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	NINDS NIH HHS [NS27514] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027514] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FANN MJ, 1993, J NEUROCHEM, V61, P1349, DOI 10.1111/j.1471-4159.1993.tb13628.x; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HALL AK, 1992, TRENDS NEUROSCI, V15, P35, DOI 10.1016/0166-2236(92)90022-Z; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; Ip Nancy Y., 1994, Current Opinion in Neurobiology, V4, P400, DOI 10.1016/0959-4388(94)90102-3; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LO DC, 1993, P NATL ACAD SCI USA, V90, P2557, DOI 10.1073/pnas.90.7.2557; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUDLAM WH, 1994, DEV BIOL, V164, P528, DOI 10.1006/dbio.1994.1221; MONTMINY M, 1986, J NEUROSCI, V6, P1161; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; NAWA H, 1990, COLD SH Q B, V55, P247; NAWA H, 1991, J NEUROCHEM, V56, P2147, DOI 10.1111/j.1471-4159.1991.tb03479.x; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAITO T, 1991, J IMMUNOL, V147, P168; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TSUKADA T, 1985, DNA-J MOLEC CELL BIO, V4, P293, DOI 10.1089/dna.1985.4.293; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	76	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8068	8075		10.1074/jbc.270.14.8068	http://dx.doi.org/10.1074/jbc.270.14.8068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713908	hybrid			2022-12-27	WOS:A1995QR52600046
J	ABE, T; ARAKAWA, Y; RAJASEKARAN, AK; YU, TH; WADA, O				ABE, T; ARAKAWA, Y; RAJASEKARAN, AK; YU, TH; WADA, O			INTERACTION OF ATRIAL-NATRIURETIC-PEPTIDE WITH ITS RECEPTORS IN BOVINE LUNG MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PARTICULATE GUANYLATE-CYCLASE; VASCULAR SMOOTH-MUSCLE; CYCLIC-GMP ACCUMULATION; LEYDIG TUMOR-CELLS; LIGAND-BINDING; PURIFICATION; RAT; ENDOPEPTIDASE-24.11; INTERNALIZATION	In bovine lung membranes, atrial natriuretic peptide (ANP) showed temperature-dependent binding to guanylate cyclase-natriuretic peptide receptor (NPR-GC). Photoaffinity labeling of the receptors with 4-azidobenzoyl (AZB)-I-125-ANP and competitive binding studies with I-125-ANP, ANP and atriopeptin I (API) revealed that NPR-GC was detected as the predominant ANP-binding protein at 0 degrees C, whereas at 37 degrees C natriuretic peptide clearance receptor (NPR-C) was detected as the predominant protein. The ratio of NPR-GC and NPR-C was 89:11 at 0 degrees C for 40 min, respectively, whereas 6:94 at 37 degrees C, AZB-I-125-ANP bound to NPR-GC dissociated from the binding site within 5 min at 37 degrees C but not at 6 degrees C, whereas ANP bound to NPR-C did not dissociate from the binding site at 0 and 37 degrees C, The dissociated AZB-I-125-ANP rapidly rebound to NPR-GC at 37 degrees C but not to NPR-C, and the dissociated NPR-GC was capable of binding. Some AZB-I-125-ANP was hydrolyzed by a membrane-bound proteinase(s). Phosphoramidon inhibited the hydrolysis of AZB-I-125-ANP, Thus, the dissociated AZB-I-125-ANP rebound to NPR-GC and NPR-C. These results suggest that usually intact ANP repeatedly binds to NPR-GC until hydrolysis, Furthermore, the majority of ANP bind to NPR-GC before binding to NPR-C under physiological temperature.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; UNIV TOKYO,FAC MED,DEPT HYG & PREVENT MED,BUNKYO KU,TOKYO 113,JAPAN	Cornell University; University of Tokyo	ABE, T (corresponding author), UNIV SHIZUOKA,SCH FOOD & NUTR SCI,DEPT HYG & PREVENT MED,52-1 YADA,SHIZUOKA 422,JAPAN.							ABE T, 1992, EUR J BIOCHEM, V209, P717, DOI 10.1111/j.1432-1033.1992.tb17340.x; ABE T, 1993, EUR J BIOCHEM, V217, P295, DOI 10.1111/j.1432-1033.1993.tb18246.x; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; BALLERMANN BJ, 1988, BIOCHEM BIOPH RES CO, V157, P755, DOI 10.1016/S0006-291X(88)80314-0; BOURNE A, 1990, BIOCHEM J, V271, P381, DOI 10.1042/bj2710381; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEVALIER RL, 1991, AM J PHYSIOL, V260, pR1218, DOI 10.1152/ajpregu.1991.260.6.R1218; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; FULLER F, 1988, J BIOL CHEM, V263, P9395; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; JOHNSON GR, 1989, J BIOL CHEM, V264, P11637; KOH GY, 1992, J BIOL CHEM, V267, P11987; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KUNO T, 1986, J BIOL CHEM, V261, P5817; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFERTY HM, 1989, CIRC RES, V65, P640, DOI 10.1161/01.RES.65.3.640; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MISONO KS, 1985, BIOCHEM BIOPH RES CO, V130, P994, DOI 10.1016/0006-291X(85)91713-9; MISONO KS, 1988, BIOCHEM BIOPH RES CO, V152, P658, DOI 10.1016/S0006-291X(88)80089-5; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OLINS GM, 1988, J BIOL CHEM, V263, P10989; PANDEY KN, 1986, BIOCHEMISTRY-US, V25, P8467, DOI 10.1021/bi00374a022; PANDEY KN, 1990, J BIOL CHEM, V265, P12342; PANDEY KN, 1993, J BIOL CHEM, V268, P4382; POTTER LR, 1992, J BIOL CHEM, V267, P14531; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RATHINAVELU A, 1991, BIOCHEM J, V276, P493, DOI 10.1042/bj2760493; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SCHENK DB, 1987, P NATL ACAD SCI USA, V84, P1521, DOI 10.1073/pnas.84.6.1521; SHIMONAKA M, 1987, J BIOL CHEM, V262, P5510; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STEPHENSON SL, 1987, BIOCHEM J, V243, P183, DOI 10.1042/bj2430183; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; VANNESTE Y, 1990, BIOCHEM J, V269, P801, DOI 10.1042/bj2690801; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WINQUIST RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7661, DOI 10.1073/pnas.81.23.7661	44	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7672	7678		10.1074/jbc.270.13.7672	http://dx.doi.org/10.1074/jbc.270.13.7672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706315	hybrid			2022-12-27	WOS:A1995QQ43100093
J	REUTER, CWM; CATLING, AD; JELINEK, T; WEBER, MJ				REUTER, CWM; CATLING, AD; JELINEK, T; WEBER, MJ			BIOCHEMICAL-ANALYSIS OF MEK ACTIVATION IN NIH3T3 FIBROBLASTS - IDENTIFICATION OF B-RAF AND OTHER ACTIVATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE-KINASE; SIGNAL-TRANSDUCTION PATHWAY; COMPLETE CODING SEQUENCE; SERINE THREONINE KINASE; NERVE GROWTH-FACTOR; PROTEIN-KINASE; IN-VITRO; PHOSPHORYLATION SITES; ONCOGENIC P21(RAS); REGULATED KINASES	Numerous potential activators of MEK have been identified, including c-Raf-1, B Raf, c-Mos, and a family of MEK kinases. However, little information gives insight into the activators actually utilized in vivo. To address this, we have used column chromatography and a coupled MEK activation assay to identify in NTH3T3 cells, two major MEK activators, and a third insulin-specific activator. The first MEK activator has an apparent M(r) of 40,000-50,000, was immunologically distinct from A-Raf, B-Raf, c-Raf-1, c-MEKK, c-Mos, MEK1, and MEK2, and was rapidly activated by serum, platelet-derived growth factor (PDGF), insulin, thrombin, and phorbol ester. The second MEK activator was identified as B-Raf. Activation of 93-95 kDa B-Raf was observed in column fi actions and B-Raf immunoprecipitates from cytosolic and particulate fractions after stimulation with serum or PDGF, but not insulin. c-Raf-1 from cytosol did not exhibit MEK activator activity; however, c-Raf-1 immunoprecipitates from the particulate fraction revealed MEK activator activity that was enhanced after stimulation with PDGF or phorbol ester, but not serum or insulin. Both c-Mos and c-MEKK, were present in NTH3T3 fibroblasts but did not show MEK activator activity. These data provide direct evidence that 93-95-kDa B-Rafisozymes and an unidentified 40-50-kDa MEK activator are major agonist-specific MEK activators in NTH3T3 fibroblasts.	UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NCI NIH HHS [CA39076] Funding Source: Medline; NIGMS NIH HHS [GM47332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1994, EMBO J, V7, P1610; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRADFORD MM, 1977, ANAL BIOCHEM, V72, P248; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EYCHENE A, 1992, ONCOGENE, V7, P1315; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FROEDIN M, 1994, J BIOL CHEM, V269, P6207; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAEFNER S, 1994, MOL CELL BIOL, V14, P6696; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HERZOG NK, 1989, ONCOGENE, V11, P1307; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REUTER CWM, 1995, IN PRESS METHODS ENZ; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6213; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEGER R, 1992, J BIOL CHEM, V267, P25628; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1990, ONCOGENE, V5, P345; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P133, DOI 10.1016/0304-419X(93)90002-T; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	96	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7644	7655		10.1074/jbc.270.13.7644	http://dx.doi.org/10.1074/jbc.270.13.7644			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706312	hybrid			2022-12-27	WOS:A1995QQ43100090
J	CHAN, PY; ARUFFO, A				CHAN, PY; ARUFFO, A			VLA-4 INTEGRIN MEDIATES LYMPHOCYTE MIGRATION ON THE INDUCIBLE ENDOTHELIAL-CELL LIGAND VCAM-1 AND THE EXTRACELLULAR-MATRIX LIGAND FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; NATURAL-KILLER-CELLS; LEUKOCYTE ADHESION DEFICIENCY; AMINO-ACID-SEQUENCE; T-CELL; TRANSENDOTHELIAL MIGRATION; ALPHA-4-BETA-1 INTEGRIN; BINDING-SITE; VASCULAR ENDOTHELIUM; PLASMA FIBRONECTIN	We herein tested the ability of lymphocytes to utilize the beta1 integrin VLA-4 to mediate cell migration when adhering to its cytokine-inducible endothelial cell ligand VCAM-1 or its extracellular matrix ligand fibronectin. We used an in vitro system consisting of purified VCAM-1/Fc fusion protein or fibronectin immobilized on porous polycarbonate membranes to quantitatively measure the migration efficiency of an Epstein-Barr virus-transformed B cell line (SLA) and T lymphoblasts derived from normal donors. We found that both SLA cells and T lymphoblasts migrated across membranes coated with VCAM-1/Fc or fibronectin in a site density-dependent manner. Above and below an optimal site density of VCAM-1/Fc or fibronectin, the migration efficiency decreased. A 6-20-fold higher number of lymphocytes migrated across membranes coated with VCAM-1/Fc than with fibronectin. The differential migration efficiency is consistent with a higher number of adherent lymphocytes and a higher avidity of adhesion for VCAM-1/Fc than for fibronectin when the ligands were immobilized on plastic, and is independent of the activation state of the cells. These results demonstrated a stringent regulation of migratory response by cell adhesion strength and a delicate balance between stationary and migratory behaviors of a cell on the adhesive substrates. Like the beta2 integrin LFA-1, VLA-4 may be a locomotive adhesion receptor which is involved in the transendothelial migration of lymphocytes and the infiltration of lymphocytes into lymphoid or peripheral tissues by binding to VCAM-1 and fibronectin.			CHAN, PY (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT CELLULAR INTERACT,3005 1ST AVE,SEATTLE,WA 98121, USA.							ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANICHINI A, 1990, INT J CANCER, V46, P508, DOI 10.1002/ijc.2910460330; ARENCIBIA I, 1989, EUR J IMMUNOL, V19, P929, DOI 10.1002/eji.1830190521; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BIRDSALL HH, 1992, J IMMUNOL, V148, P2717; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1990, BLOOD, V76, P965; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DAVIS JM, 1990, CELL IMMUNOL, V129, P67, DOI 10.1016/0008-8749(90)90187-V; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUBAND JL, 1991, J CELL SCI, V98, P517; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FELDER S, 1990, J CELL BIOL, V111, P2513, DOI 10.1083/jcb.111.6.2513; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HORVATH AR, 1990, J CELL SCI, V97, P307; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; IIGO Y, 1991, J IMMUNOL, V147, P4167; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; ISSEKUTZ TB, 1991, FASEB J, V5, pA1335; ISSEKUTZ TB, 1992, CURR OPIN IMMUNOL, V4, P287, DOI 10.1016/0952-7915(92)90078-S; ISSEKUTZ TB, 1991, CELL IMMUNOL, V138, P300, DOI 10.1016/0008-8749(91)90155-5; JONJIC N, 1992, J EXP MED, V176, P1165, DOI 10.1084/jem.176.4.1165; KAVANAUGH AF, 1991, J IMMUNOL, V146, P4149; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KOCH AE, 1991, LAB INVEST, V64, P313; KOOPMAN G, 1992, EUR J IMMUNOL, V22, P1851, DOI 10.1002/eji.1830220726; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; MOSER R, 1992, J IMMUNOL, V149, P1432; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MURRAY J, 1992, CELL MOTIL CYTOSKEL, V22, P211, DOI 10.1002/cm.970220308; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OHTSUKA A, 1992, CELL TISSUE RES, V269, P403, DOI 10.1007/BF00353895; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PELLETIER RP, 1992, J IMMUNOL, V149, P2473; PICKER LJ, 1992, CURR OPIN IMMUNOL, V4, P277, DOI 10.1016/0952-7915(92)90077-R; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; RICE GE, 1991, AM J PATHOL, V138, P385; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIOHARA T, 1991, J IMMUNOL, V146, P840; SOMERSALO K, 1992, J IMMUNOL, V149, P590; SOMERSALO K, 1991, EUR J IMMUNOL, V21, P35, DOI 10.1002/eji.1830210107; SWERLICK RA, 1992, J IMMUNOL, V149, P698; SZEKANECZ Z, 1992, J CELL SCI, V101, P885; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; VANDINTHERJANSSEN ACHM, 1991, J IMMUNOL, V147, P4207; VANEPPS DE, 1989, J IMMUNOL, V143, P3207; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YUAN Q, 1992, J BIOL CHEM, V267, P7352	91	79	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24655	24664						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693704				2022-12-27	WOS:A1993MG67300025
J	WATSON, N; WILLIAMS, KL; ALEXANDER, S				WATSON, N; WILLIAMS, KL; ALEXANDER, S			A DEVELOPMENTALLY-REGULATED GLYCOPROTEIN COMPLEX FROM DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; EXTRACELLULAR-MATRIX; SIZE POLYMORPHISMS; PROTEINS; GLYCOSYLATION; PHASE; PSA	The monoclonal antibody MUD50 recognizes an epitope on a family of developmentally regulated proteins in Dictyostelium discoideum (Alexander, S., Smith, E., Davis, L., Gooley, A., Por, S. B., Browne, L., and Williams, K. L. (1988) Differentiation 38, 82-90). This epitope is an O-linked oligosaccharide that requires the wild-type modB allele for expression. These glycoproteins are structurally diverse. Some are integral membrane proteins, while others are soluble and do not require detergent for solubilization. One of the soluble glycoproteins, PsB, is also recognized by the monoclonal antibody MUD102, which binds to the polypeptide backbone. The antibody recognizes a single 100-kDa band in Western analysis. In this report we demonstrate that the PsB molecule is part of a specific developmentally regulated multiprotein complex containing six different proteins. The complex is held together by both covalent and non-covalent bonds. Interestingly, only the PsB glycoprotein has the MUD50 O-linked oligosaccharide determinant. None of the proteins in the complex is N-glycosylated as assessed by sensitivity to peptide N-glycosidase F. Only one of the complex proteins is heavily phosphorylated. This work establishes the foundation for additional studies on the biosynthesis, processing, and assembly of the O-glycosylated PsB protein.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA; MACQUIRE UNIV, SCH BIOL SCI, SYDNEY, NSW 2109, AUSTRALIA	University of Missouri System; University of Missouri Columbia; Macquarie University								ALEXANDER S, 1988, DIFFERENTIATION, V38, P82, DOI 10.1111/j.1432-0436.1988.tb00201.x; Alexander S., 1992, P29; ALEXANDER S, 1984, J IMMUNOL, V133, P315; ALEXANDER S, 1989, METHOD ENZYMOL, V179, P505; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREEN EJ, 1987, DEVELOPMENT, V101, P313; CHAMPION A, 1991, J GEN MICROBIOL, V137, P2431, DOI 10.1099/00221287-137-10-2431; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FREEZE HH, 1992, CELL SURFACE CARBOHY, P285; GOOLEY AA, 1992, GENETICS, V130, P749; GOOLEY AA, 1992, THESIS MACQUARIE U S; GRANT WN, 1983, EMBO J, V2, P935, DOI 10.1002/j.1460-2075.1983.tb01524.x; GRANT WN, 1985, MOL CELL BIOL, V5, P2559, DOI 10.1128/MCB.5.10.2559; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HARLOW E, 1988, ANTIBODIES LABORATOR, P460; HART GW, 1988, TRENDS BIOCHEM SCI, V13, P380, DOI 10.1016/0968-0004(88)90179-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; KYHEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loomis W., 2012, DEV DICTYOSTELIUM DI; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; SMITH E, 1989, GENETICS, V122, P59; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEST CM, 1985, J BIOL CHEM, V260, P3803; WEST CM, 1990, DEV GENET, V11, P492, DOI 10.1002/dvg.1020110526; ZHOUCHOU AT, 1993, THESIS MACQUARIE U S	28	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22634	22641						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693675				2022-12-27	WOS:A1993MD34800067
J	BOBEK, LA; TSAI, H; BIESBROCK, AR; LEVINE, MJ				BOBEK, LA; TSAI, H; BIESBROCK, AR; LEVINE, MJ			MOLECULAR-CLONING, SEQUENCE, AND SPECIFICITY OF EXPRESSION OF THE GENE ENCODING THE LOW-MOLECULAR-WEIGHT HUMAN SALIVARY MUCIN (MUC7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBMANDIBULAR-SUBLINGUAL SALIVA; POLYMORPHIC EPITHELIAL MUCIN; INTESTINAL MUCIN; TERMINAL REGION; CDNA; GLYCOPROTEINS; PURIFICATION; PROTEIN; PEPTIDE; CHAIN	Previous biochemical studies have determined that human saliva contains high and low molecular weight mucin glycoproteins (MG1 and MG2, respectively) that are structurally distinct. In this study, we describe the isolation and characterization of overlapping cDNA clones which code for the MG2 protein core. DNA sequencing revealed a translated region of 1131 nucleotides encoding a protein of 377 amino acid residues with a molecular mass of 39 kDa. The first 20 N-terminal residues were very hydrophobic and probably comprise the MG2 leader peptide. The region encoding the secreted protein can be divided into three distinct domains; unique 5'- and 3'-translated regions containing 4 and 1 potential N-glycosylation sites, respectively, and a central region of six almost perfect tandem repeats of 23 amino acid residues with a high number of Thr and Ser. No sequence homology with any other human or animal mucins, and no significant homology to any other proteins was found. MG2 mRNA is about 2.5 kilobases long, and its expression appear to be species-, tissue-, and cell-specific. We propose to name this gene MUC7 in accordance with the mucin genes cloned to date named MUC1-MUC6.	SUNY Buffalo, SCH DENT MED, INST DENT RES, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	BOBEK, LA (corresponding author), SUNY Buffalo, SCH DENT MED, DEPT ORAL BIOL, 112 FOSTER HALL, BUFFALO, NY 14214 USA.				NIDCR NIH HHS [DE08240, DE07585] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008240, P01DE007585] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguirre A, 1989, Dysphagia, V4, P95, DOI 10.1007/BF02407152; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOBEK LA, 1991, BIOCHEM J, V278, P627, DOI 10.1042/bj2780627; Cohen R. E., 1989, HUMAN SALIVA CLIN CH, P101; COHEN RE, 1990, ARCH ORAL BIOL, V35, P347; COHEN RE, 1991, ARCH ORAL BIOL, V36, P127; CREPIN M, 1990, BIORHEOLOGY, V27, P471; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HEINRICH P, 1991, CURRENT PROTOCOLS S, V16, pCH7; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P1565; KINGSTON RE, 1991, CURRENT PROTOCOLS S, V14; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAN MS, 1990, J BIOL CHEM, V265, P15294; LEVINE MJ, 1987, J DENT RES, V66, P436, DOI 10.1177/00220345870660020901; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOOMIS RE, 1987, ARCH BIOCHEM BIOPHYS, V258, P452, DOI 10.1016/0003-9861(87)90366-3; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PRAKOBPHOL A, 1982, CARBOHYD RES, V108, P111, DOI 10.1016/S0008-6215(00)81896-0; RAMASUBBU N, 1991, BIOCHEM J, V280, P341, DOI 10.1042/bj2800341; REDDY MS, 1992, BIOCHEM J, V287, P639, DOI 10.1042/bj2870639; SAMBROOK J, 1989, MOL CLONING LAB MANU, pCH9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCANNAPIECO FA, 1993, CARIOLOGY 90, P85; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401	38	425	432	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20563	20569						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690757				2022-12-27	WOS:A1993LY01900092
J	COCIANCICH, S; GHAZI, A; HETRU, C; HOFFMANN, JA; LETELLIER, L				COCIANCICH, S; GHAZI, A; HETRU, C; HOFFMANN, JA; LETELLIER, L			INSECT DEFENSIN, AN INDUCIBLE ANTIBACTERIAL PEPTIDE, FORMS VOLTAGE-DEPENDENT CHANNELS IN MICROCOCCUS-LUTEUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; PERMEABLE CHANNELS; LIPID BILAYERS; ION CHANNELS; PATCH-CLAMP; MEMBRANE; EXPRESSION; LIPOSOMES; PRESSURE; IMMUNITY	Insect defensins are cationic, cysteine-rich peptides (approximately 4 kDa) that appear after bacterial challenge or injury in the hemolymph of insects belonging to a large variety of orders. These peptides possess anti-Gram-positive activity and participate in the potent antibacterial defense reactions of insects. Using recombinant insect defensin and the strain Micrococcus luteus as a test organism, we have investigated the mode of action of this peptide. We show that defensin disrupts the permeability barrier of the cytoplasmic membrane of M. luteus, resulting in a loss of cytoplasmic potassium, a partial depolarization of the inner membrane, a decrease in cytoplasmic ATP, and an inhibition of respiration. Potassium loss is inhibited below the order-disorder transition of the lipid hydrocarbon chains. It is also inhibited by divalent cations and by a decrease in the membrane potential below a threshold of 110 mV. We propose that these permeability changes reflect the formation of channels in the cytoplasmic membrane by defensin oligomers. This proposal is supported by patch-clamp experiments that show that insect defensins form channels in giant liposomes.	UNIV PARIS 11,CNRS,URA 1116,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	COCIANCICH, S (corresponding author), UNIV STRASBOURG 1,BIOL GEN LAB,CNRS,F-67070 STRASBOURG,FRANCE.		COCIANCICH, Stéphane/C-4267-2014	COCIANCICH, Stéphane/0000-0001-8601-3598				ASHE GB, 1971, BIOCHIM BIOPHYS ACTA, V233, P810, DOI 10.1016/0005-2736(71)90182-9; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; BARSUKOV LI, 1978, EUR J BIOCHEM, V90, P331, DOI 10.1111/j.1432-1033.1978.tb12609.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BUCHANAN RE, 1982, BERGEYS MANUAL DETER, P1004; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; DUZGUNES N, 1983, MEMBRANE FLUIDITY BI, V2, P187; GAO FH, 1991, APPL ENVIRON MICROB, V57, P2164, DOI 10.1128/AEM.57.8.2164-2170.1991; GHAZI A, 1981, FEBS LETT, V125, P197, DOI 10.1016/0014-5793(81)80717-X; GUIHARD G, 1993, J BIOL CHEM, V268, P17775; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KASHKET ER, 1981, J BACTERIOL, V146, P369, DOI 10.1128/JB.146.1.369-376.1981; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEHRER RI, 1983, INFECT IMMUN, V42, P10, DOI 10.1128/IAI.42.1.10-14.1983; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LETELLIER L, 1993, ALKALI CATION TRANSP, P359; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; REICHHART JM, 1992, INVERTEBR REPROD DEV, V21, P15, DOI 10.1080/07924259.1992.9672215; Rottenberg H, 1979, Methods Enzymol, V55, P547; URRUTIA R, 1989, FEBS LETT, V247, P17, DOI 10.1016/0014-5793(89)81230-X; VAARAM, 1992, MICROBIOL REV, V56, P395; WESTERHOFF HV, 1989, BIOCHIM BIOPHYS ACTA, V975, P361, DOI 10.1016/S0005-2728(89)80344-5	35	268	289	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19239	19245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690029				2022-12-27	WOS:A1993LW81900017
J	MCPHERSON, PS; CAMPBELL, KP				MCPHERSON, PS; CAMPBELL, KP			CHARACTERIZATION OF THE MAJOR BRAIN FORM OF THE RYANODINE RECEPTOR CA2+ RELEASE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CALCIUM-INDUCED RELEASE; SKELETAL-MUSCLE; H-3 RYANODINE; INOSITOL 1,4,5-TRISPHOSPHATE; CA-2+ RELEASE; RAT-BRAIN; DEPENDENT PHOSPHORYLATION; MALIGNANT HYPERTHERMIA; MICROSOMAL-MEMBRANES	At least three distinct ryanodine receptor genes appear to be expressed in mammalian brain. We have used biochemical and immunological methods to characterize the major form of ryanodine binding protein purified from brain. [H-3]Ryanodine binding to the purified brain receptor is stimulated by Ca2+, ATP, KCl, and phosphorylation and is inhibited by calmodulin, Mg2+, and ruthenium red. Immunoblot and immunoprecipitation analysis using a panel of monoclonal and polyclonal antibodies against skeletal and cardiac muscle ryanodine receptors, and two novel polyclonal antibodies against the brain ryanodine receptor, reveals that the major form of ryanodine receptor expressed in brain is immunologically similar to the cardiac ryanodine receptor, but is distinct from the skeletal muscle receptor. Digestion of cardiac and brain ryanodine receptors with trypsin or alpha-chymotrypsin generates similar proteolytic patterns as detected by immunoblot analysis or by autoradiography after labeling with a hydrophobic probe, suggesting that the two proteins are similar in both their large cytoplasmic and hydrophobic transmembrane domains. Taken together, these data indicate that the cardiac ryanodine receptor/Ca2+ release channel is the major form of ryanodine receptor expressed in brain, and that it likely functions in releasing Ca2+ from caffeine-sensitive intracellular Ca2+ stores in neurons by a mechanism of regulated Ca2+-induced Ca2+ release.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa	MCPHERSON, PS (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, PROGRAM NEUROSCI, IOWA CITY, IA 52242 USA.			Campbell, Kevin/0000-0003-2066-5889				ANDERSON K, 1989, J BIOL CHEM, V264, P1329; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BURGOYNE RD, 1991, TRENDS BIOCHEM SCI, V16, P319, DOI 10.1016/0968-0004(91)90131-E; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; KAWAI T, 1991, BRAIN RES, V540, P331, DOI 10.1016/0006-8993(91)90531-Y; KAWAI T, 1989, PFLUEGERS ARCH EUR J, V413, P473; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KNUDSON CM, 1990, J BIOL CHEM, V265, P2421; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PADUA RA, 1991, BRAIN RES, V542, P135, DOI 10.1016/0006-8993(91)91007-N; PADUA RA, 1992, J CHEM NEUROANAT, V5, P63, DOI 10.1016/0891-0618(92)90034-N; PALADE P, 1989, MOL PHARMACOL, V36, P673; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; SHARP AH, 1993, J NEUROSCI, V13, P3051; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THAYER SA, 1988, J NEUROSCI, V8, P4089; THAYER SA, 1988, MOL PHARMACOL, V34, P664; VERMA A, 1992, MOL BIOL CELL, V3, P621, DOI 10.1091/mbc.3.6.621; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; YOSHIDA A, 1992, J NEUROSCI, V12, P1094; ZIMANYI I, 1991, BRAIN RES, V561, P181, DOI 10.1016/0006-8993(91)91594-Q	55	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19785	19790						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690041				2022-12-27	WOS:A1993LW81900094
J	MARCILLA, A; RIVEROLEZCANO, OM; AGARWAL, A; ROBBINS, KC				MARCILLA, A; RIVEROLEZCANO, OM; AGARWAL, A; ROBBINS, KC			IDENTIFICATION OF THE MAJOR TYROSINE KINASE SUBSTRATE IN SIGNALING COMPLEXES FORMED AFTER ENGAGEMENT OF FC-GAMMA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; PROTEIN; CELLS; P72(SYK); ONCOGENE; CBL	We have recently identified the protein product of the c-cbl proto oncogene as an SH3 binding protein expressed in macrophages. To investigate the possibility that p120(c-cbl) is involved in signaling pathways initiated by cell surface receptors for IgG (Fc gamma R), lysates of HL60 cells were examined for tyrosine phosphorylation of p120(c-cbl) upon Fc gamma R engagement. Our findings demonstrate that p120(c-cbl) is tyrosine-phosphorylated upon Fc gamma R engagement and that this molecule represents the major tyrosine kinase substrate in this signaling pathway. Protein complexes containing p120(c-cbl), p72(syk), and p56(lyn) were observed either in resting or activated cells. In vitro studies showed that the direct association between p120(c-cbl) and p56(lyn) was mediated by the SH3 domain of p56(lyn).	NIDR, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Rivero-Lezcano, Octavio Miguel/J-9089-2015; marcilla, antonio/F-9996-2010	Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731; marcilla, antonio/0000-0003-0004-0531				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EISEMAN E, 1992, NATURE, V355, P78; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIHARA H, 1994, J BIOL CHEM, V269, P22427; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SONGYANG Z, CELL, V72, P767; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	23	129	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9115	9120		10.1074/jbc.270.16.9115	http://dx.doi.org/10.1074/jbc.270.16.9115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721825	hybrid			2022-12-27	WOS:A1995QU08900013
J	METZGER, D; ALI, S; BORNERT, JM; CHAMBON, P				METZGER, D; ALI, S; BORNERT, JM; CHAMBON, P			CHARACTERIZATION OF THE AMINO-TERMINAL TRANSCRIPTIONAL ACTIVATION FUNCTION OF THE HUMAN ESTROGEN-RECEPTOR IN ANIMAL AND YEAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MAMMALIAN-CELLS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTORS; TRANS-ACTIVATOR; DOMAINS; GAL4; REGION; TRANSACTIVATION; DROSOPHILA	We have previously reported that the transcriptional activation function AF-1, located in the A/B region of the human estrogen receptor, exhibits cell type and promoter context specificity in both animal cells and yeast. To further characterize AF-1, we have constructed a number of deletion mutants spanning the A/B region in the context of either the whole human estrogen receptor or the A/B region linked to the GAL4 DNA binding do main, and tested their transcriptional activity in chicken embryo fibroblasts and in yeast cells, two cell types in which AF-1 efficiently activates transcription on its own. Additionally, we utilized HeLa cells in which AF-1 is poorly active but can synergize with the transcriptional activation function AF-2 located in the hormone binding domain. We show that in animal cells the ''independent'' activity of AF-1 is embodied in a rather hydrophobic proline-rich 99-amino acid activating domain (amino acids 51-149), whereas amino acids 51-93 and 102-149 can independently synergize with AF-2. Interestingly, in yeast, three discrete activating domains (amino acids 1-62, 80-113, and 118-149) are almost as active on their own as the whole A/B region, indicating that multiple activating domains can operate independently in yeast. Our study also demonstrates that, within the context of the whole human estrogen receptor, the same AF-1 activating domains are ''induced'' by either estradiol or 4-hydroxytamoxifen.	UNIV STRASBOURG 1, COLL FRANCE,INST GENET & BIOL MOLEC & CELLULAIRE, CNRS,INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Metzger, Daniel/0000-0002-5555-046X; Ali, Simak/0000-0002-1320-0816				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER JA, 1988, NATURE, V332, P853; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GILL G, 1987, CELL, V51, P12; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAM J, 1992, FEBS LETT, V307, P81, DOI 10.1016/0014-5793(92)80906-W; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kastner P., 1994, Vitamin A in health and disease., P189; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Mangelsdorf David J., 1994, P319; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SEIPEL K, 1994, BIOL CHEM H-S, V375, P463, DOI 10.1515/bchm3.1994.375.7.463; SENTENAC A, 1990, ANNU REV BIOCHEM, V459, P711; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WHITE JH, 1988, COLD SPRING HARB SYM, V53, P819, DOI 10.1101/SQB.1988.053.01.093; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	77	203	203	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9535	9542		10.1074/jbc.270.16.9535	http://dx.doi.org/10.1074/jbc.270.16.9535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721882	hybrid			2022-12-27	WOS:A1995QU08900071
J	ZOLKIEWSKA, A; MOSS, J				ZOLKIEWSKA, A; MOSS, J			PROCESSING OF ADP-RIBOSYLATED INTEGRIN ALPHA-7 IN SKELETAL-MUSCLE MYOTUBES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; PROTEINS; GLYCOHYDROLASE; RECEPTOR; SURFACE; ANCHOR	Integrin alpha 7 is a major substrate in skeletal muscle cells for the cell surface, glycosylphosphatidylinositol-anchored, arginine-specific ADP-ribosyltransferase. Since ADP-ribosylarginine hydrolase, the enzyme responsible for cleavage of the ADP-ribosylarginine bond and a component with the transferase of a putative ADP-ribosylation cycle, is cytosolic, the processing of ADP-ribosylated integrin alpha 7 was investigated. Following incubation of differentiated mouse C2C12 myoblasts with [adenylate-P-32]NAD and analysis by SDS-polyacrylamide gel electrophoresis under reducing conditions, two [P-32]ADP-ribosylated forms of integrin alpha 7 were resolved, By pulse chase and purification of the radio labeled proteins on a laminin affinity column, it was demonstrated that a 105-kDa ADP-ribosylated form originated from a mono ADP-ribosylated 102-kDa form and represented integrin alpha 7 modified at more than one site, The additional site(s) of modification, utilized at higher NAD concentrations, were located in the 63-kDa N-terminal segment of integrin alpha 7. Both [P-32]ADP-ribosylated integrins were loosely associated with the cytoskeleton, bound to laminin affinity columns, and immunoprecipitated with antibodies to integrin beta 1. P-32 label was rapidly removed from [P-32]ADP-ribosylated integrin alpha 7 at either site of modification, a process inhibited by free ADP-ribose or p-nitrophenylthymidine-5'-monophosphate, an alternative substrate of 5'-nucleotide phosphodiesterase. The processed integrin alpha 7 was unavailable for subsequent ADP-ribosylation, although the amount of surface integrin alpha 7 remained constant, During the processing, no loss of label was observed from integrin alpha 7 radiolabeled with [C-14]NAD, containing C-14 in the nicotinamide proximal ribose, consistent with degradation of the ADP-ribose moiety by a cell surface 5'-nucleotide phosphodiesterase, Thus, cell surface ADP-ribosylation, in contrast to intracellular ADP-ribosylation, is not readily reversed by ADP-ribosylarginine hydrolase and seems to operate outside the postulated ADP-ribosylation cycle.			ZOLKIEWSKA, A (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,BLDG 10,RM 5N307,10 CTR RD,MSC 1434,BETHESDA,MD 20892, USA.							COLLO G, 1993, J BIOL CHEM, V268, P19019; FUKZAWA H, 1989, BIOCHIM BIOPHYS ACTA, V991, P272; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO R, 1994, CANCER METAST REV, V13, P25, DOI 10.1007/BF00690416; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1992, J BIOL CHEM, V267, P10481; MULLER HM, 1983, BIOCHEM J, V212, P459, DOI 10.1042/bj2120459; NAKABAYASHI T, 1993, J BIOCHEM-TOKYO, V99, P703; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROMANO C, 1987, J NEUROSCI, V7, P1300; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VANDERMARK H, 1991, J BIOL CHEM, V266, P23593; WILLIAMSON KC, 1990, ADP RIBOSYLATING TOX, P151; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1994, P NATL ACAD SCI USA, V138, P107	29	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9227	9233		10.1074/jbc.270.16.9227	http://dx.doi.org/10.1074/jbc.270.16.9227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721841	hybrid			2022-12-27	WOS:A1995QU08900029
J	MACLEOD, AR; SZYF, M				MACLEOD, AR; SZYF, M			EXPRESSION OF ANTISENSE TO DNA METHYLTRANSFERASE MESSENGER-RNA INDUCES DNA DEMETHYLATION AND INHIBITS TUMORIGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO METHYLATION; GENE-EXPRESSION; HUMAN NEOPLASIA; CELL-LINES; PATTERNS; GROWTH; HYPERMETHYLATION; CHROMOSOME-11; MUTATION; SEQUENCE	Many tumor cell lines overexpress DNA methyltransferase (MeTase) activity; however it is still unclear whether this increase in DNA MeTase activity plays a causal role in naturally occurring tumors and cell lines, whether it is critical for the maintenance of transformed phenotypes, and whether inhibition of the DNA MeTase in tumor cells can reverse transformation, To address these basic questions, we transfected a murine adrenocortical tumor cell line Y1 with a chimeric construct expressing 600 base pairs from the 5' of the DNA MeTase cDNA in the antisense orientation, The antisense transfectants show DNA demethylation, distinct morphological alterations, are inhibited in their ability to grow in an anchorage-independent manner, and exhibit decreased tumorigenicity in syngeneic mice. Ex vivo, cells expressing the antisense construct show increased serum requirements, decreased rate of growth, and induction of an apoptotic death program upon serum deprivation, 5-Azadeoxycytidine-treated cells exhibit a similar dose dependent reversal of the transformed phenotype, These results support the hypothesis that the DNA MeTase is actively involved in oncogenic transformation.	MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1993, CURR BIOL, V3, P384, DOI 10.1016/0960-9822(93)90209-7; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; ELDEIRY WA, 1990, P NATL ACAD SCI USA, V88, P3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PA, 1984, DNA METHYLATION BIOC, P165; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MAYSINGER D, 1993, NEUROCHEM INT, V23, P123, DOI 10.1016/0197-0186(93)90089-N; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1985, BIOCH BIOL DNA METHY, P239; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SZYF M, 1992, J BIOL CHEM, V267, P12831; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1989, P NATL ACAD SCI USA, V86, P6853, DOI 10.1073/pnas.86.18.6853; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; SZYF M, 1991, BIOCH CELL BIOL, V64, P764; TAMMAME M, 1983, MOL CELL BIOL, V3, P2287; WU JC, 1985, BIOCH BIOL DNA METHY, P119; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; WYLLIE AH, 1981, HISTOCHEM J, V13, P681, DOI 10.1007/BF01002719; YASUMURA Y, 1966, CANCER RES, V26, P529; YISRAELI J, 1985, DNA METHYLATION BIOC, P353	41	147	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8037	8043		10.1074/jbc.270.14.8037	http://dx.doi.org/10.1074/jbc.270.14.8037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713905	hybrid			2022-12-27	WOS:A1995QR52600041
J	SEOL, JH; BAEK, SH; KANG, MS; HA, DB; CHUNG, CH				SEOL, JH; BAEK, SH; KANG, MS; HA, DB; CHUNG, CH			DISTINCTIVE ROLES OF THE 2 ATP-BINDING SITES IN CLPA, THE ATPASE COMPONENT OF PROTEASE TI IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE; ACTIVATED ATPASE; MUTAGENESIS; CONTAINS; SUBUNITS; PROTEINS	ClpA is the ATPase component of the ATP dependent protease Ti (Clp) in Escherichia coli and contains two ATP-binding sites, A ClpA variant (referred to as ClpAT) carrying threonine in place of the 169th methionine has recently been shown to be highly soluble but indistinguishable from the wild type, 84-kDa ClpA in its ability to hydrolyze ATP and to support the casein-degrading activity of ClpP, Therefore, site-directed mutagenesis was performed to generate mutations in either of the two ATP-binding sites of ClpAT (i.e, to replace the Lys(220) or Lys(501) with Thr), ClpAT/K220T hydrolyzed ATP and supported the ClpP-mediated proteolysis 10-50% as well as ClpAT depending on ATP concentration, while ClpAT/K501T was unable to cleave ATP or to support the proteolysis. Without ATP, ClpAT and both of its mutant forms behaved as trimeric molecules as analyzed by gel filtration on a Sephacryl S-300 column, With 0.5 mM ATP, ClpAT and ClpAT/K501T became hexamers, but ClpAT/K220T remained trimeric, With 2 mM ATP, however, ClpAT/K220T also behaved as a hexamer, These results suggest that the first ATP-binding site of ClpA is responsible for hexamer formation, while the second is essential for ATP hydrolysis, When trimeric ClpAT/K220T was incubated with the same amount of hexameric ClpAT/K501T (i,e, at 0.5 mM ATP) and then subjected to gel filtration as above, a majority of ClpAT/K220T ran together with ClpAT/K501T as hexameric molecules. Furthermore, ClpAT/K501T in the mixture strongly inhibited the ability of ClpAT/K220T to cleave ATP and to support the ClpP-mediated proteolysis, Similar results were obtained in the presence of 2 mM ATP and also with the mixture with ClpAT, On the other hand, the ATPase activity of the mixture of ClpAT and ClpAT/R220T was significantly higher than the sum of that of each protein, particularly in the presence of 2 mM ATP, although its ability to support the proteolysis by ClpP remained un changed, These results suggest that a rapid exchange of the subunits, possibly as a trimeric unit, occurs between the ClpAT proteins in the presence of ATP and leads to the formation of mixed hexameric molecules.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MOLEC BIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, SRC CELL DIFFERENTIAT, SEOUL 151742, SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; SEOL JH, 1994, J BIOL CHEM, V269, P29468; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	22	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8087	8092		10.1074/jbc.270.14.8087	http://dx.doi.org/10.1074/jbc.270.14.8087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713911	hybrid			2022-12-27	WOS:A1995QR52600049
J	VOLCHUK, A; SARGEANT, R; SUMITANI, S; LIU, Z; HE, LJ; KLIP, A				VOLCHUK, A; SARGEANT, R; SUMITANI, S; LIU, Z; HE, LJ; KLIP, A			CELLUBREVIN IS A RESIDENT PROTEIN OF INSULIN-SENSITIVE GLUT4 GLUCOSE-TRANSPORTER VESICLES IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; PLASMA-MEMBRANE; SUBCELLULAR TRAFFICKING; TETANUS-TOXIN; VAMP FAMILY; COMPARTMENTS; EXPRESSION; TRANSLOCATION; LOCALIZATION; RECEPTORS	Insulin stimulates glucose transport in muscle and fat cells by inducing translocation of GLUT4 glucose transporters from a storage site to the cell surface. The mechanism of this translocation and the identity of the storage site are unknown, but it has been hypothesized that transporters recycle between an insulin-sensitive pool, endosomes, and the cell surface. Upon cell homogenization and fractionation, the storage site migrates with Light microsomes (LDM) separate from the plasma membrane fraction (PM). Cellubrevin is a recently identified endosomal protein that may be involved in the reexocytosis of recycling endosomes. Here we describe that cellubrevin is expressed in 3T3-L1 adipocytes and is more abundant in the LDM than in the PM. Cellubrevin was markedly induced during differentiation of 3T3-L1 fibroblasts into adipocytes, in parallel with GLUT4, and the development of insulin regulated traffic. In response to insulin, the cellubrevin content decreased in the LDM and increased in the PM, suggesting translocation akin to that of the GLUT4 glucose transporter. Vesicle-associated membrane protein 2 (VAMP-2)/synaptobrevin-II, a protein associated with regulated exocytosis in secretory cells, also redistributed in response to insulin. Both cellubrevin and VAMP-2 were susceptible to cleavage by tetanus toxin. Immunopurified GLUT4-containing vesicles contained cellubrevin and VAMP-2, and immunopurified cellubrevin-containing vesicles contained GLUT4 protein, but undiscernible amounts of VAMP-2. These observations suggest that cellubrevin and VAMP-2 are constituents of the insulin-regulated pathway of membrane traffic. These results are the first demonstration that cellubrevin is present in a regulated intracellular compartment. We hypothesize that cellubrevin and VAMP-2 may be present in different subsets of GLUT4-containing vesicles.	HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CORVERA S, 1989, J BIOL CHEM, V264, P10133; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GAISANO HY, 1994, J BIOL CHEM, V269, P19110; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LIENHARD GE, 1989, INT CONGR SER, V866, P313; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TANNER LI, 1987, J BIOL CHEM, V262, P8975; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139; WELLER U, 1989, EUR J BIOCHEM, V182, P649, DOI 10.1111/j.1432-1033.1989.tb14874.x; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	47	125	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8233	8240		10.1074/jbc.270.14.8233	http://dx.doi.org/10.1074/jbc.270.14.8233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713930	hybrid			2022-12-27	WOS:A1995QR52600069
J	MATSUBARA, E; FRANGIONE, B; GHISO, J				MATSUBARA, E; FRANGIONE, B; GHISO, J			CHARACTERIZATION OF APOLIPOPROTEIN J-ALZHEIMERS A-BETA INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MEMBRANE-ATTACK COMPLEX; CENTRAL-NERVOUS-SYSTEM; SULFATED GLYCOPROTEIN-2; CEREBROSPINAL-FLUID; MOLECULAR-CLONING; AMYLOID-BETA; GENE-EXPRESSION; SENILE PLAQUES; HUMAN HOMOLOG	The main component of Alzheimer's amyloid deposits, A beta, has been found also as a soluble (sA beta) normal constituent of biological fluids and cell culture supernatants. Whether or not sA beta is the immediate precursor of A beta, it is clear that peptides with the same amino acid sequence can have both fibrillar and non-fibrillar conformations. The interconversion mechanism from one form to another is presently under intensive investigation. We have previously described that (i) a synthetic peptide A beta(1-40) immobilized on affinity matrices was able to retrieve apolipoprotein J (apoJ) from plasma and cerebrospinal fluid; and (ii) the interaction of sA beta with apoJ occurs in vivo as demonstrated by the ability of anti-apoeT to co-precipitate sA beta from normal cerebro spinal fluid. We have characterized the binding between A beta(1-40) and apoJ and found that the interaction is saturable, specific, and reversible. The dissociation constant of 2 x 10(-9) IM is indicative of high affinity binding. The stoichiometry of the reaction is 1:1; apoJ has five times more affinity for fresh A beta(1-40) than for the aggregated peptide. Competitive inhibition studies carried out with apolipoprotein E (isoforms E2, E3, and E4), transthyretin, vitronectin, and alpha(1)-antichymotrypsin indicate that the complex apoJ . A beta(1-40) cannot be dissociated by any of these competitors at physiologic concentrations. The data strongly suggest that apoJ plays an important role as a carrier protein for sA beta.	NYU,MED CTR,DEPT PATHOL TH432,NEW YORK,NY 10016	New York University					NATIONAL INSTITUTE ON AGING [P01AG010491, R01AG005891, R35AG010953, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG10491, AG10953, AG05891] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CHOI NH, 1990, J IMMUNOL METHODS, V131, P159, DOI 10.1016/0022-1759(90)90186-Y; CHOI NH, 1989, MOL IMMUNOL, V26, P835; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; CORIA F, 1988, LAB INVEST, V58, P454; DANIK M, 1991, P NATL ACAD SCI USA, V88, P8577, DOI 10.1073/pnas.88.19.8577; DAY JR, 1990, MOL ENDOCRINOL, V4, P1995, DOI 10.1210/mend-4-12-1995; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; DUGID J, 1989, P NATL ACAD SCI USA, V86, P7260; EIKELENBOOM P, 1994, VIRCHOWS ARCH, V424, P421, DOI 10.1007/BF00190565; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; GALLO G, 1994, AM J PATHOL, V145, P526; GARDEN GA, 1991, J NEUROBIOL, V22, P590, DOI 10.1002/neu.480220605; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; ISHII T, 1984, ACTA NEUROPATHOL, V63, P296, DOI 10.1007/BF00687336; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KIRSZBAUM L, 1992, FEBS LETT, V297, P70, DOI 10.1016/0014-5793(92)80330-J; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; LADU MJ, 1994, J BIOL CHEM, V269, P23403; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAY PC, 1989, CAN J NEUROL SCI, V16, P473, DOI 10.1017/S0317167100029796; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MCGEER PL, 1992, BRAIN RES, V579, P337, DOI 10.1016/0006-8993(92)90071-G; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; OBRYAN MK, 1990, J CLIN INVEST, V85, P1477, DOI 10.1172/JCI114594; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PURRELLO M, 1991, GENOMICS, V10, P151, DOI 10.1016/0888-7543(91)90495-Z; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SLAWIN K, 1990, BIOCHEM BIOPH RES CO, V172, P160, DOI 10.1016/S0006-291X(05)80187-1; SNOW A, 1987, LAB INVEST, V57, P120; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SYLVESTER SR, 1991, BIOL REPROD, V45, P195, DOI 10.1095/biolreprod45.1.195; TOBE T, 1991, CYTOGENET CELL GENET, V57, P193, DOI 10.1159/000133144; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8; WISNIEWSKI T, 1993, ANN NEUROL, V34, P631, DOI 10.1002/ana.410340422; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; WISNIEWSKI T, 1994, ANN NEUROL, V35, P245, DOI 10.1002/ana.410350223; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825	55	179	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7563	7567		10.1074/jbc.270.13.7563	http://dx.doi.org/10.1074/jbc.270.13.7563			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706304	hybrid			2022-12-27	WOS:A1995QQ43100079
J	KOIVUNEN, E; GAY, DA; RUOSLAHTI, E				KOIVUNEN, E; GAY, DA; RUOSLAHTI, E			SELECTION OF PEPTIDES BINDING TO THE ALPHA-5-BETA-1 INTEGRIN FROM PHAGE DISPLAY LIBRARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; SITE-DIRECTED MUTAGENESIS; IIB-IIIA COMPLEX; FIBRONECTIN RECEPTOR; CELL-ADHESION; RGD PEPTIDE; SYNTHETIC PEPTIDE; RECOGNITION SITE; EPITOPE LIBRARY; ACID SEQUENCE	The alpha5beta1 integrin binds fibronectin through the integrin recognition sequence Arg-Gly-Asp (RGD). We have used a 6-amino acid peptide library expressed on filamentous phage to identify peptide ligands for alpha5beta1. We found that this integrin selectively binds RGD-containing peptides from the library. Of the 32 different sequences obtained, 28 had the RGD motif, 3 contained sequences related to RGD, and only 1 had a clearly different sequence. One of the RGD-containing phage encoded a potentially cyclic insert CRGDCL. The cyclic peptide GAC*RGDC*LGA (where * denotes cysteines forming a disulfide bond) was 10-fold more efficient than any of the linear RGD-containing hexapeptides in inhibiting the binding of RGD-expressing phage to alpha5beta1 or the attachment of alpha5beta1-expressing cells to fibronectin. This peptide also inhibited cell attachment mediated by the alpha(v)beta1, alpha(v)beta3, and alpha(v)beta5, integrins with about 10-fold higher efficiency than linear GRGDSP. One peptide containing an RGD-related sequence, NGRAHA, was also found to inhibit phage attachment and cell adhesion, especially adhesion mediated by the alpha(v)beta5 integrin. These results indicate that novel and high affinity ligands for integrins can be isolated from a random peptide library.	LA JOLLA CANC RES FDN,CTR CANC RES,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Koivunen, Erkki/0000-0002-6443-9595	NCI NIH HHS [CA42507, CA30199, CA28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, R35CA042507, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALEXANDER H, 1992, P NATL ACAD SCI USA, V89, P3352, DOI 10.1073/pnas.89.8.3352; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; AOTA S, 1991, J BIOL CHEM, V266, P15938; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DALTON SL, 1992, J BIOL CHEM, V267, P8186; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GURRATH M, 1992, EUR J BIOCHEM, V270, P911; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HUANG TF, 1987, J BIOL CHEM, V262, P16157; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMURA Y, 1992, BLOOD, V80, P1247; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SAIKI I, 1989, CANCER RES, V49, P3815; SAMANEN J, 1991, J MED CHEM, V34, P3114, DOI 10.1021/jm00114a022; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCHREINER C, 1991, CANCER RES, V51, P1738; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1987, VECTORS SURVEY MOL C, P61; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TSCHOPP JF, 1993, IN PRESS CORONARY AR; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	62	317	363	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20205	20210						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690752				2022-12-27	WOS:A1993LY01900045
J	WANG, D; HUBBARD, JM; KABAT, EA				WANG, D; HUBBARD, JM; KABAT, EA			MODELING STUDY OF ANTIBODY COMBINING SITES TO (ALPHA-1-6)DEXTRANS - PREDICTIONS OF THE CONFORMATIONAL CONTRIBUTION OF V(L)-CDR3 AND J-KAPPA SEGMENTS TO GROOVE-TYPE COMBINING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERVARIABLE REGIONS; MONOCLONAL-ANTIBODIES; LIGHT-CHAINS; REPERTOIRE; GENES; BINDING; HEAVY; ALPHA(1->6)DEXTRAN; COMPLEMENTARITY; SPECIFICITY	The shuffling of the V(kappa)-Ox1 light chain joined to J(kappa)4 or J(kappa)5 instead of J(kappa)2 reduced or abolished antigen binding of three groove-type anti-(alpha1-6)dextran monoclonal antibodies, raising questions as to the structural roles of J(kappa) in antibody combining sites. The J(kappa)4 light chain used contains Pro95A at the V(kappa)-Ox1-J(kappa)4 junction, as well as a Phe to Ile substitution at the beginning of this J(kappa)4 segment. To predict whether the defect in antigen binding is a consequence of the J(kappa) replacement, the Pro insertion or the Phe to Ile substitution, model-building studies were performed. As shown by the surface representation of antibody combining sites, the models with length variation in the V(L)-CDR3 loop by only 1 residue altered the shape of the combining site dramatically; whereas those with replacement of J. or having amino acid substitutions in V(L)-CDR3 affect the combining site less extensively. A distinct loop configuration of V(L)-CDR3 appears in models having either a Pro, Gly, or Ala insertion at position 95A. These results indicate that the length of V(L)-CDR3 is crucial for its loop conformation and may, therefore, have played a major role in abolishing dextran binding activity of the J(kappa)4 variants. The potential of V(kappa)-Ox1 genes in generating conformational diversity in the loop of V(L)-CDR3 and its influence in forming different combining sites are discussed.	COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10032 USA; SLOAN KETTERING INST CANC RES, NEW YORK, NY 10021 USA	Columbia University; Columbia University; Memorial Sloan Kettering Cancer Center	WANG, D (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA.				NCI NIH HHS [CA13696] Funding Source: Medline; NIAID NIH HHS [3RO1AI-127568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKOLKAR PN, 1987, J IMMUNOL, V139, P3911; AKOLKAR PN, 1987, J IMMUNOL, V138, P4472; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BORDEN P, 1987, P NATL ACAD SCI USA, V84, P2440, DOI 10.1073/pnas.84.8.2440; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CISAR J, 1975, J EXP MED, V142, P435, DOI 10.1084/jem.142.2.435; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; FINE R M, 1986, Proteins Structure Function and Genetics, V1, P342, DOI 10.1002/prot.340010408; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; HARTMAN AB, 1988, J IMMUNOL, V141, P932; JEANES A, 1986, MOL IMMUNOL, V23, P999, DOI 10.1016/0161-5890(86)90131-8; KAARTINEN M, 1988, EUR J IMMUNOL, V18, P1095, DOI 10.1002/eji.1830180719; KABAT EA, 1971, ANN NY ACAD SCI, V190, P382, DOI 10.1111/j.1749-6632.1971.tb13550.x; KABAT EA, 1992, SEQUENCES PROTEINS I, P165; KABAT EA, 1990, PHYS CHEM BIOL, V34, P107; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; MILSTEIN C, 1992, EUR J IMMUNOL, V22, P1627, DOI 10.1002/eji.1830220642; NASHED EM, 1990, J BIOL CHEM, V265, P20699; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; PADLAN EA, 1991, METHOD ENZYMOL, V203, P3; PADLAN EA, 1988, P NATL ACAD SCI USA, V85, P6885, DOI 10.1073/pnas.85.18.6885; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; WALLICK SC, 1989, J IMMUNOL, V142, P1235; WANG D, 1991, MOL IMMUNOL, V28, P1387, DOI 10.1016/0161-5890(91)90041-H; WANG DN, 1990, J IMMUNOL, V145, P3002; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20584	20589						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690758				2022-12-27	WOS:A1993LY01900095
J	SPERANZA, MJ; BAGLEY, AC; LYNCH, RE				SPERANZA, MJ; BAGLEY, AC; LYNCH, RE			CELLS ENRICHED FOR CATALASE ARE SENSITIZED TO THE TOXICITIES OF BLEOMYCIN, ADRIAMYCIN, AND PARAQUAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; ACTIVATED BLEOMYCIN; ESCHERICHIA-COLI; OXYGEN; IRON; DRUG; EXPRESSION; ANALOGS; COMPLEX; ASSAY	L cells were enriched about 100-fold for catalase by the transcription of the transfected cDNA for human catalase. In spite of substantial enrichment for catalase, the transfected cells (LFN7C/B3) were not resistant to the cytotoxicity of a variety of agents which reduce dioxygen, including paraquat, menadione, adriamycin, phenazine methosulfate, and bleomycin. Instead, they were more sensitive to paraquat, bleomycin, and adriamycin than the untransfected cells from which they derived. Desferrioxamine afforded the cells enriched for catalase modest protection from the toxicities of bleomycin, paraquat, or adriamycin, suggesting that enrichment for iron as a consequence of the increased cellular content of catalase accounted for some of the increased sensitivities. The increased sensitivity of the LFN7C/B3 cells to bleomycin and paraquat was also attributed to the ability of catalase in cells to prevent the drug-induced consumption of O2; by capturing H2O2 before it can escape the cell and converting it to O2, catalase can maintain the concentration of O2 either for repeated rounds of chemical reduction or for direct interaction with the toxin. As predicted by this formulation, the toxicities of paraquat and of bleomycin were increased in an atmosphere of 40% dioxygen in comparison with an atmosphere of 20% dioxygen.	VET ADM MED CTR, RES SERV, 500 FOOTHILL DR, SALT LAKE CITY, UT 84148 USA; UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah								BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BEERS RF, 1952, J BIOL CHEM, V195, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1982, J BIOL CHEM, V257, P3372; BURGER RM, 1979, J BIOL CHEM, V254, P906; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CARMAGNOL F, 1983, BIOCHIM BIOPHYS ACTA, V759, P49, DOI 10.1016/0304-4165(83)90188-5; CLARE DA, 1984, ANAL BIOCHEM, V140, P532, DOI 10.1016/0003-2697(84)90204-5; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DHAUNSI GS, 1992, J BIOL CHEM, V267, P6870; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORY EM, 1974, ANAL BIOCHEM, V58, P57, DOI 10.1016/0003-2697(74)90440-0; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P237, DOI 10.1021/bi00568a037; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; ROOS DS, 1987, P NATL ACAD SCI USA, V84, P4860, DOI 10.1073/pnas.84.14.4860; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WANDERS RJA, 1992, BIOCHIM BIOPHYS ACTA, V1115, P259, DOI 10.1016/0304-4165(92)90063-Z	28	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19039	19043						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689565				2022-12-27	WOS:A1993LV65900099
J	GARINGO, AD; SUHASINI, M; ANDREWS, NC; PILZ, RB				GARINGO, AD; SUHASINI, M; ANDREWS, NC; PILZ, RB			CAMP-DEPENDENT PROTEIN-KINASE IS NECESSARY FOR INCREASED NF-E2.DNA COMPLEX-FORMATION DURING ERYTHROLEUKEMIA CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; ALPHA-GLOBIN GENE; PORPHOBILINOGEN DEAMINASE GENE; ERYTHROID-SPECIFIC GENE; DOMINANT CONTROL REGION; LEUCINE ZIPPER PROTEIN; DNA-BINDING PROTEINS; LOCUS-CONTROL REGION; REGULATORY ELEMENT; NUCLEAR FACTOR	When murine erythroleukemia (MEL) cells are induced to differentiate by hexamethylene bisacetamide (HMBA), erythroid-specific genes are transcriptionally activated; however, transcriptional activation of these genes is severely impaired in cAMP dependent protein kinase (protein kinase A)-deficient MEL cells, The transcription factor NF-EB, composed of a 45-kDa (p45) and an 18-kDa (p18) subunit, is essential for enhancer activity of the globin locus control regions (LCRs), DNA binding of NF-E2 and alpha-globin LCR enhancer activity was significantly less in HMBA-treated protein kinase A-deficient cells compared to cells containing normal protein kinase A activity; DNA binding of several other transcription factors was the same in both cell types, In parental cells, HMBA treatment and/or prolonged activation of protein kinase A increased the amount of NF-E2 . DNA complexes without change in DNA binding affinity; the expression of p45 and p18 was the same under all conditions, p45 and p18 were phosphorylated by protein kinase A in vitro, but the phosphorylation did not affect NF-E2 . DNA complexes, suggesting that protein kinase A regulates NF-E2 . DNA complex formation indirectly, e,g, by altering expression of a regulatory factor(s), Thus, protein kinase A appears to be necessary for increased NF-E2 . DNA complex formation during differentiation of MEL cells and may influence erythroid-specific gene expression through this mechanism.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	University of California System; University of California San Diego; Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Andrews, Nancy/0000-0003-0243-4462	NATIONAL CANCER INSTITUTE [K08CA001548] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA01548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDRIDGE MG, 1992, BIOTECHNIQUES, V12, P848; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GANGULY S, 1985, J BIOL CHEM, V260, P2167; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PILZ RB, 1993, J BIOL CHEM, V268, P20252; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHARPE JA, 1993, P NATL ACAD SCI USA, V90, P11262, DOI 10.1073/pnas.90.23.11262; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TUGORES A, 1994, J BIOL CHEM, V269, P30789; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WHITELAW E, 1989, MOL CELL BIOL, V9, P241, DOI 10.1128/MCB.9.1.241; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	61	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9169	9177		10.1074/jbc.270.16.9169	http://dx.doi.org/10.1074/jbc.270.16.9169			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721832	hybrid			2022-12-27	WOS:A1995QU08900020
J	CHAMPAGNE, DE; NUSSENZVEIG, RH; RIBEIRO, JMC				CHAMPAGNE, DE; NUSSENZVEIG, RH; RIBEIRO, JMC			PURIFICATION, PARTIAL CHARACTERIZATION, AND CLONING OF NITRIC OXIDE-CARRYING HEME-PROTEINS (NITROPHORINS) FROM SALIVARY-GLANDS OF THE BLOODSUCKING INSECT RHODNIUS-PROLIXUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEMOGLOBIN	Four nitric oxide (NO) carrying proteins have been isolated from salivary glands of the blood-sucking insect Rhodnius prolixus. These have been given the collective name ''nitrophorins,'' and individual proteins are designated NP1-NP4 in order of their relative abundance in the glands. All four reversibly bind NO; spectral shifts associated with NO binding indicate the interaction of NO with an Fe(III) heme. Physical properties, amino acid composition, and amino-terminal sequences of the nitrophorins are reported. The most abundant nitrophorin was cloned, and its sequence was determined.	UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721	University of Arizona	CHAMPAGNE, DE (corresponding author), UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721, USA.			Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018694, R29AI035591, R01AI035591, R37AI018694] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35591, AI-18694] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTOINE M, 1987, GENE, V56, P41, DOI 10.1016/0378-1119(87)90156-9; Antonini E., 1971, FRONTIERS BIOL, V21; CHAMPAGNE DE, UNPUB; Dickerson R.E., 1983, HEMOGLOBIN; GARLICK RL, 1982, J BIOL CHEM, V257, P9005; IMAMURA T, 1972, J BIOL CHEM, V247, P2785; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; RIBEIRO JMC, 1990, BRIT J PHARMACOL, V101, P932, DOI 10.1111/j.1476-5381.1990.tb14183.x; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; RIGGS AF, 1991, AM ZOOL, V31, P535; RUNNEGAR B, 1984, J MOL EVOL, V2, P33; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUZUKI T, 1986, J BIOL CHEM, V261, P9257; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; VINOGRADOV SN, 1985, COMP BIOCHEM PHYS B, V82, P1, DOI 10.1016/0305-0491(85)90120-8; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	18	146	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8691	8695		10.1074/jbc.270.15.8691	http://dx.doi.org/10.1074/jbc.270.15.8691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721773	hybrid			2022-12-27	WOS:A1995QT44800051
J	MANJI, SS; ZHOU, H; FINDLAY, DM; MARTIN, TJ; NG, KW				MANJI, SS; ZHOU, H; FINDLAY, DM; MARTIN, TJ; NG, KW			TUMOR-NECROSIS-FACTOR-ALPHA FACILITATES NUCLEAR ACTIONS OF RETINOIC ACID TO REGULATE EXPRESSION OF THE ALKALINE-PHOSPHATASE GENE IN PREOSTEOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CELLS-INVITRO; BONE-RESORPTION; RAT; DIFFERENTIATION; INTERLEUKIN-1; PROLIFERATION; OSTEOBLASTS; MECHANISMS; INTERFERON	This study examines the molecular mechanisms of interaction between tumor necrosis factor alpha (TNF alpha) and retinoic acid on the expression of the alkaline phosphatase gene by rat clonal preosteoblastic cells. In this cell line, alkaline phosphatase mRNA was not constitutively expressed but was progressively induced by treatment with 1 mu M retinoic acid, detectable by 6 h. Combining retinoic acid with 0.6 nM TNF alpha resulted in alkaline phosphatase mRNA appearing by 2 h, as well as enhanced expression above that observed with retinoic acid alone at 6, 12, and 24 h, Nuclear run-on analysis showed constitutive transcription of the alkaline phosphatase gene in control and TNF alpha-treated cells, At 4 h, retinoic acid, alone or combined with TNF alpha, increased alkaline phosphatase gene transcriptional rate by 2-fold. However, at 24 h, while no retinoic acid effect was retained, retinoic acid plus TNF alpha resulted in a 5-fold increase in alkaline phosphatase transcriptional rate. Examination of the distribution of nuclear alkaline phosphatase mRNA demonstrated that pre-spliced precursor mRNA was localized to the nuclear matrix in control and all treatment groups, Retinoic acid caused a time-dependent accumulation of mature, spliced alkaline phosphatase mRNA located in the non-matrix and cytoplasmic fractions, implying a post-transcriptional action of retinoic acid in nuclear processing and nucleocytoplasmic transport, Adding TNF alpha with retinoic acid greatly enhanced this effect, which was observed after 4 h, prior to any detectable interaction between TNF alpha and retinoic acid on gene transcription, In sharp contrast, only a negligible mount of nuclear processing occurred in control and TNF alpha-treated cells, This study reveals distinct interactions between TNF alpha and retinoic acid at post transcriptional as well as transcriptional levels to regulate expression of the alkaline phosphatase gene in preosteoblasts.	UNIV MELBOURNE, ST VINCENTS HOSP, DEPT MED, FITZROY, VIC 3065, AUSTRALIA	St Vincent's Hospital Melbourne; University of Melbourne				Zhou, Hong/0000-0001-5899-9660				AGGARWAL BB, 1992, TUMOR NECROSIS FACTO; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Favaloro J, 1980, Methods Enzymol, V65, P718; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GOWEN M, 1988, ARTHRITIS RHEUM, V31, P1500, DOI 10.1002/art.1780311206; GREEN AR, 1989, LANCET, V1, P705; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; JAATTELA M, 1991, LAB INVEST, V64, P724; JARROUS N, 1994, J BIOL CHEM, V269, P23141; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; MUNDY GR, 1993, PHYSL PHARM BONE, P185; NG KW, 1988, J BONE MINER RES, V3, P53; NG KW, 1989, J MOL ENDOCRINOL, V3, P57, DOI 10.1677/jme.0.0030057; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Sambrook J, 1989, MOL CLONING LABORATO; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; THOMSON BM, 1987, J IMMUNOL, V138, P775; TOH Y, 1989, EUR J BIOCHEM, V182, P231, DOI 10.1111/j.1432-1033.1989.tb14822.x; TRINCHIERI G, 1987, CANCER RES, V47, P2236; TRINCHIERI G, 1987, BLOOD, V69, P1218; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHOU H, 1993, J CELL PHYSIOL, V155, P112, DOI 10.1002/jcp.1041550115; ZHOU H, 1991, J BONE MINER RES, V6, P767; ZHOU H, 1994, J BIOL CHEM, V269, P22433	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8958	8962		10.1074/jbc.270.15.8958	http://dx.doi.org/10.1074/jbc.270.15.8958			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721805	hybrid			2022-12-27	WOS:A1995QT44800084
J	BOSE, S; SEETHARAM, S; SEETHARAM, B				BOSE, S; SEETHARAM, S; SEETHARAM, B			MEMBRANE EXPRESSION AND INTERACTIONS OF HUMAN TRANSCOBALAMIN-II RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC FACTOR-COBALAMIN; HUMAN-PLACENTA; RAT-KIDNEY; BINDING; CELLS; PROTEINS; LIVER; PURIFICATION	Antiserum raised to purified 62-kDa human placental transcobalamin II receptor (TC II-R) has been used to study its synthesis and membrane expression. The anti-serum immunoprecipitated a 45-kDa protein from the cell-free translation using human kidney mRNA and recognized a single 124-kDa band on immunoblotting of placental and other human tissue membranes, and quantitation of the blots revealed high levels of TC II-R expression in the human kidney followed by placenta, intestine, and liver. Triton X-100 extraction of placental membranes resulted in the complete (100%) solubilization of the receptor, and immunoblotting of the Triton X-100-soluble fraction revealed a single band of 62 kDa. Lipid extraction of placental membranes with a mixture of chloroform:methanol (2:1) followed by immunoblotting revealed a single band of molecular mass 62 kDa. The molecular mass of the pure Triton X-100-bound receptor increased on SDS-polyacrylamide gel electrophoresis from 62 to 124 kDa upon its insertion in liposomes prepared using egg phosphatidylcholine and cholesterol. Chemical cross-linking of native membrane- or lipid vesicle-bound TC II-R or detergent-soluble extracts of the membrane with I-125-TC II-cobalamin revealed that both the 124- and 62-kDa forms of the receptor were active in ligand binding. Based on these results we suggest that TC II-R is synthesized as a single polypeptide of 45 kDa, and following its maturation (involving N- and O-glycosylation) the 62-kDa mature receptor is expressed in plasma membranes as a noncovalent dimer of 124 kDa. The dimerization of TC II-R in the plasma membranes is due to its interactions with annular lipids.	MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; VET ADM MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				, Santanu/0000-0002-5501-3293	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK26638] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen R H, 1975, Prog Hematol, V9, P57; Bradford MM, 1976, ANAL BIOCHEM, V112, P195; BURNETTE WN, 1981, ANAL BIOCHEM, V7, P195; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRYDEN LP, 1966, J NUTR, V90, P382, DOI 10.1093/jn/90.4.382; FIDLERNAGY C, 1975, BRIT J HAEMATOL, V31, P311; FRIEDMAN PA, 1977, J CLIN INVEST, V59, P51, DOI 10.1172/JCI108621; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; GROSSOWICZ N, 1970, AM J CLIN NUTR, V23, P127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P21, DOI 10.1016/0167-4781(93)90264-E; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LOW MG, 1980, BIOCHEMISTRY-US, V19, P3913, DOI 10.1021/bi00558a004; NEXO E, 1980, BIOCHIM BIOPHYS ACTA, V628, P190, DOI 10.1016/0304-4165(80)90366-9; OKUDA K, 1962, NATURE, V195, P292, DOI 10.1038/195292a0; OKUDA K, 1962, J NUTR, V77, P131, DOI 10.1093/jn/77.2.131; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; QUADROS EV, 1994, ARCH BIOCHEM BIOPHYS, V308, P192, DOI 10.1006/abbi.1994.1027; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1991, BIOCHEM BIOPH RES CO, V179, P543, DOI 10.1016/0006-291X(91)91405-2; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCOTT JSD, 1984, CLIN SCI, V67, P299, DOI 10.1042/cs0670299; SCOTT JSD, 1985, CLIN SCI, V68, P357, DOI 10.1042/cs0680357; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM S, 1991, BIOCHEM BIOPH RES CO, V177, P751, DOI 10.1016/0006-291X(91)91852-4; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; YAMADA S, 1991, KIDNEY INT, V19, P289; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	30	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8152	8157		10.1074/jbc.270.14.8152	http://dx.doi.org/10.1074/jbc.270.14.8152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713919	hybrid			2022-12-27	WOS:A1995QR52600058
J	CHATHAM, JC; FORDER, JR; GLICKSON, JD; CHANCE, EM				CHATHAM, JC; FORDER, JR; GLICKSON, JD; CHANCE, EM			CALCULATION OF ABSOLUTE METABOLIC FLUX AND THE ELUCIDATION OF THE PATHWAYS OF GLUTAMATE LABELING IN PERFUSED RAT-HEART BY C-13 NMR-SPECTROSCOPY AND NONLINEAR LEAST-SQUARES ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID-CYCLE; NUCLEAR-MAGNETIC-RESONANCE; NADP MALATE DEHYDROGENASE; GLUCOSE-METABOLISM; PYRUVATE CARBOXYLATION; BRAIN INVIVO; CARBON FLUX; MITOCHONDRIAL; MUSCLE; MYOCARDIUM	Absolute metabolic fluxes in isolated perfused hearts have been determined by a nonlinear least squares analysis of glutamate labeling kinetics from [1-C-13]glucose, [4-C-13]beta-hydroxybutyrate, or [2-C-13]acetate using C-13 NMR spectroscopy. With glucose as substrate, the malate-aspartate shuttle flux was too slow to account for the reducing equivalents generated by glycolysis and to predict the observed oxygen consumption rate. For acetate and beta-hydroxybutyrate, the malate-aspartate shuttle had to be reversed for the network to agree with the observed oxygen consumption and glutamate labeling. Thus, an additional redox shuttle was required to reoxidize the NADH produced by cytoplasmic malate dehydrogenase. Using this model there was good agreement between the experimentally determined oxygen consumption and glutamate labeling and the calculated values of these parameters from the model for all substrates. The contribution of exogenous substrate to the overall tricarboxylic acid (TCA) cycle flux, 89.6 +/- 6.5% (mean +/- S.D.) as measured in the tissue extracts compared well with 91.4 +/- 4.2% calculated by the model. The ratio of TCA cycle flux to oxygen consumption for acetate, was 2.2 +/- 0.1, indicating that NADH production is principally accounted for by TCA cycle flux. For glucose or beta-hydroxybutyrate, this ratio was 2.9 +/- 0.2, consistent with the existence of other NADH producing reactions (e.g. glycolysis, beta-hydroxybutyrate oxidation).	JOHNS HOPKINS UNIV, SCH MED, DEPT RADIOL & RADIOL SCI, DIV NMR RES, BALTIMORE, MD 21205 USA; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Johns Hopkins University; University of London; University College London			Glickson, Jerry/AAR-7116-2021		NATIONAL CANCER INSTITUTE [R01CA051950, R01CA051935] Funding Source: NIH RePORTER; NCI NIH HHS [CA51950, CA51935] Funding Source: Medline; NHLBI NIH HHS [HL30579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY IA, 1981, FEBS LETT, V123, P315, DOI 10.1016/0014-5793(81)80317-1; BARKER PB, 1990, 9TH ANN SCI M NEW YO; BECKMANN N, 1991, BIOCHEMISTRY-US, V30, P6362, DOI 10.1021/bi00240a002; Bergmeyer H.U., 1985, METHODS ENZYMATIC AN; BERS DM, 1991, EXCITATION CONTRACTI; BRDICZKA D, 1971, EUR J BIOCHEM, V19, P546, DOI 10.1111/j.1432-1033.1971.tb01347.x; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CHANCKO VP, 1993, AM J PHYSIOL, V264, pC755; CHATHAM JC, 1992, BIOCHIM BIOPHYS ACTA, V1138, P1, DOI 10.1016/0925-4439(92)90143-B; CHATHAM JC, 1990, J MOL CELL CARDIOL, V22, P1187, DOI 10.1016/0022-2828(90)90082-D; CHATHAM JC, 1993, J MOL CELL CARDIOL, V25, P1203, DOI 10.1006/jmcc.1993.1133; CHATHAM JC, 1994, J MOL CELL CARDIOL, V26, pR176; COHEN DM, 1994, COMPUT BIOMED RES, V27, P130, DOI 10.1006/cbmr.1994.1013; COHEN DM, 1994, AM J PHYSIOL, V266, pE341, DOI 10.1152/ajpendo.1994.266.3.E341; DAHLEN JV, 1968, ARCH BIOCHEM BIOPHYS, V127, P207, DOI 10.1016/0003-9861(68)90218-X; DAVIS EJ, 1980, EUR J BIOCHEM, V110, P255, DOI 10.1111/j.1432-1033.1980.tb04863.x; DENHOLLANDER JA, 1981, P NATL ACAD SCI-BIOL, V78, P2693; DICKINSON JR, 1983, P NATL ACAD SCI-BIOL, V80, P5847, DOI 10.1073/pnas.80.19.5847; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; HOEKENGA DE, 1988, CIRC RES, V62, P1065, DOI 10.1161/01.RES.62.6.1065; ISAACS GH, 1969, BIOCHIM BIOPHYS ACTA, V177, P196, DOI 10.1016/0304-4165(69)90128-7; Jans A W, 1989, NMR Biomed, V1, P171, DOI 10.1002/nbm.1940010404; JUE T, 1989, P NATL ACAD SCI USA, V86, P4489, DOI 10.1073/pnas.86.12.4489; KUCHEL PW, 1990, BIOMED BIOCHIM ACTA, V49, P757; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LYON RC, 1988, CANCER RES, V48, P870; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1990, BIOCHEMISTRY-US, V29, P6756, DOI 10.1021/bi00481a002; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MOWBRAY J, 1973, EUR J BIOCHEM, V36, P362, DOI 10.1111/j.1432-1033.1973.tb02920.x; NAGEL WO, 1980, J BIOL CHEM, V255, P3849; NEWSHOLME EA, 1978, BIOCHEM J, V176, P623, DOI 10.1042/bj1760623; NOLTE J, 1972, BIOCHIM BIOPHYS ACTA, V284, P497, DOI 10.1016/0005-2744(72)90148-9; NUUTINEN EM, 1981, BIOCHEM J, V194, P867, DOI 10.1042/bj1940867; PEUHKURINEN KJ, 1982, BIOCHEM J, V202, P67, DOI 10.1042/bj2020067; PEUHKURINEN KJ, 1982, BIOCHEM J, V208, P577, DOI 10.1042/bj2080577; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; PEUHKURINEN KJ, 1983, AM J PHYSIOL, V244, pH281, DOI 10.1152/ajpheart.1983.244.2.H281; PISRARENKO OI, 1986, BIOCHIM BIOPHYS ACTA, V885, P154; REO NV, 1984, J BIOL CHEM, V259, P3664; ROBITAILLE PML, 1993, J BIOL CHEM, V268, P26296; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; SAFER B, 1971, J MOL CELL CARDIOL, V2, P111, DOI 10.1016/0022-2828(71)90065-4; TAKALA T, 1980, BIOCHEM J, V192, P285, DOI 10.1042/bj1920285; WEISS RG, 1989, P NATL ACAD SCI USA, V86, P6426, DOI 10.1073/pnas.86.16.6426; WEISS RG, 1992, CIRC RES, V70, P392, DOI 10.1161/01.RES.70.2.392; [No title captured]	48	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7999	8008		10.1074/jbc.270.14.7999	http://dx.doi.org/10.1074/jbc.270.14.7999			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713900	hybrid			2022-12-27	WOS:A1995QR52600036
J	FRASER, IDC; MARSTON, SB				FRASER, IDC; MARSTON, SB			IN-VITRO MOTILITY ANALYSIS OF ACTIN-TROPOMYOSIN REGULATION BY TROPONIN AND CALCIUM - THE THIN FILAMENT IS SWITCHED AS A SINGLE COOPERATIVE UNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; SKELETAL-MUSCLE; MYOSIN SUBFRAGMENT-1; BINDING; MOVEMENT; COMPLEX; CONTRACTION; INVITRO; CA-2+	In striated muscles, contractility is controlled by Ca2+ binding to the regulatory protein complex troponin, which is a component of the thin filaments. Troponin is an allosteric inhibitor acting on tropomyosin to switch the thin filament between ''on'' and ''off'' states. We have used an in vitro motility assay to examine troponin regulation of individual actin-tropomysin filaments moving over immobilized skeletal muscle heavy meromyosin. The most striking observation is that the actin-tropomyosin filament appears to be regulated as a single unit. At pCa 9.0, addition of up to 4 nM troponin causes the proportion of filaments motile to decrease from >85% to 20% with no dissociation of the filaments from the heavy meromyosin surface or change in velocity. Increasing Ca2+ concentration causes the filaments to be switched back on the half-maximal increase in the proportion of filaments motile at pCa 5.8-6.0 and a modest increase in filament velocity. This is an ''all or none'' process in which an entire filament, up to 15 mu M long, switches rapidly as a single cooperative unit. Thus, the effect of Ca2+ upon the thin filament is to recruit motile filaments.	NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND	Imperial College London			Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907				BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BRENNER B, 1986, BASIC RES CARDIOL, V81, P54, DOI 10.1007/BF01907427; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; BRENNER B, 1986, P NATL ACAD SCI USA, V83, P3542, DOI 10.1073/pnas.83.10.3542; BRENNER B, 1980, BASIC RES CARDIOL, V75, P40, DOI 10.1007/BF02001392; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; EBASHI S, 1968, J BIOCHEM-TOKYO, V64, P465, DOI 10.1093/oxfordjournals.jbchem.a128918; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; GREENE LE, 1986, J BIOL CHEM, V261, P1279; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HEELEY DH, 1989, J BIOL CHEM, V264, P2424; HILL LE, 1992, J BIOL CHEM, V267, P16106; HONDA H, 1989, J MOL BIOL, V205, P677, DOI 10.1016/0022-2836(89)90313-6; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; Straub F.B., 1942, STUDIES I MED CHEM U, P3; VANEERD JP, 1973, BIOCHEMISTRY-US, V12, P4972, DOI 10.1021/bi00748a024; WANG F, 1993, J BIOL CHEM, V268, P3776; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048	29	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7836	7841		10.1074/jbc.270.14.7836	http://dx.doi.org/10.1074/jbc.270.14.7836			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713874	hybrid			2022-12-27	WOS:A1995QR52600010
J	JOHNSTON, JA; JOHNSON, ES; WALLER, PRH; VARSHAVSKY, A				JOHNSTON, JA; JOHNSON, ES; WALLER, PRH; VARSHAVSKY, A			METHOTREXATE INHIBITS PROTEOLYSIS OF DIHYDROFOLATE-REDUCTASE BY THE N-END RULE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SHORT-LIVED PROTEIN; SACCHAROMYCES-CEREVISIAE; DEGRADATION SIGNAL; PRECURSOR PROTEIN; UBIQUITIN; TRANSLOCATION; MITOCHONDRIA; GENES; RECOGNITION	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. In eukaryotes, the N-end rule pathway is a ubiquitin-dependent, proteasome-based system that targets and processively degrades proteins bearing certain N-terminal residues. Arg-DHFR, a modified dihydrofolate reductase bearing an N-terminal arginine (destabilizing residue in the N-end rule), is short lived in ATP-supplemented reticulocyte extract. It is shown here that methotrexate, which is a folic acid analog and high affinity ligand of DHFR, inhibits the degradation but not ubiquitination of Arg-DHFR by the N-end rule pathway. The degradation of other N-end rule substrates is not affected by methotrexate. We discuss implications of these results for the mechanism of proteasome-mediated protein degradation.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology				Johnston, Jennifer/0000-0002-4867-9230	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039520, R01DK039520, R56DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39520] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKOWITZ RA, 1992, EMBO J, V12, P243; Ausubel FM, 1988, MOL REPROD DEV; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; Creighton T.E., 1992, PROTEINS STRUCTURES; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GOLDBERG AL, 1992, NATURE, V375, P375; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1992, THESIS MIT CAMBRIDGE; LUPAS A, 1995, IN PRESS ENZYME PROT; MADURA K, 1993, J BIOL CHEM, V268, P12046; MATTHEWS DA, 1985, J BIOL CHEM, V260, P392; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	46	103	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8172	8178		10.1074/jbc.270.14.8172	http://dx.doi.org/10.1074/jbc.270.14.8172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713922	Green Accepted, hybrid			2022-12-27	WOS:A1995QR52600061
J	CHESTER, N; YUEN, IJ; MARSHAK, DR				CHESTER, N; YUEN, IJ; MARSHAK, DR			IDENTIFICATION AND CHARACTERIZATION OF PROTEIN-KINASE CKII ISOFORMS IN HELA-CELLS - ISOFORM-SPECIFIC DIFFERENCES IN RATES OF ASSEMBLY FROM CATALYTIC AND REGULATORY SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TUMOR SUPPRESSOR PROTEIN; CASEIN KINASE; II ACTIVITY; ALPHA-SUBUNIT; CELLULAR-REGULATION; ESCHERICHIA-COLI; GROWTH-FACTOR; PHOSPHORYLATION; BETA	Protein kinase CKII (formerly casein kinase II) can be isolated as a heterotetramer, containing two catalytic (a or alpha') and two regulatory (beta) subunits. We have characterized the forms of CKII in HeLa cells using antibodies specific for the alpha or alpha' subunits. Following metabolic labeling with [S-35]methionine, whole cell soluble extracts were analyzed by immunoprecipitation and gel electrophoresis. Both alpha and alpha' coprecipitate with beta and with each other. However, when extracts are depleted of alpha, a pool of CKII containing only alpha' and beta is identified. Similarly, depletion of alpha' revealed a pool exclusively of alpha and beta. Therefore, we propose that there are three distinct isoforms of CKII within HeLa cells with different catalytic subunit stoichiometries (alpha(2) beta(2), alpha alpha'beta(2), and alpha'(2) beta(2)). With our immunodepletion procedure we have characterized the isoforms by activity analysis, turnover of pulse-labeled subunits, and by localization in subcellular fractions obtained from labeled cells. We have also analyzed complex formation between the catalytic and regulatory subunits by examining the differences in the rate of signal incorporation into subunits in immunoprecipitates obtained from continuously labeled and pulse-labeled cells. We have found that the alpha(2) beta(2) and alpha alpha'beta(2) isoforms assemble relatively slowly (12-16 h), whereas complex formation of the alpha'(2) beta(2) isoform occurs more rapidly (2-4 h). Analysis of isoform complex formation in subcellular fractions from pulse-labeled cells revealed that the majority of nuclear CKII is assembled in the nucleus from free catalytic and regulatory subunit polypeptides.	COLD SPRING HARBOR LAB, ARNOLD & MABEL BECKMAN NEUROSCI CTR, WM KECK STRUCT BIOL LAB, COLD SPRING HARBOR, NY 11724 USA; SUNY STONY BROOK, GRAD PROGRAM MOLEC & CELLULAR BIOL, STONY BROOK, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA64593, CA13106] Funding Source: Medline; NIA NIH HHS [AG10208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106, P01CA064593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BARANY G, 1979, SOLID PHASE PEPTID A, V2; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1983, J BIOL CHEM, V258, P1403; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEM BIOPH RES CO, V173, P862, DOI 10.1016/S0006-291X(05)80866-6; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1994, BIOCHEM BIOPH RES CO, V198, P660, DOI 10.1006/bbrc.1994.1096; GLINEUR C, 1989, ONCOGENE, V4, P1247; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P83; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HU E, 1990, J BIOL CHEM, V265, P20609; INOUE A, 1984, BIOCHEM BIOPH RES CO, V123, P398, DOI 10.1016/0006-291X(84)90427-3; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; STALLCUP MR, 1978, BIOCHEMISTRY-US, V17, P1515, DOI 10.1021/bi00601a025; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	58	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7501	7514		10.1074/jbc.270.13.7501	http://dx.doi.org/10.1074/jbc.270.13.7501			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706297	hybrid			2022-12-27	WOS:A1995QQ43100072
J	DONG, F; GOGOL, EP; VONHIPPEL, PH				DONG, F; GOGOL, EP; VONHIPPEL, PH			THE PHAGE T4-CODED DNA-REPLICATION HELICASE (GP41) FORMS A HEXAMER UPON ACTIVATION BY NUCLEOSIDE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; RNA PRIMER SYNTHESIS; BACTERIOPHAGE-T4-DNA PRIMASE-HELICASE; ESCHERICHIA-COLI; PHYSICAL-PROPERTIES; GENE-41 PROTEIN; FUNCTIONAL INTERACTIONS; LIGAND COFACTORS; DEPENDENT ATPASE; PURIFICATION	Sedimentation and high performance liquid chromatography studies show that the functional DNA replication helicase of bacteriophage T4 (gp41) exists primarily as a dimer at physiological protein concentrations, assembling from gp41 monomers with an association constant of similar to 10(6) M(-1). Cryoelectron microscopy, analytical ultracentrifugation, and protein-protein cross-linking studies demonstrate that the binding of ATP or GTP drives the assembly of these dimers into monodisperse hexameric complexes, which redissociate following depletion of the purine nucleotide triphosphatase (PuTP) substrates by the DNA-stimulated PuTPase activity of the helicase. The hexameric state of gp41 can be stabilized for detailed study by the addition of the nonhydrolyzable PuTP analogs ATP(gamma)S and GTP(gamma)S and is not significantly affected by the presence of ADP, GDP, or single-stranded or forked DNA template constructs, although some structural details of the hexameric complex may be altered by DNA binding. Our results also indicate that the active gp41 helicase exists as a hexagonal trimer of asymmetric dimers, and that the hexamer is probably characterized by D3 symmetry. The assembly pathway of the gp41 helicase has been analyzed, and its structure and properties compared with those of other helicases involved in a variety of cellular processes. Functional implications of such structural organization are also considered.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA; UNIV MISSOURI, DIV CELL BIOL & BIOPHYS, KANSAS CITY, MO 64110 USA	University of Oregon; University of Oregon; University of Missouri System; University of Missouri Kansas City				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R37GM015792, R01GM029158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33049; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1988, CANCER CELL, V6, P1; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; ERICKSON HP, 1971, PHILOS T ROY SOC B, V261, P105, DOI 10.1098/rstb.1971.0040; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; HINGORANI MM, 1994, J CELL BIOCHEM, P151; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HINTON DM, 1987, UCLA S MOL CELLULAR, V47, P173; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2933; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; Kornberg A., 1992, DNA REPLICATION; KUROSAWA Y, 1979, J MOL BIOL, V135, P841, DOI 10.1016/0022-2836(79)90515-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MANIATIS T, 1982, MOL CLONING LABORATO, P178; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRIS CF, 1979, J BIOL CHEM, V254, P6797; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; OH EY, 1989, J BIOL CHEM, V264, P1336; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VANHOLDE KE, 1976, PROTEINS, P225; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG Y, 1993, J BIOL CHEM, V268, P13947; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WEBER K, 1969, J BIOL CHEM, V244, P4406; Weber K., 1975, PROTEINS, VI, P179; WOOD ER, 1987, J BIOL CHEM, V262, P15269; YARRANTON GT, 1979, J BIOL CHEM, V254, P2002; Young Mark C., 1994, P313; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	73	150	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7462	7473		10.1074/jbc.270.13.7462	http://dx.doi.org/10.1074/jbc.270.13.7462			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706292	hybrid			2022-12-27	WOS:A1995QQ43100067
J	FRUSTACI, JM; SANGWAN, I; OBRIAN, MR				FRUSTACI, JM; SANGWAN, I; OBRIAN, MR			GSA1 IS A UNIVERSAL TETRAPYRROLE SYNTHESIS GENE IN SOYBEAN AND IS REGULATED BY A GAGA ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMYL-TRANSFER RNA; ACID ALA SYNTHESIS; ROOT-NODULES; 1-SEMIALDEHYDE AMINOTRANSFERASE; BRADYRHIZOBIUM-JAPONICUM; DEVELOPING CHLOROPLASTS; ESCHERICHIA-COLI; GLYCINE-MAX; EXPRESSION; HEME	Expression of plant tetrapyrroles is high in photosynthetic tissues and in legume root nodules in the form of chlorophyll and heme, respectively, The universal tetrapyrrole precursor delta-aminolevulinic acid (ALA) is synthesized from glutamate 1-semialdehyde (GSA) by GSA aminotransferase in plants, which is encoded by gsa, Immunoblot analysis showed that GSA aminotransferase was expressed in soybean leaves and nodules, but not in roots, and that protein correlated with enzyme activity, These observations indicate that GSA aminotransferase expression is controlled in tetrapyrrole formation and argue against significant activity of an enzyme other than the well described aminotransferase for GSA-dependent ALA formation, gsa mRNA and protein were induced in soybean nodules, and their activation was temporally intermediate between those of the respective early and late genes enod2 and lb, A GSA aminotransferase gene, designated gsa1, was isolated and appears to be one of two gsa genes in the soybean genome. gsa1 mRNA accumulated to high levels in leaves and nodules, but not in uninfected roots as discerned with a gsa1-specific probe, Message levels were higher in leaves from etiolated plantlets than in mature plants, and expression in the former was slightly elevated by light. The expression pattern of gsa1 mRNA was qualitatively similar to that of total gsa. The data strongly suggest that gsa1 is a universal tetrapyrrole synthesis gene and that a gsa gene specific for a tissue, tetrapyrrole, or light condition is unlikely, The gsa1 promoter contained a genetic element found in numerous Drosophila melanogaster genes; the so-called GAGA element displayed single stranded character in vitro and formed a complex with nuclear factors from nodules and leaves but not from roots, From these observations we infer that the GAGA element is involved in the transcriptional control of gsa1.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEATOR J, 1993, PLANT PHYSIOL, V103, P191, DOI 10.1104/pp.103.1.191; CAETANOANOLLES G, 1991, ANNU REV MICROBIOL, V45, P345, DOI 10.1146/annurev.mi.45.100191.002021; CHAUHAN S, 1993, J BACTERIOL, V175, P7222, DOI 10.1128/JB.175.22.7222-7227.1993; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DICKSTEIN R, 1988, GENE DEV, V2, P677, DOI 10.1101/gad.2.6.677; ESTABROOK EM, 1991, PLANT CELL, V3, P299, DOI 10.1105/tpc.3.3.299; FANG G, 1992, BIOTECHNIQUES, V13, P52; FORTIN MG, 1988, NUCLEIC ACIDS RES, V16, P11377, DOI 10.1093/nar/16.23.11377; FRANSSEN HJ, 1987, P NATL ACAD SCI USA, V84, P4495, DOI 10.1073/pnas.84.13.4495; FRANSSEN HJ, 1989, PLANT MOL BIOL, V14, P103; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRUSTACI JM, 1991, J BACTERIOL, V173, P1145, DOI 10.1128/jb.173.3.1145-1150.1991; FRUSTACI JM, 1993, APPL ENVIRON MICROB, V59, P2347, DOI 10.1128/AEM.59.8.2347-2351.1993; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRIMM B, 1990, P NATL ACAD SCI USA, V87, P4169, DOI 10.1073/pnas.87.11.4169; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; HUANG LQ, 1989, PLANT PHYSIOL, V90, P1003, DOI 10.1104/pp.90.3.1003; HUANG LQ, 1990, PLANT PHYSIOL, V92, P172, DOI 10.1104/pp.92.1.172; HUANG LQ, 1989, PLANT PHYSIOL, V90, P996, DOI 10.1104/pp.90.3.996; HYLDIGNIELSEN JJ, 1982, NUCLEIC ACIDS RES, V10, P689, DOI 10.1093/nar/10.2.689; ILAG LL, 1994, PLANT CELL, V6, P265, DOI 10.1105/tpc.6.2.265; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JAHN D, 1991, J BIOL CHEM, V266, P2542; JENSEN EO, 1988, EMBO J, V7, P1265, DOI 10.1002/j.1460-2075.1988.tb02940.x; KACZOR CM, 1994, PLANT PHYSIOL, V104, P1411, DOI 10.1104/pp.104.4.1411; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MADSEN O, 1993, PLANT MOL BIOL, V23, P35, DOI 10.1007/BF00021417; MASONER M, 1975, PLANTA, V126, P111, DOI 10.1007/BF00380614; MATTERS GL, 1994, PLANT MOL BIOL, V24, P617, DOI 10.1007/BF00023558; NAP JP, 1990, SCIENCE, V250, P948, DOI 10.1126/science.250.4983.948; OBRIAN MR, 1987, P NATL ACAD SCI USA, V84, P8390, DOI 10.1073/pnas.84.23.8390; OCHMAN H, 1988, GENETICS, V120, P621; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; RIEBLE S, 1991, J BIOL CHEM, V266, P9740; Rowland LJ, 1993, BIOTECHNIQUES, V14, P735; SANGWAN I, 1992, PLANT PHYSIOL, V98, P1074, DOI 10.1104/pp.98.3.1074; SANGWAN I, 1991, SCIENCE, V251, P1220, DOI 10.1126/science.251.4998.1220; SANGWAN I, 1993, PLANT PHYSIOL, V102, P829, DOI 10.1104/pp.102.3.829; SCHNEEGURT MA, 1986, PLANT PHYSIOL, V81, P965, DOI 10.1104/pp.81.4.965; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VERKAMP E, 1992, J BIOL CHEM, V267, P8275; VERMA DPS, 1986, PLANT MOL BIOL, V7, P51, DOI 10.1007/BF00020131	48	18	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7387	7393		10.1074/jbc.270.13.7387	http://dx.doi.org/10.1074/jbc.270.13.7387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706283	hybrid			2022-12-27	WOS:A1995QQ43100056
J	NAKAMURA, K; ENDO, F; UENO, T; AWATA, H; TANOUE, A; MATSUDA, I				NAKAMURA, K; ENDO, F; UENO, T; AWATA, H; TANOUE, A; MATSUDA, I			EXCESS COPPER AND CERULOPLASMIN BIOSYNTHESIS IN LONG-TERM CULTURED-HEPATOCYTES FROM LONG-EVANS CINNAMON (LEG) RATS, A MODEL OF WILSON DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MENKES DISEASE; CANDIDATE GENE; SERUM CERULOPLASMIN; TRANSPORTING ATPASE; METALLOTHIONEIN; ACCUMULATION; SEQUENCE; LIVER; CELLS	Immortalized hepatic cell lines obtained from laboratory animals or patients with defects in copper metabolism in the liver provide new approaches to examine related metabolism and toxicity. We established a series of hepatic cell lines from the liver of Long-Evans Cinnamon (LEC) rats, using recombinant adenovirus which expresses SV40 large T, Cells from the LEC rats were cultured and accumulated larger amounts of copper than did control cells, when the concentrations of copper in the culture medium exceeded 5 mu M. The secretion of ceruloplasmin (CP) from the cultured cells was not reduced in hepatocytes from LEC cells, as compared with the control cells, As accumulation of copper did not affect CP secretion, CP production was not likely to be affected by the accumulation of copper in LEC rat hepatocytes, The production of holo CP was further investigated by transfection of human CP cDNA and detection of human holo-CP by immunological procedures and use of a monoclonal antibody (mAb CP60) which recognizes human holo-CP but not human apo-CP and rat CP. Hepatocytes from the LEC rats processed and secreted holo-CP into the medium, even with excess copper present in the medium. These observations suggest that the genetic defect in LEC rats did not alter biosynthetic and secretory pathways of CP and that the intracellular copper concentration did not regulate the synthesis and processing of CP in the cultured hepatocytes. Low ceruloplasmin levels are observed in most, but not all, patients with Wilson disease, as well as in LEC rats, Our results do suggest that the copper transporting ATPase encoded in the Wilson disease gene is not a integral part of the biochemical mechanism of copper incorporation into apoprotein. The cell lines and immunological procedures we used are expected to add to information on biologically important process related to copper metabolism and to CP biosynthesis.	KUMAMOTO UNIV,SCH MED,DEPT PEDIAT,KUMAMOTO 860,JAPAN; CHEMOSEROTHERAPEUT RES INST KAKETSUKEN,DEPT RES & DEV,KUMAMOTO 86912,JAPAN	Kumamoto University				, Kimitoshi/0000-0003-4903-2428				BOTHWELL HT, 1989, METABOLIC BASIS INHE; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; COX LA, 1993, BIOCHEMISTRY-US, V32, P4738, DOI 10.1021/bi00069a007; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DOREN KV, 1984, MOL CELL BIOL, V4, P1653; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; ENDO F, 1989, J BIOL CHEM, V264, P4476; ENDO F, 1992, J BIOL CHEM, V267, P24235; ENDO F, 1990, J CLIN INVEST, V85, P162, DOI 10.1172/JCI114407; ENDO F, 1994, J INHERIT METAB DIS, V17, P616, DOI 10.1007/BF00711601; FLEMING RE, 1992, J BIOL CHEM, V267, P479; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FREEDMAN JH, 1989, BIOCHIM BIOPHYS ACTA, V992, P145, DOI 10.1016/0304-4165(89)90003-2; FRIEDEN E, 1986, CLIN PHYSIOL BIOCH, V4, P11; GITLIN JD, 1992, BIOCHEM J, V282, P835, DOI 10.1042/bj2820835; GOLDSTEIN IM, 1979, J BIOL CHEM, V254, P4040; HOLTZMAN NA, 1967, J CLIN INVEST, V46, P993, DOI 10.1172/JCI105606; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1991, J CLIN INVEST, V87, P1858, DOI 10.1172/JCI115208; LI Y, 1991, LEC RAT NEW MODEL HE, P122; MCARDLE H, 1990, J NUTR, V2120, P1370; MERCER JFB, 1991, J NUTR, V121, P894, DOI 10.1093/jn/121.6.894; MERCER JFB, 1993, NAT GENET, V3, P14; MIYAZAKI J, 1989, GENE, V79, P269; MORELL AG, 1958, SCIENCE, V127, P588, DOI 10.1126/science.127.3298.588-a; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ORENA SJ, 1986, BIOCHEM BIOPH RES CO, V139, P822, DOI 10.1016/S0006-291X(86)80064-X; PERCIVAL SS, 1992, J NUTR, V122, P2424, DOI 10.1093/jn/122.12.2424; RYDEN L, 1976, BIOCHEMISTRY-US, V15, P3411, DOI 10.1021/bi00661a003; SAKURAI H, 1993, BIOCHEM BIOPH RES CO, V192, P893, DOI 10.1006/bbrc.1993.1499; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHEINBERG IH, 1984, WILSONS DISEASE, P1; SONE H, 1992, MOL CARCINOGEN, V5, P199, DOI 10.1002/mc.2940050306; SUNDERMAN FW, 1970, CLIN CHEM, V16, P903; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueno T, 1993, Hum Cell, V6, P126; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WALDROP GL, 1990, AM J PHYSIOL, V259, pG219, DOI 10.1152/ajpgi.1990.259.2.G219; WALKER FJ, 1990, J BIOL CHEM, V265, P1834; WLOSTOWSKI T, 1993, BIOMETALS, V6, P71, DOI 10.1007/BF00140106; WOODWORTH CD, 1987, MOL CELL BIOL, V7, P3740, DOI 10.1128/MCB.7.10.3740; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; YAMADA T, 1993, J BIOL CHEM, V268, P8965; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	50	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7656	7660		10.1074/jbc.270.13.7656	http://dx.doi.org/10.1074/jbc.270.13.7656			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706313	hybrid			2022-12-27	WOS:A1995QQ43100091
J	ZHAN, X; HU, XG; HAMPTON, B; BURGESS, WH; FRIESEL, R; MACIAG, T				ZHAN, X; HU, XG; HAMPTON, B; BURGESS, WH; FRIESEL, R; MACIAG, T			MURINE CORTACTIN IS PHOSPHORYLATED IN RESPONSE TO FIBROBLAST GROWTH FACTOR-I ON TYROSINE RESIDUES LATE IN THE G(1) PHASE OF THE BALB/C 3T3 CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL TRANSDUCTION; CDNA CLONING; RECEPTOR; BINDING; IDENTIFICATION; SUBSTRATE; ASSOCIATION; PI3-KINASE; SEQUENCE	We have previously reported that BALB/c 3T3 cells require a prolonged exposure to fibroblast growth factor (FGF)-1 for the stimulation of maximal DNA synthesis, and this event correlates with the tyrosine phosphorylation of novel proteins late in G, including a protein termed p80/p85 (Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 9611-9620). We have purified, sequenced, and cloned the cDNA encoding p80/p85 and report that it is the murine homolog of the chicken cortactin gene and a member of the human hematopoietic specific-1 gene family. Immunochemical analysis of m-cortactin-tyrosine phosphorylation in response to FGF-1 demonstrates a biphasic phosphorylation pattern both as a weak immediate-early and strong mid to late G1 response protein. Because the chicken cortactin gene was originally isolated as a substrate for v-Src, FGF-1 may influence the enzymatic activity of other cell-associated tyrosine kinases which utilize p80/p85 (cortactin) as a polypeptide substrate.	AMER RED CROSS, HOLLAND LAB, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA	American Red Cross			Hampton, Brian/G-8427-2015	Hampton, Brian/0000-0003-4650-2869	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, P50HL044336, R01HL035762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32348, HL44336, HL35762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; EGERTON M, 1992, J IMMUNOL, V149, P1847; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAA MC, 1992, ONCOGENE, V7, P2429; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAPP UR, 1991, ONCOGENE, V6, P495; Sambrook J, 1989, MOL CLONING LABORATO; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; ZHAN X, 1993, J BIOL CHEM, V268, P9611	23	116	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24427	24431						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693700				2022-12-27	WOS:A1993MF29400105
J	FRANTZ, JD; GILBERT, W				FRANTZ, JD; GILBERT, W			A YEAST GENE-PRODUCT, G4P2, WITH A SPECIFIC AFFINITY FOR QUADRUPLEX NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERIC DNA; GENOMIC RNA; PROTEIN; SEQUENCE; OLIGONUCLEOTIDE; DIMERIZATION; EXPRESSION; MUTATIONS; REGION	G4 nucleic acids are quadruplex structures involving guanine-rich sequences that form in vitro under moderate conditions. Experimental evidence exists supporting biological functions for these elements; however, direct demonstration of G4 nucleic acids in vivo has not yet been achieved, Here we purify and characterize a yeast protein, G4p2, which has a specific affinity for G4 nucleic acids, G4p2 binds equivalently to RNA and DNA in G4 form. The K-eq for G4p2 binding to a G4 DNA oligomer is 2.2 x 10(8) M(-1) under near physiological conditions, We have cloned and sequenced the gene encoding G4p2 and have shown it to be identical to MPT4 and STO1, MPT4 was isolated in a screen for multicopy suppressors of staurosporine sensitivity in POP2 cells, Pop2 is a complex regulatory factor that participates, in part, in the repression of certain genes in the absence of glucose (Sakai, A., Chibazakura, T., Shimizu, Y., and Hishinuma, F. (1992) Nucleic Acids Res. 20, 6227-6233), STO1 was isolated as a multicopy suppressor of TOM1, an uncharacterized mutation that leads to temperature sensitive cell cycle arrest at the G2/M boundary, Suppression of these mutations by G4p2 indicate this G4 nucleic acid binding protein may function in signal transduction pathways regulated by protein kinases, which control carbon source utilization, and in cell cycle progression.			FRANTZ, JD (corresponding author), HARVARD UNIV, BIOL LABS, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; DAVIS TN, 1987, METHOD ENZYMOL, V139, P248; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GALLAGHER SR, 1992, CURRENT PROTOCOLS MO, V2; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; KIM JM, 1990, GENETICS, V126, P799; KOVALCHUKE O, 1994, FASEB J, V8, pA1307; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SAKAI A, 1992, NUCLEIC ACIDS RES, V20, P6227, DOI 10.1093/nar/20.23.6227; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1992, METHOD ENZYMOL, V211, P191; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH DB, 1992, CURRENT PROTOCOLS MO, V2; SNYDER M, 1986, P NATL ACAD SCI USA, V83, P730, DOI 10.1073/pnas.83.3.730; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; Sundquist W. I., 1991, Nucleic Acids and Molecular Biology, V5, P1; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TAKEDA J, 1989, FEBS LETT, V247, P41, DOI 10.1016/0014-5793(89)81236-0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WILLIAMSON JR, 1993, CURR OPIN STRUC BIOL, V3, P357, DOI 10.1016/S0959-440X(05)80106-X; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	36	63	66	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9413	9419		10.1074/jbc.270.16.9413	http://dx.doi.org/10.1074/jbc.270.16.9413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721866	hybrid			2022-12-27	WOS:A1995QU08900055
J	KOUNNAS, MZ; CHAPPELL, DA; WONG, H; ARGRAVES, WS; STRICKLAND, DK				KOUNNAS, MZ; CHAPPELL, DA; WONG, H; ARGRAVES, WS; STRICKLAND, DK			THE CELLULAR INTERNALIZATION AND DEGRADATION OF HEPATIC LIPASE IS MEDIATED BY LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN AND REQUIRES CELL-SURFACE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; TRIGLYCERIDE LIPASE; RAT-LIVER; BINDING; HYDROLYSIS; PLASMA; CHYLOMICRONS; ACCUMULATION; CATABOLISM; INHIBITION	Hepatic lipase (HL) and lipoprotein lipase (LpL) are structurally related lipolytic enzymes that have distinct functions in lipoprotein catabolism. In addition to its lipolytic activity, LpL binds to very low density lipoproteins and promotes their interaction with the low density lipoprotein receptor-related protein (LRP) (Chappell, D. A., Fry, G. L., Waknitz, M. A., Muhonen, L. E., Pladet M. W., Iverius, P. H., and Strickland, D. K. (1993) J. Biol. Chem. 268, 14168-14175). In vitro binding assays revealed that HL also binds to purified LRP with a K-D of 52 nM. Its binding to LRP is inhibited by the 39-kDa receptor associated protein (RAP), a known LRP antagonist, and by heparin. I-125-Labeled HL is rapidly internalized and degraded by HepG2 cell lines, and approximately 70% of the cellular internalization and degradation is blocked by either exogenously added RAP or anti LRP IgG. Mouse fibroblasts that lack LRP display a greatly diminished capacity to internalize and degrade HL when compared to control fibroblasts. These data indicate that LRP-mediated cellular uptake of HL accounts for a substantial portion of the internalization of this molecule. Proteoglycans have been shown to participate in the clearance of LpL, and consequently a role for proteoglycans in HL clearance pathway was also investigated. Chinese hamster ovary cell lines that are deficient in proteoglycan biosynthesis were unable to internalize or degrade I-125-HL despite the fact that these cells express LRP. Thus, the initial binding of HL to cell surface proteoglycans is an obligatory step for the delivery of the enzyme to LRP for endocytosis. A small, but significant, amount of I-125-HL was internalized in LRP deficient cells indicating that an LRP independent pathway for HL internalization does exist. This pathway could involve cell surface proteoglycans, the LDL receptor, or some other unidentified surface protein.	AMER RED CROSS,DEPT BIOCHEM,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855; UNIV IOWA,COLL MED,DEPT MED,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,VET ADM WADSWORTH MED CTR,LIPID RES LAB,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90073	American Red Cross; University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787, HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BELCHER JP, 1988, CIRCULATION, V11, P145; BENZEEV O, 1987, BIOCHIM BIOPHYS ACTA, V919, P13, DOI 10.1016/0005-2760(87)90212-8; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHANG SY, 1993, BIOCHEM J, V293, P745, DOI 10.1042/bj2930745; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DAGGY BP, 1986, BIOCHIM BIOPHYS ACTA, V877, P252, DOI 10.1016/0005-2760(86)90302-4; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; ESKO JD, 1986, J BIOL CHEM, V261, P5725; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P1184, DOI 10.1172/JCI110717; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; HORNICK CA, 1992, J BIOL CHEM, V267, P3396; HUFF MW, 1993, ARTERIOSCLER THROMB, V13, P1282, DOI 10.1161/01.ATV.13.9.1282; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; KOMAROMY MC, 1991, J LIPID RES, V32, P963; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; KUUSI T, 1979, FEBS LETT, V104, P384, DOI 10.1016/0014-5793(79)80858-3; LABODA HM, 1986, BIOCHIM BIOPHYS ACTA, V876, P233, DOI 10.1016/0005-2760(86)90279-1; MARTEAU C, 1988, LIFE SCI, V42, P533, DOI 10.1016/0024-3205(88)90094-X; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MIKHAILENKO I, 1995, IN PRESS J BIOL CHEM, V270; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NILSSON A, 1987, J LIPID RES, V28, P510; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; SHAFI S, 1994, J LIPID RES, V35, P709; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	53	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9307	9312		10.1074/jbc.270.16.9307	http://dx.doi.org/10.1074/jbc.270.16.9307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721852	hybrid			2022-12-27	WOS:A1995QU08900040
J	LADU, MJ; PEDERSON, TM; FRAIL, DE; REARDON, CA; GETZ, GS; FALDUTO, MT				LADU, MJ; PEDERSON, TM; FRAIL, DE; REARDON, CA; GETZ, GS; FALDUTO, MT			PURIFICATION OF APOLIPOPROTEIN-E ATTENUATES ISOFORM-SPECIFIC BINDING TO BETA-AMYLOID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMER-DISEASE; CLEAVAGE; PROTEIN; ALLELE; NERVE	Apolipoprotein E (apoE), particularly the e4 allele, is genetically linked to the incidence of Alzheimer's disease. In vitro, apoE has been shown to bind beta-amyloid (A beta), an amyloidogenic peptide that aggregates to form the primary component of senile plaques. In previous work, we demonstrated that apoE3 from tissue culture medium binds to A beta with greater avidity than apoE4 (LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G, S., and Frail, D. E. (1994) J. Biol. Chem. 269, 23403-23406). This is in contrast to data using purified apoE isoforms as substrate for A beta (Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L.-M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., and Roses, A. D. (1993) Proc. Natl. Acad. Sci. U.S. A. 90, 8098-8102). Here we resolve this apparent discrepancy by demonstrating that the preferential binding of A beta to apoE3 is attenuated and even abolished with purification, a process that includes delipidation and denaturation. We compared the A beta binding capacity of unpurified apoE isoforms from both tissue culture medium and intact human very low density lipoproteins with that of apoE purified from these two sources. The interaction of human A beta-(1-40)-peptide and apoE was analyzed by nonreducing SDS-polyacrylamide gel electrophoresis followed by Western immunoblotting for either A beta or apoE immunoreactivity. While the level of the apoE3 . A beta complex was similar to 20-fold greater compared with the apoE4 . A beta complex in unpurified conditioned medium, apoE3 and apoE4 purified from this medium bound to A beta with comparable avidity. Moreover, using endogenous apoE on very low density lipoproteins from plasma of apoE3/3 and apoE4/4 homozygotes, apoE3 was again a better substrate for A beta than apoE4. However, apoE purified from these plasma lipoproteins exhibited little isoform specificity in binding to A beta. These results suggest that native preparations of apoE may be a more physiologically relevant substrate for A beta binding than purified apoE and further underscore the importance of subtle differences in apoE conformation to its biological activity.	ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	Abbott Laboratories	LADU, MJ (corresponding author), UNIV CHICAGO,DEPT PATHOL MC6079,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.			LaDu, Mary Jo/0000-0003-2141-1450	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015062, F32HL008833] Funding Source: NIH RePORTER; NHLBI NIH HHS [1F32 HL08833-01, HL15062] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; HIXSON JE, 1990, J LIPID RES, V31, P545; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; RALL SC, 1986, METHOD ENZYMOL, V128, P273; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423	23	170	175	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9039	9042		10.1074/jbc.270.16.9039	http://dx.doi.org/10.1074/jbc.270.16.9039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721816	hybrid			2022-12-27	WOS:A1995QU08900004
J	LINDSEY, S; HARWOOD, HJ				LINDSEY, S; HARWOOD, HJ			INHIBITION OF MAMMALIAN SQUALENE SYNTHETASE-ACTIVITY BY ZARAGOZIC ACID A IS A RESULT OF COMPETITIVE-INHIBITION FOLLOWED BY MECHANISM-BASED IRREVERSIBLE INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESQUALENE PYROPHOSPHATE; CHOLESTEROL-BIOSYNTHESIS; DISSOCIATION-CONSTANTS; STRUCTURE ELUCIDATION; AMMONIUM ANALOGS; POTENT INHIBITOR; RAT-LIVER; SYNTHASE; ENZYME; DIPHOSPHATE	Squalene synthetase (SQS, EC 2.5.1.21) catalyzes the first committed step in the formation of cholesterol and thus represents an ideal site for selectively inhibiting sterol formation. Previous studies have demonstrated that the fungal metabolite, zaragozic acid A (ZGA-A), inhibits SQS activity by mimicking the substrate farnesyl pyrophosphate, the reaction intermediate presqualene pyrophosphate, or both, through a process that confers increased apparent potency in the presence of reduced enzyme concentrations, an observation consist ent with either tight binding reversible competitive inhibition or mechanism-based irreversible inactivation. The studies outlined in this report provide multiple lines of evidence indicating that ZGA-A acts as a mechanism-based irreversible inactivator of SQS. 1) Inhibition of SQS by ZGA-A is dependent on the [SQS] present in the incubation reaction, and this inhibition is time dependent and follows pseudo-first order reaction kinetics, exhibiting hobs values that range between 2 x 10(-4)/s and 23 x 10(-4)/s for [ZGA-A] within the log-linear range of the inhibition curve, and a bimolecular rate constant of 2.3 x 10(5) M(-1) s(-1). 2) SQS activity is titratable by ZGA-A, such that for each [ZGA-A] evaluated, inactivation exhibits a threshold [SQS] whereby enzyme activity at lower [SQS] is totally inhibited. 3) Time dependent inactivation exhibits saturation kinetics with a K-m for the process of 2.5 nM, which is approximately equal to the IC50 for SQS inhibition under these conditions, suggesting that inactivation results from selective modification of a functional group of the enzyme active center rather than from a nonspecific bimolecular reaction mechanism and that most, if not all of the inhibition results from irreversible inactivation. 4) Saturable, time-dependent inactivation occurs with similar inactivation kinetics for both the microsomal and trypsin-solubilized forms of the enzyme, indicating that irreversible inactivation by ZGA-A is not a consequence of membrane modification but is a direct effect of the inhibitor on the enzyme. 5) Inactivation is biphasic, exhibiting a rapid (''burst'') phase followed by a second, pseudo-first order phase, similar to that previously noted for irreversible inactivators in other enzyme systems, and occurs even in the presence of 5 mM concentrations of the nucleophylic scavenger dithiothreitol, suggesting that the reaction between ZGA-A and SQS occurs at or near the active center prior to diffusion of reactive species out of the catalytic cleft. 6) Inactivation can be prevented through competition with the substrate, farnesyl pyrophosphate, further identifying the active center as the site of modification. 7) The inhibitory effects of ZGA-A cannot be reversed either by lowering the [ZGA-A] to noninhibitory levels by dilution or by removal of unreacted ZGA-A from the enzyme by repetitive centrifugation, suggesting that enzyme modification is covalent. 8) The alpha,beta-unsaturated carbonyl moiety of ZGA-A, which is similar to related Michael acceptor moieties present in a variety of mechanism-based inactivators identified in other enzyme systems, appears to be required for eliciting the time dependent irreversible inactivation of SQS by ZGA-A and related alpha,beta-unsaturated carbonyl-containing analogs. 9) Observations similar to those described above were not noted for any of a number of other competitive inhibitors of SQS from a variety of diverse structural classes, whose K-i values for SQS inhibition ranged from 3 to 700 nM, suggesting that the mechanism-based irreversible inactivation of SQS by ZGA-A appears to be specific to this class of compounds rather than to inhibition of SQS per se. These observations strongly suggest that inhibition of SQS by ZGA-A and related analogs occurs through a mechanism-based irreversible inactivation process, presumably with formation of a covalent ZGA-A-SQS adduct that is catalytically incompetent. ZGA-A and related analogs may thus serve as useful tools for probing the substrate binding sites and catalytic reaction centers within the active center of SQS and for further evaluating the unique catalytic mechanisms of this important enzyme.	PFIZER INC,PFIZER CENT RES,DEPT METAB DIS,GROTON,CT 06340	Pfizer								AGNEW WS, 1985, METHOD ENZYMOL, V110, P359; AMIN D, 1992, J LIPID RES, V33, P1657; ATOR MA, 1990, ENZYMES, V19, P213; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BAZAES S, 1987, CHEM MODIFICATION EN, P35; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; BEYTIA E, 1973, J BIOL CHEM, V248, P1856; BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BILLER SA, 1991, J MED CHEM, V34, P1912, DOI 10.1021/jm00110a024; BILLER SA, 1991, J AM CHEM SOC, V113, P8522, DOI 10.1021/ja00022a050; BROCKLEHURST K, 1979, BIOCHEM J, V181, P775, DOI 10.1042/bj1810775; BROWN GR, 1993, Patent No. 9313096; BROWN MS, 1980, J LIPID RES, V21, P505; BRUENGER E, 1986, BIOCHIM BIOPHYS ACTA, V876, P500, DOI 10.1016/0005-2760(86)90037-8; CAPSON TL, 1988, J ORG CHEM, V53, P5903, DOI 10.1021/jo00260a019; CARDEMIL E, 1987, CHEM MODIFICATIONS E, P23; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; COLEMAN RF, 1990, ENZYMES, V19, P283; CONNOLLY BA, 1979, EUR J BIOCHEM, V93, P375, DOI 10.1111/j.1432-1033.1979.tb12833.x; COPP LJ, 1987, BIOCHEMISTRY-US, V26, P169, DOI 10.1021/bi00375a024; COREY EJ, 1976, J AM CHEM SOC, V98, P1291, DOI 10.1021/ja00421a056; DAWSON MJ, 1992, J ANTIBIOT, V45, P639, DOI 10.7164/antibiotics.45.639; de Montellano P R, 1977, J Med Chem, V20, P243; DEMONTELLANO PRO, 1977, BIOCHEMISTRY-US, V16, P2680; DEWAR MJS, 1987, TETRAHEDRON, V43, P2661, DOI 10.1016/S0040-4020(01)86871-X; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; DUFRESNE C, 1992, TETRAHEDRON, V48, P10221, DOI 10.1016/S0040-4020(01)88327-7; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; FERSHT A, 1985, ENZYME STRUCTURE MEC, P248; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARWOOD HJ, 1995, ANAL BIOCHEM, V226, P268, DOI 10.1006/abio.1995.1225; HARWOOD HJ, 1993, J LIPID RES, V34, P377; HASUMI K, 1993, J ANTIBIOT, V46, P689, DOI 10.7164/antibiotics.46.689; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; KELLER RK, 1993, BIOCHIM BIOPHYS ACTA, V1170, P204, DOI 10.1016/0005-2760(93)90072-H; KELLER RK, 1987, J BIOL CHEM, V261, P12053; KIICK DM, 1984, BIOCHEMISTRY-US, V23, P5454, DOI 10.1021/bi00318a012; KOYAMA T, 1980, BIOCHIM BIOPHYS ACTA, V617, P218; LINDSEY S, 1994, FASEB J, V8, pA1285; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V311, P277, DOI 10.1006/abbi.1994.1238; OEHLSCHLAGER AC, 1991, J ORG CHEM, V56, P3856, DOI 10.1021/jo00012a016; PANINI SR, 1985, REGULATION HMG COA R, P149; PISZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P79; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; POPJAK G, 1979, MOL CELL BIOCHEM, V27, P97; Poulter C, 1981, BIOSYNTHESIS ISOPREN, P413; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1989, J AM CHEM SOC, V111, P3734, DOI 10.1021/ja00192a036; PRASHAD M, 1993, J MED CHEM, V36, P1501, DOI 10.1021/jm00062a026; PRASHAD M, 1993, EUR J MED CHEM, V28, P527, DOI 10.1016/0223-5234(93)90022-7; QUESNEYHUNEEUS V, 1983, J BIOL CHEM, V258, P378; Rando R R, 1977, Methods Enzymol, V46, P28; RENOSTO F, 1985, J BIOL CHEM, V260, P1903; RILLING HC, 1985, BIOCHEM SOC T, V13, P997, DOI 10.1042/bst0130997; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; ROGERS DH, 1980, ANAL BIOCHEM, V101, P107, DOI 10.1016/0003-2697(80)90047-0; SANDIFER RM, 1982, J AM CHEM SOC, V104, P7376, DOI 10.1021/ja00389a106; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SEGEL IH, 1976, BIOCH CALCULATIONS, P257; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SIDEBOTTOM PJ, 1992, J ANTIBIOT, V45, P648, DOI 10.7164/antibiotics.45.648; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIGER A, 1992, J ORG CHEM, V57, P3444, DOI 10.1021/jo00038a038; TAIT RM, 1992, ANAL BIOCHEM, V203, P310, DOI 10.1016/0003-2697(92)90318-2; WALSH CT, 1984, ANNU REV BIOCHEM, V53, P493, DOI 10.1146/annurev.bi.53.070184.002425; WASHBURN W N, 1977, Tetrahedron Letters, V18, P1555, DOI 10.1016/S0040-4039(01)93101-6; WESTKAEMPER RB, 1983, BIOCHEMISTRY-US, V22, P3256, DOI 10.1021/bi00282a034	72	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9083	9096		10.1074/jbc.270.16.9083	http://dx.doi.org/10.1074/jbc.270.16.9083			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721822				2022-12-27	WOS:A1995QU08900010
J	BOHM, GA; PFLEIDERER, W; BOGER, P; SCHERER, S				BOHM, GA; PFLEIDERER, W; BOGER, P; SCHERER, S			STRUCTURE OF A NOVEL OLIGOSACCHARIDE-MYCOSPORINE-AMINO ACID ULTRAVIOLET A/B SUNSCREEN PIGMENT FROM THE TERRESTRIAL CYANOBACTERIUM NOSTOC COMMUNE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV; GLYCOSIDES; EXPOSURE	Water-soluble UV-A/B-absorbing pigments are secreted by cells of the cosmopolitan terrestrial cyanobacterium Nostoc commune. The pigments constitute a complex mixture of monomers with molecular masses of up to 1801 Da. Two different chromophores with absorption maxima at 312 and 335 nm are linked to different amino acids and to oligosaccharides consisting of galactose, glucose, xylose, glucuronic acid, and glucosamine. The 335 nm chromophore is a 1,3-diaminocyclohexen derivative, while the chromophore with an absorption maximum at 312 nm is most likely a 3-aminocyclohexen-1-one derivative. These UV-inducible substances are the first mycosporines to be described covalently linked to oligosaccharides. The pigments are located in the extracellular glycan sheath of Nostoc colonies, where they form complexes of extremely high molecular mass that are attached noncovalently to the glycan sheath. Pigments occur in concentrations that permit the cells to attenuate a significant part of incident UV-B radiation.	TECH UNIV MUNICH,INST MIKROBIOL,D-85350 FREISING,GERMANY; UNIV KONSTANZ,FAK CHEM,D-78434 CONSTANCE,GERMANY; UNIV KONSTANZ,LEHRSTUHL PHYSIOL & BIOCHEM PFLANZEN,D-78434 CONSTANCE,GERMANY	Technical University of Munich; University of Konstanz; University of Konstanz			Scherer, Siegfried/I-1320-2013	Scherer, Siegfried/0000-0002-0394-9890				AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; CHIOCCARA F, 1980, B SOC CHIM BELG, V89, P1101; DILL K, 1985, ADV CARBOHYD CHEM BI, V43, P1, DOI 10.1016/S0065-2318(08)60066-9; FOSTER AB, 1957, J CHEM SOC, P81, DOI 10.1039/jr9570000081; FRANSSON LA, 1984, MOL BIOPHYSICS EXTRA, P95; GARCIAPICHEL F, 1993, APPL ENVIRON MICROB, V59, P163, DOI 10.1128/AEM.59.1.163-169.1993; GARCIAPICHEL F, 1993, APPL ENVIRON MICROB, V59, P170, DOI 10.1128/AEM.59.1.170-176.1993; GAUCH R, 1979, J CHROMATOGR, V174, P195, DOI 10.1016/S0021-9673(00)87050-8; GORIN PAJ, 1975, CAN J CHEM, V53, P1212, DOI 10.1139/v75-168; HILL DR, 1994, J BIOL CHEM, V269, P7726; ITO S, 1977, TETRAHEDRON LETT, P2429; KARENTZ D, 1991, MAR BIOL, V108, P157, DOI 10.1007/BF01313484; PLACK PA, 1981, BIOCHEM J, V199, P741, DOI 10.1042/bj1990741; POST A, 1993, AQUAT BOT, V45, P231, DOI 10.1016/0304-3770(93)90023-P; POTTS M, 1994, MICROBIOL REV, V58, P755, DOI 10.1128/MMBR.58.4.755-805.1994; REBERS PA, 1986, CARBOHYD RES, V153, P132, DOI 10.1016/S0008-6215(00)90202-7; SCHERER S, 1991, MICROBIAL ECOL, V22, P271, DOI 10.1007/BF02540229; SCHERER S, 1988, PLANT PHYSIOL, V88, P1055, DOI 10.1104/pp.88.4.1055; SCHERER S, 1989, J BIOL CHEM, V264, P12546; SHIBATA K, 1969, PLANT CELL PHYSIOL, V10, P325; SPIRO MJ, 1992, ANAL BIOCHEM, V204, P152, DOI 10.1016/0003-2697(92)90155-Z; TAKANO S, 1979, CHEM LETT, P419, DOI 10.1246/cl.1979.419; TAKANO S, 1978, TETRAHEDRON LETT, P4909; WAKABAYASHI K, 1974, CARBOHYD RES, V35, P3, DOI 10.1016/S0008-6215(00)84828-4	25	127	135	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8536	8539		10.1074/jbc.270.15.8536	http://dx.doi.org/10.1074/jbc.270.15.8536			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721752	hybrid			2022-12-27	WOS:A1995QT44800028
J	BONSCH, D; KAMMER, W; LISCHKE, A; FRIEDRICH, K				BONSCH, D; KAMMER, W; LISCHKE, A; FRIEDRICH, K			SPECIES-SPECIFIC AGONIST-ANTAGONIST ACTIVITIES OF HUMAN INTERLEUKIN-4 VARIANTS SUGGEST DISTINCT LIGAND-BINDING PROPERTIES OF HUMAN AND MURINE COMMON RECEPTOR-GAMMA CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR RECEPTOR; GROWTH-HORMONE RECEPTOR; SIGNAL-TRANSDUCTION; CELL-LINES; CYTOPLASMIC DOMAIN; MOUSE; ESTABLISHMENT; SUPERFAMILY; MUTAGENESIS; ACTIVATION	Interleukin-4 (IL-4) is a pleiotropic cytokine eliciting various responses in target cells upon binding to its receptor. Activation of the IL-4 receptor probably involves interaction of the ligand with both the IL-4 receptor alpha subunit (IL-4R alpha) and the common gamma chain (c gamma). Although human and murine IL-4 receptor alpha chains are specific for IL-4 from the same species, murine c gamma can form a signal-competent complex with human IL-4R alpha (hIL-4R alpha) and human IL-4 (hIL-4). We have generated a hIL-4 responsive murine myeloid cell line (FDC-4G) expressing a chimera comprising the extracellular domain of human IL-4R alpha and the intracellular domain of human granulocyte colony-stimulating factor receptor (hG-CSFR). This hybrid receptor was shown to form a complex with hIL-4 and the murine c gamma-chain. Biological activities of human IL-4 variants on murine FDC-4G cells and on the human erythroleukemic cell line TF-1 displayed a strikingly different pattern. Single amino acid replacements at two different positions in the C-terminal helix of hIL-4, the region of the previously defined ''signaling site,'' lead to an inverse agonist/antagonist behavior of the resulting cytokines in the two cellular systems. From these findings we conclude that upon formation of the activated IL-4 receptor complex murine and human c gamma interact with hIL-4 in a geometrically different fashion.	UNIV WURZBURG,THEODOR BOVERI INST BIOWISSENSCH BIOZENTRUM,D-97074 WURZBURG,GERMANY	University of Wurzburg								BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Duschl A, 1992, Eur Cytokine Netw, V3, P97; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HARADA N, 1992, J BIOL CHEM, V267, P22752; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; MATSUDA T, 1994, BLOOD, V83, P3457; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; MULLER T, 1994, J MOL BIOL, V237, P423, DOI 10.1006/jmbi.1994.1245; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; Sambrook J, 1989, MOL CLONING LABORATO; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	39	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8452	8457		10.1074/jbc.270.15.8452	http://dx.doi.org/10.1074/jbc.270.15.8452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721740	hybrid			2022-12-27	WOS:A1995QT44800016
J	DOKTYCZ, MJ; MORRIS, MD; DORMADY, SJ; BEATTIE, KL				DOKTYCZ, MJ; MORRIS, MD; DORMADY, SJ; BEATTIE, KL			OPTICAL MELTING OF 128-OCTAMER DNA DUPLEXES - EFFECTS OF BASE-PAIR LOCATION AND NEAREST NEIGHBORS ON THERMAL-STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; PRIMER WALKING; HYBRIDIZATION; HEXAMERS; STACKING; OLIGONUCLEOTIDES; STRATEGY; LIBRARY; STRINGS; CURVES	The use of short oligonucleotide probes is finding increased application in DNA sequencing and genome characterization techniques, but a lack of knowledge of the hybridization properties of short duplexes hinders their use. Melting data were acquired on 128 DNA duplexes based on the length proposed in sequencing by hybridization procedures and formed from the general sequences 5'-XYZTGGAC-3', 5'-GTCCAXYZ-3', 5'-GCXYZGAC-3', and 5'-GTCXYZGC-3' where X, Y, and Z are either A, T, G, or C. These molecules were designed to elucidate the effects of location and nearest neighbor stacking on the stability of base pairing in short DNA duplexes. The type of base pairs present had a major effect on stability, but was insufficient to predict stability without the inclusion of nearest-neighbor terms. Furthermore, the addition of information on position, or distance from the end, of the nearest-neighbor doublets led to statistically better fitting of the melting data. However, the positionally dependent stabilization differences are small compared with the contributions of base pairing and stacking.	OAK RIDGE NATL LAB,DIV MATH & COMP SCI,OAK RIDGE,TN 37831; HOUSTON ADV RES CTR,DNA TECHNOL LAB,THE WOODLANDS,TX 77831	United States Department of Energy (DOE); Oak Ridge National Laboratory	DOKTYCZ, MJ (corresponding author), OAK RIDGE NATL LAB,DIV HLTH SCI RES,OAK RIDGE,TN 37831, USA.		Doktycz, Mitchel J/A-7499-2011	Doktycz, Mitchel J/0000-0003-4856-8343	NHGRI NIH HHS [1 P20 HG00666] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AZHIKINA T, 1993, P NATL ACAD SCI USA, V90, P11460, DOI 10.1073/pnas.90.24.11460; BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; DELCOURT SG, 1991, J BIOL CHEM, V266, P15160; DOKTYCZ MJ, 1992, BIOPOLYMERS, V32, P849, DOI 10.1002/bip.360320712; DRMANAC R, 1993, SCIENCE, V260, P1649, DOI 10.1126/science.8503011; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1992, ELECTROPHORESIS, V13, P566, DOI 10.1002/elps.11501301115; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; GOLDSTEIN RF, 1992, BIOPOLYMERS, V32, P1679, DOI 10.1002/bip.360321210; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; KACZOROWSKI T, 1994, ANAL BIOCHEM, V221, P127, DOI 10.1006/abio.1994.1388; KIELECZAWA J, 1992, SCIENCE, V258, P1787, DOI 10.1126/science.1465615; KOTLER LE, 1993, P NATL ACAD SCI USA, V90, P4241, DOI 10.1073/pnas.90.9.4241; LEIJON M, 1992, NUCLEIC ACIDS RES, V20, P5339, DOI 10.1093/nar/20.20.5339; LYSOV YP, 1988, DOKL AKAD NAUK SSSR, V303, P1508; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MIRZABEKOV AD, 1994, TRENDS BIOTECHNOL, V12, P27, DOI 10.1016/0167-7799(94)90008-6; ORNSTEIN RL, 1983, BIOPOLYMERS, V22, P1979, DOI 10.1002/bip.360220811; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Snedecor GW, 1967, STATISTICAL METHODS, P285; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; STREZOSKA Z, 1991, P NATL ACAD SCI USA, V88, P10089, DOI 10.1073/pnas.88.22.10089; STUDIER FW, 1989, P NATL ACAD SCI USA, V86, P6917, DOI 10.1073/pnas.86.18.6917; SZYBALSKI W, 1990, GENE, V90, P177, DOI 10.1016/0378-1119(90)90458-4; VOLOGODSKII AV, 1984, J BIOMOL STRUCT DYN, V2, P131, DOI 10.1080/07391102.1984.10507552; WARTELL RM, 1985, PHYS REP, V126, P67, DOI 10.1016/0370-1573(85)90060-2; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069	28	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8439	8445		10.1074/jbc.270.15.8439	http://dx.doi.org/10.1074/jbc.270.15.8439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721738	hybrid			2022-12-27	WOS:A1995QT44800014
J	ONG, OC; YAMANE, HK; PHAN, KB; FONG, HKW; BOK, D; LEE, RH; FUNG, BKK				ONG, OC; YAMANE, HK; PHAN, KB; FONG, HKW; BOK, D; LEE, RH; FUNG, BKK			MOLECULAR-CLONING AND CHARACTERIZATION OF THE G-PROTEIN GAMMA-SUBUNIT OF CONE PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ROD OUTER SEGMENTS; BETA-SUBUNIT; CYCLIC-GMP; SIGNAL TRANSDUCTION; RETINAL ROD; CDNA CLONE; AMINO-ACID; 3RD FORM; SEQUENCE	The phototransduction process in cones has been pro posed to involve a G protein that couples the signal from light-activated visual pigment to the effector cyclic GMP phosphodiesterase. Previously, we have identified and purified a G beta gamma complex composed of a G beta(3) isoform and an immunochemically distinct G gamma subunit (G gamma(8)) from bovine retinal cones (Fung, B. K.-K., Lieberman, B. S., and Lee, R. H. (1992) J. Biol. Chem. 267, 24782-24788; Lee, R. H., Lieberman, B, S., Yamane, H. K., Bok, D., and Fung, B. K.-K. (1992a) J. Biol. Chem. 267, 24776-24781). Based on the partial amino acid sequence of this cone G gamma(8), we screened a bovine retinal cDNA library and isolated a cDNA clone encoding G gamma(8). The cDNA insert of this clone includes an open reading frame of 207 bases encoding a 69-amino acid protein. The predicted protein sequence of G gamma(8) shares a high degree of sequence identity (68%) with the G gamma (G gamma(1)) subunit of rod transducin. Similar to rod G gamma(1), it terminates in a CIIS motif that is the site for post-translational modification by farnesylation. Messenger RNA for G gamma(8) is present at a high level in the retina and at a very low level in the lung, but is undetectable in other tissues. Immunostaining of bovine retinal sections with an antipeptide antibody against the N-terminal region of G gamma(8) further shows a differential localization of G gamma(8) to cones with a pattern indistinguishable from that of G beta(3). This finding suggests that G beta(3) gamma(8) is a component of cone transducin involved in cone phototransduction and color vision.	UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROBIOL,LOS ANGELES,CA 90024; VET ADM MED CTR,MOLEC NEUROL LAB,SEPULVEDA,CA 91343; UNIV SO CALIF,SCH MED,DOHENY EYE INST,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Doheny Eye Institute; University of Southern California; University of Southern California; University of Southern California					NATIONAL EYE INSTITUTE [R37EY000444, R01EY009936, R01EY005895, R01EY000444] Funding Source: NIH RePORTER; NEI NIH HHS [EY05895, EY 00444, EY09936] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COBBS WH, 1985, NATURE, V317, P64, DOI 10.1038/317064a0; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; FUNG BKK, 1994, METHOD ENZYMOL, V237, P509; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1986, PROG RETIN RES, V6, P151; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAKATANI K, 1986, Investigative Ophthalmology and Visual Science, V27, P300; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1993, ANN REV PHARM TOXICO, V32, P201; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9	58	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8495	8500		10.1074/jbc.270.15.8495	http://dx.doi.org/10.1074/jbc.270.15.8495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721746	hybrid			2022-12-27	WOS:A1995QT44800022
J	RIGLER, MN; ROMANO, LJ				RIGLER, MN; ROMANO, LJ			DIFFERENCES IN THE MECHANISM OF STIMULATION OF T7 DNA-POLYMERASE BY 2 BINDING MODES OF ESCHERICHIA-COLI SINGLE-STRANDED DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; GENE-4 PROTEIN; REPLICATION FORK; T7-DNA POLYMERASE; SSDNA COMPLEXES; RECA-PROTEIN; INVITRO; SSB; GENE-4-PROTEIN; OPERATIVITY	Escherichia coli single-stranded DNA-binding protein (Eco SSB) has been shown previously to display several DNA binding modes depending on the ionic conditions. To determine what effect these various binding modes have on DNA replication, we have studied DNA synthesis by the T7 DNA polymerase under ionic conditions where Eco SSB interacts with either 72 or 91 nucleotides of M13 DNA. These forms presumably correspond to the previously described (SSB)(56) land (SSB)(65) (Lohman and Ferrari, 1994) that were determined using the binding of SSB to homopolymers. Here we report the stimulation induced by (SSB)(91) to be 4-fold greater than that produced by (SSB)(72) under conditions where the template is in large excess. Surprisingly, when the polymerase level is raised so that it is in molecular excess, (SSB)(91) no longer stimulates synthesis while (SSB)(72) affords a 4-fold stimulation, which is the same level of stimulation as when the template was mi excess. Both SSB forms increase the rate of DNA synthesis and were found to stimulate synthesis by relieving template secondary structures. However, (SSB)(72) specifically increases strand displacement synthesis, while (SSB)(91) stimulates synthesis by increasing the affinity of the polymerase for the template.	WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	Wayne State University					NATIONAL CANCER INSTITUTE [R01CA035451, R01CA040605] Funding Source: NIH RePORTER; NCI NIH HHS [CA40605, CA35451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1989, J MOL BIOL, V207, P249, DOI 10.1016/0022-2836(89)90454-3; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; CAMERON IL, 1980, CANCER RES, V40, P143; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; EPEL D, 1982, IONS CELL PROLIFERAT, P327; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FULLER CW, 1985, J BIOL CHEM, V260, P3197; GREIPEL J, 1987, BIOPHYS CHEM, V26, P149, DOI 10.1016/0301-4622(87)80018-2; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HAYES RC, 1983, GENE, V21, P1, DOI 10.1016/0378-1119(83)90141-5; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Kowalczykowski S.C., 1981, ENZYMES, V14, P373; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P53246; KUHN A, 1985, J BACTERIOL, V163, P906, DOI 10.1128/JB.163.3.906-912.1985; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MCCLELLAND M, 1988, NUCLEIC ACIDS RES, V16, P364, DOI 10.1093/nar/16.1.364; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; MYERS TW, 1988, J BIOL CHEM, V263, P17006; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Record M T Jr, 1985, Adv Biophys, V20, P109; RICHARDSON CC, 1971, PROCEDURES NUCLEIC A, V2, P815; RICHARDSON CC, 1983, REPLICATION VIRAL CE, P163; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; Sambrook J, 1989, MOL CLONING LABORATO; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; STEINHARDT RA, 1982, IONS CELL PROLIFERAT, P311; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; WEINER JH, 1975, J BIOL CHEM, V250, P1972	54	6	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8910	8919		10.1074/jbc.270.15.8910	http://dx.doi.org/10.1074/jbc.270.15.8910			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721799	hybrid			2022-12-27	WOS:A1995QT44800078
J	SIDDIQI, AR; SMITH, JL; ROSS, AH; QUO, RG; SYMONS, M; EXTON, JH				SIDDIQI, AR; SMITH, JL; ROSS, AH; QUO, RG; SYMONS, M; EXTON, JH			REGULATION OF PHOSPHOLIPASE-D IN HL-60 CELLS - EVIDENCE FOR A CYTOSOLIC PHOSPHOLIPASE-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; ADP-RIBOSYLATION; PHOSPHATIDIC-ACID; CHOLERA-TOXIN; GROWTH-FACTOR; HL-60 GRANULOCYTES; ENDOTHELIAL-CELLS; 3T3 CELLS; RAT-BRAIN; ACTIVATION	Phospholipase D (PLD) activity that was stimulated by guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) was detected in cytosol and membranes of HL60 cells. GTP gamma S-stimulated PLD activity was detected in the membranes when exogenous labeled phosphatidylcholine was used in the presence of phosphatidylethanolamine and phosphatidylinositol 4,5-bisphosphate, but not when [H-3]myristic acid labeled endogenous substrate was used. Cytosolic PLD co-chromatographed with small GTP-binding proteins on anion exchange columns, but subsequent chromatography separated these. Reconstitution studies demonstrated ADP ribosylation factor (ARF) as a regulator of cytosolic PLD, whereas the Rho proteins RhoA and CDC42Hs were ineffective. The cytosolic enzyme showed very little activity in the absence of GTP gamma S and was stimulated by 2 mM Ca2+, whereas the membrane enzyme had significant basal activity and was inhibited by Ca2+. Rho-specific GDP dissociation inhibitor inhibited GTP gamma S stimulation of membrane PLD activity in the presence and absence of cytosol. The stimulation in GDP dissociation inhibitor-treated membranes could be partially recovered by the addition of recombinant Rho proteins (RhoA, Rac1, CDC42Hs). RhoA and Rac1 were also stimulatory in untreated membranes. However, Western blot analysis of membranes showed the presence of RhoA, but not Rac1 or CDC42Hs, suggesting that RhoA was the endogenous small GTP-binding protein involved in GTP-dependent PLD activity in membranes in the absence of cytosol. ARF also stimulated the membrane PLD in the presence of GTP gamma S, and the combination of RhoA and ARF showed a synergistic effect. These results show the presence of ARF-dependent PLD activity in both cytosol and membranes. The membranes contain another PLD activity for which the endogenous regulator appears to be RhoA. The data suggest the existence of at least two different PLD isozymes in HL60 cells.	VANDERBILT UNIV, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOLEC BIOPHYS, NASHVILLE, TN 37232 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Bligh E., 1959, CAN J BIOCH PHYSL, V37, P11; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOUGSKI MS, 1993, NATURE, V366, P643; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHALIFOUR RJ, 1980, BIOCHEM BIOPH RES CO, V96, P742, DOI 10.1016/0006-291X(80)91417-5; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GENY B, 1992, EUR J BIOCHEM, V215, P389; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; KONDO T, 1992, J BIOL CHEM, V267, P23609; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MOSS J, 1991, METHOD ENZYMOL, V195, P243; MURAYAMA Y, 1989, J BIOL CHEM, V262, P12463; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; TSAI SC, 1988, J CELL BIOL, V107, P4017; WANG P, 1991, J BIOL CHEM, V266, P14877; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P21309	37	151	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8466	8473		10.1074/jbc.270.15.8466	http://dx.doi.org/10.1074/jbc.270.15.8466			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721742	hybrid			2022-12-27	WOS:A1995QT44800018
J	DONELSON, JE				DONELSON, JE			MECHANISMS OF ANTIGENIC VARIATION IN BORRELIA-HERMSII AND AFRICAN TRYPANOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							VARIANT SURFACE GLYCOPROTEINS; TELOMERIC EXPRESSION SITE; LYME-DISEASE AGENT; T-BRUCEI; RECIPROCAL RECOMBINATION; GENE-EXPRESSION; VSG GENE; DNA; TRANSCRIPTION; BURGDORFERI		UNIV IOWA,HOWARD HUGHES MED INST,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa	DONELSON, JE (corresponding author), UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242, USA.		Donelson, John E/F-5795-2010					AGUR Z, 1989, P NATL ACAD SCI USA, V86, P9626, DOI 10.1073/pnas.86.23.9626; ALBERTS B, 1994, MOL BIOL CELL, P1221; BALTZ T, 1986, NATURE, V319, P602, DOI 10.1038/319602a0; Barbour A G, 1993, Trends Microbiol, V1, P236, DOI 10.1016/0966-842X(93)90139-I; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1991, MOL MICROBIOL, V5, P489, DOI 10.1111/j.1365-2958.1991.tb02132.x; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BERNARDS A, 1986, GENE, V42, P313, DOI 10.1016/0378-1119(86)90235-0; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BORST P, 1982, MOL BIOCHEM PARASIT, V6, P13, DOI 10.1016/0166-6851(82)90049-4; BORST P, 1983, GENETIC REARRANGEMEN, P207; BOTH GW, 1990, MOL CELL BIOL, V10, P5187, DOI 10.1128/MCB.10.10.5187; CAPBERN A, 1977, EXP PARASITOL, V42, P6, DOI 10.1016/0014-4894(77)90055-8; CAPORALE DA, 1994, MOL BIOL EVOL, V11, P51; CARTER CJ, 1994, INFECT IMMUN, V62, P2792, DOI 10.1128/IAI.62.7.2792-2799.1994; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; Clayton C.E., 1988, Genetic Engineering, V7, P1; CORNELISSEN AWCA, 1985, CELL, V41, P825, DOI 10.1016/S0092-8674(85)80063-5; CROZATIER M, 1990, MOL BIOCHEM PARASIT, V42, P1, DOI 10.1016/0166-6851(90)90107-W; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DEGEE ALW, 1981, EXP PARASITOL, V51, P392, DOI 10.1016/0014-4894(81)90126-0; DONELSON JE, 1985, MICROBIOL REV, V49, P107, DOI 10.1128/MMBR.49.2.107-125.1985; ESSER KM, 1985, SCIENCE, V229, P190, DOI 10.1126/science.3892689; FERDOWS MS, 1989, P NATL ACAD SCI USA, V86, P5969, DOI 10.1073/pnas.86.15.5969; FINK GR, 1984, NATURE, V310, P728, DOI 10.1038/310728a0; GOLDING GB, 1987, GENETICS, V15, P169; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; HAJDUK S, 1992, AM J MED SCI, V303, P58; HINNEBUSCH J, 1992, J BACTERIOL, V174, P5251, DOI 10.1128/JB.174.16.5251-5257.1992; HOEIJMAKERS JHJ, 1980, NATURE, V284, P78, DOI 10.1038/284078a0; HOWE TR, 1986, INFECT IMMUN, V54, P207, DOI 10.1128/IAI.54.1.207-212.1986; HUGHES CAN, 1990, J BACTERIOL, V172, P6602, DOI 10.1128/jb.172.11.6602-6604.1990; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAMPER SM, 1992, MOL BIOCHEM PARASIT, V53, P33, DOI 10.1016/0166-6851(92)90004-4; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; KITTEN T, 1992, GENETICS, V132, P311; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; LONGACRE S, 1986, EMBO J, V5, P1057, DOI 10.1002/j.1460-2075.1986.tb04322.x; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; MCCORMACK WT, 1990, GENE DEV, V4, P548, DOI 10.1101/gad.4.4.548; MILLER EN, 1981, PARASITOLOGY, V82, P63, DOI 10.1017/S0031182000041871; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PASTER BJ, 1991, J BACTERIOL, V173, P6101, DOI 10.1128/JB.173.19.6101-6109.1991; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1985, NATURE, V316, P562, DOI 10.1038/316562a0; PAYS E, 1983, CELL, V34, P371, DOI 10.1016/0092-8674(83)90371-9; PLASTERK RH, 1985, NATURE, V318, P218; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; ROGERSON B, 1991, EMBO J, V10, P4331, DOI 10.1002/j.1460-2075.1991.tb05011.x; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; THON G, 1989, GENE DEV, V3, P1247, DOI 10.1101/gad.3.8.1247; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P3591, DOI 10.1093/nar/10.12.3591; VANDERPLOEG LHT, 1992, TRENDS GENET, V8, P452, DOI 10.1016/0168-9525(92)90179-8; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; VANDERPLOEG LHT, 1989, NUCLEIC ACIDS RES, V17, P3217, DOI 10.1093/nar/17.8.3217; WEIDEN M, 1991, MOL CELL BIOL, V11, P3823, DOI 10.1128/MCB.11.8.3823	68	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7783	7786		10.1074/jbc.270.14.7783	http://dx.doi.org/10.1074/jbc.270.14.7783			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713867	hybrid			2022-12-27	WOS:A1995QR52600001
J	EHLERS, M; DEHON, FD; BOS, HK; HORSTEN, U; KURAPKAT, G; VANDELEUR, HS; GROTZINGER, J; WOLLMER, A; BRAKENHOFF, JPJ; ROSEJOHN, S				EHLERS, M; DEHON, FD; BOS, HK; HORSTEN, U; KURAPKAT, G; VANDELEUR, HS; GROTZINGER, J; WOLLMER, A; BRAKENHOFF, JPJ; ROSEJOHN, S			COMBINING 2 MUTATIONS OF HUMAN INTERLEUKIN-6 THAT AFFECT GP130 ACTIVATION RESULTS IN A POTENT INTERLEUKIN-6 RECEPTOR ANTAGONIST ON HUMAN MYELOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; BIOLOGICAL-ACTIVITY; SIGNAL TRANSDUCER; BINDING SITE; INVOLVEMENT; EXPRESSION; CYTOKINES; TERMINUS; IL-6; PRODUCE	The pleiotropic cytokine interleukin-6 (IL-6) interacts with the specific ligand binding subunit (IL-6R alpha) of the IL-6 receptor, and this complex associates with the signal-transducing subunit gp130 (IL-6R beta). Human IL-6 acts on human and murine cells, whereas murine IL-6 is only active on murine cells. The construction of a set of chimeric human/murine IL-6 proteins has recently allowed us to define a region (residues 43-55) within the human IL-6 protein, which is important for the interaction with gp130. Subdividing this region shows that mainly residues 50-55 of the human IL-6 are necessary for this interaction. Recently, another human IL-6 double mutant (Q159E and T162P) showed reduced affinity to gp130 but residual activity on the human myeloma cell line XG-1. Into this IL-6 mutant we introduced the murine residues 43-49 or 50-55 together with two point mutations, F170L and S176A, which had been reported to increase the affinity of IL-6 to the IL-6R alpha. The resulting IL-6 molecule, which contained the murine residues 50-55, was inactive on human myeloma cells and in addition completely inhibited wild type IL-6 activity on these cells. Such an antagonist may be used as a specific inhibitor of IL-6 activity in vivo.	UNIV MAINZ, I MED CLIN, PATHOPHYSIOL SECT, D-55101 MAINZ, GERMANY; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT AUTOIMMUNE DIS, 1066 CX AMSTERDAM, NETHERLANDS; RHEIN WESTFAL TH AACHEN, DEPT BIOCHEM, D-52057 AACHEN, GERMANY	Johannes Gutenberg University of Mainz; RWTH Aachen University			Ehlers, Marc/C-9441-2011; Rose-John, Stefan/A-7998-2010	Ehlers, Marc/0000-0002-5383-8603; Rose-John, Stefan/0000-0002-7519-3279				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; BRAKENHOFF JPJ, 1992, SERONO S PUBLICATION, V88, P33; CASTELL J, 1990, EUR J BIOCHEM, V189, P113, DOI 10.1111/j.1432-1033.1990.tb15466.x; EHLERS M, 1994, J IMMUNOL, V153, P1744; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KLEIN B, 1991, BLOOD, V78, P1198; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MULLBERG J, 1993, FEBS LETT, V332, P174, DOI 10.1016/0014-5793(93)80507-Q; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, CANCER RES, V53, P851; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VANDAM M, 1993, J BIOL CHEM, V268, P15285; WARD LD, 1994, J BIOL CHEM, V269, P23286; WENDLING D, 1993, J RHEUMATOL, V20, P259; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	35	35	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8158	8163		10.1074/jbc.270.14.8158	http://dx.doi.org/10.1074/jbc.270.14.8158			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713920	hybrid			2022-12-27	WOS:A1995QR52600059
J	HSU, DS; KIM, ST; SUN, Q; SANCAR, A				HSU, DS; KIM, ST; SUN, Q; SANCAR, A			STRUCTURE AND FUNCTION OF THE UVRB PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI UVRB; (A)BC EXCINUCLEASE; DNA PHOTOLYASE; ACTIVE-SITE; 5' INCISION; COMPLEX; ATP; MECHANISM	UvrB plays a central role in (A)BC excinuclease. To identify the regions of UvrB which are involved in interacting with UvrA, UvrC, and DNA, deletion mutants, point mutants, and various fusion forms of UvrB were constructed and characterized. We found that the region encompassing amino acid residues 115-250 of UvrB binds to UvrA, while the region encompassing amino acid residues 547-673 binds to both UvrA and UvrC. In addition, the region between these two domains, which contains the helicase motifs II-VI, was found to be involved in binding to DNA. Within this DNA-binding region, two point mutants, E265A and E338A, were found to be unable to bind DNA while two residues, Phe-365 and Phe-496, were identified to interact with DNA. Furthermore, fluorescence quenching studies with mutants F365W and F496W and repair of thymine cyclobutane dimers by photoinduced electron transfer by these mutants suggest that residues Phe-365 and Phe-496 interact with DNA most likely through stacking interactions.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BACKENDORF C, 1986, NUCLEIC ACIDS RES, V14, P2877, DOI 10.1093/nar/14.7.2877; CRUTE JJ, 1983, J BIOL CHEM, V258, P1344; FERRARI ME, 1994, J MOL BIOL, V236, P106, DOI 10.1006/jmbi.1994.1122; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HELENE C, 1977, PHOTOCHEM PHOTOBIOL, V52, P789; HSU DS, 1994, J MOL BIOL, V241, P645, DOI 10.1006/jmbi.1994.1541; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KIM ST, 1990, PHOTOCHEM PHOTOBIOL, V52, P789, DOI 10.1111/j.1751-1097.1990.tb08683.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; KWONSHIN O, 1987, J BIOL CHEM, V262, P2121; LI YF, 1993, P NATL ACAD SCI USA, V90, P4389, DOI 10.1073/pnas.90.10.4389; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; NOSSAL NG, 1984, BACTERIOPHAGE T, V4, P71; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PHILLIPS AM, 1994, THESIS U N CAROLINA; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SANDERS GM, 1994, P NATL ACAD SCI USA, V91, P7703, DOI 10.1073/pnas.91.16.7703; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; VISSE R, 1994, BIOCHEMISTRY-US, V33, P9881, DOI 10.1021/bi00199a009	37	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8319	8327		10.1074/jbc.270.14.8319	http://dx.doi.org/10.1074/jbc.270.14.8319			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713940	hybrid, Green Published			2022-12-27	WOS:A1995QR52600079
J	KUWABARA, K; PINSKY, DJ; SCHMIDT, AM; BENEDICT, C; BRETT, J; OGAWA, S; BROEKMAN, MJ; MARCUS, AJ; SCIACCA, RR; MICHALAK, M; WANG, F; PAN, YC; GRUNFELD, S; PATTON, S; MALINSKI, T; STERN, DM; RYAN, J				KUWABARA, K; PINSKY, DJ; SCHMIDT, AM; BENEDICT, C; BRETT, J; OGAWA, S; BROEKMAN, MJ; MARCUS, AJ; SCIACCA, RR; MICHALAK, M; WANG, F; PAN, YC; GRUNFELD, S; PATTON, S; MALINSKI, T; STERN, DM; RYAN, J			CALRETICULIN, AN ANTITHROMBOTIC AGENT WHICH BINDS TO VITAMIN-K-DEPENDENT COAGULATION-FACTORS, STIMULATES ENDOTHELIAL NITRIC-OXIDE PRODUCTION, AND LIMITS THROMBOSIS IN CANINE CORONARY-ARTERIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; GAMMA-CARBOXYGLUTAMIC ACID; TUMOR NECROSIS FACTOR; HUMAN FACTOR-IX; FACTOR-X; HIGH-AFFINITY; CELL-SURFACE; FACTOR-VA; ESCHERICHIA-COLI; TISSUE FACTOR	Coagulation Factor IX/IXa has been shown to bind to cellular surfaces, and Factor IXa expresses its procoagulant activity by assembling into the intrinsic Factor X activating complex (Factors IXa/VIIIa/X), which also forms on membrane surfaces. This led us to identify cellular proteins which bind Factor IX/IXa; an approximate to 55-kDa polypeptide was purified to homogeneity from bovine lung extracts based on its capacity to bind I-125-Factor IX in a dose-dependent and saturable manner. From protein sequence data of the amino terminus and internal peptides, the approximate to 55-kDa polypeptide was identified as calreticulin, a previously identified intracellular calcium binding protein. Recombinant calreticulin bound vitamin K-dependent coagulation factors, I-125-Factor IX, I-125-Factor X, and I-125-prothrombin (K-d values of approximate to 2.7, 3.2, and 8.3 nM, respectively), via interaction with its C-domain, although it did not affect the coagulant properties of these proteins. I-125-Calreticulin also bound to endothelial cells in vitro (K-d approximate to 7.4 nM), and mouse infusion studies showed an initial rapid phase of clearance in which calreticulin could be localized on the vascular endothelium. Exposure of endothelial cells to calreticulin led to dose-dependent, immediate, and sustained increase in the production of nitric oxide, as measured using a porphyrinic microsensor. In a canine electrically induced thrombosis model, intracoronary infusion of calreticulin (n = 7) prevented occlusion of the left circumflex coronary artery in a dose-dependent manner compared with vehicle-treated controls (n = 5). These results indicate that calreticulin interacts with the endothelium to stimulate release of nitric oxide and inhibit clot formation.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, HOUSTON, TX 77225 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10010 USA; CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10010 USA; DEPT VET AFFAIRS, MED CTR, NEW YORK, NY 10010 USA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2E1, CANADA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, NUTLEY, NJ 07110 USA; OAKLAND UNIV, DEPT CHEM, ROCHESTER, MI 48309 USA	Columbia University; Columbia University; University of Texas System; University of Texas Health Science Center Houston; Cornell University; Cornell University; University of Alberta; Roche Holding; Oakland University					NHLBI NIH HHS [HL42833, HL34625] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034625, R01HL042833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J CLIN INVEST, V84, P824, DOI 10.1172/JCI114242; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BENEDICT CR, 1991, J CLIN INVEST, V88, P1760, DOI 10.1172/JCI115495; BENEDICT CR, 1986, CIRC RES, V58, P58, DOI 10.1161/01.RES.58.1.58; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; COLLINS JH, 1989, BIOCHEM BIOPH RES CO, V164, P575, DOI 10.1016/0006-291X(89)91758-0; DAVID GS, 1974, BIOCHEMISTRY-US, V13, P1014, DOI 10.1021/bi00702a028; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; ESMON NL, 1982, J BIOL CHEM, V257, P859; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; GITEL SN, 1977, P NATL ACAD SCI USA, V74, P3028, DOI 10.1073/pnas.74.7.3028; GUREWICH V, 1979, THROMB RES, V14, P931, DOI 10.1016/0049-3848(79)90011-2; HEIMARK RL, 1983, BIOCHEM BIOPH RES CO, V111, P723, DOI 10.1016/0006-291X(83)90365-0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1986, METHODS PROTEIN MICR, P315; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI J, 1993, J PHARMACOL EXP THER, V267, P371; LOLLAR P, 1980, J BIOL CHEM, V255, P279; LONDON F, 1992, CIRCULATION S1, V86, P1855; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; RAPAPORT S, 1990, PHYSL BASIS MED PRAC, P385; RIMON S, 1987, J BIOL CHEM, V262, P6023; ROKEACH LA, 1991, J IMMUNOL, V147, P3031; ROSING J, 1980, J BIOL CHEM, V255, P274; RYAN J, 1989, J BIOL CHEM, V264, P20283; RYAN J, 1992, BLOOD, V80, P966; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STERN DM, 1986, J BIOL CHEM, V261, P713; STERN DM, 1984, P NATL ACAD SCI-BIOL, V81, P913, DOI 10.1073/pnas.81.3.913; STERN DM, 1985, J BIOL CHEM, V260, P6717; STERN DM, 1987, BRIT J HAEMATOL, V66, P227, DOI 10.1111/j.1365-2141.1987.tb01303.x; SUEYOSHI T, 1991, THROMB RES, V63, P569, DOI 10.1016/0049-3848(91)90184-X; THOMPSON AR, 1986, BLOOD, V67, P565; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; TRACY PB, 1981, J BIOL CHEM, V256, P743; VAN PN, 1989, J BIOL CHEM, V264, P17494; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	51	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8179	8187		10.1074/jbc.270.14.8179	http://dx.doi.org/10.1074/jbc.270.14.8179			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713923	hybrid			2022-12-27	WOS:A1995QR52600062
J	TROPF, S; KARCHER, B; SCHRODER, G; SCHRODER, J				TROPF, S; KARCHER, B; SCHRODER, G; SCHRODER, J			REACTION-MECHANISMS OF HOMODIMERIC PLANT POLYKETIDE SYNTHASES (STILBENE AND CHALCONE SYNTHASE) - A SINGLE ACTIVE-SITE FOR THE CONDENSING REACTION IS SUFFICIENT FOR SYNTHESIS OF STILBENES, CHALCONES, AND 6'-DEOXYCHALCONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; PUTATIVE REGULATORY ELEMENTS; PINE PINUS-SYLVESTRIS; NUCLEOTIDE-SEQUENCE; FLAVANONE SYNTHASE; MULTIGENE FAMILY; PETROSELINUM-HORTENSE; SUBSTRATE-SPECIFICITY; PURIFICATION; BIOSYNTHESIS	Stilbene (STS) and chalcone (CHS) synthases are homodimeric, related plant-specific polyketide synthases. Both perform a sequential condensation of three acetate units to a starter residue to form a tetraketide intermediate that is folded to the ring systems specific to the different products. Protein cross-linking and site-directed mutagenesis identified a subunit contact site in position 158, close to the active site (Cys(169)). This suggested that the active site pockets may be neighboring, possibly alternating in the condensing reactions rather than acting independently. This was investigated by coexpression of active site mutants with differently mutated, inactive proteins. With both STS and CHS, the heterodimers synthesized the end products, indicating that each subunit performed all three condensations. In co-action with a monomeric reductase, CHS also synthesizes 6'-deoxychalcone, but with the chalcone as second product when using plant preparations. The two enzymes expressed as single species in Escherichia coli synthesized both products, and both were also obtained with a CHS heterodimer containing a single active site. The results showed that 6'-deoxychalcone synthesis required no other plant factor and that the formation of two products may be an intrinsic property of the interaction between dimeric CHS and monomeric reductase.	UNIV FREIBURG, INST BIOL 2, D-79104 FREIBURG, GERMANY	University of Freiburg								AKADA S, 1990, NUCLEIC ACIDS RES, V18, P3398, DOI 10.1093/nar/18.11.3398; AKADA S, 1993, PLANT PHYSIOL, V102, P321, DOI 10.1104/pp.102.1.321; AKADA S, 1993, PLANT PHYSIOL, V102, P317, DOI 10.1104/pp.102.1.317; AKADA S, 1993, PLANT PHYSIOL, V102, P699, DOI 10.1104/pp.102.2.699; AKADA S, 1991, PLANT MOL BIOL, V16, P751, DOI 10.1007/BF00023443; AKADA S, 1990, NUCLEIC ACIDS RES, V18, P5899, DOI 10.1093/nar/18.19.5899; AYABE SI, 1988, ARCH BIOCHEM BIOPHYS, V261, P458, DOI 10.1016/0003-9861(88)90362-1; BOREJSZAWYSOCKI W, 1994, PHYTOCHEMISTRY, V35, P623, DOI 10.1016/S0031-9422(00)90575-2; CROWE J, 1992, QIA EXPRESSIONIS; FLIEGMANN J, 1992, PLANT MOL BIOL, V18, P489, DOI 10.1007/BF00040665; GEHLERT R, 1990, MOL PLANT MICROBE IN, V3, P444, DOI 10.1094/MPMI-3-444; HAKAMATSUKA T, 1988, CHEM PHARM BULL, V36, P4225, DOI 10.1248/cpb.36.4225; HARANO K, 1993, PLANT CELL REP, V12, P66, DOI 10.1007/BF00241936; HELLER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P617, DOI 10.1016/0003-9861(80)90395-1; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HRAZDINA G, 1976, ARCH BIOCHEM BIOPHYS, V175, P392, DOI 10.1016/0003-9861(76)90526-9; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KREUZALER F, 1975, EUR J BIOCHEM, V56, P205, DOI 10.1111/j.1432-1033.1975.tb02223.x; KREUZALER F, 1978, FEBS LETT, V94, P175, DOI 10.1016/0014-5793(78)80931-4; KREUZALER F, 1979, EUR J BIOCHEM, V99, P89, DOI 10.1111/j.1432-1033.1979.tb13235.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANZ T, 1991, J BIOL CHEM, V266, P9971; Martson F.A.O., 1986, BIOCHEM J, V240, P1; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; PITTRIVE.R, 1968, BIOCHEM J, V109, P825, DOI 10.1042/bj1090825; REINECKE T, 1994, PHYTOCHEMISTRY, V35, P63, DOI 10.1016/S0031-9422(00)90510-7; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHANZ S, 1992, FEBS LETT, V313, P71, DOI 10.1016/0014-5793(92)81187-Q; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; SCHRODER G, 1992, J BIOL CHEM, V267, P20558; SCHRODER J, 1990, Z NATURFORSCH C, V45, P1; SCHRODER J, 1993, DEV PLANT PATHOL, V2, P257; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; TROPF S, 1994, J MOL EVOL, V38, P610; Weber K, 1972, Methods Enzymol, V26, P3; WELLE R, 1988, FEBS LETT, V236, P221, DOI 10.1016/0014-5793(88)80318-1; WELLE R, 1991, EUR J BIOCHEM, V196, P423, DOI 10.1111/j.1432-1033.1991.tb15833.x; WELLE R, 1987, Z NATURFORSCH C, V42, P1200; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	41	110	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7922	7928		10.1074/jbc.270.14.7922	http://dx.doi.org/10.1074/jbc.270.14.7922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713888	hybrid			2022-12-27	WOS:A1995QR52600024
J	HANASAKI, K; POWELL, LD; VARKI, A				HANASAKI, K; POWELL, LD; VARKI, A			BINDING OF HUMAN PLASMA SIALOGLYCOPROTEINS BY THE B-CELL-SPECIFIC LECTIN CD22 - SELECTIVE RECOGNITION OF IMMUNOGLOBULIN-M AND HAPTOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ANTIGEN RECEPTOR; ALPHA-2->6 SIALYLTRANSFERASE; SIALIC ACIDS; T-CELLS; ADHESION; OLIGOSACCHARIDE; GLYCOPROTEINS; LYMPHOCYTES; LIVER	CD22 is a cell-surface receptor of resting mature B cells that recognizes sialic acid (Sia) in the natural structure Sia alpha 2-GGal beta 1-4GlcNAc (Powell, L. D., Jain, Il. K., Matta, K. L., Sabesan, S., and Varki, A. (1995) J. Biol. Chem. 270, 7523-7532). Human umbilical vein endothelial cells (HEC) treated with inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) display increases in cell-surface CD22 ligands, caused by increased expression of the enzyme beta-galactoside alpha 2,6-sialyltransferase (Hanasaki, K., Varki, A., Stamenkovic, I., and Bevilacqua, M. P. (1994) J. Biol. Chem. 269, 10637-10643; Hanasaki, H., Varki, A., and Powell, L. D. (1995) J. Biol Chem. 270, 7533-7542). Thus, CD22 could direct potential interactions between mature B cells and endothelial cells during inflammatory states. However, this would have to occur in the presence of blood plasma, which contains many sialoglycoproteins known to carry alpha 2-6-linked sialic acids. We show here that human plasma can indeed inhibit Sia-dependent binding of a recombinant soluble chimeric form of human CD22 (CD22Rg) to TNF-alpha activated HEC. Affinity adsorption of individual human plasma samples with immobilized CD22Rg showed that, of the numerous alpha 2-6-sialic acid containing glycoproteins in plasma, only three polypeptides with apparent molecular mass (under reducing conditions) of 74, 44, and 25 kDa bound, and were spe specifically eluted with alpha 2-6-sialyllactose. NH2-terminal amino acid sequencing of these high affinity CD22 ligands revealed that they are subunits of immunoglobulin M (IgM) and haptoglobin. Purified human IgM from pooled human plasma can be quantitatively bound by CD22Rg, and binding is blocked by alpha 2-6-sialyllactose, but not by alpha 2-3-sialyllactose. Pretreatment by sialidase or by mild periodate oxidation of sialic acid side chains abolishes these interactions. IgM at physiological concentrations also inhibits CD22Rg binding to TNF-alpha-activated HEC in a manner dependent not only upon its sialylation but also requiring its intact multimeric structure. These data show that CD22 is capable of highly selective recognition of certain multimeric plasma sialoglycoproteins that carry alpha 2-6-linked sialic acids. Notably, the two proteins that are selectively recognized are known to be involved in immune and inflammatory responses. Haptoglobin synthesis by the liver is markedly increased during the ''acute phase response'' to systemic inflammation, while IgM is the major product resulting from activation of resting CD22-positive B cells.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,DIV CELLULAR & MOLEC MED,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego					NCI NIH HHS [KO1 CA01649] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER JU, 1979, J BIOL CHEM, V254, P4063; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; BOWMAN BH, 1982, ADV HUM GENET, V12, P453; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; CAHOUR A, 1983, BIOCHEM J, V211, P55, DOI 10.1042/bj2110055; CHEN JZ, 1993, CURR OPIN IMMUNOL, V5, P194, DOI 10.1016/0952-7915(93)90004-C; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CLARK EA, 1993, J IMMUNOL, V150, P4715; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DOUBET S, 1992, GLYCOBIOLOGY, V2, P505, DOI 10.1093/glycob/2.6.505; ENGEL P, 1993, J IMMUNOL, V150, P4719; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HICKMAN S, 1972, J BIOL CHEM, V247, P2156; JAMIESON JC, 1993, COMP BIOCHEM PHYS B, V105, P29, DOI 10.1016/0305-0491(93)90165-2; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MAEDA N, 1986, ANNU REV GENET, V20, P81; MCLEAN RL, 1971, J BIOL CHEM, V246, P803; MILLER F, 1970, IMMUNOCHEMISTRY, V7, P423, DOI 10.1016/0019-2791(70)90224-7; OLSZEWSKI W, 1989, PERIPHERAL LYMPH FOR; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; REUTER G, 1989, GLYCOCONJUGATE J, V6, P35, DOI 10.1007/BF01047888; Ritzmann SE., 1982, SERUM PROTEIN ABNORM; SASSO EH, 1989, J IMMUNOL, V142, P2778; Schauer R, 1982, SIALIC ACIDS CHEM ME, V10; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SOLIS D, 1994, J BIOL CHEM, V269, P11555; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; WANG XC, 1993, J BIOL CHEM, V268, P4355; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	49	125	142	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7543	7550		10.1074/jbc.270.13.7543	http://dx.doi.org/10.1074/jbc.270.13.7543			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706301	hybrid			2022-12-27	WOS:A1995QQ43100076
J	LEVIN, LR; REED, RR				LEVIN, LR; REED, RR			IDENTIFICATION OF FUNCTIONAL DOMAINS OF ADENYLYL-CYCLASE USING IN-VIVO CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CALMODULIN-BINDING DOMAIN; PROTEIN; CLONING; STIMULATION; EXPRESSION; ALPHA; GS; ACTIVATION; CALCIUM	Adenylyl cyclase, the effector molecule of the cAMP signaling pathway, is composed of a family of isoforms that differ in their modes of regulation, Many of these modulatory interactions are dependent upon well characterized molecules from various second messenger pathways; however, very little is known about their mechanisms or sites of action on adenylyl cyclase, Chimeras were produced by a novel in vivo mechanism between two differentially modulated adenylyl cyclases to identify their regulatory domains, The basal activity of the type I adenylyl cyclase (AC1) is activated by calcium/calmodulin, inhibited by G protein beta gamma subunits, and insensitive to protein kinase C regulation, In contrast, type II adenylyl cyclase (AC2) is insensitive to calcium/calmodulin regulation and is activated by G protein beta gamma subunits as well as by activated protein kinase C. Expression and biochemical characterization of chimeras between AC1 and AC2 identified a single specific domain of AC1 responsible for calmodulin binding and a small, well defined region near the C terminus of AC2 required for protein kinase C activation.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University			Reed, Russell/HGU-0528-2022	Levin, Lonny/0000-0002-5204-6356				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GLENNEY JR, 1984, CELL, V37, P743, DOI 10.1016/0092-8674(84)90410-0; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MINOCHERHOMJEE AEVM, 1987, BIOCHEMISTRY-US, V26, P4444, DOI 10.1021/bi00388a038; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WU ZL, 1993, J BIOL CHEM, V268, P23766; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	34	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7573	7579		10.1074/jbc.270.13.7573	http://dx.doi.org/10.1074/jbc.270.13.7573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706305	hybrid			2022-12-27	WOS:A1995QQ43100081
J	LEW, AM; ELSHOLTZ, HP				LEW, AM; ELSHOLTZ, HP			A DOPAMINE-RESPONSIVE DOMAIN IN THE N-TERMINAL SEQUENCE OF PIT-1 - TRANSCRIPTIONAL INHIBITION IN ENDOCRINE CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; POU-SPECIFIC DOMAIN; PROLACTIN PROMOTER; GROWTH-HORMONE; GENE PROMOTERS; ALPHA-SUBUNITS; D2 RECEPTOR; PITUITARY; EXPRESSION; PROTEIN	The POU transcription factor Pit-1 activates the prolactin gene in pituitary lactotrophs and may integrate responses of the gene to external signals, To study the role of Pit-1 in dopaminergic inhibition of the prolactin gene, we transiently transfected Pit-1 and dopamine D2 receptor vectors into a series of heterologous cell lines and examined dopamine regulation of the prolactin gene promoter. Regulation was Pit-1-dependent in all cell lines tested, Moreover, dopamine responsiveness was cell type-specific: stimulatory in fibroblasts (COS-7) and muscle-type cells (P19/M(2)SO-induced) and inhibitory in pancreatic endocrine (RIN, InR1-G9) and neural-like (P19/retinoic acid-induced) cells, Because dopaminergic responses in Pit-1-transfected RIN cells paralleled those in pituitary GH4 cells, the islet cell line was used to test for sequences in Pit-1 that mediate negative hormone signals, Dopamine responsiveness of the Pit-1 transactivation domain (residues 8-80) was examined using a chimeric LexA construct, LxPit-1, LxSp1, and Lx-glucocorticoid receptor fusions all activated basal transcription, but only LxPit-1 was regulated by dopamine, Regulatory responses of LxPit-1 and full-length Pit-1 were quantitatively similar, In addition, gain-of-function G(alpha) mutants that inhibit Pit-1-dependent promoters in GH4 cells also suppressed selectively Pit-l or LxPit-1-dependent promoters in RIN cells, This demonstrates that Pit-1 can function as a specific target for distinct inhibitory G protein signals. Interestingly, Pit-1 sequences N-terminal to the DNA-binding POU domain appear to be sufficient in mediating regulation by these pathways.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,BANTING & BEST DIABET CTR,TORONTO,ON M5G 1L5,CANADA	University of Toronto; University of Toronto								ALBERT PR, 1990, J BIOL CHEM, V265, P2098; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BAERTSCHI AJ, 1992, MOL ENDOCRINOL, V6, P2257, DOI 10.1210/me.6.12.2257; BARTON RE, 1994, ENDOCRINE, V2, P639; BORRELLI E, 1994, TRENDS GENET, V10, P222, DOI 10.1016/0168-9525(94)90154-6; CHIO CL, 1994, MOL PHARMACOL, V45, P51; CORMONT M, 1991, DIABETES, V40, P1170, DOI 10.2337/diabetes.40.9.1170; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; FUXE K, 1969, NEUROENDOCRINOLOGY, V5, P257, DOI 10.1159/000121887; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HAYES G, 1992, MOL ENDOCRINOL, V6, P920, DOI 10.1210/me.6.6.920; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JONG MTC, 1994, MOL ENDOCRINOL, V8, P1320, DOI 10.1210/me.8.10.1320; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KIM MK, 1993, J BIOL CHEM, V268, P23366; LEW AM, 1994, J BIOL CHEM, V269, P12007; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIU YF, 1994, J BIOL CHEM, V269, P13880; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RICHARDSON PM, 1991, J VIROL, V65, P31222; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRUTHERS RS, 1992, P NATL ACAD SCI USA, V89, P11451, DOI 10.1073/pnas.89.23.11451; TANG L, 1994, J PHARMACOL EXP THER, V268, P495; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	44	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7156	7160		10.1074/jbc.270.13.7156	http://dx.doi.org/10.1074/jbc.270.13.7156			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706253	hybrid			2022-12-27	WOS:A1995QQ43100024
J	REICH, Z; WACHTEL, EJ; MINSKY, A				REICH, Z; WACHTEL, EJ; MINSKY, A			IN-VIVO QUANTITATIVE CHARACTERIZATION OF INTERMOLECULAR INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA DOUBLE HELICES; HYDRATION FORCES; CHROMATIN; MOLECULES; BILAYERS; WATER	Extensive effort has been directed toward a quantitative evaluation of forces which operate between biomacromolecules since the characterization of such forces is essential to a thorough understanding of fundamental biological processes, However, all studies hitherto reported were conducted in vitro, using isolated species, Here we report the first quantitative characterization of forces operating between DNA molecules within living bacteria. Evaluation of x-ray scattering studies conducted on intact bacteria indicates that, at DNA-DNA surface separations characteristic of DNA assemblies, interactions are dominated by repulsive hydration forces which originate from the structuring of water molecules. The results support the notion that the mechanisms by means of which macromolecules function, fold, and interact with each other crucially depend upon their hydration properties.	WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,CHEM SERV UNIT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								BOHRMANN B, 1993, ULTRAMICROSCOPY, V49, P235, DOI 10.1016/0304-3991(93)90230-U; BRIAN AA, 1981, BIOPOLYMERS, V20, P1305, DOI 10.1002/bip.1981.360200615; GRUEN DWR, 1981, CHEM PHYS LETT, V82, P315, DOI 10.1016/0009-2614(81)85163-9; ISRAELACHVILI JN, 1988, SCIENCE, V241, P795, DOI 10.1126/science.241.4867.795; KELLENBERGER E, 1987, TRENDS BIOCHEM SCI, V12, P105, DOI 10.1016/0968-0004(87)90049-1; LEIKIN S, 1994, P NATL ACAD SCI USA, V91, P276, DOI 10.1073/pnas.91.1.276; LENEVEU DM, 1976, NATURE, V259, P601, DOI 10.1038/259601a0; LIS LJ, 1982, BIOPHYS J, V37, P657; LIVOLANT F, 1988, BIOCHEMISTRY-US, V27, P3056, DOI 10.1021/bi00408a058; MARCELJA S, 1976, CHEM PHYS LETT, V42, P129, DOI 10.1016/0009-2614(76)80567-2; PARSEGIAN VA, 1985, CHEM SCRIPTA, V25, P28; RADIC N, 1978, CHEM PHYS LETT, V55, P377, DOI 10.1016/0009-2614(78)87043-2; RAND RP, 1981, ANNU REV BIOPHYS BIO, V10, P277, DOI 10.1146/annurev.bb.10.060181.001425; RAU DC, 1992, BIOPHYS J, V61, P246, DOI 10.1016/S0006-3495(92)81831-3; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; REICH Z, 1994, SCIENCE, V264, P1460, DOI 10.1126/science.8197460; STEUTER AA, 1981, PLANT PHYSIOL, V67, P64, DOI 10.1104/pp.67.1.64; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0	18	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7045	7046		10.1074/jbc.270.13.7045	http://dx.doi.org/10.1074/jbc.270.13.7045			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706241	hybrid			2022-12-27	WOS:A1995QQ43100009
J	TOBIMATSU, T; HARA, T; SAKAGUCHI, M; KISHIMOTO, Y; WADA, Y; ISODA, M; SAKAI, T; TORAYA, T				TOBIMATSU, T; HARA, T; SAKAGUCHI, M; KISHIMOTO, Y; WADA, Y; ISODA, M; SAKAI, T; TORAYA, T			MOLECULAR-CLONING, SEQUENCING, AND EXPRESSION OF THE GENES ENCODING ADENOSYLCOBALAMIN-DEPENDENT DIOL DEHYDRASE OF KLEBSIELLA-OXYTOCA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA; COENZYME; PURIFICATION; MECHANISM; CLEAVAGE	The pdd genes encoding adenosylcobalamin-dependent diol dehydrase of Klebsiella oxytoca were cloned by using a synthetic oligodeoxyribonucleotide as a hybridization probe followed by measuring the enzyme activity of each clone. Five clones of Escherichia coli exhibited diol dehydrase activity. At least one of them was shown to express diol dehydrase genes under control of their own promoter, Sequence analysis of the DNA fragments found in common in the inserts of these five clones and the flanking regions revealed four open reading frames separated by 10-18 base pairs. The sequential three open reading frames from the second to the fourth (pddA, pddB, and pddC genes) encoded polypeptides of 554, 224, and 173 amino acid residues with predicted molecular weights of 60,348 (alpha), 24,113 (beta), and 19,173 (gamma), respectively, Overexpression of these three genes in E. coli produced more than 50 fold higher level of functional apodiol dehydrase than that in K. oxytoca. The recombinant enzyme was indistinguishable from the wild-type one of R. oxytoca by the criteria of polyacrylamide gel electrophoretic and immunochemical properties. It was thus concluded that these three gene products are the subunits of functional diol dehydrase. Comparisons of the deduced amino acid sequences of the three subunits with other proteins failed to reveal any apparent homology.			TOBIMATSU, T (corresponding author), OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,OKAYAMA 700,JAPAN.		TOBIMATSU, Takamasa/B-2646-2011					Abeles R. H., 1979, Vitamin B12, P373; BABIOR B M, 1988, Biofactors, V1, P21; BARNES WM, 1987, METHOD ENZYMOL, V152, P538; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ESSENBERG MK, 1971, J AM CHEM SOC, V93, P1242; FREY PA, 1967, J BIOL CHEM, V242, P5369; FREY PA, 1970, J AM CHEM SOC, V92, P4488, DOI 10.1021/ja00717a074; FREY PA, 1966, J BIOL CHEM, V241, P2732; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JOHNSTONDOW L, 1987, BIOTECHNIQUES, V5, P754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCGEE DE, 1981, BIOCHEMISTRY-US, V20, P4293, DOI 10.1021/bi00518a009; MCGEE DE, 1982, BIOCHEM BIOPH RES CO, V108, P547, DOI 10.1016/0006-291X(82)90863-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUI T, 1988, AGR BIOL CHEM TOKYO, V52, P983; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIZAWA K, 1987, Z NATURFORSCH C, V42, P353; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1973, BIOCHEM BIOPH RES CO, V52, P350, DOI 10.1016/0006-291X(73)90718-3; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1974, BIOCHEMISTRY-US, V13, P3895, DOI 10.1021/bi00716a012; TORAYA T, 1988, BIOCHEMISTRY-US, V27, P7677, DOI 10.1021/bi00420a016; TORAYA T, 1979, J BACTERIOL, V139, P39, DOI 10.1128/JB.139.1.39-47.1979; Toraya T., 1982, B12, P233; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	34	64	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7142	7148		10.1074/jbc.270.13.7142	http://dx.doi.org/10.1074/jbc.270.13.7142			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706251	hybrid			2022-12-27	WOS:A1995QQ43100022
J	WAGNER, JP; QUILL, DM; PETTIJOHN, DE				WAGNER, JP; QUILL, DM; PETTIJOHN, DE			INCREASED DNA-BENDING ACTIVITY AND HIGHER AFFINITY DNA-BINDING OF HIGH-MOBILITY GROUP PROTEIN HMG-1 PREPARED WITHOUT ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; CHROMOSOMAL-PROTEINS; ELECTROPHORESIS; TRANSCRIPTION; STORAGE; DOMAIN	Recently, DNA ring closure assays showed that high mobility group protein HMG-1 and its close homolog HMG-2 mediate sequence-independent DNA flexion, This DNA-bending activity appears to be central to at least some of the recently elucidated functions of HMG-1/2, such as the enhancement of progesterone receptor DNA binding, Here we show that standard purification procedures utilizing perchloric and trichloroacetic acid can produce HMG-1 significantly deficient in its abilities to bind and bend double stranded DNA, while acid-independent methods purify HMG-1 that is superior in these respects, Significant losses of DNA ring closure activity were seen upon limited 2-5-h exposures of nonacid-purified HMG-1/2 to perchloric acid and/or trichloroacetic acid, Measurements of the apparent DNA dissociation binding constant (R(d(app))) of acid extracted preparations of HMG-1 gave a wide range of values, and only those preparations demonstrating little DNA ring closure activity had K-d values near the previously published value (similar to 10(-6) M). The highest ring closure activities and lowest K-d(app) (<3 x 10(-9) M) were obtained for HMG-1 purified without acids. These combined results support the use of alternative, non-acid purification procedures for preserving the DNA-bending activity of HMG-1/2 and suggest that past procedures utilizing acids have led to an underestimation of the affinity of HMG-1 for DNA.	UNIV COLORADO,CTR CANC,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,PROGRAM MOLEC BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [R01 GM 18243] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018243] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; COCKERILL PN, 1983, BIOCHIM BIOPHYS ACTA, V745, P70, DOI 10.1016/0167-4838(83)90171-1; ELTON TS, 1985, ANAL BIOCHEM, V149, P316, DOI 10.1016/0003-2697(85)90576-7; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; KOHLSTAEDT LA, 1986, BIOCHEMISTRY-US, V25, P4562, DOI 10.1021/bi00364a016; KOHLSTAEDT LA, 1994, BIOCHEMISTRY-US, V33, P570, DOI 10.1021/bi00168a023; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; OKA T, 1992, BIOCHEM BIOPH RES CO, V189, P179, DOI 10.1016/0006-291X(92)91541-W; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEYEDIN SM, 1981, P NATL ACAD SCI-BIOL, V78, P5988, DOI 10.1073/pnas.78.10.5988; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1989, FEBS LETT, V242, P346, DOI 10.1016/0014-5793(89)80499-5; WAGNER JP, 1994, IDENTIFICATION HIGH; WALKER JM, 1980, FEBS LETT, V122, P264, DOI 10.1016/0014-5793(80)80453-4; WATANABE F, 1994, BIOCHEM BIOPH RES CO, V202, P736, DOI 10.1006/bbrc.1994.1992; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; 1983, MERCK INDEX, P1028	31	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7394	7398		10.1074/jbc.270.13.7394	http://dx.doi.org/10.1074/jbc.270.13.7394			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706284	hybrid			2022-12-27	WOS:A1995QQ43100057
J	HUANG, QQ; HARVEY, CM; PATERSON, ARP; CASS, CE; YOUNG, JD				HUANG, QQ; HARVEY, CM; PATERSON, ARP; CASS, CE; YOUNG, JD			FUNCTIONAL EXPRESSION OF NA+-DEPENDENT NUCLEOSIDE TRANSPORT-SYSTEMS OF RAT INTESTINE IN ISOLATED OOCYTES OF XENOPUS-LAEVIS - DEMONSTRATION THAT RAT JEJUNUM EXPRESSES THE PURINE-SELECTIVE SYSTEM N1 (CIF) AND A 2ND, NOVEL SYSTEM N3 HAVING BROAD-SPECIFICITY FOR PURINE AND PYRIMIDINE NUCLEOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOMA-CELLS; BORDER MEMBRANE-VESICLES; BRUSH-BORDER; NITROBENZYLTHIOINOSINE-BINDING; GUINEA-PIG; LEUKEMIA-CELLS; CHOROID-PLEXUS; ERYTHROCYTE NUCLEOSIDE; NUCLEOBASE TRANSPORT; URIDINE TRANSPORT	Isolated stage VI oocytes from Xenopus laevis expressed uridine transport activity after microinjection of mRNA from rat jejunum. Uridine uptake during 30 min (10 muM, 20-degrees-C) by mRNA-injected oocytes reached 2.5 pmol/oocyte, compared with endogenous uptake by water-injected oocytes of about 0.05 pmol/oocyte. The expressed transport activity was 96% Na+-dependent, saturable (apparent K(m) = 15 muM) and inhibited by phloridzin (IC50 = 100 muM). Nucleoside inhibition studies resolved the expressed transport activity into two components: 1) a novel Na+-dependent system of broad purine and pyrimidine specificity that was inhibited by low concentrations of guanosine, inosine, adenosine, uridine, thymidine, and cytidine and 2) a Na+-dependent system of narrower specificity that was inhibited by low concentrations of guanosine, inosine, adenosine, and uridine and by high concentrations of thymidine and cytidine. The characteristics of the latter system are consistent with those of the Na+-dependent nucleoside transport system N1 (cif), previously identified in a number of cell types and tissues, including intestinal epithelia and cultured cells of intestinal origin. The broad specificity system, which was also detected in mRNA-injected oocytes using thymidine as permeant, has been given the provisional designation N3 to distinguish it from the previously described N1 (purine-selective) and N2 (pyrimidine-selective) Na+-linked nucleoside transporters. Rat jejunal transporters N1 and N3 were both expressed maximally by the same mRNA size fraction (1.6-3.0 kb, peak 2.3 kb).	UNIV ALBERTA,DEPT PHYSIOL,7-55 MED SCI BLDG,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta; University of Alberta; University of Alberta								BAER HP, 1990, BIOCHIM BIOPHYS ACTA, V1026, P241, DOI 10.1016/0005-2736(90)90070-5; BELT J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P20; BELT JA, 1983, MOL PHARMACOL, V24, P479; BELT JA, 1988, J BIOL CHEM, V263, P13819; BELT JA, 1983, BIOCHEM BIOPH RES CO, V110, P417, DOI 10.1016/0006-291X(83)91165-8; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; BETCHER SL, 1990, AM J PHYSIOL, V259, pG504, DOI 10.1152/ajpgi.1990.259.3.G504; BRONK JR, 1988, J PHYSIOL-LONDON, V3695, P349; CASS CE, 1981, BIOCHIM BIOPHYS ACTA, V649, P769, DOI 10.1016/0005-2736(81)90182-6; DAGNINO L, 1987, P AM ASSOC CANC RES, V28, P15; DAGNINO L, 1991, J BIOL CHEM, V266, P6312; DARNOWSKI JW, 1986, CANCER RES, V46, P3490; DARNOWSKI JW, 1987, CANCER RES, V47, P2614; GATI WP, 1989, MOL PHARMACOL, V36, P134; GATI WP, 1986, BIOCHEM J, V236, P665, DOI 10.1042/bj2360665; GUTIERREZ MM, 1992, BIOCHIM BIOPHYS ACTA, V1105, P1, DOI 10.1016/0005-2736(92)90156-G; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; JACOBS ES, 1990, J BIOL CHEM, V265, P22210; JAKOBS ES, 1986, BIOCHEM BIOPH RES CO, V140, P1028, DOI 10.1016/0006-291X(86)90738-2; JARVIS SM, 1986, J MEMBRANE BIOL, V93, P1, DOI 10.1007/BF01871013; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1987, PHARMACOL THERAPEUT, V32, P339, DOI 10.1016/0163-7258(87)90080-5; JARVIS SM, 1985, J NEUROCHEM, V44, P183, DOI 10.1111/j.1471-4159.1985.tb07129.x; JARVIS SM, 1991, BIOCHEM J, V278, P605, DOI 10.1042/bj2780605; JARVIS SM, 1987, TOPICS PERSPECTIVES, P102; KWAN KF, 1984, AM J PHYSIOL, V245, P710; KWONG FYP, 1986, BIOCHEM J, V240, P349, DOI 10.1042/bj2400349; LEE CW, 1990, AM J PHYSIOL, V258, pF1203, DOI 10.1152/ajprenal.1990.258.5.F1203; LEHIR M, 1985, PFLUG ARCH EUR J PHY, V404, P238, DOI 10.1007/BF00581245; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PATERSON ARP, 1979, MOL PHARMACOL, V16, P900; PATERSON ARP, 1984, BIOCHEM J, V224, P1001, DOI 10.1042/bj2241001; PATERSON ARP, 1983, REGULATORY FUNCTION, P203; PATERSON ARP, 1983, DEV TARGET ORIENTED, P41; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1986, J CELL PHYSIOL, V128, P491, DOI 10.1002/jcp.1041280319; PLAGEMANN PGW, 1984, BIOCHIM BIOPHYS ACTA, V773, P39, DOI 10.1016/0005-2736(84)90548-0; PLAGEMANN PGW, 1986, BIOCHEM PHARMACOL, V35, P2559, DOI 10.1016/0006-2952(86)90054-7; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1025, P32, DOI 10.1016/0005-2736(90)90187-S; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; PLAGEMANN PGW, 1989, BIOCHIM BIOPHYS ACTA, V981, P315, DOI 10.1016/0005-2736(89)90043-6; RODEN M, 1988, Naunyn-Schmiedeberg's Archives of Pharmacology, V337, pR48; SCHWENK M, 1984, BIOCHIM BIOPHYS ACTA, V805, P370, DOI 10.1016/0167-4889(84)90020-X; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P594, DOI 10.1016/0006-291X(84)91344-5; SPECTOR R, 1984, J NEUROCHEM, V42, P1048, DOI 10.1111/j.1471-4159.1984.tb12709.x; SPECTOR R, 1982, ARCH BIOCHEM BIOPHYS, V216, P693, DOI 10.1016/0003-9861(82)90259-4; STEIN WD, 1986, TRANSPORT DIFFUSION, P397; UNGEMACH FR, 1978, H-S Z PHYSIOL CHEM, V359, P845, DOI 10.1515/bchm2.1978.359.2.845; VERMA A, 1985, LIFE SCI, V36, P283, DOI 10.1016/0024-3205(85)90071-2; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19149; WILLIAMS EF, 1984, CAN J PHYSIOL PHARM, V62, P31, DOI 10.1139/y84-005; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WILLIAMS TC, 1989, BIOCHEM J, V264, P223, DOI 10.1042/bj2640223; WOFFENDIN C, 1987, J MEMBRANE BIOL, V98, P89, DOI 10.1007/BF01871048; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU JSR, 1984, BIOCHEM J, V220, P499, DOI 10.1042/bj2200499; WU XC, 1992, J BIOL CHEM, V267, P8813; YOUNG JD, 1984, J BIOL CHEM, V259, P8363	60	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20613	20619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690759				2022-12-27	WOS:A1993LY01900099
J	NISHIMURA, H; ZARNOWSKI, MJ; SIMPSON, IA				NISHIMURA, H; ZARNOWSKI, MJ; SIMPSON, IA			GLUCOSE-TRANSPORTER RECYCLING IN RAT ADIPOSE-CELLS - EFFECTS OF POTASSIUM-DEPLETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; COATED PIT FORMATION; FACTOR-II BINDING; PLASMA-MEMBRANE; POTENTIAL MECHANISM; STIMULATORY ACTION; 3T3-L1 ADIPOCYTES; CLATHRIN LATTICES; INSULIN-RECEPTORS; TRANSLOCATION	Depletion of intracellular potassium (K+) induced a 4-fold increase in basal and 1 muM phorbol-12-myristate-13-acetate (PMA)-stimulated 3-O-methylglucose transport in rat adipose cells. K+ depletion had no effect on the maximum insulin (0.7 muM)-stimulated transport rate but enhanced the sensitivity to insulin 3-fold (EC50= 0.05 versus 0.15 nM) by a mechanism that did not result from changes in the insulin receptor binding, autophosphorylation, or tyrosine kinase activity. Western blotting analysis revealed that K+ depletion induced a 2.2-fold increase in GLUT4 in plasma membranes from basal cells, enhanced the PMA-stimulated GLUT4 translocation by 4-fold, and increased the 5-fold insulin-stimulated GLUT4 translocation by 15%, indicating the presence of an inactive GLUT4 intermediate. The time course for insulin's stimulation of transport activity was accelerated by K+ depletion (t1/2 = 3 versus 1.5 min). Conversely, the reversal of transport activity, on removal of insulin, was delayed (t1/2 = 11 versus 22 min). The corresponding t1/2 values for the loss of GLUT4 were 22 min in control cells and 40 min in K+-depleted cells, again indicating the existence of an inactive intermediate. Photolabeling intact cells with the impermeant, exofacial photolabel 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine in the continuous presence of insulin revealed that K+ depletion had no effect on the GLUT4 externalization rate but halved the rate of internalization. K+ depletion elicited entirely analogous effects on the recycling of insulin-like growth factor II/mannose 6-phosphate receptor, strongly supporting the involvement of a coated pit mechanism in the recycling of GLUT4 transporters. An inactive conformation of GLUT4 has been detected in plasma membranes from insulin-stimulated cells, which is enhanced by K+ depletion, suggesting a limitation in the adipose cells' capacity to express active GLUT4 transporters.	NIDDK, DIABET BRANCH, EDMNS, BLDG 10, RM 5N102, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								APPELL KC, 1988, J BIOL CHEM, V263, P10824; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BURNS CP, 1984, J CELL BIOL, V98, P1082, DOI 10.1083/jcb.98.3.1082; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLAUSEN T, 1969, BIOCHIM BIOPHYS ACTA, V183, P625, DOI 10.1016/0005-2736(69)90175-8; CORVERA S, 1989, J BIOL CHEM, V264, P10133; CULLEN MR, 1985, LINEAR MODELS BIOL; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; GLIEMANN J, 1972, BIOCHIM BIOPHYS ACTA, V286, P1, DOI 10.1016/0304-4165(72)90082-7; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HOKIN LE, 1976, TRENDS BIOCHEM SCI, V1, P233, DOI 10.1016/S0968-0004(76)80099-0; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; ILONDO MM, 1986, P NATL ACAD SCI USA, V83, P6460, DOI 10.1073/pnas.83.17.6460; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LETARTE J, 1969, BIOCHIM BIOPHYS ACTA, V183, P357, DOI 10.1016/0005-2736(69)90092-3; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SALTIS J, 1991, J BIOL CHEM, V266, P261; SATOH S, 1993, IN PRESS J BIOL CHEM, V268; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STEER CJ, 1992, INTRACELLULAR TRAFFI; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WEBER TM, 1991, CELL SIGNAL, V3, P51, DOI 10.1016/0898-6568(91)90007-H; WEBER TM, 1988, INSULIN RECEPTOR, V2, P171; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809	45	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19246	19253						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690030				2022-12-27	WOS:A1993LW81900018
J	DATTANI, MT; HINDMARSH, PC; BROOK, CGD; ROBINSON, ICAF; KOPCHICK, JJ; MARSHALL, NJ				DATTANI, MT; HINDMARSH, PC; BROOK, CGD; ROBINSON, ICAF; KOPCHICK, JJ; MARSHALL, NJ			G120R, A HUMAN GROWTH-HORMONE ANTAGONIST, SHOWS ZINC-DEPENDENT AGONIST AND ANTAGONIST ACTIVITY ON NB2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; PROLACTIN RECEPTOR; BINDING; ENHANCEMENT; BIOASSAY; DESIGN; SYSTEM	Substitution of arginine for glycine at position 120 in native 22-kDa human growth hormone (hGH) results in an analogue, G120R, which is unable to dimerize the GH receptor and is widely used to probe the molecular mechanism of action of hGH, When acting on human GH receptors, G120R antagonizes several biological effects of hGH, but is itself inactive as an agonist, It has been reported that this mutant also antagonizes hGH activation of the rat or human prolactin (PRL) receptor in cell-based assays, with no agonist activity, We have now tested this mutant in a sensitive MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-ESTA (eluted stain assay) bioassay using rat PRL receptors in the Nb2 cell Line. We confirm that G120R acts as an efficient antagonist of native hGH, but show that it can also act as an agonist to generate intracellular signals leading to metabolic activation and proliferation of Nb2 cells, We have demonstrated an unusual sensitivity to the presence of zinc (Zn2+). In the absence of added Zn2+, G120R shows weak but full agonist activity in the bioassay, and this can be blocked by co incubation with recombinant hGH binding protein, G120R can therefore be utilized to discriminate between the molecular mechanisms of hGH interactions with its somatogenic and lactogenic receptors, Future studies with G120R in the rat may need to take account of its significant agonist effects on PRL receptors.	MIDDLESEX HOSP,ENDOCRINE UNIT,LONDON W1N 8AA,ENGLAND; MIDDLESEX HOSP,DIV MOLEC PATHOL,LONDON W1N 8AA,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; OHIO UNIV,EDISON BIOTECHNOL INST,ATHENS,OH 45701	University of London; University College London; University of London; University College London; MRC National Institute for Medical Research; University System of Ohio; Ohio University			Hindmarsh, P C/C-4964-2008; DATTANI, MEHUL/C-5401-2008					BANGHAM DR, 1985, MOL CELL ENDOCRINOL, V42, P269, DOI 10.1016/0303-7207(85)90058-9; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V8, P5061; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DATTANI MT, 1993, ENDOCRINOLOGY, V133, P2803, DOI 10.1210/en.133.6.2803; DATTANI MT, 1994, J ENDOCRINOL, V140, P445, DOI 10.1677/joe.0.1400445; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EALEY PA, 1988, J MOL ENDOCRINOL, V1, pR1, DOI 10.1677/jme.0.001R001; EALEY PA, 1994, IN PRESS GROWTH REGU; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1990, J BIOL CHEM, V265, P3111; IIONDO MM, 1994, ENDOCRINOLOGY, V134, P2397; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MARSHALL NJ, 1995, IN PRESS GROWTH REGU; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253	21	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9222	9226		10.1074/jbc.270.16.9222	http://dx.doi.org/10.1074/jbc.270.16.9222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721840	hybrid			2022-12-27	WOS:A1995QU08900028
J	TENNEY, DJ; SHEAFFER, AK; HURLBURT, WW; BIFANO, M; HAMATAKE, RK				TENNEY, DJ; SHEAFFER, AK; HURLBURT, WW; BIFANO, M; HAMATAKE, RK			SEQUENCE-DEPENDENT PRIMER SYNTHESIS BY THE HERPES-SIMPLEX VIRUS HELICASE-PRIMASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ORIGIN-BINDING PROTEIN; REPLICATION ORIGIN; TEMPLATE SEQUENCE; INITIATION SITES; GENE-PRODUCTS; UL8 PROTEIN; TYPE-1; POLYMERASE; BACTERIOPHAGE-T4	The herpes simplex virus helicase-primase complex, a heterotrimer of the UL5, UL8, and UL52 proteins, displays a single predominant site of primer synthesis on phi X174 virion DNA (Tenney, D, J,, Hurlburt, W, W., Micheletti, P, M,, Bifano, M,, and Hamatake, R, K, (1994) J, Biol, Chem, 269, 5030-5035), This site was mapped and found to be deoxycytosine-rich, directing the synthesis of a primer initiating with several guanine residues, The size and sequence requirements for primer synthesis were determined using oligonucleotides containing variations of the predominant template, Although the efficiency of primer synthesis on oligonucleotides was influenced by template size, it was absolutely dependent on nucleotide sequence, Conversely, the ATPase activity on oligonucleotide templates was dependent on template size rather than nucleotide sequence, Furthermore, only oligonucleotides containing primase templates were inhibitory in a coupled primase-polymerase assay using phi X174 DNA as template, suggesting that primer synthesis or primase turnover is rate-limiting, Additionally, stimulation of helicase-primase by the UL8 component and that by the ICP8 protein were shown to differ mechanistically using different templates: the UL8 component stimulated the rate of primer synthesis on phi X174 virion DNA and oligonucleotide templates, while ICP8 stimulation occurred only on phi X174 virion DNA.			TENNEY, DJ (corresponding author), BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT VIROL,5 RES PKWY,WALLINGFORD,CT 06492, USA.			Sheaffer, Amy/0000-0002-4776-4679				CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHALLBERG MD, 1991, SEMIN VIROL, V2, P247; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DRACHEVA S, 1994, IN PRESS J BIOL CHEM; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAMATAKE RK, 1993, J GEN VIROL, V74, P2181, DOI 10.1099/0022-1317-74-10-2181; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HINTON DM, 1987, J BIOL CHEM, V262, P10873; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; KORNBERG A, 1992, DNA REPLICATION, P275; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MCLEAN GW, 1994, J GEN VIROL, V75, P2699, DOI 10.1099/0022-1317-75-10-2699; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; PARRY ME, 1993, J GEN VIROL, V74, P607, DOI 10.1099/0022-1317-74-4-607; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; SWART JR, 1993, J BIOL CHEM, V268, P12970; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; WELLER SK, 1991, HERPESVIRUS TRANSCRI, P105; YAMAGUCHI M, 1985, MOL CELL BIOL, V5, P1170, DOI 10.1128/MCB.5.5.1170; YODA KY, 1988, NUCLEIC ACIDS RES, V16, P6531, DOI 10.1093/nar/16.14.6531; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	39	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9129	9136		10.1074/jbc.270.16.9129	http://dx.doi.org/10.1074/jbc.270.16.9129			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721827				2022-12-27	WOS:A1995QU08900015
J	WOOD, TJJ; SLIVA, D; LOBIE, PE; PIRCHER, TJ; GOUILLEUX, F; WAKAO, H; GUSTAFSSON, JA; GRONER, B; NORSTEDT, G; HALDOSEN, LA				WOOD, TJJ; SLIVA, D; LOBIE, PE; PIRCHER, TJ; GOUILLEUX, F; WAKAO, H; GUSTAFSSON, JA; GRONER, B; NORSTEDT, G; HALDOSEN, LA			MEDIATION OF GROWTH HORMONE-DEPENDENT TRANSCRIPTIONAL ACTIVATION BY MAMMARY-GLAND FACTOR STAT-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR SUPERFAMILY; DNA-BINDING PROTEINS; PROLACTIN RECEPTOR; EXPRESSION; CELLS; CLONING; FAMILY; LIVER	Previous observations have shown that binding of growth hormone to its receptor leads to activation of transcription factors via a mechanism involving phosphorylation on tyrosine residues. In order to establish whether the prolactin-activated transcription factor Stat 5 (mammary gland factor) is also activated by growth hormone, nuclear extracts were prepared from COS-7 cells transiently expressing transfected Stat 5 and growth hormone receptor cDNA. Gel electrophoresis mobility shift analyses revealed the growth hormone-dependent presence of specific DNA-binding proteins in these extracts, The complexes formed could be supershifted by polyclonal anti-Stat 5 antiserum. In other experiments nuclear extracts from growth hormone-treated Chinese hamster ovary cells stably expressing transfected growth hormone receptor cDNA and liver from growth hormone-treated hypophysectomized rats were used for gel electrophoresis mobility shift analyses. These also revealed the presence of specific DNA-binding proteins sharing antigenic determinants with Stat 5. Stat 5 cDNA was shown to be capable of complementing the growth hormone-dependent activation of transcription of a reporter gene in the otherwise unresponsive COS-7 cell line. This complementation was dependent on the presence of Stat 5 tyrosine 694, suggesting a role for phosphorylation of this residue in growth hormone-dependent activation of DNA-binding and transcription.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; INST EXPTL CANC RES, TUMOR BIOL CTR, D-79106 FREIBURG, GERMANY	Friedrich Miescher Institute for Biomedical Research	WOOD, TJJ (corresponding author), KAROLINSKA INST, NOVUM, DEPT MED NUTR, S-14157 HUDDINGE, SWEDEN.		WAKAO, Hiroshi/A-4242-2012	Gouilleux, Fabrice/0000-0001-6047-1718				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARBER MC, 1992, J ENDOCRINOL, V135, P195, DOI 10.1677/joe.0.1350195; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FELDMAN M, 1993, ENDOCRINOLOGY, V133, P1602, DOI 10.1210/en.133.4.1602; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PLAUT K, 1993, ENDOCRINOLOGY, V133, P1843, DOI 10.1210/en.133.4.1843; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1979, CANCER RES, V39, P4381; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SLIVA D, 1994, J BIOL CHEM, V269, P26208; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WARREN WC, 1993, MOL CELL ENDOCRINOL, V98, P27, DOI 10.1016/0303-7207(93)90232-9; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	44	158	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9448	9453		10.1074/jbc.270.16.9448	http://dx.doi.org/10.1074/jbc.270.16.9448			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721871	Green Published, hybrid			2022-12-27	WOS:A1995QU08900060
J	BERGANTINO, E; DAINESE, P; CEROVIC, Z; SECHI, S; BASSI, R				BERGANTINO, E; DAINESE, P; CEROVIC, Z; SECHI, S; BASSI, R			A POSTTRANSLATIONAL MODIFICATION OF THE PHOTOSYSTEM-II SUBUNIT CP29 PROTECTS MAIZE FROM COLD STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B-PROTEINS; CHLOROPLAST PSBA GENE; CYTOCHROME-BF COMPLEX; THYLAKOID MEMBRANES; CHLAMYDOMONAS-REINHARDTII; LATERAL REDISTRIBUTION; ELECTRON-TRANSPORT; INVIVO DEGRADATION; STATE TRANSITIONS; BINDING PROTEINS	The resistance of maize plants to cold stress has been associated with the appearance of a new chlorophyll a/b binding protein in the thylakoid membrane following chilling treatment in the light. The cold-induced protein has been isolated, characterized by amino acid sequencing, and pulse labeled with radioactive precursors, showing that it is the product of post-translational modification by phosphorylation of the minor chlorophyll a/b protein CP29 rather than the product of a cold-regulated gene or an unprocessed CP29 precursor. We show here that the CP29 kinase activity displays unique characteristics differing from previously described thylakoid kinases and is regulated by the redox state of a quinonic site. Finally, we show that maize plants unable to perform phosphorylation have enhanced sensitivity to cold-induced photoinhibition.	UNIV PADUA,DIPARTIMENTO BIOL,I-35121 PADUA,ITALY; CTR UNIV PARIS SUD,UTILISAT RAYONNEMENT ELECTROMAGNET LAB,F-91405 ORSAY,FRANCE; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; UNIV VERONA,FAC SCI MATEMAT FIS & NAT,I-37134 VERONA,ITALY	University of Padua; UDICE-French Research Universities; Universite Paris Saclay; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Verona				bassi, roberto/0000-0002-4140-8446				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; BARBATO R, 1992, FEBS LETT, V309, P165, DOI 10.1016/0014-5793(92)81087-3; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BASSI R, 1987, J BIOL CHEM, V262, P13333; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V935, P152, DOI 10.1016/0005-2728(88)90212-5; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1979, FEBS LETT, V103, P342, DOI 10.1016/0014-5793(79)81358-7; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOYER SK, 1988, NUCLEIC ACIDS RES, V16, P8184, DOI 10.1093/nar/16.16.8184; CARLBERG I, 1992, BIOCHIM BIOPHYS ACTA, V1099, P111, DOI 10.1016/0304-4173(92)90015-7; COUGHLAN SJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P413, DOI 10.1016/0005-2728(88)90076-X; Dainese P., 1992, RES PHOTOSYNTHESIS, VII, P13; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DIPAOLO ML, 1990, PLANTA, V181, P275, DOI 10.1007/BF00195877; DUNAHAY TG, 1984, BIOCHIM BIOPHYS ACTA, V764, P179, DOI 10.1016/0005-2728(84)90027-6; EFIMOV VA, 1988, NUCLEIC ACIDS RES, V16, P5685, DOI 10.1093/nar/16.12.5685; FRID D, 1992, J BIOL CHEM, V267, P25908; GAL A, 1988, J BIOL CHEM, V263, P7785; GAL A, 1990, J BIOL CHEM, V265, P19742; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; HAYDEN DB, 1986, BIOCHIM BIOPHYS ACTA, V851, P86, DOI 10.1016/0005-2728(86)90251-3; HAYDEN DB, 1988, PHOTOSYNTH RES, V15, P257, DOI 10.1007/BF00047357; HODGES M, 1989, BIOCHIM BIOPHYS ACTA, V974, P289, DOI 10.1016/S0005-2728(89)80246-4; KRAUSE GH, 1988, PHYSIOL PLANTARUM, V74, P566, DOI 10.1111/j.1399-3054.1988.tb02020.x; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; METZ JG, 1983, PLANT PHYSIOL, V73, P452, DOI 10.1104/pp.73.2.452; MORISHIGE DT, 1992, PLANT PHYSIOL, V98, P238, DOI 10.1104/pp.98.1.238; OQUIST G, 1987, TOPICS PHOTOSYNTHESI, V9, P67; PETER GF, 1991, J BIOL CHEM, V266, P16745; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; SANTINI C, 1994, EUR J BIOCHEM, V221, P307, DOI 10.1111/j.1432-1033.1994.tb18742.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V933, P85, DOI 10.1016/0005-2728(88)90058-8	47	102	105	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8474	8481		10.1074/jbc.270.15.8474	http://dx.doi.org/10.1074/jbc.270.15.8474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721743	hybrid			2022-12-27	WOS:A1995QT44800019
J	POON, PH; MORRISON, SL; SCHUMAKER, VN				POON, PH; MORRISON, SL; SCHUMAKER, VN			STRUCTURE AND FUNCTION OF SEVERAL ANTIDANSYL CHIMERIC ANTIBODIES FORMED BY DOMAIN INTERCHANGES BETWEEN HUMAN-IGM AND MOUSE IGG2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-MEDIATED LYSIS; MU-HEAVY-CHAIN; ELECTROPHORETIC TRANSFER; SEGMENTAL FLEXIBILITY; POLYACRYLAMIDE GELS; BINDING; MECHANISM; PROTEINS; CELLS; CLQ	Two pairs of chimeric, domain-switched immunoglobulins with identical murine, anti-dansyl (5-dimethylaminonaphthalene-1-sulfonyl) variable domains have been generated, employing as parent antibodies a human IgM and a mouse IgG2b. The first pair of chimeric antibodies mu mu gamma mu and gamma gamma mu gamma was generated by switching the C mu 3 and C gamma 2 domains between IgM and IgG2b. The second pair of chimeras mu mu gamma gamma and gamma gamma mu mu were formed by switching both C mu 3 and C mu 4 with C gamma 2 and C gamma 3. SDS-polyacrylamide gel electrophoresis and analytical ultracentrifugation showed that over half (57 and 71%) of the two chimeric antibodies possessing the C mu 4 domain and tail piece formed disulfide-linked IgM-like polymers. In contrast, the two chimeric antibodies lacking the C mu 4 domain were almost entirely monomeric. Both monomeric chimeras had reduced ability to activate complement. The chimera gamma gamma mu gamma had no activity under any of the assay conditions, whereas mu mu gamma gamma caused only a small amount of cell lysis but was fully active in consuming complement at 4 degrees C. The polymeric chimera gamma gamma mu mu was much less active than IgM, bound C (1) over bar weakly and caused some cell lysis but consumed little complement with soluble antigen. The polymeric chimera mu mu gamma mu bound C (1) over bar strongly and was the most active antibody in all assays, even more active than the parental IgG2b and IgM antibodies; it was the only antibody that exhibited antigen-independent activity. The results suggest that C mu 3 alone does not constitute the complement binding site in IgM but requires both C mu(1-2) and C mu(4) for full activity.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	POON, PH (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA 16858] Funding Source: Medline; NIAID NIH HHS [AI 29470] Funding Source: Medline; NIGMS NIH HHS [GM 13914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029470, R37AI029470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASE A, 1991, J IMMUNOL METHODS, V136, P185, DOI 10.1016/0022-1759(91)90005-Z; ARYA S, 1994, J IMMUNOL, V152, P1206; BAKER MD, 1986, J IMMUNOL, V137, P1724; BEALE D, 1976, Q REV BIOPHYS, V9, P135, DOI 10.1017/S0033583500002390; BORSOS T, 1965, J IMMUNOL, V94, P510; BORSOS T, 1965, SCIENCE, V150, P505, DOI 10.1126/science.150.3695.505; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; BUBB MO, 1978, IMMUNOLOGY, V34, P449; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN FH, 1994, FASEB J, V8, pA767; CUNNIFF RV, 1968, J IMMUNOL, V100, P7; DANGL JL, 1986, THESIS STANFORD U; DAVIS AC, 1989, J IMMUNOL, V143, P1352; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DAVIS AC, 1989, EMBO J, V8, P2519, DOI 10.1002/j.1460-2075.1989.tb08389.x; DEISENHOFER J, 1976, H-S Z PHYSIOL CHEM, V357, P1421, DOI 10.1515/bchm2.1976.357.2.1421; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; EDMUNDSON AB, 1975, BIOCHEMISTRY-US, V14, P3953, DOI 10.1021/bi00689a005; FEINSTEIN A, 1966, J PHYSIOL-LONDON, V186, pP64; FEINSTEIN A, 1969, NATURE, V224, P1307, DOI 10.1038/2241307a0; FEINSTEIN A, 1983, PROTEIN CONFORMATION, P47; GEE AP, 1981, MOL IMMUNOL, V18, P609, DOI 10.1016/0161-5890(81)90031-6; HANSON DC, 1985, J BIOL CHEM, V260, P3576; Hardy RR, 1986, HDB EXPT IMMUNOLOGY, V1; HOEKZEMA R, 1988, MOL IMMUNOL, V25, P485, DOI 10.1016/0161-5890(88)90169-1; HUGHESJONES NC, 1983, EUR J IMMUNOL, V13, P635, DOI 10.1002/eji.1830130806; HURST MM, 1975, J EXP MED, V142, P1322, DOI 10.1084/jem.142.5.1322; ISHIZAKA T, 1968, J IMMUNOL, V100, P1145; JOHNSON BJ, 1976, J IMMUNOL, V117, P1491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Metzger H, 1974, Adv Immunol, V18, P169, DOI 10.1016/S0065-2776(08)60310-7; Metzger H, 1978, Contemp Top Mol Immunol, V7, P119; NORDERHAUG L, 1991, EUR J IMMUNOL, V21, P2379, DOI 10.1002/eji.1830211013; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; POON PH, 1985, J BIOL CHEM, V260, P9357; POON PH, 1991, J BIOL CHEM, V266, P5723; PRUUL H, 1978, IMMUNOCHEMISTRY, V15, P721, DOI 10.1016/0161-5890(78)90099-8; SCHNEIDER WP, 1987, PROTEINS, V2, P81, DOI 10.1002/prot.340020203; SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V15, P5175, DOI 10.1021/bi00668a035; SCHUMAKER VN, 1957, BIOCHIM BIOPHYS ACTA, V23, P628, DOI 10.1016/0006-3002(57)90386-4; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHOPES B, 1990, J IMMUNOL, V145, P3842; SIEGEL RC, 1981, BIOCHEMISTRY-US, V20, P192, DOI 10.1021/bi00504a032; SMITH RIF, 1994, BIO-TECHNOL, V12, P683, DOI 10.1038/nbt0794-683; Stollar B D, 1978, Methods Cell Biol, V18, P105; TAN LK, 1991, P NATL ACAD SCI USA, V88, P5066; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERZEE JS, 1986, MOL IMMUNOL, V23, P669, DOI 10.1016/0161-5890(86)90105-7; WEBER G, 1952, BIOCHEM J, V51, P155, DOI 10.1042/bj0510155; WEETALL M, 1990, J IMMUNOL, V145, P3849; WRIGHT JF, 1988, J BIOL CHEM, V263, P11221; ZICCARDI RJ, 1986, J IMMUNOL, V136, P3378	53	12	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8571	8577		10.1074/jbc.270.15.8571	http://dx.doi.org/10.1074/jbc.270.15.8571			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721758	hybrid			2022-12-27	WOS:A1995QT44800034
J	SHAPIRO, LH				SHAPIRO, LH			MYB AND ETS PROTEINS COOPERATE TO TRANSACTIVATE AN EARLY MYELOID GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN ERYTHROID-CELLS; HUMAN C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; HEMATOPOIETIC DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS; FUNCTIONAL DOMAINS; LEUKEMIA-VIRUS; EXPRESSION	The earliest progenitor cell committed to the granulocyte/monocyte developmental pathway can be identified by the appearance of a 150-kDa glycoprotein on the cell surface (CD13/aminopeptidase N (CD13/APN), EC 3.4.11.2). A 455-base pair genomic fragment from the CD13/APN gene containing a Myb consensus-binding site as well as three potential Ets-binding sites was found to regulate tissue-appropriate expression of reporter genes in hematopoietic cell lines. Transactivation experiments with plasmids expressing either a full-length or truncated Myb protein and the full-length Ets-1 or Ets-2 protein demonstrated that these proteins cooperate to positively regulate CD13/APN gene expression. This cooperation is synergistic, as levels of transcriptional activity produced by Myb and Ets in combination were higher than those expected from a purely additive effect. Mutation of the Myb consensus-binding site completely abolished CD13/APN promoter activity in myeloid cells. Introduction of a dominant interfering Myb allele disrupted the ability of endogenous c-Myb in myeloid cells to transactivate the CD13/APN construct. Other myeloid cell-expressed Ets family members (PU.1, Fli-1, and Elf-1) failed to produce a cooperative transactivating effect when combined with the Myb expression construct. These data contrast with previous studies indicating that full-length c-Myb is unable to positively cooperate with Ets proteins in the regulation of myeloid genes. Because intact c-Myb and Ets-g proteins, both endogenously expressed in myeloid cells, act synergistically to transactivate the CD13/APN promoter, this gene may represent a physiological target for dissection of the roles of these transcription factors in normal and malignant myelopoiesis.			SHAPIRO, LH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [R01CA042804] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-42804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1988, CURRENT PROTOCOLS MO; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FAVIER, 1994, ONCOGENE, V0009; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRIFFIN J D, 1983, International Journal of Cell Cloning, V1, P33; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOGG N, 1987, LEUCOCYTE TYPING, V3, P576; HU YL, 1991, ONCOGENE, V6, P1549; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KUEHL WM, 1988, CURR TOP MICROBIOL, V141, P318; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEMONS RS, 1978, CELL, V14, P995, DOI 10.1016/0092-8674(78)90353-7; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORKIN SH, 1992, BLOOD, V80, P575; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; ULRICH MJ, 1990, BLOOD, V75, P990; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	67	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8763	8771		10.1074/jbc.270.15.8763	http://dx.doi.org/10.1074/jbc.270.15.8763			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721782	hybrid			2022-12-27	WOS:A1995QT44800060
J	YU, GY; DESCHENES, RJ; FASSLER, JS				YU, GY; DESCHENES, RJ; FASSLER, JS			THE ESSENTIAL TRANSCRIPTION FACTOR, MCM1, IS A DOWNSTREAM TARGET OF SLN1, A YEAST 2-COMPONENT REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 2-COMPONENT REGULATORS; DNA-BINDING; GENE FUSIONS; ALPHA-FACTOR; 2ND PROTEIN; MAINTENANCE; POLYPEPTIDE; SUPPRESSOR; SUFFICIENT	In a search for mutants exhibiting altered activity of the yeast transcription factor, Mcm1, we have identified the SLN1 gene, whose product is highly related to bacterial two-component sensor-regulator proteins. sln1 alleles identified in our screen increased Mcm1p-mediated transcriptional activation, while deletion of the SLN1 locus severely reduced Mcm1p activity. Our data establish that Mcm1p is a downstream target of the Sln1 signaling pathway. Yeast Sln1p was recently shown to be involved in osmoregulation and to depend on the Hog1 MAP kinase (Maeda, T., Wurgler-Murphy, S., and Saito, H. (1994) Nature 369, 242-245). We show that SLN1-mediated regulation of Mcm1p activity is independent of the Hog1 MAP kinase, and suggest that the role of SLN1 is not restricted to osmoregulation.	UNIV IOWA,GENET PHD PROGRAM,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOL SCI,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa			Deschenes, Robert J/E-4926-2010	Deschenes, Robert J/0000-0001-8325-4257				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUHN L, 1992, MOL CELL BIOL, V12, P3563, DOI 10.1128/MCB.12.8.3563; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; FASSLER JS, 1988, GENETICS, V118, P203; FASSLER JS, 1989, MOL CELL BIOL, V12, P5602; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GUAN KL, 1992, J BIOL CHEM, V267, P10024; GUARENTE L, 1981, P NATL ACAD SCI USA, V73, P2199; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LARSON GP, 1983, GENE, V22, P31, DOI 10.1016/0378-1119(83)90061-6; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Miller J.H., 1972, EXPT MOL GENETICS; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sherman F., 1978, METHODS YEAST GENETI; STOCK JB, 1993, J CELL BIOCHEM, V51, P41; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; YU GY, 1993, MOL CELL BIOL, V13, P63, DOI 10.1128/MCB.13.1.63	34	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8739	8743		10.1074/jbc.270.15.8739	http://dx.doi.org/10.1074/jbc.270.15.8739			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721779	hybrid			2022-12-27	WOS:A1995QT44800057
J	CHEN, L; GARRETT, TPJ; FINCHER, GB; HOJ, PB				CHEN, L; GARRETT, TPJ; FINCHER, GB; HOJ, PB			A TETRAD OF IONIZABLE AMINO-ACIDS IS IMPORTANT FOR CATALYSIS IN BARLEY BETA-GLUCANASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; BACTERIOPHAGE-T4 LYSOZYME; PROTEINS; RESIDUES; BINDING; ENZYME; 4-GLUCANOHYDROLASE; ENDOHYDROLASES; IDENTIFICATION	Determination of the crystal structures of a 1,3-beta-D-glucanase (E.C. 3.2.1.39) and a 1,3-1,4-beta-D-glucanase (E.C. 3.2.1.73) from barley (Hordeum vulgare) (Varghese, J. N, Garrett, T. P. J., Cohnan, P. M., Chen, L., Hoj, P. B., and Fincher, G. B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2785-2789) showed the spatial positions of the catalytic residues in the substrate-binding clefts of the enzymes and also identified highly conserved neighboring amino acid residues. Site-directed mutagenesis of the 1,3-beta-glucanase has now been used to investigate the importance of these residues. Substitution of glutamine for the catalytic nucleophile Glu(231) (mutant E231Q) reduced the specific activity about 20,000-fold. In contrast, substitution of glutamine for the catalytic acid Glu(288) (mutant E288Q) had less severe consequences, reducing k(cat) approximately 350-fold with little effect on K-m. Substitution of two neighboring and strictly conserved active site-located residues Glu(279) (mutant E279Q) and Lys(282) (mutant K282M) led to 240- and 2500-fold reductions of k(cat), respectively, with small increases in K-m. Thus, a tetrad of ionizable amino acids is required for efficient catalysis in barley beta-glucanases. The active site-directed inhibitor 2,3-epoxypropyl beta-laminaribioside was soaked into native crystals. Crystallographic refinement revealed all four residues (Glu(231), Glu(279), Lys(282), and Glu(288)) to be in contact with the bound inhibitor, and the orientation of bound substrate in the active site of the glucanase was deduced.	LA TROBE UNIV,DEPT BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA; BIOMOLEC RES INST,PARKVILLE,VIC 3052,AUSTRALIA; UNIV ADELAIDE,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA; UNIV ADELAIDE,DEPT HORT VITICULTURE & OENOL,GLEN OSMOND,SA 5064,AUSTRALIA	La Trobe University; University of Adelaide; University of Adelaide			Hoj, Peter B/E-8526-2011					ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BRUNGER AT, 1992, X PLOR VERSION 3 3; CHEN L, 1993, J MOL BIOL, V234, P888, DOI 10.1006/jmbi.1993.1635; CHEN L, 1993, J BIOL CHEM, V268, P13318; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EDINGTON BV, 1991, PLANT MOL BIOL, V16, P81, DOI 10.1007/BF00017919; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; HOJ PB, 1992, J BIOL CHEM, V267, P25059; HOJ PB, 1991, J BIOL CHEM, V266, P11628; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HOJ PB, 1989, J BIOL CHEM, V264, P4939; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; LEGLER G, 1993, CARBOHYD RES, V250, P7; LIU L, 1993, P NATL ACAD SCI USA, V90, P8604, DOI 10.1073/pnas.90.18.8604; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MALEHORN DE, 1993, PLANT MOL BIOL, V22, P347, DOI 10.1007/BF00014941; OLSEN O, 1990, THESIS AARHUS U DENM; PAYNE G, 1990, PLANT MOL BIOL, V15, P797, DOI 10.1007/BF00039420; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; RING M, 1990, ARCH BIOCHEM BIOPHYS, V286, P342; ROBINSON AB, 1991, P NATL ACAD SCI USA, V88, P8880, DOI 10.1073/pnas.88.20.8880; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P665, DOI 10.1071/CH9900665; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMEL P, 1989, ACCOUNTS CHEM RES, V22, P232, DOI 10.1021/ar00163a001; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P9235, DOI 10.1073/pnas.90.20.9235; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SLAKESKI N, 1990, MOL GEN GENET, V224, P437, DOI 10.1007/BF00262439; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; SVENSSON B, 1990, EUR J BIOCHEM, V188, P29, DOI 10.1111/j.1432-1033.1990.tb15367.x; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; URRY DW, 1993, J AM CHEM SOC, V115, P7509, DOI 10.1021/ja00069a063; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WORRALL D, 1992, PLANT CELL, V7, P759; XU PL, 1992, GENE, V120, P157, DOI 10.1016/0378-1119(92)90089-8	43	37	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8093	8101		10.1074/jbc.270.14.8093	http://dx.doi.org/10.1074/jbc.270.14.8093			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713912	hybrid			2022-12-27	WOS:A1995QR52600050
J	DAVID, E; GARCIA, AD; HEARING, P				DAVID, E; GARCIA, AD; HEARING, P			INTERACTION OF EF-C/RFX-1 WITH THE INVERTED REPEAT OF VIRAL ENHANCE REGIONS IS REQUIRED FOR TRANSACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; B VIRUS ENHANCER; FACTOR EF-C; NUCLEAR FACTOR; FUNCTIONAL-ORGANIZATION; SV40 ENHANCER; FACTOR EF-1A; PROMOTER; SITE; ELEMENT	The hepatitis B virus (HBV) and polyomavirus (Py) enhancer regions contain multiple cis-acting elements that contribute to enhancer activity, The EF-C binding site was previously shown to be an important functional component of each enhancer region. EF-C is a ubiquitous binding activity that interacts with an inverted repeat sequence in the HBV and Py enhancer regions. Although the EF-C binding site is required for optimal enhancer function, the EF-C site does not possess intrinsic enhancer activity when assayed in the absence of flanking elements. With both the HBV and Py enhancer regions, EF-C stimulates the activity of adjacent enhancer elements in a synergistic manner. EF-C corresponds to RFX-1, a protein that binds to a conserved and functionally important site in major histocompatibility complex (MHC) class II antigen promoter regions. Interestingly, the RFX-I binding site in MHC class II promoters only contains an EF-C half-site, maintaining one arm of the inverted repeat in an EF-C binding site. We have investigated the binding of purified EF-C and RFX-1 to sites in the Py and HBV enhancer regions that carry mutations that either disrupt one arm of the EF-C inverted repeat, or alter the spacing between the repeats. Our results show that the interaction of EF-C and RFX-1 with an intact inverted repeat is required for functional activity of these viral enhancer regions. Chemical footprinting and modification interference assays show that the interaction of EF-C and RFX-1 with the DRA MHC class II promoter truly represents half-site interaction, and that this binding is unstable. In contrast, the binding of EF-C and RFX-1 to the viral inverted repeats is stable. These results suggest that an additional activity may be required to stabilize EF-C/RFX-1 interaction with the MHC class II promoter, and that viral enhancer regions have evolved high affinity binding sites to sequester dimeric EF-C/RFX-1.	SUNY STONY BROOK, HLTH SCI CTR, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [T32CA009176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029427] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176] Funding Source: Medline; NIAID NIH HHS [AI29427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLWIG GM, 1992, NUCLEIC ACIDS RES, V20, P6555, DOI 10.1093/nar/20.24.6555; BOLWIG GM, 1991, J VIROL, V65, P1884, DOI 10.1128/JVI.65.4.1884-1892.1991; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GARCIA AD, 1991, VIROLOGY, V182, P857, DOI 10.1016/0042-6822(91)90629-P; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; KHAN R, 1988, J BIOL CHEM, V263, P14374; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIOU HC, 1988, SCIENCE, V242, P69, DOI 10.1126/science.3140376; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; SAFRANY G, 1993, GENE, V132, P279, DOI 10.1016/0378-1119(93)90208-K; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; SUPAKAR PC, 1989, NUCLEIC ACIDS RES, V17, P8611, DOI 10.1093/nar/17.21.8611; VOLIVA CF, 1992, MOL CELL BIOL, V12, P2383, DOI 10.1128/MCB.12.5.2383; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	25	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8353	8360		10.1074/jbc.270.14.8353	http://dx.doi.org/10.1074/jbc.270.14.8353			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713944	hybrid			2022-12-27	WOS:A1995QR52600083
J	SHEPHERD, RM; HENQUIN, JC				SHEPHERD, RM; HENQUIN, JC			THE ROLE METABOLISM, CYTOPLASMIC CA2+, AND PH-REGULATING EXCHANGERS IN GLUCOSE-INDUCED RISE OF CYTOPLASMIC PH IN NORMAL MOUSE PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN RELEASE; BETA-CELLS; INTRACELLULAR PH; NA+/H+ EXCHANGE; B-CELL; SECRETION; AMILORIDE; ATP; ELECTROPHYSIOLOGY; INCREASE	Intact mouse islets were loaded with 2',7'-bis(2-car boxyethyl)-5(6)-carboxyfluorescein to study the effects of glucose on cytoplasmic pH (pH(i)) in pancreatic B-cells. In HCO3- buffer, glucose produced a steady-state increase in pH(i) that required metabolism of the sugar and was concentration-dependent between 0 and 10 mM (K-m similar to 5 mM) before plateauing at a maximum value of similar to 0.2 pH units. In HEPES buffer, glucose concentrations above 7 mM caused an initial rise followed by a secondary decrease and an eventual return to about initial values. Inhibition of Ca2+ influx had little effect on the pH(i) changes produced by glucose in HCO3- medium, but unmasked an alkalinizing effect in HEPES buffer. Raising cytoplasmic Ca2+ by 30 mM potassium caused a larger acidification in HEPES than in HCO3- buffer, but a subsequent rise in glucose now increased pH(i) in both types of buffer. In the presence of 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS; inhibitor of HCO3-/ Cl- exchange), the effect of glucose on pH(i) in HCO3- buffer became similar to that in HEPES buffer. After inhibition of the Na+/H+ exchanger by dimethylamiloride, glucose produced a marked and sustained fall in pH(i) in HEPES buffer. A similar fall was seen in HCO3- buffer only when DIDS and dimethylamiloride were present together. However, if Ca2+ influx was prevented when both exchangers were blocked, glucose increased pH(i). In conclusion, the metabolism of glucose tends to increase pH(i) in B-cells, whereas the concomitant rise in [Ca2+](i) exerts an acidifying action. In HEPES buffer, this acidifying effect of Ca2+ is offset by the operation of the Na+/H+ exchanger. In physiological HCO3- buffer, the activity of the HCO3-/Cl- exchanger overcompensates and leads to an increase in pH(i).	UNIV CATHOLIQUE LOUVAIN,FAC MED,UNITE ENDOCRINOL & METAB,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain								ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BEST L, 1988, J MOL ENDOCRINOL, V1, P33, DOI 10.1677/jme.0.0010033; BEST L, 1992, NUTR REGULATION INSU, P157; BIDEN TJ, 1986, AM J PHYSIOL, V250, pC207, DOI 10.1152/ajpcell.1986.250.2.C207; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BUSA WB, 1984, AM J PHYSIOL, V246, pF409; CABANTCHIK ZI, 1978, BIOCH BIOPHSY ACTA, V515, P289; COOK DL, 1990, DIABETES MELLITUS TH, P89; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; DELEERS M, 1983, FEBS LETT, V154, P97, DOI 10.1016/0014-5793(83)80882-5; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GILON P, 1992, J BIOL CHEM, V267, P20713; GRAPENGIESSER E, 1989, BIOCHIM BIOPHYS ACTA, V1014, P219, DOI 10.1016/0167-4889(89)90215-2; HENQUIN JC, 1978, NATURE, V271, P271, DOI 10.1038/271271a0; HENQUIN JC, 1976, AM J PHYSIOL, V231, P713, DOI 10.1152/ajplegacy.1976.231.3.713; HENQUIN JC, 1992, NUTRIENT REGULATION, P173; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; JUNTTIBERGGREN L, 1991, J BIOL CHEM, V266, P23537; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; LEBRUN P, 1986, BIOCHIM BIOPHYS ACTA, V886, P448, DOI 10.1016/0167-4889(86)90181-3; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; MALAISSE WJ, 1984, EXPERIENTIA, V40, P1035, DOI 10.1007/BF01971449; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; PACE CS, 1983, AM J PHYSIOL, V244, pE3, DOI 10.1152/ajpendo.1983.244.1.E3; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SEHLIN J, 1978, AM J PHYSIOL, V235, pE501, DOI 10.1152/ajpendo.1978.235.5.E501; SUGIMOTO Y, 1988, BIOMED RES-TOKYO, V9, P383, DOI 10.2220/biomedres.9.383; THELER JM, 1992, J BIOL CHEM, V267, P18110; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VIGNE P, 1984, MOL PHARMACOL, V25, P131; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; ZAWALICH WS, 1979, DIABETES, V28, P252, DOI 10.2337/diab.28.3.252	35	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7915	7921		10.1074/jbc.270.14.7915	http://dx.doi.org/10.1074/jbc.270.14.7915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713887	hybrid			2022-12-27	WOS:A1995QR52600023
J	BULENS, F; IBANEZTALLON, I; VANACKER, P; DEVRIESE, A; NELLES, L; BELAYEW, A; COLLEN, D				BULENS, F; IBANEZTALLON, I; VANACKER, P; DEVRIESE, A; NELLES, L; BELAYEW, A; COLLEN, D			RETINOIC ACID INDUCTION OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR GENE-EXPRESSION VIA A DIRECT REPEAT ELEMENT (DR5) LOCATED AT -7 KILOBASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED-IMMUNOSORBENT-ASSAY; HUMAN ENDOTHELIAL-CELLS; FRAGMENT-D-DIMER; TRANSCRIPTIONAL REGULATION; MONOCLONAL-ANTIBODIES; FUNCTIONAL-ANALYSIS; RESPONSE ELEMENT; BINDING-SITE; T-PA; DIFFERENTIATION	All-trans-retinoic acid (RA) and retinoids induce synthesis of tissue-type plasminogen activator (t-PA) in endothelial and neuroblastoma cells in vitro and in rats in vivo. In HT1080 fibrosarcoma cells, induction of t-PA-related antigen secretion and t-PA mRNA steady state levels by RA were found to depend on de novo protein and mRNA synthesis. Fragments derived from the 5'-flanking region of the t-PA gene (+197 to -9578 base pairs (bp)) were linked to the chloramphenicol acetyltransferase gene. Transfection studies demonstrated that the region spanning bp -7145 to -9578 mediated induction by RA. A functional retinoic acid response element (RARE), consisting of a direct repeat of the GGGTCA motif spaced by 5 nucleotides (t-PA/DR5), was localized at -7.3 kilobases. The t-PA/DR5 element interacted with the heterodimer composed of retinoic acid receptor alpha and retinoid X receptor alpha in vitro, whereas its mutation abolished induction by RA in transient expression. In human EA.hy926 hybrid endothelial and in SK-N-SH neuroblastoma cells, the activity of t-PA/DR5 was found to be independent of the intervening sequence (-632 to -7144 bp) and of its distance from the transcription initiation site. Staurosporine, an inhibitor of protein kinase activity, inhibited induction by RA, suggesting that it required protein phosphorylation.	CATHOLIC UNIV LEUVEN, CTR MOLEC & VASC BIOL, B-3000 LOUVAIN, BELGIUM	KU Leuven			BELAYEW, Alexandra/D-5205-2013	BELAYEW, Alexandra/0000-0001-5115-2424				ASTROM A, 1994, J BIOL CHEM, V269, P22334; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BENJAMIN LA, 1989, CANCER LETT, V44, P101, DOI 10.1016/0304-3835(89)90004-9; BULENS F, 1992, J CARDIOVASC PHARM, V19, P508, DOI 10.1097/00005344-199204000-00006; BULENS F, 1992, FIBRINOLYSIS, V6, P243, DOI 10.1016/0268-9499(92)90077-U; BULENS F, 1991, EUR J BIOCHEM, V195, P235, DOI 10.1111/j.1432-1033.1991.tb15699.x; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEN D, 1991, BLOOD, V78, P3114; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1992, THROMB HAEMOSTASIS, V67, P95; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HENDERSON BR, 1992, FEBS LETT, V309, P130, DOI 10.1016/0014-5793(92)81080-6; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; HOLVOET P, 1989, THROMB HAEMOSTASIS, V61, P307; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KOOISTRA T, 1991, THROMB HAEMOSTASIS, V65, P565; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; KUHNEL B, 1986, J MOL BIOL, V190, P367, DOI 10.1016/0022-2836(86)90008-2; KWAAN HC, 1992, PROG CARDIOVASC DIS, V34, P309, DOI 10.1016/0033-0620(92)90036-Y; LIPP HP, 1994, SOC NEUR ABSTR, V19, P799; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MADER S, 1993, J BIOL CHEM, V268, P591; MAK WWN, 1984, BIOCHEM BIOPH RES CO, V123, P633, DOI 10.1016/0006-291X(84)90276-6; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; NELLES L, 1987, J BIOL CHEM, V262, P5682; NEUMAN T, 1989, J NEUROSCI RES, V23, P274, DOI 10.1002/jnr.490230305; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROCCHI P, 1991, ANTICANCER RES, V11, P1885; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHWACHTGEN JL, 1994, BIOTECHNIQUES, V17, P882; SEEDS NW, 1990, NATO ADV SCI I A-LIF, V191, P173; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; WAHLI W, 1994, J CELL BIOCH B, V18, P339	48	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7167	7175		10.1074/jbc.270.13.7167	http://dx.doi.org/10.1074/jbc.270.13.7167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706255	hybrid			2022-12-27	WOS:A1995QQ43100026
J	DISALVO, J; BAYNE, ML; CONN, G; KWOK, PW; TRIVEDI, PG; SODERMAN, DD; PALISI, TM; SULLIVAN, KA; THOMAS, KA				DISALVO, J; BAYNE, ML; CONN, G; KWOK, PW; TRIVEDI, PG; SODERMAN, DD; PALISI, TM; SULLIVAN, KA; THOMAS, KA			PURIFICATION AND CHARACTERIZATION OF A NATURALLY-OCCURRING VASCULAR ENDOTHELIAL GROWTH-FACTOR PLACENTA GROWTH-FACTOR HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MITOGEN; PERMEABILITY FACTOR; DEVELOPMENTAL EXPRESSION; FACTOR FAMILY; SINGLE GENE; ANGIOGENESIS; BINDING; PROTEIN; VASCULOGENESIS; CLEAVAGE	Vascular endothelial growth factor (VEGF) is a potent and selective mitogen for endothelial cells that is angiogenic in vivo and induced by hypoxia, A homologous protein, placenta growth factor (PlGF), is also reported to be mitogenic for endothelial cells in culture, The rat GS-SL glioma cell line produces not only VEGF homodimers but also PlGF homodimers and a novel heterodimer composed of VEGF and PlGF subunits, All three dimeric forms were purified to apparent homogeneity, and their structures and mitogenic activities were compared, VEGF . PlGF heterodimers are vascular endothelial cell mitogens nearly as potent as VEGF homodimers, Therefore, some of the biological activities attributed to VEGF homodimers might be mediated by VEGF . PlGF heterodimers. In contrast, pure PlGF homodimers are mitogenic for endothelial cells only at high, possibly non-physiologic concentrations; thus the biological relevance of their mitogenic activity for these cells is not obvious, However, the existence of not only homodimers but also heterodimers clearly extends the similarity between the VEGF/PlGF and the homologous platelet-derived growth factor systems.	MERCK RES LABS, DEPT BIOCHEM, RAHWAY, NJ 07065 USA	Merck & Company								BANAI S, 1993, CIRCULATION, V88, P543; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; Fallon JH, 1992, GROWTH FACTORS, V6, P139; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; PARK JE, 1994, J BIOL CHEM, V269, P25646; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; THOMAS KA, 1984, P NATL ACAD SCI-BIOL, V81, P357, DOI 10.1073/pnas.81.2.357; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	39	239	251	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7717	7723		10.1074/jbc.270.13.7717	http://dx.doi.org/10.1074/jbc.270.13.7717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706320	hybrid			2022-12-27	WOS:A1995QQ43100099
J	JAKOB, U; LILIE, H; MEYER, I; BUCHNER, J				JAKOB, U; LILIE, H; MEYER, I; BUCHNER, J			TRANSIENT INTERACTION OF HSP90 WITH EARLY UNFOLDING INTERMEDIATES OF CITRATE SYNTHASE - IMPLICATIONS FOR HEAT-SHOCK IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A; PROTEIN; AGGREGATION; BINDING; OXALOACETATE; CHAPERONES; COMPLEXES; RECEPTOR; KINASE; MODEL	At normal temperatures, Hsp90 is one of the most abundant proteins in the cytosol of various eucaryotic cells, Upon heat shock, the level of Hsp90 is increased even more, suggesting that it is important for helping cells to survive under these conditions, However, studies so far have been almost exclusively concerned with the function of Hsp90 under non-stress conditions, and therefore only little is known about the role of Hsp90 during heat shock, As a model for heat shock in vitro, we have monitored the inactivation and subsequent aggregation of dimeric citrate synthase (CS) at elevated temperatures, Hsp90 effectively ''stabilized'' CS under conditions where the enzyme is normally inactivated and finally aggregates very rapidly, A kinetic dissection of the unfolding pathway of CS succeeded in revealing two intermediates which form and subsequently undergo irreversible aggregation reactions, Hsp90 apparently interacts transiently with these highly structured early unfolding intermediates, finding and subsequent release of the intermediates favorably influences the kinetic partitioning between two competing processes, the further unfolding of CS and the productive refolding to the native state, As a consequence, CS is effectively stabilized in the presence of Hsp90. The significance of this interaction is especially evident in the suppression of aggregation, the major end result of thermal unfolding events in vivo and in vitro. These effects, which are ATP-independent, seem to be a general function of members of the Hsp90 family, since yeast and bovine Hsp90 as well as the Hsp90 homologue from Escherichia coli gave similar results, It seems likely that this function also reflects the role of Hsp90 under heat shock conditions in vivo, We therefore propose that members of the Hsp90 family convey thermotolerance by transiently binding to highly structured early unfolding intermediates, thereby preventing their irreversible aggregation and stabilizing the active species.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93040 REGENSBURG, GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BENSAUDE O, 1990, P89; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIONI P, 1994, BIOPHYS CHEM, V52, P25, DOI 10.1016/0301-4622(94)00039-5; GRAGEROV AI, 1991, FEBS LETT, V291, P222, DOI 10.1016/0014-5793(91)81289-K; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLLNEUGEBAUER B, 1992, BIOCHEMISTRY-US, V30, P1609; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NOVER L., 1991, HEAT SHOCK RESPONSE; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SRERE PA, 1966, J BIOL CHEM, V241, P2157; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WIEGAND G, 1984, J MOL BIOL, V174, P205, DOI 10.1016/0022-2836(84)90373-5; WIELAND O., 1964, BIOCHEM Z, V339, P501; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; ZHI W, 1991, BIOCHEMISTRY-US, V30, P9281, DOI 10.1021/bi00102a021; ZHI W, 1992, PROTEIN SCI, V1, P552	39	307	309	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7288	7294		10.1074/jbc.270.13.7288	http://dx.doi.org/10.1074/jbc.270.13.7288			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706269	hybrid			2022-12-27	WOS:A1995QQ43100042
J	BOISCLAIR, YR; BROWN, AL; CASOLA, S; RECHLER, MM				BOISCLAIR, YR; BROWN, AL; CASOLA, S; RECHLER, MM			3 CLUSTERED SP1 SITES ARE REQUIRED FOR EFFICIENT TRANSCRIPTION OF THE TATA-LESS PROMOTER OF THE GENE FOR INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-2 FROM THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; ACTIVATOR INHIBITOR-1 GENE; RECEPTOR GENE; SYNERGISTIC ACTIVATION; IGF-I; EXPRESSION; BOX; SEQUENCE; DNA; CLONING	Insulin-like growth factor-binding protein-2 (IGFBP-2) transcription in rat liver varies with developmental age and fasting. To define the DNA elements required for efficient expression of the TATA-less rat IGFBP-2 gene, the native or mutated promoter was fused to a promoterless luciferase reporter gene and transfected into BRL-3A rat liver and 293 human embryonic kidney cell lines. Luciferase activity decreased approximately 25-fold with progressive 5' promoter deletions from nucleotide (nt) -581 to nt -189 (relative to ATG, +1). The smallest construct, however, still had >21-fold greater luciferase activity than the promoterless construct. In DNase I footprinting assays using native nt -276 to -36 promoter fragments or fragments containing block substitution mutations, BRL-3A nuclear extract and purified human transcription factor Sp1 protected a region from nt -234 to -215 containing one GC box and a broad region from nt -189 to -125 that contained three clustered but independent GC boxes. In gel retardation assays using an Spl oligonucleotide probe, BRL-3A extract formed two closely migrating complexes that were immunologically related to Spl; Spl gave a single complex that co-migrated with the more retarded BRL-3A complex. Binding was competitively inhibited by oligonucleotides corresponding to each of the four GC boxes. The proximal three GC boxes were sufficient to allow trans-activation of the IGFBP-2 promoter by Spl in Drosophila SL2 cells. Independent block mutations indicated that all three of the GC boxes are required for promoter activity and are equally important. Thus, binding of Spl or Sp1-related proteins to three clustered GC boxes in the proximal IGFBP-2 promoter is essential for promoter activity. Multiple upstream regions also contribute to the full expression of the IGFBP-2 gene.			BOISCLAIR, YR (corresponding author), NIDDKD, MOLEC & CELLULAR ENDOCRINOL BRANCH, GROWTH & DEV SECT, BLDG 10, RM 8D-14, BETHESDA, MD 20892 USA.		Casola, Stefano/AAN-8319-2021	Casola, Stefano/0000-0001-5580-0986				ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BINKERT C, 1992, MOL ENDOCRINOL, V6, P826, DOI 10.1210/me.6.5.826; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN AL, 1989, J BIOL CHEM, V264, P5148; BROWN AL, 1990, MOL ENDOCRINOL, V4, P2039, DOI 10.1210/mend-4-12-2039; CHEN XR, 1992, ONCOGENE, V7, P1805; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DONOVAN SM, 1989, ENDOCRINOLOGY, V125, P2621, DOI 10.1210/endo-125-5-2621; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FARNHAM PJ, 1990, CELL GROWTH DIFFER, V1, P179; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HILL DJ, 1992, ADV EXP MED BIOL, V321, P113; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON MR, 1992, J BIOL CHEM, V267, P12202; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEMPT M, 1992, DEVELOPMENT, V115, P765; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEE WH, 1992, MOL CELL NEUROSCI, V3, P36, DOI 10.1016/1044-7431(92)90006-N; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; ORLOWSKI CC, 1990, ENDOCRINOLOGY, V126, P644, DOI 10.1210/endo-126-1-644; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUN JM, 1992, NUCLEIC ACIDS RES, V20, P6385, DOI 10.1093/nar/20.23.6385; TSENG LYH, 1989, MOL ENDOCRINOL, V3, P1559, DOI 10.1210/mend-3-10-1559; TSENG LYH, 1992, MOL ENDOCRINOL, V6, P1195, DOI 10.1210/me.6.8.1195; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOOD TL, 1992, DEVELOPMENT, V114, P59; YU CY, 1991, J BIOL CHEM, V266, P8907; ZAPF J, 1990, J CLIN INVEST, V86, P952, DOI 10.1172/JCI114797; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	62	120	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24892	24901						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693708				2022-12-27	WOS:A1993MG67300058
J	DONATE, LE; VALPUESTA, JM; MIER, C; ROJO, F; CARRASCOSA, JL				DONATE, LE; VALPUESTA, JM; MIER, C; ROJO, F; CARRASCOSA, JL			CHARACTERIZATION OF AN RNA-BINDING DOMAIN IN THE BACTERIOPHAGE-PHI-29 CONNECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS PHAGE-PHI-29; PHI-29 CONNECTOR; 3-DIMENSIONAL STRUCTURE; RESTRICTION FRAGMENTS; NUCLEOTIDE-SEQUENCE; COLIPHAGE-LAMBDA; DNA-BINDING; PROTEIN; PROHEAD; IDENTIFICATION	The connector of bacteriophage phi29 is known to promote the viral prohead assembly, to bind DNA, and to drive DNA packaging into preformed viral shells in an RNA-dependent process. In this report, the phi29 connector protein, p10, is shown to bind RNA in a sequence-independent fashion, and to possess an RNA recognition motif comprised approximately the region between residues 21 and 94 of the p10 sequence. Substitution mutants in specific amino acids of the RNA-binding domain obtained by site-directed mutagenesis showed that amino acids Phe23, His57, Phe59, and Tyr61 are critical for RNA binding and, subsequently, for DNA packaging into proheads. Proteolytic modified forms of the phi29 connector have allowed us to conclude that the DNA- and RNA-binding domains are separated within the p10 sequence. It is also shown that RNA is stably associated to DNA-filled proheads during the DNA-packaging process.	UNIV AUTONOMA MADRID,CTR BIOL MOLEC SEVERO OCHOA,CSIC,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Valpuesta, José M/T-1977-2017; Rojo, Fernando/A-7038-2008; Valpuesta, Jose M/AAA-6002-2019	Valpuesta, José M/0000-0001-7468-8053; Rojo, Fernando/0000-0003-1848-7745; 				BAILEY S, 1990, J BIOL CHEM, V265, P22365; BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; BUCHWALD M, 1970, VIROLOGY, V42, P390, DOI 10.1016/0042-6822(70)90282-5; CAMACHO A, 1977, EUR J BIOCHEM, V73, P39, DOI 10.1111/j.1432-1033.1977.tb11290.x; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; CARRASCOSA JL, 1990, COMPUT MATH APPL, V20, P57, DOI 10.1016/0898-1221(90)90314-A; CARRUTH JAS, 1986, IEEE ENG MED BIOL, V5, P37, DOI 10.1109/MEMB.1986.5006254; Casjens S., 1988, BACTERIOPHAGES, VI; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DONATE LE, 1988, J MOL BIOL, V201, P91, DOI 10.1016/0022-2836(88)90441-X; DONATE LE, 1990, VIROLOGY, V179, P936, DOI 10.1016/0042-6822(90)90172-N; DONATE LE, 1991, VIROLOGY, V182, P534, DOI 10.1016/0042-6822(91)90594-2; DONATE LE, 1992, J BIOL CHEM, V267, P10919; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; ESCARMIS C, 1981, P NATL ACAD SCI-BIOL, V78, P1446, DOI 10.1073/pnas.78.3.1446; GARCIA JA, 1984, GENE, V30, P87, DOI 10.1016/0378-1119(84)90108-2; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; GRIMES S, 1989, J MOL BIOL, V209, P91, DOI 10.1016/0022-2836(89)90172-1; GUO P, 1987, NUCLEIC ACIDS RES, V17, P7081; GUO PX, 1987, J MOL BIOL, V197, P219, DOI 10.1016/0022-2836(87)90120-3; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1991, VIROLOGY, V185, P395, DOI 10.1016/0042-6822(91)90787-C; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; HERRANZ L, 1986, VIROLOGY, V155, P289, DOI 10.1016/0042-6822(86)90191-1; HERRANZ L, 1990, J MOL BIOL, V213, P263, DOI 10.1016/S0022-2836(05)80189-5; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HSIAO CL, 1978, VIROLOGY, V91, P15, DOI 10.1016/0042-6822(78)90351-3; IBANEZ C, 1984, NUCLEIC ACIDS RES, V12, P2351, DOI 10.1093/nar/12.5.2351; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; KOCHAN J, 1984, J MOL BIOL, V174, P175; MURIALDO H, 1978, MICROBIOL REV, V42, P529, DOI 10.1128/MMBR.42.3.529-576.1978; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; MURIALDO H, 1971, BACTERIOPHAGE LAMBDA, P711; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAKASU S, 1985, VIROLOGY, V143, P422, DOI 10.1016/0042-6822(85)90382-4; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; RAJ AS, 1974, MOL GEN GENET, V135, P175, DOI 10.1007/BF00264784; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; VALCARCEL J, 1991, J GEN VIROL, V72, P1301, DOI 10.1099/0022-1317-72-6-1301; VALPUESTA JM, 1992, J MOL BIOL, V224, P103, DOI 10.1016/0022-2836(92)90579-9; VALPUESTA JM, 1992, NUCLEIC ACIDS RES, V20, P5549, DOI 10.1093/nar/20.21.5549; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K	46	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20198	20204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690751				2022-12-27	WOS:A1993LY01900044
J	MUSTAEV, A; KASHLEV, M; ZAYCHIKOV, E; GRACHEV, M; GOLDFARB, A				MUSTAEV, A; KASHLEV, M; ZAYCHIKOV, E; GRACHEV, M; GOLDFARB, A			ACTIVE-CENTER REARRANGEMENT IN RNA-POLYMERASE INITIATION COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LAC UV5 PROMOTER; ESCHERICHIA-COLI; TERNARY COMPLEXES; FUNCTIONAL TOPOGRAPHY; PHOSPHORYLATING DERIVATIVES; TRANSCRIPTION ELONGATION; PRIMER OLIGONUCLEOTIDES; VISUALIZATION; CONTACTS; INVITRO	His1237 in the beta subunit of Escherichia coli RNA polymmerase marks the ''5' face'' of the active center since it can be cross-linked to the gamma-phosphate of the priming substrate. It is demonstrated that RNA chains up to 9 nucleotides in length can be synthesized using His1237-cross-linked nucleotide as a primer. Thus, a substantial mass of RNA can be accommodated in the active center between His1237 and the site of catalysis that remains juxtaposed to the growing 3' end. The apparent ''filling'' of the active center with RNA precedes promoter clearance and suggests a mechanism of coupling between catalysis and saltatory translocation of RNA polymerase.	PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016; RUSSIAN ACAD SCI,INST LIMINOL,IRKUTSK 664033,RUSSIA	Russian Academy of Sciences			Grachev, Mikhail/J-9279-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; FIC NIH HHS [TW00258] Funding Source: Medline; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; CHAN CL, 1993, IN PRESS TRANSCRIPTI; GODOVIKOVA TS, 1987, EUR J BIOCHEM, V166, P611, DOI 10.1111/j.1432-1033.1987.tb13557.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GRACHEV MA, 1986, BIOORG KHIM+, V12, P1678; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1981, FEBS LETT, V130, P23, DOI 10.1016/0014-5793(81)80657-6; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRACHEV MA, 1980, FEBS LETT, V115, P23, DOI 10.1016/0014-5793(80)80718-6; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HEUMANN H, 1986, EUR J BIOCHEM, V158, P575, DOI 10.1111/j.1432-1033.1986.tb09793.x; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KNORRE DG, 1976, FEBS LETT, V70, P105, DOI 10.1016/0014-5793(76)80736-3; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; LEE J, 1990, CELL, V66, P793; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SERPINSKI OI, 1982, BIOORG KHIM+, V8, P840; SPASSKY A, 1986, J MOL BIOL, V188, P99, DOI 10.1016/0022-2836(86)90484-5; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TSAREV IG, 1990, BIOORG KHIM+, V16, P765; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	31	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19185	19187						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690028				2022-12-27	WOS:A1993LW81900007
J	SHEN, BQ; BARTHELSON, RA; SKACH, W; GRUENERT, DC; SIGAL, E; MRSNY, RJ; WIDDICOMBE, JH				SHEN, BQ; BARTHELSON, RA; SKACH, W; GRUENERT, DC; SIGAL, E; MRSNY, RJ; WIDDICOMBE, JH			MECHANISM OF INHIBITION OF CAMP-DEPENDENT EPITHELIAL CHLORIDE SECRETION BY PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; CELL-LINE; TRACHEAL EPITHELIUM; TRANSPORT; CHANNEL; EXPRESSION; CFTR; IDENTIFICATION; LOCALIZATION	In T84 cells, we investigated how stimulation of protein kinase C leads to an inhibition of cAMP-dependent chloride secretion. Specifically, we tested the hypothesis that the inhibition was caused by loss of the cystic fibrosis transmembrane regulator (CFTR), an apical membrane chloride channel. As described by others (Trapnell, B. C., Zeitlin, P. L., Chu, C.-S., Yoshimura, K., Nakamura, H., Guggino, W. B., Bargon, J., Banks, T. C., Dalemans, W., Pavirani, A., Lecocq, J.-P., and Crystal, R. G. (1991) J. Biol. Chem. 266, 10319-10323), we found that treatment with the phorbol ester, phorbol myristate acetate (PMA), reduced CFTR mRNA levels by approximately 80% with a t1/2 of approximately 2 h. Chloride secretion, measured as forskolin-induced short circuit current, was also abolished by PMA with a t1/2 of approximately 2 h. Levels of mature glycosylated CFTR measured by Western blotting also declined to 50 +/- 8% (n = 7) of control after a 12-h PMA treatment. However, a 12-h exposure to PMA did not affect the forskolin-stimulated efflux of I-125 into high potassium medium, a measure of apical membrane CFTR activity. We conclude that increased turnover of apical membrane CFTR in PMA-treated cells compensates for the decline in anion channel numbers. By contrast to its lack of effect on I-125 effluxes, PMA reduced the cAMP-induced increase in Rb-86 efflux, suggesting that it inhibits chloride secretion mainly by an action on basolateral potassium channels.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,513 PARNASSUS AVE,BOX 0130,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL-42368] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1991, SCIENCE, V253, P203; BARTHELSON RA, 1987, AM J PHYSIOL, V253, pC802, DOI 10.1152/ajpcell.1987.253.6.C802; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; FRIZZELL RA, 1979, AM J PHYSIOL, V236, pF1, DOI 10.1152/ajprenal.1979.236.1.F1; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; LASKI F, 1982, NUCLEIC ACIDS RES, V210, P4609; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MCCANN JD, 1990, AM J PHYSIOL, V258, pL348; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LABORATO; SARKADI B, 1992, J BIOL CHEM, V267, P2087; Smith PK, 1985, ANAL BIOCHEM, V71, P1392; SUSSMAN I, 1985, J CELL BIOL, V101, P2316, DOI 10.1083/jcb.101.6.2316; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WELSH MJ, 1987, AM J PHYSIOL, V253, pC828, DOI 10.1152/ajpcell.1987.253.6.C828; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	28	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					19070	19075						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689566				2022-12-27	WOS:A1993LV65900103
J	BENBARUCH, A; BENGALI, KM; BIRAGYN, A; JOHNSTON, JJ; WANG, JM; KIM, J; CHUNTHARAPAI, A; MICHIEL, DF; OPPENHEIM, JJ; KELVIN, DJ				BENBARUCH, A; BENGALI, KM; BIRAGYN, A; JOHNSTON, JJ; WANG, JM; KIM, J; CHUNTHARAPAI, A; MICHIEL, DF; OPPENHEIM, JJ; KELVIN, DJ			INTERLEUKIN-8 RECEPTOR-BETA - THE ROLE OF THE CARBOXYL-TERMINUS IN SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; NEUTROPHIL-ACTIVATING PEPTIDE-2; GROWTH-STIMULATORY ACTIVITY; PROTEIN-COUPLED RECEPTORS; CHEMOTACTIC RECEPTOR; FUNCTIONAL EXPRESSION; AMINO TERMINUS; CLONING; LIGAND; IDENTIFICATION	Two interleukin-8 (IL-8) receptors, alpha and beta, have been identified and cloned. Both receptors are thought to transduce signals by coupling to GTP-binding proteins. The aim of this study is to determine whether the carboxyl terminus (C') of IL-8 receptor beta (IL-8R beta) is involved in signaling in response to IL-8. We have constructed a number of IL-8R beta genes that encode truncated forms of the IL-8R beta. The deletions consisted of amino acids 349-355, 336-355, 325-355, and 317-355 (termed beta 2, beta 3, beta 4, and beta 5, respectively). 293 human embryonic kidney cells were transfected with the wild type IL-8R beta (beta 1) and with these mutants. Cells transfected with the mutated receptors expressed the receptors and bound IL-8 with the same high affinity as cells transfected with the wild type receptor. The capacity of the mutated receptors to convey functional signals was evaluated by comparing the chemotaxis index of cells expressing the C' truncated receptors to the index of cells expressing the wild type receptor. The results indicate that while cells expressing beta 1, beta 2, beta 3, and beta 4 were chemoattracted in response to IL-8, cells expressing beta 5 did not migrate in response to IL-8 stimulation. Therefore, the data suggest that amino acids 317-324 are involved in signaling by IL-8R beta.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,FREDERICK,MD 21702; NCI,BIOL RESPONSE MODIFIERS PROGRAM,PRECLIN EVALUAT LAB,FREDERICK,MD 21702; NCI,BIOL RESPONSE MODIFIERS PROGRAM,EXPTL IMMUNOL LAB,FREDERICK,MD 21702; GENENTECH INC,S SAN FRANCISCO,CA 94080	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Roche Holding; Genentech	BENBARUCH, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702, USA.							AHUJA SK, 1993, J BIOL CHEM, V268, P20691; ALI H, 1993, J BIOL CHEM, V268, P24247; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GROB PM, 1990, J BIOL CHEM, V265, P8311; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; JOSHIA SM, 1994, BIOCHEM BIOPH RES CO, V199, P626; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOSER B, 1991, J BIOL CHEM, V266, P10666; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REMES JJ, 1993, EXP CELL RES, V209, P26, DOI 10.1006/excr.1993.1280; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHAPIRO RA, 1993, J BIOL CHEM, V268, P21734; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; TAKANO T, 1994, J BIOL CHEM, V269, P22453; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	46	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9121	9128		10.1074/jbc.270.16.9121	http://dx.doi.org/10.1074/jbc.270.16.9121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721826	hybrid			2022-12-27	WOS:A1995QU08900014
J	JOHANSON, K; APPELBAUM, E; DOYLE, M; HENSLEY, P; ZHAO, B; ABDELMEGUID, SS; YOUNG, P; COOK, R; CARR, S; MATICO, R; CUSIMANO, D; DUL, E; ANGELICHIO, M; BROOKS, I; WINBORNE, E; MCDONNELL, P; MORTON, T; BENNETT, D; SOKOLOSKI, T; MCNULTY, D; ROSENBERG, M; CHAIKEN, I				JOHANSON, K; APPELBAUM, E; DOYLE, M; HENSLEY, P; ZHAO, B; ABDELMEGUID, SS; YOUNG, P; COOK, R; CARR, S; MATICO, R; CUSIMANO, D; DUL, E; ANGELICHIO, M; BROOKS, I; WINBORNE, E; MCDONNELL, P; MORTON, T; BENNETT, D; SOKOLOSKI, T; MCNULTY, D; ROSENBERG, M; CHAIKEN, I			BINDING INTERACTIONS OF HUMAN INTERLEUKIN-5 WITH ITS RECEPTOR-ALPHA SUBUNIT - LARGE-SCALE PRODUCTION, STRUCTURAL, AND FUNCTIONAL, STUDIES OF DROSOPHILA-EXPRESSED RECOMBINANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; EOSINOPHIL DIFFERENTIATION FACTOR; HUMAN GROWTH-HORMONE; MOLECULAR-CLONING; GM-CSF; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; AFFINITY BINDING; IL-5 RECEPTORS; CELLS	Human interleukin 5 (hIL5) and soluble forms of its receptor alpha subunit were expressed in Drosophila cells and purified to homogeneity, allowing a detailed structural and functional analysis, B cell proliferation confirmed that the hIL5 was biologically active. Deglycosylated hTL5 remained active, while similarly deglycosylated receptor alpha subunit lost activity. The crystal structure of the deglycosylated hIL5 was determined to 2.6-Angstrom resolution and found to be similar to that of the protein produced in Escherichia coli. Human IL5 was shown by analytical ultracentrifugation to form a 1:1 complex with the soluble domain of the hIL5 receptor alpha subunit (shIL5R alpha). Additionally, the relative abundance of ligand and receptor in the hIL5 . shIL5R alpha complex was determined to be 1:1 by both titration calorimetry and SDS-polyacrylamide gel electrophoresis analysis of dissolved cocrystals of the complex. Titration microcalorimetry yielded equilibrium dissociation constants of 3.1 and 2.0 nM, respectively, for the binding of hIL5 to shIL5R alpha and to a chimeric form of the receptor containing shIL5R alpha fused to the immunoglobulin Fc domain (shIL5R alpha-Fc). Analysis of the binding thermodynamics of IL5 and its soluble receptor indicates that conformational changes are coupled to the binding reaction, Kinetic analysis using surface plasmon resonance yielded data consistent with the K-d values from calorimetry and also with the possibility of conformational isomerization in the interaction of hIL5 with the receptor alpha subunit, Using a radioligand binding assay, the affinity of hIL5 with full-length hIL5R alpha in Drosophila membranes was found to be 6 nM, in accord with the affinities measured for the soluble receptor forms, Hence, most of the binding energy of the alpha receptor is supplied by the soluble domain. Taken with other aspects of hIL5 structure and biological activity, the data obtained allow a prediction for how 1:1 stoichiometry and conformational change can lead to the formation of hIL5-receptor alpha beta complex and signal transduction.	SMITHKLINE BEECHAM PHARMACEUT, DEPT MOLEC IMMUNOL, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PROT BIOCHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT GENE EXPRESS SCI, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHYS & STRUCT CHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHARMACOL TECHNOL, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DIV BIOPHARMACEUT, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline			Brooks, Ian/AAI-2571-2021; Brooks, Ian/E-7052-2010; Carr, Steven A./AAH-8366-2019	Doyle, Michael/0000-0003-4569-6315; Brooks, Ian/0000-0002-3793-3635				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; ANUMULA KR, 1989, GLYCOCONJUGATE J, V6, P414; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BROOKS I, 1994, METHOD ENZYMOL, V240, P459; BROOKS I, 1994, MODERN ANAL ULTRACEN, P15; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; Christensen J.J., 1976, HDB PROTON IONIZATIO; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HSIEH P, 1984, J BIOL CHEM, V259, P2375; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KODAMA S, 1991, BIOCHEM BIOPH RES CO, V178, P514, DOI 10.1016/0006-291X(91)90137-V; KOIKE M, 1994, INT ARCH ALLERGY IMM, V104, P1, DOI 10.1159/000236702; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MCKENZIE ANJ, 1992, CHEM IMMUNOL, V51, P135; McPherson A Jr, 1976, Methods Biochem Anal, V23, P249, DOI 10.1002/9780470110430.ch4; METCALF D, 1974, J CELL PHYSIOL, V84, P275, DOI 10.1002/jcp.1040840214; MIGITA M, 1991, CELL IMMUNOL, V133, P484, DOI 10.1016/0008-8749(91)90120-Z; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MITA S, 1988, J EXP MED, V168, P863, DOI 10.1084/jem.168.3.863; Mitchell Diane L., 1993, Biochemical Society Transactions, V21, p332S; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; ROBERT CH, 1989, BIOPOLYMERS, V28, P1705, DOI 10.1002/bip.360281006; RONCO LV, 1994, J BIOL CHEM, V269, P277; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHATZMAN A, 1990, CURRENT PROTOCOLS MO, V11; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TANABE T, 1987, J BIOL CHEM, V262, P16580; TANFORD C, 1980, HYDROPHOBIC EFFECT; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; WARREN DJ, 1985, IMMUNOLOGY, V54, P615; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wyman J, 1990, BINDING LINKAGE FUNC	66	85	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9459	9471		10.1074/jbc.270.16.9459	http://dx.doi.org/10.1074/jbc.270.16.9459			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721873	hybrid			2022-12-27	WOS:A1995QU08900062
J	PFEIFER, A; NURNBERG, B; KAMM, S; UHDE, M; SCHULTZ, G; RUTH, P; HOFMANN, F				PFEIFER, A; NURNBERG, B; KAMM, S; UHDE, M; SCHULTZ, G; RUTH, P; HOFMANN, F			CYCLIC GMP-DEPENDENT PROTEIN-KINASE BLOCKS PERTUSSIS-TOXIN-SENSITIVE HORMONE-RECEPTOR SIGNALING PATHWAYS IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NUCLEOTIDE-BINDING-PROTEINS; GROWTH FACTOR-II; TYROSINE PHOSPHORYLATION; NITRIC-OXIDE; CA2+ CURRENT; MOLECULAR-CLONING; CALCIUM INFLUX; ALPHA-SUBUNIT; RAT AORTA	cGMP-dependent protein kinase (cGMP kinase) has been implicated in the regulation of the cytosolic calcium level ([Ca2+](i)). In Chinese hamster ovary (CHO) cells stably transfected with the cGMP kinase I alpha (CHO-cGK cells), cGMP kinase suppressed the thrombin-induced increase in inositol 1,4,5-trisphosphate and [Ca2+](i) (Ruth, P,, Wang, G.-X., Boekhoff, I., May, B,, Pfeifer, A., Penner, R., Korth, M,, Breer, H,, and Hofmann, F, (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 2623-2627), Cholecystokinin activated intracellular calcium release via a pertussis toxin (PTX)-insensitive pathway in CHO-cGK cells. cGMP kinase did not attenuate the CCK stimulated [Ca2+](i). In contrast, cGMP kinase suppressed calcium influx stimulated by insulinlike growth factors 1 and 2 (IGF-1 and IGF-2) via PTX-sensitive pathways. The effects of PTX and cGMP kinase on [Ca2+](i) were not additive. 8-Bromo-cGMP had no effect on [Ca2+](i) stimulated by IGF-1 or IGF-2 in wild type CHO cells, These results suggested that cGMP kinase inhibited the different signaling pathways by the phosphorylation of a PTX-sensitive G protein. cGMP kinase phosphorylated the alpha subunits of G(i1), G(i2), and G(i3) in vitro. Phosphorylation stoichiometry was 0.4 mol of phosphate/mol of G(alpha i1) after reconstitution of heterotrimeric G(i1) in phospholipid vesicles. The alpha subunit of G(i) was also phosphorylated in vivo, These results show that cGMP kinase blocks transduction of distinct hormone pathways that signal via PTX-sensitive G(i) proteins.	FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	PFEIFER, A (corresponding author), TECH UNIV MUNICH, INST PHARMAKOL & TOXIKOL, BIEDERSTEINER STR 29, D-80802 MUNICH, GERMANY.			Nurnberg, Bernd/0000-0002-5995-6555				ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BARNETT R, 1990, AM J PHYSIOL, V258, pC37, DOI 10.1152/ajpcell.1990.258.1.C37; BRAY P, 1987, P NATL ACAD SCI USA, V84, P5115, DOI 10.1073/pnas.84.15.5115; CODINA J, 1991, METHOD ENZYMOL, V195, P177; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARHAMMER R, 1994, BIOCHEM J, V303, P135, DOI 10.1042/bj3030135; HIRATA M, 1990, J BIOL CHEM, V265, P1268; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HUNG DT, 1992, J BIOL CHEM, V267, P20831; ISHIKAWA T, 1993, CIRC RES, V73, P1128, DOI 10.1161/01.RES.73.6.1128; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LAW SF, 1993, J BIOL CHEM, V268, P10721; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LINCOLN TM, 1991, SEC MESS PHOSPHOPROT, V13, P99; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; MERY PF, 1993, J BIOL CHEM, V268, P26286; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NURNBERG B, 1994, BIOCHEM J, V300, P387; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; ONO K, 1991, J PHYSIOL-LONDON, V443, P387, DOI 10.1113/jphysiol.1991.sp018839; PARK DJ, 1992, J BIOL CHEM, V267, P1496; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; ROSENTHAL W, 1986, EUR J BIOCHEM, V158, P255, DOI 10.1111/j.1432-1033.1986.tb09745.x; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WINITZ S, 1994, J BIOL CHEM, V269, P1889	53	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9052	9059		10.1074/jbc.270.16.9052	http://dx.doi.org/10.1074/jbc.270.16.9052			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721818	hybrid			2022-12-27	WOS:A1995QU08900006
J	LETOURNEUR, O; SECHI, S; WILLETTEBROWN, J; ROBERTSON, MW; KINET, JP				LETOURNEUR, O; SECHI, S; WILLETTEBROWN, J; ROBERTSON, MW; KINET, JP			GLYCOSYLATION OF HUMAN TRUNCATED FC-EPSILON-RI ALPHA-CHAIN IS NECESSARY FOR EFFICIENT FOLDING IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; EPIDERMAL LANGERHANS CELLS; IMMUNOGLOBULIN-E; IGE RECEPTOR; TRANSFECTED CELLS; SUBUNIT; RAT; EXPRESSION; BINDING; PROTEIN	The high affinity immunoglobulin E (IgE) receptor is an alpha beta gamma(2) tetrameric complex. The truncated extracellular segment (alpha t) of the heavily glycosylated alpha chain is sufficient for high affinity binding of IgE. Here we have expressed various alpha t mutants in eukaryotic and prokaryotic cells to analyze the role of glycosylation in the folding, stability, and secretion of alpha t. All seven N-linked glycosylation sites in alpha t are glycosylated and their mutations have an additive effect on the folding and secretion of alpha t. Mutation of the seven N-glycosylation sites (Delta 1-7 alpha t) induces misfolding and retention of alpha t in the endoplasmic reticulum. Similarly, tunicamycin treatment reduces substantially the folding efficiency of wild-type alpha t. In contrast, no difference in folding efficiency is detected between wild-type alpha t and Delta 1-7 alpha t expressed in Escherichia coli. In addition, maturation of N-linked oligosaccharides and addition of O-linked carbohydrates are not required for either the transport or the IgE-binding function of alpha t. Furthermore, complete enzymatic deglycosylation does not affect the stability and the IgE-binding capacity of alpha t. Therefore, glycosylation is not intrinsically necessary for proper folding of alpha t but is required for folding in the endoplasmic reticulum. Our data are compatible with the concept that specific interactions between N-linked oligosaccharides and the folding machinery of the endoplasmic reticulum are necessary for efficient folding of alpha t in eukaryotic cells.	NIAID, MOLEC ALLERGY & IMMUNOL SECT, ROCKVILLE, MD 20852 USA; MRC, CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Cambridge								ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; KINET JP, 1987, BIOCHEMISTRY-US, V26, P4605, DOI 10.1021/bi00389a002; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; LACROIX EL, 1993, MOL IMMUNOL, V30, P321, DOI 10.1016/0161-5890(93)90060-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353	29	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8249	8256		10.1074/jbc.270.14.8249	http://dx.doi.org/10.1074/jbc.270.14.8249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713932	hybrid			2022-12-27	WOS:A1995QR52600071
J	SPINELLA, MJ; BRIGLE, KE; SIERRA, EE; GOLDMAN, ID				SPINELLA, MJ; BRIGLE, KE; SIERRA, EE; GOLDMAN, ID			DISTINGUISHING BETWEEN FOLATE RECEPTOR-ALPHA-MEDIATED TRANSPORT AND REDUCED FOLATE CARRIER-MEDIATED TRANSPORT IN L1210 LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; CCRF-CEM CELLS; BINDING-PROTEIN; METHOTREXATE TRANSPORT; MEMBRANE-TRANSPORT; WILD-TYPE; KB CELLS; SYSTEM; CANCER; EXPRESSION	L1210 leukemia cells transport reduced folates and methotrexate via a well defined reduced folate carrier system and, in the absence of low folate selective pressure, do not express an alternate endocytotic route mediated by cell surface folate receptors. This laboratory previously described an L1210 leukemia cell line, MTX(r)A with acquired resistance to methotrexate (MTX) due to the loss of mobility of the reduced folate carrier. We now report on the transfection of MTX(r)A with a cDNA encoding the murine homolog of the human folate receptor isoform of KB cells to produce MTX(r)A-TF1, which constitutively expresses high levels of FR-alpha. MTX(r)A-TF1 and L1210 cells were utilized to compare transport of methotrexate mediated by FR-alpha and the reduced folate carrier, respectively. Methotrexate influx in the two lines was similar when the extracellular level was 0.1 mu M, but as the methotrexate concentration increased, influx via the reduced folate carrier increased in comparison to influx mediated by FR-alpha. Transport kinetics indicated both a similar to 20-fold lower influx K-b and V-max for MTX(r)A-TF1 as compared to L1210 cells. The two cell Lines exhibited distinct influx properties. Methotrexate influx in MTX(r)A-TF1 was markedly inhibited by 50 mu M folic acid and metabolic poisons. In L1210 cells, 1.0 mu M folic acid did not affect MTX influx, and metabolic poisons either had no effect on or increased methotrexate influx. Removal of extracellular chloride markedly inhibited transport in MTX(r)A-TF1 but stimulated influx in L1210 cells. When the pH was decreased to 6.2, methotrexate influx was not altered in MTX(r)A-TF1 but was reduced in L1210 cells. Probenecid and sulfobromophthalein inhibit methotrexate influx in both L1210 and MTX(r)A-TF1 cell Lines; however, inhibition in MTX(r)A-TF1 could be accounted for on the basis of inhibition of methotrexate binding to FR-alpha. The data indicate that the reduced folate carrier and FR-alpha function independently and exhibit distinct properties. FR-alpha expressed at sufficient levels can mediate influx of MTX and folates into cells at rates comparable to the reduced folate carrier and hence has pharmacologic and physiologic importance.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, MASSEY CANC CTR, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University			Spinella, Michael/B-7210-2014		NCI NIH HHS [CA-09349, CA-39807, F32 CA009349, CA-09340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009349, R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1992, BLOOD, V79, P2807; BOWEN BJ, 1988, J CELL PHYSIOL, V134, P1, DOI 10.1002/jcp.1041340102; BRIGLE KE, 1994, J BIOL CHEM, V269, P4267; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CONEY LR, 1991, CANCER RES, V51, P6125; COWAN KH, 1984, J BIOL CHEM, V259, P793; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1992, J BIOL CHEM, V267, P24140; DIXON KH, 1994, J BIOL CHEM, V269, P17; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FLEMING GF, 1992, SEMIN ONCOL, V19, P707; FRY DW, 1980, BIOCHIM BIOPHYS ACTA, V603, P157, DOI 10.1016/0005-2736(80)90398-3; FRY DW, 1982, CANCER RES, V42, P2532; FRY DW, 1980, CANCER RES, V40, P3669; FRY DW, 1982, J MEMBRANE BIOL, V66, P87, DOI 10.1007/BF01868485; FRY DW, 1984, CANCER RES, V44, P3366; GEWIRTZ DA, 1980, CANCER RES, V40, P1852; GEWIRTZ DA, 1984, CANCER RES, V44, P3846; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, BIOCHIM BIOPHYS ACTA, V233, P624, DOI 10.1016/0005-2736(71)90162-3; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRANT SC, 1993, CANCER INVEST, V11, P36, DOI 10.3109/07357909309020259; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; HENDERSON GB, 1985, BIOCHEM PHARMACOL, V34, P1725, DOI 10.1016/0006-2952(85)90641-0; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; JANSEN G, 1990, CANCER RES, V50, P7544; JANSEN G, 1989, CANCER RES, V49, P2455; JENNETTE JC, 1975, J LAB CLIN MED, V86, P834; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150; KAMEN BA, 1986, BIOCHEM PHARMACOL, V35, P2323, DOI 10.1016/0006-2952(86)90458-2; KANE MA, 1989, LAB INVEST, V60, P737; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; Ratnam M., 1990, FOLIC ACID METABOLIS, P91; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SELHUB J, 1984, J BIOL CHEM, V259, P6601; SHEN F, 1994, BIOCHEMISTRY-US, V33, P1209, DOI 10.1021/bi00171a021; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1979, BIOCHEM PHARMACOL, V28, P2993, DOI 10.1016/0006-2952(79)90599-9; SIROTNAK FM, 1991, CANCER RES, V51, P1412; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; WEITMAN SD, 1992, CANCER RES, V52, P3396; WHITE JC, 1978, J BIOL CHEM, V253, P242; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067	66	103	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7842	7849		10.1074/jbc.270.14.7842	http://dx.doi.org/10.1074/jbc.270.14.7842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713875	hybrid			2022-12-27	WOS:A1995QR52600011
J	STOLTZ, M; RYSAVY, P; KALOUSEK, F; BRANDSCH, R				STOLTZ, M; RYSAVY, P; KALOUSEK, F; BRANDSCH, R			FOLDING, FLAVINYLATION, AND MITOCHONDRIAL IMPORT OF 6-HYDROXY-D-NICOTINE OXIDASE FUSED TO THE PRESEQUENCE OF RATE DIMETHYLGLYCINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND FLAVIN; ARTHROBACTER-OXIDANS; HOLOENZYME FORMATION; PRECURSOR PROTEINS; LIVER MITOCHONDRIA; BINDING; MATRIX; FAD; REQUIRES; SUBUNIT	We analyzed the folding, covalent flavinylation, and mitochondrial import of the rabbit reticulocyte lysate-translated bacterial 6-hydroxy-D-nicotine oxidase (6-HDNO) fused to the mitochondrial targeting sequence of rat Liver dimethylglycine dehydrogenase, Translation of 6-HDNO in FAD-supplemented reticulocyte lysate resulted in a protein that contained covalently incorporated FED, exhibited enzyme activity, and was trypsin-resistant, a characteristic of the tight conformation of the holoenzyme, The attached mitochondrial presequence did not prevent folding, binding of FAD, or enzyme activity of the 6-HDNO moiety of the fusion protein (pre-6-HDNO), Pre-6-HDNO was imported into rat liver mitochondria and processed by the mitochondrial processing peptidase, Incubation of the trypsin-resistant pre-holo-6-HDNO protein with deenergized rat Liver mitochondria demonstrated that upon contact with mitochondria, the protein was unfolded and became trypsin sensitive. Mitochondrial import assays showed that the unfolded pre-holo-6-HDNO with covalently attached FAD was imported into rat Liver mitochondria, Inside the mitochondrion the holo-6-HDNO was refolded into the trypsin-resistant conformation, However, when pre-apo-6-HDNO was imported only part of the protein became trypsin resistant (approximately 20%). Addition of FAD and the allosteric effector glycerol 3-phosphate to apo-6-HDNO containing mitochondrial matrix was required to transform the protein into the trypsin-resistant conformation characteristic of holo-6-HDNO,	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	University of Freiburg; Yale University					NIDDK NIH HHS [DK-09527] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGUST PR, 1994, J BACTERIOL, V176, P4448, DOI 10.1128/jb.176.14.4448-4454.1994; BARILE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P442, DOI 10.1006/abbi.1993.1444; BERNAUER H, 1992, MOL MICROBIOL, V6, P1809, DOI 10.1111/j.1365-2958.1992.tb01353.x; BRANDSCH R, 1989, BIOCHEM J, V258, P187, DOI 10.1042/bj2580187; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; BRANDSCH R, 1994, FLAVINS FLAVOPROTEIN, V11, P807; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; DECKER K, 1991, BIOFACTORS, V3, P69; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; EILERS M, 1986, NATURE, V332, P228; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x; HEDERSTEDT L, 1983, EUR J BIOCHEM, V132, P589, DOI 10.1111/j.1432-1033.1983.tb07404.x; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KIM JH, 1994, J BACTERIOL, V176, P6349, DOI 10.1128/jb.176.20.6349-6361.1994; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; LAIN B, 1994, J BIOL CHEM, V269, P15588; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; MURAKAMI K, 1990, J BIOCHEM-TOKYO, V108, P207, DOI 10.1093/oxfordjournals.jbchem.a123182; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; NAGAO M, 1992, J BIOL CHEM, V267, P17925; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; REED KE, 1991, J BIOL CHEM, V266, P11425; REYES AM, 1993, J BIOL CHEM, V268, P22281; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; SUZUKI H, 1991, J BIOCHEM-TOKYO, V198, P793; TARONI F, 1991, J BIOL CHEM, V266, P13267; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YANG LM, 1994, EUR J BIOCHEM, V244, P743; ZARA V, 1992, J BIOL CHEM, V267, P12077; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	43	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8016	8022		10.1074/jbc.270.14.8016	http://dx.doi.org/10.1074/jbc.270.14.8016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713902	hybrid			2022-12-27	WOS:A1995QR52600038
J	LANDER, HM; OGISTE, JS; PEARCE, SFA; LEVI, R; NOVOGRODSKY, A				LANDER, HM; OGISTE, JS; PEARCE, SFA; LEVI, R; NOVOGRODSKY, A			NITRIC OXIDE-STIMULATED GUANINE-NUCLEOTIDE EXCHANGE ON P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONONUCLEAR-CELLS; BINDING-PROTEINS; CARBON-MONOXIDE; PC12 CELLS; T-CELL; RAS; ACTIVATION; P21RAS; SUPERFAMILY; MESSENGER	The protooncogene p21(ras), a monomeric G protein family member, plays a critical role in converting extracellular signals into intracellular biochemical events. Here, we report that nitric oxide (NO) activates p21(ras) in human T cells as evidenced by an increase in GTP-bound p21(ras). In vitro studies using pure recombinant p21(ras) demonstrate that the activation is direct and reversible. Circular dichroism analysis reveals that NO induces a profound conformational change in p21(ras) in association with GDP/GTP exchange. The mechanism of activation is due to S-nitrosylation of a critical cysteine residue which stimulates guanine nucleotide exchange. Furthermore, we demonstrate that p21(ras) is essential for NO-induced downstream signaling, such as NF-KB activation, and that endogenous NO can activate p21(ras) in the same cell. These studies identify p21(ras) as a target of NO in T cells and suggest that NO activates p21P(ras) by an action which mimics that of guanine nucleotide exchange factors.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; FELSENSTEIN MED RES CTR, IL-49100 PETAH TIQWA, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, IL-69978 TEL AVIV, ISRAEL	Cornell University; Cornell University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine					NHLBI NIH HHS [HL34215, HL46403, HL07423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL034215, T32HL007423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUDAVARI S, 1989, MERCK INDEX, P275; CARTY DJ, 1994, METHOD ENZYMOL, V237, P38; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; GRAVES JD, 1991, J IMMUNOL, V146, P3709; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUROYA K, 1992, ONCOGENE, V7, P277; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOVOGRODSKY A, 1982, P NATL ACAD SCI-BIOL, V79, P1171, DOI 10.1073/pnas.79.4.1171; PINGOUD A, 1988, BIOCHEMISTRY-US, V27, P4735, DOI 10.1021/bi00413a023; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SATOH T, 1992, J BIOL CHEM, V267, P24149; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WHITACRE CM, 1992, CELL IMMUNOL, V144, P287, DOI 10.1016/0008-8749(92)90245-K; WILKINSON FE, 1993, BIOCHEM BIOPH RES CO, V190, P229, DOI 10.1006/bbrc.1993.1035; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	41	324	328	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7017	7020		10.1074/jbc.270.13.7017	http://dx.doi.org/10.1074/jbc.270.13.7017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706235	hybrid			2022-12-27	WOS:A1995QQ43100002
J	LEVINE, AD; RANGWALA, SH; HORN, NA; PEEL, MA; MATTHEWS, BK; LEIMGRUBER, RM; MANNING, JA; BISHOP, BF; OLINS, PO				LEVINE, AD; RANGWALA, SH; HORN, NA; PEEL, MA; MATTHEWS, BK; LEIMGRUBER, RM; MANNING, JA; BISHOP, BF; OLINS, PO			HIGH-LEVEL EXPRESSION AND REFOLDING OF MOUSE INTERLEUKIN-4 SYNTHESIZED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; DEPENDENT CELL-LINES; MONOCLONAL-ANTIBODY; MESSENGER-RNA; IGE RESPONSES; FOREIGN GENES; MAST-CELLS; IL-4; PROTEINS; IGG1	Mouse Interleukin 4 is a 20-kDa glycoprotein, synthesized by activated T lymphocytes and mast cells, which regulates the growth and/or differentiation of a broad spectrum of target cells of the immune system, including B and T lymphocytes, macrophages, and hematopoietic progenitor cells. Using an inducible recA promoter and the g10-L ribosome binding site, recombinant non-glycosylated interleukin 4 (IL-4) was expressed as 17% of total cellular protein in Escherichia coli inclusion bodies, as a reduced, inactive 14.5-kDa polypeptide. The protein was refolded and aggregates dissociated when three disulfide bonds were reformed by slowly decreasing the concentration of guanidine hydrochloride and cysteine. The oxidized monomer was purified to homogeneity by sequential ion-exchange and size exclusion chromatography. When compared with native IL-4, E. coli-derived IL-4 displayed an identical specific activity of 4-7 x 10(7) units/mg. This recombinant IL-4 contained a three-amino-acid NH2-terminal extension, which did not affect its biological activity. Purified biologically active protein consisted of three isoforms as shown by two-dimensional gel electrophoresis, with a pI greater than 9.0. These data suggest that neither glycosylation nor the NH2 terminus of mouse IL-4 play a critical role in contributing to its in vitro biological activity.	MONSANTO CO, MONSANTO CORP RES, ST LOUIS, MO 63198 USA; MONSANTO CO, AGR GRP, ST LOUIS, MO 63198 USA	Monsanto; Monsanto	LEVINE, AD (corresponding author), MONSANTO CO, SEARLE DISCOVERY RES, IMMUNOL, AA4G, 700 CHESTERFIELD VILLAGE PKWY N, ST LOUIS, MO 63198 USA.							BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CONRAD DH, 1988, J IMMUNOL, V141, P1091; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1989, J IMMUNOL, V142, P403; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEWIS DB, 1991, J EXP MED, V173, P89, DOI 10.1084/jem.173.1.89; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; Maniatis T., 1982, MOL CLONING; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OBUKOWICZ MG, 1988, MOL GEN GENET, V215, P19, DOI 10.1007/BF00331297; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHARA J, 1987, J IMMUNOL, V139, P1127; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLINS PO, 1989, J BIOL CHEM, V264, P16973; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PADGETTE SR, 1987, ARCH BIOCHEM BIOPHYS, V258, P564, DOI 10.1016/0003-9861(87)90378-X; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; SNAPPER CM, 1991, J IMMUNOL, V147, P1163; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3	38	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7445	7452		10.1074/jbc.270.13.7445	http://dx.doi.org/10.1074/jbc.270.13.7445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706290	hybrid			2022-12-27	WOS:A1995QQ43100065
J	PREVIATO, JO; JONES, C; XAVIER, MT; WAIT, R; TRAVASSOS, LR; PARODI, AJ; MENDONCAPREVIATO, L				PREVIATO, JO; JONES, C; XAVIER, MT; WAIT, R; TRAVASSOS, LR; PARODI, AJ; MENDONCAPREVIATO, L			STRUCTURAL CHARACTERIZATION OF THE MAJOR GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE-ANCHORED GLYCOPROTEIN FROM EPIMASTIGOTE FORMS OF TRYPANOSOMA-CRUZI Y-STRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TRANS-SIALIDASE; NMR-SPECTROSCOPY; MAMMALIAN-CELLS; OLIGOSACCHARIDES; ACID; LIPOPEPTIDOPHOSPHOGLYCAN; MACROMOLECULES; SENSITIVITY; RESOLUTION	We have investigated the structure of the glycosylphosphatidylinositol (GPI) anchor and the O-linked glycan chains of the 40/45-kDa glycoprotein from the cell surface of the protozoan parasite Trypanosoma cruzi, This glycoconjugate is the major acceptor for sialic acid transferred by trans sialidase of T. cruzi Y-strain, epimastigote form. The GPI anchor was liberated by treatment with hot alkali, and the phosphoinositol-oligosaccharide moiety was characterized and shown to have the following structure. [GRAPHICS] STRUCTURE 1 Unusually the glucosamine was 6-O-substituted with 2-aminoethylphosphonate, and 2-aminoethylphosphonate was also present on the third mannose residue distal to glucosamine, partially replacing the ethanolamine phosphate, The beta-eliminated reduced oligosaccharide chains showed that two novel classes of O-linked N-acetylglucosamine oligosaccharide were present. The first series had the structures Galp beta 1-3GlcNAc-ol; Galp beta-6(Galp beta 1-3)GlcNAc-ol; and Galp beta 1-2Galp beta 1-6(Galp beta 1-3)GlcNAc-ol, whereas the other series had a 1-4 linkage to N-acetylglucosaminitol and had structures Galp beta 1-4GlcNAc-ol, Galp beta 1-6(Galp beta 1-4)GlcNAc-ol, and Galp beta 1-2Galp beta 1-6(Galp beta 1-4)GlcNAc-ol. We have also investigated the kinetics of in vitro sialylation of these O-linked oligosaccharides by the T. cruzi trans-sialidase and have shown that incorporation of one molecule of sialic acid hinders entry of a second molecule when two potential acceptor sites are present.	FED UNIV RIO DE JANEIRO, DEPT MICROBIOL GERAL, BR-21944970 RIO DE JANEIRO, BRAZIL; NATL INST BIOL STAND & CONTROLS, MOLEC STRUCT LAB, POTTERS BAR EN6 3QG, HERTS, ENGLAND; PUBL HLTH LAB SERV, CTR APPL MICROBIOL & RES, SALISBURY SP4 0JG, WILTS, ENGLAND; ESCOLA PAULISTA MED, DISCIPLINA BIOL CELULAR, BR-04023062 SAO PAULO, BRAZIL; FDN CAMPOMAR, INST INVEST BIOQUIM, RA-1405 BUENOS AIRES, DF, ARGENTINA	National Institute for Biological Standards & Control; Universidade Federal de Sao Paulo (UNIFESP); Leloir Institute			Travassos, Luiz R/J-3631-2012; Travassos, Luiz/V-2467-2019; Jones, Chris/AAF-4063-2021	Jones, Chris/0000-0001-7109-492X; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				ACOSTA A, 1994, BRAZ J MED BIOL RES, V27, P439; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; ALVES MJM, 1986, MOL BIOCHEM PARASIT, V21, P75, DOI 10.1016/0166-6851(86)90081-2; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDREWS NW, 1994, BRAZ J MED BIOL RES, V27, P471; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BELCHER R, 1954, ANALYST, V79, P201, DOI 10.1039/an9547900201; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; BURROWS S, 1952, NATURE, V170, P800, DOI 10.1038/170800a0; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FAUCONNET M, 1978, ANAL BIOCHEM, V91, P403, DOI 10.1016/0003-2697(78)90525-0; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; FERREROGARCIA MA, 1993, EUR J BIOCHEM, V213, P765, DOI 10.1111/j.1432-1033.1993.tb17818.x; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GORIN PAJ, 1964, CAN J CHEM, V42, P1341, DOI 10.1139/v64-206; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUTHER MLS, 1992, J BIOL CHEM, V267, P6820; HUMBEL R, 1975, CLIN CHIM ACTA, V60, P143, DOI 10.1016/0009-8981(75)90119-9; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERKREMER RM, 1976, BIOCHIM BIOPHYS ACTA, V444, P85; LEDERKREMER RMD, 1978, BIOCHEM BIOPH RES CO, V85, P1268, DOI 10.1016/0006-291X(78)91140-3; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; PARODI AJ, 1992, EMBO J, V11, P1765; PAZUR JH, 1953, SCIENCE, V117, P355, DOI 10.1126/science.117.3040.355; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; PREVIATO JO, 1992, J BIOL CHEM, V267, P24279; PREVIATO JO, 1994, GLYCOCONJUGATE J, V11, P23, DOI 10.1007/BF00732429; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; READING CL, 1978, J BIOL CHEM, V253, P5600; ROUTIER F, 1994, BRAZ J MED BIOL RES, V27, P211; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SHER A, 1982, NATURE, V300, P636; SINGH BN, 1994, J BIOL CHEM, V269, P21972; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TOENNIES G, 1951, ANAL CHEM, V23, P823, DOI 10.1021/ac60054a002; TOMLINSON S, 1994, J IMMUNOL, V153, P3141; VANDEKERCKHOVE F, 1992, GLYCOBIOLOGY, V2, P541, DOI 10.1093/glycob/2.6.541; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WAIT R, 1994, ORG MASS SPECTROM, V29, P767, DOI 10.1002/oms.1210291209; WARREN L, 1959, J BIOL CHEM, V234, P1971; WING RE, 1972, METHODS CARBOHYD CHE, V6, P42	58	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7241	7250		10.1074/jbc.270.13.7241	http://dx.doi.org/10.1074/jbc.270.13.7241			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706263	hybrid			2022-12-27	WOS:A1995QQ43100036
J	SCHULTZCHERRY, S; CHEN, H; MOSHER, DF; MISENHEIMER, TM; KRUTZSCH, HC; ROBERTS, DD; MURPHYULLRICH, JE				SCHULTZCHERRY, S; CHEN, H; MOSHER, DF; MISENHEIMER, TM; KRUTZSCH, HC; ROBERTS, DD; MURPHYULLRICH, JE			REGULATION OF TRANSFORMING GROWTH-FACTOR-BETA ACTIVATION BY DISCRETE SEQUENCES OF THROMBOSPONDIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING PEPTIDES; MELANOMA CELL-ADHESION; I REPEATS; CALCINEURIN-A; IDENTIFICATION; FIBRONECTIN; PHYSIOLOGY; EXPRESSION; PROPERDIN; PROTEINS	Transforming growth factor-beta (TGF-beta) is a potent growth regulatory protein secreted by virtually all cells in a latent form. A major mechanism of regulating TGF-beta activity occurs through factors that central the process ing of the latent to the biologically active form of the molecule. We have shown previously that thrombospondin 1 (TSP1), a platelet alpha-granule and extracellular matrix protein, activates latent TGF-beta via a protease and cell-independent mechanism and have localized the TGF-beta binding/activation region to the type 1 repeats of platelet TSP1. We now report that recombinant human TSP1, but not recombinant mouse TSP2, activates latent TGF-beta. Activation was further localized to the unique sequence RFK found between the first and the second type 1 repeats of TSP1 (amino acids 412-415) by the use of synthetic peptides. A peptide with the corresponding sequence in TSP2, RLR, was inactive. In addition, a hexapeptide GGWSHW, based on a sequence present in the type 1 repeats of both TSP1 and TSP2, inhibited the activation of latent TGF-beta by TSP1. This peptide bound to I-125-active TGF-beta and inhibited interactions of TSP1 with latent TGF-beta. TSP2 also inhibited activation of latent TGF-beta by TSP1, presumably by competitively binding to TGF-beta through the WSHW sequence. These studies show that activation of latent TGF-beta is mediated by two sequences present in the type 1 repeats of TSP1, a sequence (GGWSHW) that binds active TGF-beta and potentially orients the TSP molecule and a second sequence (RFK) that activates latent TGF-beta. Peptides based on these sites have potential therapeutic applications for modulation of TGF-beta activation.	UNIV ALABAMA, DEPT PATHOL, DIV MOLEC & CELLULAR PATHOL, BIRMINGHAM, AL 35294 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA	University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Roberts, David D./A-9699-2008; Schultz-Cherry, Stacey/N-2506-2018	Roberts, David D./0000-0002-2481-2981; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061, F32HL008640, R01HL049111] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50061, R01 HL050061, HL08640, HL49111] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ALLENHOFFMANN BL, 1988, MOL CELL BIOL, V8, P4234, DOI 10.1128/MCB.8.10.4234; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BARNARD JA, 1990, BIOCHEM BIOPH RES CO, V163, P56; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Brown JR, 1977, ALBUMIN STRUCTURE FU, P27; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHEN H, 1994, J BIOL CHEM, V269, P32226; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; MASSAGUE J, 1992, CANCER SURV, V12, P81; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; PALLEN CJ, 1988, CALCIUM BINDING PROT, P51; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; TWARDZIK DR, 1990, ANN NY ACAD SCI, V593, P276, DOI 10.1111/j.1749-6632.1990.tb16119.x; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214	36	350	374	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7304	7310		10.1074/jbc.270.13.7304	http://dx.doi.org/10.1074/jbc.270.13.7304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706271	hybrid			2022-12-27	WOS:A1995QQ43100044
J	SUGAHARA, K; OHKITA, Y; SHIBATA, Y; YOSHIDA, K; IKEGAMI, A				SUGAHARA, K; OHKITA, Y; SHIBATA, Y; YOSHIDA, K; IKEGAMI, A			STRUCTURAL STUDIES ON THE HEXASACCHARIDE ALDITOLS ISOLATED FROM THE CARBOHYDRATE-PROTEIN LINKAGE REGION OF DERMATAN SULFATE PROTEOGLYCANS OF BOVINE AORTA - DEMONSTRATION OF IDURONIC ACID-CONTAPNING COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; SWARM MOUSE-TUMOR; CHONDROITIN-6-SULFATE PROTEOGLYCANS; SHARK CARTILAGE; BIOSYNTHESIS; BINDING; DECORIN; FIBROBLASTS; INHIBITION; EPIMERASE	Five major hexasaccharide alditols were isolated from the carbohydrate-protein linkage region of bovine aorta dermatan sulfate peptidoglycans after reductive beta-elimination and subsequent chondroitinase ABC digestion. These molecules account for at least 55.3% of the total linkage region. Their structures were analyzed by enzymatic digestion in conjunction with high performance liquid chromatography, electrospray ionization mass spectrometry, and 500-MHz one- and two-dimensional H-1 NMR spectroscopy. Three of these compounds have the conventional hexasaccharide core; Delta HexA alpha(1)-3Gal-NAc beta 1-4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl-ol. One is nonsulfated, and the other two are monosulfated on C6 or C4 of the GalNAc residue. They represent at least 6.3, 5.2, and 28.8% of the total linkage region, respectively. The other two compounds have the following hitherto unreported hexasaccharide core with an internal iduronic acid residue in common; Delta HexA alpha 1-3-GalNac beta 1-4IdoA alpha 1-3Gal beta 1-3Gal beta 1-4Xyl-ol. One is monosulfated on C4 of the GalNAc, and the other is disulfated on C4 of the GalNAc and of the galactose residue substituted by the iduronic acid residue, These two compounds account for 35% of the five isolated hexasaccharide alditols and at least 4.3 and 10.7% of the total linkage region, respectively. The latter two structures form a striking contrast to the currently accepted conception that heparin, heparan sulfate, and chondroitin/dermatan sulfate share the common linkage tetrasaccharide core GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl. The biological significance of the isolated structures is discussed in relation to the biological functions and the biosynthetic mechanisms of dermatan sulfate.	SEIKAGAKU CORP,RES INST,HIGASHIYAMOTO,TOKYO 207,JAPAN	Seikagaku Corporation	SUGAHARA, K (corresponding author), KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE,HYOGO 658,JAPAN.							BELTING M, 1993, GLYCOCONJUGATE J, V10, P453, DOI 10.1007/BF00737966; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; CASU B, 1993, DERMATAN SULPHATE PR, P41; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; EHRLICH KC, 1975, ARCH BIOCHEM BIOPHYS, V171, P361, DOI 10.1016/0003-9861(75)90043-0; FONT B, 1993, J BIOL CHEM, V268, P25015; FRANSSON LA, 1979, BIOCHIM BIOPHYS ACTA, V586, P179, DOI 10.1016/0304-4165(79)90416-1; FRANSSON LA, 1968, BIOCHIM BIOPHYS ACTA, V156, P311, DOI 10.1016/0304-4165(68)90260-2; GALLAGHER JT, 1989, HEPARIN, P135; HELTING T, 1972, ACTA CHEM SCAND, V26, P3515, DOI 10.3891/acta.chem.scand.26-3515; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; Lindahl U., 1989, HEPARIN, P159; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LYON M, 1994, J BIOL CHEM, V269, P11208; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALMSTRO.A, 1971, FEBS LETT, V16, P105, DOI 10.1016/0014-5793(71)80344-7; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1982, BIOCHEM J, V201, P489, DOI 10.1042/bj2010489; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; MALMSTROM A, 1993, DERMATAN SULFATE PRO, P129; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; MEYER K, 1956, BIOCHIM BIOPHYS ACTA, V21, P506, DOI 10.1016/0006-3002(56)90188-3; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; REGISTER TC, 1990, CONNECT TISSUE RES, V25, P35, DOI 10.3109/03008209009009811; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SILBERT JE, 1993, DERMATAN SULFATE PRO, P147; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1994, CARBOHYD RES, V255, P165, DOI 10.1016/S0008-6215(00)90977-7; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WESTERGRENTHORS.G, 1991, J CELL PHYSIOL, V147, P523; YAMADA S, 1992, J BIOCH, V112, P404; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	42	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7204	7212		10.1074/jbc.270.13.7204	http://dx.doi.org/10.1074/jbc.270.13.7204			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706259	hybrid			2022-12-27	WOS:A1995QQ43100031
J	SUN, PQ; MAURER, RA				SUN, PQ; MAURER, RA			AN INACTIVATING POINT MUTATION DEMONSTRATES THAT INTERACTION OF CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB) WITH THE CREB BINDING-PROTEIN IS NOT SUFFICIENT FOR TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-TRANSCRIPTION; PHOSPHORYLATION; EXPRESSION; KINASE; ISOFORMS; SUBUNIT; SYSTEM	The cAMP response element binding protein (CREB) mediates transcriptional activation in response to the cAMP signaling pathway, Several recent studies have suggested that phosphorylation-dependent interaction of CREB with a co-activator designated CREB binding protein (CBP) is a crucial step in mediating transcriptional responses to cAMP. In the present study we have determined that replacement of Ser(142) of CREB with Asp greatly decreases the ability of the cAMP-dependent protein kinase to activate CREB, As Ser(142) is located within the region of CREB that interacts with CBP, it seemed quite likely that mutations at this site might interfere with binding to CBP. However, both in vitro and in vivo protein-protein interaction assays revealed that replacement of Ser(142) with Asp does not interfere with the binding of CREB to CBP. These studies argue strongly that although the binding of CREB to CBP is necessary, it is not sufficient for transcriptional responses to cAMP.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; UNIV IOWA,GENET PHD PROGRAM,IOWA CITY,IA 52242	Oregon Health & Science University; University of Iowa								ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERMINO FJ, 1993, P NATL ACAD SCI USA, V90, P933, DOI 10.1073/pnas.90.3.933; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	24	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7041	7044		10.1074/jbc.270.13.7041	http://dx.doi.org/10.1074/jbc.270.13.7041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706240	hybrid			2022-12-27	WOS:A1995QQ43100008
J	VIETOR, I; SCHWENGER, P; LI, W; SCHLESSINGER, J; VILCEK, J				VIETOR, I; SCHWENGER, P; LI, W; SCHLESSINGER, J; VILCEK, J			TUMOR NECROSIS FACTOR-INDUCED ACTIVATION AND INCREASED TYROSINE PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MOLECULAR-CLONING; THREONINE KINASE; FACTOR RECEPTORS; CELLS; INTERLEUKIN-1; EXPRESSION; PATHWAYS; TNF; JUN	Tumor necrosis factor (TNF) is a pleiotropic cytokine whose many demonstrated actions include effects on cell growth and differentiation. TNF treatment of cells is known to lead to a rapid increase in serine/threonine phosphorylation of many cellular proteins, but the kinases responsible remain largely unidentified. We show that TNF treatment induces a rapid and transient increase in mitogen-activated protein kinase (MAPK) activity in the human diploid FS-4 cell line, for which TNF is known to be mitogenic. TNF-induced activation of MAPK was demonstrated by its enhanced ability to phosphorylate myelin basic protein in vitro and by a characteristic shift in the electrophoretic mobility of MAPK proteins. MAPK activation was accompanied by a significant increase of MAPK phosphorylation on tyrosine residues, which was demonstrated by P-32 labeling of cells and isolation of the labeled proteins after immunoprecipitation with antibodies to phosphotyrosine, and by direct immunoblotting of SDS-polyacrylamide gel electrophoresis-fractionated unlabeled cell lysates with antibodies to phosphotyrosine. The pp42 and pp44 MAPK were the only proteins whose tyrosine phosphorylation was demonstrably increased in FS-4 cells after TNF treatment. MAPK activation is likely to represent an important component in the cascade of signals that link TNF receptors to various TNF-elicited cellular responses.	NYU MED CTR, DEPT MICROBIOL, 550 1ST AVE, NEW YORK, NY 10016 USA; SLOVAK ACAD SCI, INST EXPTL ENDOCRINOL, CS-83306 BRATISLAVA, CZECHOSLOVAKIA; NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University; Slovak Academy of Sciences; New York University					NCI NIH HHS [R35CA49731, 5-T32-CA09161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731, T32CA009161] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GUY GR, 1992, J BIOL CHEM, V267, P1846; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LI W, 1991, J BIOL CHEM, V266, P6808; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	43	141	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18994	18999						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689564				2022-12-27	WOS:A1993LV65900092
J	BARBACCI, EG; GUARINO, BC; STROH, JG; SINGLETON, DH; ROSNACK, KJ; MOYER, JD; ANDREWS, GC				BARBACCI, EG; GUARINO, BC; STROH, JG; SINGLETON, DH; ROSNACK, KJ; MOYER, JD; ANDREWS, GC			THE STRUCTURAL BASIS FOR THE SPECIFICITY OF EPIDERMAL GROWTH-FACTOR AND HEREGULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND; DIFFERENTIATION; PROTEINS	Heregulin is a ligand for the erbB3 and erbB4 receptors, with a region of high homology to epidermal growth factor (EGF). Despite this homology, these ligands bind to their corresponding receptors with great specificity. We report here the synthesis of heregulin beta 177-241 and show that a region consisting of amino acids 177-226 is sufficient both for binding and stimulation of receptor phosphorylation. Studies of chimeric EGF/heregulin peptides revealed that amino acids 177-181 of heregulin provide the specificity for binding to the heregulin receptor. The substitution of amino acids 177-181 of heregulin for the N terminus of EGF produced a unique bifunctional agonist that binds with high affinity to both the EGF receptor and the heregulin receptor.	PFIZER INC,CENT RES,GROTON,CT 06340	Pfizer								CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; NAGATA K, 1994, EMBO J, V13, P3517, DOI 10.1002/j.1460-2075.1994.tb06658.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; SHIN SY, 1994, LIFE SCI, V55, P131; SIMPSON RJ, 1985, EUR J BIOCHEM, V153, P629, DOI 10.1111/j.1432-1033.1985.tb09346.x; SLOWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TADAKI DK, 1991, FASEB J, V5, pA1183; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	24	99	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9585	9589		10.1074/jbc.270.16.9585	http://dx.doi.org/10.1074/jbc.270.16.9585			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721889	hybrid			2022-12-27	WOS:A1995QU08900078
J	OXFORD, JT; DOEGE, KJ; MORRIS, NP				OXFORD, JT; DOEGE, KJ; MORRIS, NP			ALTERNATIVE EXON SPLICING WITHIN THE AMINO-TERMINAL NONTRIPLE-HELICAL DOMAIN OF THE RAT PRO-ALPHA-1(XI) COLLAGEN CHAIN GENERATES MULTIPLE FORMS OF THE MESSENGER-RNA TRANSCRIPT WHICH EXHIBIT TISSUE-DEPENDENT VARIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PROTEIN; XI COLLAGEN; NH2-TERMINAL DOMAIN; V COLLAGEN; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; TRIPLE HELIX; 5' END; CARTILAGE; FIBRILS	Type XI collagen is an integral, although minor component of cartilage collagen fibrils, We have established that alternative exon usage is a mechanism for increasing structural diversity within the amino-terminal non-triple helical domain of the pro-alpha 1 (XI) collagen gene. cDNA clones spanning the amino-terminal domain were selected from a rat chondrosarcoma library, and were shown to contain two major sequence differences from the previously reported human sequence. The first difference was the replacement of sequence encoding an acidic domain of 39 amino acids in length by a sequence encoding a 51-amino acid basic domain with a predicted pI of 11.9. The second difference was the absence of a sequence that would translate into a highly acidic 85-amino acid sequence downstream from the first variation. These two changes, expressed together, result in the replacement of most of the acidic domain with one that is smaller and basic. These two sequence differences serve to identify subdomains of a variable region, designated V1 and V2, respectively. V1a is defined as the acidic 39 amino acid sequence element and V1b is defined as the 51-amino acid basic sequence. Analysis of genomic DNA revealed that both V1a and V1b are encoded by separate adjacent exons in the rat genome and V2 is also encoded in a single exon downstream. Analysis of mRNA from cartilage derived sources revealed a complex pattern of alpha 1 (XI) transcript expression due to differential exon usage. In non-cartilage sources, the pattern is less complex; the most prevalent form is the one containing the two acidic sequences, V1a and V2.	SHRINERS HOSP CRIPPLED CHILDRENS,DEPT BIOCHEM & MOLEC BIOL,RES DEPT,PORTLAND UNIT,PORTLAND,OR 97201; SHRINERS HOSP CRIPPLED CHILDRENS,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201				Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569	NIGMS NIH HHS [GM-39862] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; BURGESON RE, 1971, BIOCHEM BIOPH RES CO, V87, P1124; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DOEGE K, 1987, J BIOL CHEM, V262, P17757; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; EYRE D, 1987, STRUCTURE FUNCTION C, P81; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; Keene D. R., 1993, Molecular Biology of the Cell, V4, p289A; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LEES JF, 1994, J BIOL CHEM, V269, P24354; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; NAH HD, 1992, J BIOL CHEM, V267, P22581; NAH HD, 1991, J BIOL CHEM, V266, P23446; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; PIERARD GE, 1986, COLLAGEN REL RES, V6, P481; RAMIREZ F, 1990, ANN NY ACAD SCI, V580, P74, DOI 10.1111/j.1749-6632.1990.tb17919.x; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEGMILL.R, 1972, J ULTRA MOL STRUCT R, V38, P288, DOI 10.1016/S0022-5320(72)90006-8; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SMITH BD, 1975, ARCH BIOCHEM BIOPHYS, V166, P181, DOI 10.1016/0003-9861(75)90378-1; THOM JR, 1991, J BIOL CHEM, V266, P7262; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486; 1991, PROGRAM MANUAL GCG P	58	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9478	9485		10.1074/jbc.270.16.9478	http://dx.doi.org/10.1074/jbc.270.16.9478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721875	hybrid			2022-12-27	WOS:A1995QU08900064
J	RAMAGE, P; CHENEVAL, D; CHVEI, M; GRAFF, P; HEMMIG, R; HENG, R; KOCHER, HP; MACKENZIE, A; MEMMERT, K; REVESZ, L; WISHART, W				RAMAGE, P; CHENEVAL, D; CHVEI, M; GRAFF, P; HEMMIG, R; HENG, R; KOCHER, HP; MACKENZIE, A; MEMMERT, K; REVESZ, L; WISHART, W			EXPRESSION, REFOLDING, AND AUTOCATALYTIC PROTEOLYTIC PROCESSING OF THE INTERLEUKIN-1-BETA CONVERTING-ENZYME PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROTEASE; REQUIRES; SEQUENCE; PROTEINS	The interleukin-1 beta p-converting enzyme is a heterodimeric cysteine protease that is produced as a 45-kDa precursor, The full-length precursor form of the enzyme was expressed in Escherichia coli as insoluble inclusion bodies. Following solubilization and refolding of the 45-kDa protein, autoproteolytic conversion to a heterodimeric form containing 10- and 20-kDa subunits was observed. This enzyme had catalytic activity against both natural (interleukin-1 beta precursor) and synthetic peptide substrates. The inclusion of a specific inhibitor (SDZ 223-941) of the converting enzyme in the refolding mixture prevented proteolytic processing to the 10-/20 kDa form. Similarly, refolding under nonreducing conditions also prevented processing. Time course experiments showed that the 10-kDa subunit was released from the 45-kDa precursor before the 20-kDa subunit, implying that the N-terminal portion of the precursor is released last and may play a regulatory role,	SANDOZ PHARMA LTD,DEPT BONE & JOINT,CH-4002 BASEL,SWITZERLAND; SANDOZ PHARMA LTD,DEPT SIGNAL TRANSDUCT,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz; Novartis; Sandoz	RAMAGE, P (corresponding author), SANDOZ PHARMA LTD,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND.							BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CAPUTO A, 1994, STRUCT BIOL, V1, P364; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KRONHEIM SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P698, DOI 10.1016/0003-9861(92)90629-B; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; SLEATH PR, 1990, J BIOL CHEM, V365, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG XM, 1994, GENE, V145, P273; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	21	102	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9378	9383		10.1074/jbc.270.16.9378	http://dx.doi.org/10.1074/jbc.270.16.9378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721861	hybrid			2022-12-27	WOS:A1995QU08900050
J	SHERMAN, PM; LAWRENCE, DA; VERHAMME, IM; PAIELLI, D; SHORE, JD; GINSBURG, D				SHERMAN, PM; LAWRENCE, DA; VERHAMME, IM; PAIELLI, D; SHORE, JD; GINSBURG, D			IDENTIFICATION OF TISSUE-TYPE PLASMINOGEN ACTIVATOR-SPECIFIC PLASMINOGEN-ACTIVATOR INHIBITOR-1 MUTANTS - EVIDENCE THAT 2ND SITES OF INTERACTION CONTRIBUTE TO TARGET SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DEFICIENT MICE; HEPARIN COFACTOR-II; REACTIVE SITE; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; DIRECTED MUTAGENESIS; SERINE PROTEASES; ALPHA-THROMBIN; VITRONECTIN	Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of the plasminogen activators (PAs), tis sue-type plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA). A library of PAL-1 mutants containing substitutions at the P-1 and P-1' positions was screened for functional activity against tPA and thrombin. Several PAI-1 variants that were inactive against uPA in a previous study (Sherman, P. M., Lawrence, D. A., Yang, A. Y., Vandenberg, E. T., Paielli, D., Olson, S. T., Shore, J. D., and Ginsburg, D. (1992) J. Biol. Chem. 267, 7588-7595) had significant inhibitory activity toward tPA. This set of tPA specific PAI-1 mutants contained a wide range of amino acid substitutions at P-1 including Asn, Gin, His, Ser, Thr, Leu, Met, and all the aromatic amino acids. This group of mutants also demonstrated a spectrum of substitutions at P-1'. Kinetic analyses of selected variants identified P(1)Tyr and P(1)His as the most efficient tPA-specific inhibitors, with second order rate constants (k(i)) of 4.0 x 10(5) M(-1) s(-1) and 3.6 x 10(5) M(-1) s(-1), respectively. Additional PA specific PAI-1 variants containing substitutions at P-3 through P-1' were constructed. P(3)Tyr-P(2)Ser-P(1)Lys-P-1'Trp and P(3)Tyr-P(2)Ser-P(1)Tyr-P-1'Met had k(i) values of 1.7 x 10(6) M(-1) s(-1) and 2.5 x 10(6) M(-1) s(-1) against tPA, respectively, but both were inactive against uPA. In contrast, P(2)Arg-P(1)Lys-P-1'Ala inhibited uPA 74-fold more rapidly than tPA. The mutant PAI-1 Library was also screened for inhibitory activity toward thrombin in the presence and absence of the cofactor heparin. While wild-type PAI-1 and several P(1)Arg variants inhibited thrombin in the absence of heparin, a number of variants were thrombin inhibitors only in the presence of heparin. These results demonstrate the importance of the reactive center residues in determining PAI-1 target specificity and suggest that second sites of interaction between inhibitors and proteases can also contribute to target specificity. Finally, the PA-specific mutants described here should provide novel reagents for dissecting the physiological role of PAI-1 both in vitro and in vivo.	UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital				Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049184, F32HL008572, R01HL045930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49184, HL 45930A, HL 08572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; ALBERTY RA, 1979, PHYSICAL CHEM, P482; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHANG AC, 1991, BIOCHEM BIOPH RES CO, V177, P1198, DOI 10.1016/0006-291X(91)90668-W; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GEBBINK RK, 1993, BIOCHEMISTRY-US, V32, P1675, DOI 10.1021/bi00057a035; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JALLAT S, 1986, PROTEIN ENG, V1, P29, DOI 10.1093/protein/1.1.29; KEIJER J, 1991, BLOOD, V78, P1254; KEIJER J, 1991, J BIOL CHEM, V266, P10700; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LAWRENCE DA, 1995, MOL BASIS THROMBOSIS, P517; LEVIN EG, 1987, BLOOD, V70, P1090; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NASKI MC, 1993, J BIOL CHEM, V268, P12367; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PATSTON PA, 1994, BLOOD, V84, P1164; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x; YORK JD, 1991, J BIOL CHEM, V266, P8495	62	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9301	9306		10.1074/jbc.270.16.9301	http://dx.doi.org/10.1074/jbc.270.16.9301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721851	hybrid			2022-12-27	WOS:A1995QU08900039
J	STANFORD, CM; JACOBSON, PA; EANES, ED; LEMBKE, LA; MIDURA, RJ				STANFORD, CM; JACOBSON, PA; EANES, ED; LEMBKE, LA; MIDURA, RJ			RAPIDLY FORMING APATITIC MINERAL IN AN OSTEOBLASTIC CELL-LINE (UMR-106-01 BSP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; NODULES FORMED INVITRO; BONE SIALOPROTEIN BSP; PARATHYROID-HORMONE; BETA-GLYCEROPHOSPHATE; ALKALINE-PHOSPHATASE; BREFELDIN-A; INORGANIC PYROPHOSPHATE; X COLLAGEN; RAT	This study evaluated a rapid biomineralization phenomenon exhibited by an osteoblastic cell line, UMR 106-01 BSP, when treated with either organic phosphates [beta-glycerophosphate (beta-GP), Ser-P, or Thr-P], inorganic phosphate (P-i), or calcium. In a dose-dependent manner, these agents (2-10 mM) stimulated confluent cultures to deposit mineral in the cell layer (ED(50) of similar to 4.6 mM for beta-GP (30 +/- 2 nmol Ca2+/mu g DNA) and similar to 3.8 mM (29 +/- 2 nmol Ca2+/mu g DNA) for P-i) with a plateau in mineral formation by 20 h (ET(50) approximate to 12-15 h). beta-GP or P-i treatment yielded mineral crystals having an x-ray diffraction pattern similar to normal human bone, Alizarin red-S histology demonstrated calcium mineral deposition in the extracellular matrix and what appeared to be intracellular paranuclear staining. Electron microscopy revealed small, needle-like crystals associated with fibrillar, extracellular matrix deposits and intracellular spherical structures. Mineral formation was inhibited by levamisole (ED(50) approximate to 250 mu M), pyrophosphate (ED(50) approximate to 1-10 mu M), actinomycin C-1 (500 ng/ml), cycloheximide (50 mu g/ml), or brefeldin A (1 mu g/ml). These results indicate that UMR 106-01 BSP cells form a bio apatitic mineralized matrix upon addition of supplemental phosphate. This process involves alkaline phosphatase activity, ongoing RNA and protein synthesis, as well as Golgi-mediated processing and secretion.	UNIV IOWA,COLL DENT,DOW INST DENT RES,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242; NIDR,BONE RES BRANCH,BETHESDA,MD 20892	University of Iowa; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Eanes, Edward/AAM-9298-2021		NCRR NIH HHS [2 SO7 RR05313-31] Funding Source: Medline; NIAMS NIH HHS [AR-0705] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005313] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169-6009(91)90100-E; BERESFORD JN, 1993, AM J MED GENET, V45, P163, DOI 10.1002/ajmg.1320450205; BERNARD GW, 1969, AM J ANAT, V125, P271, DOI 10.1002/aja.1001250303; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Bonucci E, 1971, Clin Orthop Relat Res, V78, P108, DOI 10.1097/00003086-197107000-00010; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; Bonucci E., 1992, CALCIFICATION BIOL S, P19; CALABRO A, 1994, J BIOL CHEM, V269, P22771; CASSERBETTE M, 1990, CALCIFIED TISSUE INT, V46, P46, DOI 10.1007/BF02555824; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHRISTOFFERSEN J, 1991, ANAT RECORD, V230, P435, DOI 10.1002/ar.1092300402; EANES ED, 1992, CALCIFICATION BIOL S, P1; ECAROTCHARRIER B, 1988, BONE, V9, P147, DOI 10.1016/8756-3282(88)90004-X; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; Glimcher M. J., 1968, TREATISE COLLAGEN  B, VII, P68; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; Glimcher MJ, 1976, HDB PHYSL ENDOCRINOL, P25, DOI 10.1136/bmj.2.6038.761-a; GLIMCHER MJ, 1981, CHEM BIOL MINERALIZE, P617; GRONOWICZ G, 1989, J BONE MINER RES, V4, P313; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; HUNZIKER W, 1992, FEBS LETT, V307, P93, DOI 10.1016/0014-5793(92)80908-Y; KATOH Y, 1991, BONE, V12, P59, DOI 10.1016/8756-3282(91)90001-Y; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Klug H.P, 1974, X RAY DIFFRACTION PR, Vsecond; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; MARTIN TJ, 1979, CLIN ORTHOP RELAT R, V140, P247; MARTIN TJ, 1985, CHEM BIOL MINERALIZE, P311; MCGEERUSSELL SM, 1958, J HISTOCHEM CYTOCHEM, V6, P22, DOI 10.1177/6.1.22; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; MIDURA RJ, 1994, J BIOL CHEM, V269, P13200; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MURPHY J, 1962, ANAL CHIM ACTA, V47, P31; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110; ROBEY PG, 1992, DISORDERS BONE MINER, P241; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P1425, DOI 10.1210/me.6.9.1425; SELA J, 1992, CALCIFICATION BIOL S, P74; SODEK J, 1992, BIOL MECHANISMS TOOT, P127; TENENBAUM HC, 1987, BONE MINER, V3, P13; TENENBAUM HC, 1989, CELL TISSUE RES, V257, P555, DOI 10.1007/BF00221466; TENENBAUM HC, 1992, BONE, V13, P249, DOI 10.1016/8756-3282(92)90205-B; THOMAS JT, 1990, J CELL SCI, V95, P639; UNDERWOOD JCE, 1979, EUR J CANCER, V15, P1151, DOI 10.1016/0014-2964(79)90131-2; WU LNY, 1989, J BIOL CHEM, V264, P21346; ZIMMERMANN B, 1992, CALCIFIED TISSUE INT, V51, P54, DOI 10.1007/BF00296218; ZIMMERMANN B, 1988, CELL DIFFER DEV, V25, P145, DOI 10.1016/0922-3371(88)90007-X	57	390	406	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9420	9428		10.1074/jbc.270.16.9420	http://dx.doi.org/10.1074/jbc.270.16.9420			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721867	hybrid			2022-12-27	WOS:A1995QU08900056
J	CHUNG, DC; BRAND, SJ; TILLOTSON, LG				CHUNG, DC; BRAND, SJ; TILLOTSON, LG			MUTUALLY EXCLUSIVE INTERACTIONS BETWEEN FACTORS BINDING TO ADJACENT SP1 AND AT-RICH ELEMENTS REGULATE GASTRIN GENE-TRANSCRIPTION IN INSULINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DEVELOPMENTAL EXPRESSION; ACCURATE TRANSCRIPTION; PROMOTER; PROTEINS; ENHANCER; LINES; SITE; NESIDIOBLASTOSIS; HOMEODOMAIN	The gastrin gene is transiently expressed in fetal pancreatic islets during islet neogenesis but then switched off after birth when islet cells become fully differentiated. Previous studies identified a cis-regulatory sequence between -109 and -75 in the human gastrin promoter which binds islet cell-specific activators and a nonspecific repressor and thus may act as a molecular switch. The present study identified another cis-regulatory sequence ((-163)ACACTAAATGAAAGGGCGGGGCAG(-140)) which bound two islet nuclear proteins in a mutually exclusive manner, as defined by gel shift competition, methylation interference, and DNase I footprinting assays. The general transactivator Sp1 recognized the downstream GGGCGGGG sequence, but Sp1 binding was prevented when another islet factor bound to the adjacent AT-rich sequence (CTAAATGA). This gastrin AT-rich element is nearly identical to the binding site (ATAAATGA) for the islet-specific transcription factor beta TF-1. However, the gastrin AT-binding factor appeared to differ from beta TF-1 in its gel mobility shift pattern. Transfections of rat insulinoma cells revealed that mutations which blocked binding to the AT-rich element but allowed Sp1 binding up-regulated transcriptional activity. These results suggest that the gastrin AT-binding factor blocks transactivation by Sp1 and may have a role in the repression of gastrin transcription seen at the end of islet differentiation.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	CHUNG, DC (corresponding author), MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, JACKSON 7, BOSTON, MA 02114 USA.				NIDDK NIH HHS [DK42147, DK01410, DK07191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, R01DK042147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN AS, 1988, CURRENT PROTOCOLS MO, V2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; BRAND SJ, 1993, GASTRIN, P73; BRAND SJ, 1988, J BIOL CHEM, V263, P5341; BRAND SJ, 1988, J BIOL CHEM, V263, P16597; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEMEDIUK B H, 1992, Gastroenterology, V102, pA728; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEGENHEIMER P, 1990, METHOD ENZYMOL, V182, P714; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HERR W, 1992, TRANSCRIPTIONAL REGU, V1, P1103; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KRASINSKI SD, 1991, MOL ENDOCRINOL, V5, P433, DOI 10.1210/mend-5-3-433; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; LARSSON LI, 1976, NATURE, V262, P609, DOI 10.1038/262609a0; LARSSON LI, 1973, VIRCHOWS ARCH A, V360, P305, DOI 10.1007/BF00548351; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LI RS, 1994, J BIOL CHEM, V269, P7941; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MERCHANT J, 1994, GASTROENTEROLOGY, V106, pA827; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; SACCHI TB, 1985, VIRCHOWS ARCH B, V48, P261, DOI 10.1007/BF02890134; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; TILLOTSON LG, 1994, J BIOL CHEM, V269, P2234; WANG TC, 1990, J BIOL CHEM, V265, P8908; WANG TC, 1992, YALE J BIOL MED, V65, P705; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8829	8836		10.1074/jbc.270.15.8829	http://dx.doi.org/10.1074/jbc.270.15.8829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721790	hybrid			2022-12-27	WOS:A1995QT44800068
J	HUSSAIN, MM; INNERARITY, TL; BRECHT, WJ; MAHLEY, RW				HUSSAIN, MM; INNERARITY, TL; BRECHT, WJ; MAHLEY, RW			CHYLOMICRON METABOLISM IN NORMAL, CHOLESTEROL-FED, AND WATANABE HERITABLE HYPERLIPIDEMIC RABBITS - SATURATION OF THE SEQUESTRATION STEP OF THE REMNANT CLEARANCE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-E; LDL-RECEPTOR; WHHL RABBITS; PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMA-LIPOPROTEINS; RETINYL PALMITATE; CULTURED-CELLS; MESSENGER-RNA; BONE-MARROW	The plasma clearance of radiolabeled chylomicrons was compared in normal, cholesterol-fed, and Watanabe heritable hyperlipidemic (WHHL) rabbits. Chylomicron clearance was rapid in normal rabbits but was significantly retarded in cholesterol-fed and WHHL rabbits. At 40 min after the injection of chylomicrons, 14-17% of the injected dose remained in the plasma of normal rabbits, whereas similar to 40-50% of the injected dose remained in the plasma of cholesterol-fed and WHHL rabbits. The differences were reflected in the reduced plasma clearance by the liver and bone marrow of the cholesterol-fed and WHHL rabbits. The hyperlipidemic rabbits expressed normal levels of low density lipoprotein (LDL) receptor-related protein/alpha(2)-macroglobulin receptor in the liver, In contrast, the hepatic levels of LDL receptors were lower in hyperlipidemic rabbits; as expected, they were significantly lower in WHHL rabbits compared with normal and cholesterol-fed rabbits. Furthermore, it was demonstrated that lipoproteins accumulating in the plasma of the hyperlipidemic rabbits competed for and retarded the clearance of chylomicrons from the plasma. Competition was demonstrated by cross-circulation of normal and cholesterol-fed or normal and WHHL rabbits, in which the rapid influx of plasma containing the accumulated plasma lipoproteins from cholesterol-fed or WHHL rabbits was shown to impair the uptake of chylomicrons by the liver and bone marrow of normal rabbits. These observations were extended by infusing isolated lipoproteins into normal rabbits. The rabbit d < 1.02 g/ml (remnant) fraction and the canine cholesterol rich high density lipoproteins (HDL) with apolipoprotein E (HDL(c)) inhibited chylomicron clearance, whereas human LDL and HDL from humans and rabbits did not, We conclude that the low LDL receptor activity in the cholesterol-fed and WHHL rabbits may contribute, at least in part, to the impaired clearance by decreasing remnant uptake and causing the accumulation of chylomicron and/or very low density lipoprotein remnants, The accumulated remnant lipoproteins then compete for and saturate the mechanism responsible for the initial rapid clearance of chylomicrons from the plasma, We speculate that saturation of the initial rapid clearance may occur at the sequestration step, which involves the binding of remnants to heparan sulfate proteoglycans in the space of Disse.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUMONT JL, 1990, ATHEROSCLEROSIS, V85, P103, DOI 10.1016/0021-9150(90)90102-O; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CLARK SB, 1982, J LIPID RES, V23, P28; CLAY MA, 1989, BIOCHIM BIOPHYS ACTA, V1002, P173, DOI 10.1016/0005-2760(89)90284-1; DEMACKER PNM, 1992, BIOCHEM J, V285, P641, DOI 10.1042/bj2850641; FAINARU M, 1988, ARTERIOSCLEROSIS, V8, P130, DOI 10.1161/01.ATV.8.2.130; FAINARU M, 1982, J LIPID RES, V23, P702; FAN JL, 1994, CIRCULATION, V90, P289; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FOX JC, 1987, J BIOL CHEM, V262, P7014; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAVEL RJ, 1989, ARTERIOSCLER, V9, P33; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUETTINGER M, 1984, J CLIN INVEST, V74, P1017, DOI 10.1172/JCI111469; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; KANE JP, 1983, ARTERIOSCLEROSIS, V3, P47, DOI 10.1161/01.ATV.3.1.47; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISETHERTON PM, 1980, J LIPID RES, V21, P435; LOWRY OH, 1951, J BIOL CHEM, V13, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1980, J LIPID RES, V21, P970; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1977, AM J PATHOL, V87, P205; MAHLEY RW, 1994, METABOLIC BASES INHE, P1953; MAMO JCL, 1991, BIOCHIM BIOPHYS ACTA, V1081, P241, DOI 10.1016/0005-2760(91)90277-O; MELCHIOR GW, 1981, J LIPID RES, V22, P598; MISTRY P, 1981, J CLIN INVEST, V67, P493, DOI 10.1172/JCI110058; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; PRINCE H, 1982, Q J EXP PHYSIOL CMS, V67, P87, DOI 10.1113/expphysiol.1982.sp002628; REDGRAVE TG, 1973, BIOCHEM J, V136, P109, DOI 10.1042/bj1360109; REDGRAVE TG, 1976, ATHEROSCLEROSIS, V24, P501, DOI 10.1016/0021-9150(76)90142-8; REDGRAVE TG, 1977, METABOLISM, V26, P493, DOI 10.1016/0026-0495(77)90093-2; ROSS AC, 1977, J LIPID RES, V18, P169; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SHAFI S, 1994, J LIPID RES, V35, P709; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; THOMPSON KH, 1983, J NUTR, V113, P2002, DOI 10.1093/jn/113.10.2002; WARREN RJ, 1991, J LIPID RES, V32, P1333; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194	58	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8578	8587		10.1074/jbc.270.15.8578	http://dx.doi.org/10.1074/jbc.270.15.8578			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721759	hybrid			2022-12-27	WOS:A1995QT44800035
J	PAULL, TT; JOHNSON, RC				PAULL, TT; JOHNSON, RC			DNA LOOPING BY SACCHAROMYCES-CEREVISIAE HIGH-MOBILITY GROUP PROTEINS NHP6A/B - CONSEQUENCES FOR NUCLEOPROTEIN COMPLEX ASSEMBLY AND CHROMATIN CONDENSATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; ESCHERICHIA-COLI CHROMOSOME; SITE-SPECIFIC RECOMBINATION; LACKING HU PROTEIN; RNA POLYMERASE-II; FIS PROTEIN; DROSOPHILA-MELANOGASTER; BACTERIOPHAGE-LAMBDA; YEAST MITOCHONDRIA; MOLECULAR-DYNAMICS	The formation of higher order protein . DNA structures often requires bending of DNA strands between specific sites, a process that can be facilitated by the action of nonspecific DNA-binding proteins which serve as assembly factors. A model for this activity is the formation of the invertasome, an intermediate structure created in the Hin-mediated site-specific DNA inversion reaction, which is stimulated by the prokaryotic nucleoid-associated protein HU. Previously, we have shown that the mammalian HMG1/2 proteins substitute for HU in this system and display efficient DNA wrapping activity in vitro. In the present work, we isolate the primary sources of assembly factor activity in Saccharomyces cerevisiae, as measured by the ability to stimulate invertasome formation, and show that these are the previously identified NHP6A/B proteins. NHP6A/B have comparable or greater activity in DNA binding, bending, and supercoiling with respect to HU and HMG1 and appear to form more stable protein . DNA complexes. In addition, expression of NHPA in mutant Escherichia coli cells lacking HU and Fis restores normal morphological appearance to these cells, specifically in nucleoid condensation and segregation. From these data we predict diverse architectural roles for NHP6A/B in manipulating chromosome structure and promoting the assembly of multicomponent protein . DNA complexes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles				Paull, Tanya/0000-0002-2991-651X	NIGMS NIH HHS [GM38509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038509, R37GM038509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BALL CA, 1991, J BACTERIOL, V173, P4027, DOI 10.1128/jb.173.13.4027-4031.1991; Bellomy G R, 1990, Prog Nucleic Acid Res Mol Biol, V39, P81, DOI 10.1016/S0079-6603(08)60624-8; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DRI AM, 1991, J BACTERIOL, V173, P2852, DOI 10.1128/JB.173.9.2852-2863.1991; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; GROSSCHEDL R, 1984, TRENDS GENET, V10, P94; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HILLYARD DR, 1990, J BACTERIOL, V172, P5402, DOI 10.1128/jb.172.9.5402-5407.1990; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989; HWANG DS, 1992, J BIOL CHEM, V267, P23083; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KAO LR, 1993, P NATL ACAD SCI USA, V90, P5598, DOI 10.1073/pnas.90.12.5598; KOHLSTAEDT LA, 1994, BIOCHEMISTRY-US, V33, P570, DOI 10.1021/bi00168a023; KOLODRUBETZ D, 1988, FEBS LETT, V238, P175, DOI 10.1016/0014-5793(88)80251-5; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LANDSMAN D, 1991, MOL CELL BIOL, V11, P4483, DOI 10.1128/MCB.11.9.4483; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; Maniatis T., 1982, MOL CLONING; MAY R, 1971, Z ALLG MIKROBIOL, V11, P131, DOI 10.1002/jobm.3630110208; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; METZLER WJ, 1990, J MOL BIOL, V214, P711, DOI 10.1016/0022-2836(90)90288-W; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; NER SS, 1994, TRENDS BIOCHEM SCI, V19, P185, DOI 10.1016/0968-0004(94)90017-5; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; SCHMITZ U, 1993, J MOL BIOL, V234, P373, DOI 10.1006/jmbi.1993.1593; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHELLMAN VL, 1991, J BACTERIOL, V173, P3047, DOI 10.1128/JB.173.10.3047-3059.1991; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713	71	90	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8744	8754		10.1074/jbc.270.15.8744	http://dx.doi.org/10.1074/jbc.270.15.8744			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721780	hybrid			2022-12-27	WOS:A1995QT44800058
J	RASCHELLA, G; NEGRONI, A; SALA, A; PUCCI, S; ROMEO, A; CALABRETTA, B				RASCHELLA, G; NEGRONI, A; SALA, A; PUCCI, S; ROMEO, A; CALABRETTA, B			REQUIREMENT OF B-MYB FUNCTION FOR SURVIVAL AND DIFFERENTIATIVE POTENTIAL OF HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEURO-BLASTOMA; C-MYB; N-MYC; MORPHOLOGICAL-DIFFERENTIATION; MYELOID-LEUKEMIA; NERVOUS-SYSTEM; CDNA CLONES; A-MYB; EXPRESSION; PROLIFERATION	The B-myb gene belongs to a family of transcription factors that also includes A-myb and c-myb. B-myb is expressed in many cell types including human neuroblastoma cells. Here we demonstrate that B-myb expression is down-regulated during retinoic acid-induced neural and glial differentiation of neuroblastoma cells. This modulation is an early event, is maintained at late times of induction, and is in part regulated at the transcriptional level. Constitutive expression of B-myb prevents retinoic acid-induced neural differentiation as reflected by morphological features and the expression of (or lack of) biochemical markers associated with the undifferentiated phenotype. Furthermore, the expression of antisense B-myb transcripts does not allow the rescue of viable cells, suggesting an important role for B-myb in the survival of neuroblastoma cells. These results indicate that B-myb plays a functional role in the differentiative potential of neuroblastoma cells, raising the possibility that this gene is one of the nuclear regulators in the cascade of events leading to cellular differentiation.	THOMAS JEFFERSON UNIV,DEPT MICROBIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University			Negroni, Anna/GLS-2306-2022; sala, arturo/C-4959-2008; Pucci, Sabina/J-2542-2012	Negroni, Anna/0000-0002-2273-8837; Sala, Arturo/0000-0002-2841-7866; Pucci, Sabina/0000-0002-2418-6482				ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARSURA M, 1992, BLOOD, V79, P2708; BARLETTA C, 1991, CANCER RES, V51, P3821; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIEDLER JL, 1978, CANCER RES, V38, P3751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DELPECH B, 1978, BRIT J CANCER, V37, P33, DOI 10.1038/bjc.1978.5; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; HINO T, 1989, INT J CANCER, V44, P286, DOI 10.1002/ijc.2910440217; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RASCHELLA G, 1992, CANCER RES, V52, P4221; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sambrook J, 1989, MOL CLONING LABORATO; SCARPA S, 1987, AM J PATHOL, V129, P74; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SEEGER RC, 1982, J IMMUNOL, V128, P983; SHEA TB, 1988, DEV BRAIN RES, V43, P97, DOI 10.1016/0165-3806(88)90155-1; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SPENCE MA, 1989, CYTOGENET CELL GENET, V51, P149, DOI 10.1159/000132790; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORELLI G, 1987, CANCER RES, V47, P5266; TSOKOS M, 1987, AM J PATHOL, V128, P484; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEISS SW, 1983, LAB INVEST, V49, P299; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	51	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8540	8545		10.1074/jbc.270.15.8540	http://dx.doi.org/10.1074/jbc.270.15.8540			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721753	hybrid			2022-12-27	WOS:A1995QT44800029
J	SINGH, P; OWLIA, A; ESPEIJO, R; DAI, BS				SINGH, P; OWLIA, A; ESPEIJO, R; DAI, BS			NOVEL GASTRIN RECEPTORS MEDIATE MITOGENIC EFFECTS OF GASTRIN AND PROCESSING INTERMEDIATES OF GASTRIN ON SWISS 3T3 FIBROBLASTS - ABSENCE OF DETECTABLE CHOLECYSTOKININ (CCK)-A AND CCK-B RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE COLON CANCER; AFFINITY CROSS-LINKING; CARCINOMA CELL-LINES; MUCOSAL MEMBRANES; TYROSINE KINASES; BINDING-PROTEIN; RAT PANCREAS; GUINEA-PIGS; GROWTH; EXPRESSION	We have reported previously mitogenic effects of gastrin on several immortalized and neoplastic cell lines, including Swiss 3T3 fibroblasts. Receptor subtypes, cholecystokinin (CCK)-A and CCK-B, for a closely related peptide, cholecystokinin, were recently cloned. These studies were undertaken to investigate if CCK-A- and CCK-B receptors were perhaps mediating the mitogenic effects of gastrin on Swiss 3T3 cells. Receptor antagonists that inhibit the biological effects and binding of peptides to the CCK-A (L-364,718 (L18)) and CCK-B (L-365,260 (L60)) receptors were ineffective toward inhibiting the binding and proliferative effects of gastrin on Swiss 3T3 cells. Radiolabeled L18 and L60 demonstrated no binding to the cells, indicating that CCK-A and CCK-B receptors may be absent on Swiss 3T3 cells. Radiolabeled CCK-8, gastrin, L18, and L60, on the other hand, demonstrated specific binding to a pancreatic cancer cell line (AR42J cells) (used as a positive control). In cross-linking studies the molecular mass of the major band of gastrin receptors (GR) on Swiss 3T3 cells was determined to be similar to 45 kDa. The mitogenic potency of 0.1-1.0 nM gastrin-like peptides on Swiss 3T3 cells was in the order of G1-17 greater than or equal to G1-17-Gly > G5-17 greater than or equal to G5-17-Gly > G2-17 > CCK-8-Gly greater than or equal to G1-17-Lys greater than or equal to CCK-8. The relative binding affinity of the peptides (based on the dose dependent inhibition of binding of I-125-G1-17 to Swiss 3T3 cells) was similar to the relative mitogenic potency of the peptides as given above. Furthermore, G1-17-Gly was equally effective as G1-17 in displacing the binding of I-125-G1-17 to the 45-kDa GR from the Swiss 3T3 cells. Based on these studies it became evident that the novel gastrin preferring GR, expressed by Swiss 3T3 cells, binds and mediates the mitogenic effects of not only the mature (amidated) forms of gastrin-like peptides but also binds and meditates the mitogenic effects of glycine-extended forms of gastrin-like peptides. Possible mRNA expression of CCK-A and CCK-B receptor subtypes by gastrin-responsive rodent intestinal and fibroblast cell lines (Swiss 3T3, IEC-6, CA) was measured by the methods of Northern blot analysis and reverse transcriptase-polymerase chain reaction. mRNA from rat pancreas, AR42J cells, and rat antrum served as positive controls. We were unable to detect CCK-A and CCK-B receptor mRNA in the three cell lines by both the methods. The positive control samples, on the other hand, gave the expected results. Thus the three gastrin-responsive rodent cell lines examined in this study lacked CCK-A and CCK-B receptors, but were positive for the gastrin preferring GR that demonstrated physicochemical and pharmacological attributes distinct from CCK-A and CCK-B receptors. Since colon cancers are known to express high concentrations of non-amidated gastrin-like peptides, a possible autocrine role of glycine extended forms of gastrin becomes a highly relevant clinical question in the light of the presence of novel GR on the fibroblast and intestinal cell lines.			SINGH, P (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANAT & NEUROSCI, 10138 MED RES BLDG, 1043, GALVESTON, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA038651] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38651] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN GS, 1986, J BIOL CHEM, V261, P2252; BLACKMORE M, 1994, INT J CANCER, V57, P385, DOI 10.1002/ijc.2910570316; BLACKMORE M, 1992, BRIT J CANCER, V66, P32, DOI 10.1038/bjc.1992.212; CHICONE L, 1989, BIOCHEM BIOPH RES CO, V164, P512, DOI 10.1016/0006-291X(89)91749-X; DAI B, 1992, GASTROENTEROLOGY, V102, pA352; ELLISON BJ, 1992, CANCER RES, V53, P667; ESPEIJO R, 1992, FEB C GASTR DAN POIN; ESPEJO R, 1992, Gastroenterology, V102, pA354; GUO YS, 1989, J STEROID BIOCHEM, V33, P459, DOI 10.1016/0022-4731(89)90337-3; GUO YS, 1990, IN VITRO CELL DEV B, V26, P871; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; HADJIIVANOVA C, 1992, EUR J BIOCHEM, V204, P273, DOI 10.1111/j.1432-1033.1992.tb16634.x; HOOSEIN NM, 1988, CANCER RES, V48, P7179; ISHIZUKA J, 1994, CANCER RES, V54, P2129; ITO M, 1993, J BIOL CHEM, V268, P18300; JENSEN RT, 1994, ANN NY ACAD SCI, V713, P88, DOI 10.1111/j.1749-6632.1994.tb44055.x; Johnson L.R, 1981, PHYSL GASTROINTESTIN, V1, P169; LALLEMENT JC, 1994, EUR J PHARM-MOLEC PH, V267, P297, DOI 10.1016/0922-4106(94)90154-6; LEE YM, 1993, J BIOL CHEM, V268, P8164; LEMEUTH V, 1993, ENDOCRINOLOGY, V133, P1182, DOI 10.1210/en.133.3.1182; MAJUMDAR APN, 1990, AM J PHYSIOL, V259, pG626, DOI 10.1152/ajpgi.1990.259.4.G626; MAJUMDAR APN, 1992, PEPTIDES, V13, P795, DOI 10.1016/0196-9781(92)90189-A; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG143, DOI 10.1152/ajpgi.1987.252.1.G143; MAUSS S, 1994, ANTICANCER RES, V14, P215; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; NARAYAN S, 1990, CANCER RES, V50, P6772; NARAYAN S, 1992, MOL CELL BIOCHEM, V112, P163; NARAYAN S, 1992, CELL GROWTH DIFFER, V3, P111; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; POVOSKI SP, 1993, CANCER RES, V53, P3925; RAMANI N, 1989, ENDOCRINOLOGY, V124, P1881, DOI 10.1210/endo-124-4-1881; REHFELD JF, 1992, ADV CLIN CHEM, V29, P239, DOI 10.1016/S0065-2423(08)60226-7; RIVARD N, 1994, AM J PHYSIOL, V266, pG62, DOI 10.1152/ajpgi.1994.266.1.G62; SETHI T, 1993, CANCER RES, V53, P5208; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V212, P529, DOI 10.1111/j.1432-1033.1993.tb17690.x; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1994, AM J PHYSIOL, V266, pG459, DOI 10.1152/ajpgi.1994.266.3.G459; SINGH P, 1987, CANCER RES, V47, P5000; SINGH P, 1987, Surgical Forum (Chicago), V38, P171; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; SINGH P, 1985, AM J PHYSIOL, V249, pG761, DOI 10.1152/ajpgi.1985.249.6.G761; SIRINEK KR, 1985, AM J SURG, V149, P35, DOI 10.1016/S0002-9610(85)80006-4; SMITH JP, 1994, AM J PHYSIOL, V266, pR277, DOI 10.1152/ajpregu.1994.266.1.R277; TALKAD VD, 1994, P NATL ACAD SCI USA, V91, P1868, DOI 10.1073/pnas.91.5.1868; THUMWOOD CM, 1991, EXP CELL RES, V192, P189, DOI 10.1016/0014-4827(91)90174-S; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEINSTOCK J, 1988, CANCER RES, V48, P932; YASSIN RR, 1991, PEPTIDES, V12, P63, DOI 10.1016/0196-9781(91)90168-O; YU DH, 1990, AM J PHYSIOL, V258, pG86, DOI 10.1152/ajpgi.1990.258.1.G86; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; ZHOU WG, 1992, CANCER RES, V52, P6905	53	128	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8429	8438		10.1074/jbc.270.15.8429	http://dx.doi.org/10.1074/jbc.270.15.8429			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721737	hybrid			2022-12-27	WOS:A1995QT44800013
J	TAKAHASHI, S; CHING, YC; WANG, JL; ROUSSEAU, DL				TAKAHASHI, S; CHING, YC; WANG, JL; ROUSSEAU, DL			MICROSECOND GENERATION OF OXYGEN-BOUND CYTOCHROME-C-OXIDASE BY RAPID SOLUTION MIXING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELECTRON-TRANSFER; DIOXYGEN REDUCTION; INTERMEDIATE; TEMPERATURE; MECHANISM; SPECTROSCOPY; RESONANCE; COMPLEX; FERRYL; FLOW	Current understanding of the oxygen reduction and proton translocation processes in cytochrome c oxidase is largely derived from the data obtained by a nonphysiological method for initiating the catalytic reaction: photolyzing carbon monoxide (CO) from the CO-inhibited enzyme in the presence of oxygen (O-2). However, considerable evidence suggests that the use of CO introduces artifacts into the reaction mechanism. We have therefore developed a rapid solution mixer with a mixing time of 20 mu s to study the catalytic reaction by directly mixing the enzyme with O-2 without using CO. Unexpectedly, the resonance Raman scattering detected for the first 120 mu s after the mixing show that the CO influences neither the structure of the primary oxy-intermediate, its rate of decay, nor the rate of oxidation of cytochrome a. This implies that CO has an effect on the later stages of the catalytic process, which may involve the proton translocation steps, and calls for the re-examination of the catalytic process by using the direct mixing method. In addition, these results demonstrate the feasibility of using the rapid mixing device for the study of biological reactions in the microsecond time domain.	AT&T BELL LABS, MURRAY HILL, NJ 07974 USA	AT&T; Nokia Corporation; Nokia Bell Labs					NIGMS NIH HHS [GM-48714] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBEN JO, 1981, P NATL ACAD SCI-BIOL, V78, P234, DOI 10.1073/pnas.78.1.234; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLAIR DF, 1985, J AM CHEM SOC, V107, P7389, DOI 10.1021/ja00311a029; BRUNORI M, 1988, ADV INORG BIOCHEM, V7, P93; BRUNORI M, 1979, J BIOL CHEM, V254, P769; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANCE B, 1974, TECHNIQUES CHEM IN 2, P5; CLORE GM, 1980, BIOCHEM J, V185, P139, DOI 10.1042/bj1850139; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; FINDSEN EW, 1987, J AM CHEM SOC, V109, P5367, DOI 10.1021/ja00252a011; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; HAN SH, 1990, BIOCHEMISTRY-US, V29, P1380, DOI 10.1021/bi00458a006; HAN SH, 1990, J AM CHEM SOC, V112, P9445, DOI 10.1021/ja00182a001; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; LODDER AL, 1994, BBA-BIOENERGETICS, V1186, P67, DOI 10.1016/0005-2728(94)90136-8; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; OGURA T, 1990, J AM CHEM SOC, V112, P5630, DOI 10.1021/ja00170a032; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OLIVEBERG M, 1992, BIOCHEMISTRY-US, V31, P3560, DOI 10.1021/bi00129a002; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; PAENG KJ, 1994, ANAL SCI, V10, P157, DOI 10.2116/analsci.10.157; PAENG KJ, 1989, THESIS MARQUETTE U M; POWERS L, 1981, BIOPHYS J, V34, P465, DOI 10.1016/S0006-3495(81)84863-1; REGENFUSS P, 1985, REV SCI INSTRUM, V56, P283, DOI 10.1063/1.1138345; REGENFUSS P, 1987, BIOPHYS CHEM, V26, P83, DOI 10.1016/0301-4622(87)80010-8; ROUSSEAU DL, 1992, J RAMAN SPECTROSC, V23, P551, DOI 10.1002/jrs.1250231007; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; VAROTSIS C, 1990, J AM CHEM SOC, V112, P1297, DOI 10.1021/ja00159a091; VAROTSIS C, 1990, J BIOL CHEM, V265, P11131; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498	40	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8405	8407		10.1074/jbc.270.15.8405	http://dx.doi.org/10.1074/jbc.270.15.8405			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721733	hybrid			2022-12-27	WOS:A1995QT44800009
J	BANIK, U; AHMED, SA; MCPHIE, P; MILES, EW				BANIK, U; AHMED, SA; MCPHIE, P; MILES, EW			SUBUNIT ASSEMBLY IN THE TRYPTOPHAN SYNTHASE ALPHA(2)BETA(2) COMPLEX - STABILIZATION BY PYRIDOXAL-PHOSPHATE ALDIMINE INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BETA-SUBUNIT; ALPHA-2-BETA-2 COMPLEX; APO-BETA2 SUBUNIT; ALPHA-SUBUNIT; MECHANISM; BINDING; 5'-PHOSPHATE; FORMS	This work is aimed at understanding subunit assembly in the tryptophan synthase alpha(2) beta(2) complex and the importance of the internal aldimine between pyridoxal phosphate and lysine 87 of the beta(2) subunit of tryptophan synthase for subunit association. We utilize a mutant form of the beta(2) subunit that is unable to form the internal aldimine because lysine 87 is replaced by threonine (K87T). The K87T alpha(2) beta(2) complex is inactive in reactions catalyzed by the beta(2) subunit but retains activity in the reaction catalyzed by the alpha subunit. We find that dialysis removes pyridoxal phosphate much more rapidly from the K87T beta(2) subunit and alpha(2) beta(2) complex than from the wild type counterparts. Activity measurements, gel filtration, and subunit interchange experiments show that the alpha subunit dissociates more readily from the K87T beta(2) subunit than from the wild type beta(2) subunit. The reaction of L-serine to form an external aldimine with pyridoxal phosphate at the active site of the K87T beta(2) subunit markedly increases the affinity for the alpha subunit and slows removal of pyridoxal phosphate by dialysis. me propose that the external aldimine between L-serine and pyridoxal phosphate bridges the N-domain and the C-domain in the K87T beta(2) subunit. This interdomain bridge may mimic the internal aldimine bond in the wild type beta(2) subunit and stabilize pyridoxal phosphate binding. The interdomain bridges formed by the internal aldimine with the wild type Pa subunit and by the external aldimine with L-serine in the K87T beta(2) subunit may further stabilize interaction with the iv subunit because the alpha/beta interaction site contains residues from both N- and C-domains of the beta(2) subunit.	NIDDKD, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ADACHI O, 1974, J BIOL CHEM, V249, P7756; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BARTHOLMES P, 1980, BIOCHEMISTRY-US, V19, P4527, DOI 10.1021/bi00560a022; BARTHOLMES P, 1976, BIOCHEMISTRY-US, V15, P4712, DOI 10.1021/bi00666a027; BARTHOLMES P, 1979, EUR J BIOCHEM, V95, P323, DOI 10.1111/j.1432-1033.1979.tb12968.x; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BODE W, 1992, PROTEIN SCI, V1, P426; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; BRZOVLC P, 1991, INT UNION B, V199, P277; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; GOLDBERG ME, 1966, J MOL BIOL, V21, P71, DOI 10.1016/0022-2836(66)90080-5; HOGBERGRAIBAUD A, 1977, BIOCHEMISTRY-US, V16, P4014, DOI 10.1021/bi00637a012; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LU ZC, 1993, J BIOL CHEM, V268, P8727; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles Edith Wilson, 1994, P127, DOI 10.1002/9783527615971.ch7; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1994, ADV LIF SCI-SERIES, P113; REMETA D P, 1992, Biophysical Journal, V61, pA213; REMETA DP, 1993, BIOPHYS J, V64, pA175; REMETA DP, 1995, IN PRESS PURE APPL C; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; RUVINOV SB, 1994, J BIOL CHEM, V269, P11703; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; TSCHOPP J, 1980, BIOCHEMISTRY-US, V19, P4521, DOI 10.1021/bi00560a021; TSCHOPP J, 1980, BIOCHEMISTRY-US, V19, P4514, DOI 10.1021/bi00560a020; WADA H, 1962, J BIOL CHEM, V237, P127; WILSON DA, 1965, J BIOL CHEM, V240, P4801; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANOFSKY C, 1972, ENZYMES, V7, P1	40	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7944	7949		10.1074/jbc.270.14.7944	http://dx.doi.org/10.1074/jbc.270.14.7944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713891	hybrid			2022-12-27	WOS:A1995QR52600027
J	AARHUS, R; GEE, K; LEE, HC				AARHUS, R; GEE, K; LEE, HC			CAGED CYCLIC ADP-RIBOSE - SYNTHESIS AND USE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGG; INOSITOL TRISPHOSPHATE; CALCIUM RELEASE; CA2+ RELEASE; METABOLITE; ENZYME; NAD+; FERTILIZATION	Cyclic ADP-ribose (cADPR) is a recently discovered cyclic nucleotide with Ca2+ mobilizing activity. Caged cADPR was synthesized by reacting cADPR with 2-nitrophenethyldiazoethane. Elemental analyses, H-1 NMR, and extinction coefficient measurements indicate that the product contains only one caging group. Anion exchange high pressure liquid chromatography separated caged cADPR into two forms, which most likely represent isomers. Both forms could be uncaged with equal efficiency by UV exposure to regenerate cADPR. Photolysis of caged cADPR was accomplished effectively with a spectrofluorimeter. The efficiency of uncaging depended on wavelength with UV light shorter than about 320 nm being the most effective. Caged cADPR was biologically inactive and could induce Ca2+ release from sea urchin egg homogenates only after photolysis. Specificity of the Ca2+ release was shown by inhibition by 8-amino-cADPR, a specific antagonist of cADPR. To demonstrate its utility in live cells, caged cADPR was microinjected into sea urchin eggs. Photolysis using a mercury light source effectively regenerated cADPR and resulted in Ca2+ mobilization and activation of cortical exocytosis in the eggs.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; MOLEC PROBES INC,EUGENE,OR 97402	University of Minnesota System; University of Minnesota Twin Cities			Lee, Hon Cheung/C-4329-2009		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032040, R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32040, HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DOXSEY SJ, 1985, J CELL BIOL, V101, P19, DOI 10.1083/jcb.101.1.19; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GU QM, 1994, J AM CHEM SOC, V116, P7481, DOI 10.1021/ja00096a002; HAUGLAND RP, 1992, MOL PROBES HDB FLUOR, P182; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	22	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7745	7749		10.1074/jbc.270.13.7745	http://dx.doi.org/10.1074/jbc.270.13.7745			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706323	hybrid			2022-12-27	WOS:A1995QQ43100103
J	BOURGUIGNON, LYW; JIN, HT				BOURGUIGNON, LYW; JIN, HT			IDENTIFICATION OF THE ANKYRIN-BINDING DOMAIN OF THE MOUSE T-LYMPHOMA CELL INOSITOL 1,4,5-TRISPHOSPHATE (IP3) RECEPTOR AND ITS ROLE IN THE REGULATION OF IP3-MEDIATED INTERNAL CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; TRANSMEMBRANE GLYCOPROTEIN; SIGNAL-TRANSDUCTION; CYTOSKELETON; PROTEIN; GP85; INVOLVEMENT; CYTOPLASM	In this study we have used several complementary techniques to explore the interaction between the membrane linker molecule, ankyrin, and the inositol 1,4,5-trisphosphate (IP3) receptor in mouse T-lymphoma cells, Using double immunolabeling and laser confocal microscopy, we have found that both cytoplasmic IP3 receptor and ankyrin are preferentially accumulated within ligand-induced lymphocyte receptor capped structures, The binding between ankyrin and IP3 receptor appears to be very specific, Further analyses indicate that the amino acid sequence GGVGDVLRKPS in the IP3 receptor shares a great deal of structural homology with the ankyrin-binding domain located in certain well characterized ankyrin-binding proteins such as the cell adhesion molecule, CD44. Biochemical studies using competition binding assays and a synthetic peptide identical to GGVGDVLRKPS (a sequence detected in rat brain IP3 receptor (amino acids 2548-2558) and mouse brain IP3 receptor (amino acids 2546-2556)) indicate that this 11-amino acid peptide binds specifically to ankyrin (but not fodrin or spectrin), Furthermore, this peptide competes effectively for ankyrin binding to IP3 receptor-containing vesicles and/or purified IP3 receptor, and it blocks ankyrin-induced inhibitory effects on IP3 binding and IP3-mediated internal Ca2+ release in mouse T-lymphoma cells, These findings suggest that this amino acid sequence, GGVGDVLRKPS, which is located close to the C terminus of the IP3 receptor, resides on the cytoplasmic side (not the luminal side) of IP3 receptor-containing vesicles, This unique region appears to be an important part of the IP3 receptor ankyrin-binding domain and may play an important role in the regulation of IP3 receptor-mediated internal Ca2+ release during lymphocyte activation.			BOURGUIGNON, LYW (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,1600 NW 10TH AVE,MIAMI,FL 33101, USA.				NATIONAL CANCER INSTITUTE [R01CA036353, R01CA066163, R37CA036353] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66163, CA 36353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM RT, 1992, TRENDS BIOCHEM SCI, V17, P434, DOI 10.1016/0968-0004(92)90015-2; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BOURGUIGNON LYW, 1993, CELL BIOL INT, V17, P751, DOI 10.1006/cbir.1993.1136; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; BOURGUIGNON LYW, 1992, ENCY IMMUNOLOGY, P1044; DAVIS L, 1989, J BIOL CHEM, V264, P9665; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; JESEPH SK, 1993, J BIOL CHEM, V268, P6477; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KRAUSFRIEDMANN N, 1994, CELL MOTIL CYTOSKEL, V28, P279, DOI 10.1002/cm.970280402; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MIGNERY GA, 1989, J BIOL CHEM, V265, P12679; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x	27	96	96	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7257	7260		10.1074/jbc.270.13.7257	http://dx.doi.org/10.1074/jbc.270.13.7257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706265	hybrid			2022-12-27	WOS:A1995QQ43100038
J	LIU, ZY; FULLER, GM				LIU, ZY; FULLER, GM			DETECTION OF A NOVEL TRANSCRIPTION FACTOR FOR THE A-ALPHA FIBRINOGEN GENE IN RESPONSE TO INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; NUCLEAR FACTOR; SIGNAL-TRANSDUCTION; C/EBP FAMILY; PROTEIN; PROMOTER; EXPRESSION; ELEMENTS; BINDING; GLUCOCORTICOIDS	The three fibrinogen genes belong to the class II hepatic acute phase proteins that are regulated in part by members of the interleukin-6 (IL-6) family of cytokines and glucocorticoids. The common DNA sequence that characterizes this group of proteins is a hexanucleotide CTGGGA residing in the promoter regions of these genes. Investigations of IL-6 control of the Aa fibrinogen gene by electrophoretic mobility shift assays using a 30-base pair DNA probe containing the CTGGGA element revealed that a novel protein is associated with this site during non-IL-6-stimulated conditions. Sensitive time-course studies of IL-6 stimulation using primary hepatocyte cultures, high resolution polyacrylamide gel electrophoresis, and site-directed mutagenesis show that upon IL-6 stimulation of hepatocytes, this DNA binding protein transiently leaves the CTGGGA site and binds 12 base pairs downstream but then begins to re-associate with the original DNA site at 1 h and is completed by 2 h. A recently characterized and cloned IL-6-activated transcription factor, Stat-3, which has been reported to bind a CTGGGAA site in the alpha-2 macroglobulin gene, another member of the class II acute phase proteins, does not bind to the CTGGGA sequence in the A alpha fibrinogen gene. These findings reveal the presence of a previously undefined IL-6-regulated event, which involves a new DNA binding protein and demonstrates for the first time additional details of the kinetics of IL-6 control of fibrinogen gene expression.	UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; Ausubel FM, 1988, MOL REPROD DEV; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1993, J BIOL CHEM, V268, P25311; Crabtree G. R., 1987, MOL BASIS BLOOD DISE, P631; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; FULLER GM, 1988, METHOD ENZYMOL, V163, P474; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; NESBITT JE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P88, DOI 10.1016/0167-4781(91)90089-5; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROY SN, 1990, J BIOL CHEM, V265, P6389; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7580	7586		10.1074/jbc.270.13.7580	http://dx.doi.org/10.1074/jbc.270.13.7580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706306	hybrid			2022-12-27	WOS:A1995QQ43100082
J	LU, JY; HOFMANN, SL				LU, JY; HOFMANN, SL			DEPALMITOYLATION OF CAAX MOTIF PROTEINS - PROTEIN STRUCTURAL DETERMINANTS OF PALMITATE TURNOVER RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; RAS PROTEINS; PALMITOYLATION; RECEPTOR; P21RAS; CELLS	In the present study, we examined the effect of amino acid substitutions on the rate of turnover of palmitate bound to a model ''CAAX'' motif protein H-Ras. These experiments were designed to shed light on the specificity of the process that removes palmitate from prenylated proteins. H-Ras, protein A-Ras fusion constructs, and constructs with amino acid substitutions in the H-Ras hypervariable region were transfected into COS cells, and the turnover rate of palmitate bound to each expressed protein was measured. We found no evidence for strict sequence specificity for palmitate removal, but found a strong inverse correlation between palmitate turnover rate and the degree of membrane association for any given construct, with slower turnover rates associated with stronger membrane binding. These data support a model in which the palmitate turnover rate is determined by access to a depalmitoylating enzyme and argue against a more complex model in which specific recognition of palmitoylated proteins is required.	UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA061823] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Kato K, 1992, Semin Cancer Biol, V3, P179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESINGER MJ, 1992, LIPID MODIFICATIONS, P1; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	29	30	31	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7251	7256		10.1074/jbc.270.13.7251	http://dx.doi.org/10.1074/jbc.270.13.7251			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706264				2022-12-27	WOS:A1995QQ43100037
J	LUTZ, HU; GIANORA, O; NATER, M; SCHWEIZER, E; STAMMLER, P				LUTZ, HU; GIANORA, O; NATER, M; SCHWEIZER, E; STAMMLER, P			NATURALLY-OCCURRING ANTI-BAND-3 ANTIBODIES BIND TO PROTEIN RATHER THAN TO CARBOHYDRATE ON BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; ALTERNATIVE COMPLEMENT PATHWAY; HUMAN ERYTHROCYTE-MEMBRANE; GEL ELECTROPHORESIS; SENESCENT ANTIGEN; IMMUNE-COMPLEXES; IGG-BINDING; AUTOANTIBODIES; PHAGOCYTOSIS; GLYCOPROTEIN	Naturally occurring anti-band 3 antibodies were affinity purified from pooled human IgG (Sandoglobulin(R)) (Lutz, H. U., Flepp, R., and Stringaro-Wipf, G. (1984) J. Immunol. 133,2610-2618). They bound to the major integral membrane protein of human red blood cells and its 55-kDa NH2-terminal chymotryptic fragment but not to the carbohydrate-rich 38-kDa fragment on blots. Likewise, neither an endo-beta-galactosidase nor a neuraminidase treatment of band 3 on intact red cells reduced their binding to the blotted antigen. Lactoferrin (10 mug/ml) had no significant effect on their binding to band 3 and to its 55-kDa chymotryptic fragment. Even in the presence of 20 mug/ml lactoferrin anti-band 3 antibodies bound specifically to chymotrypsin-pretreated and oxidatively stressed red cells. Thus, naturally occurring anti-band 3 antibodies bind to protein rather than carbohydrate within band 3 protein, irrespective of whether the antibodies were depleted of anti-idiotypic and other IgG-reactive antibodies or not.			LUTZ, HU (corresponding author), SWISS FED INST TECHNOL,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND.							ADIBCONQUY M, 1993, MOL IMMUNOL, V30, P119, DOI 10.1016/0161-5890(93)90083-N; AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; BACHI T, 1977, SCAND J IMMUNOL, V6, P241, DOI 10.1111/j.1365-3083.1977.tb00390.x; BEPPU M, 1992, J BIOL CHEM, V267, P14691; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; EDBERG JC, 1988, J IMMUNOL, V141, P4258; ENDO T, 1990, BIOCHEMISTRY-US, V29, P9126, DOI 10.1021/bi00491a005; Fairbanks G, 1971, BIOCHEMISTRY-US, V10, P2607; FASLER S, 1988, ANAL BIOCHEM, V174, P593, DOI 10.1016/0003-2697(88)90061-9; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GEE AP, 1981, ANAL BIOCHEM, V116, P524, DOI 10.1016/0003-2697(81)90397-3; GUIGOU V, 1991, J IMMUNOL, V146, P1368; KAY MMB, 1992, J PROTEIN CHEM, V11, P595, DOI 10.1007/BF01024959; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; KAY MMB, 1981, NATURE, V289, P491, DOI 10.1038/289491a0; KAY MMB, 1990, GERONTOLOGY, V36, P293; KAY MMB, 1991, TRANSFUS MED REV, V3, P173; LUKACOVIC MF, 1981, BIOCHEMISTRY-US, V20, P3145, DOI 10.1021/bi00514a025; LUTZ H U, 1992, Transfusion Medicine Reviews, V6, P201, DOI 10.1016/S0887-7963(92)70170-9; LUTZ HU, 1988, BLOOD CELLS, V14, P175; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1981, SCHWEIZ MED WSCHR, V111, P1507; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; LUTZ HU, 1993, IMMUNOLOGY, V80, P191; LUTZ HU, 1984, J IMMUNOL, V133, P2610; Lutz HU, 1990, BLOOD CELL BIOCH, V1, P81; MCNEIL HP, 1990, CLIN EXP RHEUMATOL, V8, P525; MORGAN AC, 1982, CANCER RES, V42, P881; MUELLER H, 1983, Biochimica et Biophysica Acta, V729, P249; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OKADA N, 1983, IMMUNOLOGY, V50, P75; SANZ I, 1989, J IMMUNOL, V142, P4054; SCHENKEIN HA, 1981, J IMMUNOL, V126, P7; SCHLUTER K, 1986, P NATL ACAD SCI USA, V83, P6137, DOI 10.1073/pnas.83.16.6137; SCHWEIZER E, 1982, BIOCHEMISTRY-US, V21, P6807, DOI 10.1021/bi00269a029; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TURRINI F, 1991, J BIOL CHEM, V266, P23611; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WOOD PG, 1992, PROGR CELL RES, V2, P325	42	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23562	23566						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693690				2022-12-27	WOS:A1993MF51500092
J	MOYER, ML; BORROR, KC; BONA, BJ; DEFRANCO, DB; NORDEEN, SK				MOYER, ML; BORROR, KC; BONA, BJ; DEFRANCO, DB; NORDEEN, SK			MODULATION OF CELL SIGNALING PATHWAYS CAN ENHANCE OR IMPAIR GLUCOCORTICOID-INDUCED GENE-EXPRESSION WITHOUT ALTERING THE STATE OF RECEPTOR PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; PHORBOL ESTER; CHLORAMPHENICOL ACETYLTRANSFERASE; IMMUNOAFFINITY PURIFICATION; PROGESTERONE-RECEPTOR; MONOCLONAL-ANTIBODIES; DNA-BINDING; C-JUN; TRANSCRIPTION; ELEMENT	We have stably introduced expression vectors for the glucocorticoid receptor and a sensitive, hormone-responsive reporter (mouse mammary tumor virus-luciferase) into a human breast carcinoma-derived cell line. Employing this cell line, we have conducted a detailed examination of the induction of glucocorticoid-regulated genes and the phosphorylation of glucocorticoid receptor following pharmacologic manipulation of cell signaling pathways. The hormone response can be enhanced from 2 to 10-fold by activators of protein kinase A, protein kinase C, and inhibitors of protein phosphatase. Forskolin and 8-bromoadenosine 3':5'-cyclic monophosphate (BrcAMP), but not BrcGMP, enhance the hormone effect, yet surprisingly, phosphodiesterase inhibitors, isobutylmethylxanthine and Ro20-1724, strongly inhibit hormone-mediated induction of the reporter gene. These treatments do not alter cellular receptor content, dexamethasone binding, nor hormone-mediated receptor down-regulation. Tryptic peptide analysis of P-32-labeled receptor reveals that neither BrcAMP, isobutylmethylxanthine, nor the tumor promoter and protein kinase C activator, 12-O-tetradecanoyl-phorbol-13-acetate, detectably alter the state of glucocorticoid receptor phosphorylation. The only agent which alters receptor phosphorylation is the protein phosphatase inhibitor okadaic acid, but only at concentrations higher than required for maximum effects on glucocorticoid receptor transactivation. We propose that these effectors do not modify receptor directly but alter its interaction with transcription complexes.	UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,BOX B216,4200 E 9TH AVE,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,PROGRAM MOLEC BIOL,DENVER,CO 80262; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA043037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037061] Funding Source: NIH RePORTER; NCI NIH HHS [CA43037] Funding Source: Medline; NIDDK NIH HHS [DK37061] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DONG Y, 1989, J BIOL CHEM, V264, P13679; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GROUL DJ, 1986, J BIOL CHEM, V261, P4909; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOGEAT F, 1985, BIOCHEMISTRY-US, V24, P1029, DOI 10.1021/bi00325a034; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SHEPARD AR, 1992, BIOTECHNIQUES, V13, P702; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; SUGIMURA T, 1982, GANN, V73, P499; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; TOURAY M, 1991, ONCOGENE, V6, P1227; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	46	96	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22933	22940						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693681				2022-12-27	WOS:A1993MD34800108
J	GOLENBOCK, DT; LIU, YN; MILLHAM, FH; FREEMAN, MW; ZOELLER, RA				GOLENBOCK, DT; LIU, YN; MILLHAM, FH; FREEMAN, MW; ZOELLER, RA			SURFACE EXPRESSION OF HUMAN CD14 IN CHINESE-HAMSTER OVARY FIBROBLASTS IMPARTS MACROPHAGE-LIKE RESPONSIVENESS TO BACTERIAL-ENDOTOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING-PROTEIN; LIPOPOLYSACCHARIDE LPS; SCAVENGER RECEPTORS; BEARING PARTICLES; HUMAN MONOCYTES; CELL-LINE; RECOGNITION; ACCUMULATION; NEUTROPHILS; LIPOPROTEIN	Cardiovascular collapse associated with Gram-negative septicemia is believed to result from the stimulation of phagocytes by bacterial lipopolysaccharide (endotoxin, LPS). It remains unclear how endotoxin activates phagocytes, but recent evidence suggests the involvement of the glycosyl phosphatidylinositol-linked myelocyte antigen, CD14. We report that transfection of human CD14 into Chinese hamster ovary fibroblasts transfers macrophage-like responsiveness to otherwise LPS-unresponsive cells. These data demonstrate that LPS-induced responsiveness can be transferred to a heterologous non-responder cell type by expression of a single leukocyte-specific gene product.	BOSTON CITY HOSP,DEPT INTERNAL MED,DIV INFECT DIS,BOSTON,MA 02118; BOSTON CITY HOSP,DEPT SURG,CRIT CARE SECT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,LIPID METAB UNIT,BOSTON,MA 02114	Boston Medical Center; Boston Medical Center; Boston University; Harvard University; Harvard Medical School; Massachusetts General Hospital				Zoeller, Raphael/0000-0002-6560-0993	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047127] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL45098] Funding Source: Medline; NIAID NIH HHS [P01-AI33087] Funding Source: Medline; NIGMS NIH HHS [R29GM47127] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battey, 1986, BASIC METHODS MOL BI; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COUTURIER C, 1991, J IMMUNOL, V147, P1899; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HEUMANN D, 1992, J IMMUNOL, V148, P3505; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; KINGSTON RE, 1988, INTRO DNA MAMMALIAN, V1; KIRKLAND TN, 1990, J BIOL CHEM, V265, P9520; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEI MG, 1991, J IMMUNOL, V147, P1925; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; LYNN WA, 1991, J IMMUNOL, V147, P3072; LYNN WA, 1992, UNPUB; Martin M A, 1991, Infect Dis Clin North Am, V5, P739; Morrison D C, 1981, Contemp Top Mol Immunol, V8, P187; PARENT JB, 1990, J BIOL CHEM, V265, P3345; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RIETSCHEL ET, 1992, SCI AM, V267, P26; RIETVELD WJ, 1984, ANN REV CHRONOPHARMA, V1, P1; ROSENFELD ME, 1992, CURR OPIN LIPIDOL, V3, P318; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	36	128	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22055	22059						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691822				2022-12-27	WOS:A1993MC80900092
J	FEUERSTEIN, N; HUANG, D; PRYSTOWSKY, MB				FEUERSTEIN, N; HUANG, D; PRYSTOWSKY, MB			RAPAMYCIN SELECTIVELY BLOCKS INTERLEUKIN-2-INDUCED PROLIFERATING CELL NUCLEAR ANTIGEN GENE-EXPRESSION IN T-LYMPHOCYTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 KINASE ACTIVATION; ELEMENT-BINDING PROTEIN; DNA POLYMERASE-DELTA; MESSENGER-RNA LEVELS; P70 S6 KINASE; MATRIX PROTEIN; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; AUXILIARY PROTEIN; ESCHERICHIA-COLI	The macrolide rapamycin arrests T lymphocytes stimulated by interleukin-2 (IL-2) at G(1)/S. We have recently found that IL-2 induced an increase in the binding of discrete transcription factors of the ATF/cAMP-responsive element binding factor (CREB) family at G(1)/S, and that this effect was inhibited by rapamycin (Feuerstein, N., Huang, D., Hinrichs, S. H., Orten, D. J., Aiyar, N., and Prystowsky, M. B. (1995) J. Immunol, 154, 68-79), We now show, by using high resolution two-dimensional gel electrophoresis, that rapamycin inhibited selectively the synthesis of three discrete IL-2-induced soluble proteins (35 kDa/pI similar to 5, 68 kDa/pI similar to 4, 110 kDa/pI similar to 4.3), Analysis of nuclear proteins demonstrated that rapamycin selectively blocked the expression of proliferating cell nuclear antigen (PCNA), an obligate cofactor of DNA polymerase-delta, an important component for DNA replication, Rapamycin inhibited the IL-2-induced PCNA mRNA, and the murine PCNA promoter activity in IL-2-stimulated cells, Inducible CRE-binding proteins were shown previously to be required for PCNA promoter activity in IL-2-stimulated T lymphocytes, Using DNA binding gel mobility shift assay we demonstrated that rapamycin potently inhibited the binding of CREB/ATF transcription factors to CRE elements in the murine proximal PCNA promoter, These results suggest that PCNA is a preferred target in a rapamycin-sensitive transduction pathway, and that the mechanism by which rapamycin inhibits PCNA gene expression may involve the inhibition of the interaction of CREB/ATF transcription factors with CRE elements in the proximal PCNA promoter.	ALBERT EINSTEIN COLL MED,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine	FEUERSTEIN, N (corresponding author), MED COLL PENN,CGR RM 245,2900 QUEEN LN,PHILADELPHIA,PA 19129, USA.				NCI NIH HHS [R29-CA48667] Funding Source: Medline; NIA NIH HHS [AG00378] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER A, 1992, NUCLEIC ACIDS RES, V20, P1769; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLEVENGER CV, 1992, ENDOCRINOLOGY, V130, P3216, DOI 10.1210/en.130.6.3216; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DUNMONT FJ, 1990, J IMMUNOL, V144, P251; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GLOSEBROOK AL, 1980, J EXP MED, V151, P876; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIU F, 1993, J BIOL CHEM, V268, P6714; MATHEWS MB, 1989, GROWTH CONTROL CELL, P89; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOORE KS, 1987, J BIOL CHEM, V262, P8447; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; SABATH DE, 1986, P NATL ACAD SCI USA, V83, P4739, DOI 10.1073/pnas.83.13.4739; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHIPMAN PM, 1988, J CELL BIOCHEM, V38, P189, DOI 10.1002/jcb.240380306; SHIPMANAPPASAMY P, 1990, J BIOL CHEM, V265, P19180; SHIPMANAPPASAMY P, 1991, J DNA SEQUENCING MAP, V2, P181; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TAN CK, 1986, J BIOL CHEM, V261, P2310; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WONG RL, 1987, CELL IMMUNOL, V110, P443, DOI 10.1016/0008-8749(87)90137-7; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	58	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9454	9458		10.1074/jbc.270.16.9454	http://dx.doi.org/10.1074/jbc.270.16.9454			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721872	hybrid			2022-12-27	WOS:A1995QU08900061
J	OGAWA, Y; AIZAWA, S; SHIRAKAWA, H; YOSHIDA, M				OGAWA, Y; AIZAWA, S; SHIRAKAWA, H; YOSHIDA, M			STIMULATION OF TRANSCRIPTION ACCOMPANYING RELAXATION OF CHROMATIN STRUCTURE IN CELLS OVEREXPRESSING HIGH-MOBILITY GROUP-1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG CHROMOSOMAL-PROTEINS; SINGLE-STRANDED-DNA; RNA POLYMERASE-II; NUCLEOTIDE-SEQUENCE; PREFERENTIAL AFFINITY; BOVINE PAPILLOMAVIRUS; MELTING TEMPERATURE; SUPERCOILED DNA; MESSENGER-RNA; PIG THYMUS	We developed murine C-127 cell lines that stationarily overexpress high mobility group (HMG) proteins 1 and 2 by transfecting them with the bovine papilloma virus plasmid carrying their respective cDNA sequences, Using these cell lines, we examined the effects of these HMG proteins on the modulation of chromatin structure that accompanied transcription, The levels of HMG1 mRNA and protein in cells overexpressing HMG1 protein were enhanced about 7- and 3-fold, respectively, in comparison with control cells, whereas those in cells overexpressing HMG1 protein were enhanced about 17- and 9-fold, The expression of reporter genes transfected into the cells was enhanced approximately 2-fold in cells overexpressing HMG1, but not HMG2, in comparison with those in control cells, irrespective of the sources of the genes and promoters, The minichromosome derived from the reporter plasmid in cells overexpressing HMG1 protein was more susceptible to micrococcal nuclease digestion than those in cells overexpressing HMG2 protein and control cells, The enhanced accessibility to micrococcal nuclease was not restricted to the expressing gene and promoter but involved the entire minichromosome, suggesting that the enhancement of gene expression resulted from changes in the condensation of the entire minichromosomal region by HMG1 protein, Minichromosomes in cells overexpressing HMG contained enhanced amounts of the respective HMG proteins and simultaneously reduced amounts of histone His. These results suggest that HMG1 and -2 proteins have different functions in the modulation of chromatin structure, and that HMG1 protein may sustain the structure of the respective gene to ensure that its activity as a template is expressed fully, These observations on the modulation of chromatin structure accompanying gene transcription in cells overexpressing HMG protein may provide important information on the function of these proteins.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN	Tokyo University of Science			Shirakawa, Hitoshi/D-1406-2009	SHIRAKAWA, HITOSHI/0000-0002-4828-5274				AIZAWA S, 1994, BIOCHEMISTRY-US, V33, P14690, DOI 10.1021/bi00253a006; AYUSAWA D, 1986, J MOL BIOL, V190, P559, DOI 10.1016/0022-2836(86)90241-X; BEATRIZ LW, 1978, NUCLEIC ACIDS RES, V5, P4155; BIDNEY DL, 1978, BIOCHEM BIOPH RES CO, V85, P1211, DOI 10.1016/0006-291X(78)90671-X; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER JL, 1984, P NATL ACAD SCI-BIOL, V81, P2475, DOI 10.1073/pnas.81.8.2475; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUKUNAGA R, 1984, P NATL ACAD SCI-BIOL, V81, P5086, DOI 10.1073/pnas.81.16.5086; GE H, 1994, J BIOL CHEM, V269, P17136; GIRI C, 1987, J BIOL CHEM, V262, P9839; GOODWIN GH, 1978, BIOCHIM BIOPHYS ACTA, V519, P279, DOI 10.1016/0005-2787(78)90081-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMADA H, 1985, BIOCHEMISTRY-US, V24, P1428, DOI 10.1021/bi00327a022; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISACKSON PJ, 1979, J BIOL CHEM, V254, P5569; Johns EW, 1982, HMG CHROMOSOMAL PROT; JOSE M, 1987, EUR J BIOCHEM, V163, P347, DOI 10.1111/j.1432-1033.1987.tb10806.x; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LANDSMAN D, 1991, MOL CELL BIOL, V11, P4483, DOI 10.1128/MCB.11.9.4483; LAW MF, 1983, MOL CELL BIOL, V3, P2110, DOI 10.1128/MCB.3.11.2110; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; MAKIGUCHI K, 1984, J BIOCHEM-TOKYO, V95, P423, DOI 10.1093/oxfordjournals.jbchem.a134623; MAREKOV LN, 1984, BIOCHEM BIOPH RES CO, V120, P782, DOI 10.1016/S0006-291X(84)80175-8; MASUJI H, 1974, ACTA MED OKAYAMA, V28, P281; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; OUDET P, 1989, METHOD ENZYMOL, V170, P15; SAMBROOK J, 1985, EMBO J, V4, P91, DOI 10.1002/j.1460-2075.1985.tb02322.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SCOVELL WM, 1987, BIOCHEM BIOPH RES CO, V142, P826, DOI 10.1016/0006-291X(87)91488-4; SEYEDIN SM, 1979, J BIOL CHEM, V254, P1264; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4419, DOI 10.1021/bi00470a022; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; STROS M, 1987, EUR J BIOCHEM, V162, P111, DOI 10.1111/j.1432-1033.1987.tb10549.x; TENG CS, 1979, BIOCHEM J, V181, P585, DOI 10.1042/bj1810585; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; TSUDA K, 1988, BIOCHEMISTRY-US, V27, P6159, DOI 10.1021/bi00416a050; van Holde KE., 1989, SPRINGER SERIES MOL; VIDALI G, 1977, CELL, V12, P409, DOI 10.1016/0092-8674(77)90117-9; WAGA S, 1990, J BIOL CHEM, V265, P19424; WAGA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P209, DOI 10.1016/0167-4781(89)90041-9; WAGA S, 1988, BIOCHEM BIOPH RES CO, V153, P334, DOI 10.1016/S0006-291X(88)81227-0; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; YOSHIDA M, 1984, J BIOCHEM-TOKYO, V95, P117, DOI 10.1093/oxfordjournals.jbchem.a134573	51	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9272	9280		10.1074/jbc.270.16.9272	http://dx.doi.org/10.1074/jbc.270.16.9272			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721847				2022-12-27	WOS:A1995QU08900035
J	YLANNE, J; HUUSKONEN, J; OTOOLE, TE; GINSBERG, MH; VIRTANEN, I; GAHMBERG, CG				YLANNE, J; HUUSKONEN, J; OTOOLE, TE; GINSBERG, MH; VIRTANEN, I; GAHMBERG, CG			MUTATION OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN BETA(3) SUBUNIT - DIFFERENTIAL-EFFECTS ON CELL SPREADING, RECRUITMENT TO ADHESION PLAQUES, ENDOCYTOSIS, AND PHAGOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET GPIIB-IIIA; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; LIGAND-BINDING; MOLECULES CD11; ALPHA-ACTININ; PROTEIN; MODULATION	The cytoplasmic domain of the beta subunit of the alpha(IIb)beta(3) integrin is required for cell spreading on fibrinogen, Here we report that deletion of six amino acids from the COOH terminus of the beta(3) (I(757)TYRGT) totally abolished cell spreading and formation of adhesion plaques, whereas retaining Ile(757) partially preserved these functions, We further found that substitution of Tyr(747) with Ala also abolished alpha(IIb)beta(3)-mediated cell spreading. The effects of these and other mutations on additional functions of alpha(IIb)beta(3) were also studied. Progressive truncations of beta(3), in which stop codons were inserted at amino acid positions 759-756, caused partial defects in the recruitment of alpha(IIb)beta(3) to preestablished adhesion plaques and a gradual decrease in the ability of alpha(IIb)beta(3) to mediate internalization of fibrinogen-coated particles, The Tyr(747) --> Ala substitution mutant was almost totally inactive in both of these assays, Point mutations at Tyr(769), and at a conserved area close to the transmembrane domain of beta(3), decreased integrin recruitment to preestablished adhesion plaques but allowed alpha(IIb)beta(3)-mediated formation of these structures and partial cell spreading, Deletion of the cytoplasmic domain of beta(3) did not affect the constitutive endocytosis of alpha(IIb)beta(3).	UNIV HELSINKI, DEPT ANAT, SF-00014 HELSINKI, FINLAND; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA USA	University of Helsinki; Scripps Research Institute	YLANNE, J (corresponding author), UNIV HELSINKI, DEPT BIOSCI, DIV BIOCHEM, POB 5, UNIONINKATU 35, SF-00014 HELSINKI, FINLAND.		Gahmberg, Carl/AAE-1876-2019; O'Toole, Timothy/I-4172-2013	Ylanne, Jari/0000-0003-4627-021X; Gahmberg, Carl/0000-0001-9892-9296	NHLBI NIH HHS [HL28235, HL48728] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028235, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ARNAOUT MA, 1990, BLOOD, V75, P1037; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FATH KR, 1989, J CELL SCI, V92, P67; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOGG N, 1991, CHEM IMMUNOL, V50, P1; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAPLEY P, 1989, ONCOGENE, V4, P325; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; YLANNE J, 1989, INT J CANCER, V43, P1126, DOI 10.1002/ijc.2910430628; YLANNE J, 1988, BLOOD, V72, P1478	51	122	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9550	9557						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721884				2022-12-27	WOS:A1995QU08900073
J	LAMANDE, SR; CHESSLER, SD; GOLUB, SB; BYERS, PH; CHAN, D; COLE, WG; SILLENCE, DO; BATEMAN, JF				LAMANDE, SR; CHESSLER, SD; GOLUB, SB; BYERS, PH; CHAN, D; COLE, WG; SILLENCE, DO; BATEMAN, JF			ENDOPLASMIC RETICULUM-MEDIATED QUALITY-CONTROL OF TYPE-I COLLAGEN PRODUCTION BY CELLS FROM OSTEOGENESIS IMPERFECTA PATIENTS WITH MUTATIONS IN THE PRO-ALPHA-1(I) CHAIN CARBOXYL-TERMINAL PROPEPTIDE WHICH IMPAIR SUBUNIT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; PROTEIN DISULFIDE ISOMERASE; BINDING-PROTEIN; FRAMESHIFT MUTATION; LUNG FIBROBLASTS; MESSENGER-RNA; BREFELDIN-A; PROCOLLAGEN; GENE; ASSOCIATION	A heterozygous single base change in exon 49 of COL1A1, which converted the codon for pro alpha 1(I) carboxyl-terminal propeptide residue 94 from tryptophan (TGG) to cysteine (TGT) was identified in a baby with lethal osteogenesis imperfecta (OI64). The C-propeptide mutations in OI64 and in another lethal osteogenesis imperfecta cell strain (OI26), which has a frameshift mutation altering the sequence of the carboxyl-terminal half of the propeptide (Bateman, J. F., Lamande, S. R., Dahl, H.-H. M., Chan, D., Mascara, T. and Cole, W. G. (1989) J. Biol. Chem. 264, 10960-10964), disturbed procollagen folding and retarded ri,he formation of disulfide-linked trimers. Although assembly was delayed, the presence of slowly migrating, overmodified alpha 1(I) and alpha 2(I) chains indicated that mutant pro alpha 1(I) could associate with normal pro alpha 1(I) and pro alpha 2(I) to form pepsin-resistant triple-helical molecules, a proportion of which were secreted. Further evidence of the aberrant folding of mutant procollagen in OI64 and OI26 was provided by experiments demonstrating that the endoplasmic reticulum resident molecular chaperone BiP, which binds to malfolded proteins, was specifically bound to type I procollagen and was coimmunoprecipitated in the osteogenesis imperfecta cells but not control cells. Experiments with brefeldin A, which inhibits protein export from the endoplasmic reticulum, demonstrated that unassembled mutant pro alpha 1(I) chains were selectively degraded within the endoplasmic reticulum resulting in reduced collagen production by the osteogenesis imperfecta cells. This biosynthetic deficiency was reflected in the inability of OI64 and OI26 cells to produce a substantial in vitro collagenous matrix when grown in the continuous presence of ascorbic acid to allow collagen matrix formation. Both these carboxyl-terminal propeptide mutants showed a marked reduction in collagen accumulation to 20% (or less) of control cultures, comparable to the reduced collagen content of tissues from OI26.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,ORTHOPAED MOLEC BIOL RES UNIT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; CHILDRENS HOSP,DEPT GENET,CAMPERDOWN,NSW 2050,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			; Chan, Danny/C-4203-2009	Lamande, Shireen/0000-0003-2938-2711; Byers, Peter H./0000-0001-7786-7030; Bateman, John/0000-0001-8542-0730; Chan, Danny/0000-0003-3824-5778				BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BARILE FA, 1990, ARCH BIOCHEM BIOPHYS, V276, P125, DOI 10.1016/0003-9861(90)90018-T; Bateman J F, 1988, Ann N Y Acad Sci, V543, P95, DOI 10.1111/j.1749-6632.1988.tb55321.x; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1988, ANAL BIOCHEM, V168, P171, DOI 10.1016/0003-2697(88)90025-5; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BERG RA, 1973, BIOCHEMISTRY-US, V12, P3395, DOI 10.1021/bi00742a005; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BERG RA, 1984, BIOCHEMISTRY-US, V23, P2143; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; COLE WG, 1990, J MED GENET, V27, P545, DOI 10.1136/jmg.27.9.545; COLE WG, 1981, BIOCHEM J, V197, P377, DOI 10.1042/bj1970377; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; Fisher L. W., 1989, CONNECT TISSUE RES, V21, P43; FISHER LW, 1987, J BIOL CHEM, V262, P13457; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; JIMENEZ SA, 1978, J BIOL CHEM, V253, P1420; KAO WWY, 1977, J BIOL CHEM, V252, P8391; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOSEN PA, 1982, BIOCHEMISTRY-US, V21, P4278, DOI 10.1021/bi00261a016; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; RIPLEY CR, 1993, J BIOL CHEM, V268, P3677; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; WAKE SA, 1985, BIOCHEM J, V228, P425, DOI 10.1042/bj2280425; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WU H, 1990, MOL CELL BIOL, V10, P1452, DOI 10.1128/MCB.10.4.1452	50	120	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8642	8649		10.1074/jbc.270.15.8642	http://dx.doi.org/10.1074/jbc.270.15.8642			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721766	hybrid			2022-12-27	WOS:A1995QT44800043
J	LEE, CH; MURAKAMI, T; SIMONDS, WF				LEE, CH; MURAKAMI, T; SIMONDS, WF			IDENTIFICATION OF A DISCRETE REGION OF THE G-PROTEIN GAMMA-SUBUNIT CONFERRING SELECTIVITY IN BETA-GAMMA COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; INFECTED INSECT CELLS; LIMITED PROTEOLYSIS; COILED-COIL; TRANSDUCIN; DIMERS; PURIFICATION; EXPRESSION; SEQUENCE; BRAIN	The identification of multiple G protein beta and gamma subunit subtypes suggests a potential diversity of beta gamma heterodimers, which may contribute to the specificity of signal transduction between receptors and effecters. The assembly of beta and gamma subtypes is selective. For example, gamma(1) can assemble with beta(1) but not with beta(2), whereas gamma(2) assembles with both beta isoforms. To identify the structural features of the beta and gamma subunits governing selectivity in heterodimer assembly, a series of nonisoprenylated chimeras of gamma(1) and gamma 2 was constructed, and their interaction with beta(1) and beta(2) was assessed by their ability to direct beta expression to the cytosol in cotransfected COS cells. All of the gamma(1)/gamma(2) chimeras were capable of interacting with beta(1) as judged by the cotransfection assay. Chimeras containing gamma(2) sequence near the middle of the molecule between two conserved sequence motifs were capable of interacting as well with beta(2). Among 12 divergent residues in this region, it was found that replacement of three consecutive amino acids in gamma(1), Glu-Glu-Phe (residues 38-40), with the three corresponding amino acids of gamma(2), Ala-Asp-Leu (residues 35-37), conferred the ability to assemble with beta(2). The reciprocal chimera containing Glu-Glu-Phe in the context of gamma(2) failed to assemble with beta(2). The last residue of this triplet is occupied by a leucine in all known mammalian gamma subunits except gamma(1) and appears to be a key determinant of the ability of a gamma subunit to assemble with beta(2). This locus maps to a region of predicted alpha-helical structure in the gamma subunit, likely to represent a point of physical contact with the beta subunit.	NIDDK,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPIEGEL AM, 1994, G PROTEINS, P1; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TAO L, 1993, EXP EYE RES, V56, P497, DOI 10.1006/exer.1993.1063; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	52	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8779	8784		10.1074/jbc.270.15.8779	http://dx.doi.org/10.1074/jbc.270.15.8779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721784	hybrid			2022-12-27	WOS:A1995QT44800062
J	MACDONALD, GM; STEENHUIS, JJ; BARRY, BA				MACDONALD, GM; STEENHUIS, JJ; BARRY, BA			A DIFFERENCE FOURIER-TRANSFORM INFRARED SPECTROSCOPIC STUDY OF CHLOROPHYLL OXIDATION IN HYDROXYLAMINE-TREATED PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; ELECTRON-PARAMAGNETIC RESONANCE; PRIMARY QUINONE ACCEPTOR; NORMAL MODE DESCRIPTIONS; WATER-OXIDIZING COMPLEX; RHODOBACTER-SPHAEROIDES; REACTION CENTERS; RHODOPSEUDOMONAS-VIRIDIS; SPINACH-CHLOROPLASTS; EPR CHARACTERIZATION	In oxygenic photosynthesis, photosystem II is the chlorophyll-containing reaction center that carries out the light-induced transfer of electrons from water to plastoquinone. Fourier transform infrared spectroscopy can be used to obtain information about the structural changes that accompany electron transfer in photosystem II. The vibrational difference spectrum associated with the reduction of photosystem II acceptor quinones is of interest. Previously, a high concentration of the photosystem II donor, hydroxylamine, has been used to obtain a spectrum attributed to Q(A-) - Q(A) (Berthomieu, C., Nabedryk, E., Mantele, W. and Breton, J. FEBS Lett. (1990) 269, 363). Here, we use electron paramagnetic resonance, Fourier transform infrared spectroscopy, and N-15 isotopic labeling to show that the difference infrared spectrum, obtained under these conditions, also exhibits a contribution from the oxidation of chlorophyll.	UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043273, T32GM008277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43273, GM08277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGA C, 1993, BIOCHIM BIOPHYS ACTA, V1142, P36, DOI 10.1016/0005-2728(93)90081-P; ARNON DI, 1988, P NATL ACAD SCI USA, V85, P9524, DOI 10.1073/pnas.85.24.9524; BABCOCK GT, 1983, BIOCHIM BIOPHYS ACTA, V723, P276, DOI 10.1016/0005-2728(83)90127-5; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1993, PHOTOCHEM PHOTOBIOL, V57, P179, DOI 10.1111/j.1751-1097.1993.tb02275.x; BERNARD MT, 1995, J BIOL CHEM, V270, P1589, DOI 10.1074/jbc.270.4.1589; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BERTHOMIEU C, 1992, BIOCHEMISTRY-US, V31, P11460, DOI 10.1021/bi00161a026; BERTHOMIEU C, 1990, FEBS LETT, V269, P363, DOI 10.1016/0014-5793(90)81194-S; BERTHOMIEU C, 1992, RES PHOTOSYNTHESIS, V2, P53; BOLDT NJ, 1987, J AM CHEM SOC, V109, P2284, DOI 10.1021/ja00242a009; BOUGES B, 1971, BIOCHIM BIOPHYS ACTA, V234, P103, DOI 10.1016/0005-2728(71)90135-6; BOUGESBOCQUET B, 1973, BIOCHIM BIOPHYS ACTA, V292, P772, DOI 10.1016/0005-2728(73)90024-8; BUSER CA, 1992, BIOCHEMISTRY-US, V31, P11441, DOI 10.1021/bi00161a024; BUSER CA, 1992, BIOCHEMISTRY-US, V31, P11449, DOI 10.1021/bi00161a025; BUSER CA, 1990, BIOCHEMISTRY-US, V29, P8977, DOI 10.1021/bi00490a014; CANAANI O, 1990, P NATL ACAD SCI USA, V87, P9295, DOI 10.1073/pnas.87.23.9295; CHENIAE GM, 1971, PLANT PHYSIOL, V47, P568, DOI 10.1104/pp.47.4.568; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DEPAULA JC, 1986, BIOCHEMISTRY-US, V25, P6487, DOI 10.1021/bi00369a022; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; DEROSE VJ, 1991, BIOCHEMISTRY-US, V30, P1335, DOI 10.1021/bi00219a025; DONOHOE RJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P531, DOI 10.1111/j.1751-1097.1988.tb02857.x; EVANS MCW, 1982, BIOCHIM BIOPHYS ACTA, V682, P97, DOI 10.1016/0005-2728(82)90123-2; GHANOTAKIS DF, 1983, FEBS LETT, V153, P231, DOI 10.1016/0014-5793(83)80154-9; GRESE RP, 1990, J AM SOC MASS SPECTR, V1, P72, DOI 10.1016/1044-0305(90)80008-B; HEBER U, 1979, BIOCHIM BIOPHYS ACTA, V546, P292, DOI 10.1016/0005-2728(79)90047-1; HOFF AJ, 1987, PHOTOSYNTHESIS NEW C, V15, P97; HOGANSON CW, 1989, BIOCHEMISTRY-US, V28, P1448, DOI 10.1021/bi00430a004; KRETSCHMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1059, P208, DOI 10.1016/S0005-2728(05)80205-1; LEONHARD M, 1993, BIOCHEMISTRY-US, V32, P4532, DOI 10.1021/bi00068a007; MACDONALD GM, 1992, BIOCHEMISTRY-US, V31, P9848, DOI 10.1021/bi00155a043; MACDONALD GM, 1993, P NATL ACAD SCI USA, V90, P11024, DOI 10.1073/pnas.90.23.11024; MACDONALD GM, 1994, BIOCHEMISTRY-US, V33, P4393, DOI 10.1021/bi00180a037; MANTELE WG, 1988, P NATL ACAD SCI USA, V85, P8468, DOI 10.1073/pnas.85.22.8468; MESSINGER J, 1991, BIOCHEMISTRY-US, V30, P7852, DOI 10.1021/bi00245a027; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; NABEDRYK E, 1990, BIOCHEMISTRY-US, V29, P3242, DOI 10.1021/bi00465a015; NABEDRYK E, 1990, FEBS LETT, V266, P59, DOI 10.1016/0014-5793(90)81506-J; NABEDRYK E, 1992, BIOCHEMISTRY-US, V31, P10852, DOI 10.1021/bi00159a028; NOGUCHI T, 1993, BIOCHIM BIOPHYS ACTA, V1143, P333, DOI 10.1016/0005-2728(93)90205-T; NOGUCHI T, 1992, BIOCHEMISTRY-US, V31, P5953, DOI 10.1021/bi00141a001; NOREN GH, 1991, BIOCHEMISTRY-US, V30, P3943, DOI 10.1021/bi00230a020; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; NUGENT JHA, 1981, FEBS LETT, V124, P241, DOI 10.1016/0014-5793(81)80146-9; PALANIAPPAN V, 1993, J AM CHEM SOC, V115, P12035, DOI 10.1021/ja00078a048; PETERSEN J, 1990, BIOCHEMISTRY-US, V29, P3226, DOI 10.1021/bi00465a012; RADMER R, 1982, FEBS LETT, V144, P162, DOI 10.1016/0014-5793(82)80592-9; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P10043, DOI 10.1021/bi00199a031; ROGNER M, 1990, J BIOL CHEM, V265, P6189; RUTHERFORD AW, 1983, FEBS LETT, V154, P328, DOI 10.1016/0014-5793(83)80176-8; RUTHERFORD AW, 1984, BIOCHIM BIOPHYS ACTA, V767, P168, DOI 10.1016/0005-2728(84)90092-6; SIVARAJA M, 1988, BIOCHEMISTRY-US, V27, P3467, DOI 10.1021/bi00409a051; THIBODEAU DL, 1990, BIOCHIM BIOPHYS ACTA, V1020, P253, DOI 10.1016/0005-2728(90)90155-W; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; WERTZ JE, 1986, ELECTRON SPIN RESON, P462; YOCUM CF, 1981, P NATL ACAD SCI-BIOL, V78, P7507, DOI 10.1073/pnas.78.12.7507	59	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8420	8428		10.1074/jbc.270.15.8420	http://dx.doi.org/10.1074/jbc.270.15.8420			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721736	hybrid			2022-12-27	WOS:A1995QT44800012
J	ARMSTRONG, SA; HANNAH, VC; GOLDSTEIN, JL; BROWN, MS				ARMSTRONG, SA; HANNAH, VC; GOLDSTEIN, JL; BROWN, MS			CAAX GERANYLGERANYL TRANSFERASE TRANSFERS FARNESYL AS EFFICIENTLY AS GERANYLGERANYL TO RHOB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN GERANYLGERANYLTRANSFERASE; CDNA CLONING; PEPTIDE-BINDING; ALPHA-SUBUNIT; BETA-SUBUNIT; COMPONENT-A; RAT-BRAIN; FARNESYLTRANSFERASE; PRENYLATION; CHOROIDEREMIA	RhoB, a small GTP-binding protein, was shown previously to contain farnesyl (C-15) as well as geranylgeranyl (C-20) groups (Adamson, P., Marshall, C. J., Hall, A. and Tilbrook, P. A. (1992) J. Biol. Chem. 267, 20033-20038). The COOH-terminal sequence of the protein is CCKVL. According to current rules of prenylation, the COOH-terminal leucine should render the protein a substrate for CAAX geranylgeranyl transferase (GGTase-1), but not for CAAX farnesyltransferase (FTase). To determine the mechanism of farnesylation, we prepared recombinant RhoB and incubated it with recombinant preparations of either FTase or GGTase-1. RhoB was neither farnesylated nor geranylgeranylated efficiently by FTase, but it was farnesylated as well as geranylgeranylated by GGTase-1. The enzyme attached farnesyl more efficiently than geranylgeranyl to RhoB. Neither farnesylation nor geranylgeranylation required the cysteine at the fifth position from the COOH terminus. However, replacement of the cysteine at the fourth position abolished attachment of both prenyl groups. We conclude that the previously observed farnesylation of RhoB is attributable to the FTase activity of GGTase-1. These data, and other accumulating data, indicate that GGTase-1 is a highly unusual enzyme that efficiently transfers both farnesyl and geranylgeranyl groups and that the choice of prenyl group is dictated by the nature of the protein acceptor.			ARMSTRONG, SA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CASEY PJ, 1992, J LIPID RES, V33, P1731; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V268, P27705; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	27	148	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7864	7868		10.1074/jbc.270.14.7864	http://dx.doi.org/10.1074/jbc.270.14.7864			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713879	hybrid			2022-12-27	WOS:A1995QR52600015
J	TANG, PM; FOLTZ, LA; MAHONEY, WC; SCHUELER, PA				TANG, PM; FOLTZ, LA; MAHONEY, WC; SCHUELER, PA			A HIGH-AFFINITY DIGOXIN-BINDING PROTEIN DISPLAYED ON M13 IS FUNCTIONALLY IDENTICAL TO THE NATIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; MONOVALENT PHAGE DISPLAY; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; FILAMENTOUS PHAGE; CROSS-REACTIVITY; EXPRESSION; ANTIGEN; SITE; FV	Phage display of peptides and proteins has successfully been employed to produce binding molecules of altered affinity. Little is known, however, regarding the impact on affinity measurements of phage-displayed molecules compared to their native freely soluble configuration. That identical affinities can be obtained was shown by Scatchard analysis of the native antibody, its single chain derivative (scFv), and its phage-displayed single chain counterpart for the ligand digoxin. No significant difference, within one standard deviation, was detected in affinity for digoxin when the phage-displayed scFv was compared to either its soluble scFv form or the purified antibody. In addition, no change in binding specificity was detected, within two standard deviations, when the binding proteins were challenged with two commonly cross-reactive compounds (dihydrodigoxin and digitoxin). That phage-display can be employed for molecules having high binding affinities (K-d of 6 x 10(-11) M) is also known.	BOEHRINGER MANNHEIM CORP, RES & DEV, MOLEC DIAGNOST, INDIANAPOLIS, IN 46250 USA									ANTHONY J, 1992, MOL IMMUNOL, V29, P1237, DOI 10.1016/0161-5890(92)90060-B; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; COREY DR, 1993, GENE, V128, P129; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DJOJONEGORO BM, 1994, BIO-TECHNOL, V12, P169, DOI 10.1038/nbt0294-169; GARRARD LJ, 1991, BIO-TECHNOL, V9, P1373, DOI 10.1038/nbt1291-1373; GO K, 1980, ACTA CRYSTALLOGR B, V36, P1811, DOI 10.1107/S0567740880007297; HECHEMY K, 1984, LAB MANAGE, V6, P27; HECHEMY K, 1984, LAB MANAGE, V7, P26; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; IBRAHIM S, 1993, SCAND J IMMUNOL, V37, P257, DOI 10.1111/j.1365-3083.1993.tb01764.x; KABAT EA, 1966, J IMMUNOL, V97, P1; Kabat EA, 1991, SEQUENCES PROTEINS I; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MALBY RL, 1993, PROTEINS, V16, P57, DOI 10.1002/prot.340160107; MARKS JD, 1992, J BIOL CHEM, V267, P16007; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MICELI RM, 1994, FASEB J, V8, pA1408; MILLER JJ, 1992, J CLIN IMMUNOASSAY, V15, P97; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; Rodbard D, 1973, P SER, V1, P165; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE P, 1993, BRIT J CANCER, V68, P738, DOI 10.1038/bjc.1993.420; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEPPALA I, 1990, J IMMUNOL, V145, P2989; SMITH GP, 1991, CURR OPIN BIOTECH, V2, P665; SWIMMER C, 1992, P NATL ACAD SCI USA, V89, P3756, DOI 10.1073/pnas.89.9.3756; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	42	6	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7829	7835		10.1074/jbc.270.14.7829	http://dx.doi.org/10.1074/jbc.270.14.7829			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713873	hybrid			2022-12-27	WOS:A1995QR52600009
J	GAMM, DM; UHLER, MD				GAMM, DM; UHLER, MD			ISOFORM-SPECIFIC DIFFERENCES IN THE POTENCIES OF MURINE PROTEIN-KINASE INHIBITORS ARE DUE TO NONCONSERVED AMINO-TERMINAL RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; CATALYTIC SUBUNIT; GENE-TRANSCRIPTION; PEPTIDE INHIBITOR; RAT TESTIS; PURIFICATION; CLONING; FORM	We provide here a detailed characterization of two isoforms of the protein kinase inhibitor (PKI) protein of cAMP dependent protein kinase that have dramatically different inhibition constants. Murine PKI beta 1 possesses a 32-fold higher K-i than murine PKI alpha as determined by Henderson analysis. This finding led to the investigation of C subunit PKI interactions involving nonconserved regions in the carboxyl and amino termini of murine PKI alpha and PHI beta 1. Chimeric cDNAs coding for amino acid sequences from both PKI. isoforms were constructed and expressed in bacteria. Surprisingly, exchanging the carboxyl-terminal two-thirds of PKI alpha and PKI beta 1 has relatively little effect on the inhibition constants of the two isoforms. Similarly, introducing amino acid residues corresponding to a beta-turn region of PKI alpha into PKI beta 1 fails to lower PKI beta 1 inhibition constants. However, introducing the amino-terminal alpha-helical region of PKI alpha into PKI beta 1 reduces the K-i and IC50 of PKI beta 1 to values identical with full length PKl alpha. Site-directed mutagenesis of specific residues within this region implicates the presence of a tyrosine at position 7 in PKI alpha as a major contributor to its enhanced inhibitory potency. The results of this study suggest that variations in C subunit PKI interactions within an amino-terminal alpha-helix provide a major mechanism for altering the inhibitory properties of PKI isoforms.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48104; UNIV MICHIGAN,NEUROSCI PROGRAM,ANN ARBOR,MI 48104; UNIV MICHIGAN,MENTAL HLTH RES INST,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIGMS NIH HHS [GM 38788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038788, R01GM038788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; BAUDE EJ, 1994, J BIOL CHEM, V269, P18128; BEALE EG, 1977, J BIOL CHEM, V252, P6322; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAY RN, 1989, J BIOL CHEM, V264, P431; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; DEMAILLE JG, 1979, BIOCHIM BIOPHYS ACTA, V586, P374, DOI 10.1016/0304-4165(79)90106-5; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GROVE JR, 1987, SCIENCE, V238, P530; HENDERSON PJF, 1972, BIOCHEM J, V127, P31; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; POSNER JB, 1964, BIOCHEMISTRY-US, V3, P1040, DOI 10.1021/bi00896a005; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WHITEHOUSE S, 1982, J BIOL CHEM, V257, P6028	31	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7227	7232		10.1074/jbc.270.13.7227	http://dx.doi.org/10.1074/jbc.270.13.7227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706262	hybrid			2022-12-27	WOS:A1995QQ43100034
J	COOPERMAN, BS; STAVRIDI, E; NICKBARG, E; RESCORLA, E; SCHECHTER, NM; RUBIN, H				COOPERMAN, BS; STAVRIDI, E; NICKBARG, E; RESCORLA, E; SCHECHTER, NM; RUBIN, H			ANTICHYMOTRYPSIN INTERACTION WITH CHYMOTRYPSIN - PARTITIONING OF THE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; REACTIVE SITE; NEUTROPHIL SUPEROXIDE; CRYSTAL-STRUCTURE; PORCINE TRYPSIN; CATHEPSIN-G; SERPINS	The interactions of bovine pancreatic chymotrypsin (Chtr) and recombinant alpha1-antichymotrypsin (rACT) and rACT variants were studied by kinetic and gel electrophoretic analyses, leading to the formulation of a general kinetic scheme that accounts for all known results concerning this serpin-protease pair, as well as for results obtained with other such pairs. Incubation of rACT and Chtr leads rapidly to the formation-of an inhibited complex, Chtr.rACT*, that is stable toward sodium dodecyl sulfate denaturation and boiling. The extent of release of active Chtr from this complex increases markedly as ionic strength, mu, is raised. The kinetic scheme quantitatively accounts for this effect on the basis of a partitioning of Chtr.rACT* between dissociation of the complex to yield active enzyme and cleaved rACT, and Chtr.catalyzed conversion of the complex to a form that is much more resistant to release of active enzyme. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses of reaction mixtures of rACT and Chtr are consistent with the scheme. Also consistent are the results of experiments measuring the effects of 1) Chtr.rACT* concentration, 2) uncomplexed Chtr, and 3) added alpha2-Macroglobulin on active Chtr release from Chtr.rACT*. Proteolysis of Chtr.rACT* to give a resistant complex is also catalyzed by human neutrophil elastase, a process with potential physiological relevance. Comparison of the rates of Chtr dissociation from the complexes formed with rACT and with rACT variants mutated at the P1 site suggests that such rates are more sensitive to P1 substitution at low mu than at high mu. Several equivalents of the L358R-rACT variant are required for full inhibition of Chtr. This observation is also quantitatively accounted for by the proposed kinetic scheme, on the basis of another partitioning step between L358R-rACT acting as a substrate or as an inhibitor toward Chtr.	UNIV PENN,SCH MED,DEPT DERMATOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	COOPERMAN, BS (corresponding author), UNIV PENN,SCH ARTS & SCI,DEPT CHEM,CHEM BLDG,PHILADELPHIA,PA 19104, USA.				NIA NIH HHS [AG-10599] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1982, BIOCHIM BIOPHYS ACTA, V704, P221, DOI 10.1016/0167-4838(82)90149-2; BJORK I, 1982, J BIOL CHEM, V257, P9487; BOSWELL DR, 1985, BIOCHEM EDUC, V13, P98; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KASAFIREK E, 1976, EUR J BIOCHEM, V69, P1, DOI 10.1111/j.1432-1033.1976.tb10852.x; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KNOLLER S, 1991, THROMB RES, V63, P203, DOI 10.1016/0049-3848(91)90284-4; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE A, 1984, EUR J BIOCHEM, V140, P105, DOI 10.1111/j.1432-1033.1984.tb08072.x; LOBERMANN H, 1984, J MOL BIOL, V177, P531; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MORII M, 1983, J BIOL CHEM, V258, P2749; ODA K, 1977, BIOCHEM BIOPH RES CO, V76, P1062, DOI 10.1016/0006-291X(77)90964-0; OLSON ST, 1985, J BIOL CHEM, V260, P153; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; PRATT CW, 1990, J BIOL CHEM, V265, P6092; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Sambrook J, 1989, MOL CLONING LABORATO; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHUSTER MG, 1992, J BIOL CHEM, V267, P5056; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; WIMAN B, 1979, J BIOL CHEM, V254, P9291	39	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23616	23625						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693693				2022-12-27	WOS:A1993MF51500100
J	KIRKEN, RA; RUI, H; EVANS, GA; FARRAR, WL				KIRKEN, RA; RUI, H; EVANS, GA; FARRAR, WL			CHARACTERIZATION OF AN INTERLEUKIN-2 (IL-2)-INDUCED TYROSINE-PHOSPHORYLATED 116-KDA PROTEIN ASSOCIATED WITH THE IL-2 RECEPTOR BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; ERYTHROPOIETIN RECEPTOR; EXPRESSION CLONING; KINASE ACTIVATION; GAMMA-CHAIN; CELL-LINE; PROLACTIN RECEPTOR; GENE FAMILY; T-CELLS	In this paper we have extended previous results on interleukin-2 receptor (IL2-R) signal transduction and focused on the interleukin-2 (IL-2)-stimulated tyrosine phosphorylation of a 116-kDa protein (p116) observed in IL-2 responsive cells. This protein exhibited rapid and transient phosphorylation kinetics in both human T-lymphocytes and the YT cell line, attaining maximum tyrosine phosphorylation within 5 min of stimulation with IL-2. Tyrosine phosphorylated p116 co-purified with activated IL-2 receptor beta-chain (IL2-Rbeta) when IL2-R complexes were covalently stabilized with the membrane-permeable cleavable cross-linking agent dithiobis(succimidyl propionate) prior to detergent cell lysis and immunoprecipitation with monoclonal anti-IL2-Rbeta antibodies. Under these conditions comparable amounts of tyrosine-phosphorylated p116 were immuno-precipitated with either anti-IL2-Rbeta antibodies or antiphosphotyrosine antibodies, suggesting that a major portion of tyrosine phosphorylated p116 is associated with the IL2-Rbeta subunit. Furthermore, unphosphorylated p116 was also associated with unactivated IL2-Rbeta, based on the observation that p116 from unstimulated YT cells underwent tyrosine phosphorylation in IL2-Rbeta immune-complex tyrosine kinase assay as demonstrated by anti-phosphotyrosine immunoblotting. The presence of tyrosine kinase activity in affinity-purified IL2-Rbeta complexes supports the notion of a preformed receptor-kinase complex. The co-association of both p116 and tyrosine kinase activity with the IL2-Rbeta supports the critical role of the beta-chain in IL2-R signal transduction and suggests that p116 may have a role in the dynamics of IL2-R activation.	NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,CYTOKINE MECHANISM SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EINSPAHR KJ, 1992, J LEUKOCYTE BIOL, V52, P565, DOI 10.1002/jlb.52.5.565; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS GA, 1993, IN PRESS BIOCH J; FARRAR W L, 1990, Cytokine, V2, P77, DOI 10.1016/1043-4666(90)90001-A; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; FERRIS DK, 1989, J IMMUNOL, V143, P870; FOXWELL BMJ, 1992, CLIN EXP IMMUNOL, V90, P161; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUNG MR, 1991, J IMMUNOL, V147, P1253; GARCIA GG, 1992, BIOCHEM J, V285, P851, DOI 10.1042/bj2850851; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; IZQUIERDO M, 1992, EUR J IMMUNOL, V22, P817, DOI 10.1002/eji.1830220328; KOGA Y, 1988, CANCER RES, V48, P856; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; ROBB RJ, 1987, P NATL ACAD SCI USA, V84, P2002, DOI 10.1073/pnas.84.7.2002; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1993, J CELL BIOL S B, V17, P118; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SHARON M, 1989, J IMMUNOL, V143, P2530; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STRED SE, 1990, ENDOCRINOLOGY, V127, P2505; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TORIGOE T, 1992, CYTOKINE, V4, P369, DOI 10.1016/1043-4666(92)90080-B; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; YAMASAKI K, 1988, SCIENCE, V241, P852; YODOI J, 1985, J IMMUNOL, V134, P1623	56	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22765	22770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693677				2022-12-27	WOS:A1993MD34800084
J	YARWOOD, NJ; GURR, JA; SHEPPARD, MC; FRANKLYN, JA				YARWOOD, NJ; GURR, JA; SHEPPARD, MC; FRANKLYN, JA			ESTRADIOL MODULATES THYROID-HORMONE REGULATION OF THE HUMAN GLYCOPROTEIN HORMONE ALPHA-SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RESPONSIVE ELEMENT; ANTERIOR-PITUITARY CELLS; GROWTH-HORMONE; LUTEINIZING-HORMONE; RECEPTOR BINDS; STIMULATING-HORMONE; NEGATIVE REGULATION; MOLECULAR-BIOLOGY; PROLACTIN GENE; THYROTROPIN	We have examined mechanisms of regulation of the human glycoprotein hormone alpha subunit gene by thyroid hormone (T3) and estradiol. Pituitary-derived GH3 cells were transiently transfected with chimeric constructs comprising between 1,500 and 98 base pairs of human alpha subunit gene 5'-flanking sequence fused to the bacterial gene encoding chloramphenicol acetyltransferase (halphaCAT) and treated with T3 and estradiol, alone and in combination. In pituitary cells, 98 base pairs of alpha gene 5'-flanking sequence were sufficient to mediate both inhibition of alpha gene promoter activity by T3 and stimulation by estradiol; inhibition of the alpha promoter by T3 was antagonized by estradiol. Mutation of nucleotides essential for T3 receptor binding to the alpha gene thyroid hormone response element abolished the response of halphaCAT expression to estradiol as well as T3. In contrast to pituitary GH3 cells, estradiol treatment alone had no effect on expression of either halphaCAT or the endogenous alpha gene in JEG-3 choriocarcinoma cells cotransfected with a human thyroid hormone receptor expression vector, but estradiol antagonized suppression of both endogenous and transfected alpha promoter activity by T3. Gel mobility shift assays demonstrated specific binding of in vitro synthesized human estrogen receptor (ER) to the alpha gene thyroid hormone response element. These findings suggest that estradiol modulates expression of the human alpha subunit gene in pituitary and choriocarcinoma cells by direct binding of ER to the alpha gene promoter, and that interaction of ER with the alpha gene negative TRE accounts for the antagonistic effects of estradiol and T3.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	University of Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ausubel F.M., 1987, CURRENT PROTOCOLS MO, P241; BALFOUR NJ, 1990, J MOL ENDOCRINOL, V4, P187, DOI 10.1677/jme.0.0040187; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FRANKLYN JA, 1987, ENDOCRINOLOGY, V120, P2279, DOI 10.1210/endo-120-6-2279; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; GURR JA, 1983, J BIOL CHEM, V258, P208; GURR JA, 1989, DNA-J MOLEC CELL BIO, V8, P473, DOI 10.1089/dna.1.1989.8.473; GURR JA, 1985, DNA-J MOLEC CELL BIO, V4, P301, DOI 10.1089/dna.1985.4.301; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; KAMEL F, 1987, ENDOCRINOLOGY, V120, P1651, DOI 10.1210/endo-120-4-1651; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERI RA, 1991, MOL ENDOCRINOL, V5, P725, DOI 10.1210/mend-5-5-725; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KNOBIL E, 1981, RECENT PROG HORM RES, V36, P703; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; PHILLIPS CL, 1988, MOL ENDOCRINOL, V2, P641, DOI 10.1210/mend-2-7-641; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAADE G, 1989, ENDOCRINOLOGY, V124, P1744, DOI 10.1210/endo-124-4-1744; SAMBROOK J, 1982, MOL CLONING LABORATO, P21; SAMUELS HH, 1979, BIOCHEMISTRY-US, V18, P715, DOI 10.1021/bi00571a025; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAPURA VD, 1990, ENDOCRINOLOGY, V127, P1352, DOI 10.1210/endo-127-3-1352; SHUPNIK MA, 1985, ENDOCRINOLOGY, V117, P1940, DOI 10.1210/endo-117-5-1940; SHUPNIK MA, 1983, J BIOL CHEM, V258, P5120; SHUPNIK MA, 1989, ENDOCR REV, V10, P459, DOI 10.1210/edrv-10-4-459; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; SHUPNIK MA, 1989, MOL ENDOCRINOL, V3, P474, DOI 10.1210/mend-3-3-474; SHUPNIK MA, 1987, ENDOCRINOLOGY, V121, P619, DOI 10.1210/endo-121-2-619; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636	50	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21984	21989						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691820				2022-12-27	WOS:A1993MC80900082
J	RAMOTAR, D; KIM, C; LILLIS, R; DEMPLE, B				RAMOTAR, D; KIM, C; LILLIS, R; DEMPLE, B			INTRACELLULAR-LOCALIZATION OF THE APN1 DNA-REPAIR ENZYME OF SACCHAROMYCES-CEREVISIAE - NUCLEAR TRANSPORT SIGNALS AND BIOLOGICAL ROLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-IV; APURINIC APYRIMIDINIC ENDONUCLEASE; ESCHERICHIA-COLI; IONIZING-RADIATION; YEAST; DAMAGE; PROTEINS; IDENTIFICATION; MUTAGENESIS; DEOXYRIBOSE	The Apn1 DNA repair enzyme of Saccharomyces cerevisiae acts on abasic sites and oxygen radical damages. Apn1 is homologous to the repair endonuclease IV of Escherichia coli, but the yeast protein is approximately 80 residues longer at the C terminus. The Apn1 C terminus is rich in basic amino acids and includes two lysine/arginine clusters related to the nuclear transport signals of some other proteins. We show here by indirect immunofluorescence that Apn1 is localized to the yeast nucleus. Mutant Apn1 proteins were engineered with progressive deletions inward from the C terminus. Elimination of just the last 12 residues from Apn1 (to yield Apn355) did not alter the stability in yeast cells or the in vitro activity of the enzyme. Greater truncation of Apn1 produced proteins of apparently lower (Apn334) or much lower (Apn315 and Apn293) in vivo stability. Both Apn355 and Apn334 failed to concentrate in the yeast nucleus and remained in the cytoplasm. These delocalized derivatives also failed to restore wild-type resistance to oxidative or alkylating agents in a DELTAapn1 strain. Apn355 and Apn334 complemented repair-deficient E. coli as effectively, as did wild-type Apn1. Resistance to these DNA-damaging agents in yeast was restored if Apn355 and Apn334 (but not Apn315 or Apn293) were overproduced approximately 20-fold, which suggests either weak active transport or passive diffusion of these derivatives into the nucleus. Replacement of the C-terminal 12 residues of Apn1 with the nuclear targeting sequence of SV40 T-antigen did not restore effective function or nuclear localization in yeast.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOLEC & CELLULAR TOXICOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health					NIEHS NIH HHS [ES03926] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES003926] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1991, OXIDATIVE STRESS OXI, P119; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GILONI L, 1981, J BIOL CHEM, V256, P8608; HENNER WD, 1983, J BIOL CHEM, V258, P5198; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RABOW LE, 1990, J AM CHEM SOC, V112, P3196, DOI 10.1021/ja00164a049; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RAMOTAR D, 1991, MOL MICROBIOL, V5, P149, DOI 10.1111/j.1365-2958.1991.tb01835.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1983, METHODS YEAST GENETI; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411	35	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20533	20539						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690756				2022-12-27	WOS:A1993LY01900088
J	AGGELER, R; HAUGHTON, MA; CAPALDI, RA				AGGELER, R; HAUGHTON, MA; CAPALDI, RA			DISULFIDE BOND FORMATION BETWEEN THE COOH-TERMINAL DOMAIN OF THE BETA-SUBUNITS AND THE GAMMA-SUBUNITS AND EPSILON-SUBUNITS OF THE ESCHERICHIA-COLI F1-ATPASE - STRUCTURAL IMPLICATIONS AND FUNCTIONAL CONSEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; ATP SYNTHASE; CRYOELECTRON MICROSCOPY; CATALYTIC SITES; CROSS-LINKING; F1-ATPASE; BINDING; HYDROLYSIS; AUROVERTIN; NUCLEOTIDE	A set of mutants of the Escherichia coli F1F0-type ATPase has been generated by site-directed mutagenesis as follows: beta E381C, beta S383C, beta E381C/epsilon S108C, and beta S383C/epsilon S108C. Treatment of ECF(1) isolated from any of these mutants with CuCl2 induces disulfide bond formation, For the single mutants, beta E381C and beta S383C, a disulfide bond is formed in essentially 100% yield between a beta subunit and the gamma subunit, probably at Cys(87) based on the recent structure determination of F-1 (Abrahams, J, P,, Leslie, A, G, W,, Lutter, R,, and Walker, J, E, (1994) Nature 370, 621-628). In the double mutants, two disulfide bonds are formed, again in essentially full yield, one between beta and gamma, the other between a beta and the epsilon subunit via Cys(108), The same two cross-links are produced with CuCl2 treatment of ECF(1)F(0) isolated from either of the double mutants, These results show that the parts of gamma around residue 87 (a short alpha-helix) and the epsilon subunit interact with different beta subunits. The yield of covalent linkage of beta to gamma is nucleotide dependent and highest in ATP and much lower with ADP in catalytic sites, The yield of covalent linkage of beta to epsilon is also nucleotide dependent but in this case is highest in ADP and much lower in ATP, Disulfide bond formation between either beta and gamma, or beta and epsilon inhibits the ATPase activity of the enzyme in proportion to the yield of the cross-linked product, Chemical modification of the Cys at either position 381 or 383 of the beta subunit inhibits ATPase activity in a manner that appears to be dependent on the size of the modifying reagent, These results are as expected if movements of the catalytic site containing beta subunits relative to the gamma and epsilon subunits are an essential part of the cooperativity of the enzyme.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon			Haughton, Margaret/F-8033-2010		NHLBI NIH HHS [HL 24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; Battey, 1986, BASIC METHODS MOL BI; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BRUNNER J, 1978, J BIOL CHEM, V253, P7538; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; LOTSCHER HR, 1984, BIOCHEM BIOPH RES CO, V121, P331; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; WISE JG, 1981, J BIOL CHEM, V256, P383	36	124	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9185	9191		10.1074/jbc.270.16.9185	http://dx.doi.org/10.1074/jbc.270.16.9185			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721834	hybrid			2022-12-27	WOS:A1995QU08900022
J	BRUSS, M; HAMMERMANN, R; BRIMIJOIN, S; BONISCH, H				BRUSS, M; HAMMERMANN, R; BRIMIJOIN, S; BONISCH, H			ANTIPEPTIDE ANTIBODIES CONFIRM THE TOPOLOGY OF THE HUMAN NOREPINEPHRINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; BRAIN GABA TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTERS; MAMMALIAN-CELLS; EXPRESSION; CLONING; NORADRENALINE	We have raised polyclonal antibodies (N6-28, L211-226, L371-384, and C590-607) against peptides corresponding to hydrophilic sequences of the human norepinephrine transporter (hNET). The antisera immuno precipitated the [S-35]Met-labeled hNET. Antiserum L211-226, directed against a sequence of the putative second (large) extracellular loop of hNET, also immunoprecipitated the human dopamine transporter. Antisera N6-28 and C590-607, raised against a hNET peptide region of the N and the C termini, respectively, recognized a 58-kDa protein from transfected COS-7 cells expressing the hNET. This 58-kDa species represents a functional, glycosylated form of the hNET and not a degradation product, Tunicamycin treatment of transfected COS-7 cells as well as peptide-N-glycosidase F digestion of the transporter converted the 58-kDa species to a 50-kDa form, indicating that the latter represents the hNET core protein. In indirect immunofluorescence studies, our antisera confirmed the originally proposed topology of hNET, Antisera N6-28 and C590-607 detected hNET only in permeabilized cells, In contrast, antisera L211-226 and L371-384 directed against peptide sequences of the second and fourth putative extracellular loop displayed fluorescence signals with the intact cells.	UNIV BONN, INST PHARMAKOL & TOXIKOL, D-53113 BONN, GERMANY; MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	University of Bonn; Mayo Clinic								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BONISCH H, 1994, ANN NY ACAD SCI, V733, P193, DOI 10.1111/j.1749-6632.1994.tb17269.x; BONISCH H, 1990, J NEUR TR S, P413; BONISCH H, 1991, ADV BIOSCI, V82, P139; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; FRIEDRICH U, 1986, N-S ARCH PHARMACOL, V333, P246, DOI 10.1007/BF00512937; GIROS B, 1992, MOL PHARMACOL, V42, P383; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HOWARD BD, 1990, J NEUROSCI RES, V26, P149, DOI 10.1002/jnr.490260204; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; LAEMMLI UK, 1970, NATURE, V4, P680, DOI DOI 10.1038/227680A0; LEW R, 1992, BRAIN RES, V584, P266, DOI 10.1016/0006-8993(92)90905-O; LINGEN B, 1994, FEBS LETT, V342, P235, DOI 10.1016/0014-5793(94)80508-3; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PATEL A, 1993, J NEUROCHEM, V61, P496; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; SALLEE FR, 1989, FEBS LETT, V256, P219, DOI 10.1016/0014-5793(89)81752-1; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WARRALL M, 1994, BIOCHEM J, V297, P425; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHU JH, 1992, NEUROCHEM INT, V21, P521, DOI 10.1016/0197-0186(92)90083-4	28	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9197	9201						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721836				2022-12-27	WOS:A1995QU08900024
J	LEE, HC; AARHUS, R; GRAEFF, RM				LEE, HC; AARHUS, R; GRAEFF, RM			SENSITIZATION OF CALCIUM-INDUCED CALCIUM-RELEASE BY CYCLIC ADP-RIBOSE AND CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; AMINO-ACID-SEQUENCE; INOSITOL TRISPHOSPHATE; CA2+ RELEASE; MICROSOMES; METABOLITE; NAD+	Cyclic ADP-ribose (cADPR) is emerging as an endogenous regulator of Ca2+-induced Ca2+ release (CICR), and we have recently demonstrated that its action is mediated by calmodulin (CaM) (Lee, H. C,, Aarhus, R,, Graeff, R., Gurnack, M. E,, and Walseth, T. F. (1994) Nature 370, 307-309). In this study we show by immunoblot analyses that the protein factor in sea urchin eggs responsible for conferring cADPR sensitivity to egg microsomes was CaM. This was further supported by the fact that bovine CaM was equally effective as the egg factor. In contrast, plant CaM was only partially active even at 10-20-fold higher concentrations. This exquisite specificity was also shown by binding studies using I-125-labeled bovine CaM. The effectiveness of various CaMs (bovine > spinach > wheat germ) in competing for the binding sites was identical to their potency in conferring cADPR sensitivity to the microsomes. A comparison between bovine and wheat germ CaM in competing for the sites suggests only 10-14% of the total binding was crucial for the activity, Depending on the CaM concentration, the sensitivity of the microsomes to cADPR could be changed by several orders of magnitude. The requirement for CaM could be alleviated by raising the divalent cation concentration with Sr2+. Results showed that CaM, cADPR, and caffeine all act synergistically to increase the divalent cation sensitivity of the CICR mechanism, The combined action of any of the three agonists was sufficient to sensitize the mechanism so much that even the nanomolar concentration of ambient Ca2+ was enough to activate the release. Unlike the CICR mechanism, the microsomal inositol 1,4,5-trisphosphate-sensitive Ca2+ release showed no dependence on CaM. Using an antagonist of CaM, W7, it was demonstrated that the cADPR(-) but not the inositol 1,4,5-trisphosphate-dependent release mechanism could be blocked in live sea urchin eggs, These results indicate cADPR can function as a physiological modulator of CICR and, together with CaM, can alter the sensitivity of the release mechanism to divalent cation by several orders of magnitude.			LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,LYON LAB 6182,MINNEAPOLIS,MN 55455, USA.		Graeff, Richard Milton/B-3425-2011; Lee, Hon Cheung/C-4329-2009		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032040, R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484, HD32040] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HARDY DO, 1988, J MOL BIOL, V199, P223, DOI 10.1016/0022-2836(88)90392-0; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; LUKAS TJ, 1984, PLANT PHYSIOL, V75, P788, DOI 10.1104/pp.75.3.788; PRESTON RR, 1991, ANNU REV PHYSIOL, V53, P309, DOI 10.1146/annurev.ph.53.030191.001521; TODA H, 1985, J BIOCHEM-TOKYO, V98, P833, DOI 10.1093/oxfordjournals.jbchem.a135342; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017	23	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9060	9066		10.1074/jbc.270.16.9060	http://dx.doi.org/10.1074/jbc.270.16.9060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721819				2022-12-27	WOS:A1995QU08900007
J	ALBLAS, J; VANETTEN, I; KHANUM, A; MOOLENAAR, WH				ALBLAS, J; VANETTEN, I; KHANUM, A; MOOLENAAR, WH			C-TERMINAL TRUNCATION OF THE NEUROKININ-2 RECEPTOR CAUSES ENHANCED AND SUSTAINED AGONIST-INDUCED SIGNALING - ROLE OF RECEPTOR PHOSPHORYLATION IN SIGNAL ATTENUATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; HAMSTER OVARY CELLS; TACHYKININ RECEPTORS; A RECEPTOR; DESENSITIZATION; EXPRESSION; CLONING; KINASE; CDNA; LOCALIZATION	The G protein-linked receptor for neurokinin A (NKA) couples to stimulation of phospholipase C and, in some cells, adenylyl cyclase. We have examined the function of the C-terminal cytoplasmic domain in receptor signaling and desensitization. We constructed C-terminal deletion mutants of the human NK-2 receptor (epitope tagged) to remove potential Ser/Thr phosphorylation sites, and expressed them in both mammalian and insect cells, When activated, truncated receptors mediate stronger and more prolonged phosphoinositide hydrolysis than wild-type receptor; however, the amplitude and kinetics of the NKA-induced rise in cytosolic Ca2+ remain unaltered, Protein kinase C (PKC)-activating phorbol ester abolishes wild-type receptor signaling but not mutant receptor signaling. Mutant receptors also mediate enhanced and prolonged cAMP generation, at least in part via PKC activation, When expressed in COS cells or Sf9 insect cells, the wild-type receptor is phosphorylated; receptor phosphorylation increases after addition of either NKA or phorbol ester, In contrast, mutant receptors are not phosphorylated by either treatment. Our results suggest that C-terminal Ser/Thr phosphorylation sites in the NK-2 receptor have a critical role in both homologous and heterologous desensitization, Removal of these phosphorylation sites results in a receptor that mediates sustained activation of signaling pathways and is insensitive to inhibition by PKC.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Alblas, Jacqueline/0000-0002-2996-9697				AHARONY D, 1993, MOL PHARMACOL, V44, P356; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CYR CR, 1993, J BIOL CHEM, V268, P26071; DEBERNARDI MA, 1992, P NATL ACAD SCI USA, V88, P9257; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EISTETTER HE, 1993, J CELL BIOCHEM, V522, P84; EISTETTER HR, 1991, CELL REGUL, V2, P767, DOI 10.1091/mbc.2.10.767; GERARD NP, 1990, J BIOL CHEM, V265, P20455; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JALINK K, 1990, J BIOL CHEM, V265, P12232; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRIS RM, 1991, CELL GROWTH DIFFER, V2, P15; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; MANTYH PW, 1989, J NEUROSCI, V9, P258; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SAVARESE TM, 1992, BIOCHEM J, V283, P1; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	34	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8944	8951		10.1074/jbc.270.15.8944	http://dx.doi.org/10.1074/jbc.270.15.8944			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721803	hybrid			2022-12-27	WOS:A1995QT44800082
J	MALDONADO, AM; PORTILLO, F				MALDONADO, AM; PORTILLO, F			GENETIC-ANALYSIS OF THE FLUORESCEIN ISOTHIOCYANATE BINDING-SITE OF THE YEAST PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; ACTIVE-SITE; LABELED PEPTIDE; DNA; PURIFICATION; DOMAIN; GROWTH	The highly conserved motif of Saccharomyces cerevisiae H+-ATPase (474)KGAP has been proposed to participate in the formation of the phosphorylated intermediate during the catalytic cycle (Portillo, F., and Serrano, R. (1988) EMBO J. 7, 1793-1798), In addition, Lys-474 is the FITC binding site of the yeast enzyme (Portillo, F. and Serrano, R. (1989) Eur. J. Biochem. 186, 501-507). We have performed an intragenic suppressor analysis of the K474R mutation to identify the interacting regions involved in these functions. Random in vitro mutagenesis of the K474R allele resulted in seven suppressor (second-site) mutations. One mutation (V396I), located 18 residues away from the Asp-378 residue, which is phosphorylated during catalysis, is allele-specific. This provides genetic evidence of a direct interaction between the KGAP motif and the phosphorylation domain during the catalytic cycle. Three mutations (V484I, V484I/E485K, and E485K/E486K) are located near Lys-474 and may compense the structural alteration introduced by the K474R mutation. Two substitutions at the end of the predicted transmembrane stretch 2 (A165V and V169I/D170N) and another in the predicted ATP binding domain (P536L) may act as allele-nonspecific suppressors, as they are also able to suppress a mutation at the enzyme's carboxyl terminus.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV AUTONOMA MADRID, FAC MED, DEPT BIOQUIM, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid			Mary, Ana/AAA-2822-2019	Mary, Ana/0000-0002-9357-012X; Portillo Perez, Francisco/0000-0003-4922-346X				BLANPAIN JP, 1992, J BIOL CHEM, V267, P3735; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; ERASO P, 1994, J BIOL CHEM, V269, P10393; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; Freeman E. R., 1971, Computer designer's conference and exhibition (abstracts); GABER RF, 1992, INT REV CYTOL, V137A, P299; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HARRIS S, 1993, GENETICS, V135, P5; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOSEPHSON L, 1977, BIOCHEMISTRY-US, V16, P4572, DOI 10.1021/bi00640a006; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MONK BC, 1991, J BIOL CHEM, V266, P18097; NA SQ, 1993, J BIOL CHEM, V268, P11792; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PICK U, 1982, J BIOL CHEM, V257, P6120; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1986, FEBS LETT, V208, P143, DOI 10.1016/0014-5793(86)81549-6; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SERRANO R, 1985, PLASMA MEMBRANE ATPA; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHORTLE D, 1985, GENETICS, V110, P539; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; THOMAS W, 1991, GENETICS, V128, P703; VARA F, 1983, J BIOL CHEM, V258, P5334; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; [No title captured]	48	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8655	8659		10.1074/jbc.270.15.8655	http://dx.doi.org/10.1074/jbc.270.15.8655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721767	hybrid			2022-12-27	WOS:A1995QT44800045
J	SOMERSALO, K; CARPEN, O; SAKSELA, E; GAHMBERG, CG; NORTAMO, P; TIMONEN, T				SOMERSALO, K; CARPEN, O; SAKSELA, E; GAHMBERG, CG; NORTAMO, P; TIMONEN, T			ACTIVATION OF NATURAL-KILLER-CELL MIGRATION BY LEUKOCYTE INTEGRIN-BINDING PEPTIDE FROM INTRACELLULAR ADHESION MOLECULE-2 (ICAM-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; LARGE GRANULAR LYMPHOCYTES; CD4+ T-CELLS; INTERCELLULAR-ADHESION; ENDOTHELIAL-CELL; MONOCLONAL-ANTIBODY; HUMAN-NEUTROPHILS; PHOSPHOLIPASE C-GAMMA-1; COSTIMULATORY SIGNAL; ALLOGRAFT-REJECTION	Intracellular adhesion molecule-2 (ICAM-2), one of the ligands of CD11a/CD18 (LFA-1), is mainly expressed on endothelial and hematopoietic cells. The biological significance of ICAM-2 has remained unclear. Previous findings have shown that a peptide from ICAM-2, spanning residues 21-42 from the first immunoglobulin domain, enhances natural killer (NK) cell cytotoxicity and induces T cell aggregation, We have now studied the effect of the same ICAM-2 peptide on NK cell migration in the Boyden chamber assay. The peptide significantly increased NK cell migration up to 215 +/- 21%, as compared to migration of control cells (100%), and the induction was inhibited by anti-CD11a monoclonal antibodies. The ICAM-2 peptide also induced polymerization of F-actin at the leading edge of migratory Nh cells. Crosslinking of CD11a/CD18 receptors with anti-CD11a or anti-CD18 monoclonal antibodies and secondary antibodies resulted in receptor recycling, increased migration, and actin polymerization, but led to slight inhibition of cytotoxicity. The ICAM-2 peptide did not induce such a receptor recycling. Phosphotyrosine immunoblotting experiments showed that the ICAM-2 peptide increased the phosphorylation of 150- and 35-kDa proteins. During cross-linking with antibodies, only the 150-kDa protein showed increased phosphorylation. The results show that depending on the type of CD11a/CD18 receptor ligation different kinds of signals are transduced in NK cells. These signals may either trigger only locomotion, or both locomotion and cytotoxicity. Based on these findings, a major function for ICAM-2 on endothelium may be triggering of migration of adhering leukocytes.	HELSINKI UNIV, DEPT BIOCHEM, SF-00014 HELSINKI, FINLAND	Finland National Institute for Health & Welfare; University of Helsinki	SOMERSALO, K (corresponding author), HELSINKI UNIV, DEPT PATHOL, POB 21, HAARTMANINKATU 3, SF-00014 HELSINKI, FINLAND.		Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296				AKELLA R, 1992, EUR J IMMUNOL, V22, P1069, DOI 10.1002/eji.1830220429; ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; ARFORS KE, 1987, BLOOD, V69, P338; AXELSSON LG, 1981, J IMMUNOL METHODS, V46, P251, DOI 10.1016/0022-1759(81)90141-1; BIANCHI G, 1993, J IMMUNOL, V151, P5135; CARPEN O, 1991, J CELL BIOL, V115, P861, DOI 10.1083/jcb.115.3.861; CARPEN O, 1982, J IMMUNOL, V128, P2691; CARPEN O, 1983, J IMMUNOL, V131, P2695; CARTER SB, 1965, NATURE, V208, P1183, DOI 10.1038/2081183a0; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAMLE NK, 1992, J IMMUNOL, V148, P665; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FISCHER A, 1985, J CLIN INVEST, V76, P2385, DOI 10.1172/JCI112251; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GORSKI A, 1994, IMMUNOL TODAY, V15, P251, DOI 10.1016/0167-5699(94)90002-7; HAKKERT BC, 1990, EUR J IMMUNOL, V20, P2775, DOI 10.1002/eji.1830201236; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; JAASKELAINEN J, 1992, J IMMUNOL, V149, P260; JACKSON AM, 1992, IMMUNOLOGY, V76, P286; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KUHLMAN P, 1991, J IMMUNOL, V137, P2395; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPETER ER, 1992, DIABETES, V41, P1668, DOI 10.2337/diabetes.41.12.1668; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LI R, 1993, J BIOL CHEM, V268, P17513; LI R, 1993, J BIOL CHEM, V268, P21474; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARBOE CC, 1983, CLIN IMMUNOL IMMUNOP, V27, P141, DOI 10.1016/0090-1229(83)90063-6; MCVICAR DW, 1994, EUR J IMMUNOL, V24, P165, DOI 10.1002/eji.1830240125; MELERO I, 1993, EUR J IMMUNOL, V23, P1859, DOI 10.1002/eji.1830230819; MIRON S, 1992, CELL IMMUNOL, V144, P182, DOI 10.1016/0008-8749(92)90235-H; NEMLANDER A, 1983, EUR J IMMUNOL, V13, P348, DOI 10.1002/eji.1830130415; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; NORTAMO P, 1991, J IMMUNOL, V146, P2530; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; PARDI R, 1989, J IMMUNOL, V143, P3157; PEREZ HD, 1986, J IMMUNOL, V136, P1803; PRIETO J, 1988, IMMUNOLOGY, V63, P631; RENKONEN R, 1992, AM J PATHOL, V140, P763; ROBERTSON MJ, 1990, BLOOD, V76, P2421; ROEP BO, 1994, LANCET, V343, P1590, DOI 10.1016/S0140-6736(94)93055-4; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; SHIMIZU Y, 1993, J IMMUNOL, V151, P4106; SOMERSALO K, 1992, J IMMUNOL, V149, P590; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAHLS AK, 1989, SCAND J IMMUNOL, V29, P211, DOI 10.1111/j.1365-3083.1989.tb01118.x; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAFFS RE, 1991, J IMMUNOL, V147, P722; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; TIMONEN T, 1990, INT J CANCER, V46, P1035, DOI 10.1002/ijc.2910460615; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7; TIMONEN T, 1988, J IMMUNOL, V141, P1041; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VANSEVENTER GA, 1992, J IMMUNOL, V149, P3872; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VANSEVENTER GA, 1991, EUR J IMMUNOL, V21, P1711, DOI 10.1002/eji.1830210719	73	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8629	8636		10.1074/jbc.270.15.8629	http://dx.doi.org/10.1074/jbc.270.15.8629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721764	hybrid			2022-12-27	WOS:A1995QT44800041
J	TIAN, WD; WELLS, AV; CHAMPION, PM; DIPRIMO, C; GERBER, N; SLIGAR, SG				TIAN, WD; WELLS, AV; CHAMPION, PM; DIPRIMO, C; GERBER, N; SLIGAR, SG			MEASUREMENTS OF CO GEMINATE RECOMBINATION IN CYTOCHROMES P450 AND P420	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; RESONANCE RAMAN INVESTIGATIONS; CARBON-MONOXIDE BINDING; RAT-LIVER MICROSOMES; RELAXATION DYNAMICS; CRYSTAL-STRUCTURE; DISTAL HISTIDINE; MYOGLOBIN; SUBSTRATE; COMPLEX	The kinetics of CO geminate recombination in cytochrome P450(cam) are studied at room temperature subsequent to laser photolysis. The geminate rebinding kinetics of P450 are strongly affected by the presence of the camphor substrate, We observe a similar to 2% geminate yield for substrate-bound P450 and a 90% geminate yield when the substrate is absent. The drastic difference in the geminate kinetics suggests that the presence of camphor significantly alters the CO rebinding and escape rates by modifying the heme pocket environment. Two geminate phases and two bimolecular rebinding phases in the substrate free protein were observed, which could arise from slowly interconverting protein conformations. When the temperature or the viscosity of the solution is changed, the fast geminate rate remains the same, whereas the slow geminate rate and the two bimolecular rates change significantly. The geminate rebinding yield of substrate-free P420 is smaller than that of substrate free P450, but its geminate rebinding rate is faster, This demonstrates that in the absence of substrate, CO escapes from the pocket of P420 much more rapidly than from P450 and suggests that the distal pocket environment is altered in the P420 form.	UNIV ILLINOIS, DEPT BIOCHEM CHEM & BIOPHYS, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	TIAN, WD (corresponding author), NORTHEASTERN UNIV, DEPT PHYS, BOSTON, MA 02115 USA.		Di primo, Carmelo/M-6984-2018	Di primo, Carmelo/0000-0002-0509-8399	NIADDK NIH HHS [AM35090] Funding Source: Medline; NIGMS NIH HHS [GM31756] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756, R01GM031756] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANGCHAROENPAURPONG O, 1987, J CHEM PHYS, V87, P4273, DOI 10.1063/1.452885; CHAMPION PM, 1988, BIOL APPLICATIONS RA, V3, P249; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DEBEY P, 1973, FEBS LETT, V35, P86, DOI 10.1016/0014-5793(73)80583-6; DEBRUNNER PG, 1978, MET IONS BIOL SYST, V7, P241; DIPRIMO C, 1990, J BIOL CHEM, V265, P5361; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; GIBSON QH, 1989, J BIOL CHEM, V264, P20155; GRAY RD, 1982, J BIOL CHEM, V257, P1086; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HOA GHB, 1989, BIOCHEMISTRY-US, V28, P651; JUNG C, 1992, BIOCHEMISTRY-US, V31, P12855, DOI 10.1021/bi00166a021; KOLEY AP, 1994, BIOCHEMISTRY-US, V33, P2484, DOI 10.1021/bi00175a017; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; Martinis S. A., 1990, THESIS U ILLINOIS UR; MCKINNIE RE, 1981, J BIOL CHEM, V256, P8928; MIURA Y, 1991, BIOCHEMISTRY-US, V30, P3395, DOI 10.1021/bi00228a006; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OERTLE M, 1985, P NATL ACAD SCI USA, V82, P4900, DOI 10.1073/pnas.82.15.4900; OKEEFE DH, 1978, BIOCHEMISTRY-US, V17, P5845, DOI 10.1021/bi00619a036; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V151, P427, DOI 10.1016/0003-9861(72)90518-8; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; QUILLIN M L, 1992, Biophysical Journal, V61, pA466; SHIMADA H, 1979, FEBS LETT, V98, P290, DOI 10.1016/0014-5793(79)80202-1; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P4659, DOI 10.1021/bi00233a004; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P8673, DOI 10.1021/bi00195a007; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; UNO T, 1985, J BIOL CHEM, V260, P2023; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; WLETH VL, 1940, SOLUBILITIES INORGAN, V1, P217	36	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8673	8679		10.1074/jbc.270.15.8673	http://dx.doi.org/10.1074/jbc.270.15.8673			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721770	hybrid			2022-12-27	WOS:A1995QT44800048
J	VOURETCRAVIARI, V; GRALL, D; CHAMBARD, JC; RASMUSSEN, UB; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E				VOURETCRAVIARI, V; GRALL, D; CHAMBARD, JC; RASMUSSEN, UB; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E			POSTTRANSLATIONAL AND ACTIVATION-DEPENDENT MODIFICATIONS OF THE G-PROTEIN-COUPLED THROMBIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET ACTIVATION; MOLECULAR-CLONING; ALPHA-THROMBIN; GROWTH-FACTOR; DOMAIN; EXPRESSION; ANTIBODIES; MECHANISMS; PEPTIDES	The purpose of the present study was to analyze the post-translational and activation-dependent modifications of the G protein coupled thrombin receptor. A human receptor cDNA was engineered to encode an epitope tag derived from the vesicular stomatitis virus glycoprotein at the COOH terminus of the receptor and expressed in human embryonic kidney 293 cells. We show here that the mature receptor is a glycosylated protein with an apparent molecular mass ranging from 68 to 80 kDa by SDS-polyacrylamide gel electrophoresis. Removal of asparagine-linked oligosaccharides with N-glycosidase F leads to the appearance of a 36-40-kDa receptor species. The current model for receptor activation by thrombin involves specific hydrolysis of the arginine-4l/serine-42 (Arg-41/Ser-42) peptide bond. Cleavage of the receptor by thrombin was demonstrated directly by Western analyses performed on membranes and glycoprotein-enriched lysates from transfected cells. Whereas thrombin treatment of cells results in increased mobility of the receptor in SDS-polyacrylamide gel electrophoresis, we found that their treatment with the thrombin receptor agonist peptide leads to a decrease in thrombin receptor mobility due, in part, to phosphorylation. The serine proteases trypsin and plasmin also cleave and activate the receptor similar to thrombin, whereas chymotrypsin cleaves the receptor at a site distal to Arg-41, thus rendering it unresponsive to thrombin while still responsive to thrombin receptor agonist peptide.	CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 2,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Transgene SA			Van Obberghen-Schilling, Ellen/Q-4372-2019; Van Obberghen-Schilling, Ellen/O-1581-2016	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; CHAMBARD, Jean Claude/0000-0003-4722-2308				BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHEN J, 1994, J BIOL CHEM, V269, P16041; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; LANDOLTMARTICOR.C, 1994, BIOCHEM J, V302, P253; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MCGOWAN EB, 1986, J BIOL CHEM, V261, P739; MORI S, 1992, J BIOL CHEM, V267, P6429; Rasmussen JR., 1992, CURR OPIN STRUC BIOL, V2, P682; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; TAM SW, 1980, J BIOL CHEM, V255, P6626; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	28	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8367	8372		10.1074/jbc.270.14.8367	http://dx.doi.org/10.1074/jbc.270.14.8367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713946	hybrid			2022-12-27	WOS:A1995QR52600085
J	BROWN, JA; BHARATHI, A; GHOSH, A; WHALEN, W; FITZGERALD, E; DHAR, R				BROWN, JA; BHARATHI, A; GHOSH, A; WHALEN, W; FITZGERALD, E; DHAR, R			A MUTATION IN THE SCHIZOSACCHAROMYCES-POMBE RAE1 GENE CAUSES DEFECTS IN POLY(A)(+) RNA EXPORT AND IN THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; MICROTUBULE FUNCTION; BETA-SUBUNITS; PROTEIN; TRANSPORT; MUTANT; INITIATION	A collection of fission yeast Schizosaccharomyces pombe conditional mutants was screened for defective nucleocytoplasmic transport of poly(A)(+) RNA by fluorescence in situ hybridization, We identified a temperature-sensitive mutant that accumulated poly(A)(+) RNA in the nucleus and have named it rae1-1, for ribonucleic acid export. All rae1-1 cells exhibit the defect in poly(A)(+) RNA export within 30 min following a shift to the nonpermissive temperature, In addition, in the rae1-1 mutant, actin and tubulin become disorganized, and cells undergo an irreversible cycle arrest, Results from experiments in which rae1-1 cells were arrested in various phases of the cell division cycle and then shifted to nonpermissive temperature suggest that cells are particularly vulnerable to loss of rae1 function during G(2)/M. However, the inability to export RNA from the nucleus to the cytoplasm was not limited to a particular phase of the cell division cycle, The rae1 gene was isolated by complementation and encodes a predicted protein of 352 amino acids with four beta-transducin/WD40 repeats.	NCI, MOLEC VIROL LAB, BETHESDA, MD 20892 USA; NCI, SURG BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Alfa C, 1993, EXPT FISSION YEAST L; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BREVIARIO D, 1988, EMBO J, V7, P1805, DOI 10.1002/j.1460-2075.1988.tb03012.x; BROWN AJP, 1989, YEAST, V5, P239, DOI 10.1002/yea.320050405; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDSTEIN DJ, 1992, VIROLOGY, V190, P889, DOI 10.1016/0042-6822(92)90932-F; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUTCHISON HT, 1969, J BACTERIOL, V99, P807, DOI 10.1128/JB.99.3.807-814.1969; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MERTINS P, 1987, NUCLEIC ACIDS RES, V15, P7369, DOI 10.1093/nar/15.18.7369; MOERSCHELL RP, 1991, METHOD ENZYMOL, V194, P362; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; Robinow C, 1989, MOL BIOL FISSION YEA, P273; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SETHI N, EMBO J, V12, P2697; SHERMAN F, 1986, LABORATORY COURSE MA; SHIOKAWA K, 1974, P NATL ACAD SCI USA, V71, P2658, DOI 10.1073/pnas.71.7.2658; STEARNS T, 1990, GENETICS, V124, P251; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WINSTON F, 1983, METHOD ENZYMOL, V101, P211	42	135	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7411	7419		10.1074/jbc.270.13.7411	http://dx.doi.org/10.1074/jbc.270.13.7411			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706287	hybrid			2022-12-27	WOS:A1995QQ43100060
J	GILBOA, L; BENLEVY, R; YARDEN, Y; HENIS, YI				GILBOA, L; BENLEVY, R; YARDEN, Y; HENIS, YI			ROLES FOR A CYTOPLASMIC TYROSINE AND TYROSINE KINASE-ACTIVITY IN THE INTERACTIONS OF NEU RECEPTORS WITH COATED PITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FLUORESCENCE PHOTOBLEACHING RECOVERY; LIGAND-INDUCED INTERNALIZATION; LYSOSOMAL ACID-PHOSPHATASE; LOW-DENSITY-LIPOPROTEIN; EGF RECEPTOR; POINT MUTATION; LATERAL MOBILITY; HUMAN-BREAST; ASIALOGLYCOPROTEIN RECEPTOR	The neu proto-oncogene product, p185(neu) (HER2, c-ErbB-2), encodes a cell-surface tyrosine kinase receptor with high oncogenic potential, which correlates with increased tyrosine kinase activity and a rapid receptor internalization rate, To investigate the interactions and signal(s) leading to the endocytosis of Neu receptors, we employed lateral mobility and internalization studies, Fluorescence photobleaching recovery measurements revealed that activation of Neu receptors (induced by mutation or by agonistic antibodies) markedly reduced their mobile fractions, To elucidate the signals involved, other mutants, all carrying a constitutively dimerizing oncogenic mutation, were analyzed, A kinase-negative mutant and a mutant lacking all cytoplasmic tyrosine phosphorylation consensus sequences exhibited high mobile fractions, similar to nonactivated Neu, Retention of a single tyrosine autophosphorylation site (Tyr-1253) out of the five known such sites was sufficient to immobilize a large fraction of the receptor, For all mutants, internalization correlated with receptor immobilization and was blocked by treatments that interfere with coated pit structure, indicating that the immobilization is due to interactions with coated pits, This was supported by the coimmunoprecipitation of alpha-adaptin only with the constitutively activated Neu mutants, We conclude that activated Neu receptors become stably associated with coated pits via plasma membrane adaptor complexes (AP-2), Efficient Neu receptor endocytosis requires activation, a functional kinase domain, and at least one tyrosine autophosphorylation site.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Tel Aviv University; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012	Henis, Yoav/0000-0002-1408-3877	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; BRANDTZAEG P, 1973, SCAND J IMMUNOL, V2, P273, DOI 10.1111/j.1365-3083.1973.tb02037.x; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELSON EL, 1979, J SUPRAMOL STR CELL, V12, P481, DOI 10.1002/jss.400120408; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1983, BIOCHIM BIOPHYS ACTA, V762, P281, DOI 10.1016/0167-4889(83)90082-4; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KOPPEL DE, 1976, BIOPHYS J, V16, P1315, DOI 10.1016/S0006-3495(76)85776-1; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KURKELA R, 1988, J IMMUNOL METHODS, V110, P229, DOI 10.1016/0022-1759(88)90108-1; LIVNEH E, 1986, J CELL BIOL, V103, P327, DOI 10.1083/jcb.103.2.327; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PETERSEN NO, 1986, HDB EXPT IMMUNOLOGY; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROTH MG, 1993, ENDOSOMES LYSOSOMES, P19; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SEGATTO O, 1990, New Biologist, V2, P187; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STANCOVSKI I, 1992, J STEROID BIOCHEM, V43, P95, DOI 10.1016/0960-0760(92)90192-L; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	77	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7061	7067		10.1074/jbc.270.13.7061	http://dx.doi.org/10.1074/jbc.270.13.7061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706244	hybrid			2022-12-27	WOS:A1995QQ43100012
J	BUDDE, RJA				BUDDE, RJA			EVIDENCE FOR KINETICALLY DISTINCT FORMS OF PP60(C-SRC) WITH DIFFERENT K(M) VALUES FOR THEIR PROTEIN SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; PP60C-SRC; PHOSPHORYLATION; SRC; CELLS; PHOSPHOTYROSINE; IDENTIFICATION; PURIFICATION	The biphasic kinetics for phosphorylation of poly(E4Y) by the protein tyrosine kinase pp60c-src were examined. At pH 6.5 substrate inhibition was observed, whereas at pH 8.0 the kinetics were still biphasic, but the enzyme was no longer inhibited. The reaction rate increased in a nonlinear fashion with increasing concentration of substrate. The kinetics were examined from the view that the biphasic kinetics at pH 8.0 were due to two enzymes acting simultaneously on the same substrate. A 55-fold difference in K(m) values (0.029 versus 1.6 mg/ml) was calculated. The low K(m) form of the enzyme (0.043 mg/ml) was physically separated from the mixture of kinetic variants by immunoaffinity chromatography, and phosphorylation by protein kinase A resulted in the formation of an enzyme with an intermediate K(m) (0.3-0. 4 mg/ml). The presence of multiple kinetic forms of this tyrosine kinase has important implications in our efforts to understand the role of pp60c-src in human oncology.			BUDDE, RJA (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEROONCOL, BOX 316, HOUSTON, TX 77030 USA.				NATIONAL CANCER INSTITUTE [U01CA053617, U19CA053617, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA16672, CA53617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BURNELL JN, 1984, ARCH BIOCHEM BIOPHYS, V231, P175, DOI 10.1016/0003-9861(84)90375-8; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CASSIDY R, 1992, LC GC-MAG SEP SCI, V10, P692; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; DIXON M, 1979, ENZYMES, P75; GARCIA R, 1991, ONCOGENE, V6, P1983; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KATO G, 1991, BIOCHEM BIOPH RES CO, V178, P764, DOI 10.1016/0006-291X(91)90174-6; KITAS EA, 1990, BIOCHEM BIOPH RES CO, V170, P635, DOI 10.1016/0006-291X(90)92139-Q; LILLEY ER, 1991, CANCER RES, V51, P3906; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; NIMAN HL, 1990, IMMUNODIAGNOSIS CANC, P189; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSMUNDSEN H, 1975, BIOCHEM BIOPH RES CO, V67, P324, DOI 10.1016/0006-291X(75)90319-8; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; WHITEHOUSEHILLS S, 1990, BIOCHIM BIOPHYS ACTA, V1037, P380, DOI 10.1016/0167-4838(90)90040-M; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; YU G, 1987, J BIOL CHEM, V262, P17543	31	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24868	24872						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693707				2022-12-27	WOS:A1993MG67300054
J	LAMMERS, R; BOSSENMAIER, B; COOL, DE; TONKS, NK; SCHLESSINGER, J; FISCHER, EH; ULLRICH, A				LAMMERS, R; BOSSENMAIER, B; COOL, DE; TONKS, NK; SCHLESSINGER, J; FISCHER, EH; ULLRICH, A			DIFFERENTIAL ACTIVITIES OF PROTEIN-TYROSINE PHOSPHATASES IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR CHARACTERIZATION; ENDOPLASMIC-RETICULUM; INSULIN-RECEPTOR; GENE-TRANSFER; NEU ONCOGENE; CDNA CLONING; EGF RECEPTOR; SH2 DOMAINS; EXPRESSION	We have employed transient co-overexpression of protein tyrosine phosphatases (PTPs) with a panel of receptor tyrosine kinases (RTKs) to investigate molecular parameters that regulate dephosphorylation activity and specificity in intact cells. Our results demonstrate clear differences in susceptibility of various forms of different RTKs to the action of PTP 1B, T-cell phosphatase (TC-PTP), and CD45, which suggests cellular compartmentalization as a major factor defining activity and overall function. TC-M PTP, a nonlocalized cytosolic mutant, is deregulated and is therefore able to efficiently suppress v-erbB- and v-fms-induced cell transformation, which is not observed with the intact TC-PTP or PTP 1B. The transmembrane PTP CD45 displays more selectivity but appears to be already active during transport to the cell surface. Dephosphorylation activity is also dependent on relative RTK/PTP expression levels and can be modulated by the SH2 domain-containing noncatalytic subunit of phosphatidylinositol 3'-kinase, p85. Overexpression of high affinity binding proteins could therefore contribute to RTK-induced cell transformation and cancer.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	Max Planck Society; University of Washington; University of Washington Seattle; Cold Spring Harbor Laboratory; New York University			Bossenmaier, Birgit/AAN-7075-2020		NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWNSHIMER S, 1992, CANCER RES, V52, P478; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENDLY BM, 1990, CANCER RES, V50, P1550; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HERBST R, 1991, J BIOL CHEM, V266, P19908; HUDZIAK RM, 1991, J BIOL CHEM, V266, P24109; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SCHLESSINGER J, 1992, NEURON, V9, P1; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	48	151	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22456	22462						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693671				2022-12-27	WOS:A1993MD34800043
J	SANTINI, F; BEAVEN, MA				SANTINI, F; BEAVEN, MA			TYROSINE PHOSPHORYLATION OF A MITOGEN-ACTIVATED PROTEIN KINASE-LIKE PROTEIN OCCURS AT A LATE STEP IN EXOCYTOSIS - STUDIES WITH TYROSINE PHOSPHATASE INHIBITORS AND VARIOUS SECRETAGOGUES IN RAT RBL-2H3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; MAST-CELLS; GROWTH-FACTOR; SIGNAL TRANSDUCTION; MAP KINASE; PHOSPHOLIPASE C-GAMMA-1; HISTAMINE-RELEASE; 2H3 CELLS; RECEPTOR; SECRETION	Several inhibitors of tyrosine phosphatases, which included vanadate/H2O2, phenylarsine oxide, and diamide, blocked exocytosis in basophilic RBL-2H3 cells that had been transfected with the gene for the muscarinic m1 receptor. Because this block was observed whether the secretagogue acted through receptors (i.e. antigen and the muscarinic agonist, carbachol) or by direct activation of intracellular mechanisms (i.e. A23187, A23187 in combination with phorbol 12-myristate 13-acetate, and thapsigargin), the inhibitors appeared to act at a step distal to the mobilization of Ca2+ and activation of protein kinase C. All secretagogues caused the tyrosine phosphorylation of a 40-kDa protein, whereas the inhibitors caused a hyperphosphorylation of this protein. Therefore, both tyrosine kinase and phosphatase activities appear to regulate this phosphorylation which may, in turn, regulate secretion. The 40-kDa protein was identified as a mitogen-activated protein kinase-like protein on the basis of its reactivity to anti-mitogen-activated protein kinase antibodies. In addition, when cells were stimulated the tyrosine phosphorylated and the immunoreactive protein comigrated as a doublet on one-dimensional and as multiple phosphorylated forms on two-dimensional gel-electrophoretic systems.	NHLBI,CHEM PHARMACOL LAB,RM 8N114,BLDG 10,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ALBER G, 1991, J BIOL CHEM, V266, P22613; ALI H, 1989, BIOCHIM BIOPHYS ACTA, V1010, P88, DOI 10.1016/0167-4889(89)90188-2; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; COLLADOESCOBAR D, 1990, J IMMUNOL, V144, P3449; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EISEMAN E, 1992, NATURE, V355, P78; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HARLOW E, 1988, ATNIBODIES LABORATOR; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JENA BP, 1991, J BIOL CHEM, V266, P1744; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LILLIE THW, 1992, PHILOS T ROY SOC B, V336, P25, DOI 10.1098/rstb.1992.0040; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; METZGER H, 1992, J IMMUNOL, V149, P1477; MONTEIRO HP, 1991, FEBS LETT, V295, P146, DOI 10.1016/0014-5793(91)81405-W; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TATHAM PER, 1989, BIOSCIENCE REP, V9, P99, DOI 10.1007/BF01117516; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WAGNER PD, 1990, J BIOL CHEM, V265, P10352; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMADA K, 1992, J IMMUNOL, V149, P1031; YU KT, 1991, J BIOL CHEM, V266, P22564; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	47	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22716	22722						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693676				2022-12-27	WOS:A1993MD34800078
J	WANG, JL; STUEHR, DJ; IKEDASAITO, M; ROUSSEAU, DL				WANG, JL; STUEHR, DJ; IKEDASAITO, M; ROUSSEAU, DL			HEME COORDINATION AND STRUCTURE OF THE CATALYTIC SITE IN NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LOW-SPIN EQUILIBRIUM; RESONANCE RAMAN; CYTOCHROME-P-450; BRAIN; HEMOPROTEIN; ARGININE; ENZYME; LIGAND; FORMS	Nitric oxide (NO), recently found to play many physiological roles, is generated by the catalysis Of L-arginine and O2 to L-citrulline and NO by nitric oxide synthases (NOSs). Resonance Raman spectra from the heme of resting, reduced, and CO-bound forms of rat brain NOS firmly establish that the enzyme belongs to the P-450 class of enzymes. The electron density marker line (nu4) in the Raman spectrum of ligand-free ferrous NOS has a low frequency (1347 cm-1), indicating a thiolate axial ligand on the heme. The assignment of a thiolate axial ligand is confirmed in the CO-bound form of the enzyme by the frequency of the Fe-C-O bending mode at 562 cm-1. The heme in resting NOS is five-coordinate high spin and thereby differs from the resting state of most substrate-free P-450s, which are predominantly six-coordinate low spin. The frequency of the Fe-CO stretching mode in the CO-bound enzyme at 491 cm-1, identified by isotope substitution, is higher than that in substrate-free P-450s. Thus, in the ferric and the CO-bound forms of the enzyme, the sixth-ligand binding site on the heme is restricted by steric or hydrophobic interactions. In addition, the Fe-CO stretching mode is broad (30 cm-1) and may be resolved into two overlapping lines of equal intensity, indicating that the heme domains can adopt two distinct conformations.	AT&T BELL LABS, MURRAY HILL, NJ 07974 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM & BIOPHYS, CLEVELAND, OH 44106 USA; CLEVELAND CLIN FDN, DEPT IMMUNOL, CLEVELAND, OH 44195 USA	AT&T; Nokia Corporation; Nokia Bell Labs; Case Western Reserve University; Cleveland Clinic Foundation			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008					ANZENBACHER P, 1984, 9TH P INT C RAM SPEC, P474; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; HAN S, 1990, P NATL ACAD SCI USA, V87, P205, DOI 10.1073/pnas.87.1.205; HILDEBRANDT P, 1989, EUR J BIOCHEM, V186, P291, DOI 10.1111/j.1432-1033.1989.tb15208.x; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; JUNG C, 1991, BIOCHIM BIOPHYS ACTA, V1076, P130, DOI 10.1016/0167-4838(91)90229-S; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LANCASTER JR, 1992, AM SCI, V80, P248; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; OZAKI Y, 1978, BIOCHEMISTRY-US, V17, P5826, DOI 10.1021/bi00619a033; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; ROUSSEAU DL, 1984, OPTICAL TECHNIQUES B, P66; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SPIRO TG, 1987, BIOL APPLICATIONS RA, V3, P1; SPIRO TG, 1988, BIOL APPLICATIONS RA, V3; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; TSUBAKI M, 1990, BIOCHEMISTRY-US, V29, P8805, DOI 10.1021/bi00489a043; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Yu N.-T., 1988, RESONANCE RAMAN SPEC, V3, P39	32	101	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22255	22258						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693663				2022-12-27	WOS:A1993MD34800011
J	RUDNICK, CM; DOWTON, SB				RUDNICK, CM; DOWTON, SB			SERUM AMYLOID-P (FEMALE PROTEIN) OF THE SYRIAN-HAMSTER - GENE STRUCTURE AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; ACUTE-PHASE RESPONSE; MESSENGER-RNA; COMPONENT; MOUSE; TESTOSTERONE; CDNA; INTERLEUKIN-6; INFLAMMATION; SEQUENCES	The structure and expression of the gene encoding serum amyloid P (SAP) component of the Syrian hamster have been studied by isolation of cosmid clones, nucleotide sequence analyses, and quantitation of nuclear run-on transcripts, nuclear RNA, mRNA, and protein levels. Hamster SAP, originally identified as female protein (FP), is a unique pentraxin because pretranslational expression of this gene is modulated by mediators of inflammation and sex steroids. SAP(FP) levels are high in sera from female hamsters and low in males. The response to inflammation is divergent; SAP(FP) levels decrease in females and increase in males during an acute phase response. The SAP(FP) gene encodes a 211 amino acid residue mature polypeptide as well as a 22-residue signal peptide. The intron/exon organization is similar to that of other pentraxins, but additional transcripts are generated from alternate polyadenylation sites in the 3' region. Circulating levels of SAP(FP) and the corresponding hepatic transcript levels are augmented by estrogen, while testosterone, dexamethasone, and progesterone cause a decrease in these levels. In addition the cytokines interleukin-1, -6, and tumor necrosis factor mediate a decrease in hepatic SAP(FP) transcript levels in female hamsters but did not cause a significant elevation of SAP(FP) mRNA in livers of male hamsters. The differences in expression of the SAP(FP) gene between male and female hamsters and between unstimulated male hamsters and male hamsters stimulated with an injection of lipopolysaccharide are due, at least in part, to alterations in transcription.	WASHINGTON UNIV,EDWARD MALLINKRODT DEPT PEDIAT,DIV MED GENET,1 CHILDRENS PL,ST LOUIS,MO 63130; WASHINGTON UNIV,JAMES S MCDONNELL DEPT GENET,ST LOUIS,MO 63130	Washington University (WUSTL); Washington University (WUSTL)				Dowton, Stephen/0000-0003-0828-1073	NIAID NIH HHS [AI24835-07] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024835] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BREATHNACH SM, 1989, J EXP MED, V170, P1433, DOI 10.1084/jem.170.4.1433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COE JE, 1977, P NATL ACAD SCI USA, V74, P730, DOI 10.1073/pnas.74.2.730; COE JE, 1983, J EXP MED, V157, P1421, DOI 10.1084/jem.157.5.1421; COE JE, 1981, J EXP MED, V153, P977, DOI 10.1084/jem.153.4.977; DOWTON SB, 1985, SCIENCE, V228, P1206, DOI 10.1126/science.2408337; DOWTON SB, 1990, BIOCHEM J, V270, P553, DOI 10.1042/bj2700553; DOWTON SB, 1991, INFLAMMATION, V15, P391, DOI 10.1007/BF00917355; DOWTON SB, 1991, BIOCHEMISTRY-US, V30, P9531, DOI 10.1021/bi00103a021; FALUS A, 1990, MOL IMMUNOL, V27, P197, DOI 10.1016/0161-5890(90)90115-G; FIEDEL BA, 1986, THROMB HAEMOSTASIS, V55, P406; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; HU SI, 1986, BIOCHEMISTRY-US, V25, P7834, DOI 10.1021/bi00372a008; HUSBY G, 1986, AMYLOIDOSIS, P23; KALARIA RN, 1992, BIOCHEM BIOPH RES CO, V186, P461, DOI 10.1016/S0006-291X(05)80830-7; Kushin'ska-Sitsin'ska Ia, 1989, Akush Ginekol (Mosk), P69; KYLE RA, 1990, AMYLOID AMYLOIDOSIS, P147; LE PT, 1984, J LEUKOCYTE BIOL, V35, P587; MACINTYRE SS, 1985, J BIOL CHEM, V260, P4169; MAGNUS JH, 1992, SCAND J RHEUMATOL, V21, P155; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MARZLUFF WF, 1984, TRANSCRIPTION TRANSL; MCADAM KPWJ, 1982, ANN NY ACAD SCI, V389, P126, DOI 10.1111/j.1749-6632.1982.tb22131.x; MORTENSEN RF, 1983, J IMMUNOL, V130, P885; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; NISHIGUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P1366, DOI 10.1016/S0006-291X(88)81292-0; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; PEPYS MB, 1982, ANN NY ACAD SCI, V389, P286, DOI 10.1111/j.1749-6632.1982.tb22144.x; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PRELLI F, 1985, J BIOL CHEM, V260, P2895; QUERAT B, 1991, J MOL ENDOCRINOL, V7, P81, DOI 10.1677/jme.0.0070081; RAY A, 1992, J AM SOC NEPHROL, V2, P214; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Sambrook J, 1989, MOL CLONING LABORATO; SAMOLS D, 1985, BIOCHEM J, V227, P759, DOI 10.1042/bj2270759; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RJ, 1980, BIOCHEMISTRY-US, V19, P5883, DOI 10.1021/bi00566a034; SORIMACHI K, 1990, BIOCHEM INT, V22, P447; SQUIRES EJ, 1990, CAN J PHYSIOL PHARM, V68, P769, DOI 10.1139/y90-118; TONIATTI C, 1990, MOL BIOL MED, V7, P199; VOLIVA CF, 1991, J MOL ENDOCRINOL, V7, P155, DOI 10.1677/jme.0.0070155; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; WHITEHEAD AS, 1989, BIOCHEM J, V263, P25, DOI 10.1042/bj2630025; WOO P, 1985, J BIOL CHEM, V260, P3384	54	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21760	21769						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691816				2022-12-27	WOS:A1993MC80900053
J	BILIR, BM; GONG, TWL; KWASIBORSKI, V; SHEN, CS; FILLMORE, CS; BERKOWITZ, CM; GUMUCIO, JJ				BILIR, BM; GONG, TWL; KWASIBORSKI, V; SHEN, CS; FILLMORE, CS; BERKOWITZ, CM; GUMUCIO, JJ			NOVEL CONTROL OF THE POSITION-DEPENDENT EXPRESSION OF GENES IN HEPATOCYTES - THE GLUT-1 TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER; RAT-LIVER; PERIVENOUS HEPATOCYTES; INSITU HYBRIDIZATION; GLUTAMINE-SYNTHETASE; ALBUMIN GENE; CELLS; TRANSCRIPTION; MODULATION; METABOLISM	The basal hepatocyte phenotype is conferred by the expression of liver-specific genes. In the adult liver, the basal hepatocyte phenotype is further modified by transcriptional and post-transcriptional regulation of genes which result in the appearance of specific proteins in selected hepatocytes. One of these proteins is the erythroid/brain or GLUT-1 glucose transporter. The GLUT-1 protein is detected in the plasma membrane of only one or two hepatocytes located at the end of the liver cell plate, contiguous to the hepatic venule. The objective of this study was to define the molecular mechanisms responsible for the restricted expression of the GLUT-1 protein in rat liver. Hepatocytes were isolated from either the proximal (''periportal'') or the distal (''perivenular'') half of the liver cell plate. The GLUT-1 mRNA as well as the GLUT-1 protein content and intracellular distribution were defined after subcellular fractionation of each hepatocyte population. In addition, the location of the GLUT-1 protein in liver tissue was determined by confocal microscopy. We propose that the GLUT-1 gene is transcribed and the mRNA is translated by both ''periportal'' and ''perivenular'' hepatocytes. However, insertion of the GLUT-1 protein into the plasma membrane occurs only in the last two hepatocytes contiguous to the hepatic venule. In other hepatocytes, the protein remains in a different cellular compartment characterized here as a ''low density microsomal'' fraction.	VET AFFAIRS MED CTR,DEPT MED 111D,2215 FULLER RD,ANN ARBOR,MI 48105; VET AFFAIRS MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,ANN ARBOR,MI 48105	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan				Berkowitz, Caryn/0000-0002-4087-6037	NIDDK NIH HHS [F32DK08572, DK32842] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032842, F32DK008572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPINI G, 1989, GASTROENTEROLOGY, V97, P1248, DOI 10.1016/0016-5085(89)91696-X; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; BILIR B, 1991, HEPATOLOGY, V13, P804, DOI 10.1016/0270-9139(91)92586-W; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOYER JL, 1975, BIOCHIM BIOPHYS ACTA, V401, P59, DOI 10.1016/0005-2736(75)90341-7; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHARY SC, 1987, P NATL ACAD SCI USA, V84, P680; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRYSDALE JW, 1966, J BIOL CHEM, V241, P3630; FLIER JJ, 1987, P NATL ACAD SCI USA, V83, P5784; GEBHARDT R, 1988, FEBS LETT, V241, P89, DOI 10.1016/0014-5793(88)81037-8; GUMUCIO JJ, 1989, HEPATOLOGY, V9, P154, DOI 10.1002/hep.1840090124; GUMUCIO JJ, 1986, HEPATOLOGY, V6, P932, DOI 10.1002/hep.1840060521; HACKER HJ, 1991, HISTOCHEMISTRY, V96, P435, DOI 10.1007/BF00316001; HAUSSINGER D, 1986, ADV ENZYME REGUL, V25, P159, DOI 10.1016/0065-2571(86)90013-0; INGELMANSUNDBERG M, 1988, BIOCHEM BIOPH RES CO, V157, P55, DOI 10.1016/S0006-291X(88)80010-X; ISHII M, 1989, GASTROENTEROLOGY, V97, P1238; KRUMLAUF R, 1985, MOL CELL BIOL, V5, P1939; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; LINDROS KO, 1985, BIOCHEM J, V228, P757, DOI 10.1042/bj2280757; LOWRY OH, 1951, J BIOL CHEM, V193, P265; POLIARD AM, 1986, J CELL BIOL, V103, P777, DOI 10.1083/jcb.103.3.777; REICH E, 1961, SCIENCE, V134, P556, DOI 10.1126/science.134.3478.556; RHOADS DB, 1986, P NATL ACAD SCI USA, V83, P5784; SCHURMANN A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P245, DOI 10.1016/0167-4781(92)90022-R; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SLOTT PA, 1990, GASTROENTEROLOGY, V99, P466, DOI 10.1016/0016-5085(90)91030-A; SMITH DD, 1983, J BIOL CHEM, V258, P2265; SONG CS, 1969, J CELL BIOL, V41, P124, DOI 10.1083/jcb.41.1.124; TAI PKK, 1990, J BIOL CHEM, V265, P21828; TAL M, 1990, J CLIN INVEST, V86, P986, DOI 10.1172/JCI114801; TAL M, 1991, ENDOCRINOLOGY, V129, P1933, DOI 10.1210/endo-129-4-1933; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; WOJCIK E, 1988, J CLIN INVEST, V82, P658, DOI 10.1172/JCI113645; YAMAUCHI M, 1988, HEPATOLOGY, V8, P243, DOI 10.1002/hep.1840080209; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	37	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19776	19784						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690040				2022-12-27	WOS:A1993LW81900093
J	OTTLINGER, ME; PUKAC, LA; KARNOVSKY, MJ				OTTLINGER, ME; PUKAC, LA; KARNOVSKY, MJ			HEPARIN INHIBITS MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION IN INTACT RAT VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MYC MESSENGER-RNA; C-MYC; PHOSPHORYLATION; FOS; PROLIFERATION; TRANSCRIPTION; PROGRESSION; SUPPRESSES; EXPRESSION; MECHANISM	Heparin is potently antiproliferative for vascular smooth muscle cells in vivo and in vitro, inhibiting early proto-oncogene expression and blocking proliferation in the G1 phase of the cell cycle. The mitogen-activated protein kinase (MAPK) family of serine- and threonine-specific kinases is activated in response to a wide range of mitogenic and other factors and is a key intermediate in cell signaling. We found that heparin inhibits activation of MAPK in response to fetal calf serum and phorbol 12-myristate 13-acetate, but not epidermal growth factor, revealing heparin-sensitive and -insensitive pathways of MAPK activation. This report tentatively links suppression of early proto-oncogene expression and inhibition of cellular proliferation by heparin with inhibition of a mitogenically relevant kinase in living cells.			OTTLINGER, ME (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,200 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008322, S15HL047718] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08322-02, HL47718] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1990, J BIOL CHEM, V265, P11487; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AU YPT, 1992, J BIOL CHEM, V267, P3438; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DAMON DH, 1992, EXP CELL RES, V201, P154, DOI 10.1016/0014-4827(92)90359-G; DICCIANNI MB, 1991, BIOCHEMISTRY-US, V30, P9090, DOI 10.1021/bi00101a026; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOUELI SA, 1991, FEBS LETT, V282, P445, DOI 10.1016/0014-5793(91)80533-9; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HERBERT JM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P432; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LIPPMAN M, 1968, EPITHELIAL MESENCHYM, P208; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; REILLY CF, 1989, J BIOL CHEM, V264, P6990; SMITH CD, 1992, BIOCHEM J, V281, P803, DOI 10.1042/bj2810803; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199	28	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19173	19176						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690027				2022-12-27	WOS:A1993LW81900004
J	WONG, NCW; RAYMOND, J; CARR, FE				WONG, NCW; RAYMOND, J; CARR, FE			A LIVER-SPECIFIC NUCLEAR-PROTEIN REPRESSES TRANSCRIPTION OF THE S14 GENE IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RESPONSIVE GENE; THYROID-HORMONE; RAT-LIVER; MESSENGER-RNA; EXPRESSION; HYPOTHYROIDISM; PROMOTER; BINDING; REGION; LEVEL	P1 is a nuclear protein found exclusively in rat liver and binds to a motif that spans nucleotides -310 to -288 of the thyroid hormone responsive gene, S14. We expect P1 to play an important role in regulating gene expression because the binding motif for this factor is contained within a DNase I-hypersensitive site of S14 chromatin. In this report, we have attempted to define the function of P1 by correlating its DNA binding activity with levels of mRNA-S 14 in response to aging and obesity. Results of all studies revealed inverse relationships between the activity of P1 and levels of mRNA-S14, thus suggesting that P1 may function as a repressor of S14 gene expression. Accordingly, we tested the repressor hypothesis using cell-free transcription and transient transfection assays to measure the activity of reporter constructs with and without the P1 binding motif. In the presence of the P1 motif, S14 promoter activity was repressed and the negative effect on gene transcription was further enhanced by thyroid hormone. These observations are consistent with P1 being a repressor of S14 gene transcription.	UNIV CALGARY,DEPT MED,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA; WALTER REED ARMY MED CTR,KYLE METAB UNIT,WASHINGTON,DC 20307	University of Calgary; University of Calgary; United States Department of Defense; United States Army; Walter Reed National Military Medical Center								CARR FE, 1983, J CLIN INVEST, V72, P154, DOI 10.1172/JCI110953; DESCHAMPS BJ, 1992, J BIOL CHEM, V267, P25167; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1986, ENDOCRINOLOGY, V118, P1892, DOI 10.1210/endo-118-5-1892; JUMP DB, 1987, J BIOL CHEM, V262, P778; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KINLAW WB, 1989, J BIOL CHEM, V264, P19779; KINLAW WB, 1987, ENDOCRINOLOGY, V120, P1563, DOI 10.1210/endo-120-4-1563; KNOWLES BB, 1984, ADV HEPATITIS RES; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; LIAW CW, 1984, J BIOL CHEM, V259, P7253; Maniatis T., 1982, MOL CLONING; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; NARAYAN P, 1985, MOL CELL BIOL, V5, P2642, DOI 10.1128/MCB.5.10.2642; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PEREZCASTILLO A, 1987, AM J PHYSIOL, V253, pE530; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RUSSELL JC, 1989, ARTERIOSCLEROSIS, V9, P869, DOI 10.1161/01.ATV.9.6.869; SEELIG S, 1981, P NATL ACAD SCI-BIOL, V78, P4733, DOI 10.1073/pnas.78.8.4733; WATANABE K, 1987, J BIOL CHEM, V262, P4812; WONG NCW, 1990, J BIOL CHEM, V265, P8775; WONG NCW, 1989, J BIOL CHEM, V264, P4466	28	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19431	19435						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690031				2022-12-27	WOS:A1993LW81900045
J	TIAN, XQ; HOLICK, MF				TIAN, XQ; HOLICK, MF			CATALYZED THERMAL-ISOMERIZATION BETWEEN PREVITAMIN-D-3 AND VITAMIN-D-3 VIA BETA-CYCLODEXTRIN COMPLEXATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PI-FACIAL SELECTIVITY; D CALCIFEROL; HUMAN-SKIN; ANALOGS; PHOTOSYNTHESIS; STABILITY; SHIFTS	To examine the effect of microenviroments on previtamin D-3 reversible arrow vitamin D-3 isomerization, we have conducted kinetic studies of the reaction in an aqueous solution of beta-cyclodextrin. Our results showed that at 5 degrees C, the forward (k(1)) and reverse (k(2)) rate constants for previtamin D-3 reversible arrow vitamin D-3 isomerization were increased by more than 40 and 600 times, respectively, compared with those in n-hexane (k(1), 8.65 x 10(-6) versus 1.76 x 10(-7) s(-1); k(2), 8.48 x 10(-6) versus 1.40 x 10(-8) s(-1)), the fastest rate of this isomerization ever reported at this temperature. Thermodynamic studies revealed that the equilibrium constant of the reaction was significantly reduced by more than 12-fold when compared to that in n-hexane at 5 degrees C, and the percentage of vitamin D-3 at equilibrium was increased as the temperature was increased in beta-cyclodextrin. When complexed with beta-cyclodextrin, the previtamin D-3 reversible arrow vitamin D-3 isomerization became endothermic (Delta H degrees reversible arrow 13.05 kJ mol(-1)) in contrast to being exothermic in other media. We propose that thermodynamically unfavorable cZc conformers of previtamin D-3 are stabilized by beta-cyclodextrin, and thus the rate of the isomerization is increased. This conformation-controlled process may play an important role in the modulation of previtamin D-3 reversible arrow vitamin D-3 endocrine system in vivo such as in the sea urchin.	BOSTON UNIV, MED CTR,DEPT MED,ENDOCRINOL RES SECT, VITAMIN D SKIN & BONE RES LAB, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, DEPT PHYSIOL, BOSTON, MA 02118 USA	Boston University; Boston University				Holick, Michael/0000-0001-6023-9062	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR-36963] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS E, 1992, J PHARM SCI-US, V81, P756, DOI 10.1002/jps.2600810808; BERMAN E, 1979, VITAMIN D BASIC RES, P65; BOGOSLOVSKY NA, 1988, VITAMIN D MOL CELLUL, P1021; BRESLOW R, 1984, INCLUSION COMPOUNDS, V3, P473; CASSIS EG, 1982, PHOTOCHEM PHOTOBIOL, V35, P439; CHEN ET, 1993, ANAL CHEM, V65, P2563, DOI 10.1021/ac00067a003; CURTIN ML, 1991, J AM CHEM SOC, V113, P6958, DOI 10.1021/ja00018a038; DAUBEN WG, 1988, J ORG CHEM, V53, P5376, DOI 10.1021/jo00257a039; DAUBEN WG, 1988, J ORG CHEM, V53, P5070, DOI 10.1021/jo00256a031; DORMANEN MC, 1994, BIOCHEM BIOPH RES CO, V201, P394, DOI 10.1006/bbrc.1994.1714; DUVENECK GL, 1989, J PHYS CHEM-US, V93, P7166, DOI 10.1021/j100357a028; ENAS JD, 1991, J AM CHEM SOC, V113, P1355, DOI 10.1021/ja00004a043; ESVELT RP, 1978, ARCH BIOCHEM BIOPHYS, V188, P282, DOI 10.1016/S0003-9861(78)80010-1; HANEWALD KH, 1961, RECL TRAV CHIM PAY B, V80, P1003; HAVINGA E, 1973, EXPERIENTIA, V29, P1181, DOI 10.1007/BF01935064; HOBBS RN, 1987, CHEM SCRIPTA, V27, P199; HOEGER CA, 1987, J AM CHEM SOC, V109, P4690, DOI 10.1021/ja00249a035; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; HOLICK MF, 1979, BIOCHEMISTRY-US, V18, P1003, DOI 10.1021/bi00573a011; Jacobs H.J.C., 1979, ADV PHOTOCHEM, V11, P305, DOI DOI 10.1002/9780470133415.CH4; LIU FY, 1990, PHARMACEUT RES, V7, P869, DOI 10.1023/A:1015973218303; MACLAUGHLIN JA, 1982, SCIENCE, V216, P1001, DOI 10.1126/science.6281884; MYLES AMC, 1994, BBA-GEN SUBJECTS, V1199, P27, DOI 10.1016/0304-4165(94)90092-2; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; PITCHUMANI K, 1994, PHOTOCHEM PHOTOBIOL, V59, P399, DOI 10.1111/j.1751-1097.1994.tb05054.x; RIEKE PC, 1992, ACS SYM SER, V499, P61; SAENGER W, 1984, INCLUSION COMPOUNDS, V2, P231; SZEJTLI J, 1980, PHARMAZIE, V35, P779; Szejtli J., 1984, INCLUSION COMPOUNDS, P331; TABUSHI I, 1984, INCLUSION COMPOUNDS, V3, P445; TERENETSKAYA IP, 1992, J MOL STRUCT, V267, P93, DOI 10.1016/0022-2860(92)87015-N; TIAN XQ, 1993, J BIOL CHEM, V268, P14888; TIAN XQ, 1994, ENDOCRINOLOGY, V135, P655, DOI 10.1210/en.135.2.655; Ueno A., 1991, PHOTOCHEMISTRY ORG C, P739; WOODWARD RB, 1965, J AM CHEM SOC, V87, P2511, DOI 10.1021/ja01089a050; WU KM, 1990, J ORG CHEM, V55, P4025, DOI 10.1021/jo00300a015; YAMAMOTO JK, 1985, BIOCHEMISTRY-US, V24, P3338, DOI 10.1021/bi00334a039	37	31	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8706	8711		10.1074/jbc.270.15.8706	http://dx.doi.org/10.1074/jbc.270.15.8706			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721775	hybrid			2022-12-27	WOS:A1995QT44800053
J	BREUKINK, E; NOUWEN, N; VANRAALTE, A; MIZUSHIMA, S; TOMMASSEN, J; DEKRUIJFF, B				BREUKINK, E; NOUWEN, N; VANRAALTE, A; MIZUSHIMA, S; TOMMASSEN, J; DEKRUIJFF, B			THE C-TERMINUS OF SECA IS INVOLVED IN BOTH LIPID-BINDING AND SECB BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION ATPASE; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; ACIDIC PHOSPHOLIPIDS; ESSENTIAL COMPONENT; INNER MEMBRANES; SIGNAL SEQUENCE; PHOSPHATIDYLGLYCEROL; SECRETION; PEPTIDE	Using C-terminal deletion mutations in secA, we localized the previously proposed (Breukink, E., Keller, R. C. A., and de Kruijff, B. (1993), FEBS Lett. 331, 19-24) second lipid binding site on Seek Since removal of these residues completely abolished the property of SecA to cause aggregation of negatively charged phosphatidylglycerol vesicles, we conclude that the C-terminal 70 amino acid residues of SecA are involved in lipid-binding. The C-terminal 70 amino acid residues of SecA are important for efficient in vitro translocation of the SecB dependent precursor of PhoE across inverted inner membrane vesicles, Moreover, in vivo studies showed that this region is essential for growth. SecB and a SecB-precursor complex were shown to inhibit the SecA-mediated lipid vesicle aggregation, suggesting that the overall acidic SecB protein binds at or near the second lipid binding site on Seek This together with the observation that the SecA mutant protein lacking the C-terminal 70 residues had a strongly reduced ability to mediate binding of SecB-precursor complexes to inverted inner membrane vesicles demonstrates that the C terminus of SecA is also involved in SecB binding.	UNIV UTRECHT, INST BIOMEMBRANES, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT BIOCHEM MEMBRANES, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, DEPT MOLEC CELL BIOL, 3584 CH UTRECHT, NETHERLANDS; TOKYO COLL PHARM & LIFE SCI, SCH LIFE SCI, HACHIOJI, TOKYO 19203, JAPAN	Utrecht University; Utrecht University; Utrecht University; Tokyo University of Pharmacy & Life Sciences			Breukink, Eefjan/I-3039-2016; Tommassen, Jan/I-1690-2016	Breukink, Eefjan/0000-0002-7311-0660; Tommassen, Jan/0000-0001-7633-4945				AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; Bolivar F, 1979, Methods Enzymol, V68, P245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1993, FEBS LETT, V331, P19, DOI 10.1016/0014-5793(93)80289-7; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; JACQ A, 1993, CURR OPIN STRUC BIOL, V3, P541, DOI 10.1016/0959-440X(93)90080-5; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; KUSTERS R, 1994, J BIOL CHEM, V269, P1560; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Maniatis T., 1982, MOL CLONING; MATSUYAMA S, 1989, J BIOL CHEM, V264, P3583; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PHOENIX DA, 1993, FEBS LETT, V324, P113, DOI 10.1016/0014-5793(93)81543-9; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SCHMIDT MG, 1991, J BACTERIOL, V173, P6605, DOI 10.1128/jb.173.20.6605-6611.1991; SHIBUYA I, 1985, J BACTERIOL, V161, P1086, DOI 10.1128/JB.161.3.1086-1092.1985; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMANE K, 1987, J BIOL CHEM, V262, P2358	41	136	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7902	7907		10.1074/jbc.270.14.7902	http://dx.doi.org/10.1074/jbc.270.14.7902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713885	hybrid			2022-12-27	WOS:A1995QR52600021
J	HOLEVINSKY, KO; NELSON, DJ				HOLEVINSKY, KO; NELSON, DJ			SIMULTANEOUS DETECTION OF FREE-RADICAL RELEASE AND MEMBRANE CURRENT DURING PHAGOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING-SYSTEM; HYDROGEN-PEROXIDE PRODUCTION; B-CELL LINES; HUMAN-GRANULOCYTES; POTENTIAL CHANGES; RESPIRATORY BURST; HUMAN-NEUTROPHILS; XENOPUS-OOCYTES	Stimulation of macrophages induces the ''respiratory burst'' response which is associated with the generation of superoxide (O-2(-)), a drop in cytoplasmic pH, and a pronounced depolarization of the membrane potential. The purpose of the present studies was to determine whether an increase in O-2(-) was temporally related to changes in membrane potential and transmembrane current. Release of O-2(-) at the single cell level was photometrically monitored during phagocytosis of immune complexes while simultaneously measuring whole-cell current. Membrane depolarization and the generation of a non-selective current followed an increase in O-2(-) production with a variable lag time which was correlated with the state of cellular maturation in culture. In the absence of phagocytosis, the exposure of macrophages to O-2(-) generated by a xanthine-xanthine oxidase reaction activated a non-selective current similar to that seen after phagocytosis. These results provide the first demonstration of the relationship between free radical release and the ensuing electrophysiological signaling events which are linked to particle engulfment in phagocytic cells.	UNIV CHICAGO, DEPT NEUROL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago					NIGMS NIH HHS [R01 GM36823] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER HA, 1993, J BIOL CHEM, V268, P2037; BIGGAR WD, 1976, INFECT IMMUN, V14, P6, DOI 10.1128/IAI.14.1.6-10.1976; CHARPENTIER G, 1993, P ROY SOC B-BIOL SCI, V254, P15, DOI 10.1098/rspb.1993.0120; COMMINS LM, 1990, INFLAMMATION, V14, P705, DOI 10.1007/BF00916373; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DECHATELET LR, 1975, J INFECT DIS, V131, P443, DOI 10.1093/infdis/131.4.443; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; FOURNIER F, 1993, FEBS LETT, V317, P118, DOI 10.1016/0014-5793(93)81504-S; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; JONES GS, 1981, J CELL PHYSIOL, V106, P75, DOI 10.1002/jcp.1041060109; KITAGAWA S, 1986, J IMMUNOL, V136, P2605; KITAGAWA S, 1984, J CLIN INVEST, V73, P1062, DOI 10.1172/JCI111291; KITAGAWA S, 1985, J IMMUNOL, V135, P3417; KORCHAK HM, 1978, P NATL ACAD SCI USA, V75, P3818, DOI 10.1073/pnas.75.8.3818; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LOEGERING DJ, 1991, BIOCHEM BIOPH RES CO, V180, P268, DOI 10.1016/S0006-291X(05)81287-2; MALY FE, 1988, J IMMUNOL, V140, P2334; MUSSON RA, 1982, J RETICULOENDOTH SOC, V31, P261; NELSON DJ, 1990, J MEMBRANE BIOL, V117, P29, DOI 10.1007/BF01871563; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; OIKE M, 1993, PFLUG ARCH EUR J PHY, V424, P159, DOI 10.1007/BF00374607; RYAN TC, 1990, J IMMUNOL METHODS, V130, P223, DOI 10.1016/0022-1759(90)90052-W; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWACHA MG, 1993, J IMMUNOL, V150, P236; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEIM S, 1982, ACTA PATH MICRO IM C, V90, P179; SELIGMANN BE, 1983, J CELL PHYSIOL, V115, P105, DOI 10.1002/jcp.1041150202; SELIGMANN BE, 1980, J CLIN INVEST, V66, P493, DOI 10.1172/JCI109880; SIMCHOWITZ L, 1979, IMMUNOLOGY, V234, P2428; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; WHITIN JC, 1980, J BIOL CHEM, V255, P1874	35	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8328	8336		10.1074/jbc.270.14.8328	http://dx.doi.org/10.1074/jbc.270.14.8328			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713941	hybrid			2022-12-27	WOS:A1995QR52600080
J	JEOHN, GH; TAKAHASHI, K				JEOHN, GH; TAKAHASHI, K			PURIFICATION AND CHARACTERIZATION OF A VASOACTIVE INTESTINAL POLYPEPTIDE-DEGRADING ENDOPROTEASE FROM PORCINE ANTRAL MUCOSAL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GASTRIC-MUCOSA; PROCESSING ENDOPROTEASES; SYNAPTIC-MEMBRANES; SUBSTANCE-P; ENDOPEPTIDASE; SECRETION; CLEAVAGE; STOMACH; ACID; NEUROTENSIN	A neutral endoprotease was isolated from porcine antral mucosa and purified to homogeneity as examined by SDS-polyacrylamide gel electrophoresis (PAGE). Throughout the purification, t-butyloxycarbonyl-Arg-Val-Arg-Arg-4-methylcoumaryl-7-amide (MCA) was used as a substrate, which was found to be hydrolyzed specifically by the enzyme at the Arg-Arg bond. Unexpectedly, however, the enzyme was also found to hydrolyze vasoactive intestinal polypeptide (VIP) fairly specifically and more efficiently when various neuropeptides and related peptides were examined as substrates. It could degrade VIP by cleaving three peptides bonds not containing an arginine residues(s) with K-m = 7.7 x 10(-6) M and k(cat)/K-m = 7.4 x 10(6) M(-1) s(-1) (at pH 7.6 in the presence of 0.1% Lubrol PX), whereas only secretin, substance P, and a few others were hydrolyzed at much slower rates among the various peptides examined. Both activities toward the MCA substrate and VIP behaved in parallel throughout the purification procedures and showed essentially the same pH optimum and susceptibility toward various inhibitors and detergents. Therefore, both activities are thought to be due to the same enzyme. This endoprotease required 0.001% or a higher concentration of a detergent such as Lubrol PX or Triton X-100 for its maximal activity. Its optimum pH was about 7.5 and the molecular weight was estimated to be approximately 37,000 by SDS-PAGE. This enzyme was strongly inhibited by serine protease inhibitors such as diisopropylfluorophosphate and phenylmethanesulfonyl fluoride. It was also inhibited by p-chloromercuribenzoic acid, but not by some other cysteine protease inhibitors. Therefore, the enzyme appears to be most likely a kind of serine protease although its possibility as a cysteine protease cannot be completely excluded. Analysis of its cleavage specific amino acid sequences(s) and/or conformation in the vicinity of the cleavage site of the target peptide. Various characteristics of the endoprotease suggest that it is a novel membrane-bound neuropeptide-degrading endoprotease fairly specific for VIP.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BUNNETT NW, 1990, AM J PHYSIOL, V258, pG143, DOI 10.1152/ajpgi.1990.258.1.G143; BUNNETT NW, 1992, GASTROENTEROLOGY, V102, P76, DOI 10.1016/0016-5085(92)91786-4; CARVALHO KD, 1992, P NATL ACAD SCI USA, V89, P84, DOI 10.1073/pnas.89.1.84; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CHECLER F, 1985, J NEUROCHEM, V45, P1509, DOI 10.1111/j.1471-4159.1985.tb07220.x; FELLEY CP, 1992, AM J PHYSIOL, V263, pG901, DOI 10.1152/ajpgi.1992.263.6.G901; Fruton J. S., 1971, ENZYMES, V3, P119; GOETZL EJ, 1989, BIOCHEM BIOPH RES CO, V158, P850, DOI 10.1016/0006-291X(89)92800-3; HIRAO T, 1984, J BIOCHEM-TOKYO, V95, P871, DOI 10.1093/oxfordjournals.jbchem.a134680; HOSOI K, 1978, BIOCHEM BIOPH RES CO, V85, P558, DOI 10.1016/0006-291X(78)91199-3; JOUDIOU C, 1993, BICOHEMISTRY, V32, P5969; KAGEYAMA T, 1980, J BIOCHEM, V87, P725, DOI 10.1093/oxfordjournals.jbchem.a132801; KEAST JR, 1985, J COMP NEUROL, V236, P403, DOI 10.1002/cne.902360308; KOBAYASHI R, 1994, PEPTIDES, V15, P323, DOI 10.1016/0196-9781(94)90020-5; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1957, METHOD ENZYMOL, V4, P371; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MILLICAN PE, 1991, BIOCHEM J, V276, P583, DOI 10.1042/bj2760583; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OZAKI H, 1992, J PHYSIOL-LONDON, V447, P351, DOI 10.1113/jphysiol.1992.sp019006; Perrin D.D, 1974, BUFFERS PH METAL ION, P48; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; SCHUBERT ML, 1993, GASTROENTEROLOGY, V104, P834, DOI 10.1016/0016-5085(93)91020-I; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAYLOR IL, 1991, TXB GASTROENTEROLOGY, V1, P24; TAZISAAD K, 1992, PEPTIDES, V13, P233, DOI 10.1016/0196-9781(92)90102-9; TERASHIMA H, 1992, PEPTIDES, V13, P71; TSURU D, 1978, J BIOCHEM, V84, P467, DOI 10.1093/oxfordjournals.jbchem.a132148; UCHINO T, 1993, J BIOL CHEM, V268, P527; USUI Y, 1982, BIOCHIM BIOPHYS ACTA, V719, P539, DOI 10.1016/0304-4165(82)90244-6; WANG YX, 1993, PEPTIDES, V14, P573, DOI 10.1016/0196-9781(93)90147-9; WOOLLEY DE, 1976, BIOCHEM J, V153, P119, DOI 10.1042/bj1530119	36	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7809	7815		10.1074/jbc.270.14.7809	http://dx.doi.org/10.1074/jbc.270.14.7809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713870	hybrid			2022-12-27	WOS:A1995QR52600006
J	TIPPLES, G; MCCLARTY, G				TIPPLES, G; MCCLARTY, G			CLONING AND EXPRESSION OF THE CHLAMYDIA-TRACHOMATIS GENE FOR CTP SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; RELA GENE; SEQUENCE; REGION	A HindIII partial digest Chlamydia trachomatis L2 Library in pUC19 was screened for the CTP synthetase gene by functional complementation in CTP synthetase-deficient Escherichia coli JF646. A complementing clone was isolated and contained a recombinant plasmid (pH-1) with a 2.7-kilobase C. trachomatis DNA insert. The entire insert was sequenced and found to encode two complete open reading frames (ORFs) that overlapped by 25 bases and the start of a third ORF that overlapped with ORF2 by 14 bases. The derived amino acid sequence of ORFs 1 and 2 shows 37% identity to kdsB, an E. coli gene that codes for CMP-2-keto-3-deoxyoctulosonic acid synthetase and 48% identity to pyrG, an E. coli gene that codes for CTP synthetase, respectively. To obtain downstream sequence data for ORF3, colony hybridization screening of the HindIII. chlamydial DNA library was used to isolate a second recombinant plasmid (pH-11) that contained a 1.7-kilobase chlamydial DNA insert. The deduced amino acid sequence of ORF3 is not significantly homologous to any protein in the translated GenBank data base. Recombinant chlamydial CTP synthetase appears to be similar to the E. coli enzyme in that it is sensitive to inhibition by CTP, requires UTP, ATP, Mg2+, GTP, and glutamine for activity, and can also utilize ammonia as an amido-group donor.	UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA	University of Manitoba								ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BIRKELUND S, 1992, J BACTERIOL, V174, P2742, DOI 10.1128/JB.174.9.2742-2747.1992; FAN HZ, 1991, J BACTERIOL, V173, P6670, DOI 10.1128/jb.173.21.6670-6677.1991; FRAIZ J, 1988, ANNU REV MED, V39, P357, DOI 10.1146/annurev.me.39.020188.002041; FRIESEN JD, 1976, J BACTERIOL, V127, P917, DOI 10.1128/JB.127.2.917-922.1976; FRIESEN JD, 1978, CELL, V15, P1187, DOI 10.1016/0092-8674(78)90045-4; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; KOSHLAND DE, 1994, ENZYMES, V10, P539; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Long C, 1978, Methods Enzymol, V51, P79; MAMT U, 1993, MOL MICROBIOL, V10, P935; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; MCCLARTY G, 1993, J BACTERIOL, V175, P4652, DOI 10.1128/JB.175.15.4652-4661.1993; McClarty Grant, 1994, Trends in Microbiology, V2, P157, DOI 10.1016/0966-842X(94)90665-3; MCPARTLAND RP, 1979, J BIOL CHEM, V254, P1394; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; OZIERKALOGEROPO.O, 1991, MOL GEN GENET, V0231; OZIERKALOGEROPO.O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PAZZANI C, 1993, J BACTERIOL, V175, P5978, DOI 10.1128/JB.175.18.5978-5983.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Sambrook J, 1989, MOL CLONING LABORATO; Stephens RS., 1993, INFECT AGENT DIS, V1, P279; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; UNGER FM, 1981, ADV CARBOHYD CHEM BI, V38, P23; WANG LL, 1994, MOL MICROBIOL, V14, P271, DOI 10.1111/j.1365-2958.1994.tb01288.x; WENG M, 1986, J BIOL CHEM, V261, P5568; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; ZALKIN H, 1988, J BIOL CHEM, V263, P1595	30	29	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7908	7914		10.1074/jbc.270.14.7908	http://dx.doi.org/10.1074/jbc.270.14.7908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713886	hybrid			2022-12-27	WOS:A1995QR52600022
J	BERNARDS, MA; LOPEZ, ML; ZAJICEK, J; LEWIS, NG				BERNARDS, MA; LOPEZ, ML; ZAJICEK, J; LEWIS, NG			HYDROXYCINNAMIC ACID-DERIVED POLYMERS CONSTITUTE THE POLYAROMATIC DOMAIN OF SUBERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED POTATO PERIDERM; SOLID-STATE; ANIONIC PEROXIDASE; SOLANUM-TUBEROSUM; CELL-WALL; LIGNIN; C-13; TYRAMINE; TISSUE; CUTINS	Suberin is an abundant, complex, intractable, plant cell wall polymeric network that forms both protective and wound-healing layers. Its function is, therefore, critical to the survival of all vascular plants. Its chemical structure and biosynthesis are poorly defined, although it is known to consist of both aromatic and aliphatic domains, While the composition of the aliphatic component has been fairly well characterized, that of the phenolic component has not. Using a combination of specific carbon-13 labeling techniques, and in situ solid state C-13 NMR spectroscopic analysis, we now provide the first direct evidence for the nature of the phenolic domain of suberin and report here that it is almost exclusively comprised of a covalently linked, hydroxycinnamic acid-derived polymeric matrix.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, CTR NMR SPECT, PULLMAN, WA 99164 USA	Washington State University; Washington State University				Lewis, Norman/0000-0001-5742-032X				ADAMOVICS JA, 1977, PHYTOCHEMISTRY, V16, P1089, DOI 10.1016/S0031-9422(00)86746-1; BERNARDS MA, 1992, PHYTOCHEMISTRY, V31, P3409, DOI 10.1016/0031-9422(92)83695-U; BORGOLIVIER O, 1989, CR ACAD SCI III-VIE, V308, P141; BORGOLIVIER O, 1993, PHYTOCHEMISTRY, V32, P601, DOI 10.1016/S0031-9422(00)95143-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTLE W, 1982, PLANT PHYSIOL, V69, P393, DOI 10.1104/pp.69.2.393; EBERHARDT TL, 1993, J BIOL CHEM, V268, P21088; Esau K., 1977, ANATOMY SEED PLANTS, P183; ESPELIE KE, 1986, PLANT PHYSIOL, V81, P487, DOI 10.1104/pp.81.2.487; GARBOW JR, 1989, PLANT PHYSIOL, V90, P783, DOI 10.1104/pp.90.3.783; HAYASHI S, 1991, B CHEM SOC JPN, V64, P685, DOI 10.1246/bcsj.64.685; KATAYAMA T, 1987, TECH B FAC AGR KAGAW, V39, P47; KOLATTUKUDY PE, 1984, CAN J BOT, V62, P2918, DOI 10.1139/b84-391; KOLATTUKUDY PE, 1974, PLANT PHYSIOL, V54, P116, DOI 10.1104/pp.54.1.116; LAPIERRE C, 1986, HOLZFORSCHUNG, V40, P47, DOI 10.1515/hfsg.1986.40.1.47; LEWIS NG, 1987, SCIENCE, V237, P1344, DOI 10.1126/science.237.4820.1344; LEWIS NG, 1987, MACROMOLECULES, V20, P1752, DOI 10.1021/ma00174a006; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; LEWIS NG, 1994, ACS SYM SER, V562, P202; LOFTY S, 1994, PHYTOCHEMISTRY, V35, P1419, DOI 10.1016/S0031-9422(00)86867-3; MATZKE K, 1991, PLANTA, V185, P233, DOI 10.1007/BF00194066; NEGREL J, 1993, J PLANT PHYSIOL, V142, P518, DOI 10.1016/S0176-1617(11)80392-5; RALPH J, 1992, J CHEM SOC PERK T 1, P2971, DOI 10.1039/p19920002971; RILEY RG, 1975, PLANT PHYSIOL, V56, P650, DOI 10.1104/pp.56.5.650; ROBERTS E, 1988, PLANT MOL BIOL, V11, P15, DOI 10.1007/BF00016010; SCHMUTZ A, 1993, PLANTA, V189, P453, DOI 10.1007/BF00194445; STARK RE, 1994, PLANT PHYSIOL, V104, P527, DOI 10.1104/pp.104.2.527; STARK RE, 1989, ACS SYM SER, V399, P214; WUTHRICH K, 1976, NMR BIOL RES PEPTIDE, P178; YOUNG MR, 1966, CAN J BOTANY, V44, P341, DOI 10.1139/b66-040; ZIMMERMANN W, 1985, HOLZFORSCHUNG, V39, P45, DOI 10.1515/hfsg.1985.39.1.45	31	141	147	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7382	7386		10.1074/jbc.270.13.7382	http://dx.doi.org/10.1074/jbc.270.13.7382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706282	hybrid			2022-12-27	WOS:A1995QQ43100055
J	DUFF, JL; MONIA, BP; BERK, BC				DUFF, JL; MONIA, BP; BERK, BC			MITOGEN-ACTIVATED PROTEIN (MAP) KINASE IS REGULATED BY THE MAP KINASE PHOSPHATASE (MKP-1) IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE-PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDES; MESSENGER-RNA; GENE-PRODUCT; PHOSPHORYLATION; EXPRESSION; 3CH134; PROLIFERATION; STIMULATION	Angiotensin II stimulates hypertrophic growth of vascular smooth muscle cells (VSMC) and activates many growth-promoting kinases such as mitogen activated protein (MAP) kinase, A novel transcriptionally regulated phosphatase, MAP kinase phosphatase-l (MKP-1), is induced by angiotensin II in VSMC and selectively dephosphorylates MAP kinase in vitro. Using actinomycin D and antisense oligonucleotides targeted to MKP-1, we demonstrate that MKP-1 regulates MAP kinase in VSMC. Both actinomycin D and MKP-1 antisense oligo nucleotides inhibited MKP-1 mRNA expression and caused prolonged activation of the p42 and p44 MAP kinases as measured by in-gel kinase assays and Western blot, For example, MAP kinase activity 120 min after angiotensin II treatment was 30% (range 25-35%), 79%, and 74% of maximum in control, actinomycin D-treated (3 mu g/ml, 30 min), and antisense oligonucleotide-treated (300 nM, 6 h) cells, respectively. A sense oligonucleotide was without effect (34%). MKP-1 antisense oligonucleotides did not affect the activity of MEK indicating that sustained activation of MAP kinase was due to inhibition of MKP-1 expression. These findings demonstrate that inactivation of MAP kinase by angiotensin II is mediated predominantly by MKP-1, suggesting an important role for MKP-1 and other related phosphatases in the regulation of MAP kinases in VSMC.	UNIV WASHINGTON,DEPT MED,DIV CARDIOL,SEATTLE,WA 98195; EMORY UNIV,DEPT BIOCHEM,ATLANTA,GA 30322; ISIS PHARMACEUT,DEPT MOLEC PHARMACOL,CARLSBAD,CA 92008	University of Washington; University of Washington Seattle; Emory University; Isis Pharmaceuticals Inc				Berk, Bradford/0000-0002-2767-4115				ALESSI DR, 1993, ONCOGENE, V8, P2015; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAN JH, 1993, J BIOL CHEM, V268, P25009; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KING A, 1994, J CELL BIOCH B, V18, pI438; KOZMA LM, 1992, METHOD ENZYMOL, V201, P28; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MONIA BP, 1992, J BIOL CHEM, V267, P19954; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; PANG L, 1994, J BIOL CHEM, V269, P10604; PELECH SL, 1993, SCIENCE, V257, P1355; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	41	173	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7161	7166		10.1074/jbc.270.13.7161	http://dx.doi.org/10.1074/jbc.270.13.7161			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706254	hybrid			2022-12-27	WOS:A1995QQ43100025
J	HOUSTEK, J; ANDERSSON, U; TVRDIK, P; NEDERGAARD, J; CANNON, B				HOUSTEK, J; ANDERSSON, U; TVRDIK, P; NEDERGAARD, J; CANNON, B			THE EXPRESSION OF SUBUNIT-C CORRELATES WITH AND THUS MAY LIMIT THE BIOSYNTHESIS OF THE MITOCHONDRIAL F0F1-ATPASE IN BROWN ADIPOSE-TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN COMPONENTS; SYNTHASE BETA-SUBUNIT; ATP SYNTHASE; UNCOUPLING PROTEIN; BINDING-SITES; MESSENGER-RNA; RAT-LIVER; TRANSLATIONAL EFFICIENCY; THERMOGENIC MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE	A low content of mitochondrial ATPase in brown adipose tissue (BAT) has previously been found to contrast with high levels of the transcripts of the beta-subunit of the F-1 part of the ATPase and of the transcripts of the mitochondrial encoded subunits (Houstek, J., Tvrdik, P., Pavelka, S., and Baudysova, M. (1991) FEES Lett. 294, 191-194). To delineate which subunit limits the synthesis of the ATPase complex, we have studied the expression of the nuclear genes encoding subunits alpha, beta, and gamma of the catalytic F-1 part and the b, c, d, and OSCP subunits of the F-0 part of the ATPase. In comparison with other tissues of mice, high levels of transcripts of alpha-F-1, beta-F-1, gamma-F-1, b-F-0, d-F-0, and OSCP were found in BAT. The only genes expressed at a low level in BAT were those of the c-F-0 subunit. The levels of c-F, transcripts were 4-70-fold lower in BAT than in other tissues. An analogous expression pattern of the ATPase genes was found in BAT of adult rat and hamster, In BAT of newborn lamb, which, in contrast to other mammals, has a high content of mitochondrial ATPase, correspondingly high levels of c-F-0 mRNA were found, Expression of the c-F-0 genes also correlated well with the ontogenic development of EAT in the hamster, being high during the first postnatal week when mitochondria are nonthermogenic and contain a relatively high amount of ATPase, but low on subsequent days when ATPase content decreases, as the thermogenic function develops. It is suggested that expression of the c-P-0 genes and subsequent synthesis of the hydrophobic subunit c of the membrane-intrinsic F-0 part of the enzyme may control the biosynthesis of the ATPase complex in BAT. An analogous regulatory role of the c-F-0 subunit could be postulated in other tissues.	UNIV STOCKHOLM,WENNER GREN INST,ARRHENIUS LABS F3,S-10691 STOCKHOLM,SWEDEN	Stockholm University	HOUSTEK, J (corresponding author), ACAD SCI CZECH REPUBL,INST PHYSIOL,VIDENSKA 1083,CR-14220 PRAGUE,CZECH REPUBLIC.		Nedergaard, Jan/A-1706-2010; Tvrdik, Petr/AAK-4398-2021; Nedergaard, Jan/Q-8286-2019; Houstek, Josef/C-5019-2012; Andersson, Ulf/ABD-5162-2021; Cannon, Barbara/B-3089-2016	Houstek, Josef/0000-0002-8413-4772; Andersson, Ulf/0000-0003-0316-3860; Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587; Tvrdik, Petr/0000-0002-8750-9672				ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNON B, 1977, COMP BIOCHEM PHYS B, V56, P87, DOI 10.1016/0305-0491(77)90227-9; CANNON B, 1977, FEBS LETT, V76, P284, DOI 10.1016/0014-5793(77)80169-5; CASTEILLA L, 1987, AM J PHYSIOL, V252, pE627, DOI 10.1152/ajpendo.1987.252.5.E627; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FARRELL LB, 1987, BIOCHEM BIOPH RES CO, V144, P1257, DOI 10.1016/0006-291X(87)91446-X; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HOUSTEK J, 1988, EUR J BIOCHEM, V173, P1, DOI 10.1111/j.1432-1033.1988.tb13959.x; HOUSTEK J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P441, DOI 10.1016/0005-2728(90)90077-H; HOUSTEK J, 1978, COMP BIOCHEM PHYS B, V60, P209, DOI 10.1016/0305-0491(78)90088-3; HOUSTEK J, 1988, BIOCHIM BIOPHYS ACTA, V935, P19, DOI 10.1016/0005-2728(88)90103-X; HOUSTEK J, 1991, FEBS LETT, V294, P191, DOI 10.1016/0014-5793(91)80666-Q; HOUSTEK J, 1977, BIOCHIM BIOPHYS ACTA, V484, P127, DOI 10.1016/0005-2744(77)90119-X; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P247, DOI 10.1111/j.1432-1033.1992.tb17044.x; LUIS AM, 1993, J BIOL CHEM, V268, P1868; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NEDERGAARD J, 1979, METHOD ENZYMOL, V55, P1; Nicholls D. G., 1986, BROWN ADIPOSE TISSUE; RICQUIER D, 1986, BROWN ADIPOSE TISSUE; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; SVOBODA P, 1981, BIOCHIM BIOPHYS ACTA, V634, P321, DOI 10.1016/0005-2728(81)90150-X; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TVRDIK P, 1992, FEBS LETT, V313, P23, DOI 10.1016/0014-5793(92)81175-L; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WALKER JE, 1987, J MOL BIOL, V197, P89, DOI 10.1016/0022-2836(87)90611-5; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764	46	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7689	7694		10.1074/jbc.270.13.7689	http://dx.doi.org/10.1074/jbc.270.13.7689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706317	hybrid			2022-12-27	WOS:A1995QQ43100095
J	KIM, YH; BOYD, CD; CSISZAR, K				KIM, YH; BOYD, CD; CSISZAR, K			A NEW GENE WITH SEQUENCE AND STRUCTURAL SIMILARITY TO THE GENE ENCODING HUMAN LYSYL OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; STREPTOMYCES-GLAUCESCENS; MOUSE CHROMOSOME-18; H-RAS; EXPRESSION; RECEPTOR; PROTEIN; MAPS; ASSIGNMENT; TYROSINASE	We have isolated a number of recombinant clones from a human skin fibroblast cDNA library that contain extensive sequence homology to several coding domains within the human lysyl oxidase mRNA. Using one of these lysyl oxidase-like cDNAs, we obtained several overlapping genomic DNA recombinants. Restriction mapping and DNA sequence analysis revealed that the complete sequence of the lysyl oxidase-like mRNA was encoded by seven exons distributed throughout 25 kilobases of genomic DNA. Exons 2-6 encoded the region of greatest homology to lysyl oxidase. The size of these five exons, moreover, was exactly the same as the size of the corresponding exons within the lysyl oxidase gene. Northern blot analysis also revealed the concomitant appearance of lysyl oxidase and lysyl oxidase-like mRNA in several human tissues. It appears therefore that the genes encoding lysyl oxidase and a lysyl oxidase-like protein share a common evolutionary origin and may also be functionally related.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT SURG,NEW BRUNSWICK,NJ 08903	Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [HL37438, HL 39869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037438, R01HL039869, R29HL039869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CHANG YS, 1993, CYTOGENET CELL GENET, V63, P47, DOI 10.1159/000133500; CONTENTE S, 1993, GENOMICS, V16, P395, DOI 10.1006/geno.1993.1202; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CSISZAR K, 1993, GENOMICS, V16, P401, DOI 10.1006/geno.1993.1203; DORIT RL, 1991, CURR OPIN DEV, V4, P464; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; GIOVANNA P, 1991, MOL CELL BIOL, V11, P4796; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HIGGS DR, 1990, ANN NY ACAD SCI, V612, P15; HUBER M, 1988, BIOCHEMISTRY-US, V27, P5610, DOI 10.1021/bi00415a032; HUBER M, 1985, BIOCHEMISTRY-US, V24, P6038, DOI 10.1021/bi00343a003; JACOB ST, 1990, CRIT REV EUKARYOTIC, V7, P49; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1991, AM J RESPIR CELL MOL, V3, P206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KREBS CJ, 1993, BIOCHIM BIOPHYS ACTA, V1202, P7, DOI 10.1016/0167-4838(93)90056-W; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUIVANIEMI H, 1985, BIOCHEM J, V230, P639, DOI 10.1042/bj2300639; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOSSIE AC, 1993, MAMM GENOME, V4, P177, DOI 10.1007/BF00352234; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MOCK BA, 1992, GENOMICS, V14, P822, DOI 10.1016/S0888-7543(05)80201-0; SACCONE C, 1991, EUR J BIOCHEM, V1, P151; Sambrook J., 1989, MOL CLONING; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SEELAN RS, 1993, GENOMICS, V18, P527; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; SVINARICH DM, 1992, J BIOL CHEM, V267, P14382; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11; WU Y, 1992, J BIOL CHEM, V267, P24199	42	105	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7176	7182		10.1074/jbc.270.13.7176	http://dx.doi.org/10.1074/jbc.270.13.7176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706256	hybrid			2022-12-27	WOS:A1995QQ43100027
J	WANG, Q; ORRISON, BM; MARINI, JC				WANG, Q; ORRISON, BM; MARINI, JC			2 ADDITIONAL CASES OF OSTEOGENESIS IMPERFECTA WITH SUBSTITUTIONS FOR GLYCINE IN THE ALPHA-2(I) COLLAGEN CHAIN - A REGIONAL MODEL RELATING MUTATION LOCATION WITH PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I PROCOLLAGEN; POINT MUTATIONS; TRIPLE HELIX; COL1A1; VALINE; GENE; FEATURES	The relationship between the clinical severity of osteogenesis imperfecta (OI) and the location and type of amino acid substitution in type I collagen is not identical for mutations in the alpha1(I) and alpha2(I) chains. Furthermore, the alpha2(I) chain, once thought to be associated with moderate forms of OI, has now been associated with approximately as many lethal as non-lethal cases. We describe two novel substitutions for glycine in the alpha2(I) chain, one associated with a lethal phenotype in twins and the other with a moderate non-lethal phenotype. The type I collagen of all probands was characterized electrophoretically by two populations of alpha chains, one normal and one with delayed migration. Cyanogen bromide peptides of the overmodified alpha1(I) chains revealed delayed migration of all peptides except CB6. The indicated target region of alpha1(I) and alpha2(I) cDNA of the probands was analyzed by RNA-DNA hybrid analysis with RNase A digestion. All probands had mismatches in the region of alpha2(I) coding for amino acids 642-912. The lethal phenotype was associated with a G --> A mutation, resulting in Gly706 --> serine; the non-lethal mutation was a G --> T change resulting in Gly676 --> valine. Both mutations occurred de novo in the probands; parental leukocyte DNA was normal. In conjunction with the previously described exon deletions and point mutations in alpha2(I), these mutations define five alternating non-lethal/lethal regions along the chain and support a regional, as opposed to a gradient, model of OI pathophysiology. These mutations in particular help to define a lethal/non-lethal junction at about alpha2(I) amino acid 700.	NICHHD,HUMAN GENET BRANCH,CONNECT TISSUE DISORDERS SECT,BLDG 10,RM 95242,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BATEMAN JF, 1991, BIOCHEM J, V276, P765, DOI 10.1042/bj2760765; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BONAVENTURE J, 1992, HUM GENET, V89, P640; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; BYERS PH, 1988, AM J HUM GENET, V42, P237; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE WG, 1992, J MED GENET, V29, P112, DOI 10.1136/jmg.29.2.112; FERRIE RM, 1992, AM J HUM GENET, V51, P251; FILIE JD, 1993, IN PRESS HUMAN MUTAT; GRANGE DK, 1990, NUCLEIC ACIDS RES, V18, P4227, DOI 10.1093/nar/18.14.4227; LAMANDE SR, 1989, J BIOL CHEM, V264, P15809; MARINI JC, 1989, J BIOL CHEM, V264, P11893; MARINI JC, 1993, J BIOL CHEM, V268, P2667; PATTERSON E, 1989, J BIOL CHEM, V264, P10083; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; TSUNEYOSHI T, 1991, J BIOL CHEM, V266, P15608; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590	20	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					25162	25167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693712				2022-12-27	WOS:A1993MG67300092
J	OTEY, CA; VASQUEZ, GB; BURRIDGE, K; ERICKSON, BW				OTEY, CA; VASQUEZ, GB; BURRIDGE, K; ERICKSON, BW			MAPPING OF THE ALPHA-ACTININ BINDING-SITE WITHIN THE BETA-1 INTEGRIN CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTORS; OVERLAY TECHNIQUE; VINCULIN; PROTEINS; TALIN; ADHESION; MUSCLE	The actin cross-linking protein alpha-actinin binds to the cytoplasmic domain of the beta1 subunit of integrin, suggesting that alpha-actinin may form a direct link between the actin cytoskeleton and the transmembrane fibronectin receptor. In this study, we have used short synthetic peptides to localize the binding site for alpha-actinin within the cytoplasmic domain of beta1 integrin. Four 13-residue peptides were tested in both an affinity chromatographic assay and a solid-phase binding assay. The results indicated that two regions of sequence contribute to the binding of alpha-actinin: one near where the beta1 cytoplasmic tail emerges from the membrane and a second segment located near the C terminus of the cytoplasmic tail. This binding pattern was investigated in more detail using an adaptation of the mimotope assay, in which each of the 32 overlapping sequential decapeptide segments from the beta1 cytoplasmic domain was assembled on the head of a different plastic pin. The peptide-pin constructs were used to detect the binding of I-125-alpha-actinin. As predicted from our initial results, alpha-actinin was found to bind to two distinct clusters of peptide segments. This represents a novel use of the mimotope pin assay to map interactive sites on structural proteins.	UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042031, R01GM029860] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29860, GM-42031] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1990, CELL DIFFER DEV, V32, P337, DOI 10.1016/0922-3371(90)90048-2; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GOLDMANN WH, 1991, BIOCHEM BIOPH RES CO, V178, P718, DOI 10.1016/0006-291X(91)90167-6; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SIMON KO, 1991, CURR TOP MEMBR, V38, P57; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WILKINS JA, 1983, BIOCHEM BIOPH RES CO, V116, P1026, DOI 10.1016/S0006-291X(83)80245-9	22	242	248	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21193	21197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691808				2022-12-27	WOS:A1993MA28800081
J	FUKUTA, M; MATSUNO, K; HUI, CC; NAGATA, T; TAKIYA, S; XU, PX; UENO, K; SUZUKI, Y				FUKUTA, M; MATSUNO, K; HUI, CC; NAGATA, T; TAKIYA, S; XU, PX; UENO, K; SUZUKI, Y			MOLECULAR-CLONING OF A POU DOMAIN-CONTAINING FACTOR INVOLVED IN THE REGULATION OF THE BOMBYX SERICIN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; SILK GLAND; CELLS; STIMULATION; REPLICATION; PROTEINS; UPSTREAM; INVITRO; REGION	The POU domain is a highly conserved region found in a number of transcription factors and products of developmental control genes. We report here the isolation and characterization of a POU domain-containing cDNA (POU-M1) from the middle silk gland of Bombyx mori. It encodes a protein with a POU domain identical to that of the Drosophila Cf1-a protein. By mobility shift and nuclease protection assays, the POU-M1 protein and the putative silk gland factor 3 (SGF-3) were found to interact in an indistinguishable manner with the SC region (positions -204 to -183) of the sericin-1 gene, a key cis-acting element involved in the regulation of the gene through the interaction with SGF-3. Antibodies raised against the synthetic oligopeptide corresponding to the COOH-terminal region of the putative POU-M1 sequence reacted specifically to both the POU-M1 protein and SGF-3. Northern blot hybridization and Western blotting revealed that POU-M1 expression is regulated both temporally and spatially during silk gland development. We conclude that the POU-M1 protein is SGF-3 and propose that the differential expression of the POU-M1 gene is probably involved in the transcriptional regulation of the silk protein genes.	NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,OKAZAKI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Takiya, Shigeharu/A-6439-2012					AMANAI K, 1991, DEV GROWTH DIFFER, V33, P421; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MATSUNO K, 1990, NUCLEIC ACIDS RES, V18, P1853, DOI 10.1093/nar/18.7.1853; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SUZUKI N, 1990, EMBO J, V9, P435; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; Suzuki Y., 1990, MOL INSECT SCI, P83; SWANSON LW, 1989, NATURE, V340, P35; TASHIRO Y, 1968, J CELL BIOL, V38, P574, DOI 10.1083/jcb.38.3.574; TSUDA M, 1983, P NATL ACAD SCI-BIOL, V80, P7442, DOI 10.1073/pnas.80.24.7442; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x	26	56	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19471	19475						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690034				2022-12-27	WOS:A1993LW81900051
J	CALVO, D; VEGA, MA				CALVO, D; VEGA, MA			IDENTIFICATION, PRIMARY STRUCTURE, AND DISTRIBUTION OF CLA-1, A NOVEL MEMBER OF THE CD36/LIMPII GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; INTEGRAL MEMBRANE-PROTEIN; MONOCLONAL-ANTIBODY; THROMBOSPONDIN RECEPTOR; INFECTED ERYTHROCYTES; PLATELET-AGGREGATION; SIGNAL TRANSDUCTION; SURFACE EXPRESSION; ENDOTHELIAL-CELLS; HUMAN-MONOCYTES	The thrombospondin and collagen type I receptor CD36 is a plasma membrane glycoprotein present in a restricted number of cell types. By contrast, rat lysosomal integral membrane protein II (LIMPII) is expressed on the membrane of lysosomes in all cell types so far examined. Nevertheless, both belong to the same gene family based on alignment of their respective amino acid sequences. To explore the existence of other related members, we have used the polymerase chain reaction with primers derived from highly conserved amino acid regions between CD36 and rat LIMPII. A human cDNA corresponding to a novel member of this family has been identified and isolated. This new member has been designated as CD36 and LIMPII Analogous-1 (CLA-1) . Human CLA-1 cDNA predicts a protein 409 amino acids long with a 20% amino acid identity with CD36 and rat LIMPII. Further studies revealed that the sequenced cDNA clone may result by alternative splicing from a longer mRNA form having an insertion of 300 nucleotides located 126 nucleotides downstream from the initiation codon of cloned CLA-1. This form would encode a protein 509 amino acids long, whose sequence matches without any long gap to amino acid sequences of CD36 and rat LIMPII. Northern blot analysis indicates that CLA-1 is widely expressed although its mRNA steady state levels vary considerably among the analyzed cell types. Transient transfection experiments of a CD36-CLA-1 chimera, constructed by replacing the carboxyl cytoplasmic tail of CD36 for the carboxyl cytoplasmic tail of CLA-1, suggest that native CLA-1 protein is found on the plasma membrane.	HOSP PRINCESA,UNIDAD BIOL MOLEC,PLANTA 9,C DIEGO LEON 62,E-28006 MADRID,SPAIN	Hospital de La Princesa			Vega, Miguel A/M-1367-2016	Vega, Miguel A/0000-0001-6151-4193				AIKEN ML, 1990, BLOOD, V76, P2501; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; EDELMAN P, 1986, BLOOD, V67, P56; GREENWALT DE, 1985, J CELL BIOL, V100, P397, DOI 10.1083/jcb.100.2.397; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JUHLIN L, 1989, ACTA DERM-VENEREOL, V69, P403; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; VANSCHRAVENDIJK MR, 1992, BLOOD, V80, P2105; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VEGA MA, 1991, J BIOL CHEM, V266, P16269	33	252	276	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18929	18935						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689561				2022-12-27	WOS:A1993LV65900083
J	CORSI, D; GALLUZZI, L; CRINELLI, R; MAGNANI, M				CORSI, D; GALLUZZI, L; CRINELLI, R; MAGNANI, M			UBIQUITIN IS CONJUGATED TO THE CYTOSKELETAL PROTEIN ALPHA-SPECTRIN IN MATURE ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANE SKELETON; DEGRADATION; RESOLUTION; PATHWAY; BINDING; QUANTITATION; INVITRO; LIGASE; CYCLIN	Ubiquitination of red blood cell (RBC) proteins was investigated by encapsulation of I-125-ubiquitin into human erythrocytes using a procedure of hypotonic dialysis, isotonic resealing, and reannealing. Incubation (37 degrees C, up to 2 h) of I-125-ubiquitin-loaded cells resulted in the recovery of I-125-ubiquitin with the cytosolic proteins (9.22 +/- 0.4 mu g/ml RBC) and conjugated to membrane proteins (2.18 +/- 0.05 mu g/ml RBC). This conjugation was time-dependent, and the predominant membrane protein band that became labeled showed an apparent molecular mass of 240 kDa on SDS-polyacrylamide gel electrophoresis (PAGE). Western blotting experiments with three different anti-ubiquitin antibodies revealed that this protein is also ubiquitinated in vivo. Cell-free experiments have shown that fraction II (a DEAE-bound protein fraction eluted by 0.5 M KCl) prepared from both mature erythrocytes and reticulocytes is able to conjugate ubiquitin to this protein. Ubiquitin conjugation was ATP-dependent (K-m 0.09 mM), time-dependent, and fraction II-dependent (8 +/- 0.5 pmol of I-125-ubiquitin/h/mg of fraction II). Isolation of the major RBC membrane protein that is ubiquitinated was obtained by using biotinylated ubiquitin. Membrane proteins, once ubiquitinated with this derivative, were extracted and purified by affinity chromatography on immobilized avidin. The major components retained by the column were two peptides of molecular masses 220 and 240 kDa. Both proteins are recognized by a monoclonal anti-spectrin antibody, but only the 240-kDa component is detected by streptavidin peroxidase conjugate. That indeed the ubiquitinated membrane protein of 240-kDa is alpha-spectrin was confirmed by immunoaffinity chromatography using I-125-ubiquitin and a monoclonal anti-spectrin antibody. Antigen-antibody complexes were purified by protein A chromatography and analyzed by SDS-PAGE and autoradiography. Again two bands of 240 and 220 kDa were eluted (alpha- and beta-spectrin), but only one band corresponding to the electrophoretic mobility of alpha-spectrin was detected by autoradiography. Thus, alpha-spectrin is a substrate for the ATP-dependent ubiquitination system, suggesting that the cytoskeleton is convalently modified by ubiquitination both in reticulocytes and mature RBC.	UNIV URBINO, IST CHIM BIOL G FORNAINI, I-61029 URBINO, ITALY	University of Urbino			Magnani, Mauro/A-1919-2008; Galluzzi, Luca/G-3969-2012	Galluzzi, Luca/0000-0002-1747-526X; Crinelli, Rita/0000-0002-1235-8910; Magnani, Mauro/0000-0001-6456-6626				BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COHEN CM, 1983, SEMIN HEMATOL, V20, P141; COOK WJ, 1992, J BIOL CHEM, V267, P15116; DeLoach J. R, 1992, USE RESEALED ERYTHRO; DUNIGAN DD, 1988, VIROLOGY, V165, P310, DOI 10.1016/0042-6822(88)90691-5; FEBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRIED VA, 1987, P NATL ACAD SCI USA, V84, P3685, DOI 10.1073/pnas.84.11.3685; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1991, ADV EXP MED BIOL, V307, P191; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HANSPAL M, 1992, SEMIN HEMATOL, V29, P305; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KONG SK, 1992, J BIOL CHEM, V267, P14189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNANI M, 1992, ANN NY ACAD SCI, V673, P103, DOI 10.1111/j.1749-6632.1992.tb27441.x; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RECHSTEIMER M, 1988, UBIQUITIN; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROSSI L, 1992, BIOTECHNOL APPL BIOC, V15, P207; SATO SB, 1983, EUR J BIOCHEM, V130, P19; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STJOHN T, 1986, SCIENCE, V231, P845, DOI 10.1126/science.3003914; SULLIVAN ML, 1990, PLANT PHYSIOL, V94, P710, DOI 10.1104/pp.94.2.710; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	40	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8928	8935		10.1074/jbc.270.15.8928	http://dx.doi.org/10.1074/jbc.270.15.8928			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721801	hybrid			2022-12-27	WOS:A1995QT44800080
J	LIU, YS; GOROSPE, M; YANG, CL; HOLBROOK, NJ				LIU, YS; GOROSPE, M; YANG, CL; HOLBROOK, NJ			ROLE OF MITOGEN-ACTIVATED PROTEIN-KINASE PHOSPHATASE DURING THE CELLULAR-RESPONSE TO GENOTOXIC STRESS - INHIBITION OF C-JUN N-TERMINAL KINASE-ACTIVITY AND AP-1-DEPENDENT GENE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IMMEDIATE-EARLY GENE; TYROSINE-PHOSPHATASE; GROWTH; COMPLEX; AP-1; FOS; PRODUCT; 3CH134	Irradiation of mammalian cells with short wavelength ultraviolet light (UVC) evokes a cascade of phosphorylation events leading to altered gene expression. Both the classic mitogen-activated protein (MAP) kinases and the distantly related c-Jun N-terminal kinases (JNK) contribute to the response via phosphorylation of transcription factors including AP-1. These kinases are themselves regulated via reversible phosphorylation, and several recently identified specific MAP kinase phosphatases (MKP) have been implicated in down regulating MAP kinase-dependent gene expression in response to mitogens. Here, we provide evidence that MKP-1 plays a role in regulating transcriptional activation in response to UVC as well as another genotoxic agent, methyl methanesulfonate (MMS). We further demonstrate that JNK is a likely target for MKP-1. JNK is shown to be activated by UVC and MMS treatment, while MAP kinase activation occurs only with UVC. Like JNK activation, MKP-1 mRNA is induced by both treatments, and elevated MKP-1 expression coincides with a decline in JNK activity. Constitutive expression of MKP-1 in vivo inhibits JNK activity and reduces UVC- and MMS-induced activation of AP-1-dependent reporter genes.	NIA,GENE EXPRESS & AGING SECT,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				ABDELHAFIZ HAM, 1992, MOL ENDOCRINOL, V16, P2079; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLBROOK NJ, 1992, OXIDATIVE DAMAGE REP, P202; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YAN MH, 1994, NATURE, V372, P798	37	273	278	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8377	8380		10.1074/jbc.270.15.8377	http://dx.doi.org/10.1074/jbc.270.15.8377			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721728	hybrid			2022-12-27	WOS:A1995QT44800002
J	ZHANG, XL; MATHEWS, CK				ZHANG, XL; MATHEWS, CK			NATURAL DNA PRECURSOR POOL ASYMMETRY AND BASE SEQUENCE CONTEXT AS DETERMINANTS OF REPLICATION FIDELITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYMERASES; GENOME	Previous studies showed a complex relationship between nucleotide composition of a gene and the rate of the gene's evolutionary variation. We have investigated mechanisms by constructing M13 phagemids containing part of the Escherichia coli lacZ gene, in which an opal codon is flanked either by nine adenine . thymine base pairs on each side, or by nine guanine . cytosine pairs, or by its wild-type sequence context. Reversions or pseudoreversions within the opal codon yield a lacZ alpha-peptide that can undergo alpha-complementation and yield a blue plaque when plated with a chromogenic substrate. When these constructs were replicated in HeLa cell extracts, in the presence of equimolar deoxyribonucleoside triphosphate (dNTP) mixtures, reversion was near background levels in both the AT-rich and GC-rich contexts. By contrast, when the DNAs were replicated at dNTP concentrations approximating those in HeLa cell nuclei, increases over background were seen in all three contexts. Replication of the phagemids in vivo led to even higher mutation frequencies. Replication in the presence of dGMP, added to inhibit proofreading, caused extraordinarily high reversion frequencies in the GC-flanked opal codon. Apparently, dNTP concentrations approximating intracellular concentrations are mildly but significantly mutagenic, and pool asymmetries and base sequence context both contribute to the natural fidelity of DNA replication.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; NIEHS,RES TRIANGLE PK,NC 27709	Oregon State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								BECKMAN RA, 1994, Q REV BIOPHYS, V26, P225; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNZ BA, 1994, MUTAT RES, V318, P175; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; NORTH TW, 1980, J BIOL CHEM, V255, P6640; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0	15	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8401	8404		10.1074/jbc.270.15.8401	http://dx.doi.org/10.1074/jbc.270.15.8401			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721732	hybrid			2022-12-27	WOS:A1995QT44800008
J	FRODIN, M; SEKINE, N; ROCHE, E; FILLOUX, C; PRENTKI, M; WOLLHEIM, CB; VANOBBERGHEN, E				FRODIN, M; SEKINE, N; ROCHE, E; FILLOUX, C; PRENTKI, M; WOLLHEIM, CB; VANOBBERGHEN, E			GLUCOSE, OTHER SECRETAGOGUES, AND NERVE GROWTH-FACTOR STIMULATE MITOGEN-ACTIVATED PROTEIN-KINASE IN THE INSULIN-SECRETING BETA-CELL LINE, INS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CYTOSOLIC CA2+; CAMP; PHOSPHORYLATION; PATHWAY; ISLETS; RAF-1; NUCLEOTIDES	The signaling pathways whereby glucose and hormonal secretagogues regulate insulin-secretory function, gene transcription, and proliferation of pancreatic beta-cells are not well defined. We show that in the glucose-responsive beta-cell line INS-1, major secretagogue-stimulated signaling pathways converge to activate 44-kDa mitogen-activated protein (MAP) kinase. Thus, glucose-induced insulin secretion was found to be associated with a small stimulatory effect on 44-kDa MAP kinase, which was synergistically enhanced by increased levels of intracellular cAMP and by the hormonal secretagogues glucagon-like peptide-1 and pituitary adenylate cyclase-activating polypeptide. Activation of 44-kDa MAP kinase by glucose was dependent on Ca2+ influx and may in part be mediated by MEK-1, a MAP kinase kinase. Stimulation of Ca2+ influx by KCl was in itself sufficient to activate 44-kDa MAP kinase and MEK-1. Phorbol ester, an activator of protein kinase C, stimulated 44-kDa MAP kinase by both Ca2+-dependent and -independent pathways. Nerve growth factor, independently of changes in cytosolic Ca2+, efficiently stimulated 44-kDa MAP kinase without-causing insulin release, indicating that activation of this kinase is not sufficient for secretion. In the presence of glucose, however, nerve growth factor potentiated insulin secretion. In INS-1 cells, activation of 44-kDa MAP kinase was partially correlated with the induction of early response genes junB, nur77, and zif268 but not with stimulation of DNA synthesis, Our findings suggest a role of 44-kDa MAP kinase in mediating some of the pleiotropic actions of secretagogues on the pancreatic beta-cell.	FAC MED NICE, INSERM, U145, F-06107 NICE 2, FRANCE; UNIV GENEVA, DEPT MED, DIV BIOCHIM CLIN, CH-1211 GENEVA 4, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Geneva			Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672; Frodin, Morten/0000-0003-3691-9820				AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUN T, 1993, J BIOL CHEM, V268, P18905; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SA, 1990, ENDOCRINOLOGY, V126, P1895, DOI 10.1210/endo-126-4-1895; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EDWARDS RH, 1989, CELL, V58, P161, DOI 10.1016/0092-8674(89)90412-1; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; FEHMANN HC, 1992, MOL CELL ENDOCRINOL, V85, pC39, DOI 10.1016/0303-7207(92)90118-P; FRODIN M, 1993, J BIOL CHEM, V42, P1829; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARIE S, 1993, J BIOL CHEM, V268, P23881; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SCHARFMANN R, 1993, DIABETES, V42, P1829, DOI 10.2337/diabetes.42.12.1829; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P9313, DOI 10.1021/bi00102a025; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; THELER JM, 1992, J BIOL CHEM, V267, P18110; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YADA T, 1994, J BIOL CHEM, V269, P1290	54	193	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7882	7889		10.1074/jbc.270.14.7882	http://dx.doi.org/10.1074/jbc.270.14.7882			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713882	hybrid			2022-12-27	WOS:A1995QR52600018
J	HARAYOKOYAMA, M; HIRABAYASHI, Y; IRIE, F; SYUTO, B; MORIISHI, K; SUGIYA, H; FURUYAMA, S				HARAYOKOYAMA, M; HIRABAYASHI, Y; IRIE, F; SYUTO, B; MORIISHI, K; SUGIYA, H; FURUYAMA, S			IDENTIFICATION OF GANGLIOSIDES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASES OF PERTUSSIS TOXIN AND EXOENZYME C3 FROM CLOSTRIDIUM-BOTULINUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; ISLET-ACTIVATING PROTEIN; BORDETELLA-PERTUSSIS; BOVINE BRAIN; MEDIATED MODULATION; NAD GLYCOHYDROLASE; POLY(ADP-RIBOSE) SYNTHETASE; MOLECULAR CHARACTERIZATION; INTERMEDIATE FILAMENTS; RIBOSYLATION REACTION	We have previously reported the presence of an endogenous inhibitory activity in bovine brain for the ADP-ribosylation of GTP-binding proteins catalyzed by pertussis toxin (PT) (Hara-Yokoyama, M., and Furuyama, S, (1989) Biochem. Biophys. Res. Commun. 160, 67-71). In the present study, we identified the inhibitor as a ganglioside, The screening of various gangliosides revealed that G(Q1b alpha) most effectively inhibited the ADP-ribosyltransferase activities of both the holoenzyme and the catalytic subunit of PT. G(Q1b alpha) is a ganglioside newly identified as one of the antigens recognized by the cholinergic neuron-specific antibody, anti-Chol-1 alpha (Hirabayashi, Y,, Nakao, T,, Irie, F,, Whittaker, V,P., Ken, R,, and Ando, S. (1992) J. Biol. Chem. 267, 12973-12978), G(Q1b alpha) also inhibited the PT-catalyzed NAD(+) glycohydrolysis. Unlike PT activity, the ADP-ribosylation and the NAD(+) glycohydrolysis catalyzed by the C3 exoenzyme from Clostridium botulinum type C were inhibited by G(T1b) and G(Q1b). The ADP-ribosylation catalyzed by either PT or the C3 exoenzyme was not inhibited by ceramide, galactocerebroside, or sialic acid. In addition to the inhibitory action of gangliosides on ADP-ribosylation, the importance of gangliosides as regulators of NAD(+) metabolism is discussed.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,GLYCO CELL BIOL LAB,WAKO,SAITAMA 35101,JAPAN; HOKKAIDO UNIV,FAC VET MED,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	RIKEN; Hokkaido University	HARAYOKOYAMA, M (corresponding author), NIHON UNIV,SCH DENT,DEPT PHYSIOL,NISHI KU,2-870-1 SAKAE CHO,MATSUDO,CHIBA 271,JAPAN.		Moriishi, Kohji/I-4173-2019	Moriishi, Kohji/0000-0002-9542-5188; Hirabayashi, Yoshio/0000-0002-5774-7354				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BANASIK M, 1990, FEBS LETT, V263, P222, DOI 10.1016/0014-5793(90)81378-2; BOHM M, 1991, BIOCHEM J, V277, P223; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; BROWN EB, 1975, BIOCHIM BIOPHYS ACTA, V399, P124, DOI 10.1016/0304-4165(75)90218-4; BRUNE B, 1990, P NATL ACAD SCI USA, V87, P3304, DOI 10.1073/pnas.87.9.3304; BURNS DL, 1986, J BIOL CHEM, V261, P4324; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DIGIROLAMO M, 1992, J BIOL CHEM, V267, P17397; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUNAGA K, 1990, J NEUROCHEM, V54, P102, DOI 10.1111/j.1471-4159.1990.tb13288.x; GILLARD BK, 1992, CELL MOTIL CYTOSKEL, V21, P255, DOI 10.1002/cm.970210402; GILLARD BK, 1993, GLYCOBIOLOGY, V3, P57, DOI 10.1093/glycob/3.1.57; GILLARD BK, 1991, EXP CELL RES, V192, P433, DOI 10.1016/0014-4827(91)90062-Y; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARAYOKOYAMA M, 1988, FEBS LETT, V234, P27, DOI 10.1016/0014-5793(88)81295-X; HARAYOKOYAMA M, 1989, BIOCHEM BIOPH RES CO, V160, P67, DOI 10.1016/0006-291X(89)91621-5; HARDY DL, 1992, BIOCHEM J, V283, P849, DOI 10.1042/bj2830849; HAUSMAN SZ, 1993, INFECT IMMUN, V61, P335, DOI 10.1128/IAI.61.1.335-337.1993; HEMMI H, 1982, BIOCHEM BIOPH RES CO, V109, P669, DOI 10.1016/0006-291X(82)91992-1; HIGASHI H, 1992, J BIOL CHEM, V267, P9831; HIGASHI H, 1992, J BIOL CHEM, V267, P9839; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HOKOMORI S, 1990, J BIOL CHEM, V265, P18713; HOSHINO S, 1990, FEBS LETT, V276, P227, DOI 10.1016/0014-5793(90)80548-W; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; IRIE F, 1994, FEBS LETT, V351, P291, DOI 10.1016/0014-5793(94)00883-3; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KOTANI M, 1994, CELL STRUCT FUNCT, V19, P81, DOI 10.1247/csf.19.81; KRUEGER KM, 1993, J BIOL CHEM, V268, P12570; Ledeen R W, 1976, Adv Exp Med Biol, V71, P83; MACHIDA M, 1985, J BIOL CHEM, V260, P6143; MAEHAMA T, 1991, J BIOL CHEM, V266, P10062; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MATSUYAMA S, 1991, J NEUROCHEM, V57, P1380, DOI 10.1111/j.1471-4159.1991.tb08304.x; MILLERPODRAZA H, 1983, J NEUROCHEM, V41, P860, DOI 10.1111/j.1471-4159.1983.tb04819.x; MORIISHI K, 1990, J BIOL CHEM, V265, P16614; MORIISHI K, 1991, J BACTERIOL, V173, P6025, DOI 10.1128/jb.173.19.6025-6029.1991; MOSS J, 1983, J BIOL CHEM, V258, P1879; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; MULLER HM, 1983, BIOCHEM J, V212, P459, DOI 10.1042/bj2120459; MURCIA G, 1988, BIOCH CELL BIOL, V66, P626; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; NISHINA H, 1994, BIOCHEM BIOPH RES CO, V203, P1318, DOI 10.1006/bbrc.1994.2326; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAUKKONEN K, 1992, P NATL ACAD SCI USA, V89, P118, DOI 10.1073/pnas.89.1.118; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SHIMA T, 1969, J BIOL CHEM, V244, P6632; SONNINO S, 1979, J NEUROCHEM, V33, P117, DOI 10.1111/j.1471-4159.1979.tb11713.x; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKESAWA S, 1993, J BIOL CHEM, V268, P26052; TAKI T, 1986, J BIOL CHEM, V261, P3075; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; TAMURA M, 1983, J BIOL CHEM, V258, P6756; TANUMA S, 1989, BIOCHIM BIOPHYS ACTA, V1010, P246, DOI 10.1016/0167-4889(89)90168-7; TANUMA S, 1988, J BIOL CHEM, V263, P5485; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VEDIA LMY, 1989, BIOCHEM J, V261, P841, DOI 10.1042/bj2610841; WEST RE, 1985, J BIOL CHEM, V260, P4428; WITVLIET MH, 1989, INFECT IMMUN, V57, P3324, DOI 10.1128/IAI.57.11.3324-3330.1989; YAJIMA M, 1978, J BIOCHEM-TOKYO, V83, P295, DOI 10.1093/oxfordjournals.jbchem.a131904; YAJIMA M, 1978, J BIOCHEM-TOKYO, V83, P305, DOI 10.1093/oxfordjournals.jbchem.a131905; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	81	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8115	8121		10.1074/jbc.270.14.8115	http://dx.doi.org/10.1074/jbc.270.14.8115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713915	hybrid			2022-12-27	WOS:A1995QR52600053
J	WARD, NE; GRAVITT, KR; OBRIAN, CA				WARD, NE; GRAVITT, KR; OBRIAN, CA			IRREVERSIBLE INACTIVATION OF PROTEIN-KINASE-C BY A PEPTIDE-SUBSTRATE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; AFFINITY LABELS; DOMAIN; ACTIVATION; INHIBITOR; BINDING	Protein kinase C (PKC) is a phospholipid-dependent isozyme family that plays a pivotal role in mammalian signal-transduction pathways that mediate cell growth and differentiation and pathological developments, such as the acquisition of drug resistance by cancer cells, Several peptide-substrate analogs have been shown to reversibly inhibit PKC with high potency and selectivity, but peptide-substrate analogs that antagonize PKC by forming a covalent complex with the enzyme have not been reported, The development of active site-directed irreversible inactivators of PKC could provide new insights into the catalytic mechanism and might ultimately lead to the design of novel therapeutics targeted at PKC. In this report, we show that the peptide substrate analog Arg-Lys-Arg-Cys-Leu-Arg-Arg-Leu (RKRCLRRL) irreversibly inactivates PKC in a dithiothreitol-sensitive manner, The inactivation mechanism most consistent with our results is the formation of a covalent Linkage between the inhibitor-peptide and the enzyme at its active-site, Limited proteolysis of PKC produces a catalytic domain fragment that is independent of the phospholipid cofactor, RKRCLRRL antagonized the histone kinase activity of PKC and its catalytic-domain fragment with similar efficacies, achieving >50% inactivation at an RKRCLRRL concentration of 10 mu M. In contrast, RKRCLRRL analogs with single amino acid substitutions at Cys were non-inhibitory, The inactivated complex of the catalytic domain fragment and RKRCLRRL was stable upon dilution, and the inactivation of PKC and the catalytic-domain fragment by RKRCLRRL was quenched by dithiothreitol, providing evidence that the enzyme and the synthetic peptide may be covalently linked in an inactivated complex by a disulfide bond, Substrates and substrate analogs protected the catalytic-domain fragment against inactivation by RKRCLRRL, providing evidence that inactivation entailed binding of RKRCLRRL at the active-site of the enzyme. S-Thiolation is the formation of mixed disulfides between proteins and low molecular weight thiols, PRC is thought to have a highly reactive Cys residue in its active-site, and Cys residues that are flanked by basic residues, as is the case in RKRCLRRL, display enhanced reactivity, Our results support an inactivation mechanism that entails S-thiolation of the active-site of PKC by RKRCLRRL. This is the first report of irreversible inactivation of PKC by an active site-directed peptide.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R29CA052460] Funding Source: NIH RePORTER; NCI NIH HHS [CA52460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAMSON HN, 1982, J BIOL CHEM, V257, P575; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; DEBONT HBA, 1989, INT J PEPT PROT RES, V33, P115; DEKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V47, P425, DOI 10.1016/0006-2952(94)90037-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1988, J BIOL CHEM, V263, P14839; KUO JF, 1994, PROTEIN KINASE C; LESTER DS, 1992, PROTEIN KINASE C CUR; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; OBRIAN CA, 1990, BIOCHEM PHARMACOL, V39, P49, DOI 10.1016/0006-2952(90)90647-4; OBRIAN CA, 1989, MOL PHARMACOL, V36, P355; OBRIAN CA, 1991, INVEST NEW DRUG, V9, P169, DOI 10.1007/BF00175084; OBRIAN CA, 1993, ADV MOL CEL, V7, P61; OBRIAN CA, 1995, IN PRESS ATYPICAL MU; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SALERNO A, 1993, J BIOL CHEM, V268, P13043; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; SU HD, 1986, BIOCHEM BIOPH RES CO, V134, P78, DOI 10.1016/0006-291X(86)90529-2; TURNER RS, 1985, J BIOL CHEM, V260, P1503; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020	31	33	35	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8056	8060		10.1074/jbc.270.14.8056	http://dx.doi.org/10.1074/jbc.270.14.8056			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713907	hybrid			2022-12-27	WOS:A1995QR52600044
J	DREWES, G; TRINCZEK, B; ILLENBERGER, S; BIERNAT, J; SCHMITTULMS, G; MEYER, HE; MANDELKOW, EM; MANDELKOW, E				DREWES, G; TRINCZEK, B; ILLENBERGER, S; BIERNAT, J; SCHMITTULMS, G; MEYER, HE; MANDELKOW, EM; MANDELKOW, E			MICROTUBULE-ASSOCIATED PROTEIN MICROTUBULE AFFINITY-REGULATING KINASE (P110(MARK)) - A NOVEL PROTEIN-KINASE THAT REGULATES TAU-MICROTUBULE INTERACTIONS AND DYNAMIC INSTABILITY BY PHOSPHORYLATION AT THE ALZHEIMER-SPECIFIC SITE SERINE-262	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3; ABNORMAL PHOSPHORYLATION; BINDING DOMAINS; DISEASE; TUBULIN; SEQUENCE; STATE; IDENTIFICATION; LOCALIZATION	Aberrant phosphorylation of the microtubule-associated protein tau is one of the pathological features of neuronal degeneration in Alzheimer's disease. The phosphorylation of Ser-262 within the microtubule binding region of tau is of particular interest because so far it is observed only in Alzheimer's disease (Hasegawa, M., Morishima-Kawashima, M., Takio, K,, Suzuki, M., Titani, K., and Ihara, Y. (1992) J. Biol. Chem. 26, 17047-17054) and because phosphorylation of this site alone dramatically reduces the affinity for microtubules in vitro (Biernat, J., Gustke, N., Drewes, G., Mandelkow, E. M., and Mandelkow, E. (1993) Neuron 11, 153-163). Here we describe the purification and characterization of a protein-serine kinase from brain tissue with an apparent molecular mass of 110 kDa on SDS gels. This kinase specifically phosphorylates tau on its KIGS or KCGS motifs in the repeat domain, whereas no significant phosphorylation outside this region was detected. Phosphorylation occurs mainly on Ser-262 located in the first repeat. This largely abolishes tau's binding to microtubules and makes them dynamically unstable, in contrast to other protein kinases that phosphorylate tau at or near the repeat domain. The data suggest a role for this novel kinase in cellular events involving rearrangement of the microtubule associated proteins/microtubule arrays and their pathological degeneration in Alzheimer's disease.	MAX PLANCK UNIT STRUCT MOLEC BIOL, D-22603 HAMBURG, GERMANY; RUHR UNIV BOCHUM, INST PHYSIOL CHEM, D-44780 BOCHUM, GERMANY	Max Planck Society; Ruhr University Bochum				Drewes, Gerard/0000-0003-0575-6766				ANDERTON BH, 1993, HIPPOCAMPUS, V3, P227; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1991, BIOCHEM J, V279, P831, DOI 10.1042/bj2790831; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GONG CX, 1994, J NEUROCHEM, V62, P803; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GROSS U, 1994, MOL BIOL CELL, V5, P289; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1994, CELL MOTIL CYTOSKEL, V28, P195, DOI 10.1002/cm.970280302; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE G, 1992, J CELL SCI, V102, P227; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STEINER B, 1993, THESIS U HAMBURG; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506	70	321	330	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7679	7688		10.1074/jbc.270.13.7679	http://dx.doi.org/10.1074/jbc.270.13.7679			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706316	hybrid			2022-12-27	WOS:A1995QQ43100094
J	LEE, BS; UNDERHILL, DM; CRANE, MK; GLUCK, SL				LEE, BS; UNDERHILL, DM; CRANE, MK; GLUCK, SL			TRANSCRIPTIONAL REGULATION OF THE VACUOLAR H+-ATPASE B2 SUBUNIT GENE IN DIFFERENTIATING THP-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; PROMOTER REGION; BOVINE KIDNEY; RECEPTOR GENE; FACTOR AP-2; ENDOCYTIC VESICLES; CYTOPLASMIC PH; EXPRESSION; PUMP; SEQUENCE	Monocyte-macrophage differentiation was used as a model system for studying gene regulation of the human vacuolar H+-ATPase (V-ATPase). We examined mRNA levels of various V-ATPase subunits during differentiation of both native monocytes and the cell line THP-1, and found that transcriptional and post-transcriptional mechanisms could account for increases in cell V-ATPase content. From nuclear runoff experiments, we found that one subunit in particular, the B2 isoform (M(r) = 56,000), was amplified primarily by transcriptional means. We have begun to examine the structure of the B2 subunit promoter region. Isolation and sequencing of the first exon and 5'-flanking region of this gene reveal a TATA-less promoter with a high G+C content. Primer extension and ribonuclease protection analyses indicate a single major transcriptional start site. We transfected promoter-luciferase reporter plasmids into THP-1 cells to define sequences that mediate transcriptional control during monocyte differentiation. We found that sequences downstream from the transcriptional start site were sufficient to confer increased expression during THP-1 differentiation. DNase I footprinting and sequence analysis revealed the existence of multiple AP2 and Spl binding sites in the 5'-untranslated and proximal coding regions.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	LEE, BS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, DIV RENAL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Lee, Beth S/E-9578-2010; UNDERHILL, DAVID/ABE-2185-2021	Lee, Beth S/0000-0002-1468-6387; Underhill, David/0000-0002-2989-658X	NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK09976, DK38848] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848, P01DK009976] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAKI E, 1987, J BIOL CHEM, V262, P16186; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARON R, 1989, CONNECT TISSUE RES, V20, P109, DOI 10.3109/03008208909023879; BAUER J, 1988, J IMMUNOL METHODS, V112, P213, DOI 10.1016/0022-1759(88)90360-2; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brown T, 1987, CURRENT PROTOCOLS MO; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GABIG TG, 1981, ANNU REV MED, V32, P313, DOI 10.1146/annurev.me.32.020181.001525; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GILLESPIE GAJ, 1991, P NATL ACAD SCI USA, V88, P4289, DOI 10.1073/pnas.88.10.4289; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P221; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MANOLSON MF, 1992, J EXP BIOL, V172, P105; MARUSHACK MM, 1992, AM J PHYSIOL, V263, pF171, DOI 10.1152/ajprenal.1992.263.1.F171; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PAN YX, 1991, FEBS LETT, V247, P147; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Sambrook J, 1989, MOL CLONING LABORATO; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STARKE T, 1991, Z NATURFORSCH C, V46, P613; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SWALLOW CJ, 1989, J SURG RES, V46, P588, DOI 10.1016/0022-4804(89)90025-5; TSUCHIYA S, 1982, CANCER RES, V42, P1530; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590	58	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7320	7329		10.1074/jbc.270.13.7320	http://dx.doi.org/10.1074/jbc.270.13.7320			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706273	hybrid			2022-12-27	WOS:A1995QQ43100046
J	PEASE, RJ; LEIPER, JM; HARRISON, GB; SCOTT, J				PEASE, RJ; LEIPER, JM; HARRISON, GB; SCOTT, J			STUDIES ON THE TRANSLOCATION OF THE AMINO-TERMINUS OF APOLIPOPROTEIN-B INTO THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; GROWTH-FACTOR RECEPTOR; HEP G2 CELLS; TRANSLATION SYSTEM; RAT-LIVER; PROTEIN TRANSLOCATION; MEMBRANE-PROTEINS; PAUSE TRANSFER; STOP-TRANSFER; APO-B	Apolipoprotein (apo) B is either co-translationally assembled into lipoproteins, or becomes associated with the membrane of the endoplasmic reticulum (ER) and is subsequently degraded, It has been proposed that apoB undergoes a novel process of translocation which generates cytoplasmically exposed apoB in the ER of hepatic and non-hepatic cells. Transmembrane forms of apoB can also be generated by in vitro translation (Chuck, S. L., and Lingappa, V. R. (1992) Cell 68, 9-21), which might explain the origin of untranslocated apoB in vivo. Here we have investigated a protocol which generates transmembrane forms of apoB during in vitro translation of truncated RNA transcripts, We observe that apoB can become transmembrane at sites of ribosome pausing and be held in this configuration by persistence of tRNA on the peptide chains. Ribosome pausing also occurs at these same sites in the absence of acceptor microsomes. Transmembrane topology can be generated at sites of ribosome pausing in a cytosolic protein, sea urchin cyclin when fused to a signal sequence, Mapping of the ribosome pause sites in apoB and in cyclin revealed no amino acid sequence homology, Chimeric constructs with engineered downstream glycosylation sites showed no evidence that ribosome pause sequences affect translocation of transcripts with termination codons. Transmembrane forms of apoB and cyclin were not generated during translocation into the ER in transfected COS cells.			PEASE, RJ (corresponding author), ROYAL POSTGRAD MED SCH,MRC,MOLEC MED GRP,DU CANE RD,LONDON W12 0NN,ENGLAND.							BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; CAULFIELD MP, 1986, J BIOL CHEM, V261, P953; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; DU EZ, 1994, J BIOL CHEM, V269, P24169; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIBBONS GF, 1990, BIOCHEM J, V268, P1; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KNIGHT AM, 1992, EUR J IMMUNOL, V22, P879, DOI 10.1002/eji.1830220339; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; MARCHESI VT, 1976, ANNU REV BIOCHEM, V45, P667, DOI 10.1146/annurev.bi.45.070176.003315; MINSHULL J, 1989, THESIS U CAMBRIDGE U; MUECKLER M, 1986, NATURE, V322, P549, DOI 10.1038/322549a0; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PEASE RJ, 1992, NATURE, V356, P116; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; ROITSCH T, 1988, EUR J BIOCHEM, V174, P699, DOI 10.1111/j.1432-1033.1988.tb14154.x; ROSS AH, 1982, J BIOL CHEM, V257, P4152; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SPIESS M, 1989, J BIOL CHEM, V264, P19117; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WILKINSON J, 1992, FEBS LETT, V304, P24, DOI 10.1016/0014-5793(92)80581-Z; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YANG CY, 1986, NATURE, V323, P788; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	52	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7261	7271		10.1074/jbc.270.13.7261	http://dx.doi.org/10.1074/jbc.270.13.7261			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706266	hybrid			2022-12-27	WOS:A1995QQ43100039
J	RAY, A; HANNINK, M; RAY, BK				RAY, A; HANNINK, M; RAY, BK			CONCERTED PARTICIPATION OF NF-KB AND C/EBP HETEROMER IN LIPOPOLYSACCHARIDE INDUCTION OF SERUM AMYLOID A GENE-EXPRESSION IN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; ACUTE-PHASE RESPONSE; LEUCINE ZIPPER PROTEINS; KAPPA-B; A GENE; TRANSCRIPTION FACTOR; NUCLEAR FACTORS; FAMILY; NF-IL6; INTERLEUKIN-6	The promoter region of the rabbit serum amyloid A (SAA) gene contains two adjacent C/EBP and one NF-kappa B binding element. Involvement of these elements in SAA gene induction, following lipopolysaccharide (LPS) stimulation of the liver, has been studied by investigating LPS-activated transcription factors and their interaction with the promoter elements of the SAA gene. Appearance of complexes in the electrophoretic mobility shift assay has indicated that DNA-binding proteins that interact with the NF-KB element of the SAA promoter are induced in the LPS-treated rabbit liver. Presence of RelA (p65 subunit of NF-kappa B) in these complexes was demonstrated by the ability of RelA-specific antisera to supershift the DNA-protein complexes. LPS also induced several members of the C/EBP family of transcription factors, which interacted with the C/EBP motifs of the SAA promoter. Activated C/EBP and RelA form a RelA . C/EBP heteromeric complex that associates with varying affinity to NF-kappa B and C/EBP elements of the SAA gene. Transfection assays using both transcription factor genes have demonstrated that the hetero complex of NF-kappa B and C/EBP is a much more potent transactivator of SAA expression than each transcription factor alone. The heteromeric complex efficiently promotes transcription from both NF-kappa B and C/EBP sites.	UNIV MISSOURI,DEPT VET MICROBIOL,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					NIDDK NIH HHS [DK 45144-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK045144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ANDERS RF, 1977, J IMMUNOL, V118, P229; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRILLI M, 1993, INT REV CYTOL, V148, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1994, J IMMUNOL, V153, P153; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1991, J BIOL CHEM, V266, P15192; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray Alpana, 1993, Gene Expression, V3, P151; RAY BK, 1991, BIOCHEM BIOPH RES CO, V180, P1258, DOI 10.1016/S0006-291X(05)81331-2; RAY BK, 1994, EUR J BIOCHEM, V222, P891, DOI 10.1111/j.1432-1033.1994.tb18937.x; RAY BK, 1993, BIOCHEM BIOPH RES CO, V193, P1159, DOI 10.1006/bbrc.1993.1747; RAY BK, 1993, EUR J BIOCHEM, V216, P127, DOI 10.1111/j.1432-1033.1993.tb18124.x; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	46	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7365	7374		10.1074/jbc.270.13.7365	http://dx.doi.org/10.1074/jbc.270.13.7365			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706280	hybrid			2022-12-27	WOS:A1995QQ43100053
J	WUNDERLICH, M; GLOCKSHUBER, R				WUNDERLICH, M; GLOCKSHUBER, R			IN-VIVO CONTROL OF REDOX POTENTIAL DURING PROTEIN-FOLDING CATALYZED BY BACTERIAL PROTEIN DISULFIDE-ISOMERASE (DSBA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMYLASE-TRYPSIN-INHIBITOR; CIS-TRANS-ISOMERASE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; BONDS; SEQUENCE; STRAINS; BUFFER; CELL	The formation of disulfide bonds in Escherichia coli is catalyzed by periplasmic protein disulfide-isomerase (DsbA). When the alpha-amylase/trypsin inhibitor from Ragi, a protein containing five intramolecular disulfide bridges, is secreted into the periplasm of E. coli, large amounts of misfolded inhibitor with incomplete or incorrect disulfides are accumulated. Folding of the inhibitor in the periplasm is not improved when DsbA is coexpressed and cosecreted. However, an up to 14-fold increase in correctly folded inhibitor is observed by coexpression of DsbA in conjugation with the addition of reduced glutathione to the growth medium. This peptide acts as a disulfide-shuffling reagent and can pass the outer membrane of E. coli. Since the influence of DsbA on the folding yield of the inhibitor is reduced in the presence of oxidized glutathione, the in vivo function of DsbA appears to be dependent on the ratio between oxidizing and reducing thiol equivalents in the periplasm. The high stability of thiol reagents against air oxidation during growth of E. coli allows the investigation of oxidative protein folding in vivo under controlled, thiol-dependent redox conditions.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,D-93040 REGENSBURG,GERMANY	University of Regensburg								BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bieth J., 1974, BAYER S, P463; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CAMPOS FAP, 1983, FEBS LETT, V152, P300, DOI 10.1016/0014-5793(83)80400-1; DECAD GM, 1976, J BACTERIOL, V128, P325, DOI 10.1128/JB.128.1.325-336.1976; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Freedman Robert B., 1992, P455; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Goldenberg David P., 1992, P353; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HEPPEL LA, 1962, J BIOL CHEM, V237, P841; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOUYE H, 1982, J BACTERIOL, V149, P434, DOI 10.1128/JB.149.2.434-439.1982; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; LASKOWSKI M, 1986, NUTRITIONAL TOXICOLO, P1; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PAYNE JW, 1968, J BIOL CHEM, V243, P6291; POERIO E, 1991, EUR J BIOCHEM, V199, P595, DOI 10.1111/j.1432-1033.1991.tb16159.x; Sambrook J, 1989, MOL CLONING LABORATO; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SCHONBRUNNER ER, 1992, P NATL ACAD SCI USA, V89, P4510, DOI 10.1073/pnas.89.10.4510; SHIVARAJ B, 1981, BIOCHEM J, V193, P29, DOI 10.1042/bj1930029; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, IN PRESS J MOL BIOL; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	39	90	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24547	24550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693702				2022-12-27	WOS:A1993MG67300009
J	JAMES, PL; JONES, SB; BUSBY, WH; CLEMMONS, DR; ROTWEIN, P				JAMES, PL; JONES, SB; BUSBY, WH; CLEMMONS, DR; ROTWEIN, P			A HIGHLY CONSERVED INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN (IGFBP-5) IS EXPRESSED DURING MYOBLAST DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; FACTOR-II; MOLECULAR-CLONING; MUSCLE DIFFERENTIATION; RIBONUCLEIC-ACID; GENE; FIBROBLASTS; DNA; IDENTIFICATION; SECRETION	Insulin-like growth factor-binding proteins (IGFBPs) are a family of secreted proteins that bind insulin-like growth factors I and II (IGFs I and II) and are capable of modulating IGF actions on target cells. We have shown previously that C2 myoblasts secrete a single approximately 29-kDa IGFBP during their terminal differentiation (Tollefsen, S. E., Lajara, R., McCusker, R. H., Clemmons, D. R., and Rotwein, P. (1989) J. Biol. Chem. 264, 13810-13817). In this study, we have purified the protein from C2 cell-conditioned media by conventional and IGF-affinity chromatography, cloned its cDNA by PCR-based and traditional library screening, and identified it as mouse IGFBP-5. The resultant 5561 nucleotide cDNA encodes a 252-amino acid mature protein (predicted M(r) approximately 28,400) that is 97% identical to rat and human IGFBP-5. In differentiating C2 myoblasts and in F3 azamyoblasts the >6-kilobase IGFBP-5 mRNA accumulates concomitantly with induction of myogenin mRNA, an early marker of muscle differentiation. Ligand blot analysis shows that IGFBP-5 protein is secreted within 12 h of the onset of differentiation in these cells and that it is the only IGFBP produced in several fusing skeletal muscle cell lines. In vivo, IGFBP-5 transcripts are expressed in a variety of mouse tissues including striated muscle, but, unlike other IGFBPs, it is barely detectable in liver. IGFBP-5 is more conserved than other IGFBPs in mammals; its conserved structure and sequence also extends to non-mammalian vertebrates. Hybridization of a mouse BP5 coding region probe to RNA from several chicken and Xenopus tissues demonstrated similarly sized transcripts in these species. A partial Xenopus cDNA is identical in 38/45 deduced amino acids to the mammalian proteins. Identification of an IGF-binding protein that is produced during myoblast differentiation provides a model system in which to study the potential modulatory role of IGFBPs in development.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,BOX 8231,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599	Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Rotwein, Peter/R-5783-2019; Jones, Stephanie/Q-8153-2019	Jones, Stephanie/0000-0001-8342-0374; Rotwein, Peter/0000-0002-9505-1817	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042748, P60DK020579] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26309] Funding Source: Medline; NIDDK NIH HHS [DK20579, R01 DK042748, DK42748] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DROP SLS, 1992, GROWTH REGULAT, V2, P69; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ERNST CW, 1992, ENDOCRINOLOGY, V130, P607, DOI 10.1210/en.130.2.607; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FOWLKES J, 1992, ENDOCRINOLOGY, V131, P2071, DOI 10.1210/en.131.5.2071; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JONES JI, 1993, J BIOL CHEM, V268, P1125; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LIU XJ, 1993, ENDOCRINOLOGY, V132, P1176, DOI 10.1210/en.132.3.1176; MAGRI KA, 1991, ADV EXP MED BIOL, V293, P57; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nei M., 1987, MOL EVOLUTIONARY GEN; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHOEN TJ, 1992, ENDOCRINOLOGY, V131, P2846, DOI 10.1210/en.131.6.2846; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SZEBENYI G, 1991, J BIOL CHEM, V266, P5534; SZEBENYI G, 1991, ADV EXP MED BIOL, V293, P289; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZAPF J, 1990, J BIOL CHEM, V265, P14892; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	51	137	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22305	22312						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693664				2022-12-27	WOS:A1993MD34800021
J	GUO, W; CAMPBELL, KP				GUO, W; CAMPBELL, KP			ASSOCIATION OF TRIADIN WITH THE RYANODINE RECEPTOR AND CALSEQUESTRIN IN THE LUMEN OF THE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM RELEASE CHANNEL; RABBIT SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; DIHYDROPYRIDINE RECEPTORS; GLYCOPROTEIN TRIADIN; LOCALIZATION; PROTEIN; INVOLVEMENT; SUBUNITS	Triadin is a major membrane protein that is specifically localized in the junctional sarcoplasmic reticulum of skeletal muscle and is thought to play an important role in muscle excitation-contraction coupling. In order to identify the proteins in the skeletal muscle that interact with triadin, the cytoplasmic and luminal domains of triadin were expressed as glutathione S-transferase fusion proteins and immobilized to glutathione-Sepharose to form affinity columns. Using these affinity columns, we find that triadin binds specifically to the ryanodine receptor/Ca2+ release channel and the Ca2+-binding protein calsequestrin from CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid)-solubilized skeletal muscle homogenates. The luminal but not the cytoplasmic domain of triadin-glutathione S-transferase fusion protein binds [H-3]ryanodine receptor, whereas neither the cytoplasmic nor the luminal portion of triadin binds [H-3]PN-200-100-labeled dihydropyridine receptor, In addition, the luminal domain of triadin interacts with calsequestrin in a Ca2+-dependent manner and is capable of inhibiting the reassociation of calsequestrin to the junctional face membrane. These results suggest that triadin is the previously unidentified transmembrane protein that anchors calsequestrin to the junctional region of the sarcoplasmic reticulum, and is involved in the functional coupling between calsequestrin and the ryanodine receptor/Ca2+ release channel.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYS & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa				Campbell, Kevin/0000-0003-2066-5889				CALA SE, 1983, J BIOL CHEM, V258, P1932; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; HE ZP, 1993, J BIOL CHEM, V268, P24635; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; KAWAMOTO RM, 1986, J CELL BIOL, V103, P1405, DOI 10.1083/jcb.103.4.1405; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LIU GH, 1994, J BIOL CHEM, V269, P33028; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	30	206	208	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9027	9030		10.1074/jbc.270.16.9027	http://dx.doi.org/10.1074/jbc.270.16.9027			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721813	hybrid			2022-12-27	WOS:A1995QU08900001
J	LITTLE, E; LEE, AS				LITTLE, E; LEE, AS			GENERATION OF A MAMMALIAN-CELL LINE DEFICIENT IN GLUCOSEREGULATED PROTEIN STRESS INDUCTION THROUGH TARGETED RIBOZYME DRIVEN BY A STRESS-INDUCIBLE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; CALCIUM IONOPHORE A23187; ENDOPLASMIC-RETICULUM; HEAT-SHOCK; TRANSMEMBRANE PROTEIN; MALFOLDED PROTEINS; GRP78 PROMOTER; GENES; GRP94; GLYCOSYLATION	GRP94 is an endoplasmic reticulum (ER) localized glycoprotein with Ca2+ binding and protein chaperoning properties. Using a ribozyme driven by a stress-inducible promoter and targeted against grp94 mRNA, we have generated a cell line deficient in its ability to induce GRP94. The effect of the ribozyme is mediated by the cleavage of the grp94 message just downstream of the initiation codon, and not by an antisense effect, as determined by the level of intact grp94 mRNA. Unexpectedly, this cell line's ability to induce GRP78 is also impaired. Transient overexpression of recombinant human lysosomal hydrolase alpha-L-iduronidase in the ribozyme expressing cells indicates that the secretion ratio of this enzyme is reduced by about B-fold. Additionally, the ribozyme expressing cells showed increased sensitivity to Ca2+ depletion from ER caused by either A23187 or thapsigargin, an ER-Ca2+-ATPase inhibitor, but not to tunicamycin. These combined results show that the induction of GRP94 may play important roles in ER to nuclear signaling, protein sorting and secretion, and specific protection against Ca2+ depletion stress.	UNIV SO CALIF, SCH MED, DEPT BIOCHEM & MOLEC BIOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, NORRIS CANC CTR, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California				Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [R37 CA27607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CALA SE, 1994, J BIOL CHEM, V269, P5926; Castanotto Daniela, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P331; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HUTCHISON KA, 1993, ANN NY ACAD SCI, V684, P35, DOI 10.1111/j.1749-6632.1993.tb32269.x; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; KANG HS, 1991, J BIOL CHEM, V266, P5643; KIM YK, 1987, J CELL PHYSIOL, V133, P553, DOI 10.1002/jcp.1041330317; KOCH G, 1986, J CELL SCI, V86, P217; KOIZUMI M, 1988, FEBS LETT, V228, P228, DOI 10.1016/0014-5793(88)80004-8; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1986, J CELL PHYSIOL, V129, P277, DOI 10.1002/jcp.1041290302; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI WWF, 1993, J BIOL CHEM, V268, P12003; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LIN AY, 1986, MOL CELL BIOL, V6, P1235, DOI 10.1128/MCB.6.4.1235; LITTLE E, 1994, GENE EXP, V4, P1; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MENORET A, 1994, INT J CANCER, V56, P400, DOI 10.1002/ijc.2910560319; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MORI K, 1993, CELL, V74, P743; NAEVE GS, 1992, CELL GROWTH DIFFER, V3, P919; NAVARRO D, 1992, VIROLOGY, V186, P99, DOI 10.1016/0042-6822(92)90064-V; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RAMAKRISHNAN M, 1995, IN PRESS DNA CELL BI; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; ROME LH, 1978, ARCH BIOCHEM BIOPHYS, V189, P344, DOI 10.1016/0003-9861(78)90221-7; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SUGAWARA S, 1993, CANCER RES, V53, P6001; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; Wooden S.K., 1992, DNA Sequence, V3, P41, DOI 10.3109/10425179209039694; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; ZHAO JJG, 1993, NATURE, V365, P448, DOI 10.1038/365448a0	57	94	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9526	9534		10.1074/jbc.270.16.9526	http://dx.doi.org/10.1074/jbc.270.16.9526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721881	hybrid			2022-12-27	WOS:A1995QU08900070
J	LUCERO, HA; CHOJNICKI, EWT; MANDIYAN, S; NELSON, H; NELSON, N				LUCERO, HA; CHOJNICKI, EWT; MANDIYAN, S; NELSON, H; NELSON, N			CLONING AND EXPRESSION OF A YEAST GENE ENCODING A PROTEIN WITH ATPASE ACTIVITY AND HIGH IDENTITY TO THE SUBUNIT-4 OF THE HUMAN 26-S PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-MEDIATED TRANSACTIVATION; VACUOLAR H+-ATPASE; CONSENSUS SEQUENCE; MOLECULAR-CLONING; BINDING-PROTEIN; UBIQUITIN; COMPLEX; MODULATOR; FAMILY; DOMAIN	The cloning, expression, and biochemical character characterization of an essential gene of Saccharomyces cerevisiae that encodes for a new member of the TBP1-like subfamily of putative ATPases are described. The protein is 72% identical at the amino acid level to subunit four (S4) of the human 26 S protease and 73% identical to Schizosaccharomyces pombe MTS2 gene product. The purified, recombinant protein, designated Yhs4p, has an estimated molecular mass of 49 kDa and exhibits a Mg2+-dependent ATPase activity with nucleotide specificity and K-m for ATP similar to those exhibited by the human 26 S protease, The observed ATPase activity was reduced by 73% upon the introduction of point mutation K229Q in the ''P-loop'' domain of the ATP-binding site relative to the nonmutated form of the protein, This is the first direct biochemical evidence supporting the putative ATPase activity of a member of the TBP1-like subfamily, Furthermore, the experimental results demonstrate a regulatory function for the amino-terminal region of the molecule, The amino-terminal truncated form of Yhs4p lacking two clusters of positively charged amino acids exhibits a greater ATPase activity, The ATPase activity of both the truncated and complete forms of Yhs4p is stimulated by polyanions, Polylysine partially inhibits the ATPase activity of the aminoterminal truncated form having no observable effect on the complete protein, N-Ethylmaleimide inhibits the ATPase activity of both forms of Yhs4p. We propose that Yhs4p ATPase may play an essential role in the regulatory function of the proteolytic activity of the yeast 26 S protease.	BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, SYRACUSE, NY 13221 USA; ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Bristol-Myers Squibb	LUCERO, HA (corresponding author), BOSTON UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02118 USA.							ARMON T, 1990, J BIOL CHEM, V265, P20723; BURKE M, 1990, FEBS LETT, V262, P185, DOI 10.1016/0014-5793(90)80185-L; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FUJII G, 1993, BIOCHIM BIOPHYS ACTA, V1216, P65, DOI 10.1016/0167-4781(93)90038-F; FUYIWARA T, 1990, J BIOL CHEM, V256, P16604; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, ENZYME PROTEIN, V47, P189, DOI 10.1159/000468678; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA CP, 1994, J BIOL CHEM, V269, P3539; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SENIOR AE, 1993, J BIOL CHEM, V268, P6989; Sherman F., 1983, METHODS YEAST GENETI; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1992, NEW BIOL, V4, P173; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; XIE XS, 1988, METHOD ENZYMOL, V157, P634	41	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9178	9184		10.1074/jbc.270.16.9178	http://dx.doi.org/10.1074/jbc.270.16.9178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721833	hybrid			2022-12-27	WOS:A1995QU08900021
J	MANZI, A; SALIMATH, PV; SPIRO, RC; KEIFER, PA; FREEZE, HH				MANZI, A; SALIMATH, PV; SPIRO, RC; KEIFER, PA; FREEZE, HH			IDENTIFICATION OF A NOVEL GLYCOSAMINOGLYCAN CORE-LIKE MOLECULE .1. 500 MHZ H-1-NMR ANALYSIS USING A NANO-NMR PROBE INDICATES THE PRESENCE OF A TERMINAL ALPHA-GALNAC RESIDUE CAPPING 4-METHYLUMBELLIFERYL-BETA-D-XYLOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; BETA-D-XYLOSIDES; CHONDROITIN SULFATE BIOSYNTHESIS; EMBRYONIC-CHICKEN CARTILAGE; SHARK CARTILAGE; OLIGOSACCHARIDES; PROTEOGLYCANS; CHAINS; ANALOGS; H-1-NMR	beta-Xylosides compete with endogenous proteoglycan core proteins and act as alternate accepters for synthesizing protein-free glycosaminoglycan chains, Their assembly on these alternate accepters utilizes the same glycosyltransferases that make the protein-bound chains, Most studies using alternate accepters focus on the production of sulfated glycosaminoglycan chains that are thought to be the major products. However, we previously showed that labeling melanoma cells with [6-H-3]galactose in the presence of 4-methylumbelliferyl (MU) or p-nitrophenyl (pNP) beta-xylosides led to the synthesis of mostly di- to tetrasaccharide products including incomplete core structures, We have solved the structure of one of the previously unidentified products as, GalNAc alpha(1,4)GlcA beta(1,3)Gal beta(1,3)Gal beta(1,4)Xyl beta MU, based on compositional analysis by high performance liquid chromatography, fast atom bombardment, electrospray mass spectrometry, and one dimensional and two dimensional H-1 NMR spectroscopy, The novel aspect of this molecule is the presence of a terminal alpha-Gal-NAc residue at a position that is normally occupied by beta-GalNAc in chondroitin/dermatan sulfate or by alpha-GlcNAc in heparin or heparan sulfate chains. An alpha-GalNAc residue at this critical location may prevent further chain extension or influence the type of chain subsequently added to the common tetrasaccharide core.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA; VARIAN NMR INSTRUMENTS, PALO ALTO, CA 94304 USA; TELIOS PHARMACEUT INC, SAN DIEGO, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego				Freeze, Hudson/0000-0001-6316-0501	NCRR NIH HHS [1 S10 RR07273] Funding Source: Medline; PHS HHS [R01 49243, R01 38701] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allen H. J., 1992, GLYCOCONJUGATES COMP; BARBARA TM, 1994, J MAGN RESON SER A, V109, P265, DOI 10.1006/jmra.1994.1168; CHAI WG, 1992, EUR J BIOCHEM, V207, P973, DOI 10.1111/j.1432-1033.1992.tb17132.x; DABROWSKI J, 1987, METHOD ENZYMOL, V83, P69; DABROWSKI U, 1993, BIOCHEM BIOPH RES CO, V192, P1057, DOI 10.1006/bbrc.1993.1524; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HASE S, 1990, J BIOL CHEM, V265, P1858; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MEEZAN E, 1994, J BIOL CHEM, V269, P11503; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RIVERASAGREDO A, 1991, CARBOHYD RES, V221, P37, DOI 10.1016/0008-6215(91)80047-Q; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; RODEN L, 1994, J BIOL CHEM, V269, P11509; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P271, DOI 10.1007/BF01047847; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; PROTON NMR SPECTRA	36	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9154	9163		10.1074/jbc.270.16.9154	http://dx.doi.org/10.1074/jbc.270.16.9154			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721830	hybrid			2022-12-27	WOS:A1995QU08900018
J	YAMADA, M; KURACHI, Y				YAMADA, M; KURACHI, Y			SPERMINE GATES INWARD-RECTIFYING MUSCARINIC BUT NOT ATP-SENSITIVE K+ CHANNELS IN RABBIT ATRIAL MYOCYTES - INTRACELLULAR SUBSTANCE-MEDIATED MECHANISM OF INWARD RECTIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEART; RECTIFIER POTASSIUM CHANNEL; CELL-FREE MEMBRANE; VENTRICULAR CELLS; ACETYLCHOLINE ACTIVATION; FUNCTIONAL EXPRESSION; MAGNESIUM BLOCK; ADENOSINE; CONDUCTANCE; POLYAMINES	The effect of spermine, a low molecular mass aliphatic amine with positive charges, on the strongly inwardly rectifying muscarinic K+ (K-ACh) channel was examined in rabbit atrial myocytes. In inside-out patch membranes, the single channel current-voltage relationship of K-ACh channels activated by guanosine 5'-3-O-(thio)triphosphate became linear in the absence of intracellular Mg2+. The open probability (P-o) of the channels did not show significant voltage dependence under these conditions. Spermine specifically reduced P-o of outwardly flowing K-ACh channel currents without affecting the unitary current amplitude at depolarized potentials, but had no effect on inward K-ACh currents under hyperpolarization, This voltage dependence of P-o of K-ACh channels in the presence of spermine resembled that normally observed in the whole cell or open cell-attached configurations. Spermine (300 nM to 3 mu M) also restored the relaxation of K-ACh currents which had been lost in the inside-out configuration, The effect of spermine was concentration-dependent with IC50 of similar to 10 nM at +40 mV, The order of potency of polyamines in reducing P-o at +40 mV was spermine greater than or equal to spermidine > putrescine > ornithine; arginine had no significant effect. Intracellular Mg2+ antagonized the effect of spermine. Neither the single channel conductance nor P-o of the ATP-sensitive K+ channel, a weak inward rectifier, was affected by spermine, Because submillimolar concentrations of spermine and spermidine are available in the cytosol of most cells, these substances may be the unidentified intracellular gating factors for strong inward rectifiers such as K-ACh and I-K1 channels.	OSAKA UNIV,FAC MED,DEPT PHARMACOL 2,SUITA,OSAKA 565,JAPAN	Osaka University								ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; CIANI S, 1978, J MEMBRANE BIOL, V44, P103, DOI 10.1007/BF01976035; COLQUHOUN D, 1983, FITTING STAT ANAL SI, P191; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINDLAY I, 1987, PFLUG ARCH EUR J PHY, V410, P313, DOI 10.1007/BF00580282; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; GUNNING R, 1983, J PHYSIOL-LONDON, V342, P437, DOI 10.1113/jphysiol.1983.sp014861; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1991, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; HORIE M, 1989, J PHYSIOL-LONDON, V408, P313, DOI 10.1113/jphysiol.1989.sp017461; HORIE M, 1987, AM J PHYSIOL, V253, pH210, DOI 10.1152/ajpheart.1987.253.1.H210; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; Kurachi Y., 1990, REGULATION POTASSIUM, P403; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; MORGAN DML, 1990, BIOCHEM SOC T, V18, P1080, DOI 10.1042/bst0181080; MORGAN DML, 1990, BIOCHEM SOC T, V18, P1079; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	36	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9289	9294		10.1074/jbc.270.16.9289	http://dx.doi.org/10.1074/jbc.270.16.9289			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721849				2022-12-27	WOS:A1995QU08900037
J	HITOSHI, S; KUSUNOKI, S; KANAZAWA, I; TSUJI, S				HITOSHI, S; KUSUNOKI, S; KANAZAWA, I; TSUJI, S			MOLECULAR-CLONING AND EXPRESSION OF 2 TYPES OF RABBIT BETA-GALACTOSIDE ALPHA-1,2-FUCOSYL-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION-CELLS; GDP-L-FUCOSE; HUMAN-SERUM; DETERMINANTS; PURIFICATION; TRANSFERASE; GENETICS; EMBRYOS; CDNA	Two DNA clones encoding rabbit beta-galactoside alpha 1,2-fucosyltransferase (RFT-I and RFT-II) have been isolated from a rabbit genomic DNA library. The DNA sequences revealed open reading frames coding for 373 (RFT-I) and 354 (RFT-II) amino acids, respectively. The deduced amino acid sequences of RFT-I and RFT-II showed 56% identity with each other, and that of RFT-I showed 80% identity with that of human H blood type alpha 1,2-fucosyltransferase. Northern blot analysis of embryo and adult rabbit tissues revealed that the RFT-I gene was expressed in adult brain, and that the RFT-II gene was expressed in salivary and lactating mammary glands. The identities of these enzymes were confirmed by constructing recombinant fucosyltransferases in which the N-terminal part including the cytoplasmic tail and signal anchor domain was replaced with the immunoglobulin signal peptide sequence. RFT-I expressed in COS-7 cells exhibited similar transferase activity to that of human H blood type alpha 1,2-fucosyltransferase. RFT-II expressed in COS-7 cells showed higher affinity for type 1 (Gal beta 1,3GlcNAc) and type 3 (Gal beta 1,3GalNAc) acceptors than type 2 (Gal beta 1,4GlcNAc) ones, which suggested that RFT-II was a putative secretor-type alpha 1,2-fucosyltransferase.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROL,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo								BEYER TA, 1980, J BIOL CHEM, V255, P5373; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KUSUNOKI S, 1992, NEUROSCI RES, V15, P74, DOI 10.1016/0168-0102(92)90019-9; KUSUNOKI S, 1991, NEUROSCI LETT, V126, P159, DOI 10.1016/0304-3940(91)90543-3; KUSUNOKI S, 1989, BRAIN RES, V494, P391, DOI 10.1016/0006-8993(89)90611-2; KUSUNOKI S, 1994, BBA-LIPID LIPID MET, V1214, P27, DOI 10.1016/0005-2760(94)90005-1; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; LEPENDU J, 1982, AM J HUM GENET, V34, P402; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; PACUSZKA T, 1976, EUR J BIOCHEM, V64, P499, DOI 10.1111/j.1432-1033.1976.tb10328.x; PEREIRA MEA, 1978, ARCH BIOCHEM BIOPHYS, V185, P108, DOI 10.1016/0003-9861(78)90149-2; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; Sambrook J, 1989, MOL CLONING LABORATO; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; SZULMAN AE, 1962, J EXP MED, V115, P977, DOI 10.1084/jem.115.5.977; SZULMAN AE, 1964, J EXP MED, V119, P503, DOI 10.1084/jem.119.4.503; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Watkins W M, 1980, Adv Hum Genet, V10, P1	27	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8844	8850		10.1074/jbc.270.15.8844	http://dx.doi.org/10.1074/jbc.270.15.8844			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721792	hybrid			2022-12-27	WOS:A1995QT44800070
J	LANNE, B; OLSSON, BM; JOVALL, PA; ANGSTROM, J; LINDER, H; MARKLUND, BI; BERGSTROM, J; KARLSSON, KA				LANNE, B; OLSSON, BM; JOVALL, PA; ANGSTROM, J; LINDER, H; MARKLUND, BI; BERGSTROM, J; KARLSSON, KA			GLYCOCONJUGATE RECEPTORS FOR P-FIMBRIATED ESCHERICHIA-COLI IN THE MOUSE - AN ANIMAL-MODEL OF URINARY-TRACT INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; SMALL-INTESTINE; BACTERIAL ADHERENCE; EMBRYONIC ANTIGEN-1; STRUCTURAL-ANALYSIS; SSEA-1 DETERMINANT; HEAD GROUP; GLYCOLIPIDS; GLYCOSPHINGOLIPIDS; EXPRESSION	Glycosphingolipids were isolated;ed from kidneys, urethers, and bladders (including urethrae) of C3H/HeN mice. Binding was studied of a clinical isolate and recombinant strains of uropathogenic P-fimbriated Escherichia coli to these glycolipids. A series of receptor-active glycolipids with Gal alpha 4Gal in common, previously shown to be recognized by these bacteria, was identified by use of specific monoclonal antibodies, fast-atom bombardment and electron-impact mass spectrometry, and proton nuclear magnetic resonance spectroscopy: galabiosylceramide (Gal alpha 4Gal beta Cer), globotriaosylceramide (Gal alpha 4Gal beta 4Glc beta Cer), globoside (GalNac beta 3Gal alpha 4Gal beta-4Glc beta Cer), the Forssman glycolipid (GalNAc alpha 3GalNAc-beta 3Gal alpha 4Gal beta 4Glc beta Cer), Gal beta 4GlcNAc beta 6(Gal beta 3)GalNAc-beta 3Gal alpha 4Gal beta 4Glc beta Cer, and Gal beta 4(Fuc alpha 3)GlcNAc beta 6-(Gal beta 3)GalNAc beta 3Gal alpha 4Gal beta 4Glc beta Cer. The binding pattern for mouse kidney glycolipids differed from that for kidney glycolipids of man and monkey, In particular, the dominant 8-sugar glycolipid in the mouse was not detected in the primates. A second difference was found in the binding of E. coli to kidney glycoproteins on blots after electrophoresis; the mouse showed distinct receptor-active bands while human and monkey did not. These differences may be of relevance when using the mouse as a model for clinical urinary tract infection of man.			LANNE, B (corresponding author), GOTHENBURG UNIV, DEPT BIOCHEM MED, MEDICINAREGATAN 9A, S-41390 GOTHENBURG, SWEDEN.			Bergstrom, Jorgen/0000-0003-3255-5150				ADAMS EP, 1968, CHEM PHYS LIPIDS, V2, P147, DOI 10.1016/0009-3084(68)90018-2; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BJORK S, 1987, J BIOL CHEM, V262, P6758; BOCK K, 1985, J BIOL CHEM, V260, P8545; Breimer M.E., 1985, GLYCOCONJUGATE J, V2, P375; BREIMER ME, 1985, J BIOCHEM, V98, P1169, DOI 10.1093/oxfordjournals.jbchem.a135383; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DEREE JM, 1985, FEMS MICROBIOL LETT, V29, P91, DOI 10.1016/0378-1097(85)90277-0; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; GARCIA E, 1988, CURR MICROBIOL, V17, P333, DOI 10.1007/BF01570873; HAKOMORI S, 1983, HDB LIPID RES, P1; HANFLAND P, 1981, BIOCHEMISTRY-US, V20, P5310, DOI 10.1021/bi00521a034; HANSSON GC, 1982, FEBS LETT, V139, P291, DOI 10.1016/0014-5793(82)80873-9; HANSSON GC, 1988, MOL IMMUNOLOGY COMPL, P465; HOLTHOFER H, 1994, KIDNEY INT, V45, P123, DOI 10.1038/ki.1994.14; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; IWAHI T, 1983, INFECT IMMUN, V39, P1307, DOI 10.1128/IAI.39.3.1307-1315.1983; JOHNSON JR, 1984, AM J MED SCI, V307, P335; KALLENIUS G, 1981, LANCET, V2, P1369; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1991, CARBOHYD RES, V221, P49, DOI 10.1016/0008-6215(91)80048-R; KARLSSON KA, 1968, BIOCHIM BIOPHYS ACTA, V152, P230, DOI 10.1016/0005-2760(68)90029-5; KARLSSON KA, 1992, FEMS SYMP, V61, P115; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEFFLER H, 1980, FEMS MICROBIOL LETT, V8, P127, DOI 10.1111/j.1574-6968.1980.tb05064.x; LEVERY SB, 1986, CARBOHYD RES, V151, P311, DOI 10.1016/S0008-6215(00)90351-3; LINDBERG FP, 1984, EMBO J, V3, P1167, DOI 10.1002/j.1460-2075.1984.tb01946.x; LINDSTEDT R, 1991, INFECT IMMUN, V59, P1086, DOI 10.1128/IAI.59.3.1086-1092.1991; LUND B, 1987, P NATL ACAD SCI USA, V84, P5898, DOI 10.1073/pnas.84.16.5898; MARCUS DM, 1970, J IMMUNOL, V104, P1530; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MARKLUND BI, 1991, THESIS U UMEA SWEDEN; MARTENSSON E, 1966, BIOCHIM BIOPHYS ACTA, V116, P296, DOI 10.1016/0005-2760(66)90012-9; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MCKIBBIN JM, 1982, J BIOL CHEM, V257, P755; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; Mirelman D, 1986, MICROBIAL LECTINS AG, P1; PAPPE AK, 1991, J PHYS CHEM-US, V95, P3358; PARKKINEN J, 1988, INFECT IMMUN, V56, P2623, DOI 10.1128/IAI.56.10.2623-2630.1988; POPPE L, 1990, J AM CHEM SOC, V112, P7762, DOI 10.1021/ja00177a042; SCARSDALE JN, 1986, J AM CHEM SOC, V108, P6778, DOI 10.1021/ja00281a053; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P563, DOI 10.1093/jb/101.3.563; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P553, DOI 10.1093/jb/101.3.553; SEKINE M, 1988, J BIOCHEM-TOKYO, V103, P722, DOI 10.1093/oxfordjournals.jbchem.a122335; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVANBORGEDEN C, 1976, LANCET, V2, P490, DOI DOI 10.1016/S0140-6736(76)90788-1; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TENNENT JM, 1990, MOL BASIS BACTERIAL, P79; TULLUS K, 1984, J INFECT DIS, V150, P728, DOI 10.1093/infdis/150.5.728; UMESAKI Y, 1989, BIOCHIM BIOPHYS ACTA, V1001, P157; VANCE WR, 1966, BIOCHEMISTRY-US, V5, P435, DOI 10.1021/bi00866a007; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; WESTERLUND B, 1993, ZBL BAKT-INT J MED M, V278, P229; Yamakawa T., 1983, RED BLOOD CELLS DOME, P37; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YANG ZT, 1994, J BIOL CHEM, V269, P14620; [No title captured]	67	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					9017	9025		10.1074/jbc.270.15.9017	http://dx.doi.org/10.1074/jbc.270.15.9017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721812	hybrid			2022-12-27	WOS:A1995QT44800093
J	IKEDA, K; CLARK, JC; SHAWWHITE, JR; STAHLMAN, MT; BOUTELL, CJ; WHITSETT, JA				IKEDA, K; CLARK, JC; SHAWWHITE, JR; STAHLMAN, MT; BOUTELL, CJ; WHITSETT, JA			GENE STRUCTURE AND EXPRESSION OF HUMAN THYROID TRANSCRIPTION FACTOR-I IN RESPIRATORY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; TRANSGENIC MICE; REGIONS; IDENTIFICATION; ELEMENTS; PROTEIN	The human gene encoding thyroid transcription factor-1 (TTF-1), a homeodomain-containing nuclear transcription protein of the Nkx2 gene family, was isolated and characterized, Human TTF-1 was encoded by a single gene locus spanning approximately 3.3 kilobases and consisted of two exons and a single intron, The TTF-1 cDNA and polypeptide of 371 amino acids have been highly conserved, sharing 98% identity with the rat TTF-1 polypeptide, Human TTF-1 mRNA and polypeptide were selectively expressed in human and mouse pulmonary adenocarcinoma cell lines, In addition to its presence in thyroid gland epithelium, the human TTF-1 protein was detected by immunohistochemistry in human fetal lung as early as 11 weeks of gestation, being localized in the nuclei of epithelial cells of the developing airways, After birth, TIE-I was selectively expressed in Type II epithelial cells in the alveoli and in subsets of bronchiolar epithelial cells in the conducting regions of the lung, The 5'-flanking region of the human TTF-1 gene directed transcription of luciferase cDNA in a lung epithelial cell-selective manner, The conservation and distribution of TTF-1 in the human respiratory tract support its role in the regulation of lung development and surfactant homeostasis.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229; VANDERBILT UNIV,SCH MED,DIV NEONATOL,NASHVILLE,TN 37232	Cincinnati Children's Hospital Medical Center; Vanderbilt University				Boutell, Chris/0000-0002-2970-7785	NHLBI NIH HHS [HL14214, HL51832, HL41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, P01HL051832, P50HL014214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVITAREALE D, 1989, EMBO J, V8, P2533; DAMANTE G, 1991, P NATL ACAD SCI USA, V88, P5388, DOI 10.1073/pnas.88.12.5388; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; MACGREGOR GR, 1989, METHOD MOL BIOL, V7, P1; PRICE M, 1992, NEURON, V8, P1; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; Sternberger LA, 1979, IMMUNOCYTOCHEMISTRY, P104; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029	18	165	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8108	8114		10.1074/jbc.270.14.8108	http://dx.doi.org/10.1074/jbc.270.14.8108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713914	hybrid			2022-12-27	WOS:A1995QR52600052
J	KIRSHENBAUM, LA; SCHNEIDER, MD				KIRSHENBAUM, LA; SCHNEIDER, MD			ADENOVIRUS E1A REPRESSES CARDIAC GENE-TRANSCRIPTION AND REACTIVATES DNA-SYNTHESIS IN VENTRICULAR MYOCYTES, VIA ALTERNATIVE POCKET PROTEIN-BINDING AND P300-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-ANTIGEN TRANSGENES; MYOSIN HEAVY-CHAIN; GROWTH-FACTORS; EXPRESSION; MUSCLE; CELL; DIFFERENTIATION; INHIBITION; BINDING; MICE	To examine the potential impact of disrupting ''pocket'' protein function on cardiac differentiation and growth, we introduced 12 S E1A genes into neonatal ventricular myocytes, by adenoviral gene transfer. In the absence of E1B, E1A was cytotoxic, with features typical of apoptosis. In the presence of E1B, E1A preferentially inhibited transcription of cardiac-restricted alpha-actin promoters, and reactivated DNA synthesis in cardiac myocytes, without cell death. Mutations that abrogate known activities of the amino terminus of E1A, versus conserved region 2, demonstrate that the ''pocket'' protein- and p300-binding domains each suffice, in the absence of the other, for transcriptional repression and re-entry into S phase.	BAYLOR COLL MED, DEPT MED, MOLEC CARDIOL UNIT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PHYSIOL & MOLEC BIOPHYS, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Kirshenbaum, Lorrie A./F-5742-2014	Ryplanski, Kairee/0000-0002-3737-7181	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953, R01HL047567, T32HL007706] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL47567, P01 HL49953, T32 HL07706] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARBEAU D, 1994, ONCOGENE, V9, P359; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARRIER L, 1992, CIRC RES, V70, P999, DOI 10.1161/01.RES.70.5.999; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CLARK WA, 1981, J BIOL CHEM, V256, P4863; DELEON JR, 1994, P NATL ACAD SCI USA, V91, P519, DOI 10.1073/pnas.91.2.519; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KIM KK, 1994, J BIOL CHEM, V269, P22607; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MARTIN AF, 1977, J BIOL CHEM, V252, P3422; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MYMRYK JS, 1992, BIOCHEM CELL BIOL, V70, P1268, DOI 10.1139/o92-173; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROCHETTE EC, 1990, GENE DEV, V4, P151; SANDS AT, 1993, MOL REPROD DEV, V34, P117, DOI 10.1002/mrd.1080340202; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SEN A, 1988, J BIOL CHEM, V263, P19132; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; UENO H, 1988, J CELL BIOL, V107, P1911, DOI 10.1083/jcb.107.5.1911; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	39	140	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7791	7794		10.1074/jbc.270.14.7791	http://dx.doi.org/10.1074/jbc.270.14.7791			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713869	hybrid			2022-12-27	WOS:A1995QR52600003
J	PANNEERSELVAM, K; REITZ, H; KHAN, SA; BISHAYEE, S				PANNEERSELVAM, K; REITZ, H; KHAN, SA; BISHAYEE, S			A CONFORMATION-SPECIFIC ANTIPEPTIDE ANTIBODY TO THE BETA-TYPE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR ALSO RECOGNIZES THE ACTIVATED EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVATION; PDGF RECEPTORS; PHOSPHORYLATION; AUTOPHOSPHORYLATION; IDENTIFICATION; DIMERIZATION; EXPRESSION; BINDING; DOMAINS; PROTEIN	Earlier we reported the generation of a conformation-specific antibody (Ab P2) to the beta-type platelet-derived growth factor receptor (Bishayee, S., Majumdar, S., Scher, C.D., and Khan, S. (1988) Mol. Cell. Biol. 8, 3696-3702). Ab P2 is directed to a 16-amino acid peptide (Glu-Gly-Tyr-Lys-Lys-Lys-Tyr-Gln-Gln-Val-Asp-Glu-Glu-Phe-Leu-Arg) of the cytoplasmic domain of the receptor, and it recognized the phosphorylated platelet-derived growth factor receptor but not the unphosphorylated receptor. We now report that Ab P2 also interacts with the epidermal growth factor receptor and that the recognition is specific for a conformation induced by phosphorylation of the receptor; however, Ab P2 is not directed to phosphotyrosine. Studies conducted with P2-derived peptides suggest that the conformation-specific antibody is directed to an acidic tripeptide, Asp-Glu-Glu, and this sequence is also present in the cytoplasmic domain of the epidermal growth factor receptor. With respect to the C terminus amino acid or ATP-binding site, Asp-Glu-Glu is located in different regions in these receptors; nevertheless, this tripeptide along with the surrounding amino acids is cryptic in the unphosphorylated receptor, and tyrosine phosphorylation uncovers this site. This suggests that the Asp-Glu-Glu sequence may be important in receptor functions.	CORIELL INST MED RES, CAMDEN, NJ 08103 USA; INFIN BIOTECH RES & RESOURCE, UPLAND, PA 19015 USA	Coriell Institute for Medical Research								BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BISHAYEE S, 1986, P NATL ACAD SCI USA, V83, P6756, DOI 10.1073/pnas.83.18.6756; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DAS M, 1977, P NATL ACAD SCI USA, V74, P2790, DOI 10.1073/pnas.74.7.2790; DAS M, 1984, EUR J BIOCHEM, V141, P429, DOI 10.1111/j.1432-1033.1984.tb08209.x; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1986, J CELL BIOL, V103, P333, DOI 10.1083/jcb.103.2.333; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAJ S, 1992, BIOCHEMISTRY-US, V31, P1774, DOI 10.1021/bi00121a027; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	25	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7975	7979		10.1074/jbc.270.14.7975	http://dx.doi.org/10.1074/jbc.270.14.7975			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713896	hybrid			2022-12-27	WOS:A1995QR52600032
J	ROESLER, WJ; GRAHAM, JG; KOLEN, R; KLEMM, DJ; MCFIE, PJ				ROESLER, WJ; GRAHAM, JG; KOLEN, R; KLEMM, DJ; MCFIE, PJ			THE CAMP RESPONSE ELEMENT-BINDING PROTEIN SYNERGIZES WITH OTHER TRANSCRIPTION FACTORS TO MEDIATE CAMP RESPONSIVENESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; CYCLIC-AMP; GENE-TRANSCRIPTION; NUCLEAR-PROTEIN; FACTOR CREB; SOMATOSTATIN GENE; HEPATOMA-CELLS; ALPHA-SUBUNIT; ALBUMIN GENE; PROMOTER	The cAMP responsiveness of the promoter for phosphoenolpyruvate carboxykinase (EC 4.1.1.32) is mediated by a synergistic interaction between a complex regulatory region, which binds liver-enriched transcription factors, and a typical cAMP response element (CRE). Although a role for the CRE-binding protein (CREB) in the cAMP-responsiveness of this promoter has been generally assumed, some uncertainty remains due to the observations that several C/EBP-related proteins bind with near equal affinity, relative to CREB, to this particular CRE. Thus, a detailed analysis of the involvement of CREB in this synergism was undertaken in HepG2 cells. Gel mobility shift assays demonstrate that a CRE probe is bound by CREB present in HepG2 cells. Furthermore, we show that a dominant repressor of CREB is able to significantly reduce the cAMP responsiveness of the PEPCK promoter in HepG2 cells. Finally, we demonstrate using a GAL4-CREB fusion protein that CREB is able to synergize with the liver-enriched factors bound upstream on the PEPCK promoter to mediate a liver-specific response to cAMP. Examination of several mutant forms of CREB allow us to conclude that the ''synergy'' domain of CREB resides within amino acid residues 83-203, and that residues 83-145 can mediate a partial synergistic response. This study establishes that CREB is able to synergize with liver-enriched transcription factors to mediate a tissue-specific response to cAMP.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206	National Jewish Health	ROESLER, WJ (corresponding author), UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON,SK S7N 0W0,CANADA.							BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FABER S, 1993, J BIOL CHEM, V268, P24976; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU JS, 1991, J BIOL CHEM, V266, P19095; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; QUINN PG, 1993, J BIOL CHEM, V268, P16999; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	43	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8225	8232		10.1074/jbc.270.14.8225	http://dx.doi.org/10.1074/jbc.270.14.8225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713929	hybrid			2022-12-27	WOS:A1995QR52600068
J	BIRKENBIHL, RP; SUBRAMANI, S				BIRKENBIHL, RP; SUBRAMANI, S			THE RAD21 GENE-PRODUCT OF SCHIZOSACCHAROMYCES-POMBE IS A NUCLEAR, CELL-CYCLE-REGULATED PHOSPHOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; FISSION YEAST; DNA-REPAIR; PROTEINS; EXPRESSION; SEQUENCES; THIAMINE; CLEAVAGE; CLONING; MUTANTS	The rad21 gene of Schizosaccharomyces pombe is involved in the repair of double-strand breaks in DNA and is essential for mitotic growth (Birkenbihl, R. P., and Subramani, S. (1992) Nucleic Acids Res. 20, 6605-6611), We show that the Rad21 protein migrates with an aberrantly slow mobility, has a thrombin cleavage site, and is multiply phosphorylated mainly at serine residues. The expression of the rad21 mRNA and the Rad21 protein is cell cycle-regulated, with the peak of mRNA and protein expression occurring near the G(1) to S transition. Following translation of the protein, hypophosphorylated forms of the protein appear. However, the most phosphorylated form of Rad21 appears only later in the cell cycle (in S to G(2)). Analysis of the radiosensitive mutant rad21-45 revealed that the mutant protein is permanently hypophosphorylated. The Rad21 protein is nuclear during the cell cycle. The nuclear localization signal was identified in the C-terminal third of the protein. Upon repression of the Rad21 protein expressed from the repressible nmt1 promoter, the unphosphorylated and hypophosphorylated forms of Rad21 disappeared first. When the concentration of the most highly phosphorylated form of Rad21 sank under a critical level, the cells underwent aberrant mitoses, They exhibited loss of proper nuclear organization and abnormal septation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031253] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31253] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BACH ML, 1987, CURR GENET, V121, P527; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGAN IM, 1988, J CELL SCI, V89, P343; HOOD MT, 1990, NUCLEIC ACIDS RES, V18, P688, DOI 10.1093/nar/18.3.688; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN AR, 1991, MUTAT RES, V250, P205, DOI 10.1016/0027-5107(91)90177-P; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; NASIM A, 1975, GENETICS, V79, P573; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Sambrook J, 1989, MOL CLONING LABORATO; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUBRAMANI S, 1991, MOL MICROBIOL, V5, P2311, DOI 10.1111/j.1365-2958.1991.tb02075.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WENCHING L, 1991, J CELL BIOL, V113, P1	29	86	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7703	7711		10.1074/jbc.270.13.7703	http://dx.doi.org/10.1074/jbc.270.13.7703			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706319	hybrid			2022-12-27	WOS:A1995QQ43100097
J	HANASAKI, K; VARKI, A; POWELL, LD				HANASAKI, K; VARKI, A; POWELL, LD			CD22-MEDIATED CELL-ADHESION TO CYTOKINE-ACTIVATED HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; N-LINKED OLIGOSACCHARIDES; HUMAN LYMPHOCYTES-B; LEUKOCYTE ADHESION; ALPHA-2->6 SIALYLTRANSFERASE; SIALIC ACIDS; L-SELECTIN; RAT-LIVER; T-CELLS; CD22	We previously showed that cultured human umbilical vein endothelial cells (HEC) exposed to the inflammatory cytokines tumor necrosis factor-alpha or interleukin-1 display increased activity of beta-galactoside alpha 2,6-sialyltransferase, This is associated with enhanced expression of ligands for the B cell receptor CD22 beta, which recognizes alpha 2-6-linked sialic acids (Hanasaki, K., Varki, A., Stamenkovic, I., and Bevilacqua, M. P. (1994) J. Biol. Chem. 269, 10637-10643), Here we report that increased expression of CD22 ligands is a feature of dermal microvascular endothelial cells as well, and is also observed in response to the cytokine interleukin-4. Tumor necrosis factor-alpha stimulation of HEC causes no change in the profile of endothelial glycoproteins recognized by CD22, but doubles the proportion of total cellular N-linked oligosaccharides capable of binding tightly to CD22, This modest change is sufficient to cause a marked increase in alpha 2-6-linked sialic acid-dependent binding of Chinese hamster ovary (CHO) cells expressing recombinant human CD22, In contrast, B lymphoma cell lines expressing higher levels of cell surface CD22 do not show such sialic acid-dependent binding to activated HEC, Since B lymphoma cells themselves also express high levels of alpha 2-6-linked sialic acids, their CD22 molecules might be rendered nonfunctional by endogenous ligands, In support of this, the lectin function of CD22 can be directly detected on transfected CHO cells, but not on B lymphoma cells, Furthermore, coexpression of beta-galactoside alpha 2,6-sialyltransferase with CD22 in the CHO cells abrogates sialic acid dependent binding to cytokine-activated HEC. However, such co-transfected cells can bind to B lymphoma cells in a manner apparently less dependent upon alpha 2-6-linked sialic acid, suggesting CD22-mediated interactions that may not be directly dependent on its lectin function, Thus, CD22-mediated interactions between B cells and activated vascular endothelium may be positively regulated by induction of alpha 2-6-linked sialic acid-bearing endothelial cell ligands, but negatively regulated by such ligands on the B cells expressing CD22, Since expression of both CD22 and beta-galactoside alpha 2,6-sialyltransferase are regulated during B cell ontogeny, these findings could be of importance in B cell function and/or trafficking.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [KO1 CA01649] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CLARK EA, 1993, J IMMUNOL, V150, P4715; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DELAU WBM, 1993, J IMMUNOL, V150, P4911; DORKEN B, 1986, J IMMUNOL, V136, P4470; ENGEL P, 1993, J IMMUNOL, V150, P4719; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; EVANS SS, 1993, J CELL BIOL, V123, P1889, DOI 10.1083/jcb.123.6.1889; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; GUY K, 1991, IMMUNOLOGY, V74, P206; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; JAMIESON JC, 1993, COMP BIOCHEM PHYS B, V105, P29, DOI 10.1016/0305-0491(93)90165-2; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KNIEP B, 1990, FEBS LETT, V261, P347, DOI 10.1016/0014-5793(90)80588-A; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; PAULSON JC, 1977, J BIOL CHEM, V252, P8624; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SCHAUER R, 1983, SIALIC ACIDS CHEM ME, V10; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEISS P, 1989, J BIOL CHEM, V264, P11572; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	60	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7533	7542		10.1074/jbc.270.13.7533	http://dx.doi.org/10.1074/jbc.270.13.7533			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706300	hybrid			2022-12-27	WOS:A1995QQ43100075
J	TOYODA, H; KOMURASAKI, T; UCHIDA, D; TAKAYAMA, Y; ISOBE, T; OKUYAMA, T; HANADA, K				TOYODA, H; KOMURASAKI, T; UCHIDA, D; TAKAYAMA, Y; ISOBE, T; OKUYAMA, T; HANADA, K			EPIREGULIN - A NOVEL EPIDERMAL GROWTH-FACTOR WITH MITOGENIC ACTIVITY FOR RAT PRIMARY HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR FAMILY; FACTOR-ALPHA; TRANSGENIC MICE; TGF-ALPHA; MOLECULAR-CLONING; NEU ONCOGENE; HUMAN COLON; CELLS; EXPRESSION; PROTEIN	Epiregulin, a novel epidermal growth factor (EGF)related growth regulating peptide, was purified from conditioned medium of the mouse fibroblast-derived tumor cell line NIH3T3/clone T7. It was a 46-amino-acid single chain polypeptide, and its amino acid sequence exhibited 24-50% amino acid sequence identity with sequences of other EGF related growth factors. Epiregulin exhibited bifunctional regulatory properties: it inhibited the growth of several epithelial tumor cells and stimulated the growth of fibroblasts and various other types of cells. Epiregulin bound to the EGF receptors of epidermoid carcinoma A431 cells much more weakly than did EGF, but was nevertheless much more potent than EGF as a mitogen for rat primary hepatocytes and Balb/c 3T3 A31 fibroblasts, These findings suggest that epiregulin plays important roles in regulating the growth of epithelial cells and fibroblasts by binding to receptors for EGF-related ligands.	TAISHO PHARMACEUT CO LTD,RES CTR,DEPT APPL BIOL,OMIYA,SAITAMA 330,JAPAN; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,HACHIOJI,TOKYO 19203,JAPAN	Taisho Pharmaceutical Holdings Co Ltd; Tokyo Metropolitan University			Isobe, Toshiaki/Q-9279-2017					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CIARDIELLO F, 1991, P NATL ACAD SCI USA, P7792; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DELARCO JE, 1980, J BIOL CHEM, V255, P3685; ENGLER DA, 1988, J BIOL CHEM, V263, P1234; GROBE RI, 1993, P NATL ACAD SCI USA, V90, P823; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIROSE M, 1988, ANAL BIOCHEM, V168, P193, DOI 10.1016/0003-2697(88)90028-0; HOMES WE, 1992, SCIENCE, V256, P1205; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; KINOSHITA T, 1992, BIOCHEM BIOPH RES CO, V177, P330; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; LU C, 1991, P NATL ACAD SCI USA, V89, P9215; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHYOAB M, 1988, P NATL ACAD SCI USA, V85, P6528; SING Y, 1993, SCIENCE, V259, P1604; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; TANAKA K, 1978, J BIOCHEM-TOKYO, V84, P937, DOI 10.1093/oxfordjournals.jbchem.a132207; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	43	252	264	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7495	7500		10.1074/jbc.270.13.7495	http://dx.doi.org/10.1074/jbc.270.13.7495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706296				2022-12-27	WOS:A1995QQ43100071
J	KADEREIT, S; GEWERT, DR; GALABRU, J; HOVANESSIAN, AG; MEURS, EF				KADEREIT, S; GEWERT, DR; GALABRU, J; HOVANESSIAN, AG; MEURS, EF			MOLECULAR-CLONING OF 2 NEW INTERFERON-INDUCED, HIGHLY RELATED NUCLEAR PHOSPHOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; NF-KAPPA-B; PROTEIN-KINASE; MESSENGER-RNA; HUMAN-CELLS; CONSTITUTIVE EXPRESSION; GAMMA-INTERFERON; HUMAN-FIBROBLASTS; BINDING DOMAINS; 2-5A SYNTHETASE	During the molecular cloning of the human dsRNA activated-p68 kinase (PKR), polyclonal antibodies against PKR selected, in addition to cDNAs corresponding to PKR, another cDNA presenting only slight homology with PKR cDNA. This cDNA recognized an mRNA species of 2 kilobases induced by both alpha- and gamma-interferons. Its transcription did not require protein synthesis. On further library screening, it selected two highly related cDNAs, referred to as 75 and 41, displaying perfect homology over 612 base pairs and divergent at both ends. In addition, cDNA 75 presents an insertion of 150 base pairs highly homologous to a region common to both sequences. The 75 and 41 peptidic sequences are very hydrophilic, rich in basic amino acid residues, and contain several potential phosphorylation sites for different serine/threonine kinases. Furthermore, they present two protamine- and histone-like nuclear targeting sequences as well as some homology with helix-loop-helix motifs of some DNA-binding proteins. The 75-encoded product, which resolved as a 52-kDa protein after in vitro expression in rabbit reticulocyte lysates, was found to migrate as a 65-67-kDa protein after in vivo expression in insect cells. In accord with sequence data, this 65-67-kDa protein was found to be phosphorylated in vivo in the insect cells and was recovered from the membrane/nuclear pellet. In contrast, the 41-encoded product (30-kDa protein in reticulocyte lysates) could not be expressed in vivo, as it provoked a rapid and severe shut-off of protein synthesis in insect cells. The function of the 75 and 41 proteins and their relation to PKR remains to be determined. However, the presence of nuclear targeting sequences, phosphorylation sites, and helix-loop-helix motif is consistent with a role of these proteins in the mechanism of transduction of the interferon action.	INST PASTEUR, VIROL & CELLULAR IMMUNOL UNIT, F-75724 PARIS 15, FRANCE; WELLCOME FDN LTD, DEPT CELL BIOL, BECKENHAM BR3 3BS, KENT, ENGLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AMALDI I, 1989, J IMMUNOL, V142, P999; BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHEBATH J, 1983, NUCLEIC ACIDS RES, V11, P1213, DOI 10.1093/nar/11.5.1213; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FAN XD, 1989, MOL CELL BIOL, V9, P1922, DOI 10.1128/MCB.9.5.1922; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KORANT BD, 1984, J BIOL CHEM, V259, P4835; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MARIE I, 1992, J BIOL CHEM, V267, P9933; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MERLIN G, 1983, P NATL ACAD SCI-BIOL, V80, P4904, DOI 10.1073/pnas.80.16.4904; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS E, 1988, EMBO J, V7, P1689, DOI 10.1002/j.1460-2075.1988.tb02997.x; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUBIN BY, 1988, J VIROL, V62, P1875, DOI 10.1128/JVI.62.6.1875-1880.1988; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	59	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24432	24441						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693701				2022-12-27	WOS:A1993MF29400106
J	COOK, SP; BABCOCK, DF				COOK, SP; BABCOCK, DF			ACTIVATION OF CA2+ PERMEABILITY BY CAMP IS COORDINATED THROUGH THE PH(I) INCREASE INDUCED BY SPERACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; EGG PEPTIDE SPERACT; DEPENDENT PROTEIN-KINASE; PLASMA-MEMBRANE; GUANYLATE-CYCLASE; HEMICENTROTUS-PULCHERRIMUS; ADENYLATE-CYCLASE; HUMAN-NEUTROPHILS; ACROSOME REACTION; INTRACELLULAR PH	The egg peptide speract activates sperm K channels by transient stimulation of guanylyl cyclase (see the accompanying paper, Cook, S. P., and Babcock, D. F. (1993) J. Biol. Chem. 268, 22402-22407). Behavioral responses to speract are thought to require the brief elevations of cAMP and cytosolic [Ca2+] (Ca(i)) also evoked by speract through yet unknown mechanisms. Here we present evidence that cAMP mediates activation of a putative, Mn2+-permeable Ca channel that is responsible for increased Ca(i). We find that: 1) prolonged elevation of Ca(i) was produced by treatments previously shown to selectively enhance accumulation of cAMP; 2) elevation of Ca(i) and entry of Mn2+ are prevented by those manipulations of external [Na+] and [K+] previously shown to prevent accumulation of cAMP; 3) the blockade to Ca2+ entry imposed by increased external K+ is bypassed by elevation of cytosolic pH (pH(i)) with NH4Cl; 4) in the absence of speract, NH4Cl allows Mn2+ entry that is enhanced by papaverine, an inhibitor of sperm cAMP phosphodiesterase. These results thus also suggest that elevation of pH(i) is both necessary and sufficient to activate adenylylcyclase. This study provides tentative identification of sperm Ca channels as downstream targets of cAMP action and indicates that pH(i) may determine whether cGMP- or cAMP-mediated second messenger pathways predominate in speract signal transduction.	UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Babcock, Donner/0000-0002-4461-4544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022973] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22973] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BABCOCK DF, 1992, P NATL ACAD SCI USA, V89, P6001, DOI 10.1073/pnas.89.13.6001; BENTLEY JK, 1986, BIOL REPROD, V35, P1249, DOI 10.1095/biolreprod35.5.1249; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; BOOKBINDER LH, 1990, J CELL BIOL, V111, P1859, DOI 10.1083/jcb.111.5.1859; BOOKBINDER LH, 1991, MOL REPROD DEV, V28, P150, DOI 10.1002/mrd.1080280208; BRACHO GE, 1992, J CELL BIOL, V119, pA170; CARLYLE WC, 1991, THESIS U MINNESOTA; CLAPPER DL, 1985, J CELL BIOL, V100, P1817, DOI 10.1083/jcb.100.6.1817; COOK SP, 1993, J BIOL CHEM, V268; DANGOTT LJ, 1989, P NATL ACAD SCI USA, V86, P2128, DOI 10.1073/pnas.86.7.2128; DANGOTT LJ, 1984, J BIOL CHEM, V259, P3712; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GARBERS DL, 1982, J BIOL CHEM, V257, P2734; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; GARCIASOTO J, 1985, FEBS LETT, V190, P33, DOI 10.1016/0014-5793(85)80421-X; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P2235; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P163; HARUMI T, 1992, DEV GROWTH DIFFER, V34, P151; KACZOROWSKI GJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P287, DOI 10.1016/0304-4157(89)90022-1; LEE HC, 1986, J BIOL CHEM, V261, P6026; LEE MYW, 1976, BIOCHIM BIOPHYS ACTA, V429, P123, DOI 10.1016/0005-2744(76)90035-8; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LIEVANO A, 1990, J GEN PHYSIOL, V95, P273, DOI 10.1085/jgp.95.2.273; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MILLER RL, 1982, AM ZOOL, V22, P827; MINTA A, 1989, J BIOL CHEM, V264, P19449; NEGULESCU PA, 1990, CELL REGUL, V1, P259, DOI 10.1091/mbc.1.3.259; POTTER LR, 1992, J BIOL CHEM, V267, P14531; SCHACKMANN RW, 1986, J BIOL CHEM, V261, P8719; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; SHIMOMURA H, 1986, J BIOL CHEM, V261, P5778; SIMCHOWITZ L, 1990, J BIOL CHEM, V265, P13449; SUZUKI N, 1992, COMP BIOCHEM PHYS B, V102, P679, DOI 10.1016/0305-0491(92)90064-X; SUZUKI N, 1981, BIOCHEM BIOPH RES CO, V99, P1238, DOI 10.1016/0006-291X(81)90752-X; SUZUKI N, 1984, J BIOL CHEM, V259, P4874; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TOOWICHARANONT P, 1988, J BIOL CHEM, V263, P6877; WARD GE, 1985, J CELL BIOL, V101, P2324, DOI 10.1083/jcb.101.6.2324; WELLS JN, 1976, BIOL REPROD, V15, P46, DOI 10.1095/biolreprod15.1.46; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YOSHINO K, 1992, EUR J BIOCHEM, V206, P887, DOI 10.1111/j.1432-1033.1992.tb16997.x; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	47	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22408	22413						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693668				2022-12-27	WOS:A1993MD34800036
J	MCGUIRE, TF; COREY, SJ; SEBTI, SM				MCGUIRE, TF; COREY, SJ; SEBTI, SM			LOVASTATIN INHIBITS PLATELET-DERIVED GROWTH-FACTOR (PDGF) STIMULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY AS WELL AS ASSOCIATION OF P85 SUBUNIT TO TYROSINE-PHOSPHORYLATED PDGF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMPETITIVE INHIBITOR; SIGNAL TRANSDUCTION; BETA-RECEPTOR; BOVINE BRAIN; RAT-LIVER; KINASE; CELLS; CHOLESTEROL; BINDING; POLYPHOSPHOINOSITIDES	Lovastatin inhibits mitogenesis in cultured cells and growth of tumors in vivo by unknown mechanism(s). Phosphatidylinositol 3-kinase (PI-3-kinase) is a putative second messenger-generating enzyme whose physical association with the platelet-derived growth factor receptor (PDGFR) has been demonstrated to be required for the mitogenic activity of PDGF in cultured fibroblasts. Here we examine the effect of lovastatin on PDGF- and insulin-stimulated PI-3-kinase activity. In quiescent NIH-3T3 cells, PDGF (25 ng/ml) and insulin (200 nM) stimulate PI-3-kinase activity 10- and 6-fold, respectively. However, overnight pretreatment of cells with 10 muM lovastatin inhibits this stimulation of PI-3-kinase activity by PDGF and insulin. Immunoprecipitation of the PI-3-kinase p85 subunit demonstrates a PDGF-dependent association of PI-3-kinase with the tyrosine-autophosphorylated PDGFR. However, upon exposure of cells to 10 muM lovastatin for 40 h, the level of autophosphorylated PDGFR associating with PI-3-kinase after PDGF stimulation decreases significantly (75% reduction). No change in the expression of the PI-3-kinase p85 subunit was observed after treatment of cells with lovastatin. These results demonstrate that lovastatin disrupts a major growth factor signaling pathway and that inhibition of PDGF-induced association of PI-3-kinase with PDGFR and subsequent inhibition of PI-3-kinase activity is one potential mechanism by which lovastatin inhibits cell growth.	UNIV PITTSBURGH,SCH MED,DEPT OBSTET & GYNECOL,PITTSBURGH,PA 15261; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAIRBANKS KP, 1984, J BIOL CHEM, V259, P1546; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HELDIN CH, 1990, J CELL SCI, V96, P193; ILLINGWORTH DR, 1989, ARTERIOSCLEROSIS, V9, pI121; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMIJAN DA, 1989, P NATL ACAD SCI USA, V86, P8232; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; Rodwell V W, 1976, Adv Lipid Res, V14, P1; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SUSA M, 1992, J BIOL CHEM, V267, P22951; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	27	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22227	22230						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693661				2022-12-27	WOS:A1993MD34800004
J	RICH, DP; BERGER, HA; CHENG, SH; TRAVIS, SM; SAXENA, M; SMITH, AE; WELSH, MJ				RICH, DP; BERGER, HA; CHENG, SH; TRAVIS, SM; SAXENA, M; SMITH, AE; WELSH, MJ			REGULATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CL- CHANNEL BY NEGATIVE CHARGE IN THE R-DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; K+ CHANNELS; PHOSPHORYLATION; INACTIVATION; EXPRESSION; EFFICIENT; CELLS; GENE; IDENTIFICATION; MUTAGENESIS	Phosphorylation by cAMP-dependent protein kinase (PKA) regulates the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. We previously showed that in vivo PKA phosphorylated 4 serines (Ser-660, Ser-737, Ser-795, and Ser-813) within the R domain. Here we show that a mutant CFTR lacking all 4 serines can still be phosphorylated by PKA to yield an activated Cl- channel, but channel open-state probability was substantially reduced. We also observed phosphorylation and Cl- channel activity in another mutant lacking all 8 consensus PKA serines in the R domain. We were unable to identify the residual phosphorylation sites by tryptic phosphopeptide mapping. These data suggest two possible interpretations: (a) additional, as yet unidentified, phosphorylation sites within CFTR may also open the channel, or (b) the 4 serines, previously identified as in vivo PKA phosphorylation sites, are the primary regulatory sites within CFTR, but in their absence, other sites can be phosphorylated to open the channel. The additional sites are likely located within the R domain: CFTRDELTAR-S660A, which lacks much of the R domain (residues 708-835) and replaces Ser-660 with an alanine, was no longer regulated by PKA. Substitution of aspartate for consensus PKA phosphorylation sites in the R domain mimicked the effect of phosphorylation. Mutants containing six or more serine-to-aspartate substitutions generated Cl- channels that opened without PKA phosphorylation. These results suggest that the R domain keeps the channel closed and that phosphorylation of the R domain or insertion of the negatively charged aspartate opens the channel, perhaps by electrostatic interactions.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	University of Iowa; Sanofi-Aventis; Genzyme Corporation	RICH, DP (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Cheng, Seng H/AAC-6564-2022	Welsh, Michael/0000-0002-1646-6206; Berger, Herbert/0000-0003-4383-2643	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHENG SH, 1988, MOL CELL BIOL, V6, P1562; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FONG YL, 1989, J BIOL CHEM, V264, P16759; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURRELL-LAGNADO R D, 1992, Biophysical Journal, V61, pA290; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIODAN JR, 1993, ANNU REV PHYSIOL, V55, P609; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TILLY BC, 1992, J BIOL CHEM, V267, P9470; WANG YH, 1992, J BIOL CHEM, V267, P16759; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	45	134	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20259	20267						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690753				2022-12-27	WOS:A1993LY01900053
J	WANG, H; LAMBOWITZ, AM				WANG, H; LAMBOWITZ, AM			REVERSE TRANSCRIPTION OF THE MAURICEVILLE PLASMID OF NEUROSPORA - LACK OF RIBONUCLEASE-H ACTIVITY ASSOCIATED WITH THE REVERSE-TRANSCRIPTASE AND POSSIBLE USE OF MITOCHONDRIAL RIBONUCLEASE-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA LINKED MSDNA; MYXOCOCCUS-XANTHUS; CRYSTAL-STRUCTURE; DNA-SYNTHESIS; VIRUS; INTRONS; EVOLUTION; SEQUENCE; CRASSA; IDENTIFICATION	The Mauriceville mitochondrial plasmid of Neurospora encodes a reverse transcriptase that synthesizes a full-length cDNA copy of the major plasmid transcript beginning directly opposite the 3' end of the template RNA (Kuiper, M. T. R., and Lambowitz, A. M. (1988) Cell 55, 693-704). Here, we show that the Mauriceville plasmid reverse transcriptase has no detectable RNase H activity and that cDNAs synthesized either by the column-purified reverse transcriptase or by the endogenous reverse transcriptase in purified ribonucleoprotein particles remain in a full-length duplex with the template RNA. The column-purified Mauriceville plasmid reverse transcriptase initiates cDNA synthesis by using short DNA primers, which remain attached to the 5' end of the (-) strand DNA (Wang, H., Kennell, J. C., Kuiper, M. T. R., Sabourin, J. R., Saldanha, R., and Lambowitz, A. M. (1992) Mol. Cell. Biol. 12, 5131-5144). We rind that these primer DNAs can be precisely removed by S1 nuclease digestion of the initial cDNA.RNA duplex, suggesting a mechanism whereby this structure may contribute to primer removal in vivo. Finally, we show that Neurospora mitochondria contain an endogenous RNase H activity, which is present in mitochondrial ribonucleoprotein particle preparations prior to their purification. This mitochondrial RNase H can degrade the endogenous plasmid transcript in ribonucleoprotein particles in vitro and could play a similar role in vivo. The finding that the Mauriceville plasmid reverse transcriptase, which is believed to be a primitive enzyme, has no detectable RNase H activity is consistent with the hypothesis that retroviral reverse transcriptases acquired their RNase H domains from a gene encoding a cellular RNase H.	OHIO STATE UNIV,DEPT MOLEC GENET,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1988, J MOL BIOL, V204, P1, DOI 10.1016/0022-2836(88)90594-3; AKINS RA, 1989, MOL CELL BIOL, V9, P678, DOI 10.1128/MCB.9.2.678; COLLINS RA, 1981, CELL, V24, P443, DOI 10.1016/0092-8674(81)90335-4; CROUCH R J, 1990, New Biologist, V2, P771; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DREHER TW, 1988, J MOL BIOL, V201, P31, DOI 10.1016/0022-2836(88)90436-6; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GILBOA E, 1979, CELL, V16, P863, DOI 10.1016/0092-8674(79)90101-6; INOUYE S, 1989, CELL, V56, P709, DOI 10.1016/0092-8674(89)90593-X; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; KUIPER MTR, 1990, J BIOL CHEM, V265, P6936; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MAJUMDER AL, 1989, MOL CELL BIOL, V9, P2089, DOI 10.1128/MCB.9.5.2089; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; NARGANG FE, 1986, MOL BIOL EVOL, V3, P19; NARGANG FE, 1984, CELL, V38, P441, DOI 10.1016/0092-8674(84)90499-9; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; STARNES MC, 1989, J BIOL CHEM, V264, P7073; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	43	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18951	18959						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689563				2022-12-27	WOS:A1993LV65900086
J	KATAYAMA, T; CROOKE, E				KATAYAMA, T; CROOKE, E			DNAA PROTEIN IS SENSITIVE TO A SOLUBLE FACTOR AND IS SPECIFICALLY INACTIVATED FOR INITIATION OF IN-VITRO REPLICATION OF THE ESCHERICHIA-COLI MINICHROMOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAM METHYLTRANSFERASE; CELL-CYCLE; ORIGIN; CHROMOSOME; GENE; SEQUENCE; INVITRO; BINDING; METHYLATION; PRIMOSOME	DnaA protein loses the capacity to initiate chromosomal replication when treated with a soluble cell extract, This inactivation depends upon DNA and hydrolyzable ribonucleoside triphosphate. The extract does not affect the activities of other replicative proteins or the ability of DnaA to initiate replication of single-stranded DNA that contains a DnaA-binding hairpin, indicating that the inhibitory effect is specific for the action of DnacA at oriC. Gel filtration experiments implicate a 150-kDa factor as being responsible. Mutant DnaAcos protein, which causes overinitiation in vivo, is insensitive to the inactivating factor, suggesting a requirement for this negative control in vivo. We propose that a soluble factor controls initiation through downregulation of DnaA protein.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Stanford University; Georgetown University				Katayama, Tsutomu/0000-0001-9994-1684	NIGMS NIH HHS [R01 GM049700, GM 49700] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049700, R21GM049700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CROOKE E, 1992, J BIOL CHEM, V267, P16779; CROOKE E, 1993, J MOL BIOL, V233, P166; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; HANSEN FG, 1977, MOL GEN GENET, V155, P219, DOI 10.1007/BF00393163; HATTMAN S, 1978, J MOL BIOL, V126, P367, DOI 10.1016/0022-2836(78)90046-3; HELMSTETTER CE, 1987, ESCHERICHIA COLI SAL, V2, P1594; HIRAGA S, 1974, MOL GEN GENET, V132, P49, DOI 10.1007/BF00268230; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KELLENBERGERGUJ.G, 1978, MOL GEN GENET, V162, P9; Kornberg A., 1992, DNA REPLICATION; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MARINUS MG, 1975, MUTAT RES, V28, P15, DOI 10.1016/0165-1218(75)90278-5; MARINUS MG, 1983, MOL GEN GENET, V192, P288, DOI 10.1007/BF00327681; MASAI H, 1990, J BIOL CHEM, V265, P15134; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; PARADA CA, 1991, J BIOL CHEM, V266, P18895; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; Sambrook J, 1989, MOL CLONING LABORATO; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STEMMER WPC, 1991, BIOTECHNIQUES, V10, P726; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	39	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9265	9271		10.1074/jbc.270.16.9265	http://dx.doi.org/10.1074/jbc.270.16.9265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721846	hybrid			2022-12-27	WOS:A1995QU08900034
J	PODLISNY, MB; OSTASZEWSKI, BL; SQUAZZO, SL; KOO, EH; RYDELL, RE; TEPLOW, DB; SELKOE, DJ				PODLISNY, MB; OSTASZEWSKI, BL; SQUAZZO, SL; KOO, EH; RYDELL, RE; TEPLOW, DB; SELKOE, DJ			AGGREGATION OF SECRETED AMYLOID BETA-PROTEIN INTO SODIUM DODECYL SULFATE-STABLE OLIGOMERS IN CELL-CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CORTICAL-NEURONS; NEURITIC PLAQUES; APOLIPOPROTEIN-E; PEPTIDE; NEUROTOXICITY; BRAIN; IDENTIFICATION; LOCALIZATION	Filamentous aggregates of the 40-42-residue amyloid beta-protein (A beta) accumulate progressively in the limbic and cerebral cortex in Alzheimer's disease, where they are intimately associated with neuronal and glial cytopathology, Attempts to model this cytotoxicity in vitro using synthetic peptides have shown that monomeric A beta is relatively inert, whereas aggregated A beta reproducibly exerts a variety of neurotoxic effects, The processes that mediate the conversion of monomeric A beta into a toxic aggregated state are thus of great interest. Previous studies of this conversion have employed high concentrations (10(-5)-10(-3) M) of synthetic A beta peptides under nonbiological conditions, We report here the detection of small amounts (<10(-9) M) of SDS-stable A beta oligomers in the culture media of Chinese hamster ovary cells expressing endogenous or transfected amyloid beta-protein precursor genes, The identity of these oligomers (primarily dimers and trimers) was established by immunoprecipitation with a panel of A beta antibodies, by electrophoretic comigration with synthetic A beta oligomers, and by amino acid sequencing, The oligomeric A beta species comprised similar to 10-20% of the total immunoprecipitable A beta in these cultures. A truncated A beta species beginning at Arg 5 was enriched in the oligomers, suggesting that amino-terminal heterogeneity can influence A beta oligomerization in this system. Addition of Congo red (10 mu M) during metabolic labeling of the cells led to increased monomeric and decreased oligomeric A beta. The ability to detect and quantitate oligomers of secreted A beta peptides in cell culture should facilitate dynamic studies of the critical process of initial A beta aggregation under physiological conditions.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BIOPOLYMER LAB,BOSTON,MA 02115; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	PODLISNY, MB (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE ON AGING [R35AG007911] Funding Source: NIH RePORTER; NIA NIH HHS [AG07911] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSCIGLIO J, 1993, J NEUROCHEM, V61, P1565, DOI 10.1111/j.1471-4159.1993.tb13658.x; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOWING E, 1994, J BIOL CHEM, V269, P10987; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PODLISNY MB, 1993, AM J PATHOL, V142, P17; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; PODLISNY MB, 1994, NEUROBIOL AGING, V15, P82; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1993, MOL PHARMACOL, V15, P373; SNOW AD, 1988, AM J PATHOL, V133, P456; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; YAMAGUCHI H, 1990, BRAIN RES, V508, P320, DOI 10.1016/0006-8993(90)90416-9; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	62	327	342	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9564	9570		10.1074/jbc.270.16.9564	http://dx.doi.org/10.1074/jbc.270.16.9564			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721886	hybrid			2022-12-27	WOS:A1995QU08900075
J	LOCKER, JK; OPSTELTEN, DJE; ERICSSON, M; HORZINEK, MC; ROTTIER, PJM				LOCKER, JK; OPSTELTEN, DJE; ERICSSON, M; HORZINEK, MC; ROTTIER, PJM			OLIGOMERIZATION OF A TRANS-GOLGI TRANS-GOLGI NETWORK RETAINED PROTEIN OCCURS IN THE GOLGI-COMPLEX AND MAY BE PART OF ITS RETENTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; INFLUENZA-VIRUS HEMAGGLUTININ; MEMBRANE-SPANNING DOMAIN; CORONAVIRUS-M-PROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; LOCALIZATION; SIGNAL	The mouse hepatitis virus M protein is a triple spanning membrane glycoprotein that, when expressed independently, localizes to trans-Golgi as well as to the trans-Golgi network (TGN). Passage of this protein from the endoplasmic reticulum through the intermediate compartment to the late Golgi and TGN can be conveniently followed by analyzing its O-linked sugars. Using pulse-chase analyses we studied the oligomerization of the M protein in sucrose gradients. The Golgi and TGN forms migrated as large heterogeneous complexes, whereas the endoplasmic reticulum and intermediate compartment forms of the protein appeared to migrate as monomer. Moreover, a mutant of the M protein lacking the 22 COOH-terminal amino acids, that is transported to the plasma membrane, gave rise to similar complexes, albeit smaller in size, that persisted at the plasma membrane. We propose that the trans-Golgi/TGN retention of the MHV-M protein is governed by two mechanisms: oligomerization possibly mediated by the transmembrane domains and binding of its cytoplasmic tail to cellular factors in trans Golgi/TGN.	UNIV UTRECHT, FAC VET MED, INST VIROL, DEPT IMMUNOL & INFECT DIS, 3584 CL UTRECHT, NETHERLANDS; EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	Utrecht University; European Molecular Biology Laboratory (EMBL)			Locker, Jacomine Krijnse/AAX-1185-2020; Locker, Jacomine Krijnse/E-1009-2016					ARMSTRONG J, 1991, J CELL SCI, V98, P567; ARMSTRONG J, 1990, J CELL SCI, V95, P191; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1992, J BIOL CHEM, V267, P24433; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LOCKER JK, 1994, J BIOL CHEM, V269, P28263; LOCKER JK, 1994, J CELL BIOL, V124, P55; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OPSTELTEN DJE, 1994, ARCH VIROL, P319; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981; ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TANG BL, 1992, J BIOL CHEM, V267, P7072; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	51	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8815	8821		10.1074/jbc.270.15.8815	http://dx.doi.org/10.1074/jbc.270.15.8815			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721788	Green Submitted, hybrid			2022-12-27	WOS:A1995QT44800066
J	REGAN, LM; FAY, PJ				REGAN, LM; FAY, PJ			CLEAVAGE OF FACTOR-VIII LIGHT-CHAIN IS REQUIRED FOR MAXIMAL GENERATION OF FACTOR VIIIA ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; VONWILLEBRAND FACTOR COMPLEX; PORCINE FACTOR-VIII; FACTOR-XA; PHOSPHOLIPID-VESICLES; FACTOR-IXA; C2 DOMAIN; CONFORMATIONAL SENSITIVITY; THROMBIN ACTIVATION; A1/A3-C1-C2 DIMER	Thrombin-catalyzed activation of heterodimeric factor VIII occurs by limited proteolysis, yielding subunits A1 and A2 derived from the heavy chain (HC) and A3-C1-C2 derived from the light chain (LC). The roles of these cleavages in the function of procoagulant activity are poorly understood. To determine whether LC cleavage contributes to the potentiation of factor VIII activity, factor VIII heterodimers were reconstituted from native HC and either thrombin-cleaved LC (A3-C1-C2) or intact LC and purified by Mono S chromatography. The reconstituted factor VIII form containing the A3-C1-C2 subunit had a specific activity (2 units/mu g) that was similar to 3-fold greater than that of the reconstituted factor VIII form containing native LC (0.6 units/mu g). Factor Xa generation assays using the hybrid heterodimer showed an initial rate that was unaffected by the presence of von Willebrand factor and a reduced lag time when compared with the native heterodimer. The A1/A3-C1-C2 dimer was dissociated by chelation, and the purified A1 subunit was reacted with either the A3-C1-C2 subunit or the LC in the presence of Mn2+ to reconstitute the dimer. Factor VIIIa heterotrimers were reconstituted from either A1/A3-C1-C2 or A1/LC plus the A2 subunit. The authentic factor VIIIa heterotrimer (A1/A3-C1-C2/A2) had 3-fold greater activity than the form containing the LC. However, upon reaction with thrombin, the activity of the latter form was increased to that of the factor VIIIa form containing native subunits. The incremental increase in fluorescence anisotropy of fluorescein-Phe-Phe-Arg chloromethyl ketone-modified factor IXa was markedly greater in the presence of HC/A3-C1-C2 (Delta r = 0.037) compared with HC/LC (Delta r = 0.011) and approached the value obtained with factor VIIIa (Delta r = 0.051). These results suggest that cleavage of factor VIII LC directly contributes to the potentiation of coagulant activity by modulating the conformation of the factor IXa active site.	UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30616, HL38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BIHOREAU N, 1989, EUR J BIOCHEM, V185, P111, DOI 10.1111/j.1432-1033.1989.tb15089.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FOSTER PA, 1993, THROMB HAEMOSTASIS, V69, P1089; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HAMER RJ, 1987, EUR J BIOCHEM, V166, P36; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KNOWLES JR, 1987, SCIENCE, V236, P1252; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LAJMONOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P123; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; OWEN WG, 1982, THROMB DIATH HAEMO, V27, P505; PIETERS J, 1989, BLOOD, V74, P1021; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; SAENKO EL, 1993, BLOOD, V82, pA339; SHIMA M, 1989, BLOOD, V74, P1612; TOOLE JJ, 1984, NATURE, V312, P330; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WISE RJ, 1993, BLOOD, V82, pA339; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; YE J, 1991, J BIOL CHEM, V266, P23016	47	69	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8546	8552		10.1074/jbc.270.15.8546	http://dx.doi.org/10.1074/jbc.270.15.8546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721754	hybrid			2022-12-27	WOS:A1995QT44800030
J	CHANG, YY; CRONAN, JE				CHANG, YY; CRONAN, JE			DETECTION BY SITE-SPECIFIC DISULFIDE DISULFIDE CROSS-LINKING OF A CONFORMATIONAL CHANGE IN BINDING OF ESCHERICHIA-COLI PYRUVATE OXIDASE TO LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; ALPHA-PEPTIDE; ACTIVATION; ENZYME; RECONSTITUTION; PROTEINS; CLONING; CHAIN	Escherichia coli pyruvate oxidase, a peripheral membrane homotetrameric flavoprotein, exposes its C-terminal lipid binding site in the presence of substrate pyruvate and co-factor thiamine pyrophosphate Mg2+ and binds tightly to phospholipid bilayers during catalysis. Using site-specific disulfide cross-linking, we demonstrate that disulfide cross-links are formed between C termini of D560C pyruvate oxidase and that the degree of cross-linking is greatly increased by the presence of substrate and co-factors indicating a conformational change that results in juxtaposition of two subunit C termini. The cross-linked oxidase is enzymatically active and remains able to associate with lipid micelles. These results argue strongly that lipid bilayer binding of pyruvate oxidase involves pairing of the C termini of two subunits.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	CHANG, YY (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,407 S GOODWIN,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019		NIGMS NIH HHS [GM 26156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDO S, 1991, J MOL BIOL, V217, P721; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; CHANG YY, 1983, J BACTERIOL, V154, P756, DOI 10.1128/JB.154.2.756-762.1983; CHANG YY, 1986, J BACTERIOL, V167, P312, DOI 10.1128/jb.167.1.312-318.1986; CHANG YY, 1984, P NATL ACAD SCI-BIOL, V81, P4348, DOI 10.1073/pnas.81.14.4348; CHANG YY, 1982, J BACTERIOL, V151, P1279, DOI 10.1128/JB.151.3.1279-1289.1982; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIEHL P, 1993, J BACTERIOL, V175, P2263, DOI 10.1128/JB.175.8.2263-2270.1993; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GRABAU C, 1989, J BIOL CHEM, V264, P12510; GRABAU C, 1986, BIOCHEMISTRY-US, V25, P3748, DOI 10.1021/bi00361a003; GRABAU C, 1986, NUCLEIC ACIDS RES, V14, P5449, DOI 10.1093/nar/14.13.5449; KOLAND JG, 1982, BIOCHEMISTRY-US, V21, P4438, DOI 10.1021/bi00261a038; KOLAND JG, 1982, J BIOL CHEM, V257, P6023; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P445, DOI 10.1021/bi00298a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHER M, 1982, J BIOL CHEM, V257, P2887; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; OBRIEN TA, 1982, BIOCHIM BIOPHYS ACTA, V705, P321, DOI 10.1016/0167-4838(82)90254-0; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RECNY MA, 1985, J BIOL CHEM, V260, P4287; RECNY MA, 1982, J BIOL CHEM, V257, P2878; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MI, 1992, P NATL ACAD SCI USA, V89, P4144; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; WANG AY, 1991, J BIOL CHEM, V266, P10959; ZHANG TF, 1987, ARCH BIOCHEM BIOPHYS, V255, P201, DOI 10.1016/0003-9861(87)90311-0	28	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7896	7901		10.1074/jbc.270.14.7896	http://dx.doi.org/10.1074/jbc.270.14.7896			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713884	hybrid			2022-12-27	WOS:A1995QR52600020
J	EKLUND, EA; SKALNIK, DG				EKLUND, EA; SKALNIK, DG			CHARACTERIZATION OF A GP91-PHOX PROMOTER ELEMENT THAT IS REQUIRED FOR INTERFERON-GAMMA-INDUCED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CHAIN GENE-EXPRESSION; LEUKEMIA CELL-LINE; ETS-RELATED PROTEIN; CYTOCHROME-B HEAVY; NADPH OXIDASE; BOX BINDING; RNA; ENHANCER; SEQUENCE	The cytochrome b(558) heavy chain (gp91-phox) is expressed nearly exclusively in terminally differentiating myelomonocytic cells, thereby providing a model to study the events of late myeloid differentiation. We describe a tissue culture assay for studying interferon gamma induction of gp91-phox expression and a cis-element in the gp91-phox promoter that is necessary but not sufficient for this activity. In vitro assays reveal two DNA-binding proteins that interact with this cis-element. One factor is restricted to hematopoietic cells, is required for an interferon gamma response, and binds to an element similar to the Ets protein family consensus, although it does not correspond to known family members. The second factor is the ubiquitous CCAAT-binding protein CP1, which is dispensable for an interferon gamma response. Single base pair mutations in the gp91-phox promoter that specifically abolish the binding of the hematopoietic-associated factor have previously been identified in chronic granulomatous disease patients (Newburger, P. E., Skalnik, D. G., Hopkins, P. J., Eklund, E. A., and Curnutte, J. T. (1994) J. Clin, Invest. 94, 1205-1211). The data reported here directly demonstrate the functional significance of the hematopoietic-associated factor for gp91-phox promoter activity and reveal the binding properties and tissue distribution of this novel DNA-binding protein.	INDIANA UNIV,SCH MED,DEPT PEDIAT,HERMAN B WELLS CTR PEDIAT RES,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NCI NIH HHS [CA58947] Funding Source: Medline; NHLBI NIH HHS [K08 HL03139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058947, R29CA058947] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BRADLEY TR, 1982, BRIT J HAEMATOL, V51, P595, DOI 10.1111/j.1365-2141.1982.tb02823.x; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHOMCZYNSKI P, 1992, NUCLEIC ACIDS RES, V20, P3791, DOI 10.1093/nar/20.14.3791; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEY GO, 1952, CANCER RES, V12, P264; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KOIZUMI H, 1993, MOL CELL BIOL, V13, P6690, DOI 10.1128/MCB.13.11.6690; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; REDDY ESP, 1991, ONCOGENE, V6, P2285; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT LM, 1992, BLOOD, V80, P1725; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TUCKER KA, 1987, BLOOD, V70, P372; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P725; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WOODMAN RC, 1995, BLOOD, V85, P231, DOI 10.1182/blood.V85.1.231.bloodjournal851231; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG LQ, 1993, ONCOGENE, V8, P1621	60	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8267	8273		10.1074/jbc.270.14.8267	http://dx.doi.org/10.1074/jbc.270.14.8267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713934	hybrid			2022-12-27	WOS:A1995QR52600073
J	RIDGWAY, ND; LAGACE, TA				RIDGWAY, ND; LAGACE, TA			BREFELDIN-A RENDERS CHINESE-HAMSTER OVARY CELLS INSENSITIVE TO TRANSCRIPTIONAL SUPPRESSION BY 25-HYDROXYCHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; COENZYME-A REDUCTASE; STEROL REGULATORY REGION; LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; GOLGI-APPARATUS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; OXYGENATED STEROLS; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM	The effect of disruption of the Golgi apparatus on 25-hydroxycholesterol-mediated transcriptional suppression and activation of acyl-CoA:cholesterol acyltransferase was examined. In Chinese hamster ovary (CHO) cells, brefeldin A (BFA) caused dose-dependent inhibition of 25-hydroxycholesterol-mediated suppression of mRNAs for four sterol-regulated genes: 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase, HMG-CoA synthase, farnesyl-diphosphate synthase, and the low density lipoprotein receptor, BFA prevented suppression whether added prior to or following a 4-h pretreatment with 25-hydroxycholesterol. In the presence of BFA (1 mu g/ml), 25-hydroxycholesterol-mediated suppression of mRNAs for HMG-CoA reductase, the low density lipoprotein receptor, and farnesyl-diphosphate synthase was almost completely blocked, HMG-CoA synthase mRNA was 80-90% suppressed by 25-hydroxycholesterol compared with 50-60% suppression in the presence of BFA. These effects of BFA were not due to alterations in mRNA stability. Disruption of the Golgi apparatus, as assessed by staining with a fluorescent lectin, correlated with concentrations of BFA that reversed mRNA suppression. Monensin was also found to block the effects of 25-hydroxycholesterol on suppression of HMG-CoA reductase. However, this ionophore decreased the other three sterol-regulated mRNAs to a similar degree as 25-hydroxycholesterol. In contrast to CHO cells, BFA-resistant PtK1 cells displayed normal down-regulation of HMG-CoA reductase and an intact Gels apparatus in the presence of BFA and 25-hydroxycholesterol. Cholesterol esterification in CHO cells was stimulated to a similar extent by BFA (1 mu g/ml) and 25-hydroxycholesterol, and simultaneous treatment of CHO cells with both compounds was 60-70% additive. These results suggest that an intact Golgi apparatus is required for 25-hydroxycholesterol-mediated suppression of mRNA.	DALHOUSIE UNIV, ATLANTIC RES CTR, HALIFAX, NS B3H 4H7, CANADA	Dalhousie University	RIDGWAY, ND (corresponding author), DALHOUSIE UNIV, DEPT PEDIAT & BIOCHEM, 5849 UNIV AVE, HALIFAX, NS B3H 4H7, CANADA.			Ridgway, Neale/0000-0002-0441-6228				BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNING A, 1992, J BIOL CHEM, V267, P7726; BRUNING A, 1992, J BIOL CHEM, V267, P5052; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; COXEY RA, 1993, J LIPID RES, V34, P1165; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KANDUTSCH AA, 1980, J BIOL CHEM, V255, P813; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LANGE Y, 1991, J LIPID RES, V32, P329; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1126, P291, DOI 10.1016/0005-2760(92)90243-O; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1125, P28, DOI 10.1016/0005-2760(92)90151-K; SUCKLING KE, 1985, J LIPID RES, V26, P647; TAYLOR FR, 1985, METHOD ENZYMOL, V110, P9; TAYLOR FR, 1984, J BIOL CHEM, V259, P12384; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; URBANI L, 1990, J BIOL CHEM, V265, P1919; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	50	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8023	8031		10.1074/jbc.270.14.8023	http://dx.doi.org/10.1074/jbc.270.14.8023			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713903	hybrid			2022-12-27	WOS:A1995QR52600039
J	HOGGER, P; SHOCKLEY, MS; LAMEH, J; SADEE, W				HOGGER, P; SHOCKLEY, MS; LAMEH, J; SADEE, W			ACTIVATING AND INACTIVATING MUTATIONS IN N-TERMINAL AND C-TERMINAL I3 LOOP JUNCTIONS OF MUSCARINIC ACETYLCHOLINE HM1 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD CYTOPLASMIC LOOP; BETA-ADRENERGIC-RECEPTOR; SYNTHETIC PEPTIDES; CHOLINERGIC RECEPTOR; INTRACELLULAR LOOP; AMINO-ACIDS; PROTEIN; GS; INTERNALIZATION; DOMAINS	The N- and C-terminal junctions of the third intracellular loop (i3) of G protein coupled receptors play a role in the coupling process, We had previously constructed two triple point alanine mutants of the i3 junction of the muscarinic Hm1 receptor, W209A/I211A/Y212A and E360A/K362A/T366A, which are defective in mediating carbachol stimulation of phosphatidylinositol (PI) turnover (Moro, O., Lameh, J., Hogger, P., and Sadee, W. (1993) J. Biol. Chem. 268, 22273-22276). Each of the corresponding six single point mutations were constructed to determine residues crucial to receptor coupling. Mutants W209A and T366A were similar to or only slightly less effective than wild type Hm1 in stimulating PI turnover. In the N-terminal junction, I211A and Y212A were defective in coupling, and I211A was even more defective than the corresponding triple mutant, Therefore, the triple mutation compensated at least partially for the effect of these two single point mutations. In the C-terminal i3 loop junction, mutant K362A was again more strongly defective than the corresponding triple mutant, In contrast, mutation E360A was found to be activating, leading to elevated PI turnover in the absence of agonist and sensitization toward carbachol activation. Activating mutations in the C terminal i3 loop junction have been reported previously for the adrenergic receptors, but E360A represents the first muscarinic receptor with substantial basal activity, The effects of the single point mutations observed in this study were not readily predictable from similar mutations from closely related G protein-coupled receptors despite sequence conservation in the is loop junctions. Our results caution against defining precise coupling domains in these regions by mutagenesis results.	UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08388, GM 43102] Funding Source: Medline; NIMH NIH HHS [K21 MH 00996] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BLUML K, 1994, J BIOL CHEM, V269, P402; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DENG WP, 1993, ANAL BIOCHEM, V200, P81; DUERSON K, 1993, FEBS LETT, V324, P103, DOI 10.1016/0014-5793(93)81541-7; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; KJELSBERG MA, 1992, J BIOL CHEM, V276, P1430; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; MORO O, 1993, J BIOL CHEM, V268, P22273; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REN Q, 1983, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SHAPIRO RA, 1993, J BIOL CHEM, V268, P21734; TIBERI M, 1994, J BIOL CHEM, V269, P27925; VOSS T, 1993, J BIOL CHEM, V268, P4637; WADE SM, 1994, J BIOL CHEM, V45, P1191; WANG Z, 1994, LIFE SCI, V54, P339; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WONG SKF, 1990, J BIOL CHEM, V265, P6219	36	80	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7405	7410						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706286				2022-12-27	WOS:A1995QQ43100059
J	OHBO, K; TAKASAWA, N; ISHII, N; TANAKA, N; NAKAMURA, M; SUGAMURA, K				OHBO, K; TAKASAWA, N; ISHII, N; TANAKA, N; NAKAMURA, M; SUGAMURA, K			FUNCTIONAL-ANALYSIS OF THE HUMAN INTERLEUKIN-2 RECEPTOR-GAMMA CHAIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; BOX-BINDING-PROTEINS; VIRUS TYPE-I; IL-2 RECEPTOR; TRANSCRIPTION FACTORS; TRANSACTIVATOR GENE; PHORBOL DIESTER; TAX GENE; EXPRESSION; CLONING	The third component of the interleukin (IL) 2 receptor, gamma chain, is essential not only for IL-2- but also for IL-4-, IL-7-, IL-9-, and IL-15-induced proliferation of lymphocytes. To elucidate the mechanisms by which the gamma chain is expressed, we have analyzed the promoter region of the gamma chain gene. The 633-base pair fragment upstream of the initiation codon showed the promoter activity in human hematopoietic cell lines, Jurkat and THP-1, when linked to the luciferase gene. With a series of 5'-deletion mutants, the basal promoter activity was found in a fragment from nucleotide 80 to 58 upstream from the RNA start site, including an Ets binding sequence, Treatment of cells with either 12-O-tetradecanoylphorbol-13-acetate or phytohemagglutinin but not forskolin induced transcription from the gamma chain gene promoter. A viral trans acting transcriptional activator, Tax, of human T-cell leukemia virus type I elevated expression of the gamma chain gene. In contrast, IL-2 decreased transcription from the IL-2 receptor gamma chain promoter. These results suggest that expression of the gamma chain is regulated at the transcription level by extracellular stimuli and may be implicated in immune response.			OHBO, K (corresponding author), TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 98077,JAPAN.			Ishii, Naoto/0000-0002-0549-8245				ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P3054; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHII N, 1994, INT IMMUNOL, V6, P1273, DOI 10.1093/intimm/6.8.1273; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Nakamura M, 1993, Semin Immunol, V5, P309, DOI 10.1006/smim.1993.1037; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TSUCHIYA S, 1982, CANCER RES, V42, P1530; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7479	7486		10.1074/jbc.270.13.7479	http://dx.doi.org/10.1074/jbc.270.13.7479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706294	hybrid			2022-12-27	WOS:A1995QQ43100069
J	SHIMIZU, RT; BLANK, RS; JERVIS, R; LAWRENZSMITH, SC; OWENS, GK				SHIMIZU, RT; BLANK, RS; JERVIS, R; LAWRENZSMITH, SC; OWENS, GK			THE SMOOTH-MUSCLE ALPHA-ACTIN GENE PROMOTER IS DIFFERENTIALLY REGULATED IN SMOOTH-MUSCLE VERSUS NONSMOOTH MUSCLE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; HEAVY-CHAIN ISOFORMS; LOOP-HELIX PROTEINS; FOS PROTO-ONCOGENES; CARDIAC ACTIN; TRANSCRIPTION FACTOR; SKELETAL-MUSCLE; MESSENGER-RNA; GROWTH-FACTOR; MYOGENIC DIFFERENTIATION	To identify potential regulators of smooth muscle cell (SMC) differentiation, we studied the molecular mechanisms that control the tissue-specific transcriptional expression of SM alpha-actin, the most abundant protein in fully differentiated SMCs. A construct containing the region from -1 to -125 of the promoter (p125CAT) had high transcriptional activity in SMCs (57-fold > promoterless) and endothelial cells (ECs) (18-fold) but not in skeletal myoblasts or myotubes. Mutation of either of two highly conserved CC(AT-rich)(6)GG (CArG) motifs at -62 and -112 abolished the activity of p125CAT in SMCs but had no effect in ECs. In contrast, high transcriptional activity in skeletal myotubes, which also express SM alpha-actin, required at least 271 base pairs of the promoter (-1 to greater than or equal to -271). Constructs containing 547 base pairs or more of the promoter were transcriptionally active in SMCs and skeletal myotubes but had no activity in skeletal myoblasts or ECs, cell types that do not express SM alpha-actin. Electrophoretic mobility shift assays provided evidence for binding of a unique serum response factor-containing complex of factors to the CArG box elements in SMCs. Results indicate that: 1) transcriptional expression of SM alpha-actin in SMCs requires the interaction of the CArG boxes with SMC nucleoprotein(s); 2) expression of SM alpha-actin in skeletal myotubes requires different cis-elements and trans-factors than in SMCs; and 3) negative-acting cis-elements are important in restricting transcription in cells that do not express SM alpha-actin.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908	University of Virginia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-38854] Funding Source: Medline; NIGMS NIH HHS [T32 GM-07267] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANK RS, 1992, J BIOL CHEM, V267, P984; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GABBIANI G, 1992, KIDNEY INT, V41, P530, DOI 10.1038/ki.1992.75; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOWN AM, 1986, AM J PATHOL, V125, P191; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUNNING P, 1990, DEV BIOL, V138, P443, DOI 10.1016/0012-1606(90)90210-A; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HIPSKIND RA, 1993, NATURE, V254, P531; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; KAIRSER HE, 1992, IN VIVO, V6, P451; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; LOEB AL, 1985, HYPERTENSION, V7, P804, DOI 10.1161/01.HYP.7.5.804; MIN BH, 1990, J BIOL CHEM, V265, P16667; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; MONICAL PL, 1988, BIOPHYS J, V53, P580; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NAKANO Y, 1991, GENE, V99, P285; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OWENS GK, 1986, J BIOL CHEM, V261, P3373; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6179; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; REDDY S, 1990, J BIOL CHEM, V265, P1683; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHWARTZ SM, 1984, PROG CARDIOVASC DIS, V26, P355, DOI 10.1016/0033-0620(84)90010-0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SKALLI O, 1989, J HISTOCHEM CYTOCHEM, V37, P315, DOI 10.1177/37.3.2918221; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; TAYLOR M, 1989, DEVELOPMENT, V106, P67; THINAKARAN G, 1993, BIOCHEM CELL BIOL, V71, P260, DOI 10.1139/o93-040; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VANDEKERCKHOVE J, 1981, EUR J BIOCHEM, V113, P595, DOI 10.1111/j.1432-1033.1981.tb05104.x; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WALSH K, 1987, J BIOL CHEM, V262, P9429; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; 1993, MMWR-MORBID MORTAL W, V42, P891	85	150	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7631	7643		10.1074/jbc.270.13.7631	http://dx.doi.org/10.1074/jbc.270.13.7631			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706311	hybrid			2022-12-27	WOS:A1995QQ43100089
J	YU, JC; LI, WQ; WANG, LM; UREN, A; PIERCE, JH; HEIDARAN, MA				YU, JC; LI, WQ; WANG, LM; UREN, A; PIERCE, JH; HEIDARAN, MA			DIFFERENTIAL REQUIREMENT OF A MOTIF WITHIN THE CARBOXYLTERMINAL DOMAIN OF ALPHA-PLATELET-DERIVED GROWTH-FACTOR (ALPHA-PDGF) RECEPTOR FOR PDGF FOCUS-FORMING ACTIVITY CHEMOTAXIS, OR GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE INSERT DOMAIN; SIGNALING PATHWAYS; PHOSPHOLIPASE-C; EXPRESSION; SEQUENCE; PROTEIN	To determine the molecular basis for the transforming function of platelet derived growth factor (PDGF)-A in NIH/3T3 cells, we have constructed chimerae consisting of the extracellular domain of the human CSF-1R (fms) linked to the cytoplasmic domain of the alpha PDGF receptor (alpha R) containing a series of deletion or point mutations. The ability of fms/alpha R chimerae to mediate CSF-l-dependent anchorage-independent growth, focus formation, and chemotaxis of NIH/3T3 cells was then examined. Our results provide evidence that a domain encompassing amino acid residues 977-1024 of the alpha PDGFR is required for ligand-dependent focus formation, but not chemotaxis or anchorage-independent growth, and that tyrosine residues within this domain constitute the major binding site for phospholipase C gamma. Therefore, our findings suggest that: (i) the focus forming function of alpha PDGFR correlates well with the ability of the receptor to bind phospholipase C gamma, and (ii) the mechanism of focus formation mediated by (alpha PDGFR may be distinguished from that required for chemotaxis or anchorage-independent growth.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; KUNDRA V, 1994, NATURE, V367, P476; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; RAPESH LA, 1989, INVAS METAST, V9, P192; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	23	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7033	7036		10.1074/jbc.270.13.7033	http://dx.doi.org/10.1074/jbc.270.13.7033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706238	hybrid			2022-12-27	WOS:A1995QQ43100006
J	BENHAMOU, M; RYBA, NJP; KIHARA, H; NISHIKATA, H; SIRAGANIAN, RP				BENHAMOU, M; RYBA, NJP; KIHARA, H; NISHIKATA, H; SIRAGANIAN, RP			PROTEIN-TYROSINE KINASE P72(SYK) IN HIGH-AFFINITY IGE RECEPTOR SIGNALING - IDENTIFICATION AS A COMPONENT OF PP72 AND ASSOCIATION WITH THE RECEPTOR GAMMA-CHAIN AFTER RECEPTOR AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; WHEAT-GERM-AGGLUTININ; PHOSPHOLIPASE C-GAMMA-1; MAST-CELLS; ANTIGEN RECEPTOR; MEDIATED SIGNAL; ZETA-CHAIN; PHOSPHORYLATION; RBL-2H3; TRANSDUCTION	Protein-tyrosine phosphorylation plays a critical role in the high-affinity IgE receptor (FcepsilonRI) signaling. Here we investigated the involvement of the tyrosine kinase p72syk in FcepsilonRI signaling in the rat mast cell line RBL-2H3. Specific antibodies were raised against peptides synthesized on the basis of the deduced peptide sequence of an essentially full-length rat syk cDNA. The expression of p72syk in RBL-2H3 cells was demonstrated with these antibodies. The aggregation of FcepsilonRI led to the tyrosine phosphorylation of p72syk that was detected after 15 s of stimulation, reached a plateau by 5 min, and was not induced by calcium influx or protein kinase C activation. Association of p72syk with the tyrosine phosphorylated FcepsilonRIgamma chain was detected only after receptor aggregation. We previously demonstrated that aggregation of the FcepsilonRI on mast cells results in the tyrosine phosphorylation of a 72-kDa protein (pp72) involved in IgE signaling. The depletion of p72syk from RBL-2H3 cell lysates resulted in only a slight decrease in the amount of pp72. These results demonstrate that pp72 is composed of several phosphoproteins and identify p72syk as one component of pp72. These data, together with recent observations in T cells, indicate that the interaction between p72syk-related tyrosine kinases and zeta-related proteins could play an important role in signal transduction.			BENHAMOU, M (corresponding author), NIDR, IMMUNOL LAB, BETHESDA, MD 20892 USA.			Ryba, Nicholas/0000-0002-2060-8393; Benhamou, Marc/0000-0001-7763-3795				ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERENSTEIN EH, 1990, FASEB J, V4, pA1874; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; EISEMAN E, 1992, NATURE, V355, P78; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KUMADA T, 1993, BIOCHEM BIOPH RES CO, V191, P1363, DOI 10.1006/bbrc.1993.1367; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; NISHIKATA H, 1992, J IMMUNOL, V149, P862; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; SIEGEL JN, 1992, CURRENT PROTOCOLS IM, V2; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIRAGANIAN RP, 1993, ALLERGY PRINCIPLES P, V1, P105; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YAMADA T, 1991, BIOCHEM BIOPH RES CO, V180, P1325, DOI 10.1016/S0006-291X(05)81340-3; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YU KT, 1991, J BIOL CHEM, V266, P22564; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	37	245	247	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23318	23324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693687				2022-12-27	WOS:A1993MF51500058
J	CHANG, JY; SCHINDLER, P; RAMSEIER, U; LAI, PH				CHANG, JY; SCHINDLER, P; RAMSEIER, U; LAI, PH			THE DISULFIDE FOLDING PATHWAY OF HUMAN EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-A; PROTEIN; BPTI; IDENTIFICATION	Human epidermal growth factor (EGF) contains three disulfides and 53 amino acids. Reduced/denatured EGF refolds spontaneously in vitro to acquire its native structure, The mechanism of this folding process has been elucidated by structural analysis of both acid and iodoacetate trapped intermediates, The results reveal that the folding is accompanied by a sequential flow of unfolded EGF (O-disulfide) through three groups of folding intermediates, namely 1-disulfide, 2-disulfide, and 3-disulfide (scrambled) EGF isomers, to reach the native structure. Equilibrium occurs among isomers of each class of disulfide species, and the composition of intermediates appears to be highly heterogeneous. Together, at least 27 fractions of folding intermediates have been identified, but there exist only limited numbers of well populated species which constitute more than 80% of the total intermediates found during EGF folding. Six species of such well populated intermediates have been isolated, which included two 1-S-S, two 2-S-S, and two 3-S-S scrambled species. Their disulfide structures have been identified here. Both 1-S-S isomers are found to contain non-native disulfides. One of the 2-S-S species consists of two non-native disulfides and the other admits two native disulfides, Among the six disulfides of the two scrambled species, only one is native. Together, native disulfides constitute 25% of the total disulfides found in these six well populated intermediates, These results contrast sharply to those observed with bovine pancreatic trypsin inhibitor, which has shown that well populated folding intermediates consist of exclusively native disulfides (Weissman, J, S,, and Kim, P. S, (1991) Science 253, 1386-1393). We propose that well populated folding intermediates, regardless of whether they contain native or non-native disulfides, do not necessarily represent the productive species and specify the folding pathway. Furthermore, conditions influencing the efficiency of EGF folding have been investigated, It is demonstrated here that under optimized compositions of redox agents, including the use of cysteine/cystine and protein disulfide isomerase, the in vitro folding of EGF could be achieved quantitatively within 1 min.	PROT INST INC,BROOMALL,PA 19008		CHANG, JY (corresponding author), CIBA GEIGY LTD,PHARMACEUT RES LABS,K-121,104,CH-4002 BASEL,SWITZERLAND.							ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOERNSEN KO, 1990, CHIMIA, V44, P412; BULLEID NJ, 1993, ADV PROTEIN CHEM, V44, P125, DOI 10.1016/S0065-3233(08)60566-5; CARVER JA, 1986, FEBS LETT, V205, P77, DOI 10.1016/0014-5793(86)80869-9; CHANG JY, 1993, J BIOL CHEM, V268, P4043; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHANG JY, 1994, J BIOL CHEM, V269, P22087; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; HANIU M, 1994, INT J PEPT PROT RES, V43, P81; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KONISHI Y, 1981, BIOCHEMISTRY-US, V20, P3945, DOI 10.1021/bi00517a001; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; RAMSEIER U, 1994, ANAL BIOCHEM, V221, P231, DOI 10.1006/abio.1994.1406; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; WEISSMAN JS, 1992, SCIENCE, V256, P112, DOI 10.1126/science.256.5053.112; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	29	59	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9207	9216		10.1074/jbc.270.16.9207	http://dx.doi.org/10.1074/jbc.270.16.9207			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721838	hybrid			2022-12-27	WOS:A1995QU08900026
J	MCCARTNEY, S; LITTLE, BM; LANGEBERG, LK; SCOTT, JD				MCCARTNEY, S; LITTLE, BM; LANGEBERG, LK; SCOTT, JD			CLONING AND CHARACTERIZATION OF A-KINASE ANCHOR PROTEIN-100 (AKAP100) - A PROTEIN THAT TARGETS A-KINASE TO THE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; BOVINE BRAIN; SUBCELLULAR-LOCALIZATION; CATALYTIC SUBUNIT; POTASSIUM CHANNEL; GOLGI-COMPLEX; EXPRESSION; BETA; PHOSPHORYLATION; BINDING	Differential localization of the type II cAMP-dependent protein kinase (PKA) is achieved by interaction of the regulatory subunit (RII) with A-kinase anchor proteins (AKAPs). Anchoring is a likely means to adapt PKA for regulation of cAMP-responsive events through colocalization of the kinase with preferred substrates, Using an interaction cloning strategy with an RII alpha protein probe, we have identified a 655-amino acid protein (named AKAP100), Recombinant AKAP100, expressed in Escherichia coli, binds RII alpha in a solid-phase overlay assay, The cellular and subcellular distribution of AKAP100 was analyzed by various methods. Northern blot analysis with the AKAP100 cDNA as a probe detected an 8-kilobase message in some human tissues including various brain regions; however, the message was predominately expressed in cardiac and skeletal muscle, Anti-AKAP100 antibodies confirmed expression in the rat cardiac and skeletal muscle cell lines, H9c2 and L6P, whereas immunohistochemical analysis revealed that AKAP100 was localized to the sarcoplasmic reticulum of both cell types, RII was also detected in these regions, AKAP100 was detected in preparations of RII purified from L6P cell extracts by cAMP-agarose affinity chromatography, Collectively, these results suggest that AKAP100 functions to maintain the type II PKA at the sarcoplasmic reticulum.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CAI YC, 1993, J BIOL CHEM, V268, P23720; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHEIN CT, 1991, P NATL ACAD SCI USA, V88, P9578; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORBIN JD, 1975, J BIOL CHEM, V250, P218; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; HARPER JF, 1985, VITAM HORM, V42, P197; HATHAWAY DR, 1981, J BIOL CHEM, V256, P8183; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JOACHIM S, 1990, EUR J CELL BIOL, V51, P76; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KAWANO S, 1992, CIRC RES, V71, P585, DOI 10.1161/01.RES.71.3.585; KREBS EG, 1979, ANNU REV BIOCHEM, V43, P923; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI USA, V81, P4887; LORY P, 1992, BIOCHEM BIOPH RES CO, V182, P1059, DOI 10.1016/0006-291X(92)91839-I; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SALAVATORI S, 1990, BIOCHEM J, V267, P679; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOPTT JD, 1994, MOL ENDOCRINOL, V13, P5; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND EW, 1972, SCIENCE, V171, P401; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH KB, 1992, J GEN PHYSIOL, V100, P847, DOI 10.1085/jgp.100.5.847	47	91	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9327	9333		10.1074/jbc.270.16.9327	http://dx.doi.org/10.1074/jbc.270.16.9327			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721854	hybrid			2022-12-27	WOS:A1995QU08900043
J	SOLIOZ, M; ODERMATT, A				SOLIOZ, M; ODERMATT, A			COPPER AND SILVER TRANSPORT BY COPB-ATPASE IN MEMBRANE-VESICLES OF ENTEROCOCCUS-HIRAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; CANDIDATE GENE; MENKES DISEASE; CADMIUM-RESISTANCE; PROTEIN; ACTIVATION; ENCODES; BINDING	The P-type ATPase, CopB, of Enterococcus hirae is required for the copper resistance displayed by this organism and thus was postulated to be a copper pump. Using Cu-64(+) and Ag-110m(+), we here show ATP-driven copper and silver accumulation catalyzed by CopB in native inside-out membrane vesicles of E. hirae. CopB ATPase exhibited an apparent K-m for Cu+ and Ag+ of 1 mu M and for ATP of 10 mu M. Transport was maximal at pH 6 and had an apparent V-max of 0.07 nmol . min(-1). mg(-1) for both copper and silver transport. Vanadate displayed a biphasic effect on transport: maximal inhibition was observed at 40 mu M vanadate for copper transport and 60 mu M for silver transport, respectively. At higher vanadate concentrations, these inhibitions were reversed. The CopB ATPase off. hirae is thus a pump for the extrusion of monovalent copper and silver ions, with copper probably being the natural substrate.			SOLIOZ, M (corresponding author), UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND.		Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721; Odermatt, Alex/0000-0002-6820-2712				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CERVANTES C, 1994, FEMS MICROBIOL REV, V14, P121, DOI 10.1016/0168-6445(94)90002-7; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; FURST P, 1989, P NATL ACAD SCI USA, V86, P5267, DOI 10.1073/pnas.86.14.5267; GE ZM, 1995, MOL MICROBIOL, V15, P97, DOI 10.1111/j.1365-2958.1995.tb02224.x; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; IVEY DM, 1992, J BACTERIOL, V174, P4878, DOI 10.1128/JB.174.15.4878-4884.1992; KAHN D, 1989, J BACTERIOL, V171, P929, DOI 10.1128/jb.171.2.929-939.1989; KANAMARU K, 1994, MOL MICROBIOL, V13, P369, DOI 10.1111/j.1365-2958.1994.tb00430.x; LEBRUN M, 1994, J BACTERIOL, V176, P3040, DOI 10.1128/JB.176.10.3040-3048.1994; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; ODERMATT A, 1992, ANN NY ACAD SCI, V671, P484, DOI 10.1111/j.1749-6632.1992.tb43836.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; ODERMATT A, 1995, J BIOL CHEM, V269, P4349; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; POPE MT, 1968, Q REV CHEM SOC, V22, P527, DOI 10.1039/qr9682200527; SILVER S, 1993, MOL MICROBIOL, V10, P7, DOI 10.1111/j.1365-2958.1993.tb00898.x; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; SOLIOZ M, 1994, J BIOL CHEM, V269, P9453; SOUNESS JE, 1985, J CYCLIC NUCL PROT, V10, P383; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; VILSEN B, 1989, J BIOL CHEM, V264, P21024; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	32	223	229	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9217	9221		10.1074/jbc.270.16.9217	http://dx.doi.org/10.1074/jbc.270.16.9217			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721839	hybrid			2022-12-27	WOS:A1995QU08900027
J	CLARKE, VA; PLATT, N; BUTTERS, TD				CLARKE, VA; PLATT, N; BUTTERS, TD			CLONING AND EXPRESSION OF THE BETA-N-ACETYLGLUCOSAMINIDASE GENE FROM STREPTOCOCCUS-PNEUMONIAE - GENERATION OF TRUNCATED ENZYMES WITH MODIFIED AGLYCON SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCI; PROTEIN-A; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CELL-WALL; ACETYLHEXOSAMINIDASE; PURIFICATION; HOMOLOGY; PYOGENES; COMPLEX	The gene encoding a beta-N acetylglucosaminidase from Streptococcus pneumoniae has been obtained by screening an expression library for beta-N-acetylglucosaminidase activity. Clones of different nucleotide sizes each having arylglycoside activity were obtained, and DNA sequencing revealed a gene of 3933 base pairs possessing typical bacterial transcription initiation and termination sequences and terminating in an ochre stop codon. Computer analysis of the translated protein of 1311 amino acids (144,210 Da) identified a tandem repeat within which lies a sequence homologous with six other hexosaminidase gene products from a wide variety of species ranging from bacteria to humans. Also found were an amino-terminal putative secretion signal peptide and a carboxyl-terminal cell sorting/anchorage motif typically found in over 20 other Gram-positive surface proteins. The expression of an almost complete DNA clone in Escherichia coli produced a functional and authentic beta-N-acetylglucosaminidase with aglycon specificity identical to the wild-type enzyme. However, enzymes produced from truncated DNA clones show more restricted aglycon specificity and are unable to hydrolyze terminal beta 1-2GlcNAc residues from N-glycans containing a bisecting N-acetylglucosamine, The availability of these clones allows structural analyses to be made of catalytic and oligosaccharide recognition protein domains that enhance functional activity.	UNIV OXFORD,DEPT BIOCHEM,INST GLYCOBIOL,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3QX,ENGLAND	University of Oxford; University of Oxford								ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; BECCARI T, 1992, BIOCHEM J, V285, P593, DOI 10.1042/bj2850593; BOULNOIS GJ, 1992, J GEN MICROBIOL, V138, P249, DOI 10.1099/00221287-138-2-249; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BUTTERS TD, 1991, BIOCHEM J, V279, P189, DOI 10.1042/bj2790189; CANNON RD, 1994, J BACTERIOL, V176, P2640, DOI 10.1128/JB.176.9.2640-2647.1994; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE VA, 1994, INT J BIOCHROM, V1, P151; FARRELL AM, 1993, J GEN MICROBIOL, V139, P267, DOI 10.1099/00221287-139-2-267; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOWARD CR, 1993, TRENDS BIOCHEM SCI, V18, P136, DOI 10.1016/0968-0004(93)90021-E; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; HAANES EJ, 1989, J BACTERIOL, V171, P6397, DOI 10.1128/jb.171.12.6397-6408.1989; HUGHES RC, 1964, BIOCHEMISTRY-US, V3, P1543, DOI 10.1021/bi00898a026; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; LINDER TE, 1994, MICROB PATHOGENESIS, V16, P435, DOI 10.1006/mpat.1994.1043; LOEFDAHL S, 1983, P NATL ACAD SCI USA, V80, P697; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH HE, 1992, INFECT IMMUN, V60, P2361, DOI 10.1128/IAI.60.6.2361-2367.1992; SOMERVILLE CC, 1993, P NATL ACAD SCI USA, V90, P6751, DOI 10.1073/pnas.90.14.6751; SOTOGIL RW, 1989, J BIOL CHEM, V264, P14778; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; YAMASHITA K, 1981, BIOCHEM BIOPH RES CO, V100, P226, DOI 10.1016/S0006-291X(81)80086-1	34	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8805	8814		10.1074/jbc.270.15.8805	http://dx.doi.org/10.1074/jbc.270.15.8805			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721787	hybrid			2022-12-27	WOS:A1995QT44800065
J	DATTA, PK; GHOSH, AK; JACOB, ST				DATTA, PK; GHOSH, AK; JACOB, ST			THE RNA-POLYMERASE-I PROMOTER-ACTIVATING FACTOR CPBF IS FUNCTIONALLY AND IMMUNOLOGICALLY RELATED TO THE BASIC HELIX-LOOP-HELIX-ZIPPER DNA-BINDING PROTEIN-USF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; MAJOR LATE PROMOTER; RIBOSOMAL-RNA; ENHANCER ELEMENT; FACTOR E1BF; GENE; REGION; UPSTREAM; SEQUENCE; SPACER	Analysis of the core promoter sequence of the mam malian ribosomal RNA genes revealed an E-box like sequence (CACGCTG) to which the upstream stimulatory factor (USF) binds. Because the core promoter binding factor (CPBF) binds specifically to the core promoter sequence of the ribosomal RNA gene (Liu, Z., and Jacob, S. T. (1994) J. Biol. Chem. 269, 16618-16626) and resembles USP in some respects, we explored the potential relationship between USF and CPBF. Competition electrophoretic mobility shift assay using labeled core promoter probe and several unlabeled competitor oligonucleotides showed that USF can indeed bind to the core promoter and that only those oligonucleotides with an E-box sequence could compete in the promoter-protein complex formation characteristic of CPBF. This complex formation was thermostable, a unique property of USF. Furthermore, antibodies raised against USF cross-reacted with the 44-kDa component of rat CPBF. To prove further the relationship between CPBF and USF, we examined the effects of the unlabeled USF and ribosomal gene core promoter oligonucleotides on polymerase (pol) I and pol II transcription. Both oligonucleotides inhibited rDNA transcription as well as transcription from the adenovirus major late promoter. Only the oligonucleotides that contain the E-box sequence competed in the transcription. These data indicate that the promoter sequence of mammalian ribosomal RNA gene contains an USE-binding site, that the 44-kDa polypeptide of CPBF is related to the 44/43-kDa polypeptide of human USF, and that USF or USF-related protein can transactivate both pol I and pol II promoters.	CHICAGO MED SCH, DEPT PHARMACOL & MOLEC BIOL, N CHICAGO, IL 60064 USA	Chicago Medical School				Datta, Prasun/0000-0001-5133-253X	NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DIXIT A, 1987, J BIOL CHEM, V262, P11616; DUMENCO VM, 1986, GENE, V46, P227, DOI 10.1016/0378-1119(86)90407-5; FINANCSEK I, 1982, P NATL ACAD SCI-BIOL, V79, P3092, DOI 10.1073/pnas.79.10.3092; GHOSH AK, 1994, GENE, V141, P271, DOI 10.1016/0378-1119(94)90584-3; GHOSH AK, 1993, GENE, V125, P217, DOI 10.1016/0378-1119(93)90332-W; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; HARRINGTON CA, 1983, NUCLEIC ACIDS RES, V11, P3317, DOI 10.1093/nar/11.10.3317; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1993, BIOCHEM BIOPH RES CO, V190, P747, DOI 10.1006/bbrc.1993.1112; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; KURL RN, 1984, P NATL ACAD SCI-BIOL, V81, P6672, DOI 10.1073/pnas.81.21.6672; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LI JM, 1994, MOL CELL BIOL, V14, P2191, DOI 10.1128/MCB.14.3.2191; Liu Z., UNPUB; LIU ZJ, 1994, J BIOL CHEM, V269, P16618; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Niu Huifeng, 1995, Gene Expression, V4, P111; Paule Marvin R., 1993, Gene Expression, V3, P1; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8637	8641		10.1074/jbc.270.15.8637	http://dx.doi.org/10.1074/jbc.270.15.8637			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721765	hybrid			2022-12-27	WOS:A1995QT44800042
J	HEIMBERG, H; DEVOS, A; PIPELEERS, D; THORENS, B; SCHUIT, F				HEIMBERG, H; DEVOS, A; PIPELEERS, D; THORENS, B; SCHUIT, F			DIFFERENCES IN GLUCOSE-TRANSPORTER GENE-EXPRESSION BETWEEN RAT PANCREATIC ALPHA-CELLS AND BETA-CELLS ARE CORRELATED TO DIFFERENCES IN GLUCOSE-TRANSPORT BUT NOT IN GLUCOSE-UTILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; A-CELLS; B-CELLS; SEQUENCE; GLUT-1; LIVER; HETEROGENEITY; GLUCOKINASE; GLUCAGON; ISOFORMS	Glucose exerts inverse effects upon the secretory function of islet alpha- and beta-cells, suppressing glucagon release and increasing insulin release, This diverse action may result from differences in glucose transport and metabolism between the two cell types. The present study compares glucose transport in rat alpha- and beta-cells. beta-Cells transcribed GLUT2 and, to a lesser extent, GLUT 1; alpha-cells contained GLUT1 but no GLUT2 mRNA No other GLUT-like sequences were found among cDNAs from alpha- or beta-cells. Both cell types expressed 43-kDa GLUT1 protein which was enhanced by culture. The 62-kDa beta-cell GLUT2 protein was converted to a 58-kDa protein after trypsin treatment of the cells without detectable consequences upon glucose transport kinetics. In beta-cells, the rates of glucose transport were 10-fold higher than in alpha-cells. In both cell types, glucose uptake exceeded the rates of glucose cose utilization by a factor of 10 or more. Glycolytic flux, measured as D-[5(3)H]glucose utilization, was comparable in alpha- and beta-cells between 1 and 10 mmol/liter substrate. In conclusion, differences in glucose transporter gene expression between alpha- and beta-cells can be correlated with differences in glucose transport kinetics but not with different glucose utilization rates.	FREE UNIV BRUSSELS,DIABET RES CTR,DEPT BIOCHEM,B-1090 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,DIABET RES CTR,DEPT ENDOCRINOL & METAB,B-1090 BRUSSELS,BELGIUM; UNIV LAUSANNE,INST PHARMACOL,CH-1005 LAUSANNE,SWITZERLAND	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Lausanne				Heimberg, Harry/0000-0003-1954-7375; Pipeleers, Daniel/0000-0002-6440-2485; De Vos, Anick/0000-0001-5311-1589				CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; DEVOS A, 1991, BIOCHEM INT, V24, P117; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GERICH JE, 1974, J CLIN INVEST, V54, P833, DOI 10.1172/JCI107823; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GORUS FK, 1984, J BIOL CHEM, V259, P1196; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GREENBAUM CJ, 1991, J CLIN INVEST, V88, P767, DOI 10.1172/JCI115375; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LING Z, 1994, DIABETOLOGIA, V37, P15; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2902; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P817, DOI 10.1210/endo-117-3-817; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; TAL M, 1992, J BIOL CHEM, V267, P17241; TAL M, 1992, MOL CELL BIOL, V12, P422, DOI 10.1128/MCB.12.1.422; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; THORENS B, 1992, INT REV CYTOL, V137A, P209; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525	35	118	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8971	8975		10.1074/jbc.270.15.8971	http://dx.doi.org/10.1074/jbc.270.15.8971			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721807	hybrid			2022-12-27	WOS:A1995QT44800086
J	MUKUND, S; ADAMS, MWW				MUKUND, S; ADAMS, MWW			GLYCERALDEHYDE-3-PHOSPHATE FERREDOXIN OXIDOREDUCTASE, A NOVEL TUNGSTEN-CONTAINING ENZYME WITH A POTENTIAL GLYCOLYTIC ROLE IN THE HYPERTHERMOPHILIC ARCHAEON PYROCOCCUS-FURIOSUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IRON-SULFUR PROTEIN; ARCHAEBACTERIUM; PATHWAY; DEHYDROGENASE; ORGANISMS	The archaeon Pyrococcus furiosus grows optimally at 100 degrees C by the fermentation of carbohydrates to yield acetate, CO2, and H-2. Cell-free extracts contain very low activity of the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase, but extremely high activity of glyceraldehyde-3-phosphate ferredoxin oxidoreductase (GAPOR). GAPOR was purified under strictly anaerobic conditions. It is a monomeric, O-2-sensitive protein of M(r) similar to 63,000 which contains pterin and approximately 1 tungsten and 6 iron atoms per molecule. The enzyme oxidized glyceraldehyde-3-phosphate (K-m 28 mu M) to 3-phosphoglycerate and reduced P. furiosus ferredoxin (K-m 6 mu M), but it did not oxidize formaldehyde, acetaldehyde, glyceraldehyde, benzaldehyde, glucose, glucose 6-phosphate, or glyoxylate, nor did it use NAD(P) as an electron acceptor. It is proposed that GAPOR has a glycolytic role and functions in place of glyceraldehyde-3-phosphate dehydrogenase and possibly phosphoglycerate kinase.	UNIV GEORGIA,DEPT MOLEC BIOL & BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Adams, Michael/0000-0002-9796-5014				Adams M.W.W., 1994, ENCY INORGANIC CHEM, P4284; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; JOHNSON JL, 1993, J BIOL CHEM, V268, P4848; KENGEN SWM, 1994, FEMS MICROBIOL LETT, V117, P305, DOI 10.1016/0378-1097(94)90576-2; KENGEN SWM, 1994, ARCH MICROBIOL, V161, P168, DOI 10.1007/BF00276479; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; MA K, 1994, J BACTERIOL, V176, P6509, DOI 10.1128/JB.176.21.6509-6517.1994; MA K, 1994, FEMS MICROBIOL LETT, V122, P263; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; MUKUND S, 1993, J BIOL CHEM, V268, P13592; NEGELEIN E, 1957, METHOD ENZYMOL, V3, P216, DOI 10.1016/S0076-6879(57)03376-5; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; SCHAFER T, 1994, FEMS MICROBIOL LETT, V121, P107, DOI 10.1016/0378-1097(94)90153-8; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; SCHMITZ RA, 1992, EUR J BIOCHEM, V209, P1013, DOI 10.1111/j.1432-1033.1992.tb17376.x; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; WHITE H, 1991, BIOL CHEM H-S, V372, P999, DOI 10.1515/bchm3.1991.372.2.999; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	22	168	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8389	8392		10.1074/jbc.270.15.8389	http://dx.doi.org/10.1074/jbc.270.15.8389			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721730	hybrid			2022-12-27	WOS:A1995QT44800005
J	PFEFFERKORN, LC; VANDEWINKEL, JGJ; SWINK, SL				PFEFFERKORN, LC; VANDEWINKEL, JGJ; SWINK, SL			A NOVEL ROLE FOR IGG-FC - TRANSDUCTIONAL POTENTIATION FOR HUMAN HIGH-AFFINITY FC-GAMMA RECEPTOR (FC-GAMMA-RI) SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HUMAN MONONUCLEAR PHAGOCYTES; MOUSE MONOCLONAL-ANTIBODIES; NADPH OXIDASE ACTIVITY; HUMAN IMMUNOGLOBULIN-G; CROSS-LINKING; TRANSIENT ACTIVATION; IFN-GAMMA; CELL-LINE; BINDING	Human type 1 FC gamma receptors (Fc gamma RI) bind with high affinity (K-d = similar to 10(-9) M) Fc regions of monomeric IgG1 and IgG3. As demonstrated in this report, interaction of IgG-Fc with the ligand binding site on Fc gamma RI alters its capacity for aggregation-dependent signaling. This Fc-dependence was demonstrated in normal monocytes and U937-10.6 cells exposed to monomeric IgG and then to anti-Fc gamma RI F(ab')(2) that cross-link the receptor. Using O-2(-) production to measure cell signaling, we found that binding by high affinity IgGs of various species, as well as by murine hybrid IgGs containing only one high affinity heavy chain, resulted in a marked increase in Fc gamma RI-mediated signaling. Preaggregated Fc gamma RI/IgG had a ratio of one. IgG binding after aggregation of unligated Fc gamma RI did not restore signaling. Dose responses indicated that concentrations of IgG that saturated Fc gamma RI optimized transductional activity. The inclusion of unligated with ligated Fc gamma RI in aggregates depressed activity, indicating a lack of trans-activation of unligated Fc gamma RI. Significantly, IgG-binding markedly increased aggregation-dependent tyrosine phosphorylation of Fc gamma RI gamma-chains and the association of tyrosine phosphorylated Syk. Thus, the consequences of IgG-Fc binding were increases in aggregation-dependent phosphorylation of Fc gamma RI gamma-chains, recruitment of pp72Syk to Fc gamma RI, and signaling of the NADPH oxidase pathway.	UNIV UTRECHT HOSP, DEPT EXPTL IMMUNOL, UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center	PFEFFERKORN, LC (corresponding author), DARTMOUTH COLL, SCH MED, DEPT MICROBIOL, LEBANON, NH 03756 USA.				NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029455] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108] Funding Source: Medline; NIAID NIH HHS [AI29455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1986, IMMUNOL TODAY, V7, P264, DOI 10.1016/0167-5699(86)90007-1; BASS DA, 1988, J BIOL CHEM, V263, P19610; BENDER JG, 1983, J IMMUNOL, V130, P2316; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BROWN JC, 1977, P NATL ACAD SCI USA, V74, P5682, DOI 10.1073/pnas.74.12.5682; BROWN JC, 1975, P NATL ACAD SCI USA, V72, P5111, DOI 10.1073/pnas.72.12.5111; DUCHEMIN AM, 1994, J BIOL CHEM, V269; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GERGELY J, 1989, IMMUNOL LETT, V20, P1, DOI 10.1016/0165-2478(89)90059-X; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HALLETT MB, 1983, BIOCHEM J, V216, P459, DOI 10.1042/bj2160459; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KANE PM, 1988, J CELL BIOL, V107, P969, DOI 10.1083/jcb.107.3.969; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KOOLWIJK P, 1989, J IMMUNOL, V143, P1656; KOOLWIJK P, 1991, J IMMUNOL, V147, P595; LAW CL, 1994, J BIOL CHEM, V269, P12310; LI S, 1986, J IMMUNOL, V137, P3378; LONGMORE GD, 1993, J CELL BIOL, V123, P1305, DOI 10.1083/jcb.123.6.1305; METZGER H, 1992, J IMMUNOL, V149, P1477; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; ORTEGA E, 1991, BIOCHEMISTRY-US, V30, P3473, DOI 10.1021/bi00228a018; PAN L, 1990, J IMMUNOL, V145, P267; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; PFEFFERKORN LC, 1990, MOL IMMUNOL, V27, P263, DOI 10.1016/0161-5890(90)90139-Q; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PFEFFERKORN LC, 1989, J IMMUNOL, V143, P2640; PFEFFERKORN LC, 1994, FASEB J, V8, pA749; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROZSNYAY Z, 1989, IMMUNOLOGY, V66, P491; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SHEN L, 1989, J IMMUNOL, V143, P4117; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3; ZHENG Y, 1992, BIOCHEMISTRY-US, V31, P7446, DOI 10.1021/bi00148a004; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8164	8171		10.1074/jbc.270.14.8164	http://dx.doi.org/10.1074/jbc.270.14.8164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713921	hybrid			2022-12-27	WOS:A1995QR52600060
J	ROBBGASPERS, LD; THOMAS, AP				ROBBGASPERS, LD; THOMAS, AP			COORDINATION OF CA2+ SIGNALING BY INTERCELLULAR PROPAGATION OF CA2+ WAVES IN THE INTACT LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE COUPLETS; CALCIUM WAVES; INOSITOL 1,4,5-TRISPHOSPHATE; CONFOCAL MICROSCOPY; OSCILLATIONS; TRISPHOSPHATE; VASOPRESSIN; STIMULATION; MESSENGER; GLUTAMATE	Activation of the inositol lipid signaling system results in cytosolic Ca2+ oscillations and intra- and intercellular Ca2+ waves in many isolated cell preparations. However, this form of temporal and spatial organization of signaling has not been demonstrated in intact tissues. Digital imaging fluorescence microscopy was used to monitor Ca2+ at the cellular and subcellular level in intact perfused rat liver loaded with fluorescent Ca2+ indicators, Perfusion with low doses of vasopressin induced oscillations of hepatocyte Ca2+ that were coordinated across entire lobules of the Liver by propagation of Ca2+ waves along the hepatic plates. At the subcellular level these periodic Ca2+ waves initiated from the sinusoidal domain of cells within the periportal region and propagated radially across cell-cell contacts into the pericentral region, or until terminated by annihilation collision with other Ca2+ wave fronts. With increasing agonist dose, the frequency but not the amplitude of the Ca2+ waves increased. Intracellular Ca2+ wave rates were constant, but transcellular signal propagation was determined by agonist dose, giving rise to a dose-dependent increase in the rate at which Ca2+ waves spread through the liver. At high vasopressin doses, a single Ca2+ wave was observed and the direction of Ca2+ wave propagation was reversed, initiating in the pericentral region and spreading to the periportal region. It is concluded that intercellular Ca2+ waves may provide a mechanism to coordinate responses across the functional units of the liver.	THOMAS JEFFERSON UNIV,DEPT ANAT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University			Gaspers, Lawrence/W-8766-2019; Thomas, Andrew/C-6755-2013	Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [T32-AA07463, AA07215] Funding Source: Medline; NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; COMBETTES L, 1994, BIOCHEM J, V304, P585, DOI 10.1042/bj3040585; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; GRAF P, 1987, BIOCHEM J, V241, P933, DOI 10.1042/bj2410933; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1992, CELL CALCIUM, V13, P89, DOI 10.1016/0143-4160(92)90002-A; OSTROWSKI NL, 1993, ENDOCRINOLOGY, V133, P1849, DOI 10.1210/en.133.4.1849; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SNEYD J, 1994, AM J PHYSIOL, V266, pC293, DOI 10.1152/ajpcell.1994.266.1.C293; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; THOMAS AP, 1991, CELL CALCIUM, V12, P8111; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	23	183	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8102	8107		10.1074/jbc.270.14.8102	http://dx.doi.org/10.1074/jbc.270.14.8102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713913	hybrid			2022-12-27	WOS:A1995QR52600051
J	SWARTS, HGP; KLAASSEN, CHW; STEKHOVEN, FMAHS; DEPONT, JJHHM				SWARTS, HGP; KLAASSEN, CHW; STEKHOVEN, FMAHS; DEPONT, JJHHM			SODIUM ACTS AS A POTASSIUM ANALOG ON GASTRIC H,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(H+ + K+)-ATPASE; (NA++K+)-ACTIVATED ATPASE; BETA-SUBUNIT; PHOSPHORYLATION; IONS; (NA++K+)-ATPASE; PROTONS; K+; DEPHOSPHORYLATION; MECHANISM	The effects of Na+ on gastric H,K-ATPase were investigated using leaky and ion-tight H,K-ATPase vesicles. Na+ activated the total ATPase activity in the absence of K+, reaching levels of 15% relative to those in the presence of K+. The Na+ activation, which takes place at the luminal side of the membrane, depended on the ATP concentration and the type of buffer used. The steady-state ATP phosphorylation level, studied with leaky vesicles, was reduced by Na+ due to both activation of the dephosphorylation reaction and a shift to E(2) in the E(1)<->E(2) equilibrium. By studying this equilibrium in ion-tight H,K-ATPase vesicles, it was found that Na+ drives the enzyme via a cytosolic site to the nonphosphorylating E(2) conformation. No H+-like properties of cytosolic Na+ could be detected. We therefore conclude that Na+ behaves like K+ rather than like H+ in the H,K-ATPase reaction.	UNIV NIJMEGEN, DEPT BIOCHEM, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEJONG ML, 1986, THESIS NIJMEGEN NETH, P112; FU YF, 1985, BIOCHIM BIOPHYS ACTA, V817, P7, DOI 10.1016/0005-2736(85)90062-8; HARA Y, 1986, J BIOCHEM, V99, P531, DOI 10.1093/oxfordjournals.jbchem.a135509; HELMICHDEJONGML, 1986, BIOCHIM BIOPHYS ACTA, V860, P841; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; LEWIS SA, 1989, METHOD ENZYMOL, V171, P715; LJUNGSTROM M, 1984, BIOCHIM BIOPHYS ACTA, V769, P220, DOI 10.1016/0005-2736(84)90026-9; LJUNGSTROM M, 1979, ACTA CHEM SCAND B, V33, P618, DOI 10.3891/acta.chem.scand.33b-0618; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; POLVANI C, 1989, J BIOL CHEM, V264, P17854; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, J BIOL CHEM, V265, P19594; RAY TK, 1985, FEBS LETT, V185, P24, DOI 10.1016/0014-5793(85)80733-X; REENSTRA WW, 1988, J BIOL CHEM, V263, P19618; SCHWARZ W, 1994, CELL PHYSIOL BIOCHEM, V4, P77, DOI 10.1159/000154713; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P391; STEKHOVEN FMAHS, 1986, BIOCHIM BIOPHYS ACTA, V854, P21; STEKHOVEN FMAHS, 1986, BIOCHIM BIOPHYS ACTA, V855, P375; STEWART B, 1981, J BIOL CHEM, V256, P2682; SWARTS HGP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P283, DOI 10.1016/0005-2736(91)90068-J; SWARTS HGP, 1994, BBA-BIOMEMBRANES, V1189, P143, DOI 10.1016/0005-2736(94)90059-0; VANUEM TJF, 1992, MOL ASPECTS TRANSPOR, P27; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1979, J BIOL CHEM, V254, P1899	28	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7890	7895		10.1074/jbc.270.14.7890	http://dx.doi.org/10.1074/jbc.270.14.7890			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713883	Green Published, hybrid			2022-12-27	WOS:A1995QR52600019
J	SCHMITZ, ML; STELZER, G; ALTMANN, H; MEISTERERNST, M; BAEUERLE, PA				SCHMITZ, ML; STELZER, G; ALTMANN, H; MEISTERERNST, M; BAEUERLE, PA			INTERACTION OF THE COOH-TERMINAL TRANSACTIVATION DOMAIN OF P65 NF-KAPPA-B WITH TATA-BINDING PROTEIN, TRANSCRIPTION FACTOR IIB, AND AND COACTIVATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DNA TOPOISOMERASE-I; RNA POLYMERASE-II; ACTIVATION DOMAIN; FACTOR-TFIIB; V-REL; C-REL; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE PRODUCT; 65-KD SUBUNIT	We show that the transactivating COOH terminus of the p65 subunit of human transcription factor NF-kappa B directly binds the general transcription factors TFIIB and TATA-binding protein (TBP) in vitro. Interaction of p65 with TFIIB required the most COOH-terminal se quence repeat within TFIIB. A functional interaction of TFIIB with p65 was evident from assays in yeast cells. Cotransfection experiments in COS cells revealed that only overexpression of TBP was able to further stimulate p65-dependent transactivation of a reporter gene. The coexpression of neither TBP nor TFIIB was able to relieve squelching, indicating the involvement of additional factors in transactivation by p65. A cell-free assay using highly purified factors revealed a specific transcriptional stimulation through the COOH terminal activation domain of NF-kappa B by at least one cofactor, PC1, isolated from HeLa cells. These data show that the potent acidic transactivation domains in the COOH terminus of p65 are able to functionally recruit various components of the basic transcription machinery as well as coactivators.	GENE CTR, MOLEC BIOL LAB, D-81675 MUNICH, GERMANY; LUDWIGS MAXIMILIANS UNIV, INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	University of Munich; University of Munich	SCHMITZ, ML (corresponding author), UNIV FREIBURG, INST BIOCHEM, HERMANN HERDER STR 7, D-79104 FREIBURG, GERMANY.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROKER M, 1991, APPL MICROBIOL BIOT, V34, P756; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CASWELL R, 1993, J GEN VIROL, V74, P2691, DOI 10.1099/0022-1317-74-12-2691; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GRILLI M, 1993, INT REV CYTOL, V143, P1; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Manet Evelyne, 1993, Gene Expression, V3, P49; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Ransone Lynn J., 1993, Gene Expression, V3, P37; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHMITZ ML, 1994, BIOTECHNIQUES, V17, P714; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMITH CA, 1993, J VIROL, V67, P4676, DOI 10.1128/JVI.67.8.4676-4687.1993; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	85	142	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7219	7226		10.1074/jbc.270.13.7219	http://dx.doi.org/10.1074/jbc.270.13.7219			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706261	hybrid			2022-12-27	WOS:A1995QQ43100033
J	SMITH, DF; ALBERS, MW; SCHREIBER, SL; LEACH, KL; DEIBEL, MR				SMITH, DF; ALBERS, MW; SCHREIBER, SL; LEACH, KL; DEIBEL, MR			FKBP54, A NOVEL FK506-BINDING PROTEIN IN AVIAN PROGESTERONE-RECEPTOR COMPLEXES AND HELA EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; 59-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; POLYCLONAL ANTIBODY; IMMUNOPHILINS; HSP56; COMPONENT; FK506; FORM	Avian progesterone receptor complexes contain five major co-purifying proteins, including hsp90, hsp70, and a 23-kDa protein. The other receptor-associated proteins, p50 and p54, share amino acid sequence similarities with a 52-59-kDa component (p59, hsp56, or FKBP52) of mammalian steroid receptor complexes that is also a member of the FK506-binding proteins (FKBP) family of immunophilins. We show here that p50, but not p54, cross-reacts with a rabbit antiserum prepared against human FKBP52. Both p50 and p54 bind an FK506 affinity resin at 0.5 M KCl, but only p50 binds efficiently in low salt conditions. Glycerol density gradient analyses show that both p50 and p54 exist predominantly in oligomeric complexes at low ionic strength. The poor retention of p54 on FK506 resin at low ionic strength compared with the high retention of p50 suggests that these proteins may largely exist in separate complexes and may interact with other proteins, such as progesterone receptor, in distinctive manners. In HeLa cell extracts, a 55-kDa FK506-binding protein, distinct from FKBP52, cross-reacts with anti-p54 antibody FF1. We conclude that p50 is avian FKBP52, whereas p54 and the 55-kDa human FF1 antigen are FKBP54, a novel immunophilin.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UPJOHN CO,DEPT CELL BIOL & BIOCHEM,KALAMAZOO,MI 49001	Harvard University; Pfizer	SMITH, DF (corresponding author), UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44923] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULLIVAN WP, 1985, BIOCHEMISTRY-US, V24, P4214, DOI 10.1021/bi00336a060; TAI PKK, 1985, CAN J BIOCHEM CELL B, V63, P41, DOI 10.1139/o85-006; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TRANDINH CC, 1992, FASEB J, V6, P3410, DOI 10.1096/fasebj.6.15.1464374; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VISHWANATHA JK, 1986, J BIOL CHEM, V261, P6619; YEM AW, 1992, J BIOL CHEM, V267, P2868	22	66	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24270	24273						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693698				2022-12-27	WOS:A1993MF29400082
J	SCHILDBACH, JF; NEAR, RI; BRUCCOLERI, RE; HABER, E; JEFFREY, PD; NG, SC; NOVOTNY, J; SHERIFF, S; MARGOLIES, MN				SCHILDBACH, JF; NEAR, RI; BRUCCOLERI, RE; HABER, E; JEFFREY, PD; NG, SC; NOVOTNY, J; SHERIFF, S; MARGOLIES, MN			HEAVY-CHAIN POSITION-50 IS A DETERMINANT OF AFFINITY AND SPECIFICITY FOR THE ANTIDIGOXIN ANTIBODY-26-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SOMATIC MUTATION; BINDING; ENERGY; ANTIBODIES; PROTEINS; DIVERSITY; COMPLEXES	Antibody produced by a variant of the murine anti-digoxin hybridoma 26-10 has reduced afrinity for digoxin but enhanced recognition of the digoxin 12-hydroxyl due to a Tyr to His substitution at heavy chain position 50 (Schildbach, J. F., Panka, D. J., Parks, D. R., Jager, G. C., Novotny, J., Herzenberg, L. A., Mudgett-Hunter, M., Bruccoleri, R. E., Haber, E., and Margolies, M. N. (1991) J. Biol. Chem. 266, 4640-4647). Consistent with these data, the 26-10 Fab-digoxin x-ray crystal structure (Jeffrey, P. D., Strong, R. K., Sieker, L. C., Chang, C. Y., Campbell, R. L., Petsko, G. A., Haber, E., Margolies, M. N., and Sheriff, S. (1993) Proc. Natl. Acad. Sci. U. S. A., in press) reveals that Tyr-50 contacts a region of digoxin that includes the hapten- 12 carbon. To determine the effects of other heavy chain position 50 substitutions, mutant antibodies were engineered, and their affinities for digoxin and digoxin analogues were measured. The affinity of the mutant antibodies for digoxin roughly correlates with the size of the position 50 side chain. Substitutions of Trp or Phe have no effect on affinity, whereas substitutions of Asn, His, Leu, Ala, Gly, and Asp confer progressively lower affinities. Although Trp and Phe mutants exhibit wild-type specificity, Asn and Asp mutants have improved affinity for digoxin relative to digitoxin (12-deshydroxydigoxin). Leu, Ala, and Gly mutants have improved affinity for 12-acetyldigoxin relative to digoxin as compared with 26-10. These results indicate that position 50 is a determinant of both antibody affinity and fine specificity for antibody 26-10 and that single-amino acid substitutions can alter antibody fine specificity. Models of the mutants were computationally constructed, and haptens were docked into the modeled binding sites. The results suggest that 12-acetyldigoxigenin occupies different orientations in the 26-10 and in the Ala mutant binding sites, resulting in altered binding.	MASSACHUSETTS GEN HOSP,DEPT MED,JACKSON 1402,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114; HARVARD UNIV,GRAD SCH ARTS & SCI,PROGRAM IMMUNOL,CAMBRIDGE,MA 02138; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,PRINCETON,NJ 08543; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOL SCI,CARDIOVASC BIOL LAB,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Bristol-Myers Squibb; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health				Schildbach, Joel/0000-0002-3038-9745; Jeffrey, Philip/0000-0002-4351-5341; Near, Richard/0000-0003-3307-9619	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047415, P01HL019259] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL47415, P01-HL19259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; FULLERTON DS, 1980, MOL PHARMACOL, V17, P43; GILARDI RD, 1973, ACTA CRYSTALLOGR B, V29, P1842, DOI 10.1107/S0567740873005625; GILARDI RD, 1970, ACTA CRYSTALL B-STRU, VB 26, P207, DOI 10.1107/S0567740870002169; GLOCKSHUBER R, 1991, BIOCHEMISTRY-US, V30, P3049, DOI 10.1021/bi00226a010; GO K, 1981, CRYST STRUCT COMMUN, V10, P1329; GO K, 1980, ACTA CRYSTALLOGR B, V36, P1811, DOI 10.1107/S0567740880007297; GO K, 1989, ACTA CRYSTALLOGR B, V45, P306, DOI 10.1107/S0108768189001734; GO K, 1982, CRYST STRUCT COMMUN, V11, P279; GO K, 1982, CRYST STRUCT COMMUN, V11, P285; GO K, 1984, ACTA CRYSTALLOGR C, V40, P1866, DOI 10.1107/S0108270184009860; GO K, 1980, ACTA CRYSTALLOGR B, V36, P3034, DOI 10.1107/S0567740880010746; HORTON N, 1992, PROTEIN SCI, V1, P169; JEFFREY PD, 1993, IN PRESS P NATL ACAD; Kabat EA, 1991, SEQUENCES PROTEINS I; KARLE IL, 1969, ACTA CRYSTALLOGR C, V40, P1866; KARTHA G, 1981, CRYST STRUCT COMMUN, V10, P1323; Landsteiner K, 1929, J EXP MED, V50, P407, DOI 10.1084/jem.50.4.407; Landsteiner K, 1928, J EXP MED, V48, P315, DOI 10.1084/jem.48.3.315; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MESSERSCHMIDT A, 1980, CRYST STRUCT COMMUN, V9, P1185; MOSTAD A, 1982, ACTA CHEM SCAND B, V36, P635, DOI 10.3891/acta.chem.scand.36b-0635; MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4; MUDGETTHUNTER M, 1982, J IMMUNOL, V129, P1165; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NEAR RI, 1990, MOL IMMUNOL, V27, P901, DOI 10.1016/0161-5890(90)90157-U; NEAR RI, 1991, J IMMUNOL, V146, P627; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PRASAD L, 1983, ACTA CRYSTALLOGR C, V39, P273, DOI 10.1107/S0108270183004370; PRZYBYLSKA M, 1979, ACTA CRYSTALLOGR B, V35, P2436, DOI 10.1107/S0567740879009572; RIECHMANN L, 1992, J MOL BIOL, V224, P913, DOI 10.1016/0022-2836(92)90459-W; ROBERTS S, 1987, NATURE, V328, P731, DOI 10.1038/328731a0; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHIH HHL, 1985, P NATL ACAD SCI USA, V82, P1697, DOI 10.1073/pnas.82.6.1697; WILLIAMS DE, 1988, J COMPUT CHEM, V9, P745, DOI 10.1002/jcc.540090705	50	34	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21739	21747						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691815				2022-12-27	WOS:A1993MC80900050
J	VUORI, K; RUOSLAHTI, E				VUORI, K; RUOSLAHTI, E			ACTIVATION OF PROTEIN-KINASE-C PRECEDES ALPHA(5)BETA(1) INTEGRIN-MEDIATED CELL SPREADING ON FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE KINASE; EXTRACELLULAR-MATRIX; EMBRYO FIBROBLASTS; FOCAL ADHESIONS; CALPHOSTIN-C; PHOSPHORYLATION; MODULATION; PP125(FAK); RECEPTOR	Increasing evidence indicates that the integrin family of cell adhesion receptors can transduce biochemical signals from the extracellular matrix to the cell interior to modulate cell behavior. We have investigated the role of protein kinase C in alpha5beta1 integrin-mediated signal transduction in Chinese hamster ovary cells. Up-regulation of protein kinase C activity by phorbol esters was found to enhance cell adhesion, spreading, and migration on a fibronectin substrate, without affecting the cell surface expression or fibronectin binding of the alpha5beta1 integrin, whereas inhibition of protein kinase C activity by calphostin C inhibited these functions as well in unstimulated cells. In addition, we observed that protein kinase C activity in the cell membrane fraction transiently increases preceding cell spreading on fibronectin, but not on polylysine, additionally implying a specific role of protein kinase C in alpha5beta1 integrin-mediated spreading on fibronectin. Experiments with phorbol esters and calphostin C also suggested that protein kinase C activity is required for enhanced phosphorylation of the focal adhesion kinase, pp125fak, in cells plated on fibronectin. Protein kinase C-alpha was not, however, found to directly act on pp125fak, suggesting that other mechanisms are involved in this phenomenon.	LA JOLLA CANC RES FDN,CANC RES CTR,10901 N TORREY PINES RD,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA 28896, CA 42507, CA 30199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, R35CA042507, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; BROWN PJ, 1988, BIOCHEM BIOPH RES CO, V155, P603, DOI 10.1016/S0006-291X(88)80537-0; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHUN JS, 1993, MOL BIOL CELL, V4, P271; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P660; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hay E. D., 1981, CELL BIOL EXTRACELLU; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SINGER II, 1988, J CELL BIOL, V106, P2171, DOI 10.1083/jcb.106.6.2171; TAPLEY P, 1989, ONCOGENE, V4, P325; WOODS A, 1992, J CELL SCI, V101, P277; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	34	347	348	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21459	21462						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691809				2022-12-27	WOS:A1993MC80900002
J	UCKUN, FM; BURKHARDT, AL; JARVIS, L; JUN, X; STEALEY, B; DIBIRDIK, I; MYERS, DE; TUELAHLGREN, L; BOLEN, JB				UCKUN, FM; BURKHARDT, AL; JARVIS, L; JUN, X; STEALEY, B; DIBIRDIK, I; MYERS, DE; TUELAHLGREN, L; BOLEN, JB			SIGNAL-TRANSDUCTION THROUGH THE CD19 RECEPTOR DURING DISCRETE DEVELOPMENTAL STAGES OF HUMAN B-CELL ONTOGENY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTEIN-TYROSINE KINASES; POKEWEED ANTIVIRAL PROTEIN; MOUSE LYMPHOCYTES-B; ANTIGEN RECEPTOR; SRC FAMILY; MEMBRANE IMMUNOGLOBULIN; DIFFERENTIATION ANTIGEN; MONOCLONAL-ANTIBODY; DEPENDENT PATHWAY	We present evidence that the CD19 receptor is functionally operative and transmits pleiotropic signals throughout the pro-B, pre-pre-B, pre-B, early B, and mature B cell stages of human B-cell ontogeny. The signaling ability of CD19 does not depend on the existence of a functional B-cell antigen receptor complex (ARC). In B-cell precursors (BCP) lacking a functional ARC, CD19 is physically and functionally associated with Src family protein tyrosine kinases (PTK). The engagement of the CD19 receptor on BCP with a high affinity anti-CD19 monoclonal antibody (mAb) or its homoconjugate rapidly activates the associated PTK and results in tyrosine phosphorylation of CD19. Moreover, this proximal PTK activation step triggers downstream stimulation of several different intracellular messenger systems. Remarkably, CD19 becomes rapidly phosphorylated on tyrosine residues upon engagement of several other surface receptors as well, suggesting that it may function as a common response element linked via tyrosine phosphorylation to multiple BCP/B-cell receptors and signaling pathways. Furthermore, in all B-lineage lymphoid cell populations, co-approximation of the receptors CD19 and CD72 (ligand for the CD5 T-cell receptor) generates a stronger signal than the engagement of either individual receptor. These convergent observations constitute a strong argument for an important regulatory function of CD19 in human BCP and prompt the hypothesis that the CD19 receptor may play an important role in cognate interactions between B- and T-lineage lymphoid compartments as well as the coordinate production of BCP at multiple stages of human B-cell ontogeny.	UNIV MINNESOTA,HLTH SCI CTR,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,HLTH SCI CTR,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,HLTH SCI CTR,BONE MARROW TRANSPLANT PROGRAM,MINNEAPOLIS,MN 55455; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MOLEC BIOL,SIGNAL TRANSDUCT LAB,PRINCETON,NJ 08543	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb	UCKUN, FM (corresponding author), UNIV MINNESOTA,HLTH SCI CTR,DEPT THERAPEUT RADIOL RADIAT ONCOL,TUMOR IMMUNOL LAB,MINNEAPOLIS,MN 55455, USA.			Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [R01-CA-51425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON PM, 1992, BLOOD, V80, P2826; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRADBURY L, 1991, FASEB J, V5, P611; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GROSSMAN Z, 1992, P NATL ACAD SCI USA, V89, P10365, DOI 10.1073/pnas.89.21.10365; KAMAL M, 1991, EUR J IMMUNOL, V21, P1419, DOI 10.1002/eji.1830210614; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; LIN JJ, 1992, J IMMUNOL, V149, P1548; LUO W, 1992, J IMMUNOL, V148, P1630; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MYERS DE, 1991, J IMMUNOL METHODS, V136, P221, DOI 10.1016/0022-1759(91)90009-5; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; RIJKERS GT, 1990, P NATL ACAD SCI USA, V87, P8766, DOI 10.1073/pnas.87.22.8766; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TEDDER TF, 1989, J IMMUNOL, V143, P712; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1989, BLOOD, V73, P1000; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1992, BLOOD, V79, P3369; UCKUN FM, 1990, BLOOD, V76, P2449; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UCKUN FM, 1990, BLOOD, V76, P1908; UCKUN FM, 1988, BLOOD, V71, P13; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VAN DE VELDE H, 1991, NATURE, V351, P662; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519	42	104	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21172	21184						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691807				2022-12-27	WOS:A1993MA28800079
J	OLAH, TV; PERRAULT, AR; COOPERMAN, BS; MONTESANORODITIS, L; MCWILLIAMS, R; GLITZ, DG				OLAH, TV; PERRAULT, AR; COOPERMAN, BS; MONTESANORODITIS, L; MCWILLIAMS, R; GLITZ, DG			INCORPORATION OF DINITROPHENYL DERIVATIVES OF PROTEIN-S6, PROTEIN-S13, PROTEIN-S16, AND PROTEIN-S18 INTO THE 30-S SUBUNIT OF ESCHERICHIA-COLI RIBOSOMES BY TOTAL RECONSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION; ANTIBODY; LOCATION; BINDING; MICROSCOPY; OMISSION	This is the third paper in a series (Olah, T. V., Olson, H. M., Glitz, D. G., and Cooperman, B. S. (1988) J. Biol. Chem. 263, 4795-4800; Olson, H. M., Olah, T., Cooperman, B. S., and Glitz, D. G. (1988) J. Biol. Chem. 263, 4801-4806) describing the use of 2,4-dinitrophenyl (DNP) derivatives of Escherichia coli 30 S ribosomal proteins to locate the positions of these proteins within the 30 S subunit by immune electron microscopy. In it we describe the derivatization of proteins S6, S13, S16, and S18 with [H-3]2,4-dinitrofluorobenzene, identify the nature of the derivatized amino acids within each protein, and demonstrate that each DNP protein, denoted DNP-Sx, can be taken up into a reconstituted 30 S subunit when added to a reconstitution mixture containing 16 S rRNA and total 30 S protein depleted in Sx. We further demonstrate that each DNP-Sx binds within the 30 S subunit in a position identical or similar to that of the unmodified Sx protein, as judged by its meeting one or more of the following three criteria: (i) unmodified Sx competes with the uptake of DNP-Sx into 30 S subunits; (ii) DNP-Sx restores functional activity to those single protein omission reconstitution particles lacking full activity; (iii) DNP-Sx induces the uptake of proteins into 30 S subunits that depend on the presence of Sx. The fourth paper in this series (Montesano-Roditis, L., McWilliams, R., Glitz, D. G., Olah, T. V., Perrault, A. R., and Cooperman, B. S. (1993) J. Biol. Chem. 268, 18701-18709), which follows this one, describes the localization of the DNP-Sx proteins within the 30 S subunit by immune electron microscopy.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of Pennsylvania; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032769] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32769] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMANN U, 1990, BIOCHEM INT, V21, P741; BUCK MA, 1990, BIOCHEMISTRY-US, V29, P5374, DOI 10.1021/bi00474a024; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; BUCK MA, 1991, BIOCHIMIE, V73, P769, DOI 10.1016/0300-9084(91)90056-7; CAPEL MS, 1988, J MOL BIOL, V200, P65, DOI 10.1016/0022-2836(88)90334-8; GHRIST BFD, 1990, HPLC BIOL MACROMOLEC, P403; GINZBURG I, 1973, J MOL BIOL, V79, P481, DOI 10.1016/0022-2836(73)90400-2; GOLDMAN RA, 1980, FEBS LETT, V118, P113, DOI 10.1016/0014-5793(80)81230-0; GRANT PG, 1983, J BIOL CHEM, V258, P1305; HELD WA, 1974, J BIOL CHEM, V249, P3103; KERLAVAGE AR, 1986, BIOCHEMISTRY-US, V25, P8002, DOI 10.1021/bi00372a032; KOJOUHAROVA MS, 1988, DOKL BOLG AKAD NAUK, V41, P109; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MONTESANORODITIS L, 1993, J BIOL CHEM, V268, P18701; NAG B, 1991, J BIOL CHEM, V266, P11116; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OLAH TV, 1988, J BIOL CHEM, V263, P4795; OLSON HM, 1988, J BIOL CHEM, V263, P4801; PORTER RR, 1948, BIOCHEM J, V63, P282; SANGER F, 1945, BIOCHEM J, V39, P507, DOI 10.1042/bj0390507; SHALTIEL S, 1967, BIOCHEM BIOPH RES CO, V29, P178, DOI 10.1016/0006-291X(67)90583-9; STOFFLERMEILICKE M, 1984, MOL GEN GENET, V197, P8, DOI 10.1007/BF00327916; STOFFLERMEILICKE M, 1983, FEBS LETT, V163, P94, DOI 10.1016/0014-5793(83)81171-5; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; SUBRAMANIAN AR, 1980, J BIOL CHEM, V255, P6941; Traub P, 1971, METHOD ENZYMOL, V20, P391; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; YAGUCHI M, 1976, FEBS LETT, V59, P217	29	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18696	18700						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689558				2022-12-27	WOS:A1993LV65900053
J	STERNER, JM; MURATA, Y; KIM, HG; KENNETT, SB; TEMPLETON, DJ; HOROWITZ, JM				STERNER, JM; MURATA, Y; KIM, HG; KENNETT, SB; TEMPLETON, DJ; HOROWITZ, JM			DETECTION OF A NOVEL CELL-CYCLE-REGULATED KINASE-ACTIVITY THAT ASSOCIATES WITH THE AMINO-TERMINUS OF THE RETINOBLASTOMA PROTEIN IN G(2)/M PHASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA CELLS; LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; TUMOR SUPPRESSOR; RB PROTEIN; FUNCTIONAL-ANALYSIS; CDC2 KINASE; C-MYC; BINDING	Recent genetic and functional evidence suggests that the amino terminus of the retinoblastoma (Rb) protein plays an important role in Rb-mediated growth suppression, To explore the mechanism(s) by which this portion of Rb may regulate cell growth, we have sought to characterize cellular proteins that associate with the Rb amino terminus using an in vitro protein-binding assay, Here we report that at least one such protein is a cell cycle-regulated Rb/histone H1 kinase (RbK) whose enzymatic and/or Rb association activity is most prevalent in G(2)/M phases of cells, In contrast to previously characterized cyclin-dependent and Rb-associated kinases, such as cdk1 (cdc2) and cdk2, G(2)/M RbK 1) is not depleted by incubation with p13(suc)-beads, 2) is not detected with antisera against several Rb-associated cyclins-cdks, and 3) associates with Rb via the Rb amino terminus, a region that is dispensable for interaction with other Rb-associated kinases, RbK is clearly distinct from previously characterized mitotic cdks since cyclin A-cdc2, cyclin A-cdk2, cyclin B-cdc2, and cyclin B-cdk2 did not associate with the Rb amino terminus. Coprecipitation experiments with Rb antisera confirmed the association of Rb with a RbK like kinase in metaphase-arrested cells in vivo, Interestingly, G(2)/M RbK did not appreciably associate with an analogous portion of p107, a Rb-related protein, Taken together, these data indicate that the Rb amino terminus specifically associates with a novel cell cycle-regulated kinase in late cell cycle stages.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,PROGRAM CELL BIOL,CLEVELAND,OH 44106	Duke University; Duke University; Case Western Reserve University; Case Western Reserve University			Templeton, Dennis J/F-7695-2011		NCI NIH HHS [CA53248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIGNON YJ, 1990, CELL GROWTH DIFFER, V7, P647; BOEHMELT G, 1994, CELL GROWTH DIFFER, V5, P221; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARANTZA V, 1993, MOL CELL BIOL, V13, P6640, DOI 10.1128/MCB.13.11.6640; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MADREPERLA SA, 1991, CANCER RES, V51, P6381; MANCASTER MM, 1992, CANCER RES, P654; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MURATA Y, 1994, J BIOL CHEM, V269, P20674; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1988, ONCOGENE, V3, P471; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	68	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9281	9288		10.1074/jbc.270.16.9281	http://dx.doi.org/10.1074/jbc.270.16.9281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721848	hybrid			2022-12-27	WOS:A1995QU08900036
J	DESDOUITS, F; COHEN, D; NAIRN, AC; GREENGARD, P; GIRAULT, JA				DESDOUITS, F; COHEN, D; NAIRN, AC; GREENGARD, P; GIRAULT, JA			PHOSPHORYLATION OF DARPP-32, A DOPAMINE-REGULATED AND CAMP-REGULATED PHOSPHOPROTEIN, BY CASEIN KINASE-I IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-5'-MONOPHOSPHATE-REGULATED PHOSPHOPROTEIN; PROTEIN PHOSPHATASE INHIBITOR-1; INNERVATED BRAIN-REGIONS; RABBIT SKELETAL-MUSCLE; LARGE T-ANTIGEN; NEURONAL PHOSPHOPROTEIN; SUBSTRATE DETERMINANTS; CATALYTIC SUBUNIT; SITES; IDENTIFICATION	DARPP-32 (dopamine- and ! cAMP-regulated phosphoprotein, M(r) = 32,000) is a potent inhibitor of protein phosphatase-1 when it is phosphorylated on Thr-34 by cAMP-dependent protein kinase. DARPP-32 is highly enriched in some specific cell populations such as striatonigral neurons and choroid plexus epithelial cells. Here we show that recombinant rat DARPP-32 is phosphorylated by casein kinase I on seryl residues to a stoichiometry of approximate to 2 mol of phosphate/mol of protein. DARPP-32 is one of the best known substrates for casein kinase I (K-m = 3.4 +/- 0.3 mu M), whereas the homologous phosphatase-1 inhibitor, inhibitor-1, is not. Phosphorylation of DARPP-32 by casein kinase I does not alter its ability to inhibit protein phosphatase-1. Residues phosphorylated by casein kinase I were identified as Ser-137 and Ser-189 by site directed mutagenesis and by protein sequencing. Ser-137 and the preceding stretch of 16-18 acidic residues are conserved in DARPP-32 among all species examined, whereas Ser-189 is not. Phosphorylation of Ser-137 induces an unusual increase in DARPP-32 electrophoretic mobility in polyacrylamide gels in the presence of SDS. In striatonigral neurons, DARPP-32 is phosphorylated on Ser-137 and the stoichiometry of phosphorylation on this residue in vivo appears to be higher in the substantia nigra (axon terminals) than in the striatum (soma and dendrites). These results indicate that casein kinase I is highly active in striatonigral neurons in which it may play important roles, including in protein phosphatase-1 modulation via phosphorylation of DARPP-32.	ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA	Rockefeller University	DESDOUITS, F (corresponding author), COLL FRANCE, INSERM, U114, CHAIRE NEUROPHARMACOL, 11 PL MARCELIN BERTHELOT, F-75005 PARIS, FRANCE.		Girault, Jean-Antoine/F-7518-2013	Girault, Jean-Antoine/0000-0002-7900-1705; Nairn, Angus/0000-0002-7075-0195	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGOSTINIS P, 1992, FEBS LETT, V305, P121, DOI 10.1016/0014-5793(92)80877-J; AGOSTINIS P, 1987, FEBS LETT, V224, P385, DOI 10.1016/0014-5793(87)80489-1; BRENE S, 1994, J NEUROSCI, V14, P985, DOI 10.1523/JNEUROSCI.14-03-00985.1994; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CHAUHAN VPS, 1993, BIOCHIM BIOPHYS ACTA, V1177, P318, DOI 10.1016/0167-4889(93)90128-C; CHIJIWA T, 1989, J BIOL CHEM, V264, P492; COHEN P, 1988, METHOD ENZYMOL, V159, P427; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DESDOUITS F, 1995, IN PRESS P NATL ACAD; EHRLICH ME, 1990, DEV BRAIN RES, V54, P257, DOI 10.1016/0165-3806(90)90148-R; EHRLICH ME, 1990, J MOL NEUROSCI, V2, P1, DOI 10.1007/BF02896920; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FLOYD CC, 1991, J BIOL CHEM, V266, P4987; GIRAULT JA, 1993, NEUROCHEM INT, V23, P1, DOI 10.1016/0197-0186(93)90139-V; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GIRAULT JA, 1990, J NEUROCHEM, V55, P1772, DOI 10.1111/j.1471-4159.1990.tb04968.x; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; HEMMINGS HC, 1986, J NEUROSCI, V6, P1469; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KLIMCZAK LJ, 1993, BIOCHEM J, V293, P283, DOI 10.1042/bj2930283; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LINK WT, 1993, NEUROSCI LETT, V151, P89, DOI 10.1016/0304-3940(93)90053-N; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MILNE DM, 1992, ONCOGENE, V7, P1361; NEYROZ P, 1993, J BIOL CHEM, V268, P24022; OUIMET CC, 1984, J NEUROSCI, V4, P111; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SICILIANO JC, 1992, NEUROPROTOCOLS, V1, P185; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; WALAAS SI, 1983, NATURE, V301, P69; WALAAS SI, 1984, J NEUROSCI, V4, P84; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9	51	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8772	8778		10.1074/jbc.270.15.8772	http://dx.doi.org/10.1074/jbc.270.15.8772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721783	hybrid			2022-12-27	WOS:A1995QT44800061
J	NAKANISHI, T; SHIMOARAISO, M; KUBO, T; NATORI, S				NAKANISHI, T; SHIMOARAISO, M; KUBO, T; NATORI, S			STRUCTURE-FUNCTION RELATIONSHIP OF YEAST S-II IN TERMS OF STIMULATION OF RNA-POLYMERASE-II, ARREST RELIEF, AND SUPPRESSION OF 6-AZAURACIL SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTOR; ASCITES TUMOR-CELLS; FACTOR-SII; SACCHAROMYCES-CEREVISIAE; DEPENDENT TRANSCRIPTION; TERMINATION SITES; CALF THYMUS; DMS-II; GENE; DNA	The yeast S-II null mutant is viable, but the mutation induces sensitivity to 6-azauracil. To examine whether the region needed for stimulation of RNA polymerase II and that for suppression of 6-azauracil sensitivity in the S-II molecule could be separated, we constructed various deletion mutants of S-II and expressed them in the null mutant using the GAL1 promoter to see if the mutant proteins suppressed 6-azauracil sensitivity. We also expressed these constructs in Escherichia coli, purified the mutant proteins to homogeneity, and examined if they stimulated RNA polymerase II, We found that a mutant protein lacking the first 147 amino acid residues suppressed 6-azauracil sensitivity but that removal of 2 additional residues completely abolished the Suppression, A mutant protein lacking the first 141 residues had activity to stimulate RNA polymerase II, whereas re moval of 10 additional residues completely abolished this activity. We also examined arrest-relief activity of these mutant proteins and found that there is a good correlation between RNA polymerase II-stimulating activity and arrest-relief activity, Therefore, at least the last 168 residues of S-II are sufficient for expressing these three activities.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo				Kubo, Takeo/0000-0002-5914-5269				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HOMMA K, 1994, J BIOL CHEM, V269, P15258; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JONSON TL, 1994, CELL, V77, P217; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; QUIAN X, 1993, NATURE, V365, P277; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0; WIEST DK, 1992, J BIOL CHEM, V267, P7733; XU QH, 1994, J BIOL CHEM, V269, P3100; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	47	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8991	8995		10.1074/jbc.270.15.8991	http://dx.doi.org/10.1074/jbc.270.15.8991			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721809	hybrid			2022-12-27	WOS:A1995QT44800089
J	OLIVEIRA, CC; MCCARTHY, JEG				OLIVEIRA, CC; MCCARTHY, JEG			THE RELATIONSHIP BETWEEN EUKARYOTIC TRANSLATION AND MESSENGER-RNA STABILITY - A SHORT UPSTREAM OPEN READING FRAME STRONGLY INHIBITS TRANSLATIONAL INITIATION AND GREATLY ACCELERATES MESSENGER-RNA DEGRADATION IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; SECONDARY STRUCTURE; NONSENSE MUTATIONS; CODING REGION; CODONS; ACID; AUG; REINITIATION; EFFICIENCY; RIBOSOMES	A new strategy was developed to study the relationship between the translation and degradation of a specific mRNA in the yeast Saccharomyces cerevisiae. A series of 5'-untranslated regions (UTR) was combined with the cat gene from the bacterial transposon Tn9, allowing us to test the influence of upstream open reading frames (uORFs) on translation and mRNA stability. The 5'-UTR sequences were designed so that the minimum possible sequence alteration, a single nucleotide substitution, could be used to create a 7-codon ORF upstream of the cat gene. The uORF was translated efficiently, but at the same time inhibited translation of the cat ORF and destabilized the cat mRNA. Investigations of various derivatives of the 5'-UTR indicated that cat translation was primarily attributable to leaky scanning of ribosomes past the uORF rather than to reinitiation. Therefore, these data directly demonstrate destabilization of a specific mRNA linked to changes in translational initiation on the same transcript. In contrast to the previously proposed nonsense-mediated mRNA decay pathway, destabilization was not triggered by premature translational termination in the main ORF and was not discernibly dependent upon a reinitiation-driven mechanism. This suggests the existence of an as yet not described pathway of translation-linked mRNA degradation.	GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS, D-38124 BRAUNSCHWEIG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH			Oliveira, Carla C/F-2323-2011	Oliveira, Carla C/0000-0002-1098-9241				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Belasco J.G., 2012, CONTROL MESSENGER RN; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; DONAHUE TF, 1990, METHODS NEYZMOL, V193, P366; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PARKER R, 1991, METHOD ENZYMOL, V194, P415; PELSY F, 1984, CURR GENET, V8, P277, DOI 10.1007/BF00419725; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PELTZ SW, 1993, PROTEIN SYNTHESIS TA, P1; PIERRAT B, 1993, GENE, V131, P43, DOI 10.1016/0378-1119(93)90667-R; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAGLIOCCO FA, 1994, J BIOL CHEM, V269, P18630; SAMBROOK J, 1989, MOL CLONING LABOR MA; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; SHERMAN F, 1986, LABORATORY COURSE MA, P117; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS A, 1980, J BIOL CHEM, V255, P3080; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034	38	96	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8936	8943		10.1074/jbc.270.15.8936	http://dx.doi.org/10.1074/jbc.270.15.8936			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721802	hybrid			2022-12-27	WOS:A1995QT44800081
J	PINOT, F; GRANT, DF; BEETHAM, JK; PARKER, AG; BORHAN, B; LANDT, S; JONES, AD; HAMMOCK, BD				PINOT, F; GRANT, DF; BEETHAM, JK; PARKER, AG; BORHAN, B; LANDT, S; JONES, AD; HAMMOCK, BD			MOLECULAR AND BIOCHEMICAL-EVIDENCE FOR THE INVOLVEMENT OF THE ASP-333-HIS-523 PAIR IN CATALYTIC MECHANISM OF SOLUBLE EPOXIDE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY ESTERS; HUMAN-LIVER; EXPRESSION; PROTEINS; CLONING; CDNA; PRODUCTS; ANTIBODY; ENZYMES; GENE	In order to investigate the involvement of amino acids in the catalytic mechanism of the soluble epoxide hydrolase, different mutants of the murine enzyme were produced using the baculovirus expression system. Our results are consistent with the involvement of Asp-333 and His-523 in a catalytic mechanism similar to that of other alpha/beta hydrolase fold enzymes. Mutation of His-263 to asparagine led to the loss of approximately half the specific activity compared to wild-type enzyme. When His-332 was replaced by asparagine, 96.7% of the specific activity was lost and mutation of the conserved His-523 to glutamine led to a more dramatic loss of 99.9% of the specific activity. No activity was detectable after the replacement of Asp-333 by serine. However, more than 20% of the wild-type activity was retained in an Asp-333 --> Asn mutant produce din Spodoptera frugiperda cells. We purified, by affinity chromatography, the wild-type and the Asp-333 --> Asn mutant enzymes produced in Trichoplusia ni cells. We labeled these enzymes by incubating them with the epoxide containing radiolabeled substrate juvenile hormone III (JH III). The purified Asp-333 --> Asn mutant bound 6% of the substrate compared to the wild-type soluble epoxide hydrolase. The mutant also showed 8% of the specific activity of the wild-type. Preincubation of the purified Asp-333 --> Asn mutant at 37 degrees C (pH 8), however, led to a complete recovery of activity and to a change of isoelectric point (pI), both of which are consistent with hydrolysis of Asn-333 to aspartic acid. This intramolecular hydrolysis of asparagine to aspartic acid may explain the activity observed in this mutant. Wild-type enzyme that had been radiolabeled with the substrate was digested with trypsin. Using reverse phase-high pressure liquid chromatography, we isolated four radiolabeled peptides of similar polarity. These peptides were not radiolabeled if the enzyme was preincubated with a selective competitive inhibitor of soluble epoxide hydrolase 4-fluorochalcone oxide. This strongly suggested that these peptides contained a catalytic amino acid. Each peptide was characterized with N-terminal amino acid sequencing and electrospray mass spectrometry. All four radiolabeled peptides contained overlapping sequences. The only aspartic acid present in all four peptides and conserved in all epoxide hydrolases was Asp-333. These peptides resulted from cleavage at different trypsin sites and the mass of each was consistent with the covalent linkage of Asp-333 to the substrate.	LAWRENCE LIVERMORE NATL LAB,DEPT ENTOMOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616; LAWRENCE LIVERMORE NATL LAB,FACIL ADV INSTRUMENTAT,DAVIS,CA 95616	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002710, P30ES005707] Funding Source: NIH RePORTER; NIEHS NIH HHS [2 RO1 ES02710, C1 P30 ES05707] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; FALANY CN, 1987, J BIOL CHEM, V262, P5924; GRANT DF, 1993, J BIOL CHEM, V268, P17628; GUENGERICH FP, 1982, REV BIOCHEM TOXICOL, V4, P5; GUENTHNER TM, 1981, POLYCYCLIC HYDROCARB, P183; HALARNKAR PP, 1989, ARCH BIOCHEM BIOPHYS, V272, P226, DOI 10.1016/0003-9861(89)90214-2; HALARNKAR PP, 1992, ARCH BIOCHEM BIOPHYS, V294, P586, DOI 10.1016/0003-9861(92)90729-G; HAMMOCK BD, 1994, BIOCHEM BIOPH RES CO, V198, P850, DOI 10.1006/bbrc.1994.1121; HASSETT C, 1989, ARCH BIOCHEM BIOPHYS, V271, P380, DOI 10.1016/0003-9861(89)90287-7; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; KIYOSUE T, 1994, PLANT J, V6, P259, DOI 10.1046/j.1365-313X.1994.6020259.x; KNEHR M, 1993, J BIOL CHEM, V268, P17623; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE BG, 1987, TOXICOLOGY, V44, P213, DOI 10.1016/0300-483X(87)90151-X; MEIJER J, 1987, CHEM-BIOL INTERACT, V62, P249, DOI 10.1016/0009-2797(87)90026-3; MEIJER J, 1988, CHEM-BIOL INTERACT, V64, P207, DOI 10.1016/0009-2797(88)90100-7; MULLIN CA, 1982, ARCH BIOCHEM BIOPHYS, V216, P423, DOI 10.1016/0003-9861(82)90231-4; MUMBY SM, 1979, PESTIC BIOCHEM PHYS, V11, P275, DOI 10.1016/0048-3575(79)90067-1; NOUROOZZADEH J, 1992, ARCH BIOCHEM BIOPHYS, V294, P675, DOI 10.1016/0003-9861(92)90741-E; OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; SALTO R, 1994, J BIOL CHEM, V269, P10691; SEIDEGARD J, 1983, BIOCHIM BIOPHYS ACTA, V695, P251, DOI 10.1016/0304-419X(83)90014-8; SKODA RC, 1988, J BIOL CHEM, V263, P1549; STAPLETON A, 1994, PLANT J, V6, P251, DOI 10.1046/j.1365-313X.1994.6020251.x; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WIXTROM RN, 1988, ANAL BIOCHEM, V169, P71, DOI 10.1016/0003-2697(88)90256-4; WIXTROM RN, 1985, BIOCH PHARM TOXICOLO, V1, P1; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	35	78	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7968	7974		10.1074/jbc.270.14.7968	http://dx.doi.org/10.1074/jbc.270.14.7968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713895	hybrid			2022-12-27	WOS:A1995QR52600031
J	SUBAUSTE, JS; KOENIG, RJ				SUBAUSTE, JS; KOENIG, RJ			COMPARISON OF THE DNA-BINDING SPECIFICITY AND FUNCTION OF V-ERBA AND THYROID-HORMONE RECEPTOR ALPHA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; TRANSCRIPTION FACTOR; C-ERBA; CELL-TRANSFORMATION; RESPONSIVE ELEMENT; HIGH-AFFINITY; GENE; ONCOGENE; PROTEIN	The oncoprotein v-ErbA is a mutated version of thyroid hormone receptor alpha 1. Although the basis for the oncogenic action of v-ErbA is unknown, expression of this protein is known to inhibit thyroid hormone and retinoic acid induction of target genes. The DNA binding domain of v-ErbA differs from that of thyroid hormone receptor alpha 1 in two amino acids felt to be crucial for determining the specificity of DNA binding. However, the DNA binding properties of v-ErbA have not been examined independent of a comparison of binding to already known thyroid hormone response elements. In the current studies a non-biased strategy was used to select from a pool of random DNA those sequences that bind v-ErbA with high affinity. The highest affinity binding sequence was identified as the decamer 5'-T(A/G)AGGTCACG, which is closely related to the optimal thyroid hormone receptor alpha 1 binding sequence, TAAG-GTCA. Transfection studies demonstrate that among equal thyroid hormone responsive elements, those that contain the optimal v-ErbA consensus will be repressed by v-ErbA in preference to those that do not. These studies indicate that v-ErbA and thyroid hormone receptor alpha 1 regulate overlapping sets of response elements, and that all sequences that are highly responsive to thyroid hormone are not necessarily responsive to v-ErbA.	UNIV MICHIGAN,MED CTR,DIV ENDOCRINOL & METAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [DK44155] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUERSTENBERG S, 1992, EMBO J, V1, P3355; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HALL BL, 1992, CELL GROWTH DIFFER, V3, P207; HARDING PP, 1992, J BIOL CHEM, V267, P14145; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MOORE DD, 1986, GENE AMST, V45, P107; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; ZECHEL C, 1994, EMBO J, V13, P141	37	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7957	7962		10.1074/jbc.270.14.7957	http://dx.doi.org/10.1074/jbc.270.14.7957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713893	hybrid			2022-12-27	WOS:A1995QR52600029
J	SCARIA, PV; WILL, S; LEVENSON, C; SHAFER, RH				SCARIA, PV; WILL, S; LEVENSON, C; SHAFER, RH			PHYSICOCHEMICAL STUDIES OF THE D(G(3)T(4)G(3))ASTERISK-D(G(3)A(4)G(3))CENTER-DOT-D(C3T4C3) TRIPLE-HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONATED POLYNUCLEOTIDES STRUCTURES; RESONANCE ENERGY-TRANSFER; SITE-SPECIFIC CLEAVAGE; FORMING-OLIGONUCLEOTIDES; POLY(DG) POLY(DC); DNA; TRANSCRIPTION; RECOGNITION; INHIBITION; GENE	We have targeted the d(G(3)A(4)G(3)). d(C3T4C3) duplex for tripler formation with d(G(3)T(4)G(3)) in the presence of MgCl2. The resulting triple helix, d(G(3)T(4)G(3))*d(G(3)-A(4)G(3)) . d(C3T4C3), is considerably weaker than the related tripler, d(G(3)A(4)G(3))*d(G(3)A(4)G(3)). d(C3T4C3), and melts in a biphasic manner, with the third strand dissociating at temperatures about 20-30 degrees C below that of the remaining duplex. This is in distinct contrast to the d(G(3)A(4)G(3))*d(G(3)A(4)G(3)). d(C3T4C3) tripler, which melts in essentially a single transition, Gel electrophoresis under non-denaturing conditions shows the presence of the d(G(3)T(4)G(3))*d(G(3)A(4)G(3)). d(C3T4C3) tripler as a band of low mobility compared to the duplex or the single strand bands. Binding of the d(G(3)T(4)G(3)) third strand and the purine strand of the duplex can be monitored by imino proton NMR spectra, While these spectra are typically very broad for intermolecular triplexes, the line widths can be dramatically narrowed by the addition of two thymines to both ends of the pyrimidine strand, Ther modynamic analysis of UV melting curves shows that this tripler is considerably less stable than related triplexes formed with the same duplex, The orientation of the third strand was addressed by a combination of fluorescence energy transfer and UV melting experiments, Results from these experiments suggest that, in the unlabeled tripler, the preferred orientation of the third strand is parallel to the purine strand of the duplex.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; ROCHE MOLEC SYST, ALAMEDA, CA 94501 USA	University of California System; University of California San Francisco; Roche Holding								BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; CHAN SS, 1993, BIOCHEMISTRY-US, V32, P11776, DOI 10.1021/bi00095a005; CHEN FM, 1991, BIOCHEMISTRY-US, V30, P4472, DOI 10.1021/bi00232a014; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COOPER JP, 1990, BIOCHEMISTRY-US, V29, P9261, DOI 10.1021/bi00491a022; DAGNEAU C, 1994, 8TH P CONV STAT U NE, P103; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GRISWOLD BL, 1951, ANAL CHEM, V23, P192, DOI 10.1021/ac60049a041; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; HU S, 1992, EUR J BIOCHEM, V204, P31, DOI 10.1111/j.1432-1033.1992.tb16602.x; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; JAYASENA SD, 1993, BIOCHEMISTRY-US, V32, P2800, DOI 10.1021/bi00062a010; JAYASENA SD, 1992, BIOCHEMISTRY-US, V31, P320, DOI 10.1021/bi00117a002; LEVENSON C, 1990, PCR PROTOCOLS GUIDE, P99; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1979, DOI 10.1093/nar/5.6.1979; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; MERGNY JL, 1994, NUCLEIC ACIDS RES, V22, P920, DOI 10.1093/nar/22.6.920; MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; OUALI M, 1993, J AM CHEM SOC, V115, P4264, DOI 10.1021/ja00063a049; PILCH DS, 1991, BIOCHEMISTRY-US, V30, P6083, DOI 10.1021/bi00239a001; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; ROY C, 1993, NUCLEIC ACIDS RES, V21, P2845, DOI 10.1093/nar/21.12.2845; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUN JS, 1991, CR ACAD SCI III-VIE, V313, P585; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; THIELE D, 1978, NUCLEIC ACIDS RES, V5, P1997, DOI 10.1093/nar/5.6.1997; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; UMEMOTO K, 1990, J AM CHEM SOC, V112, P4539, DOI 10.1021/ja00167a063	39	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7295	7303		10.1074/jbc.270.13.7295	http://dx.doi.org/10.1074/jbc.270.13.7295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706270	hybrid			2022-12-27	WOS:A1995QQ43100043
J	SIDHU, SS; KALMAR, GB; WILLIS, LG; BORGFORD, TJ				SIDHU, SS; KALMAR, GB; WILLIS, LG; BORGFORD, TJ			PROTEASE EVOLUTION IN STREPTOMYCES-GRISEUS - DISCOVERY OF A NOVEL DIMERIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; SUBSTRATE-BINDING; PRO-REGION; RESOLUTION; INHIBITOR; CLONING; CLEAVAGE; ANTIGEN	This report describes the cloning and sequencing of a novel protease gene derived from Streptomyces griseus, Also described is the heterologous expression of the gene in Bacillus subtilis and characterization of the gene product, The sprD gene encodes a prepro mature protease of 392 amino acids tentatively named S. griseus protease D (SGPD). A significant component of the enzyme preregion was found to be homologous with the mitochondrial import signal of hsp60. The sprD gene was subcloned into an Escherichia coli/B. subtilis shuttle vector system such that the pro mature portion of SGPD was fused in flame with the promoter, ribosome binding site, and signal sequences of subtilisin. The gene fusion was subsequently expressed in B. subtilis DB104, and active protease was purified, SGPD has a high degree of sequence homology to previously described S. griseus proteases A, B, C, and E and the alpha-lytic protease of Lysobacter enzymogenes, but unlike all previously characterized members of the chymotrypsin superfamily, the recombinant SGPD forms a stable alpha(2) dimer. The amino acid sequence of the protein in the region of the specificity pocket is similar to that of S. griseus proteases A, B, and C, The purified enzyme was found to have a primary specificity for large aliphatic or aromatic amino acids. Nucleotide sequence data were used to construct a phylogenetic tree using a method of maximum parsimony which reflects the relationships and potentially the lineage of the chymotrypsin-like proteases of S. griseus.	SIMON FRASER UNIV,DEPT CHEM,BURNABY,BC V5A 1S6,CANADA; SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY,BC V5A 1S6,CANADA	Simon Fraser University; Simon Fraser University								BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CHEREPOVA NV, 1986, J GEN MICROBIOL, V132, P669; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fersht A., 1985, ENZYME STRUCTURE MEC; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GREENAWALT JW, 1975, BACTERIOL REV, V39, P405, DOI 10.1128/MMBR.39.4.405-463.1975; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; HARTLEY BS, 1979, PROC R SOC SER B-BIO, V205, P443, DOI 10.1098/rspb.1979.0078; HENDERSON G, 1987, J BACTERIOL, V169, P3778, DOI 10.1128/jb.169.8.3778-3784.1987; HORNE D, 1985, J BACTERIOL, V161, P18, DOI 10.1128/JB.161.1.18-24.1985; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUTTER R, 1988, ACTINOMYCETES BIOTEC, P89; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; KIM JC, 1991, BIOCHEM BIOPH RES CO, V181, P707, DOI 10.1016/0006-291X(91)91248-B; KURYLOWICZ W, 1975, ATLAS ULTRASTRUCTURE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NAKASONE N, 1987, MICROBIOL IMMUNOL, V31, P403, DOI 10.1111/j.1348-0421.1987.tb03103.x; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; NIENABER VL, 1993, BIOCHEMISTRY-US, V32, P11469, DOI 10.1021/bi00094a001; Ostermann Joachim, 1990, V8, P219; PRENDERGAST JA, 1991, J MOL BIOL, V220, P867, DOI 10.1016/0022-2836(91)90359-E; RANDALL LL, 1984, MICROBIOL REV, V48, P290, DOI 10.1128/MMBR.48.4.290-298.1984; READ RJ, 1983, BIOCHEMISTRY-US, V22, P4420, DOI 10.1021/bi00288a012; Sambrook J, 1989, MOL CLONING LABORATO; SIDHU SS, 1993, BIOCHEM CELL BIOL, V71, P454, DOI 10.1139/o93-067; SIDHU SS, 1994, J BIOL CHEM, V269, P20167; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; VENNER TJ, 1990, BIOCHIM BIOPHYS ACTA, V1087, P336, DOI 10.1016/0167-4781(90)90008-P; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7594	7600		10.1074/jbc.270.13.7594	http://dx.doi.org/10.1074/jbc.270.13.7594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706307	hybrid			2022-12-27	WOS:A1995QQ43100084
J	VIVIEN, D; ATTISANO, L; WRANA, JL; MASSAGUE, J				VIVIEN, D; ATTISANO, L; WRANA, JL; MASSAGUE, J			SIGNALING ACTIVITY OF HOMOLOGOUS AND HETEROLOGOUS TRANSFORMING GROWTH-FACTOR-BETA RECEPTOR KINASE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; II RECEPTOR; EXPRESSION CLONING; RESPONSIVENESS; IDENTIFICATION; TRANSDUCTION; BINDING; MUTANTS; FORMS	Transforming growth factor-beta (TGF-beta) signaling in Mv1Lu lung epithelial cells requires coexpression of TGF-beta receptors I (T beta R-I) and II (T beta R-II), two distantly related transmembrane serine/threonine kinases that form a heteromeric complex upon ligand binding, Here, we examine the formation of TGF-beta receptor homooligomers and their possible contribution to signaling. T beta R-I can contact ligand bound to T beta R-II, but not ligand free in the medium, and thus cannot form ligand-induced homo-oligomers, T beta R-II, which binds ligand on its own, formed oligomeric complexes when overexpressed in transfected COS cells. However, these complexes were largely ligand independent and involved immature receptor protein, Since ligand-induced homooligomers could not be obtained with the wild type TGF-beta receptors, we studied receptor cytoplasmic domain homo oligomerization by using receptor chimeras, The extracellular domain of T beta R-II was fused to the transmembrane and cytoplasmic domains of T beta R-I, yielding T beta R-II/I, and the extracellular domain of T beta R-I was fused to the transmembrane and cytoplasmic domains of T beta R-II, yielding T beta R-I/II. When cotransfected with wild-type receptors and exposed to ligand, T beta R-II/I formed a complex with T beta R-I, and T beta R-I/II formed a complex with T beta R-II, thus yielding complexes with homologous cytoplasmic domains, TPR-II/I transfected alone or with T beta R-I did not restore TGF-beta responsiveness in T beta R-II-defective cell mutants. Furthermore, T beta R-II/I acted in a dominant negative fashion, inhibiting restoration of TGF-beta responsiveness by a cotransfected T beta R-II in T beta R-II-defective cells and by a cotransfected T beta R-I in T beta R-I-defective cells, Similarly, T beta R-I/II transfected alone or with T beta R-II did not restore TGF-beta responsiveness and acted in a dominant negative fashion against T beta R-I, Together with previous genetic and biochemical evidence, these results suggest that TGF-beta mediates transcriptional and antiproliferative responses through the heteromeric T beta R-I T beta R-II complex and not through homo-oligomeric T beta R-I . T beta R-II complexes.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	VIVIEN, D (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,BOX 116,NEW YORK,NY 10021, USA.		Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408; VIVIEN, DENIS/0000-0002-7636-2185	NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA08748, CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WIESER R, 1995, IN PRESS EMBO J; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	36	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7134	7141		10.1074/jbc.270.13.7134	http://dx.doi.org/10.1074/jbc.270.13.7134			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706250	hybrid			2022-12-27	WOS:A1995QQ43100021
J	SCHWANINGER, M; BLUME, R; OETJEN, E; LUX, G; KNEPEL, W				SCHWANINGER, M; BLUME, R; OETJEN, E; LUX, G; KNEPEL, W			INHIBITION OF CAMP-RESPONSIVE ELEMENT-MEDIATED GENE-TRANSCRIPTION BY CYCLOSPORINE-A AND FK506 AFTER MEMBRANE DEPOLARIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PANCREATIC-ISLET CELLS; SOMATOSTATIN GENE; RAT SOMATOSTATIN; GLUCAGON GENE; BETA-CELLS; ACTIVATION; CREB; IDENTIFICATION; CALCINEURIN	The cAMP-responsive element (CRE) and its cognate transcription factor CREB can mediate induction of gene transcription in response to membrane depolarization and calcium influx. In this study, the effect of cyclosporin A (CsA) and FK506 on depolarization-induced glucagon gene transcription was investigated in a pancreatic islet cell line by transfection of reporter fusion genes. CsA and FK506 inhibited depolarization-induced glucagon gene transcription, FK506 being more potent than CsA. CsA/FK506 responsiveness was mediated by the glucagon CRE and also by well characterized CREs of the choriogonadotropin and somatostatin genes. Rapamycin antagonized the inhibitory effect of FK506 but not CsA, suggesting that FK506 and CsA may act through complex formation with distinct intracellular immunophilins. Overexpression of calcineurin, which is known to be inhibited by drug-immunophilin complexes, rendered pancreatic islet cells more resistant to the inhibitory effects of CsA and FK506. These results demonstrate an inhibition by CsA and FK506 of CRE-mediated, calcium-induced transcription and suggest that membrane depolarization relies on calcineurin phosphatase activity for activation of CREB/CRE-mediated gene transcription. The interference with CRE-mediated gene transcription represents a novel mechanism of CsA/FK506 action, which may underlie pharmacological effects and toxic manifestations of these potent immunosuppressive drugs.	UNIV GOTTINGEN,CTR PHARMACOL & TOXICOL,DEPT BIOCHEM PHARMACOL,ROBERT KOCH STR 40,D-37070 GOTTINGEN,GERMANY	University of Gottingen				Schwaninger, Markus/0000-0002-4510-9718				ANDERSSON A, 1984, DIABETOLOGIA, V27, P66, DOI 10.1007/BF00275649; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; ERLANGER BF, 1992, IMMUNOL TODAY, V13, P487, DOI 10.1016/0167-5699(92)90023-Z; EUN HM, 1987, DIABETES, V36, P952, DOI 10.2337/diabetes.36.8.952; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOTO S, 1992, NEUROSCI LETT, V143, P51, DOI 10.1016/0304-3940(92)90231-U; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MASON J, 1989, PHARMACOL REV, V41, P423; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORRIS SM, 1992, J BIOL CHEM, V267, P13768; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; POWERS AC, 1989, J BIOL CHEM, V264, P10048; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V	28	70	74	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23111	23115						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693684				2022-12-27	WOS:A1993MF51500026
J	KOUNNAS, MZ; HENKIN, J; ARGRAVES, WS; STRICKLAND, DK				KOUNNAS, MZ; HENKIN, J; ARGRAVES, WS; STRICKLAND, DK			LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN/ALPHA(2)-MACROGLOBULIN RECEPTOR MEDIATES CELLULAR UPTAKE OF PROUROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; DEGRADATION; CELLS; TISSUE; BINDS; COMPLEXES; PURIFICATION; INTERNALIZES	The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP) is a large cell surface receptor consisting of a 515-kDa heavy chain and an 85-kDa light chain proteolytically derived from a 600-kDa precursor. Previous work has shown that LRP is responsible for mediating the internalization of urinary-type plasminogen activator (uPA) complexed to plasminogen activator inhibitor type I (PAI-1) (Nykjaer et al, 1992; Herz et al., 1992). The current study indicates that pro-urokinase (pro-uPA) and two chain urokinase (tc-uPA) bind directly to purified LRP, and that LRP mediates their internalization and degradation in Hep G2 cells. In vitro binding assays demonstrated that pro-uPA and tc-uPA bind to purified LRP with affinities (K(d) = 45 and 60 nM, respectively) that are approximately 15 to 20-fold weaker than the affinity of uPA.PAI-1 complex for LRP (K(d) = 3 nM). Competitive binding experiments revealed that pro-uPA and tc-uPA completely inhibit binding of uPA.PAI-1 complexes to purified LRP. The binding of I-125-pro-uPA to LRP is blocked by the 39-kDa receptor-associated protein, but not by an amino-terminal fragment of uPA, which is known to block binding of uPA to the urokinase receptor. I-125-Pro-uPA can be internalized and degraded by Hep G2 cells independent of PAI-1. Both the internalization and degradation are completely blocked by receptor-associated protein or affinity-purified LRP antibodies, indicating that LRP is mediating this process. These processes are also blocked by the amino-terminal fragment, which suggests that the favored pathway for uPA metabolism is initial binding to the urokinase receptor, followed by ligand transfer to LRP, then internalization leading to degradation.	AMER RED CROSS,BIOCHEM LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855; ABBOTT LABS,N CHICAGO,IL 60064	American Red Cross; Abbott Laboratories					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30200] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BLASI F, 1990, CELL DIFFER DEV, V32, P247, DOI 10.1016/0922-3371(90)90037-W; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BROMMER EJP, 1992, THROMB HAEMOSTASIS, V68, P180; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; COLLEN D, 1984, THROMB HAEMOSTASIS, V52, P24; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; HEARING VJ, 1988, CANCER RES, V48, P1270; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIRAMATSU R, 1989, FIBRINOLYSIS, P147; ISAACS IJ, 1988, J BIOL CHEM, V263, P6709; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KUIPER J, 1992, J BIOL CHEM, V267, P1589; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LIJNEN HR, 1992, EUR J BIOCHEM, V205, P701, DOI 10.1111/j.1432-1033.1992.tb16832.x; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; UENO T, 1979, THROMB HAEMOSTASIS, V42, P885; VASSALLI J, 1976, CELL, V18, P271; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	41	161	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21862	21867						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691818				2022-12-27	WOS:A1993MC80900065
J	KOJIMA, S; MURAMATSU, H; AMANUMA, H; MURAMATSU, T				KOJIMA, S; MURAMATSU, H; AMANUMA, H; MURAMATSU, T			MIDKINE ENHANCES FIBRINOLYTIC-ACTIVITY OF BOVINE ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RESPONSIVE GENE; GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR; EMBRYONAL CARCINOMA-CELLS; RETINOIC ACID; MOLECULAR-CLONING; UP-REGULATION; VITAMIN-A; EXPRESSION; DIFFERENTIATION	A hitherto unknown function of midkine (MK) was found in the regulation of fibrinolytic activity of vascular endothelial cells. Recombinant murine MR enhanced plasminogen activator (PA)/plasmin levels in bovine aortic endothelial cells (BAECs) in a dose- and time dependent manner. After incubation with 10 ng/ml MK for 18 h, PA and plasmin levels increased 6- and 4-fold, respectively. This effect was attributed to a moderate upregulation of urokinase-type PA expression as well as to a significant down-regulation of PA inhibitor-1 (PAI-1) expression. BAECs constitutively synthesized and secreted MK and its production was enhanced 2-fold with 1 mu M retinoic acid or 10 mu M retinol. It was found that MK served as a substrate for tissue transglutaminase. In the culture medium, MK existed as a transglutaminase-mediated complex of 36 kDa. Addition of anti-MR antibody to BAEC cultures resulted in a decrease of basal PA activity and an increase of basal PAI-1 levels and attenuated the ability of retinol to enhance PA activity 50% and potentiated the ability to increase PAI-1 levels 4-fold. Furthermore, MK and basic fibroblast growth factor (bFGF) acted more than additively in enhancing PA levels. We conclude that in BAECs MK is a novel autocrine factor sustaining the fibrinolytic property. MK functions as a mediator of retinoid and cooperates with bFGF to enhance fibrinolytic activity of BAECs.	NAGOYA UNIV, SCH MED, DEPT BIOCHEM, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Nagoya University	KOJIMA, S (corresponding author), INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, GENE TECHNOL & SAFETY LAB, TSUKUBA, IBARAKI 305, JAPAN.		Kojima, Soichi/N-7104-2015	Kojima, Soichi/0000-0002-5252-1612				BEACH RS, 1983, BIOCHEM BIOPH RES CO, V114, P395, DOI 10.1016/0006-291X(83)91640-6; BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BRAUNHUT SJ, 1991, MICROVASC RES, V41, P47, DOI 10.1016/0026-2862(91)90007-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECLERCK PJ, 1988, BLOOD, V71, P220; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; Gudas Lorraine J., 1994, P443; HALL SW, 1991, J BIOL CHEM, V266, P12329; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; INADA Y, 1985, BIOCHEM BIOPH RES CO, V130, P182, DOI 10.1016/0006-291X(85)90399-7; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOJIMA S, 1986, BIOSCIENCE REP, V6, P1029, DOI 10.1007/BF01141023; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V206, P468, DOI 10.1006/bbrc.1995.1066; KOJIMA S, 1986, BIOMED RES-TOKYO, V7, P155; KRATZSCHMAR J, 1993, GENE, V125, P177, DOI 10.1016/0378-1119(93)90325-W; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1988, METHOD ENZYMOL, V163, P293; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MARTIN TJ, 1993, GROWTH REGULAT, V3, P209; MARUTA H, 1993, GROWTH FACTORS, V8, P119, DOI 10.3109/08977199309046932; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MICHIKAWA M, 1993, J NEUROSCI RES, V35, P530, DOI 10.1002/jnr.490350509; MICHIKAWA M, 1993, BIOCHEM BIOPH RES CO, V192, P1312, DOI 10.1006/bbrc.1993.1559; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MULLINS DE, 1990, HDB EXPT PHARM, V95, P481; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; MURASE K, 1991, BIOCHEM INT, V25, P29; NARA K, 1989, J BIOL CHEM, V264, P19308; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; PAIGE K, 1991, IN VITRO CELL DEV B, V27, P151; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; Sambrook J, 1989, MOL CLONING LABORATO; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TOMOMURA M, 1990, BIOCHEM BIOPH RES CO, V171, P603, DOI 10.1016/0006-291X(90)91189-Y; TSUTSUI J, 1993, CANCER RES, V53, P1281; URIOS P, 1991, BIOCHEM BIOPH RES CO, V175, P617, DOI 10.1016/0006-291X(91)91610-O	53	125	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9590	9596		10.1074/jbc.270.16.9590	http://dx.doi.org/10.1074/jbc.270.16.9590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721890	hybrid			2022-12-27	WOS:A1995QU08900079
J	DEVRIES, T; SRNKA, CA; PALCIC, MM; SWIEDLER, SJ; VANDENEIJNDEN, DH; MACHER, BA				DEVRIES, T; SRNKA, CA; PALCIC, MM; SWIEDLER, SJ; VANDENEIJNDEN, DH; MACHER, BA			ACCEPTOR SPECIFICITY OF DIFFERENT LENGTH CONSTRUCTS OF HUMAN RECOMBINANT ALPHA-1,3/4-FUCOSYL-TRANSFERASES - REPLACEMENT OF THE STEM REGION AND THE TRANSMEMBRANE DOMAIN OF FUCOSYL-TRANSFERASE-V BY PROTEIN-A RESULTS IN AN ENZYME WITH GDP-FUCOSE HYDROLYZING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; DIMERIC LEX ANTIGEN; E-SELECTIN LIGAND; EMBRYONIC ANTIGEN; SUBSTRATE SPECIFICITIES; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; DETERMINES EXPRESSION	The acceptor specificity of recombinant full-length, membrane-bound fucosyltransferases, expressed in COS-7 cells, and soluble, protein-A chimeric forms of alpha 1,3-fucosyltransferase (Fuc-T) III, Fuc-TIV, and Fuc-TV was analyzed toward a broad panel of oligosaccharide, glycolipid, and glycoprotein substrates. Our results on the full-length enzymes confirm and extend previous studies. However, chimeric Fuc-Ts showed increased activity toward glycoproteins, whereas chimeric Fuc-TIII and Fuc-TV had a decreased activity with glycosphingolipids, compared to the full-length enzymes. Unexpectedly, chimeric Fuc-TV exhibited a GDP-fucose hydrolyzing activity. In substrates with multiple acceptor sites, the preferred site of fucosylation was identified. Fuc-TIII and Fuc-TV catalyzed fucose transfer exclusively to OH-3 of glucose in lacto-N-neotetraose and lacto-N-tetraose, respectively, as was demonstrated by H-1 MMR spectroscopy. Thin layer chromatography immunostaining revealed that FucT-IV preferred the distal GlcNAc residue in nLc(6)Cer, whereas Fuc-TV preferred the proximal GlcNAc residue. Incubation of Fuc-TIV or Fuc-TV with VI(3)NeuAcnLc(6)Cer resulted in products with the sialyl-Lewis(X) epitope as well as the VIM-2 structure. To identify polar groups on accepters that function in enzyme binding, deoxygenated substrate analogs were tested as accepters. All three Fuc-Ts had an absolute requirement for a hydroxyl at C-6 of galactose in addition to the accepting hydroxyl at C-3 or C-4 of GlcNAc.	SAN FRANCISCO STATE UNIV, DEPT CHEM & BIOCHEM, SAN FRANCISCO, CA 94132 USA; GLYCOMED INC, ALAMEDA, CA 94501 USA; UNIV ALBERTA, DEPT CHEM, EDMONTON, AB T6G 2G2, CANADA	California State University System; San Francisco State University; University of Alberta	DEVRIES, T (corresponding author), VRIJE UNIV AMSTERDAM, DEPT MED CHEM, VAN DE BOECHORSTSTR 7, 1081 BT AMSTERDAM, NETHERLANDS.				NCI NIH HHS [CA32826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BREG J, 1988, CARBOHYD RES, V183, P19, DOI 10.1016/0008-6215(88)80042-9; BUEHLER J, 1986, ANAL BIOCHEM, V158, P283, DOI 10.1016/0003-2697(86)90551-8; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; DEVRIES T, 1994, BIOCHEMISTRY-US, V33, P9937, DOI 10.1021/bi00199a016; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DONALD ASR, 1988, CARBOHYD RES, V178, P79, DOI 10.1016/0008-6215(88)80103-4; EASTON EW, 1993, BLOOD, V81, P2978; FEIZI T, 1987, BIOCHEM J, V245, P1; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HAO YL, 1973, BIOCHIM BIOPHYS ACTA, V322, P99, DOI 10.1016/0005-2795(73)90180-3; HE PG, 1993, ARCH BIOCHEM BIOPHYS, V305, P350, DOI 10.1006/abbi.1993.1432; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HUANG LC, 1983, BLOOD, V61, P1020; ICHIKAWA Y, 1992, J AM CHEM SOC, V114, P9283, DOI 10.1021/ja00050a007; JEZEQUELCUER M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P252, DOI 10.1016/0304-4165(93)90107-J; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; JOHNSON PH, 1993, GLYCOCONJUGATE J, V10, P152, DOI 10.1007/BF00737712; JOHNSON PH, 1989, 10TH P INT S GLYC, P214; JOZIASSE DH, 1985, J BIOL CHEM, V260, P4941; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LEMIEUX RU, 1985, 8TH P INT S MED CHEM, V1, P329; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MATSUSAKO T, 1991, BIOCHEM BIOPH RES CO, V181, P1218, DOI 10.1016/0006-291X(91)92068-U; MATSUSHITA Y, 1991, EXP CELL RES, V196, P20, DOI 10.1016/0014-4827(91)90451-Y; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PLATZER N, 1989, CARBOHYD RES, V191, P191, DOI 10.1016/0008-6215(89)85064-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROBINSON NE, 1994, GLYCOBIOLOGY, V4, P317, DOI 10.1093/glycob/4.3.317; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P67, DOI 10.1007/BF01047891; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TOWNSEND RR, 1989, ANAL BIOCHEM, V182, P1; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WESTRICK MA, 1983, CANCER RES, V43, P5890; WLASICHUK KB, 1993, J BIOL CHEM, V268, P13971; YOUNG WW, 1981, J BIOL CHEM, V256, P967	69	132	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8712	8722		10.1074/jbc.270.15.8712	http://dx.doi.org/10.1074/jbc.270.15.8712			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721776	hybrid			2022-12-27	WOS:A1995QT44800054
J	OBIRI, NI; DEBINSKI, W; LEONARD, WJ; PURI, RK				OBIRI, NI; DEBINSKI, W; LEONARD, WJ; PURI, RK			RECEPTOR FOR INTERLEUKIN-13 - INTERACTION WITH INTERLEUKIN-4 BY A MECHANISM THAT DOES NOT INVOLVE THE COMMON GAMMA-CHAIN SHARED BY RECEPTORS FOR INTERLEUKIN-2, INTERLEUKIN-4, INTERLEUKIN-7, INTERLEUKIN-9 AND INTERLEUKIN-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELLS; FUNCTIONAL COMPONENT; IL-2 RECEPTOR; IGE SYNTHESIS; KILLER-CELLS; EXPRESSION; CYTOKINE; DIFFERENTIATION; PROLIFERATION; ACTIVATION	Interleukin 13 (IL-13) shares many biological properties with IL-4, and although the receptor for IL-4 (IL-4R) has been characterized, the expression and structure of IL-13 receptor are unknown. We report here that human renal cell carcinoma (RCC) cells express large numbers of functional IL-13R. Human B lymphocytes and monocytes expressed a very small number of IL-13R, while resting or activated human T cells expressed little or no IL-13R, IL-4 did not compete for IL-13 binding, while IL-13 competed for IL-4 binding, even though IL-4R and IL-13R are structurally distinct on human RCC cells. IL-13 cross-linked with one major protein that is similar in size to the gamma(c) subunit of IL-2, -4, -7, -9, and -15 receptors but was not recognized by anti-gamma(c) or anti-IL-4R antibodies. IL-4, on the other hand, cross linked with two major proteins, the smaller of which appears to be similar in size to IL-13R and gamma(c), but (like the IL-13R) it did not react with anti-gamma(c) antibody. Although as shown in this study and in previous studies, gamma(c) is a functional component of IL-4R in lymphoid cells, it does not appear to be associated with IL-4R on RCC cells. Even in the absence of common gamma chain IL-4 and IL-13 were able to up-regulate intracellular adhesion molecule-1 antigen on RCC cells. These data suggest that the interaction of IL-13 with IL-4R does not involve gamma(c) and IL-13R itself may be a novel subunit of the IL-4R.	US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,MOLEC TUMOR BIOL LAB,BETHESDA,MD 20892; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT SURG,DIV NEUROSURG,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033; NHLBI,MOLEC IMMUNOL LAB,BETHESDA,MD 20892	US Food & Drug Administration (FDA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Leonard, Warren/AAA-1397-2022					AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BROWN KD, 1989, J IMMUNOL, V142, P679; CARLSSON M, 1989, EUR J IMMUNOL, V19, P913, DOI 10.1002/eji.1830190519; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; DEFRANCET, 1994, J EXP MED, V179, P135; DEWIT H, 1994, BLOOD, V84, P608; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RIGLEY KP, 1991, INT IMMUNOL, V3, P197, DOI 10.1093/intimm/3.2.197; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WEBB DSA, 1991, J IMMUNOL, V146, P3682; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	31	244	257	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8797	8804		10.1074/jbc.270.15.8797	http://dx.doi.org/10.1074/jbc.270.15.8797			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721786	hybrid			2022-12-27	WOS:A1995QT44800064
J	OTOOLE, TE; YLANNE, J; CULLEY, BM				OTOOLE, TE; YLANNE, J; CULLEY, BM			REGULATION OF INTEGRIN AFFINITY STATES THROUGH AN NPXY MOTIF IN THE BETA-SUBUNIT CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; AMINO-ACID-SEQUENCE; DENSITY-LIPOPROTEIN RECEPTOR; PLATELET GPIIB-IIIA; FIBRONECTIN RECEPTOR; LAMININ RECEPTOR; CELL-ADHESION; ALPHA; INTERNALIZATION; ACTIVATION	The ligand binding affinities of the integrins are regulated through their cytoplasmic domains. To identify specific residues that are involved in this process, we have generated mutants in the beta(1) and beta(3) tails and coexpressed them in Chinese hamster ovary cells with constitutively active alpha subunits. These alpha subunits are chimera of extracellular and transmembrane alpha(IIb) joined to the cytoplasmic domains of alpha(5), alpha(6A), or alpha(6B), and confer an energy-dependent high affinity state when expressed in Chinese hamster ovary cells. The affinity state of these transfectants was determined by analyzing the binding of PAC1, an antibody that specifically recognizes the activated form of the reporter group, extracellular alpha(IIb)beta(3). We have identified point mutants in several areas of the beta tails, which result in a reduced ability to bind ligand. Complete abolition of PAC1 binding was obtained with mutants in an NPXY motif found in many integrin beta subunits and implicated in the internalization of other cell surface receptors. Similar effects on PAC1 binding were observed whether coexpression was with alpha chimera containing alpha(5), alpha(6A), or alpha(6B) cytoplasmic sequences. These studies identify a novel role for the NPXY motif in the regulation of integrin binding affinity.	HELSINKI UNIV, DEPT BIOCHEM, SF-00014 HELSINKI, FINLAND	Finland National Institute for Health & Welfare; University of Helsinki	OTOOLE, TE (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA.		O'Toole, Timothy/I-4172-2013	Ylanne, Jari/0000-0003-4627-021X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHEN YP, 1994, J BIOL CHEM, V269, P18307; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CROWE DT, 1994, J BIOL CHEM, V269, P1411; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG MH, 1980, BLOOD, V55, P661; GINSBERG MH, 1983, METHODS HEMATOLOGY, P158; HAYASHI Y, 1990, J CELL BIOL, V110, P75; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KAWAGUCHI S, 1994, MOL BIOL CELL, V5, P977, DOI 10.1091/mbc.5.9.977; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KISHIMOTO TK, 1987, J CELL BIOL, V108, P703; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LUSKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Maniatis T, 1989, DECONTAMINATION DILU; MCLEAN JW, 1990, J BIOLL CHEM, V265, P17216; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; RABB H, 1993, J IMMUNOL, V151, P990; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; TAPLEY P, 1989, ONCOGENE, V4, P325; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VIGNOUD L, 1994, BIOCHEM BIOPH RES CO, V199, P603, DOI 10.1006/bbrc.1994.1271; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478	48	170	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8553	8558		10.1074/jbc.270.15.8553	http://dx.doi.org/10.1074/jbc.270.15.8553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721755	hybrid			2022-12-27	WOS:A1995QT44800031
J	AZARYAN, AV; KRIEGER, TJ; HOOK, VYH				AZARYAN, AV; KRIEGER, TJ; HOOK, VYH			PURIFICATION AND CHARACTERISTICS OF THE CANDIDATE PROHORMONE PROCESSING PROTEASES PC2 AND PC1/3 FROM BOVINE ADRENAL-MEDULLA CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-LIKE PROTEASE; ENKEPHALIN PRECURSOR; PROPROTEIN CONVERTASES; THIOL PROTEASE; YEAST KEX2; ENZYMATIC CHARACTERIZATION; FUNCTIONAL EXPRESSION; ENDOPROTEASE FAMILY; SERINE PROTEASE; MAMMALIAN-CELLS	The prohormone-processing proteases PC1/3 and PC2 belong to the family of mammalian subtilisin-related proprotein convertases (PC) possessing homology to the yeast Kex2 protease. The presence of PC1/3 and PC2 in secretory vesicles of bovine adrenal medulla (chromaffin granules) implicates their role in the processing the precursors of enkephalin, neuropeptide Y, somatostatin, and other neuropeptides that are present in chromaffin granules. In this study, PC1/3 and PC2 were purified to apparent homogeneity from the soluble fraction of chromaffin granules by chromatography on concanavalin A-Sepharose, Sephacryl S-200, pepstatin A-agarose, and anti-PC1/3 or anti-PC2 immunoaffinity resins. PC1/3 and PC2 were monitored during purification by measuring proteolytic activities with S-35-enkephalin precursor and Boc-Arg-Val-Arg-Arg-methylcoumarin amide (MCA) substrates and by following PC1/3 and PC2 immunoreactivity with specific anti-PC1/3 and anti-PC2 sera generated in this study. Purified PC1/3 and PC2 on SDS-polyacrylamide gels each show a molecular mass of 66 kDa. PC2 in the soluble fraction of chromaffin granules was present at 5- and 10-fold higher enzyme protein and activity, respectively, compared with that of PC1/3. PC1/3 and PC2 cleaved paired basic and monobasic sites within peptide-MCA substrates, with Boc-Arg-Val-Arg-Arg-MCA and pGlu-Arg-Thr-Lys-Arg-MCA as the most effectively cleaved peptides tested. PC1/3 and PC2 showed pH optima of 6.5 and 7.0, respectively. Kinetic studies indicated apparent K-m values for hydrolysis of Boc-Arg-Val-Arg-Arg-MCA as 66 and 40 mu M, with V-max values of 255 and 353 nmol/h/mg for PC1/3 and PC2, respectively. Specificity of the PC enzymes for dibasic sites was confirmed by potent inhibition by the active site-directed peptide inhibitors (D-Tyr)-Glu-Phe-Lys-Arg-CH2Cl and Ac-Arg-Arg-Ch(2)Cl. Inhibition by EGTA and activation by Ca2+ indicated PC1/3 and PC2 as Ca2+-dependent proteases. In addition, PC enzymes were activated by dithiothreitol and inhibited by thiol-blocking reagents, p-hydroxymercuribenzoate and mercuric chloride. These results illustrate the properties of endogenous PC1/3 and PC2 as prohormone-processing enzymes.	UNIV CALIF SAN DIEGO, MED CTR, DEPT MED, SAN DIEGO, CA 92103 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT BIOCHEM, BETHESDA, MD 20814 USA	University of California System; University of California San Diego; Uniformed Services University of the Health Sciences - USA								ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Azaryan A. V., 1992, Society for Neuroscience Abstracts, V18, P269; AZARYAN AV, 1992, BIOCHEM BIOPH RES CO, V185, P398, DOI 10.1016/S0006-291X(05)80999-4; AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; AZARYAN AV, 1994, ARCH BIOCHEM BIOPHYS, V314, P171, DOI 10.1006/abbi.1994.1426; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRENNAN SO, 1994, FEBS LETT, V338, P147, DOI 10.1016/0014-5793(94)80353-6; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; CARMICHAEL SW, 1990, NEUROSCIENCE, V34, P433, DOI 10.1016/0306-4522(90)90152-T; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOOK VYH, 1990, BIOCHEM BIOPH RES CO, V167, P722, DOI 10.1016/0006-291X(90)92085-E; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; HOOK VYH, 1992, GROWTH FACTORS PEPTI, P61; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; POLLARD HB, 1979, J BIOL CHEM, V254, P1170; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SPRUCE BA, 1988, J BIOL CHEM, V263, P19788; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V202, P1452, DOI 10.1006/bbrc.1994.2094; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; UNGAR A, 1983, PHYSIOL REV, V63, P787, DOI 10.1152/physrev.1983.63.3.787; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; YI Z, 1993, J BIOL CHEM, V268, P5615; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301	60	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8201	8208		10.1074/jbc.270.14.8201	http://dx.doi.org/10.1074/jbc.270.14.8201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713926	hybrid			2022-12-27	WOS:A1995QR52600065
J	HAEFNER, B; BAXTER, R; FINCHAM, VJ; DOWNES, CP; FRAME, MC				HAEFNER, B; BAXTER, R; FINCHAM, VJ; DOWNES, CP; FRAME, MC			COOPERATION OF SRC HOMOLOGY DOMAINS IN THE REGULATED BINDING OF PHOSPHATIDYLINOSITOL-3-KINASE - A ROLE FOR THE SRC HOMOLOGY-2 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; EPIDERMAL GROWTH-FACTOR; KINASE-ACTIVITY; SH3 DOMAIN; V-SRC; PI 3-KINASE; PP60V-SRC; PROTEIN; TRANSFORMATION; ASSOCIATION	Fibroblasts transformed by the v-Src oncoprotein exhibit elevated activity of the enzyme phosphatidylinositol 3'-kinase (PI 3-kinase), which binds to, and is activated by, a wide range of receptor tyrosine kinases as well as v-Src and transforming polyoma middle T/c-Src complexes. Here we consider the role of the v-Src homology (SH) domains, SH3 and SH2, and the tyrosine kinase catalytic domain, in the stimulation of v-Src-associated PI 3-kinase activity in response to rapid activation of the oncoprotein. As shown by others, we find that the v-Src SH3 domain tightly binds the PI 3-kinase p85 regulatory subunit in normal growing chicken embryo fibroblasts. However, we also find that in transformed cells there is additional efficient binding of PI 3-kinase to the v-Src SH2 domain in a catalytically active form. Furthermore, the binding of p85 to the SH2 domain, which is almost undetectable in quiescent cells, is rapidly stimulated upon activation of temperature-sensitive v-Src and consequent cell cycle entry, demonstrating that binding is a target for regulation. We also show that v-Src-associated PI 3-kinase differs considerably hom PDGF receptor-associated enzyme by a different mode of binding, a lack of substantial allosteric activation, and a dependence on the tyrosine kinase activity of v-Src. The rapidly induced binding and activation of PI 3-kinase thus provides sensitive regulation of recruitment of PI 3-kinase to its substrates and into other signaling complexes at the cell membrane, which involves all the Src homology domains.	BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	Beatson Institute; University of Dundee								BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CATLING AD, 1993, ONCOGENE, V8, P1875; CATLING AD, 1994, J VIROL, V7, P4392; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNES CP, 1991, CELL SIGNAL, V3, P747; FINCHAM V, 1994, CELL BIOL INT, V18, P337, DOI 10.1006/cbir.1994.1083; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1994, J BIOL CHEM, V269, P5403; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLEIMAN CM, 1994, SCIENCE, V163, P1609; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	36	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7937	7943		10.1074/jbc.270.14.7937	http://dx.doi.org/10.1074/jbc.270.14.7937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713890	hybrid			2022-12-27	WOS:A1995QR52600026
J	HIGUCHI, Y; LINN, S				HIGUCHI, Y; LINN, S			PURIFICATION OF ALL FORMS OF HELA-CELL MITOCHONDRIAL-DNA AND ASSESSMENT OF DAMAGE TO IT CAUSED BY HYDROGEN-PEROXIDE TREATMENT OF MITOCHONDRIA OR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DAMAGE; MOUSE L; OXYGEN; SEQUENCE; GENOME; REPAIR; ACID	A purification scheme for mitochondrial DNA (mtDNA) ws designed which maximized the yield of all forms of the DNA while minimizing damage to the DNA during its isolation. Treatment of intact mitochondria with DNase I removed nuclear DNA and the avoidance of phenol and the isolation by CsCl density gradients in the absence of ethidium bromide and subsequent detection by southern hybridization of dot-blots minimized DNA damage. Four different mtDNA forms free of apparent nuclear DNA were obtained: closed circular (I), open circular (II), linear (III), and a large multimer complex (C) which were characterized by agarose gel electrophoresis and electron microscopy. Using this procedure, mtDNA was obtained from both whole cells or intact mitochondria treated with H2O2. Significant fragmentation was observed after treatment at 37 degrees C, but not at 0 degrees C, and more damage was observed when treating whole cells than isolated mitochondria. Very low levels of 8-hydroxydeoxyguanosine were observed in all cases. However, at doses of H2O2 which were just lethal, neither increased DNA damage nor inactivation of cytochrome c oxidase was observed.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIEHS NIH HHS [P30ES011896] Funding Source: Medline; NIGMS NIH HHS [R29GM19020] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R43ES011896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019020, R01GM019020] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AUDIC A, 1993, PHOTOCHEM PHOTOBIOL, V57, P508, DOI 10.1111/j.1751-1097.1993.tb02327.x; BEAUFAY H, 1959, BIOCHEM J, V73, P623, DOI 10.1042/bj0730623; Becker R, 1974, METHODS ENZYMATIC AN, V3, P286; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLAYCAMP HG, 1992, CARCINOGENESIS, V13, P1289, DOI 10.1093/carcin/13.7.1289; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CURTIS PJ, 1966, BIOCHEM J, V98, P818, DOI 10.1042/bj0980818; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P113; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; FISCHERNIELSEN A, 1992, FREE RADICAL BIO MED, V13, P121, DOI 10.1016/0891-5849(92)90073-P; Halliwell B., 1990, METHOD ENZYMOL, V186, P1; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; LIN JH, 1991, BIOCHEM BIOPH RES CO, V176, P690, DOI 10.1016/S0006-291X(05)80239-6; LINN S, 1994, MOL ASPECTS AGING; LOW RL, 1987, J BIOL CHEM, V262, P16164; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; MYERS KA, 1988, CARCINOGENESIS, V9, P285, DOI 10.1093/carcin/9.2.285; PALVA TK, 1985, FEBS LETT, V192, P267, DOI 10.1016/0014-5793(85)80122-8; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; WALLACE DC, 1992, SCIENCE, V265, P628; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	31	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					7950	7956		10.1074/jbc.270.14.7950	http://dx.doi.org/10.1074/jbc.270.14.7950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713892	hybrid			2022-12-27	WOS:A1995QR52600028
J	BACK, K; CHAPPELL, J				BACK, K; CHAPPELL, J			CLONING AND BACTERIAL EXPRESSION OF A SESQUITERPENE CYCLASE FROM HYOSCYAMUS-MUTICUS AND ITS MOLECULAR COMPARISON TO RELATED TERPENE CYCLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPEARMINT MENTHA-SPICATA; CELL-SUSPENSION CULTURES; MONOTERPENE CYCLASE; 4S-LIMONENE SYNTHASE; FUSARIUM-SPOROTRICHIOIDES; ARISTOLOCHENE SYNTHASE; PENICILLIUM-ROQUEFORTI; ENZYMATIC CYCLIZATION; GLANDULAR TRICHOMES; X-PIPERITA	Genomic and cDNA clones for vetispiradiene synthase, a sesquiterpene cyclase found in Hyoscyamus muticus, were isolated using a combination of reverse transcription-polymerase chain reactions and conventional cloning procedures, RNA blot hybridization demonstrated an induction of mRNA consistent with the induction of cyclase enzyme activity in elicitor-treated cells, DNA blot hybridization indicated a gene family of 6 to 8 members, and bacterial expression of 3 cDNA clones indicated that each coded for a vetispiradiene synthase enzyme activity catalyzing the synthesis of a single reaction product. Intron-exon organization of the vetispiradiene synthase gene was identical with that previously described for 5-epi-aristolochene synthase (tobacco sesquiterpene cyclase) and casbene synthase (castor bean diterpene cyclase), and the vetispiradiene synthase amino acid sequence was 77% identical with and 81% similar to the tobacco sesquiterpene cyclase, Regions of the vetispiradiene synthase sequence centered around amino acids 60, 100, and 370 were conspicuously different relative to the tobacco sesquiterpene cyclase, The sequence similarity between the tobacco and H. muticus enzymes is suggested to be reflective of the conservation of several partial reactions common to both enzymes, and the differences may be reflective of a partial reaction unique to each enzyme.	UNIV KENTUCKY,DEPT AGRON,PLANT PHYSIOL BIOCHEM MOLEC BIOL PROGRAM,LEXINGTON,KY 40546	University of Kentucky								ALONSO WR, 1992, J BIOL CHEM, V267, P7582; AYERS AR, 1976, PLANT PHYSIOL, V57, P760, DOI 10.1104/pp.57.5.760; BACK KW, 1994, ARCH BIOCHEM BIOPHYS, V315, P527, DOI 10.1006/abbi.1994.1533; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1985, BIOORG CHEM, V13, P246, DOI 10.1016/0045-2068(85)90027-6; CANE DE, 1987, ARCH BIOCHEM BIOPHYS, V254, P421, DOI 10.1016/0003-9861(87)90120-2; CHAPPELL J, 1987, PLANT PHYSIOL, V85, P469, DOI 10.1104/pp.85.2.469; CHAPPELL J, 1994, PLANT PHYSIOL, V107, P1; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1994, ARCH BIOCHEM BIOPHYS, V309, P184, DOI 10.1006/abbi.1994.1101; CROTEAU R, 1993, ARCH BIOCHEM BIOPHYS, V307, P397, DOI 10.1006/abbi.1993.1606; CROTEAU R, 1988, J BIOL CHEM, V263, P10063; CROTEAU R, 1986, ARCH BIOCHEM BIOPHYS, V251, P777, DOI 10.1016/0003-9861(86)90390-5; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; GAMBLIEL H, 1984, J BIOL CHEM, V259, P740; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUEDES MEM, 1982, PHYTOCHEMISTRY, V21, P2987, DOI 10.1016/0031-9422(80)85086-2; GUO ZH, 1994, ARCH BIOCHEM BIOPHYS, V308, P103, DOI 10.1006/abbi.1994.1015; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; HOHN TM, 1986, ARCH BIOCHEM BIOPHYS, V251, P756, DOI 10.1016/0003-9861(86)90386-3; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V272, P137, DOI 10.1016/0003-9861(89)90204-X; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MOESTA P, 1985, ARCH BIOCHEM BIOPHYS, V238, P325, DOI 10.1016/0003-9861(85)90171-7; MUNCK SL, 1990, ARCH BIOCHEM BIOPHYS, V282, P58, DOI 10.1016/0003-9861(90)90086-E; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; PYUN HJ, 1994, ARCH BIOCHEM BIOPHYS, V308, P488, DOI 10.1006/abbi.1994.1069; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V296, P49, DOI 10.1016/0003-9861(92)90543-6; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE TJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P581, DOI 10.1006/abbi.1993.1464; SAVAGE TJ, 1994, J BIOL CHEM, V269, P4012; VOGELI U, 1990, PLANT PHYSIOL, V93, P182, DOI 10.1104/pp.93.1.182; WAGSCHAL KC, 1994, ARCH BIOCHEM BIOPHYS, V308, P477, DOI 10.1006/abbi.1994.1068; WEST CA, 1981, BIOSYNTHESIS ISOPREN, P375; WHEELER CJ, 1987, P NATL ACAD SCI USA, V84, P4856, DOI 10.1073/pnas.84.14.4856; WHITEHEAD IM, 1990, PLANTA, V182, P81, DOI 10.1007/BF00239988	40	140	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7375	7381		10.1074/jbc.270.13.7375	http://dx.doi.org/10.1074/jbc.270.13.7375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706281	hybrid			2022-12-27	WOS:A1995QQ43100054
J	CHOU, MM; HANAFUSA, H				CHOU, MM; HANAFUSA, H			A NOVEL LIGAND FOR SH3 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; EXPRESSION CLONING; GROWTH-FACTOR; RAS; NCK; BINDS; PHOSPHORYLATION	We have previously shown that overexpression of the SH2- and SH3-containing Nck adaptor protein causes transformation of mammalian fibroblasts. To elucidate the mechanism by which it deregulates growth, we have sought to identify potential effecters for Nck. We report that a serine/threonine kinase, which we term NAK (for Nck-associated kinase), associates with Nck in vivo and in vitro. Using glutathione S-transferase fusion proteins generated with isolated domains of Nck, we demonstrate that NAK binds specifically to the second of Nck's three SH3 domains. NAK is complexed with Nck in a wide variety of cell types, including NIH3T3, A431, PC12, and HeLa cells.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356, T32CA009673] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09673, R35CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIBE S, 1990, SCIENCE, V248, P1253; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1993, J BIOL CHEM, V268, P14956	28	46	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7359	7364		10.1074/jbc.270.13.7359	http://dx.doi.org/10.1074/jbc.270.13.7359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706279	hybrid			2022-12-27	WOS:A1995QQ43100052
J	MINOWADA, G; WELCH, W				MINOWADA, G; WELCH, W			VARIATION IN THE EXPRESSION AND/OR PHOSPHORYLATION OF THE HUMAN LOW-MOLECULAR-WEIGHT STRESS PROTEIN DURING IN-VITRO CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; EHRLICH ASCITES TUMOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION; PHORBOL ESTER; HL-60 CELLS; RAPID PHOSPHORYLATION; MAMMALIAN-CELLS; GROWTH; FIBROBLASTS	Members of the low molecular weight heat shock protein (hsp) family show regulated expression in both Drosophila and mice during development and differentiation. Here we have examined whether similar regulation of the single low molecular weight hsp (hsp 28) of humans exhibits differences in either its expression and/or phosphorylation during the course of in vitro differentiation of hematopoietic cells, In the promyelocytic leukemic cell line, HL-60, we show that early after commit ment of the cells to a macrophage like phenotype (via exposure to phorbol ester myristate, PMA) there occurs an accompanying increased phosphorylation of hsp 28. Over time and as the cells become terminally differentiated the levels of hsp 28 increase significantly, In con contrast, cells stimulated to adopt a granulocyte-like phenotype (e.g. exposed to either dimethyl sulfoxide or retinoic acid) show no changes in either the phosphorylation or expression of hsp 28. Moreover, once differentiated the granulocyte-like cells no longer appear capable of phosphorylating hsp 28, Human K562 cells, in response to hemin, rapidly increase their expression and phosphorylation of hsp 28 during the course of their differentiation into erythroid-like cells, Addition of PMA to the K562 cells induces differentiation into a megakaryocyte-like phenotype but is not accompanied by changes in hsp 28 phosphorylation/expression. In the case of the HL 60 cells, differentiation toward the macrophage like lineage is accompanied by an increased adherence of the cells to their substratum and an apparent association of hsp 28 with the actin cytoskeleton.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015526, R01GM033551] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM 15526, GM33551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BIELKA H, 1988, BIOMED BIOCHIM ACTA, V47, P557; BUZIN CH, 1984, P NATL ACAD SCI-BIOL, V81, P4075, DOI 10.1073/pnas.81.13.4075; CHENEY CM, 1983, DEV BIOL, V95, P325, DOI 10.1016/0012-1606(83)90033-7; COFFER A, 1985, CANCER RES, V45, P3681; COLAMONICI OR, 1986, MEGAKARYOCYTE DEV FU, P187; COLLINS SJ, 1987, BLOOD, V70, P1233; CORCES V, 1980, P NATL ACAD SCI-BIOL, V77, P5390, DOI 10.1073/pnas.77.9.5390; DUNN DK, 1993, J STEROID BIOCHEM, V46, P469, DOI 10.1016/0960-0760(93)90101-2; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; FEUERSTEIN N, 1984, J BIOL CHEM, V259, P2782; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GERNOLD M, 1993, DEV GENET, V14, P103, DOI 10.1002/dvg.1020140204; GUY GR, 1991, J BIOL CHEM, V266, P14343; HEIKKILA JJ, 1993, DEV GENET, V14, P87, DOI 10.1002/dvg.1020140202; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HORWITZ J, P NATL ACAD SCI USA, V89, P10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JACOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; KURTZ S, 1984, P NATL ACAD SCI-BIOL, V81, P7323, DOI 10.1073/pnas.81.23.7323; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MCALISTER L, 1979, CURR GENET, V1, P63, DOI 10.1007/BF00413307; MEYER WH, 1983, BLOOD, V62, P308; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Morimoto RI, 1990, STRESS PROTEINS BIOL; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; PETERSON GL, 1983, METHOD ENZYMOL, V91, P369; RICHARDS FM, 1988, CANCER RES, V48, P6715; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; SIROTKIN K, 1982, DEV BIOL, V89, P196, DOI 10.1016/0012-1606(82)90307-4; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SPECTOR NL, 1993, J CELL PHYSIOL, V156, P619, DOI 10.1002/jcp.1041560322; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; STRAHLER JR, 1990, J CLIN INVEST, V85, P200, DOI 10.1172/JCI114413; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; TISSIERES A, 1979, J MOL BIOL, V84, P389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG KY, 1994, J BIOL CHEM, V269, P13601; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Welch WJ, 1990, STRESS PROTEINS BIOL, P223	56	42	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7047	7054		10.1074/jbc.270.13.7047	http://dx.doi.org/10.1074/jbc.270.13.7047			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706242	hybrid			2022-12-27	WOS:A1995QQ43100010
J	TAMAI, K; SILOS, SA; LI, KH; KORKEELA, E; ISHIKAWA, H; UITTO, J				TAMAI, K; SILOS, SA; LI, KH; KORKEELA, E; ISHIKAWA, H; UITTO, J			TISSUE-SPECIFIC EXPRESSION OF THE 230-KDA BULLOUS PEMPHIGOID ANTIGEN GENE (BPAG1) - IDENTIFICATION OF A NOVEL KERATINOCYTE REGULATORY CIS-ELEMENT KRE3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE ZONE; DNA-SEQUENCES; CDNA CLONING; I COLLAGEN; POU DOMAIN; TRANSCRIPTION; PROTEIN; BINDING; DIFFERENTIATION; ACTIVATION	The 230-kDa bullous pemphigoid antigen gene (BPAG1) is expressed exclusively in basal keratinocytes of epidermis. In this study, we have identified a novel cis element, keratinocyte responsive element 3 (KRE3), at position -216 to -197 of the human BPAG1 gene. A promoter-CAT construct containing this element had similar to 50-fold higher expression than a similar construct devoid of this sequence when tested in transient transfections of cultured human keratinocytes. However, there was no effect on the low base-line level of expression in cultured skin fibroblasts. KRE3 contains a palindromic sequence 5'-CAAATATTTG-3', and mutations in this sequence significantly reduced the promoter activity. Gel mobility shift assays with an oligomer containing KRE3 sequence demonstrated binding activity with nuclear proteins isolated from keratinocytes. One of the DNA/protein complexes was clearly specific, since competition with >12.5-fold excess of the unlabeled oligomer resulted in disappearance of this band. No specific binding activity was noted with nuclear proteins extracted from fibroblasts, Thus, KRE3 appears to serve as the binding site for keratinocyte-specific trans-activating factor(s), and KRE3 may thus confer the tissue-specific expression to the BPAG1 gene.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923, T32AR007561] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARNEMANN J, 1993, J CELL SCI, V104, P741; BOAST S, 1990, J BIOL CHEM, V265, P13351; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HUFF CA, 1993, J BIOL CHEM, V268, P377; JORDAN RE, 1967, JAMA-J AM MED ASSOC, V200, P91; JORDON RE, 1971, ARCH DERMATOL, V103, P486, DOI 10.1001/archderm.103.5.486; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LI KH, 1993, J BIOL CHEM, V268, P8825; LI KH, 1992, J INVEST DERMATOL, V99, P258, DOI 10.1111/1523-1747.ep12616611; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUTASIM DF, 1985, J INVEST DERMATOL, V84, P47, DOI 10.1111/1523-1747.ep12274684; MYERS JC, 1981, P NATL ACAD SCI-BIOL, V78, P3516, DOI 10.1073/pnas.78.6.3516; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1992, J INVEST DERMATOL, V98, P942; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; TAMAKA M, 1994, GENE DEV, V269, P493; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANAKA T, 1991, J BIOL CHEM, V266, P12555; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; UITTO J, 1988, COLLAGEN, V4, P109; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	46	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7609	7614		10.1074/jbc.270.13.7609	http://dx.doi.org/10.1074/jbc.270.13.7609			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706309	hybrid			2022-12-27	WOS:A1995QQ43100086
J	KIRKLAND, TN; FINLEY, F; LETURCQ, D; MORIARTY, A; LEE, JD; ULEVITCH, RJ; TOBIAS, PS				KIRKLAND, TN; FINLEY, F; LETURCQ, D; MORIARTY, A; LEE, JD; ULEVITCH, RJ; TOBIAS, PS			ANALYSIS OF LIPOPOLYSACCHARIDE-BINDING BY CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING; BACTERIAL LIPOPOLYSACCHARIDE; 70Z/3 CELLS; PROTEIN; RECEPTOR; SITES; IDENTIFICATION; ENDOTOXINS; PHAGOCYTES; COMPLEXES	The cell surface protein CD14 binds bacterial lipopolysaccharide (LPS) in the presence of the serum protein, LPS-binding protein (LBP). This interaction is important for LPS-induced activation of mammalian myeloid cells. We performed quantitative studies of H-3-labeled LPS binding to human CD14 expressed on Chinese hamster ovary cells and on a human macrophage cell line (THP-1). At the concentrations studied (20-100 nM) LPS binding required the expression of CD14 and could be inhibited by a subset of anti-CD14 monoclonal antibodies. LBP was required for LPS binding to CD14. The binding occurred within 10 min and was relatively unaffected by temperature over the range of 4-37-degrees-C. Quantitative binding assays were performed at 10-degrees-C, or at 37-degrees-C, using Chinese hamster ovary cells depleted of ATP. In both cases, 75-90% of the LPS could be released by treatment with phosphatidylinositol-specific phospholipase C, suggesting that it remains associated with the glycosyl phosphatidylinostol-anchored CD14. The apparent dissociation constant of recombinant human CD14 expressed on Chinese hamster ovary cells for LPS at 10-degrees-C was 2.74 (+/- 0.99) x 10(-8) M; the apparent dissociation constant of CD14 expressed on THP-1 cells at 10-degrees-C was 4.89 (+/- 1.42) x 10(-8) M. In both cell lines, at saturating LPS concentrations, the molar ratio of LPS bound per surface CD14 was approximately 20:1. At 37-degrees-C the apparent dissociation constant of recombinant human CD14 for LPS at 37-degrees-C was 2.7 (+/- 1.2) x 10(-8) M, and the molar ratio of LPS bound per surface CD14 was approximately 8:1. Although the difference in molar ratio of LPS bound per surface CD14 at the two temperatures is difficult to interpret, it is clear that at both temperatures the molar ratio is not 1:1. The basis of this phenomenon is unclear, but may involve the repeated leucine-rich motifs, which are found within CD14.	UNIV CALIF SAN DIEGO, DEPT PATHOL, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	KIRKLAND, TN (corresponding author), VET ADM MED CTR, 111F, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.		Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, P01GM037696, R37GM028485] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696, GM28485] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHMUN RA, 1987, BLOOD, V69, P886; BRANDENBURG K, 1992, J STRUCT BIOL, V108, P93, DOI 10.1016/1047-8477(92)90010-8; COUTURIER C, 1991, J IMMUNOL, V147, P1899; FERRERO E, 1990, J IMMUNOL, V145, P331; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GOLENBOCK DT, 1990, INFECT IMMUN, V58, P4069, DOI 10.1128/IAI.58.12.4069-4075.1990; HEUMANN D, 1992, J IMMUNOL, V148, P3505; KIRKLAND TN, 1990, J BIOL CHEM, V265, P9520; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEI MG, 1988, J IMMUNOL, V141, P996; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TAKAYAMA K, 1990, J BIOL CHEM, V265, P14023; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; ULEVITCH RJ, 1981, J CLIN INVEST, V67, P827, DOI 10.1172/JCI110100; WOLFF SM, 1974, NEW ENGL J MED, V291, P733, DOI 10.1056/NEJM197410032911411; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	23	140	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1993	268	33					24818	24823						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MG673	7693705				2022-12-27	WOS:A1993MG67300047
J	KO, YH; THOMAS, PJ; DELANNOY, MR; PEDERSEN, PL				KO, YH; THOMAS, PJ; DELANNOY, MR; PEDERSEN, PL			THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF WILD-TYPE AND DELTA-F508 MUTANT FORMS OF THE 1ST NUCLEOTIDE-BINDING FOLD IN FUSION WITH THE MALTOSE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; SYNTHETIC PEPTIDE; SEQUENCE ANALYSIS; DNA-POLYMERASE; R-DOMAIN; GENE; IDENTIFICATION; PHOSPHORYLATION; NUCLEOSIDE; MUTATIONS	The first nucleotide binding fold (NBF1) of the cystic fibrosis transmembrane conductance regulator (CFTR) and its disease-causing mutant form (DELTAF508,NBF1) were overexpressed in high yield in Escherichia coli in fusion with the maltose-binding protein (MBP). The rationale for producing the chimerae was to aid in domain purification, solubilization, and crystallization and to examine the effect of protein-protein interactions on the properties of the mutant NBF1. Both the purified wild type and DELTAF508 mutant fusion proteins fold into functional nucleotide binding domains as determined by using the fluorescent nucleotide analog TNP-ATP (2'-(3')-O-(2,4,6-trinitrophenyl)adenosine-5'-triphosphate). Moreover, the prominent secondary structural features of the two proteins as assessed by ultraviolet circular dichroism spectropolarimetry are very similar, as is the higher order structure evident in three separate protease digestion patterns. Finally, the stability of the nucleotide binding function of the two proteins is similar as assessed by sensitivity to urea. Gel filtration chromatography and electron and confocal microscopy reveal that both fusion proteins, but not MBP alone, form organized fibers, suggesting that NBF1 self-associates, thus raising the possibility that CFTR may be oligomeric in the plasma membrane. Significantly, in the presence of high salt, these fusion proteins also have a propensity to form microcrystals. Finally, the two separate domains (NBF1 and MBP) constituting the fusion proteins appear to interact quite strongly as both proteins remain associated even after cleavage of their fusion junction. The possible relevance of these novel findings to those approaches that might be taken to elucidate the three-dimensional structural differences between the wild type and DELTAF508 mutant forms of CFTR, as well as to ameliorate the severity of cystic fibrosis, is discussed.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [DK 43962] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043962] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Cheadle Jeremy P., 1992, Human Molecular Genetics, V1, P123, DOI 10.1093/hmg/1.2.123; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GUAN C, 1987, GENE, V67, P21; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KEREM B, 1980, SCIENCE, V245, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Marston F. A. O., 1987, DNA CLONING, P59; MCDONALD TV, 1992, J BIOL CHEM, V267, P3242; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MULLEN GP, 1989, J BIOL CHEM, V264, P19637; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; TILLY BC, 1992, J BIOL CHEM, V267, P9470; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WITHOLT B, 1976, BIOCHIM BIOPHYS ACTA, V443, P534, DOI 10.1016/0005-2736(76)90471-5; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	69	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24330	24338						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693699				2022-12-27	WOS:A1993MF29400092
J	STOCKMANN, A; HESS, S; DECLERCK, P; TIMPL, R; PREISSNER, KT				STOCKMANN, A; HESS, S; DECLERCK, P; TIMPL, R; PREISSNER, KT			MULTIMERIC VITRONECTIN - IDENTIFICATION AND CHARACTERIZATION OF CONFORMATION-DEPENDENT SELF-ASSOCIATION OF THE ADHESIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; THROMBIN-ANTITHROMBIN-III; SERUM SPREADING FACTOR; HEPARIN-BINDING PROPERTIES; HUMAN-ENDOTHELIAL-CELLS; HUMAN S-PROTEIN; COMPLEMENT COMPLEX; POLYMERIZATION; MEMBRANE; INVITRO	The adhesive glycoprotein vitronectin (VN) shows a high degree of conformational flexibility implicating that different molecular forms of the molecule may exist. Conformation-dependent monoclonal antibodies 13H1 or 16A7 that, per se, did not react with plasma VN bound to VN treated with heparin, chaotropes, detergents, pH below 6, or by heating at 56-degrees-C. Dependent on the stimulus, recognition of VN by these antibodies varied and preceded heparin binding and self-association of VN resulting in the formation of noncovalently linked multimeric species of the protein. Both monoclonal antibodies also reacted with VN in serum or in platelet releasates as well as with VN in extracellular matrices of endothelial cells and inhibited cell adhesion on immobilized VN. Critical VN levels were needed for concentration-dependent multimerization indicating a nonlinear type of polymerization process. The nature of VN multimers was judged by nondenaturing gel electrophoresis, gel filtration, and sucrose gradient ultracentrifugation and revealed the formation of 3- to 16-mer multimeric species within an M(r) range of 200-1200 kDa representing a mean sedimentation coefficient of 9.6 S. In electron microscopy, multimeric VN occurred as globular specimens with an average diameter of 15-28 nm (monomeric plasma VN, 6-8 nm). In contrast to plasma VN, VN multimers were efficiently stabilized by covalent inter-molecular bonds following chemical or transglutaminase-induced cross-linking. A synthetic peptide comprising the central heparin binding region of VN (residues 348-361) not only bound to plasma VN but induced its multimerization also in plasma. During plasmin proteolysis of VN, fragments were generated that lacked the heparin binding region and that lost the ability to multimerize following urea or detergent treatment, implicating that the highly basic region is essential for multimer formation. These data suggest that non-plasma forms of VN, which are abundant in platelets and subendothelium, represent the prototype conformer of the reactive heparin binding form of VN. Our findings implicate that conformationally altered forms of VN enable the adhesive protein to multimerize in a characteristic fashion and thereby endow extracellular matrix sites with unique multivalent properties.	MAX PLANCK INST PHYSIOL & CLIN RES,KERCKHOFF KLIN,HAEMOSTASIS RES UNIT,SPRUDELHOF 11,D-61231 BAD NAUHEIM,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED MUNCH,GERMANY; CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM	Kerckhoff Clinic; Max Planck Society; Max Planck Society; KU Leuven			Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				BARNES DW, 1985, J BIOL CHEM, V260, P9117; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L; COMPER WD, 1977, BIOPOLYMERS, V16, P2113, DOI 10.1002/bip.1977.360161004; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAHLBACK K, 1986, ACTA DERM-VENEREOL, V66, P461; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; DEGROOT PG, 1990, BRIT J HAEMATOL, V75, P308; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GUETTIER C, 1989, VIRCHOWS ARCH A, V414, P309, DOI 10.1007/BF00734084; Hantgan RR, 1987, HEMOSTASIS THROMBOSI, P269; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; ISHIKAWA M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P173, DOI 10.1016/0167-4838(92)90351-D; KOBAYASHI R, 1989, ANAL BIOCHEM, V183, P9, DOI 10.1016/0003-2697(89)90162-0; KOST C, 1992, J BIOL CHEM, V267, P12098; KUBOTA K, 1988, CELL STRUCT FUNCT, V13, P123, DOI 10.1247/csf.13.123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERROW JS, 1981, J SUPRAMOL STRUCT, V17, P275; OBRIEN RD, 1978, ANAL BIOCHEM, V86, P602, DOI 10.1016/0003-2697(78)90788-1; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; PARKER CJ, 1989, BRIT J HAEMATOL, V71, P245, DOI 10.1111/j.1365-2141.1989.tb04262.x; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1985, J IMMUNOL, V135, P452; PREISSNER KT, 1993, THROMB HAEMOSTASIS, V69, P422; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; ROTKER J, 1986, EUR J BIOCHEM, V155, P583, DOI 10.1111/j.1432-1033.1986.tb09528.x; RUS HG, 1987, IMMUNOL LETT, V16, P15, DOI 10.1016/0165-2478(87)90054-X; SANE DC, 1991, BIOCHEM BIOPH RES CO, V174, P465, DOI 10.1016/0006-291X(91)91439-J; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; TATUNASHVILI LV, 1990, J MOL BIOL, V211, P161, DOI 10.1016/0022-2836(90)90018-H; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER DD, 1985, J CELL BIOL, V101, P112, DOI 10.1083/jcb.101.1.112; YATHOGO T, 1988, CELL STRUCT FUNCT, V13, P281; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	47	151	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22874	22882						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693680				2022-12-27	WOS:A1993MD34800100
J	TRZASKOS, JM; MAGOLDA, RL; FAVATA, MF; FISCHER, RT; JOHNSON, PR; CHEN, HW; KO, SS; LEONARD, DA; GAYLOR, JL				TRZASKOS, JM; MAGOLDA, RL; FAVATA, MF; FISCHER, RT; JOHNSON, PR; CHEN, HW; KO, SS; LEONARD, DA; GAYLOR, JL			MODULATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE BY 15-ALPHA-FLUOROLANOST-7-EN-3-BETA-OL - A MECHANISM-BASED INHIBITOR OF CHOLESTEROL-BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG COA REDUCTASE; LANOSTEROL 14-ALPHA-METHYL DEMETHYLASE; MEVALONATE-DERIVED PRODUCT; STEROL REGULATORY REGION; MESSENGER-RNA; OXIDATIVE DEMETHYLATION; CELL-CULTURES; HEP G2; ACCUMULATION	The chemical synthesis and metabolic characteristics of the lanosterol analogue, 15alpha-fluorolanost-7-en-3beta-ol, are described. The 15alpha-fluorosterol is shown to be a competitive inhibitor of the lanosterol 14alpha-methyl demethylase (K(i) = 315 muM), as well as substrate for the demethylase enzyme. Metabolic studies show that the 15alpha-fluorosterol is converted to the corresponding 15alpha-fluoro-3beta-hydroxylanost-7-en-32-aldehyde by hepatic microsomal lanosterol 14alpha-methyl demethylase but that further metabolic conversion to cholesterol biosynthetic intermediates is blocked by virtue of the 15alpha-fluoro substitution. When cultured cells are treated with the fluorinated lanosterol analogue, a decrease in 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activity and immunoreactive protein was observed. However, when the lanosterol 14alpha-methyl demethylase-deficient mutant cell line, AR45, is treated with the fluorosterol, no effect upon HMG-CoA reductase is observed. Thus, metabolic conversion of the sterol to its 32-carboxaldehyde analogue by the lanosterol 14alpha-methyl demethylase is required for HMG-CoA reductase suppressor activity. Measurement of HMG-CoA reductase mRNA levels in 15alpha-fluorosterol-treated Chinese hamster ovary (CHO) cells reveals that mRNA levels are not decreased by the sterol as would be expected for a sterol regulator of HMG-CoA reductase activity. The decrease in HMG-CoA reductase protein is due to inhibition of enzyme synthesis, suggesting that the 15alpha-fluorosterol reduces the translational efficiency of the reductase mRNA. Measurements of the half-life of HMG-CoA reductase show that, in contrast to other oxysterols, the 15alpha-fluorolanostenol does not increase the rate of degradation of the enzyme. Collectively, these data support the premise that oxylanosterols regulate HMG-CoA reductase expression through a post-transcriptional process which may be distinct from other previously described sterol regulatory mechanisms.	JOHNSON & JOHNSON,NEW BRUNSWICK,NJ 08933; W VIRGINIA UNIV,DEPT BIOL,MORGANTOWN,WV 26506	Johnson & Johnson; Johnson & Johnson USA; West Virginia University	TRZASKOS, JM (corresponding author), DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880, USA.							Battey, 1986, BASIC METHODS MOL BI; BLOCH K, 1958, J BIOL CHEM, V233, P1343; BROWN MS, 1980, J LIPID RES, V21, P505; CHEN HW, 1988, J BIOL CHEM, V263, P1248; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; COHEN LH, 1988, BIOCHEM J, V255, P61, DOI 10.1042/bj2550061; FAVATA MF, 1987, J BIOL CHEM, V262, P12254; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; FISCHER RT, 1989, J LIPID RES, V20, P1621; GIBBONS GF, 1975, J CHEM SOC CHEM COMM, P213, DOI 10.1039/c39750000213; GIBBONS GF, 1984, J BIOL CHEM, V259, P4399; GIBBONS GF, 1980, J BIOL CHEM, V255, P395; GIBBONS GF, 1968, J CHEM SOC CHEM COMM, V22, P1458; GUNTHER H, 1980, NMR SPECTROSCOPY INT, P351; KATCOFF P, 1980, P NATL ACAD SCI US; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; MANNING RW, 1988, MOL BRAIN RES, V3, P293, DOI 10.1016/0169-328X(88)90052-6; MAYER RJ, 1991, J BIOL CHEM, V266, P20070; MORISAKI M, 1987, J BIOCHEM-TOKYO, V99, P597; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NELSON JA, 1981, J BIOL CHEM, V256, P1067; ORCI L, 1984, CELL, V36, P835, DOI 10.1016/0092-8674(84)90033-3; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PANINI SR, 1984, J BIOL CHEM, V259, P7767; PANINI SR, 1992, J BIOL CHEM, V267, P12647; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PHILLIPS GN, 1976, BIOORG CHEM, V5, P1, DOI 10.1016/0045-2068(76)90011-0; Rodwell V W, 1976, Adv Lipid Res, V14, P1; SAUCIER SE, 1987, J BIOL CHEM, V262, P14056; SAUCIER SE, 1985, J BIOL CHEM, V260, P4571; SEXTON RC, 1983, BIOCHEMISTRY-US, V22, P5687, DOI 10.1021/bi00294a001; SHAFIEE A, 1986, J LIPID RES, V27, P1; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; TRZASKOS JM, 1986, J BIOL CHEM, V261, P6937; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; TRZASKOS JM, 1985, ENZYMES BIOL MEMBR, V2, P177; WOODWARD RB, 1957, J CHEM SOC, P1131, DOI 10.1039/jr9570001131	42	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22591	22599						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693673				2022-12-27	WOS:A1993MD34800062
J	WU, CY; BAUER, JS; JULIANO, RL; MCDONALD, JA				WU, CY; BAUER, JS; JULIANO, RL; MCDONALD, JA			THE ALPHA-5-BETA-1 INTEGRIN FIBRONECTIN RECEPTOR, BUT NOT THE ALPHA-5 CYTOPLASMIC DOMAIN, FUNCTIONS IN AN EARLY AND ESSENTIAL STEP IN FIBRONECTIN MATRIX ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CELL-ADHESION; EXPRESSION; FIBROBLASTS; MODULATION; ANTIBODIES; DEFICIENT; BINDING; MODULES; ROLES	The alpha5beta1 integrin mediates cell adhesion and migration on fibronectin, a glycoprotein critical for normal vertebrate embryonic development. Indirect evidence reported to date suggests that this receptor also functions in the deposition of fibronectin matrices. We used a molecular genetic approach to critically evaluate this role of alpha5beta1 integrins. Mutant Chinese hamster ovary (CHO) cells deficient in alpha5 integrin expression could not assemble a fibronectin matrix. Reconstituting alpha5beta1 integrin expression by transfecting them with a full-length cDNA encoding the human alpha5 chain completely restored fibronectin matrix assembly. CHO cells expressing an alpha5 chain lacking the cytoplasmic domain also assembled a fibronectin matrix. Removing the cytoplasmic domain of alpha5 appears to increase its activity in fibronectin matrix assembly. In addition to alpha5beta1 integrin binding to fibronectin's RGD-containing domain, cells must bind with high affinity to fibronectin's amino-terminal 29-kDa matrix assembly domain to form a fibronectin matrix. Studies with the alpha5-deficient CHO cells show that the expression of alpha5beta1 integrin is also necessary for cells to bind fragments containing this distinct site in fibronectin and that a fibronectin matrix increases binding of the 29-kDa fragment. Thus, alpha5beta1 integrins not only mediate cell adhesion to fibronectin, but also play an essential role in the assembly of a fibronectin matrix. This role includes direct binding to fibronectin and modulating a distinct binding event involving the interaction of fibronectin's amino-terminal matrix assembly domain with the cell surface.	MAYO CLIN SCOTTSDALE, SAMUEL C JOHNSON MED RES CTR, 13400 E SHEA BLVD, SCOTTSDALE, AZ 85259 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27514 USA	Mayo Clinic; Mayo Clinic Phoenix; University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM-38276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALLEN HBL, 1987, J BIOL CHEM, V262, P14361; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HOLERS VM, 1989, J EXP MED, V169, P1589, DOI 10.1084/jem.169.5.1589; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167, DOI 10.1111/j.1749-6632.1991.tb43701.x; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHREINER C, 1991, CLIN EXP METASTAS, V9, P163, DOI 10.1007/BF01756387; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SMITH JC, 1990, DEVELOPMENT, V108, P229; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; VARTIO T, 1987, J CELL SCI, V88, P419; VILLIGER B, 1981, J CELL BIOL, V90, P711, DOI 10.1083/jcb.90.3.711; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	37	158	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					21883	21888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691819				2022-12-27	WOS:A1993MC80900068
J	BAEK, KJ; THIEL, BA; LUCAS, S; STUEHR, DJ				BAEK, KJ; THIEL, BA; LUCAS, S; STUEHR, DJ			MACROPHAGE NITRIC-OXIDE SYNTHASE SUBUNITS - PURIFICATION, CHARACTERIZATION, AND ROLE OF PROSTHETIC GROUPS AND SUBSTRATE IN REGULATING THEIR ASSOCIATION INTO A DIMERIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; CYTOCHROME P-450 REDUCTASE; ESCHERICHIA-COLI HEMOFLAVOPROTEIN; 2 FUNCTIONAL DOMAINS; SULFITE REDUCTASE; FLAVIN MONONUCLEOTIDE; BACILLUS-MEGATERIUM; C REDUCTASE; L-ARGININE; FLAVOPROTEIN	The cytokine-induced nitric oxide synthase (NOS) of macrophages is a homodimeric enzyme that contains iron protoporphorin IX (heme), FAD, FMN, tetrahydrobiopterin, and calmodulin. To investigate how the enzyme's quaternary structure relates to its catalytic activity and binding of prosthetic groups, dimeric NOS and its subunits were purified separately and their composition and catalytic properties compared. In contrast to dimeric NOS, purified subunits did not synthesize NO or contain bound heme or tetrahydrobiopterin. However, the subunits did contain FAD, FMN, and calmodulin in amounts comparable with dimeric NOS, displayed the light absorbance spectrum of an FAD- and FMN-containing flavoprotein, and generated an air-stable flavin semiquinone radical upon reduction of their ferricyanide-oxidized form. Dimeric NOS and NOS subunits were equivalent in catalyzing electron transfer from NADPH to cytochrome c, dichlorophenolindophenol, or ferricyanide at rates that were 8-30-fold faster than the maximal rate of NO synthesis by dimeric NOS. Reconstitution of subunit NO synthesis required their incubation with L-arginine, tetrahydrobiopterin, and stoichiometric amounts of heme and correlated with formation of a proportional amount of dimeric NOS in all cases. The dimeric NOS reconstituted from its subunits contained 0.9 heme and 0.44 tetrahydrobiopterin bound per subunit and had the spectral and catalytic properties of native dimeric NOS. Thus, NOS subunits are NADPH-dependent reductases that acquire the capacity to synthesize NO only through their dimerization and binding of heme and tetrahydrobiopterin. The ability of heme, tetrahydrobiopterin, and L-arginine to promote subunit dimerization is unprecedented and suggests novel roles for these molecules in forming and stabilizing the active dimeric NOS.	CLEVELAND CLIN,DEPT IMMUNOL,NN-1,9500 EUCLID AVE,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University					NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brunori, 1972, HEMOGLOBIN MYOGLOBIN; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; FAEDER EJ, 1974, J BIOL CHEM, V249, P1599; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; Jaenicke R, 1986, Methods Enzymol, V131, P218; JAENICKE R, 1980, P NATL ACAD SCI-BIOL, V77, P1966, DOI 10.1073/pnas.77.4.1966; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KLATT P, 1992, J BIOL CHEM, V267, P11374; KREBS H, 1979, EUR J BIOCHEM, V100, P356; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; KWON NS, 1989, J BIOL CHEM, V264, P20496; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI HY, 1991, J BIOL CHEM, V266, P11909; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OTVOS JD, 1986, BIOCHEMISTRY-US, V25, P7220, DOI 10.1021/bi00370a068; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; RUDOLPH R, 1978, EUR J BIOCHEM, V87, P601, DOI 10.1111/j.1432-1033.1978.tb12412.x; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SILVER J, 1983, INORG CHIM A-BIOINOR, V78, P219, DOI 10.1016/S0020-1693(00)86516-0; STEUHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAKESHI F, 1980, ANAL BIOCHEM, V102, P176; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	42	381	386	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21120	21129						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691806				2022-12-27	WOS:A1993MA28800073
J	JONES, D; CANDIDO, EPM				JONES, D; CANDIDO, EPM			NOVEL UBIQUITIN-LIKE RIBOSOMAL-PROTEIN FUSION GENES FROM THE NEMATODES CAENORHABDITIS-ELEGANS AND CAENORHABDITIS-BRIGGSAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL FEATURES; EXTENSION PROTEINS; POLYUBIQUITIN GENE; INTRON ENHANCER; SPLICED LEADER; EXPRESSION; YEAST; SEQUENCE; IDENTIFICATION; ENCODES	Among eukaryotes studied to date, homologs of the yeast 76-amino acid ribosomal protein have invariably been found to be cotranslated with ubiquitin. However, in the nematodes Caenorhabditis elegans and Caenorhabditis briggsae, a 70-amino acid domain with only 40% identity to ubiquitin is cotranslated with a homolog of the ribosomal protein. In the nematode ubiquitin-like (UbL) proteins, the nucleotide sequence of the UbL coding region is 92% identical in C. elegans and C. briggsae. The corresponding gene sequence contains a single intron at a location identical to that found in the polyubiquitin gene of C. elegans, further confirming that the ubl genes are evolutionarily related to ubiquitin. The ribosomal protein portion of the UbL polypeptide consists of 93 amino acids and is 68% identical to the human homolog. The ribosomal protein portion of UbL is longer than in other homologs, with the additional sequence being present as a basic carboxyl extension. The ubl gene is constitutively expressed in all life cycle stages of C. elegans. A comparison of the nematode UbL sequences with other ubiquitin-like genes reveals a pattern of sequence conservation, which suggests that the ubiquitin-like proteins may have conserved functional domains.			JONES, D (corresponding author), UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA.							ANTONUCCI TK, 1985, RECOMBINANT DNA TECH, V6, P22; BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BOND U, 1985, MOL CELL BIOL, V5, P949, DOI 10.1128/MCB.5.5.949; BUTT TR, 1988, J BIOL CHEM, V263, P16364; CALLIS J, 1990, J BIOL CHEM, V265, P12486; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; GRAHAM RW, 1989, MOL CELL BIOL, V9, P268, DOI 10.1128/MCB.9.1.268; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HESCHL MFP, 1990, J MOL EVOL, V31, P3, DOI 10.1007/BF02101786; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; JONES D, 1989, DNA-J MOLEC CELL BIO, V8, P481, DOI 10.1089/dna.1.1989.8.481; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; KENNEDY BP, 1993, J MOL BIOL, V229, P890, DOI 10.1006/jmbi.1993.1094; KIRCHHOFF LV, 1988, J BIOL CHEM, V263, P12698; Krause M., 1986, P151; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEE HS, 1988, MOL CELL BIOL, V8, P4727, DOI 10.1128/MCB.8.11.4727; LEVYWILSON B, 1992, J BIOL CHEM, V267, P18735; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LUND PK, 1985, J BIOL CHEM, V260, P7609; MONIA BP, 1989, J BIOL CHEM, V264, P4093; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; Rechsteiner M., 1988, UBIQUITIN; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ JR, 1991, MOL CELL BIOL, V11, P1901, DOI 10.1128/MCB.11.4.1901; SULSTON JE, 1974, GENETICS, V77, P95; SWINDLE J, 1988, EMBO J, V7, P1121, DOI 10.1002/j.1460-2075.1988.tb02921.x; TACCIOLI GE, 1989, NUCLEIC ACIDS RES, V17, P6153, DOI 10.1093/nar/17.15.6153; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; WARNER JR, 1989, NATURE, V338, P379, DOI 10.1038/338379a0; Wood WB, 1988, NEMATODE CAENORHABDI	45	35	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1993	268	26					19545	19551						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LW819	7690036				2022-12-27	WOS:A1993LW81900062
J	MARCHESE, P; MURATA, M; MAZZUCATO, M; PRADELLA, P; DEMARCO, L; WARE, J; RUGGERI, ZM				MARCHESE, P; MURATA, M; MAZZUCATO, M; PRADELLA, P; DEMARCO, L; WARE, J; RUGGERI, ZM			IDENTIFICATION OF 3 TYROSINE RESIDUES OF GLYCOPROTEIN IB-ALPHA WITH DISTINCT ROLES IN VON-WILLEBRAND-FACTOR AND ALPHA-THROMBIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID-SEQUENCE; BERNARD-SOULIER SYNDROME; PLATELET MEMBRANE; PROTEIN; COMPLEX; DOMAIN; SULFATION; SITE; BOTROCETIN	The interaction between von Willebrand factor (vWF) and the platelet membrane glycoprotein (GP) Ib-IX-V complex is essential for platelet adhesion at sites of vascular injury under high shear stress flow conditions. Moreover, GP Ib-IX-V may contribute to the mechanisms of platelet activation through its high affinity binding of alpha-thrombin. There are two distinct but partially overlapping regions of GP Ib alpha thought to be involved in interacting with vWF (residues 251-279) and alpha-thrombin (residues 271-284); they share three tyrosine residues (positions 276, 278, and 279) that have recently been shown to be sulfated (Dong, J., Li, C. Q., and Lopez, J., A. (1994) Biochemistry 33, 13946-13953). To define the functional role of these three residues, we have introduced selected mutations in a soluble recombinant GP Ib(alpha fragment (corresponding to the sequence 1-302 of the mature protein) that binds vWF and alpha-thrombin with the same attributes as intact GP Ib-IX-V complex. Fragments containing a single Tyr --> Phe substitution either at position 276 or 278 or 279 exhibited normal interaction with vWF but markedly reduced or absent binding of a-thrombin. GP Ib alpha fragment with normal sequence but synthesized under sulfate free conditions also failed to bind alpha-thrombin and, in addition, had markedly reduced interaction with vWF. The simultaneous substitution of three neighboring Asp residues with Asn at positions 272, 274, and 277, a multiple mutation that may impair Tyr sulfation, also resulted in loss of binding of both ligands. These results define distinct structural features of GP Ib alpha selectively involved in supporting the interaction with vWF or alpha-thrombin.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; KEIO UNIV, DEPT INTERNAL MED, TOKYO 160, JAPAN; CTR RIFERIMENTO ONCOL, SERV IMMUNOTRASFUS & ANAL CLIN, I-33081 AVIANO, ITALY	Scripps Research Institute; Scripps Research Institute; Keio University; IRCCS Aviano (CRO)			Mazzucato, Mario/ABF-5472-2020	Mazzucato, Mario/0000-0001-8319-053X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042846, R37HL042846, P01HL048728] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-48728, HL-42846] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; DU XP, 1987, BLOOD, V69, P1524; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HANDA M, 1986, J BIOL CHEM, V261, P2579; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; MURATA M, 1993, J CLIN INVEST, V91, P2133, DOI 10.1172/JCI116438; MURATA M, 1991, J BIOL CHEM, V266, P15474; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692	37	111	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9571	9578		10.1074/jbc.270.16.9571	http://dx.doi.org/10.1074/jbc.270.16.9571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721887	hybrid			2022-12-27	WOS:A1995QU08900076
J	SIDHAR, SK; LOMAS, DA; CARRELL, RW; FOREMAN, RC				SIDHAR, SK; LOMAS, DA; CARRELL, RW; FOREMAN, RC			MUTATIONS WHICH IMPEDE LOOP SHEET POLYMERIZATION ENHANCE THE SECRETION OF HUMAN ALPHA(1)-ANTITRYPSIN DEFICIENCY VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-1-PROTEINASE INHIBITOR; HUMAN ALPHA-1-ANTITRYPSIN; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; XENOPUS-OOCYTES; LIVER; ACCUMULATION; OVALBUMIN; ACID; PIZ	alpha(1)-Antitrypsin plasma deficiency variants which form hepatic inclusion bodies within the endoplasmic path way include the common Z variant (Glu(342) --> Lys) and the rarer alpha(1)-antitrypsin S-iiyama (Ser(53) --> Phe). It has been proposed that retention of both abnormal proteins is accompanied by a common mechanism of loop-sheet polymerization with the insertion of the reactive center loop of one molecule into a beta-pleated sheet of another. We have compared the biosynthesis, glycosylation, and secretion of normal, Z and S-iiyama variants of alpha(1)-antitrypsin using Xenopus oocytes. S-iiyama and Z alpha(1)-antitrypsin both duplicated the secretory defect seen in hepatocytes that results in decreased plasma alpha(1)-antitrypsin levels. Digestion with endoglycosidase H localized both variants to a pre-Golgi compartment. The mutation Phe(51) --> Leu abolished completely the intracellular blockage of S-iiyama alpha(1)-antitrypsin and reduced significantly the retention of Z alpha(1)-antitrypsin. The secretory properties of M and Z alpha(1)-antitrypsin variants containing amino acid substitutions designed to decrease loop mobility and sheet insertion were investigated. A reduction in intracellular levels of Z alpha(1)-antitrypsin was achieved with the replacement of P-11/12 alanines by valines. Thus a decrease in Z and S-iiyama alpha(1)-antitrypsin retention was observed with mutations which either closed the A sheet or decreased loop mobility at the loop hinge region.	UNIV SOUTHAMPTON,DEPT PHYSIOL & PHARMACOL,SOUTHAMPTON SO16 7PX,HANTS,ENGLAND; UNIV CAMBRIDGE,MRC CTR,DEPT HEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Southampton; MRC Laboratory Molecular Biology; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATHURST IC, 1985, FEBS LETT, V183, P304, DOI 10.1016/0014-5793(85)80798-5; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; FOREMAN RC, 1984, FEBS LETT, V168, P84, DOI 10.1016/0014-5793(84)80211-2; FOREMAN RC, 1987, FEBS LETT, V216, P79, DOI 10.1016/0014-5793(87)80760-3; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; KWON KS, 1994, J BIOL CHEM, V269, P9627; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LE A, 1990, J BIOL CHEM, V265, P14001; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; PERLMUTTER DH, 1985, P NATL ACAD SCI USA, V82, P6918, DOI 10.1073/pnas.82.20.6918; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; SHARP H L, 1971, Hospital Practice, V6, P83; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0	31	57	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8393	8396		10.1074/jbc.270.15.8393	http://dx.doi.org/10.1074/jbc.270.15.8393			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721731	hybrid			2022-12-27	WOS:A1995QT44800006
J	VALERO, E; DEBONIS, S; FILHOL, O; WADE, RH; LANGOWSKI, J; CHAMBAZ, EM; COCHET, C				VALERO, E; DEBONIS, S; FILHOL, O; WADE, RH; LANGOWSKI, J; CHAMBAZ, EM; COCHET, C			QUATERNARY STRUCTURE OF CASEIN KINASE-2 - CHARACTERIZATION OF MULTIPLE OLIGOMERIC STATES AND RELATION WITH ITS CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; II ACTIVITY; BINDING-ACTIVITY; PROTEIN-KINASES; BETA-SUBUNIT; PURIFICATION; ENZYME; IDENTIFICATION; ACTIVATION; INHIBITION	The structure-activity relationship of casein kinase 2 (CK2) was examined with regard to its previously reported property to self-aggregate in vitro. Sedimentation velocity and electron microscopy studies showed that the purified kinase exhibited four major, different oligomeric forms in aqueous solution. This self-polymerization was a reproducible and fully reversible process, highly dependent upon the ionic strength of the medium, suggesting that electrostatic interactions are mostly involved. At high salt concentrations (e.g. 0.5 M NaCl), CK2 appears as spherical moieties with a 18.7 +/- 1.6 nm average diameter, roughly corresponding to the alpha(2) beta(2) protomer, as deduced by measurements of the Stokes radius and by light scattering studies. At lower ionic strength (e.g. 0.2 M NaCl), the protomers associate to form ring-like structures with a diameter (averaging 36.6 +/- 2.1 nm) and Stokes radius indicating that they are most likely made of four circularly associated alpha(2) beta(2) protomers. At 0.1 M NaCl, two additional polymeric structures were visualized: thin filaments (16.4 +/- 1.4 nm average), as long as 1 to 5 mu m, and thick and shorter filaments (28.5 +/- 1.6 nm average). Examination of the molecular organization of CK2 under different catalytic conditions revealed that the ring-like structure is the favored conformation adopted by the enzyme in the presence of saturating concentrations of substrates and cofactors. During catalysis, well-known cofactors like MgCl2 or spermine are the main factors governing the stabilization of the active ring-like structure, On the other hand, inhibitory high salt concentrations promote the dissociation of the active ring-like structure into protomers. Such observations suggest a strong correlation between the ring-like conformation of the enzyme and optimal specific activity. Thus, CK2 may be considered as an associating-dissociating enzyme, and this remarkable property supports the hypothesis of a cooperative and allosteric regulation of the kinase in response to appropriate regulatory ligands possibly taking place in intact cells.	CEN GRENOBLE, DEPT BIOL MOLEC & STRUCT, INSERM, U244, CEA, F-38054 GRENOBLE 9, FRANCE; INST BIOL STRUCT, MICROSCOPIE ELECTR STRUCT LAB, F-38027 GRENOBLE, FRANCE; INST MAX VON LAUE PAUL LANGEVIN, EUROPEAN MOLEC BIOL LAB, F-38042 GRENOBLE, FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)			Filhol-Cochet, Odile/I-3962-2016; Langowski, Jörg/A-1843-2011	Langowski, Jörg/0000-0001-8600-0666; Cochet, Claude/0000-0002-1772-4270; Filhol, Odile/0000-0003-1964-7958				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1981, BIOCHIM BIOPHYS ACTA, V658, P191, DOI 10.1016/0005-2744(81)90289-8; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEIGE JJ, 1983, BIOCHEMISTRY-US, V22, P1452, DOI 10.1021/bi00275a020; FEIGE JJ, 1980, FEBS LETT, V121, P139, DOI 10.1016/0014-5793(80)81283-X; FEIGE JJ, 1985, RECENT PROGR POLYAMI, V13, P181; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEM BIOPH RES CO, V173, P862, DOI 10.1016/S0006-291X(05)80866-6; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GLOVER CVC, 1986, J BIOL CHEM, V261, P14349; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LANGOWSKI J, 1991, N-HOLLAND D, P325; MAMRACK MD, 1989, MOL CELL BIOCHEM, V85, P147, DOI 10.1007/BF00577110; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1986, EUR J BIOCHEM, V159, P31, DOI 10.1111/j.1432-1033.1986.tb09829.x; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; TUAZON PT, 1991, ADV SEC MESS PHOSPH, P124	32	85	86	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8345	8352		10.1074/jbc.270.14.8345	http://dx.doi.org/10.1074/jbc.270.14.8345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713943	hybrid			2022-12-27	WOS:A1995QR52600082
J	GRAVINA, SA; HO, LB; ECKMAN, CB; LONG, KE; OTVOS, L; YOUNKIN, LH; SUZUKI, N; YOUNKIN, SG				GRAVINA, SA; HO, LB; ECKMAN, CB; LONG, KE; OTVOS, L; YOUNKIN, LH; SUZUKI, N; YOUNKIN, SG			AMYLOID-BETA PROTEIN (A-BETA) IN ALZHEIMERS-DISEASE BRAIN - BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A-BETA-40 OR A-BETA-42(43)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDE; DEPOSITS; PLAQUES; CELLS	Biochemical and immunocytochemical analyses were performed to evaluate the composition of the amyloid beta protein (A beta) deposited in the brains of patients with Alzheimer's disease (AD), To quantitate all A beta s present, cerebral cortex was homogenized in 70% formic acid, and the supernatant was analyzed by sandwich enzyme-linked immunoabsorbent assays specific for various forms of A beta. In 9 of 27 AD brains examined, there was minimal congophilic angiopathy and virtually all A beta (96%) ended at A beta 42(43), The other 18 AD brains contained increasing amounts of A beta ending at A beta 40. From this set, 6 brains with substantial congophilic angiopathy were separately analyzed, In these brains, the amount of A beta ending at A beta 42(43) was much the same as in brains with minimal congophilic angiopathy, but a large amount of A beta ending at A beta 40 (76% of total A beta) was also present. Immunocytochemical analysis with monoclonal antibodies selective for A beta s ending at A beta 42(43) or A beta 40 confirmed that, in brains with minimal congophilic angiopathy, virtually all A beta is A beta ending at A beta 42(43) and showed that this A beta is deposited in senile plaques of all types, In the remaining AD brains, A beta 42(43) was deposited in a similar fashion in plaques, but, in addition, widely varying amounts of A beta ending at A beta 40 were deposited, primarily in blood vessel walls, where some A beta ending at A beta 42(43) was also present, These observations indicate that A beta s ending at A beta 42(43), which are a minor component of the A beta in human cerebrospinal fluid and plasma, are critically important in AD where they deposit selectively in plaques of all kinds.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; TAKEDA CHEM IND LTD,DIV DISCOVERY RES,TSUKUBA,IBARAKI 30042,JAPAN; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Case Western Reserve University; Takeda Chemical Industries; The Wistar Institute					NATIONAL INSTITUTE ON AGING [R01AG006656, R01AG012685] Funding Source: NIH RePORTER; NIA NIH HHS [AG06656, AG12685] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; GOWING E, 1994, J BIOL CHEM, V269, P10987; HAAS C, 1992, NATURE, V359, P332; HILBICH C, 1993, J BIOL CHEM, V268, P26571; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, IN PRESS ANN NEUROL; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; MASLIAH E, 1990, AM J PATHOL, V137, P1293; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI N, 1994, AM J PATHOL, V145, P452; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P19965; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113	22	562	597	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7013	7016		10.1074/jbc.270.13.7013	http://dx.doi.org/10.1074/jbc.270.13.7013			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706234	hybrid			2022-12-27	WOS:A1995QQ43100001
J	HARTSOUGH, MT; MULDER, KM				HARTSOUGH, MT; MULDER, KM			TRANSFORMING GROWTH-FACTOR-BETA ACTIVATION OF P44(MAPK) IN PROLIFERATING CULTURES OF EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; SERINE THREONINE KINASE; TGF-BETA; PROTEIN-KINASE; II RECEPTOR; MAP KINASE; C-MYC; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INHIBITION	Transforming growth factor-beta (TGF-beta) is a potent growth inhibitor of a variety of epithelial cell types. The primary signaling mechanism involved in mediating this and other cellular effects of TGF-beta is still unknown. We report here that both TGF-beta(1) and TGF-beta(2) resulted in a rapid activation of mitogen-activated protein kinase (MAPK) p44(mapk), occurring within 5-10 min of growth factor addition. This effect occurred in exponentially proliferating cultures of intestinal epithelial (IEC) 4-1 cells under conditions in which DNA synthesis was inhibited by 95% to 98%, Furthermore, TGF-beta(2) induced a sustained activation of p44(mapk) under these conditions, lasting for at least 90 min after initial growth factor treatment. Another TGF-beta sensitive epithelial cell line (CCL 64) displayed a similar rapid increase in p44(mapk) activity when treated with TGF-beta(1). In contrast, in LEC 4-6 cells that are resistant to TGF-P effects on growth and DNA synthesis, TGF-beta(2) treatment did not result in an activation of p44(mapk), In contrast to the results in proliferating cultures, treatment of quiescent cultures of IEC 4-1 cells with TGF-beta(2) resulted in no significant change in either DNA synthesis or p44(mapk) activity within 15 min of TGF-P addition. In contrast, addition of the growth-stimulatory combination of factors (epidermal growth factor + insulin + transferrin = EIT) to quiescent and proliferating IEC 4-1 cells stimulated DNA synthesis and resulted in a sustained activation of p44(mapk), Together, our results suggest an association between activation of p44(mapk) and both TGF-beta mediated growth inhibition and FIT-mediated growth stimulation, This suggests that the specificity for the cellular effects of growth factors may not occur at the level of MAPK activation per se, but rather at downstream events that include phosphorylation of distinct transcriptional complexes and activation of a select assortment of genes, With regard to TGF-beta specifically, we have proposed a model to explain how activation of p44(mapk) may be associated with a growth inhibitory response.			HARTSOUGH, MT (corresponding author), PENN STATE UNIV,COLL MED,DEPT PHARMACOL,500 UNIV DR,HERSHEY,PA 17033, USA.				NATIONAL CANCER INSTITUTE [R01CA051452, R01CA054816, R29CA051452, K04CA059552] Funding Source: NIH RePORTER; NCI NIH HHS [CA51452, CA54816, K04 CA59552] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1990, J BIOL CHEM, V265, P11495; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; BHUSHAN A, 1994, MOL CELL BIOL, V14, P4280, DOI 10.1128/MCB.14.6.4280; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRAND T, 1993, J BIOL CHEM, V268, P11500; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOOSEIN NM, 1987, CANCER RES, V47, P2950; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MULDER KM, 1988, INT J CANCER, V42, P64, DOI 10.1002/ijc.2910420113; MULDER KM, 1990, J CELL PHYSIOL, V145, P501, DOI 10.1002/jcp.1041450316; MULDER KM, 1988, BIOCHEM BIOPH RES CO, V150, P711, DOI 10.1016/0006-291X(88)90449-4; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; YAN ZF, 1994, J BIOL CHEM, V269, P13231	69	278	284	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7117	7124		10.1074/jbc.270.13.7117	http://dx.doi.org/10.1074/jbc.270.13.7117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706248	hybrid			2022-12-27	WOS:A1995QQ43100019
J	HUANG, CYF; YUAN, CJ; BLUMENTHAL, DK; GRAVES, DJ				HUANG, CYF; YUAN, CJ; BLUMENTHAL, DK; GRAVES, DJ			IDENTIFICATION OF THE SUBSTRATE AND PSEUDOSUBSTRATE BINDING-SITES OF PHOSPHORYLASE-KINASE GAMMA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LIGHT-CHAIN KINASES; CATALYTIC SUBUNIT; INTRASTERIC REGULATION; CRYSTAL-STRUCTURE; BETA-SUBUNITS; CALMODULIN; EXPRESSION; SPECIFICITY; DOMAINS	Using site directed mutagenesis, we proposed that an autoinhibitory domain(s) is located at the C-terminal region (301-388) of the phosphorylase kinase gamma-subunit (Huang, C.-Y.F., Yuan, C.-J., Livanova, N. B., and Graves, D. J. (1993) Mol. Cell. Biochem. 127/128, 7-18). Removal of the putative inhibitory domain(s) by truncation results in the generation of a constitutively active and calmodulin-independent form, gamma(1-300). To probe the structural basis of autoinhibition of gamma-subunit activity, two synthetic peptides, PhK13 (gamma(303-327)) and PhK5 (gamma(343-367)), corresponding to the two calmodulin-binding regions, were assayed for their ability to inhibit gamma(1-300). Competitive inhibition of gamma(1-300) by PhK13 was found versus phosphorylase b (K-i = 1.8 mu M) and noncompetitive inhibition versus ATP, PhK5 showed noncompetitive inhibition with respect to both phosphorylase b and ATP. Calmodulin released the inhibition caused by both peptides. These results indicate that there are two distinct autoinhibitory domains within the C terminus of the gamma-subunit and that these two domains overlap with the calmodulin-binding regions. Two mutant forms of gamma(1-300), E111K and E154R, were used to probe the enzyme-substrate-binding region using peptide substrate analogs corresponding to residues 9-18 of phosphorylase b (KRK(11)Q(12)ISVRGL). The data suggest that Glu(111) interacts with the P-3 position of the substrate (Lys(11)) and Glu(154) interacts with the P-2 site (Gln(12)). Both E111K and E154R were competitively inhibited with respect to phosphorylase b by PhK13, with 14- and 8-fold higher K-i values, respectively, than that observed with the wildtype enzyme. These data are consistent with a model for the regulation of the gamma-subunit of phosphorylase kinase in which PhK13 acts as a competitive pseudosubstrate that directly binds the substrate binding site of the gamma-subunit (Glu(111) and Glu(154)).	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA; UNIV UTAH, DEPT PHARMACOL & TOXICOL, SALT LAKE CITY, UT 84112 USA	Iowa State University; Utah System of Higher Education; University of Utah				Blumenthal, Donald/0000-0002-8614-1167; Huang, Chi-Ying F/0000-0003-4898-4937	NIGMS NIH HHS [GM-39290, GM-09587] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039290, R01GM009587] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANN JG, 1994, FASEB J, V8, pA1223; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALALB MB, 1992, J BIOL CHEM, V267, P1455; CAWLEY KC, 1989, BIOCHEM J, V263, P223, DOI 10.1042/bj2630223; CHEN LR, 1989, BIOCHEM BIOPH RES CO, V161, P746, DOI 10.1016/0006-291X(89)92663-6; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P10274, DOI 10.1021/bi00106a027; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GRAVES DJ, 1983, METHOD ENZYMOL, V99, P268; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HEILMEYER LMG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P168, DOI 10.1016/0167-4889(91)90005-I; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUANG CYF, 1994, BIOCHEMISTRY-US, V33, P5877, DOI 10.1021/bi00185a027; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; KEE SM, 1987, J BIOL CHEM, V262, P9448; KEE SM, 1986, J BIOL CHEM, V261, P4732; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANCIOTTI R, 1994, FASEB J, V8, pA1236; LANCIOTTI RA, 1994, BIOCHEM J, V299, P183, DOI 10.1042/bj2990183; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; NEWSHOLME P, 1992, J BIOL CHEM, V267, P810; ORR JW, 1994, J BIOL CHEM, V269, P8383; PAUDEL HK, 1987, J BIOL CHEM, V262, P11912; Pickett-Gies CA., 1986, ENZYMES, V17, P395; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; SANCHEZ VE, 1993, J BIOL CHEM, V268, P17889; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TESSMER GW, 1977, J BIOL CHEM, V252, P5666; TOMODA T, 1993, BIOCHIM BIOPHYS ACTA, V1175, P333, DOI 10.1016/0167-4889(93)90226-F; VIRIYA J, 1979, BIOCHEM BIOPH RES CO, V87, P17, DOI 10.1016/0006-291X(79)91641-3; YUAN CJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P317, DOI 10.1016/0003-9861(89)90445-1; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	44	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7183	7188		10.1074/jbc.270.13.7183	http://dx.doi.org/10.1074/jbc.270.13.7183			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706257	hybrid			2022-12-27	WOS:A1995QQ43100028
J	JACKMAN, JK; MOTTO, DG; SUN, QM; TANEMOTO, M; TURCK, CW; PELZ, GA; KORETZKY, GA; FINDELL, PR				JACKMAN, JK; MOTTO, DG; SUN, QM; TANEMOTO, M; TURCK, CW; PELZ, GA; KORETZKY, GA; FINDELL, PR			MOLECULAR-CLONING OF SLP-76, A 76-KDA TYROSINE PHOSPHOPROTEIN ASSOCIATED WITH GRB2 IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; SH3 DOMAINS; RECEPTOR; PROTEIN; RAS; ACTIVATION; PATHWAYS; P21(RAS); COMPLEX	The activation of protein tyrosine kinases is a critical event in T cell antigen receptor (TCR)-mediated signaling, One substrate of the TCR-activated protein tyrosine kinase pathway is a 76-kDa protein (pp76) that associates with the adaptor protein Grb2. In this report we describe the purification of pp76 and the molecular cloning of its cDNA, which encodes a novel 533-amino acid protein with a single carboxyl-terminal Src homology 2 (SH2) domain, Although no recognizable motifs related to tyrosine, serine/threonine, or lipid kinase domains are present in the predicted amino acid sequence, it contains several potential motifs recognized by SH2 and SH3 domains, A cDNA encoding the murine homologue of pp76 was also isolated and predicts a protein with 84% amino acid identity to human pp76, Northern analysis demonstrates that pp76 mRNA is expressed solely in peripheral blood leukocytes, thymus, and spleen; and in human T cell, B cell and monocytic cell lines, In vitro translation of pp76 cDNA gives rise to a single product of 76 kDa that associates with a GrST/Grb2 fusion protein, demonstrating a direct association between these two molecules. Additionally, a GST fusion protein consisting of the predicted SH2 domain of pp76 precipitates two tyrosine phosphoproteins from Jurkat cell lysates, and antiserum directed against phospho lipase C-gamma 1 coprecipitates a tyrosine phosphoprotein with an electrophoretic mobility identical to that of pp76, These results demonstrate that this novel protein, which we term SLP 76 (SH2 domain containing Leukocyte Protein of 76 kDa), is likely to play an important role in TCR-mediated intracellular signal transduction.	SYNTEX INC,DISCOVERY RES,INST BIOCHEM & CELL BIOL,PALO ALTO,CA 94304; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	Syntex Corporation; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007638] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07638] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, J IMMUNOL, V144, P1591; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9376; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAHESMAA R, 1993, J IMMUNOL, V150, P4125; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1993, CELL, V70, P431; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REIF K, 1994, J BIOL CHEM, V269, P14081; REYNOLDS JA, 1970, P NATL ACAD SCI USA, V66, P1002, DOI 10.1073/pnas.66.3.1002; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEIH M, 1994, MOL CELL BIOL, V14, P4435; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE AMST, V76, P31; WEISS A, 1993, CELL, V73, P203; WOODROW M, 1993, J EXP MED, V178, P15170; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	30	299	312	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7029	7032		10.1074/jbc.270.13.7029	http://dx.doi.org/10.1074/jbc.270.13.7029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706237	hybrid			2022-12-27	WOS:A1995QQ43100005
J	NOMURA, M; BARTSCH, S; NAWATA, H; OMURA, T; MOROHASHI, K				NOMURA, M; BARTSCH, S; NAWATA, H; OMURA, T; MOROHASHI, K			AN E-BOX ELEMENT IS REQUIRED FOR THE EXPRESSION OF THE AD4BP GENE, A MAMMALIAN HOMOLOG OF FTZ-F1 GENE, WHICH IS ESSENTIAL FOR ADRENAL AND GONADAL DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULLERIAN INHIBITING SUBSTANCE; HORMONE RECEPTOR SUPERFAMILY; TRANSCRIPTION FACTOR BINDS; SEX-DETERMINING REGION; MAJOR LATE PROMOTER; LOOP-HELIX PROTEIN; DNA-BINDING; C-MYC; ACTIVATES TRANSCRIPTION; INVITRO TRANSCRIPTION	Ad4BP, also known as SF-1, is a cell type-specific transcription factor regulating all the steroidogenic P-450 genes, Recently, the targeted disruption of the mouse ftz-f1 gene encoding Ad4BP/SF-1 has established its essential function in both adrenal and gonadal development and sexual differentiation. As an initial step toward understanding its role in the cascade of gene activations necessary for the differentiation of the steroidogenic tissues and the sex differentiation of the gonads, we isolated and characterized the rat ad4bp gene. A sequence analysis of the ad4bp gene revealed that another nuclear factor ELF was also transcribed from the same gene by alternative promoter usage and splicing. The promoter of the ad4bp gene showed activities in the steroidogenic cells such as Y-1 adrenocortical cells and I-10 testicular Leydig cells when examined by transient transfection assays. Using deletion analysis and site-directed mutagenesis, we identified a cis-element at the position from -82 bp to -77 bp in the 5'-upstream region, The cis-element was identical to the consensus E box element, which is the binding site for the basic-helix-loop-helix proteins, Gel mobility shift analyses revealed the amount of a binding factor to this E box in the nuclear extract prepared from the rat testes attained a maximal level 1 week after birth and then decreased dramatically thereafter, and only trace amounts were detected in adult rats. In contrast, the binding factor in the ovaries attained a maximal level just after birth and kept its level thereafter. These dimorphic expressions of the binding factor to the E box correlated well with those of Ad4BP, and thus suggested that the expression of Ad4BP is transcriptionally regulated through this E box element.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,FUKUOKA 812,JAPAN; KYUSHU UNIV,SCH MED,DEPT INTERNAL MED 3,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University								ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; DUFAU ML, 1988, ANNU REV PHYSIOL, V50, P483, DOI 10.1146/annurev.ph.50.030188.002411; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HATANO O, 1994, DEVELOPMENT, V120, P2787; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V102, P559, DOI 10.1093/oxfordjournals.jbchem.a122089; MOROHASHI KI, 1994, MOL ENDOCRINOL, V6, P643; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NOMURA M, 1993, J BIOCHEM-TOKYO, V113, P144, DOI 10.1093/oxfordjournals.jbchem.a124018; Omura T., 1993, CYTOCHROME P450; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; RICE DA, 1990, J BIOL CHEM, V265, P11713; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; WONG LH, 1989, NATURE, V340, P163; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	72	87	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7453	7461		10.1074/jbc.270.13.7453	http://dx.doi.org/10.1074/jbc.270.13.7453			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706291	hybrid			2022-12-27	WOS:A1995QQ43100066
J	RECHTIN, TM; BLACK, ME; MAO, F; LEWIS, ML; DRAKE, RR				RECHTIN, TM; BLACK, ME; MAO, F; LEWIS, ML; DRAKE, RR			PURIFICATION AND PHOTOAFFINITY-LABELING OF HERPES-SIMPLEX VIRUS TYPE-1 THYMIDINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE BINDING-SITE; THYMIDYLATE KINASE; ADENYLATE KINASE; IDENTIFICATION; MUTANTS; DNA; CHROMATOGRAPHY; POLYMERASE; SELECTION; DOMAIN	The molecular basis for the treatment of human herpesviruses with nucleoside drugs is the phosphorylation of these drugs by the viral-encoded thymidine kinases. In order to better understand the structural and enzymatic mechanisms by which herpesviral thymidine ki kinases recognize their substrates, photoaffinity labeling with [alpha-P-32]B-azido-2'-deoxyuridine-5'-monophosphate and [gamma-P-92]8-azidoadenosine-5'-triphosphate was used to characterize the thymidine, thymidylate, and ATP active sites of the herpes simplex virus-1 (HSV-1) thymi dine kinase. For this study, HSV-1 thymidine kinase and a site-specific mutant enzyme (C336Y, known to confer acyclovir resistance) were expressed in bacteria and purified by a rapid, two-step protocol, The specificity of photoaffinity labeling of these HSV-1 thymidine kinases was demonstrated by the ability of site directed substrates such as thymidine, thymidylate, acyclovir, 8-bromovinyl-2'-deoxyuridine, and ATP to inhibit photoinsertion, Differences in inhibition patterns of photoaffinity labeling correlated with kinetic differences between the wild-type and C336Y HSV-1 thymidine kinases, Cumulative results suggest that the acyclovir-resistant cysteine 336 mutation primarily affects the ATP binding site; yet it also leads to alteration in the binding affinity of nucleoside drugs in the thymidine site, In this study, azidonucleotide photoaffinity analogs are shown to be effective tools for studying the active-site environment of HSV-1 thymidine kinase and related site-specific mutants.	UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA; UNIV WASHINGTON, DEPT PATHOL, JOSEPH GOTTSTEIN MEM CANC RES LAB, SEATTLE, WA 98195 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Washington; University of Washington Seattle			Mao, Feng/B-8280-2019					BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; BLACK ME, 1990, J BIOL CHEM, V265, P17584; BLACK ME, 1992, J BIOL CHEM, V267, P9743; BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; CHEN MS, 1979, J BIOL CHEM, V254, P747; CHEN MS, 1977, BIOCHEMISTRY-US, V16, P3310, DOI 10.1021/bi00634a005; CHEN MS, 1978, J BIOL CHEM, V253, P1325; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; Czarnecki J, 1979, Methods Enzymol, V56, P642; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DUBE DK, 1991, BIOCHEMISTRY-US, V30, P11760, DOI 10.1021/bi00115a004; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FURLONG N. BURR, 1963, ANALYT BIOCHEM, V5, P515; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOODCHILD J, 1983, J MED CHEM, V26, P1252, DOI 10.1021/jm00363a009; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HARRISON PT, 1991, J GEN VIROL, V72, P2583, DOI 10.1099/0022-1317-72-10-2583; KIT S, 1974, INT J CANCER, V13, P203, DOI 10.1002/ijc.2910130208; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARDER BA, 1983, J BIOL CHEM, V258, P2027; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MACHIDA H, 1986, ANTIMICROB AGENTS CH, V29, P524, DOI 10.1128/AAC.29.3.524; MAGA G, 1994, BIOCHEM J, V302, P279, DOI 10.1042/bj3020279; OAKES JE, 1975, J INFECT DIS, V131, P51, DOI 10.1093/infdis/131.1.51; OKAZAKI R, 1964, J BIOL CHEM, V239, P275; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; RAM Z, 1993, CANCER RES, V53, P83; SAFRIN S, 1992, J ACQ IMMUN DEF SYND, V5, pS29; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WHITLEY RJ, 1985, HERPESVIRUSES, V4, P339	35	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7055	7060		10.1074/jbc.270.13.7055	http://dx.doi.org/10.1074/jbc.270.13.7055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706243	hybrid			2022-12-27	WOS:A1995QQ43100011
J	ZELEZNIKAR, RJ; DZEJA, PP; GOLDBERG, ND				ZELEZNIKAR, RJ; DZEJA, PP; GOLDBERG, ND			ADENYLATE KINASE-CATALYZED PHOSPHORYL TRANSFER COUPLES ATP UTILIZATION WITH ITS GENERATION BY GLYCOLYSIS IN INTACT MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SKELETAL-MUSCLE; CARBOHYDRATE-METABOLISM; SATURATION-TRANSFER; CREATINE-KINASE; COMPARTMENTATION; CELLS; HYDROLYSIS; TRANSPORT; PROTEINS	We previously suggested that an importance of adenylate kinase (AdK) in skeletal muscle is to function as a high energy phosphoryl transfer system regulating ATP generation in correspondence with its consumption by specific cellular processes. The present experiments are intended to define the ATP-generating system coupled to and regulated by AdK-catalyzed phosphotransfer in skeletal muscle and also to examine the relationship between AdK- and creatine kinase (CK)-catalyzed phosphotransfer, Rates of phosphoryl transfer catalyzed by AdK were assessed in intact, isolated rat diaphragm by determining rates of AMP phosphorylation with endogenously generated [gamma-O-18]ATP under conditions of altered anaerobic and aerobic ATP production, AdK-catalyzed phosphoryl transfer rates accelerated incrementally up to 12-fold in direct proportion to stimulated contractile frequency in parallel with equivalent increases in rates of ATP generation by lactate producing glycolysis, Stoichiometric equivalent increases of AdK-catalyzed phosphotransfer and anaerobic ATP production also occurred up to more than 20-fold when oxidative phosphorylation was impaired by either O-2 deprivation or treatment with KCN or p-(trifluoromethoxy)-phenylhydrazone. These enhanced rates of AMP phosphorylation were balanced by virtually identically increased rates of AdK catalyzed generation of AMP. This ARP was traced to arise from AdK-catalyzed phosphotransfer involving ADP generated by a muscle ATPase. Increased AdK-catalyzed phosphotransfer paired with the apparent compensatory increase in ATP generation by anaerobic glycolysis in oxygen deprived muscle occurred coincident with diminished rates of CK-catalyzed phosphoryl transfer indicative of a pairing between oxidatively produced ATP and CK-catalyzed phosphotransfer. A metabolic model consistent with these results and conforming to the Mitchell general principle of vectorial ligand conduction is suggested.	UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NIGMS NIH HHS [GM28818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028818] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BESSMAN SP, 1978, MICROENVIRONMENTS ME, P111; Boyer P.D, 1973, ENZYMES, P279; BREY WS, 1958, PRINCIPLES PHYSICAL, P160; DEAMER DW, 1989, J MEMBRANE BIOL, V143, P275; DZEJA P, 1985, BIOCHEM INT, V10, P259; DZEJA PP, 1994, J MOL CELL CARDIOL, V26, pA153; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GADIAN DG, 1981, BIOCHEM J, V194, P215, DOI 10.1042/bj1940215; GERLACH G, 1986, BIOCHIM BIOPHYS ACTA, V881, P398, DOI 10.1016/0304-4165(86)90032-2; Goldberg A L, 1975, Methods Enzymol, V39, P82; GOLDBETER A, 1976, PROG THEOR BIOL, V4, P65; GOODMAN DM, 1992, PEDIATR RES, V31, P30; GRAY P, 1990, CHEM OSCILLATIONS IN, P292; GUPTA RK, 1979, BIOCHIM BIOPHYS ACTA, V586, P189, DOI 10.1016/0304-4165(79)90417-3; HOCHACHAKA PW, 1994, MUSCLES MOL METABOLI; KASPRZAK AA, 1980, EUR J BIOCHEM, V104, P443, DOI 10.1111/j.1432-1033.1980.tb04446.x; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LOW OH, 1972, FLEXIBLE SYSTEM ENZY, P146; LOWRY OH, 1964, J BIOL CHEM, V239, P18; LYNCH RM, 1987, AM J PHYSIOL, V252, pC328, DOI 10.1152/ajpcell.1987.252.3.C328; MCDONALD TF, 1971, PFLUG ARCH EUR J PHY, V322, P95, DOI 10.1007/BF00592292; MITCHELL P, 1979, EUR J BIOCHEM, V95, P1, DOI 10.1111/j.1432-1033.1979.tb12934.x; MITCHELL P, 1991, BIOSCIENCE REP, V11, P297, DOI 10.1007/BF01130212; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OGUCHI M, 1973, J BIOL CHEM, V248, P5562; OLSON LK, 1991, FASEB J, V5, pA1557; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RACKER E, 1983, J BIOL CHEM, V258, P3702; ROCK CO, 1981, ARCH BIOCHEM BIOPHYS, V211, P113, DOI 10.1016/0003-9861(81)90436-7; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; SHULTZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STANLEY WC, 1991, FASEB J, V5, P2155, DOI 10.1096/fasebj.5.8.1827082; Start C, 1973, REGULATION METABOLIS, P88; THORSTENSSON A, 1977, ACTA PHYSIOL SCAND, V99, P225, DOI 10.1111/j.1748-1716.1977.tb10373.x; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; WALLIMANN T, 1989, MUSCLE ENERGETICS, P159; WALSETH TF, 1988, METHOD ENZYMOL, V159, P60; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; WILKINSON RS, 1989, AM J PHYSIOL, V256, pC1176, DOI 10.1152/ajpcell.1989.256.6.C1176; ZAHLER R, 1987, BIOPHYS J, V51, P883, DOI 10.1016/S0006-3495(87)83416-1; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1991, J BIOL CHEM, V266, P15110	45	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	1995	270	13					7311	7319		10.1074/jbc.270.13.7311	http://dx.doi.org/10.1074/jbc.270.13.7311			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QQ431	7706272	hybrid			2022-12-27	WOS:A1995QQ43100045
J	BJORK, P; JONSSON, U; SVEDBERG, H; LARSSON, K; LIND, P; DILLNER, J; HEDLUND, G; DOHLSTEN, M; KALLAND, T				BJORK, P; JONSSON, U; SVEDBERG, H; LARSSON, K; LIND, P; DILLNER, J; HEDLUND, G; DOHLSTEN, M; KALLAND, T			ISOLATION, PARTIAL CHARACTERIZATION, AND MOLECULAR-CLONING OF A HUMAN COLON ADENOCARCINOMA CELL-SURFACE GLYCOPROTEIN RECOGNIZED BY THE C215 MOUSE MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; TUMOR-CELLS; PROTEIN; DNA; IMMUNOTHERAPY; PEPTIDES; THERAPY; FAMILY; CANCER; KS1/4	The monoclonal antibody C215 (IgG2a) was obtained by the immunization of BALB/c mice with the human colon adenocarcinoma cell line COLO 205 and used in the targeting of colorectal carcinomas. The partial characterization and purification of the C215 target molecule from solubilized COLO 205 membranes indicated that it is an integral membrane glycoprotein of the non-mucin type. The denatured antigen appeared as a major 40-kDa form in Western blots after SDS-polyacrylamide gel electrophoresis and migrated as a monomeric 36-kDa species after the reductive cleavage of intramolecular disulfide bridges. Using a five-step procedure, the antigen was purified 4,300-fold from COLO 205 tumors raised in nude mice to a homogeneity of 95% when assessed by capillary electrophoresis. Removal of N-linked carbohydrate by peptide: N-glycosidase treatment did not affect the visualization of the purified antigen in immunoblots but resulted in a faster migration in the SDS gels. The amino acid sequence was partially determined. Seventeen contiguous NH2-terminal amino acids were identified and coincided exactly with residues 82-98 of the GA733-2 protein cloned by Szala et al. (Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewske, Z., Koprowski, H., and Linnenback, A. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3542-3546). Therefore, the predicted amino acid sequence of this protein was used to prepare overlapping synthetic peptides that cover the entire extracellular domain ih order to identify the C215 epitope. A likely epitope, close to the NH2 terminus and corresponding to the first distinct hydrophilic stretch after the putative signal sequence, was identified in a peptide enzyme-linked immunosorbent assay. Moreover, GA733-2 cDNA was used for the cloning of the C215 protein from COLO 205 cells and the subsequent transfection to K36.16 mouse T cell leukemia cells. The transfected cells were C215 reactive in fluorescence-activated cell sorter analysis, and a 42 kDa band was visualized in Western blots under both non-reducing and reducing conditions. Our findings indicate a close relationship between the C215 antigen and other members of the GA-733 family, some of which are currently being used as targets in clinical trials with monoclonal antibodies. The mammalian expression system described here will enable further studies into the biological role of this protein and the construction of animal models in order to develop optimal therapeutic strategies.	DEPT PHARMACOKINET,S-25109 HELSINGBORG,SWEDEN; BIOSCI CTR,S-11287 STOCKHOLM,SWEDEN; KABI PHARM AB,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; LUND UNIV,WALLENBERG LAB,DEPT TUMOR IMMUNOL,S-22007 LUND 7,SWEDEN	Karolinska Institutet; Lund University	BJORK, P (corresponding author), DEPT IMMUNOL,KABI PHARM ONCOL,SCHEELEVAGEN 22,S-22363 LUND,SWEDEN.							BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLSTEN M, 1991, P NATL ACAD SCI USA, V88, P9287, DOI 10.1073/pnas.88.20.9287; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EDWARDS DP, 1986, CANCER RES, V46, P1306; ELIAS DJ, 1990, CANCER RES, V50, P4154; FERNSTEN PD, 1990, CANCER RES, V50, P4656; FESTENSTEIN H, 1981, IMMUNOL REV, V60, P85, DOI 10.1111/j.1600-065X.1981.tb00363.x; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; HERLYN D, 1991, AM J CLIN ONCOL-CANC, V14, P371, DOI 10.1097/00000421-199110000-00002; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P675; JOHANSSON C, 1991, INT J CANCER, V48, P297, DOI 10.1002/ijc.2910480224; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDO PA, 1993, CANCER IMMUNOL IMMUN, V36, P223, DOI 10.1007/BF01740903; LARSON LN, 1988, INT J CANCER, V42, P877, DOI 10.1002/ijc.2910420615; LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27; LUSKY M, 1981, NATURE, V301, P214; MOSS B, 1972, J BIOL CHEM, V247, P5194; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEREZ MS, 1989, J IMMUNOL, V142, P3662; ROSS AH, 1986, BIOCHEM BIOPH RES CO, V135, P297, DOI 10.1016/0006-291X(86)90976-9; ROSS AH, 1986, HYBRYDOMA S1, V5, P21; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHETYE J, 1988, CANCER IMMUNOL IMMUN, V27, P154; SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRNAD J, 1989, CANCER RES, V49, P314; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; WETTENDORFF M, 1989, P NATL ACAD SCI USA, V86, P3787, DOI 10.1073/pnas.86.10.3787	35	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1993	268	32					24232	24241						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF294	7693697				2022-12-27	WOS:A1993MF29400077
J	KASAHARA, K; KARTASOVA, T; REN, XQ; IKUTA, T; CHIDA, K; KUROKI, T				KASAHARA, K; KARTASOVA, T; REN, XQ; IKUTA, T; CHIDA, K; KUROKI, T			HYPERPHOSPHORYLATION OF KERATINS BY TREATMENT WITH OKADAIC ACID OF BALB/MK-2 MOUSE KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CREATINE PHOSPHOKINASE-B; INTERMEDIATE FILAMENTS; TUMOR PROMOTER; PHOSPHORYLATION SITES; VIMENTIN FILAMENTS; POTENT INHIBITOR; NUCLEAR LAMINA; CDC2 KINASE; CELL-CYCLE	Protein hyper- or hypophosphorylation induced by okadaic acid (OA) treatment was examined using quiescent cultures of the BALB/MK-2 mouse epidermal keratinocytes. Treatment with OA enhanced the phosphorylation of five proteins with molecular weights of 65,000, 55,000, 50,000, 28,000 and 15,000 (p65, p55, p50, p28, and p15, respectively) and decreased that of two proteins with molecular weights of 22,000 and 20,000 (p22 and p20, respectively). The two major phosphorylated proteins, p65 and p55, were identified as type II and type I keratins, respectively, by immunoblotting and immunoprecipitation with keratin specific antibodies. Serine was the only phosphoamino acid residue in hydrolysates of the P-32-labeled keratins purified from OA-treated cells. Two-dimensional tryptic peptide maps of the phosphorylated keratins showed that the hyperphosphorylation was largely due to phosphorylation at several additional sites in both keratins. The hyperphosphorylation of keratins induced by OA treatment resulted in a drastic change in their solubility. This change closely correlated with reorganization of the keratin filament network, which finally collapsed into large perinuclear aggregates. Concomitantly the cells changed from a typical epithelial shape to a round shape. Of several protein kinase inhibitors tested, only staurosporine interfered with this OA-induced morphological change and reorganization of the keratin network.	UNIV TOKYO, INST MED SCI,DEPT CANC CELL RES,SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351; Kasahara, Kohji/0000-0001-7010-8365				BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P346, DOI 10.1016/S0006-291X(05)81063-0; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P351, DOI 10.1016/S0006-291X(05)81064-2; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GEORGATOS SD, 1993, FEBS LETT, V318, P101, DOI 10.1016/0014-5793(93)80001-B; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HIRANO K, 1992, J MUSCLE RES CELL M, V13, P341, DOI 10.1007/BF01766462; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; KASAHARA K, 1991, J BIOL CHEM, V266, P20018; KASAHARA K, 1993, EUR J BIOCHEM, V213, P1101, DOI 10.1111/j.1432-1033.1993.tb17859.x; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TANABE K, 1981, J BIOL CHEM, V256, P3098; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1989, MOL CARCINOGEN, V2, P150, DOI 10.1002/mc.2940020308; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WONG TW, 1983, J BIOL CHEM, V258, P1022; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; YATSUNAMI J, 1991, BIOCHEM BIOPH RES CO, V177, P1165, DOI 10.1016/0006-291X(91)90662-Q; YATSUNAMI J, 1993, CANCER RES, V53, P239; YATSUNAMI J, 1993, CANCER RES, V53, P992	44	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1993	268	31					23531	23537						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MF515	7693689				2022-12-27	WOS:A1993MF51500088
J	IANNELLO, RC; KOLA, I; DAHL, HHM				IANNELLO, RC; KOLA, I; DAHL, HHM			TEMPORAL AND TISSUE-SPECIFIC INTERACTIONS INVOLVING NOVEL TRANSCRIPTION FACTORS AND THE PROXIMAL PROMOTER OF THE MOUSE PDHA-2 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC EXPRESSION; PROTAMINE MESSENGER-RNA; E1-ALPHA SUBUNIT GENES; TRANSLATIONAL REGULATION; TRANSGENIC MICE; GERM-CELLS; INVITRO TRANSCRIPTION; GEL-ELECTROPHORESIS; MEIOTIC PROPHASE; TESTICULAR CELLS	We have determined by deletion analysis that the most proximal region of the Pdha-2 promoter between nucleotide position -187 to +22 harbors a transcriptionally active core. This ''core'' promoter directs high levels of CAT (chloramphenicol acetyltransferase) reporter gene transcription in HeLa cells. DNase I foot-printing of the proximal promoter revealed four regions of protection. One of these contains the consensus sequence for the Sp1 binding site and another the ATF/CREB binding site. The cis-sequences of the remaining two protected regions (designated MEP-2 and MEP-3; Mouse E1apha Promoter site) show no apparent consensus homology with cis-elements of other known transcription factors. Results of electrophoretic mobility shift assays confirm that the ATF/CREB and MEP binding sites interact in a characteristic and specific manner with factors present in nuclei of both testis and somatic tissue. The factor which recognizes the MEP-3 motif appears to be ubiquitous, whereas the MEP-2-protein complexes were tissue-specific. Interestingly, formation of a complex involving MEP-2 and a putative testis-specific binding factor (tay-MEP-2BF) is first observed in the testis of 2-week-old mice, this correlates with the expression of Pdha-2. In contrast, the formation of complexes between the MEP-2 binding site and a somatic variant of MEP-2BF (sigma-MEP-2BF) decreases in the testis as spermatogenesis proceeds. Our results suggest that 1) the MEP-2 binding factors are temporally regulated during spermatogenesis, and 2) interactions involving these factors with the MEP-2 cis-element may be important for modulating Pdha-2 expression.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,CTR EARLY HUMAN DEV,CLAYTON,VIC 3168,AUSTRALIA	Monash University	IANNELLO, RC (corresponding author), ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA.		Kola, Ismail/C-5254-2013					BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BROWN RM, 1990, SOMAT CELL MOLEC GEN, V16, P487, DOI 10.1007/BF01233198; BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE KD, 1986, J BIOL CHEM, V261, P7178; CUNLIFFE V, 1990, EMBO J, V9, P197, DOI 10.1002/j.1460-2075.1990.tb08096.x; ERICKSON RP, 1980, P NATL ACAD SCI-BIOL, V77, P6086, DOI 10.1073/pnas.77.10.6086; FITZGERALD J, 1992, BIOCHIM BIOPHYS ACTA, V1131, P83, DOI 10.1016/0167-4781(92)90102-6; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GOLDSBOROUGH A, 1990, NUCLEIC ACIDS RES, V18, P1634, DOI 10.1093/nar/18.6.1634; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTO M, 1991, NUCLEIC ACIDS RES, V19, P3959, DOI 10.1093/nar/19.14.3959; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; GRIMES SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P402, DOI 10.1016/0003-9861(92)90590-S; HAKE LE, 1990, DEVELOPMENT, V110, P249; Hecht N B, 1988, Prog Clin Biol Res, V267, P291; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; IANNELLO RC, 1992, BIOL REPROD, V47, P48, DOI 10.1095/biolreprod47.1.48; JEN J, 1990, MOL REPROD DEV, V25, P14, DOI 10.1002/mrd.1080250104; JOHNSON PA, 1991, BIOL REPROD, V44, P127, DOI 10.1095/biolreprod44.1.127; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; LIM K, 1992, J BIOL CHEM, V267, P15271; NAGAO Y, 1989, IN VITRO CELL DEV B, V25, P1088, DOI 10.1007/BF02621259; NAYERNIA K, 1992, MOL REPROD DEV, V31, P241, DOI 10.1002/mrd.1080310403; NELKI D, 1990, NUCLEIC ACIDS RES, V18, P3655, DOI 10.1093/nar/18.12.3655; OLIVA R, 1988, DEV BIOL, V125, P332, DOI 10.1016/0012-1606(88)90216-3; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; Sambrook J, 1989, MOL CLONING LABORATO; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKAKUBO F, 1992, EXP CELL RES, V199, P39, DOI 10.1016/0014-4827(92)90459-L; TAMARU M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P331, DOI 10.1016/0167-4781(90)90106-C; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; TANAKA S, 1986, BIOCHEM BIOPH RES CO, V136, P760, DOI 10.1016/0006-291X(86)90504-8; THOMAS K, 1990, DEVELOPMENT, V109, P483; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	54	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1993	268	30					22581	22590						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MD348	7693672				2022-12-27	WOS:A1993MD34800061
J	MAJIMA, E; KOIKE, H; HONG, YM; SHINOHARA, Y; TERADA, H				MAJIMA, E; KOIKE, H; HONG, YM; SHINOHARA, Y; TERADA, H			CHARACTERIZATION OF CYSTEINE RESIDUES OF MITOCHONDRIAL ADP/ATP CARRIER WITH THE SH-REAGENTS EOSIN 5-MALEIMIDE AND N-ETHYLMALEIMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; BEEF-HEART MITOCHONDRIA; ATRACTYLATE BINDING-PROTEIN; ADENINE-NUCLEOTIDE; 5'-TRIPHOSPHATE CARRIER; ROTATIONAL DIFFUSION; PHOSPHATE-TRANSPORT; INNER MEMBRANE; TRANSLOCATOR; TOPOGRAPHY	The effects of the membrane-impermeable fluorescent sulfhydryl reagent eosin 5-maleimide (EMA) and the membrane-permeable sulfhydryl reagent N-ethylmaleimide (NEM) on ADP transport via the ADP/ATP carrier and their labeling sites in the carrier were studied in bovine heart submitochondrial particles. Of the 4 cysteine residues in the carrier, EMA labeled Cys159 very rapidly, Cys56 slowly, and Cys256 very slowly and did not label Cys128. Its labeling of Cys159 was associated with inhibition of the ADP transport, suggesting that the peptide segment containing Cys159 is involved in the transport of adenine nucleotides. In contrast to the very rapid binding of EMA to Cys159, NEM bound to Cys56 more slowly and labeled Cys159 and Cys256 much more slowly. Like EMA, it did not react with Cys128. The labeling of Cys56 with NEM also inhibited ADP transport. From these results, the locations of these cysteine residues in the ADP/ATP carrier are discussed in relation to the transport of adenine nucleotides mediated by the ADP/ATP carrier.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,SHOMACHI 1,TOKUSHIMA 770,JAPAN; APRO,INST LIFE SCI,KUROSAKI,NARUTO 772,JAPAN	Tokushima University								AQUILA H, 1982, EUR J BIOCHEM, V122, P141, DOI 10.1111/j.1432-1033.1982.tb05859.x; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BOULAY F, 1983, BIOCHEMISTRY-US, V22, P477, DOI 10.1021/bi00271a034; BOULAY F, 1984, BIOCHEMISTRY-US, V23, P4807, DOI 10.1021/bi00315a042; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; GUPTE SS, 1991, BIOCHIM BIOPHYS ACTA, V1069, P131, DOI 10.1016/0005-2736(91)90114-N; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; HANSEN M, 1964, BIOCHIM BIOPHYS ACTA, V81, P214, DOI 10.1016/0926-6569(64)90036-7; HOUSTEK J, 1985, J BIOL CHEM, V260, P6288; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KLINGENBERG M, 1992, BIOCHEM SOC T, V20, P547, DOI 10.1042/bst0200547; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC P, 1972, FEBS LETT, V23, P107, DOI 10.1016/0014-5793(72)80296-5; MARTY I, 1992, BIOCHEMISTRY-US, V31, P4058, DOI 10.1021/bi00131a023; MAYINGER P, 1989, FEBS LETT, V244, P421, DOI 10.1016/0014-5793(89)80576-9; MULLER M, 1982, J BIOL CHEM, V257, P1117; MULLER M, 1984, J BIOL CHEM, V259, P3037; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; RICCIO P, 1975, FEBS LETT, V56, P129, DOI 10.1016/0014-5793(75)80126-8; RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SHINOHARA Y, 1987, BIOCHEM BIOPH RES CO, V148, P1081, DOI 10.1016/S0006-291X(87)80242-5; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Stubbs M., 1981, INHIBITORS MITOCHOND, P283; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VIGNAIS PV, 1972, FEBS LETT, V26, P27, DOI 10.1016/0014-5793(72)80534-9	29	122	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1993	268	29					22181	22187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MC809	7691823				2022-12-27	WOS:A1993MC80900110
J	UGAROVA, TP; BUDZYNSKI, AZ; SHATTIL, SJ; RUGGERI, ZM; GINSBERG, MH; PLOW, EF				UGAROVA, TP; BUDZYNSKI, AZ; SHATTIL, SJ; RUGGERI, ZM; GINSBERG, MH; PLOW, EF			CONFORMATIONAL-CHANGES IN FIBRINOGEN ELICITED BY ITS INTERACTION WITH PLATELET MEMBRANE GLYCOPROTEIN-GPIIB-IIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA; MONOCLONAL-ANTIBODIES; ACTIVATED PLATELETS; ELECTRON-MICROSCOPY; ENDOTHELIAL-CELLS; RECEPTOR; RECOGNITION; INTEGRINS; ADHESION; SEQUENCE	The binding of fibrinogen to membrane glycoprotein GPIIb-IIIa on activated platelets leads to platelet aggregation. This interaction results in conformational changes in fibrinogen as evidenced by the expression of receptor-induced binding sites, RIBS, epitopes which are expressed by the bound but not the free ligand. In the present study, two RIBS epitopes have been localized. One sequence resides at gamma112-119 and is recognized by mAb 9F9; the second is the RGDF sequence at Aalpha 95-98 and is recognized by mAb 155B16. These epitopes are also exposed by adsorption of fibrinogen onto a plastic surface and digestion of the molecule by plasmin. Proteolytic exposure of the epitopes coincides with cleavage of the carboxyl-terminal aspects of the Aalpha-chains to form fragment X2. The inaccessibility of the RGDF sequence at Aalpha 95-98 in fibrinogen suggests that this sequence does not participate in the initial binding of the molecule to GPII-bIIIa. The location of these RIBS epitopes suggests a model in which binding of fibrinogen to its receptor alters the conformation of the carboxyl-terminal aspects of the Aalpha-chains, exposing the sequences which reside in the coiled-coil connector segments between the D and E domains of the molecule. These sequences may then serve as epitopes and may mediate unique functions of the receptor-bound molecule.	SCRIPPS RES INST, COMM VASC BIOL CVB-1, LA JOLLA, CA 92037 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania					NHLBI NIH HHS [HL38292, HL36221, HL16411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL038292, R01HL036221] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ABRAMS CS, 1990, BLOOD, V75, P128; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DEVINE DV, 1991, THROMB HAEMOSTASIS, V65, P904; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GRAMSE M, 1978, J CLIN INVEST, V61, P1027, DOI 10.1172/JCI109001; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOLB WP, 1975, P NATL ACAD SCI USA, V72, P1687, DOI 10.1073/pnas.72.5.1687; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KUNICKI TJ, 1984, THROMB RES, V35, P169, DOI 10.1016/0049-3848(84)90212-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONAHEY P, 1966, INT ARCH ALLER A IMM, V29, P181; MEDVED LV, 1983, FEBS LETT, V160, P291, DOI 10.1016/0014-5793(83)80985-5; MIHALYI E, 1976, BIOCHEMISTRY-US, V15, P5372, DOI 10.1021/bi00669a025; MORAN JB, 1981, BIOCHIM BIOPHYS ACTA, V659, P161, DOI 10.1016/0005-2744(81)90280-1; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; OUYANG C, 1976, BIOCHIM BIOPHYS ACTA, V420, P298, DOI 10.1016/0005-2795(76)90321-4; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PHILLIPS DR, 1988, BLOOD, V71, P831; PIZZO SV, 1972, J BIOL CHEM, V247, P636; PLOW EF, 1973, P NATL ACAD SCI USA, V70, P1169, DOI 10.1073/pnas.70.4.1169; PLOW EF, 1992, J LAB CLIN MED, V18, P324; RUDEE ML, 1981, ULTRAMICROSCOPY, V7, P193, DOI 10.1016/0304-3991(81)90010-3; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHIELEN WJG, 1989, P NATL ACAD SCI USA, V86, P8951, DOI 10.1073/pnas.86.22.8951; SCHIELEN WJG, 1991, BLOOD, V77, P2169; SHATTIL SJ, 1987, BLOOD, V70, P307; SHIBA E, 1991, AM J PHYSIOL, V260, pC965, DOI 10.1152/ajpcell.1991.260.5.C965; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SOKAL PG, 1962, ACTA HAEMATOL-BASEL, V28, P313; SORIA J, 1985, J COLLOID INTERF SCI, V107, P204, DOI 10.1016/0021-9797(85)90163-8; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; WALL J, 1983, ANN NY ACAD SCI, V408, P164, DOI 10.1111/j.1749-6632.1983.tb23243.x; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WINTROUB BU, 1980, P NATL ACAD SCI-BIOL, V77, P5448, DOI 10.1073/pnas.77.9.5448; ZAMARRON C, 1991, J BIOL CHEM, V266, P16193; [No title captured]	51	121	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1993	268	28					21080	21087						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MA288	7691805				2022-12-27	WOS:A1993MA28800068
J	WATABE, A; SUGIMOTO, Y; HONDA, A; IRIE, A; NAMBA, T; NEGISHI, M; ITO, S; NARUMIYA, S; ICHIKAWA, A				WATABE, A; SUGIMOTO, Y; HONDA, A; IRIE, A; NAMBA, T; NEGISHI, M; ITO, S; NARUMIYA, S; ICHIKAWA, A			CLONING AND EXPRESSION OF CDNA FOR A MOUSE EP(1) SUBTYPE OF PROSTAGLANDIN-E RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE-A2 RECEPTOR; CELLS; PROTEIN; BINDING; ANALOGS; PGE2	A functional cDNA clone encoding a mouse EP1 sub-type of prostaglandin (PG) E receptor was isolated from a mouse cDNA library by cross-hybridization with the mouse thromboxane A2 receptor cDNA. The clone isolated encodes a protein consisting of 405 amino acid residues with putative seven-transmembrane domains. [H-3]PGE2 specifically bound to the membrane of Chinese hamster ovary cells expressing this clone. The binding to the membrane was displaced with unlabeled PGs in the order of PGE2 > iloprost (a prostacyclin analogue) > PGE1 > PGF2alpha > U-46619 (a thromboxane A2 analogue) > PGD2. The binding was also inhibited by 17-phenyl trinor PGE2 (an EP1 agonist) and sulprostone (an EP1 and EP3 agonist) but not by 11-deoxy PGE, (an EP2 and EP3 agonist) and butaprost (an EP2 agonist). PGE2 induced a rapid increase in intracellular Ca2+ Concentration in Chinese hamster ovary cells expressing the receptor. These results suggest that this receptor belongs to EP1 subtype of PGE receptor. Northern blot analysis demonstrated that the mRNA of this receptor is expressed abundantly in kidney and in a lessor amount in lung.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; OSAKA BIOSCI INST,DEPT CELL BIOL,SUITA 565,JAPAN	Kyoto University; Kyoto University			Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				ABOOLIAN A, 1989, AM J PHYSIOL, V256, pF1135, DOI 10.1152/ajprenal.1989.256.6.F1135; ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; CARPIO H, 1987, PROSTAGLANDINS, V33, P169, DOI 10.1016/0090-6980(87)90004-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN R A, 1987, British Journal of Pharmacology, V91, p407P; COLEMAN R A, 1985, British Journal of Pharmacology, V85, p273P; COLEMAN RA, 1985, PROSTAGLANDINS, V29, P363, DOI 10.1016/0090-6980(85)90096-6; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; EHRENPREIS S, 1973, NATURE-NEW BIOL, V245, P280, DOI 10.1038/newbio245280a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; HEBERT RL, 1991, PROSTAG LEUKOTR ESS, V42, P143, DOI 10.1016/0952-3278(91)90148-X; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ITO S, 1991, J NEUROCHEM, V56, P531, DOI 10.1111/j.1471-4159.1991.tb08182.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MONCADA S, 1985, PHARMACOL BASIS THER, P660; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SMITH WL, 1987, KIDNEY INT, V31, P287; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; YAMAGUCHI DT, 1988, J BIOL CHEM, V263, P10745	30	363	370	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1993	268	27					20175	20178						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LY019	7690750				2022-12-27	WOS:A1993LY01900040
